Selective O
costimulation O
modulators: O
a O
novel O
approach O
for O
the O
treatment O
of O
rheumatoid O
arthritis. O
T O
cells O
have O
a O
central O
role O
in O
the O
orchestration O
of O
the O
immune O
pathways O
that O
contribute O
to O
the O
inflammation O
and O
joint O
destruction O
characteristic O
of O
rheumatoid O
arthritis O
(RA). O
The O
requirement O
for O
a O
dual O
signal O
for O
T-cell O
activation O
and O
the O
construction O
of O
a O
fusion O
protein O
that O
prevents O
engagement O
of O
the O
costimulatory O
molecules O
required O
for O
this O
activation O
has O
led O
to O
a O
new O
approach O
to O
RA O
therapy. O
This O
approach O
is O
mechanistically O
distinct O
from O
other O
currently O
used O
therapies; O
it O
targets O
events O
early O
rather O
than O
late O

in O
the O
immune O
cascade, O
and O
it O
results O
in O
immunomodulation O
rather O
than O
complete O
immunosuppression. O
The O
fusion O
protein O
abatacept O
is O
a O
selective O
costimulation O
modulator O
that O
avidly O
binds O
to O
the O
CD80/CD86 B-GENE-Y
ligands O
on O
an O
antigen-presenting O
cell, O
resulting O
in O
the O
inability O
of O
these O
ligands O
to O
engage O
the O
CD28 B-GENE-N
receptor I-GENE-N
on O
the O
T O
cell. O
Abatacept O
dose-dependently O
reduces O
T-cell O
proliferation, O
serum O
concentrations O
of O
acute-phase O
reactants, O
and O
other O
markers O
of O
inflammation, O
including O
the O
production O
of O
rheumatoid O
factor O
by O
B O

cells. O
Recent O
studies O
have O
provided O
consistent O
evidence O
that O
treatment O
with O
abatacept O
results O
in O
a O
rapid O
onset O
of O
efficacy O
that O
is O
maintained O
over O
the O
course O
of O
treatment O
in O
patients O
with O
inadequate O
response O
to O
methotrexate B-CHEMICAL
and O
anti-tumor B-GENE-N
necrosis I-GENE-N
factor I-GENE-N
therapies. O
This O
efficacy O
includes O
patient-centered O
outcomes O
and O
radiographic O
measurement O
of O
disease O
progression. O
Abatacept O
has O
also O
demonstrated O
a O
very O
favorable O
safety O
profile O
to O
date. O
This O
article O
reviews O
the O
rationale O
for O
this O
therapeutic O
approach O
and O
highlights O
some O
of O
the O
recent O
studies O
that O
demonstrate O
the O
benefits O
obtained O
by O
using O
abatacept. O
This O
clinical O
experience O
indicates O
that O
abatacept O
is O
a O
significant O
addition O
to O

the O
therapeutic O
armamentarium O
for O
the O
management O
of O
patients O
with O
RA. O
Emerging O
role O
of O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
inhibition O
in O
therapy O
for O
advanced O
malignancy: O
focus O
on O
NSCLC. O
Combination O
chemotherapy O
regimens O
have O
emerged O
as O
the O
standard O
approach O
in O
advanced O
non-small-cell O
lung O
cancer. O
Meta-analyses O
have O
demonstrated O
a O
2-month O
increase O
in O
median O
survival O
after O
platinum-based B-CHEMICAL
therapy O
vs. O
best O
supportive O
care, O
and O
an O
absolute O
10% O
improvement O
in O
the O
1-year O
survival O
rate. O
Just O
as O
importantly, O
cytotoxic O
therapy O
has O
produced O
benefits O
in O
symptom O
control O
and O
quality O
of O

life. O
Newer O
agents, O
including O
the O
taxanes, B-CHEMICAL
vinorelbine, B-CHEMICAL
gemcitabine, B-CHEMICAL
and O
irinotecan, B-CHEMICAL
have O
expanded O
our O
therapeutic O
options O
in O
the O
treatment O
of O
advanced O
non-small-cell O
lung O
cancer. O
Despite O
their O
contributions, O
we O
have O
reached O
a O
therapeutic O
plateau, O
with O
response O
rates O
seldom O
exceeding O
30-40% O
in O
cooperative O
group O
studies O
and O
1-year O
survival O
rates O
stable O
between O
30% O
and O
40%. O
It O
is O
doubtful O
that O
substituting O
one O
agent O
for O
another O
in O
various O
combinations O
will O
lead O
to O
any O
further O
improvement O
in O
these O
rates. O
The O
thrust O
of O
current O
research O
has O
focused O
on O
targeted O
therapy, O
and O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y

inhibition O
is O
one O
of O
the O
most O
promising O
clinical O
strategies. O
Epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
inhibitors O
currently O
under O
investigation O
include O
the O
small O
molecules O
gefitinib B-CHEMICAL
(Iressa, B-CHEMICAL
ZD1839) B-CHEMICAL
and O
erlotinib B-CHEMICAL
(Tarceva, B-CHEMICAL
OSI-774), B-CHEMICAL
as O
well O
as O
monoclonal O
antibodies O
such O
as O
cetuximab B-CHEMICAL
(IMC-225, B-CHEMICAL
Erbitux). B-CHEMICAL
Agents O
that O
have O
only O
begun O
to O
undergo O
clinical O
evaluation O
include O
CI-1033, B-CHEMICAL
an O
irreversible O
pan-erbB B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor, O
and O
PKI166 B-CHEMICAL
and O

GW572016, B-CHEMICAL
both O
examples O
of O
dual O
kinase B-GENE-N
inhibitors O
(inhibiting O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
and O
Her2). B-GENE-Y
Preclinical O
models O
have O
demonstrated O
synergy O
for O
all O
these O
agents O
in O
combination O
with O
either O
chemotherapy O
or O
radiotherapy, O
leading O
to O
great O
enthusiasm O
regarding O
their O
ultimate O
contribution O
to O
lung O
cancer O
therapy. O
However, O
serious O
clinical O
challenges O
persist. O
These O
include O
the O
identification O
of O
the O
optimal O
dose(s); O
the O
proper O
integration O
of O
these O
agents O
into O
popular, O
established O
cytotoxic O
regimens; O
and O
the O
selection O
of O
the O
optimal O
setting(s) O
in O
which O
to O
test O
these O
compounds. O
Both O

gefitinib B-CHEMICAL
and O
erlotinib B-CHEMICAL
have O
shown O
clinical O
activity O
in O
pretreated, O
advanced O
non-small-cell O
lung O
cancer, O
but O
placebo-controlled O
randomized O
Phase O
III O
studies O
evaluating O
gefitinib B-CHEMICAL
in O
combination O
with O
standard O
cytotoxic O
therapy, O
to O
our O
chagrin, O
have O
failed O
to O
demonstrate O
a O
survival O
advantage O
compared O
with O
chemotherapy O
alone. O
Effects O
of O
chronic O
social O
defeat O
stress O
on O
behavior O
and O
choline B-GENE-Y
acetyltransferase, I-GENE-Y
78-kDa B-GENE-Y
glucose-regulated I-GENE-Y
protein, I-GENE-Y
and O
CCAAT/enhancer-binding B-GENE-Y
protein I-GENE-Y
(C/EBP) I-GENE-Y
homologous I-GENE-Y

protein I-GENE-Y
in O
adult O
mice. O
RATIONALE: O
Social O
defeat O
stress O
induces O
physiological O
and O
behavioral O
symptoms, O
including O
anxiety, O
anhedonia, O
immune O
deficits, O
and O
altered O
expression O
of O
key O
brain O
genes. O
OBJECTIVES: O
The O
present O
study O
investigated O
the O
effects O
of O
social O
defeat O
stress O
on O
the O
behaviors O
and O
expressions O
of O
Chat, B-GENE-Y
Grp78, B-GENE-Y
and O
chop B-GENE-Y
in O
the O
brains O
of O
adult O
mice. O
METHODS: O
Adult O
mice O
were O
divided O
into O
susceptible O
and O
unsusceptible O
groups O
after O
10 O
days O
of O
social O
defeat O
stress. O
In O
experiment O
1, O
behavioral O
tests O
were O
conducted, O
and O
brains O
were O
processed O
for O
Western O
blotting O

at O
day O
27 O
after O
stress. O
In O
experiment O
2, O
social O
avoidance O
tests O
were O
conducted, O
and O
brains O
were O
processed O
for O
Western O
blotting O
at O
day O
12 O
after O
stress. O
RESULTS: O
The O
results O
indicate O
decreased O
and O
increased O
locomotion O
and O
anxiety O
behavior O
in O
all O
defeated O
mice. O
Decrease O
in O
social O
interaction, O
increased O
immobility, O
and O
impaired O
memory O
performance O
were O
only O
observed O
in O
susceptible O
mice. O
A O
decrease O
in O
the O
Chat O
level O
at O
days O
12 O
and O
27 O
was O
noted O
in O
the O
prefrontal O
cortex O
(PFC), O
amygdala O
(Amyg), O
and O
dorsal O
hippocampus O
(HIP) O
in O
defeated O
mice. O

The O
expression O
levels O
of O
Grp78 B-GENE-Y
and O
chop B-GENE-Y
measured O
on O
days O
12 O
and O
27 O
were O
significantly O
greater O
in O
the O
Amyg O
of O
susceptible O
mice. O
In O
the O
PFC O
and O
HIP, O
defeated O
mice O
displayed O
different O
patterns O
in O
the O
levels O
of O
Grp78 B-GENE-Y
and O
chop B-GENE-Y
expressions O
measured O
on O
days O
12 O
and O
27. O
CONCLUSIONS: O
The O
present O
study O
demonstrated O
that O
chronic O
social O
defeat O
stress O
in O
mice O
produces O
stress-related O
behaviors. O
Different O
response O
patterns O
were O
noted O
for O
Grp78 B-GENE-Y
and O
chop B-GENE-Y
expression O
among O
the O
groups O
in O
terms O
of O
brain O
regions O
and O
time-course O
effects. O
Hepatocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
activator I-GENE-Y
inhibitor I-GENE-Y
type I-GENE-Y
2 I-GENE-Y

(HAI-2) B-GENE-Y
modulates O
hepcidin B-GENE-Y
expression O
by O
inhibiting O
the O
cell O
surface O
protease B-GENE-N
matriptase-2. B-GENE-Y
Matriptase-2, B-GENE-Y
a O
recently O
identified O
cell O
surface O
protease, B-GENE-N
is O
the O
key O
enzyme O
of O
iron B-CHEMICAL
homoeostasis O
modulating O
the O
expression O
of O
the O
liver O
peptide O
hormone O
hepcidin. B-GENE-Y
HAI B-GENE-N
(hepatocyte B-GENE-N
growth I-GENE-N
factor I-GENE-N
activator I-GENE-N
inhibitor) I-GENE-N
types I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
(HAI-1 B-GENE-Y
and O
HAI-2 B-GENE-Y
respectively) O
have O
been O
shown O
to O
inhibit O
the O
close O
homologue, O
i.e. O

matriptase. B-GENE-N
By O
co-expressing O
matriptase-2 B-GENE-Y
and O
the O
inhibitor O
HAI-2 B-GENE-Y
we O
have O
identified O
HAI-2 B-GENE-Y
displaying O
high O
inhibitory O
potential O
against O
matriptase-2 B-GENE-N
at O
the O
cell O
surface O
as O
well O
as O
in O
conditioned O
medium. O
Accordingly, O
complex O
formation O
between O
matriptase-2 B-GENE-Y
and O
HAI-2 B-GENE-Y
was O
demonstrated O
by O
isolation O
of O
the O
complex O
via O
immobilizing O
either O
HAI-2 B-GENE-Y
or O
matriptase-2 B-GENE-Y
from O
lysates O
and O
conditioned O
medium O
of O
co-expressing O
cells. O
Furthermore, O
HAI-2 B-GENE-Y
indirectly O
influences O
the O
expression O
of O
the O
hepcidin-encoding B-GENE-Y
gene O

HAMP. B-GENE-Y
The O
inhibitor O
abrogates O
the O
matriptase-2-mediated B-GENE-Y
suppression O
of O
HAMP B-GENE-Y
expression, O
presumably O
by O
inhibiting O
the O
supposed O
potential O
of O
matriptase-2 B-GENE-Y
to O
cleave O
membrane-bound O
HJV O
(haemojuvelin). O
Taken O
together, O
the O
results O
of O
the O
present O
study O
have O
characterized O
HAI-2 B-GENE-Y
as O
an O
inhibitor O
of O
matriptase-2 B-GENE-Y
that O
modulates O
the O
synthesis O
of O
hepcidin B-GENE-Y
and O
provides O
new O
insights O
into O
the O
regulatory O
mechanism O
of O
iron B-CHEMICAL
homoeostasis, O
with O
clinical O
importance O
for O
a O
treatment O
of O
iron B-CHEMICAL
overload O
diseases. O

Alprenolol B-CHEMICAL
and O
bromoacetylalprenololmenthane B-CHEMICAL
are O
competitive O
slowly O
reversible O
antagonists O
at O
the O
beta B-GENE-Y
1-adrenoceptors I-GENE-Y
of O
rat O
left O
atria. O
We O
studied O
the O
effects O
of O
alprenolol B-CHEMICAL
and O
bromoacetylalprenololmenthane B-CHEMICAL
(BAAM) B-CHEMICAL
on O
rat O
left O
atria. O
Alprenolol B-CHEMICAL
and O
BAAM B-CHEMICAL
at O
10(-7), O
3 O
x O
10(-7), O
and O
10(-6) O
M O
inhibited O
the O
cardiac O
stimulation O
response O
slightly, O
which O
is O
indicative O
of O
membrane-stabilizing O
activity O
independent O
of O

beta-adrenoceptor B-GENE-N
blockade. O
This O
membrane-stabilizing O
activity O
was O
readily O
reversible. O
Alprenolol B-CHEMICAL
and O
BAAM B-CHEMICAL
also O
caused O
surmountable O
antagonism O
of O
isoprenaline B-CHEMICAL
responses, O
and O
this O
beta B-GENE-Y
1-adrenoceptor I-GENE-Y
antagonism O
was O
slowly O
reversible. O
Inhibition O
of O
the O
isoprenaline B-CHEMICAL
responses O
with O
alprenolol B-CHEMICAL
and O
BAAM B-CHEMICAL
at O
10(-6) O
M O
was O
at O
equilibrium O
after O
60 O
min, O
which O
is O
indicative O
of O
reversible O
antagonism. O
We O
conclude O
that O
alprenolol B-CHEMICAL
and O
BAAM B-CHEMICAL
are O
competitive O
slowly O
reversible O
beta B-GENE-Y

1-adrenoceptor I-GENE-Y
antagonists O
on O
rat O
left O
atria. O
Covalent O
linkage O
of O
apolipoprotein B-GENE-Y
e I-GENE-Y
to O
albumin B-GENE-Y
nanoparticles O
strongly O
enhances O
drug O
transport O
into O
the O
brain. O
Drug O
delivery O
to O
the O
brain O
is O
becoming O
more O
and O
more O
important O
but O
is O
severely O
restricted O
by O
the O
blood-brain O
barrier. O
Nanoparticles O
coated O
with O
polysorbates B-CHEMICAL
have O
previously O
been O
shown O
to O
enable O
the O
transport O
of O
several O
drugs O
across O
the O
blood-brain O
barrier, O
which O
under O
normal O
circumstances O
is O
impermeable O
to O
these O
compounds. O
Apolipoprotein B-GENE-Y
E I-GENE-Y
was O
suggested O
to O
mediate O
this O
drug O
transport O
across O
the O
blood-brain O

barrier. O
In O
the O
present O
study, O
apolipoprotein B-GENE-Y
E I-GENE-Y
was O
coupled O
by O
chemical O
methods O
to O
nanoparticles O
made O
of O
human B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
(HSA-NP). B-GENE-Y
Loperamide, B-CHEMICAL
which O
does O
not O
cross O
the O
blood-brain O
barrier O
but O
exerts O
antinociceptive O
effects O
after O
direct O
injection O
into O
the O
brain, O
was O
used O
as O
model O
drug. O
Apolipoprotein B-GENE-Y
E I-GENE-Y
was O
chemically O
bound O
via O
linkers O
to O
loperamide-loaded B-CHEMICAL
HSA-NP. B-GENE-Y
This O
preparation O
induced O
antinociceptive O
effects O
in O
the O
tail-flick O
test O
in O
ICR O
mice O
after O
i.v. O
injection. O
In O

contrast, O
nanoparticles O
linked O
to O
apolipoprotein B-GENE-Y
E I-GENE-Y
variants O
that O
do O
not O
recognize O
lipoprotein B-GENE-N
receptors I-GENE-N
failed O
to O
induce O
these O
effects. O
These O
results O
indicate O
that O
apolipoprotein B-GENE-Y
E I-GENE-Y
attached O
to O
the O
surface O
of O
nanoparticles O
facilitates O
transport O
of O
drugs O
across O
the O
blood-brain O
barrier, O
probably O
after O
interaction O
with O
lipoprotein B-GENE-N
receptors I-GENE-N
on O
the O
brain O
capillary O
endothelial O
cell O
membranes. O
Discovery O
and O
optimization O
of O
anthranilic B-CHEMICAL
acid I-CHEMICAL
sulfonamides I-CHEMICAL
as O
inhibitors O
of O
methionine B-GENE-Y
aminopeptidase-2: I-GENE-Y
a O
structural O
basis O
for O
the O
reduction O
of O
albumin B-GENE-Y

binding. O
Methionine B-GENE-Y
aminopeptidase-2 I-GENE-Y
(MetAP2) B-GENE-Y
is O
a O
novel O
target O
for O
cancer O
therapy. O
As O
part O
of O
an O
effort O
to O
discover O
orally O
active O
reversible O
inhibitors O
of O
MetAP2, B-GENE-Y
a O
series O
of O
anthranilic B-CHEMICAL
acid I-CHEMICAL
sulfonamides I-CHEMICAL
with O
micromolar O
affinities O
for O
human B-GENE-Y
MetAP2 I-GENE-Y
were O
identified O
using O
affinity O
selection O
by O
mass O
spectrometry O
(ASMS) O
screening. O
These O
micromolar O
hits O
were O
rapidly O
improved O
to O
nanomolar O
leads O
on O
the O
basis O
of O
insights O
from O
protein O
crystallography; O
however, O
the O
compounds O
displayed O
extensive O
binding O
to O
human B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
and O
had O

limited O
activity O
in O
cellular O
assays. O
Modifications O
based O
on O
structural O
information O
on O
the O
binding O
of O
lead O
compounds O
to O
both O
MetAP2 B-GENE-Y
and O
domain B-GENE-N
III I-GENE-N
of I-GENE-N
albumin I-GENE-N
allowed O
the O
identification O
of O
compounds O
with O
significant O
improvements O
in O
both O
parameters, O
which O
showed O
good O
cellular O
activity O
in O
both O
proliferation O
and O
methionine B-CHEMICAL
processing O
assays. O
Keratinocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
and O
acidic B-GENE-Y
fibroblast I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
are O
mitogens O
for O
primary O
cultures O
of O
mammary O
epithelium. O
Mammary O
epithelial O
cells O
derived O
from O
the O
entire O
mammary O
parenchyma O
or O
only O
end O
buds O
were O
isolated O
by O
collagenase B-GENE-N
digestion O
of O

mammary O
glands O
from O
virgin O
mice. O
Cells O
were O
cultured O
within O
collagen O
gels O
in O
serum-free O
medium O
containing O
insulin. B-GENE-Y
Keratinocyte B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(KGF B-GENE-Y
or O
FGF-7) B-GENE-Y
and O
acidic B-GENE-Y
fibroblast I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(aFGF B-GENE-Y
or O
FGF-1) B-GENE-Y
stimulated O
multifold O
proliferation O
when O
added O
alone O
to O
this O
medium. O
Growth O
occurred O
as O
three-dimensional O
colonies O
within O
the O
collagen B-GENE-N
gel O
matrix. O
KGF B-GENE-Y
stimulated O
growth O
was O
unaffected O
by O
adding O
heparin. O
Conversely, O
multifold O
growth O
stimulation O
by O
acidic B-GENE-Y
FGF I-GENE-Y
required O
heparin. O
Since O
end O

buds O
are O
the O
actively O
proliferating O
cell O
population O
of O
ductal O
glands, O
organ O
cultures O
of O
these O
structures O
were O
prepared. O
KGF B-GENE-Y
stimulated O
3H-thymidine B-CHEMICAL
incorporation O
in O
these O
end O
buds O
in O
the O
absence O
and O
presence O
of O
epidermal B-GENE-Y
growth I-GENE-Y
factor. I-GENE-Y
These O
data O
suggest O
that O
acidic B-GENE-Y
FGF I-GENE-Y
and O
KGF B-GENE-Y
may O
represent O
in O
vivo O
stromal O
factors O
capable O
of O
regulating O
mammary O
gland O
development. O
Configuration O
of O
a O
scintillation O
proximity O
assay O
for O
the O
activity O
assessment O
of O
recombinant O
human B-GENE-Y
adenine I-GENE-Y
phosphoribosyltransferase. I-GENE-Y
Adenine B-GENE-Y

phosphoribosyltransferase I-GENE-Y
plays O
a O
role O
in O
purine B-CHEMICAL
salvage O
by O
catalyzing O
the O
direct O
conversion O
of O
adenine B-CHEMICAL
to O
adenosine B-CHEMICAL
monophosphate. I-CHEMICAL
The O
involvement O
of O
the O
purine B-CHEMICAL
salvage O
pathway O
in O
tumor O
proliferation O
and O
angiogenesis O
makes O
adenine B-GENE-Y
phosphoribosyltransferase I-GENE-Y
a O
potential O
target O
for O
oncology O
drug O
discovery. O
We O
have O
expressed O
and O
characterized O
recombinant, O
N-terminally B-CHEMICAL
His-tagged B-CHEMICAL
human B-GENE-Y
adenine I-GENE-Y
phosphoribosyltransferase. I-GENE-Y
Two O
assay O
formats O
were O
assessed O
for O
use O
in O
a O
high O
throughput O
screen: O
a O

spectrophotometric-based O
enzyme-coupled O
assay O
system O
and O
a O
radiometric O
ionic O
capture O
scintillation O
proximity O
bead O
assay O
format. O
Ultimately, O
the O
scintillation O
proximity O
assay O
format O
was O
chosen O
because O
of O
automated O
screening O
compatibility O
limitations O
of O
the O
coupled O
assay. O
We O
describe O
here O
the O
biochemical O
characterization O
of O
adenine B-GENE-Y
phosphoribosyltransferase I-GENE-Y
and O
the O
development O
of O
a O
robust, O
homogeneous, O
384-well O
assay O
suitable O
for O
high O
throughput O
screening. O
Cholinesterase B-GENE-Y
inhibitors O
for O
Alzheimer's O
disease. O
BACKGROUND: O
Since O
the O
introduction O
of O
the O
first O

cholinesterase B-GENE-Y
inhibitor O
(ChEI) O
in O
1997, O
most O
clinicians O
and O
probably O
most O
patients O
would O
consider O
the O
cholinergic O
drugs, O
donepezil, B-CHEMICAL
galantamine B-CHEMICAL
and O
rivastigmine, B-CHEMICAL
to O
be O
the O
first O
line O
pharmacotherapy O
for O
mild O
to O
moderate O
Alzheimer's O
disease.The O
drugs O
have O
slightly O
different O
pharmacological O
properties, O
but O
they O
all O
work O
by O
inhibiting O
the O
breakdown O
of O
acetylcholine, B-CHEMICAL
an O
important O
neurotransmitter O
associated O
with O
memory, O
by O
blocking O
the O
enzyme O
acetylcholinesterase. B-GENE-Y
The O
most O
that O
these O
drugs O
could O
achieve O
is O
to O
modify O
the O

manifestations O
of O
Alzheimer's O
disease. O
Cochrane O
reviews O
of O
each O
ChEI O
for O
Alzheimer's O
disease O
have O
been O
completed O
(Birks O
2005, O
Birks O
2005b O
and O
Loy O
2005). O
Despite O
the O
evidence O
from O
the O
clinical O
studies O
and O
the O
intervening O
clinical O
experience O
the O
debate O
on O
whether O
ChEIs O
are O
effective O
continues. O
OBJECTIVES: O
To O
assess O
the O
effects O
of O
donepezil, B-CHEMICAL
galantamine B-CHEMICAL
and O
rivastigmine B-CHEMICAL
in O
people O
with O
mild, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease. O
SEARCH O
STRATEGY: O
The O
Cochrane O
Dementia O
and O
Cognitive O

Improvement O
Group's O
Specialized O
Register O
was O
searched O
using O
the O
terms O
'donepezil', B-CHEMICAL
'E2020' B-CHEMICAL
, O
'Aricept' B-CHEMICAL
, O
galanthamin* B-CHEMICAL
galantamin* B-CHEMICAL
reminyl, B-CHEMICAL
rivastigmine, B-CHEMICAL
exelon, B-CHEMICAL
"ENA B-CHEMICAL
713" I-CHEMICAL
and O
ENA-713 B-CHEMICAL
on O
12 O
June O
2005. O
This O
Register O
contains O
up-to-date O
records O
of O
all O
major O
health O
care O
databases O
and O
many O
ongoing O
trial O
databases. O
SELECTION O
CRITERIA: O
All O
unconfounded, O
blinded, O
randomized O
trials O
in O
which O
treatment O
with O
a O
ChEI O
was O
compared O
with O
placebo O
or O
another O

ChEI O
for O
patients O
with O
mild, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease. O
DATA O
COLLECTION O
AND O
ANALYSIS: O
Data O
were O
extracted O
by O
one O
reviewer O
(JSB), O
pooled O
where O
appropriate O
and O
possible, O
and O
the O
pooled O
treatment O
effects, O
or O
the O
risks O
and O
benefits O
of O
treatment O
estimated. O
MAIN O
RESULTS: O
The O
results O
of O
13 O
randomized, O
double O
blind, O
placebo O
controlled O
trials O
demonstrate O
that O
treatment O
for O
periods O
of O
6 O
months O
and O
one O
year, O
with O
donepezil, B-CHEMICAL
galantamine B-CHEMICAL
or O
rivastigmine B-CHEMICAL
at O
the O
recommended O
dose O
for O
people O
with O

mild, O
moderate O
or O
severe O
dementia O
due O
to O
Alzheimer's O
disease O
produced O
improvements O
in O
cognitive O
function, O
on O
average O
-2.7 O
points O
(95%CI O
-3.0 O
to O
-2.3), O
in O
the O
midrange O
of O
the O
70 O
point O
ADAS-Cog O
Scale. O
Study O
clinicians O
blind O
to O
other O
measures O
rated O
global O
clinical O
state O
more O
positively O
in O
treated O
patients. O
Benefits O
of O
treatment O
were O
also O
seen O
on O
measures O
of O
activities O
of O
daily O
living O
and O
behaviour. O
None O
of O
these O
treatment O
effects O
are O
large. O
There O
is O
nothing O
to O
suggest O
the O
effects O
are O
less O
for O
patients O
with O
severe O
dementia O
or O
mild O
dementia, O
although O
there O

is O
very O
little O
evidence O
for O
other O
than O
mild O
to O
moderate O
dementia.More O
patients O
leave O
ChEI O
treatment O
groups, O
approximately O
29 O
%, O
on O
account O
of O
adverse O
events O
than O
leave O
the O
placebo O
groups O
(18%). O
There O
is O
evidence O
of O
more O
adverse O
events O
in O
total O
in O
the O
patients O
treated O
with O
a O
ChEI O
than O
with O
placebo. O
Although O
many O
types O
of O
adverse O
event O
were O
reported, O
nausea, O
vomiting, O
diarrhoea, O
were O
significantly O
more O
frequent O
in O
the O
ChEI O
groups O
than O
in O
placebo. O
There O
are O
four O
studies, O
all O
supported O
by O
one O
of O
the O
pharmaceutical O
companies, O
in O
which O
two O
ChEIs O
were O
compared, O
two O
studies O
of O

donepezil B-CHEMICAL
compared O
with O
galantamine, B-CHEMICAL
and O
two O
of O
donepezil B-CHEMICAL
compared O
with O
rivastigmine. B-CHEMICAL
In O
three O
studies O
the O
patients O
were O
not O
blinded O
to O
treatment, O
only O
the O
fourth, O
DON O
vs O
RIV/Bullock O
is O
double O
blind. O
Two O
of O
the O
studies O
provide O
little O
evidence, O
they O
are O
of O
12 O
weeks O
duration, O
which O
is O
barely O
long O
enough O
to O
complete O
the O
drug O
titration. O
There O
is O
no O
evidence O
from O
DON O
vs O
GAL/Wilcock O
of O
a O
treatment O
difference O
between O
donepezil B-CHEMICAL
and O
galantamine B-CHEMICAL
at O
52 O
weeks O
for O
cognition, O
activities O
of O
daily O
living, O
the O
numbers O
who O
leave O
the O
trial O

before O
the O
end O
of O
treatment, O
the O
number O
who O
suffer O
any O
adverse O
event, O
or O
any O
specific O
adverse O
event. O
There O
is O
no O
evidence O
from O
DON O
vs O
RIV/Bullock O
of O
a O
difference O
between O
donepezil B-CHEMICAL
and O
rivastigmine B-CHEMICAL
for O
cognitive O
function, O
activities O
of O
daily O
living O
and O
behavioural O
disturbance O
at O
two O
years. O
Fewer O
patients O
suffer O
adverse O
events O
on O
donepezil B-CHEMICAL
than O
rivastigmine. B-CHEMICAL
AUTHORS' O
CONCLUSIONS: O
The O
three O
cholinesterase B-GENE-Y
inhibitors O
are O
efficacious O
for O
mild O
to O
moderate O
Alzheimer's O
disease. O
It O
is O
not O
possible O
to O
identify O
those O
who O
will O
respond O

to O
treatment O
prior O
to O
treatment. O
There O
is O
no O
evidence O
that O
treatment O
with O
a O
ChEI O
is O
not O
cost O
effective. O
Despite O
the O
slight O
variations O
in O
the O
mode O
of O
action O
of O
the O
three O
cholinesterase B-GENE-Y
inhibitors O
there O
is O
no O
evidence O
of O
any O
differences O
between O
them O
with O
respect O
to O
efficacy. O
There O
appears O
to O
be O
less O
adverse O
effects O
associated O
with O
donepezil B-CHEMICAL
compared O
with O
rivastigmine. B-CHEMICAL
It O
may O
be O
that O
galantamine B-CHEMICAL
and O
rivastigmine B-CHEMICAL
match O
donepezil B-CHEMICAL
in O
tolerability O
if O
a O
careful O
and O
gradual O
titration O
routine O
over O
more O
than O
three O
months O
is O
used. O
Titration O
with O
donepezil B-CHEMICAL
is O
more O
straightforward O
and O
the O

lower O
dose O
may O
be O
worth O
consideration. O
The O
effects O
of O
mitiglinide B-CHEMICAL
(KAD-1229), B-CHEMICAL
a O
new O
anti-diabetic O
drug, O
on O
ATP-sensitive B-GENE-N
K+ I-GENE-N
channels I-GENE-N
and O
insulin B-GENE-Y
secretion: O
comparison O
with O
the O
sulfonylureas B-CHEMICAL
and O
nateglinide. B-CHEMICAL
Mitiglinide B-CHEMICAL
(KAD-1229), B-CHEMICAL
a O
new O
anti-diabetic O
drug, O
is O
thought O
to O
stimulate O
insulin B-GENE-Y
secretion O
by O
closing O
the O
ATP-sensitive B-GENE-N
K+ I-GENE-N
(K(ATP)) I-GENE-N
channels I-GENE-N
in O
pancreatic O
beta-cells. O
However, O
its O
selectivity O
for O
the O
various O
K(ATP) B-GENE-N
channels I-GENE-N
is O
not O

known. O
In O
this O
study, O
we O
examined O
the O
effects O
of O
mitiglinide B-CHEMICAL
on O
various O
cloned O
K(ATP) B-GENE-N
channels I-GENE-N
(Kir6.2/SUR1, B-GENE-Y
Kir6.2/SUR2A, B-GENE-Y
and O
Kir6.2/SUR2B) B-GENE-Y
reconstituted O
in O
COS-1 O
cells, O
and O
compared O
them O
to O
another O
meglitinide-related B-CHEMICAL
compound, O
nateglinide. B-CHEMICAL
Patch-clamp O
analysis O
using O
inside-out O
recording O
configuration O
showed O
that O
mitiglinide B-CHEMICAL
inhibits O
the O
Kir6.2/SUR1 B-GENE-Y
channel O
currents O
in O
a O
dose-dependent O
manner O

(IC50 O
value, O
100 O
nM) O
but O
does O
not O
significantly O
inhibit O
either O
Kir6.2/SUR2A B-GENE-Y
or O
Kir6.2/SUR2B B-GENE-Y
channel O
currents O
even O
at O
high O
doses O
(more O
than O
10 O
microM). O
Nateglinide B-CHEMICAL
inhibits O
Kir6.2/SUR1 B-GENE-Y
and O
Kir6.2/SUR2B B-GENE-Y
channels O
at O
100 O
nM, O
and O
inhibits O
Kir6.2/SUR2A B-GENE-Y
channels O
at O
high O
concentrations O
(1 O
microM). O
Binding O
experiments O
on O
mitiglinide, B-CHEMICAL
nateglinide, B-CHEMICAL
and O

repaglinide B-CHEMICAL
to O
SUR1 B-GENE-Y
expressed O
in O
COS-1 O
cells O
revealed O
that O
they O
inhibit O
the O
binding O
of O
[3H]glibenclamide B-CHEMICAL
to O
SUR1 B-GENE-Y
(IC50 O
values: O
mitiglinide, B-CHEMICAL
280 O
nM; O
nateglinide, B-CHEMICAL
8 O
microM; O
repaglinide, B-CHEMICAL
1.6 O
microM), O
suggesting O
that O
they O
all O
share O
a O
glibenclamide B-CHEMICAL
binding O
site. O
The O
insulin B-GENE-N
responses O
to O
glucose, B-CHEMICAL
mitiglinide, B-CHEMICAL
tolbutamide, B-CHEMICAL
and O
glibenclamide B-CHEMICAL
in O
MIN6 O
cells O
after O
chronic O

mitiglinide, B-CHEMICAL
nateglinide, B-CHEMICAL
or O
repaglinide B-CHEMICAL
treatment O
were O
comparable O
to O
those O
after O
chronic O
tolbutamide B-CHEMICAL
and O
glibenclamide B-CHEMICAL
treatment. O
These O
results O
indicate O
that, O
similar O
to O
the O
sulfonylureas, B-CHEMICAL
mitiglinide B-CHEMICAL
is O
highly O
specific O
to O
the O
Kir6.2/SUR1 B-GENE-Y
complex, O
i.e., O
the O
pancreatic O
beta-cell O
K(ATP) B-GENE-N
channel, I-GENE-N
and O
suggest O
that O
mitiglinide B-CHEMICAL
may O
be O
a O
clinically O
useful O
anti-diabetic O
drug. O
A O
systematic O
comparison O
of O
the O
properties O
of O
clinically O
used O
angiotensin B-GENE-Y
II I-GENE-Y

type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
antagonists. O
Angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
antagonists O
(ARBs) O
have O
become O
an O
important O
drug O
class O
in O
the O
treatment O
of O
hypertension O
and O
heart O
failure O
and O
the O
protection O
from O
diabetic O
nephropathy. O
Eight O
ARBs O
are O
clinically O
available O
[azilsartan, B-CHEMICAL
candesartan, B-CHEMICAL
eprosartan, B-CHEMICAL
irbesartan, B-CHEMICAL
losartan, B-CHEMICAL
olmesartan, B-CHEMICAL
telmisartan, B-CHEMICAL
valsartan]. B-CHEMICAL
Azilsartan B-CHEMICAL
(in O
some O
countries), O
candesartan, B-CHEMICAL
and O
olmesartan B-CHEMICAL

are O
orally O
administered O
as O
prodrugs, O
whereas O
the O
blocking O
action O
of O
some O
is O
mediated O
through O
active O
metabolites. O
On O
the O
basis O
of O
their O
chemical O
structures, O
ARBs O
use O
different O
binding O
pockets O
in O
the O
receptor, O
which O
are O
associated O
with O
differences O
in O
dissociation O
times O
and, O
in O
most O
cases, O
apparently O
insurmountable O
antagonism. O
The O
physicochemical O
differences O
between O
ARBs O
also O
manifest O
in O
different O
tissue O
penetration, O
including O
passage O
through O
the O
blood-brain O
barrier. O
Differences O
in O
binding O
mode O
and O
tissue O
penetration O
are O
also O
associated O
with O
differences O
in O
pharmacokinetic O
profile, O
particularly O
duration O
of O
action. O
Although O
generally O
highly O
specific O

for O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptors, I-GENE-Y
some O
ARBs, O
particularly O
telmisartan, B-CHEMICAL
are O
partial O
agonists O
at O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor-γ. I-GENE-Y
All O
of O
these O
properties O
are O
comprehensively O
reviewed O
in O
this O
article. O
Although O
there O
is O
general O
consensus O
that O
a O
continuous O
receptor O
blockade O
over O
a O
24-hour O
period O
is O
desirable, O
the O
clinical O
relevance O
of O
other O
pharmacological O
differences O
between O
individual O
ARBs O
remains O
to O
be O
assessed. O
Diuretic O
effects O
of O
cannabinoids. O
In O
vivo O
effects O
of O
cannabinoid O
(CB) O
agonists O
are O
often O
assessed O
using O
four O
well-established O

measures: O
locomotor O
activity, O
hypothermia, O
cataleptic-like O
effects, O
and O
analgesia. O
The O
present O
studies O
demonstrate O
that O
doses O
of O
CB O
agonists O
that O
produce O
these O
effects O
also O
reliably O
increase O
diuresis. O
Diuretic O
effects O
of O
several O
CB O
agonists O
were O
measured O
in O
female O
rats O
over O
2 O
hours O
immediately O
after O
drug O
injection, O
and O
results O
were O
compared O
with O
hypothermic O
effects. O
Direct-acting O
CB1 B-GENE-Y
agonists, O
including O
Δ(9)-tetrahydrocannabinol, B-CHEMICAL
WIN B-CHEMICAL
55,212 I-CHEMICAL

[R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone B-CHEMICAL
mesylate], I-CHEMICAL
AM2389 B-CHEMICAL
[9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], B-CHEMICAL
and O
AM4054 B-CHEMICAL

[9β-(hydroxymethyl)-3-(1-adamantyl)-hexahydrocannabinol], B-CHEMICAL
produced O
dose-dependent O
increases O
in O
diuresis O
and O
decreases O
in O
colonic O
temperature, O
with O
slightly O
lower O
ED(50) O
values O
for O
diuresis O
than O
for O
hypothermia. O
The O
highest O
doses O
of O
cannabinoid O
drugs O
yielded, O
on O
average, O
26-32 O
g/kg O
urine; O
comparable O
effects O
were O
obtained O
with O
10 O
mg/kg O
furosemide B-CHEMICAL
and O
3.0 O
mg/kg O

trans-(-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide B-CHEMICAL
(U50-488). B-CHEMICAL
Methanandamide B-CHEMICAL
(10.0 O
mg/kg) O
had O
lesser O
effect O
than O
other O
CB O
agonists, O
and O
the O
CB2 B-GENE-Y
agonist O
AM1241 B-CHEMICAL

[1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], B-CHEMICAL
the O
anandamide B-CHEMICAL
transport O
inhibitor O
AM404, B-CHEMICAL
and O
the O
CB O
antagonist O
rimonabant B-CHEMICAL
did O
not O
have O
diuretic O
effects. O
In O
further O
studies, O
the O
diuretic O
effects O
of O
the O
CB1 B-GENE-Y
agonist O
AM4054 B-CHEMICAL
were O
similar O
in O
male O
and O
female O
rats, O
displayed O
a O
relatively O
rapid O
onset O
to O
action, O
and O
were O
dose-dependently O
antagonized O
by O
30 O
minutes O
pretreatment O
with O
rimonabant, B-CHEMICAL
but O
not O

by O
the O
vanilloid B-GENE-Y
receptor I-GENE-Y
type I-GENE-Y
I I-GENE-Y
antagonist O
capsazepine, B-CHEMICAL
nor O
were O
the O
effects O
of O
WIN B-CHEMICAL
55,212 I-CHEMICAL
antagonized O
by O
the O
CB2 B-GENE-Y
antagonist O
AM630 B-CHEMICAL
[(6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl) B-CHEMICAL
methanone)]. I-CHEMICAL
These O
data O
indicate O
that O
cannabinoids O
have O
robust O
diuretic O
effects O
in O
rats O
that O
are O
mediated O
via O
CB1 B-GENE-Y
receptor O
mechanisms. O
Nonsteroidal O
anti-inflammatory O

drugs O
induce O
apoptosis O
in O
association O
with O
activation O
of O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
in O
rheumatoid O
synovial O
cells. O
Nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
have O
been O
reported O
to O
induce O
apoptosis O
in O
a O
variety O
of O
cell O
lines. O
In O
this O
study, O
we O
examined O
the O
effect O
of O
NSAIDs O
on O
the O
growth O
and O
apoptosis O
of O
synovial O
cells O
from O
patients O
with O
rheumatoid O
arthritis O
and O
analyzed O
the O
activation O
of O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
(PPARgamma) B-GENE-Y
as O
a O
possible O
mechanism O
of O
action O
of O

NSAIDs. O
Cell O
proliferation O
and O
viability O
were O
assessed O
from O
5-bromo-2'-deoxyuridine B-CHEMICAL
incorporation O
and O
by O
4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene B-CHEMICAL
disulfonate I-CHEMICAL
(WST-1) B-CHEMICAL
assay, O
respectively. O
The O
apoptosis O
of O
synovial O
cells O
was O
identified O
by O
DNA O
fragmentation O
assay O
and O
terminal O
deoxynucleotidyl O
transferase-mediated O
dUTP O

nick-end O
labeling O
assay. O
Indometacin, B-CHEMICAL
diclofenac, B-CHEMICAL
oxaprozin, B-CHEMICAL
and O
zaltoprofen B-CHEMICAL
reduced O
cell O
proliferation O
and O
induced O
apoptotic O
cell O
death O
in O
synovial O
cells, O
whereas O
ketoprofen B-CHEMICAL
and O
acetaminophen B-CHEMICAL
did O
not. O
N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide B-CHEMICAL
(NS-398), B-CHEMICAL
a O
selective O
cyclooxygenase-2 B-GENE-Y
inhibitor, O
also O
inhibited O
cell O
proliferation, O

whereas O
it O
did O
not O
cause O
apoptosis. O
Rheumatoid O
synovial O
cells O
expressed O
PPARgamma B-GENE-Y
mRNA, O
and O
the O
PPARgamma B-GENE-Y
ligands O
15-deoxy-Delta(12,14)-prostaglandin B-CHEMICAL
J(2) I-CHEMICAL
and O
troglitazone B-CHEMICAL
reduced O
the O
proliferation O
and O
induced O
apoptosis O
in O
synovial O
cells. O
Luciferase O
reporter O
assay O
demonstrated O
that O
not O
only O
PPARgamma B-GENE-Y
ligands O
but O
also O
NSAIDs, O
which O
could O
induce O
apoptosis, O
increased O
the O
activation O
of O
PPARgamma B-GENE-Y
in O
synovial O
cells. O
Furthermore, O
the O

ability O
of O
NSAIDs O
and O
PPARgamma B-GENE-Y
ligands O
to O
stimulate O
the O
activation O
of O
PPARgamma B-GENE-Y
correlated O
with O
their O
ability O
to O
decrease O
cell O
viability(r O
= O
0.92, O
p O
< O
0.01) O
and O
ability O
to O
induce O
DNA O
fragmentation O
(r O
= O
0.97, O
p O
< O
0.001) O
in O
synovial O
cells. O
These O
results O
suggest O
that O
PPARgamma B-GENE-Y
is O
an O
attractive O
target O
for O
induction O
of O
apoptosis O
in O
rheumatoid O
synovial O
cells O
and O
that O
the O
activation O
of O
the O
PPARgamma B-GENE-Y
pathway O
is O
associated O
with O
the O
apoptotic O
action O
of O
NSAIDs. O

Anisotropy O
of O
chemical O
bonding O
in O
semifluorinated O
graphite B-CHEMICAL
C2F B-CHEMICAL
revealed O
with O
angle-resolved O
X-ray O
absorption O
spectroscopy. O
Highly O
oriented O
pyrolytic O
graphite B-CHEMICAL
characterized O
by O
a O
low O
misorientation O
of O
crystallites O
is O
fluorinated O
using O
a O
gaseous O
mixture O
of O
BrF(3) B-CHEMICAL
with O
Br(2) B-CHEMICAL
at O
room O
temperature. O
The O
golden-colored O
product, O
easily O
delaminating O
into O
micrometer-size O
transparent O
flakes, O
is O
an O
intercalation O
compound O
where O
Br(2) B-CHEMICAL
molecules O
are O
hosted O
between O
fluorinated O
graphene B-CHEMICAL
layers O
of O
approximate O

C(2)F B-CHEMICAL
composition. O
To O
unravel O
the O
chemical O
bonding O
in O
semifluorinated O
graphite, B-CHEMICAL
we O
apply O
angle-resolved O
near-edge O
X-ray O
absorption O
fine O
structure O
(NEXAFS) O
spectroscopy O
and O
quantum-chemical O
modeling. O
The O
strong O
angular O
dependence O
of O
the O
CK O
and O
FK O
edge O
NEXAFS O
spectra O
on O
the O
incident O
radiation O
indicates O
that O
room-temperature-produced O
graphite B-CHEMICAL
fluoride I-CHEMICAL
is O
a O
highly O
anisotropic O
material, O
where O
half O
of O
the O
carbon B-CHEMICAL
atoms O
are O
covalently O
bonded O
with O
fluorine, B-CHEMICAL
while O
the O
rest O
of O
the O
carbon O
atoms O
preserve O
π O
electrons. O

Comparison O
of O
the O
experimental O
CK O
edge O
spectrum O
with O
theoretical O
spectra O
plotted O
for O
C(2)F B-CHEMICAL
models O
reveals O
that O
fluorine B-CHEMICAL
atoms O
are O
more O
likely O
to O
form O
chains. O
This O
conclusion O
agrees O
with O
the O
atomic O
force O
microscopy O
observation O
of O
a O
chain-like O
pattern O
on O
the O
surface O
of O
graphite B-CHEMICAL
fluoride I-CHEMICAL
layers. O
Two O
novel O
mutations O
in O
the O
MEN1 B-GENE-Y
gene O
in O
subjects O
with O
multiple O
endocrine O
neoplasia-1. O
Multiple O
endocrine O
neoplasia O
type O
1 O
(MEN1) B-GENE-Y
is O
characterized O
by O
parathyroid, O
enteropancreatic O
endocrine O
and O
pituitary O
adenomas O
as O
well O

as O
germline O
mutation O
of O
the O
MEN1 B-GENE-Y
gene. O
We O
describe O
2 O
families O
with O
MEN1 B-GENE-Y
with O
novel O
mutations O
in O
the O
MEN1 B-GENE-Y
gene. O
One O
family O
was O
of O
Turkish O
origin, O
and O
the O
index O
patient O
had O
primary O
hyperparathyroidism O
(PHPT) O
plus O
a O
prolactinoma; O
three O
relatives O
had O
PHPT O
only. O
The O
index O
patient O
in O
the O
second O
family O
was O
a O
46-yr-old O
woman O
of O
Chinese O
origin O
living O
in O
Taiwan. O
This O
patient O
presented O
with O
a O
complaint O
of O
epigastric O
pain O
and O
watery O
diarrhea O
over O
the O
past O
3 O
months, O
and O
had O
undergone O
subtotal O

parathyroidectomy O
and O
enucleation O
of O
pancreatic O
islet O
cell O
tumor O
about O
10 O
yr O
before. O
There O
was O
also O
a O
prolactinoma. O
Sequence O
analysis O
of O
the O
MEN1 B-GENE-Y
gene O
from O
leukocyte O
genomic O
DNA O
revealed O
heterozygous O
mutations O
in O
both O
probands. O
The O
Turkish O
patient O
and O
her O
affected O
relatives O
all O
had O
a O
heterozygous O
A B-GENE-N
to I-GENE-N
G I-GENE-N
transition I-GENE-N
at I-GENE-N
codon I-GENE-N
557 I-GENE-N
(AAG-->GAG) B-GENE-N
of O
exon O
10 O
of O
MEN1 B-GENE-Y
that O
results O
in O
a O
replacement O
of O
lysine B-CHEMICAL
by O
glutamic B-CHEMICAL
acid. I-CHEMICAL
The O
Chinese O
index O

patient O
and O
one O
of O
her O
siblings O
had O
a O
heterozygous O
mutation O
at O
codon O
418 O
of O
exon O
9 O
(GAC-->TAT) B-GENE-N
that O
results O
in O
a O
substitution O
of O
aspartic B-CHEMICAL
acid I-CHEMICAL
by O
tyrosine. B-CHEMICAL
In O
conclusion, O
we O
have O
identified O
2 O
novel O
missense O
mutations O
in O
the O
MEN1 B-GENE-Y
gene. O
Mutation O
of O
arginine B-CHEMICAL
228 O
to O
lysine B-CHEMICAL
enhances O
the O
glucosyltransferase B-GENE-N
activity O
of O
bovine B-GENE-Y
beta-1,4-galactosyltransferase I-GENE-Y
I. I-GENE-Y
Beta-1,4-galactosyltransferase B-GENE-Y
I I-GENE-Y

(beta4Gal-T1) B-GENE-Y
normally O
transfers O
Gal B-CHEMICAL
from O
UDP-Gal B-CHEMICAL
to O
GlcNAc B-CHEMICAL
in O
the O
presence O
of O
Mn(2+) B-CHEMICAL
ion O
(Gal-T B-GENE-N
activity) O
and O
also O
transfers O
Glc B-CHEMICAL
from O
UDP-Glc B-CHEMICAL
to O
GlcNAc B-CHEMICAL
(Glc-T B-GENE-N
activity), O
albeit O
at O
only O
0.3% O
efficiency. O
In O
addition, O
alpha-lactalbumin B-GENE-Y
(LA) B-GENE-Y
enhances O
this O
Glc-T B-GENE-N
activity O
more O
than O
25 O
times. O
Comparison O
of O
the O
crystal O
structures O
of O
UDP-Gal- B-CHEMICAL
and O

UDP-Glc-bound B-CHEMICAL
beta4Gal-T1 B-GENE-Y
reveals O
that O
the O
O4 B-CHEMICAL
hydroxyl I-CHEMICAL
group O
in O
both O
Gal B-CHEMICAL
and O
Glc B-CHEMICAL
moieties O
forms O
a O
hydrogen B-CHEMICAL
bond O
with O
the O
side O
chain O
carboxylate B-CHEMICAL
group O
of O
Glu317. O
The O
orientation O
of O
the O
O4 B-CHEMICAL
hydroxyl I-CHEMICAL
of I-CHEMICAL
glucose I-CHEMICAL
causes O
a O
steric O
hindrance O
to O
the O
side O
chain O
carboxylate B-CHEMICAL
group O
of O
Glu317, O
accounting O
for O
the O
enzyme's O
low O
Glc-T B-GENE-N
activity. O
In O
this O
study, O
we O
show O
that O
mutation O
of O
Arg228, O
a O
residue O
in O
the O
vicinity O
of O

Glu317, O
to O
lysine B-CHEMICAL
(R228K-Gal-T1) B-GENE-N
results O
in O
a O
15-fold O
higher O
Glc-T B-GENE-N
activity, O
which O
is O
further O
enhanced O
by O
LA O
to O
nearly O
25% O
of O
the O
Gal-T B-GENE-N
activity O
of O
the O
wild O
type. O
The O
kinetic O
parameters O
indicate O
that O
the O
main O
effect O
of O
the O
mutation O
of O
Arg228 O
to O
lysine B-CHEMICAL
is O
on O
the O
k(cat) O
of O
Glc-T, B-GENE-N
which O
increases O
3-4-fold, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
LA; O
simultaneously, O
the O
k(cat) O
for O
the O
Gal-T B-GENE-N
reaction O
is O
reduced O

30-fold. O
The O
crystal O
structure O
of O
R228K-Gal-T1 B-GENE-N
complexed O
with O
LA, O
UDP-Gal, B-CHEMICAL
and O
Mn(2+) B-CHEMICAL
determined O
at O
1.9 O
A O
resolution O
shows O
that O
the O
Asp318 O
side O
chain O
exhibits O
a O
minor O
alternate O
conformation, O
compared O
to O
that O
in O
the O
wild O
type. O
This O
alternate O
conformation O
now O
causes O
a O
steric O
hindrance O
to O
the O
O4 B-CHEMICAL
hydroxyl I-CHEMICAL
group O
of O
the O
Gal B-CHEMICAL
moiety O
of O
UDP-Gal, B-CHEMICAL
probably O
causing O
the O
dissociation O
of O
UDP-Gal B-CHEMICAL
and O
the O
reduced O
k(cat) O
of O
the O

Gal-T B-GENE-N
reaction. O
Discovery O
of O
novel O
2-hydroxydiarylamide B-CHEMICAL
derivatives O
as O
TMPRSS4 B-GENE-Y
inhibitors. O
TMPRSS4 B-GENE-Y
is O
a O
novel O
type B-GENE-N
II I-GENE-N
transmembrane I-GENE-N
serine I-GENE-N
protease I-GENE-N
that O
has O
been O
implicated O
in O
the O
invasion O
and O
metastasis O
of O
colon O
cancer O
cells. O
In O
this O
study, O
a O
novel O
series O
of O
2-hydroxydiarylamide B-CHEMICAL
derivatives O
were O
synthesized O
and O
evaluated O
for O
inhibiting O
TMPRSS4 B-GENE-Y
serine B-GENE-N
protease I-GENE-N
activity O
and O
suppressing O
cancer O
cell O
invasion. O
These O
derivatives O
demonstrated O
good O
inhibitory O
activity O
against O
TMPRSS4 B-GENE-Y
serine B-GENE-N

protease, I-GENE-N
which O
correlated O
with O
the O
promising O
anti-invasive O
activity O
of O
colon O
cancer O
cells O
overexpressing O
TMPRSS4. B-GENE-Y
Conformationally O
restricted O
homotryptamines. B-CHEMICAL
Part O
6: O
Indole-5-cycloalkyl B-CHEMICAL
methylamines I-CHEMICAL
as O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors. O
Racemic B-CHEMICAL
5-(trans-2-aminomethylcyclopropyl)indoles, I-CHEMICAL
5-(trans-2-aminomethylcyclopentyl) B-CHEMICAL
indoles, I-CHEMICAL
and O

5-(cis-2-aminomethylcyclopentyl)indoles B-CHEMICAL
were O
synthesized O
and O
evaluated O
as O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors. O
These O
analogs O
followed O
SAR O
trends O
similar O
to O
those O
previously O
reported O
for O
3-cycloalkyl B-CHEMICAL
substituted I-CHEMICAL
indoles. I-CHEMICAL
The O
most O
potent O
analogs O
exhibited O
single O
digit O
nanomolar O
inhibition O
at O
the O
human B-GENE-Y
serotonin I-GENE-Y
transporter I-GENE-Y
but O
were O
10-fold O
less O
active O
than O
the O
previously O
reported O
compounds. O
Beta1 B-GENE-Y
adrenergic I-GENE-Y
receptor-mediated I-GENE-Y
enhancement O
of O
hippocampal O
CA3 O
network O
activity. O
Norepinephrine B-CHEMICAL
is O
an O

endogenous O
neurotransmitter O
distributed O
throughout O
the O
mammalian O
brain. O
In O
higher O
cortical O
structures O
such O
as O
the O
hippocampus, O
norepinephrine, B-CHEMICAL
via O
beta B-GENE-N
adrenergic I-GENE-N
receptor I-GENE-N
(AR) B-GENE-N
activation, O
has O
been O
shown O
to O
reinforce O
the O
cognitive O
processes O
of O
attention O
and O
memory. O
In O
this O
study, O
we O
investigated O
the O
effect O
of O
beta1AR B-GENE-Y
activation O
on O
hippocampal O
cornu O
ammonis O
3 O
(CA3) O
network O
activity. O
AR B-GENE-N
expression O
was O
first O
determined O
using O
immunocytochemistry O
with O
antibodies O
against O
beta1ARs, B-GENE-Y
which O
were O
found O
to O
be O
exceptionally O
dense O
in O
hippocampal O

CA3 O
pyramidal O
neurons. O
CA3 O
network O
activity O
was O
then O
examined O
in O
vitro O
using O
field O
potential O
recordings O
in O
rat O
brain O
slices. O
The O
selective O
betaAR B-GENE-N
agonist O
isoproterenol B-CHEMICAL
caused O
an O
enhancement O
of O
hippocampal O
CA3 O
network O
activity, O
as O
measured O
by O
an O
increase O
in O
frequency O
of O
spontaneous O
burst O
discharges O
recorded O
in O
the O
CA3 O
region. O
In O
the O
presence O
of O
alphaAR B-GENE-N
blockade, O
concentration-response O
curves O
for O
isoproterenol, B-CHEMICAL
norepinephrine, B-CHEMICAL
and O
epinephrine B-CHEMICAL
suggested O
that O
a O
beta1AR B-GENE-Y
was O
involved O
in O
this O
response, O
and O
the O
rank O
order O
of O
potency O
was O
isoproterenol B-CHEMICAL

> O
norepinephrine B-CHEMICAL
= O
epinephrine. B-CHEMICAL
Finally, O
equilibrium O
dissociation O
constants O
(pK(b)) O
of O
subtype-selective O
betaAR B-GENE-N
antagonists O
were O
functionally O
determined O
to O
characterize O
the O
AR B-GENE-N
subtype O
modulating O
hippocampal O
CA3 O
activity. O
The O
selective O
beta1AR B-GENE-Y
antagonists O
atenolol B-CHEMICAL
and O
metoprolol B-CHEMICAL
blocked O
isoproterenol-induced B-CHEMICAL
enhancement, O
with O
apparent O
K(b) O
values O
of O
85 O
+/- O
36 O
and O
3.9 O
+/- O
1.7 O
nM, O
respectively. O
In O
contrast, O
the O
selective O
beta2AR B-GENE-Y
antagonists O

ICI-118,551 B-CHEMICAL
and O
butoxamine B-CHEMICAL
inhibited O
isoproterenol-mediated B-CHEMICAL
enhancement O
with O
apparent O
low O
affinities O
(K(b) O
of O
222 O
+/- O
61 O
and O
9268 O
+/- O
512 O
nM, O
respectively). O
Together, O
this O
pharmacological O
profile O
of O
subtype-selective O
betaAR B-GENE-N
antagonists O
indicates O
that O
in O
this O
model, O
beta1AR B-GENE-Y
activation O
is O
responsible O
for O
the O
enhanced O
hippocampal O
CA3 O
network O
activity O
initiated O
by O
isoproterenol. B-CHEMICAL
P2Y(2) B-GENE-Y
receptor I-GENE-Y
agonist O
INS37217 B-CHEMICAL
enhances O
functional O
recovery O
after O
detachment O
caused O
by O

subretinal O
injection O
in O
normal O
and O
rds O
mice. O
PURPOSE: O
To O
evaluate O
the O
effects O
of O
INS37217 B-CHEMICAL
on O
the O
recovery O
of O
retinal B-CHEMICAL
function O
after O
experimental O
retinal B-CHEMICAL
detachment O
induced O
by O
subretinal O
injection. O
METHODS: O
Subretinal O
injections O
of O
1 O
micro O
L O
of O
fluorescent O
microbeads, O
saline, O
or O
INS37217 B-CHEMICAL
(1-200 O
micro O
M) O
were O
made O
by O
the O
transvitreal O
method O
in O
normal O
(C57BL/6) O
mice O
and O
in O
mice O
heterozygous O
for O
the O
retinal B-CHEMICAL
degeneration O
slow O
(rds) O
gene. O

Control, O
mock-injected O
animals O
underwent O
corneal O
puncture O
without O
injection. O
Histologic O
and O
ERG O
evaluations O
were O
made O
at O
0 O
to O
1 O
and O
8 O
hours, O
and O
1, O
3, O
7, O
10, O
14, O
and O
60 O
days O
post O
injection O
(PI). O
DNA O
fragmentation O
was O
evaluated O
by O
terminal O
deoxynucleotidyl B-CHEMICAL
transferase-mediated O
uridine B-CHEMICAL
5'-triphosphate-biotin I-CHEMICAL
nick O
end O
labeling O
(TUNEL). O
RESULTS: O
A O
single O
subretinal O
injection O
of O
saline O
solution O
containing O
fluorescent O
beads O
caused O
a O
histologically O
evident O
retinal O

detachment O
and O
distributed O
the O
microbeads O
to O
almost O
all O
the O
subretinal O
space. O
Spontaneous O
reattachment O
occurred O
within O
24 O
hours O
after O
injection O
and O
was O
accompanied O
by O
evident O
retinal B-CHEMICAL
folding O
that O
appeared O
largely O
resolved O
by O
6 O
days O
later. O
Relative O
to O
controls, O
injection O
of O
saline O
resulted O
in O
approximately O
40% O
recovery O
of O
dark-adapted O
a-wave O
amplitude O
at O
24 O
hours O
PI O
and O
gradually O
improved O
to O
approximately O
90% O
of O
controls O
at O
2 O
months O
PI. O
Subretinal O
injection O
of O
saline O
containing O
INS37217 B-CHEMICAL
(10 O
micro O
M) O
significantly O
increased O
rod O
and O
cone O
ERG O
of O
normal O
and O
rds(+/-) O
mice O

at O
1 O
and O
10 O
days O
PI, O
when O
compared O
with O
injection O
of O
saline O
alone. O
Additionally, O
INS37217 B-CHEMICAL
reduced O
the O
number O
of O
TUNEL-positive O
photoreceptors O
and O
the O
enhanced O
rate O
of O
reattachment. O
CONCLUSIONS: O
Enhancement O
of O
ERG O
recovery O
by O
INS37217 B-CHEMICAL
is O
likely O
due O
to O
reduced O
retinal B-CHEMICAL
folding O
and O
cell O
death O
associated O
with O
detachment. O
These O
results O
support O
the O
use O
of O
INS37217 B-CHEMICAL
to O
help O
restore O
function O
after O
therapies O
that O
involve O
subretinal O
administration O
of O
drugs O
in O
animal O
models O
of O
retinal B-CHEMICAL
diseases. O
Selective O
antagonism O
of O

GluR5 B-GENE-Y
kainate-receptor-mediated B-GENE-N
synaptic O
currents O
by O
topiramate B-CHEMICAL
in O
rat O
basolateral O
amygdala O
neurons. O
Topiramate B-CHEMICAL
is O
a O
widely O
used O
antiepileptic O
agent O
whose O
mechanism O
of O
action O
is O
poorly O
understood. O
The O
drug O
has O
been O
reported O
to O
interact O
with O
various O
ion B-GENE-N
channel I-GENE-N
types, O
including O
AMPA/kainate B-GENE-N
receptors. I-GENE-N
In O
whole-cell O
voltage-clamp O
recordings O
from O
principal O
neurons O
of O
the O
rat O
basolateral O
amygdala, O
topiramate B-CHEMICAL
at O
low O
concentrations O
(IC50, O
approximately O
0.5 O
microm) O
selectively O
inhibited O
pharmacologically O
isolated O

excitatory O
synaptic O
currents O
mediated O
by O
kainate B-GENE-N
receptors I-GENE-N
containing O
the O
GluR5 B-GENE-Y
subunit. O
Topiramate B-CHEMICAL
also O
partially O
depressed O
predominantly O
AMPA-receptor-mediated B-GENE-N
EPSCs, O
but O
with O
lower O
efficacy. O
Topiramate B-CHEMICAL
did O
not O
alter O
the O
degree O
of O
facilitation O
in O
paired-pulse O
experiments, O
and O
it O
reduced O
the O
amplitude O
of O
miniature O
EPSCs O
without O
affecting O
their O
frequency, O
demonstrating O
that O
the O
block O
of O
synaptic O
responses O
occurs O
postsynaptically. O
Inhibition O
of O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
could O
represent O
a O
key O
mechanism O
underlying O
the O
anticonvulsant O
activity O
of O
topiramate. B-CHEMICAL
Moreover, O
these O
results O
support O
the O

concept O
that O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
represent O
a O
novel O
target O
for O
antiepileptic O
drug O
development. O
From O
traditional O
European O
medicine O
to O
discovery O
of O
new O
drug O
candidates O
for O
the O
treatment O
of O
dementia O
and O
Alzheimer's O
disease: O
acetylcholinesterase B-GENE-Y
inhibitors. O
The O
leading O
Alzheimer's O
disease O
(AD) O
therapeutics O
to O
date O
involves O
inhibitors O
of O
acetylcholinesterase B-GENE-Y
(AChE), B-GENE-Y
which O
should, O
in O
principle, O
elevate O
cholinergic O
signaling O
and O
limit O
inflammation. O
In O
spite O
of O
the O
effectiveness O
in O
20%-30% O
of O
AD O
patients, O
more O
attention O
has O
been O
paid O
to O
find O
new O

anti-AChE B-GENE-Y
agents O
from O
medicinal O
plants. O
Galanthamine, B-CHEMICAL
contained O
in O
the O
bulbs O
and O
flowers O
of O
Galanthus O
and O
related O
genera O
like O
Narcissus, O
represents O
a O
good O
example. O
The O
aim O
of O
this O
study O
is O
to O
review O
the O
role O
of O
possible O
AChE B-GENE-Y
inhibitors O
(AChEI) O
present O
in O
plants O
traditionally O
used O
in O
European O
medicine O
for O
improving O
memory. O
Starting O
from O
Galanthamine, B-CHEMICAL
properties O
of O
Melissa O
species, O
Salvia O
officinalis, O
Arnica O
chamissonis O
and O
Ruta O
graveolens O
are O
discussed O
to O
point O
to O
the O
role O
of O
these O
plants O
as O
potential O
sources O
for O
the O
development O
of O
therapeutic O
agents O
for O

AD. O
Structure O
of O
acetylcholinesterase B-GENE-Y
complexed O
with O
(-)-galanthamine B-CHEMICAL
at O
2.3 O
A O
resolution. O
(-)-Galanthamine B-CHEMICAL
(GAL), B-CHEMICAL
an O
alkaloid O
from O
the O
flower, O
the O
common O
snowdrop O
(Galanthus O
nivalis), O
shows O
anticholinesterase O
activity. O
This O
property O
has O
made O
GAL O
the O
target O
of O
research O
as O
to O
its O
effectiveness O
in O
the O
treatment O
of O
Alzheimer's O
disease. O
We O
have O
solved O
the O
X-ray O
crystal O
structure O
of O
GAL O
bound O
in O
the O
active O
site O
of O
Torpedo B-GENE-Y
californica I-GENE-Y

acetylcholinesterase I-GENE-Y
(TcAChE) B-GENE-Y
to O
2.3 O
A O
resolution. O
The O
inhibitor O
binds O
at O
the O
base O
of O
the O
active O
site O
gorge O
of O
TcAChE, B-GENE-Y
interacting O
with O
both O
the O
choline-binding B-GENE-N
site I-GENE-N
(Trp-84) B-CHEMICAL
and O
the O
acyl-binding B-GENE-N
pocket I-GENE-N
(Phe-288, B-CHEMICAL
Phe-290). B-CHEMICAL
The O
tertiary B-CHEMICAL
amine I-CHEMICAL
group O
of O
GAL O
does O
not O
interact O
closely O
with O
Trp-84; B-CHEMICAL
rather, O
the O
double O
bond O
of O
its O
cyclohexene B-CHEMICAL
ring O
stacks O
against O
the O
indole B-CHEMICAL
ring. O
The O
tertiary O
amine O
appears O
to O
make O
a O

non-conventional O
hydrogen B-CHEMICAL
bond, O
via O
its O
N-methyl B-CHEMICAL
group, O
to O
Asp-72, B-CHEMICAL
near O
the O
top O
of O
the O
gorge. O
The O
hydroxyl B-CHEMICAL
group O
of O
the O
inhibitor O
makes O
a O
strong O
hydrogen B-CHEMICAL
bond O
(2.7 O
A) O
with O
Glu-199. B-CHEMICAL
The O
relatively O
tight O
binding O
of O
GAL O
to O
TcAChE B-GENE-Y
appears O
to O
arise O
from O
a O
number O
of O
moderate O
to O
weak O
interactions O
with O
the O
protein, O
coupled O
to O
a O
low O
entropy O
cost O
for O
binding O
due O
to O
the O
rigid O
nature O
of O
the O
inhibitor. O
Methyl B-CHEMICAL
transfer O
in O
glycine B-GENE-Y
N-methyltransferase. I-GENE-Y
A O
theoretical O
study. O
Density O
functional O
theory O
calculations O
using O
the O

hybrid O
functional O
B3LYP O
have O
been O
performed O
to O
study O
the O
methyl B-CHEMICAL
transfer O
step O
in O
glycine B-GENE-Y
N-methyltransferase I-GENE-Y
(GNMT). B-GENE-Y
This O
enzyme O
catalyzes O
the O
S-adenosyl-L-methionine B-CHEMICAL
(SAM)-dependent B-CHEMICAL
methylation O
of O
glycine B-CHEMICAL
to O
form O
sarcosine. B-CHEMICAL
The O
starting O
point O
for O
the O
calculations O
is O
the O
recent O
X-ray O
crystal O
structure O
of O
GNMT B-GENE-Y
complexed O
with O
SAM B-CHEMICAL
and O
acetate. O
Several O
quantum O
chemical O
models O
with O
different O
sizes, O
employing O
up O
to O
98 O
atoms, O
were O
used. O
The O
calculations O
demonstrate O
that O
the O
suggested O
mechanism, O
where O

the O
methyl O
group O
is O
transferred O
in O
a O
single O
S(N)2 O
step, O
is O
thermodynamically O
plausible. O
By O
adding O
or O
eliminating O
various O
groups O
at O
the O
active O
site, O
it O
was O
furthermore O
demonstrated O
that O
hydrogen B-CHEMICAL
bonds O
to O
the O
amino B-CHEMICAL
group O
of O
the O
glycine B-CHEMICAL
substrate O
lower O
the O
reaction O
barrier, O
while O
hydrogen B-CHEMICAL
bonds O
to O
the O
carboxylate B-CHEMICAL
group O
raise O
the O
barrier. O
Water O
extract O
of O
licorice O
had O
anti-viral O
activity O
against O
human O
respiratory O
syncytial O
virus O
in O
human O
respiratory O
tract O
cell O
lines. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Licorice O

(Glycyrrhiza O
uralensis O
Fisch., O
Leguminosae) O
has O
been O
used O
in O
herbal O
medicine O
and O
food O
supplement O
worldwide O
for O
centuries. O
Licorice O
is O
a O
common O
ingredient O
of O
several O
prescriptions O
of O
traditional O
Chinese O
medicine O
which O
have O
been O
proved O
to O
inhibit O
infection O
of O
human O
respiratory O
syncytial O
virus O
(HRSV). O
There O
are O
two O
preparations O
of O
licorice, O
Radix O
Glycyrrhizae O
and O
Radix O
Glycyrrhizae O
Preparata. O
However, O
it O
is O
unknown O
whether O
licorice O
or O
which O
preparation O
of O
licorice O
is O
effective O
against O

HRSV, O
nor O
is O
its O
active O
constituent. O
AIM O
OF O
THE O
STUDY: O
We O
tested O
the O
hypothesis O
that O
Radix O
Glycyrrhizae O
can O
effectively O
decrease O
HRSV-induced O
plaque O
formation O
in O
respiratory O
mucosal O
cell O
lines. O
We O
also O
tried O
to O
find O
out O
the O
active O
constituent. O
MATERIALS O
AND O
METHODS: O
Anti-HRSV O
activities O
of O
hot O
water O
extracts O
of O
preparations O
of O
licorice, O
glycyrrhizin B-CHEMICAL
and O
18β-glycyrrhetinic B-CHEMICAL
acid I-CHEMICAL
(18β-GA), B-CHEMICAL
the O
active O
constituents O
of O
licorice, O
were O

examined O
by O
plaque O
reduction O
assay O
in O
both O
human O
upper O
(HEp-2) O
and O
low O
(A549) O
respiratory O
tract O
cell O
lines. O
Abilities O
of O
crude O
licorice O
to O
inhibit O
viral O
replication O
and O
to O
stimulate O
IFN-β B-GENE-Y
were O
evaluated O
by O
reverse O
transcription O
polymerase O
chain O
reaction O
(RT-PCR) O
and O
enzyme-linked O
immunosorbent O
assay O
(ELISA), O
respectively. O
RESULTS: O
Radix O
Glycyrrhizae O
and O
Radix O
Glycyrrhizae O
Preparata O
dose-dependently O
inhibited O

HRSV-induced O
plaque O
formation O
in O
both O
HEp-2 O
and O
A549 O
cell O
lines O
(p<0.0001). O
The O
effect O
of O
Radix O
Glycyrrhizae O
was O
better O
than O
that O
of O
Radix O
Glycyrrhizae O
Preparata O
on O
HEp-2 O
cells. O
However, O
there O
was O
no O
difference O
of O
their O
anti-HRSV O
effects O
on O
A549 O
cells. O
Besides, O
glycyrrhizin B-CHEMICAL
was O
ineffective O
at O
all. O
Nevertheless, O
18β-GA B-CHEMICAL
showed O
a O
potent O
anti-HRSV O
activity. O
Radix O

Glycyrrhizae O
was O
more O
effective O
when O
given O
before O
viral O
inoculation O
(p<0.0001) O
which O
may O
be O
due O
to O
its O
inhibition O
of O
viral O
attachment O
on O
(p<0.0001) O
and O
penetration O
(p<0.0001) O
into O
the O
host O
cells. O
The O
anti-HRSV O
activity O
of O
Radix O
Glycyrrhizae O
was O
further O
confirmed O
by O
RT-PCR O
and O
qRT-PCR. O
300μg/ml O
Radix O
Glycyrrhizae O
markedly O
decreased O
the O
viral O
amounts O
within O
the O
cells O
and O
in O
the O
suspension. O

Radix O
Glycyrrhizae O
might O
further O
stimulate O
mucosal O
cells O
to O
secrete O
IFN-β B-GENE-Y
to O
counteract O
viral O
infection. O
CONCLUSIONS: O
Both O
Radix O
Glycyrrhizae O
and O
Radix O
Glycyrrhizae O
Preparata O
are O
effective O
against O
HRSV O
infection O
on O
airway O
epithelial O
cells. O
Radix O
Glycyrrhizae O
inhibited O
HRSV O
mainly O
by O
preventing O
viral O
attachment, O
internalization, O
and O
by O
stimulating O
IFN B-GENE-N
secretion. O
18β-GA B-CHEMICAL
may O
be O
one O
of O
its O
active O
constituents. O

Parental O
exposure O
to O
natural O
mixtures O
of O
POPs O
reduced O
embryo O
production O
and O
altered O
gene O
transcription O
in O
zebrafish O
embryos. O
Determination O
of O
toxicity O
of O
complex O
mixtures O
has O
been O
proposed O
to O
be O
one O
of O
the O
most O
important O
challenges O
for O
modern O
toxicology. O
In O
this O
study O
we O
performed O
genome O
wide O
transcriptome O
profiling O
to O
assess O
potential O
toxicant O
induced O
changes O
in O
gene O
regulation O
in O
zebrafish O
embryos O
following O
parental O
exposure O
to O
two O
natural O
mixtures O
of O
persistent O
organic O
pollutants O
(POPs). O
The O
mixtures O
used O
were O
extracted O
from O
burbot O
(Lota O
lota) O
liver O
originating O

from O
two O
lakes O
(Lake O
Mjøsa O
and O
Lake O
Losna) O
belonging O
to O
the O
same O
freshwater O
system O
in O
Norway. O
The O
dominating O
groups O
of O
contaminants O
were O
polybrominated B-CHEMICAL
diphenyl I-CHEMICAL
ethers I-CHEMICAL
(PBDEs), B-CHEMICAL
polychlorinated B-CHEMICAL
biphenyls I-CHEMICAL
(PCBs) B-CHEMICAL
and O
dichlorodiphenyltrichloroethane B-CHEMICAL
metabolites O
(DDTs). O
Because O
both O
mixtures O
used O
in O
the O
present O
study O
induced O
similar O
effects, O
it O
is O
likely O
that O
the O
same O
toxicants O
are O
involved. O
The O
Mjøsa O
mixture O
contains O
high O
levels O
of O
PBDEs B-CHEMICAL
while O
this O
group O
of O

pollutants O
is O
low O
in O
the O
Losna O
mixture. O
However, O
both O
mixtures O
contain O
substantial O
concentrations O
of O
PCB B-CHEMICAL
and O
DDT B-CHEMICAL
suggesting O
these O
contaminants O
as O
the O
predominant O
contributors O
to O
the O
toxicity O
observed. O
The O
observed O
effects O
included O
phenotypic O
traits, O
like O
embryo O
production O
and O
survival, O
and O
gene O
transcription O
changes O
corresponding O
with O
disease O
and O
biological O
functions O
such O
as O
cancer, O
reproductive O
system O
disease, O
cardiovascular O
disease, O
lipid O
and O
protein O
metabolism, O
small O
molecule O
biochemistry O
and O
cell O
cycle. O
The O
changes O
in O
gene O
transcription O
included O
genes O
regulated O
by O
HNF4A, B-GENE-Y
insulin, B-GENE-Y
LH, B-GENE-N
FSH B-GENE-N
and O
NF-κB B-GENE-N
which O
are O
known O
to O
be O

central O
regulators O
of O
endocrine O
signaling, O
metabolism, O
metabolic O
homeostasis, O
immune O
functions, O
cancer O
development O
and O
reproduction. O
The O
results O
suggest O
that O
relative O
low O
concentrations O
of O
the O
natural O
mixtures O
of O
POPs O
used O
in O
the O
present O
study O
might O
pose O
a O
threat O
to O
wild O
freshwater O
fish O
living O
in O
the O
lakes O
from O
which O
the O
POPs O
mixtures O
originated. O
Complexities O
of O
androgen B-CHEMICAL
action. O
Androgens B-CHEMICAL
mediate O
a O
wide O
range O
of O
processes O
during O
embryogenesis O
and O
in O
the O
adult. O
In O
mammals, O
the O
principal O
androgens B-CHEMICAL
are O
testosterone B-CHEMICAL
and O
its O
5alpha-reduced O
metabolite, O

5alpha-dihydrotestosterone B-CHEMICAL
(DHT). B-CHEMICAL
Although O
these O
androgenic O
hormones O
are O
diverse O
in O
character, O
it O
is O
believed O
that O
their O
effects O
are O
mediated O
via O
the O
protein O
products O
of O
a O
single O
androgen B-GENE-Y
receptor I-GENE-Y
gene O
encoded O
on O
the O
X-chromosome. O
A O
great O
deal O
of O
information O
has O
now O
accumulated O
pertaining O
to O
the O
mechanisms O
by O
which O
nuclear B-GENE-N
receptors, I-GENE-N
such O
as O
the O
androgen B-GENE-Y
receptor, I-GENE-Y
modulate O
the O
activity O
of O
responsive O
genes. O
The O
studies O
have O
demonstrated O
the O
participation O
of O
a O
number O
of O
ancillary O
proteins O
in O
modulating O
activation O
or O
repression O
by O
nuclear B-GENE-N
receptors. I-GENE-N
In O
addition O
to O
studies O
focused O
on O
the O
mechanisms O
of O
nuclear B-GENE-N
receptor I-GENE-N

function, O
additional O
work O
has O
illuminated O
the O
mechanism O
by O
which O
androgens B-CHEMICAL
are O
metabolized O
in O
selected O
tissues. O
This O
information O
provides O
a O
perspective O
on O
the O
number O
of O
levels O
of O
complexity O
by O
which O
differential O
gene O
regulation O
by O
androgens B-CHEMICAL
may O
occur O
in O
different O
tissues O
and O
in O
different O
cell O
types. O
Combining O
QSAR O
classification O
models O
for O
predictive O
modeling O
of O
human B-GENE-N
monoamine I-GENE-N
oxidase I-GENE-N
inhibitors. O
Due O
to O
their O
role O
in O
the O
metabolism O
of O
monoamine O
neurotransmitters, O
MAO-A B-GENE-Y
and O
MAO-B B-GENE-Y
present O
a O
significant O
pharmacological O
interest. O
For O
instance O
the O
inhibitors O
of O
human B-GENE-Y
MAO-B I-GENE-Y
are O
considered O

useful O
tools O
for O
the O
treatment O
of O
Parkinson O
Disease. O
Therefore, O
the O
rational O
design O
and O
synthesis O
of O
new O
MAOs B-GENE-N
inhibitors O
is O
considered O
of O
great O
importance O
for O
the O
development O
of O
new O
and O
more O
effective O
treatments O
of O
Parkinson O
Disease. O
In O
this O
work, O
Quantitative O
Structure O
Activity O
Relationships O
(QSAR) O
has O
been O
developed O
to O
predict O
the O
human B-GENE-N
MAO I-GENE-N
inhibitory O
activity O
and O
selectivity. O
The O
first O
step O
was O
the O
selection O
of O
a O
suitable O
dataset O
of O
heterocyclic O
compounds O
that O
include O
chromones, B-CHEMICAL
coumarins, B-CHEMICAL
chalcones, B-CHEMICAL
thiazolylhydrazones, B-CHEMICAL
etc. O
These O
compounds O
were O
previously O
synthesized O
in O
one O

of O
our O
laboratories, O
or O
elsewhere, O
and O
their O
activities O
measured O
by O
the O
same O
assays O
and O
for O
the O
same O
laboratory O
staff. O
Applying O
linear O
discriminant O
analysis O
to O
data O
derived O
from O
a O
variety O
of O
molecular O
representations O
and O
feature O
selection O
algorithms, O
reliable O
QSAR O
models O
were O
built O
which O
could O
be O
used O
to O
predict O
for O
test O
compounds O
the O
inhibitory O
activity O
and O
selectivity O
toward O
human B-GENE-N
MAO. I-GENE-N
This O
work O
also O
showed O
how O
several O
QSAR O
models O
can O
be O
combined O
to O
make O
better O
predictions. O
The O
final O
models O
exhibit O
significant O
statistics, O
interpretability, O
as O
well O
as O
displaying O
predictive O
power O
on O
an O
external O
validation O
set O
made O
up O
of O
chromone O
derivatives O
with O
unknown O
activity O

(that O
are O
being O
reported O
here O
for O
first O
time) O
synthesized O
by O
our O
group, O
and O
coumarins B-CHEMICAL
recently O
reported O
in O
the O
literature. O
Dasatinib B-CHEMICAL
(BMS-354825) B-CHEMICAL
inhibits O
KITD816V, B-GENE-Y
an O
imatinib-resistant B-CHEMICAL
activating O
mutation O
that O
triggers O
neoplastic O
growth O
in O
most O
patients O
with O
systemic O
mastocytosis. O
Mastocytosis O
is O
associated O
with O
an O
activating O
mutation O
in O
the O
KIT B-GENE-Y
oncoprotein O
(KITD816V) B-GENE-Y
that O
results O
in O
autophosphorylation O
of O
the O
KIT B-GENE-Y
receptor O
in O
a O
ligand-independent O
manner. O

This O
mutation O
is O
inherently O
resistant O
to O
imatinib B-CHEMICAL
and, O
to O
date, O
there O
remains O
no O
effective O
curative O
therapy O
for O
systemic O
mastocytosis O
associated O
with O
KITD816V. B-GENE-Y
Dasatinib B-CHEMICAL
(BMS-354825) B-CHEMICAL
is O
a O
novel O
orally O
bioavailable O
SRC/ABL B-GENE-Y
inhibitor O
that O
has O
activity O
against O
multiple O
imatinib-resistant B-CHEMICAL
BCR-ABL B-GENE-Y
isoforms O
in O
vitro O
that O
is O
presently O
showing O
considerable O
promise O
in O
early-phase O
clinical O
trials O
of O
chronic O
myeloid O
leukemia O
(CML). O
Pharmacokinetic O
analysis O
suggests O
that O
high O
nanomolar O

concentrations O
of O
dasatinib B-CHEMICAL
can O
be O
achieved O
safely O
in O
humans. O
In O
this O
study, O
we O
demonstrate O
significant O
inhibitory O
activity O
of O
dasatinib B-CHEMICAL
against O
both O
wild-type O
KIT B-GENE-Y
and O
the O
KITD816V B-GENE-Y
mutation O
in O
the O
nanomolar O
range O
in O
in O
vitro O
and O
cell-based O
kinase B-GENE-N
assays. O
Additionally, O
dasatinib B-CHEMICAL
leads O
to O
growth O
inhibition O
of O
a O
KITD816V-harboring B-GENE-Y
human O
masto-cytosis O
cell O
line. O
Significantly, O
dasatinib B-CHEMICAL
selectively O
kills O
primary O
neoplastic O
bone O
marrow O
mast O
cells O
from O
patients O
with O
systemic O
mastocytosis O
while O

sparing O
other O
hematopoietic O
cells. O
Computer O
modeling O
suggests O
that O
the O
KITD816V B-GENE-Y
mutation O
destabilizes O
the O
inactive O
conformation O
of O
the O
KIT B-GENE-N
activation I-GENE-N
loop I-GENE-N
to O
which O
imatinib B-CHEMICAL
binds, O
but O
it O
is O
not O
predicted O
to O
impair O
binding O
of O
KIT B-GENE-Y
by O
dasatinib. B-CHEMICAL
Based O
upon O
our O
results, O
further O
evaluation O
of O
dasatinib B-CHEMICAL
for O
the O
treatment O
of O
systemic O
masto-cytosis O
in O
clinical O
trials O
is O
warranted. O
Moreover, O
dasatinib B-CHEMICAL
may O
be O
of O
clinical O
utility O
in O
other O
disease O
settings O
driven O
by O
activating O
KIT B-GENE-Y
mutations. O
A O
water-alcohol B-CHEMICAL
extract O
of O
Citrus O
grandis O
whole O

fruits O
has O
beneficial O
metabolic O
effects O
in O
the O
obese O
Zucker O
rats O
fed O
with O
high O
fat/high O
cholesterol B-CHEMICAL
diet. O
Epidemiological O
studies O
suggest O
that O
citrus O
fruits O
and O
compounds O
such O
as O
flavonoids, B-CHEMICAL
limonoids O
and O
pectins O
have O
health O
promoting O
effects. O
Our O
aim O
was O
to O
study O
the O
effects O
of O
Citrus O
grandis O
(L.) O
Osbeck O
var. O
tomentosa O
hort. O
fruit O
extract O
on O
the O
energy O
metabolism. O
A O
whole O
fruit O
powder O
from O
dry O
water O
and O
alcohol B-CHEMICAL
extracts O
of O
C. O
grandis O
containing O
19% O
naringin B-CHEMICAL
flavonoid O
was O
prepared. O
The O
effects O
of O
the O

citrus O
extract O
were O
followed O
in O
the O
obese O
Zucker O
rats O
fed O
with O
the O
HFD. O
The O
circulatory O
levels O
of O
GLP-1 B-GENE-Y
decreased O
significantly O
by O
the O
extract O
in O
comparison O
to O
the O
HFD O
group, O
whereas O
the O
decreased O
ghrelin B-GENE-Y
levels O
were O
reversed. O
The O
levels O
of O
PYY B-GENE-Y
were O
decreased O
in O
all O
HFD O
groups. O
The O
leptin B-GENE-Y
amounts O
decreased O
but O
not O
significantly O
whereas O
insulin B-GENE-N
and O
amylin B-GENE-Y
were O
unchanged. O
The O
cholesterol B-CHEMICAL
and O
glucose B-CHEMICAL
levels O
were O
somewhat O
but O
not O
systematically O
improved O
in O
the O
HFD O
fed O
rats. O
Further O
studies O
are O
needed O
to O
identify O
the O
active O
compounds O
and O
their O
mechanisms. O

Dopamine B-GENE-Y
D(2) I-GENE-Y
receptor-induced I-GENE-Y
COX-2-mediated B-GENE-Y
production O
of O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
in O
D(2)-transfected B-GENE-Y
Chinese O
hamster O
ovary O
cells O
without O
simultaneous O
administration O
of O
a O
Ca(2+)-mobilizing B-CHEMICAL
agent. O
We O
have O
earlier O
demonstrated O
that O
dopamine O
stimulates O
the O
liberation O
of O
the O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
(PGE(2)) B-CHEMICAL
precursor, O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
in O
Chinese O
hamster O
ovary O
cells O
transfected O
with O
the O
rat B-GENE-Y
dopamine I-GENE-Y
D(2) I-GENE-Y
receptor I-GENE-Y
(long I-GENE-Y
isoform), I-GENE-Y

also O
without O
concomitant O
administration O
of O
a O
Ca(2+)-releasing B-CHEMICAL
agent O
[Nilsson O
et O
al., O
Br O
J O
Pharmacol O
1998;124:1651-8]. O
In O
the O
present O
report, O
we O
show O
that O
dopamine, B-CHEMICAL
under O
the O
same O
conditions, O
also O
induces O
a O
concentration-dependent O
increase O
in O
the O
production O
of O
PGE(2), B-CHEMICAL
with O
a O
maximal O
effect O
of O
235% O
at O
approximately O
100 O
microM, O
and O
with O
an O
EC(50) O
of O
794 O
nM. O
The O
effect O
was O
counteracted O
by O
the O
D(2) B-GENE-Y
antagonist O
eticlopride, B-CHEMICAL
pertussis B-GENE-N

toxin, I-GENE-N
the O
inhibitor O
of O
intracellular O
Ca(2+) B-CHEMICAL
release O
TMB-8, O
incubation O
in O
Ca(2+)-free B-CHEMICAL
experimental O
medium, O
and O
PKC B-GENE-N
desensitization O
obtained O
by O
chronic O
pretreatment O
with O
the O
phorbol O
ester O
TPA. O
It O
was O
also O
antagonized O
by O
the O
non-specific O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
inhibitor, O
indomethacin, B-CHEMICAL
and O
by O
the O
selective O
COX-2 B-GENE-Y
inhibitor, O
NS-398, B-CHEMICAL
but O
not O
by O
the O
specific O
COX-1 B-GENE-Y
inhibitor, O
valeryl B-CHEMICAL

salicylate. I-CHEMICAL
Both O
the O
non-specific O
phospholipase B-GENE-Y
A(2) I-GENE-Y
inhibitor, O
quinacrine, B-CHEMICAL
and O
an O
inhibitor O
of O
cPLA(2) B-GENE-Y
and O
iPLA(2), B-GENE-Y
AACOF3, O
counteracted O
the O
effect; O
in O
contrast, O
a O
selective O
iPLA(2) B-GENE-Y
inhibitor, O
BEL, O
and O
a O
selective O
sPLA(2) B-GENE-N
inhibitor, O
TAPC, O
were O
ineffective. O
No O
effects O
of O
dopamine B-CHEMICAL
were O
obtained O
in O
control O
cells O
mock-transfected O
with O
the O
p3C O
vector O
only. O
The O
results O
reinforce O
previous O
assumptions O
that O
dopamine B-CHEMICAL
may O
interact O
with O

eicosanoid B-CHEMICAL
metabolism O
by O
means O
of O
D(2) B-GENE-Y
receptor I-GENE-Y
activation, O
and O
implicate O
an O
involvement O
of O
cPLA(2) B-GENE-Y
and O
COX-2 B-GENE-Y
in O
this O
effect. O
It O
is O
suggested O
that O
measurement O
of O
dopamine-induced B-CHEMICAL
PGE(2) O
production O
may O
serve O
as O
a O
convenient O
way O
to O
study O
D(2) B-GENE-Y
receptor I-GENE-Y
function O
in O
vitro. O
A O
high O
throughput O
assay O
for O
the O
glucuronidation O
of O
7-hydroxy-4-trifluoromethylcoumarin B-CHEMICAL
by O
recombinant O
human B-GENE-N
UDP-glucuronosyltransferases I-GENE-N
and O

liver O
microsomes. O
Abstract O
1. O
UDP-glucuronosyltransferases B-GENE-N
(UGTs) B-GENE-N
are O
versatile O
and O
important O
conjugation O
enzymes O
in O
the O
metabolism O
of O
drugs O
and O
other O
xenobiotics. O
2. O
We O
have O
developed O
a O
convenient O
quantitative O
multi-well O
plate O
assay O
to O
measure O
the O
glucuronidation O
rate O
of O
7-hydroxy-4-trifluoromethylcoumarin B-CHEMICAL
(HFC) B-CHEMICAL
for O
several O
UGTs. B-GENE-N
3. O
We O
have O
used O
this O
method O
to O
screen O
11 O
recombinant O
human B-GENE-N
UGTs B-GENE-N
for I-GENE-N
HFC O

glucuronidation B-CHEMICAL
activity O
and O
studied O
the O
reaction O
kinetics O
with O
the O
most O
active O
enzymes. O
We O
have O
also O
examined O
the O
HFC O
glucuronidation B-CHEMICAL
activity O
of O
liver O
microsomes O
from O
human, O
pig, O
rabbit O
and O
rat. O
4. O
At O
a O
substrate O
concentration O
of O
20 O
µM, O
the O
most O
active O
HFC O
glucuronidation B-CHEMICAL
catalysts O
were O
UGT1A10 B-GENE-Y
followed B-GENE-Y
by O
UGT1A6 B-GENE-Y
>UGT1A7 B-GENE-Y
>UGT2A1, B-GENE-Y
whereas B-GENE-Y
at O
300 O
µM O
UGT1A6 B-GENE-Y
was B-GENE-Y
about O
10 O
times O
better O
catalyst O
than O
the O
other O
recombinant O

UGTs. B-GENE-N
The B-GENE-N
activities O
of O
UGTs O
1A3, B-GENE-N
1A8, I-GENE-N
1A9, I-GENE-N
2B4 I-GENE-N
and I-GENE-N
2B7 I-GENE-N
were I-GENE-N
low, O
whereas O
UGT1A1 B-GENE-Y
and B-GENE-Y
UGT2B17 B-GENE-Y
exhibited B-GENE-Y
no O
HFC O
glucuronidation B-CHEMICAL
activity. O
UGT1A6 B-GENE-Y
exhibited B-GENE-Y
a O
significantly O
higher O
Vmax O
and O
Km O
values O
toward O
both O
HFC O
and B-CHEMICAL
UDP-glucuronic B-CHEMICAL
acid B-CHEMICAL
than I-CHEMICAL
the O
other O
UGTs. B-GENE-N
5. B-GENE-N
Human, O
pig O
and O
rabbit, O
but O
not O
rat O
liver O
microsomes, O
catalyzed O
HFC O
glucuronidation B-CHEMICAL
at O
high O
rates. O

6. O
This O
new O
method O
is O
particularly O
suitable O
for O
fast O
activity O
screenings O
of O
UGTs O
1A6, B-GENE-N
1A7, I-GENE-N
1A10 I-GENE-N
and I-GENE-N
2A1 I-GENE-N
and I-GENE-N
HFC I-GENE-N
glucuronidation B-CHEMICAL
activity O
determination O
from O
various O
samples. O
Influence O
of O
the O
novel O
histamine B-GENE-Y
H3 I-GENE-Y
receptor I-GENE-Y
antagonist O
ST1283 O
on O
voluntary O
alcohol B-CHEMICAL
consumption O
and O
ethanol-induced B-CHEMICAL
place O
preference O
in O
mice. O
RATIONALE: O
Growing O
evidence O
supports O
a O
role O
for O
the O
central O
histaminergic O
system O
to O
have O
a O
modulatory O
influence O
on O
drug O
addiction O
in O
general O
and O
alcohol-use B-CHEMICAL
disorders O
in O
particular O
through O
histamine B-GENE-Y
H3 I-GENE-Y
receptors I-GENE-Y
(H3R). B-GENE-Y

OBJECTIVE: O
In O
the O
present O
study, O
the O
effects O
of O
systemic O
injection O
of O
the O
newly O
synthesized O
H3R B-GENE-Y
antagonist O
ST1283 O
on O
ethanol B-CHEMICAL
(EtOH) B-CHEMICAL
voluntary O
intake O
and O
EtOH-conditioned B-CHEMICAL
reward O
in O
mice O
have O
been O
investigated. O
METHODS: O
Oral O
EtOH, B-CHEMICAL
saccharin, B-CHEMICAL
and O
quinine B-CHEMICAL
intake O
was O
assessed O
in O
a O
two-bottle O
choice O
paradigm O
using O
escalating O
concentrations O
of O
alcohol B-CHEMICAL
or O
tastant O
solutions. O
EtOH-induced B-CHEMICAL
place O
preference O
(CPP), O
EtOH-induced B-CHEMICAL
locomotor O
activity, O
and O
blood O
ethanol B-CHEMICAL
concentration O
(BEC) O
were O
also O

measured. O
RESULTS: O
Following O
administration O
of O
the O
H3R B-GENE-Y
antagonist O
(2.5, O
5, O
and O
10 O
mg/kg, O
i.p.), O
there O
was O
a O
significant O
dose-dependent O
decrease O
in O
alcohol B-CHEMICAL
consumption O
and O
preference. O
Importantly, O
vehicle- O
and O
ST1283 O
(5 O
mg/kg)-treated O
mice O
showed O
similar O
consumption O
and O
preference O
to O
increasing O
concentration O
of O
both O
sweet O
and O
bitter O
tastes. O
More O
interestingly, O
systemic O
administration O
of O
ST1283 O
inhibited O
EtOH-CPP B-CHEMICAL
and O
EtOH-enhanced B-CHEMICAL
locomotion. O
This O
inhibition O
was O
blocked O
when O
mice O
were O
pretreated O
with O
the O

selective O
H3R B-GENE-Y
agonist O
R-(alpha)-methyl-histamine B-CHEMICAL
(10 O
mg/kg). O
Finally, O
vehicle- O
and O
ST1283-treated O
mice O
had O
similar O
BECs. O
CONCLUSION: O
Our O
results O
show O
that O
ST1283 O
may O
decrease O
voluntary O
EtOH B-CHEMICAL
consumption O
and O
EtOH-CPP B-CHEMICAL
by O
altering O
its O
reinforcing O
effects, O
suggesting O
a O
novel O
role O
for O
histamine B-CHEMICAL
signaling O
in O
regulation O
of O
alcoholism. O
Lastly, O
the O
results O
add O
to O
the O
growing O
literature O
on O
H3R B-GENE-Y
modulation O
in O
the O
pharmacotherapy O
of O
EtOH B-CHEMICAL
addiction. O
The O

tricyclic B-CHEMICAL
antidepressant O
clomipramine B-CHEMICAL
increases O
plasma O
glucose B-CHEMICAL
levels O
of O
mice. O
Effects O
of O
the O
tricyclic B-CHEMICAL
antidepressant O
clomipramine B-CHEMICAL
on O
plasma O
glucose B-CHEMICAL
levels O
in O
mice O
were O
studied. O
Clomipramine B-CHEMICAL
at O
doses O
ranging O
5 O
- O
20 O
mg/kg O
elicited O
significant O
hyperglycemia O
in O
mice. O
Hyperglycemia O
elicited O
by O
clomipramine B-CHEMICAL
was O
not O
reduced O
by O
pretreatment O
with O
the O
5-hydroxytryptamine B-CHEMICAL
(5-HT) B-CHEMICAL
depleter O
p-chlorophenylalanine. B-CHEMICAL
The O

5-HT(1/2/5/7)-receptor B-GENE-N
antagonist O
methysergide O
and O
the O
5-HT(2A/2B/2C)-receptor B-GENE-N
antagonist O
LY B-CHEMICAL
53857 I-CHEMICAL
enhanced O
clomipramine-induced B-CHEMICAL
hyperglycemia, O
while O
the O
5-HT(1A/1B)-receptor B-GENE-N
antagonist O
(-)-propranolol B-CHEMICAL
and O
the O
5-HT(3/4)-receptor B-GENE-N
antagonist O
tropisetron B-CHEMICAL
did O
not O
affect O
it. O
The O
5-HT(2B/2C)-receptor B-GENE-N
antagonist O
SB B-CHEMICAL
206553 I-CHEMICAL

facilitated O
hyperglycemia O
induced O
by O
clomipramine, B-CHEMICAL
although O
the O
5-HT(2A)-receptor B-GENE-Y
antagonist O
ketanserin B-CHEMICAL
was O
without O
effect. O
Clomipramine-induced B-CHEMICAL
hyperglycemia O
was O
reduced O
by O
prior O
adrenalectomy. O
These O
results O
suggest O
that O
clomipramine B-CHEMICAL
induces O
hyperglycemia O
in O
mice O
by O
blocking O
the O
5-HT(2B B-GENE-Y
)and/or I-GENE-Y
5-HT(2C) B-GENE-Y
receptors, O
which O
results O
in O
facilitation O
of O
adrenaline B-CHEMICAL
release. O
p300-mediated B-GENE-Y
acetylation O
of O
TRF2 B-GENE-Y
is O
required O
for O
maintaining O

functional O
telomeres. O
The O
human B-GENE-Y
telomeric I-GENE-Y
protein I-GENE-Y
TRF2 I-GENE-Y
is O
required O
to O
protect O
chromosome O
ends O
by O
facilitating O
their O
organization O
into O
the O
protective O
capping O
structure. O
Post-translational O
modifications O
of O
TRF2 B-GENE-Y
such O
as O
phosphorylation, O
ubiquitination, O
SUMOylation, O
methylation O
and O
poly(ADP-ribosyl)ation B-CHEMICAL
have O
been O
shown O
to O
play O
important O
roles O
in O
telomere O
function. O
Here O
we O
show O
that O
TRF2 B-GENE-Y
specifically O
interacts O
with O
the O
histone B-GENE-Y
acetyltransferase I-GENE-Y
p300, I-GENE-Y
and O
that O
p300 B-GENE-Y

acetylates O
the O
lysine B-CHEMICAL
residue O
at O
position O
293 O
of O
TRF2. B-GENE-Y
We O
also O
report O
that O
p300-mediated B-GENE-Y
acetylation O
stabilizes O
the O
TRF2 B-GENE-Y
protein O
by O
inhibiting O
its O
ubiquitin-dependent B-GENE-N
proteolysis O
and O
is O
required O
for O
efficient O
telomere O
binding O
of O
TRF2. B-GENE-Y
Furthermore, O
overexpression O
of O
the O
acetylation-deficient O
mutant, O
K293R, B-GENE-N
induces O
DNA-damage O
response O
foci O
at O
telomeres, O
thereby O
leading O
to O
induction O
of O
impaired O
cell O
growth, O
cellular O
senescence O
and O
altered O
cell O
cycle O
distribution. O
A O
small O

but O
significant O
number O
of O
metaphase O
chromosomes O
show O
no O
telomeric O
signals O
at O
chromatid O
ends, O
suggesting O
an O
aberrant O
telomere O
structure. O
These O
findings O
demonstrate O
that O
acetylation O
of O
TRF2 B-GENE-Y
by O
p300 B-GENE-Y
plays O
a O
crucial O
role O
in O
the O
maintenance O
of O
functional O
telomeres O
as O
well O
as O
in O
the O
regulation O
of O
the O
telomere-associated O
DNA-damage O
response, O
thus O
providing O
a O
new O
route O
for O
modulating O
telomere O
protection O
function. O
Externalization O
of O
phosphatidylserine B-CHEMICAL
during O
apoptosis O
does O
not O
specifically O
require O
either O
isoform O
of O

phosphatidylserine B-GENE-N
synthase. I-GENE-N
Phosphatidylserine B-CHEMICAL
(PtdSer) B-CHEMICAL
is O
made O
in O
mammalian O
cells O
by O
two O
PtdSer B-GENE-N
synthases, I-GENE-N
PSS1 B-GENE-N
and O
PSS2. B-GENE-N
In O
the O
plasma O
membrane O
PtdSer B-CHEMICAL
is O
normally O
localized O
on O
the O
inner O
leaflet O
but O
undergoes O
transbilayer O
movement O
during O
apoptosis O
and O
becomes O
exposed O
on O
the O
cell O
surface. O
We O
induced O
apoptosis O
with O
staurosporine B-CHEMICAL
in O
four O
Chinese O
hamster O
ovary O
(CHO) O
cell O
lines O
that O
are O
deficient O
in O
PSS1 B-GENE-Y

and/or O
PSS2 B-GENE-Y
to O
determine O
if O
PtdSer B-CHEMICAL
generated O
by O
either O
of O
these O
enzymes O
is O
required O
for O
externalization O
on O
the O
cell O
surface O
during O
apoptosis. O
The O
onset O
of O
apoptosis O
was O
confirmed O
by O
the O
appearance O
of O
morphological O
changes O
and O
DNA O
fragmentation O
while O
the O
plasma O
membrane O
remained O
largely O
intact. O
In O
all O
cell O
lines, O
regardless O
of O
their O
content O
of O
PSS1 B-GENE-Y
and/or O
PSS2, B-GENE-Y
apoptosis O
occurred O
to O
approximately O
the O
same O
extent, O
and O
within O
approximately O
the O
same O
time O
frame, O
as O
in O
parental O
CHO-K1 O
cells. O
The O
exposure O
of O
PtdSer B-CHEMICAL
on O
the O
cell O
surface O
was O
assessed O
by O

annexin O
V O
labeling O
and O
flow O
cytometry. O
Cells O
that O
were O
deficient O
in O
either O
PSS1 B-GENE-Y
or O
PSS2, B-GENE-Y
as O
well O
as O
cells O
that O
were O
deficient O
in O
both O
PSS1 B-GENE-Y
and O
PSS2, B-GENE-Y
externalized O
normal O
amounts O
of O
PtdSer. B-CHEMICAL
Our O
study O
demonstrates, O
that O
reduction O
of O
in O
vitro O
serine-exchange B-CHEMICAL
activity, O
even O
by O
97%, O
does O
not O
restrict O
the O
externalization O
of O
PtdSer B-CHEMICAL
during O
apoptosis. O
Moreover, O
a O
normal O
level O
of O
expression O
of O
PSS1 B-GENE-Y
and/or O
PSS2 B-GENE-Y
is O
not O
required O
for O
generating O
the O
pool O
of O

PtdSer B-CHEMICAL
externalized O
during O
apoptosis. O
Characterization O
of O
the O
interaction O
of O
ingenol B-CHEMICAL
3-angelate I-CHEMICAL
with O
protein B-GENE-N
kinase I-GENE-N
C. I-GENE-N
Ingenol B-CHEMICAL
3-angelate I-CHEMICAL
(I3A) B-CHEMICAL
is O
one O
of O
the O
active O
ingredients O
in O
Euphorbia O
peplus, O
which O
has O
been O
used O
in O
traditional O
medicine. O
Here, O
we O
report O
the O
initial O
characterization O
of O
I3A B-CHEMICAL
as O
a O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
ligand. O
I3A B-CHEMICAL
bound O
to O
PKC-alpha B-GENE-Y
in O
the O
presence O
of O
phosphatidylserine B-CHEMICAL
with O
high O
affinity; O
however, O
under O
these O
assay O
conditions, O
little O

PKC B-GENE-N
isoform O
selectivity O
was O
observed. O
PKC B-GENE-N
isoforms O
did O
show O
different O
sensitivity O
and O
selectivity O
for O
down-regulation O
by O
I3A B-CHEMICAL
and O
phorbol B-CHEMICAL
12-myristate I-CHEMICAL
13-acetate I-CHEMICAL
(PMA) B-CHEMICAL
in O
WEHI-231, O
HOP-92, O
and O
Colo-205 O
cells. O
In O
all O
of O
the O
three O
cell O
types, O
I3A B-CHEMICAL
inhibited O
cell O
proliferation O
with O
somewhat O
lower O
potency O
than O
did O
PMA. B-CHEMICAL
In O
intact O
CHO-K1 O
cells, O
I3A B-CHEMICAL
was O
able O
to O
translocate O
different O
green B-GENE-Y
fluorescent I-GENE-Y
protein-tagged I-GENE-Y
PKC B-GENE-N

isoforms, O
visualized O
by O
confocal O
microscopy, O
with O
equal O
or O
higher O
potency O
than O
PMA. B-CHEMICAL
PKC-delta B-GENE-Y
in O
particular O
showed O
a O
different O
pattern O
of O
translocation O
in O
response O
to O
I3A B-CHEMICAL
and O
PMA. B-CHEMICAL
I3A B-CHEMICAL
induced O
a O
higher O
level O
of O
secretion O
of O
the O
inflammatory O
cytokine B-GENE-N
interleukin B-GENE-Y
6 I-GENE-Y
compared O
with O
PMA B-CHEMICAL
in O
the O
WEHI-231 O
cells O
and O
displayed O
a O
marked O
biphasic O
dose-response O
curve O
for O
the O
induction. O
I3A B-CHEMICAL
was O
unable O
to O
cause O
the O
same O
extent O
of O
association O
of O
the O
C1b B-GENE-N
domain I-GENE-N
of O
PKC-delta B-GENE-Y
with O

lipids, O
compared O
with O
PMA B-CHEMICAL
or O
the O
physiological O
regulator O
diacylglycerol, B-CHEMICAL
and O
was O
able O
to O
partially O
block O
the O
association O
induced O
by O
these O
agents, O
measured O
by O
surface O
plasmon O
resonance. O
The O
in O
vitro O
kinase O
activity O
of O
PKC-alpha B-GENE-Y
induced O
by O
I3A B-CHEMICAL
was O
lower O
than O
that O
induced O
by O
PMA. B-CHEMICAL
The O
novel O
pattern O
of O
behavior O
of O
I3A B-CHEMICAL
makes O
it O
of O
great O
interest O
for O
further O
evaluation. O
In O
ovo O
effects O
of O
two O
organophosphate B-CHEMICAL
flame O
retardants, O
TCPP B-CHEMICAL
and O
TDCPP, B-CHEMICAL
on O
pipping O
success, O
development, O
mRNA O
expression O
and O
thyroid O
hormone O
levels O
in O
chicken O

embryos. O
Tris(1-chloro-2-propyl) B-CHEMICAL
phosphate I-CHEMICAL
(TCPP) B-CHEMICAL
and O
tris(1,3-dichloro-2-propyl) B-CHEMICAL
phosphate I-CHEMICAL
(TDCPP) B-CHEMICAL
are O
organic O
flame O
retardants O
detected O
in O
the O
environment O
and O
biota O
for O
which O
toxicological O
data O
for O
avian O
species O
are O
limited. O
In O
this O
study, O
domestic O
chicken O
eggs O
were O
injected O
with O
TCPP B-CHEMICAL
or O
TDCPP B-CHEMICAL
(maximum O
dose O
= O
51600 O
and O
45000 O
ng/g O
egg, O
respectively) O
to O
determine O
dose-dependent O
effects O
on O
pipping O
success, O
development, O
hepatic O

messenger O
RNA O
(mRNA) O
expression O
levels O
of O
genes O
associated O
with O
xenobiotic O
metabolism O
and O
the O
thyroid O
hormone O
(TH) O
pathway, O
and O
TH O
levels O
following O
20-22 O
days O
of O
incubation. O
Neither O
compound O
reduced O
pipping O
success; O
however, O
TCPP B-CHEMICAL
significantly O
delayed O
pipping O
at O
9240 O
and O
51600 O
ng/g O
and O
reduced O
tarsus O
length O
at O
51600 O
ng/g. O
TDCPP B-CHEMICAL
exposure O
resulted O
in O
significant O
decreases O
in O
head O
plus O
bill O
length, O
embryo O
mass O
and O
gallbladder O
size O
at O
45000 O
ng/g O
and O
reduced O
plasma O
free O
T4 O
levels O
at O
7640 O

ng/g. O
Type B-GENE-Y
I I-GENE-Y
deiodinase, I-GENE-Y
liver B-GENE-Y
fatty-acid I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
and O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
3A37 I-GENE-Y
mRNA O
levels O
were O
significantly O
induced O
by O
TCPP, B-CHEMICAL
while O
TDCPP B-CHEMICAL
induced O
CYP3A37 B-GENE-Y
and O
CYP2H1. B-GENE-Y
Chemical O
analysis O
of O
egg O
contents O
at O
incubation O
days O
0, O
5, O
11, O
18, O
and O
19 O
revealed O
that O
>92% O
of O
the O
injected O
TCPP B-CHEMICAL
or O
TDCPP B-CHEMICAL
concentration O
was O
detectable O
up O
to O
day O
5; O
however, O
<1% O
was O
detected O
by O
day O
19. O
The O
observed O
phenotypic O
responses O
to O
TCPP B-CHEMICAL
and O

TDCPP B-CHEMICAL
exposure O
may O
be O
associated O
with O
disruption O
of O
the O
TH-axis, O
which O
is O
critical O
for O
normal O
growth O
and O
development O
in O
birds. O
The O
effects O
of O
TDCPP B-CHEMICAL
on O
the O
gallbladder O
indicate O
that O
the O
disturbance O
of O
lipid O
metabolism O
is O
a O
likely O
target O
in O
its O
mechanism O
of O
toxicity. O
Insulin-degrading B-GENE-Y
enzyme I-GENE-Y
(IDE): B-GENE-Y
a O
novel O
heat B-GENE-N
shock-like I-GENE-N
protein. I-GENE-N
Insulin-degrading B-GENE-Y
enzyme I-GENE-Y
(IDE) B-GENE-Y
is O
a O
highly O
conserved O
zinc B-GENE-N
metallopeptidase I-GENE-N
that O
is O
ubiquitously O
distributed O
in O
human O
tissues, O
and O
particularly O
abundant O
in O
the O
brain, O
liver, O
and O
muscles. O
IDE B-GENE-Y
activity O
has O

been O
historically O
associated O
with O
insulin B-GENE-Y
and O
β-amyloid B-GENE-Y
catabolism. O
However, O
over O
the O
last O
decade, O
several O
experimental O
findings O
have O
established O
that O
IDE B-GENE-Y
is O
also O
involved O
in O
a O
wide O
variety O
of O
physiopathological O
processes, O
including O
ubiquitin B-GENE-N
clearance O
and O
Varicella O
Zoster O
Virus O
infection. O
In O
this O
study, O
we O
demonstrate O
that O
normal O
and O
malignant O
cells O
exposed O
to O
different O
stresses O
markedly O
up-regulate O
IDE B-GENE-Y
in O
a O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
(HSP)-like B-GENE-N
fashion. O
Additionally, O
we O
focused O
our O
attention O
on O
tumor O
cells O
and O
report O
that O
(i) O
IDE B-GENE-Y
is O
overexpressed O
in O
vivo O

in O
tumors O
of O
the O
central O
nervous O
system O
(CNS); O
(ii) O
IDE-silencing B-GENE-Y
inhibits O
neuroblastoma O
(SHSY5Y) O
cell O
proliferation O
and O
triggers O
cell O
death; O
(iii) O
IDE B-GENE-Y
inhibition O
is O
accompanied O
by O
a O
decrease O
of O
the O
poly-ubiquitinated O
protein O
content O
and O
co-immunoprecipitates O
with O
proteasome O
and O
ubiquitin O
in O
SHSY5Y O
cells. O
In O
this O
work, O
we O
propose O
a O
novel O
role O
for O
IDE B-GENE-Y
as O
a O
heat B-GENE-N
shock I-GENE-N
protein I-GENE-N
with O
implications O
in O
cell O
growth O
regulation O
and O
cancer O
progression, O
thus O
opening O

up O
an O
intriguing O
hypothesis O
of O
IDE B-GENE-Y
as O
an O
anticancer O
target. O
Development O
of O
a O
cell-based O
high-throughput O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptors I-GENE-N
(PPARs) B-GENE-N
screening O
model O
and O
its O
application O
for O
evaluation O
of O
the O
extracts O
from O
Rhizoma O
Coptis. O
To O
date, O
peroxisome B-GENE-N
proliferator-activated I-GENE-N
receptors I-GENE-N
(PPARs) B-GENE-N
are O
becoming O
the O
new O
therapeutic O
targets O
for O
the O
treatment O
of O
metabolic O
diseases, O
such O
as O
Type O
2 O
diabetes, O
obesity, O
and O
cardiovascular O
disease. O
In O
this O
study, O
a O
cell-based O
high-throughput O
PPARs B-GENE-N

(PPARα/β/γ) B-GENE-N
model O
was O
developed O
for O
the O
screening O
of O
PPARs B-GENE-N
agonists. O
The O
screening O
conditions O
were O
evaluated O
through O
analyzing O
the O
expression O
value O
of O
luciferase. O
Finally, O
24 O
h O
of O
drug O
acting O
time, O
5 O
times O
of O
the O
dilution O
factor O
of O
luciferase O
zymolyte, O
and O
about O
2 O
× O
10(4) O
cells/ O
well O
on O
HeLa O
cells O
in O
96-well O
plates O
were O
used, O
respectively. O
Furthermore, O
the O
quality O
of O
high-throughput O
screening O
(HTS) O
in O
stability O
and O
reliability O
was O
evaluated O
by O
the O
Z'-factor. O
Additionally, O
different O
extracts O
of O

Rhizoma O
Coptis O
and O
berberine B-CHEMICAL
were O
tested O
by O
the O
developed O
method. O
The O
results O
suggested O
that O
both O
the O
EtOAc B-CHEMICAL
extract O
and O
berberine B-CHEMICAL
were O
able O
to O
activate O
PPARα/β/γ, B-GENE-N
and O
Rhizoma O
Coptis O
contains O
potential O
natural O
agonists O
of O
PPARs B-GENE-N
besides O
berberine. B-CHEMICAL
In O
conclusion, O
the O
developed O
HTS O
assay O
is O
a O
simple, O
rapid, O
stable, O
and O
specific O
method O
for O
the O
screening O
of O
PPARs B-GENE-N
natural O
agonists. O
Synthesis O
of O

2-aminomethyl-4-phenyl-1-azabicyclo[2.2.1]heptanes B-CHEMICAL
via O
LiAlH₄-induced B-CHEMICAL
reductive O
cyclization O
of O
2-(4-chloro-2-cyano-2-phenylbutyl)aziridines B-CHEMICAL
and O
evaluation O
of O
their O
antimalarial O
activity. O
2-(4-Chloro-2-cyano-2-phenylbutyl)aziridines B-CHEMICAL
were O
employed O
for O
the O
one-step O
stereoselective O
construction O
of O
both O

endo- B-CHEMICAL
and I-CHEMICAL
exo-2-aminomethyl-4-phenyl-1-azabicyclo[2.2.1]heptanes I-CHEMICAL
as O
new O
azaheterobicyclic B-CHEMICAL
scaffolds O
via O
a O
double O
LiAlH(4)-induced B-CHEMICAL
reductive O
cyclization O
protocol. O
Antiplasmodial O
assessment O
of O
these O
1-azabicyclo[2.2.1]heptanes B-CHEMICAL
revealed O
moderate O
to O
good O
activities O
in O
the O
micromolar O
range, O
with O
the O
exo-isomers O
being O
the O
most O
promising O
structures. O
Furthermore, O
the O

proposed O
mode O
of O
action O
was O
supported O
by O
ligand O
docking O
studies, O
pointing O
to O
a O
strong O
binding O
interaction O
with O
the O
enzyme O
plasmepsin B-GENE-Y
II. I-GENE-Y
Pretreatment O
renal O
vascular O
tone O
predicts O
the O
effect O
of O
specific O
renin B-GENE-Y
inhibition O
on O
natriuresis O
in O
essential O
hypertension. O
BACKGROUND: O
In O
essential O
hypertension O
an O
elevated O
renal O
vascular O
resistance O
(RVR) O
may O
be O
a O
marker O
of O
renin-angiotensin-aldosterone B-GENE-Y
system-mediated O
impairment O
of O
renal O
sodium B-CHEMICAL
excretion. O
This O
hypothesis O
was O
tested O
by O
investigating O
whether, O
in O
subjects O
with O

essential O
hypertension, O
the O
natriuretic O
response O
to O
specific O
renin-angiotensin-aldosterone B-GENE-Y
system O
(RAAS) O
blockade O
by O
renin-inhibitor B-GENE-Y
remikiren B-CHEMICAL
could O
be O
predicted O
from O
pretreatment O
renal O
vascular O
tone. O
MATERIALS O
AND O
METHODS: O
Renal O
hemodynamics, O
and O
the O
effects O
of O
single O
(n O
= O
17) O
and O
multiple O
doses O
(n O
= O
8, O
8 O
days) O
of O
remikiren B-CHEMICAL
(600 O
mg O
day-1) O
on O
sodium B-CHEMICAL
excretion O
were O
studied O
under O
conditions O
of O
carefully O
controlled O
sodium B-CHEMICAL
balance. O
RESULTS: O

Pretreatment O
renal O
vascular O
tone O
showed O
considerable O
individual O
differences: O
filtration O
fraction O
(FF) O
ranged O
from O
21.2 O
to O
30.3% O
and O
RVR O
from O
18.8 O
to O
33.5 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
single O
dose O
study, O
and O
FF O
from O
20.8 O
to O
24.9% O
and O
RVR O
from O
14.8 O
to O
28.8 O
10-2 O
mmHg O
min O
mL-1 O
in O
the O
multiple O
dose O
study. O
Remikiren B-CHEMICAL
induced O
a O
fall O
in O
blood O
pressure, O
FF O
and O
RVR, O
with O
considerable O
interindividual O
variability O
in O
natriuretic O

response. O
During O
single O
dose, O
cumulative O
sodium B-CHEMICAL
loss O
was O
5.1 O
mmol O
per O
5 O
h O
(-8.8 O
to O
+24.6), O
whereas O
after O
8 O
days O
treatment O
cumulative O
sodium B-CHEMICAL
loss O
was O
72 O
+/- O
30 O
mmol O
(-46 O
to O
+187). O
The O
natriuretic O
response O
to O
remikiren B-CHEMICAL
during O
single O
as O
well O
as O
multiple O
dose O
significantly O
correlated O
with O
pretreatment O
renal O
vascular O
tone O
(estimated O
from O
FF O
and O
RVR) O
but O
not O
with O
remikiren-induced B-CHEMICAL
changes O
in O
renal O
hemodynamics O
or O
in O
hormonal O
parameters. O
Cumulative O
sodium B-CHEMICAL
loss O
was O
largest O
in O
patients O
with O

a O
higher O
pretreatment O
FF O
and O
RVR O
(r O
= O
0.74, O
P O
< O
0.001 O
and O
r O
= O
0.52, O
P O
< O
0.05, O
respectively, O
single O
dose; O
and O
r O
= O
0.75, O
P O
< O
0.05 O
and O
r O
= O
0.73, O
P O
< O
0.05, O
respectively, O
multiple O
dose). O
CONCLUSION: O
These O
data O
support O
the O
hypothesis O
that O
in O
essential O
hypertension O
an O
elevated O
renal O
vascular O
tone O
is O
a O
marker O
of O
RAAS-mediated O
impairment O
of O
sodium B-CHEMICAL
excretion. O
Cloning, O
functional O
expression O
and O
brain O
localization O
of O
a O
novel O

unconventional O
outward B-GENE-N
rectifier I-GENE-N
K+ I-GENE-N
channel. I-GENE-N
Human B-GENE-Y
TWIK-1, I-GENE-Y
which O
has O
been O
cloned O
recently, O
is O
a O
new O
structural O
type O
of O
weak O
inward B-GENE-N
rectifier I-GENE-N
K+ I-GENE-N
channel. I-GENE-N
Here O
we O
report O
the O
structural O
and O
functional O
properties O
of O
TREK-1, B-GENE-Y
a O
mammalian B-GENE-Y
TWIK-1-related I-GENE-Y
K+ I-GENE-Y
channel. I-GENE-Y
Despite O
a O
low O
amino B-CHEMICAL
acid I-CHEMICAL
identity O
between O
TWIK-1 B-GENE-Y
and O
TREK-1 B-GENE-Y
(approximately O
28%), O
both O
channel O
proteins O
share O
the O
same O
overall O
structural O
arrangement O
consisting O
of O
two O
pore-forming B-GENE-N
domains I-GENE-N
and O
four O
transmembrane O
segments O
(TMS). O
This O
structural O
similarity O
does O
not O

give O
rise O
to O
a O
functional O
analogy. O
K+ B-CHEMICAL
currents O
generated O
by O
TWIK-1 B-GENE-Y
are O
inwardly O
rectifying O
while O
K+ B-CHEMICAL
currents O
generated O
by O
TREK-1 B-GENE-Y
are O
outwardly O
rectifying. O
These O
channels O
have O
a O
conductance O
of O
14 O
pS. O
TREK-1 B-GENE-Y
currents O
are O
insensitive O
to O
pharmacological O
agents O
that O
block O
TWIK-1 B-GENE-Y
activity O
such O
as O
quinine B-CHEMICAL
and O
quinidine. B-CHEMICAL
Extensive O
inhibitions O
of O
TREK-1 B-GENE-Y
activity O
are O
observed O
after O
activation O
of O
protein B-GENE-N
kinases I-GENE-N
A I-GENE-N
and I-GENE-N
C. I-GENE-N
TREK-1 B-GENE-Y
currents O
are O
sensitive O
to O
extracellular O
K+ B-CHEMICAL
and O

Na+. B-CHEMICAL
TREK-1 B-GENE-Y
mRNA O
is O
expressed O
in O
most O
tissues O
and O
is O
particularly O
abundant O
in O
the O
lung O
and O
in O
the O
brain. O
Its O
localization O
in O
this O
latter O
tissue O
has O
been O
studied O
by O
in O
situ O
hybridization. O
TREK-1 B-GENE-Y
expression O
is O
high O
in O
the O
olfactory O
bulb, O
hippocampus O
and O
cerebellum. O
These O
results O
provide O
the O
first O
evidence O
for O
the O
existence O
of O
a O
K+ B-GENE-N
channel I-GENE-N
family O
with O
four O
TMS O
and O
two O
pore B-GENE-N
domains I-GENE-N
in O
the O
nervous O
system O
of O
mammals. O
They O
also O
show O
that O
different O
members O
in O
this O
structural O
family O
can O
have O
totally O
different O
functional O
properties. O
Dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y

occupancy O
by O
risperidone: B-CHEMICAL
implications O
for O
the O
timing O
and O
magnitude O
of O
clinical O
response. O
The O
objective O
of O
the O
study O
is O
to O
investigate O
whether O
dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y
occupancy O
by O
risperidone B-CHEMICAL
and O
plasma O
levels O
over O
time O
can O
account O
for O
therapeutic O
efficacy O
and O
the O
latency O
period O
to O
response. O
Thirty-eight O
examinations O
with O
(123)I-IBZM B-CHEMICAL
single O
photon O
emission O
computed O
tomography O
were O
performed O
on O
22 O
patients O
with O
schizophrenia, O
at O
diagnosis, O
48 O
h O
after O
starting O
risperidone B-CHEMICAL
treatment O
and O
at O
a O
stable O
dose. O
Risperidone B-CHEMICAL
plasma O
levels O
were O
determined O
and O

psychopathologic O
evaluations O
(Brief O
Psychiatric O
Rating O
Scale, O
Positive O
and O
Negative O
Syndrome O
Scale) O
were O
carried O
out. O
No O
differences O
in O
the O
striatal/occipital O
(S/O) O
ratio O
or O
plasma O
levels O
were O
found O
between O
examinations O
at O
the O
48-h O
time O
point O
and O
when O
a O
stable O
dose O
level O
had O
been O
established, O
so O
these O
parameters O
could O
not O
account O
for O
the O
latency O
period O
required O
for O
clinical O
response. O
D2 B-GENE-Y
receptor I-GENE-Y
occupancy O
at O
48 O
h O
correlated O
positively O
with O
clinical O
improvement O
after O
2 O
weeks O
of O
treatment. O
Therefore, O
if O
these O
results O
are O
confirmed, O
D2 B-GENE-Y
receptor I-GENE-Y

occupancy O
at O
the O
beginning O
of O
treatment O
with O
risperidone B-CHEMICAL
may O
be O
a O
predictor O
of O
subsequent O
clinical O
response. O
Overexpression O
of O
beta B-GENE-Y
1-adrenoceptors I-GENE-Y
in O
adult O
rat O
ventricular O
myocytes O
enhances O
CGP B-CHEMICAL
12177A I-CHEMICAL
cardiostimulation: O
implications O
for O
'putative' O
beta B-GENE-N
4-adrenoceptor I-GENE-N
pharmacology. O
1. O
CGP B-CHEMICAL
12177A I-CHEMICAL
mediates O
cardiostimulation O
by O
activation O
of O
the O
'putative' O
beta(4)-adrenoceptor; B-GENE-N
however, O
it O
has O
recently O
been O
reported O
that O
disruption O
of O
the O

beta(1)-adrenoceptor B-GENE-Y
gene O
abolishes O
this O
effect. O
We O
have O
adenovirally O
overexpressed O
beta(1)-adrenoceptors B-GENE-Y
in O
isolated, O
cultured O
adult O
rat O
ventricular O
cardiomyocytes O
and O
observed O
the O
inotropic O
potency O
of O
isoprenaline B-CHEMICAL
and O
CGP B-CHEMICAL
12177A I-CHEMICAL
(in O
the O
presence O
of O
1 O
microm O
propranolol). B-CHEMICAL
2. O
Isoprenaline B-CHEMICAL
was O
a O
full O
inotropic O
agonist O
at O
rat O
ventricular O
myocytes O
(pD(2) O
7.69+/-0.12). O
CGP B-CHEMICAL

12177A I-CHEMICAL
was O
a O
nonconventional O
partial O
agonist O
(pD(2) O
6.34+/-0.09), O
increasing O
inotropy O
and O
lusitropy, O
with O
an O
intrinsic O
activity O
of O
0.34 O
and O
antagonised O
by O
bupranolol. B-CHEMICAL
3. O
beta(1)-adrenoceptor B-GENE-Y
overexpression O
enhanced O
the O
inotropic O
potency O
of O
isoprenaline B-CHEMICAL
by O
11.7-fold O
(pD(2) O
8.76+/-0.14) O
and O
CGP O
12177A O
by O
5.9-fold O

(7.11+/-0.10), O
respectively. O
Green O
fluorescent O
protein O
(GFP) O
overexpression O
did O
not O
alter O
the O
potency O
of O
isoprenaline B-CHEMICAL
or O
CGP O
12177A O
(pD(2) O
7.41+/-0.24 O
and O
pD(2) O
6.60+/-0.50, O
respectively). O
4. O
The O
cardiostimulant O
effects O
of O
CGP B-CHEMICAL
12177A I-CHEMICAL
were O
enhanced O
by O
IBMX O
(phosphodiesterase B-GENE-N
inhibitor) O
and O
decreased O
by O
Rp-cAMPS B-CHEMICAL
(cAMP B-CHEMICAL
antagonist). O
CGP B-CHEMICAL

12177A I-CHEMICAL
also O
increased O
cAMP B-CHEMICAL
levels. O
CGP B-CHEMICAL
12177A I-CHEMICAL
but O
not O
isoprenaline B-CHEMICAL
initiated O
arrhythmias O
at O
lower O
concentrations O
following O
beta(1)-adrenoceptor B-GENE-Y
overexpression. O
5. O
(125)I-Cyanopindolol B-CHEMICAL
saturation O
binding O
in O
Adv.beta(1) O
myocytes O
demonstrated O
approximately O
18-fold O
increase O
in O
beta(1)-adrenoceptors. B-GENE-Y
(3)H-CGP B-CHEMICAL
12177A I-CHEMICAL
saturation O
binding, O
in O
the O
presence O
of O
propranolol, B-CHEMICAL
increased O
approximately O
5-fold O
following O

overexpression O
of O
beta(1)-adrenoceptors. B-GENE-Y
6. O
This O
study O
demonstrates O
enhanced O
cardiostimulation O
by O
CGP B-CHEMICAL
12177A I-CHEMICAL
(in O
the O
presence O
of O
propranolol) B-CHEMICAL
in O
rat O
ventricular O
myocytes O
overexpressing O
beta(1)-adrenoceptors, B-GENE-Y
mediated O
by O
a O
Gs/cAMP B-GENE-N
signalling O
pathway. O
'Putative' O
beta(4)-adrenoceptor B-GENE-N
pharmacology O
appears O
to O
be O
mediated O
by O
activation O
of O
a O
novel O
affinity O
state O
of O
the O
beta(1)-adrenoceptor. B-GENE-Y
Antithrombin O
binding O
of O
low O

molecular O
weight O
heparins O
and O
inhibition O
of O
factor B-GENE-Y
Xa. I-GENE-Y
Fluorescence O
and O
stopped O
flow O
methods O
were O
used O
to O
compare O
clinically O
used O
heparins O
with O
regard O
to O
their O
ability O
to O
bind O
to O
antithrombin B-GENE-Y
and O
to O
accelerate O
the O
inactivation O
of O
factor B-GENE-Y
Xa. I-GENE-Y
Titration O
of O
antithrombin B-GENE-Y
with O
both O
low O
molecular O
weight O
heparin O
(LMWH) O
(enoxaparin, O
fragmin O
and O
ardeparin) O
and O
unfractionated O
heparin O
(UFH) O
produced O
an O
equivalent O
fluorescence O
increase O
and O
indicates O
similar O
affinity O
of O
all O
heparin O
preparations O
to O

antithrombin. B-GENE-Y
However, O
relative O
to O
UFH O
enoxaparin, O
the O
LMWH O
with O
the O
smallest O
average O
molecular O
mass, O
contained O
only O
12% O
material O
with O
high O
affinity O
for O
antithrombin. B-GENE-Y
The O
rate O
of O
factor B-GENE-Y
Xa I-GENE-Y
inhibition O
by O
antithrombin B-GENE-Y
increased O
with O
the O
concentration O
of O
the O
examined O
heparins O
to O
the O
same O
limiting O
value, O
but O
the O
concentration O
required O
for O
maximal O
acceleration O
depended O
on O
the O
preparation. O
According O
to O
these O
data O
the O
high O
affinity O
fraction O
of O
the O
heparin O
preparations O
increased O
the O
intrinsic O
fluorescence O
and O
inhibitory O
activity O
equally O
without O
additional O
effects O
by O
variations O
in O
chain O
length O
and O
chemical O
composition. O
In O
contrast, O
in O

the O
presence O
of O
Ca B-CHEMICAL
UFH O
accelerated O
the O
inhibition O
of O
factor B-GENE-Y
Xa I-GENE-Y
by O
antithrombin B-GENE-Y
10-fold O
more O
efficiently O
than O
comparable O
concentrations O
of O
the O
high O
affinity O
fractions O
of O
enoxaparin O
and O
fragmin. O
The O
bell-shaped O
dependence O
of O
this O
accelerating O
effect O
suggests O
simultaneous O
binding O
of O
both O
proteins O
to O
heparin. O
In O
conclusion, O
under O
physiologic O
conditions O
the O
anti-factor B-GENE-Y
Xa I-GENE-Y
activity O
of O
heparin O
results O
from O
a O
composite O
effect O
of O
chain O
length O
and O
the O
content O
of O
material O
with O
high O
affinity O
to O
antithrombin. B-GENE-Y
Thus, O
the O
reduced O
antithrombotic O
activity O
of O
LMWH O

relative O
to O
UFH O
results O
from O
a O
smaller O
content O
of O
high O
affinity O
material O
and O
the O
absence O
of O
a O
stimulating O
effect O
of O
calcium. B-CHEMICAL
Further O
insights O
into O
the O
effect O
of O
quinidine B-CHEMICAL
in O
short O
QT O
syndrome O
caused O
by O
a O
mutation O
in O
HERG. B-GENE-Y
INTRODUCTION: O
The O
principal O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
quinidine B-CHEMICAL
in O
suppressing O
IKr B-GENE-N
in O
vitro O
and O
in O
modulating O
the O
rate O
dependence O
of O
the O
QT O
interval O
in O
the O
"SQT1" O
form O
of O
the O
short O
QT O
syndrome. O
METHODS O
AND O
RESULTS: O

Graded-intensity O
bicycle O
exercise O
testing O
was O
performed O
off O
drug O
in O
three O
patients O
and O
during O
oral O
quinidine B-CHEMICAL
in O
two O
patients O
with O
short O
QT O
syndrome O
and O
compared O
to O
a O
control O
group O
of O
healthy O
normal O
subjects. O
The O
in O
vitro O
effects O
of O
quinidine B-CHEMICAL
on O
currents O
in O
patch O
clamp O
technique O
were O
investigated. O
Off O
drugs O
QTpV3/heart O
rate O
correlation O
is O
much O
weaker O
in O
patients O
with O
short O
QT O
syndrome, O
and O
QTpV3 O
shortens O
less O
with O
heart O
rate O
increase O
compared O
to O
normal O
subjects. O
In O
addition O
to O
prolonging O
the O
QT O
interval O
into O
the O
normal O
range, O
quinidine B-CHEMICAL
restored O
the O
heart O
rate O
dependence O
of O

the O
QT O
interval O
toward O
a O
range O
of O
adaptation O
reported O
for O
normal O
subjects. O
Data O
from O
heterologous O
expression O
of O
wild-type O
and O
mutant O
HERG B-GENE-Y
genes O
indicate O
the O
mutation O
causes O
a O
20-fold O
increase O
in O
IC50 O
of O
d-sotalol O
but O
only O
a O
5.8-fold O
increase O
in O
IC50 O
of O
quinidine. B-CHEMICAL
CONCLUSION: O
Oral O
quinidine B-CHEMICAL
is O
effective O
in O
suppressing O
the O
gain O
of O
function O
in O
IKr B-GENE-N
responsible O
for O
some O
cases O
of O
short O
QT O
syndrome O
with O
a O
mutation O
in O
HERG B-GENE-Y
and O
thus O
restoring O
normal O
rate O
dependence O
of O
the O
QT O
interval O
and O
rendering O
ventricular O

tachycardia/ventricular O
fibrillation O
noninducible. O
Apoptotic O
cell O
death O
in O
rat O
epididymis O
following O
epichlorohydrin B-CHEMICAL
treatment. O
Epichlorohydrin B-CHEMICAL
(ECH) B-CHEMICAL
is O
an O
antifertility O
agent O
that O
acts O
both O
as O
an O
epididymal O
toxicant O
and O
an O
agent O
capable O
of O
directly O
affecting O
sperm O
motility. O
This O
study O
identified O
the O
time O
course O
of O
apoptotic O
cell O
death O
in O
rat O
epididymides O
after O
ECH O
treatment. O
Rats O
were O
administrated O
with O
a O
single O
oral O
dose O
of O
ECH B-CHEMICAL
(50 O
mg/kg). O

ECH-induced B-CHEMICAL
apoptotic O
changes O
were O
evaluated O
by O
terminal B-GENE-Y
deoxynucleotidyl I-GENE-Y
transferase I-GENE-Y
dUTP B-CHEMICAL
nick O
end O
labeling O
(TUNEL) O
assay O
and O
its O
related O
mechanism O
was O
confirmed O
by O
Western O
blot O
analysis O
and O
colorimetric O
assay. O
The O
TUNEL O
assay O
showed O
that O
the O
number O
of O
apoptotic O
cells O
increased O
at O
8 O
h, O
reached O
a O
maximum O
level O
at O
12 O
h, O
and O
then O
decreased O
progressively. O
The O
Western O
blot O
analysis O
demonstrated O
no O
significant O
changes O
in O
proapoptotic O
Bcl-2-associated B-GENE-Y
X I-GENE-Y
(Bax) B-GENE-Y
and O
anti-apoptotic O

Bcl-2 B-GENE-Y
expression O
during O
the O
time O
course O
of O
the O
study. O
However, O
phospho-p38 B-GENE-N
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(p-p38 B-GENE-N
MAPK) B-GENE-N
and O
phospho-c-Jun B-GENE-N
amino-terminal I-GENE-N
kinase I-GENE-N
(p-JNK) B-GENE-N
expression O
increased O
at O
8-24 O
h. O
Caspase-3 B-GENE-Y
and O
caspase-8 B-GENE-Y
activities O
also O
increased O
at O
8-48 O
h O
and O
12-48 O
h, O
respectively, O
in O
the O
same O
manner O
as O
p-p38 B-GENE-N
MAPK B-GENE-N
and O
p-JNK B-GENE-N
expression. O
These O
results O
indicate O
that O
ECH O
induced O
apoptotic O
changes O

in O
rat O
epididymides O
and O
that O
the O
apoptotic O
cell O
death O
may O
be O
related O
more O
to O
the O
MAPK B-GENE-N
pathway O
than O
to O
the O
mitochondrial O
pathway. O
Effects O
of O
an O
ethanolic O
salix O
extract O
on O
the O
release O
of O
selected O
inflammatory O
mediators O
in O
vitro. O
Salix O
extracts O
are O
in O
current O
use O
for O
the O
treatment O
of O
pain O
and O
inflammation. O
In O
order O
to O
obtain O
an O
insight O
into O
the O
mechanism(s) O
of O
action O
of O
the O
ethanolic O
Salix O
extract O
1520L--which O
is O
essentially O
similar O
to O
an O
extract O
for O
which O
clinical O
studies O
have O
demonstrated O
analgesic O
effectiveness--its O
effects O
were O
evaluated O
in O
an O
established O
in O
vitro O

assay O
test O
system O
using O
primary O
human O
monocytes. O
The O
IC50-values O
obtained O
for O
the O
inhibition O
of O
lipopolysaccharide O
(LPS)-induced O
release O
of O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
reflecting O
cyclooxygenase B-GENE-Y
(COX)-2-mediated I-GENE-Y
PGE2 B-CHEMICAL
release O
were O
47 O
microg/ml O
and O
0.6 O
microg/ml, O
for O
the O
Salix O
extract O
1520L O
and O
rofecoxib-like B-CHEMICAL
research O
compound O
L745337, B-CHEMICAL
respectively. O
There O
was O
no O
effect O
on O
COX-1 B-GENE-Y
and O

COX-2 B-GENE-Y
activity. O
The O
Salix O
extract O
inhibited O
the O
LPS-induced O
release O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha, I-GENE-Y
interleukin-1beta B-GENE-Y
and O
interleukin-6 B-GENE-Y
with O
IC50-values O
of O
180.0, O
33.0 O
and O
86.0 O
microg/ml, O
respectively. O
Both, O
salicin B-CHEMICAL
and O
salicylate, B-CHEMICAL
had O
no O
effect O
in O
any O
of O
the O
parameters. O
Our O
results O
indicate O
that O
Salix O
extract O
1520L O
inhibits O
COX-2-mediated B-GENE-Y
PGE2 B-CHEMICAL
release O
through O
compounds O
other O
than O
salicin B-CHEMICAL
or O
salicylate. B-CHEMICAL
Our O

data O
further O
suggest O
that O
the O
proprietary O
Salix O
extract O
is O
a O
weak O
inhibitor O
of O
proinflammatory O
cytokines. B-GENE-N
Mutations O
in O
the O
follicle-stimulating B-GENE-N
hormone-beta I-GENE-N
(FSH B-GENE-N
beta) I-GENE-N
and O
FSH B-GENE-N
receptor I-GENE-N
genes O
in O
mice O
and O
humans. O
Follicle-stimulating B-GENE-N
hormone I-GENE-N
(FSH), B-GENE-N
a O
dimeric O
glycoprotein O
synthesized O
in O
the O
anterior O
pituitary O
gland, O
is O
important O
for O
the O
production O
of O
sex O
steroids B-CHEMICAL
and O
gametes. O
FSH-beta B-GENE-Y
(FSH B-GENE-Y
beta) I-GENE-Y
and O
FSH B-GENE-Y
receptor I-GENE-Y
(FSHR) B-GENE-Y
knockout O

mice O
display O
impaired O
ovarian O
follicular O
development O
and O
infertility O
in O
females O
and O
small O
testes, O
oligospermia, O
and O
fertility O
in O
males. O
Humans O
with O
FSH B-GENE-Y
beta I-GENE-Y
gene O
mutations O
tend O
to O
have O
a O
more O
severe O
phenotype O
than O
those O
with O
FSHR B-GENE-Y
gene O
mutations, O
although O
infertility O
and O
varying O
degrees O
of O
impaired O
sex O
steroid B-CHEMICAL
production O
occur O
in O
both O
types O
of O
mutations. O
Data O
from O
human O
and O
mouse O
mutations O
in O
the O
FSH B-GENE-N
beta I-GENE-N
and O
FSHR B-GENE-N
genes O
suggest O
that O
FSH B-GENE-N
is O
necessary O
for O
normal O
pubertal O
development O
and O
fertility O
in O
males O
and O
females. O
Antipsychotic O
profile O
of O

rolipram: B-CHEMICAL
efficacy O
in O
rats O
and O
reduced O
sensitivity O
in O
mice O
deficient O
in O
the O
phosphodiesterase-4B B-GENE-Y
(PDE4B) B-GENE-Y
enzyme. O
RATIONALE: O
Recent O
studies O
provide O
evidence O
for O
reduced O
phosphodiesterase-4B B-GENE-Y
(PDE4B) B-GENE-Y
as O
a O
genetic O
susceptibility O
factor O
as O
well O
as O
suggesting O
an O
association O
of O
several O
single O
nucleotide B-CHEMICAL
polymorphisms O
(SNPs) O
in O
PDE4B B-GENE-Y
that O
are O
associated O
with O
an O
increased O
incidence O
of O
schizophrenia. O
OBJECTIVES: O
The O
aim O
of O
the O
current O
study O
was O
to O

assess O
the O
activity O
of O
rolipram, B-CHEMICAL
a O
nonsubtype-selective O
PDE4 B-GENE-N
inhibitor, O
in O
several O
animal O
models O
predictive O
of O
antipsychotic-like O
efficacy O
and O
side-effect O
liability O
and O
to O
use O
PDE4B B-GENE-Y
wild-type O
and O
knockout O
mice O
to O
begin O
to O
understand O
the O
subtypes O
involved O
in O
the O
activity O
of O
rolipram. B-CHEMICAL
RESULTS: O
In O
rats, O
rolipram B-CHEMICAL
antagonized O
both O
phencyclidine B-CHEMICAL
hydrochloride- I-CHEMICAL
and O
D-amphetamine-induced B-CHEMICAL
hyperactivity O
and O
inhibited O
conditioned O
avoidance O
responding O
(CAR). O
In O

PDE4B B-GENE-Y
wild-type O
mice, O
rolipram B-CHEMICAL
dose-dependently O
suppressed O
CAR O
(ED(50) O
= O
2.4 O
mg/kg); O
however, O
in O
knockout O
mice, O
their O
sensitivity O
to O
rolipram B-CHEMICAL
at O
the O
higher O
doses O
(1.0 O
and O
3.2 O
mg/kg) O
was O
reduced, O
resulting O
in O
a O
threefold O
shift O
in O
the O
ED(50) O
(7.3 O
mg/kg), O
suggesting O
PDE4B B-GENE-Y
is O
involved, O
at O
least O
in O
part, O
with O
the O
activity O
of O
rolipram. B-CHEMICAL
Only O
the O
highest O
dose O
of O
rolipram B-CHEMICAL
(3.2 O

mg/kg) O
produced O
a O
modest O
but O
significant O
degree O
of O
catalepsy. O
CONCLUSIONS: O
Rolipram B-CHEMICAL
has O
a O
pharmacologic O
profile O
similar O
to O
that O
of O
the O
atypical O
antipsychotics O
and O
has O
low O
extrapyramidal O
symptom O
liability. O
These O
results O
suggest O
that O
PDE4B B-GENE-Y
mediates O
the O
antipsychotic O
effects O
of O
rolipram B-CHEMICAL
in O
CAR O
and O
that O
the O
PDE4B-regulated B-GENE-Y
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate I-CHEMICAL
signaling O
pathway O
may O
play O
a O
role O
in O
the O
pathophysiology O
and O
pharmacotherapy O
of O

psychosis. O
Improving O
the O
tolerability O
of O
anticholinergic O
agents O
in O
the O
treatment O
of O
overactive O
bladder. O
Pharmacological O
treatment O
for O
overactive O
bladder O
has O
centred O
around O
the O
interruption O
of O
the O
detrusor O
activity O
that O
is O
central O
to O
urge O
and O
incontinence O
symptoms. O
The O
majority O
of O
patients O
with O
this O
disorder O
are O
treated O
with O
antimuscarinic O
agents. O
These O
drugs O
have O
been O
demonstrated O
to O
improve O
urgency, O
frequency O
of O
micturition O
and O
urge O
incontinence, O
all O
of O
which O
are O
primary O
symptoms O
of O
overactive O
bladder; O
however, O
they O
are O
also O
commonly O
associated O
with O
anticholinergic O
adverse O
effects, O
most O
notably O
dry O

mouth. O
Attempts O
to O
increase O
tolerability O
have O
included O
the O
development O
of O
advanced O
formulations O
that O
regulate O
release O
of O
the O
active O
ingredient O
and O
the O
development O
of O
pharmacological O
agents O
that O
target O
the O
desired O
bladder O
receptors O
more O
specifically O
and O
accurately. O
Although O
all O
agents O
provide O
good O
efficacy, O
tolerability O
is O
greatly O
affected O
by O
the O
formulation O
used O
to O
deliver O
the O
active O
pharmacological O
agent, O
as O
well O
as O
the O
specificity O
of O
the O
targeted O
receptors. O
Clinical O
trials O
involving O
a O
transdermal O
formulation O
of O
oxybutynin B-CHEMICAL
have O
shown O
that O
this O
delivery O
method O
may O
be O
associated O
with O
a O
lower O
incidence O
of O
anticholinergic O
adverse O
events O
compared O
with O
both O
the O
immediate-release O
and O
the O

extended-release O
oral O
formulations O
of O
traditional O
agents, O
as O
well O
as O
the O
most O
recently O
approved O
agents O
- O
trospium B-CHEMICAL
chloride, I-CHEMICAL
solifenacin B-CHEMICAL
and O
darifenacin. B-CHEMICAL
Much O
is O
still O
being O
learned O
about O
the O
function O
and O
specificity O
of O
muscarinic B-GENE-N
receptors, I-GENE-N
which O
will O
support O
the O
development O
of O
agents O
with O
sustained O
efficacy O
and O
enhanced O
tolerability O
compared O
with O
the O
available O
formulations O
to O
date. O
These O
include O
the O
S-isomer B-CHEMICAL
of I-CHEMICAL
oxybutynin, I-CHEMICAL
as O
well O
as O
selective O
muscarinic B-GENE-Y
M2 I-GENE-Y
receptor I-GENE-Y
antagonists. O
Intradialytic O
parenteral O
nutrition: O
comparison O
of O
olive O
oil O
versus O
soybean O

oil-based O
lipid O
emulsions. O
Lipid, O
oxidative O
and O
inflammatory O
parameters O
are O
frequently O
altered O
in O
dialysis O
patients O
and O
may O
be O
worsened O
by O
intravenous O
lipid O
emulsions O
(ILE). O
We O
assessed O
the O
efficacy O
and O
tolerance O
of O
olive O
as O
compared O
with O
standard O
soybean O
oil-based O
ILE O
during O
intradialytic O
parenteral O
nutrition O
(IDPN). O
IDPN O
mixtures O
containing O
amino B-CHEMICAL
acids, I-CHEMICAL
glucose, B-CHEMICAL
and O
either O
olive O
oil O
(OO O
group, O
n O
17) O
or O
soybean O
oil-based O
ILE O
(SO O
group, O
n O
18) O
were O
administered O
in O

a O
5-week O
randomized, O
double-blind O
study. O
On O
days O
0 O
and O
35, O
patients' O
nutritional O
status O
was O
assessed O
by O
BMI, O
normalized O
protein O
catabolic O
rate, O
predialytic O
creatinine, B-CHEMICAL
serum B-GENE-Y
albumin I-GENE-Y
and O
transthyretin; B-GENE-Y
lipid O
metabolism O
by O
plasma O
LDL- B-GENE-N
and O
HDL-cholesterol, B-GENE-N
triacylglycerols, B-CHEMICAL
phospholipids, O
apo B-GENE-N
A-I, I-GENE-N
A-II, I-GENE-N
B, I-GENE-N
C-II, I-GENE-N
C-III, I-GENE-N
E I-GENE-N
and O
lipoprotein B-GENE-Y
(a); I-GENE-Y
oxidative O
status O
by O

alpha-tocopherol, B-CHEMICAL
retinol, B-CHEMICAL
selenium, B-CHEMICAL
glutathione B-GENE-N
peroxidase, I-GENE-N
malondialdehyde B-CHEMICAL
and O
advanced O
oxidized O
protein O
products; O
inflammatory O
status O
by O
serum O
C-reactive B-GENE-Y
protein, I-GENE-Y
orosomucoid, B-GENE-N
IL-2 B-GENE-Y
and O
IL-6. B-GENE-Y
No O
serious O
adverse O
event O
was O
observed. O
Significant O
changes O
were O
observed O
from O
day O
0 O
to O
day O
35 O
(P<0.05): O
nutritional O
criteria O
improved O
(albumin B-GENE-Y
in O
OO; O
albumin, B-GENE-Y
transthyretin B-GENE-Y
and O
creatinine B-CHEMICAL
in O
SO); O
LDL-cholesterol, B-GENE-N
apo B-GENE-N

B, I-GENE-N
C-II, I-GENE-N
C-III I-GENE-N
and O
apo B-GENE-N
A-I/A-II I-GENE-N
ratio O
increased O
in O
both O
groups. O
HDL-cholesterol B-GENE-N
decreased O
in O
OO; O
apo B-GENE-Y
E I-GENE-Y
increased O
and O
lipoprotein B-GENE-Y
(a) I-GENE-Y
decreased O
in O
SO; O
alpha-tocopherol/cholesterol B-CHEMICAL
ratio O
increased O
in O
OO; O
malondialdehyde B-CHEMICAL
decreased O
in O
both O
groups; O
IL-2 B-GENE-Y
increased O
in O
both O
groups. O
The O
between-group O
comparison O
only O
showed O
the O
following O
differences: O
alpha-tocopherol/cholesterol B-CHEMICAL
increased O
in O
OO; O
lipoprotein B-GENE-Y
(a) I-GENE-Y
decreased O
in O

SO. O
From O
these O
data, O
it O
was O
concluded O
that O
OO- O
and O
SO-based O
IDPNs O
similarly O
improved O
nutritional O
status O
and O
influenced O
plasma O
lipid, O
oxidative, O
inflammatory O
and O
immune O
parameters. O
Transcriptional O
control O
of O
the O
arginine/lysine B-GENE-N
transporter, I-GENE-N
cat-1, B-GENE-Y
by O
physiological O
stress. O
Cells O
respond O
to O
physiological O
stress O
by O
phosphorylating O
the O
alpha O
subunit O
of O
the O
translation O
initiation O
factor O
eIF2. B-GENE-N
This O
adaptive O
response O
inhibits O
protein O
synthesis O
and O
up-regulates O
genes O
essential O
for O
cell O
survival. O
Cat-1, B-GENE-Y
the O
transporter O
for O
the O
essential O
amino B-CHEMICAL
acids, I-CHEMICAL

arginine B-CHEMICAL
and O
lysine, B-CHEMICAL
is O
one O
of O
the O
up-regulated O
genes. O
We O
previously O
showed O
that O
stress O
increases O
cat-1 B-GENE-Y
expression O
by O
coordinated O
stabilization O
of O
the O
mRNA O
and O
increased O
mRNA O
translation. O
This O
induction O
is O
triggered O
by O
amino B-CHEMICAL
acid I-CHEMICAL
depletion O
and O
the O
unfolded B-GENE-N
protein I-GENE-N
response I-GENE-N
(UPR), B-GENE-N
which O
is O
caused O
by O
unfolded O
proteins O
in O
the O
endoplasmic O
reticulum. O
We O
show O
here O
that O
cat-1 B-GENE-Y
gene O
transcription O
is O
also O
increased O
by O
cellular O
stress. O
Our O
studies O
demonstrate O
that O
the O
cat-1 B-GENE-N
gene I-GENE-N
promoter/regulatory I-GENE-N
region O
is O
TATA-less B-GENE-N
and O
is O
located O
in O
a O
region O
that O
includes O
94 O
bases O
of O
the O
first O

exon. O
Transcription O
from O
this O
promoter O
is O
stimulated O
8-fold O
by O
cellular O
stress. O
An O
amino B-CHEMICAL
acid I-CHEMICAL
response O
element O
within O
the O
first O
exon O
is O
shown O
to O
be O
required O
for O
the O
response O
to O
amino B-CHEMICAL
acid I-CHEMICAL
depletion O
but O
not O
to O
the O
UPR. O
The O
stimulation O
of O
transcription O
by O
amino B-CHEMICAL
acid I-CHEMICAL
depletion O
requires O
activation O
of O
GCN2 B-GENE-Y
kinase, B-GENE-N
which O
phosphorylates O
eIF2alpha. B-GENE-Y
This O
phosphorylation O
also O
induces O
translation O
of O
the O
cat-1 B-GENE-Y
mRNA, O
demonstrating O
that O
stress-induced O
transcriptional O
and O
translational O
control O
of O
cat-1 B-GENE-Y
are O
downstream O
targets O
of O
a O
signaling O
pathway O
initiating O
with O

eIF2alpha B-GENE-Y
phosphorylation. O
Our O
studies O
show O
that O
the O
increase O
in O
cat-1 B-GENE-Y
gene O
expression O
by O
cellular O
stress O
involves O
at O
least O
three O
types O
of O
coordinate O
regulation: O
regulation O
of O
transcription, O
regulation O
of O
mRNA O
stability, O
and O
regulation O
of O
mRNA O
translation. O
Physiological O
oxygenation O
status O
is O
required O
for O
fully O
differentiated O
phenotype O
in O
kidney O
cortex O
proximal O
tubules. O
Hypoxia O
has O
been O
suspected O
to O
trigger O
transdifferentiation O
of O
renal O
tubular O
cells O
into O
myofibroblasts O
in O
an O
epithelial-to-mesenchymal O
transition O
(EMT) O
process. O
To O
determine O
the O
functional O
networks O
potentially O

altered O
by O
hypoxia, O
rat O
renal O
tubule O
suspensions O
were O
incubated O
under O
three O
conditions O
of O
oxygenation O
ranging O
from O
normoxia O
(lactate O
uptake) O
to O
severe O
hypoxia O
(lactate O
production). O
Transcriptome O
changes O
after O
4 O
h O
were O
analyzed O
on O
a O
high O
scale O
by O
restriction O
fragment O
differential O
display. O
Among O
1,533 O
transcripts O
found, O
42% O
were O
maximally O
expressed O
under O
severe O
hypoxia O
and O
8% O
under O
mild O
hypoxia O
(Po(2) O
= O
48 O
mmHg), O
suggesting O
two O
different O
levels O
of O
oxygen B-CHEMICAL
sensing. O
Normoxia O
was O
required O
for O

full O
expression O
of O
the O
proximal O
tubule-specific O
transcripts O
25-hydroxyvitamin B-GENE-Y
D I-GENE-Y
1-hydroxylase I-GENE-Y
(Cyp27b1) B-GENE-Y
and O
l-pyruvate B-GENE-Y
kinase I-GENE-Y
(Pklr), B-GENE-Y
transcripts O
involved O
in O
tissue O
cohesion O
such O
as O
fibronectin B-GENE-Y
(Fn1) B-GENE-Y
and O
N-cadherin B-GENE-Y
(Cdh2), B-GENE-Y
and O
non-muscle-type B-GENE-N
myosin I-GENE-N
transcripts. O
Mild O
hypoxia O
increased O
myogenin B-GENE-Y
transcript O
level. O
Conversely, O
severe O
hypoxia O
increased O
transcripts O
involved O
in O
extracellular O
matrix O
remodeling, O

those O
of O
muscle-type B-GENE-N
myosins, I-GENE-N
and O
others O
involved O
in O
creatine O
phosphate B-CHEMICAL
synthesis O
and O
lactate O
transport O
(Slc16a7). B-GENE-Y
Accordingly, O
microscopy O
showed O
loss O
of O
tubule O
aggregation O
under O
hypoxia, O
without O
tubular O
disruption. O
Hypoxia O
also O
increased O
the O
levels O
of O
kidney-specific O
transcripts O
normally O
restricted O
to O
the O
less O
oxygenated O
medullary O
zone O
and O
others O
specific O
for O
the O
distal O
part O
of O
the O
nephron. O
We O
conclude O
that O
extensive O
oxygen B-CHEMICAL
supply O
to O
the O
kidney O
tubule O
favors O
expression O
of O
its O
differentiated O
functions O
specifically O
in O
the O
proximal O
tubule, O
whose O
embryonic O

origin O
is O
mesenchymal. O
The O
phenotype O
changes O
could O
potentially O
permit O
transient O
adaptation O
to O
hypoxia O
but O
also O
favor O
pathological O
processes O
such O
as O
tissue O
invasion. O
A O
human O
hemi-cornea O
model O
for O
eye O
irritation O
testing: O
quality O
control O
of O
production, O
reliability O
and O
predictive O
capacity. O
We O
have O
developed O
a O
3-dimensional O
human O
hemi-cornea O
which O
comprises O
an O
immortalized O
epithelial O
cell O
line O
and O
keratocytes O
embedded O
in O
a O
collagen B-GENE-N
stroma. O
In O
the O
present O
study, O
we O
have O
used O
MTT B-CHEMICAL
reduction O
of O
the O
whole O
tissue O
to O
clarify O
whether O
the O
production O
of O
this O
complex O

3-D-model O
is O
transferable O
into O
other O
laboratories O
and O
whether O
these O
tissues O
can O
be O
constructed O
reproducibly. O
Our O
results O
demonstrate O
the O
reproducible O
production O
of O
the O
hemi-cornea O
model O
according O
to O
standard O
operation O
procedures O
using O
15 O
independent O
batches O
of O
reconstructed O
hemi-cornea O
models O
in O
two O
independent O
laboratories O
each. O
Furthermore, O
the O
hemi-cornea O
tissues O
have O
been O
treated O
with O
20 O
chemicals O
of O
different O
eye-irritating O
potential O
under O
blind O
conditions O
to O
assess O
the O
performance O
and O
limitations O
of O
our O
test O
system O
comparing O
three O
different O
prediction O
models. O
The O
most O
suitable O
prediction O
model O
revealed O
an O
overall O
in O
vitro-in O
vivo O

concordance O
of O
80% O
and O
70% O
in O
the O
participating O
laboratories, O
respectively, O
and O
an O
inter-laboratory O
concordance O
of O
80%. O
Sensitivity O
of O
the O
test O
was O
77% O
and O
specificity O
was O
between O
57% O
and O
86% O
to O
discriminate O
classified O
from O
non-classified O
chemicals. O
We O
conclude O
that O
additional O
physiologically O
relevant O
endpoints O
in O
both O
epithelium O
and O
stroma O
have O
to O
be O
developed O
for O
the O
reliable O
prediction O
of O
all O
GHS O
classes O
of O
eye O
irritation O
in O
one O
stand O
alone O
test O
system. O
Steroidal B-CHEMICAL
glycosides I-CHEMICAL
from O
the O
bulbs O
of O
Easter O
lily O
(Lilium O
longiflorum O

Thunb.) O
promote O
dermal O
fibroblast O
migration O
in O
vitro. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Preparations O
derived O
from O
bulbs O
of O
various O
Lilium O
species O
have O
been O
used O
to O
promote O
the O
healing O
of O
skin O
abrasions, O
sores O
and O
burns O
and O
to O
aid O
in O
healing O
wounds O
in O
Traditional O
Chinese O
and O
Greco-Roman O
Medicine. O
AIM O
OF O
THE O
STUDY: O
To O
evaluate O
fractionated O
Easter O
lily O
bulb O
extracts O
and O
their O
steroidal B-CHEMICAL
glycosides I-CHEMICAL
(1-5) O
for O
the O
promotion O
of O
dermal O
fibroblast O
migration O
in O

vitro, O
as O
a O
model O
for O
the O
early O
events O
in O
wound O
healing. O
MATERIALS O
AND O
METHODS: O
An O
activity-guided O
screening O
approach O
was O
used O
by O
coupling O
sequential O
solvent O
extraction, O
gel O
permeation O
chromatography O
(GPC), O
and O
semi-preparative O
reverse-phase O
high O
performance O
liquid O
chromatography O
(RP-HPLC) O
with O
an O
in O
vitro O
dermal O
fibroblast O
migration O
assay. O
Cytotoxicity O
was O
evaluated O
with O
methyl B-CHEMICAL
thiazole I-CHEMICAL
tetrazolium I-CHEMICAL
(MTT). B-CHEMICAL
To O
gain O
insight O
into O
the O
mode O
of O
action O
of O
the O
steroidal B-CHEMICAL

glycosides, I-CHEMICAL
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
production, O
and O
expression O
of O
genes O
for O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
beta-1 I-GENE-Y
(TGF-β) B-GENE-Y
and O
its O
receptors O
were O
evaluated. O
RESULTS: O
Fractionated O
bulb O
extracts O
and O
the O
two O
isolated O
steroidal B-CHEMICAL
glycoalkaloids I-CHEMICAL
(1) O
and O
(2) O
induced O
NO B-CHEMICAL
production O
and O
TGF-β B-GENE-Y
receptor I-GENE-Y
I I-GENE-Y
mRNA O
expression O
in O
fibroblast O
cell O
culture. O
In O
a O
cytotoxicity O
assay, O
steroidal B-CHEMICAL
glycosides I-CHEMICAL
(1) O
and O
(3) O
had O
IC50 O
values O
of O
8.2 O
and O

8.7µM, O
but O
the O
natural O
acetylation O
of O
the O
C-6″' O
hydroxy B-CHEMICAL
of O
the O
terminal O
glucose B-CHEMICAL
unit O
in O
(2) O
resulted O
in O
a O
3-fold O
decrease O
in O
cell O
cytotoxicity O
when O
compared O
with O
(1). O
Results O
from O
the O
dermal O
fibroblast O
migration O
assay O
revealed O
that O
the O
steroidal B-CHEMICAL
glycoalkaloids I-CHEMICAL
(1) O
and O
(2), O
and O
the O
furostanol B-CHEMICAL
saponin I-CHEMICAL
(3) O
promoted O
fibroblast O
migration O
from O
the O
range O
of O
23.7±5.7 O
to O
37.7±5.1%, O
as O
compared O
with O
the O

control. O
CONCLUSION: O
Collectively, O
our O
data O
demonstrate O
that O
the O
steroidal B-CHEMICAL
glycosides I-CHEMICAL
present O
in O
Easter O
lily O
bulbs O
induce, O
at O
least O
in O
part, O
the O
observed O
dermal O
fibroblast O
migration O
activity O
of O
the O
bulb O
extracts. O
This O
is O
the O
first O
evidence O
that O
steroidal B-CHEMICAL
glycosides I-CHEMICAL
from O
L. O
longiflorum O
may O
potentially O
play O
a O
role O
in O
the O
wound O
healing O
process O
and O
may O
provide O
a O
scientific O
basis O
for O
the O
historical O
use O
of O
lily O
bulbs O
for O
this O
purpose. O
Species-specific O
pharmacological O
properties O
of O
human B-GENE-Y
alpha(2A)-adrenoceptors. I-GENE-Y
On O
the O
basis O

of O
data O
obtained O
in O
rabbits, O
the O
imidazoline B-GENE-N
receptor I-GENE-N
ligand O
rilmenidine B-CHEMICAL
has O
been O
suggested O
to O
decrease O
blood O
pressure O
in O
humans O
by O
activating O
central O
alpha(2A)-adrenoceptors. B-GENE-Y
A O
prerequisite O
for O
this O
hypothesis O
was O
the O
unproved O
assumption O
that O
rabbit O
and O
human O
alpha(2A)-adrenoceptors B-GENE-N
are O
equally O
activated O
by O
rilmenidine. B-CHEMICAL
Because O
alpha(2A)-adrenoceptors B-GENE-N
in O
the O
brain O
and O
on O
cardiovascular O
sympathetic O
nerve O
terminals O
are O
identical, O
the O
latter O
were O
used O
as O
a O
model O
for O
the O
former O
to O
confirm O
or O
disprove O
this O

assumption. O
Human O
atrial O
appendages O
and O
rabbit O
pulmonary O
arteries O
were O
used O
to O
determine O
the O
potencies O
of O
alpha(2)-adrenoceptor B-GENE-N
agonists O
in O
inhibiting O
the O
electrically O
(2 O
Hz) O
evoked O
[(3)H]norepinephrine B-CHEMICAL
release O
and O
of O
antagonists O
in O
counteracting O
the O
alpha(2)-adrenoceptor-mediated B-GENE-N
inhibition O
induced O
by O
moxonidine. B-CHEMICAL
In O
the O
rabbit O
pulmonary O
artery, O
rilmenidine B-CHEMICAL
and O
oxymetazoline B-CHEMICAL
are O
potent O
full O
agonists, O
whereas O
in O
the O
human O
atrial O
appendages O
they O
are O

antagonists O
at O
the O
alpha(2)-autoreceptors, B-GENE-N
sharing O
this O
property O
with O
rauwolscine, B-CHEMICAL
phentolamine, B-CHEMICAL
and O
idazoxan. B-CHEMICAL
In O
contrast, O
prazosin B-CHEMICAL
is O
ineffective. O
In O
addition, O
a O
partial O
nucleotide O
and O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
of O
the O
rabbit B-GENE-Y
alpha(2A)-adrenoceptor I-GENE-Y
(a O
region O
known O
to O
substantially O
influence O
the O
pharmacological O
characteristics O
of O
the O
alpha(2)-adrenoceptor) B-GENE-N
revealed O
marked O
differences O
between O
the O
rabbit O
and O
the O
human O
alpha(2A)-adrenoceptor. B-GENE-N
The O
sympathetic O
nerves O
of O
both O
the O

human O
atrial O
appendages O
and O
rabbit O
pulmonary O
artery O
are O
endowed O
with O
alpha(2A)-autoreceptors, B-GENE-N
at O
which, O
however, O
both O
rilmenidine B-CHEMICAL
and O
oxymetazoline B-CHEMICAL
exhibit O
different O
properties O
(antagonism O
and O
agonism, O
respectively). O
The O
antagonistic O
property O
of O
rilmenidine B-CHEMICAL
at O
human B-GENE-Y
alpha(2A)-adrenoceptors I-GENE-Y
indicates O
that O
in O
contrast O
to O
the O
suggestion O
based O
on O
rabbit O
data, O
the O
hypotensive O
property O
of O
the O
drug O
in O
humans O
is O
not O
due O
to O
activation O
of O
alpha(2A)-adrenoceptors B-GENE-Y
but O
other, O
presumably O

I(1)-imidazoline B-GENE-Y
receptors, I-GENE-Y
are O
probably O
involved. O
Gonadotropin-releasing B-GENE-Y
hormone I-GENE-Y
receptor I-GENE-Y
gene O
expression O
during O
pubertal O
development O
of O
male O
rats. O
Appropriate O
expression O
of O
the O
GnRH B-GENE-Y
receptor I-GENE-Y
(GnRH-R) B-GENE-Y
in O
gonadotropes O
is O
critical O
for O
GnRH B-GENE-Y
signaling O
and O
hence O
for O
gonadotropin B-GENE-N
secretion O
and O
sexual O
development. O
In O
the O
present O
work, O
we O
have O
studied O
the O
ontogeny O
of O
the O
steady-state O
GnRH-R B-GENE-Y
mRNA O
levels O
in O
pituitaries O
of O
male O
rats O
from O
Day O
5 O
to O
Day O
55, O
when O
sexual O
maturity O
is O
attained. O

Developmental O
changes O
of O
gonadotropin B-GENE-N
subunit O
(alpha, O
FSHbeta, B-GENE-Y
and O
LHbeta) B-GENE-Y
mRNA O
levels O
were O
also O
assessed. O
In O
addition, O
the O
role O
of O
the O
endogenous O
GnRH B-GENE-Y
on O
the O
maturational O
changes O
of O
GnRH-R B-GENE-Y
and O
gonadotropin B-GENE-N
subunit O
gene O
expression O
was O
investigated. O
Messenger O
RNA O
levels O
were O
determined O
by O
Northern O
blot O
analysis O
of O
total O
RNA O
from O
anterior O
pituitaries. O
Amounts O
of O
the O
most O
abundant O
(5.0 O
kb) O
GnRH-R B-GENE-Y
mRNA O
increased O
slowly O
from O
Day O
5 O
through O
the O
infantile O
and O
the O
juvenile O
periods, O
to O
peak O

at O
Day O
35 O
(12-fold O
increase O
vs. O
Day O
5). O
Thereafter, O
the O
levels O
of O
the O
GnRH-R B-GENE-Y
mRNA O
decline O
slightly O
until O
Day O
55 O
(33% O
decrease O
vs. O
Day O
35). O
Parallel O
changes O
were O
observed O
on O
the O
4.5-kb O
transcript O
of O
the O
GnRH-R B-GENE-Y
gene. O
Alpha O
subunit O
mRNA O
was O
easily O
detected O
at O
Day O
5, O
and O
its O
levels O
increased O
progressively O
through O
the O
infantile O
period O
(2.5-fold O
increase) O
and O
peaked O
at O
Day O
25 O
(3.3-fold O
increase O
vs. O
Day O
5) O
with O
a O
smooth O
nonstatistically O
significant O
increment O

until O
Day O
35; O
then O
it O
decreased O
by O
41.5% O
at O
Day O
55. O
FSHbeta B-GENE-Y
and O
LHbeta B-GENE-Y
mRNA O
levels O
rose O
slowly O
until O
Day O
25. O
A O
sharp O
rise O
occurred O
thereafter O
to O
reach O
maximum O
levels O
at O
Day O
35 O
(5.8-fold O
for O
FSHbeta B-GENE-Y
and O
3.8-fold O
for O
LHbeta B-GENE-Y
vs. O
Day O
25). O
Thereafter, O
the O
levels O
of O
both O
mRNAs O
fell O
until O
Day O
55 O
(44.1% O
decrease O
for O
FSHbeta B-GENE-Y
and O
37.1% O
decrease O
for O
LHbeta B-GENE-Y
vs. O
Day O
35). O
To O
ascertain O
whether O
developmental O
activation O
of O

the O
GnRH-R B-GENE-Y
and O
gonadotropin B-GENE-N
subunit O
gene O
expression O
is O
GnRH B-GENE-Y
dependent, O
we O
have O
studied O
the O
effect O
of O
blocking O
the O
endogenous O
GnRH B-GENE-Y
action O
by O
treating O
developing O
male O
rats O
with O
the O
specific O
GnRH B-GENE-Y
antagonist O
cetrorelix O
(1.5 O
mg/kg O
body O
weight/week, O
s.c.) O
through O
the O
infantile O
(Days O
5-20) O
and O
the O
juvenile O
periods O
(Days O
20-35). O
Cetrorelix B-CHEMICAL
completely O
blocked O
the O
rise O
of O
levels O
of O
the O
two O
most O
abundant O
species, O
5.0 O
kb O
and O
4.5 O
kb, O
of O
the O

GnRH-R B-GENE-Y
mRNA, O
during O
both O
the O
infantile O
and O
the O
juvenile O
periods. O
Cetrorelix B-CHEMICAL
also O
abolished O
the O
developmental O
rise O
of O
the O
gonadotropin B-GENE-N
beta I-GENE-N
subunit O
mRNAs O
during O
the O
two O
periods O
of O
the O
study. O
In O
contrast, O
the O
alpha O
subunit O
gene O
expression O
was O
not O
altered O
by O
cetrorelix O
treatment O
during O
any O
of O
the O
two O
periods. O
These O
data O
demonstrate O
that O
sexual O
maturation O
of O
male O
rats O
is O
accompanied O
by O
a O
progressive O
and O
concerted O
induction O
of O
GnRH-R B-GENE-Y
and O
gonadotropin B-GENE-N
subunit O
gene O
expression. O
Developmental O
activation O
of O
GnRH-R B-GENE-Y
and O
gonadotropin B-GENE-N
beta I-GENE-N
subunit O
genes O
is O

GnRH B-GENE-Y
dependent. O
The O
apparent O
GnRH-independent B-GENE-Y
regulation O
of O
the O
alpha-glycoprotein B-GENE-N
subunit O
mRNA O
levels O
may O
be O
due O
to O
the O
contribution O
of O
thyrotropes O
and O
perhaps O
to O
the O
presence O
of O
exclusive O
regulatory O
signals O
for O
this O
gene. O
Nonsedating O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonists. O
The O
chemistry, O
pharmacology, O
pharmacokinetics, O
clinical O
efficacy, O
adverse O
effects, O
and O
dosages O
of O
the O
nonsedating O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonists O
terfenadine, B-CHEMICAL
astemizole, B-CHEMICAL
loratadine, B-CHEMICAL
and O
acrivastine B-CHEMICAL
are O
reviewed. O

Terfenadine B-CHEMICAL
and O
astemizole B-CHEMICAL
are O
chemically O
unrelated O
to O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonists O
such O
as O
diphenhydramine B-CHEMICAL
and O
chlorpheniramine. B-CHEMICAL
Loratadine B-CHEMICAL
is O
structurally O
related O
to O
the O
antihistamine O
azatadine, B-CHEMICAL
and O
acrivastine B-CHEMICAL
is O
a O
side-chain-reduced O
metabolite O
of O
the O
antihistamine O
triprolidine. B-CHEMICAL
Like O
other O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonists, O
they O
competitively O
block O
histamine B-GENE-N
receptor I-GENE-N
sites O
rather O
than O
inhibiting O
histamine B-CHEMICAL
release. O
All O
four O
drugs O
have O
relatively O
long O
half-lives O
and O
are O
rapidly O
absorbed O
after O
oral O
administration. O

Terfenadine, B-CHEMICAL
astemizole, B-CHEMICAL
and O
loratadine B-CHEMICAL
are O
metabolized O
extensively O
in O
the O
liver; O
terfenadine B-CHEMICAL
and O
astemizole B-CHEMICAL
are O
both O
97% O
protein O
bound. O
Terfenadine B-CHEMICAL
60 O
mg O
twice O
daily O
has O
been O
shown O
to O
be O
as O
effective O
as O
conventional O
antihistamines O
for O
the O
treatment O
of O
seasonal O
allergic O
rhinitis. O
In O
clinical O
trials, O
astemizole B-CHEMICAL
10 O
mg O
daily O
was O
comparable O
to O
or O
better O
than O
chlorpheniramine B-CHEMICAL
for O
treatment O
of O
chronic O
rhinitis. O
Both O
terfenadine B-CHEMICAL
and O
astemizole B-CHEMICAL
were O
effective O
for O
treatment O
of O
chronic O
urticaria. O
For O
treatment O
of O
seasonal O

allergic O
rhinitis, O
loratadine B-CHEMICAL
combined O
with O
pseudoephedrine B-CHEMICAL
may O
be O
preferable O
to O
triprolidine-pseudoephedrine B-CHEMICAL
and O
acrivastine-pseudoephedrine B-CHEMICAL
combinations O
that O
require O
more O
frequent O
dosing. O
Acrivastine B-CHEMICAL
must O
be O
administered O
more O
frequently O
than O
the O
other O
nonsedating O
antihistamines. O
None O
of O
these O
four O
agents O
impairs O
psychomotor O
activity. O
Infrequently O
reported O
adverse O
effects O
include O
dry O
mouth, O
skin O
reactions, O
and O
weight O
gain. O
The O
absence O
of O
substantial O
sedative O
effects O
and O
the O
less-frequent O
dosing O
schedules O
make O
these O
agents O
good O
alternatives O
to O
the O
classic O

antihistamines O
for O
treatment O
of O
seasonal O
and O
chronic O
rhinitis O
and O
chronic O
urticaria. O
Anti-inflammatory O
effect O
of O
prunetin B-CHEMICAL
via O
the O
suppression O
of O
NF-κB B-GENE-N
pathway. O
Prunetin B-CHEMICAL
is O
an O
O-methylated B-CHEMICAL
isoflavone, I-CHEMICAL
which O
is O
found O
in O
Prunus O
yedoensis. O
To O
date O
no O
report O
has O
been O
published O
on O
anti-inflammatory O
activities O
of O
prunetin. B-CHEMICAL
In O
the O
present O
study, O
the O
anti-inflammatory O
effect O
of O
prunetin B-CHEMICAL
on O
LPS-stimulated O
RAW O
264.7 O
macrophage O
and O
LPS-induced O
septic O
shock O
model O
were O
investigated. O

Inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS), B-GENE-Y
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α), B-GENE-Y
interleukin-6 B-GENE-Y
(IL-6), B-GENE-Y
and O
interleukin-1β B-GENE-Y
(IL-1β) B-GENE-Y
expressions O
were O
determined O
by O
western O
blot O
and O
or O
realtime-PCR O
(RT-PCR). O
To O
elucidate O
its O
underlying O
mechanism, O
nuclear B-GENE-N
factor-kappa I-GENE-N
B I-GENE-N
(NF-κb) B-GENE-N
activation O
and O
its O
downstream O
pathways O
were O
investigated O
by O

NF-κB B-GENE-N
transcription O
factor O
assay, O
reporter O
gene O
expression, O
and O
western O
blot. O
In O
vivo O
anti-inflammatory O
effects O
of O
prunetin B-CHEMICAL
were O
evaluated O
in O
LPS-induced O
endotoxemia. O
Promoter O
assay O
revealed O
that O
prunetin B-CHEMICAL
inhibits O
LPS-induced O
nitric B-CHEMICAL
oxide I-CHEMICAL
and O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
production O
through O
the O
suppression O
of O
iNOS B-GENE-Y
and O
COX-2 B-GENE-Y
at O
the O
transcriptional O
level. O
In O
addition, O
prunetin B-CHEMICAL
inhibits O
NF-κB-dependent B-GENE-N
inflammatory O
responses O
by O
modulating O
IκB B-GENE-N
kinase I-GENE-N
(IKK)-inhibitor B-GENE-N

κBα I-GENE-Y
(IκBα)-NF-κB B-GENE-Y
signaling. O
Consistent O
with O
these O
results, O
prunetin B-CHEMICAL
significantly O
reduced O
serum O
levels O
of O
inflammatory O
cytokines B-GENE-N
and O
mortality O
in O
mice O
challenged O
with O
lipopolysaccharide. O
These O
findings O
offer O
a O
potential O
mechanism O
for O
the O
anti-inflammatory O
activity O
of O
prunetin. B-CHEMICAL
G6PC2: B-GENE-Y
A O
Negative O
Regulator O
of O
Basal O
Glucose-Stimulated B-CHEMICAL
Insulin B-GENE-Y
Secretion. O
Elevated O
fasting O
blood O
glucose B-CHEMICAL
(FBG) O
is O
associated O
with O
increased O
risk O
for O
the O
development O
of O
type O
2 O
diabetes O
and O

cardiovascular-associated O
mortality. O
Genome-wide O
association O
studies O
(GWAS) O
have O
linked O
polymorphisms O
in O
G6PC2 B-GENE-Y
with O
variations O
in O
FBG O
and O
body O
fat, O
although O
not O
insulin B-GENE-Y
sensitivity O
or O
glucose B-CHEMICAL
tolerance. O
G6PC2 B-GENE-Y
encodes O
an O
islet-specific, O
endoplasmic O
reticulum-resident O
glucose-6-phosphatase B-GENE-Y
catalytic I-GENE-Y
subunit. I-GENE-Y
A O
combination O
of O
in O
situ O
perfused O
pancreas, O
in O
vitro O
isolated O
islet, O
and O
in O
vivo O
analyses O
were O
used O
to O
explore O
the O
function O
of O
G6pc2 B-GENE-Y
in O
mice. O
G6pc2 B-GENE-Y

deletion O
had O
little O
effect O
on O
insulin B-GENE-N
sensitivity O
and O
glucose B-CHEMICAL
tolerance, O
whereas O
body O
fat O
was O
reduced O
in O
female O
G6pc2 B-GENE-Y
knockout O
(KO) O
mice O
on O
both O
a O
chow O
and O
high-fat O
diet, O
observations O
that O
are O
all O
consistent O
with O
human O
GWAS O
data. O
G6pc2 B-GENE-Y
deletion O
resulted O
in O
a O
leftward O
shift O
in O
the O
dose-response O
curve O
for O
glucose-stimulated B-CHEMICAL
insulin B-GENE-N
secretion O
(GSIS). O
As O
a O
consequence, O
under O
fasting O
conditions O
in O
which O
plasma O
insulin B-GENE-N
levels O
were O
identical, O
blood O
glucose B-CHEMICAL
levels O
were O
reduced O
in O
G6pc2 B-GENE-Y
KO O
mice, O
again O
consistent O
with O
human O
GWAS O

data. O
Glucose-6-phosphatase B-GENE-Y
activity O
was O
reduced, O
whereas O
basal O
cytoplasmic O
calcium B-CHEMICAL
levels O
were O
elevated O
in O
islets O
isolated O
from O
G6pc2 B-GENE-Y
KO O
mice. O
These O
data O
suggest O
that O
G6pc2 B-GENE-Y
represents O
a O
novel, O
negative O
regulator O
of O
basal O
GSIS O
that O
acts O
by O
hydrolyzing O
glucose-6-phosphate, B-CHEMICAL
thereby O
reducing O
glycolytic O
flux. O
Transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
β I-GENE-Y
integrates O
Smad B-GENE-Y
3 I-GENE-Y
to O
mechanistic B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
complexes O
to O
arrest O
deptor B-GENE-Y
abundance O
for O
glomerular O
mesangial O
cell O
hypertrophy. O

In O
many O
renal O
diseases, O
transforming B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
β I-GENE-Y
(TGFβ)-stimulated B-GENE-Y
canonical O
Smad B-GENE-Y
3 I-GENE-Y
and O
noncanonical O
mechanistic B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
(mTOR) B-GENE-Y
promote O
increased O
protein O
synthesis O
and O
mesangial O
cell O
hypertrophy. O
The O
cellular O
underpinnings O
involving O
these O
signaling O
molecules O
to O
regulate O
mesangial O
cell O
hypertrophy O
are O
not O
fully O
understood. O
Deptor B-GENE-Y
has O
recently O
been O
identified O
as O
an O
mTOR B-GENE-Y
interacting O
protein O
and O
functions O
as O
an O
endogenous O
inhibitor O
of O
the O
kinase B-GENE-N
activity O
for O
both O
TORC1 B-GENE-Y
and O
TORC2. B-GENE-Y
Prolonged O
incubation O
of O
mesangial O

cells O
with O
TGFβ B-GENE-Y
reduced O
the O
levels O
of O
deptor B-GENE-Y
concomitant O
with O
an O
increase O
in O
TORC1 B-GENE-Y
and O
TORC2 B-GENE-Y
activity. O
Sustained O
TGFβ B-GENE-Y
activation O
was O
required O
to O
inhibit O
association O
of O
deptor B-GENE-Y
with O
mTOR, B-GENE-N
whereas O
rapid O
activation O
had O
no O
effect. O
Using O
the O
mTOR B-GENE-Y
inhibitor O
PP242, B-CHEMICAL
we O
found O
that O
TGFβ-induced B-GENE-Y
both O
early O
and O
sustained O
activation O
of O
TORC1 B-GENE-Y
and O
TORC2 B-GENE-Y
was O
necessary O
for O
deptor B-GENE-Y
suppression. O
PP242-induced B-CHEMICAL
reversal O
of O
deptor B-GENE-Y
suppression O
by O
TGFβ B-GENE-Y
was O
associated O
with O
a O
significant O
inhibition O
of O

TGFβ-stimulated B-GENE-Y
protein O
synthesis O
and O
hypertrophy. O
Interestingly, O
expression O
of O
siRNA O
against O
Smad B-GENE-Y
3 I-GENE-Y
or O
Smad B-GENE-Y
7, I-GENE-Y
which O
blocks O
TGFβ B-GENE-N
receptor-specific I-GENE-N
Smad B-GENE-Y
3 I-GENE-Y
signaling, O
prevented O
TGFβ-induced B-GENE-Y
suppression O
of O
deptor B-GENE-Y
abundance O
and O
TORC1/2 B-GENE-N
activities. O
Furthermore, O
overexpression O
of O
Smad B-GENE-Y
3 I-GENE-Y
decreased O
deptor B-GENE-Y
expression O
similar O
to O
TGFβ B-GENE-Y
stimulation O
concomitant O
with O
increased O
TORC1 B-GENE-Y
and O
TORC2 B-GENE-Y
activities. O
Finally, O
knockdown O
of O
deptor B-GENE-Y
reversed O
Smad B-GENE-Y
7-mediated I-GENE-Y
inhibition O
of O
protein O
synthesis O
and O
mesangial O

cell O
hypertrophy O
induced O
by O
TGFβ. B-GENE-Y
These O
data O
reveal O
the O
requirement O
of O
both O
early O
and O
late O
activation O
of O
mTOR B-GENE-Y
for O
TGFβ-induced B-GENE-Y
protein O
synthesis. O
Our O
results O
support O
that O
TGFβ-stimulated B-GENE-Y
Smad B-GENE-Y
3 I-GENE-Y
acts O
as O
a O
key O
node O
to O
instill O
a O
feedback O
loop O
between O
deptor B-GENE-Y
down-regulation O
and O
TORC1/2 B-GENE-N
activation O
in O
driving O
mesangial O
cell O
hypertrophy. O
R-modafinil B-CHEMICAL
(armodafinil): B-CHEMICAL
a O
unique O
dopamine B-CHEMICAL
uptake O
inhibitor O
and O
potential O
medication O
for O
psychostimulant O
abuse. O

BACKGROUND: O
(+/-)-Modafinil B-CHEMICAL
has O
piqued O
interest O
as O
a O
treatment O
for O
attention-deficit/hyperactivity O
disorder O
and O
stimulant O
dependence. O
The O
R-enantiomer B-CHEMICAL
of I-CHEMICAL
modafinil I-CHEMICAL
might O
have O
unique O
pharmacological O
properties O
that O
should O
be O
further O
investigated. O
METHODS: O
(+/-)-Modafinil B-CHEMICAL
and O
its O
R-(-)- O
and O
S-(+)-enantiomers O
were O
synthesized O
and O
tested O
for O
inhibition O
of O
[(3)H] B-CHEMICAL
dopamine I-CHEMICAL
(DA) B-CHEMICAL
uptake O
and O

[(3)H]WIN B-CHEMICAL
35428 I-CHEMICAL
binding O
in O
human B-GENE-Y
dopamine I-GENE-Y
transporter I-GENE-Y
(DAT) B-GENE-Y
wild-type O
and O
mutants O
with O
altered O
conformational O
equilibria. O
Data O
were O
compared O
with O
cocaine B-CHEMICAL
and O
the O
atypical O
DA B-CHEMICAL
uptake O
inhibitor, O
JHW B-CHEMICAL
007. I-CHEMICAL
R- B-CHEMICAL
and I-CHEMICAL
S-modafinil I-CHEMICAL
were O
also O
evaluated O
in O
microdialysis O
studies O
in O
the O
mouse O
nucleus O
accumbens O
shell O
and O
in O
a O
cocaine B-CHEMICAL
discrimination O
procedure. O
RESULTS: O
(+/-)-, B-CHEMICAL
R-, I-CHEMICAL
and I-CHEMICAL
S-modafinil I-CHEMICAL
bind O
to O
the O
DAT B-GENE-Y
and O
inhibit O

DA B-CHEMICAL
uptake O
less O
potently O
than O
cocaine, B-CHEMICAL
with O
R-modafinil B-CHEMICAL
having O
approximately O
threefold O
higher O
affinity O
than O
its O
S-enantiomer. O
Molecular O
docking O
studies O
revealed O
subtle O
differences O
in O
binding O
modes O
for O
the O
enantiomers. O
R-modafinil B-CHEMICAL
was O
significantly O
less O
potent O
in O
the O
DAT B-GENE-Y
Y156F B-GENE-N
mutant O
compared O
with O
wild-type O
DAT, B-GENE-Y
whereas O
S-modafinil B-CHEMICAL
was O
affected O
less. O
Studies O
with O
the O
Y335A B-GENE-N
DAT B-GENE-Y
mutant O
showed O
that O
the O
R- O
and O
S-enantiomers O
tolerated O
the O
inward-facing O
conformation O
better O
than O
cocaine, B-CHEMICAL
which O
was O
further O
supported O
by O

[2-(trimethylammonium)ethyl]-methanethiosulfonate B-CHEMICAL
reactivity O
on O
the O
DAT B-GENE-Y
E2C B-GENE-N
I159C. B-GENE-N
Microdialysis O
studies O
demonstrated O
that O
both O
R- B-CHEMICAL
and I-CHEMICAL
S-modafinil I-CHEMICAL
produced O
increases O
in O
extracellular O
DA B-CHEMICAL
concentrations O
in O
the O
nucleus O
accumbens O
shell O
less O
efficaciously O
than O
cocaine B-CHEMICAL
and O
with O
a O
longer O
duration O
of O
action. O
Both O
enantiomers O
fully O
substituted O
in O
mice O
trained O
to O
discriminate O
cocaine B-CHEMICAL
from O
saline. O
CONCLUSIONS: O
R-modafinil B-CHEMICAL
displays O
an O
in O
vitro O
profile O
different O
from O

cocaine. B-CHEMICAL
Future O
trials O
with O
R-modafinil B-CHEMICAL
as O
a O
substitute O
therapy O
with O
the O
potential O
benefit O
of O
cognitive O
enhancement O
for O
psychostimulant O
addiction O
are O
warranted. O
Apple O
polyphenols B-CHEMICAL
suppress O
antigen O
presentation O
of O
ovalbumin B-GENE-N
by O
THP-1-derived O
dendritic O
cells. O
Apple O
polyphenol B-CHEMICAL
extract O
(AP) O
and O
procyanidin B-CHEMICAL
contained O
in O
AP O
were O
investigated O
for O
their O
immunomodulatory O
effects O
using O
THP-1-derived O
human O
dendritic O
cells O
(TDDCs). O
The O
expression O
levels O
of O
HLA-DR B-GENE-N
(MHC B-GENE-N
class I-GENE-N
II) I-GENE-N
and O
CD86 B-GENE-N

(costimulatory O
molecule) O
were O
measured O
as O
an O
indicator O
of O
antigen O
presentation O
in O
TDDCs. O
A O
significant O
decrease O
in O
HLA-DR B-GENE-N
expression O
was O
observed O
in O
the O
AP O
and O
fractionated O
procyanidin-treated B-CHEMICAL
cells O
in O
the O
presence O
of O
ovalbumin B-GENE-N
(OVA), B-GENE-N
but O
no O
effect O
on O
CD86 B-GENE-N
expression O
was O
observed. O
The O
uptake O
of O
OVA B-GENE-N
was O
not O
inhibited O
by O
AP O
treatment, O
and O
the O
gene O
expression O
of O
membrane-associated O
RING-CH B-GENE-N
ubiquitin B-GENE-N
E3 I-GENE-N
ligase, I-GENE-N
MARCH1, B-GENE-N
was O
up-regulated O
by O
AP O
treatment. O
It O
can O
therefore O
be O
presumed O
that O
AP O
suppresses O

HLA-DR B-GENE-N
expression O
via O
the O
ubiquitin-proteasome B-GENE-N
pathway. O
Furthermore, O
the O
up-regulation O
of O
IL-12 B-GENE-N
and O
TNF-α B-GENE-N
was O
found O
in O
the O
procyanidin B-CHEMICAL
trimers-treated O
cells O
in O
the O
presence O
of O
OVA. B-GENE-N
These O
results O
suggest O
that O
apple O
polyphenols B-CHEMICAL
would O
be O
an O
effective O
factor O
for O
the O
development O
of O
immunomodulatory O
agents O
with O
suppressive O
effects O
of O
antigen O
presentation. O
Alternariol B-CHEMICAL
induces O
abnormal O
nuclear O
morphology O
and O
cell O
cycle O
arrest O
in O
murine O
RAW O
264.7 O
macrophages. O
The O
mycotoxin O
alternariol B-CHEMICAL

(AOH), B-CHEMICAL
a O
frequent O
contaminant O
in O
fruit O
and O
cereal O
products, O
is O
known O
to O
induce O
DNA O
damage O
with O
subsequent O
cell O
cycle O
arrest. O
Here O
we O
elucidated O
the O
effects O
of O
AOH B-CHEMICAL
on O
stages O
of O
cell O
cycle O
progression O
using O
the O
RAW O
264.7 O
macrophage O
model. O
AOH B-CHEMICAL
resulted O
in O
an O
accumulation O
of O
cells O
in O
the O
G2/M-phase O
(4N). O
Most O
cells O
exhibited O
a O
large O
G2 O
nucleus O
whereas O
numbers O
of O
true O
mitotic O
cells O
were O
reduced O
relative O
to O
control. O
Both O
cyclin B-GENE-Y
B1 I-GENE-Y
and O
p-cdc2 B-GENE-Y
levels O
increased, O
while O
cyclin B-GENE-Y
B1 I-GENE-Y
remained O
in O
the O

cytoplasm; O
suggesting O
arrest O
in O
the O
G2/M O
transition O
point. O
Remarkably, O
after O
exposure O
to O
AOH B-CHEMICAL
for O
24h, O
most O
of O
the O
cells O
exhibited O
abnormally O
shaped O
nuclei, O
as O
evidenced O
by O
partly O
divided O
nuclei, O
nuclear O
blebs, O
polyploidy O
and O
micronuclei O
(MN). O
AOH B-CHEMICAL
treatment O
also O
induced O
abnormal O
Aurora B-GENE-Y
B I-GENE-Y
bridges, O
suggesting O
that O
cytokinesis O
was O
interfered O
within O
cells O
undergoing O
karyokinesis. O
A O
minor O
part O
of O
the O
resultant O
G1 O
tetraploid O
(4N) O
cells O
re-entered O
the O
S-phase O
and O
progressed O
to O
8N O

cells. O
Long O
acting O
beta-agonists O
versus O
theophylline B-CHEMICAL
for O
maintenance O
treatment O
of O
asthma. O
BACKGROUND: O
Theophylline B-CHEMICAL
and O
long O
acting O
beta2-agonists O
are O
bronchodilators O
used O
for O
the O
management O
of O
persistent O
asthma O
symptoms, O
especially O
nocturnal O
asthma. O
They O
represent O
different O
classes O
of O
drug O
with O
differing O
side-effect O
profiles. O
OBJECTIVES: O
To O
assess O
the O
comparative O
efficacy, O
safety O
and O
side-effects O
of O
long-acting O
beta-agonists O
and O
theophylline B-CHEMICAL
in O
the O
maintenance O
treatment O
of O
asthma. O
SEARCH O

STRATEGY: O
Randomised, O
controlled O
trials O
(RCTs) O
were O
identified O
using O
the O
Cochrane O
Airways O
Group O
register. O
The O
register O
was O
searched O
using O
the O
following O
terms: O
asthma O
and O
theophylline B-CHEMICAL
and O
long O
acting O
beta-agonist O
or O
formoterol B-CHEMICAL
or O
foradile B-CHEMICAL
or O
eformoterol B-CHEMICAL
or O
salmeterol B-CHEMICAL
or O
bambuterol B-CHEMICAL
or O
bitolterol. B-CHEMICAL
Titles O
and O
abstracts O
were O
then O
screened O
to O
identify O
potentially O
relevant O
studies. O
The O
bibliography O
of O
each O
RCT O
was O
searched O
for O
additional O
RCTs. O
Authors O
of O
identified O
RCTs O
were O
contacted O
for O
other O
relevant O
published O
and O
unpublished O
studies. O

SELECTION O
CRITERIA: O
All O
included O
studies O
were O
RCTs O
involving O
adults O
and O
children O
with O
clinical O
evidence O
of O
asthma. O
These O
studies O
must O
have O
compared O
oral O
sustained O
release O
and/or O
dose O
adjusted O
theophylline B-CHEMICAL
with O
an O
inhaled O
long-acting O
beta-agonist. O
DATA O
COLLECTION O
AND O
ANALYSIS: O
Potentially O
relevant O
trials, O
identified O
by O
screening O
titles O
and/or O
abstracts, O
were O
obtained. O
Two O
reviewers O
independently O
assessed O
full O
text O
versions O
of O
these O
trials O
to O
decided O
whether O
the O
trial O
should O
be O
included O
in O
the O
review, O
and O
assessed O
its O
methodological O
quality. O
Where O
there O
was O
disagreement O
between O

reviewers, O
this O
was O
resolved O
by O
consensus, O
or O
reference O
to O
a O
third O
party. O
Data O
were O
extracted O
by O
two O
independent O
reviewers. O
Inter-rater O
reliability O
was O
assessed O
by O
simple O
agreement. O
Study O
authors O
were O
contacted O
to O
clarify O
randomisation O
methods, O
provide O
missing O
data, O
verify O
the O
data O
extracted O
and O
identify O
unpublished O
studies. O
Relevant O
pharmaceutical O
manufacturers O
were O
also O
contacted. O
MAIN O
RESULTS: O
Six O
trials O
met O
the O
inclusion O
criteria. O
Five O
used O
salmeterol B-CHEMICAL
and O
one, O
biltoterol. B-CHEMICAL
They O
were O
of O
varying O
quality. O
There O
was O
a O
trend O
for O
salmeterol B-CHEMICAL
to O
improve O
FEV1 O
more O
than O
theophylline B-CHEMICAL
in O
three O

studies O
and O
salmeterol B-CHEMICAL
use O
was O
associated O
with O
more O
symptom O
free O
nights. O
Bitolterol, B-CHEMICAL
used O
in O
only O
one O
study, O
was O
reported O
to O
be O
less O
effective O
than O
theophylline. B-CHEMICAL
Subjects O
taking O
salmeterol B-CHEMICAL
experienced O
fewer O
adverse O
events O
than O
those O
using O
theophylline B-CHEMICAL
(Relative O
Risk O
0.38; O
95%Confidence O
Intervals O
0.25, O
0.57). O
Significant O
reductions O
were O
reported O
for O
central O
nervous O
system O
adverse O
events O
(Relative O
Risk O
0.51; O
95%Confidence O
Intervals O
0.30, O
0.88) O
and O
gastrointestinal O

adverse O
events O
(Relative O
Risk O
0.32; O
95%Confidence O
Intervals O
0.17, O
0.59). O
REVIEWER'S O
CONCLUSIONS: O
Salmeterol B-CHEMICAL
may O
be O
more O
effective O
than O
theophylline B-CHEMICAL
in O
reducing O
asthma O
symptoms O
including O
night O
waking O
and O
improving O
lung O
function. O
More O
adverse O
events O
occurred O
in O
subjects O
using O
theophylline B-CHEMICAL
when O
compared O
to O
salmeterol. B-CHEMICAL
Prohormone B-GENE-Y
convertase-1 I-GENE-Y
will O
process O
prorelaxin, B-GENE-N
a O
member O
of O
the O
insulin B-GENE-Y
family O
of O
hormones. O
Relaxin B-GENE-N
is O
a O
polypeptide O
hormone O
involved O
in O

remodeling O
of O
the O
birth O
canal O
during O
parturition. O
It O
is O
synthesized O
as O
a O
preprohormone O
precursor, O
which O
undergoes O
specific O
processing O
to O
form O
the O
mature O
two-chain O
disulfide-linked B-CHEMICAL
active O
species O
that O
is O
secreted O
by O
the O
cell. O
A O
major O
part O
of O
this O
processing O
requires O
endoproteolytic O
cleavage O
at O
specific O
pairs O
of O
basic O
amino B-CHEMICAL
acid I-CHEMICAL
residues, O
an O
event O
necessary O
for O
the O
maturation O
of O
a O
variety O
of O
important O
biologically O
active O
proteins, O
such O
as O
insulin B-GENE-Y
and O
nerve B-GENE-Y
growth I-GENE-Y
factor. I-GENE-Y
Human B-GENE-Y
type I-GENE-Y
2 I-GENE-Y
preprorelaxin I-GENE-Y
was O
coexpressed O
in O
human O
kidney O
293 O
cells O
with O
the O
candidate O

prohormone B-GENE-N
convertase-processing I-GENE-N
enzymes I-GENE-N
mPC1 B-GENE-Y
or O
mPC2, B-GENE-Y
both O
cloned O
from O
the O
mouse O
pituitary O
tumor O
AtT-20 O
cell O
line, O
or O
with O
the O
yeast B-GENE-Y
kex2 I-GENE-Y
alpha-mating B-GENE-Y
factor-converting I-GENE-Y
enzyme I-GENE-Y
from O
Saccharomyces O
cerevisiae. O
Prorelaxin B-GENE-N
expressed O
alone O
in O
293 O
cells O
was O
secreted O
into O
the O
culture O
medium O
unprocessed. O
Transient O
coexpression O
with O
mPC1 B-GENE-Y
or O
kex2, B-GENE-Y
but O
not O
with O
mPC2, B-GENE-Y
resulted O
in O
the O
secretion O
of O
a O
low O
mol O
wt O
species O
with O
an O
electrophoretic O
mobility O
very O

similar, O
if O
not O
identical, O
to O
that O
of O
authentic O
mature O
relaxin B-GENE-N
purified O
from O
human O
placenta. O
This O
species O
was O
precipitable O
by O
monoclonal O
antibodies O
specific O
for O
relaxin B-GENE-N
and O
had O
a O
retention O
time O
on O
reverse O
phase O
HPLC O
comparable O
to O
that O
of O
relaxin. B-GENE-N
Its O
analysis O
by O
both O
electrospray O
and O
fast O
atom O
bombardment O
mass O
spectrometry O
generated O
mass O
data O
that O
were O
consistent O
only O
with O
mature O
relaxin. B-GENE-N
The O
basic O
residues O
required O
for O
mPC1-dependent B-GENE-Y
cleavage O
of O
prorelaxin B-GENE-N
are O
defined O
by O
site-directed O
mutagenesis. O
Binding O
between O
heparin O
and O
the O
integrin B-GENE-N

VLA-4. B-GENE-Y
Heparin O
possesses O
antimetastatic O
effects O
that O
were O
related O
to O
various O
molecular O
mechanisms O
beyond O
anticoagulant O
activities. O
The O
ability O
of O
heparin O
to O
interfere O
with O
the O
function O
of O
adhesion B-GENE-N
receptors I-GENE-N
in O
the O
metastatic O
course O
appears O
as O
a O
promising O
therapeutic O
approach. O
This O
refers O
to O
numerous O
findings O
that O
heparin O
attenuates O
metastasis O
in O
a O
selectin-dependent O
manner. O
We O
recently O
demonstrated O
that O
heparin O
interferes O
with O
the O
integrin B-GENE-N
VLA-4 B-GENE-Y
on O
murine O
melanoma O
cells O
binding O
to O
VCAM-1. B-GENE-Y
To O
confirm O
this O
activity O
and O
to O
obtain O
further O
insight O
into O
molecular O
recognition O
of O

heparin O
by O
VLA-4, B-GENE-Y
we O
investigated O
the O
inhibition O
of O
VLA-4 B-GENE-Y
mediated O
binding O
of O
human O
melanoma O
MV3 O
cells O
to O
immobilised O
VCAM-1 B-GENE-Y
by O
different O
heparins. O
The O
size O
of O
heparin O
has O
an O
important O
impact O
on O
inhibition. O
Unfractionated O
heparin O
(UFH) O
and O
tinzaparin, B-CHEMICAL
a O
low-molecular-weight O
heparin O
(LMWH) O
representing O
a O
mean O
of O
about O
18-20 O
monomers, O
displayed O
high O
inhibitory O
activity. O
Fractionating O
tinzaparin B-CHEMICAL
to O
14-18 O
monomers O
reduced O
inhibition O

slightly, O
while O
the O
pentasaccharide B-CHEMICAL
fondaparinux I-CHEMICAL
was O
without O
effects. O
To O
confirm O
molecular O
recognition O
of O
tinzaparin B-CHEMICAL
by O
VLA-4, B-GENE-Y
a O
surface O
acoustic O
wave-biosensor O
was O
applied. O
A O
VLA-4 B-GENE-Y
containing O
membrane O
preparation O
of O
MV3 O
cells O
was O
immobilised O
at O
the O
sensors O
to O
allow O
for O
detection O
of O
kinetic O
binding O
constants O
of O
tinzaparin B-CHEMICAL
compared O
to O
VCAM-1. B-GENE-Y
Tinzaparin B-CHEMICAL
binds O
to O
VLA-4 B-GENE-Y
with O
affinity O
in O
the O
low O
micromolar O
range O
(4.61 O
x O
10(-6) O
M), O
which O
clearly O
indicates O
specific O
molecular O
recognition. O
Furthermore, O

tinzaparin B-CHEMICAL
displays O
a O
nearly O
identical O
k(off) O
compared O
to O
VCAM-1 B-GENE-Y
(5.13 O
x O
10(-3) O
s(-1) O
versus O
3.44 O
x O
10(-3) O
s(-1)) O
which O
is O
evident O
for O
interference O
with O
the O
ligand O
binding. O
The O
data O
provide O
evidence O
for O
a O
direct O
confirmation O
of O
heparin O
binding O
to O
VLA-4 B-GENE-Y
and O
thus, O
contribute O
to O
understand O
the O
antimetastatic O
activity O
of O
heparin. O
Extracellular B-GENE-N
loop I-GENE-N
3 I-GENE-N
(EL3) B-GENE-N
and O
EL3-proximal B-GENE-N
transmembrane I-GENE-N
helix I-GENE-N
7 I-GENE-N
of O
the O
mammalian B-GENE-N
type I-GENE-N
I I-GENE-N

and I-GENE-N
type I-GENE-N
II I-GENE-N
gonadotropin-releasing I-GENE-N
hormone I-GENE-N
(GnRH) I-GENE-N
receptors I-GENE-N
determine O
differential O
ligand O
selectivity O
to O
GnRH-I B-GENE-Y
and O
GnRH-II. B-GENE-Y
Mammalian B-GENE-N
type I-GENE-N
I I-GENE-N
and I-GENE-N
II I-GENE-N
gonadotropin-releasing I-GENE-N
hormone I-GENE-N
(GnRH) I-GENE-N
receptors I-GENE-N
(GnRHRs) B-GENE-N
show O
differential O
ligand O
preference O
for O
GnRH-I B-GENE-Y
and O
GnRH-II, B-GENE-Y
respectively. O
Using O
a O
variety O
of O
chimeric O
receptors O
based O
on O
green B-GENE-Y
monkey I-GENE-Y
GnRHR-2 I-GENE-Y
(gmGnRHR-2), B-GENE-Y
a O
representative O
type B-GENE-Y
II I-GENE-Y

GnRHR, I-GENE-Y
and O
rat B-GENE-Y
GnRHR, I-GENE-Y
a O
representative O
type B-GENE-Y
I I-GENE-Y
GnRHR, I-GENE-Y
this O
study O
elucidated O
specific O
domains O
responsible O
for O
this O
ligand O
selectivity. O
A O
chimeric O
gmGnRHR-2 B-GENE-Y
with O
the O
extracellular B-GENE-N
loop I-GENE-N
3 I-GENE-N
(EL3) B-GENE-N
and O
EL3-proximal B-GENE-N
transmembrane I-GENE-N
helix I-GENE-N
7 I-GENE-N
(TMH7) B-GENE-N
of O
rat B-GENE-Y
GnRHR I-GENE-Y
showed O
a O
great O
increase O
in O
ligand O
sensitivity O
to O
GnRH-I B-GENE-Y
but O
not O
to O
GnRH-II. B-GENE-Y
Point-mutation O
studies O
indicate O
that O
four O
amino B-CHEMICAL

acids, I-CHEMICAL
Leu/Phe(7.38), B-CHEMICAL
Leu/Phe(7.43), B-CHEMICAL
Ala/Pro(7.46), B-CHEMICAL
and O
Pro/Cys(7.47) B-CHEMICAL
in O
TMH7 B-GENE-N
are O
critical O
for O
ligand O
selectivity O
as O
well O
as O
receptor O
conformation. O
Furthermore, O
a O
combinatory O
mutation O
(Pro(7.31)-Pro(7.32)-Ser(7.33) B-CHEMICAL
motif O
to O
Ser-Glu-Pro B-CHEMICAL
in O
EL3 B-GENE-N
and O
Leu(7.38), B-CHEMICAL
Leu(7.43), B-CHEMICAL

Ala(7.46), B-CHEMICAL
and O
Pro(7.47) B-CHEMICAL
to O
those O
of O
rat B-GENE-Y
GnRHR) I-GENE-Y
in O
gmGnRH-2 B-GENE-Y
exhibited O
an O
approximately O
500-fold O
increased O
sensitivity O
to O
GnRH-I, B-GENE-Y
indicating O
that O
these O
residues O
are O
critical O
for O
discriminating O
GnRH-II B-GENE-Y
from O
GnRH-I. B-GENE-Y
[Trp(7)]GnRH-I B-GENE-Y
and O
[Trp(8)]GnRH-I B-GENE-Y
but O
not O
[His(5)]GnRH-I B-GENE-Y
exhibit O
a O
higher O
potency O
in O
activating O
wild-type O

gmGnRHR-2 B-GENE-Y
than O
native O
GnRH-I, B-GENE-Y
indicating O
that O
amino B-CHEMICAL
acids I-CHEMICAL
at O
positions O
7 O
and O
8 O
of O
GnRHs B-GENE-N
are O
more O
important O
than O
position O
5 O
for O
differential O
recognition O
by O
type B-GENE-N
I I-GENE-N
and I-GENE-N
type I-GENE-N
II I-GENE-N
GnRHRs. I-GENE-N
As O
a O
whole, O
these O
data O
suggest O
a O
molecular O
coevolution O
of O
ligands O
and O
their O
receptors O
and O
facilitate O
the O
understanding O
of O
the O
molecular O
interaction O
between O
GnRHs B-GENE-N
and O
their O
cognate O
receptors. O
Success O
of O
pyridostigmine, B-CHEMICAL
physostigmine, B-CHEMICAL
eptastigmine B-CHEMICAL
and O
phosphotriesterase B-GENE-N
treatments O
in O
acute O

sarin B-CHEMICAL
intoxication. O
The O
acute O
toxicity O
of O
organophosphorus B-CHEMICAL
(OP) O
compounds O
in O
mammals O
is O
due O
to O
their O
irreversible O
inhibition O
of O
acetylcholinesterase B-GENE-N
(AChE) B-GENE-N
in O
the O
nervous O
system, O
which O
leads O
to O
increased O
synaptic O
acetylcholine B-CHEMICAL
levels. O
The O
protective O
actions O
of O
intravenously O
(i.v.) O
administered O
pyridostigmine, B-CHEMICAL
physostigmine, B-CHEMICAL
eptastigmine, B-CHEMICAL
and O
an O
organophosphate B-GENE-N
hydrolase, I-GENE-N
phosphotriesterase, B-GENE-N
in O
acute O
sarin B-CHEMICAL
intoxication O
were O
studied O
in O

mice. O
The O
acute O
intragastric O
(i.g.) O
toxicity O
(LD50) O
of O
sarin B-CHEMICAL
with O
and O
without O
the O
pretreatments O
was O
tested O
by O
the O
up-and-down O
method. O
The O
mice O
received O
pyridostigmine B-CHEMICAL
(0.06 O
mg/kg O
body O
weight), O
physostigmine B-CHEMICAL
(0.09 O
mg/kg O
body O
weight), O
the O
physostigmine B-CHEMICAL
derivative O
eptastigmine B-CHEMICAL
(0.90 O
mg/kg O
body O
weight) O
or O
phosphotriesterase B-GENE-N
(104 O
U/g, O
10.7 O
microg/g O
body O
weight) O

10 O
min O
prior O
to O
the O
i.g. O
administration O
of O
sarin. B-CHEMICAL
Physostigmine B-CHEMICAL
was O
also O
administered O
with O
phosphotriesterase. B-GENE-N
Phosphotriesterase B-GENE-N
was O
the O
most O
effective O
antidote O
in O
sarin B-CHEMICAL
intoxication. O
The O
LD50 O
value O
for O
sarin B-CHEMICAL
increased O
3.4-fold O
in O
mice O
receiving O
phosphotriesterase. B-GENE-N
Physostigmine B-CHEMICAL
was O
the O
most O
effective O
carbamate B-CHEMICAL
in O
sarin B-CHEMICAL
exposure. O
The O
protective O
ratios O
of O
physostigmine B-CHEMICAL
and O
pyridostigmine B-CHEMICAL
were O
1.5- O
and O
1.2-1.3-fold, O

respectively. O
Eptastigmine B-CHEMICAL
did O
not O
give O
any O
protection O
against O
sarin B-CHEMICAL
toxicity. O
Both O
the O
phosphotriesterase B-GENE-N
and O
physostigmine B-CHEMICAL
treatments O
protected O
the O
brain O
AChE B-GENE-Y
activities O
measured O
24 O
h O
after O
sarin B-CHEMICAL
exposure. O
In O
phosphotriesterase B-GENE-N
and O
physostigmine-treated B-CHEMICAL
mice, O
a O
4- O
and O
2-fold O
higher O
sarin B-CHEMICAL
dose, O
respectively, O
was O
needed O
to O
cause O
a O
50% O
inhibition O
of O
brain O
AChE B-GENE-Y
activity. O
Moreover, O
the O
combination O
of O
phosphotriesterase-physostigmine B-GENE-N
increased O
the O
LD50 O
value O
for O
sarin B-CHEMICAL

4.3-fold. O
The O
animals O
pretreated O
with O
phosphotriesterase-ephysostigmine B-GENE-N
tolerated O
four O
times O
the O
lethal O
dose O
in O
control O
animals, O
furthermore O
their O
survival O
time O
was O
2-3 O
h O
in O
comparison O
to O
20 O
min O
in O
controls. O
In O
conclusion, O
phosphotriesterase B-GENE-N
and O
physostigmine B-CHEMICAL
were O
the O
most O
effective O
treatments O
against O
sarin B-CHEMICAL
intoxication. O
However, O
eptastigmine B-CHEMICAL
did O
not O
provide O
any O
protection O
against O
sarin B-CHEMICAL
toxicity. O
Phase O
1 O
and O
phase O
2 O
drug O
metabolism O
and O
bile B-CHEMICAL
acid I-CHEMICAL
production O
of O
HepaRG O
cells O
in O
a O
bioartificial O
liver O

in O
absence O
of O
dimethyl B-CHEMICAL
sulfoxide. I-CHEMICAL
The O
human O
liver O
cell O
line O
HepaRG O
has O
been O
recognized O
as O
a O
promising O
source O
for O
in O
vitro O
testing O
of O
metabolism O
and O
toxicity O
of O
compounds. O
However, O
currently O
the O
hepatic O
differentiation O
of O
these O
cells O
relies O
on O
exposure O
to O
dimethylsulfoxide B-CHEMICAL
(DMSO), B-CHEMICAL
which, O
as O
a O
side O
effect, O
has O
a O
cytotoxic O
effect O
and O
represses O
an O
all-round O
hepatic O
functionality. O
The O
AMC-bioartificial O
liver O
(AMC-BAL) O
is O
a O
three-dimensional O
bioreactor O
that O
has O
previously O
been O
shown O
to O

upregulate O
various O
liver O
functions O
of O
cultured O
cells. O
We O
therefore O
cultured O
HepaRG O
cells O
in O
the O
AMC-BAL O
without O
DMSO B-CHEMICAL
and O
characterized O
the O
drug O
metabolism. O
Within O
14 O
days O
of O
culture, O
the O
HepaRG-AMC-BALs O
contained O
highly O
polarized O
viable O
liver-like O
tissue O
with O
heterogeneous O
expression O
of O
CYP3A4. B-GENE-Y
We O
found O
a O
substantial O
metabolism O
of O
the O
tested O
substrates, O
ranging O
from O
26% O
(UDP-glucuronosyltransferase B-GENE-Y
1A1), I-GENE-Y
47% O
(CYP3A4), B-GENE-Y
to O
240% O

(CYP2C9) B-GENE-Y
of O
primary O
human O
hepatocytes. O
The O
CYP3A4 B-GENE-Y
activity O
could O
be O
induced O
2-fold O
by O
rifampicin, B-CHEMICAL
whereas O
CYP2C9 B-GENE-Y
activity O
remained O
equally O
high. O
The O
HepaRG-AMC-BAL O
secreted O
bile B-CHEMICAL
acids I-CHEMICAL
at O
43% O
the O
rate O
of O
primary O
human O
hepatocytes O
and O
demonstrated O
hydroxylation, O
conjugation, O
and O
transport O
of O
bile B-CHEMICAL
salts. I-CHEMICAL
Concluding, O
culturing O
HepaRG O
cells O
in O
the O
AMC-BAL O
yields O
substantial O
phase O
1 O
and O
phase O
2 O
drug O
metabolism, O
while O
maintaining O
high O

viability, O
rendering O
DMSO B-CHEMICAL
addition O
superfluous O
for O
the O
promotion O
of O
drug O
metabolism. O
Therefore, O
AMC-BAL O
culturing O
makes O
the O
HepaRG O
cells O
more O
suitable O
for O
testing O
metabolism O
and O
toxicity O
of O
drugs. O
Dose-dependent O
effects O
of O
vitamin B-CHEMICAL
D I-CHEMICAL
on O
transdifferentiation O
of O
skeletal O
muscle O
cells O
to O
adipose O
cells. O
Fat O
infiltration O
within O
muscle O
is O
one O
of O
a O
number O
of O
features O
of O
vitamin B-CHEMICAL
D I-CHEMICAL
deficiency, O
which O
leads O
to O
a O
decline O
in O
muscle O
functionality. O
The O
origin O
of O
this O
fat O
is O
unclear, O
but O
one O
possibility O
is O
that O
it O
forms O
from O
myogenic O
precursor O
cells O
present O
in O
the O
muscle, O
which O
transdifferentiate O
into O
mature O

adipocytes. O
The O
current O
study O
examined O
the O
effect O
of O
the O
active O
form O
of O
vitamin B-CHEMICAL
D₃, I-CHEMICAL
1,25-dihydroxyvitamin B-CHEMICAL
D₃ I-CHEMICAL
(1,25(OH)₂D₃), B-CHEMICAL
on O
the O
capacity O
of O
the O
C2C12 O
muscle O
cell O
line O
to O
differentiate O
towards O
the O
myogenic O
and O
adipogenic O
lineages. O
Cells O
were O
cultured O
in O
myogenic O
or O
adipogenic O
differentiation O
media O
containing O
increasing O
concentrations O
(0, O
10⁻¹³, O
10⁻¹¹, O
10⁻⁹, O
10⁻⁷ O
or O
10⁻⁵ O
M) O
of O
1,25(OH)₂D₃ B-CHEMICAL
for O
up O
to O

6 O
days O
and O
markers O
of O
muscle O
and O
fat O
development O
measured. O
Mature O
myofibres O
were O
formed O
in O
both O
adipogenic O
and O
myogenic O
media, O
but O
fat O
droplets O
were O
only O
observed O
in O
adipogenic O
media. O
Relative O
to O
controls, O
low O
physiological O
concentrations O
(10⁻¹³ O
and O
10⁻¹¹ O
M) O
of O
1,25(OH)₂D3 B-CHEMICAL
increased B-CHEMICAL
fat O
droplet O
accumulation, O
whereas O
high O
physiological O
(10⁻⁹ O
M) O
and O
supraphysiological O
concentrations O
(≥10⁻⁷ O
M) O
inhibited O
fat O
accumulation. O
This O
increased O
accumulation O
of O
fat O
with O
low O
physiological O
concentrations O
(10⁻¹³ O
and O
10⁻¹¹ O

M) O
was O
associated O
with O
a O
sequential O
up-regulation O
of O
PPARγ2 B-GENE-Y
(PPARG) B-GENE-Y
and B-GENE-Y
FABP4 O
mRNA, B-GENE-Y
indicating O
formation O
of O
adipocytes, O
whereas O
higher O
concentrations O
(≥10⁻⁹ O
M) O
reduced O
all O
these O
effects, O
and O
the O
highest O
concentration O
(10⁻⁵ O
M) O
appeared O
to O
have O
toxic O
effects. O
This O
is O
the O
first O
study O
to O
demonstrate O
dose-dependent O
effects O
of O
1,25(OH)₂D₃ B-CHEMICAL
on B-CHEMICAL
the B-CHEMICAL
transdifferentiation O
of O
muscle O
cells O
into O
adipose O
cells. O
Low O
physiological O
concentrations O
(possibly O
mimicking O
a O
deficient O
state) O
induced O
adipogenesis, O
whereas O
higher O
(physiological O
and O

supraphysiological) O
concentrations O
attenuated O
this O
effect. O
PF-04859989 B-CHEMICAL
as O
a O
template O
for O
structure-based O
drug O
design: O
identification O
of O
new O
pyrazole B-CHEMICAL
series O
of O
irreversible O
KAT B-GENE-Y
II I-GENE-Y
inhibitors O
with O
improved O
lipophilic O
efficiency. O
The O
structure-based O
design, O
synthesis, O
and O
biological O
evaluation O
of O
a O
new O
pyrazole B-CHEMICAL
series O
of O
irreversible O
KAT B-GENE-Y
II I-GENE-Y
inhibitors O
are O
described O
herein. O
The O
modification O
of O
the O
inhibitor O
scaffold O
of O
1 O
and O
2 O
from O
a O
dihydroquinolinone B-CHEMICAL
core O
to O
a O

tetrahydropyrazolopyridinone B-CHEMICAL
core O
led O
to O
discovery O
of O
a O
new O
series O
of O
potent O
KAT B-GENE-Y
II I-GENE-Y
inhibitors O
with O
excellent O
physicochemical O
properties. O
Compound O
20 O
is O
the O
most O
potent O
and O
lipophilically O
efficient O
of O
these O
new O
pyrazole B-CHEMICAL
analogs, O
with O
a O
k(inact)/K(i) O
value O
of O
112,000 O
M(-1)s(-1) O
and O
lipophilic O
efficiency O
(LipE) O
of O
8.53. O
The O
X-ray O
crystal O
structure O
of O
20 O
with O
KAT B-GENE-Y
II I-GENE-Y
demonstrates O
key O
features O
that O
contribute O
to O
this O
remarkable O
potency O
and O
binding O

efficiency. O
A O
single O
residue O
in O
leucyl-tRNA B-GENE-Y
synthetase I-GENE-Y
affecting O
amino B-CHEMICAL
acid I-CHEMICAL
specificity O
and O
tRNA O
aminoacylation. O
Human B-GENE-Y
mitochondrial I-GENE-Y
leucyl-tRNA I-GENE-Y
synthetase I-GENE-Y
(hs B-GENE-Y
mt I-GENE-Y
LeuRS) I-GENE-Y
achieves O
high O
aminoacylation O
fidelity O
without O
a O
functional O
editing O
active O
site, O
representing O
a O
rare O
example O
of O
a O
class B-GENE-N
I I-GENE-N
aminoacyl-tRNA I-GENE-N
synthetase I-GENE-N
(aaRS) B-GENE-N
that O
does O
not O
proofread O
its O
products. O
Previous O
studies O
demonstrated O
that O
the O
enzyme O
achieves O
high O
selectivity O
by O
using O
a O
more O
specific O
synthetic O
active O
site O
that O
is O
not O
prone O
to O
errors O
under O
physiological O
conditions. O

Interestingly, O
the O
synthetic O
active O
site O
of O
hs B-GENE-Y
mt I-GENE-Y
LeuRS I-GENE-Y
displays O
a O
high O
degree O
of O
homology O
with O
prokaryotic, O
lower O
eukaryotic, O
and O
other O
mitochondrial O
LeuRSs B-GENE-Y
that O
are O
less O
specific. O
However, O
there O
is O
one O
residue O
that O
differs O
between O
hs B-GENE-N
mt I-GENE-N
and I-GENE-N
Escherichia I-GENE-N
coli I-GENE-N
LeuRSs I-GENE-N
located O
on O
a O
flexible O
closing O
loop O
near O
the O
signature O
KMSKS B-GENE-N
motif. I-GENE-N
Here O
we O
describe O
studies O
indicating O
that O
this O
particular O
residue O
(K600 O
in O
hs B-GENE-Y
mt I-GENE-Y
LeuRS I-GENE-Y
and O
L570 O
in O
E. B-GENE-Y
coli I-GENE-Y
LeuRS) I-GENE-Y
strongly O
impacts O
aminoacylation O
in O
two O

ways: O
it O
affects O
both O
amino B-CHEMICAL
acid I-CHEMICAL
discrimination O
and O
transfer O
RNA O
(tRNA) O
binding. O
While O
this O
residue O
may O
not O
be O
in O
direct O
contact O
with O
the O
amino B-CHEMICAL
acid I-CHEMICAL
or O
tRNA O
substrate, O
substitutions O
of O
this O
position O
in O
both O
enzymes O
lead O
to O
altered O
catalytic O
efficiency O
and O
perturbations O
to O
the O
discrimination O
of O
leucine B-CHEMICAL
and O
isoleucine. B-CHEMICAL
In O
addition, O
tRNA O
recognition O
and O
aminoacylation O
is O
affected. O
These O
findings O
indicate O
that O
the O
conformation O
of O
the O
synthetic O
active O
site, O
modulated O
by O
this O
residue, O
may O
be O
coupled O
to O
specificity O
and O
provide O
new O
insights O
into O
the O
origins O
of O
selectivity O
without O
editing. O
Neurochemical O
control O
of O

rapid O
stress-induced O
changes O
in O
brain O
aromatase B-GENE-Y
activity. O
In O
the O
male O
brain, O
the O
medial O
preoptic O
nucleus O
(POM) O
is O
known O
to O
be O
a O
critical O
relay O
for O
the O
activation O
of O
sexual O
behaviour, O
with O
the O
aromatisation O
of O
testosterone B-CHEMICAL
into O
17β-oestradiol B-CHEMICAL
(E2 O
) O
playing O
a O
key O
role. O
Acute O
stress O
has O
been O
shown O
to O
differentially O
modulate O
the O
aromatase B-GENE-Y
enzyme O
in O
this O
and O
other O
brain O
nuclei O
in O
a O
sex-specific O
manner. O
In O
POM O
specifically, O
stress O
induces O
increases O
in O
aromatase B-GENE-Y
activity O
(AA) O
that O
are O
both O
rapid O
and O
reversible. O
How O
the O
physiological O
processes O

initiated O
during O
an O
acute O
stress O
response O
mediate O
sex- O
and O
nuclei- O
specific O
changes O
in O
AA O
and O
which O
stress O
response O
hormones O
are O
involved O
remains O
to O
be O
determined. O
By O
examining O
the O
relative O
effects O
of O
corticosterone B-CHEMICAL
(CORT), B-CHEMICAL
arginine B-GENE-N
vasotocin I-GENE-N
(AVT, B-GENE-N
the O
avian O
homologue O
to O
arginine B-GENE-Y
vasopressin) I-GENE-Y
and O
corticotrophin-releasing B-GENE-Y
factor I-GENE-Y
(CRF), B-GENE-Y
the O
present O
study O
aimed O
to O
define O
the O
hormone O
profile O
regulating O
stress-induced O
increases O
in O
AA O
in O
the O
POM. O
We O
found O
that O
CORT, B-CHEMICAL
AVT B-GENE-N
and O
CRF B-GENE-Y
all O
appear O
to O

play O
some O
role O
in O
these O
changes O
in O
the O
male O
brain. O
In O
addition, O
these O
effects O
occur O
in O
a O
targeted O
manner, O
such O
that O
modulation O
of O
the O
enzyme O
by O
these O
hormones O
only O
occurs O
in O
the O
POM O
rather O
than O
in O
all O
aromatase-expressing B-GENE-Y
nuclei. O
Similarly, O
in O
the O
female O
brain, O
the O
experimental O
effects O
were O
restricted O
to O
the O
POM O
but O
only O
CRF B-GENE-Y
was O
capable O
of O
inducing O
the O
stress-like O
increases O
in O
AA. O
These O
data O
further O
demonstrate O
the O
high O
degree O
of O
specificity O
(nuclei-, O
sex- O
and O
hormone-specific O
effects) O
in O
this O
system, O
highlighting O
the O
complexity O
of O
the O
stress-aromatase B-GENE-Y
link O
and O
suggesting O
modes O
through O
which O
the O

nongenomic O
modulation O
of O
this O
enzyme O
can O
result O
in O
targeted, O
rapid O
changes O
in O
local O
oestrogen B-CHEMICAL
concentrations. O
Differential O
inhibition O
of O
[3H]-oxotremorine-M B-CHEMICAL
and O
[3H]-quinuclinidyl B-CHEMICAL
benzilate I-CHEMICAL
binding O
to O
muscarinic B-GENE-N
receptors I-GENE-N
in O
rat O
brain O
membranes O
with O
acetylcholinesterase B-GENE-Y
inhibitors. O
The O
potential O
interaction O
of O
acetylcholinesterase B-GENE-Y
inhibitors O
with O
cholinergic B-GENE-N
receptors I-GENE-N
may O
play O
a O
significant O
role O
in O
the O
therapeutic O
and/or O
side-effects O
associated O
with O
this O
class O
of O
compound. O
In O
the O
present O
study, O
the O

capacity O
of O
acetylcholinesterase B-GENE-Y
inhibitors O
to O
interact O
with O
muscarinic B-GENE-N
receptors I-GENE-N
was O
assessed O
by O
their O
ability O
to O
displace O
both O
[3H]-oxotremorine-M B-CHEMICAL
and O
[3H]-quinuclinidyl B-CHEMICAL
benzilate I-CHEMICAL
binding O
in O
rat O
brain O
membranes. O
The O
[3H]-quinuclinidyl B-CHEMICAL
benzilate/[3H]-oxotremorine-M I-CHEMICAL
affinity O
ratios O
permitted O
predictions O
to O
be O
made O
of O
either O
the O
antagonist O
or O
agonist O
properties O
of O
the O
different O
compounds. O
A O
series O
of O
compounds, O
representative O
of O
the O
principal O
classes O
of O

acetylcholinesterase B-GENE-Y
inhibitors, O
displaced O
[3H]-oxotremorine-M B-CHEMICAL
binding O
with O
high-to-moderate O
potency O
(ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> B-CHEMICAL
edrophonium=galanthamine>desoxypeganine) B-CHEMICAL
whereas O
only O
ambenonium B-CHEMICAL
and O
tacrine B-CHEMICAL
displaced O
[3H]-quinuclinidyl B-CHEMICAL
benzilate I-CHEMICAL
binding. O
Inhibitors O
such O
as O
desoxypeganine, B-CHEMICAL
parathion O
and O
gramine O
demonstrated O
negligible O
inhibition O

of O
the O
binding O
of O
both O
radioligands. O
Scatchard O
plots O
constructed O
from O
the O
inhibition O
of O
[3H]-oxotremorine-M B-CHEMICAL
binding O
in O
the O
absence O
and O
presence O
of O
different O
inhibitors O
showed O
an O
unaltered O
Bmax O
and O
a O
reduced O
affinity O
constant, O
indicative O
of O
potential O
competitive O
or O
allosteric O
mechanisms. O
The O
capacity O
of O
acetylcholinesterase B-GENE-Y
inhibitors, O
with O
the O
exception O
of O
tacrine B-CHEMICAL
and O
ambenonium, B-CHEMICAL
to O
displace O
bound O
[3H]-oxotremorine-M B-CHEMICAL
in O
preference O
to O
[3H]quinuclinidyl B-CHEMICAL
benzilate I-CHEMICAL
predicts O

that O
the O
former O
compounds O
could O
act O
as O
potential O
agonists O
at O
muscarinic B-GENE-N
receptors. I-GENE-N
Moreover, O
the O
rank O
order O
for O
potency O
in O
inhibiting O
acetylcholinesterase B-GENE-Y
(ambenonium>neostigmine=physostigmine B-CHEMICAL
=tacrine>pyridostigmine=edrophonium=galanthamine B-CHEMICAL
>desoxypeganine>parathion>gramine) B-CHEMICAL
indicated O
that O
the O
most O
effective O
inhibitors O
of O
acetylcholinesterase B-GENE-Y
also O
displaced O
[3H]-oxotremorine-M B-CHEMICAL
to O
the O
greatest O
extent. O
The O
capacity O

of O
these O
inhibitors O
to O
displace O
[3H]-oxotremorine-M B-CHEMICAL
binding O
preclude O
their O
utilisation O
for O
the O
prevention O
of O
acetylcholine B-CHEMICAL
catabolism O
in O
rat O
brain O
membranes, O
the O
latter O
being O
required O
to O
estimate O
the O
binding O
of O
acetylcholine O
to O
[3H]-oxotremorine-M-labelled B-CHEMICAL
muscarinic B-GENE-N
receptors. I-GENE-N
However, O
fasciculin-2, O
a O
potent O
peptide O
inhibitor O
of O
acetylcholinesterase B-GENE-Y
(IC50 O
24 O
nM), O
did O
prevent O
catabolism O
of O

acetylcholine B-CHEMICAL
in O
rat O
brain O
membranes O
with O
an O
atypical O
inhibition O
isotherm O
of O
[3H]-oxotremorine-M B-CHEMICAL
binding, O
thus O
permitting O
an O
estimation O
of O
the O
"global O
affinity" O
of O
acetylcholine B-CHEMICAL
(Ki O
85 O
nM) O
for O
[3H]-oxotremorine-M-labelled B-CHEMICAL
muscarinic B-GENE-N
receptors I-GENE-N
in O
rat O
brain. O
Abnormally O
high O
plasma O
levels O
of O
vitamin B-CHEMICAL
B6 I-CHEMICAL
in O
children O
with O
autism O
not O
taking O
supplements O
compared O
to O
controls O
not O
taking O
supplements. O
BACKGROUND: O
There O
have O
been O
many O

studies O
of O
the O
effect O
of O
high-dose O
supplementation O
of O
vitamin B-CHEMICAL
B6 I-CHEMICAL
on O
children O
and O
adults O
with O
autism, O
with O
all O
but O
one O
reporting O
benefits. O
OBJECTIVE: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
biochemical O
basis O
for O
vitamin B-CHEMICAL
B6 I-CHEMICAL
therapy O
by O
measuring O
the O
level O
of O
total O
vitamin B-CHEMICAL
B6 I-CHEMICAL
in O
the O
plasma O
of O
unsupplemented O
children O
with O
autism O
spectrum O
disorder O
compared O
to O
unsupplemented O
control O
subjects. O
PARTICIPANTS: O
Children O
with O
autism O
spectrum O
disorders O
(n O
= O
35, O
age O
3-9 O
years) O
and O
unrelated O
typical O
children O
(n O
= O
11, O
age O
6-9 O
years), O
all O
from O

Arizona, O
were O
studied. O
(This O
includes O
the O
data O
from O
24 O
children O
with O
autism O
from O
our O
previous O
study.) O
METHODOLOGY: O
A O
microbiologic O
assay O
was O
used O
to O
measure O
the O
level O
of O
total O
vitamin B-CHEMICAL
B6 I-CHEMICAL
(including O
phosphorylated O
and O
unphosphorylated O
forms), O
in O
a O
blinded O
fashion. O
RESULTS: O
Children O
with O
autism O
had O
a O
75% O
higher O
level O
of O
total O
vitamin B-CHEMICAL
B6 I-CHEMICAL
than O
the O
controls O
(medians O
of O
56 O
versus O
32 O
ng/mL, O
respectively, O
p O
= O
0.00002). O
Most O
of O
the O
autistic O
children O
(77%) O

had O
levels O
that O
were O
more O
than O
2 O
standard O
deviations O
above O
the O
median O
value O
of O
the O
controls. O
The O
autistic O
girls O
(n O
= O
5) O
also O
had O
elevated O
levels O
(mean O
of O
54.6 O
ng/mL, O
median O
of O
60 O
ng/mL). O
DISCUSSION: O
These O
results O
are O
consistent O
with O
previous O
studies O
that O
found O
that: O
(1) O
pyridoxal B-GENE-Y
kinase I-GENE-Y
had O
a O
very O
low O
activity O
in O
children O
with O
autism O
and O
(2) O
pyridoxal B-CHEMICAL
5 I-CHEMICAL
phosphate I-CHEMICAL
(PLP) B-CHEMICAL
levels O
are O
unusually O
low O
in O
children O
with O
autism. O
Thus, O
it O
appears O
that O
the O
low O
conversion O
of O
pyridoxal B-CHEMICAL

and O
pyridoxine B-CHEMICAL
to O
PLP B-CHEMICAL
results O
in O
low O
levels O
of O
PLP, B-CHEMICAL
which O
is O
the O
active O
cofactor O
for O
113 O
known O
enzymatic O
reactions, O
including O
the O
formation O
of O
many O
key O
neurotransmitters. O
CONCLUSIONS: O
Total O
vitamin B-CHEMICAL
B6 I-CHEMICAL
is O
abnormally O
high O
in O
autism, O
consistent O
with O
previous O
reports O
of O
an O
impaired O
pyridoxal B-GENE-Y
kinase I-GENE-Y
for O
the O
conversion O
of O
pyridoxine B-CHEMICAL
and O
pyridoxal B-CHEMICAL
to O
PLP. B-CHEMICAL
This O
may O
explain O
the O
many O
published O
studies O
of O
benefits O
of O
high-dose O
vitamin B-CHEMICAL
B6 I-CHEMICAL
supplementation O
in O
some O
children O
and O
adults O
with O
autism. O
Synthesis, O
molecular O

modeling O
and O
evaluation O
of O
novel O
N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone B-CHEMICAL
derivatives O
as O
dual O
inhibitors O
for O
cholinesterases B-GENE-Y
and O
Aβ B-GENE-Y
aggregation. O
To O
develop O
new O
drugs O
for O
treatment O
of O
Alzheimer's O
disease, O
a O
group O
of O
N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones B-CHEMICAL
was O
designed, O
synthesized O
and O
tested O
for O
their O
ability O
to O
inhibit O
acetylcholinesterase, B-GENE-Y
butyrylcholinesterase B-GENE-Y

and O
aggregation O
of O
amyloid B-GENE-N
beta I-GENE-N
peptides I-GENE-N
(1-40, I-GENE-N
1-42 I-GENE-N
and I-GENE-N
1-40_1-42). I-GENE-N
The O
enzyme O
inhibition O
assay O
results O
indicated O
that O
compounds O
moderately O
inhibit O
both O
acetylcholinesterase B-GENE-Y
and O
butyrylcholinesterase. B-GENE-Y
β-Amyloid B-GENE-Y
aggregation O
results O
showed O
that O
all O
compounds O
exhibited O
remarkable O
Aβ B-GENE-Y
fibril O
aggregation O
inhibition O
activity O
with O
a O
nearly O
similar O
potential O
as O
the O
reference O
compound O
rifampicin, B-CHEMICAL
which O
makes O
them O
promising O
anti-Alzheimer O
drug O
candidates. O
Docking O
experiments O
were O
carried O
out O
with O
the O
aim O
to O
understand O
the O
interactions O
of O
the O

most O
active O
compounds O
with O
the O
active O
site O
of O
the O
cholinesterase B-GENE-Y
enzymes. O
Effect O
of O
anabolic-androgenic O
steroids B-CHEMICAL
and O
glucocorticoids O
on O
the O
kinetics O
of O
hAR B-GENE-Y
and O
hGR B-GENE-Y
nucleocytoplasmic O
translocation. O
Although O
the O
qualitative O
nucleocytoplasmic O
transport O
of O
nuclear B-GENE-N
hormone I-GENE-N
receptors I-GENE-N
(NHRs) B-GENE-N
has O
been O
studied, O
there O
is O
little O
documentation O
of O
the O
cellular O
kinetics O
of O
this O
transport. O
Here, O
translocation O
studies O
using O
the O
human B-GENE-Y
androgen I-GENE-Y
receptor I-GENE-Y
(hAR) B-GENE-Y
and O
the O
human B-GENE-Y
glucocorticoid I-GENE-Y
receptor I-GENE-Y
(hGR) B-GENE-Y
were O
performed O
to O
aid O

in O
identifying O
the O
mechanism O
by O
which O
anabolic-androgenic O
steroids B-CHEMICAL
(AAS) O
were O
activating O
hAR B-GENE-Y
and O
potentially O
interacting O
with O
hGR B-GENE-Y
and O
how O
glucocorticoid O
ligands O
were O
interacting O
with O
the O
hGR B-GENE-Y
and O
hAR. B-GENE-Y
The O
real-time O
analysis O
of O
EGFP-labeled O
hAR B-GENE-Y
and O
hGR B-GENE-Y
ligand-induced O
cytoplasm-to-nucleus O
translocation O
was O
performed O
using O
fluorescence O
microscopy O
to O
better O
understand O
the O
action O
of O
these O
NHRs B-GENE-N
in O
a O
physiologically O
relevant O
cell-based O
model. O
After O
transient O
transfection, O
the O
hAR B-GENE-Y
and O
hGR B-GENE-Y

individually O
translocate O
as O
expected O
(i.e., O
transport O
is O
ligand-induced O
and O
dose-dependent) O
in O
this O
model O
biological O
system. O
Testosterone B-CHEMICAL
(TEST) B-CHEMICAL
had O
the O
fastest O
translocation O
rate O
for O
the O
hAR B-GENE-Y
of O
0.0525 O
min(-1). O
The O
other O
endogenous O
steroids, B-CHEMICAL
androstenedione B-CHEMICAL
(ANE) B-CHEMICAL
and O
dihydrotestosterone B-CHEMICAL
(DHT), B-CHEMICAL
had O
considerably O
lower O
hAR B-GENE-Y
transport O
rates. O
The O
rates O
of O
hAR B-GENE-Y
transport O
for O
the O
exogenous O
steroids B-CHEMICAL
methyltrienelone B-CHEMICAL
(MET), B-CHEMICAL
nandrolone B-CHEMICAL

(NAN), B-CHEMICAL
and O
oxandrolone B-CHEMICAL
(OXA) B-CHEMICAL
are O
lower O
than O
that O
of O
testosterone B-CHEMICAL
and O
similar O
to O
those O
of O
the O
endogenous O
steroids B-CHEMICAL
ANE B-CHEMICAL
and O
DHT. B-CHEMICAL
The O
hGR B-GENE-Y
transport O
rates O
for O
cortisol O
(COR) O
and O
dexamethasone O
(DEX) O
are O
also O
presented. O
The O
synthetic O
GC, O
DEX, O
had O
a O
more O
rapid O
translocation O
rate O
(0.1599 O
min(-1)) O
at O
the O
highest O
dose O
of O
100 O
nM O
compared O
to O
the O
endogenous O
GC O
COR O
(0.0431 O
min(-1)). O
The O

data O
obtained O
agrees O
with O
the O
existing O
qualitative O
data O
and O
adds O
an O
important O
ligand-dependent O
kinetic O
component O
to O
hAR B-GENE-Y
and O
hGR B-GENE-Y
transport. O
These O
kinetic O
data O
can O
aid O
our O
understanding O
of O
NHR B-GENE-N
action O
and O
interaction O
with O
other O
regulatory O
proteins, O
and O
can O
be O
useful O
in O
the O
development O
of O
new O
therapies. O
Licofelone, B-CHEMICAL
a O
balanced O
inhibitor O
of O
cyclooxygenase B-GENE-N
and O
5-lipoxygenase, B-GENE-Y
reduces O
inflammation O
in O
a O
rabbit O
model O
of O
atherosclerosis. O
Licofelone, B-CHEMICAL
a O
dual O
anti-inflammatory O
drug O
that O
inhibits O
5-lipoxygenase B-GENE-Y
(LOX) B-GENE-N
and O

cyclooxygenase B-GENE-N
(COX) B-GENE-N
enzymes, O
may O
have O
a O
better O
cardiovascular O
profile O
that O
cycloxygenase-2 B-GENE-Y
inhibitors O
due O
to O
cycloxygenase-1 B-GENE-Y
blockade-mediated O
antithrombotic O
effect O
and O
a O
better O
gastrointestinal O
tolerability. O
We O
examined O
the O
anti-inflammatory O
effect O
of O
licofelone B-CHEMICAL
on O
atherosclerotic O
lesions O
as O
well O
as O
in O
isolated O
neutrophils O
from O
whole O
blood O
of O
rabbits O
compared O
with O
a O
selective O
inhibitor O
of O
COX-2, B-GENE-Y
rofecoxib. B-CHEMICAL
We O
also O
assessed O
the O
antithrombotic O

effect O
of O
licofelone B-CHEMICAL
in O
rabbit O
platelet-rich O
plasma. O
For O
this O
purpose, O
30 O
rabbits O
underwent O
injury O
of O
femoral O
arteries, O
and O
they O
were O
randomized O
to O
receive O
10 O
mg/kg/day O
licofelone B-CHEMICAL
or O
5 O
mg/kg/day O
rofecoxib B-CHEMICAL
or O
no O
treatment O
during O
4 O
weeks O
with O
atherogenic O
diet O
in O
all O
cases. O
Ten O
healthy O
rabbits O
were O
used O
as O
controls. O
Neutrophils O
and O
platelets O
were O
isolated O
from O
peripheral O
blood O
of O
rabbits O
for O
ex O
vivo O
studies. O
Licofelone B-CHEMICAL
reduced O
intima/media O
ratio O
in O
injured O
arteries, O
the O
macrophages O
infiltration O

in O
the O
neointimal O
area, O
monocyte B-GENE-Y
chemoattractant I-GENE-Y
protein-1 I-GENE-Y
(MCP-1) B-GENE-Y
gene O
expression, O
and O
the O
activation O
of O
nuclear B-GENE-N
factor-kappaB I-GENE-N
in O
rabbit O
atheroma. O
Moreover, O
licofelone B-CHEMICAL
inhibited O
COX-2 B-GENE-Y
and O
5-LOX B-GENE-Y
protein O
expression O
in O
vascular O
lesions. O
Rofecoxib B-CHEMICAL
only O
diminished O
COX-2 B-GENE-Y
protein O
expression O
and O
MCP-1 B-GENE-Y
gene O
expression O
in O
vascular O
atheroma. O
Prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
in O
rabbit O
plasma O
was O
attenuated O
by O
both O
drugs. O
Licofelone B-CHEMICAL
almost O
abolished O
5-LOX B-GENE-Y
activity O
by O

inhibiting O
leukotriene B-CHEMICAL
B4 I-CHEMICAL
generation O
in O
rabbit O
neutrophils O
and O
prevented O
platelet O
thromboxane B-CHEMICAL
B2 I-CHEMICAL
production O
from O
whole O
blood. O
Licofelone B-CHEMICAL
reduces O
neointimal O
formation O
and O
inflammation O
in O
an O
atherosclerotic O
rabbit O
model O
more O
markedly O
than O
rofecoxib. B-CHEMICAL
This O
effect, O
together O
with O
the O
antiplatelet O
activity O
of O
licofelone, B-CHEMICAL
suggests O
that O
this O
drug O
may O
have O
a O
favorable O
cardiovascular O
profile. O
No O
influence O
of O
moderate O
hepatic O
impairment O
on O
the O
pharmacokinetics O
of O
lumiracoxib, B-CHEMICAL
an O
oral O
COX-2 B-GENE-Y
selective O

inhibitor. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
hepatic O
impairment O
on O
the O
pharmacokinetics O
(PK) O
of O
the O
novel O
cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
selective O
inhibitor O
lumiracoxib B-CHEMICAL
(Prexige), B-CHEMICAL
so O
that O
dose O
recommendations O
for O
clinical O
use O
can O
be O
provided. O
This O
was O
an O
open-label, O
single O
dose, O
case-controlled O
study O
in O
which O
eight O
subjects O
with O
liver O
cirrhosis O
classed O
as O
moderate O
hepatic O
impairment O
(Child-Pugh O
score: O
7-9) O
and O
eight O
demographically-matched O

healthy O
subjects O
received O
a O
single O
oral O
400 O
mg O
dose O
of O
lumiracoxib. B-CHEMICAL
Routine O
safety O
assessments O
were O
made O
and O
blood O
samples O
were O
taken O
for O
determination O
of O
lumiracoxib B-CHEMICAL
concentrations O
for O
96 O
h O
post O
dose. O
The O
ex O
vivo O
binding O
of O
lumiracoxib B-CHEMICAL
to O
plasma O
proteins O
was O
determined O
pre O
dose O
and O
at O
2 O
and O
12 O
h O
post O
dose. O
An O
analysis O
of O
variance O
was O
used O
to O
detect O
differences O
in O
PK O
parameters O
(AUC, O
Cmax O
and O
Tmax) O
between O
the O
treatment O
groups. O
There O
were O
no O
significant O
differences O
between O
subjects O
with O
moderate O
hepatic O
insufficiency O
and O
healthy O
subjects O
in O
the O
area O
under O
the O
lumiracoxib B-CHEMICAL

plasma O
concentration-time O
curves O
(AUC(0-infinity)): O
29.2 O
+/- O
6.7 O
microg O
h O
ml(-1) O
versus O
28.7 O
+/- O
6.3 O
mircrog O
h O
ml(-1). O
The O
rate O
of O
absorption O
of O
lumiracoxib B-CHEMICAL
was O
not O
significantly O
altered O
by O
hepatic O
impairment O
based O
on O
Cmax O
and O
Tmax. O
The O
protein-bound O
fraction O
of O
lumiracoxib B-CHEMICAL
exceeded O
98% O
both O
in O
healthy O
control O
subjects O
and O
in O
those O
with O
moderate O
hepatic O
insufficiency. O
A O
single O
dose O
of O
400 O
mg O
lumiracoxib B-CHEMICAL

was O
well O
tolerated. O
In O
conclusion, O
no O
dose O
adjustments O
appear O
to O
be O
required O
when O
lumiracoxib B-CHEMICAL
is O
administered O
to O
patients O
with O
either O
mild O
or O
moderate O
hepatic O
impairment. O
Alcohol B-CHEMICAL
modulates O
expression O
of O
DNA B-GENE-N
methyltranferases I-GENE-N
and O
methyl B-GENE-N
CpG-/CpG I-GENE-N
domain-binding I-GENE-N
proteins I-GENE-N
in O
murine O
embryonic O
fibroblasts. O
Fetal O
alcohol B-CHEMICAL
syndrome O
(FAS), O
presenting O
with O
a O
constellation O
of O
neuro-/psychological, O
craniofacial O
and O
cardiac O
abnormalities, O
occurs O
frequently O
in O
offspring O
of O
women O
who O
consume O
alcohol B-CHEMICAL
during O
pregnancy, O
with O
a O
prevalence O
of O

1-3 O
per O
1000 O
livebirths. O
The O
present O
study O
was O
designed O
to O
test O
the O
hypothesis O
that O
alcohol B-CHEMICAL
alters O
global O
DNA O
methylation, O
and O
modulates O
expression O
of O
the O
DNA B-GENE-N
methyltransferases I-GENE-N
(DNMTs) B-GENE-N
and O
various O
methyl B-CHEMICAL
CpG-binding B-GENE-N
proteins. I-GENE-N
Murine O
embryonic O
fibroblasts O
(MEFs), O
utilized O
as O
an O
in O
vitro O
embryonic O
model O
system, O
demonstrated O
∼5% O
reduction O
in O
global O
DNA O
methylation O
following O
exposure O
to O
200mM O
ethanol. B-CHEMICAL
In O
addition, O
ethanol B-CHEMICAL
induced O
degradation O
of O
DNA B-GENE-N
methyltransferases I-GENE-N

(DNMT-1, B-GENE-Y
DNMT-3a, B-GENE-Y
and O
DNMT-3b), B-GENE-Y
as O
well O
as O
the O
methyl B-GENE-N
CpG-binding I-GENE-N
proteins I-GENE-N
(MeCP-2, B-GENE-Y
MBD-2 B-GENE-Y
and O
MBD-3), B-GENE-Y
in O
MEF O
cells O
by O
the O
proteasomal O
pathway. O
Such O
degradation O
could O
be O
completely O
rescued O
by O
pretreatment O
of O
MEF O
cells O
with O
the O
proteasomal O
inhibitor, O
MG-132. B-CHEMICAL
These O
data O
support O
a O
potential O
epigenetic O
molecular O
mechanism O
underlying O
the O
pathogenesis O
of O
FAS O
during O
mammalian O
development. O
Clock B-GENE-Y
Gene O
Expression O
in O
the O
Liver O

of O
Streptozotocin-induced B-CHEMICAL
and O
Spontaneous O
Type O
1 O
Diabetic O
Rats. O
Several O
investigations O
have O
shown O
a O
relation O
between O
diabetes O
and O
alterations O
of O
the O
liver O
circadian O
clock. B-GENE-Y
We O
investigated O
the O
diurnal O
expression O
of O
clock B-GENE-Y
genes O
and O
clock-controlled B-GENE-N
genes I-GENE-N
(CCGs) B-GENE-N
in O
3-hour O
intervals O
for O
a O
24-h O
period O
in O
the O
livers O
of O
male O
streptozotocin B-CHEMICAL
(STZ)-treated B-CHEMICAL
rats, O
male O
spontaneous O
type O
1 O
diabetic O
LEW.1AR1-iddm O
(Iddm) O
rats, O
and O
Iddm O
rats O
treated O
for O
10 O
days O
with O
insulin. B-GENE-Y

Hepatic O
mRNA O
was O
extracted, O
and O
the O
relative O
expression O
of O
clock B-GENE-Y
genes O
(Per1, B-GENE-Y
Per2, B-GENE-Y
Bmal1, B-GENE-Y
Clock, B-GENE-Y
Cry1), B-GENE-Y
as O
well O
as O
CCGs B-GENE-N
(Dbp, B-GENE-Y
E4bp4, B-GENE-Y
RevErbα, B-GENE-Y
Rorα, B-GENE-N
Pparγ), B-GENE-Y
was O
analyzed O
by O
reverse O
transcription O
followed O
by O
real-time O
polymerase O
chain O
reaction. O
Diabetic O
STZ B-CHEMICAL
and O
Iddm O
rats, O
as O
well O
as O
insulin-substituted B-GENE-Y
Iddm O
rats, O
exhibited O
a O
significant O
diurnal O
expression O
pattern O
of O
clock B-GENE-Y
genes O
as O
determined O
by O
Cosinor O
analysis; O
however, O
the O
MESOR O

(midline O
estimating O
statistic O
of O
rhythm) O
of O
Bmal1, B-GENE-Y
Per2, B-GENE-Y
and O
Clock B-GENE-Y
transcript O
expression O
was O
altered O
in O
Iddm O
and O
insulin-substituted B-GENE-Y
Iddm O
rats. O
The O
hepatic O
expression O
of O
the O
CCGs B-GENE-N
Dbp B-GENE-Y
and O
RevErbα B-GENE-Y
revealed O
a O
diurnal O
rhythm O
in O
all O
investigated O
groups. O
Insulin B-GENE-Y
administration O
to O
Iddm O
rats O
normalized O
the O
enhanced O
MESOR O
in O
the O
expression O
of O
Dbp, B-GENE-Y
RevErbα, B-GENE-Y
and O
E4bp4 B-GENE-Y
to O
the O
levels O
of O
normoglycemic O
controls. O
Cosinor O
analysis O
indicated O
no O
diurnal O
rhythm O
of O

Pparγ B-GENE-Y
expression O
in O
the O
livers O
of O
diabetic O
STZ B-CHEMICAL
or O
Iddm O
rats O
or O
in O
those O
of O
insulin-substituted B-GENE-Y
Iddm O
rats. O
Also, O
insulin B-GENE-Y
substitution O
could O
not O
reverse O
the O
decreased O
MESOR O
of O
Pparγ B-GENE-Y
expression O
in O
Iddm O
rats. O
In O
consequence O
of O
the O
diabetic O
disease, O
changes O
in O
the O
expression O
of O
clock B-GENE-Y
genes O
and O
CCGs B-GENE-N
suggest O
alterations O
in O
the O
hepatic O
peripheral O
clock B-GENE-Y
mechanism. O
Comparison O
of O
the O
monoamine B-GENE-N
oxidase I-GENE-N
inhibiting O
properties O
of O
two O
reversible O
and O
selective O
monoamine B-GENE-Y
oxidase-A I-GENE-Y
inhibitors O
moclobemide B-CHEMICAL
and O

toloxatone, B-CHEMICAL
and O
assessment O
of O
their O
effect O
on O
psychometric O
performance O
in O
healthy O
subjects. O
1. O
The O
effects O
of O
two O
reversible, O
predominantly O
monoamine B-GENE-Y
oxidase-A I-GENE-Y
(MAO-A) B-GENE-Y
inhibitors, O
moclobemide B-CHEMICAL
(150 O
mg O
three O
times O
daily) O
and O
toloxatone B-CHEMICAL
(400-200-400 O
mg O
day-1) O
on O
monoamine B-CHEMICAL
metabolites O
and O
psychometric O
performance O
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
crossover O
study O
in O
12 O
healthy O
subjects. O
2. O
After O
7 O
days O
of O
moclobemide/toloxatone/placebo B-CHEMICAL
administration O

subjects O
were O
hospitalized O
for O
24 O
h O
on O
day O
8. O
Blood O
samples O
were O
drawn O
every O
2 O
h O
for O
determination O
of O
plasma O
noradrenaline B-CHEMICAL
(NA), B-CHEMICAL
3,4-dihydroxyphenylglycol B-CHEMICAL
(DHPG), B-CHEMICAL
homovanillic B-CHEMICAL
acid I-CHEMICAL
(HVA) B-CHEMICAL
and O
5-hydroxyindolacetic B-CHEMICAL
acid I-CHEMICAL
(5-HIAA). B-CHEMICAL
Urine O
was O
collected O
for O
measurements O
of O
normetanephrine B-CHEMICAL
and O
3-methoxytyramine B-CHEMICAL
excretion. O
Psychometric O
performance O
(short- O
and O
long-term O
memory, O
critical O
flicker O
fusion O
frequency, O
choice O

reaction O
time) O
and O
subjective O
feelings O
were O
assessed O
before O
each O
drug O
intake O
(in O
the O
morning, O
at O
noon, O
in O
the O
evening). O
3. O
Compared O
with O
placebo, O
both O
reversible O
monoamine B-GENE-N
oxidase I-GENE-N
inhibitors O
decreased O
the O
plasma O
concentration O
of O
DHPG B-CHEMICAL
and O
HVA. B-CHEMICAL
The O
overall O
fall O
in O
DHPG B-CHEMICAL
(AUC O
from O
0 O
to O
24 O
h) O
was O
44% O
during O
moclobemide B-CHEMICAL
and O
12% O
during O
toloxatone B-CHEMICAL
(P O
less O
than O
0.001) O
and O
the O
overall O
decrease O
in O
HVA B-CHEMICAL
was O
38% O
and O
20% O
(P O
less O
than O
0.005) O
on O

moclobemide B-CHEMICAL
and O
toloxatone, B-CHEMICAL
respectively. O
4. O
Before O
the O
next O
drug O
intake, O
MAO-A B-GENE-Y
inhibition, O
as O
judged O
by O
the O
decrease O
of O
plasma O
DHPG B-CHEMICAL
concentration, O
was O
significantly O
different O
from O
placebo O
with O
moclobemide B-CHEMICAL
but O
not O
with O
toloxatone. B-CHEMICAL
5. O
Moclobemide, B-CHEMICAL
but O
not O
toloxatone, B-CHEMICAL
exerted O
a O
moderate, O
but O
significant O
inhibition O
of O
the O
deamination O
of O
5-hydroxytryptamine B-CHEMICAL
(5-HT) B-CHEMICAL
as O
judged O
by O
the O
fall O
in O
plasma O
5-HIAA B-CHEMICAL
concentration. O
Neither O
drug O
influenced O
plasma O

NA B-CHEMICAL
concentration. O
6. O
A O
significant O
rise O
in O
urinary O
excretion O
of O
normetanephrine B-CHEMICAL
was O
observed O
on O
moclobemide B-CHEMICAL
and O
to O
a O
lesser O
extent O
on O
toloxatone. B-CHEMICAL
The O
urinary O
excretion O
of O
3-methoxytyramine B-CHEMICAL
was O
significantly O
raised O
by O
moclobemide B-CHEMICAL
but O
not O
by O
toloxatone. B-CHEMICAL
7. O
Neither O
moclobemide B-CHEMICAL
nor O
toloxatone B-CHEMICAL
altered O
memory O
function, O
vigilance, O
subjective O
feelings O
or O
sleep O
characteristics O
of O
the O
subjects. O
Synthesis O
and O
evaluation O
of O
nicotinamide B-CHEMICAL
derivative O
as O
anti-angiogenic O

agents. O
Previously, O
we O
have O
found O
that O
BRN-103, B-CHEMICAL
a O
nicotinamide B-CHEMICAL
derivative, O
inhibits O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF)-mediated B-GENE-Y
angiogenesis O
signaling O
in O
human O
endothelial O
cells. O
During O
our O
continuous O
efforts O
to O
identify O
more O
potent O
anti-angiogenic O
agents, O
we O
synthesized O
various O
nicotinamide B-CHEMICAL
derivatives O
and O
evaluated O
their O
anti-angiogenic O
effects. O
We O
found O
that O

2-{1-[1-(6-chloro-5-fluoropyrimidin-4-yl)ethyl]piperidin-4-ylamino}-N-(3-chlorophenyl) B-CHEMICAL
pyridine-3-carboxamide I-CHEMICAL
(BRN-250) B-CHEMICAL
significantly O
inhibited O
human O
umbilical O
vascular O
endothelial O
cells O
(HUVECs) O
proliferation, O
migration, O
tube O
formation, O
and O
microvessel O
growth O
in O
a O
concentration O
range O
of O
10-100 O
nM. O
Furthermore, O
BRN-250 B-CHEMICAL
inhibited O
the O

VEGF-induced B-GENE-Y
phosphorylation O
and O
intracellular O
tyrosine B-GENE-N
kinase I-GENE-N
activity O
of O
VEGF B-GENE-Y
receptor I-GENE-Y
2 I-GENE-Y
(VEGFR2) B-GENE-Y
and O
the O
activation O
of O
its O
downstream O
AKT B-GENE-N
pathway. O
Taken O
together, O
these O
findings O
suggest O
that O
BRN-250 B-CHEMICAL
be O
considered O
a O
potential O
lead O
compound O
for O
cancer O
therapy. O
Inhibition O
of O
gelatinase B-GENE-Y
A I-GENE-Y
(MMP-2) B-GENE-Y
by O
batimastat B-CHEMICAL
and O
captopril B-CHEMICAL
reduces O
tumor O
growth O
and O
lung O
metastases O
in O
mice O
bearing O
Lewis O
lung O
carcinoma. O
We O
have O
examined O
the O
effects O
of O
the O
synthetic O
matrix B-GENE-N
metalloproteinase I-GENE-N
inhibitor, O
batimastat B-CHEMICAL

(BB-94) B-CHEMICAL
and O
the O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
inhibitor, O
captopril, B-CHEMICAL
on O
metalloproteinase B-GENE-N
activity O
of O
murine O
Lewis-lung-carcinoma O
cells O
(3LL) O
in O
vitro, O
and O
on O
local O
growth O
and O
lung O
metastasis O
of O
the O
same O
tumor O
implanted O
intramuscularly O
in O
syngeneic O
C57BL/6 O
mice. O
The O
effect O
of O
BB-94 B-CHEMICAL
and O
captopril B-CHEMICAL
on O
the O
survival O
of O
the O
3LL-tumor-bearing O
mice O
was O
also O
examined. O
Here O
we O
report O
that O
captopril B-CHEMICAL
treatment O
resulted O
in O
decreased O
transcription O
and O
protein O
levels O
of O

gelatinase B-GENE-Y
A I-GENE-Y
by O
3LL O
cells. O
Both O
BB-94 B-CHEMICAL
and O
captopril O
also O
prevented O
substrate O
degradation O
by O
gelatinase B-GENE-N
A I-GENE-N
and I-GENE-N
B I-GENE-N
released O
in O
conditioned O
medium O
by O
cultured O
cells. O
Treatment O
of O
tumor-bearing O
animals O
with O
BB-94 B-CHEMICAL
(i.p.) O
or O
captopril B-CHEMICAL
(in O
drinking O
water) O
resulted O
in O
significant O
inhibition O
of O
the O
mean O
tumor O
volume O
(25 O
and O
33% O
respectively) O
and O
of O
the O
mean O
lung O
metastasis O
number O
(26 O
and O
29% O
respectively). O
When O
both O
agents O
were O
given, O
they O
acted O
in O
synergy, O
resulting O
in O
51 O
and O
80% O
inhibition O
of O
tumor O
growth O
and O

metastasis. O
The O
survival O
time O
of O
the O
mice O
treated O
with O
both O
BB-94 B-CHEMICAL
and O
captopril B-CHEMICAL
was O
also O
significantly O
longer O
compared O
with O
the O
groups O
treated O
with O
each O
agent O
alone O
or O
with O
the O
vehicle. O
Our O
data O
support O
the O
hypothesis O
of O
an O
essential O
role O
of O
metalloproteinase(s) B-GENE-N
in O
the O
metastatic O
process. O
Moreover, O
blockade O
of O
invasion, O
angiogenesis O
and O
other O
processes O
mediated O
by O
metalloproteinases B-GENE-N
may O
underlie O
the O
anti-tumor O
and O
anti-metastatic O
effect O
of O
BB-94 B-CHEMICAL
and O
captopril B-CHEMICAL
and O
their O
combination. O
It O
is O
conceivable O
that O
this O
combination O
could O
be O
tested O
in O
selected O
clinical O
conditions O
as O
an O

adjuvant O
modality O
to O
cytotoxic O
therapy. O
Methionine B-GENE-Y
synthase I-GENE-Y
reductase I-GENE-Y
polymorphisms O
are O
associated O
with O
serum O
osteocalcin B-GENE-Y
levels O
in O
postmenopausal O
women. O
Homocysteine B-CHEMICAL
(Hcy) B-CHEMICAL
is O
thought O
to O
play O
an O
important O
role O
in O
the O
development O
of O
osteoporosis O
and O
fracture. O
Methionine B-GENE-Y
synthase I-GENE-Y
reductase I-GENE-Y
(MTRR) B-GENE-Y
is O
an O
enzyme O
involved O
in O
the O
conversion O
of O
Hcy B-CHEMICAL
to O
methionine. B-CHEMICAL
We O
hypothesized O
that O
certain O
genetic O
polymorphisms O
of O
MTRR B-GENE-Y
leading O
to O

reduced O
enzyme O
activity O
may O
cause O
hyperhomocysteinemia O
and O
affect O
bone O
metabolism. O
We O
therefore O
examined O
the O
associations O
of O
the O
A66G B-GENE-N
and O
C524T B-GENE-N
polymorphisms O
of O
the O
MTRR B-GENE-Y
gene O
with O
bone O
mineral O
density O
(BMD) O
and O
serum O
osteocalcin B-GENE-Y
levels O
in O
postmenopausal O
women. O
Although O
we O
did O
not O
detect O
any O
significant O
associations O
between O
MTRR B-GENE-Y
polymorphisms O
and O
BMD O
or O
serum O
osteocalcin B-GENE-Y
levels, O
we O
found O
that O
the O
66G/524C O
haplotype, O
which O
has O
reduced O
enzyme O
activity, O
was O
significantly O
associated O
with O
serum O

osteocalcin B-GENE-Y
levels O
in O
a O
gene-dose O
dependent O
manner O
(P O
= O
0.002). O
That O
is, O
the O
highest O
osteocalcin B-GENE-Y
levels O
(34.5 O
+/- O
16.8 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
two O
copies, O
intermediate O
osteocalcin B-GENE-Y
levels O
(32.6 O
+/- O
14.4 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
one O
copy, O
and O
the O
lowest O
levels O
of O
osteocalcin B-GENE-Y
(28.8 O
+/- O
10.9 O
ng/ml) O
were O
observed O
in O
subjects O
bearing O
no O
copies. O
These O
results O
suggest O
that O
the O

66G/524C O
haplotype O
of O
the O
MTRR B-GENE-Y
gene O
affect O
bone O
turn O
over O
rate. O
Glutathione B-GENE-N
peroxidases I-GENE-N
and O
redox-regulated O
transcription O
factors. O
Analysis O
of O
the O
selenoproteome O
identified O
five O
glutathione B-GENE-N
peroxidases I-GENE-N
(GPxs) B-GENE-N
in O
mammals: O
cytosolic B-GENE-N
GPx I-GENE-N
(cGPx, B-GENE-N
GPx1), B-GENE-N
phospholipid B-GENE-N
hydroperoxide I-GENE-N
GPx I-GENE-N
(PHGPX, B-GENE-N
GPx4), B-GENE-N
plasma B-GENE-N
GPx I-GENE-N
(pGPX, B-GENE-N
GPx3), B-GENE-N
gastrointestinal B-GENE-N
GPx I-GENE-N

(GI-GPx, B-GENE-N
GPx2) B-GENE-N
and, O
in O
humans, B-GENE-Y
GPx6, I-GENE-Y
which O
is O
restricted O
to O
the O
olfactory O
system. O
GPxs B-GENE-N
reduce O
hydroperoxides O
to O
the O
corresponding O
alcohols B-CHEMICAL
by O
means O
of O
glutathione B-CHEMICAL
(GSH). B-CHEMICAL
They O
have O
long O
been O
considered O
to O
only O
act O
as O
antioxidant O
enzymes. O
Increasing O
evidence, O
however, O
suggests O
that O
nature O
has O
not O
created O
redundant O
GPxs B-GENE-N
just O
to O
detoxify O
hydroperoxides. O
cGPx B-GENE-Y
clearly O
acts O
as O
an O
antioxidant, O
as O
convincingly O
demonstrated O
in O
GPx1-knockout B-GENE-Y
mice. O

PHGPx B-GENE-N
specifically O
interferes O
with O
NF-kappaB B-GENE-N
activation O
by O
interleukin-1, B-GENE-N
reduces O
leukotriene B-CHEMICAL
and O
prostanoid B-CHEMICAL
biosynthesis, O
prevents O
COX-2 B-GENE-Y
expression, O
and O
is O
indispensable O
for O
sperm O
maturation O
and O
embryogenesis. O
GI-GPx, B-GENE-N
which O
is O
not O
exclusively O
expressed O
in O
the O
gastrointestinal O
system, O
is O
upregulated O
in O
colon O
and O
skin O
cancers O
and O
in O
certain O
cultured O
cancer O
cells. O
GI-GPx B-GENE-N
is O
a O
target O
for O
Nrf2, B-GENE-Y
and O
thus O
is O
part O
of O
the O
adaptive O
response O
by O
itself, O
while O

PHGPx B-GENE-N
might O
prevent O
cancer O
by O
interfering O
with O
inflammatory O
pathways. O
In O
conclusion, O
cGPx, B-GENE-Y
PHGPx B-GENE-N
and O
GI-GPx B-GENE-N
have O
distinct O
roles, O
particularly O
in O
cellular O
defence O
mechanisms. O
Redox O
sensing O
and O
redox O
regulation O
of O
metabolic O
events O
have O
become O
attractive O
paradigms O
to O
unravel O
the O
specific O
and O
in O
part O
still O
enigmatic O
roles O
of O
GPxs. B-GENE-N
Efficacy O
and O
long-term O
safety O
of O
alipogene O
tiparvovec O
(AAV1-LPL(S447X)) B-GENE-Y
gene O
therapy O
for O
lipoprotein B-GENE-Y
lipase I-GENE-Y
deficiency: O
an O
open-label O
trial. O
We O
describe O

the O
2-year O
follow-up O
of O
an O
open-label O
trial O
(CT-AMT-011-01) O
of O
AAV1-LPL(S447X) B-GENE-Y
gene O
therapy O
for O
lipoprotein B-GENE-Y
lipase I-GENE-Y
(LPL) B-GENE-Y
deficiency O
(LPLD), O
an O
orphan O
disease O
associated O
with O
chylomicronemia, O
severe O
hypertriglyceridemia, O
metabolic O
complications O
and O
potentially O
life-threatening O
pancreatitis. O
The O
LPL(S447X) B-GENE-Y
gene O
variant, O
in O
an O
adeno-associated O
viral O
vector O
of O
serotype O
1 O
(alipogene O
tiparvovec), O

was O
administered O
to O
14 O
adult O
LPLD O
patients O
with O
a O
prior O
history O
of O
pancreatitis. O
Primary O
objectives O
were O
to O
assess O
the O
long-term O
safety O
of O
alipogene O
tiparvovec O
and O
achieve O
a O
40% O
reduction O
in O
fasting O
median O
plasma O
triglyceride B-CHEMICAL
(TG) O
at O
3-12 O
weeks O
compared O
with O
baseline. O
Cohorts O
1 O
(n=2) O
and O
2 O
(n=4) O
received O
3 O
× O
10(11) O
gc O
kg(-1), O
and O
cohort O
3 O
(n=8) O
received O
1 O
× O
10(12) O
gc O
kg(-1). O

Cohorts O
2 O
and O
3 O
also O
received O
immunosuppressants O
from O
the O
time O
of O
alipogene O
tiparvovec O
administration O
and O
continued O
for O
12 O
weeks. O
Alipogene O
tiparvovec O
was O
well O
tolerated, O
without O
emerging O
safety O
concerns O
for O
2 O
years. O
Half O
of O
the O
patients O
demonstrated O
a O
40% O
reduction O
in O
fasting O
TG O
between O
3 O
and O
12 O
weeks. O
TG O
subsequently O
returned O
to O
baseline, O
although O
sustained O
LPL(S447X) B-GENE-Y
expression O
and O
long-term O
changes O
in O
TG-rich O
lipoprotein O
characteristics O
were O
noted O
independently O
of O
the O
effect O
on O
fasting O
plasma O
TG. O

2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated B-CHEMICAL
production O
of O
reactive O
oxygen B-CHEMICAL
species O
is O
an O
essential O
step O
in O
the O
mechanism O
of O
action O
to O
accelerate O
human O
keratinocyte O
differentiation. O
Chloracne O
is O
commonly O
observed O
in O
humans O
exposed O
to O
2,3,7,8-tetrachlorodibenzo-p-dioxin B-CHEMICAL
(TCDD); B-CHEMICAL
yet, O
the O
mechanism O
of O
toxicity O
is O
not O
well O
understood. O
Using O
normal O
human O
epidermal O
keratinocytes, O
we O
investigated O
the O
mechanism O
of O
TCDD-mediated B-CHEMICAL
enhancement O
of O

epidermal O
differentiation O
by O
integrating O
functional O
genomic, O
metabolomic, O
and O
biochemical O
analyses. O
TCDD B-CHEMICAL
increased O
the O
expression O
of O
40% O
of O
the O
genes O
of O
the O
epidermal O
differentiation O
complex O
found O
on O
chromosome O
1q21 O
and O
75% O
of O
the O
genes O
required O
for O
de O
novo O
ceramide B-CHEMICAL
biosynthesis. O
Lipid O
analysis O
demonstrated O
that O
eight O
of O
the O
nine O
classes O
of O
ceramides B-CHEMICAL
were O
increased O
by O
TCDD, B-CHEMICAL
altering O
the O
ratio O
of O
ceramides B-CHEMICAL
to O
free O
fatty B-CHEMICAL
acids. I-CHEMICAL
TCDD B-CHEMICAL
decreased O
the O
expression O
of O
the O
glucose B-GENE-N
transporter, I-GENE-N
SLC2A1, B-GENE-Y
and O
most O
of O
the O

glycolytic O
transcripts, O
followed O
by O
decreases O
in O
glycolytic O
intermediates, O
including O
pyruvate. B-CHEMICAL
NADH B-CHEMICAL
and O
Krebs O
cycle O
intermediates O
were O
decreased, O
whereas O
NAD(+) B-CHEMICAL
was O
increased. O
Mitochondrial O
glutathione B-GENE-N
(GSH) I-GENE-N
reductase I-GENE-N
activity O
and O
the O
GSH/glutathione B-CHEMICAL
disulfide I-CHEMICAL
ratio O
were O
decreased O
by O
TCDD, B-CHEMICAL
ultimately O
leading O
to O
mitochondrial O
dysfunction, O
characterized O
by O
decreased O
inner O
mitochondrial O
membrane O
potential O
and O
ATP B-CHEMICAL
production, O
and O
increased O
production O
of O
the O
reactive O
oxygen B-CHEMICAL
species O
(ROS), O
hydrogen B-CHEMICAL
peroxide. I-CHEMICAL
Aryl B-GENE-Y

hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AHR) B-GENE-Y
antagonists O
blocked O
the O
response O
of O
many O
transcripts O
to O
TCDD, B-CHEMICAL
and O
the O
endpoints O
of O
decreased O
ATP B-CHEMICAL
production O
and O
differentiation, O
suggesting O
regulation O
by O
the O
AHR. B-GENE-Y
Cotreatment O
of O
cells O
with O
chemical O
antioxidants O
or O
the O
enzyme O
catalase B-GENE-Y
blocked O
the O
TCDD-mediated B-CHEMICAL
acceleration O
of O
keratinocyte O
cornified O
envelope O
formation, O
an O
endpoint O
of O
terminal O
differentiation. O
Thus, O
TCDD-mediated B-CHEMICAL
ROS O
production O
is O
a O
critical O
step O
in O
the O
mechanism O
of O
this O
chemical O
to O
accelerate O
keratinocyte O
differentiation. O
ATP-binding B-GENE-Y
cassette I-GENE-Y
transporter I-GENE-Y
A1 I-GENE-Y
is O
involved O
in O

hepatic O
alpha-tocopherol B-CHEMICAL
secretion. O
Vitamin B-CHEMICAL
E I-CHEMICAL
(alpha-tocopherol) B-CHEMICAL
is O
an O
essential O
fat-soluble O
nutrient O
with O
antioxidant O
properties. O
alpha-Tocopherol B-GENE-Y
transfer I-GENE-Y
protein I-GENE-Y
(alpha-TTP), B-GENE-Y
the O
product O
of O
the O
gene O
responsible O
for O
familial O
isolated O
vitamin B-CHEMICAL
E I-CHEMICAL
deficiency, O
plays O
an O
important O
role O
in O
maintaining O
the O
plasma O
alpha-tocopherol B-CHEMICAL
level O
by O
mediating O
the O
secretion O
of O
alpha-tocopherol B-CHEMICAL
by O
the O
liver. O
However, O
the O
mechanisms O
underlying O
hepatic O
alpha-tocopherol B-CHEMICAL
secretion O
are O
not O
fully O
understood. O
This O
study O
was O
undertaken O
to O

elucidate O
the O
mechanism O
of O
alpha-tocopherol B-CHEMICAL
re-efflux O
from O
hepatocytes, O
the O
cells O
that O
have O
the O
most O
important O
role O
in O
regulating O
plasma-alpha-tocopherol B-CHEMICAL
concentrations. O
From O
in O
vitro O
experiments O
using O
[(3)H]alpha-tocopheryl B-CHEMICAL
acetate I-CHEMICAL
and O
McARH7777 O
cells O
that O
stably O
express O
alpha-tocopherol B-GENE-Y
transfer I-GENE-Y
protein I-GENE-Y
(alpha-TTP), B-GENE-Y
the O
following O
results O
were O
obtained. O
First, O
addition O
of O
apolipoprotein B-GENE-Y
A-I I-GENE-Y
(apoA-I), B-GENE-Y
a O
direct O
acceptor O
of O

the O
ATP-binding B-GENE-Y
cassette I-GENE-Y
transporter I-GENE-Y
A1 I-GENE-Y
(ABCA1)-secreted B-GENE-Y
lipids, O
increased O
alpha-tocopherol B-CHEMICAL
secretion O
in O
a O
dose-dependent O
manner. O
Second, O
probucol, B-CHEMICAL
an O
antiatherogenic O
compound O
reported O
to O
be O
an O
inactivator O
of O
ABCA1 B-GENE-Y
reduced O
hepatic O
alpha-tocopherol B-CHEMICAL
secretion. O
Third, O
ABCA1-RNAi B-GENE-Y
suppressed O
hepatic O
alpha-tocopherol B-CHEMICAL
secretion. O
In O
a O
mouse O
in O
vivo O
experiment, O
addition O
of O
1% O
probucol B-CHEMICAL
to O
the O
diet O
decreased O
plasma O
alpha-tocopherol B-CHEMICAL
concentrations. O
These O
results O
strongly O
suggest O

that O
ABCA1 B-GENE-Y
is O
substantially O
involved O
in O
hepatic O
alpha-tocopherol B-CHEMICAL
secretion. O
Crystal O
structures O
of O
protein B-GENE-N
phosphatase-1 I-GENE-N
bound O
to O
motuporin B-CHEMICAL
and O
dihydromicrocystin-LA: B-CHEMICAL
elucidation O
of O
the O
mechanism O
of O
enzyme O
inhibition O
by O
cyanobacterial O
toxins. O
The O
microcystins B-CHEMICAL
and O
nodularins B-CHEMICAL
are O
tumour O
promoting O
hepatotoxins O
that O
are O
responsible O
for O
global O
adverse O
human O
health O
effects O
and O
wildlife O
fatalities O
in O
countries O
where O
drinking O
water O
supplies O
contain O
cyanobacteria. O
The O
toxins O
function O
by O
inhibiting O
broad O

specificity O
Ser/Thr B-GENE-N
protein I-GENE-N
phosphatases I-GENE-N
in O
the O
host O
cells, O
thereby O
disrupting O
signal O
transduction O
pathways. O
A O
previous O
crystal O
structure O
of O
a O
microcystin B-CHEMICAL
bound O
to O
the O
catalytic O
subunit O
of O
protein B-GENE-N
phosphatase-1 I-GENE-N
(PP-1c) B-GENE-N
showed O
distinct O
changes O
in O
the O
active O
site O
region O
when O
compared O
with O
protein B-GENE-N
phosphatase-1 I-GENE-N
structures O
bound O
to O
other O
toxins. O
We O
have O
elucidated O
the O
crystal O
structures O
of O
the O
cyanotoxins, B-GENE-N
motuporin B-CHEMICAL
(nodularin-V) B-CHEMICAL
and O
dihydromicrocystin-LA B-CHEMICAL
bound O
to O
human B-GENE-Y
protein I-GENE-Y

phosphatase-1c I-GENE-Y
(gamma I-GENE-Y
isoform). I-GENE-Y
The O
atomic O
structures O
of O
these O
complexes O
reveal O
the O
structural O
basis O
for O
inhibition O
of O
protein B-GENE-N
phosphatases I-GENE-N
by O
these O
toxins. O
Comparisons O
of O
the O
structures O
of O
the O
cyanobacterial B-GENE-N
toxin:phosphatase I-GENE-N
complexes O
explain O
the O
biochemical O
mechanism O
by O
which O
microcystins B-CHEMICAL
but O
not O
nodularins B-CHEMICAL
permanently O
modify O
their O
protein B-GENE-N
phosphatase I-GENE-N
targets O
by O
covalent O
addition O
to O
an O
active O
site O
cysteine B-CHEMICAL
residue. O
A O
cocaine-sensitive B-CHEMICAL
Drosophila B-GENE-Y
serotonin I-GENE-Y
transporter: I-GENE-Y
cloning, O
expression, O
and O

electrophysiological O
characterization. O
A O
cocaine-sensitive, B-CHEMICAL
high-affinity O
Drosophila B-GENE-Y
serotonin I-GENE-Y
(5-hydroxytryptamine; I-GENE-Y
5HT) I-GENE-Y
transporter I-GENE-Y
cDNA, O
denoted O
dSERT1, B-GENE-Y
was O
isolated O
and O
characterized O
in O
oocytes. O
dSERT1 B-GENE-Y
shows O
little O
transport O
of O
other O
monoamines B-CHEMICAL
and O
is O
Na+ B-CHEMICAL
and O
Cl- B-CHEMICAL
dependent. O
Sequence O
analysis O
indicates O
12 O
putative O
transmembrane O
domains O
and O
strong O
homologies O
(approximately O
50%) O
among O
dSERT1 B-GENE-Y
and O
mammalian B-GENE-N
5HT, I-GENE-N
norepinephrine, I-GENE-N
and I-GENE-N
dopamine I-GENE-N
transporters. I-GENE-N

Interestingly, O
the O
pharmacological O
properties O
of O
dSERT1, B-GENE-Y
including O
sensitivity O
to O
antidepressants, O
are O
more O
similar O
to O
those O
of O
mammalian B-GENE-N
catecholamine I-GENE-N
transporters I-GENE-N
than O
to O
mammalian B-GENE-N
5HT I-GENE-N
transporters. I-GENE-N
Two-electrode O
voltage-clamp O
analysis O
demonstrated O
5HT-induced, B-CHEMICAL
voltage-dependent O
currents. O
Cloning O
and O
characterization O
of O
dSERT1 B-GENE-Y
adds O
significantly O
to O
our O
knowledge O
of O
the O
diversity O
of O
5HT B-GENE-Y
transporters I-GENE-Y
with O
regard O
to O
primary O
sequence, O
pharmacological O
profile, O
and O
permeation O
properties. O
Formation O
of O
mainstream O
cigarette O
smoke O
constituents O
prioritized O
by O
the O
World O
Health O
Organization--yield O

patterns O
observed O
in O
market O
surveys, O
clustering O
and O
inverse O
correlations. O
The O
WHO O
TobReg O
proposed O
mandating O
ceilings O
on O
selected O
smoke O
constituents O
determined O
from O
the O
market-specific O
median O
of O
nicotine-normalized B-CHEMICAL
yield O
distributions. O
Data O
validating O
this O
regulatory O
concept O
were O
obtained O
from O
essentially O
single-blend O
surveys. O
This O
process O
is O
strongly O
impacted O
by O
inverse O
correlations O
among O
yields. O
In O
the O
present O
study, O
18 O
priority O
WHO O
smoke O
constituent O
yields O
(nicotine-normalized) B-CHEMICAL
were O
determined O
(using O
two O
smoking O
regimens) O
from O
262 O
commercial O
brands O
including O
American, O
Virginia O
and O
local O
blends O
from O
13 O
countries. O
Principal O
Component O
Analysis O
was O
used O
to O
identify O
yields O

patterns, O
clustering O
of O
blend O
types O
and O
the O
inverse O
correlations O
causing O
these O
clusters. O
Three O
principal O
components O
explain O
about O
75% O
of O
total O
data O
variability. O
PC1 O
was O
sensitive O
to O
the O
relative O
levels O
of O
gas- O
and O
particle-phase O
compounds. O
PC2 O
and O
PC3 O
cluster O
American- O
and O
Virginia-blends, O
revealing O
inverse O
correlations: O
Nitrogen B-CHEMICAL
oxides I-CHEMICAL
and O
amino- B-CHEMICAL
or O
nitroso-aromatic B-CHEMICAL
compounds O
inversely O
correlate O
to O
either O
formaldehyde B-CHEMICAL
and O
acrolein, B-CHEMICAL
or O
benzo(a)pyrene B-CHEMICAL
and O
di-hydroxybenzenes. B-CHEMICAL
These O
results O
can O
be O
explained O
by O
reviewing O
the O
processes O

determining O
each O
components O
smoke O
delivery. O
Regulatory O
initiatives O
simultaneously O
targeting O
selected O
smoke O
constituents O
in O
markets O
with O
mixed O
blend O
styles O
will O
be O
strongly O
impacted O
by O
the O
inverse O
correlations O
described. O
It O
is O
difficult O
to O
predict O
the O
ultimate O
impact O
of O
such O
regulations O
on O
public O
health, O
considering O
the O
complex O
chemistry O
of O
cigarette O
smoke O
formation. O
Atypical O
neuroleptics O
have O
low O
affinity O
for O
dopamine B-GENE-Y
D2 I-GENE-Y
receptors I-GENE-Y
or O
are O
selective O
for O
D4 B-GENE-Y
receptors. I-GENE-Y
This O
review O
examines O
the O
possible O
receptor O
basis O
of O
the O
atypical O
action O
of O
those O
atypical O
antipsychotic O
drugs O
that O
elicit O
low O
levels O
of O
Parkinsonism. O
Such O
an O
examination O
requires O
consistent O
and O
accurate O
dissociation O
constants O
for O

the O
antipsychotic O
drugs O
at O
the O
relevant O
dopamine B-GENE-N
and I-GENE-N
serotonin I-GENE-N
receptors. I-GENE-N
It O
has O
long O
been O
known, O
however, O
that O
the O
dissociation O
constant O
of O
a O
given O
antipsychotic O
drug O
at O
the O
dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y
varies O
between O
laboratories. O
Although O
such O
variation O
depends O
on O
several O
factors, O
it O
has O
recently O
been O
recognized O
that O
the O
radioligand O
used O
to O
measure O
the O
competition O
between O
the O
antipsychotic O
drug O
and O
the O
radioligand O
is O
an O
important O
variable. O
The O
present O
review O
summarizes O
information O
on O
this O
radioligand O
dependence. O
In O
general, O
a O
radioligand O
of O
low O
solubility O
in O
the O
membrane O

(i.e., O
low O
tissue:buffer O
partition) O
results O
in O
a O
low O
value O
for O
the O
antipsychotic O
dissociation O
constant O
when O
the O
drug O
competes O
with O
the O
radioligand. O
Hence, O
by O
first O
obtaining O
the O
antipsychotic O
dissociation O
constants O
using O
different O
radioligands O
of O
different O
solubility O
in O
the O
membrane, O
one O
can O
then O
extrapolate O
the O
data O
to O
low O
or O
"zero" O
ligand O
solubility. O
The O
extrapolated O
value O
represents O
the O
radioligand-independent O
dissociation O
constant O
of O
the O
antipsychotic. O
These O
values O
are O
here O
given O
for O
dopamine B-GENE-N
D2 I-GENE-N
and I-GENE-N
D4 I-GENE-N
receptors, I-GENE-N

as O
well O
as O
for O
serotonin B-GENE-Y
5-HT2A I-GENE-Y
receptors. I-GENE-Y
These O
values, O
moreover, O
agree O
with O
the O
dissociation O
constant O
directly O
obtained O
with O
the O
radioactive O
antipsychotic O
itself. O
For O
example, O
clozapine B-CHEMICAL
revealed O
a O
radioligand-independent O
value O
of O
1.6 O
nM O
at O
the O
dopamine B-GENE-Y
D4 I-GENE-Y
receptor, I-GENE-Y
agreeing O
with O
the O
value O
directly O
measured O
with O
[3H]-clozapine B-CHEMICAL
at O
D4. B-GENE-Y
However, O
because O
clozapine B-CHEMICAL
competes O
with O
endogenous O
dopamine, B-CHEMICAL
the O
in O
vivo O
concentration O
of O
clozapine B-CHEMICAL
(to O
occupy O
dopamine B-GENE-Y
D4 I-GENE-Y
receptors) I-GENE-Y

can O
be O
derived O
to O
be O
about O
13 O
nM, O
agreeing O
with O
the O
value O
of O
12 O
to O
20 O
nM O
in O
the O
plasma O
water O
or O
spinal O
fluid O
observed O
in O
treated O
patients. O
The O
atypical O
neuroleptics O
remoxipride, B-CHEMICAL
clozapine, B-CHEMICAL
perlapine, B-CHEMICAL
seroquel, B-CHEMICAL
and O
melperone B-CHEMICAL
had O
low O
affinity O
for O
the O
dopamine B-CHEMICAL
D2 B-GENE-Y
receptor I-GENE-Y
(radioligand-independent O
dissociation O
constants O
of O
30 O
to O
90 O
nM). O
Such O
low O
affinity O
makes O
these O
latter O
five O
drugs O
readily O
displaceable O
by O
high O
levels O
of O
endogenous O
dopamine B-CHEMICAL
in O
the O
caudate O
or O

putamen. O
Most O
typical O
neuroleptics O
have O
radioligand-independent O
values O
of O
0.3 O
to O
5 O
nM O
at O
dopamine B-GENE-Y
D2 I-GENE-Y
receptors, I-GENE-Y
making O
them O
more O
resistant O
to O
displacement O
by O
endogenous O
dopamine. B-CHEMICAL
Finally, O
a O
relation O
was O
found O
between O
the O
neuroleptic O
doses O
for O
rat O
catalepsy O
and O
the O
D2:D4 B-GENE-Y
ratio O
of O
the O
radioligand-independent O
K O
values O
for O
these O
two O
receptors. O
Thus, O
the O
atypical O
neuroleptics O
appear O
to O
fall O
into O
two O
groups, O
those O
that O
have O
a O
low O
affinity O
for O
dopamine B-GENE-Y
D2 I-GENE-Y
receptors I-GENE-Y
and O
those O
that O
are O
selective O
for O

dopamine B-GENE-Y
D4 I-GENE-Y
receptors. I-GENE-Y
alpha7 B-GENE-N
nicotinic I-GENE-N
receptor I-GENE-N
gene I-GENE-N
promoter I-GENE-N
polymorphisms O
in O
inbred O
mice O
affect O
expression O
in O
a O
cell O
type-specific O
fashion. O
Inbred O
mouse O
strains O
display O
significant O
differences O
in O
their O
levels O
of O
brain O
alpha7 B-GENE-Y
nicotinic I-GENE-Y
acetylcholine I-GENE-Y
receptor I-GENE-Y
(alpha7 B-GENE-Y
nAChR) I-GENE-Y
expression, O
as O
measured O
by O
binding O
of O
the O
alpha7-selective O
antagonist O
alpha-bungarotoxin. O
Variations O
in O
alpha-bungarotoxin B-GENE-Y
binding O
have O
been O
shown O
to O
correlate O
with O
an O
animal's O
sensitivity O
to O
nicotine-induced B-CHEMICAL
seizures O
and O
sensory O
gating. O
In O
two O

inbred O
mouse O
strains, O
C3H/2Ibg O
(C3H) O
and O
DBA/2Ibg O
(DBA/2), O
the O
inter-strain O
binding O
differences O
are O
linked O
to O
a O
restriction O
length O
polymorphism O
in O
the O
alpha7 B-GENE-Y
nAChR I-GENE-Y
gene, O
Chrna7. B-GENE-Y
Despite O
this O
finding, O
the O
molecular O
mechanism(s) O
through O
which O
genetic O
variability O
in O
Chrna7 B-GENE-Y
may O
contribute O
to O
alpha7 B-GENE-Y
nAChR I-GENE-Y
expression O
differences O
remains O
unknown. O
However, O
studies O
of O
the O
human B-GENE-Y
alpha7 I-GENE-Y
nAChR I-GENE-Y
gene O
(CHRNA7) B-GENE-Y
previously O
have O
demonstrated O
that O
CHRNA7 B-GENE-N
promoter I-GENE-N

polymorphisms O
are O
associated O
with O
differences O
in O
promoter O
activity O
as O
well O
as O
differences O
in O
sensory O
processing. O
In O
the O
present O
study, O
a O
947-base O
pair O
region O
of O
the O
Chrna7 B-GENE-N
promoter I-GENE-N
was O
cloned O
from O
both O
the O
C3H O
and O
DBA/2 O
inbred O
mouse O
strains O
in O
an O
attempt O
to O
identify O
polymorphisms O
that O
may O
underlie O
alpha7 B-GENE-Y
nAChR I-GENE-Y
differential O
expression. O
Sequence O
analysis O
of O
these O
fragments O
identified O
14 O
single O
nucleotide B-CHEMICAL
polymorphisms O
(SNPs). O
A O
combination O
of O
two O
of O
these O
SNPs O
affects O
promoter O
activity O
in O
an O
in O
vitro O
luciferase O
reporter O

assay. O
These O
results O
suggest O
a O
mechanism O
through O
which O
the O
Chrna7 B-GENE-N
promoter I-GENE-N
genotype O
may O
influence O
interstrain O
variations O
in O
alpha7 B-GENE-Y
nAChR I-GENE-Y
expression. O
Synthesis O
and O
in O
vitro O
pharmacology O
at O
AMPA B-CHEMICAL
and O
kainate B-CHEMICAL
preferring O
glutamate B-GENE-N
receptors I-GENE-N
of O
4-heteroarylmethylidene B-CHEMICAL
glutamate I-CHEMICAL
analogues. O
2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic B-CHEMICAL
acid I-CHEMICAL
(1) O
is O
a O
potent O
AMPA B-GENE-N
receptor I-GENE-N
agonist O
with O
moderate O

affinity O
for O
native O
kainic B-GENE-N
acid I-GENE-N
(KA) I-GENE-N
receptors, I-GENE-N
whereas O
(S)-E-4-(2,2-dimethylpropylidene)glutamic B-CHEMICAL
acid I-CHEMICAL
(3) O
show O
high O
affinity O
for O
the O
GluR5 B-GENE-Y
subtype O
of O
KA B-GENE-N
receptors I-GENE-N
and O
much O
lower O
affinity O
for O
the O
GluR2 B-GENE-Y
subtype O
of O
AMPA B-GENE-N
receptors. I-GENE-N
As O
an O
attempt O
to O
develop O
new O
pharmacological O
tools O
for O
studies O
of O
GluR5 B-GENE-Y
receptors, O
(S)-E-4-(2-thiazolylmethylene)glutamic B-CHEMICAL
acid I-CHEMICAL
(4a) O
was O

designed O
as O
a O
structural O
hybrid O
between O
1 O
and O
3. O
4a O
was O
shown O
to O
be O
a O
potent O
GluR5 B-GENE-Y
agonist O
and O
a O
high O
affinity O
ligand O
and O
to O
indiscriminately O
bind O
to O
the O
AMPA B-GENE-N
receptor I-GENE-N
subtypes O
GluR1-4 B-GENE-N
with O
lower O
affinities. O
Compounds O
4b-h, O
in O
which O
the O
2-thiazolyl B-CHEMICAL
substituent O
of O
4a O
was O
replaced O
by O
other O
heterocyclic B-CHEMICAL
rings, O
which O
have O
previously O
been O
incorporated O
as O
5-substituents O
in O
AMPA B-CHEMICAL
analogues, O
as O
exemplified O
by O
1 O
were O
also O
synthesized. O

Compounds O
4b-h O
were O
either O
inactive O
(4e,f) O
or O
weaker O
than O
4a O
as O
affinity O
ligands O
for O
GluR1-4 B-GENE-N
and O
GluR5 B-GENE-Y
with O
relative O
potencies O
comparable O
with O
those O
of O
the O
corresponding O
AMPA B-CHEMICAL
analogues O
as O
AMPA B-GENE-N
receptor I-GENE-N
agonists. O
Compounds O
4a-h O
may O
be O
useful O
tools O
for O
the O
progressing O
pharmacophore O
mapping O
of O
the O
GluR5 B-GENE-Y
agonist O
binding O
site. O
Pranlukast, B-CHEMICAL
a O
leukotriene B-GENE-N
receptor I-GENE-N
antagonist, O
inhibits O
interleukin-5 B-GENE-Y
production O
via O
a O
mechanism O
distinct O
from O

leukotriene B-GENE-N
receptor I-GENE-N
antagonism. O
BACKGROUND: O
Pranlukast, B-CHEMICAL
a O
cysteinyl B-GENE-Y
leukotriene I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
(CysLTR1) B-GENE-Y
antagonist, O
inhibits O
not O
only O
airway O
smooth O
muscle O
contraction, O
but O
also O
allergic O
inflammation. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
mechanism O
of O
pranlukast-induced B-CHEMICAL
interleukin-5 B-GENE-Y
(IL-5) B-GENE-Y
inhibition O
in O
allergic O
inflammation. O
METHODS: O
Surgically O
resected O
human O
lung O
tissue O
was O
passively O
sensitized O
in O
vitro O
with O

mite-allergen-sensitized O
sera, O
followed O
by O
stimulation O
with O
mite O
allergen O
after O
pretreatment O
of O
the O
tissue O
with O
pranlukast, B-CHEMICAL
dexamethasone, B-CHEMICAL
or O
both. O
The O
IL-5 B-GENE-Y
protein O
level O
in O
the O
culture O
medium O
was O
measured, O
and O
in O
situ O
hybridization O
of O
IL-5 B-GENE-Y
and O
CysLTR1 B-GENE-Y
mRNA O
was O
performed O
using O
lung O
tissues. O
RESULTS: O
Pretreatment O
of O
lung O
tissues O
with O
pranlukast B-CHEMICAL
alone O
significantly O
decreased O
the O
amount O
of O
IL-5 B-GENE-Y
protein O
in O
the O
culture O
medium O
by O
40%. O
The O
combination O
of O
pranlukast B-CHEMICAL

and O
dexamethasone B-CHEMICAL
synergistically O
enhanced O
this O
effect. O
Quantitative O
in O
situ O
hybridization O
with O
image O
analysis O
revealed O
abundant O
expression O
of O
IL-5 B-GENE-Y
mRNA O
in O
eosinophils, O
lymphocytes, O
and O
mast O
cells O
in O
sensitized O
and O
allergen-stimulated O
lung O
tissues. O
CysLTR1 B-GENE-Y
mRNA O
was O
detected O
in O
macrophages, O
smooth O
muscle O
cells, O
eosinophils, O
and O
mast O
cells, O
but O
was O
less O
expressed O
in O
lymphocytes. O
Pranlukast-induced B-CHEMICAL
inhibition O
of O
IL-5 B-GENE-Y
mRNA O
expression O
was O
noted O
in O
various O
cells, O
irrespective O

of O
their O
CysLTR1 B-GENE-Y
mRNA O
expression O
status. O
In O
addition, O
cysteinyl B-CHEMICAL
leukotrienes I-CHEMICAL
per O
se O
failed O
to O
upregulate O
the O
IL-5 B-GENE-Y
production. O
CONCLUSION: O
Our O
results O
indicate O
that O
pranlukast B-CHEMICAL
inhibits O
IL-5 B-GENE-Y
synthesis O
via O
a O
mechanism O
distinct O
from O
CysLTR1 B-GENE-Y
antagonism. O
The O
platelet B-GENE-N
P2 I-GENE-N
receptors I-GENE-N
as O
molecular O
targets O
for O
old O
and O
new O
antiplatelet O
drugs. O
Platelet O
activation O
by O
ADP B-CHEMICAL
and O
ATP B-CHEMICAL
plays O
a O
crucial O
role O
in O
haemostasis O
and O
thrombosis, O
and O
their O
so-called O
P2 B-GENE-N
receptors I-GENE-N
are O
potential O
targets O
for O

antithrombotic O
drugs. O
The O
ATP-gated B-GENE-Y
channel I-GENE-Y
P2X1 I-GENE-Y
and O
the O
2 O
G B-GENE-Y
protein-coupled I-GENE-Y
P2Y1 I-GENE-Y
and O
P2Y12 B-GENE-Y
ADP B-GENE-N
receptors I-GENE-N
selectively O
contribute O
to O
platelet O
aggregation. O
The O
P2Y1 B-GENE-Y
receptor O
is O
responsible O
for O
ADP-induced B-CHEMICAL
shape O
change O
and O
weak O
and O
transient O
aggregation, O
while O
the O
P2Y12 B-GENE-Y
receptor O
is O
responsible O
for O
the O
completion O
and O
amplification O
of O
the O
response O
to O
ADP B-CHEMICAL
and O
to O
all O
platelet O
agonists, O
including O
thromboxane B-CHEMICAL
A2 I-CHEMICAL
(TXA2), B-CHEMICAL
thrombin, B-GENE-Y
and O
collagen. B-GENE-N
The O

P2X1 B-GENE-Y
receptor O
is O
involved O
in O
platelet O
shape O
change O
and O
in O
activation O
by O
collagen B-GENE-N
under O
shear O
conditions. O
Due O
to O
its O
central O
role O
in O
the O
formation O
and O
stabilization O
of O
a O
thrombus, O
the O
P2Y12 B-GENE-Y
receptor O
is O
a O
well-established O
target O
of O
antithrombotic O
drugs O
like O
ticlopidine B-CHEMICAL
or O
clopidogrel, B-CHEMICAL
which O
have O
proved O
efficacy O
in O
many O
clinical O
trials O
and O
experimental O
models O
of O
thrombosis. O
Competitive O
P2Y12 B-GENE-Y
antagonists O
have O
also O
been O
shown O
to O
be O
effective O
in O
experimental O
thrombosis O
as O
well O
as O
in O
several O
clinical O
trials. O
Studies O
in O
P2Y1 B-GENE-Y

and O
P2X1 B-GENE-Y
knockout O
mice O
and O
experimental O
thrombosis O
models O
using O
selective O
P2Y1 B-GENE-Y
and O
P2X1 B-GENE-Y
antagonists O
have O
shown O
that, O
depending O
on O
the O
conditions, O
these O
receptors O
could O
also O
be O
potential O
targets O
for O
new O
antithrombotic O
drugs. O
Effect O
of O
thiazolidinediones B-CHEMICAL
on O
equilibrative B-GENE-Y
nucleoside I-GENE-Y
transporter-1 I-GENE-Y
in O
human O
aortic O
smooth O
muscle O
cells. O
Thiazolidinediones B-CHEMICAL
are O
a O
new O
class O
of O
anti-diabetic O
agents O
which O
increase O
insulin B-GENE-Y
sensitivity O
by O
binding O
to O
the O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y

(PPAR(gamma)) B-GENE-Y
and O
stimulating O
the O
expression O
of O
insulin-responsive B-GENE-Y
genes O
involved O
in O
glucose B-CHEMICAL
and O
lipid O
metabolism. O
These O
drugs O
also O
have O
vasodilatory O
and O
anti-proliferative O
effects O
on O
vascular O
smooth O
muscle O
cells. O
However O
the O
mechanisms O
for O
these O
actions O
are O
not O
fully O
understood. O
Adenosine O
is O
a O
vasodilator O
and O
a O
substrate O
of O
equilibrative B-GENE-N
nucleoside I-GENE-N
transporters I-GENE-N
(ENT). B-GENE-N
The O
present O
study O
studied O
the O
effects O
of O
three O
thiazolidinediones, B-CHEMICAL
troglitazone, B-CHEMICAL
pioglitazone B-CHEMICAL
and O
ciglitazone, B-CHEMICAL

on O
ENT1 B-GENE-Y
in O
the O
human O
aortic O
smooth O
muscle O
cells O
(HASMCs). O
Although O
incubating O
HASMCs O
for O
48h O
with O
thiazolidinediones B-CHEMICAL
had O
no O
effect O
on O
ENT1 B-GENE-Y
mRNA O
and O
protein O
levels, O
troglitazone B-CHEMICAL
acutely O
inhibited O
[3H]adenosine B-CHEMICAL
uptake O
and O
[3H]NBMPR B-CHEMICAL
binding O
of O
HASMCs O
with O
IC50 O
values O
of O
2.35+/-0.35 O
and O
3.99+/-0.57microM, O
respectively. O
The O
effect O
of O
troglitazone B-CHEMICAL

on O
ENT1 B-GENE-Y
was O
PPAR(gamma)-independent B-GENE-Y
and O
kinetic O
studies O
revealed O
that O
troglitazone B-CHEMICAL
was O
a O
competitive O
inhibitor O
of O
ENT1. B-GENE-Y
In O
contrast, O
pioglitazone B-CHEMICAL
and O
ciglitazone B-CHEMICAL
had O
minimal O
effects O
on O
[3H]adenosine B-CHEMICAL
uptake O
by O
HASMCs. O
Troglitazone B-CHEMICAL
differs O
from O
pioglitazone B-CHEMICAL
and O
ciglitazone B-CHEMICAL
in O
that O
its O
side-chain O
contains O
a O
Vitamin B-CHEMICAL
E I-CHEMICAL
moiety. O
The O
difference O
in O
structure O
of O
troglitazone B-CHEMICAL
did O
not O
account O
for O
its O
inhibitory O
effect O
on O
ENT1 B-GENE-Y
because O
Vitamin B-CHEMICAL
E I-CHEMICAL
did O
not O

inhibit O
[3H]adenosine B-CHEMICAL
uptake O
by O
HASMCs. O
Using O
the O
nucleoside B-GENE-N
transporter I-GENE-N
deficient O
PK15NTD O
cells O
stably O
expressing O
ENT1 B-GENE-Y
and O
ENT2, B-GENE-Y
it O
was O
found O
that O
troglitazone B-CHEMICAL
inhibited O
ENT1 B-GENE-Y
but O
had O
no O
effect O
on O
ENT2. B-GENE-Y
From O
these O
results, O
it O
is O
suggested O
that O
troglitazone B-CHEMICAL
may O
enhance O
the O
vasodilatory O
effect O
of O
adenosine B-CHEMICAL
by O
inhibiting O
ENT1. B-GENE-Y
Pharmacologically, O
troglitazone B-CHEMICAL
is O
a O
novel O
inhibitor O
of O
ENT1. B-GENE-Y
Genetic O

predictors O
of O
the O
maximum O
doses O
patients O
receive O
during O
clinical O
use O
of O
the O
anti-epileptic O
drugs O
carbamazepine B-CHEMICAL
and O
phenytoin. B-CHEMICAL
Phenytoin B-CHEMICAL
and O
carbamazepine B-CHEMICAL
are O
effective O
and O
inexpensive O
anti-epileptic O
drugs O
(AEDs). O
As O
with O
many O
AEDs, O
a O
broad O
range O
of O
doses O
is O
used, O
with O
the O
final O
"maintenance" O
dose O
normally O
determined O
by O
trial O
and O
error. O
Although O
many O
genes O
could O
influence O
response O
to O
these O
medicines, O
there O
are O
obvious O
candidates. O
Both O
drugs O
target O
the O
alpha-subunit B-GENE-N
of I-GENE-N
the I-GENE-N
sodium I-GENE-N
channel, I-GENE-N
encoded O
by O
the O
SCN B-GENE-N
family O
of O
genes. O

Phenytoin B-CHEMICAL
is O
principally O
metabolized O
by O
CYP2C9, B-GENE-Y
and O
both O
are O
probable O
substrates O
of O
the O
drug B-GENE-N
transporter I-GENE-N
P-glycoprotein. B-GENE-N
We O
therefore O
assessed O
whether O
variation O
in O
these O
genes O
associates O
with O
the O
clinical O
use O
of O
carbamazepine B-CHEMICAL
and O
phenytoin B-CHEMICAL
in O
cohorts O
of O
425 O
and O
281 O
patients, O
respectively. O
We O
report O
that O
a O
known O
functional O
polymorphism O
in O
CYP2C9 B-GENE-Y
is O
highly O
associated O
with O
the O
maximum O
dose O
of O
phenytoin B-CHEMICAL
(P O
= O
0.0066). O
We O
also O
show O
that O
an O
intronic O
polymorphism O
in O
the O

SCN1A B-GENE-Y
gene O
shows O
significant O
association O
with O
maximum O
doses O
in O
regular O
usage O
of O
both O
carbamazepine B-CHEMICAL
and O
phenytoin B-CHEMICAL
(P O
= O
0.0051 O
and O
P O
= O
0.014, O
respectively). O
This O
polymorphism O
disrupts O
the O
consensus O
sequence O
of O
the O
5' O
splice O
donor O
site O
of O
a O
highly O
conserved O
alternative O
exon O
(5N), O
and O
it O
significantly O
affects O
the O
proportions O
of O
the O
alternative O
transcripts O
in O
individuals O
with O
a O
history O
of O
epilepsy. O
These O
results O
provide O
evidence O
of O
a O
drug O
target O
polymorphism O
associated O
with O
the O
clinical O
use O
of O
AEDs O
and O
set O
the O
stage O
for O
a O
prospective O
evaluation O

of O
how O
pharmacogenetic O
diagnostics O
can O
be O
used O
to O
improve O
dosing O
decisions O
in O
the O
use O
of O
phenytoin B-CHEMICAL
and O
carbamazepine. B-CHEMICAL
Although O
the O
case O
made O
here O
is O
compelling, O
our O
results O
cannot O
be O
considered O
definitive O
or O
ready O
for O
clinical O
application O
until O
they O
are O
confirmed O
by O
independent O
replication. O
Fisetin B-CHEMICAL
regulates O
obesity O
by O
targeting O
mTORC1 B-GENE-N
signaling. O
Fisetin, B-CHEMICAL
a O
flavonol B-CHEMICAL
present O
in O
vegetables O
and O
fruits, O
possesses O
antioxidative O
and O
anti-inflammatory O
properties. O
In O
this O
study, O
we O
have O
demonstrated O
that O
fisetin B-CHEMICAL
prevents O
diet-induced O
obesity O
through O
regulation O
of O
the O
signaling O
of O

mammalian B-GENE-N
target I-GENE-N
of I-GENE-N
rapamycin I-GENE-N
complex I-GENE-N
1 I-GENE-N
(mTORC1), B-GENE-N
a O
central O
mediator O
of O
cellular O
growth, O
cellular O
proliferation O
and O
lipid O
biosynthesis. O
To O
evaluate O
whether O
fisetin B-CHEMICAL
regulates O
mTORC1 B-GENE-N
signaling, O
we O
investigated O
the O
phosphorylation O
and O
kinase B-GENE-N
activity O
of O
the O
70-kDa B-GENE-Y
ribosomal I-GENE-Y
protein I-GENE-Y
S6 I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(S6K1) B-GENE-Y
and O
mTORC1 B-GENE-N
in O
3T3-L1 O
preadipocytes. O
Fisetin B-CHEMICAL
treatment O
of O
preadipocytes O
reduced O
the O
phosphorylation O
of O
S6K1 B-GENE-Y
and O

mTORC1 B-GENE-N
in O
a O
time- O
and O
concentration-dependent O
manner. O
To O
further O
our O
understanding O
of O
how O
fisetin B-CHEMICAL
negatively O
regulates O
mTORC1 B-GENE-N
signaling, O
we O
analyzed O
the O
phosphorylation O
of O
S6K1, B-GENE-Y
mTOR B-GENE-Y
and O
Akt B-GENE-N
in O
fisetin-treated B-CHEMICAL
TSC2-knockdown B-GENE-Y
cells. O
The O
results O
suggested O
that O
fisetin B-CHEMICAL
treatment O
inhibits O
mTORC1 B-GENE-N
activity O
in O
an O
Akt-dependent B-GENE-N
manner. O
Recent O
studies O
have O
shown O
that O
adipocyte O
differentiation O
is O
dependent O
on O
mTORC1 B-GENE-N
activity. O
Fisetin B-CHEMICAL
treatment O
inhibited O
adipocyte O
differentiation, O
consistent O
with O
the O
negative O

effect O
of O
fisetin B-CHEMICAL
on O
mTOR. B-GENE-Y
The O
inhibitory O
effect O
of O
fisetin B-CHEMICAL
on O
adipogenesis O
is O
dependent O
of O
mTOR B-GENE-Y
activity, O
suggesting O
that O
fisetin B-CHEMICAL
inhibits O
adipogenesis O
and O
the O
accumulation O
of O
intracellular O
triglycerides B-CHEMICAL
during O
adipocyte O
differentiation O
by O
targeting O
mTORC1 B-GENE-N
signaling. O
Fisetin B-CHEMICAL
supplementation O
in O
mice O
fed O
a O
high-fat O
diet O
(HFD) O
significantly O
attenuated O
HFD-induced O
increases O
in O
body O
weight O
and O
white O
adipose O
tissue. O
We O
also O
observed O
that O
fisetin B-CHEMICAL
efficiently O
suppressed O
the O
phosphorylation O
of O
Akt, B-GENE-N

S6K1 B-GENE-Y
and O
mTORC1 B-GENE-N
in O
adipose O
tissue. O
Collectively, O
these O
results O
suggest O
that O
inhibition O
of O
mTORC1 B-GENE-N
signaling O
by O
fisetin B-CHEMICAL
prevents O
adipocyte O
differentiation O
of O
3T3-L1 O
preadipocytes O
and O
obesity O
in O
HFD-fed O
mice. O
Therefore, O
fisetin B-CHEMICAL
may O
be O
a O
useful O
phytochemical O
agent O
for O
attenuating O
diet-induced O
obesity. O
Cyclin B-GENE-Y
E-cdk2 I-GENE-Y
activation O
is O
associated O
with O
cell O
cycle O
arrest O
and O
inhibition O
of O
DNA O
replication O
induced O
by O
the O
thymidylate B-GENE-Y
synthase I-GENE-Y
inhibitor O
Tomudex. B-CHEMICAL

Tomudex B-CHEMICAL
(ZD1694) B-CHEMICAL
is O
a O
specific O
antifolate-based O
thymidylate B-GENE-Y
synthase I-GENE-Y
inhibitor O
active O
in O
a O
variety O
of O
solid O
tumor O
malignancies. O
Studies O
were O
carried O
out O
in O
vitro O
to O
evaluate O
downstream O
molecular O
alterations O
induced O
as O
a O
consequence O
of O
the O
potent O
and O
sustained O
inhibition O
of O
thymidylate B-GENE-Y
synthase I-GENE-Y
by O
Tomudex. B-CHEMICAL
Twenty-four O
hours O
following O
the O
initial O
2-h O
treatment O
with O
Tomudex, B-CHEMICAL
human O
A253 O
head O
and O
neck O
squamous O
carcinoma O
cells, O
not O
expressing O
p53 B-GENE-Y
and O
p21(WAF1), B-GENE-Y
were O
accumulated O
with O
DNA O
content O
characteristic O
of O
early O

S O
phase O
of O
the O
cell O
cycle O
with O
a O
concomitant O
reduction O
of O
cells O
in O
G1 O
and O
G2/M O
phases. O
The O
changes O
in O
cyclin B-GENE-N
and O
cdk B-GENE-N
protein O
expression O
and O
their O
kinase B-GENE-N
activities O
were O
examined O
in O
control O
and O
drug-treated O
A253 O
cells. O
Tomudex B-CHEMICAL
treatment O
resulted O
in O
the O
decrease O
in O
p27(kip1) B-GENE-Y
expression, O
with O
an O
increase O
in O
cyclin B-GENE-Y
E I-GENE-Y
and O
cdk2 B-GENE-Y
protein O
expression O
and O
kinase B-GENE-N
activities O
24 O
h O
after O
a O
2-h O
exposure. O
Although O
cyclin B-GENE-Y
A I-GENE-Y
protein O
expression O
was O
markedly O
increased, O
cyclin B-GENE-Y
A I-GENE-Y
kinase B-GENE-N
activity O
was O
only O
slightly O
increased. O

Cyclin B-GENE-Y
D1, I-GENE-Y
cyclin B-GENE-Y
B, I-GENE-Y
cdk4, B-GENE-Y
and O
cdc2 B-GENE-Y
protein O
expression O
and O
kinase B-GENE-N
activities O
remain O
constant. O
Lack O
of O
activation O
of O
cyclin B-GENE-N
A- I-GENE-N
and I-GENE-N
B-cdc2 I-GENE-N
was O
associated O
with O
a O
reduced O
proportion O
of O
cells O
in O
G2/M O
phases. O
Increased O
cyclin B-GENE-Y
E-cdk2 I-GENE-Y
protein O
expression O
was O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis, O
with O
a O
decrease O
in O
E2F-1 B-GENE-Y
expression. O
These O
results O
propose O
that O
cyclin B-GENE-Y
E-cdk2 I-GENE-Y
kinase B-GENE-N
can O
negatively O
regulate O
DNA O
replication. O
The O
studies O
with O
dThyd O

rescue O
from O
cyclin B-GENE-Y
E-cdk2 I-GENE-Y
protein O
overexpression O
and O
growth O
inhibition O
by O
Tomudex B-CHEMICAL
indicate O
that O
increased O
cyclin B-GENE-Y
E-cdk2 I-GENE-Y
protein O
expression O
is O
associated O
with O
effective O
inhibition O
of O
thymidylate B-GENE-Y
synthase I-GENE-Y
and O
resultant O
dNTP O
pool O
imbalance. O
Provision O
of O
dThyd O
more O
than O
24 O
h O
after O
exposure O
to O
Tomudex B-CHEMICAL
allowed O
cells O
to O
replicate O
DNA O
for O
a O
single O
cycle O
back O
to O
G1, O
but O
did O
not O
prevent O
the O
profound O
growth-inhibitory O
effect O
manifested O
in O
the O
following O
5 O
days. O
Tomudex B-CHEMICAL
treatment O
resulted O
in O
a O
time-dependent O

induction O
of O
the O
megabase O
DNA O
fragments, O
followed O
by O
secondary O
50- O
to O
300-kb O
DNA O
fragmentation. O
The O
50- O
to O
300-kb O
DNA O
fragmentation O
may O
be O
derived O
from O
the O
inhibition O
of O
DNA O
synthesis O
associated O
with O
cyclin B-GENE-Y
E-cdk2 I-GENE-Y
activation. O
These O
results O
suggest O
that O
the O
megabase O
DNA O
fragmentation O
is O
induced O
as O
a O
consequence O
of O
inhibition O
of O
thymidylate B-GENE-Y
synthase I-GENE-Y
by O
Tomudex B-CHEMICAL
and O
kilobase O
DNA O
fragmentation O
may O
correlate O
with O
the O
reduction O
of O
p27(kip1) B-GENE-Y
expression O
and O
the O
increase O
in O
cyclin B-GENE-Y
E I-GENE-Y
and O
cdk2 B-GENE-Y

kinase B-GENE-N
activities. O
Activation O
of O
cyclin B-GENE-Y
E I-GENE-Y
and O
cdk2 B-GENE-Y
kinases B-GENE-N
allows O
cells O
to O
transit O
from O
G1 O
to O
S O
phase O
accompanied O
by O
the O
inhibition O
of O
DNA O
synthesis. O
The O
changes O
in O
cell O
cycle O
regulatory O
proteins O
associated O
with O
growth O
inhibition O
and O
DNA O
damage O
by O
Tomudex B-CHEMICAL
are O
not O
p53 B-GENE-Y
dependent. O
Modulation O
of O
cellular O
insulin B-GENE-N
signaling O
and O
PTP1B B-GENE-Y
effects O
by O
lipid O
metabolites O
in O
skeletal O
muscle O
cells. O
Normal O
glucose B-CHEMICAL
regulation O
is O
achieved O
by O
having O
adequate O
insulin B-GENE-Y
secretion O
and O
effective O
glucose B-CHEMICAL
uptake/disposal. O
Excess O
lipids O
in O
peripheral O
tissues O
- O
skeletal O
muscle, O
liver O
and O
adipose O
tissue O
- O
may O

attenuate O
insulin B-GENE-Y
signaling O
through O
the O
protein B-GENE-N
kinase I-GENE-N
B I-GENE-N
(AKt) B-GENE-N
pathway O
and O
up-regulate O
protein B-GENE-Y
tyrosine I-GENE-Y
phosphatase I-GENE-Y
1B I-GENE-Y
(PTP1B), B-GENE-Y
a O
negative O
regulator O
of O
insulin B-GENE-Y
signaling. O
We O
studied O
accumulation O
of O
lipid O
metabolites O
[triglycerides B-CHEMICAL
(TAGs), B-CHEMICAL
diglycerides B-CHEMICAL
(DAGs)] B-CHEMICAL
and O
ceramides B-CHEMICAL
in O
relation O
to O
insulin B-GENE-N
signaling O
and O
expression O
and O
phosphorylation O
of O
PTP1B B-GENE-Y
by O
preincubating O
rat O
skeletal O
muscle O
cells O
(L6 O
myotubes) O
with O
three O
saturated O
and O
three O
unsaturated O
free O

fatty B-CHEMICAL
acids I-CHEMICAL
(FFAs) O
(200 O
μM). O
Cells O
were O
also O
evaluated O
in O
the O
presence O
of O
wortmannin, B-CHEMICAL
an O
inhibitor O
of O
phosphatidylinositol B-GENE-N
3-kinases I-GENE-N
and O
thus O
AKt B-GENE-N
(0-100 O
nM). O
Unsaturated O
FFAs O
increased O
DAGs, B-CHEMICAL
TAGs B-CHEMICAL
and O
PTP1B B-GENE-Y
expression O
significantly, O
but O
cells O
remained O
insulin B-GENE-N
sensitive O
as O
assessed O
by O
robust O
AKt B-GENE-N
and O
PTP1B B-GENE-Y
phosphorylation O
at O
serine B-CHEMICAL
(Ser) B-CHEMICAL
50, O
Ser B-CHEMICAL
398 O
and O
tyrosine B-CHEMICAL
152. O
Saturated O
palmitic B-CHEMICAL
and I-CHEMICAL
stearic I-CHEMICAL
acids I-CHEMICAL

increased O
ceramides, B-CHEMICAL
up-regulated O
PTP1B, B-GENE-Y
and O
had O
AKt B-GENE-N
and O
PTP1B B-GENE-Y
phosphorylation O
at O
Ser B-CHEMICAL
50 O
impaired. O
We O
show O
a O
significant O
correlation O
between O
phosphorylation O
levels O
of O
AKt B-GENE-N
and O
of O
PTP1B B-GENE-Y
at O
Ser O
50 O
(R(2)=0.84, O
P<.05). O
The O
same O
was O
observed O
with O
increasing O
wortmannin B-CHEMICAL
dose O
(R(2)=0.73, O
P<.05). O
Only O
FFAs O
that O
increased O
ceramides B-CHEMICAL
caused O
impairment O
of O
AKt B-GENE-N
and O
PTP1B B-GENE-Y
phosphorylation O

at O
Ser B-CHEMICAL
50. O
PTP1B B-GENE-Y
overexpression O
in O
the O
presence O
of O
excess O
lipids O
may O
not O
directly O
cause O
insulin B-GENE-N
resistance O
unless O
it O
is O
accompanied O
by O
decreased O
PTP1B B-GENE-Y
phosphorylation. O
A O
clear O
relationship O
between O
PTP1B B-GENE-Y
phosphorylation O
levels O
at O
Ser B-CHEMICAL
50 O
and O
its O
negative O
effect O
on O
insulin B-GENE-N
signaling O
is O
shown. O
Functional O
analyses O
of O
glycyl-tRNA B-GENE-Y
synthetase I-GENE-Y
mutations O
suggest O
a O
key O
role O
for O
tRNA-charging B-GENE-N
enzymes I-GENE-N
in O
peripheral O
axons. O
Charcot-Marie-Tooth O
disease O
type O
2D O
(CMT2D) O
and O
distal O
spinal O
muscular O
atrophy O
type O

V O
(dSMA-V) O
are O
axonal O
neuropathies O
characterized O
by O
a O
phenotype O
that O
is O
more O
severe O
in O
the O
upper O
extremities. O
We O
previously O
implicated O
mutations O
in O
the O
gene O
encoding O
glycyl-tRNA B-GENE-Y
synthetase I-GENE-Y
(GARS) B-GENE-Y
as O
the O
cause O
of O
CMT2D O
and O
dSMA-V. O
GARS B-GENE-Y
is O
a O
member O
of O
the O
family O
of O
aminoacyl-tRNA B-GENE-N
synthetases I-GENE-N
responsible O
for O
charging O
tRNA O
with O
cognate O
amino B-CHEMICAL
acids; I-CHEMICAL
GARS B-GENE-Y
ligates O
glycine B-CHEMICAL
to O
tRNA(Gly). O
Here, O
we O
present O
functional O
analyses O
of O

disease-associated O
GARS B-GENE-Y
mutations O
and O
show O
that O
there O
are O
not O
any O
significant O
mutation-associated O
changes O
in O
GARS B-GENE-Y
expression O
levels; O
that O
the O
majority O
of O
identified O
GARS B-GENE-Y
mutations O
modeled O
in O
yeast O
severely O
impair O
viability; O
and O
that, O
in O
most O
cases, O
mutant O
GARS B-GENE-Y
protein O
mislocalizes O
in O
neuronal O
cells. O
Indeed, O
four O
of O
the O
five O
mutations O
studied O
show O
loss-of-function O
features O
in O
at O
least O
one O
assay, O
suggesting O
that O
tRNA-charging O
deficits O
play O
a O
role O
in O
disease O
pathogenesis. O
Finally, O
we O
detected O
endogenous O
GARS-associated B-GENE-Y
granules O
in O
the O
neurite O
projections O
of O
cultured O
neurons O

and O
in O
the O
peripheral O
nerve O
axons O
of O
normal O
human O
tissue. O
These O
data O
are O
particularly O
important O
in O
light O
of O
the O
recent O
identification O
of O
CMT-associated O
mutations O
in O
another O
tRNA B-GENE-N
synthetase I-GENE-N
gene O
[YARS B-GENE-Y
(tyrosyl-tRNA B-GENE-Y
synthetase I-GENE-Y
gene)]. O
Together, O
these O
findings O
suggest O
that O
tRNA-charging B-GENE-N
enzymes I-GENE-N
play O
a O
key O
role O
in O
maintaining O
peripheral O
axons. O
IFN-gamma-induced B-GENE-Y
IDO B-GENE-Y
and O
WRS B-GENE-Y
expression O
in O
microglia O
is O
differentially O
regulated O
by O
IL-4. B-GENE-Y
Indoleamine B-GENE-Y
2,3-dioxygenase I-GENE-Y
(IDO), B-GENE-Y
a O

tryptophan B-CHEMICAL
catabolizing O
enzyme, O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
various O
neurological O
disorders. O
IDO B-GENE-Y
expression O
is O
induced O
by O
IFN-gamma B-GENE-Y
and O
leads O
to O
neurotoxicity O
by O
generating O
quinolinic B-CHEMICAL
acid. I-CHEMICAL
Additionally, O
it O
inhibits O
the O
immune O
response O
through O
both O
tryptophan B-CHEMICAL
depletion O
and O
generating O
other O
tryptophan B-CHEMICAL
catabolites. O
IL-4 B-GENE-Y
and O
IL-13 B-GENE-Y
have O
been O
shown O
to O
control O
IDO B-GENE-Y
expression O
by O
antagonizing O
the O
effects O
of O
IFN-gamma B-GENE-Y
in O
different O
cell O
types. O
Here, O
we O
investigated O
the O
effects O
of O
these O
cytokines B-GENE-N
on O

IDO B-GENE-Y
expression O
in O
microglia. O
Interestingly, O
we O
observed O
that O
both O
IL-4 B-GENE-Y
and O
IL-13 B-GENE-Y
greatly O
enhanced O
IFN-gamma-induced B-GENE-Y
IDO B-GENE-Y
expression. O
However, O
tryptophanyl-tRNA B-GENE-Y
synthetase I-GENE-Y
(WRS), B-GENE-Y
which O
is O
coinduced O
with O
IDO B-GENE-Y
by O
IFN-gamma, B-GENE-Y
is O
downregulated O
by O
IL-4 B-GENE-Y
and O
IL-13. B-GENE-Y
The O
effect O
of O
IL-4 B-GENE-Y
and O
IL-13 B-GENE-Y
was O
independent O
of O
STAT-6. B-GENE-Y
Modulation O
of O
IDO B-GENE-Y
but O
not O
WRS B-GENE-Y
was O
eliminated O
by O
inhibition O
of O
protein B-GENE-N
phosphatase I-GENE-N
2A I-GENE-N
(PP2A) B-GENE-N

activity. O
The O
phosphatidylinositol B-GENE-N
3-kinase I-GENE-N
(PI3K) B-GENE-N
pathway O
further O
differentiated O
the O
regulation O
of O
these O
two O
enzymes, O
as O
inhibiting O
the O
PI3K B-GENE-N
pathway O
eliminated O
IFN-gamma B-GENE-Y
induction O
of O
IDO, B-GENE-Y
whereas O
such O
inhibition O
greatly O
enhanced O
WRS B-GENE-Y
expression. O
These O
findings O
show O
discordance O
between O
modulations O
of O
expression O
of O
two O
distinct O
enzymes O
utilizing O
tryptophan B-CHEMICAL
as O
a O
common O
substrate, O
and O
raise O
the O
possibility O
of O
their O
involvement O
in O
regulating O
immune O
responses O
in O
various O
neurological O
disorders. O
SIRT1 B-GENE-Y
inhibits O
NADPH B-GENE-N
oxidase I-GENE-N
activation O
and O
protects O

endothelial O
function O
in O
the O
rat O
aorta: O
Implications O
for O
vascular O
aging. O
Vascular O
aging O
is O
characterized O
by O
up-regulation O
of O
NADPH B-GENE-N
oxidase, I-GENE-N
oxidative O
stress O
and O
endothelial O
dysfunction. O
Previous O
studies O
demonstrate O
that O
the O
activity O
of O
the O
evolutionarily O
conserved O
NAD(+)-dependent B-GENE-Y
deacetylase I-GENE-Y
SIRT1 I-GENE-Y
declines O
with O
age O
and O
that O
pharmacological O
activators O
of O
SIRT1 B-GENE-Y
confer O
significant O
anti-aging O
cardiovascular O
effects. O
To O
determine O
whether O
dysregulation O
of O
SIRT1 B-GENE-Y
promotes O
NADPH B-GENE-N

oxidase-dependent I-GENE-N
production O
of O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
and O
impairs O
endothelial O
function O
we O
assessed O
the O
effects O
of O
three O
structurally O
different O
inhibitors O
of O
SIRT1 B-GENE-Y
(nicotinamide, B-CHEMICAL
sirtinol, B-CHEMICAL
EX527) B-CHEMICAL
in O
aorta O
segments O
isolated O
from O
young O
Wistar O
rats. O
Inhibition O
of O
SIRT1 B-GENE-Y
induced O
endothelial O
dysfunction, O
as O
shown O
by O
the O
significantly O
reduced O
relaxation O
to O
the O
endothelium-dependent O
vasodilators O
acetylcholine B-CHEMICAL
and O
the O
calcium B-CHEMICAL
ionophore O
A23187. B-CHEMICAL
Endothelial O

dysfunction O
induced O
by O
SIRT1 B-GENE-Y
inhibition O
was O
prevented O
by O
treatment O
of O
the O
vessels O
with O
the O
NADPH B-GENE-N
oxidase I-GENE-N
inhibitor O
apocynin B-CHEMICAL
or O
superoxide B-GENE-N
dismutase. I-GENE-N
Inhibition O
of O
SIRT1 B-GENE-Y
significantly O
increased O
vascular O
superoxide B-CHEMICAL
production, O
enhanced O
NADPH B-GENE-N
oxidase I-GENE-N
activity, O
and O
mRNA O
expression O
of O
its O
subunits O
p22(phox) B-GENE-Y
and O
NOX4, B-GENE-Y
which O
were O
prevented O
by O
resveratrol. B-CHEMICAL
Peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor-α I-GENE-Y
(PPARα) B-GENE-Y
activation O
mimicked O
the O
effects O
of O
resveratrol B-CHEMICAL
while O

PPARα B-GENE-Y
inhibition O
prevented O
the O
effects O
of O
this O
SIRT1 B-GENE-Y
activator. O
SIRT1 B-GENE-Y
co-precipitated O
with O
PPARα B-GENE-Y
and O
nicotinamide B-CHEMICAL
increased O
the O
acetylation O
of O
the O
PPARα B-GENE-Y
coactivator O
PGC-1α, B-GENE-Y
which O
was O
suppressed O
by O
resveratrol. B-CHEMICAL
In O
conclusion, O
impaired O
activity O
of O
SIRT1 B-GENE-Y
induces O
endothelial O
dysfunction O
and O
up-regulates O
NADPH B-GENE-N
oxidase-derived I-GENE-N
ROS O
production O
in O
the O
vascular O
wall, O
mimicking O
the O
vascular O
aging O
phenotype. O
Moreover, O
a O
new O
mechanism O
for O
controlling O

endothelial O
function O
after O
SIRT1 B-GENE-Y
activation O
involves O
a O
decreased O
PGC-1α B-GENE-Y
acetylation O
and O
the O
subsequent O
PPARα B-GENE-Y
activation, O
resulting O
in O
both O
decreased O
NADPH B-GENE-N
oxidase-driven I-GENE-N
ROS O
production O
and O
NO B-CHEMICAL
inactivation. O
EROD B-GENE-N
activity O
induction O
in O
peripheral O
blood O
lymphocytes, O
liver O
and O
brain O
tissues O
of O
rats O
orally O
exposed O
to O
polycyclic B-CHEMICAL
aromatic I-CHEMICAL
hydrocarbons. I-CHEMICAL
Little O
is O
known O
in O
terms O
of O
multi-matrix O
cytochrome B-GENE-N
P450 I-GENE-N
activity O
induction O
under O
repeated O
oral O
exposure O
to O
planar O
halogenated B-CHEMICAL
and I-CHEMICAL
polycyclic I-CHEMICAL
aromatic I-CHEMICAL

hydrocarbons I-CHEMICAL
(PHH, O
PAH). B-CHEMICAL
In O
the O
present O
study, O
60 O
rats O
were O
daily O
exposed, O
during O
28days, O
to O
oral O
ingestion O
of O
a O
mixture O
consisting O
of O
phenanthrene, B-CHEMICAL
pyrene B-CHEMICAL
and O
benzo(a)pyrene B-CHEMICAL
at O
0, O
6 O
or O
600μg/day. O
EROD B-GENE-N
activity, O
reflecting O
almost O
exclusively O
CYP1A1 B-GENE-Y
and O
CYP1B1 B-GENE-Y
activities, O
was O
measured O
in O
brain O
and O
liver O
microsomes O
as O
well O
as O
in O
peripheral O
blood O
lymphocytes O
(PBLs). O
All O
induction O
kinetics O
could O
be O
appropriately O
fitted O
using O
logistic-like O

models. O
After O
28days O
of O
exposure O
to O
a O
6μg/day O
dose, O
EROD B-GENE-N
activity O
was O
found O
to O
be O
91, O
152 O
and O
94-fold O
increased O
in O
lymphocytes, O
liver O
and O
brain, O
respectively, O
compared O
to O
day O
0. O
Plateau O
activities O
could O
be O
appropriately O
fitted O
versus O
ingested O
doses O
using O
Hill O
or O
Michaelis-Menten O
models. O
Correlations O
between O
matrices O
made O
it O
possible O
to O
conclude O
that O
EROD B-GENE-N
activity O
in O
PBL O
should O
be O
considered O
as O
a O
sensitive, O
convenient O
and O
non-destructive O
approach O
for O
(i) O
evaluating O
EROD B-GENE-N
activity O
in O
liver, O
which O
was O
found O
to O
represent O
98% O
of O
the O
observed O
EROD B-GENE-N
activities O
in O
the O
three O
tested O

matrices O
and O
(ii) O
evaluating O
oral O
exposure O
of O
homogeneous O
groups O
of O
farm O
animals O
(race, O
diet) O
to O
CYP B-GENE-N
inducing O
PAH O
and O
PHH. B-CHEMICAL
Genome-wide O
screen O
for O
modulation O
of O
hepatic O
apolipoprotein B-GENE-Y
A-I I-GENE-Y
(ApoA-I) B-GENE-Y
secretion. O
Control O
of O
plasma O
cholesterol B-CHEMICAL
levels O
is O
a O
major O
therapeutic O
strategy O
for O
management O
of O
coronary O
artery O
disease O
(CAD). O
Although O
reducing O
LDL B-GENE-N
cholesterol B-CHEMICAL
(LDL-c) B-GENE-N
levels O
decreases O
morbidity O
and O
mortality, O
this O
therapeutic O
intervention O
only O
translates O
into O
a O
25-40% O
reduction O

in O
cardiovascular O
events. O
Epidemiological O
studies O
have O
shown O
that O
a O
high O
LDL-c B-GENE-N
level O
is O
not O
the O
only O
risk O
factor O
for O
CAD; O
low O
HDL B-GENE-N
cholesterol B-CHEMICAL
(HDL-c) B-GENE-N
is O
an O
independent O
risk O
factor O
for O
CAD. O
Apolipoprotein B-GENE-Y
A-I I-GENE-Y
(ApoA-I) B-GENE-Y
is O
the O
major O
protein O
component O
of O
HDL-c B-GENE-N
that O
mediates O
reverse O
cholesterol B-CHEMICAL
transport O
from O
tissues O
to O
the O
liver O
for O
excretion. O
Therefore, O
increasing O
ApoA-I B-GENE-Y
levels O
is O
an O
attractive O
strategy O
for O
HDL-c B-GENE-N
elevation. O
Using O
genome-wide O
siRNA O
screening, O

targets O
that O
regulate O
hepatocyte O
ApoA-I B-GENE-Y
secretion O
were O
identified O
through O
transfection O
of O
21,789 O
siRNAs O
into O
hepatocytes O
whereby O
cell O
supernatants O
were O
assayed O
for O
ApoA-I. B-GENE-Y
Approximately O
800 O
genes O
were O
identified O
and O
triaged O
using O
a O
convergence O
of O
information, O
including O
genetic O
associations O
with O
HDL-c B-GENE-N
levels, O
tissue-specific O
gene O
expression, O
druggability O
assessments, O
and O
pathway O
analysis. O
Fifty-nine O
genes O
were O
selected O
for O
reconfirmation; O
40 O
genes O
were O
confirmed. O
Here O
we O
describe O
the O
siRNA O
screening O
strategy, O
assay O
implementation O
and O
validation, O
data O

triaging, O
and O
example O
genes O
of O
interest. O
The O
genes O
of O
interest O
include O
known O
and O
novel O
genes O
encoding O
secreted O
enzymes, O
proteases, O
G-protein-coupled B-GENE-N
receptors, I-GENE-N
metabolic O
enzymes, O
ion B-GENE-N
transporters, I-GENE-N
and O
proteins O
of O
unknown O
function. O
Repression O
of O
farnesyltransferase B-GENE-Y
(FNTA) B-GENE-Y
by O
siRNA O
and O
the O
enzyme O
inhibitor O
manumycin B-CHEMICAL
A I-CHEMICAL
caused O
elevation O
of O
ApoA-I B-GENE-Y
secretion O
from O
hepatocytes O
and O
from O
transgenic O
mice O
expressing O
hApoA-I B-GENE-Y
and O
cholesterol B-CHEMICAL
ester I-CHEMICAL
transfer O
protein O
transgenes. O
In O
total, O
this O
work O
underscores O
the O
power O

of O
functional O
genetic O
assessment O
to O
identify O
new O
therapeutic O
targets. O
Update O
on O
the O
use O
of O
aromatase B-GENE-Y
inhibitors O
in O
breast O
cancer. O
Estrogens B-CHEMICAL
are O
biosynthesised O
from O
androgens B-CHEMICAL
by O
the O
CYP450 B-GENE-N
enzyme O
complex O
called O
aromatase. B-GENE-Y
Aromatase B-GENE-Y
is O
expressed O
in O
the O
ovary, O
placenta, O
brain, O
bone, O
adipose O
tissue O
and O
breast O
tissue. O
In O
breast O
cancer, O
intratumoural O
aromatase B-GENE-Y
is O
the O
source O
for O
local O
estrogen B-CHEMICAL
production O
in O
the O
tissue. O
Inhibition O
of O
aromatase B-GENE-Y
is O
an O
important O
approach O
for O
reducing O
growth O
stimulatory O
effects O
of O
estrogens B-CHEMICAL
in O

estrogen-dependent B-CHEMICAL
breast O
cancer. O
The O
potent O
and O
selective O
third-generation O
aromatase B-GENE-Y
inhibitors O
anastrozole, B-CHEMICAL
letrozole B-CHEMICAL
and O
exemestane O
were O
introduced O
to O
the O
market O
as O
endocrine O
therapy O
in O
postmenopausal O
patients O
failing O
anti-estrogen B-CHEMICAL
therapy O
alone, O
or O
multiple O
hormonal O
therapies. O
Anastrozole B-CHEMICAL
and O
letrozole B-CHEMICAL
are O
both O
non-steroidal B-CHEMICAL
aromatase B-GENE-Y
inhibitors O
that O
compete O
with O
the O
substrate O
for O
binding O
to O
the O
enzyme O
active O
site. O
Exemestane O
is O
a O
mechanism-based O
steroidal B-CHEMICAL
inhibitor O
that O
mimics O
the O
substrate, O
is O
converted O
by O
the O
enzyme O

to O
a O
reactive O
intermediate, O
and O
results O
in O
inactivation O
of O
aromatase. B-GENE-Y
These O
third-generation O
aromatase B-GENE-Y
inhibitors O
are O
currently O
approved O
as O
first-line O
therapy O
for O
the O
treatment O
of O
postmenopausal O
women O
with O
metastatic O
estrogen-dependent B-CHEMICAL
breast O
cancer. O
The O
use O
of O
an O
aromatase B-GENE-Y
inhibitor O
as O
initial O
therapy, O
or O
after O
treatment O
with O
tamoxifen, B-CHEMICAL
is O
now O
recommended O
as O
adjuvant O
hormonal O
therapy O
for O
postmenopausal O
women O
with O
hormone-dependent O
breast O
cancer. O
Several O
clinical O
studies O
of O
aromatase B-GENE-Y
inhibitors O
focus O
on O
the O
use O
of O
these O
agents O
in O
the O
adjuvant O
setting, O
for O
the O
treatment O
of O

early O
breast O
cancer. O
Recently O
published O
results O
show O
improved O
responses O
with O
these O
agents O
compared O
with O
tamoxifen. B-CHEMICAL
High B-GENE-N
density I-GENE-N
lipoprotein I-GENE-N
as O
a O
source O
of O
cholesterol B-CHEMICAL
for O
adrenal O
steroidogenesis: O
a O
study O
in O
individuals O
with O
low O
plasma O
HDL-C. B-GENE-N
Few O
studies O
have O
addressed O
the O
delivery O
of O
lipoprotein-derived B-GENE-N
cholesterol B-CHEMICAL
to O
the O
adrenals O
for O
steroid B-CHEMICAL
production O
in O
humans. O
While O
there O
is O
evidence O
against O
a O
role O
for O
low-density B-GENE-N
lipoprotein I-GENE-N
(LDL), B-GENE-N
it O
is O
unresolved O
whether O
high B-GENE-N
density I-GENE-N
lipoprotein I-GENE-N
(HDL) B-GENE-N
contributes O
to O

adrenal O
steroidogenesis. O
To O
study O
this, O
steroid B-CHEMICAL
hormone I-CHEMICAL
profiles O
in O
urine O
were O
assessed O
in O
male O
subjects O
suffering O
from O
functional O
mutations O
in O
ATP B-GENE-Y
binding I-GENE-Y
cassette I-GENE-Y
transporter I-GENE-Y
A1 I-GENE-Y
(ABCA1) B-GENE-Y
(n O
= O
24), O
lecithin:cholesterol B-GENE-Y
acyltransferase I-GENE-Y
(LCAT) B-GENE-Y
(n O
= O
40), O
as O
well O
as O
in O
11 O
subjects O
with O
low O
HDL B-GENE-N
cholesterol B-CHEMICAL
(HDL-C) B-GENE-N
without O
ABCA1/LCAT B-GENE-Y
mutations. O
HDL-C B-GENE-N
levels O
were O
39% O
lower O
in O
the O
ABCA1, B-GENE-Y
LCAT, B-GENE-Y
and O
low O

HDL-C B-GENE-N
groups O
compared O
with O
controls O
(all O
P O
< O
0.001). O
In O
all O
groups O
with O
low O
HDL-C B-GENE-N
levels, O
urinary O
excretion O
of O
17-ketogenic B-CHEMICAL
steroids I-CHEMICAL
was O
reduced O
by O
33%, O
27%, O
and O
32% O
compared O
with O
controls O
(all O
P O
< O
0.04). O
In O
seven O
carriers O
of O
either O
type O
of O
mutation, O
adrenocorticotropic B-GENE-Y
hormone I-GENE-Y
(ACTH) B-GENE-Y
stimulation O
did O
not O
reveal O
differences O
from O
normolipidemic O
controls. O
In O
conclusion, O
this O
study O
shows O
that O
basal O
but O
not O
stimulated O
corticosteroid O
metabolism O
is O
attenuated O
in O
subjects O

with O
low O
HDL-C, B-GENE-N
irrespective O
of O
its O
molecular O
origin. O
These O
findings O
lend O
support O
to O
a O
role O
for O
HDL B-GENE-N
as O
a O
cholesterol B-CHEMICAL
donor O
for O
basal O
adrenal O
steroidogenesis O
in O
humans. O
Neural O
tube O
defects O
and O
folate B-CHEMICAL
pathway O
genes: O
family-based O
association O
tests O
of O
gene-gene O
and O
gene-environment O
interactions. O
BACKGROUND: O
Folate B-CHEMICAL
metabolism O
pathway O
genes O
have O
been O
examined O
for O
association O
with O
neural O
tube O
defects O
(NTDs) O
because O
folic B-CHEMICAL
acid I-CHEMICAL
supplementation O
reduces O
the O
risk O
of O
this O
debilitating O
birth O
defect. O
Most O
studies O
addressed O
these O
genes O
individually, O
often O
with O
different O
populations O
providing O

conflicting O
results. O
OBJECTIVES: O
Our O
study O
evaluates O
several O
folate B-CHEMICAL
pathway O
genes O
for O
association O
with O
human O
NTDs, O
incorporating O
an O
environmental O
cofactor: O
maternal O
folate B-CHEMICAL
supplementation. O
METHODS: O
In O
304 O
Caucasian O
American O
NTD O
families O
with O
myelomeningocele O
or O
anencephaly, O
we O
examined O
28 O
polymorphisms O
in O
11 O
genes: O
folate B-GENE-Y
receptor I-GENE-Y
1, I-GENE-Y
folate B-GENE-Y
receptor I-GENE-Y
2, I-GENE-Y
solute B-GENE-Y
carrier I-GENE-Y
family I-GENE-Y
19 I-GENE-Y
member I-GENE-Y
1, I-GENE-Y
transcobalamin B-GENE-Y
II, I-GENE-Y
methylenetetrahydrofolate B-GENE-Y
dehydrogenase I-GENE-Y
1, I-GENE-Y
serine B-GENE-Y

hydroxymethyl-transferase I-GENE-Y
1, I-GENE-Y
5,10-methylenetetrahydrofolate B-GENE-Y
reductase I-GENE-Y
(MTHFR), B-GENE-Y
5-methyltetrahydrofolate-homo-cysteine B-GENE-Y
methyltransferase, I-GENE-Y
5-methyltetrahydrofolate-homocysteine B-GENE-Y
methyltransferase I-GENE-Y
reductase, I-GENE-Y
betaine-homocysteine B-GENE-Y
methyltransferase I-GENE-Y
(BHMT), B-GENE-Y
and O
cystathionine-beta-synthase. B-GENE-Y
RESULTS: O
Only O
single O

nucleotide B-CHEMICAL
polymorphisms O
(SNPs) O
in O
BHMT B-GENE-Y
were O
significantly O
associated O
in O
the O
overall O
data O
set; O
this O
significance O
was O
strongest O
when O
mothers O
took O
folate-containing B-CHEMICAL
nutritional O
supplements O
before O
conception. O
The O
BHMT B-GENE-Y
SNP O
rs3733890 O
was O
more O
significant O
when O
the O
data O
were O
stratified O
by O
preferential O
transmission O
of O
the O
MTHFR B-GENE-Y
rs1801133 O
thermolabile O
T O
allele O
from O
parent O
to O
offspring. O
Other O
SNPs O
in O
folate B-CHEMICAL
pathway O
genes O
were O
marginally O
significant O
in O
some O
analyses O
when O
stratified O
by O
maternal O
supplementation, O

MTHFR, B-GENE-Y
or O
BHMT B-GENE-Y
allele O
transmission. O
CONCLUSIONS: O
BHMT B-GENE-Y
rs3733890 O
is O
significantly O
associated O
in O
our O
data O
set, O
whereas O
MTHFR B-GENE-Y
rs1801133 O
is O
not O
a O
major O
risk O
factor. O
Further O
investigation O
of O
folate B-CHEMICAL
and O
methionine B-CHEMICAL
cycle O
genes O
will O
require O
extensive O
SNP O
genotyping O
and/or O
resequencing O
to O
identify O
novel O
variants, O
inclusion O
of O
environmental O
factors, O
and O
investigation O
of O
gene-gene O
interactions O
in O
large O
data O
sets. O
Identification O
and O
synthesis O
of O
N-(thiophen-2-yl) B-CHEMICAL
benzamide I-CHEMICAL

derivatives O
as O
BRAF(V600E) B-GENE-Y
inhibitors. O
The O
V600E B-GENE-N
BRAF B-GENE-Y
kinase B-GENE-N
mutation, O
which O
activates O
the O
downstream O
MAPK B-GENE-N
signaling O
pathway, O
commonly O
occurs O
in O
about O
8% O
of O
all O
human O
malignancies O
and O
about O
50% O
of O
all O
melanomas. O
In O
this O
study, O
we O
employed O
virtual O
screening O
and O
chemical O
synthesis O
to O
identify O
a O
series O
of O
N-(thiophen-2-yl) B-CHEMICAL
benzamide I-CHEMICAL
derivatives O
as O
potent O
BRAF(V600E) B-GENE-Y
inhibitors. O
Structure-activity O
relationship O
studies O
of O
these O
derivatives O
revealed O
that O
compounds O
b40 O
and O
b47 O
are O
the O
two O
most O
potent O

BRAF(V600E) B-GENE-Y
inhibitors O
in O
this O
series. O
Robust O
array-based O
coregulator O
binding O
assay O
predicting O
ERα-agonist B-GENE-Y
potency O
and O
generating O
binding O
profiles O
reflecting O
ligand O
structure. O
Testing O
chemicals O
for O
their O
endocrine-disrupting O
potential, O
including O
interference O
with O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER) B-GENE-Y
signaling, O
is O
an O
important O
aspect O
of O
chemical O
safety O
testing. O
Because O
of O
the O
practical O
drawbacks O
of O
animal O
testing, O
the O
development O
of O
in O
vitro O
alternatives O
for O
the O
uterotrophic O
assay O
and O
other O
in O
vivo O
(anti)estrogenicity O
tests O
has O
high O
priority. O
It O
was O
previously O
demonstrated O
that O
an O
in O

vitro O
assay O
that O
profiles O
ligand-induced O
binding O
of O
ERα B-GENE-Y
to O
a O
microarray O
of O
coregulator-derived O
peptides O
might O
be O
a O
valuable O
candidate O
for O
a O
panel O
of O
in O
vitro O
assays O
aiming O
at O
an O
ultimate O
replacement O
of O
the O
uterotrophic O
assay. O
In O
the O
present O
study, O
the O
reproducibility O
and O
robustness O
of O
this O
coregulator O
binding O
assay O
was O
determined O
by O
measuring O
the O
binding O
profiles O
of O
14 O
model O
compounds O
that O
are O
recommended O
by O
the O
Office O
of O
Prevention, O
Pesticides O
and O
Toxic O
Substances O
for O
testing O
laboratory O
proficiency O
in O
estrogen B-GENE-Y
receptor I-GENE-Y
transactivation O
assays. O

With O
a O
median O
coefficient O
of O
variation O
of O
5.0% O
and O
excellent O
correlation O
(R(2) O
= O
0.993) O
between O
duplicate O
measurements, O
the O
reproducibility O
of O
the O
ERα-coregulator B-GENE-Y
binding O
assay O
was O
better O
than O
the O
reproducibility O
of O
other O
commonly O
used O
in O
vitro O
ER B-GENE-Y
functional O
assays. O
In O
addition, O
the O
coregulator O
binding O
assay O
is O
correctly O
predicting O
the O
estrogenicity O
for O
13 O
out O
of O
14 O
compounds O
tested. O
When O
the O
potency O
of O
the O
ER-agonists B-GENE-Y
to O
induce O
ERα-coregulator B-GENE-Y
binding O
was O
compared O
to O
their O
ER B-GENE-Y
binding O
affinity, O
their O
ranking O

was O
similar, O
and O
the O
correlation O
between O
the O
EC50 O
values O
was O
excellent O
(R(2) O
= O
0.96), O
as O
was O
the O
correlation O
with O
their O
potency O
in O
a O
transactivation O
assay O
(R(2) O
= O
0.94). O
Moreover, O
when O
the O
ERα-coregulator B-GENE-Y
binding O
profiles O
were O
hierarchically O
clustered O
using O
Euclidian O
cluster O
distance, O
the O
structurally O
related O
compounds O
were O
found O
to O
cluster O
together, O
whereas O
the O
steroid B-CHEMICAL
test O
compounds O
having O
an O
aromatic O
A-ring O
were O
separated O
from O
those O
with O
a O
cyclohexene B-CHEMICAL
A-ring. O
We O
concluded O
that O
this O
assay O
is O

capable O
of O
distinguishing O
ERα B-GENE-Y
agonists O
and O
antagonists O
and O
that O
it O
even O
reflects O
the O
structural O
similarity O
of O
ERα B-GENE-Y
agonists, O
indicating O
a O
potential O
to O
achieve O
identification O
and O
classification O
of O
ERα B-GENE-Y
endocrine O
disruptors O
with O
high O
fidelity. O
Rapid O
and O
specific O
purification O
of O
Argonaute-small B-GENE-N
RNA O
complexes O
from O
crude O
cell O
lysates. O
Small O
interfering O
RNAs O
(siRNAs) O
direct O
Argonaute B-GENE-N
proteins, O
the O
core O
components O
of O
the O
RNA-induced B-GENE-N
silencing I-GENE-N
complex I-GENE-N
(RISC), B-GENE-N
to O
cleave O
complementary O
target O
RNAs. O
Here, O
we O
describe O
a O
method O
to O
purify O
active O
RISC B-GENE-N
containing O

a O
single, O
unique O
small O
RNA O
guide O
sequence. O
We O
begin O
by O
capturing O
RISC B-GENE-N
using O
a O
complementary O
2'-O-methyl B-CHEMICAL
oligonucleotide O
tethered O
to O
beads. O
Unlike O
other O
methods O
that O
capture O
RISC B-GENE-N
but O
do O
not O
allow O
its O
recovery, O
our O
strategy O
purifies O
active, O
soluble O
RISC B-GENE-N
in O
good O
yield. O
The O
method O
takes O
advantage O
of O
the O
finding O
that O
RISC O
partially O
paired O
to O
a O
target O
through O
its O
siRNA O
guide O
dissociates O
more O
than O
300 O
times O
faster O
than O
a O
fully O
paired O
siRNA O
in O
RISC. B-GENE-N
We O
use O
this O
strategy O
to O
purify O
fly B-GENE-Y
Ago1- I-GENE-Y
and O

Ago2-RISC, B-GENE-Y
as O
well O
as O
mouse B-GENE-Y
AGO2-RISC. I-GENE-Y
The O
method O
can O
discriminate O
among O
RISCs B-GENE-N
programmed O
with O
different O
guide O
strands, O
making O
it O
possible O
to O
deplete O
and O
recover O
specific O
RISC B-GENE-N
populations. O
Endogenous O
microRNA:Argonaute B-GENE-N
complexes O
can O
also O
be O
purified O
from O
cell O
lysates. O
Our O
method O
scales O
readily O
and O
takes O
less O
than O
a O
day O
to O
complete. O
Sodium B-CHEMICAL
fluoride I-CHEMICAL
induces O
apoptosis O
in O
odontoblasts O
via O
a O
JNK-dependent B-GENE-N
mechanism. O
Sodium B-CHEMICAL
fluoride I-CHEMICAL
(NaF) B-CHEMICAL
is O
widely O
used O
for O
the O
treatment O

of O
dental O
caries O
and O
dentin O
hypersensitivity. O
However, O
its O
pro-apoptotic O
effect O
on O
odontoblasts O
may O
lead O
to O
harmful O
side-effects. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
pro-apoptotic O
effects O
of O
NaF B-CHEMICAL
in O
odontoblasts O
and O
elucidate O
the O
possible O
underlying O
molecular O
mechanisms. O
NaF B-CHEMICAL
generated O
cytotoxic O
effects O
in O
odontoblast-lineage O
cell O
(OLC) O
in O
a O
dose- O
and O
time-dependent O
manner. O
Exposure O
of O
cells O
to O
4mM O
NaF B-CHEMICAL
for O
24h O
induced O
caspase-3 B-GENE-Y
activation, O

ultrastructural O
alterations, O
and O
resulted O
in O
the O
translocation O
of O
Bax B-GENE-Y
to O
the O
mitochondria O
and O
the O
release O
of O
cytochrome B-GENE-Y
c I-GENE-Y
from O
the O
mitochondrial O
inter-membrane O
space O
into O
the O
cytosol, O
indicating O
that O
fluoride-mediated B-CHEMICAL
apoptosis O
is O
mitochondria-dependent. O
Fluoride B-CHEMICAL
treatment O
also O
increased O
phosphorylation O
of O
JNK B-GENE-N
and O
ERK, B-GENE-N
but O
not O
p38, B-GENE-N
and O
apoptosis O
induced O
by O
fluoride B-CHEMICAL
was O
notably O
or O
partly O
suppressed O
by O
treatment O
with O
JNK B-GENE-N
or O
ERK B-GENE-N
inhibitors, O
respectively. O
Taken O
together, O
these O
findings O
suggest O
that O
NaF B-CHEMICAL
induces O

apoptosis O
in O
OLC O
odontoblasts O
through O
a O
JNK-dependent B-GENE-N
mitochondrial O
pathway. O
The O
potassium B-GENE-Y
channel I-GENE-Y
subunit I-GENE-Y
Kvbeta3 I-GENE-Y
interacts O
with O
pannexin B-GENE-Y
1 I-GENE-Y
and O
attenuates O
its O
sensitivity O
to O
changes O
in O
redox O
potentials. O
Pannexin B-GENE-Y
1 I-GENE-Y
(Panx1), B-GENE-Y
a O
member O
of O
the O
second O
gap B-GENE-N
junction I-GENE-N
protein I-GENE-N
family O
identified O
in O
vertebrates, O
appears O
to O
preferentially O
form O
non-junctional O
membrane O
channels. O
A O
candidate O
regulatory O
protein O
of O
Panx1 B-GENE-Y
is O
the O
potassium B-GENE-Y
channel I-GENE-Y
subunit I-GENE-Y
Kvbeta3, I-GENE-Y
previously O
identified O
by O
bacterial O
two-hybrid O
strategies. O
Here, O
we O
report O
on O
the O
physical O

association O
of O
Panx1 B-GENE-Y
with O
Kvbeta3 B-GENE-Y
by O
immunoprecipitation O
when O
co-expressed O
in O
a O
neuroblastoma O
cell O
line O
(Neuro2A). O
Furthermore, O
in O
vivo O
co-expression O
of O
Panx1 B-GENE-Y
and O
Kvbeta3 B-GENE-Y
was O
shown O
to O
occur O
in O
murine O
hippocampus O
and O
cerebellum. O
Kvbeta3 B-GENE-Y
is O
known O
to O
accelerate O
inactivation O
of O
otherwise O
slowly O
inactivating O
potassium B-GENE-N
channels I-GENE-N
under O
reducing O
conditions. O
We O
subsequently O
found O
that O
Panx1 B-GENE-Y
channel O
currents O
exhibit O
a O
significant O
reduction O
when O
exposed O
to O
reducing O
agents, O
and O
that O
this O
effect O
is O

attenuated O
in O
the O
presence O
of O
Kvbeta3. B-GENE-Y
Apparently, O
Kvbeta3 B-GENE-Y
is O
involved O
in O
regulating O
the O
susceptibility O
of O
Panx1 B-GENE-Y
channels O
to O
redox O
potential. O
Furthermore, O
the O
Panx1 B-GENE-Y
channel O
blockers O
carbenoxolone B-CHEMICAL
and O
Probenecid B-CHEMICAL
were O
less O
effective O
in O
inhibiting O
Panx1 B-GENE-Y
currents O
when O
Kvbeta3 B-GENE-Y
was O
co-expressed. O
The O
influence O
of O
Kvbeta3 B-GENE-Y
on O
Panx1 B-GENE-Y
is O
the O
first O
example O
of O
modulation O
of O
Panx1 B-GENE-Y
channel O
function(s) O
by O
interacting O
proteins, O
and O
suggests O
the O
physiological O
importance O
of O
sensing O
changes O
in O
redox O

potentials. O
Optoelectronic O
Processes O
in O
Squaraine B-CHEMICAL
Dye-Doped I-CHEMICAL
OLEDs O
for O
Emission O
in O
the O
Near-Infrared. O
A O
novel O
all-organic O
host-guest O
system O
for O
emission O
in O
the O
NIR O
is O
introduced O
and O
investigated O
with O
respect O
to O
its O
opto-electronic O
processes. O
The O
good O
agreement O
between O
theoretical O
and O
experimental O
results O
highlights O
the O
model O
character O
of O
this O
system O
and O
its O
potential O
for O
electroluminescent O
application. O
Comparative O
measurements O
provide O
access O
to O
the O
recombination O
mechanisms O
on O
molecular O
length O
scale O
and O
show O
that O
the O
emission O
behavior O
of O
the O
device O
under O
operation O
is O
controlled O
by O
charge O
carrier O
dynamics. O

Phosphodiesterase B-GENE-N
inhibitors. O
Part O
5: O
hybrid O
PDE3/4 B-GENE-N
inhibitors O
as O
dual O
bronchorelaxant/anti-inflammatory O
agents O
for O
inhaled O
administration. O
(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one B-CHEMICAL
(KCA-1490) B-CHEMICAL
exhibits O
moderate O
dual O
PDE3/4-inhibitory B-GENE-N
activity O
and O

promises O
as O
a O
combined O
bronchodilatory/anti-inflammatory O
agent. O
N-alkylation B-CHEMICAL
of O
the O
pyridazinone B-CHEMICAL
ring O
markedly O
enhances O
potency O
against O
PDE4 B-GENE-N
but O
suppresses O
PDE3 B-GENE-N
inhibition. O
Addition O
of O
a O
6-aryl-4,5-dihydropyridazin-3(2H)-one B-CHEMICAL
extension O
to O
the O
N-alkyl B-CHEMICAL
group O
facilitates O
both O
enhancement O
of O
PDE4-inhibitory B-GENE-N
activity O
and O
restoration O
of O
potent O
PDE3 B-GENE-N
inhibition. O
Both O
dihydropyridazinone B-CHEMICAL
rings, O
in O
the O
core O
and O
extension, O
can O
be O
replaced O

by O
achiral O
4,4-dimethylpyrazolone B-CHEMICAL
subunits O
and O
the O
core O
pyrazolopyridine B-CHEMICAL
by O
isosteric O
bicyclic O
heteroaromatics. O
In O
combination, O
these O
modifications O
afford O
potent O
dual O
PDE3/4 B-GENE-N
inhibitors O
that O
suppress O
histamine-induced B-CHEMICAL
bronchoconstriction O
in O
vivo O
and O
exhibit O
promising O
anti-inflammatory O
activity O
via O
intratracheal O
administration. O
Using O
a O
fragment-based O
approach O
to O
target O
protein-protein O
interactions. O
The O
ability O
to O
identify O
inhibitors O
of O
protein-protein O
interactions O
represents O
a O
major O
challenge O
in O
modern O
drug O
discovery O
and O
in O
the O
development O
of O
tools O
for O

chemical O
biology. O
In O
recent O
years, O
fragment-based O
approaches O
have O
emerged O
as O
a O
new O
methodology O
in O
drug O
discovery; O
however, O
few O
examples O
of O
small O
molecules O
that O
are O
active O
against O
chemotherapeutic O
targets O
have O
been O
published. O
Herein, O
we O
describe O
the O
fragment-based O
approach O
of O
targeting O
the O
interaction O
between O
the O
tumour O
suppressor O
BRCA2 B-GENE-Y
and O
the O
recombination O
enzyme O
RAD51; B-GENE-Y
it O
makes O
use O
of O
a O
screening O
pipeline O
of O
biophysical O
techniques O
that O
we O
expect O
to O
be O
more O
generally O
applicable O
to O
similar O
targets. O
Disruption O
of O
this O
interaction O
in O
vivo O
is O
hypothesised O
to O
give O
rise O
to O
cellular O
hypersensitivity O
to O
radiation O

and O
genotoxic O
drugs. O
We O
have O
used O
protein O
engineering O
to O
create O
a O
monomeric O
form O
of O
RAD51 B-GENE-Y
by O
humanising O
a O
thermostable O
archaeal O
orthologue, O
RadA, B-GENE-N
and O
used O
this O
protein O
for O
fragment O
screening. O
The O
initial O
fragment O
hits O
were O
thoroughly O
validated O
biophysically O
by O
isothermal O
titration O
calorimetry O
(ITC) O
and O
NMR O
techniques O
and O
observed O
by O
X-ray O
crystallography O
to O
bind O
in O
a O
shallow O
surface O
pocket O
that O
is O
occupied O
in O
the O
native O
complex O
by O
the O
side O
chain O
of O
a O
phenylalanine B-CHEMICAL
from O
the O
conserved O
FxxA B-GENE-N
interaction I-GENE-N
motif I-GENE-N

found O
in O
BRCA2. B-GENE-Y
This O
represents O
the O
first O
report O
of O
fragments O
or O
any O
small O
molecule O
binding O
at O
this O
protein-protein O
interaction O
site. O
Fumarate B-GENE-N
reductase I-GENE-N
is O
essential O
for O
Helicobacter O
pylori O
colonization O
of O
the O
mouse O
stomach. O
Fumarate B-GENE-N
reductase I-GENE-N
(FRD) B-GENE-N
is O
the O
key O
enzyme O
in O
fumarate B-CHEMICAL
respiration O
induced O
by O
anaerobic O
growth O
of O
bacteria. O
In O
Helicobacter O
pylori, O
this O
enzyme O
appears O
to O
be O
constitutively O
expressed O
under O
microaerobic O
conditions O
and O
is O
not O
essential O
for O
its O
survival O
in O
vitro. O
In O
this O
study, O
the O
role O
of O

FRD B-GENE-N
in O
the O
colonization O
of O
H. O
pylori O
was O
investigated O
using O
a O
mouse O
model. O
The O
frdA B-GENE-Y
gene O
coding O
for O
subunit B-GENE-Y
A I-GENE-Y
of I-GENE-Y
FRD, I-GENE-Y
and O
two O
control O
genes, O
copA B-GENE-Y
and O
copP B-GENE-Y
associated O
with O
the O
export O
of O
copper B-CHEMICAL
out O
of O
H. O
pylori, O
were O
inactivated O
by O
insertion O
of O
the O
chloramphenicol B-CHEMICAL
acetyltransferase O
cassette O
into O
these O
individual O
genes. O
The O
isogenic O
mutants O
of O
H. O
pylori O
strain O
AH244 O
were O
obtained O
by O
natural O
transformation. O
Seventy-five O
ICR O
mice O
(15 O
mice/group) O
were O
orogastrically O
dosed O
with O
either O
the O

wild O
type O
H. O
pylori O
strain O
AH244, O
its O
isogenic O
mutants, O
or O
Brucella O
broth O
(negative O
control). O
Five O
mice O
from O
each O
group O
were O
killed O
at O
2, O
4 O
and O
8 O
weeks O
post-inoculation O
(WPI), O
respectively. O
H. O
pylori O
colonization O
was O
not O
detected O
in O
mouse O
gastric O
mucosa O
infected O
with O
the O
frdA B-GENE-Y
mutant O
at O
any O
time O
point O
in O
the O
study O
by O
both O
quantitative O
culture O
and O
PCR. O
In O
contrast, O
the O
mice O
inoculated O
with O
either O
wild O
type O
AH244, O
copA B-GENE-Y
or O
copPH. B-GENE-Y
pylori O
mutants O
became O
readily O
infected. O

These O
data O
indicate O
that O
FRD B-GENE-N
plays O
a O
crucial O
role O
in O
H. O
pylori O
survival O
in O
the O
gastric O
mucosa O
of O
mice. O
Given O
that O
FRD, B-GENE-N
present O
in O
all O
H. O
pylori O
strains, O
is O
immunogenic O
in O
H. O
pylori O
-infected O
patients O
and O
H. O
pylori O
growth O
in O
vitro O
can O
be O
inhibited O
by O
three O
anthelmintics O
(morantel, B-CHEMICAL
oxantel B-CHEMICAL
and O
thiabendazole), B-CHEMICAL
this O
enzyme O
could O
potentially O
be O
used O
both O
as O
a O
novel O
drug O
target O
as O
well O
as O
in O
the O
development O
of O
vaccines O
for O
H. O
pylori O
prevention O
and O

eradication. O
Tryptophan B-GENE-Y
hydroxylase I-GENE-Y
mRNA O
levels O
are O
elevated O
by O
repeated O
immobilization O
stress O
in O
rat O
raphe O
nuclei O
but O
not O
in O
pineal O
gland. O
Repeated O
stress O
triggers O
a O
wide O
range O
of O
adaptive O
changes O
in O
the O
central O
nervous O
system O
including O
the O
elevation O
of O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
metabolism O
and O
an O
increased O
susceptibility O
to O
affective O
disorders. O
To O
begin O
to O
examine O
whether O
these O
changes O
are O
mediated O
by O
alterations O
in O
gene O
expression O
for O
tryptophan B-GENE-Y
hydroxylase I-GENE-Y
(TPH), B-GENE-Y
the O
rate-limiting O
enzyme O
in O
5-HT B-CHEMICAL
biosynthesis, O
we O

quantitated O
its O
mRNA O
levels O
by O
competitive O
reverse O
transcription-polymerase O
chain O
reaction O
(RT-PCR). O
Repeated O
immobilization O
stress O
(2 O
h, O
7 O
days) O
elicited O
a O
six- O
or O
ten-fold O
rise O
in O
TPH B-GENE-Y
mRNA O
in O
median O
raphe O
nucleus O
(MRN) O
and O
dorsal O
raphe O
nucleus O
(DRN), O
respectively, O
without O
significantly O
altering O
TPH B-GENE-Y
mRNA O
levels O
in O
the O
pineal O
gland. O
In O
contrast, O
there O
was O
little O
change O
in O
mRNA O
levels O
for O
GTP B-GENE-Y
cyclohydrolase I-GENE-Y
I I-GENE-Y
(GTPCH), B-GENE-Y
the O
rate O
limiting O
enzyme O

in O
synthesis O
of O
the O
tetrahydrobiopterin B-CHEMICAL
(BH4), B-CHEMICAL
the O
obligate O
cofactor O
for O
TPH. B-GENE-Y
This O
is O
the O
first O
study O
to O
reveal O
stress-elicited O
activation O
of O
TPH B-GENE-Y
gene O
expression. O
Iron B-CHEMICAL
and O
zinc B-CHEMICAL
bioavailability O
in O
Caco-2 O
cells: O
influence O
of O
caseinophosphopeptides. B-GENE-N
A O
study O
has O
been O
made O
of O
the O
influence O
of O
two O
pools O
of O
caseinophosphopeptides B-GENE-N
(CPPs) B-GENE-N
obtained O
from O
α(s)- B-GENE-N
and I-GENE-N
β-casein I-GENE-N
(CN) B-GENE-N
fractions, O
and O
of O
three O
specific O
CPPs B-GENE-N

(β-CN(1-25)4P, B-GENE-Y
α(s1)-CN(64-74)4P B-GENE-Y
and O
α(s2)-CN(1-19)4P), B-GENE-N
on O
iron B-CHEMICAL
bioavailability O
(ferritin B-GENE-Y
synthesis) O
and O
zinc B-CHEMICAL
bioavailability O
(retention, O
transport O
and O
uptake O
of O
zinc) B-CHEMICAL
in O
Caco-2 O
cells. O
α-CPP B-GENE-N
and O
β-CPP B-GENE-N
pools O
did O
not O
improve O
ferritin B-GENE-Y
synthesis, O
but O
the O
three O
specific O
CPPs B-GENE-N
showed O
an O
increase O
in O
ferritin B-GENE-Y
synthesis O
in O
Caco-2 O
cells O
versus O
iron B-CHEMICAL

sulphate, I-CHEMICAL
β-CN(1-25)4P B-GENE-Y
being O
the O
most O
effective. O
In O
relation O
to O
zinc B-CHEMICAL
bioavailability, O
α-CPPs, B-GENE-N
β-CPPs, B-GENE-N
α(s1)-CN(64-74)4P B-GENE-Y
and O
β-CN(1-25)4P B-GENE-Y
increased O
zinc B-CHEMICAL
uptake. O
However, O
this O
increase O
was O
of O
the O
same O
order O
as O
the O
increase O
due O
to O
the O
presence O
of O
zinc B-CHEMICAL
sulphate. I-CHEMICAL
An O
overview O
on O
the O
marine O
neurotoxin, O
saxitoxin: B-CHEMICAL
genetics, O
molecular O
targets, O
methods O
of O
detection O
and O
ecological O
functions. O
Marine O
neurotoxins O

are O
natural O
products O
produced O
by O
phytoplankton O
and O
select O
species O
of O
invertebrates O
and O
fish. O
These O
compounds O
interact O
with O
voltage-gated B-GENE-N
sodium, I-GENE-N
potassium I-GENE-N
and I-GENE-N
calcium I-GENE-N
channels I-GENE-N
and O
modulate O
the O
flux O
of O
these O
ions O
into O
various O
cell O
types. O
This O
review O
provides O
a O
summary O
of O
marine O
neurotoxins, O
including O
their O
structures, O
molecular O
targets O
and O
pharmacologies. O
Saxitoxin B-CHEMICAL
and O
its O
derivatives, O
collectively O
referred O
to O
as O
paralytic O
shellfish O
toxins O
(PSTs), O
are O
unique O
among O
neurotoxins O
in O
that O
they O
are O
found O
in O
both O
marine O
and O
freshwater O
environments O
by O
organisms O
inhabiting O
two O
kingdoms O
of O

life. O
Prokaryotic O
cyanobacteria O
are O
responsible O
for O
PST O
production O
in O
freshwater O
systems, O
while O
eukaryotic O
dinoflagellates O
are O
the O
main O
producers O
in O
marine O
waters. O
Bioaccumulation O
by O
filter-feeding O
bivalves O
and O
fish O
and O
subsequent O
transfer O
through O
the O
food O
web O
results O
in O
the O
potentially O
fatal O
human O
illnesses, O
paralytic O
shellfish O
poisoning O
and O
saxitoxin B-CHEMICAL
pufferfish O
poisoning. O
These O
illnesses O
are O
a O
result O
of O
saxitoxin's B-CHEMICAL
ability O
to O
bind O
to O
the O
voltage-gated B-GENE-N
sodium I-GENE-N
channel, I-GENE-N
blocking O
the O
passage O
of O
nerve O
impulses O
and O
leading O
to O
death O
via O
respiratory O
paralysis. O

Recent O
advances O
in O
saxitoxin B-CHEMICAL
research O
are O
discussed, O
including O
the O
molecular O
biology O
of O
toxin O
synthesis, O
new O
protein O
targets, O
association O
with O
metal-binding B-GENE-N
motifs I-GENE-N
and O
methods O
of O
detection. O
The O
eco-evolutionary O
role(s) O
PSTs O
may O
serve O
for O
phytoplankton O
species O
that O
produce O
them O
are O
also O
discussed. O
Pulmonary O
delivery O
of O
an O
aerosolized O
recombinant O
human B-GENE-Y
butyrylcholinesterase I-GENE-Y
pretreatment O
protects O
against O
aerosolized O
paraoxon B-CHEMICAL
in O
macaques. O
Butyrylcholinesterase B-GENE-Y
(BChE) B-GENE-Y
is O
the O
leading O
pretreatment O
candidate O
against O
exposure O

to O
organophosphates B-CHEMICAL
(OPs), O
which O
pose O
an O
ever O
increasing O
public O
and O
military O
health. O
Since O
respiratory O
failure O
is O
the O
primary O
cause O
of O
death O
following O
acute O
OP O
poisoning, O
an O
inhaled O
BChE B-GENE-Y
therapeutic O
could O
prove O
highly O
efficacious O
in O
preventing O
acute O
toxicity O
as O
well O
as O
the O
associated O
delayed O
neuropathy. O
To O
address O
this, O
studies O
have O
been O
performed O
in O
mice O
and O
macaques O
using O
Chinese O
Hamster O
Ovary O
cells O
(CHO)-derived O
recombinant O
(r) O
BChE B-GENE-Y
delivered O
by O
the O
pulmonary O
route, O
to O
examine O
whether O
the O
deposition O
of O
both O
macaque O
(Ma) O
and O
human O
(Hu) O

rBChE B-GENE-Y
administered O
as O
aerosols O
(aer) O
favored O
the O
creation O
and O
retention O
of O
an O
efficient O
protective O
"pulmonary O
bioshield" O
that O
could O
scavenge O
incoming O
(inhaled) O
OPs O
in O
situ O
thereby O
preventing O
entry O
into O
the O
circulation O
and O
inhibition O
of O
plasma O
BChE B-GENE-Y
and O
AChE B-GENE-Y
on O
red O
blood O
cells O
(RBC-AChE) B-GENE-Y
and O
in O
cholinergic O
synapses. O
In O
contrast O
to O
parenteral O
delivery O
of O
rBChE, B-GENE-Y
which O
currently O
requires O
posttranslational O
modification O
for O
good O
plasma O
stability, O
an O
unmodified O
aer-rBChE B-GENE-Y
pretreatment O
given O

1-40h O
prior O
to O
>1 O
LD50 O
of O
aer-paraoxon B-CHEMICAL
(Px) O
was O
able O
to O
prevent O
inhibition O
of O
circulating O
cholinesterase B-GENE-Y
in O
a O
dose-dependent O
manner. O
These O
studies O
are O
the O
first O
to O
show O
protection O
by O
rBChE B-GENE-Y
against O
a O
pesticide O
such O
as O
paraoxon B-CHEMICAL
when O
delivered O
directly O
into O
the O
lung O
and O
bode O
well O
for O
the O
use O
of O
a O
non-invasive O
and O
consumer O
friendly O
method O
of O
rHuBChE B-GENE-Y
delivery O
as O
a O
human O
treatment O
to O
counteract O
OP O
toxicity. O
Anti-diabetic O
property O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
is O
mediated O
through O

the O
expression O
of O
Glut-4 B-GENE-Y
in O
L6 O
myotubes. O
Tinospora O
cordifolia O
is O
a O
well O
reported O
plant O
possessing O
numerous O
medicinal O
values O
including O
anti-diabetic O
property. O
Aim O
of O
the O
present O
study O
is O
to O
study O
the O
mechanism O
of O
action O
of O
Tinospora O
cordifolia O
and O
its O
active O
compound O
in O
differentiated O
myocytes, O
L6 O
cells. O
Key O
marker O
of O
diabetes O
in O
cells O
is O
the O
insulin B-GENE-Y
dependent I-GENE-Y
glucose I-GENE-Y
transporter-4 I-GENE-Y
(Glut-4) B-GENE-Y
which O
also O
responds O
to O
exogenous O
chemicals, O
and O
is O
over O
expressed O
up O
to O
5- O
and O
4-fold, O
by O
Tinospora O
cordifolia O
and O

palmatine, B-CHEMICAL
respectively. O
Next O
to O
Glut-4, B-GENE-Y
the O
predominant O
protein O
influencing O
glucose B-CHEMICAL
metabolism O
is O
PPARα B-GENE-N
and I-GENE-N
γ I-GENE-N
whose O
expressions O
were O
also O
positively O
modulated. O
Further, O
the O
inhibitors O
of O
insulin B-GENE-N
pathway O
prevented O
glucose B-CHEMICAL
uptake O
mediated O
by O
Tinospora O
cordifolia O
and O
palmatine B-CHEMICAL
which O
shows O
that O
the O
activity O
is O
majorly O
mediated O
through O
insulin B-GENE-N
pathway. O
Differential O
IL-2 B-GENE-N
receptor I-GENE-N
expression O
in O
renal O
allograft O
recipients O
treated O
with O
an O
anti-IL-2-receptor B-GENE-N
antibody. O
Patients O
were O
entered O
into O
a O
randomized O
trial O
of O
prophylaxis O
for O
renal O
allograft O
rejection O
by O
the O
administration O

of O
an O
anti-human B-GENE-N
IL-2 I-GENE-N
receptor I-GENE-N
antibody, O
anti-Tac, O
during O
the O
first O
ten O
days O
posttransplant. O
Interleukin-2 B-GENE-N
receptor I-GENE-N
(IL-2 B-GENE-N
R) I-GENE-N
expression O
was O
measured O
using O
two O
anti-IL-2 B-GENE-N
R I-GENE-N
monoclonal O
antibodies O
(moAbs), O
anti-Tac O
and O
1HT4-4H3. O
These O
two O
antibodies O
recognize O
closely O
spaced O
epitopes O
on O
the O
55 O
kD O
chain O
of O
the O
IL-2 B-GENE-N
R. I-GENE-N
IL-2 B-GENE-N
R I-GENE-N
expression O
was O
examined O
on O
peripheral O
blood O
small O
lymphocytes O
in O
three O
groups O
of O
patients O
who O
received: O
(A) B-CHEMICAL

cyclosporine I-CHEMICAL
CsA B-CHEMICAL
and O
prednisone B-CHEMICAL
for O
baseline O
immunosuppression O
(n O
= O
9); O
(B) O
anti-Tac O
with O
CsA B-CHEMICAL
and O
prednisone B-CHEMICAL
as O
baseline O
immunosuppression O
(n O
= O
12); O
and O
(C) O
anti-Tac O
with O
azathioprine B-CHEMICAL
and O
prednisone B-CHEMICAL
as O
baseline O
immunosuppression O
(n O
= O
5). O
We O
found O
that O
large O
numbers O
of O
T O
cells O
express O
IL-2 B-GENE-N
receptors I-GENE-N
despite O
the O
presence O
of O
anti-Tac O
(average O
of O
IL-2 B-GENE-N
R-positive I-GENE-N
cells O
at O

day O
of O
peak O
IL-2 B-GENE-N
R I-GENE-N
expression O
56.0 O
+/- O
20.8% O
in O
group O
A, O
65.2 O
+/- O
26.6% O
in O
group O
B, O
21.0 O
+/- O
7.4% O
in O
group O
C). O
IL-2 B-GENE-N
R I-GENE-N
expression O
did O
not O
correlate O
with O
clinical O
activity, O
and O
the O
presence O
or O
accessibility O
of O
epitopes O
on O
the O
same O
55 O
kD O
chain O
varied O
dramatically O
from O
patient O
to O
patient. O
Medical O
therapy O
and O
quality O
of O
life. O
The O
risk O
of O
mortality O
and O
long-term O
morbidity, O
including O
loss O
of O
sexual O
function, O
associated O
with O
surgical O
procedures O
for O
symptomatic O

benign O
prostatic O
hyperplasia O
(BPH) O
has O
prompted O
research O
into O
alternative O
medical O
therapies. O
Phytotherapy O
involves O
the O
use O
of O
herbal O
formulations, O
where O
the O
mechanisms O
of O
action O
are O
usually O
obscure O
and O
although O
studies O
have O
confirmed O
their O
effectiveness O
in O
symptom O
relief O
and O
improving O
quality O
of O
life O
(QOL), O
few O
placebo-controlled O
trials O
exist. O
Both O
the O
5 B-GENE-N
alpha-reductase I-GENE-N
inhibitor O
finasteride B-CHEMICAL
and O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
antagonists O
(e.g. O
alfuzosin, B-CHEMICAL
doxazosin, B-CHEMICAL
prazosin, B-CHEMICAL
tamsulosin B-CHEMICAL
and O
terazosin) B-CHEMICAL

have O
been O
recommended O
as O
appropriate O
treatment O
options O
for O
patients O
with O
lower O
urinary O
tract O
symptoms O
(LUTS) O
associated O
with O
benign O
prostatic O
obstruction O
(BPO), O
and O
their O
efficacy O
has O
been O
proven O
in O
several O
placebo-controlled O
trials. O
Finasteride B-CHEMICAL
reduces O
the O
static O
component O
of O
BPO--by O
reducing O
the O
size O
of O
the O
prostate--and, O
as O
a O
result, O
symptom O
relief O
is O
slow O
(6-12 O
months) O
and O
is O
predominantly O
restricted O
to O
patients O
with O
large O
prostates O
(> O
40 O
g). O
The O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
antagonists, O
on O
the O
other O
hand, O
reduce O
the O

dynamic O
component O
of O
obstruction--relaxation O
of O
smooth O
muscle O
in O
the O
prostate, O
urethra O
and O
bladder O
neck--and O
provide O
rapid O
symptom O
relief O
after O
only O
a O
few O
doses, O
relieving O
LUTS O
more O
effectively O
than O
finasteride B-CHEMICAL
and O
irrespective O
of O
prostate O
size. O
All O
of O
the O
various O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
antagonists O
provide O
effective O
and O
comparable O
relief O
of O
LUTS, O
and O
an O
improvement O
in O
bothersomeness O
and O
symptom-related O
QOL. O
However, O
it O
is O
also O
important O
that O
the O
therapy O
is O
fast O
acting O
and O
acceptable O
to O
the O
patient, O
in O
that O
it O
does O
not O
interfere O
with O

other O
medication O
or O
produce O
unpleasant O
side O
effects. O
These O
documented O
properties O
of O
the O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
antagonists O
make O
them O
an O
ideal O
choice O
for O
the O
medical O
treatment O
of O
symptomatic O
BPH. O
Bioinspired O
Water-Enhanced O
Mechanical O
Gradient O
Nanocomposite O
Films O
That O
Mimic O
the O
Architecture O
and O
Properties O
of O
the O
Squid O
Beak. O
Inspired O
by O
the O
water-enhanced O
mechanical O
gradient O
character O
of O
the O
squid O
beak, O
we O
herein O
report O
a O
nanocomposite O
that O
mimics O
both O
the O
architecture O
and O
properties O
of O
this O
interesting O
natural O
material. O
Similar O
to O
the O
squid O
beak, O
we O
have O
developed O

nanocomposites O
where O
the O
degree O
of O
cross-linking O
is O
controlled O
along O
the O
length O
of O
the O
film. O
In O
this O
study, O
we O
utilized O
tunicate O
cellulose O
nanocrystals O
as O
the O
nanofiller O
that O
are O
functionalized O
with O
allyl B-CHEMICAL
moieties. O
Using O
photoinduced O
thiol-ene B-CHEMICAL
chemistry, O
we O
have O
been O
able O
to O
cross-link O
the O
CNC O
nanofiller. O
In O
the O
dry O
state O
where O
strong O
CNC O
interactions O
can O
occur, O
only O
a O
small O
mechanical O
contrast O
is O
observed O
between O
the O
cross-linked O
and O
uncross-linked O
samples. O
However, O
when O
the O
films O
are O
exposed O
to O
water, O

which O
"switches O
off" O
the O
noncovalent O
CNC O
interactions, O
a O
significant O
mechanical O
contrast O
is O
observed O
between O
the O
same O
films. O
For O
example, O
at O
20 O
wt O
% O
CNC O
(in O
the O
dry O
film), O
an O
increase O
in O
wet O
modulus O
from O
60 O
to O
300 O
MPa O
(∼500% O
increase) O
is O
observed O
after O
photoirradiation. O
Furthermore, O
we O
show O
that O
the O
wet O
modulus O
can O
be O
controlled O
by O
altering O
the O
UV O
exposure O
time O
which O
allows O
access O
to O
mechanical O
gradient O
films. O
Wired O
Enzyme O
Electrodes-A O
Retroperspective O
Story O
about O
an O
Exciting O
Time O
at O
University O
of O
Texas O
at O
Austin O
and O
Its O
Impact O
on O

My O
Scientific O
Career. O
The O
present O
paper O
features O
an O
exciting O
time O
in O
the O
late O
1980s O
when O
I, O
as O
a O
visiting O
scientist, O
had O
the O
privilege O
to O
participate O
in O
the O
early O
and O
very O
exciting O
development O
of O
the O
in O
vivo O
redox-polymer-wired O
glucose B-CHEMICAL
sensor O
in O
Professor O
Adam O
Heller's O
laboratory O
at O
the O
Department O
of O
Chemical O
Engineering O
at O
University O
of O
Texas O
at O
Austin. O
This O
story O
is O
followed O
by O
an O
overview O
of O
the O
research O
my O
visit O
initiated O
at O
Uppsala O
University. O
In O
collaboration O
with O
Swedish O
colleagues, O
we O
explored O
a O
few O
of O
the O
many O
possibilities O
to O
form O
new O
biosensors O
by O
utilizing O
Prof. O
Heller's O
concept O
of O
cross-linked O

redox-polymer/redox-enzyme O
electrodes. O
Antithrombotic O
activity O
of O
a O
newly O
synthesized O
coumarin B-CHEMICAL
derivative O
3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide. B-CHEMICAL
Anti-platelet O
therapy O
is O
a O
useful O
strategy O
to O
prevent O
acute O
thromboembolic O
artery O
occlusions. O
This O

study O
was O
designed O
to O
assess O
the O
efficacy O
of O
seselin B-CHEMICAL
derivatives O
against O
murine O
pulmonary O
thromboembolism, O
bleeding O
time, O
platelet O
activation O
and O
thrombosis. O
Administration O
of O
C3 O
(16 O
mg/kg) O
offered O
70% O
protection O
against O
collagen- B-GENE-N
and O
epinephrine-induced B-CHEMICAL
pulmonary O
thromboembolism O
and O
30% O
protection O
against O
arachidonic B-CHEMICAL
acid-induced I-CHEMICAL
death O
in O
mice, O
without O
adversely O
affecting O
bleeding O
time. O
No O
significant O
difference O
was O
observed O
by O
C3 O
in O
ferric B-CHEMICAL
chloride-induced I-CHEMICAL
arterial O
thrombosis O
in O
rats. O
Significant O
reduction O
in O
thrombus O
weight O
was O

observed O
in O
arteriovenous O
shunt O
model. O
In O
rat O
PRP, O
C3 O
reduced O
ADP B-CHEMICAL
and O
collagen-induced B-GENE-N
platelet O
aggregation. O
In O
chronic O
hamster O
model O
of O
dyslipidemia, O
administration O
of O
C3 O
(16 O
mg/kg O
p.o. O
for O
90 O
days) O
had O
no O
effect O
on O
plasma O
lipids, O
vasoreactivity O
and O
platelet O
adhesion. O
C3 O
fed O
hamsters O
showed O
reduced O
whole-blood O
aggregation O
response O
to O
ADP B-CHEMICAL
and O
collagen B-GENE-N
compared O
to O
HC-fed O
hamsters. O
In O
addition, O
C3 O
augmented O
thrombin O
time; O
however, O

time O
to O
occlusion O
was O
not O
increased. O
These O
results O
convincingly O
demonstrated O
that O
C3 O
is O
a O
novel O
molecule O
that O
reduces O
the O
risk O
of O
thrombosis O
and O
alleviates O
prothrombotic O
state O
associated O
with O
hyperlipidemia O
without O
any O
adverse O
effect O
on O
bleeding O
time. O
The O
high O
benefit/risk O
ratio O
of O
this O
compound O
makes O
it O
a O
suitable O
candidate O
for O
future O
valid O
studies. O
Central O
5-HT3 B-GENE-Y
receptor O
stimulation O
by O
m-CPBG B-CHEMICAL
increases O
blood O
glucose B-CHEMICAL
in O
rats. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
role O
of O
central O
5-HT3 B-GENE-Y
receptors O
on O
the O
control O
of O
blood O
glucose B-CHEMICAL
in O
stressed O
and O
non-stressed O
rats O
in O

both O
fasted O
and O
fed O
states. O
Adult O
Wistar O
male O
rats O
had O
each O
their O
third O
ventricle O
cannulated O
7 O
days O
before O
the O
experiments. O
Injections O
of O
m-CPBG, B-CHEMICAL
a O
selective O
5-HT3 B-GENE-Y
receptor O
agonist, O
induced O
a O
significant O
increase O
in O
blood O
glucose B-CHEMICAL
in O
non-stressed O
rats O
in O
both O
fasted O
and O
in O
fed O
states. O
The O
same O
procedure O
was O
unable O
to O
modify O
stress-induced O
hyperglycemia. O
The O
hyperglycemic O
effect O
of O
m-CPBG B-CHEMICAL
central O
administration O
was O
blocked O
by O
pretreatment O
with O
ondansetron, O
a O
specific O
5-HT3 B-GENE-Y
receptor O
antagonist, O
indicating O

that O
the O
effects O
here O
obtained O
with O
m-CPBG B-CHEMICAL
were O
a O
result O
of O
its O
interaction O
with O
5-HT3 B-GENE-Y
receptors. O
Third O
ventricle O
injections O
of O
ondansetron B-CHEMICAL
alone O
were O
not O
able O
to O
modify O
blood O
glucose B-CHEMICAL
in O
non-stressed O
animals O
and O
did O
not O
change O
the O
hyperglycemic O
responses O
observed O
after O
immobilization O
stress. O
We O
conclude O
that O
pharmacological O
activation O
of O
the O
central O
5-HT3 B-GENE-Y
receptor O
induces O
a O
hyperglycemic O
effect O
in O
non-stressed O
animals. O
3'-R/S-Hydroxyvoacamine, B-CHEMICAL
a O
potent O
acetylcholinesterase B-GENE-Y
inhibitor O
from O

Tabernaemontana O
divaricata. O
Guided O
by O
the O
acetylcholinesterase B-GENE-Y
inhibiting O
activity, O
the O
bisindole B-CHEMICAL
alkaloid I-CHEMICAL
3'-R/S-hydroxyvoacamine B-CHEMICAL
was O
isolated O
from O
a O
stem O
extract O
of O
Tabernaemontana O
divaricata, O
a O
plant O
used O
in O
Thailand O
in O
traditional O
rejuvenation O
remedies O
for O
improving O
the O
memory. O
The O
structure O
of O
the O
alkaloid O
was O
elucidated O
by O
extensive O
use O
of O
NMR O
spectroscopy O
and O
the O
complete O
assignment O
of O
the O
(1)H B-CHEMICAL
and O
(13)C B-CHEMICAL
NMR O
spectra O
is O

reported. O
The O
alkaloid O
acted O
as O
a O
non-competitive O
inhibitor O
against O
AChE B-GENE-Y
with O
an O
IC50 O
value O
of O
7.00±1.99μM. O
An O
HPLC O
method O
was O
developed O
for O
the O
quantitative O
analysis O
of O
the O
AChE B-GENE-Y
inhibitor. O
It O
suggested O
that O
there O
was O
12.4% O
(w/w) O
of O
3'-R/S-hydroxyvoacamine B-CHEMICAL
in O
the O
alkaloid O
enriched O
fraction O
of O
T. O
divaricata O
stem. O
TCF7L2 B-GENE-Y
Variation O
and O
Proliferative O
Diabetic O
Retinopathy. O
Proliferative O
diabetic O
retinopathy O

(PDR) O
is O
the O
most O
severe O
vision-threatening O
complication O
of O
diabetes. O
To O
investigated O
genetic O
association O
between O
TCF7L2 B-GENE-Y
and O
PDR O
in O
Caucasian O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
its O
functional O
consequences, O
383 O
T2DM O
patients O
with O
PDR O
(T2DM-PDR) O
and O
756 O
T2DM O
patients O
without O
diabetic O
retinopathy O
(T2DM-no O
DR) O
were O
genotyped O
with O
rs7903146 O
in O
TCF7L2. B-GENE-Y
We O
found O
that O
risk O
allele O
(T) O
frequency O
of O
rs7903146 O
was O
significantly O
higher O
in O

T2DM-PDR O
patients O
(allelic O
P O
= O
2.52E-04). O
In O
lymphoblastoid O
cells O
induced O
to O
undergo O
endoplasmic O
reticulum O
(ER) O
stress O
by O
treatment O
of O
tunicamycin, B-CHEMICAL
higher O
fold O
change O
of O
TCF7L2 B-GENE-Y
and O
VEGFA B-GENE-Y
mRNA O
levels O
were O
observed O
in O
rs7903146-TT O
cells O
than O
that O
in O
rs7903146-CC O
cells O
(P O
= O
0.02 O
for O
TCF7L2; B-GENE-Y
P O
= O
0.004 O
for O
VEGFA), B-GENE-Y
suggesting O
ER O
stress O
plays O
a O
role O
in O
PDR O

pathogenesis. O
Silencing O
TCF7L2 B-GENE-Y
resulted O
in O
decreased O
mRNA O
levels O
of O
both O
TCF7L2 B-GENE-Y
and O
VEGFA B-GENE-Y
(P O
< O
0.001). O
Retinas O
of O
oxygen-induced B-CHEMICAL
retinopathy O
(OIR) O
mice O
(a O
model O
for O
PDR) O
had O
higher O
TCF7L2 B-GENE-Y
and O
VEGFA B-GENE-Y
mRNA O
levels O
than O
controls O
(P O
= O
2.9E-04 O
for O
TCF7L2; B-GENE-Y
P O
= O
1.9E-07 O
for O
VEGFA). B-GENE-Y
Together, O
our O
study O
showed O
that O
TCF7L2-rs7903146 B-GENE-Y
is O
associated O

with O
PDR O
in O
Caucasian O
T2DM O
and O
suggested O
TCF7L2 B-GENE-Y
promoted O
pathological O
retinal O
neovascularization O
via O
ER O
stress-dependent O
upregulation O
of O
VEGFA. B-GENE-Y
α-Amino-α´-Halomethylketones: B-CHEMICAL
Synthetic O
Methodologies O
and O
Pharmaceutical O
Applications O
as O
Serine B-GENE-N
and I-GENE-N
Cysteine I-GENE-N
Protease I-GENE-N
Inhibitors. O
α-Amino-α´-halomethylketones B-CHEMICAL
are O
interesting O
scaffolds O
bearing O
(at O
least) O
two O
sequential O
electrophilic O
carbons B-CHEMICAL
that O
by O
interacting O
with O
the O
nucleophilic O

moieties O
of O
several O
enzymes, O
represent O
the O
ideal O
candidates O
for O
in O
vivo O
and O
in O
vitro O
inhibition O
studies. O
In O
this O
work O
a O
summary O
of O
their O
use O
as O
optimal O
inhibitors O
of O
physiologically O
relevant O
serine B-GENE-N
and I-GENE-N
cysteine I-GENE-N
proteases I-GENE-N
is O
given O
with O
a O
particular O
emphasis O
on O
recently O
established O
SAR O
studies. O
A O
brief O
survey O
of O
the O
most O
relevant O
synthetic O
processes O
for O
their O
obtainment O
and O
the O
importance O
they O
possess O
in O
synthetic O
medicinal O
chemistry O
is O
reported. O
5-Lipoxygenase B-GENE-Y
inhibitors: O
a O
review O
of O
recent O
patents O
(2010 O
- O
2012). O
Introduction: O
5-Lipoxygenase B-GENE-Y
(5-LO) B-GENE-Y
is O

a O
crucial O
enzyme O
of O
the O
arachidonic B-CHEMICAL
acid I-CHEMICAL
(AA) O
cascade O
and O
catalyzes O
the O
formation O
of O
bioactive O
leukotrienes O
(LTs) O
with O
the O
help O
of O
FLAP, B-GENE-Y
the O
5-LO-activating B-GENE-Y
protein. I-GENE-Y
LTs O
are O
inflammatory O
mediators O
playing O
a O
pathophysiological O
role O
in O
different O
diseases O
like O
asthma, O
allergic O
rhinitis O
as O
well O
as O
cardiovascular O
diseases O
and O
certain O
types O
of O
cancer. O
With O
the O
rising O
number O
of O
indications O
for O
anti-LT O
therapy, O
5-LO B-GENE-Y
inhibitor O
drug O
development O
becomes O
increasingly O
important. O
Areas O
covered: O
Here, O
both O
recent O
findings O

regarding O
the O
pathophysiological O
role O
of O
5-LO B-GENE-Y
and O
the O
patents O
claimed O
for O
5-LO B-GENE-Y
inhibitors O
are O
discussed. O
Focusing O
on O
direct O
inhibitors, O
several O
patents O
disclosing O
FLAP B-GENE-Y
antagonists O
are O
also O
subject O
of O
this O
review. O
Novel O
compounds O
include O
1,5-diarylpyrazoles, B-CHEMICAL
indolizines B-CHEMICAL
and O
indoles B-CHEMICAL
and O
several O
natural O
product O
extracts. O
Expert O
opinion: O
Evaluation O
of O
the O
patent O
activities O
revealed O
only O
quite O
moderate O
action. O
Nevertheless, O
several O
auspicious O
drug-like O
molecules O
were O
disclosed. O
It O
seems O
that O
in O
the O
near O
future, O
FLAP B-GENE-Y
inhibitors O
can O
be O
expected O
to O
enter O
the O

market O
for O
the O
treatment O
of O
asthma. O
With O
the O
resolved O
structure O
of O
5-LO, B-GENE-Y
structure-based O
drug O
design O
is O
now O
applicable. O
Together O
with O
the O
identification O
of O
downstream O
enzyme O
inhibitors O
and O
dual-targeting O
drugs O
within O
the O
AA O
cascade, O
several O
tools O
are O
at O
hand O
to O
cope O
with O
5-LOs B-GENE-Y
increasing O
pathophysiological O
roles. O
Super-stable O
ultrafine O
beta-tungsten B-CHEMICAL
nanocrystals O
with O
metastable O
phase O
and O
related O
magnetism. O
Ultrafine O
tungsten B-CHEMICAL
nanocrystals O
(average O
size O
of O
3 O
nm) O
with O
a O
metastable O
phase O
(beta-tungsten B-CHEMICAL
with O
A15 O

structure, O
β-W) B-CHEMICAL
have O
been O
prepared O
by O
laser O
ablation O
of O
tungsten B-CHEMICAL
in O
liquid O
nitrogen. B-CHEMICAL
The O
as-prepared O
metastable O
nanocrystals O
exhibited O
super-stablity, O
and O
can O
keep O
the O
same O
metastable O
structure O
over O
a O
period O
of O
6 O
months O
at O
room O
temperature. O
This O
super-stability O
is O
attributed O
to O
the O
nanosized O
confinement O
effect O
of O
ultrafine O
nanocrystals. O
The O
magnetism O
measurements O
showed O
that O
the O
β-W B-CHEMICAL
nanocrystals O
have O
weak O
ferromagnetic O
properties O
at O
2 O
K, O
which O
may O
arise O
from O
surface O
defects O
and O
unpaired O
electrons O
on O
the O
surface O
of O
the O
ultrafine O

nanocrystals. O
These O
findings O
provided O
useful O
information O
for O
the O
application O
of O
ultrafine O
β-W B-CHEMICAL
nanocrystals O
in O
microelectronics O
and O
spintronics. O
Transport O
Function O
and O
Transcriptional O
Regulation O
of O
a O
Liver-Enriched O
Human B-GENE-Y
Organic I-GENE-Y
Anion I-GENE-Y
Transporting I-GENE-Y
Polypeptide I-GENE-Y
2B1 I-GENE-Y
Transcriptional O
Start O
Site O
Variant. O
Human B-GENE-Y
Organic I-GENE-Y
Anion I-GENE-Y
Transporting I-GENE-Y
Polypeptide I-GENE-Y
2B1 I-GENE-Y
(OATP2B1) B-GENE-Y
is O
a O
membrane O
transporter O
that O
facilitates O
the O
cellular O
uptake O
of O
a O
number O
of O
endogenous O
compounds O
and O
drugs. O
OATP2B1 B-GENE-Y

is O
widely O
expressed O
in O
tissues O
including O
the O
small O
intestine, O
liver, O
kidney, O
placenta, O
heart, O
skeletal O
muscle O
and O
platelets. O
Recently, O
it O
has O
been O
shown O
that O
differential O
promoter O
usage O
in O
tissues O
results O
in O
expression O
of O
five O
OATP2B1 B-GENE-Y
transcriptional O
start O
site O
variants O
which O
utilize O
distinct O
first O
exons O
but O
share O
common O
subsequent O
exons. O
These O
variants O
are O
expected O
to O
encode O
either O
a O
full O
length O
(OATP2B1-FL) B-GENE-Y
or O
shortened O
protein O
lacking O
22 O
N-terminus B-CHEMICAL
amino B-CHEMICAL
acids I-CHEMICAL
(OATP2B-Short). B-GENE-Y
Little O
is O
known O
regarding O
the O
transport O
activity O
and O
regulation O
of O
OATP2B1 B-GENE-Y
variants O

with O
N-terminus B-CHEMICAL
truncation. O
Here, O
using O
absolute O
quantitative O
polymerase O
chain O
reaction O
we O
find O
the O
full O
length O
variant O
is O
the O
major O
form O
expressed O
in O
duodenum O
but O
the O
short O
variant O
predominates O
in O
liver. O
Using O
a O
transient O
heterologous O
cell O
expression O
system, O
we O
find O
that O
the O
transport O
activities O
of O
the O
short B-GENE-Y
OATP2B1 I-GENE-Y
variant O
towards O
substrates O
estrone B-CHEMICAL
sulfate I-CHEMICAL
and O
rosuvastatin B-CHEMICAL
are O
similar O
to O
the O
well-characterized O
full O
length O
variant. O
Transcriptional O
activity O
screening O
of O
the O
liver O
enriched O
OATP2B1 B-GENE-N
variant I-GENE-N
promoter I-GENE-N
identified O
hepatocyte B-GENE-Y
nuclear I-GENE-Y
factor I-GENE-Y
4 I-GENE-Y
alpha I-GENE-Y

(HNF4α) B-GENE-Y
as O
a O
novel O
transacting O
factor. O
With O
a O
combination O
of O
in O
silico O
screening, O
promoter O
mutation O
in O
cell-based O
reporter O
assays, O
siRNA O
knockdown O
and O
chromatin O
immunoprecipitation O
studies, O
we O
identified O
a O
functional O
HNF4α B-GENE-Y
binding O
site O
close O
to O
the O
transcription O
start O
site O
(-17 O
to O
-4 O
bp). O
We O
conclude O
that O
the O
major O
OATP2B1 B-GENE-Y
protein O
form O
in O
liver O
is O
transport O
competent O
and O
its O
hepatic O
expression O
is O
regulated O
by O
HNF4α. B-GENE-Y
TLR4 B-GENE-Y
antagonist O
reduces O
early-stage O
atherosclerosis O
in O

diabetic O
apolipoprotein B-GENE-Y
E-deficient I-GENE-Y
mice. O
Although O
it O
has O
been O
reported O
that O
deficiency O
of O
toll-like B-GENE-Y
receptor I-GENE-Y
4 I-GENE-Y
(TLR4) B-GENE-Y
is O
associated O
with O
reduced O
atherosclerosis O
in O
atherosclerosis-prone O
mice O
and O
attenuated O
pro-inflammatory O
state O
in O
diabetic O
mice, O
it O
remains O
undetermined O
whether O
treatment O
with O
a O
TLR4 B-GENE-Y
antagonist O
reduces O
atherosclerosis O
in O
nondiabetic O
or O
diabetic O
mice O
that O
have O
TLR4 B-GENE-Y
expression. O
In O
this O
study, O
we O
determined O
the O
effect O
of O
Rhodobacter O
sphaeroides O
lipopolysaccharide O

(Rs-LPS), O
an O
established O
TLR4 B-GENE-Y
antagonist, O
on O
early-stage O
atherosclerosis O
in O
nondiabetic O
and O
streptozotocin-induced B-CHEMICAL
diabetic O
apolipoprotein B-GENE-Y
E-deficient I-GENE-Y
(Apoe(-/-)) B-GENE-Y
mice. O
Analysis O
of O
atherosclerotic O
lesions O
of O
both O
en O
face O
aortas O
and O
cross O
sections O
of O
aortic O
roots O
showed O
that O
administration O
of O
Rs-LPS O
in O
14-week-old O
diabetic O
Apoe(-/-) B-GENE-Y
mice O
for O
10 O
weeks O
significantly O
reduced O
atherosclerotic O
lesions. O
Although O

atherosclerotic O
lesions O
in O
nondiabetic O
Apoe(-/-) B-GENE-Y
mice O
appeared O
to O
be O
decreased O
by O
Rs-LPS O
treatment, O
the O
difference O
was O
not O
statistically O
significant. O
Metabolic O
study O
showed O
that O
Rs-LPS O
significantly O
lowered O
serum O
levels O
of O
cholesterol B-CHEMICAL
and O
triglycerides B-CHEMICAL
in O
nondiabetic O
mice O
but O
not O
in O
diabetic O
mice. O
Furthermore, O
immunohistochemistry O
studies O
showed O
that O
Rs-LPS O
inhibited O
the O
expression O
of O
interleukin B-GENE-Y
6 I-GENE-Y
and O
matrix B-GENE-Y
metalloproteinase-9 I-GENE-Y
and O
reduced O
the O
content O
of O
monocytes O
and O
macrophages O

in O
atherosclerotic O
plaques. O
Taken O
together, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
TLR4 B-GENE-Y
antagonist O
inhibited O
vascular O
inflammation O
and O
atherogenesis O
in O
diabetic O
Apoe(-/-) B-GENE-Y
mice O
and O
lowered O
serum O
cholesterol B-CHEMICAL
and O
triglyceride B-CHEMICAL
levels O
in O
nondiabetic O
Apoe(-/-) B-GENE-Y
mice. O
The O
neuropharmacological O
basis O
for O
the O
use O
of O
memantine B-CHEMICAL
in O
the O
treatment O
of O
Alzheimer's O
disease. O
Memantine B-CHEMICAL
has O
been O
demonstrated O
to O
be O
safe O
and O
effective O
in O
the O
symptomatic O
treatment O
of O
Alzheimer's O
disease O

(AD). O
While O
the O
neurobiological O
basis O
for O
the O
therapeutic O
activity O
of O
memantine B-CHEMICAL
is O
not O
fully O
understood, O
the O
drug O
is O
not O
a O
cholinesterase B-GENE-Y
inhibitor O
and, O
therefore, O
acts O
differently O
from O
current O
AD O
therapies. O
Memantine B-CHEMICAL
can O
interact O
with O
a O
variety O
of O
ligand-gated B-GENE-N
ion I-GENE-N
channels. I-GENE-N
However, O
NMDA B-GENE-N
receptors I-GENE-N
appear O
to O
be O
a O
key O
target O
of O
memantine B-CHEMICAL
at O
therapeutic O
concentrations. O
Memantine B-CHEMICAL
is O
an O
uncompetitive O
(channel O
blocking) O
NMDA B-GENE-N
receptor I-GENE-N
antagonist. O
Like O
other O
NMDA B-GENE-N
receptor I-GENE-N
antagonists, O
memantine B-CHEMICAL
at O
high O
concentrations O
can O
inhibit O
mechanisms O
of O

synaptic O
plasticity O
that O
are O
believed O
to O
underlie O
learning O
and O
memory. O
However, O
at O
lower, O
clinically O
relevant O
concentrations O
memantine B-CHEMICAL
can O
under O
some O
circumstances O
promote O
synaptic O
plasticity O
and O
preserve O
or O
enhance O
memory O
in O
animal O
models O
of O
AD. O
In O
addition, O
memantine B-CHEMICAL
can O
protect O
against O
the O
excitotoxic O
destruction O
of O
cholinergic O
neurons. O
Blockade O
of O
NMDA B-GENE-N
receptors I-GENE-N
by O
memantine B-CHEMICAL
could O
theoretically O
confer O
disease-modifying O
activity O
in O
AD O
by O
inhibiting O
the O
"weak" O
NMDA B-GENE-N
receptor-dependent I-GENE-N
excitotoxicity O
that O
has O
been O
hypothesized O
to O
play O
a O
role O

in O
the O
progressive O
neuronal O
loss O
that O
underlies O
the O
evolving O
dementia. O
Moreover, O
recent O
in O
vitro O
studies O
suggest O
that O
memantine B-CHEMICAL
abrogates O
beta-amyloid B-GENE-Y
(Abeta) B-GENE-Y
toxicity O
and O
possibly O
inhibits O
Abeta B-GENE-Y
production. O
Considerable O
attention O
has O
focused O
on O
the O
investigation O
of O
theories O
to O
explain O
the O
better O
tolerability O
of O
memantine B-CHEMICAL
over O
other O
NMDA B-GENE-N
receptor I-GENE-N
antagonists, O
particularly O
those O
that O
act O
by O
a O
similar O
channel O
blocking O
mechanism O
such O
as O
dissociative O
anesthetic-like O
agents O
(phencyclidine, B-CHEMICAL
ketamine, B-CHEMICAL
MK-801). B-CHEMICAL
A O
variety O
of O

channel-level O
factors O
could O
be O
relevant, O
including O
fast O
channel-blocking O
kinetics O
and O
strong O
voltage-dependence O
(allowing O
rapid O
relief O
of O
block O
during O
synaptic O
activity), O
as O
well O
as O
reduced O
trapping O
(permitting O
egress O
from O
closed O
channels). O
These O
factors O
may O
allow O
memantine B-CHEMICAL
to O
block O
channel O
activity O
induced O
by O
low, O
tonic O
levels O
of O
glutamate--an B-CHEMICAL
action O
that O
might O
contribute O
to O
symptomatic O
improvement O
and O
could O
theoretically O
protect O
against O
weak O
excitotoxicity--while O
sparing O
synaptic O
responses O
required O
for O
normal O
behavioral O
functioning, O
cognition O
and O
memory. O
Expansion O
of O
the O
Homeostasis O

Model O
Assessment O
of O
β-Cell O
Function O
and O
Insulin B-GENE-Y
Resistance O
to O
Enable O
Clinical O
Trial O
Outcome O
Modeling O
Through O
the O
Interactive O
Adjustment O
of O
Physiology O
and O
Treatment O
Effects--iHOMA2. O
OBJECTIVETo O
describe O
and O
make O
available O
an O
interactive, O
24-variable O
homeostasis O
model O
assessment O
(iHOMA2) O
that O
extends O
the O
HOMA2 O
model, O
enabling O
the O
modeling O
of O
physiology O
and O
treatment O
effects, O
to O
present O
equations O
of O
the O
HOMA2 O
and O
iHOMA2 O
models, O
and O
to O
exemplify O
iHOMA2 O
in O
two O
widely O
differing O
scenarios: O

changes O
in O
insulin B-GENE-N
sensitivity O
with O
thiazolidinediones B-CHEMICAL
and O
changes O
in O
renal O
threshold O
with O
sodium B-GENE-N
glucose I-GENE-N
transporter I-GENE-N
(SGLT2) B-GENE-Y
inhibition.RESEARCH O
DESIGN O
AND O
METHODSiHOMA2 O
enables O
a O
user O
of O
the O
available O
software O
to O
examine O
and O
modify O
the O
mathematical O
functions O
describing O
the O
organs O
and O
tissues O
involved O
in O
the O
glucose B-CHEMICAL
and O
hormonal O
compartments. O
We O
exemplify O
this O
with O
SGLT2 B-GENE-Y
inhibition O
modeling O
(by O
changing O
the O
renal O
threshold O
parameters) O
using O
published O
data O
of O
renal O
effect, O
showing O
that O
the O
modeled O
effect O
is O
concordant O
with O
the O
effects O
on O

fasting O
glucose B-CHEMICAL
from O
independent O
data.RESULTSiHOMA2 O
modeling O
of O
thiazolidinediones B-CHEMICAL
effect O
suggested O
that O
changes O
in O
insulin O
sensitivity O
in O
the O
fasting O
state O
are O
predominantly O
hepatic. O
SGLT2 B-GENE-Y
inhibition O
modeled O
by O
iHOMA2 O
resulted O
in O
a O
decrease O
in O
mean O
glucose B-CHEMICAL
of O
1.1 O
mmol/L. O
Observed O
data O
showed O
a O
decrease O
in O
glucose B-CHEMICAL
of O
0.9 O
mmol/L. O
There O
was O
no O
significant O
difference O
between O
the O
model O
and O
the O
independent O
data. O
Manipulation O
of O
iHOMA2s O
renal O
excretion O
threshold O
variable O
suggested O
that O
a O
decrease O

of O
17% O
was O
required O
to O
obtain O
a O
0.9 O
mmol/L O
decrease O
in O
mean O
glucose.CONCLUSIONSiHOMA2 B-CHEMICAL
is O
an O
extended O
mathematical O
model O
for O
the O
assessment O
of O
insulin B-GENE-Y
resistance O
and O
β-cell O
function. O
The O
model O
can O
be O
used O
to O
evaluate O
therapeutic O
agents O
and O
predict O
effects O
on O
fasting O
glucose B-CHEMICAL
and O
insulin O
and O
on O
β-cell O
function O
and O
insulin B-GENE-Y
sensitivity. O
Roles O
of O
rifampicin B-CHEMICAL
in O
drug-drug O
interactions: O
underlying O
molecular O
mechanisms O
involving O
the O
nuclear B-GENE-Y
pregnane I-GENE-Y
X I-GENE-Y
receptor. I-GENE-Y
Rifampicin, B-CHEMICAL
an O
important O
drug O
in O
the O
treatment O
of O
tuberculosis, O
is O
used O
extensively O
despite O
its O
broad O
effects O
on O

drug-drug O
interactions, O
creating O
serious O
problems. O
The O
clinical O
importance O
of O
such O
interactions O
includes O
autoinduction O
leading O
to O
suboptimal O
or O
failed O
treatment. O
The O
concomitantly O
administered O
effects O
of O
rifampicin B-CHEMICAL
on O
other O
drugs O
can O
result O
in O
their O
altered O
metabolism O
or O
transportation O
that O
are O
metabolised O
by O
cytochromes B-GENE-N
P450 I-GENE-N
or O
transported O
by O
p-glycoprotein B-GENE-N
in O
the O
gastrointestinal O
tract O
and O
liver. O
This O
review O
paper O
summarises O
recent O
findings O
with O
emphases O
on O
the O
molecular O
mechanisms O
used O
to O
explain O
these O
broad O
drug-drug O
interactions. O
In O
general, O
rifampicin B-CHEMICAL
can O
act O
on O

a O
pattern: O
rifampicin B-CHEMICAL
activates O
the O
nuclear B-GENE-Y
pregnane I-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
that O
in O
turn O
affects O
cytochromes B-GENE-N
P450, I-GENE-N
glucuronosyltransferases B-GENE-N
and O
p-glycoprotein B-GENE-N
activities. O
This O
pattern O
of O
action O
may O
explain O
many O
of O
the O
rifampicin B-CHEMICAL
inducing O
drug-drug O
interactions. O
However, O
effects O
through O
other O
mechanisms O
have O
also O
been O
reported O
and O
these O
make O
any O
explanation O
of O
such O
drug-drug O
interactions O
more O
complex. O
Screening O
for O
(anti)androgenic O
properties O
using O
a O
standard O
operation O
protocol O
based O
on O
the O
human O
stably O
transfected O
androgen B-CHEMICAL
sensitive O
PALM O
cell O

line. O
First O
steps O
towards O
validation. O
Despite O
more O
than O
a O
decade O
of O
research O
in O
the O
field O
of O
endocrine O
active O
compounds O
targeting O
the O
androgen B-GENE-Y
receptor I-GENE-Y
(AR), B-GENE-Y
and O
although O
suitable O
cell O
lines O
can O
be O
obtained, O
no O
validated O
human O
stably O
transfected O
androgen B-CHEMICAL
sensitive O
transactivation O
assay O
is O
available. O
Bayer O
Schering O
Pharma O
(BSP) O
and O
the O
Flemish O
Institute O
for O
Technological O
Research O
(VITO), O
partners O
within O
the O
EU-sponsored O
6th O
framework O
project O
ReProTect, O
made O
first O
steps O
towards O
such O
a O
validation. O
A O
standard O
operation O
protocol O
(SOP) O
developed O
at O
BSP O
based O
on O
the O
androgen B-CHEMICAL

sensitive O
PALM O
cell O
line O
was O
transferred O
to O
VITO O
and O
its O
performance O
and O
transferability O
were O
thoroughly O
studied. O
The O
investigation O
followed O
a O
generic O
protocol O
prepared O
for O
all O
reporter O
gene O
assays O
evaluated O
within O
ReProTect, O
and O
in O
both O
laboratories O
at O
least O
three O
independent O
experiments O
were O
performed. O
The O
highest O
concentration O
to O
be O
tested O
was O
limited O
to O
10 O
microM, O
if O
needed. O
A O
few O
compounds, O
17alpha-methyltestosterone B-CHEMICAL
(17alpha-MT), B-CHEMICAL
vinclozolin B-CHEMICAL
and O
linuron, B-CHEMICAL
were O
studied O
using O
a O
real O
world O
scenario, O
i.e., O
assuming O
that O
their O
interaction O
with O
the O
AR B-GENE-Y
was O
not O
known: O

A O
prescreening O
for O
agonism O
and O
true, O
competitive O
antagonism O
was O
used O
to O
select O
conditions O
such O
as O
the O
appropriate O
mode O
of O
action, O
and O
the O
working O
range O
excluding O
cytotoxicity O
for O
the O
final O
screening. O
All O
other O
compounds O
were O
tested O
according O
to O
the O
generic O
protocol: O
Compounds O
screened O
for O
agonism O
were O
the O
reference O
androgen B-CHEMICAL
17alpha-methyldihydrotestosterone B-CHEMICAL
(MDHT), B-CHEMICAL
levonorgestrel, B-CHEMICAL
norethynodrel, B-CHEMICAL
progesterone, B-CHEMICAL
o,p'-DDT, B-CHEMICAL
and O
dibutylphthalate B-CHEMICAL
(DBP), B-CHEMICAL
while O
compounds O
screened O

for O
antagonism O
were O
the O
reference O
anti-androgen B-CHEMICAL
flutamide, B-CHEMICAL
prochloraz, B-CHEMICAL
o,p'-DDT, B-CHEMICAL
progesterone, B-CHEMICAL
norethynodrel, B-CHEMICAL
and O
DBP. B-CHEMICAL
Cytotoxicity O
was O
assessed O
in O
parallel O
as O
lactate B-GENE-N
dehydrogenase I-GENE-N
release. O
The O
prescreen O
classified O
17alpha-MT B-CHEMICAL
as O
androgenic, O
vinclozolin B-CHEMICAL
and O
linuron O
as O
anti-androgenic O
and O
compounds O
were O
tested O
accordingly. O
In O
the O
absence O
of O
cytotoxicity, O
appropriate O
androgenic O
properties O
of O
reference O
and O
test O
compounds O
were O
detected O
by O
both O
laboratories, O

o,p'-DDT B-CHEMICAL
and O
DBP B-CHEMICAL
had O
no O
androgenic O
activity. O
Across O
the O
two O
laboratories O
EC(50)-values O
for O
MDHT, B-CHEMICAL
17alpha-MT, B-CHEMICAL
and O
levonorgestrel B-CHEMICAL
varied O
by O
not O
more O
than O
a O
factor O
of O
3.4, O
for O
norethynodrel B-CHEMICAL
by O
a O
factor O
of O
9.7. O
Progesterone B-CHEMICAL
effects O
could O
not O
fully O
be O
evaluated, O
as O
frequently O
concentration O
response O
curves O
were O
incomplete. O
In O
the O
absence O
of O
cytotoxicity O
anti-androgenic O
properties O
of O
reference O
and O
test O
compounds O
were O
also O
detected O
in O
both O
laboratories. O
DBP, B-CHEMICAL
the O
putative O
negative O
reference O

compound, O
was O
inactive, O
norethynodrel B-CHEMICAL
rather O
showed O
agonistic O
properties. O
Progesterone B-CHEMICAL
was O
an O
antagonist O
at O
low O
concentrations, O
but O
agonistic O
properties O
were O
observed O
in O
one O
laboratory O
at O
high O
concentrations. O
Since O
the O
highest O
test O
concentration O
was O
limited O
to O
10 O
microM, O
for O
some O
compounds O
no O
complete O
concentration O
response O
curves O
were O
obtained O
and O
estimation O
of O
EC(50)-values O
was O
less O
robust. O
Our O
data O
demonstrated O
that O
the O
SOP O
was O
transferable, O
and O
that O
the O
assay O
was O
able O
to O
rank O
compounds O
with O
strong, O
weak, O
and O
without O
affinity O
for O
the O
AR B-GENE-Y
and O
to O
discriminate O
agonists O
and O
antagonists. O
The O
sensitivity O
of O
the O

assay O
could O
be O
improved O
further, O
if O
the O
limit O
of O
solubility O
or O
beginning O
cytotoxicity O
was O
chosen O
as O
the O
highest O
test O
concentration. O
The O
assay O
avoids O
the O
use O
of O
tissues O
from O
laboratory O
animals, O
and O
thus O
contributes O
to O
the O
3R O
concept. O
Furthermore, O
it O
could O
be O
adjusted O
to O
an O
intermediate/high O
throughput O
format. O
On O
the O
whole, O
this O
PALM O
assay O
is O
a O
promising O
candidate O
for O
further O
validation. O
Evidence O
for O
a O
new O
binding O
mode O
to O
GSK-3: B-GENE-N
allosteric O
regulation O
by O
the O
marine O
compound O
palinurin. B-CHEMICAL
Glycogen B-GENE-Y
synthase I-GENE-Y
kinase I-GENE-Y
3β I-GENE-Y

(GSK-3β) B-GENE-Y
is O
widely O
recognised O
as O
a O
relevant O
player O
in O
the O
pathogenesis O
of O
several O
highly O
prevalent O
disorders O
such O
as O
Alzheimer's O
disease, O
mood O
disorders, O
diabetes O
and O
cancer. O
Therefore, O
this O
enzyme O
constitutes O
a O
highly O
attractive O
therapeutic O
target O
for O
the O
development O
of O
selective O
inhibitors O
as O
new O
promising O
drugs O
for O
the O
treatment O
of O
these O
pathologies. O
We O
describe O
here O
the O
isolation O
and O
biochemical O
characterization O
of O
the O
marine O
natural O
sesquiterpene B-CHEMICAL
palinurin B-CHEMICAL
as O
a O
GSK-3β B-GENE-Y
inhibitor. O
Experimental O
studies O
performed O
for O
characterizing O
the O
inhibitory O
mechanism O
indicate O
that O
GSK-3β B-GENE-Y
inhibition O
by O
palinurin B-CHEMICAL

cannot O
be O
competed O
out O
by O
ATP B-CHEMICAL
nor O
peptide O
substrate. O
Molecular O
modelling O
techniques O
have O
enabled O
us O
to O
propose O
an O
unconventional O
binding O
mode O
to O
GSK-3β. B-GENE-Y
Moreover, O
molecular O
dynamics O
simulations O
have O
identified O
an O
allosteric O
mechanism O
by O
which O
binding O
of O
palinurin B-CHEMICAL
leads O
to O
GSK-3β B-GENE-Y
inhibition. O
The O
inhibitory O
activities O
determined O
for O
a O
series O
of O
structurally O
related O
analogues O
support O
the O
proposed O
binding O
mode O
of O
palinurin, B-CHEMICAL
which O
is O
the O
first O
compound O
described O
to O
target O
this O
allosteric O
site. O
The O
results O
offer O
new O
opportunities O
for O
designing O
and O
developing O
selective O
inhibitors O
with O
novel O
mechanisms O
of O
action. O
Pharmacological O
Inhibition O
of O

Platelet-tumor O
Cell O
Cross-talk O
Prevents O
Platelet-induced O
Overexpression O
of O
Cyclooxygenase-2 B-GENE-Y
in O
HT29 O
Human O
Colon O
Carcinoma O
Cells. O
Cyclooxygenase(COX)-2-derived B-GENE-Y
prostanoids B-CHEMICAL
can O
influence O
several O
processes O
that O
are O
linked O
to O
carcinogenesis. O
We O
aimed O
to O
address O
the O
hypothesis O
that O
platelets O
contribute O
to O
aberrant O
COX-2 B-GENE-Y
expression O
in O
HT29 O
colon O
carcinoma O
cells O
and O
to O
reveal O
the O
role O
of O
platelet-induced O
COX-2 B-GENE-Y
on O
the O
expression O
of O
proteins O
involved O
in O

malignancy O
and O
marker O
genes O
of O
epithelial-mesenchymal O
transition(EMT). O
Human O
platelets O
co-cultured O
with O
HT29 O
cells O
rapidly O
adhered O
to O
cancer O
cells O
and O
induced O
COX-2 B-GENE-Y
mRNA O
expression, O
but O
not O
protein O
synthesis O
which O
required O
the O
late O
release O
of O
platelet O
PDGF B-GENE-N
and O
COX-2 B-GENE-Y
mRNA O
stabilization. O
Platelet-induced O
COX-2-dependent B-GENE-Y
PGE2 B-CHEMICAL
synthesis O
in O
HT29 O
cells O
was O
involved O
in O
downregulation O
of O
p21(WAF1/CIP1) B-GENE-Y
and O
upregulation O
of O

cyclinB1, B-GENE-Y
since O
these O
effects O
were O
prevented O
by O
rofecoxib(a B-CHEMICAL
selective O
COX-2 B-GENE-Y
inhibitor) O
and O
rescued O
by O
exogenous O
PGE2. B-CHEMICAL
Galectin-3, B-GENE-Y
highly O
expressed O
in O
HT29 O
cells, O
is O
unique O
among O
galectins O
because O
it O
contains O
a O
collagen-like B-GENE-N
domain. I-GENE-N
Thus, O
we O
studied O
the O
role O
of O
galectin-3 B-GENE-Y
and O
platelet B-GENE-Y
collagen I-GENE-Y
receptors I-GENE-Y
in O
platelet-induced O
COX-2 B-GENE-Y
overexpression. O
Inhibitors O
of O
galectin-3 B-GENE-Y
function(β-lactose, B-CHEMICAL
a O
dominant-negative O
form O
of O

galectin-3,Gal-3C, B-GENE-Y
and O
anti-galectin-3 B-GENE-Y
antibody O
M3/38) O
or O
collagen B-GENE-Y
receptor-mediated I-GENE-Y
platelet O
adhesion(revacept, O
a O
dimeric O
collagen B-GENE-Y
receptor I-GENE-Y
GPVI-Fc) B-GENE-Y
prevented O
aberrant O
COX-2 B-GENE-Y
expression. O
Inhibition O
of O
platelet-cancer O
cell O
interaction O
by O
revacept O
was O
more O
effective O
than O
rofecoxib B-CHEMICAL
in O
preventing O
platelet-induced O
mRNA O
changes O
of O
EMT O
markers O
suggesting O
that O
direct O
cell-cell O
contact O
and O
aberrant O
COX-2 B-GENE-Y
expression O
synergistically O
induced O
gene O

expression O
modifications O
associated O
with O
EMT. O
In O
conclusion, O
our O
findings O
provide O
the O
rationale O
for O
testing O
blockers O
of O
collagen B-GENE-N
binding I-GENE-N
sites, I-GENE-N
such O
as O
revacept, O
and O
galectin-3 B-GENE-Y
inhibitors O
in O
the O
prevention O
of O
colon O
cancer O
metastasis O
in O
animal O
models O
followed O
by O
studies O
in O
patients. O
Targeting O
protein-protein O
interactions O
within O
the O
cyclic B-CHEMICAL
AMP I-CHEMICAL
signaling O
system O
as O
a O
therapeutic O
strategy O
for O
cardiovascular O
disease. O
The O
cAMP B-CHEMICAL
signaling O
system O
can O
trigger O
precise O
physiological O
cellular O
responses O
that O
depend O
on O
the O
fidelity O
of O
many O
protein-protein O
interactions, O
which O
act O
to O
bring O
together O
signaling O
intermediates O
at O
defined O
locations O
within O
cells. O
In O
the O

heart, O
cAMP B-CHEMICAL
participates O
in O
the O
fine O
control O
of O
excitation-contraction O
coupling, O
hence, O
any O
disregulation O
of O
this O
signaling O
cascade O
can O
lead O
to O
cardiac O
disease. O
Due O
to O
the O
ubiquitous O
nature O
of O
the O
cAMP B-CHEMICAL
pathway, O
general O
inhibitors O
of O
cAMP B-CHEMICAL
signaling O
proteins O
such O
as O
PKA, B-GENE-N
EPAC B-GENE-Y
and O
PDEs B-GENE-N
would O
act O
non-specifically O
and O
universally, O
increasing O
the O
likelihood O
of O
serious O
'off O
target' O
effects. O
Recent O
advances O
in O
the O
discovery O
of O
peptides O
and O
small O
molecules O
that O
disrupt O
the O
protein-protein O
interactions O
that O
underpin O
cellular O
targeting O
of O
cAMP B-CHEMICAL
signaling O
proteins O
are O
described O
and O
discussed. O

Anxiolytic- O
but O
not O
antidepressant-like O
activity O
of O
Lu B-CHEMICAL
AF21934, I-CHEMICAL
a O
novel, O
selective O
positive O
allosteric O
modulator O
of O
the O
mGlu₄ B-GENE-Y
receptor. O
Previous O
studies O
demonstrated O
that O
the O
Group B-GENE-N
III I-GENE-N
mGlu I-GENE-N
receptor-selective I-GENE-N
orthosteric O
agonist, O
LSP1-2111 B-CHEMICAL
produced O
anxiolytic- O
but O
not O
antidepressant-like O
effects O
upon O
peripheral O
administration. O
Herein, O
we O
report O
the O
pharmacological O
actions O
of O
Lu B-CHEMICAL
AF21934, I-CHEMICAL
a O
novel, O
selective, O
and O
brain-penetrant O
positive O
allosteric O
modulator O

(PAM) O
of O
the O
mGlu(4) B-GENE-Y
receptor O
in O
the O
stress-induced O
hyperthermia O
(SIH), O
four-plate, O
marble-burying O
and O
Vogel's O
conflict O
tests. O
In O
all O
models, O
except O
Vogel's O
conflict O
test, O
a O
dose-dependent O
anxiolytic-like O
effect O
was O
seen. O
The O
anti-hyperthermic O
effect O
of O
Lu B-CHEMICAL
AF21934 I-CHEMICAL
(5 O
mg/kg) O
in O
the O
SIH O
test O
was O
inhibited O
by O
the O
benzodiazepine B-GENE-Y
receptor I-GENE-Y
antagonist O
flumazenil B-CHEMICAL
(10 O
mg/kg) O
and O
was O
not O

serotonin-dependent, B-CHEMICAL
as O
it O
persisted O
in O
serotonin-deficient B-CHEMICAL
mice O
and O
upon O
blockade O
of O
either O
5-HT(1A) B-GENE-Y
receptors O
by O
WAY100635, B-CHEMICAL
or O
5-HT(2A/2C) B-GENE-N
receptors O
by O
ritanserin. B-CHEMICAL
These O
results O
suggest O
that O
the O
GABAergic O
system, O
but O
not O
the O
serotonergic O
system, O
is O
involved O
in O
the O
mechanism O
of O
the O
anxiolytic-like O
phenotype O
of O
Lu B-CHEMICAL
AF21934 I-CHEMICAL
in O
rodents. O
Lu B-CHEMICAL
AF21934 I-CHEMICAL
did O
not O
produce O
antidepressant-like O
effects O
in O
the O
tail O
suspension O
test O

(TST) O
in O
mice; O
however, O
it O
decreased O
the O
basal O
locomotor O
activity O
of O
mice O
that O
were O
not O
habituated O
to O
activity O
cages. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic B-GENE-N
Glutamate I-GENE-N
Receptors'. I-GENE-N
Lead-induced O
ER O
calcium B-CHEMICAL
release O
and O
inhibitory O
effects O
of O
methionine B-CHEMICAL
choline I-CHEMICAL
in O
cultured O
rat O
hippocampal O
neurons. O
Lead, O
a O
ubiquitous O
neurotoxicant, O
can O
result O
in O
learning O
and O
memory O
dysfunction. O
Long O
term O
potentiation O
in O
the O
hippocampus, O
a O
potential O
neural O
substrate O
for O
learning O
and O
memory, O
is O

thought O
to O
be O
linked O
to O
calcium-triggered B-CHEMICAL
intracellular O
events. O
In O
this O
study, O
laser O
scanning O
confocal O
microscopy O
was O
used O
to O
examine O
the O
effects O
of O
Pb(2+) B-CHEMICAL
on O
intracellular O
and O
endoplasmic O
reticulum O
free O
calcium B-CHEMICAL
concentration O
([Ca(2+)](i) B-CHEMICAL
and O
[Ca(2+)](ER)) B-CHEMICAL
in O
cultured O
neonatal O
rat O
hippocampal O
neurons O
and O
their O
possible O
antagonism O
by O
methionine B-CHEMICAL
choline; I-CHEMICAL
understanding O
these O
effects O
would O
help O
explain O
the O
lead-induced O
cognitive O
and O
learning O
dysfunction O
and O
explore O
efficient O
safety O
and O

relief O
strategies. O
The O
results O
showed O
that O
Pb(2+) B-CHEMICAL
increased O
[Ca(2+)](i) B-CHEMICAL
and O
decreased O
[Ca(2+)](ER) B-CHEMICAL
linearly O
in O
a O
time- O
and O
concentration-dependant O
manner, O
and O
Pb(2+) B-CHEMICAL
addition O
after O
the O
applying O
of O
a O
ryanodine B-GENE-N
receptor I-GENE-N
(RyR) B-GENE-N
antagonist O
and O
an O
inositol-1,4,5-triphosphate B-GENE-N
receptor I-GENE-N
(IP(3)R) B-GENE-N
antagonist O
did O
not O
increase O
[Ca(2+)](i). B-CHEMICAL
The O
addition O
of O
10, O
20, O
or O
40 O

mmol/L O
methionine B-CHEMICAL
choline I-CHEMICAL
simultaneously O
with O
addition O
of O
10 O
μmol/L O
Pb(2+) B-CHEMICAL
decreased O
[Ca(2+)](i) B-CHEMICAL
in O
Ca(2+)-free B-CHEMICAL
culture O
medium O
by O
39.0%, O
66.0%, O
and O
61.6%, O
respectively, O
in O
a O
concentration-dependant O
manner O
in O
a O
certain O
dose O
range. O
Our O
results O
suggest O
that O
Pb(2+) B-CHEMICAL
induces O
ER O
calcium B-CHEMICAL
release O
to O
increase O
the O
resting O
[Ca(2+)](i); B-CHEMICAL
and O
methionine B-CHEMICAL
choline I-CHEMICAL
inhibit O
this O
increase O
in O

[Ca(2+)](i). B-CHEMICAL
Critical O
amino B-CHEMICAL
acids I-CHEMICAL
in O
phosphodiesterase-5 B-GENE-Y
catalytic O
site O
that O
provide O
for O
high-affinity O
interaction O
with O
cyclic B-CHEMICAL
guanosine I-CHEMICAL
monophosphate I-CHEMICAL
and O
inhibitors. O
The O
molecular O
bases O
for O
phosphodiesterase B-GENE-Y
5 I-GENE-Y
(PDE5) B-GENE-Y
catalytic-site O
affinity O
for O
cyclic B-CHEMICAL
guanosine I-CHEMICAL
monophosphate I-CHEMICAL
(cGMP) B-CHEMICAL
and O
potency O
of O
inhibitors O
are O
poorly O
understood. O
Cocrystal O
structures O
of O
PDE5 B-GENE-N
catalytic I-GENE-N
(C) I-GENE-N
domain I-GENE-N
with O
inhibitors O
reveal O
a O
hydrogen B-CHEMICAL
bond O
and O
hydrophobic O
interactions O
with O

Tyr-612, B-CHEMICAL
hydrogen B-CHEMICAL
bonds O
with O
Gln-817, B-CHEMICAL
a O
hydrophobic O
clamp O
formed O
by O
Phe-820 B-CHEMICAL
and O
Val-782, B-CHEMICAL
and O
contacts O
with O
His-613, B-CHEMICAL
Leu-765, B-CHEMICAL
and O
Phe-786 B-CHEMICAL
[Sung O
et O
al. O
(2003) O
Nature O
425, O
98-102; O
Huai O
et O
al. O
(2004) O
J. O
Biol. O
Chem. O
279, O
13095-13101]. O
Present O
results O
of O
point O
mutations O
of O
full-length O
PDE5 B-GENE-Y
showed O
that O
maximum O
catalysis O
was O
decreased O
2650-fold O
in O
H613A B-GENE-N
and O

55-fold O
in O
F820A. B-GENE-N
Catalytic-site O
affinities O
for O
cGMP, B-CHEMICAL
vardenafil, B-CHEMICAL
sildenafil, B-CHEMICAL
tadalafil, B-CHEMICAL
or O
3-isobutyl-1-methylxanthine B-CHEMICAL
(IBMX) B-CHEMICAL
were O
respectively O
weakened O
14-, O
123-, O
30-, O
51-, O
and O
43-fold O
for O
Y612A; B-GENE-N
63-, O
511-, O
43-, O
95- O
and O
61-fold O
for O
Q817A; B-GENE-N
and O
59-, O
448-, O
71-, O
137-, O
and O
93-fold O
for O

F820A. B-GENE-N
The O
data O
indicate O
that O
these O
three O
amino B-CHEMICAL
acids I-CHEMICAL
are O
major O
determinants O
of O
affinity O
for O
cGMP B-CHEMICAL
and O
potency O
of O
selective O
and O
nonselective O
inhibitors, O
and O
that O
higher O
vardenafil B-CHEMICAL
potency O
over O
sildenafil B-CHEMICAL
and O
tadalafil B-CHEMICAL
results O
from O
stronger O
contacts O
with O
Tyr-612, B-CHEMICAL
Gln-817, B-CHEMICAL
and O
Phe-820. B-CHEMICAL
Affinity O
of O
V782A B-GENE-N
for O
cGMP, B-CHEMICAL
vardenafil, B-CHEMICAL
sildenafil, B-CHEMICAL
tadalafil, B-CHEMICAL
or O
IBMX B-CHEMICAL
was O
reduced O
5.5-, O
23-, O

10-, O
3-, O
and O
12-fold, O
respectively. O
Change O
in O
affinity O
for O
cGMP, B-CHEMICAL
vardenafil, B-CHEMICAL
sildenafil, B-CHEMICAL
or O
IBMX B-CHEMICAL
in O
Y612F, B-GENE-N
H613A, B-GENE-N
L765A, B-GENE-N
or O
F786A B-GENE-N
was O
less, O
but O
affinity O
of O
H613A B-GENE-N
or O
F786A B-GENE-N
for O
tadalafil B-CHEMICAL
was O
weakened O
37- O
and O
17-fold, O
respectively. O
The O
results O
quantify O
the O
role O
of O
PDE5 B-GENE-Y
catalytic-site O
residues O
for O
cGMP B-CHEMICAL
and O
inhibitors, O
indicate O
that O
Tyr-612, B-CHEMICAL
Gln-817, B-CHEMICAL
and O

Phe-820 B-CHEMICAL
are O
the O
most O
important O
cGMP B-CHEMICAL
or O
inhibitor O
contacts O
studied, O
and O
identify O
residues O
that O
contribute O
to O
selectivity O
among O
different O
classes O
of O
inhibitors. O
Alteration O
of O
α-tocopherol-associated B-GENE-Y
protein I-GENE-Y
(TAP) B-GENE-Y
expression O
in O
human O
breast O
epithelial O
cells O
during O
breast O
cancer O
development. O
Breast O
cancer O
is O
the O
most O
common O
malignancy O
among O
women O
and O
has O
an O
age-specific O
incidence O
profile. O
Over O
the O
last O
decade, O
many O
studies O
have O
demonstrated O
the O
anticancer O
activity O
of O
α-tocopherol, B-CHEMICAL
the O
main O
and O
most O
active O
form O
of O
natural O
vitamin B-CHEMICAL
E. I-CHEMICAL
α-Tocopherol-associated B-GENE-Y

protein I-GENE-Y
(TAP) B-GENE-Y
was O
found O
to O
be O
one O
of O
the O
major O
α-tocopherol B-GENE-N
binding I-GENE-N
proteins I-GENE-N
in O
human O
serum O
and O
in O
liver, O
brain, O
and O
prostate O
tissues. O
In O
this O
study, O
we O
found O
that O
reduced O
TAP B-GENE-Y
expression O
was O
significantly O
correlated O
with O
Her2/neu B-GENE-Y
receptor O
expression, O
breast O
cancer O
stage O
and O
nodal O
stage O
in O
paired O
normal O
and O
cancerous O
breast O
tissue O
samples O
from O
93 O
patients O
using O
real-time O
PCR O
analysis. O
A O
cell O
viability O
assay O
showed O
that O
α-tocopheryl B-CHEMICAL
succinate I-CHEMICAL
(α-TOS), B-CHEMICAL
a O
synthetic O
derivative O
of O
α-tocopherol, B-CHEMICAL
enhanced O
the O
cells' O
sensitivity O
to O

doxorubicin B-CHEMICAL
and O
resulted O
in O
a O
reduction O
in O
cell O
viability O
in O
breast O
cancers. O
Taken O
together, O
these O
data O
suggest O
that O
the O
use O
of O
vitamin B-CHEMICAL
E I-CHEMICAL
or O
its O
analogue O
as O
a O
dietary O
supplement O
may O
be O
beneficial O
for O
the O
treatment O
of O
cancer. O
International O
Union O
of O
Pharmacology. O
LXXXVII. O
Complement B-GENE-N
peptide I-GENE-N
C5a, I-GENE-N
C4a, I-GENE-N
and I-GENE-N
C3a I-GENE-N
receptors. I-GENE-N
The O
activation O
of O
the O
complement B-GENE-N
cascade, O
a O
cornerstone O
of O
the O
innate O
immune O
response, O
produces O
a O
number O
of O
small O
(74-77 O
amino B-CHEMICAL
acid) I-CHEMICAL
fragments, O
originally O
termed O
anaphylatoxins, B-GENE-N
that O
are O

potent O
chemoattractants O
and O
secretagogues O
that O
act O
on O
a O
wide O
variety O
of O
cell O
types. O
These O
fragments, O
C5a, B-GENE-Y
C4a, B-GENE-Y
and O
C3a, B-GENE-Y
participate O
at O
all O
levels O
of O
the O
immune O
response O
and O
are O
also O
involved O
in O
other O
processes O
such O
as O
neural O
development O
and O
organ O
regeneration. O
Their O
primary O
function, O
however, O
is O
in O
inflammation, O
so O
they O
are O
important O
targets O
for O
the O
development O
of O
antiinflammatory O
therapies. O
Only O
three O
receptors O
for O
complement O
peptides O
have O
been O
found, O
but O
there O
are O
no O
satisfactory O
antagonists O
as O
yet, O
despite O
intensive O
investigation. O
In O
humans, O
there O
is O
a O
single O
receptor O
for O
C3a B-GENE-Y

(C3a B-GENE-Y
receptor), I-GENE-Y
no O
known O
receptor O
for O
C4a, B-GENE-Y
and O
two O
receptors O
for O
C5a B-GENE-Y
(C5a₁ B-GENE-Y
receptor I-GENE-Y
and O
C5a₂ B-GENE-Y
receptor). I-GENE-Y
The O
most O
recently O
characterized O
receptor, O
the O
C5a₂ B-GENE-Y
receptor O
(previously O
known O
as O
C5L2 B-GENE-Y
or O
GPR77), B-GENE-Y
has O
been O
regarded O
as O
a O
passive O
binding O
protein, O
but O
signaling O
activities O
are O
now O
ascribed O
to O
it, O
so O
we O
propose O
that O
it O
be O
formally O
identified O
as O
a O
receptor O
and O
be O
given O
a O
name O
to O
reflect O
this. O
Here, O
we O
describe O
the O
complex O
biology O
of O
the O
complement O
peptides, O
introduce O
a O
new O
suggested O
nomenclature, O
and O
review O
our O

current O
knowledge O
of O
receptor O
pharmacology. O
Short-term O
heating O
reduces O
the O
anti-inflammatory O
effects O
of O
fresh O
raw O
garlic O
extracts O
on O
the O
LPS-induced O
production O
of O
NO B-CHEMICAL
and O
pro-inflammatory O
cytokines B-GENE-N
by O
downregulating O
allicin B-CHEMICAL
activity O
in O
RAW O
264.7 O
macrophages. O
Garlic O
has O
a O
variety O
of O
biologic O
activities, O
including O
anti-inflammatory O
properties. O
Although O
garlic O
has O
several O
biologic O
activities, O
some O
people O
dislike O
eating O
fresh O
raw O
garlic O
because O
of O
its O
strong O
taste O
and O
smell. O
Therefore, O
garlic O
formulations O
involving O
heating O
procedures O
have O
been O
developed. O
In O
this O
study, O
we O
investigated O
whether O
short-term O

heating O
affects O
the O
anti-inflammatory O
properties O
of O
garlic. O
Fresh O
and O
heated O
raw O
garlic O
extracts O
(FRGE O
and O
HRGE) O
were O
prepared O
with O
incubation O
at O
25°C O
and O
95°C, O
respectively, O
for O
2h. O
Treatment O
with O
FRGE O
and O
HRGE O
significantly O
reduced O
the O
LPS-induced O
increase O
in O
the O
pro-inflammatory O
cytokine B-GENE-N
concentration O
(TNF-α, B-GENE-Y
IL-1β, B-GENE-Y
and O
IL-6) B-GENE-Y
and O
NO B-CHEMICAL
through O
HO-1 B-GENE-Y
upregulation O
in O
RAW O
264.7 O
macrophages. O
The O
anti-inflammatory O
effect O
was O
greater O
in O
FRGE O
than O
in O

HRGE. O
The O
allicin B-CHEMICAL
concentration O
was O
higher O
in O
FRGE O
than O
in O
HRGE. O
Allicin B-CHEMICAL
treatment O
showed O
reduced O
production O
of O
pro-inflammatory O
cytokines B-GENE-N
and O
NO B-CHEMICAL
and O
increased O
HO-1 B-GENE-Y
activity. O
The O
results O
show O
that O
the O
decrease O
in O
LPS-induced O
NO B-CHEMICAL
and O
pro-inflammatory O
cytokines B-GENE-N
in O
RAW O
264.7 O
macrophages O
through O
HO-1 B-GENE-Y
induction O
was O
greater O
for O
FRGE O
compared O
with O
HRGE. O
Additionally, O
the O
results O
indicate O
that O
allicin B-CHEMICAL
is O
responsible O
for O
the O
anti-inflammatory O
effect O
of O
FRGE. O
Our O
results O
suggest O
a O
potential O
therapeutic O
use O
of O

allicin B-CHEMICAL
in O
the O
treatment O
of O
chronic O
inflammatory O
disease. O
MORAb-003, O
a O
fully O
humanized O
monoclonal O
antibody O
against O
the O
folate B-GENE-Y
receptor I-GENE-Y
alpha, I-GENE-Y
for O
the O
potential O
treatment O
of O
epithelial O
ovarian O
cancer. O
Morphotek O
Inc O
is O
developing O
MORAb-003, O
a O
humanized O
monoclonal O
antibody O
directed O
against O
folate B-GENE-Y
receptor I-GENE-Y
alpha, I-GENE-Y
for O
the O
potential O
treatment O
of O
ovarian O
cancer. O
Phase O
II O
clinical O
trialsof O
MORAb-003, O
either O
alone O
or O
in O
combination O
with O
platinum/taxane B-CHEMICAL
chemotherapy, O
are O
underway O
in O
ovarian O
cancer O
patients O

experiencing O
their O
first O
disease O
recurrence. O
Artificial O
sweeteners O
and O
salts O
producing O
a O
metallic O
taste O
sensation O
activate O
TRPV1 B-GENE-Y
receptors. O
Throughout O
the O
world O
many O
people O
use O
artificial O
sweeteners O
(AS) O
for O
the O
purpose O
of O
reducing O
caloric O
intake. O
The O
most O
prominently O
used O
of O
these O
molecules O
include O
saccharin, B-CHEMICAL
aspartame B-CHEMICAL
(Nutrasweet), B-CHEMICAL
acesulfame-K, B-CHEMICAL
and O
cyclamate. B-CHEMICAL
Despite O
the O
caloric O
advantage O
they O
provide, O
one O
key O
concern O
in O
their O
use O
is O
their O
aversive O
aftertaste O
that O
has O
been O
characterized O
on O
a O
sensory O
level O
as O
bitter O
and/or O

metallic. O
Recently, O
it O
has O
been O
shown O
that O
the O
activation O
of O
particular O
T2R B-GENE-N
bitter O
taste O
receptors O
is O
partially O
involved O
with O
the O
bitter O
aftertaste O
sensation O
of O
saccharin B-CHEMICAL
and O
acesulfame-K. B-CHEMICAL
To O
more O
fully O
understand O
the O
biology O
behind O
these O
phenomena O
we O
have O
addressed O
the O
question O
of O
whether O
AS O
could O
stimulate O
transient B-GENE-Y
receptor I-GENE-Y
potential I-GENE-Y
vanilloid-1 I-GENE-Y
(TRPV1) I-GENE-Y
receptors, I-GENE-Y
as O
these O
receptors O
are O
activated O
by O
a O
large O
range O
of O
structurally O
different O
chemicals. O
Moreover, O
TRPV1 B-GENE-Y
receptors O
and/or O
their O
variants O
are O
found O
in O
taste O
receptor O
cells O
and O
in O
nerve O
terminals O
throughout O
the O
oral O
cavity. O
Hence, O
TRPV1 B-GENE-Y

activation O
could O
be O
involved O
in O
the O
AS O
aftertaste O
or O
even O
contribute O
to O
the O
poorly O
understood O
metallic O
taste O
sensation. O
Using O
Ca(2+) B-CHEMICAL
imaging O
on O
TRPV1 B-GENE-Y
receptors O
heterologously O
expressed O
in O
the O
human O
embryonic O
kidney O
(HEK) O
293 O
cells O
and O
on O
dissociated O
primary O
sensory O
neurons, O
we O
find O
that O
in O
both O
systems, O
AS O
activate O
TRPV1 B-GENE-Y
receptors, O
and, O
moreover, O
they O
sensitize O
these O
channels O
to O
acid O
and O
heat. O
We O
also O
found O
that O
TRPV1 B-GENE-Y
receptors O
are O
activated O
by O
CuSO(4), B-CHEMICAL
ZnSO(4), B-CHEMICAL
and O

FeSO(4), B-CHEMICAL
three O
salts O
known O
to O
produce O
a O
metallic O
taste O
sensation. O
In O
summary, O
our O
results O
identify O
a O
novel O
group O
of O
compounds O
that O
activate O
TRPV1 B-GENE-Y
and, O
consequently, O
provide O
a O
molecular O
mechanism O
that O
may O
account O
for O
off O
tastes O
of O
sweeteners O
and O
metallic O
tasting O
salts. O
Molecular O
mechanisms O
of O
fibrosis-associated O
promotion O
of O
liver O
carcinogenesis. O
Hepatocellular O
carcinoma O
(HCC) O
mostly O
develops O
in O
patients O
with O
advanced O
fibrosis; O
however, O
the O
mechanisms O
of O
interaction O
between O
a O
genotoxic O
insult O
and O
fibrogenesis O
are O
not O
well O
understood. O
This O
study O
tested O
a O
hypothesis O
that O
fibrosis O
promotes O

HCC O
via O
a O
mechanism O
that O
involves O
activation O
of O
liver O
stem O
cells. O
First, O
B6C3F1 O
mice O
were O
administered O
diethylnitrosamine B-CHEMICAL
(DEN; B-CHEMICAL
single O
ip O
injection O
of O
1mg/kg O
at O
14 O
days O
of O
age). O
Second, O
carbon B-CHEMICAL
tetrachloride I-CHEMICAL
(CCl(4); B-CHEMICAL
0.2ml/kg, O
2/week O
ip O
starting O
at O
8 O
weeks O
of O
age) O
was O
administered O
for O
9 O
or O
14 O
weeks O
to O
develop O
advanced O
liver O
fibrosis. O
In O
animals O
treated O
with O
DEN B-CHEMICAL
as O
neonates, O
presence O
of O
liver O
fibrosis O
led O
to O
more O
than O
doubling O
(to O

100%) O
of O
the O
liver O
tumor O
incidence O
as O
early O
as O
5 O
months O
of O
age. O
This O
effect O
was O
associated O
with O
activation O
of O
cells O
with O
progenitor O
features O
in O
noncancerous O
liver O
tissue, O
including O
markers O
of O
replicative O
senescence O
(p16), B-GENE-Y
oncofetal O
transformation O
(Afp, B-GENE-Y
H19, B-GENE-Y
and O
Bex1), B-GENE-Y
and O
increased O
"stemness" O
(Prom1 B-GENE-Y
and O
Epcam). B-GENE-Y
In O
contrast, O
the O
dose O
of O
DEN B-CHEMICAL
used O
did O
not O
modify O
the O
extent O
of O
liver O
inflammation, O
fibrogenesis, O
oxidative O
stress, O
proliferation, O
or O
apoptosis O
induced O
by O
subchronic O

CCl(4) B-CHEMICAL
administration. O
This O
study O
demonstrates O
the O
potential O
role O
of O
liver O
stem-like O
cells O
in O
the O
mechanisms O
of O
chemical-induced, O
fibrosis-promoted O
HCC. O
We O
posit O
that O
the O
combination O
of O
genotoxic O
and O
fibrogenic O
insults O
is O
a O
sensible O
approach O
to O
model O
liver O
carcinogenesis O
in O
experimental O
animals. O
These O
results O
may O
contribute O
to O
identification O
of O
cirrhotic O
patients O
predisposed O
to O
HCC O
by O
analyzing O
the O
expression O
of O
hepatic O
progenitor O
cell O
markers O
in O
the O
noncancerous O
liver O
tissue. O
2-Arylpropionic B-CHEMICAL
CXC B-GENE-Y
chemokine I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y

(CXCR1) B-GENE-Y
ligands O
as O
novel O
noncompetitive O
CXCL8 B-GENE-Y
inhibitors. O
The O
CXC B-GENE-N
chemokine I-GENE-N
CXCL8/IL-8 B-GENE-Y
plays O
a O
major O
role O
in O
the O
activation O
and O
recruitment O
of O
polymorphonuclear O
(PMN) O
cells O
at O
inflammatory O
sites. O
CXCL8 B-GENE-Y
activates O
PMNs O
by O
binding O
the O
seven-transmembrane B-GENE-N
(7-TM) I-GENE-N
G-protein-coupled I-GENE-N
receptors I-GENE-N
CXC B-GENE-Y
chemokine I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
(CXCR1) B-GENE-Y
and O
CXC B-GENE-Y
chemokine I-GENE-Y
receptor I-GENE-Y
2 I-GENE-Y
(CXCR2). B-GENE-Y

(R)-Ketoprofen B-CHEMICAL
(1) O
was O
previously O
reported O
to O
be O
a O
potent O
and O
specific O
noncompetitive O
inhibitor O
of O
CXCL8-induced B-GENE-Y
human O
PMNs O
chemotaxis. O
We O
report O
here O
molecular O
modeling O
studies O
showing O
a O
putative O
interaction O
site O
of O
1 O
in O
the O
TM O
region O
of O
CXCR1. B-GENE-Y
The O
binding O
model O
was O
confirmed O
by O
alanine B-CHEMICAL
scanning O
mutagenesis O
and O
photoaffinity O
labeling O
experiments. O
The O
molecular O
model O
driven O
medicinal O
chemistry O
optimization O
of O
1 O
led O
to O
a O
new O
class O
of O
potent O
and O
specific O
inhibitors O
of O
CXCL8 B-GENE-Y
biological O
activity. O
Among O
these, O
repertaxin B-CHEMICAL
(13) O

was O
selected O
as O
a O
clinical O
candidate O
drug O
for O
prevention O
of O
post-ischemia O
reperfusion O
injury. O
Role O
of O
organic B-GENE-Y
cation/carnitine I-GENE-Y
transporter I-GENE-Y
1 I-GENE-Y
in O
uptake O
of O
phenformin B-CHEMICAL
and O
inhibitory O
effect O
on O
complex B-GENE-N
I I-GENE-N
respiration O
in O
mitochondria. O
Phenformin B-CHEMICAL
causes O
lactic O
acidosis O
in O
clinical O
situations O
due O
to O
inhibition O
of O
mitochondrial B-GENE-N
respiratory I-GENE-N
chain I-GENE-N
complex I-GENE-N
I. I-GENE-N
It O
is O
reportedly O
taken O
up O
by O
hepatocytes O
and O
exhibits O
mitochondrial O
toxicity O
in O
the O
liver. O
In O
this O
study, O
uptake O
of O
phenformin B-CHEMICAL
and O
[(14)C]tetraethylammonium B-CHEMICAL
(TEA) B-CHEMICAL
and O

complex B-GENE-N
I I-GENE-N
inhibition O
by O
phenformin B-CHEMICAL
were O
examined O
in O
isolated O
liver O
and O
heart O
mitochondria. O
Uptake O
of O
phenformin B-CHEMICAL
into O
isolated O
rat O
liver O
mitochondria O
was O
higher O
than O
that O
into O
heart O
mitochondria. O
It O
was O
inhibited O
by O
several O
cat O
ionic O
compounds, O
which O
suggests O
the O
involvement O
of O
multispecific O
transport O
system(s). O
Similar O
characteristics O
were O
also O
observed O
for O
uptake O
of O
TEA; B-CHEMICAL
however, O
uptake O
of O
phenformin B-CHEMICAL
into O
mitochondria O
of O
organic B-GENE-Y
cation/carnitine I-GENE-Y
transporter I-GENE-Y
1 I-GENE-Y
(OCTN1) B-GENE-Y
knockout O
mice O
was O
lower O
than O
that O
in O

wild-type O
mice, O
whereas O
uptake O
of O
TEA B-CHEMICAL
was O
comparable O
between O
the O
two O
strains, O
suggesting O
the O
involvement O
of O
distinct O
transport O
mechanisms O
for O
these O
two O
cations O
in O
mitochondria. O
Inhibition O
by O
phenformin B-CHEMICAL
of O
oxygen B-CHEMICAL
consumption O
via O
complex B-GENE-N
I I-GENE-N
respiration O
in O
isolated O
rat O
liver O
mitochondria O
was O
greater O
than O
that O
in O
heart O
mitochondria, O
whereas O
inhibitory O
effect O
of O
phenformin B-CHEMICAL
on O
complex B-GENE-N
I I-GENE-N
respiration O
was O
similar O
in O
inside-out O
structured O
submitochondrial O
particles O
prepared O
from O
rat O
livers O
and O
hearts. O
Lactic O
acidosis O
provoked O
by O
iv O
infusion O
of O
phenformin B-CHEMICAL
was O
weaker O
in O

octn1(-/-) B-GENE-Y
mice O
than O
that O
in O
wild-type O
mice. O
These O
observations O
suggest O
that O
uptake O
of O
phenformin B-CHEMICAL
into O
liver O
mitochondria O
is O
at O
least O
partly O
mediated O
by O
OCTN1 B-GENE-Y
and O
functionally O
relevant O
to O
its O
inhibition O
potential O
of O
complex B-GENE-N
I I-GENE-N
respiration. O
This O
study O
was, O
thus, O
the O
first O
to O
demonstrate O
OCTN1-mediated B-GENE-Y
mitochondrial O
transport O
and O
toxicity O
of O
biguanide O
in O
vivo O
in O
rodents. O
Synthesis O
and O
biological O
evaluation O
of O
xanthine B-CHEMICAL
derivatives O
on O
dipeptidyl B-GENE-Y
peptidase I-GENE-Y
4. I-GENE-Y
A O
series O
of O
xanthine B-CHEMICAL
derivatives O
in O
which O
a O
methylene B-CHEMICAL

was O
inserted O
at O
position O
8 O
of O
xanthine B-CHEMICAL
scaffold O
was O
synthesized O
and O
evaluated O
as O
inhibitors O
of O
dipeptidyl B-GENE-Y
peptidase I-GENE-Y
4 I-GENE-Y
(DPP-4) B-GENE-Y
for O
the O
treatment O
of O
type O
2 O
diabetes. O
As O
the O
results O
of O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
series, O
the O
compounds O
with O
4-methyl-quinazoline-2-yl-methyl B-CHEMICAL
group O
at O
N-1 O
position O
and O
2-aminoethylaminomethyl B-CHEMICAL
group O
gave O
better O
activities. O
Compounds O
H4 O
and O
H9 O
showed O
good O
DPP-4 B-GENE-Y
inhibition O
and O
more O
than O
100-fold O

selectivity O
over O
DPP-7 B-GENE-Y
and O
DPP-8. B-GENE-Y
5-HT1B B-GENE-Y
receptors, O
alpha2A/2C- O
and, O
to O
a O
lesser O
extent, O
alpha1-adrenoceptors B-GENE-N
mediate O
the O
external O
carotid O
vasoconstriction O
to O
ergotamine B-CHEMICAL
in O
vagosympathectomised O
dogs. O
It O
has O
previously O
been O
suggested O
that O
ergotamine B-CHEMICAL
produces O
external O
carotid O
vasoconstriction O
in O
vagosympathectomised O
dogs O
via O
5-HT1B/1D B-GENE-N
receptors O
and O
alpha2-adrenoceptors. B-GENE-N
The O
present O
study O
has O

reanalysed O
this O
suggestion O
by O
using O
more O
selective O
antagonists O
alone O
and O
in O
combination. O
Fifty-two O
anaesthetised O
dogs O
were O
prepared O
for O
ultrasonic O
measurements O
of O
external O
carotid O
blood O
flow. O
The O
animals O
were O
divided O
into O
thirteen O
groups O
(n=4 O
each) O
receiving O
an O
i.v. O
bolus O
injection O
of, O
either O
physiological O
saline O
(0.3 O
ml/kg; O
control), O
or O
the O
antagonists O
SB224289 B-CHEMICAL
(300 O
microg/kg; O
5-HT1B), B-GENE-Y
BRL15572 B-CHEMICAL
(300 O
microg/kg; O

5-HT1D), B-GENE-Y
rauwolscine B-CHEMICAL
(300 O
microg/kg; O
alpha2), O
SB224289 B-CHEMICAL
+ O
BRL15572 B-CHEMICAL
(300 O
microg/kg O
each), O
SB224289 B-CHEMICAL
+ O
rauwolscine B-CHEMICAL
(300 O
microg/kg O
each), O
BRL15572 B-CHEMICAL
+ O
rauwolscine B-CHEMICAL
(300 O
microg/kg O
each), O
rauwolscine B-CHEMICAL
(300 O
microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O
microg/kg; O
alpha1), O
SB224289 B-CHEMICAL
(300 O

microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O
microg/kg), O
SB224289 B-CHEMICAL
(300 O
microg/kg) O
+ O
rauwolscine B-CHEMICAL
(300 O
microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O
microg/kg), O
SB224289 B-CHEMICAL
(300 O
microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O
microg/kg) O
+ O
BRL44408 B-CHEMICAL
(1,000 O
microg/kg; O
alpha2A), O
SB224289 B-CHEMICAL
(300 O
microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O

microg/kg)+ O
imiloxan B-CHEMICAL
(1,000 O
microg/kg; O
alpha2B), O
or O
SB224289 B-CHEMICAL
(300 O
microg/kg) O
+ O
prazosin B-CHEMICAL
(100 O
microg/kg) O
+ O
MK912 B-CHEMICAL
(300 O
microg/kg; O
alpha2C). O
Each O
group O
received O
consecutive O
1-min O
intracarotid O
infusions O
of O
ergotamine B-CHEMICAL
(0.56, O
1, O
1.8, O
3.1, O
5.6, O
10 O
and O
18 O
microg/min), O
following O
a O
cumulative O
schedule. O
In O
saline-pretreated O

animals, O
ergotamine B-CHEMICAL
induced O
dose-dependent O
decreases O
in O
external O
carotid O
blood O
flow O
without O
affecting O
arterial O
blood O
pressure O
or O
heart O
rate. O
These O
control O
responses O
were: O
unaffected O
by O
SB224289, B-CHEMICAL
BRL15572, B-CHEMICAL
rauwolscine B-CHEMICAL
or O
the O
combinations O
of O
SB224289 B-CHEMICAL
+ O
BRL15572, B-CHEMICAL
BRL15572 B-CHEMICAL
+ O
rauwolscine, B-CHEMICAL
rauwolscine B-CHEMICAL
+ O
prazosin, B-CHEMICAL
SB224289 B-CHEMICAL
+ O
prazosin, B-CHEMICAL
or O
SB224289 B-CHEMICAL
+ O
prazosin B-CHEMICAL
+ O

imiloxan; B-CHEMICAL
slightly O
blocked O
by O
SB224289 B-CHEMICAL
+ O
rauwolscine; B-CHEMICAL
and O
markedly O
blocked O
by O
SB224289 B-CHEMICAL
+ O
rauwolscine B-CHEMICAL
+ O
prazosin, B-CHEMICAL
SB224289 B-CHEMICAL
+ O
prazosin B-CHEMICAL
+ O
BRL44408 B-CHEMICAL
or O
SB224289 B-CHEMICAL
+ O
prazosin B-CHEMICAL
+ O
MK912. B-CHEMICAL
Thus, O
the O
cranio-selective O
vasoconstriction O
elicited O
by O
ergotamine B-CHEMICAL
in O
dogs O
is O
predominantly O
mediated O
by O
5-HT1B B-GENE-Y
receptors O
as O
well O
as O

alpha2A/2C-adrenoceptor B-GENE-N
subtypes O
and, O
to O
a O
lesser O
extent, O
by O
alpha1-adrenoceptors. B-GENE-N
Influence O
of O
the O
dopamine B-GENE-N
D2 I-GENE-N
receptor I-GENE-N
(DRD2) I-GENE-N
exon I-GENE-N
8 I-GENE-N
genotype O
on O
efficacy O
of O
tiapride B-CHEMICAL
and O
clinical O
outcome O
of O
alcohol B-CHEMICAL
withdrawal. O
We O
tested O
the O
hypothesis O
that O
allelic O
variants O
of O
the O
human B-GENE-N
dopamine I-GENE-N
D2 I-GENE-N
receptor I-GENE-N
E8 I-GENE-N
genotype O
are O
associated O
with O
(i) O
dopamine B-GENE-Y
D2 I-GENE-Y
antagonist O
tiapride O
dose O
in O
treatment O
of O
alcohol B-CHEMICAL
withdrawal O
(n O
= O
50) O
and O
(ii) O
with O
anxiety O
and O

depression O
in O
patients O
during O
alcoholism O
detoxification O
therapy O
(admission O
n O
= O
87; O
discharge O
n O
= O
50). O
DRD2 B-GENE-N
E8 I-GENE-N
A/A O
genotype O
was O
associated O
with O
increased O
dose O
of O
tiapride B-CHEMICAL
during O
a O
9-day O
detoxification O
therapy O
and O
with O
increased O
anxiety O
and O
depression O
scores O
on O
admission O
and O
2 O
weeks O
later. O
The O
findings O
suggest O
a O
pharmacogenetic O
influence O
of O
DRD2 B-GENE-N
E8 I-GENE-N
genotype O
on O
tiapride O
efficacy O
in O
alcohol O
withdrawal. O
In O
an O
earlier O
report, O
DRD2 B-GENE-Y
E8 O
A/A O
genotype O
was O
associated O
with O
reduced O
responsiveness O
to O
the O

dopamine B-GENE-Y
D2 I-GENE-Y
agonist O
apomorphine; B-CHEMICAL
however, O
it O
is O
not O
clear O
whether O
both O
findings O
share O
the O
same O
biological O
basis. O
Earlier O
findings O
concerning O
association O
of O
DRD2 B-GENE-N
E8 I-GENE-N
A/A O
with O
increased O
anxiety O
and O
depression O
are O
replicated O
for O
the O
first O
time. O
Peroxynitrite B-CHEMICAL
mediates O
testosterone-induced B-CHEMICAL
vasodilation O
of O
microvascular O
resistance O
vessels. O
Our O
knowledge O
of O
how O
androgens B-CHEMICAL
influence O
the O
cardiovascular O
system O
is O
far O
from O
complete, O
and O
this O
lack O
of O
understanding O
is O
especially O
true O
of O
how O
androgens B-CHEMICAL
affect O
resistance O
vessels. O
Our O
aim O
was O
to O
identify O
the O
signaling O
mechanisms O
stimulated O
by O
testosterone B-CHEMICAL
(TES) B-CHEMICAL

in O
microvascular O
arteries O
and O
to O
understand O
how O
these O
mechanisms O
mediate O
TES-induced B-CHEMICAL
vasodilation. O
Mesenteric O
microvessels O
were O
isolated O
from O
male O
Sprague-Dawley O
rats. O
Tension O
studies O
demonstrated O
a O
rapid, O
concentration-dependent, O
vasodilatory O
response O
to O
TES B-CHEMICAL
that O
did O
not O
involve O
protein O
synthesis O
or O
aromatization O
to O
17β-estradiol. B-CHEMICAL
Dichlorofluorescein B-CHEMICAL
fluorescence O
and O
nitrotyrosine B-CHEMICAL
immunoblot O
experiments O
indicated O
that O
TES B-CHEMICAL
stimulated O
peroxynitrite B-CHEMICAL
formation O
in O
microvessels, O
and O
functional O
studies O
demonstrated O
that O

TES-induced B-CHEMICAL
vasodilation O
was O
inhibited O
by O
scavenging O
peroxynitrite. B-CHEMICAL
As O
predicted, O
TES B-CHEMICAL
enhanced O
the O
production O
of O
both O
peroxynitrite B-CHEMICAL
precursors O
(i.e., O
superoxide B-CHEMICAL
and O
nitic B-CHEMICAL
oxide), I-CHEMICAL
and O
xanthine B-GENE-Y
oxidase I-GENE-Y
was O
identified O
as O
the O
likely O
source O
of O
TES-stimulated B-CHEMICAL
superoxide B-CHEMICAL
production. O
Functional O
and O
biochemical O
studies O
indicated O
that O
TES B-CHEMICAL
signaling O
involved O
activity O
of O
the O
phosphoinositide B-GENE-N
3 I-GENE-N
(PI3) I-GENE-N
kinase-protein I-GENE-N
kinase I-GENE-Y
B I-GENE-Y
(Akt) B-GENE-Y
cascade O
initiated O
by O
activation O
of O
the O
androgen B-GENE-Y
receptor I-GENE-Y

and O
culminated O
in O
enhanced O
production O
of O
cGMP B-CHEMICAL
and O
microvascular O
vasodilation. O
These O
findings, O
derived O
from O
a O
variety O
of O
analytical O
and O
functional O
approaches, O
provide O
evidence O
for O
a O
novel O
nongenomic O
signaling O
mechanism O
for O
androgen B-CHEMICAL
action O
in O
the O
microvasculature: O
TES-stimulated B-CHEMICAL
vasodilation O
mediated O
primarily O
by O
peroxynitrite B-CHEMICAL
formed O
from O
xanthine B-GENE-Y
oxidase-generated I-GENE-Y
superoxide B-CHEMICAL
and O
NO. B-CHEMICAL
This O
response O
was O
associated O
with O
activation O
of O
the O
PI3 B-GENE-N
kinase-Akt I-GENE-N
signaling O
cascade O
initiated O
by O
activation O
of O
the O
androgen B-GENE-Y
receptor. I-GENE-Y
We O
propose O
this O
mechanism O
could O
account O
for O
TES-stimulated B-CHEMICAL

cGMP B-CHEMICAL
production O
in O
microvessels O
and, O
ultimately, O
vasodilation. O
Mouse B-GENE-Y
brain I-GENE-Y
serine I-GENE-Y
racemase I-GENE-Y
catalyzes O
specific O
elimination O
of O
L-serine B-CHEMICAL
to O
pyruvate. B-CHEMICAL
D-Serine B-CHEMICAL
was O
previously O
identified O
in O
mammalian O
brain O
and O
was O
shown O
to O
be O
a O
co-agonist O
at O
the O
'glycine' B-CHEMICAL
site O
of O
the O
N-methyl-D-aspartate B-GENE-N
(NMDA)-type I-GENE-N
receptors. I-GENE-N
Racemization O
of O
serine B-CHEMICAL
is O
catalyzed O
by O
serine B-GENE-Y
racemase, I-GENE-Y
a O
pyridoxal B-CHEMICAL
5'-phosphate-dependent I-CHEMICAL
enzyme O
expressed O
mainly O
in O
brain O

and O
liver. O
NMDA B-GENE-N
receptor I-GENE-N
overactivation O
has O
been O
implicated O
in O
a O
number O
of O
pathological O
conditions O
and O
inhibitors O
of O
serine B-GENE-Y
racemase I-GENE-Y
are O
thus O
potentially O
interesting O
targets O
for O
therapy. O
We O
expressed O
recombinant O
mouse B-GENE-Y
serine I-GENE-Y
racemase I-GENE-Y
in O
insect O
cells O
and O
purified O
it O
to O
near O
homogeneity. O
The O
enzyme O
is O
a O
non-covalent O
homodimer O
in O
solution O
and O
requires O
divalent O
cations O
Mg(2+), B-CHEMICAL
Ca(2+) B-CHEMICAL
or O
Mn(2+) B-CHEMICAL
for O
activity O
but O
not O
for O
dimerization. O
In O
addition O
to O
the O
racemization O
it O
also O
catalyzes O
specific O
elimination O

of O
L-Ser B-CHEMICAL
to O
pyruvate. B-CHEMICAL
D-Serine B-CHEMICAL
is O
eliminated O
much O
less O
efficiently. O
Both O
L-serine B-CHEMICAL
racemization O
and O
elimination O
activities O
of O
serine B-CHEMICAL
racemase O
are O
of O
comparable O
magnitude, O
display O
alkaline B-CHEMICAL
pH O
optimum O
and O
are O
negligible O
below O
pH O
6.5. O
Ankyrin B-GENE-N
repeat O
and O
suppressors O
of O
cytokine B-GENE-N
signaling I-GENE-N
box I-GENE-N
protein I-GENE-N
asb-9 B-GENE-Y
targets O
creatine B-GENE-Y
kinase I-GENE-Y
B I-GENE-Y
for O
degradation. O
The O
suppressors B-GENE-N
of I-GENE-N
cytokine I-GENE-N
signaling I-GENE-N
(SOCS) I-GENE-N
proteins I-GENE-N
inhibit O
cytokine B-GENE-N
action O
by O
direct O
interaction O
with O
Janus B-GENE-N
kinases I-GENE-N
or O
activated O
cytokine B-GENE-N

receptors. I-GENE-N
In O
addition O
to O
the O
N-terminal B-CHEMICAL
and O
Src B-GENE-N
homology I-GENE-N
2 I-GENE-N
domains I-GENE-N
that O
mediate O
these O
interactions, O
SOCS B-GENE-N
proteins O
contain O
a O
C-terminal B-CHEMICAL
SOCS B-GENE-N
box. I-GENE-N
DNA O
data O
base O
searches O
have O
identified O
a O
number O
of O
other O
protein O
families O
that O
possess O
a O
SOCS B-GENE-N
box, I-GENE-N
of O
which O
the O
ankyrin B-GENE-N
repeat O
and O
SOCS B-GENE-N
box-containing I-GENE-N
(Asb) B-GENE-N
proteins O
constitute O
the O
largest. O
Although O
it O
is O
known O
that O
the O
SOCS B-GENE-N
proteins O
are O
involved O
in O
the O
negative O
regulation O
of O
cytokine B-GENE-N
signaling, O
the O
biological O
and O
biochemical O
functions O
of O
the O
Asbs B-GENE-N
are O
largely O
undefined. O
Using O
a O
proteomics O
approach, O

we O
demonstrate O
that O
creatine B-GENE-Y
kinase I-GENE-Y
B I-GENE-Y
(CKB) B-GENE-Y
interacts O
with O
Asb-9 B-GENE-Y
in O
a O
specific, O
SOCS B-GENE-N
box-independent I-GENE-N
manner. O
This O
interaction O
increases O
the O
polyubiquitylation O
of O
CKB B-GENE-Y
and O
decreases O
total O
CKB B-GENE-Y
levels O
within O
the O
cell. O
The O
targeting O
of O
CKB B-GENE-Y
for O
degradation O
by O
Asb-9 B-GENE-Y
was O
primarily O
SOCS B-GENE-N
box-dependent I-GENE-N
and O
suggests O
that O
Asb-9 B-GENE-Y
acts O
as O
a O
specific O
ubiquitin B-GENE-N
ligase I-GENE-N
regulating O
levels O
of O
this O
evolutionarily O
conserved O
enzyme. O
Tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
versus O
tamoxifen B-CHEMICAL
and O
danazol B-CHEMICAL
in O

metastatic O
breast O
cancer--a O
randomized O
study. O
A O
prospective O
randomized O
trial O
of O
tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
versus O
tamoxifen B-CHEMICAL
and O
danazol B-CHEMICAL
in O
metastatic O
breast O
cancer O
was O
conducted O
from O
December O
1980 O
to O
September O
1985. O
Patients O
were O
eligible O
regardless O
of O
site O
of O
disease, O
estrogen B-GENE-Y
receptor I-GENE-Y
status, O
or O
age. O
Sixty-two O
of O
sixty-three O
randomized O
patients O
were O
evaluable O
for O
response. O
Overall O
response O
for O
tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
was O
11% O
with O
61% O
stabilization O
of O
disease, O
versus O
12% O
response O
rate O
for O
tamoxifen B-CHEMICAL
and O

danazol B-CHEMICAL
with O
59% O
stabilization. O
Toxicities O
with O
tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
were O
greater O
with O
an O
increase O
in O
masculinization. O
We O
conclude O
that O
the O
response O
rates O
to O
the O
combinations O
of O
tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
or O
tamoxifen B-CHEMICAL
and O
danazol B-CHEMICAL
reported O
are O
equivalent O
in O
this O
study O
but O
that O
the O
increased O
toxicity O
with O
tamoxifen B-CHEMICAL
and O
fluoxymesterone B-CHEMICAL
would O
make O
tamoxifen B-CHEMICAL
and O
danazol B-CHEMICAL
the O
treatment O
of O
choice O
if O
a O
combination O
were O
to O
be O
used. O
Effect O
of O
quercetin-rich B-CHEMICAL
onion O
peel O
extracts O

on O
arterial O
thrombosis O
in O
rats. O
The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
oral O
supplementation O
of O
quercetin-rich B-CHEMICAL
onion O
peel O
extract O
(OPE) O
influences O
blood O
coagulation O
and O
arterial O
thrombosis O
in O
Sprague-Dawley O
(SD) O
rats. O
24 O
male O
rats, O
5weeks O
old, O
were O
divided O
into O
three O
groups O
with O
different O
diets O
(C: O
control, O
2mg O
OPE: O
chow O
diet O
with O
2mg O
OPE O
supplementation, O
10mg O
OPE: O
chow O
diet O
with O
10mg O
OPE O
supplementation) O

for O
6weeks. O
Blood O
coagulation O
parameters O
including O
prothrombin B-GENE-Y
time O
(PT), O
activated O
partial O
thromboplastin B-GENE-Y
time O
(aPTT) O
and O
platelet O
aggregation O
were O
examined. O
The O
OPE O
did O
not O
affect O
blood O
cholesterol B-CHEMICAL
levels O
but O
significantly O
decreased O
blood O
triglyceride B-CHEMICAL
and O
glucose B-CHEMICAL
levels. O
PT, O
aPTT O
and O
platelet O
aggregation O
were O
not O
significantly O
different O
among O
all O
tested O
groups. O
However, O
in O
vivo O
arterial O
thrombosis O
was O
significantly O
delayed O
in O
groups O
that O
were O
fed O
2mg O
and O
10mg O
OPE O
diets O
compared O
to O
the O
control O
group. O

In O
addition, O
the O
OPE O
greatly O
diminished O
thrombin-induced B-GENE-Y
expression O
of O
tissue B-GENE-Y
factor I-GENE-Y
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs), O
a O
coagulation O
initiator. O
In O
addition, O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
and O
c-Jun B-GENE-Y
N-terminal I-GENE-Y
kinase I-GENE-Y
(JNK) B-GENE-Y
signaling O
pathways O
activated O
by O
thrombin B-GENE-Y
treatment O
were O
prevented O
by O
the O
OPE O
pre-treatment. O
These O
results O
indicate O
that O
OPE O
may O
have O
anti-thrombotic O
effects O
through O
restricting O
the O
induced O
expression O
of O
tissue B-GENE-Y
factor I-GENE-Y
via O
down-regulating O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N

(MAPK) B-GENE-N
activation O
upon O
coagulation O
stimulus, O
leading O
to O
the O
prolongation O
of O
time O
for O
arterial O
thrombosis. O
Thyroid B-GENE-N
hormone I-GENE-N
receptors/THR I-GENE-N
genes O
in O
human O
cancer. O
Thyroid B-CHEMICAL
hormone I-CHEMICAL
(triiodothyronine, B-CHEMICAL
T3) O
is O
a O
pleiotropic O
regulator O
of O
growth, O
differentiation O
and O
tissue O
homeostasis O
in O
higher O
organisms O
that O
acts O
through O
the O
control O
of O
target O
gene O
expression. O
Most, O
if O
not O
all, O
major O
T3 O
actions O
are O
mediated O
by O
specific O
high O
affinity O
nuclear B-GENE-N
receptors I-GENE-N
(TR) B-GENE-N
which O
are O
encoded O
by O
two O
genes, O
THRA B-GENE-Y
and O
THRB. B-GENE-Y
Several O

TRalpha B-GENE-Y
and O
TRbeta B-GENE-Y
receptor O
isoforms O
are O
expressed. O
Abundant O
and O
contradictory O
literature O
exists O
on O
the O
relationship O
between O
circulating O
thyroid B-CHEMICAL
hormone I-CHEMICAL
levels, O
thyroid O
diseases O
and O
human O
cancer. O
In O
1986, O
a O
connection O
between O
TR B-GENE-N
and O
cancer O
became O
evident O
when O
the O
chicken B-GENE-Y
TRalpha1 I-GENE-Y
was O
characterized O
as O
the O
c-erbA B-GENE-Y
proto-oncogene, O
the O
cellular O
counterpart O
of O
the O
retroviral O
v-erbA B-GENE-N
oncogene. O
V-erbA B-GENE-N
causes O
erythroleukemias O
and O
sarcomas O
in O
birds, O
and O
hepatocellular O

carcinomas O
in O
transgenic O
mice. O
In O
recent O
years, O
many O
studies O
have O
analyzed O
the O
presence O
of O
quantitative O
(abnormal O
levels) O
or O
qualitative O
(mutations) O
alterations O
in O
the O
expression O
of O
THR B-GENE-N
genes O
in O
different O
types O
of O
human O
neoplasias. O
While O
their O
role O
in O
tumor O
generation O
or O
progression O
is O
currently O
unclear, O
both O
gross O
chromosomal O
and O
minor O
mutations O
(deletions, O
aberrant O
splicing, O
point O
mutations) O
and O
changes O
in O
the O
level O
of O
expression O
of O
THRA B-GENE-Y
and O
THRB B-GENE-Y
genes O
have O
been O
found. O
Together O
with O
other O
in O
vitro O
data O
indicating O
connections O
between O
TR B-GENE-N
and O
p53, B-GENE-Y

Rb, B-GENE-Y
cyclin B-GENE-N
D I-GENE-N
and O
other O
cell O
cycle O
regulators O
and O
oncogenes, O
these O
results O
suggest O
that O
THRA B-GENE-Y
and O
THRB B-GENE-Y
may O
be O
involved O
in O
human O
cancer. O
Warfarin B-CHEMICAL
dose O
and O
the O
pharmacogenomics O
of O
CYP2C9 B-GENE-Y
and O
VKORC1 B-GENE-Y
- O
rationale O
and O
perspectives. O
Warfarin B-CHEMICAL
is O
the O
most O
widely O
prescribed O
oral O
anticoagulant, O
but O
there O
is O
greater O
than O
10-fold O
interindividual O
variability O
in O
the O
dose O
required O
to O
attain O
a O
therapeutic O
response. O
Information O
from O
pharmacogenomics, O
the O
study O
of O
the O
interaction O
of O
an O

individual's O
genotype O
and O
drug O
response, O
can O
help O
optimize O
drug O
efficacy O
while O
minimizing O
adverse O
drug O
reactions. O
Pharmacogenetic O
analysis O
of O
two O
genes, O
the O
warfarin B-CHEMICAL
metabolic O
enzyme O
CYP2C9 B-GENE-Y
and O
warfarin B-CHEMICAL
target O
enzyme, O
vitamin B-GENE-Y
K I-GENE-Y
epoxide I-GENE-Y
reductase I-GENE-Y
complex I-GENE-Y
1 I-GENE-Y
VKORC1, B-GENE-Y
confirmed O
their O
influence O
on O
warfarin B-CHEMICAL
maintenance O
dose. O
Possession O
of O
CYP2C9*2 B-GENE-Y
or O
CYP2C9*3 B-GENE-Y
variant O
alleles, O
which O
result O
in O
decreased O
enzyme O
activity, O
is O
associated O
with O
a O
significant O
decrease O
in O
the O
mean O
warfarin B-CHEMICAL
dose. O
Several O
single O

nucleotide B-CHEMICAL
polymorphisms O
(SNPs) O
in O
VKORC1 B-GENE-Y
are O
associated O
with O
warfarin B-CHEMICAL
dose O
across O
the O
normal O
dose O
range. O
Haplotypes O
based O
on O
these O
SNPs O
explain O
a O
large O
fraction O
of O
the O
interindividual O
variation O
in O
warfarin B-CHEMICAL
dose, O
and O
VKORC1 B-GENE-Y
has O
an O
approximately O
three-fold O
greater O
effect O
than O
CYP2C9. B-GENE-Y
Algorithms O
incorporating O
genetic O
(CYP2C9 B-GENE-Y
and O
VKORC1), B-GENE-Y
demographic, O
and O
clinical O
factors O
to O
estimate O
the O
warfarin B-CHEMICAL
dosage, O
could O
potentially O
minimize O
the O
risk O
of O
over O
dose O
during O
warfarin B-CHEMICAL

induction. O
Pseudoephedrine B-CHEMICAL
inhibits O
T-cell O
activation O
by O
targeting O
NF-kappaB, B-GENE-N
NFAT B-GENE-N
and O
AP-1 B-GENE-Y
signaling O
pathways. O
Pseudoephedrine B-CHEMICAL
(PSE) B-CHEMICAL
is O
a O
stereoisomer O
of O
ephedrine B-CHEMICAL
that O
is O
commonly O
used O
as O
a O
nasal O
decongestant O
in O
combination O
with O
other O
anti-inflammatory O
drugs O
for O
the O
symptomatic O
treatment O
of O
some O
common O
pathologies O
such O
as O
common O
cold. O
Herein, O
we O
describe O
for O
the O
first O
time O
the O
effects O
of O
PSE B-CHEMICAL
on O
T-cell O
activation O
events. O
We O
found O
that O
PSE B-CHEMICAL
inhibits O
interleukin-2 B-GENE-Y

(IL-2) B-GENE-Y
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF) I-GENE-Y
alpha-gene I-GENE-Y
transcription O
in O
stimulated O
Jurkat O
cells, O
a O
human O
T-cell O
leukemia O
cell O
line. O
To O
further O
characterize O
the O
inhibitory O
mechanisms O
of O
PSE B-CHEMICAL
at O
the O
transcriptional O
level, O
we O
examined O
the O
transcriptional O
activities O
of O
nuclear B-GENE-N
factor I-GENE-N
kappa I-GENE-N
B I-GENE-N
(NF-kappaB), B-GENE-N
nuclear B-GENE-N
factor I-GENE-N
of I-GENE-N
activated I-GENE-N
T I-GENE-N
cells I-GENE-N
(NFAT), B-GENE-N
and O
activator B-GENE-Y
protein-1 I-GENE-Y
(AP-1) B-GENE-Y
transcription O
factors O
and O
found O
that O
PSE B-CHEMICAL
inhibited O
NF-kappaB-dependent B-GENE-N
transcriptional O
activity O
without O
affecting O
either O
the O

phosphorylation, O
the O
degradation O
of O
the O
cytoplasmic O
NF-kappaB B-GENE-Y
inhibitory I-GENE-Y
protein, I-GENE-Y
IkappaBalpha B-GENE-Y
or O
the O
DNA-binding O
activity. O
However, O
phosphorylation O
of O
the O
p65/RelA B-GENE-Y
subunit O
was O
clearly O
inhibited O
by O
PSE B-CHEMICAL
in O
stimulated O
cells. O
In O
addition, O
PSE B-CHEMICAL
inhibited O
the O
transcriptional O
activity O
of O
NFAT B-GENE-N
without O
interfering O
with O
the O
calcium-induced B-CHEMICAL
NFAT B-GENE-N
dephosphorylation O
event, O
which O
represents O
the O
major O
signaling O
pathway O
for O
its O
activation. O
NFAT B-GENE-N
cooperates O
with O
c-Jun, B-GENE-Y
a O
compound O
of O
the O

AP-1 B-GENE-Y
complex, O
to O
activate O
target O
genes, O
and O
we O
also O
found O
that O
PSE B-CHEMICAL
inhibited O
both O
JNK B-GENE-N
activation O
and O
AP-1 B-GENE-Y
transcriptional O
activity. O
These O
findings O
provide O
new O
mechanistic O
insights O
into O
the O
potential O
immunomodulatory O
activities O
of O
PSE B-CHEMICAL
and O
highlight O
their O
potential O
in O
designing O
novel O
therapeutic O
strategies O
to O
manage O
inflammatory O
diseases. O
Diethylcarbamazine B-CHEMICAL
activity O
against O
Brugia O
malayi O
microfilariae O
is O
dependent O
on O
inducible B-GENE-Y
nitric-oxide I-GENE-Y
synthase I-GENE-Y
and O
the O
cyclooxygenase B-GENE-N
pathway. O
BACKGROUND: O
Diethylcarbamazine B-CHEMICAL

(DEC) B-CHEMICAL
has O
been O
used O
for O
many O
years O
in O
the O
treatment O
of O
human O
lymphatic O
filariasis. O
Its O
mode O
of O
action O
is O
not O
well O
understood, O
but O
it O
is O
known O
to O
interact O
with O
the O
arachidonic B-CHEMICAL
acid I-CHEMICAL
pathway. O
Here O
we O
have O
investigated O
the O
contribution O
of O
the O
nitric B-CHEMICAL
oxide I-CHEMICAL
and O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
pathways O
to O
the O
activity O
of O
DEC B-CHEMICAL
against O
B. O
malayi O
microfilariae O
in O
mice. O
METHODS: O
B. O
malayi O
microfilariae O
were O
injected O
intravenously O
into O
mice O
and O
parasitaemia O
was O
measured O
24 O
hours O
later. O

DEC B-CHEMICAL
was O
then O
administered O
to O
BALB/c O
mice O
with O
and O
without O
pre-treatment O
with O
indomethacin B-CHEMICAL
or O
dexamethasone B-CHEMICAL
and O
the O
parasitaemia O
monitored. O
To O
investigate O
a O
role O
for O
inducible O
nitric B-CHEMICAL
oxide I-CHEMICAL
in O
DEC's O
activity, O
DEC B-CHEMICAL
and O
ivermectin B-CHEMICAL
were O
administered O
to O
microfilaraemic O
iNOS-/- B-GENE-Y
mice O
and O
their O
background O
strain O
(129/SV). O
Western O
blot O
analysis O
was O
used O
to O
determine O
any O
effect O
of O
DEC B-CHEMICAL
on O
the O
production O
of O
COX B-GENE-N
and O
inducible O
nitric-oxide B-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
proteins. O

RESULTS: O
DEC O
administered O
alone O
to O
BALB/c O
mice O
resulted O
in O
a O
rapid O
and O
profound O
reduction O
in O
circulating O
microfilariae O
within O
five O
minutes O
of O
treatment. O
Microfilarial O
levels O
began O
to O
recover O
after O
24 O
hours O
and O
returned O
to O
near O
pre-treatment O
levels O
two O
weeks O
later, O
suggesting O
that O
the O
sequestration O
of O
microfilariae O
occurs O
independently O
of O
parasite O
killing. O
Pre-treatment O
of O
animals O
with O
dexamethasone B-CHEMICAL
or O
indomethacin B-CHEMICAL
reduced O
DEC's O
efficacy O
by O
almost O
90% O
or O
56%, O
respectively, O
supporting O
a O
role O
for O
the O
arachidonic B-CHEMICAL
acid I-CHEMICAL
and O

cyclooxygenase B-GENE-N
pathways O
in O
vivo. O
Furthermore, O
experiments O
showed O
that O
treatment O
with O
DEC B-CHEMICAL
results O
in O
a O
reduction O
in O
the O
amount O
of O
COX-1 B-GENE-Y
protein O
in O
peritoneal O
exudate O
cells. O
Additionally, O
in O
iNOS-/- B-GENE-Y
mice O
infected O
with O
B. O
malayi O
microfilariae, O
DEC B-CHEMICAL
showed O
no O
activity, O
whereas O
the O
efficacy O
of O
another O
antifilarial O
drug, O
ivermectin, B-CHEMICAL
was O
unaffected. O
CONCLUSION: O
These O
results O
confirm O
the O
important O
role O
of O
the O
arachidonic B-CHEMICAL
acid I-CHEMICAL
metabolic O
pathway O
in O
DEC's O
mechanism O
of O
action O
in O

vivo O
and O
show O
that O
in O
addition O
to O
its O
effects O
on O
the O
5-lipoxygenase B-GENE-Y
pathway, O
it O
targets O
the O
cyclooxygenase B-GENE-N
pathway O
and O
COX-1. B-GENE-Y
Moreover, O
we O
show O
for O
the O
first O
time O
that O
inducible O
nitric B-CHEMICAL
oxide I-CHEMICAL
is O
essential O
for O
the O
rapid O
sequestration O
of O
microfilariae O
by O
DEC. B-CHEMICAL
SUR-dependent B-GENE-Y
modulation O
of O
KATP B-GENE-N
channels I-GENE-N
by O
an O
N-terminal B-CHEMICAL
KIR6.2 B-GENE-Y
peptide. O
Defining O
intersubunit O
gating O
interactions. O
Ntp O
and O
Ctp, O
synthetic O
peptides O
based O
on O
the O
N- B-CHEMICAL
and O

C-terminal B-CHEMICAL
sequences O
of O
K(IR)6.0, B-GENE-Y
respectively, O
were O
used O
to O
probe O
gating O
of O
K(IR)6.0/SUR B-GENE-Y
K(ATP) B-GENE-N
channels. I-GENE-N
Micromolar O
Ntp O
dose-dependently O
increased O
the O
mean O
open O
channel O
probability O
in O
ligand-free O
solution O
(P(O(max))) O
and O
attenuated O
the O
ATP B-CHEMICAL
inhibition O
of O
K(IR)6.2/SUR1, B-GENE-Y
but O
had O
no O
effect O
on O
homomeric O
K(IR)6.2 B-GENE-Y
channels. O
Ntp O
(up O
to O
approximately O
10(-4) O

m) O
did O
not O
affect O
significantly O
the O
mean O
open O
or O
"fast," O
K(+) B-CHEMICAL
driving O
force-dependent, O
intraburst O
closed O
times, O
verifying O
that O
Ntp O
selectively O
modulates O
the O
ratio O
of O
mean O
burst O
to O
interburst O
times. O
Ctp O
and O
Rnp, O
a O
randomized O
Ntp, O
had O
no O
effect, O
indicating O
that O
the O
effects O
of O
Ntp O
are O
structure O
specific. O
Ntp O
opened O
K(IR)6.1/SUR1 B-GENE-Y
channels O
normally O
silent O
in O
the O
absence O
of O
stimulatory O
Mg(-) O
nucleotide(s) B-CHEMICAL
and O
attenuated O
the O

coupling O
of O
high-affinity O
sulfonylurea B-CHEMICAL
binding O
with O
K(ATP) B-GENE-N
pore O
closure. O
These O
effects O
resemble O
those O
seen O
with O
N-terminal B-CHEMICAL
deletions O
(DeltaN) O
of O
K(IR)6.0, B-GENE-Y
and O
application O
of O
Ntp O
to O
DeltaNK(ATP) B-GENE-N
channels I-GENE-N
decreased O
their O
P(O(max)) O
and O
apparent O
IC(50) O
for O
ATP B-CHEMICAL
in O
the O
absence O
of O
Mg(2+). B-CHEMICAL
The O
results O
are O
consistent O
with O
a O
competition O
between O
Ntp O
and O
the O
endogenous O
N B-CHEMICAL
terminus O
for O
a O
site O
of O
interaction O
on O
the O
cytoplasmic O
face O
of O
the O
channel O
or O
with O

partial O
replacement O
of O
the O
deleted O
N B-CHEMICAL
terminus O
by O
Ntp, O
respectively. O
The O
K(IR) B-GENE-Y
N B-CHEMICAL
terminus O
and O
the O
TMD0-L0 O
segment O
of O
SUR1 B-GENE-Y
are O
known O
to O
control O
the O
P(O(max)). O
The O
L0 O
linker O
has O
been O
reported O
to O
be O
required O
for O
glibenclamide B-CHEMICAL
binding, O
and O
DeltaNK(IR)6.2/SUR1 B-GENE-Y
channels O
exhibit O
reduced O
labeling O
of O
K(IR) B-GENE-Y
with O
(125)I-azidoglibenclamide, B-CHEMICAL
implying O
that O
the O
K(IR) B-GENE-Y
N B-CHEMICAL
terminus O
and O
L0 O
of O

SUR1 B-GENE-Y
are O
in O
proximity. O
We O
hypothesize O
that O
L0 O
interacts O
with O
the O
K(IR) B-GENE-Y
N B-CHEMICAL
terminus O
in O
ligand-inhibited O
K(ATP) B-GENE-N
channels I-GENE-N
and O
put O
forward O
a O
model, O
based O
on O
the O
architecture O
of O
BtuCD, B-GENE-N
MsbA, B-GENE-N
and O
the O
KcsA B-GENE-N
channel, O
in O
which O
TMD0-L0 O
links O
the O
MDR-like B-GENE-N
core O
of O
SUR B-GENE-Y
with O
the O
K(IR) B-GENE-Y
pore. O
Monocarboxylate B-GENE-N
transporters I-GENE-N
in O
the O
central O
nervous O
system: O
distribution, O
regulation O
and O
function. O
Monocarboxylate B-GENE-N
transporters I-GENE-N

(MCTs) B-GENE-N
are O
proton-linked O
membrane O
carriers O
involved O
in O
the O
transport O
of O
monocarboxylates B-CHEMICAL
such O
as O
lactate, B-CHEMICAL
pyruvate, B-CHEMICAL
as O
well O
as O
ketone B-CHEMICAL
bodies. O
They O
belong O
to O
a O
larger O
family O
of O
transporters O
composed O
of O
14 O
members O
in O
mammals O
based O
on O
sequence O
homologies. O
MCTs B-GENE-N
are O
found O
in O
various O
tissues O
including O
the O
brain O
where O
three O
isoforms, O
MCT1, B-GENE-Y
MCT2 B-GENE-Y
and O
MCT4, B-GENE-Y
have O
been O
described. O
Each O
of O
these O
isoforms O
exhibits O
a O
distinct O
regional O
and O
cellular O
distribution O
in O
rodent O
brain. O
At O
the O
cellular O
level, O
MCT1 B-GENE-Y
is O
expressed O
by O

endothelial O
cells O
of O
microvessels, O
by O
ependymocytes O
as O
well O
as O
by O
astrocytes. O
MCT4 B-GENE-Y
expression O
appears O
to O
be O
specific O
for O
astrocytes. O
By O
contrast, O
the O
predominant O
neuronal O
monocarboxylate B-GENE-N
transporter I-GENE-N
is O
MCT2. B-GENE-Y
Interestingly, O
part O
of O
MCT2 B-GENE-Y
immunoreactivity O
is O
located O
at O
postsynaptic O
sites, O
suggesting O
a O
particular O
role O
of O
monocarboxylates B-CHEMICAL
and O
their O
transporters O
in O
synaptic O
transmission. O
In O
addition O
to O
variation O
in O
expression O
during O
development O
and O
upon O
nutritional O
modifications, O
new O
data O
indicate O
that O
MCT B-GENE-N
expression O

is O
regulated O
at O
the O
translational O
level O
by O
neurotransmitters. O
Understanding O
how O
transport O
of O
monocarboxylates B-CHEMICAL
is O
regulated O
could O
be O
of O
particular O
importance O
not O
only O
for O
neuroenergetics O
but O
also O
for O
areas O
such O
as O
functional O
brain O
imaging, O
regulation O
of O
food O
intake O
and O
glucose B-CHEMICAL
homeostasis, O
or O
for O
central O
nervous O
system O
disorders O
such O
as O
ischaemia O
and O
neurodegenerative O
diseases. O
Lysine B-CHEMICAL
48-linked O
polyubiquitination O
of O
organic B-GENE-Y
anion I-GENE-Y
transporter-1 I-GENE-Y
is O
essential O
for O
its O
protein B-GENE-N
kinase I-GENE-N
C-regulated I-GENE-N
endocytosis. O
Organic B-GENE-Y
anion I-GENE-Y
transporter-1 I-GENE-Y
(OAT1) B-GENE-Y

mediates O
the O
body's O
disposition O
of O
a O
diverse O
array O
of O
environmental O
toxins O
and O
clinically O
important O
drugs. O
Therefore, O
understanding O
the O
regulation O
of O
this O
transporter O
has O
profound O
clinical O
significance. O
We O
had O
previously O
established O
that O
OAT1 B-GENE-Y
undergoes O
constitutive O
internalization O
from O
and O
recycling O
back O
to O
the O
cell O
surface O
and O
that O
acute O
activation O
of O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
inhibits O
OAT1 B-GENE-Y
activity O
by O
reducing O
OAT1 B-GENE-Y
cell-surface O
expression O
through O
accelerating O
its O
internalization O
from O
cell O
surface O
to O
intracellular O
compartments. O
However, O
the O
underlying O
mechanisms O
are O
poorly O
understood. O
In O
the O
current O
study, O
we O
provide O
novel O
evidence O
that O

acute O
activation O
of O
PKC B-GENE-N
significantly O
enhances O
OAT1 B-GENE-Y
ubiquitination O
both O
in O
vitro O
and O
ex O
vivo. O
We O
further O
show O
that O
ubiquitination O
of O
cell-surface O
OAT1 B-GENE-Y
increases O
in O
cells O
transfected O
with O
dominant O
negative O
mutant O
of O
dynamin-2, B-GENE-Y
a O
maneuver O
blocking O
OAT1 B-GENE-Y
internalization, O
which O
suggests O
that O
OAT1 B-GENE-Y
ubiquitination O
proceeds O
before O
OAT1 B-GENE-Y
internalization. O
Mass O
spectroscopy O
has O
revealed O
that O
ubiquitination O
of O
OAT1 B-GENE-Y
consists O
of O
polyubiquitin O
chains, O
primarily O
through O
lysine B-CHEMICAL
48 O
linkage. O
Transfection O
of O

cells O
with O
the O
dominant O
negative O
mutant O
of O
ubiquitin O
Ub-K48R, O
which O
prevents O
the O
formation O
of O
Lys48-linked B-CHEMICAL
polyubiquitin O
chains, O
abolishes O
PKC-stimulated B-GENE-N
OAT1 B-GENE-Y
ubiquitination O
and O
internalization. O
Together, O
our O
findings O
demonstrate O
for O
the O
first O
time O
that O
Lys48-linked B-CHEMICAL
polyubiquitination O
is O
essential O
for O
PKC-regulated B-GENE-N
OAT1 B-GENE-Y
trafficking. O
Differentiating O
the O
roles O
of O
mGlu2 B-GENE-Y
and O
mGlu3 B-GENE-Y
receptors O
using O
LY541850, B-CHEMICAL
an O
mGlu2 B-GENE-Y
agonist/mGlu3 B-GENE-Y

antagonist. O
Despite O
the O
potential O
therapeutic O
relevance O
of O
group B-GENE-N
II I-GENE-N
metabotropic I-GENE-N
glutamate I-GENE-N
(mGlu) I-GENE-N
receptors, I-GENE-N
there O
has O
been O
a O
lack O
of O
pharmacological O
tools O
for O
separating O
the O
roles O
of O
mGlu2 B-GENE-Y
and O
mGlu3 B-GENE-Y
receptor O
subtypes. O
LY541850 B-CHEMICAL
was O
claimed O
from O
human B-GENE-N
mGlu I-GENE-N
receptors I-GENE-N
expressed O
in O
non-neuronal O
cells O
to O
be O
a O
selective O
orthosteric O
mGlu2 B-GENE-Y
agonist O
and O
mGlu3 B-GENE-Y
antagonist. O
We O
have O
verified O
this O
pharmacological O
profile O
of O
LY541850 B-CHEMICAL
in O
hippocampal O
slices. O
Field O
excitatory O

post-synaptic O
potentials O
(fEPSPs) O
evoked O
by O
stimulation O
of O
the O
temporo-ammonic O
path O
(TAP) O
input O
to O
CA1 O
stratum O
lacunosum O
moleculare O
(SLM) O
were O
inhibited O
by O
LY541850 B-CHEMICAL
in O
mGlu3-/- B-GENE-Y
mice O
(EC(50) O
38 O
nM) O
and O
wild-type O
littermates O
(EC(50) O
42 O
nM) O
to O
a O
similar O
extent O
but O
were O
not O
significantly O
affected O
in O
mGlu2-/- B-GENE-Y
mice. O
The O
group O
II O
agonist, O
DCG-IV, O
inhibited O
the O

fEPSP O
in O
all O
three O
genotypes. O
Co-application O
of O
DCG-IV O
and O
LY541850 B-CHEMICAL
in O
mGlu3-/- B-GENE-Y
and O
wild-type O
littermates O
resulted O
in O
an O
additive O
effect, O
whereas O
in O
mGlu2-/- B-GENE-Y
mice, O
LY541850 B-CHEMICAL
reversed O
the O
inhibitory O
action O
of O
DCG-IV. O
These O
results O
confirm O
the O
selective O
mGlu2 B-GENE-Y
agonist O
and O
mGlu3 B-GENE-Y
antagonist O
actions O
of O
LY541850. B-CHEMICAL
A O
similar O
profile O
of O
activity O
was O
seen O
in O
medial O
perforant O
path O
synapse O
to O
the O
dentate O
gyrus. O

Systemic O
administration O
of O
LY541850 B-CHEMICAL
to O
wild-type O
mice, O
reduced O
the O
increase O
in O
locomotor O
activity O
following O
both O
phencyclidine B-CHEMICAL
and O
amphetamine B-CHEMICAL
administration. O
These O
data O
support O
the O
hypothesis O
that O
mGlu2 B-GENE-Y
receptors O
mediate O
the O
antipsychotic O
effects O
of O
mixed O
group O
II O
agonists. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic B-GENE-N
Glutamate I-GENE-N
Receptors'. I-GENE-N
Characterization O
of O
rat B-GENE-Y
brain I-GENE-Y
aldosterone I-GENE-Y
receptors I-GENE-Y
reveals O
high O
affinity O
for O
corticosterone. B-CHEMICAL
The O
two O
[3H]aldosterone-binding B-CHEMICAL
proteins O
of O
rat O
brain O

cytosol O
were O
characterized O
by O
a O
dextran-coated O
charcoal O
method. O
With O
molybdate B-CHEMICAL
present O
to O
stabilize O
receptors, O
the O
affinities O
of O
the O
two O
sites O
for O
[3H]aldosterone B-CHEMICAL
in O
adrenalectomized O
perfused O
rat O
brain O
cytosols O
were O
0.28 O
and O
18.0 O
nM O
at O
4 O
C. O
High O
affinity O
sites O
comprised O
15% O
of O
the O
total O
receptor O
number. O
A O
small O
contamination O
of O
perfused O
brain O
cytosol O
preparations O
with O
corticosteroid-binding B-GENE-Y
globulin I-GENE-Y
(CBG) B-GENE-Y
was O
found. O
However, O
due O
to O
the O
very O
high O
affinity O
of O

CBG B-GENE-Y
for O
corticosterone B-CHEMICAL
at O
4 O
C, O
this O
slight O
contamination O
resulted O
in O
significant O
alterations O
in O
the O
apparent O
affinity O
of O
steroids B-CHEMICAL
competing O
for O
aldosterone-binding B-CHEMICAL
sites. O
Selective O
precipitation O
of O
cytosol O
receptors O
with O
36% O
(NH4)2SO4 B-CHEMICAL
reduced O
CBG B-GENE-Y
concentrations O
to O
negligible O
levels. O
After O
blockade O
of O
low O
affinity O
sites O
with O
a O
highly O
selective O
glucocorticoid O
(RU B-CHEMICAL
26988), I-CHEMICAL
the O
order O
of O
steroids B-CHEMICAL
in O
competing O
for O
the O
high O
affinity O
receptor O
was O
desoxycorticosterone B-CHEMICAL
greater O
than O
fludrocortisone B-CHEMICAL
greater O
than O
corticosterone B-CHEMICAL

greater O
than O
aldosterone B-CHEMICAL
greater O
than O
progesterone B-CHEMICAL
greater O
than O
dexamethasone. B-CHEMICAL
Readdition O
of O
a O
small O
quantity O
of O
dialyzed O
serum O
to O
cytosol O
preparations O
yielded O
a O
profile O
of O
steroid B-CHEMICAL
binding O
similar O
to O
that O
of O
the O
kidney O
mineralocorticoid B-GENE-Y
receptor I-GENE-Y
(aldosterone B-CHEMICAL
greater O
than O
desoxycorticosterone B-CHEMICAL
greater O
than O
corticosterone). B-CHEMICAL
The O
distribution O
of O
both O
receptors O
in O
brain O
regions O
of O
adrenalectomized O
rats O
was O
determined. O
Both O
receptors O
were O
at O
greatest O
density O
in O
the O
hippocampus O
and O
lowest O
density O
in O
the O
hypothalamus. O
The O
high O
affinity O
site O
was O
at O

greatest O
density O
in O
limbic O
regions, O
whereas O
the O
low O
affinity O
receptor, O
apparently O
identical O
to O
the O
glucocorticoid B-GENE-N
type I-GENE-N
II I-GENE-N
receptor, I-GENE-N
was O
at O
greatest O
density O
in O
cortex O
and O
cerebellum. O
It O
is O
concluded O
that O
the O
high O
affinity O
aldosterone B-GENE-Y
receptor I-GENE-Y
of O
rat O
brain, O
which O
had O
been O
identified O
in O
preliminary O
studies O
as O
a O
mineralocorticoid B-GENE-Y
receptor, I-GENE-Y
may O
bind O
either O
corticosterone B-CHEMICAL
or O
aldosterone B-CHEMICAL
in O
vivo. O
Acromegaly: O
molecular O
expression O
of O
somatostatin B-GENE-N
receptor I-GENE-N
subtypes O
and O
treatment O
outcome. O
About O
a O
third O
of O
acromegalic O
patients O
are O
resistant O
to O
the O
currently O
commercially O

available O
somatostatin B-CHEMICAL
analogs O
(SA) O
octreotide B-CHEMICAL
and O
lanreotide. B-CHEMICAL
Such O
resistance O
is O
related O
to O
an O
overall O
reduction O
of O
somatostatin B-GENE-N
receptor I-GENE-N
(SSTR) B-GENE-N
density O
or O
to O
a O
differentiated O
expression O
of O
SSTR B-GENE-N
subtypes. O
There O
are O
five O
known O
SSTR B-GENE-N
subtypes. O
SSTR2 B-GENE-Y
and O
SSTR5 B-GENE-Y
are O
usually O
expressed O
in O
GH-secreting B-GENE-Y
pituitary O
tumors, O
and O
both O
octreotide B-CHEMICAL
and O
lanreotide B-CHEMICAL
bind O
preferentially O
to O
SSTR2 B-GENE-Y
and, O
to O
a O
lesser O
extent, O
to O
SSTR5. B-GENE-Y
SA O
inhibitory O
effects O
on O
GH B-GENE-Y

secretion O
and O
tumor O
cell O
proliferation O
can O
occur O
together O
or O
be O
dissociated O
events, O
depending O
on O
the O
tumor O
expression O
of O
SSTR B-GENE-N
subtypes O
involved O
in O
each O
mechanism. O
The O
development O
of O
specific O
somatostatin B-CHEMICAL
subtypes O
analogs, O
mainly O
for O
SSTR5, B-GENE-Y
of O
a O
SSTR2-SSTR5 B-GENE-Y
bispecific O
compound, O
and O
of O
a O
"universal" O
analog O
with O
high O
affinity O
to O
SSTR1, B-GENE-N
2, I-GENE-N
3, I-GENE-N
and I-GENE-N
5 I-GENE-N
showed O
preliminary, O
albeit O
promising O
results O
for O
the O
treatment O
of O
resistant O
somatotropic O
adenomas. O
REMNANT O
UPTAKE O
AS O
A O
POSTOPERATIVE O

ONCOLOGIC O
QUALITY O
INDICATOR. O
BACKGROUND: O
The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
utility O
of O
remnant O
uptake O
on O
postoperative O
radioiodine B-CHEMICAL
scans O
as O
an O
oncologic O
indicator O
after O
thyroidectomy O
for O
differentiated O
thyroid O
cancer O
(DTC). O
METHODS: O
We O
conducted O
a O
retrospective O
review O
of O
patients O
undergoing O
total O
thyroidectomy O
for O
DTC O
and O
subsequent O
radioactive O
iodine B-CHEMICAL
(RAI) O
treatment. O
Of O
the O
eight O
surgeons O
included, O
three O
were O
considered O
high O
volume, O
performing O
at O
least O
20 O

thyroidectomies O
per O
year. O
Patients O
with O
distant O
metastases O
at O
diagnosis O
or O
poorly O
differentiated O
variants O
were O
excluded. O
To O
control O
for O
the O
effect O
of O
varying O
RAI O
doses, O
the O
remnant O
uptake O
was O
analyzed O
as O
a O
ratio O
of O
the O
percentage O
uptake O
to O
the O
dose O
received O
(uptake O
to O
dose O
ratio, O
UDR). O
Multivariate O
logistic O
regression O
was O
used O
to O
determine O
the O
influence O
of O
UDR O
on O
recurrence. O
RESULTS: O
Of O
the O
223 O
patients O
who O
met O
inclusion O
criteria, O
21 O
patients O
(9.42%) O
experienced O
a O
recurrence. O
Those O
who O
recurred O
had O
a O
ten-fold O
higher O

UDR O
compared O
to O
those O
who O
did O
not O
recur O
(0.030 O
vs. O
0.003, O
p O
= O
0.001). O
Similarly, O
patients O
with O
increasing O
postoperative O
thyroglobulin B-GENE-Y
measurements O
(0.339 O
vs. O
0.003, O
p<0.001) O
also O
had O
significantly O
greater O
UDRs O
compared O
to O
those O
with O
stable O
thyroglobulin. B-GENE-Y
The O
UDRs O
of O
high O
volume O
surgeons O
were O
significantly O
smaller O
than O
low O
volume O
surgeons O
(0.003 O
vs. O
0.025, O
p O
= O
0.002). O
When O
combined O
with O
other O
known O
predictors O

for O
recurrence, O
UDR O
(OR O
3.71, O
C.I O
1.05 O
- O
13.10, O
p O
= O
0.041) O
was O
significantly O
associated O
with O
recurrence. O
High O
volume O
surgeons O
maintained O
a O
low O
level O
of O
permanent O
complications O
across O
all O
UDRs O
whereas O
low O
volume O
surgeons O
had O
greater O
permanent O
complications O
associated O
with O
higher O
uptake. O
Bioactivation O
of O
the O
nasal O
toxicant O
2,6-dichlorobenzonitrile: B-CHEMICAL
an O
assessment O
of O
metabolic O
activity O
in O
human O
nasal O
mucosa O
and O
identification O
of O
indicators O
of O
exposure O
and O
potential O
toxicity. O
The O
herbicide O

2,6-dichlorobenzonitrile B-CHEMICAL
(DCBN) B-CHEMICAL
is O
a O
potent O
nasal O
toxicant O
in O
rodents; O
however, O
it O
is O
not O
known O
whether O
DCBN B-CHEMICAL
causes O
similar O
nasal O
toxicity O
in O
humans. O
The O
tissue-selective O
toxicity O
of O
DCBN B-CHEMICAL
in O
mouse O
nasal O
mucosa O
is O
largely O
dependent O
on O
target O
tissue O
bioactivation O
by O
CYP2A5. B-GENE-Y
The O
human O
orthologues O
of O
CYP2A5, B-GENE-Y
CYP2A6 B-GENE-Y
and O
CYP2A13, B-GENE-Y
are O
both O
expressed O
in O
nasal O
mucosa O
and O
are O
capable O
of O
activating O
DCBN. B-CHEMICAL
In O
this O
study, O
we O
directly O
determined O
the O

ability O
of O
human O
nasal O
mucosa O
to O
bioactivate O
DCBN. B-CHEMICAL
We O
also O
tested O
the O
suitability O
of O
a O
glutathione B-CHEMICAL
conjugate O
of O
DCBN B-CHEMICAL
(GS-DCBN) B-CHEMICAL
or O
its O
derivatives O
as O
biomarkers O
of O
DCBN B-CHEMICAL
exposure O
and O
nasal O
toxicity O
in O
mouse O
models. O
We O
found O
that O
human O
fetal O
nasal O
mucosa O
microsomes O
catalyze O
the O
formation O
of O
GS-DCBN, B-CHEMICAL
with O
a O
Km O
value O
comparable O
to O
that O
of O
adult O
mouse O
nasal O
mucosa O
microsomes. O
The O
activity O
of O
the O
human O
nasal O
mucosa O
microsomes O
was O
inhibited O
by O

8-methoxypsoralen, B-CHEMICAL
a O
known O
CYP2A B-GENE-N
inhibitor. O
GS-DCBN B-CHEMICAL
and O
its O
metabolites O
were O
detected O
in O
the O
nasal O
mucosa O
and O
nasal-wash O
fluid O
obtained O
from O
DCBN-treated B-CHEMICAL
mice, O
in O
amounts O
that O
increased O
with O
escalations O
in O
DCBN B-CHEMICAL
dose, O
and O
they O
were O
all O
still O
detectable O
at O
24 O
h O
after O
a O
DCBN B-CHEMICAL
treatment O
(at O
10 O
mg/kg). O
Further O
studies O
in O
Cyp2a5-null B-GENE-Y
mice O
indicated O
that O
GS-DCBN B-CHEMICAL
and O
its O
metabolites O
in O
nasal-wash O
fluid O
were O
generated O
in O
the O
nasal O
mucosa, O

rather O
than O
in O
other O
organs. O
Thus, O
our O
data O
indicate O
for O
the O
first O
time O
that O
the O
human O
nasal O
mucosa O
is O
capable O
of O
bioactivating O
DCBN B-CHEMICAL
and O
that O
GS-DCBN B-CHEMICAL
and O
its O
metabolites O
in O
nasal-wash O
fluid O
may O
collectively O
serve O
as O
indicators O
of O
DCBN B-CHEMICAL
exposure O
and O
potential O
nasal O
toxicity O
in O
humans. O
Effects O
of O
some O
mono- B-CHEMICAL
and I-CHEMICAL
bisquaternary I-CHEMICAL
ammonium I-CHEMICAL
compounds O
on O
the O
reactivatability O
of O
soman-inhibited B-CHEMICAL
human B-GENE-Y
acetylcholinesterase I-GENE-Y
in O
vitro. O
Acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
inhibited O
by O
the O

organophosphate B-CHEMICAL
soman B-CHEMICAL
(1,2,2-trimethyl-propylmethylphosphonofluoridate) B-CHEMICAL
rapidly O
becomes O
resistant O
to O
reactivation O
by O
oximes B-CHEMICAL
due O
to O
dealkylation O
of O
the O
soman-enzyme B-CHEMICAL
complex. O
This O
reaction O
is O
called O
aging. O
The O
effect O
of O
the O
four O
mono- B-CHEMICAL
and I-CHEMICAL
bisquaternary I-CHEMICAL
ammonium I-CHEMICAL
compounds O
tetramethylammonium B-CHEMICAL
(TMA), B-CHEMICAL
hexamethonium, B-CHEMICAL
decamethonium B-CHEMICAL
and O
suxamethonium B-CHEMICAL
on O
the O
reactivatability O
of O
soman-inhibited, B-CHEMICAL
solubilized O
AChE B-GENE-Y
from O
human O

erythrocytes O
was O
investigated O
in O
vitro. O
All O
compounds O
were O
reversible O
inhibitors O
of O
AChE; B-GENE-Y
the O
respective O
dissociation O
constants O
and O
the O
type O
of O
inhibition O
exhibited O
considerable O
differences. O
The O
affinities O
to O
both O
the O
active O
and O
the O
allosteric O
site O
were O
considerably O
higher O
for O
suxamethonium B-CHEMICAL
(Kii O
81.3 O
microM; O
Ki O
15.9 O
microM) O
and O
decamethonium B-CHEMICAL
(Kii O
15.4 O
microM; O
Ki O
4.4 O
microM) O
than O
for O
TMA B-CHEMICAL
(Kii O
1 O
mM; O
Ki O
289.6 O
microM) O
and O
hexamethonium B-CHEMICAL

(Kii O
4.5 O
mM; O
Ki O
331.8 O
microM). O
The O
reactivation O
experiments O
were O
performed O
in O
a O
four-step O
procedure O
(soman-inhibition B-CHEMICAL
at O
0 O
degree O
and O
pH O
10, O
aging O
at O
37 O
degrees O
and O
pH O
7.3, O
reactivation O
by O
the O
oxime B-CHEMICAL
HI O
6 O
at O
37 O
degrees O
and O
pH O
7.3 O
followed O
by O
AChE B-GENE-Y
assay). O
After O
these O
four O
steps O
(total O
duration O
55 O
min), O
AChE B-GENE-Y
was O
inhibited O
by O
soman O
to O
95-100%. O
HI O
6 O
could O
reactivate O
about O
20% O
of O
the O
inhibited O
enzyme. O
All O
effectors O

increased O
the O
AChE B-GENE-Y
reactivatability O
by O
HI O
6 O
when O
added O
before O
aging O
was O
started. O
The O
maximal O
increase O
in O
reactivatability O
was O
higher O
in O
the O
presence O
of O
1.6 O
mM O
suxamethonium B-CHEMICAL
(+35.8%) O
and O
150 O
microM O
decamethonium B-CHEMICAL
(+40%) O
than O
of O
22 O
mM O
TMA B-CHEMICAL
(+22.5%) O
and O
8.3 O
mM O
hexamethonium B-CHEMICAL
(+19.2%). O
If O
the O
effectors O
were O
added O
after O
5 O
min O
of O
aging O
they O
increased O
the O
activity O
of O
soman-inhibited B-CHEMICAL
AChE, B-GENE-Y
but O
to O

a O
considerably O
smaller O
extent O
than O
HI O
6. O
A O
good O
correlation O
of O
the O
respective O
Kii O
values O
and O
the O
effective O
concentrations O
of O
these O
drugs O
was O
observed, O
indicating O
that O
an O
allosteric O
binding O
site O
of O
AChE B-GENE-Y
might O
be O
involved O
in O
the O
protective O
effect O
of O
these O
drugs. O
Atp-bound O
topoisomerase B-GENE-Y
ii I-GENE-Y
as O
a O
target O
for O
antitumor O
drugs. O
Topoisomerase B-GENE-Y
II I-GENE-Y
(TOP2) B-GENE-Y
poisons O
interfere O
with O
the O
breakage/reunion O
reaction O
of O
TOP2 B-GENE-Y
resulting O
in O
DNA O
cleavage. O
In O
the O
current O
studies, O
we O
show O
that O
two O
different O
classes O
(ATP-sensitive B-CHEMICAL
and O
-insensitive) O
of O
TOP2 B-GENE-Y

poisons O
can O
be O
identified O
based O
on O
their O
differential O
sensitivity O
to O
the O
ATP-bound B-CHEMICAL
conformation O
of O
TOP2. B-GENE-Y
First, O
in O
the O
presence O
of O
1 O
mm O
ATP B-CHEMICAL
or O
the O
nonhydrolyzable O
analog O
adenosine B-CHEMICAL
5'-(beta,gamma-imino)triphosphate, I-CHEMICAL
TOP2-mediated B-GENE-Y
DNA O
cleavage O
induced O
by O
ATP-sensitive B-CHEMICAL
TOP2 B-GENE-Y
poisons O
(e.g. O
doxorubicin, B-CHEMICAL
etoposide, B-CHEMICAL
mitoxantrone, B-CHEMICAL
and O
4'-(9-acridinylamino)methanesulfon-m-anisidide) B-CHEMICAL

was O
30-100-fold O
stimulated, O
whereas O
DNA O
cleavage O
induced O
by O
ATP-insensitive B-CHEMICAL
TOP2 B-GENE-Y
poisons O
(e.g. O
amonafide, B-CHEMICAL
batracylin, B-CHEMICAL
and O
menadione) B-CHEMICAL
was O
only O
slightly O
(less O
than O
3-fold) O
affected. O
In O
addition, O
ADP B-CHEMICAL
was O
shown O
to O
strongly O
antagonize O
TOP2-mediated B-GENE-Y
DNA O
cleavage O
induced O
by O
ATP-sensitive B-CHEMICAL
but O
not O
ATP-insensitive B-CHEMICAL
TOP2 B-GENE-Y
poisons. O
Second, O
C427A B-GENE-N
mutant O
human B-GENE-Y
TOP2alpha, I-GENE-Y
which O
exhibits O
reduced O
ATPase B-GENE-N
activity, O
was O
shown O
to O
exhibit O
cross-resistance O
to O
all O

ATP-sensitive B-CHEMICAL
but O
not O
ATP-insensitive B-CHEMICAL
TOP2 B-GENE-Y
poisons. O
Third, O
using O
ciprofloxacin B-CHEMICAL
competition O
assay, O
TOP2-mediated B-GENE-Y
DNA O
cleavage O
induced O
by O
ATP-sensitive B-CHEMICAL
but O
not O
ATP-insensitive B-CHEMICAL
poisons O
was O
shown O
to O
be O
antagonized O
by O
ciprofloxacin. B-CHEMICAL
These O
results O
suggest O
that O
ATP-bound B-CHEMICAL
TOP2 B-GENE-Y
may O
be O
the O
specific O
target O
of O
ATP-sensitive B-CHEMICAL
TOP2 B-GENE-Y
poisons. O
Using O
Lac B-GENE-N
repressor-operator I-GENE-N
complexes I-GENE-N
as O
roadblocks, O
we O
show O
that O
ATP-bound B-CHEMICAL
TOP2 B-GENE-Y
acts O
as O
a O
circular O
clamp O
capable O
of O
entering O
DNA O

ends O
and O
sliding O
on O
unobstructed O
duplex O
DNA. O
Tunable O
morphology O
and O
mesophase O
formation O
by O
naphthalene-containing B-CHEMICAL
poly(aryl B-CHEMICAL
ether) I-CHEMICAL
dendron-based O
low-molecular-weight O
fluorescent O
gels. O
Novel O
poly(aryl B-CHEMICAL
ether) I-CHEMICAL
dendron-based O
low-molecular-weight O
organogelaters O
(LMWG) O
containing O
naphthalene B-CHEMICAL
units O
at O
the O
core O
have O
been O
synthesized, O
and O
the O
self-assembly O
of O
the O
system O
has O
been O
examined O
in O
a O
variety O
of O
solvents O
and O
solvent O
mixtures. O
The O
compounds O
readily O
form O
gels O
with O
attractive O
critical O
gel O
concentration O
values O

associated O
with O
gelation-induced O
enhanced O
emission O
(GIEE). O
In O
addition O
to O
the O
remarkable O
properties O
of O
the O
previously O
reported O
anthracene B-CHEMICAL
and O
pyrene B-CHEMICAL
analogues O
(Rajamalli, O
P.; O
Prasad, O
E. O
Org. O
Lett.2011, O
13, O
3714 O
and O
Rajamalli, O
P.; O
Prasad, O
E. O
Soft O
Matter2012, O
8, O
8896), O
the O
self-assembled O
systems O
exhibit O
distinctly O
different O
structure-property O
relationships. O
Unlike O
the O
reported O
ones, O
the O
present O
system O
forms O
sheetlike O
morphology O
in O
nonpolar O
solvent O
mixtures, O
giant O
vesicles O
in O
polar O
solvent O
mixtures, O
and O

lamellar O
or O
hexagonal O
columnar O
phases O
in O
single O
solvents. O
The O
unique O
properties O
of O
the O
self-assembled O
systems, O
which O
were O
analyzed O
through O
electron O
microscopic O
(SEM, O
TEM, O
AFM) O
and O
spectroscopic O
techniques O
(POM, O
fluorescence), O
are O
attributed O
to O
the O
replacement O
of O
anthracene/pyrene B-CHEMICAL
units O
by O
naphthalene B-CHEMICAL
units. O
The O
present O
work O
unravels O
the O
subtle O
role O
of O
minute O
structural O
change O
in O
altering O
the O
properties O
of O
LMWGs O
based O
on O
poly(aryl B-CHEMICAL
ether) I-CHEMICAL
dendrons. O
Turnover O
of O
type B-GENE-N
II I-GENE-N
collagen I-GENE-N
and O

aggrecan B-GENE-Y
in O
cartilage O
matrix O
at O
the O
onset O
of O
inflammatory O
arthritis O
in O
humans: O
relationship O
to O
mediators O
of O
systemic O
and O
local O
inflammation. O
OBJECTIVE: O
To O
determine O
in O
vivo O
the O
extent O
of O
damage O
to, O
and O
changes O
in O
turnover O
of, O
articular O
cartilage O
type B-GENE-N
II I-GENE-N
collagen I-GENE-N
(CII) B-GENE-N
and O
the O
proteoglycan B-GENE-N
aggrecan B-GENE-Y
following O
the O
onset O
of O
inflammatory O
arthritis O
in O
humans, O
and O
to O
examine O
the O
hypothesis O
that O
there O
are O
direct O
relationships O
between O
cartilage O
biomarkers O
of O
damage/turnover O
and O
clinical, O
histologic, O
and O
molecular O
markers O
of O
inflammation. O

METHODS: O
Synovial O
fluid O
(SF) O
and O
synovial O
membrane O
(SM) O
were O
obtained O
by O
arthroscopy, O
and O
a O
synovitis O
score O
was O
determined, O
in O
32 O
patients O
with O
rheumatoid O
arthritis O
(RA) O
(13 O
with O
early O
untreated O
disease, O
19 O
with O
established O
disease), O
18 O
with O
psoriatic O
arthritis O
(PsA), O
and O
10 O
with O
osteoarthritis O
(OA). O
Systemic O
disease O
activity O
markers O
were O
recorded, O
and O
SM O
CD3+ O
T O
cells, O
CD4+ O
T O
cells, O
CD68+ O

macrophages, O
and O
lining O
layer O
hyperplasia O
were O
quantified. O
SF O
levels O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TNFalpha), B-GENE-Y
interleukin-10 B-GENE-Y
(IL-10), B-GENE-Y
matrix B-GENE-Y
metalloproteinase I-GENE-Y
1 I-GENE-Y
(MMP-1), B-GENE-Y
MMP-3, B-GENE-Y
Col2-3/4C(Long B-GENE-N
mono) I-GENE-N
neoepitope I-GENE-N
(C2C) B-GENE-N
(reflecting O
collagenase B-GENE-N
cleavage O
of O
cartilage O
CII), B-GENE-N
C-propeptide B-GENE-N
of I-GENE-N
type I-GENE-N
II I-GENE-N
procollagen I-GENE-N
(PIICP) B-GENE-N
(a O
biosynthesis O

marker), O
keratan O
sulfate B-CHEMICAL
(KS), O
and O
the O
846 O
epitope O
of O
aggrecan B-GENE-Y
(turnover) O
were O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
or O
radioimmunoassay. O
RESULTS: O
Levels O
of O
cartilage O
degradation O
products O
in O
early O
RA O
or O
early O
PsA O
were O
not O
elevated O
above O
levels O
in O
OA, O
although O
in O
early O
inflammatory O
arthritis, O
TNFalpha B-GENE-Y
and O
MMP-1 B-GENE-Y
levels O
were O
similar O
to O
those O
observed O
in O
late O
inflammatory O
disease O
and O
higher O
than O
those O
in O
OA. O
PIICP B-GENE-N
was O
reduced O
in O
early O
RA. O

Correlations O
were O
observed O
between O
the O
SF O
C2C B-GENE-N
neoepitope I-GENE-N
level O
and O
the O
Health O
Assessment O
Questionnaire O
score, O
C-reactive B-GENE-Y
protein I-GENE-Y
level, O
plasma O
viscosity, O
synovitis O
score, O
and O
SF O
TNFalpha B-GENE-Y
and O
MMP-1 B-GENE-Y
levels. O
KS O
epitope O
content O
was O
reduced O
in O
direct O
relation O
to O
SM O
macrophage O
infiltration O
in O
the O
sublining O
and O
lining O
layers O
and O
in O
the O
presence O
of O
elevated O
SF O
MMP-3. B-GENE-Y
Both O
SF O
MMP-1 B-GENE-Y
and O
SF O
MMP-3 B-GENE-Y
levels O
correlated O
with O
CD4+ O
T O
cell O
infiltration O
and O
lining O
layer O
hyperplasia O
in O
the O
SM, O

and O
MMP-1 B-GENE-Y
levels O
correlated O
with O
lining O
layer O
CD68 B-GENE-Y
levels, O
but O
TNFalpha B-GENE-Y
and O
IL-10 B-GENE-Y
levels O
did O
not. O
CONCLUSION: O
Except O
for O
CII B-GENE-N
synthesis, O
there O
were O
no O
significant O
changes O
in O
extracellular O
matrix O
turnover O
of O
aggrecan B-GENE-Y
or O
CII B-GENE-N
in O
the O
early O
stages O
of O
human O
inflammatory O
arthritis. O
However, O
the O
direct O
correlation O
between O
the O
increases O
in O
TNFalpha B-GENE-Y
and O
MMP-1 B-GENE-Y
production O
and O
collagen B-GENE-N
degradation O
suggests O
that O
collagenase B-GENE-N
cleavage O
of O
cartilage O
collagen B-GENE-N
is O
related O
to O
the O
activities O
of O
TNFalpha B-GENE-Y
and O
MMP-1. B-GENE-Y
The O

reduction O
in O
CII B-GENE-N
synthesis O
in O
early O
RA O
may O
contribute O
to O
the O
developing O
pathology, O
since O
a O
lack O
of O
synthesis O
of O
this O
molecule O
would O
inhibit O
maintenance O
of O
cartilage O
matrix. O
Activation O
of O
ALDH2 B-GENE-Y
with O
ethanol B-CHEMICAL
attenuates O
diabetes O
induced O
myocardial O
injury O
in O
rats. O
This O
study O
assessed O
changes O
in O
myocardial O
ALDH2 B-GENE-Y
expression O
in O
the O
diabetic O
rat, O
in O
particular O
the O
diabetic O
rat O
pretreated O
with O
ALDH2 B-GENE-Y
activator O
ethanol B-CHEMICAL
(EtOH). B-CHEMICAL
The O
rats O
were O
divided O
into O
six O
groups: O
control, O
EtOH B-CHEMICAL
control, O
diabetic O
rat O
at O
4th O
week O

(DM4W), O
8th O
week O
(DM8W), O
12th O
week O
(DM12W) O
and O
EtOH+DM8W B-CHEMICAL
groups. O
Compared O
with O
control O
group, O
fasting O
blood O
glucose B-CHEMICAL
(FBG) O
and O
glycosylated B-GENE-N
hemoglobin I-GENE-N
(HbA1c) B-GENE-N
levels O
were O
increased O
in O
DM O
groups. O
HbA1c B-GENE-N
level O
in O
DM12W O
group O
was O
higher O
than O
in O
DM4W O
group, O
HbA1c B-GENE-N
level O
in O
EtOH+DM8W B-CHEMICAL
group O
was O
lower O
than O
in O
DM8W O
group. O
Compared O
with O
control O

group, O
there O
were O
no O
changes O
of O
LVDP, O
HR O
and O
±dp/dtmax O
in O
DM4W O
group, O
but O
there O
were O
decreased O
in O
DM8W O
and O
DM12W O
groups, O
and O
increased O
in O
the O
EtOH+DM8W B-CHEMICAL
group. O
In O
DM O
groups, O
SOD B-GENE-N
activity, O
ALDH2 B-GENE-Y
mRNA O
and O
protein O
levels O
were O
reduced, O
MDA B-CHEMICAL
content O
was O
increased O
compared O
with O
control O
group; O
which O
decreased O
further O
as O
diabetes O
progressed. O
Compared O
with O
DM8W O
group, O
SOD B-GENE-N
and O
ALDH2 B-GENE-Y
in O
EtOH+DM8W B-CHEMICAL
group O
was O
increased, O
MDA B-CHEMICAL

was O
decreased. O
Our O
results O
indicated O
with O
the O
development O
of O
diabetes, O
myocardial O
ALDH2 B-GENE-Y
expression O
was O
further O
decreased O
accompanying O
decreased O
ventricular O
function. O
However, O
activation O
of O
ALDH2 B-GENE-Y
can O
decrease O
diabetes O
induced O
myocardial O
injury. O
ALDH2 B-GENE-Y
may O
be O
one O
key O
endogenous O
cardiac O
protective O
factor O
in O
diabetic O
individuals. O
Kinetic O
mechanism O
of O
quinone B-GENE-Y
oxidoreductase I-GENE-Y
2 I-GENE-Y
and O
its O
inhibition O
by O
the O
antimalarial O
quinolines. B-CHEMICAL
Quinone B-GENE-Y
oxidoreductase I-GENE-Y
2 I-GENE-Y
(QR2) B-GENE-Y
purified O
from O
human O
red O
blood O
cells O
was O
recently O
shown O
to O
be O

a O
potential O
target O
of O
the O
quinoline B-CHEMICAL
antimalarial O
compounds O
[Graves O
et O
al., O
(2002) O
Mol. O
Pharmacol. O
62, O
1364]. O
QR2 B-GENE-Y
catalyzes O
the O
two-electron O
reduction O
of O
menadione B-CHEMICAL
via O
the O
oxidation O
of O
N-alkylated B-CHEMICAL
or O
N-ribosylated B-CHEMICAL
nicotinamides. I-CHEMICAL
To O
investigate O
the O
mechanism O
and O
consequences O
of O
inhibition O
of O
QR2 B-GENE-Y
by O
the O
quinolines B-CHEMICAL
further, O
we O
have O
used O
steady-state O
and O
transient-state O
kinetics O
to O
define O
the O
mechanism O
of O
QR2. B-GENE-Y
Importantly, O
we O
have O
shown O
that O
QR2 B-GENE-Y

when O
isolated O
from O
an O
overproducing O
strain O
of O
E. O
coli O
is O
kinetically O
equivalent O
to O
the O
enzyme O
from O
the O
native O
human O
red O
blood O
cell O
source. O
We O
observe O
ping-pong O
kinetics O
consistent O
with O
one O
substrate/inhibitor O
binding O
site O
that O
shows O
selectivity O
for O
the O
oxidation O
state O
of O
the O
FAD O
cofactor, O
suggesting O
that O
selective O
inhibition O
of O
the O
liver O
versus O
red O
blood O
cell O
forms O
of O
malaria O
may O
be O
possible. O
The O
reductant O
N-methyldihydronicotinamide B-CHEMICAL
and O
the O
inhibitor O
primaquine B-CHEMICAL
bind O
exclusively O
to O
the O
oxidized O
enzyme. O
In O
contrast, O
the O
inhibitors O
quinacrine B-CHEMICAL
and O

chloroquine B-CHEMICAL
bind O
exclusively O
to O
the O
reduced O
enzyme. O
The O
quinone B-CHEMICAL
substrate O
menadione, B-CHEMICAL
on O
the O
other O
hand, O
binds O
nonspecifically O
to O
both O
forms O
of O
the O
enzyme. O
Single-turnover O
kinetics O
of O
the O
reductive O
half-reaction O
are O
chemically O
and O
kinetically O
competent O
and O
confirm O
the O
inhibitor O
selectivity O
seen O
in O
the O
steady-state O
experiments. O
Our O
studies O
shed O
light O
on O
the O
possible O
in O
vivo O
potency O
of O
the O
quinolines B-CHEMICAL
and O
provide O
a O
foundation O
for O
future O
studies O
aimed O
at O
creating O
more O
potent O
QR2 B-GENE-Y
inhibitors O
and O
at O
understanding O
the O
physiological O
significance O
of O
QR2. B-GENE-Y
HISTONE B-GENE-N

DEACETYLASE I-GENE-N
INHIBITION O
AFFECTS O
SODIUM B-GENE-Y
IODIDE I-GENE-Y
SYMPORTER I-GENE-Y
(NIS) B-GENE-Y
EXPRESSION O
AND O
INDUCES O
¹³¹I B-CHEMICAL
CYTOTOXICITY O
IN O
ANAPLASTIC O
THYROID O
CANCER O
CELLS. O
Background: O
Anaplastic O
thyroid O
cancers O
(ATC) O
represent O
only O
1-2% O
of O
all O
thyroid O
tumors, O
but O
they O
account O
for O
up O
to O
50% O
of O
the O
mortality. O
Treatment O
of O
differentiated O
thyroid O
carcinomas O
is O
well O
standardized O
and O
the O
use O

of O
radioiodine B-CHEMICAL
represents O
an O
essential O
step; O
in O
contrast, O
there O
is O
no O
standardized O
therapeutic O
approach O
for O
anaplastic O
tumors O
and O
their O
prognosis O
is O
poor. O
The O
resistance O
of O
anaplastic O
thyroid O
cancer O
to O
radioiodine B-CHEMICAL
treatment O
is O
principally O
due O
to O
the O
absence O
of O
expression O
of O
the O
sodium B-GENE-Y
iodide I-GENE-Y
symporter I-GENE-Y
(NIS), B-GENE-Y
mainly O
due O
to O
epigenetic O
silencing. O
The O
acetylation O
status O
of O
histones B-GENE-N
is O
involved O
in O
the O
epigenetic O
control O
of O
gene O
expression O
and O
is O
usually O
disrupted O
in O
advanced O
thyroid O
cancer. O
Histone B-GENE-N
deacetylase I-GENE-N
inhibitors O
have O
been O
demonstrated O
as O
potent O
anticancer O
drugs O

with O
several O
different O
effects O
on O
cell O
viability O
and O
differentiation. O
Methods: O
Stabilized O
anaplastic O
thyroid O
cancer O
cell O
lines O
(BHT-101 O
and O
CAL-62) O
and O
primary O
cultures O
from O
patients O
who O
underwent O
thyroidectomy O
for O
anaplastic O
thyroid O
cancer O
were O
treated O
with O
the O
histone B-GENE-N
deacetylase I-GENE-N
inhibitor O
LBH589. B-CHEMICAL
After O
treatment, O
we O
evaluated O
the O
expression O
and O
function O
of O
NIS. B-GENE-Y
Gene O
expression O
was O
evaluated O
by O
real-time O
PCR O
(RT-PCR); O
NIS B-GENE-N
promoter I-GENE-N
activity O
was O
determined O
with O
a O
luciferase O
reporter O
assay; O
and O
protein O
expression O
was O
assessed O

through O
immunofluorescence. O
We O
tested O
the O
protein O
function O
by O
125I B-CHEMICAL
uptake O
and O
efflux O
experiments; O
finally O
the O
cytotoxic O
effect O
of O
131I B-CHEMICAL
was O
determined O
with O
a O
clonogenic O
assay. O
Results: O
Our O
results O
demonstrate O
that O
treatment O
with O
LBH589 B-CHEMICAL
leads O
to O
NIS B-GENE-Y
RNA O
expression O
as O
shown O
by O
RT-PCR O
and O
luciferase O
assay, O
and O
to O
protein O
expression O
as O
determined O
by O
immunofluorescence O
in O
vitro O
and O
by O
immunohistochemistry O
in O
xenograft O
tumors. O
Moreover, O
125I B-CHEMICAL
uptake O
and O
efflux O
experiments O

show O
the O
correct O
protein O
function O
and O
iodine B-CHEMICAL
retention, O
that O
translate O
into O
cytotoxicity O
effects, O
as O
demonstrated O
by O
a O
clonogenic O
assay O
with O
131I B-CHEMICAL
. O
Conclusions: O
This O
study O
supplies O
a O
new O
potential O
strategy O
for O
the O
treatment O
of O
ATC O
by O
modifying O
gene O
expression O
with O
the O
aim O
of O
inducing O
responsiveness O
towards O
radioiodine B-CHEMICAL
therapy. O
EphB4 B-GENE-Y
enhances O
the O
process O
of O
endochondral O
ossification O
and O
inhibits O
remodeling O
during O
bone O
fracture O
repair. O
Previous O
reports O
have O
identified O
a O
role O
for O
the O
tyrosine B-GENE-N
kinase I-GENE-N
receptor I-GENE-N
EphB4 B-GENE-Y
and O
its O

ligand, O
ephrinB2, B-GENE-Y
as O
potential O
mediators O
of O
both O
bone O
formation O
by O
osteoblasts O
and O
bone O
resorption O
by O
osteoclasts. O
In O
the O
present O
study, O
we O
examined O
the O
role O
of O
EphB4 B-GENE-Y
during O
bone O
repair O
after O
traumatic O
injury. O
We O
performed O
femoral O
fractures O
with O
internal O
fixation O
in O
transgenic O
mice O
that O
overexpress O
EphB4 B-GENE-Y
under O
the O
collagen B-GENE-N
type I-GENE-N
1 I-GENE-N
promoter I-GENE-N
(Col1-EphB4) B-GENE-N
and O
investigated O
the O
bone O
repair O
process O
up O
to O
12 O
weeks O
postfracture. O
The O
data O
indicated O
that O
Col1-EphB4 B-GENE-N
mice O
exhibited O
stiffer O

and O
stronger O
bones O
after O
fracture O
compared O
with O
wild-type O
mice. O
The O
fractured O
bones O
of O
Col1-EphB4 B-GENE-N
transgenic O
mice O
displayed O
significantly O
greater O
tissue O
and O
bone O
volume O
2 O
weeks O
postfracture O
compared O
with O
that O
of O
wild-type O
mice. O
These O
findings O
correlated O
with O
increased O
chondrogenesis O
and O
mineral O
formation O
within O
the O
callus O
site O
at O
2 O
weeks O
postfracture, O
as O
demonstrated O
by O
increased O
safranin B-CHEMICAL
O I-CHEMICAL
and O
von O
Kossa O
staining, O
respectively. O
Interestingly, O
Col1-EphB4 B-GENE-N
mice O
were O
found O
to O
possess O
significantly O
greater O
numbers O
of O
clonogenic O
mesenchymal O
stromal O
progenitor O
cells O

(CFU-F), O
with O
an O
increased O
capacity O
to O
form O
mineralized O
nodules O
in O
vitro O
under O
osteogenic O
conditions, O
when O
compared O
with O
those O
of O
the O
wild-type O
control O
mice. O
Furthermore, O
Col1-EphB4 B-GENE-N
mice O
had O
significantly O
lower O
numbers O
of O
TRAP-positive B-GENE-Y
multinucleated O
osteoclasts O
within O
the O
callus O
site. O
Taken O
together, O
these O
observations O
suggest O
that O
EphB4 B-GENE-Y
promotes O
endochondral O
ossification O
while O
inhibiting O
osteoclast O
development O
during O
callus O
formation O
and O
may O
represent O
a O
novel O
drug O
target O
for O
the O
repair O
of O
fractured O
bones. O
Inverted O

CdSe/CdS/ZnS B-CHEMICAL
quantum O
dot O
light O
emitting O
devices O
with O
titanium B-CHEMICAL
dioxide I-CHEMICAL
as O
an O
electron-injection O
contact. O
We O
demonstrated O
the O
fabrication O
of O
inverted O
CdSe/CdS/ZnS B-CHEMICAL
quantum O
dot O
light O
emitting O
devices O
(QD-LEDs) O
using O
titanium B-CHEMICAL
dioxide I-CHEMICAL
(TiO2) B-CHEMICAL
as O
an O
electron-injection O
layer O
and O
investigated O
the O
operating O
mechanism O
by O
utilizing O
different O
hole-transport O
materials, O
4,4-N,N-dicarbazole-biphenyl B-CHEMICAL
(CBP) B-CHEMICAL
and O

4,4',4''-tris(carbazol-9-yl)-triphenylamine B-CHEMICAL
(TCTA). B-CHEMICAL
A O
more O
efficient O
device O
with O
CBP O
as O
the O
hole-transport O
layer O
(HTL) O
was O
obtained O
compared O
with O
the O
TCTA B-CHEMICAL
based O
device. O
The O
peak O
efficiency O
of O
6.70 O
cd O
A(-1) O
for O
the O
CBP O
based O
device O
was O
found O
to O
be O
about O
74.5% O
higher O
than O
the O
TCTA B-CHEMICAL
based O
device O
(3.84 O
cd O
A(-1)). O
The O
studies O
on O
the O
time-resolved O
photoluminescence O
spectra O
of O

the O
QD-HTL O
composite O
structures O
showed O
that O
the O
energy O
transfer O
(ET) O
efficiencies O
from O
the O
two O
HTLs O
to O
the O
QD O
layer O
were O
similar O
and O
the O
charge O
separation O
between O
QDs O
and O
HTLs O
could O
be O
neglected. O
The O
enhancement O
in O
the O
performance O
of O
the O
CBP O
based O
device O
was O
attributed O
to O
the O
more O
efficient O
hole-injection O
from O
CBP O
to O
QDs. O
Pharmacokinetic O
Interactions O
between O
Monoamine B-GENE-Y
Oxidase I-GENE-Y
A I-GENE-Y
Inhibitor O
Harmaline B-CHEMICAL
and O
5-Methoxy-N,N-Dimethyltryptamine, B-CHEMICAL
and O
the O
Impact O
of O
CYP2D6 B-GENE-Y

Status. O
5-Methoxy-N,N-dimethyltryptamine B-CHEMICAL
(5-MeO-DMT B-CHEMICAL
or O
street O
name O
"5-MEO") B-CHEMICAL
is O
a O
newer O
designer O
drug O
belonging O
to O
a O
group O
of O
naturally O
occurring O
indolealkylamines. B-CHEMICAL
Our O
recent O
study O
has O
demonstrated O
that O
coadministration O
of O
monoamine B-GENE-Y
oxidase I-GENE-Y
A I-GENE-Y
(MAO-A) B-GENE-Y
inhibitor O
harmaline B-CHEMICAL
(5 O
mg/kg) O
increases O
systemic O
exposure O
to O
5-MeO-DMT B-CHEMICAL
(2 O
mg/kg) O
and O
active O
metabolite O
bufotenine. O
This O
study O
is O
aimed O
at O

delineating O
harmaline B-CHEMICAL
and O
5-MeO-DMT B-CHEMICAL
pharmacokinetic O
(PK) O
interactions O
at O
multiple O
dose O
levels, O
as O
well O
as O
the O
impact O
of O
CYP2D6 B-GENE-Y
that O
affects O
harmaline B-CHEMICAL
PK O
and O
determines O
5-MeO-DMT B-CHEMICAL
O-demethylation B-CHEMICAL
to O
produce O
bufotenine. B-CHEMICAL
Our O
data O
revealed O
that O
inhibition O
of O
MAO-A-mediated B-GENE-Y
metabolic O
elimination O
by O
harmaline B-CHEMICAL
(2, O
5, O
and O
15 O
mg/kg) O
led O
to O
a O
sharp O
increase O
in O
systemic O
and O
cerebral O
exposure O
to O
5-MeO-DMT B-CHEMICAL
(2 O
and O
10 O
mg/kg) O

at O
all O
dose O
combinations. O
A O
more O
pronounced O
effect O
on O
5-MeO-DMT B-CHEMICAL
PK O
was O
associated O
with O
greater O
exposure O
to O
harmaline B-CHEMICAL
in O
wild-type O
mice O
than O
CYP2D6-humanized B-GENE-Y
(Tg-CYP2D6) B-GENE-Y
mice. O
Harmaline B-CHEMICAL
(5 O
mg/kg) O
also O
increased O
blood O
and O
brain O
bufotenine B-CHEMICAL
concentrations O
that O
were O
generally O
higher O
in O
Tg-CYP2D6 B-GENE-Y
mice. O
Surprisingly, O
greater O
harmaline B-CHEMICAL
dose O
(15 O
mg/kg) O
reduced O
bufotenine B-CHEMICAL
levels. O
The O
in O
vivo O
inhibitory O
effect O
of O
harmaline B-CHEMICAL
on O

CYP2D6-catalyzed B-GENE-Y
bufotenine B-CHEMICAL
formation O
was O
confirmed O
by O
in O
vitro O
study O
using O
purified O
CYP2D6. B-GENE-Y
Given O
these O
findings, O
a O
unified O
PK O
model O
including O
the O
inhibition O
of O
MAO-A- B-GENE-Y
and O
CYP2D6-catalyzed B-GENE-Y
5-MeO-DMT B-CHEMICAL
metabolism O
by O
harmaline B-CHEMICAL
was O
developed O
to O
describe O
blood O
harmaline, B-CHEMICAL
5-MeO-DMT, B-CHEMICAL
and O
bufotenine B-CHEMICAL
PK O
profiles O
in O
both O
wild-type O
and O
Tg-CYP2D6 B-GENE-Y
mouse O
models. O
This O
PK O
model O
may O
be O
further O
employed O
to O
predict O

harmaline B-CHEMICAL
and O
5-MeO-DMT B-CHEMICAL
PK O
interactions O
at O
various O
doses, O
define O
the O
impact O
of O
CYP2D6 B-GENE-Y
status, O
and O
drive O
harmaline-5-MeO-DMT B-CHEMICAL
pharmacodynamics. O
Iodine-129 B-CHEMICAL
microdosing O
for O
protein O
and O
peptide O
drug O
development: O
erythropoietin B-GENE-Y
as O
a O
case O
study. O
BACKGROUND: O
Microdosing O
is O
a O
technique O
for O
studying O
the O
behavior O
of O
compounds O
in O
vivo O
at O
1/100th O
of O
the O
dose O
of O
a O
test O
substance O
calculated, O
based O
on O
animal O
data, O
to O
yield O
a O

pharmacologic O
effect. O
In O
microdosing, O
use O
is O
made O
of O
accelerator O
MS O
(AMS). O
In O
this O
study, O
we O
investigated O
whether O
(129)I-labeling B-CHEMICAL
of O
proteins O
with O
subsequent O
AMS O
measurements O
is O
a O
suitable O
method O
to O
perform O
microdose O
studies O
with O
therapeutic O
proteins. O
We O
used O
erythropoietin B-GENE-Y
(EPO) B-GENE-Y
as O
a O
case O
study. O
RESULTS: O
In O
an O
animal O
study O
with O
(129)I-labeled B-CHEMICAL
EPO B-GENE-Y
in O
Han-Wistar O
rats, O
an O
increase O
of O
(129)I-EPO B-CHEMICAL
is O
observed O
after O
dose O
administration. O
The O
half-life O
was O

found O
to O
be O
2 O
and O
5.5 O
h O
for O
two O
different O
EPOs. B-GENE-Y
These O
results O
are O
in O
accordance O
with O
expected O
values. O
CoNCLUSION: O
Although O
further O
research O
is O
required, O
(129)I-labeling B-CHEMICAL
of O
proteins O
seems O
a O
feasible O
method O
for O
AMS O
microdose O
studies O
with O
peptide O
and O
protein O
drugs, O
such O
as O
biosimilars. O
Compared O
pharmacological O
characteristics O
in O
humans O
of O
racemic O
cetirizine B-CHEMICAL
and O
levocetirizine, B-CHEMICAL
two O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonists. O
The O
potent O
histamine B-GENE-Y
H(1)-receptor I-GENE-Y
antagonist O
cetirizine B-CHEMICAL
(Zyrtec) B-CHEMICAL
is O
a O
racemic O

mixture O
of O
levocetirizine B-CHEMICAL
(now O
available O
under O
the O
trademark O
Xyzal B-CHEMICAL
and O
dextrocetirizine. B-CHEMICAL
In O
this O
Commentary, O
we O
examine O
some O
biological O
properties O
of O
cetirizine B-CHEMICAL
and O
levocetirizine, B-CHEMICAL
namely O
enantioselectivity O
in O
pharmacological O
activity O
and O
pharmacokinetic O
properties, O
with O
emphasis O
on O
the O
possibility O
of O
racemization, O
the O
compared O
behavior O
of O
the O
two O
enantiomers, O
and O
the O
potential O
for O
interactions O
with O
other O
drugs. O
Recent O
data O
demonstrate O
that O
the O
antihistaminergic O
activity O
of O
the O
racemate O
is O
primarily O
due O
to O
levocetirizine. B-CHEMICAL

Levocetirizine B-CHEMICAL
is O
rapidly O
and O
extensively O
absorbed, O
poorly O
metabolized, O
and O
not O
subject O
to O
racemization. O
Its O
pharmacokinetic O
characteristics O
are O
comparable O
after O
administration O
alone O
or O
in O
the O
racemate. O
Its O
apparent O
volume O
of O
distribution O
is O
smaller O
than O
that O
of O
dextrocetirizine B-CHEMICAL
(0.41 O
L O
kg(-1) O
vs. O
0.60 O
L O
kg(-1)). O
Moreover, O
the O
non-renal O
(mostly O
hepatic) O
clearance O
of O
levocetirizine B-CHEMICAL
is O
also O
significantly O
lower O
than O
that O
of O
dextrocetirizine B-CHEMICAL
(11.8 O
mL O

min(-1) O
vs. O
29.2 O
mL O
min(-1)). O
Our O
conclusion O
is O
that O
levocetirizine B-CHEMICAL
is O
indeed O
the O
eutomer O
of O
cetirizine. B-CHEMICAL
The O
evidence O
reviewed O
here O
confirms O
preclinical O
findings O
and O
offers O
a O
rationale O
for O
the O
chiral O
switch O
from O
the O
racemate O
to O
levocetirizine. B-CHEMICAL
Vegfrecine, B-CHEMICAL
an O
Inhibitor O
of O
VEGF B-GENE-N
Receptor I-GENE-N
Tyrosine I-GENE-N
Kinases I-GENE-N
Isolated O
from O
the O
Culture O
Broth O
of O
Streptomyces O
sp. O
A O
new O
inhibitor O
of O
VEGF B-GENE-N
receptor I-GENE-N
tyrosine I-GENE-N
kinases, I-GENE-N

vegfrecine B-CHEMICAL
(1), O
was O
isolated O
from O
the O
culture O
broth O
of O
Streptomyces O
sp. O
MK931-CF8. O
The O
molecular O
structure O
of O
1 O
was O
determined O
by O
NMR O
and O
MS O
analysis O
combined O
with O
synthesis. O
Compound O
1 O
showed O
potent O
inhibitory O
activity O
against O
vascular B-GENE-N
endothelial I-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
(VEGFR) B-GENE-N
tyrosine B-GENE-N
kinases I-GENE-N
in O
in O
vitro O
enzyme O
assays, O
but O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptors I-GENE-N
(PDGFRs), B-GENE-N
fibroblast B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
(FGFR), B-GENE-N
and O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y

(EGFR) B-GENE-Y
responded O
only O
weakly. O
Compound O
1 O
is O
a O
promising O
new O
selective O
VEGFR B-GENE-N
inhibitor O
for O
investigating O
new O
treatments O
of O
cancer O
and O
inflammatory O
diseases. O
Substrate O
specificity O
of O
the O
human B-GENE-N
renal I-GENE-N
sodium I-GENE-N
dicarboxylate I-GENE-N
cotransporter, I-GENE-N
hNaDC-3, B-GENE-Y
under O
voltage-clamp O
conditions. O
Proximal O
tubule O
cells O
extract O
dicarboxylates O
from O
filtrate O
and O
blood, O
using O
cotransporters O
located O
in O
the O
brush O
border O
[sodium B-GENE-N
dicarboxylate I-GENE-N
cotransporter I-GENE-N
(NaDC-1)] B-GENE-Y
and O
basolateral O
cell O
membrane O

(NaDC-3). B-GENE-Y
We O
expressed O
the O
human B-GENE-Y
NaDC-3 I-GENE-Y
(hNaDC-3) B-GENE-Y
in O
Xenopus O
laevis O
oocytes O
and O
characterized O
it O
by O
the O
two-electrode O
voltage-clamp O
technique. O
At O
-60 O
mV, O
succinate B-CHEMICAL
(4 O
carbons) B-CHEMICAL
and O
glutarate B-CHEMICAL
(5 O
carbons) B-CHEMICAL
generated O
inward O
currents O
due O
to O
translocation O
of O
three O
sodium B-CHEMICAL
ions O
and O
one O
divalent O
dicarboxylate, O
whereas O
oxalate B-CHEMICAL
(2 O
carbons) B-CHEMICAL
and O
malonate B-CHEMICAL
(3 O
carbons) B-CHEMICAL
did O
not. O
The O
cis-dicarboxylate B-CHEMICAL
maleate I-CHEMICAL
produced O
currents O
smaller O

in O
magnitude, O
whereas O
the O
trans-dicarboxylate B-CHEMICAL
fumarate I-CHEMICAL
generated O
currents O
similar O
to O
succinate. B-CHEMICAL
The O
substituted O
succinate B-CHEMICAL
derivatives, O
malate, B-CHEMICAL
2,2- B-CHEMICAL
and I-CHEMICAL
2,3-dimethylsuccinate, I-CHEMICAL
and O
2,3-dimercaptosuccinate B-CHEMICAL
elicited O
inward O
currents, O
whereas O
aspartate B-CHEMICAL
and O
guanidinosuccinate B-CHEMICAL
showed O
hardly O
detectable O
currents. O
The O
C-5 B-CHEMICAL
dicarboxylates I-CHEMICAL
glutarate I-CHEMICAL
and O
alpha-ketoglutarate B-CHEMICAL
produced O
larger O
currents O
than O
succinate; B-CHEMICAL
glutamate B-CHEMICAL
and O
folate B-CHEMICAL
failed O
to O
cause O
inward O
currents. O

Kinetic O
analysis O
revealed, O
at O
-60 O
mV, O
K(0.5) O
values O
of O
25 O
+/- O
12 O
microM O
for O
succinate B-CHEMICAL
and O
45 O
+/- O
13 O
microM O
for O
alpha-ketoglutarate, B-CHEMICAL
values O
close O
to O
the O
plasma O
concentration O
of O
these O
compounds. O
For O
both O
compounds, O
the O
K(0.5) O
was O
independent O
of O
voltage, O
whereas O
the O
maximal O
current O
increased O
with O
hyperpolarization. O
As O
opposed O
to O
the O
rat O
and O
flounder O
orthologs, O
hNaDC-3 B-GENE-Y
was O
hardly O
inhibited O
by O
lithium B-CHEMICAL
concentrations O
up O
to O
5 O
mM. O
In O
the O
absence O
of O

sodium, B-CHEMICAL
however, O
lithium B-CHEMICAL
can O
mediate O
succinate-dependent B-CHEMICAL
currents. O
The O
narrow O
substrate O
specificity O
prevents O
interaction O
of O
drugs O
with O
dicarboxylate-like O
structure O
with O
hNaDC-3 B-GENE-Y
and O
ensures O
sufficient O
support O
of O
the O
proximal O
tubule O
cells O
with O
alpha-ketoglutarate B-CHEMICAL
for O
anion O
secretion O
via O
organic B-GENE-N
anion I-GENE-N
transporter I-GENE-N
1 I-GENE-N
or I-GENE-N
3. I-GENE-N
Effects O
of O
inhibition O
of O
urokinase-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(u-PA) B-GENE-Y
by O
amiloride B-CHEMICAL
in O
the O
cornea O
and O
tear O
fluid O
of O
eyes O
irradiated O
with O
UVB. O
The O
purpose O
of O
the O
present O
study O
was O

to O
test O
our O
hypothesis O
that O
amiloride, B-CHEMICAL
a O
specific O
u-PA B-GENE-Y
inhibitor, O
effectively O
decreases O
u-PA B-GENE-Y
activity O
in O
cornea O
as O
well O
as O
in O
tear O
fluid O
and O
favourably O
affects O
corneal O
healing. O
Therefore, O
comparative O
histochemical O
and O
biochemical O
studies O
of O
u-PA B-GENE-Y
and O
the O
effects O
of O
amiloride B-CHEMICAL
were O
performed O
on O
rabbit O
corneas O
and O
tear O
fluid O
using O
the O
sensitive O
fluorogenic O
substrate O
Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin. B-CHEMICAL
Rabbit O
eyes O
were O
repeatedly O
irradiated O
with O
UVB O
for O
9 O
days O
and O
during O
the O
irradiation O
topically O

treated O
with O
amiloride B-CHEMICAL
(1 O
mg/ml O
saline) O
or O
placebo O
(saline) O
(dropwise, O
5 O
times O
daily). O
Results O
show O
that O
in O
placebo-treated O
eyes, O
UVB O
evoked O
the O
appearance O
of O
u-PA B-GENE-Y
activity O
in O
cornea O
and O
tear O
fluid O
in O
early O
stages O
of O
irradiation, O
and O
u-PA B-GENE-Y
levels O
increased O
during O
irradiation. O
Corneal O
epithelium O
was O
gradually O
lost O
and O
remnants O
of O
the O
epithelium O
as O
well O
as O
keratocytes O
in O
the O
upper O
part O
of O
corneal O
stroma O
showed O
high O
u-PA B-GENE-Y
activity. O
Finally, O
corneas O
lost O
their O

epithelium O
completely. O
In O
corneal O
stroma, O
numerous O
u-PA-containing B-GENE-Y
inflammatory O
cells O
were O
present. O
Corneas O
were O
vascularized. O
When O
amiloride B-CHEMICAL
was O
dropped O
on O
the O
eye O
surface O
on O
the O
first O
day O
of O
irradiation O
and O
subsequently O
daily O
until O
the O
end O
of O
the O
experiment, O
u-PA B-GENE-Y
activity O
in O
both O
cornea O
and O
tear O
fluid O
was O
strongly O
inhibited. O
Corneas O
were O
covered O
with O
a O
continuous O
epithelium O
until O
the O
end O
of O
the O
experiment. O
The O
number O
of O
inflammatory O
cells O
was O
significantly O
decreased. O
Corneal O
vascularization O
was O
reduced O
by O
50%. O
In O
conclusion, O
early O
application O
of O
amiloride B-CHEMICAL

inhibited O
u-PA B-GENE-Y
activity O
in O
UVB-irradiated O
corneas O
as O
well O
as O
in O
tear O
fluid O
and O
diminished O
the O
development O
of O
corneal O
pathology. O
Rapid O
glucocorticoid B-GENE-Y
receptor-mediated I-GENE-Y
inhibition O
of O
hypothalamic-pituitary-adrenal O
ultradian O
activity O
in O
healthy O
males. O
A O
complex O
dynamic O
ultradian O
rhythm O
underlies O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
circadian O
rhythm. O
We O
have O
investigated O
in O
normal O
human O
male O
subjects O
the O
importance, O
site O
of O
action, O
and O
receptor-mediated O
processes O
involved O
in O
rapid O
basal O
corticosteroid B-CHEMICAL
feedback O

and O
its O
interaction O
with O
corticotrophin B-GENE-Y
releasing I-GENE-Y
hormone I-GENE-Y
(CRH) B-GENE-Y
drive. O
Pro-opiomelanocortin B-GENE-Y
(POMC), B-GENE-Y
ACTH, O
and O
cortisol O
were O
measured O
every O
10 O
min O
from O
healthy O
males O
during O
the O
awakening O
period O
or O
late O
afternoon O
using O
an O
automated O
blood O
sampling O
system. O
Mathematical O
modeling O
into O
discrete O
pulses O
of O
activity O
revealed O
that O
intravenous O
infusion O
of O
the O
synthetic O
mixed O
glucocorticoid/mineralocorticoid O
agonist O
prednisolone B-CHEMICAL
produced O
rapid O
inhibition O
of O
ACTH O
and O
cortisol B-CHEMICAL
pulsatility O
within O
30 O
min O
in O
the O
morning O
and O
afternoon. O

Any O
pulse O
that O
had O
commenced O
at O
the O
time O
of O
injection O
was O
unaffected, O
and O
subsequent O
pulsatility O
was O
inhibited. O
Prednisolone B-CHEMICAL
also O
inhibited O
ACTH O
and O
cortisol B-CHEMICAL
secretion O
in O
response O
to O
exogenous O
CRH B-GENE-Y
stimulation, O
inferring O
rapid O
feedback O
inhibition O
at O
the O
anterior O
pituitary. O
Circulating O
POMC B-GENE-Y
peptide O
concentrations O
were O
unaffected, O
suggesting O
that O
the O
rapid O
corticosteroid B-CHEMICAL
inhibitory O
effect O
specifically O
targeted O
ACTH O
secretion O
from O
pituitary O
corticotrophs. O
Prednisolone B-CHEMICAL
fast O
feedback O
was O
only O
reduced O
by O

glucocorticoid B-GENE-Y
receptor I-GENE-Y
antagonist O
pretreatment O
and O
not O
by O
mineralocorticoid B-GENE-Y
receptor I-GENE-Y
antagonism, O
suggesting O
a O
glucocorticoid B-GENE-Y
receptor-mediated I-GENE-Y
pathway. O
The O
intravenous O
prednisolone B-CHEMICAL
suppression O
test O
provides O
a O
powerful O
new O
tool O
to O
investigate O
HPA O
abnormalities O
underlying O
metabolic O
and O
psychiatric O
disease O
states. O
Localization O
of O
L-glutamate B-GENE-N
decarboxylase I-GENE-N
and O
GABA B-GENE-Y
transaminase I-GENE-Y
immunoreactivity O
in O
the O
sympathetic O
ganglia O
of O
the O
rat. O
The O
location O
of O
L-glutamate B-GENE-N
decarboxylase I-GENE-N
and O
gamma-aminobutyrate B-GENE-Y

(GABA)-transaminase I-GENE-Y
immunoreactivity O
in O
the O
superior O
cervical O
ganglion O
and O
in O
the O
coeliac-superior O
mesenteric O
ganglion O
complex O
of O
the O
rat O
was O
studied O
by O
an O
indirect O
immunofluorescence O
method O
and O
by O
immunoelectron O
microscopy, O
with O
specific O
antisera O
raised O
in O
rabbits O
against O
the O
corresponding O
enzymes. O
In O
light O
microscopy, O
several O
glutamate B-GENE-N
decarboxylase- I-GENE-N
or O
GABA-transaminase-immunoreactive B-GENE-Y
principal O
nerve O
cells O
were O
detected O
in O
the O
superior O
cervical O
ganglion O
and O

coeliac-superior O
mesenteric O
ganglion O
complex. O
In O
addition, O
numerous O
small O
cells O
in O
both O
the O
superior O
cervical O
ganglion O
and O
coeliac-superior O
mesenteric O
ganglion O
complex O
showed O
intense O
immunoreactivity O
to O
glutamate B-GENE-N
decarboxylase I-GENE-N
or O
GABA-transaminase. B-GENE-Y
The O
small O
cells O
were O
10-20 O
micron O
in O
diameter O
and O
resembled O
in O
size O
and O
morphology O
the O
small O
intensely O
fluorescent O
cells. O
In O
consecutive O
sections, O
the O
small O
glutamate B-GENE-N
decarboxylase-immunoreactive I-GENE-N
cell O
clusters O
also O
showed O
immunoreactivity O
to O
tyrosine B-GENE-Y

hydroxylase, I-GENE-Y
suggesting O
that O
these O
cells O
contain O
the O
enzymes O
for O
both O
GABA B-CHEMICAL
and O
catecholamine B-CHEMICAL
synthesis. O
In O
the O
superior O
cervical O
ganglion O
and O
in O
the O
coeliac-superior O
mesenteric O
ganglion O
complex, O
GABA-transaminase B-GENE-Y
immunoreactivity O
was O
also O
localized O
in O
fibre-like O
processes O
around O
and O
between O
the O
principal O
nerve O
cells, O
in O
nerve O
trunks O
traversing O
the O
ganglia, O
and O
around O
or O
in O
close O
contact O
with O
ganglionic O
blood O
vessels. O
Furthermore, O
GABA-transaminase B-GENE-Y
immunoreactivity O
was O
observed O
in O
fibre-like O
structures O
close O
to O
the O
capsule O
of O

the O
ganglia. O
Division O
of O
the O
preganglionic O
nerve O
trunk O
of O
the O
superior O
cervical O
ganglion O
caused O
no O
detectable O
change O
in O
GABA-transaminase B-GENE-Y
immunoreactivity O
in O
the O
ganglion. O
In O
immunoelectron O
microscopy O
of O
the O
superior O
cervical O
ganglion, O
GABA-transaminase B-GENE-Y
immunoreactivity O
was O
localized O
in O
nerve O
fibres O
in O
association O
with O
neurotubules. O
A O
large O
number O
of O
GABA-transaminase B-GENE-Y
labelled O
principal O
nerve O
cells O
were O
detected, O
containing O
immunoreactivity O
evenly O
distributed O
in O
their O

cytoplasm. O
GABA-transaminase B-GENE-Y
immunoreactivity O
was O
also O
observed O
in O
satellite O
cells O
and O
their O
processes O
in O
the O
superior O
cervical O
ganglion. O
The O
present O
immunocytochemical O
results O
provide O
evidence O
that O
the O
rat O
sympathetic O
ganglia O
contain O
an O
intrinsic O
neuronal O
system O
showing O
histochemical O
markers O
for O
GABA B-CHEMICAL
synthesis O
and O
inactivation, O
but O
its O
functional O
role O
in O
the O
modulation O
of O
ganglionic O
neurotransmission O
remains O
to O
be O
established. O
Albiglutide: O
a O
new O
GLP-1 B-GENE-Y
receptor I-GENE-Y
agonist O
for O
the O
treatment O
of O
type O
2 O
diabetes. O

OBJECTIVE: O
To O
review O
the O
pharmacology, O
pharmacokinetics, O
safety, O
and O
efficacy O
of O
albiglutide, O
a O
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
receptor I-GENE-Y
agonist O
(GLP-1 B-GENE-Y
RA) I-GENE-Y
in O
type O
2 O
diabetes O
(T2D). O
DATA O
SOURCES: O
A O
MEDLINE O
search O
(1950-June O
2014) O
was O
conducted O
using O
the O
keyword O
albiglutide. O
References O
were O
reviewed O
to O
identify O
additional O
sources. O
STUDY O
SELECTION O
AND O
DATA O
EXTRACTION: O
Articles O

evaluating O
pharmacokinetics, O
pharmacodynamics, O
safety, O
or O
efficacy O
of O
albiglutide O
were O
included. O
DATA O
SYNTHESIS: O
Albiglutide O
is O
a O
long-acting O
GLP-1 B-GENE-Y
RA I-GENE-Y
that O
lowers O
glycosylated B-GENE-Y
hemoglobin I-GENE-Y
(A1C) B-GENE-Y
and O
reduces O
weight O
by O
stimulating O
glucose-dependent B-CHEMICAL
insulin B-GENE-Y
secretion, O
suppressing O
glucagon B-GENE-Y
secretion, O
delaying O
gastric O
emptying, O
and O
promoting O
satiety. O
Albiglutide O
has O
a O
long O
half-life O
as O
a O
result O
of O
resistance O
to O
degradation O
by O

dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
and O
fusion O
to O
albumin, B-GENE-Y
thus O
allowing O
once-weekly O
dosing. O
Albiglutide O
has O
been O
studied O
as O
monotherapy O
and O
add-on O
therapy O
to O
metformin, B-CHEMICAL
sulfonylureas, B-CHEMICAL
thiazolidinediones, B-CHEMICAL
insulin B-GENE-Y
glargine, O
and O
varying O
combinations O
of O
these O
agents. O
Clinical O
studies O
have O
shown O
albiglutide O
to O
be O
superior O
to O
placebo, O
sitagliptin, B-CHEMICAL
and O
glimepiride B-CHEMICAL
and O
noninferior O
to O
insulin B-GENE-Y
glargine O
and O
insulin B-GENE-Y
lispro O
at O
reducing O
A1C B-GENE-Y
in O
T2D O

patients, O
with O
A1C B-GENE-Y
changes O
from O
baseline O
ranging O
from O
-0.55% O
to O
-0.9%. O
Noninferiority O
was O
not O
achieved O
when O
compared O
to O
liraglutide O
and O
pioglitazone. B-CHEMICAL
Weight O
changes O
ranged O
from O
+0.28 O
to O
-1.21 O
kg. O
The O
most O
common O
side O
effects O
are O
upper-respiratory-tract O
infections, O
diarrhea, O
nausea, O
and O
injection-site O
reactions. O
CONCLUSION: O
Albiglutide O
is O
the O
fourth O
GLP-1 B-GENE-Y
RA I-GENE-Y
approved O
in O
the O
United O
States. O
Advantages O
include O
once-weekly O
dosing O
and O
fewer O

gastrointestinal O
side O
effects O
compared O
with O
liraglutide, O
but O
it O
is O
less O
effective O
at O
reducing O
A1C B-GENE-Y
and O
weight O
compared O
to O
liraglutide. O
It O
has O
not O
been O
compared O
head O
to O
head O
with O
other O
GLP-1 B-GENE-Y
RAs. I-GENE-Y
Pharmacophore O
identification O
of O
c-Myc B-GENE-Y
inhibitor O
10074-G5. B-CHEMICAL
A O
structure-activity O
relationship O
(SAR) O
study O
of O
the O
c-Myc B-GENE-Y
(Myc) B-GENE-Y
inhibitor O
10074-G5 B-CHEMICAL

(N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, B-CHEMICAL
1) O
- O
which O
targets O
a O
hydrophobic O
domain O
of O
the O
Myc B-GENE-Y
oncoprotein O
that O
is O
flanked O
by O
arginine B-CHEMICAL
residues O
- O
was O
executed O
in O
order O
to O
determine O
its O
pharmacophore. O
Whilst O
the O
7-nitrobenzofurazan B-CHEMICAL
was O
found O
to O
be O
critical O
for O
inhibitory O
activity, O
the O
ortho-biphenyl B-CHEMICAL
could O
be O
replaced O
with O

a O
para-carboxyphenyl B-CHEMICAL
group O
to O
furnish O
the O
new O
inhibitor O
JY-3-094 B-CHEMICAL
(3q). O
Around O
five O
times O
as O
potent O
as O
the O
lead O
with O
an O
IC(50) O
of O
33 O
μM O
for O
disruption O
of O
the O
Myc-Max B-GENE-Y
heterodimer, O
JY-3-094 B-CHEMICAL
demonstrated O
excellent O
selectivity O
over O
Max-Max B-GENE-Y
homodimers, O
with O
no O
apparent O
effect O
at O
100 O
μM. O
Importantly, O
the O
carboxylic O
acid O
of O
JY-3-094 B-CHEMICAL
improves O
the O
physicochemical O
properties O
of O
the O
lead O
compound, O
which O
will O
facilitate O
the O
incorporation O
of O

additional O
hydrophobicity O
that O
might O
enhance O
Myc B-GENE-Y
inhibitory O
activity O
further O
still. O
Treatment O
of O
Niemann-Pick O
disease O
type O
C O
in O
two O
children O
with O
miglustat: B-CHEMICAL
initial O
responses O
and O
maintenance O
of O
effects O
over O
1 O
year. O
Niemann-Pick O
disease O
type O
C O
(NP-C) O
is O
a O
lipid O
storage O
disorder O
characterized O
by O
the O
accumulation O
of O
unesterified O
cholesterol B-CHEMICAL
and O
glycolipids O
in O
the O
lysosomal/late O
endosomal O
system O
of O
certain O
cells O
in O
the O
central O
nervous O
system O
(CNS) O
and O
visceral O
organs. O
Clinical O
symptoms O
include O
progressive O
neurological O
deterioration O
and O

visceral O
organomegaly. O
Miglustat, B-CHEMICAL
a O
small O
iminosugar O
molecule O
approved O
for O
the O
treatment O
of O
Gaucher O
disease, O
reversibly O
inhibits O
glucosylceramide B-GENE-Y
synthase, I-GENE-Y
which O
catalyses O
the O
first O
committed O
step O
in O
glycosphingolipid O
synthesis. O
The O
physicochemical O
properties O
of O
miglustat O
allow O
it O
to O
cross O
the O
blood-brain O
barrier O
and O
suggest O
possible O
benefits O
in O
lysosomal O
storage O
diseases O
affecting O
the O
CNS. O
Here, O
we O
present O
findings O
in O
two O
children O
with O
NP-C, O
aged O
14 O
years O
(patient O
1) O
and O
9 O

years O
(patient O
2), O
treated O
with O
miglustat B-CHEMICAL
for O
1 O
year. O
Before O
treatment, O
patient O
1 O
presented O
with O
severe O
difficulties O
in O
swallowing O
and O
walking, O
and O
patient O
2 O
with O
problems O
mostly O
affecting O
communication O
and O
social O
interaction. O
Videofluoroscopic O
studies O
in O
patient O
1 O
demonstrated O
a O
substantial O
improvement O
in O
swallowing O
by O
month O
6 O
of O
treatment, O
and O
ambulation O
index O
measurements O
indicated O
improved O
walking. O
Mini O
Mental-State O
Examination O
(MMSE) O
assessments O
in O
patient O
2 O
showed O
cognitive O
improvement O
by O
month O
6, O
which O
was O
sustained O
up O
to O
month O
12. O
Liver/spleen O
volume O
and O
plasma O
chitotriosidase B-GENE-Y
activities O
were O
stabilized O
in O
both O
cases. O
There O

was O
no O
weight O
loss O
during O
treatment. O
Patient O
1 O
experienced O
severe O
but O
self-limiting O
paresthesia, O
which O
was O
not O
associated O
with O
peripheral O
neuropathy. O
We O
conclude O
that O
miglustat B-CHEMICAL
can O
provide O
therapeutic O
benefits O
in O
CNS O
symptoms O
and O
allows O
stabilization O
of O
systemic O
disease O
in O
childhood-onset O
NP-C. O
Further O
follow-up O
is O
crucial O
to O
determine O
the O
long-term O
maintenance O
of O
these O
effects. O
Safrole-2',3'-oxide B-CHEMICAL
induces O
atherosclerotic O
plaque O
vulnerability O
in O
apolipoprotein B-GENE-Y
E-knockout I-GENE-Y
mice. O
Safrole-2',3'-oxide B-CHEMICAL

(SFO) B-CHEMICAL
is O
the O
major O
electrophilic O
metabolite O
of O
safrole B-CHEMICAL
(4-allyl-1, B-CHEMICAL
2-methylenedioxybenzene), I-CHEMICAL
a O
natural O
plant O
constituent O
found O
in O
essential O
oils O
of O
numerous O
edible O
herbs O
and O
spices O
and O
in O
food O
containing O
these O
herbs, O
such O
as O
pesto O
sauce, O
cola O
beverages O
and O
bologna O
sausages. O
The O
effects O
of O
SFO B-CHEMICAL
in O
mammalian O
systems, O
especially O
the O
cardiovascular O
system, O
are O
little O
known. O
Disruption O
of O
vulnerable O
atherosclerotic O
plaques O
in O
atherosclerosis, O
a O
chronic O
inflammatory O
disease, O
is O
the O

main O
cause O
of O
cardiovascular O
events. O
In O
this O
study, O
we O
investigated O
SFO-induced B-CHEMICAL
atherosclerotic O
plaque O
vulnerability O
(possibility O
of O
rupture) O
in O
apolipoprotein B-GENE-Y
E-knockout I-GENE-Y
(apoE(-/-)) B-GENE-Y
mice. O
Lipid O
area O
in O
vessel O
wall O
reached O
59.8% O
in O
high O
dose O
SFO B-CHEMICAL
(SFO-HD) B-CHEMICAL
treated O
group, O
which O
is O
only O
31.2% O
in O
control O
group. O
SFO B-CHEMICAL
treatment O
changed O
the O
lesion O
composition O
to O
an O
unstable O
phenotype, O
increased O
the O
number O
of O
apoptotic O
cells O
in O
plaque O
and O
the O
endothelium O
in O
plaques O
was O
damaged O

after O
SFO B-CHEMICAL
treatment. O
Furthermore, O
compared O
with O
control O
groups, O
the O
plaque O
endothelium O
level O
of O
p75(NTR) B-GENE-Y
was O
3-fold O
increased O
and O
the O
liver O
level O
of O
p75(NTR) B-GENE-Y
was O
17.4-fold O
increased O
by O
SFO-HD. B-CHEMICAL
Meanwhile, O
the O
serum O
level O
of O
KC O
(a O
functional O
homolog O
of O
IL-8 B-GENE-N
and O
the O
main O
proinflammatory O
alpha B-GENE-N
chemokine I-GENE-N
in O
mice) O
in O
apoE(-/-) B-GENE-Y
mice O
was O
up O
to O
357pg/ml O
in O
SFO-HD B-CHEMICAL
treated O
group. O
Thus, O
SFO B-CHEMICAL
contributes O
to O
the O
instability O
of O

atherosclerotic O
plaque O
in O
apoE(-/-) B-GENE-Y
mice O
through O
activating O
p75(NTR) B-GENE-Y
and O
IL-8 B-GENE-N
and O
cell O
apoptosis O
in O
plaque. O
Mechanism O
of O
action O
of O
dopaminergic O
agents O
in O
Parkinson's O
disease. O
As O
the O
substantia O
nigra O
degenerates O
in O
Parkinson's O
disease O
(PD), O
the O
nigrostriatal O
pathway O
is O
disrupted, O
reducing O
striatal O
dopamine B-CHEMICAL
and O
producing O
PD O
symptoms. O
Although O
dopamine B-CHEMICAL
does O
not O
readily O
cross O
the O
blood-brain O
barrier, O
its O
precursor, O
levodopa, B-CHEMICAL
does. O
Levodopa B-CHEMICAL

is O
absorbed O
in O
the O
small O
bowel O
and O
is O
rapidly O
catabolized O
by O
aromatic-L-amino-acid B-GENE-Y
decarboxylase I-GENE-Y
(AADC) B-GENE-Y
and O
catechol-O-methyltransferase B-GENE-Y
(COMT). B-GENE-Y
Because O
gastric O
AADC B-GENE-Y
and O
COMT B-GENE-Y
degrade O
levodopa, B-CHEMICAL
the O
drug O
is O
given O
with O
inhibitors O
of O
AADC B-GENE-Y
(carbidopa B-CHEMICAL
or O
benserazide), B-CHEMICAL
and O
inhibitors O
of O
COMT B-GENE-Y
will O
also O
enter O
clinical O
use. O
Although O
the O
exact O
site O
of O
decarboxylation O
of O
exogenous O
levodopa B-CHEMICAL
to O
dopamine B-CHEMICAL
in O
the O
brain O
is O

unknown, O
most O
striatal O
AADC B-GENE-Y
is O
located O
in O
nigrostriatal O
dopaminergic O
nerve O
terminals. O
Newly O
synthesized O
dopamine O
is O
stored O
in O
the O
terminals O
and O
then O
released, O
stimulating O
postsynaptic O
dopamine B-GENE-N
receptors I-GENE-N
and O
mediating O
the O
antiparkinsonian O
action O
of O
levodopa. B-CHEMICAL
Dopamine B-CHEMICAL
agonists O
act O
directly O
on O
postsynaptic O
dopamine B-GENE-N
receptors, I-GENE-N
thus O
obviating O
the O
need O
for O
metabolic O
conversion, O
storage, O
and O
release. O
How O
the O
actions O
of O
dopaminergic O
drugs O
produce O
side O
effects O
and O
how O
these O
side O
effects O
should O
be O
managed O
are O
discussed. O
Soy O
protein O

suppresses O
gene O
expression O
of O
acetyl-coA B-GENE-Y
carboxylase I-GENE-Y
alpha I-GENE-Y
from O
promoter B-GENE-N
PI I-GENE-N
in O
rat O
liver. O
Dietary O
soy O
protein O
isolate O
(SPI) O
reduces O
hepatic O
lipogenesis O
by O
suppressing O
gene O
expression O
of O
lipogenic O
enzymes, O
including O
acetyl-CoA B-GENE-N
carboxylase I-GENE-N
(ACC). B-GENE-N
In O
order O
to O
elucidate O
the O
mechanism O
of O
this O
regulation, O
the O
effect O
of O
dietary O
SPI O
on O
promoter B-GENE-N
(PI I-GENE-N
and I-GENE-N
PII) I-GENE-N
specific O
gene O
expression O
of O
ACC B-GENE-Y
alpha I-GENE-Y
was O
investigated. O
Rats O
were O
fed O
experimental O
diets O
containing O
SPI O
or O
casein B-GENE-N
as O
a O
nitrogen B-CHEMICAL
source. O
SPI O
feeding O

decreased O
the O
hepatic O
contents O
of O
total O
ACC B-GENE-N
mRNA O
as O
well O
as O
triglyceride B-CHEMICAL
(TG) B-CHEMICAL
content, O
but O
dietary O
SPI O
affected O
the O
amount O
of O
sterol-regulatory B-GENE-Y
element I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
(SREBP)-1 I-GENE-Y
mRNA O
and O
protein O
very O
little. O
The O
amount O
of O
ACC B-GENE-N
mRNA O
transcribed O
from O
PII B-GENE-N
promoter I-GENE-N
containing O
SRE B-GENE-N
was O
not O
significantly O
affected O
by O
dietary O
protein, O
while O
a O
significant O
decrease O
in O
PI-generated B-GENE-N
ACC B-GENE-N
mRNA O
content O
was O
observed O
in O
rats O
fed O
the O
SPI O
diet. O
These O
data O
suggest O
that O
SPI O
feeding O
decreased O
the O
hepatic O
contents O
of O
ACC B-GENE-Y
alpha I-GENE-Y
mRNA O
mainly O
by O
regulating O

PI B-GENE-N
promoter I-GENE-N
via O
a O
nuclear O
factor(s) O
other O
than O
SREBP-1. B-GENE-Y
Polymethoxyflavones B-CHEMICAL
as O
agents O
that O
prevent O
formation O
of O
cataract: O
nobiletin B-CHEMICAL
congeners O
show O
potent O
growth O
inhibitory O
effects O
in O
human O
lens O
epithelial O
cells. O
Posterior O
capsular O
opacification O
(PCO) O
is O
the O
most O
frequent O
complication O
and O
the O
primary O
reason O
for O
visual O
decrease O
after O
extracapsular O
cataract O
surgery. O
The O
proliferation O
and O
migration O
of O
leftover O
lens O
epithelial O
cells O
(LECs) O
after O
surgery O
may O
contribute O
to O
the O
development O
of O
PCO. O
To O
prevent O

PCO, O
a O
rational O
approach O
would O
be O
to O
inhibit O
both O
the O
proliferation O
and O
the O
migration O
of O
LECs O
using O
nontoxic O
xenobiotics. O
Nobiletin, B-CHEMICAL
one O
of O
the O
most O
abundant O
polymethoxyflavones B-CHEMICAL
(PMFs) B-CHEMICAL
in O
citrus O
peel, O
and O
its O
synthetic O
congeners O
displayed O
a O
potent O
inhibition O
of O
LEC O
proliferation. O
Structural O
features O
which O
enhance O
anti-proliferative O
activity O
have O
also O
been O
discussed. O
The O
in O
vivo O
antioxidant O
and O
antifibrotic O
properties O
of O
green O
tea O
(Camellia O
sinensis, O
Theaceae). O
The O
in O
vivo O

antioxidant O
and O
antifibrotic O
properties O
of O
green O
tea O
(Camellia O
sinensis, O
Theaceae) O
were O
investigated O
with O
a O
study O
of O
carbon B-CHEMICAL
tetrachloride I-CHEMICAL
(CCl(4))-induced B-CHEMICAL
oxidative O
stress O
and O
hepatic O
fibrosis O
in O
male O
ICR O
mice. O
Oral O
administration O
of O
green O
tea O
extract O
at O
doses O
of O
125, O
625 O
and O
1250 O
mg/kg O
for O
8 O
weeks O
significantly O
reduced O
(p<0.05) O
the O
levels O
of O
thiobarbituric B-CHEMICAL
acid-reactive I-CHEMICAL
substances O
(TBARS) O
and O
protein O
carbonyls B-CHEMICAL
in O
the O
liver O
by O
at O
least O
28% O
compared O
with O
that O

was O
induced O
by O
CCl(4) B-CHEMICAL
(1 O
mL/kg) O
in O
mice. O
Moreover, O
green O
tea O
extract O
administration O
significantly O
increased O
(p<0.05) O
the O
activities O
of O
catalase, B-GENE-Y
glutathione B-GENE-N
peroxidase I-GENE-N
(GSH-Px) B-GENE-N
and O
glutathione B-GENE-Y
reductase I-GENE-Y
(GSH-Rd) B-GENE-Y
in O
the O
liver. O
Our O
study O
found O
that O
oral O
administration O
of O
green O
tea O
extract O
prevented O
CCl(4)-induced B-CHEMICAL
hepatic O
fibrosis, O
as O
evidenced O
by O
a O
decreased O
hydroxyproline B-CHEMICAL
level O
in O
the O
liver O
and O
a O
reduced O
incidence O
of O
hepatic O
fibrosis O

by O
histological O
observations. O
These O
results O
indicate O
that O
green O
tea O
exhibits O
potent O
protective O
effects O
against O
CCl(4)-induced B-CHEMICAL
oxidative O
stress O
and O
hepatic O
fibrosis O
in O
mice O
by O
inhibiting O
oxidative O
damage O
and O
increasing O
antioxidant O
enzyme O
activities. O
Comparison O
of O
vaginal B-GENE-N
aminopeptidase I-GENE-N
enzymatic O
activities O
in O
various O
animals O
and O
in O
humans. O
The O
specific O
enzymatic O
activity O
of O
four O
different O
aminopeptidases B-GENE-N
(aminopeptidase B-GENE-N
N, I-GENE-N
leucine B-GENE-N
aminopeptidase, I-GENE-N
aminopeptidase B-GENE-N
A I-GENE-N
and O
aminopeptidase B-GENE-N
B) I-GENE-N
in O

vaginal O
homogenates O
from O
rabbit, O
rat, O
guinea-pig, O
sheep O
and O
humans O
was O
compared. O
The O
purpose O
of O
the O
study O
was O
to O
find O
an O
appropriate O
animal O
model O
that O
can O
be O
used O
in O
degradation O
studies O
of O
protein O
and O
peptide O
drugs. O
Different O
substrates O
were O
used O
as O
the O
relative O
specific O
substrates O
for O
the O
determination O
of O
aminopeptidase B-GENE-N
enzymatic O
activity: O
4-methoxy-2-naphthylamide B-CHEMICAL
of O
L-alanine B-CHEMICAL
for O
aminopeptidase B-GENE-N
N, I-GENE-N
4-methoxy-2-naphthylamide B-CHEMICAL
of O
L-leucine B-CHEMICAL
for O
leucine B-GENE-N

aminopeptidase, I-GENE-N
4-methoxy-2-naphthylamide B-CHEMICAL
of O
L-glutamic B-CHEMICAL
acid I-CHEMICAL
for O
aminopeptidase B-GENE-N
A I-GENE-N
and O
4-methoxy-2-naphthylamide B-CHEMICAL
of O
L-arginine B-CHEMICAL
for O
aminopeptidase B-GENE-N
B. I-GENE-N
The O
vaginal B-GENE-N
aminopeptidase I-GENE-N
enzymatic O
activity O
of O
different O
species O
was O
determined O
spectrofluorometrically. O
The O
inhibition O
of O
aminopeptidase B-GENE-N
activity O
in O
the O
presence O
of O
bestatin B-CHEMICAL
and O
puromycin B-CHEMICAL
inhibitors O
was O
also O
investigated. O
The O
results O
showed O
the O
presence O
of O

aminopeptidase B-GENE-N
enzymatic O
activity O
in O
all O
vaginal O
homogenates O
in O
the O
order: O
sheep O
> O
guinea-pig O
> O
rabbit O
> O
or O
= O
human O
> O
or O
= O
rat. O
Based O
on O
the O
results O
of O
the O
hydrolysis O
and O
inhibition O
of O
the O
4-methoxy-2-naphthylamide B-CHEMICAL
substrates, O
it O
was O
difficult O
to O
have O
an O
exact O
decision O
on O
the O
aminopeptidase B-GENE-N
type O
in O
the O
vaginal O
homogenates O
from O
the O
species O
studied. O
It O
was O
found O
that O
the O
aminopeptidase B-GENE-N
activity O
in O
rat, O
rabbit O
and O
humans O
was O
not O
statistically O
different. O
Therefore, O
we O
suggest O

that O
rats O
and O
rabbits O
could O
be O
used O
as O
model O
animals O
for O
vaginal O
enzymatic O
activity O
studies O
and O
for O
determination O
of O
the O
degradation O
of O
protein O
and O
peptide O
drugs O
in O
the O
vagina. O
In O
silico O
identification O
of O
poly(ADP-ribose)polymerase-1 B-GENE-Y
inhibitors O
and O
their O
chemosensitizing O
effects O
against O
cisplatin-resistant B-CHEMICAL
human O
gastric O
cancer O
cells. O
Poly(ADP-ribose)polymerase-1 B-GENE-Y
(PARP-1) B-GENE-Y
enzyme O
is O
involved O
in O
the O
repair O
of O
DNA O
damages O
made O
by O
certain O
anticancer O
agents. O
It O
is O
suggested O
that O
PARP-1 B-GENE-Y

inhibitors O
potentiate O
the O
cytotoxic O
effects O
and O
circumvent O
the O
resistance O
of O
DNA-modifying O
anticancer O
agents O
such O
as O
cisplatin. B-CHEMICAL
In O
this O
study, O
we O
conducted O
virtual O
screening O
of O
Korea O
Chemical O
Bank O
database O
targeting O
PARP-1 B-GENE-Y
and O
identified O
several O
potent O
PARP-1 B-GENE-Y
inhibitors O
with O
submicromolar O
IC50 O
values O
(77-79nM). O
We O
then O
examined O
the O
chemosensitization O
of O
cisplatin B-CHEMICAL
by O
pre-treatment O
of O
PARP-1 B-GENE-Y
inhibitors O
in O
cisplatin-resistant B-CHEMICAL
human O
gastric O
cancer O
cells. O
Our O
results O
show O
that O

PARP-1 B-GENE-Y
inhibitors O
suppress O
the O
formation O
of O
poly(ADP-ribose) B-CHEMICAL
and O
enhance O
the O
cytotoxicity O
of O
cisplatin. B-CHEMICAL
Peptidyl-prolyl B-GENE-Y
cis/trans-isomerase I-GENE-Y
A1 I-GENE-Y
(Pin1) B-GENE-Y
is O
a O
target O
for O
modification O
by O
lipid O
electrophiles. O
Oxidation O
of O
membrane O
phospholipids O
is O
associated O
with O
inflammation, O
neurodegenerative O
disease, O
and O
cancer. O
Oxyradical O
damage O
to O
phospholipids O
results O
in O
the O
production O
of O
reactive O
aldehydes B-CHEMICAL
that O
adduct O
proteins O
and O
modulate O
their O

function. O
4-Hydroxynonenal B-CHEMICAL
(HNE), B-CHEMICAL
a O
common O
product O
of O
oxidative O
damage O
to O
lipids, O
adducts O
proteins O
at O
exposed O
Cys, B-CHEMICAL
His, B-CHEMICAL
or O
Lys B-CHEMICAL
residues. O
Here, O
we O
demonstrate O
that O
peptidyl-prolyl B-GENE-Y
cis/trans-isomerase I-GENE-Y
A1 I-GENE-Y
(Pin1), B-GENE-Y
an O
enzyme O
that O
catalyzes O
the O
conversion O
of O
the O
peptide O
bond O
of O
pSer/pThr-Pro B-CHEMICAL
moieties O
in O
signaling O
proteins O
from O
cis O
to O
trans, O
is O
highly O
susceptible O
to O
HNE B-CHEMICAL
modification. O
Incubation O
of O
purified O
Pin1 B-GENE-Y
with O

HNE B-CHEMICAL
followed O
by O
MALDI-TOF/TOF O
mass O
spectrometry O
resulted O
in O
detection O
of O
Michael O
adducts O
at O
the O
active O
site O
residues O
His-157 B-CHEMICAL
and O
Cys-113. B-CHEMICAL
Time O
and O
concentration O
dependencies O
indicate O
that O
Cys-113 B-CHEMICAL
is O
the O
primary O
site O
of O
HNE B-CHEMICAL
modification. O
Pin1 B-GENE-Y
was O
adducted O
in O
MDA-MB-231 O
breast O
cancer O
cells O
treated O
with O
8-alkynyl-HNE B-CHEMICAL
as O
judged O
by O
click O
chemistry O
conjugation O
with O
biotin B-CHEMICAL
followed O
by O
streptavidin-based O
pulldown O
and O
Western O
blotting O
with O
anti-Pin1 B-GENE-Y
antibody. O
Furthermore, O

orbitrap O
MS O
data O
support O
the O
adduction O
of O
Cys-113 B-CHEMICAL
in O
the O
Pin1 B-GENE-Y
active O
site O
upon O
HNE B-CHEMICAL
treatment O
of O
MDA-MB-231 O
cells. O
siRNA O
knockdown O
of O
Pin1 B-GENE-Y
in O
MDA-MB-231 O
cells O
partially O
protected O
the O
cells O
from O
HNE-induced B-CHEMICAL
toxicity. O
Recent O
studies O
indicate O
that O
Pin1 B-GENE-Y
is O
an O
important O
molecular O
target O
for O
the O
chemopreventive O
effects O
of O
green O
tea O
polyphenols. B-CHEMICAL
The O
present O
study O
establishes O
that O
it O
is O
also O
a O
target O
for O
electrophilic O
modification O
by O
products O
of O
lipid O
peroxidation. O
Withdrawal O
from O
free-choice O
ethanol B-CHEMICAL
consumption O
results O
in O

increased O
packing O
density O
of O
glutamine B-GENE-Y
synthetase-immunoreactive I-GENE-Y
astrocytes O
in O
the O
prelimbic O
cortex O
of O
alcohol-preferring B-CHEMICAL
rats. O
Excess O
activation O
of O
glutamatergic O
neurotransmission O
in O
the O
cerebral O
cortex O
following O
ethanol B-CHEMICAL
withdrawal O
is O
considered O
to O
contribute O
to O
significant O
behavioural O
disturbances, O
and O
to O
alcohol B-CHEMICAL
craving. O
Astrocytes O
may O
play O
a O
role O
in O
these O
manifestations O
because O
astrocytes O
are O
essential O
in O
the O
regulation O
of O
released O
glutamate B-CHEMICAL
and O
its O
conversion O
to O
glutamine B-CHEMICAL
through O
the O
enzyme O
glutamine B-GENE-Y
synthetase I-GENE-Y
(GS). B-GENE-Y
However, O
it O
is O

unclear O
if O
withdrawal O
from O
free-choice O
ethanol B-CHEMICAL
drinking O
causes O
changes O
in O
the O
numbers O
of O
astrocytes O
expressing O
GS B-GENE-Y
or O
the O
cytoskeletal O
protein O
of O
astrocytes O
glial B-GENE-Y
fibrillary I-GENE-Y
acidic I-GENE-Y
protein I-GENE-Y
(GFAP). B-GENE-Y
Alcohol-preferring B-CHEMICAL
(P) O
rats O
exposed O
to O
free-choice O
ethanol B-CHEMICAL
drinking O
were O
either O
maintained O
without O
forced O
interruption O
of O
ethanol B-CHEMICAL
drinking, O
subjected O
to O
a O
3-day O
withdrawal O
period O
at O
the O
end O
of O
2 O
months, O
or O
subjected O
to O
three O
3-day O
withdrawal O
periods O
along O
6 O
months. O
At O
2 O
months, O
P O
rats O
were O
also O
compared O
with O
alcohol-naive B-CHEMICAL
alcohol B-CHEMICAL
non-preferring O
rats O
(NP) O

rats. O
Packing O
density O
of O
GS B-GENE-Y
and O
GFAP-immunoreactive B-GENE-Y
(IR) O
astrocytes O
was O
measured O
in O
sections O
from O
the O
prelimbic O
cortex O
(PLC) O
using O
the O
optical O
disector O
probe. O
An O
alcohol B-CHEMICAL
deprivation O
effect O
was O
observed O
in O
P O
rats O
with O
withdrawals O
during O
a O
6-month O
ethanol O
drinking O
period. O
Ethanol B-CHEMICAL
withdrawal O
significantly O
increased O
the O
packing O
density O
of O
GS- B-GENE-Y
and O
GFAP-IR B-GENE-Y
astrocytes O
in O
the O
PLC O
of O
P O
rats O
as O
compared O
with O
P O
rats O
with O
continuous O
access O
to O
ethanol. O
In O
addition, O
there O
was O
a O
positive O
correlation O
between O
the O
pre-withdrawal O

ethanol B-CHEMICAL
consumption O
and O
the O
packing O
density O
of O
GS-IR B-GENE-Y
astrocytes. O
The O
present O
results O
suggest O
the O
involvement O
of O
astrocytes O
in O
the O
regulation O
of O
the O
glutamatergic O
activation O
associated O
with O
withdrawal O
from O
free-choice O
ethanol B-CHEMICAL
consumption O
and O
point O
to O
differential O
adaptations O
of O
GS B-GENE-Y
and O
GFAP B-GENE-Y
to O
prolonged O
alcohol B-CHEMICAL
drinking O
in O
the O
PLC O
of O
P O
rats. O
Fetal O
PGC-1α B-GENE-Y
overexpression O
programs O
adult O
pancreatic O
β-cell O
dysfunction. O
Adult O
β-cell O
dysfunction, O
a O
hallmark O
of O
type O
2 O
diabetes, O
can O
be O
programmed O
by O
adverse O
fetal O
environment. O
We O
have O
shown O
that O
fetal O

glucocorticoids O
(GCs) O
participate O
in O
this O
programming O
through O
inhibition O
of O
β-cell O
development. O
Here O
we O
have O
investigated O
the O
molecular O
mechanisms O
underlying O
this O
regulation. O
We O
showed O
that O
GCs O
stimulate O
the O
expression O
of O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor-γ I-GENE-Y
coactivator-1α I-GENE-Y
(PGC-1α), B-GENE-Y
a O
coregulator O
of O
the O
GCs B-GENE-Y
receptor I-GENE-Y
(GR), B-GENE-Y
and O
that O
the O
overexpression O
of O
PGC-1α B-GENE-Y
represses O
genes O
important O
for O
β-cell O
development O
and O
function. O
More O
precisely, O
PGC-1α B-GENE-Y
inhibited O
the O
expression O
of O
the O
key O

β-cell O
transcription O
factor O
pancreatic B-GENE-Y
duodenal I-GENE-Y
homeobox I-GENE-Y
1 I-GENE-Y
(Pdx1). B-GENE-Y
This O
repression O
required O
the O
GR B-GENE-Y
and O
was O
mediated O
through O
binding O
of O
a O
GR/PGC-1α B-GENE-Y
complex O
to O
the O
Pdx1 B-GENE-N
promoter. I-GENE-N
To O
explore O
PGC-1α B-GENE-Y
function, O
we O
generated O
mice O
with O
inducible O
β-cell O
PGC-1α B-GENE-Y
overexpression. O
Mice O
overexpressing O
PGC-1α B-GENE-Y
exhibited O
at O
adult O
age O
impaired O
glucose B-CHEMICAL
tolerance O
associated O
with O
reduced O
insulin O
secretion, O
decreased O
β-cell O
mass, O
and O
β-cell O
hypotrophy. O
Interestingly, O

PGC-1α B-GENE-Y
expression O
in O
fetal O
life O
only O
was O
sufficient O
to O
impair O
adult O
β-cell O
function O
whereas O
β-cell O
PGC-1α B-GENE-Y
overexpression O
from O
adult O
age O
had O
no O
consequence O
on O
β-cell O
function. O
Altogether, O
our O
results O
demonstrate O
that O
the O
GR B-GENE-Y
and O
PGC-1α B-GENE-Y
participate O
in O
the O
fetal O
programming O
of O
adult O
β-cell O
function O
through O
inhibition O
of O
Pdx1 B-GENE-Y
expression. O
Rufinamide B-CHEMICAL
attenuates O
mechanical O
allodynia O
in O
a O
model O
of O
neuropathic O
pain O
in O
the O
mouse O
and O
stabilizes O
voltage-gated B-GENE-N
sodium I-GENE-N
channel I-GENE-N
inactivated O
state. O

BACKGROUND: O
Voltage-gated B-GENE-N
sodium I-GENE-N
channels I-GENE-N
dysregulation O
is O
important O
for O
hyperexcitability O
leading O
to O
pain O
persistence. O
Sodium B-GENE-N
channel I-GENE-N
blockers O
currently O
used O
to O
treat O
neuropathic O
pain O
are O
poorly O
tolerated. O
Getting O
new O
molecules O
to O
clinical O
use O
is O
laborious. O
We O
here O
propose O
a O
drug O
already O
marketed O
as O
anticonvulsant, O
rufinamide. B-CHEMICAL
METHODS: O
We O
compared O
the O
behavioral O
effect O
of O
rufinamide B-CHEMICAL
to O
amitriptyline B-CHEMICAL
using O
the O
Spared O
Nerve O
Injury O
neuropathic O
pain O
model O
in O
mice. O
We O
compared O
the O
effect O

of O
rufinamide B-CHEMICAL
on O
sodium B-CHEMICAL
currents O
using O
in O
vitro O
patch O
clamp O
in O
cells O
expressing O
the O
voltage-gated B-GENE-N
sodium I-GENE-N
channel I-GENE-N
Nav1.7 B-GENE-Y
isoform O
and O
on O
dissociated O
dorsal O
root O
ganglion O
neurons O
to O
amitriptyline B-CHEMICAL
and O
mexiletine. B-CHEMICAL
RESULTS: O
In O
naive O
mice, O
amitriptyline B-CHEMICAL
(20 O
mg/kg) O
increased O
withdrawal O
threshold O
to O
mechanical O
stimulation O
from O
1.3 O
(0.6-1.9) O
(median O
[95% O
CI]) O
to O
2.3 O
g O
(2.2-2.5) O
and O
latency O
of O
withdrawal O

to O
heat O
stimulation O
from O
13.1 O
(10.4-15.5) O
to O
30.0 O
s O
(21.8-31.9), O
whereas O
rufinamide B-CHEMICAL
had O
no O
effect. O
Rufinamide B-CHEMICAL
and O
amitriptyline B-CHEMICAL
alleviated O
injury-induced O
mechanical O
allodynia O
for O
4 O
h O
(maximal O
effect: O
0.10 O
+/- O
0.03 O
g O
(mean O
+/- O
SD) O
to O
1.99 O
+/- O
0.26 O
g O
for O
rufinamide B-CHEMICAL
and O
0.25 O
+/- O
0.22 O
g O
to O
1.92 O
+/- O
0.85 O
g O
for O

amitriptyline). B-CHEMICAL
All O
drugs O
reduced O
peak O
current O
and O
stabilized O
the O
inactivated O
state O
of O
voltage-gated B-GENE-N
sodium I-GENE-N
channel I-GENE-N
Nav1.7, B-GENE-Y
with O
similar O
effects O
in O
dorsal O
root O
ganglion O
neurons. O
CONCLUSIONS: O
At O
doses O
alleviating O
neuropathic O
pain, O
amitriptyline B-CHEMICAL
showed O
alteration O
of O
behavioral O
response O
possibly O
related O
to O
either O
alteration O
of O
basal O
pain O
sensitivity O
or O
sedative O
effect O
or O
both. O
Side-effects O
and O
drug O
tolerance/compliance O
are O
major O
problems O
with O
drugs O
such O
as O
amitriptyline. B-CHEMICAL
Rufinamide B-CHEMICAL
seems O
to O
have O
a O
better O
tolerability O
profile O
and O
could O
be O
a O

new O
alternative O
to O
explore O
for O
the O
treatment O
of O
neuropathic O
pain. O
All-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
protects O
hepatocellular O
carcinoma O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
upregulating O
collagen B-GENE-Y
8A2. I-GENE-Y
As O
a O
therapeutic O
or O
chemopreventative O
agent O
for O
various O
cancers, O
all-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
(atRA) B-CHEMICAL
has O
been O
reported O
to O
inhibit O
growth, O
induce O
apoptosis O
or O
cause O
differentiation. O
It O
was O
found O
that O
atRA B-CHEMICAL
could O
protect O
hepatocellular O
carcinoma O
(HCC) O
cells O
against O
cell O
death O
induced O
by O
serum O
starvation. O
Furthermore, O
it O
was O
found O
that O

atRA B-CHEMICAL
could O
enhance O
cell O
adhesion, O
but O
had O
no O
effect O
on O
the O
cell O
cycle O
and O
apoptosis. O
Using O
an O
Illumina O
Human O
HT-12 O
v4 O
expression O
microarray, O
207 O
upregulated O
and O
173 O
downregulated O
genes O
were O
identified O
in O
HepG2 O
cells O
treated O
with O
atRA. B-CHEMICAL
The O
most O
upregulated O
genes O
are O
cytochrome B-GENE-Y
P450 I-GENE-Y
family I-GENE-Y
26 I-GENE-Y
subfamily I-GENE-Y
A I-GENE-Y
polypeptide I-GENE-Y
1 I-GENE-Y
(CYP26A1), B-GENE-Y
histidine B-GENE-Y
triad I-GENE-Y
nucleotide I-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
3 I-GENE-Y
(HINT3), B-GENE-Y
miR-1282 B-GENE-Y
and O
cytochrome B-GENE-Y

P450 I-GENE-Y
family I-GENE-Y
26 I-GENE-Y
subfamily I-GENE-Y
B I-GENE-Y
polypeptide I-GENE-Y
1 I-GENE-Y
(CYP26B1), B-GENE-Y
which O
showed O
more O
than O
fivefold O
greater O
expression. O
Using O
Gene O
Ontology O
analysis, O
the O
greatest O
significance O
was O
found O
in O
extracellular-matrix-related O
molecular O
functions O
and O
the O
cellular O
component O
in O
upregulated O
genes. O
The O
upregulation O
of O
collagen B-GENE-Y
8A2 I-GENE-Y
(COL8A2) B-GENE-Y
was O
further O
confirmed O
using O
quantitative O
RT-PCR O
and O
western O
blotting. O
Knockdown O
of O
COL8A2 B-GENE-Y
blocked O
enhancement O
in O
the O
early O
stage O
of O
cell O
adhesion O
by O
atRA B-CHEMICAL
treatment. O
Re-expression O
of O

COL8A2 B-GENE-Y
in O
COL8A2-knocked-down B-GENE-Y
HCC O
cells O
reversed O
the O
effect O
of O
small O
interfering O
RNA-COL8A2. B-GENE-Y
In O
addition, O
COL8A2 B-GENE-Y
could O
increase O
HCC O
cell O
migration O
and O
invasion. O
Thus, O
COL8A2 B-GENE-Y
was O
identified O
as O
the O
key O
protein O
involved O
in O
the O
enhancement O
of O
cell O
adhesion O
of O
atRA B-CHEMICAL
under O
serum-free O
conditions. O
In O
conclusion, O
atRA B-CHEMICAL
protects O
HCC O
cells O
against O
serum-starvation-induced O
cell O
death O
by O
enhancing O
cell O
adhesion, O
and O
COL8A2 B-GENE-Y
plays O
an O
important O
role O
in O
HCC O
cell O
migration O
and O
invasion. O
Cloning O
and O
expression O

of O
a O
heme B-GENE-N
binding I-GENE-N
protein I-GENE-N
from O
the O
genome O
of O
Saccharomyces O
cerevisiae. O
The O
YLR205c B-GENE-Y
gene O
of O
Saccharomyces O
cerevisiae O
does O
not O
show O
significant O
sequence O
identity O
to O
any O
known O
gene, O
except O
for O
heme B-GENE-N
oxygenase I-GENE-N
(22% O
to O
human B-GENE-Y
HO-1). I-GENE-Y
The O
YLR205 B-GENE-N
ORF I-GENE-N
was O
cloned O
and O
overexpressed O
in O
both O
Escherichia O
coli O
and O
S. O
cerevisiae. O
Both O
expression O
systems O
yielded O
proteins O
that O
bound O
heme O
tightly. O
The O
isolated O
YLR205c B-GENE-Y
protein O
underwent O
reduction O
in O
the O
presence O
of O
either O

NADPH-cytochrome B-GENE-Y
P450 I-GENE-Y
reductase I-GENE-Y
or O
NADH-putidaredoxin-putidaredoxin B-GENE-N
reductase I-GENE-N
but O
did O
not O
exhibit O
heme B-GENE-N
oxygenase I-GENE-N
activity. O
The O
protein O
exhibited O
modest O
H(2)O(2)-dependent B-CHEMICAL
peroxidase B-GENE-N
activities O
with O
guaiacol, B-CHEMICAL
potassium B-CHEMICAL
iodide, I-CHEMICAL
and O
2,2(')-azino-bis(3-ethylbenzothiazoline-6-sulfonic B-CHEMICAL
acid I-CHEMICAL
(ABTS). B-CHEMICAL
Thus, O
YLR205c B-GENE-Y
codes O
for O
a O
hemoprotein B-GENE-N
of O
unknown O
physiological O

function O
that O
exhibits O
peroxidase B-GENE-N
activity. O
Transcriptional O
regulation O
of O
human B-GENE-Y
ferredoxin I-GENE-Y
1 I-GENE-Y
in O
ovarian O
granulosa O
cells. O
Ferredoxin B-GENE-Y
1 I-GENE-Y
(FDX1; B-GENE-Y
adrenodoxin) B-GENE-Y
is O
an O
iron-sulfur B-CHEMICAL
protein O
that O
is O
involved O
in O
various O
metabolic O
processes, O
including O
steroid B-CHEMICAL
hormone I-CHEMICAL
synthesis O
in O
mammalian O
tissues. O
We O
investigated O
the O
transcriptional O
regulation O
of O
FDX1 B-GENE-Y
in O
ovarian O
granulosa O
cells. O
Previously, O
we O
reported O
that O
the O
NR5A B-GENE-N
family, O
including O
steroidogenic B-GENE-Y
factor-1 I-GENE-Y
(SF-1) B-GENE-Y
and O
liver B-GENE-Y
receptor I-GENE-Y

homolog-1 I-GENE-Y
could O
induce O
differentiation O
of O
human O
mesenchymal O
stem O
cells O
(hMSCs) O
into O
steroidogenic O
cells. O
A O
ChIP O
assay O
showed O
that O
SF-1 B-GENE-Y
could O
bind O
to O
the O
FDX1 B-GENE-N
promoter I-GENE-N
in O
differentiated O
hMSCs. O
Luciferase O
reporter O
assays O
showed O
that O
transcription O
of O
FDX1 B-GENE-Y
was O
synergistically O
activated O
by O
the O
NR5A B-GENE-N
family O
and O
8Br-cAMP B-CHEMICAL
treatment O
through O
two O
SF-1 B-GENE-Y
binding O
sites O
and O
a O
CRE-like B-GENE-N
sequence O
in O
a O
human O
ovarian O
granulosa O
cell O
line, O
KGN. O
Knockdown O
of O

FDX1 B-GENE-Y
attenuated O
progesterone B-CHEMICAL
production O
in O
KGN O
cells. O
These O
results O
indicate O
transcription O
of O
FDX1 B-GENE-Y
is O
regulated O
by O
the O
NR5A B-GENE-N
family O
and O
cAMP B-CHEMICAL
signaling, O
and O
participates O
in O
steroid B-CHEMICAL
hormone O
production O
in O
ovarian O
granulosa O
cells. O
Evaluation O
of O
flutamide B-CHEMICAL
genotoxicity O
in O
rats O
and O
in O
primary O
human O
hepatocytes. O
Flutamide, B-CHEMICAL
an O
effective O
competitive O
inhibitor O
of O
the O
androgen B-GENE-Y
receptor I-GENE-Y
used O
orally O
for O
palliative O
treatment O
of O
prostatic O
carcinoma O
and O
regulation O
of O
prostatic O
hyperplasia O
was O
evaluated O
for O
its O

genotoxic O
effects O
in O
the O
intact O
rat O
and O
in O
primary O
cultures O
of O
human O
hepatocytes. O
Negative O
responses O
were O
obtained O
in O
all O
the O
in O
vivo O
assays O
as O
well O
as O
in O
the O
in O
vitro O
assay. O
In O
rats O
given O
a O
single O
oral O
dose O
of O
500 O
mg/kg O
flutamide, B-CHEMICAL
fragmentation O
and O
repair O
of O
liver O
DNA O
were O
absent, O
and O
no O
increase O
was O
observed O
in O
the O
frequency O
of O
micronucleated O
hepatocytes. O
In O
the O
liver O
of O
rats O
given O
flutamide B-CHEMICAL
as O
initiating O
agent O
at O
the O
dose O
of O
500 O
mg/kg/week O
for O
6 O
successive O
weeks, O

gamma-glutamyltraspeptidase-positive B-GENE-N
foci O
were O
detected O
only O
in O
3 O
of O
10 O
rats. O
There O
was O
no O
evidence O
of O
a O
promoting O
effect O
on O
the O
development O
of O
aberrant O
crypt O
foci O
in O
rats O
given O
100 O
mg/kg O
flutamide B-CHEMICAL
on O
alternate O
days O
for O
8 O
successive O
weeks. O
In O
primary O
cultures O
of O
human O
hepatocytes O
from O
one O
male O
and O
one O
female O
donor O
DNA O
fragmentation O
as O
measured O
by O
the O
Comet O
assays, O
and O
DNA O
repair O
synthesis O
as O
revealed O
by O
quantitative O
autoradiography, O
were O
absent O
after O
a O
20 O
hr O
exposure O
to O
flutamide B-CHEMICAL
concentrations O
ranging O
from O
18 O
to O
56 O
microM. O

Taken O
as O
a O
whole, O
our O
results O
seem O
to O
indicate O
that O
flutamide B-CHEMICAL
is O
a O
non-genotoxic O
drug. O
Novel O
non-canonical O
TGF-β B-GENE-N
signaling O
networks: O
emerging O
roles O
in O
airway O
smooth O
muscle O
phenotype O
and O
function. O
The O
airway O
smooth O
muscle O
(ASM) O
plays O
an O
important O
role O
in O
the O
pathophysiology O
of O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
(COPD). O
ASM O
cells O
express O
a O
wide O
range O
of O
receptors O
involved O
in O
contraction, O
growth, O
matrix O
protein O
production O
and O
the O
secretion O
of O
cytokines B-GENE-N
and O
chemokines. B-GENE-N
Transforming B-GENE-N
growth I-GENE-N
factor I-GENE-N

beta I-GENE-N
(TGF-β) B-GENE-N
is O
one O
of O
the O
major O
players O
in O
determining O
the O
structural O
and O
functional O
abnormalities O
of O
the O
ASM O
in O
asthma O
and O
COPD. O
It O
is O
increasingly O
evident O
that O
TGF-β B-GENE-N
functions O
as O
a O
master O
switch, O
controlling O
a O
network O
of O
intracellular O
and O
autocrine O
signaling O
loops O
that O
effect O
ASM O
phenotype O
and O
function. O
In O
this O
review, O
the O
various O
elements O
that O
participate O
in O
non-canonical O
TGF-β B-GENE-N
signaling, O
including O
MAPK, B-GENE-N
PI3K, B-GENE-N
WNT/β-catenin, B-GENE-N
and O
Ca(2+), B-CHEMICAL
are O
discussed, O
focusing O
on O
their O

effect O
on O
ASM O
phenotype O
and O
function. O
In O
addition, O
new O
aspects O
of O
ASM O
biology O
and O
their O
possible O
association O
with O
non-canonical O
TGF-β B-GENE-N
signaling O
will O
be O
discussed. O
Oxidative O
status O
in O
ICU O
patients O
with O
septic O
shock. O
The O
aim O
of O
this O
pilot O
study O
was O
to O
investigate O
variability O
of O
oxidative O
stress O
during O
sepsis O
evolution. O
ICU O
patients O
with O
the O
diagnosis O
of O
septic O
shock O
were O
included. O
Thiobarbituric-acid B-CHEMICAL
reactive O
substances, O
total O
antioxidant O
capacity, O
protein O
carbonyls B-CHEMICAL
in O
plasma, O
reduced, O
oxidized O
glutathione B-CHEMICAL
and O
catalase O
activity O

in O
erythrocyte O
lysate O
were O
assessed O
in O
the O
1st, O
3rd, O
5th O
and O
8thday O
after O
sepsis O
appearance. O
A O
total O
of O
17 O
patients O
were O
divided O
in O
two O
groups: O
survivors O
(n=7) O
and O
non-survivors O
(n=10). O
APACHE O
II O
was O
11.5±5.4 O
and O
19.9±4.97 O
in O
survivors O
and O
non-survivors O
respectively O
(p=0.005), O
while O
mean O
age O
and O
SOFA O
score O
at O
sepsis O
diagnosis, O
were O
similar O
between O
the O
two O
groups. O
GSH B-CHEMICAL
levels, O
catalase O
activity O
and O
protein O
carbonyls B-CHEMICAL
presented O
significant O

different O
course O
in O
time O
between O
survivors O
and O
non-survivors O
(p<0.05). O
Catalase B-GENE-Y
activity O
was O
significantly O
higher O
in O
survivors O
(238.8±51.5) O
than O
non-survivors O
(166.4±40.2; O
p=0.005), O
while O
protein O
carbonyls B-CHEMICAL
levels O
were O
significantly O
lower O
in O
survivors O
(0.32±0.09) O
than O
non-survivors O
(0.48±0.16; O
p=0.036) O
on O
the O
1stday. O
Yet, O
non-survivors O
exhibited O
a O
declining O
course O
in O
GSH B-CHEMICAL
levels O
during O
time, O
while O
GSH B-CHEMICAL
levels O
were O
maintained O

in O
survivors. O
Conclusively, O
a O
longstanding O
antioxidant O
deficiency O
in O
non-surviving O
patients O
was O
noted. O
This O
phenomenon O
was O
clearly O
prominent O
in O
patients' O
erythrocytes. O
NADPH B-GENE-Y
Oxidase I-GENE-Y
NOX5-S I-GENE-Y
and O
Nuclear B-GENE-Y
Factor I-GENE-Y
κB1 I-GENE-Y
Mediate O
Acid-Induced O
Microsomal B-GENE-Y
Prostaglandin I-GENE-Y
E I-GENE-Y
Synthase-1 I-GENE-Y
Expression O
in O
Barrett's O
Esophageal O
Adenocarcinoma O
Cells. O
The O
mechanisms O
of O
progression O
from O
Barrett's O
esophagus O
(BE) O
to O
esophageal O
adenocarcinoma O
(EA) O
are O
not O

known. O
Cycloxygenase-2 B-GENE-Y
(COX-2)-derived B-GENE-Y
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
has O
been O
shown O
to O
be O
important O
in O
esophageal O
tumorigenesis. O
We O
have O
shown O
that O
COX-2 B-GENE-Y
mediates O
acid-induced O
PGE2 B-CHEMICAL
production. O
The O
prostaglandin B-GENE-Y
E I-GENE-Y
synthase I-GENE-Y
(PGES) B-GENE-Y
responsible O
for O
acid-induced O
PGE2 B-CHEMICAL
production O
in O
BE, O
however, O
is O
not O
known. O
We O
found O
that O
microsomal B-GENE-Y
PGES1 I-GENE-Y
(mPGES1), B-GENE-Y
mPGES2, B-GENE-Y
and O

cytosolic B-GENE-Y
PGES I-GENE-Y
(cPGES) B-GENE-Y
were O
present O
in O
FLO O
EA O
cells. O
Pulsed O
acid O
treatment O
significantly O
increased O
mPGES1 B-GENE-Y
mRNA O
and O
protein O
levels O
but O
had O
little O
or O
no O
effect O
on O
mPGES2 B-GENE-Y
or O
cPGES B-GENE-Y
mRNA. O
Knockdown O
of O
mPGES1 B-GENE-Y
by O
mPGES1 B-GENE-Y
small O
interfering O
RNA O
(siRNA) O
blocked O
acid-induced O
increase O
in O
PGE2 B-CHEMICAL
production O
and O
thymidine B-CHEMICAL
incorporation. O
Knockdown O
of O
NADPH B-GENE-N
oxidase, I-GENE-N
NOX5-S, B-GENE-Y
a O
variant O
lacking O
calcium-binding B-GENE-N
domains, I-GENE-N
by O

NOX5 B-GENE-Y
siRNA O
significantly O
inhibited O
acid-induced O
increase O
in O
mPGES1 B-GENE-Y
expression, O
thymidine B-CHEMICAL
incorporation, O
and O
PGE2 B-CHEMICAL
production. O
Overexpression O
of O
NOX5-S B-GENE-Y
significantly O
increased O
the O
luciferase O
activity O
in O
FLO O
cells O
transfected O
with O
a O
nuclear B-GENE-N
factor I-GENE-N
κB I-GENE-N
(NF-κB) B-GENE-N
in O
vivo O
activation O
reporter O
plasmid O
pNF-κB-Luc. B-GENE-N
Knockdown O
of O
NF-κB1 B-GENE-Y
p50 B-GENE-Y
by O
p50 B-GENE-Y
siRNA O
significantly O
decreased O
acid-induced O
increase O
in O
mPGES1 B-GENE-Y
expression, O
thymidine B-CHEMICAL
incorporation, O
and O
PGE2 B-CHEMICAL

production. O
Two O
novel O
NF-κB B-GENE-N
binding I-GENE-N
elements, I-GENE-N
GGAGTCTCCC B-GENE-N
and O
CGGGACACCC, B-GENE-N
were O
identified O
in O
the O
mPGES1 B-GENE-N
gene I-GENE-N
promoter. I-GENE-N
We O
conclude O
that O
mPGES1 B-GENE-Y
mediates O
acid-induced O
increase O
in O
PGE2 B-CHEMICAL
production O
and O
cell O
proliferation. O
Acid-induced O
mPGES1 B-GENE-Y
expression O
depends O
on O
activation O
of O
NOX5-S B-GENE-Y
and O
NF-κB1 B-GENE-Y
p50. B-GENE-Y
Microsomal B-GENE-Y
PGES1 I-GENE-Y
may O
be O
a O
potential O
target O
to O
prevent O
or O
treat O
EA. O
Butein B-CHEMICAL
protects O
human O
dental O
pulp O
cells O
from O
hydrogen B-CHEMICAL
peroxide-induced I-CHEMICAL
oxidative O

toxicity O
via O
Nrf2 B-GENE-Y
pathway-dependent O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
expressions. O
Rhus O
verniciflua O
Stokes O
is O
a O
plant O
that O
is O
native O
to O
East O
Asian O
countries, O
such O
as O
Korea, O
China, O
and O
Japan. O
Butein, B-CHEMICAL
a O
plant O
polyphenol, B-CHEMICAL
is O
one O
of O
the O
major O
active O
components O
of O
R. O
verniciflua. O
Reactive O
oxygen B-CHEMICAL
species O
(ROS), O
produced O
via O
dental O
adhesive O
bleaching O
agents O
and O
pulpal O
disease, O
can O
cause O
oxidative O
stress. O
Here, O
we O
found O
that O
butein B-CHEMICAL
possesses O
cytoprotective O
effects O
on O
hydrogen B-CHEMICAL
peroxide I-CHEMICAL

(H2O2)-induced B-CHEMICAL
dental O
cell O
death. O
H2O2 B-CHEMICAL
is O
a O
representative O
ROS O
and O
causes O
cell O
death O
through O
necrosis O
in O
human O
dental O
pulp O
(HDP) O
cells. O
H2O2-induced B-CHEMICAL
cytotoxicity O
and O
production O
of O
ROS O
were O
blocked O
in O
the O
presence O
of O
butein, B-CHEMICAL
and O
these O
effects O
were O
dose O
dependent. O
Butein B-CHEMICAL
also O
increased O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
protein O
expression O
and O
HO B-GENE-Y
activity. O
In O
addition, O
butein-dependent B-CHEMICAL
HO-1 B-GENE-Y
expression O
was O
required O
for O
the O
inhibition O
of O
H2O2-induced B-CHEMICAL
cell O
death O
and O
ROS O
generation. O

Furthermore, O
butein B-CHEMICAL
treatment O
caused O
nuclear O
accumulation O
of O
nuclear B-GENE-Y
factor-E2-related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2) B-GENE-Y
and O
increased O
the O
promoter O
activity O
of O
antioxidant B-GENE-N
response I-GENE-N
elements I-GENE-N
(AREs). B-GENE-N
Treatment O
of O
HDP O
cells O
with O
a O
c-Jun B-GENE-N
NH2-terminal I-GENE-N
kinase I-GENE-N
(JNK) B-GENE-N
inhibitor O
also O
reduced O
butein-induced B-CHEMICAL
HO-1 B-GENE-Y
expression, O
and O
butein B-CHEMICAL
treatment O
led O
to O
increased O
JNK B-GENE-N
phosphorylation. O
These O
results O
indicate O
that O
butein B-CHEMICAL
may O
be O
used O
to O
prevent O
functional O
dental O
cell O
death O
and O
thus O
may O
be O
useful O
as O
a O
pulpal O
disease O
agent. O
Folding O
pathway O
of O

guanidine-denatured B-CHEMICAL
disulfide-intact B-CHEMICAL
wild-type O
and O
mutant O
bovine B-GENE-Y
pancreatic I-GENE-Y
ribonuclease I-GENE-Y
A. I-GENE-Y
The O
refolding O
kinetics O
of O
guanidine-denatured B-CHEMICAL
disulfide-intact B-CHEMICAL
bovine B-GENE-Y
pancreatic I-GENE-Y
ribonuclease I-GENE-Y
A I-GENE-Y
(RNase B-GENE-Y
A) I-GENE-Y
and O
its O
proline-42-to-alanine B-GENE-N
mutant O
(Pro42Ala) B-GENE-N
have O
been O
studied O
by O
monitoring O
tyrosine B-CHEMICAL
burial O
and O
2'-cytidine B-CHEMICAL
monophosphate I-CHEMICAL
(2'CMP) B-CHEMICAL
inhibitor O
binding. O
The O
folding O
rate O
for O

wild-type O
RNase B-GENE-Y
A I-GENE-Y
is O
faster O
in O
the O
presence O
of O
the O
inhibitor O
2'CMP B-CHEMICAL
than O
in O
its O
absence, O
indicating O
that O
the O
transition-state O
structure O
in O
the O
rate-determining O
step O
is O
stabilized O
by O
2'CMP. B-CHEMICAL
The O
folding O
rate O
monitored O
by O
2'CMP B-CHEMICAL
binding O
to O
the O
major O
slow-folding O
species O
of O
Pro42Ala B-GENE-N
RNase B-GENE-Y
A I-GENE-Y
is O
faster O
than O
the O
folding O
rate O
monitored O
by O
tyrosine B-CHEMICAL
burial; O
however, O
the O
folding O
rate O
monitored O
by O
inhibitor O
binding O
to O
the O
minor O
slow-folding O
species O
is O
decreased O
significantly O
over O
the O
folding O
rate O
monitored O
by O
tyrosine B-CHEMICAL
burial, O
indicating O
that O
the O
major O
and O
minor O
slow-folding O

species O
of O
Pro42Ala B-GENE-N
fold O
to O
the O
native O
state O
with O
different O
transition-state O
conformations O
in O
the O
rate-determining O
step. O
Nutrient O
signaling O
in O
protein O
homeostasis: O
an O
increase O
in O
quantity O
at O
the O
expense O
of O
quality. O
The O
discovery O
that O
rapamycin B-CHEMICAL
extends O
the O
life O
span O
of O
diverse O
organisms O
has O
triggered O
many O
studies O
aimed O
at O
identifying O
the O
underlying O
molecular O
mechanisms. O
Mammalian B-GENE-N
target I-GENE-N
of I-GENE-N
rapamycin I-GENE-N
complex I-GENE-N
1 I-GENE-N
(mTORC1) B-GENE-N
regulates O
cell O
growth O
and O
may O
regulate O
organismal O
aging O
by O
controlling O
mRNA O
translation. O
However, O
how O
inhibiting O
mTORC1 B-GENE-N
and O
decreasing O
protein O
synthesis O
can O
extend O
life O
span O
remains O
an O

unresolved O
issue. O
We O
showed O
that O
constitutively O
active O
mTORC1 B-GENE-N
signaling O
increased O
general O
protein O
synthesis O
but O
unexpectedly O
reduced O
the O
quality O
of O
newly O
synthesized O
polypeptides. O
We O
demonstrated O
that O
constitutively O
active O
mTORC1 B-GENE-N
decreased O
translation O
fidelity O
by O
increasing O
the O
speed O
of O
ribosomal O
elongation. O
Conversely, O
rapamycin B-CHEMICAL
treatment O
restored O
the O
quality O
of O
newly O
synthesized O
polypeptides O
mainly O
by O
slowing O
the O
rate O
of O
ribosomal O
elongation. O
We O
also O
found O
distinct O
roles O
for O
mTORC1 B-GENE-N
downstream O
targets O
in O
maintaining O
protein O
homeostasis. O
Loss O
of O
S6 B-GENE-N
kinases, I-GENE-N
but O
not O

4E-BP B-GENE-N
family O
proteins, O
which O
are O
both O
involved O
in O
regulation O
of O
translation, O
attenuated O
the O
effects O
of O
rapamycin B-CHEMICAL
on O
the O
quality O
of O
newly O
translated O
proteins. O
Our O
results O
reveal O
a O
mechanistic O
connection O
between O
mTORC1 B-GENE-N
and O
protein O
quality, O
highlighting O
the O
central O
role O
of O
nutrient O
signaling O
in O
growth O
and O
aging. O
Cortisol B-CHEMICAL
and O
interferon O
tau O
regulation O
of O
endometrial O
function O
and O
conceptus O
development O
in O
female O
sheep. O
During O
early O
pregnancy O
in O
sheep, O
the O
elongating O
conceptus O
secretes O
interferon-τ B-GENE-N
(IFNT) B-GENE-N
and O
the O
conceptus O
as O
well O
as O
endometrial O

epithelia O
produce O
prostaglandins B-CHEMICAL
(PG) O
via O
PG B-GENE-Y
synthase I-GENE-Y
2 I-GENE-Y
(PTGS2) B-GENE-Y
and O
cortisol B-CHEMICAL
via O
hydroxysteroid B-GENE-Y
(11-β) I-GENE-Y
dehydrogenase I-GENE-Y
1 I-GENE-Y
(HSD11B1). B-GENE-Y
Ovarian O
progesterone B-CHEMICAL
induces O
and O
PG O
and O
IFNT B-GENE-N
stimulates O
endometrial O
HSD11B1 B-GENE-Y
expression O
and O
keto-reductase B-GENE-N
activity O
as O
well O
as O
many O
epithelial O
genes O
that O
govern O
trophectoderm O
proliferation, O
migration, O
and O
attachment O
during O
elongation. O
The O
primary O
aim O
of O
these O
studies O
was O
to O

test O
the O
hypothesis O
that O
HSD11B1-derived B-GENE-Y
cortisol B-CHEMICAL
has O
a O
biological O
role O
in O
endometrial O
function O
and O
conceptus O
development O
during O
early O
pregnancy O
in O
sheep. O
In O
study O
1, O
cyclic O
ewes O
received O
vehicle, O
cortisol, B-CHEMICAL
PF B-CHEMICAL
915275 I-CHEMICAL
(PF; O
a O
selective O
inhibitor O
of O
HSD11B1), B-GENE-Y
cortisol B-CHEMICAL
and O
PF, O
meloxicam B-CHEMICAL
(a O
selective O
inhibitor O
of O
PTGS2), B-GENE-Y
cortisol B-CHEMICAL
and O
meloxicam, B-CHEMICAL
recombinant O
ovine B-GENE-N
IFNT, I-GENE-N
or O
IFNT B-GENE-N
and O
PF O
into O
the O
uterus O
from O

day O
10 O
to O
day14 O
after O
estrus. O
Cortisol B-CHEMICAL
and O
IFNT B-GENE-N
stimulated O
endometrial O
HSD11B1 B-GENE-Y
expression O
and O
activity, O
increased O
endometrial O
PTGS2 B-GENE-Y
activity O
and O
the O
amount O
of O
PG O
in O
the O
uterine O
lumen, O
and O
up-regulated O
many O
conceptus O
elongation-related O
genes O
in O
the O
endometrium. O
Some O
effects O
of O
cortisol B-CHEMICAL
and O
IFNT B-GENE-N
were O
mediated O
by O
PTGS2-derived B-GENE-Y
PG. O
In O
study O
2, O
bred O
ewes O
received O
PF B-CHEMICAL
915275 I-CHEMICAL
or O
recombinant O
ovine B-GENE-N
IFNT I-GENE-N
and O
into O
the O
uterus O

from O
day O
10 O
to O
day O
14 O
after O
mating. O
Inhibition O
of O
HSD11B1 B-GENE-Y
activity O
in O
utero O
prevented O
conceptus O
elongation, O
whereas O
IFNT B-GENE-N
rescued O
conceptus O
elongation O
in O
PF-infused O
ewes. O
These O
results O
suggest O
that O
HSD11B1-derived B-GENE-Y
cortisol B-CHEMICAL
mediates, O
in O
part, O
actions O
of O
ovarian O
progesterone B-CHEMICAL
and O
the O
conceptus O
on O
endometrial O
function O
and O
support O
the O
hypothesis O
that O
IFNT, B-GENE-N
PG, O
and O
cortisol B-CHEMICAL
coordinately O
regulate O
endometrial O
functions O
important O
for O
conceptus O
elongation O
and O
implantation O
during O
early O
pregnancy O
in O

sheep. O
2-(2-Aminoethyl)-quinoline B-CHEMICAL
(D-1997): B-CHEMICAL
a O
novel O
agonist O
at O
5-hydroxytryptamine1-like B-GENE-N
receptors I-GENE-N
in O
the O
canine O
basilar O
artery. O
This O
study O
aimed O
to O
investigate O
the O
mechanisms O
involved O
in O
the O
contractile O
effects O
produced O
by O
the O
novel O
quinoline B-CHEMICAL
derivative, O
2-(2-aminoethyl)-quinoline B-CHEMICAL
(D-1997), B-CHEMICAL
in O
the O
canine O
isolated O
basilar O
artery. O
For O
comparison, O
the O
effects O
of O
D-1997 B-CHEMICAL
were O
also O
evaluated O
on O
rat O
aorta. O
Canine O
basilar O
artery O

and O
rat O
aortic O
rings O
were O
prepared O
and O
mounted O
in O
organ O
baths O
to O
record O
isometric O
tension O
changes. O
The O
contractile O
effects O
of O
D-1997 B-CHEMICAL
in O
the O
basilar O
artery O
were O
compared O
with O
those O
produced O
by O
5-hydroxytryptamine B-CHEMICAL
(5-HT) B-CHEMICAL
and O
the O
5-HT B-GENE-N
receptor I-GENE-N
agonist O
quipazine. B-CHEMICAL
Thus, O
4-HT B-CHEMICAL
(10(-10)-10(-6)M), O
D-1997 B-CHEMICAL
(3.1 O
x O
10(-8)-10(-4) O
M) O
and O
quipazine B-CHEMICAL
(3.1 O
x O

10(-7)-10(-4) O
M) O
each O
caused O
concentration-dependent O
contractions O
of O
the O
canine O
basilar O
artery O
with O
a O
rank O
order O
of O
agonist O
potency O
of O
5-HT B-CHEMICAL
> O
D-1997 B-CHEMICAL
> O
quipazine. B-CHEMICAL
5-HT B-CHEMICAL
and O
D-1997 B-CHEMICAL
exhibited O
similar O
maximum O
effects O
which O
were O
higher O
than O
that O
of O
quipazine. B-CHEMICAL
Similar O
concentrations O
of O
D-1997 B-CHEMICAL
failed O
to O
produce O
contraction O
in O
rat O
aorta. O
The O
effects O
of O
D-1997 B-CHEMICAL
in O
the O
basilar O
artery O
were O
not O
modified O
by O
incubation O
with O
either O
the O
5-HT2 B-GENE-N
receptor I-GENE-N
antagonist O
ketanserin B-CHEMICAL

(0.01-1 O
microM), O
the O
5-HT3 B-GENE-N
and O
5-HT4 B-GENE-Y
receptor O
antagonist O
ICS205930 O
(tropisetron; B-CHEMICAL
0.1-10 O
microM), O
the O
5-HT1A B-GENE-Y
receptor O
antagonist O
spiroxatrine B-CHEMICAL
(0.01-1 O
microM), O
the O
beta-adrenoceptor B-GENE-N
blocker O
with O
high O
affinity O
for O
5-HT1A B-GENE-Y
and O
5-HT1B B-GENE-Y
binding O
sites O
(+/-)-pindolol B-CHEMICAL
(0.01-1 O
microM), O
or O
the O
alpha B-GENE-N

1-adrenoceptor I-GENE-N
antagonist O
prazosin B-CHEMICAL
(0.01-1 O
microM). O
In O
contrast, O
the O
D-1997-induced B-CHEMICAL
responses O
were O
potently O
and O
concentration-dependently O
antagonized O
by O
the O
mixed O
5-HT1-like B-GENE-N
and O
5-HT2 B-GENE-N
receptor I-GENE-N
antagonist O
methiothepin B-CHEMICAL
(0.01-1 O
microM). O
It O
is O
concluded O
that O
D-1997 B-CHEMICAL
contracts O
the O
canine O
basilar O
artery O
by O
stimulating O
5-HT1-like B-GENE-N
receptors I-GENE-N
unrelated O
to O
either O
the O
5-HT1A B-GENE-Y
or O
5-HT1B B-GENE-Y
receptor O
subtypes. O
The O

compound O
seems O
to O
be O
devoid O
of O
5-HT2 B-GENE-N
receptor I-GENE-N
agonist O
properties O
in O
rat O
aorta. O
Vitamin B-CHEMICAL
K2 I-CHEMICAL
covalently O
binds O
to O
Bak B-GENE-Y
and O
induces O
Bak-mediated B-GENE-Y
apoptosis. O
Vitamin B-CHEMICAL
K2 I-CHEMICAL
(VK2, B-CHEMICAL
menaquinone) B-CHEMICAL
is O
known O
to O
have O
anticancer O
activity O
in O
vitro O
and O
in O
vivo. O
Although O
its O
effect O
is O
thought O
to O
be O
mediated, O
at O
least O
in O
part, O
by O
the O
induction O
of O
apoptosis, O
the O
underlying O
molecular O
mechanism O
remains O
elusive. O
Here, O
we O
identified O
Bcl-2 B-GENE-Y
antagonist O
killer O
1 O
(Bak) B-GENE-Y
as O
a O
molecular O
target O
of O

VK2-induced B-CHEMICAL
apoptosis. O
VK2 B-CHEMICAL
directly O
interacts O
with O
Bak B-GENE-Y
and O
induces O
mitochondrial-mediated O
apoptosis. O
Although O
Bak B-GENE-Y
and O
Bcl-2-associated B-GENE-Y
X I-GENE-Y
protein I-GENE-Y
(Bax), B-GENE-Y
another O
member O
of O
the O
Bcl-2 B-GENE-Y
family, O
are O
generally O
thought O
to O
be O
functionally O
redundant, O
only O
Bak B-GENE-Y
is O
necessary O
and O
sufficient O
for O
VK2-induced B-CHEMICAL
cytochrome B-GENE-Y
c I-GENE-Y
(cyt B-GENE-Y
c) I-GENE-Y
release O
and O
cell O
death. O
Moreover, O
VK2-2,3 B-CHEMICAL
epoxide, I-CHEMICAL
an O
intracellular O
metabolite O
of O
VK2, B-CHEMICAL
was O
shown O
to O
covalently O
bind O

to O
the O
cysteine-166 B-CHEMICAL
residue O
of O
Bak. B-GENE-Y
Several O
lines O
of O
evidence O
suggested O
that O
the O
covalent O
attachment O
of O
VK2 B-CHEMICAL
is O
critical O
for O
apoptosis O
induction. O
Thus O
this O
study O
reveals O
a O
specific O
role O
for O
Bak B-GENE-Y
in O
mitochondria-mediated O
apoptosis. O
This O
study O
also O
provides O
insight O
into O
the O
anticancer O
effects O
of O
VK2 B-CHEMICAL
and O
suggests O
that O
Bak B-GENE-Y
may O
be O
a O
potential O
target O
of O
cancer O
therapy. O
Effect O
of O
developmental O
dioxin B-CHEMICAL
exposure O
on O
methylation O
and O
expression O
of O
specific O
imprinted O
genes O
in O
mice. O

2,3,7,8-Tetrachlorodibenzo-p-dioxin B-CHEMICAL
(TCDD) B-CHEMICAL
is O
an O
endocrine O
disruptor O
affecting O
the O
reproductive O
system O
in O
humans. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
TCDD B-CHEMICAL
administered O
to O
pregnant O
mice O
at O
two O
different O
doses O
(2-10 O
ng/kg/day), O
on O
imprinted O
genes O
in O
the O
male O
offspring. O
The O
degree O
of O
methylation O
and O
the O
mRNA O
expression O
of O
Snrpn, B-GENE-Y
Peg3 B-GENE-Y
and O
Igf2r B-GENE-Y
were O
analyzed O
in O
the O
sperm, O
skeletal O
muscle O
and O
liver. O
TCDD B-CHEMICAL
administration O
(10 O

ng/kg/day) O
decreased O
the O
sperm O
count O
in O
the O
male O
offspring. O
It O
did O
not O
affect O
methylation O
but O
increased O
mRNA O
expression O
of O
Snrpn, B-GENE-Y
Peg3, B-GENE-Y
Igf2r B-GENE-Y
and O
Air B-GENE-Y
ncRNA. I-GENE-Y
In O
muscle O
and O
liver, O
TCDD B-CHEMICAL
(10 O
ng/kg/day) O
induced O
increases O
in O
methylation O
and O
decreases O
in O
mRNA O
expression O
of O
Igf2r. B-GENE-Y
These O
results O
show O
that O
the O
robust O
effects O
of O
TCDD B-CHEMICAL
on O
the O
mRNA O
expression O
of O
Snrpn, B-GENE-Y
Peg3 B-GENE-Y
and O
Igf2r B-GENE-Y
genes O
in O
the O
sperm O
and O
of O
Igf2r B-GENE-Y
in O

the O
muscle O
and O
liver O
are O
unrelated O
to O
changes O
in O
methylation O
in O
their O
respective O
genes. O
Rasagiline B-CHEMICAL
protects O
against O
alpha-synuclein B-GENE-Y
induced O
sensitivity O
to O
oxidative O
stress O
in O
dopaminergic O
cells. O
Rasagiline B-CHEMICAL
is O
a O
propargylamine B-CHEMICAL
and O
irreversible O
monoamine B-GENE-Y
oxidase I-GENE-Y
(MAO) I-GENE-Y
B I-GENE-Y
inhibitor O
used O
for O
the O
treatment O
of O
Parkinson's O
disease O
(PD). O
It O
has O
demonstrated O
neuroprotective O
properties O
in O
laboratory O
studies. O
Current O
concepts O
of O
PD O
aetiopathogenesis O
include O
the O
role O
of O
alpha-synuclein, B-GENE-Y
protein O
aggregation, O
free O

radical O
metabolism O
and O
mitochondrial O
dysfunction O
in O
contributing O
to O
cell O
death. O
We O
have O
used O
a O
combination O
of O
alpha-synuclein B-GENE-Y
and O
free O
radical O
mediated O
toxicity O
in O
a O
dopaminergic O
cell O
line O
to O
provide O
a O
model O
of O
nigral O
toxicity O
in O
order O
to O
investigate O
the O
potential O
molecular O
mechanisms O
that O
mediate O
rasagiline B-CHEMICAL
protection. O
We O
demonstrate O
that O
rasagiline B-CHEMICAL
protects O
against O
cell O
death O
induced O
by O
the O
combination O
of O
free O
radicals O
generated O
by O
paraquat B-CHEMICAL
and O
either O
wild-type O
or O
A53T B-GENE-N
mutant O
alpha-synuclein B-GENE-Y
over-expression. O
This O
protection O
was O
associated O
with O
a O
reduction O
in O
caspase B-GENE-Y
3 I-GENE-Y
activation, O
a O
reduction O
in O

superoxide B-CHEMICAL
generation O
and O
a O
trend O
to O
ameliorate O
the O
fall O
in O
mitochondrial O
membrane O
potential. O
Rasagiline B-CHEMICAL
induced O
an O
increase O
in O
cellular O
glutathione B-CHEMICAL
levels. O
The O
results O
support O
a O
role O
for O
rasagiline B-CHEMICAL
in O
protecting O
dopaminergic O
cells O
against O
free O
radical O
mediated O
damage O
and O
apoptosis O
in O
the O
presence O
of O
alpha-synuclein B-GENE-Y
over-expression. O
The O
data O
are O
of O
relevance O
to O
the O
interpretation O
of O
the O
potential O
mechanisms O
of O
action O
of O
rasagiline B-CHEMICAL
in O
explaining O
the O
results O
of O
disease O
modification O
trials O
in O
PD. O
Tolvaptan B-CHEMICAL
and O
its O
potential O
in O
the O
treatment O
of O
hyponatremia. O

Tolvaptan B-CHEMICAL
is O
a O
selective O
arginine B-GENE-Y
vasopressin I-GENE-Y
(AVP) I-GENE-Y
V(2) I-GENE-Y
receptor I-GENE-Y
blocker O
used O
to O
induce O
free O
water O
diuresis O
in O
the O
treatment O
of O
euvolemic O
or O
hypervolemic O
hyponatremia. O
Currently O
the O
orally O
active O
medication O
is O
in O
the O
final O
stages O
prior O
to O
approval O
by O
the O
FDA O
for O
outpatient O
therapy. O
It O
appears O
to O
be O
safe O
and O
effective O
at O
promoting O
aquaresis O
and O
raising O
serum O
sodium B-CHEMICAL
levels O
in O
both O
short- O
and O
long-term O
studies. O
Tolvaptan B-CHEMICAL
is O
also O
effective O
for O
treatment O
of O
congestive O
heart O
failure O

(CHF) O
exacerbation, O
but O
whether O
there O
are O
long O
standing O
beneficial O
effects O
on O
CHF O
is O
still O
controversial. O
Prolonged O
use O
of O
tolvaptan B-CHEMICAL
leads O
to O
increased O
endogenous O
levels O
of O
AVP B-GENE-Y
and O
perhaps O
over-stimulation O
of O
V(1A) B-GENE-Y
receptors. I-GENE-Y
Theoretically O
this O
activation O
could O
lead O
to O
increased O
afterload O
and O
cardiac O
myocyte O
fibrosis, O
causing O
progression O
of O
CHF. O
However, O
after O
52 O
weeks O
of O
tolvaptan B-CHEMICAL
therapy O
there O
was O
no O
worsening O
of O
left O
ventricular O
dilatation. O
In O
addition, O
tolvaptan B-CHEMICAL
is O
metabolized O
by O
the O

CYP3A4 B-GENE-Y
system; O
thus O
physicians O
should O
be O
aware O
of O
the O
potential O
for O
increased O
interactions O
with O
other O
medications. O
Tolvaptan B-CHEMICAL
is O
a O
breakthrough O
in O
the O
therapy O
of O
hyponatremia O
as O
it O
directly O
combats O
elevated O
AVP B-GENE-Y
levels O
associated O
with O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic B-GENE-Y
hormone, I-GENE-Y
congestive O
heart O
failure, O
and O
cirrhosis O
of O
the O
liver. O
alpha(1B) B-GENE-Y
adrenergic I-GENE-Y
receptors I-GENE-Y
in O
gonadotrophin-releasing B-GENE-Y
hormone I-GENE-Y
neurones: O
relation O
to O
Transport-P. O
1. O
Peptidergic O
neurones O
accumulate O
amines B-CHEMICAL
via O
an O

unusual O
uptake O
process, O
designated O
Transport-P. O
[(3)H]-prazosin B-CHEMICAL
binds O
to O
alpha(1) B-GENE-N
adrenoceptors I-GENE-N
on O
these O
cells O
and O
is O
displaceable O
by O
unlabelled O
prazosin B-CHEMICAL
in O
concentrations O
up O
to O
10(-7) O
M. O
However, O
at O
greater O
concentrations O
of O
prazosin, B-CHEMICAL
there O
is O
a O
paradoxical O
accumulation O
of O
[(3)H]-prazosin B-CHEMICAL
which O
we O
have O
attributed O
to O
Transport-P. O
Uptake O
of O
prazosin B-CHEMICAL
via O
Transport-P O
is O
detectable O
at O
10(-10) O
M O
prazosin B-CHEMICAL

concentration, O
is O
linear O
up O
to O
10(-7) O
M O
and O
at O
greater O
concentrations O
becomes O
non-linear. O
In O
contrast, O
in O
noradrenergic O
neurones, O
noradrenaline B-CHEMICAL
uptake O
is O
linear O
and O
saturates O
above O
10(-7) O
M. O
In O
noradrenergic O
neurones O
and O
in O
non-neuronal O
cells, O
there O
is O
no O
uptake O
of O
prazosin B-CHEMICAL
in O
concentrations O
up O
to O
10(-6) O
M, O
suggesting O
that O
Transport-P O
is O
a O
specialised O
function O
of O
peptidergic O
neurones. O
2. O
Using O
a O
mouse O
peptidergic O

(gonadotrophin-releasing B-GENE-Y
hormone, I-GENE-Y
GnRH) B-GENE-Y
neuronal O
cell O
line O
which O
possesses O
Transport-P, O
we O
have O
studied O
the O
interaction O
of O
alpha(1) B-GENE-N
adrenoceptors I-GENE-N
with O
Transport-P. O
Polymerase O
chain O
reactions O
and O
DNA O
sequencing O
of O
the O
products O
demonstrated O
that O
only O
the O
alpha(1B) B-GENE-Y
sub-type I-GENE-Y
of I-GENE-Y
adrenoceptors I-GENE-Y
is O
present O
in O
GnRH B-GENE-Y
cells. O
3. O
In O
COS O
cells O
transfected O
with O
alpha(1b) B-GENE-Y
adrenoceptor I-GENE-Y
cDNA O
and O
in O
DDT(1) O
MF-2 O
cells O
which O
express O
native O

alpha(1B) B-GENE-Y
adrenoceptors, I-GENE-Y
[(3)H]-prazosin B-CHEMICAL
was O
displaced O
by O
unlabelled O
prazosin B-CHEMICAL
in O
a O
normal O
equilibrium O
process, O
with O
no O
prazosin B-CHEMICAL
paradox O
in O
concentrations O
up O
to O
10(-6) O
M. O
In O
DDT(1) O
MF-2 O
cells, O
[(3)H]-prazosin B-CHEMICAL
was O
displaced O
likewise O
by O
a O
series O
of O
alpha(1) B-GENE-N
adrenergic O
agonists, O
none O
of O
which O
increased O
the O
binding O
of O
[(3)H]-prazosin. B-CHEMICAL
Hence, O
the O
prazosin B-CHEMICAL

paradox O
is O
not O
due O
to O
some O
function O
of O
alpha(1) B-GENE-N
adrenoceptors, I-GENE-N
such O
as O
internalization O
of O
ligand-receptor O
complexes. O
4. O
In O
neurones O
which O
possess O
Transport-P, O
transfection O
with O
alpha(1b) B-GENE-Y
adrenoceptor I-GENE-Y
cDNA O
resulted O
in O
over-expression O
of O
alpha(1B) B-GENE-Y
adrenoceptors, I-GENE-Y
but O
the O
prazosin B-CHEMICAL
paradox O
was O
unaltered. O
Thus, O
alpha(1) B-GENE-N
adrenoceptors I-GENE-N
and O
Transport-P O
mediate O
distinct O
functions O
in O
peptidergic O
neurones. O
Fisetin B-CHEMICAL
averts O

oxidative O
stress O
in O
pancreatic O
tissues O
of O
streptozotocin-induced B-CHEMICAL
diabetic O
rats. O
Persistent O
hyperglycemia O
is O
associated O
with O
chronic O
oxidative O
stress O
which O
contributes O
to O
the O
development O
and O
progression O
of O
diabetes-associated O
complications. O
The O
sensitivity O
of O
pancreatic O
β-cells O
to O
oxidative O
stress O
has O
been O
attributed O
to O
their O
low O
content O
of O
antioxidants O
compared O
with O
other O
tissues. O
Bioactive O
compounds O
with O
potent O
antidiabetic O
properties O
have O
been O
shown O
to O
ameliorate O
hyperglycemia O
mediated O
oxidative O
stress. O
Recently, O
we O
have O
reported O
that O
oral O
administration O
of O

fisetin B-CHEMICAL
(10 O
mg/Kg O
b.w.), O
a O
bioflavonoid B-CHEMICAL
found O
to O
be O
present O
in O
strawberries, O
persimmon, O
to O
STZ-induced B-CHEMICAL
experimental O
diabetic O
rats O
significantly O
improved O
normoglycemia. O
The O
present O
study O
was O
aimed O
to O
evaluate O
the O
antioxidant O
potential O
of O
fisetin B-CHEMICAL
in O
both O
in O
vitro O
and O
in O
vivo. O
Diabetes O
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
streptozotocin B-CHEMICAL
(50 O
mg/kg O
body O
weight). O
Fisetin B-CHEMICAL
was O
administered O
orally O
for O
30 O
days. O
At O
the O
end O
of O
the O

study, O
all O
animals O
were O
killed. O
Blood O
samples O
were O
collected O
for O
the O
biochemical O
estimations. O
The O
antioxidant O
status O
was O
evaluated. O
Histological O
examinations O
were O
performed O
on O
pancreatic O
tissues. O
Fisetin B-CHEMICAL
treatment O
showed O
a O
significant O
decline O
in O
the O
levels O
of O
blood O
glucose, B-CHEMICAL
glycosylated B-GENE-N
hemoglobin I-GENE-N
(HbA1c), B-GENE-N
NF-kB B-GENE-N
p65 B-GENE-Y
unit O
(in O
pancreas) O
and O
IL-1β B-GENE-Y
(plasma), O
serum O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
with O
an O
elevation O
in O
plasma O
insulin. B-GENE-N
The O
treatment O
also O
improved O
the O
antioxidant O
status O
in O
pancreas O
as O
well O
as O

plasma O
of O
diabetic O
rats O
indicating O
the O
antioxidant O
potential O
of O
fisetin. B-CHEMICAL
In O
addition, O
the O
results O
of O
DPPH B-CHEMICAL
and O
ABTS B-CHEMICAL
assays O
substantiate O
the O
free O
radical O
scavenging O
activity O
of O
fisetin. B-CHEMICAL
Histological O
studies O
of O
the O
pancreas O
also O
evidenced O
the O
tissue O
protective O
nature O
of O
fisetin. B-CHEMICAL
It O
is O
concluded O
that, O
fisetin B-CHEMICAL
possesses O
antioxidant O
and O
anti-inflammatory O
property O
and O
may O
be O
considered O
as O
an O
adjunct O
for O
the O
treatment O
of O
diabetes. O
Inhibition O
of O
the O
uterotropic O
activity O
of O
estrogens O
and O
antiestrogens O
by O
the O
short O
acting O
antiestrogen O

LY117018. B-CHEMICAL
The O
aim O
of O
the O
study O
was O
to O
determine O
whether O
the O
dihydroxylated O
antiestrogen O
LY117018, B-CHEMICAL
with O
a O
high O
affinity O
for O
the O
estrogen B-GENE-Y
receptor I-GENE-Y
and O
low O
intrinsic O
estrogenic O
activity, O
could O
inhibit O
the O
uterotropic O
actions O
of O
steroidal O
[estradiol-17 B-CHEMICAL
beta I-CHEMICAL
(E2)] B-CHEMICAL
and O
nonsteroidal O
[ICI O
3188 O
and O
trianisylchloroethylene B-CHEMICAL
(TACE)] B-CHEMICAL
estrogens O
in O
immature O
rats O
and O
also O
the O
uterotropic O
actions O
of O
tamoxifen B-CHEMICAL
and O

monohydroxytamoxifen B-CHEMICAL
in O
the O
ovariectomized O
mouse O
and O
immature O
rat. O
In O
the O
first O
series O
of O
experiments, O
LY117018 B-CHEMICAL
was O
compared O
with O
monohydroxytamoxifen. B-CHEMICAL
Both O
antiestrogens O
inhibited O
the O
uterotropic O
actions O
of O
E2 B-CHEMICAL
(0.32 O
micrograms O
daily), O
ICI O
3188 O
(5 O
micrograms O
daily), O
and O
TACE O
(40 O
and O
160 O
micrograms O
daily) O
in O
a O
dose-related O
manner O
(0.32-82 O
micrograms O
daily). O
The O
potency O
of O
the O

antiestrogens O
against O
E2 O
and O
ICI O
3188 O
was O
similar, O
however, O
at O
higher O
doses O
(20.48 O
and O
82 O
micrograms O
daily) O
LY117018 B-CHEMICAL
reduced O
uterine O
weights O
to O
below O
the O
lowest O
level O
achieved O
by O
monohydroxytamoxifen. B-CHEMICAL
In O
contrast, O
LY117018 B-CHEMICAL
was O
less O
effective O
against O
the O
long O
acting O
estrogen O
TACE. O
The O
competitive O
interaction O
of O
LY117018 B-CHEMICAL
with O
tamoxifen B-CHEMICAL
and O
monohydroxytamoxifen B-CHEMICAL
was O
compared O
in O
3-day O
ovariectomized O
mouse O
and O
immature O
rat O
uterine O
weight O
tests. O

Tamoxifen B-CHEMICAL
and O
monohydroxytamoxifen B-CHEMICAL
were O
fully O
estrogenic O
in O
the O
mouse O
(5 O
micrograms O
daily) O
and O
partially O
estrogenic O
in O
the O
rat O
(1.5-20 O
micrograms O
daily). O
LY117018 B-CHEMICAL
was O
a O
partial O
estrogen O
in O
the O
mouse O
and O
a O
weekly O
active O
partial O
estrogen O
in O
the O
rat O
(2.5-120 O
micrograms O
daily). O
LY117018 B-CHEMICAL
produced O
dose-related O
decreases O
in O
the O
uterine O
weight O
increases O
induced O
by O
tamoxifen B-CHEMICAL
and O
monohydroxytamoxifen B-CHEMICAL
in O
both O
species. O
However, O
in O
the O
rat, O

LY117018 B-CHEMICAL
was O
more O
effective O
against O
the O
less O
potent O
compound O
tamoxifen, B-CHEMICAL
at O
a O
6:1 O
dosage O
ratio O
compared O
with O
a O
24:1 O
dosage O
ratio O
required O
for O
the O
potent O
compound O
monohydroxytamoxifen. B-CHEMICAL
LY117018 B-CHEMICAL
had O
a O
short O
duration O
of O
action O
as O
an O
antiestrogen O
when O
compared O
with O
monohydroxytamoxifen. B-CHEMICAL
LY117018 B-CHEMICAL
(120 O
micrograms) O
was O
only O
completely O
effective O
as O
an O
antiestrogen O
if O
administered O
repeatedly O
with O
E2 B-CHEMICAL
whereas O
a O
single O
injection O
of O
monohydroxytamoxifen B-CHEMICAL
(120 O
micrograms) O
was O
sufficient O
to O

inhibit O
fully O
E2 B-CHEMICAL
action O
in O
the O
uterus O
for O
up O
to O
4 O
days. O
Because O
LY117018 B-CHEMICAL
has O
a O
shorter O
duration O
of O
action O
than O
monohydroxytamoxifen, B-CHEMICAL
a O
high O
dosage O
ratio O
of O
LY117018 B-CHEMICAL
over O
monohydroxytamoxifen B-CHEMICAL
is O
required O
to O
maintain O
effective O
competitive O
antagonism O
in O
the O
uterus. O
Overall, O
these O
findings O
suggest O
that O
monohydroxytamoxifen B-CHEMICAL
and O
LY117018 B-CHEMICAL
probably O
act O
through O
the O
same O
mechanism O
of O
action O
via O
the O
estrogen B-GENE-Y
receptor. I-GENE-Y
High-glucose B-CHEMICAL
environment O
enhanced O
oxidative O
stress O
and O
increased O
interleukin-8 B-GENE-Y

secretion O
from O
keratinocytes: O
New O
insights O
on O
impaired O
diabetic O
wound O
healing. O
Impaired O
wound O
healing O
frequently O
occurs O
in O
patients O
with O
diabetes. O
Interluekin-8 B-GENE-Y
(IL-8) B-GENE-Y
production O
by O
keratinocyte O
is O
responsible O
for O
recruiting O
neutrophils O
during O
healing. O
Intense O
inflammation O
is O
associated O
with O
diabetic O
wounds O
while O
reduction O
of O
neutrophil O
infiltration O
is O
associated O
with O
enhanced O
healing. O
We O
hypothesized O
that O
increased O
neutrophil O
recruitment O
by O
keratinocytes O
may O
contribute O
to O
the O
delayed O
healing O
of O
diabetic O
wound. O
Using O
cultured O
human O

keratinocytes O
and O
diabetic O
rat O
model, O
the O
current O
study O
showed O
that O
high-glucose B-CHEMICAL
environment O
enhanced O
IL-8 B-GENE-Y
production O
via O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
-extracelluar B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
pathway O
in O
a O
reactive O
oxygen B-CHEMICAL
species O
(ROS)-dependent O
manner O
in O
keratinocytes. O
In O
addition, O
diabetic O
rat O
skin O
showed O
enhanced O
EGFR, B-GENE-Y
ERK B-GENE-N
and O
IL-8 B-GENE-N
expression O
as O
compared O
to O
control O
rats. O
The O
dermal O
neutrophil O
infiltration O
of O
the O
wound, O
as O
represented O
by O
expression O
of O
myeloperoxidase B-GENE-Y

level, O
was O
also O
significantly O
higher O
in O
diabetic O
rats. O
Treating O
diabetic O
rats O
with O
dapsone, B-CHEMICAL
an O
agent O
known O
to O
inhibit O
neutrophil O
function, O
was O
associated O
with O
improved O
healing. O
In O
conclusion, O
IL-8 B-GENE-Y
production O
and O
neutrophil O
infiltration O
are O
increased O
in O
high-glucose B-CHEMICAL
environment O
due O
to O
elevated O
ROS O
level O
and O
contributed O
to O
impaired O
wound O
healing O
in O
diabetic O
skin. O
Targeting O
these O
dysfunctions O
may O
present O
novel O
therapeutic O
approaches. O
Effects O
of O
2-amino-1-methyl-6-phenylimidazo B-CHEMICAL
[4, I-CHEMICAL
5-b] I-CHEMICAL
pyridine I-CHEMICAL

(PhIP) B-CHEMICAL
on O
histopathology, O
oxidative O
stress, O
and O
expression O
of O
c-fos, B-GENE-Y
c-jun B-GENE-Y
and O
p16 B-GENE-Y
in O
rat O
stomachs. O
2-Amino-1-methyl-6-phenylimidazo B-CHEMICAL
[4, I-CHEMICAL
5-b] I-CHEMICAL
pyridine I-CHEMICAL
(PhIP) B-CHEMICAL
is O
one O
of O
the O
most O
abundant O
heterocyclic B-CHEMICAL
amines I-CHEMICAL
(HCAs) B-CHEMICAL
generated O
from O
overcooking O
meat O
at O
high O
temperatures. O
To O
understand O
the O
possible O
mechanism O
of O
PhIP-associated B-CHEMICAL
stomach O
cancer, O
the O
effects O
of O
PhIP B-CHEMICAL
on O
morphology, O
oxidative O
stress, O
gene O
expression O

of O
c-fos, B-GENE-Y
c-jun B-GENE-Y
and O
p16 B-GENE-Y
in O
rat O
stomachs O
were O
investigated. O
The O
results O
showed O
that O
(1) O
15mg/kg O
body O
weight O
PhIP B-CHEMICAL
induced O
obvious O
histopathological O
changes O
in O
gastric O
mucosa; O
(2) O
PhIP B-CHEMICAL
(10 O
and/or O
15mg/kg) O
significantly O
decreased O
superoxide B-GENE-N
dismutase I-GENE-N
(SOD) B-GENE-N
and O
glutathioneperoxidase B-GENE-N
(GPx) B-GENE-N
activities, O
while O
increased O
catalase B-GENE-Y
(CAT) B-GENE-Y
activity O
compared O
with O
the O
control. O
With O
the O
elevated O
doses O
of O
PhIP, B-CHEMICAL
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL

contents, O
protein O
carbonyl B-CHEMICAL
(PCO) O
contents O
and O
DNA-protein O
crosslinks O
(DPC) O
coefficients O
were O
significantly O
raised O
in O
a O
dose-dependent O
manner; O
(3) O
PhIP B-CHEMICAL
at O
the O
doses O
of O
10mg/kg O
and/or O
15mg/kg O
significantly O
inhibited O
p16 B-GENE-Y
mRNA O
and O
protein O
expression, O
whereas O
enhanced O
c-fos B-GENE-Y
and O
c-jun B-GENE-Y
expression O
relative O
to O
control. O
The O
data O
indicated O
that O
PhIP B-CHEMICAL
could O
cause O
stomach O
injury, O
oxidative O
stress O
in O
rat O
stomachs O
as O
well O
as O
the O
activation O
of O
c-fos B-GENE-Y
and O
c-jun B-GENE-Y
and O
inactivation O
of O
p16, B-GENE-Y
which O

may O
play O
a O
role O
in O
the O
pathogenesis O
of O
PhIP-associated B-CHEMICAL
stomach O
cancer. O
A O
novel O
method O
for O
preparing O
complete O
antigens O
of O
gonyautoxin B-CHEMICAL
2,3 I-CHEMICAL
and O
their O
feature O
of O
immunogenicity. O
In O
this O
paper, O
a O
novel O
method O
was O
proposed O
to O
prepare O
artificial O
antigens O
of O
gonyaulax O
parlaytic O
shellfish O
toxin O
2 O
and O
3 O
(GTX2,3). B-CHEMICAL
An O
intermediate O
GTX2,3-aldehyde B-CHEMICAL
was O
first O
synthesized O
by O
activating O
the O
NH2 B-CHEMICAL
group O
of O
the O
2nd O
and O
8th O
amino B-CHEMICAL
acid I-CHEMICAL
residues O
with O
three O
different O
aldehydes B-CHEMICAL
and O
two O
artificial O
complete O
antigens O

GTX2,3-aldehyde-bovine B-CHEMICAL
serum I-GENE-Y
albumin I-GENE-Y
(BSA) B-GENE-Y
and O
GTX2,3-aldehyde- B-CHEMICAL
keyhole B-GENE-N
limpet I-GENE-N
hemocyanin I-GENE-N
(KLH) B-GENE-N
were O
then O
prepared O
by O
cross-linking O
the O
intermediate O
with O
BSA B-GENE-Y
or O
KLH. B-GENE-N
The O
successful O
preparation O
of O
the O
two O
complete O
antigens O
was O
confirmed O
by O
UV O
spectral O
scanning, O
HPLC, O
production O
of O
antibodies O
with O
titer O
of O
1.28 O
× O
10(4) O
from O
mice O
immunized O
with O
the O
two O
complete O
antigens, O
indirect O
ELISA O
and O
Western-blot. O
In O
conclusion, O
the O
synthesized O

complete O
antigens O
have O
strong O
immunogenicity, O
which O
provides O
a O
solid O
foundation O
for O
preparing O
GTX2,3 B-CHEMICAL
monoclonal O
antibody O
and O
rapid O
detection O
kit. O
Tetrahydrobiopterin B-CHEMICAL
in O
nitric B-CHEMICAL
oxide I-CHEMICAL
synthesis: O
a O
novel O
biological O
role O
for O
pteridines. B-CHEMICAL
Ever O
since O
the O
discovery O
that O
(6R)-5,6,7,8-tetrahydro-L-biopterin B-CHEMICAL
(BH4) B-CHEMICAL
is O
a O
cofactor O
of O
NOS, B-GENE-N
its O
function O
has O
been O
the O
object O
of O
intense O
research O
and O
occasional O
controversy. O
Only O
in O
the O
last O
couple O
of O
years O
a O
consensus O
has O

been O
reached O
on O
what O
constitutes O
the O
main O
role O
of O
BH4 B-CHEMICAL
in O
NO B-CHEMICAL
synthesis. O
In O
this O
review O
we O
aim O
to O
provide O
an O
outline O
of O
the O
various O
ways O
in O
which O
BH4 B-CHEMICAL
affects O
NOS B-GENE-N
catalysis. O
First O
we O
give O
a O
brief O
general O
description O
of O
the O
structure O
and O
catalytic O
mechanism O
of O
NOS, B-GENE-N
with O
special O
emphasis O
on O
those O
aspects O
of O
catalysis O
that O
are O
actively O
debated, O
and O
that O
directly O
or O
indirectly O
involve O
BH4. B-CHEMICAL
Foremost O
among O
those O
issues O
is O
uncoupled O
catalysis, O
i.e. O
the O
NOS-catalyzed B-GENE-N
oxidation O
of O
NADPH B-CHEMICAL
in O
the O
absence O
of O
substrate O
or O
pterin O
that O

does O
not O
result O
in O
NO B-CHEMICAL
production. O
We O
also O
shortly O
discuss O
the O
ongoing O
debate O
on O
whether O
NO B-CHEMICAL
is O
the O
actual O
reaction O
product O
of O
NOS B-GENE-N
catalysis, O
as O
well O
as O
the O
phenomenon O
of O
NO-mediated B-CHEMICAL
autoinhibition. O
We O
describe O
the O
function O
of O
BH4 B-CHEMICAL
in O
aromatic B-CHEMICAL
amino I-CHEMICAL
acid I-CHEMICAL
hydroxylation, O
and O
discuss O
the O
allosteric O
and O
structural O
effects O
that O
BH4 B-CHEMICAL
exerts O
on O
NOS. B-GENE-N
Next O
we O
turn O
our O
attention O
to O
what O
is O
now O
becoming O
accepted O
as O
the O
central O
function O
of O
BH4: B-CHEMICAL
its O
capacity O
to O
act O
as O
a O
1-electron O
donor O
during O
reductive O
activation O
of O
the O
oxyferrous B-CHEMICAL
complex O
of O
the O
heme. O

Finally, O
we O
illustrate O
how O
BH4 B-CHEMICAL
might O
transform O
the O
NOS B-GENE-N
dimer O
into O
an O
efficient O
S-nitrosoglutathione B-GENE-N
synthase,and I-GENE-N
briefly O
touch O
on O
some O
more O
speculative O
aspects O
of O
the O
role O
of O
BH4 B-CHEMICAL
in O
NO B-CHEMICAL
synthesis. O
Prostacyclin B-CHEMICAL
analogues O
inhibit O
tissue B-GENE-Y
factor I-GENE-Y
expression O
in O
the O
human O
monocytic O
cell O
line O
THP-1 O
via O
a O
cyclic B-CHEMICAL
AMP-dependent I-CHEMICAL
mechanism. O
Increased O
expression O
of O
tissue B-GENE-Y
factor I-GENE-Y
procoagulant O
by O
peripheral O
blood O
monocytes O
has O
been O
implicated O
in O
a O
number O
of O
thrombotic O
disorders. O
The O
present O
studies O
were O
undertaken O
to O
determine O
whether O
stable O
analogues O
of O

prostacyclin, B-CHEMICAL
a O
potent O
endothelium-derived O
platelet O
inhibitor O
and O
vasodilator, O
could O
inhibit O
tissue B-GENE-Y
factor I-GENE-Y
expression O
by O
human O
monocytic O
cells. O
Exposure O
of O
monocytic O
tumor O
THP-1 O
cells O
to O
100 O
ng/ml O
endotoxin, O
2 O
units/ml O
interleukin-1 B-GENE-Y
beta, I-GENE-Y
or O
5 O
ng/ml O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
for O
4 O
hours O
led O
to O
increased O
tissue B-GENE-Y
factor I-GENE-Y
procoagulant O
activity. O
Preincubation O
for O
30 O
minutes O
with O
iloprost, B-CHEMICAL
ciprostene, B-CHEMICAL
and O
carbacyclin B-CHEMICAL
led O
to O

a O
dose-dependent O
inhibition O
of O
tissue B-GENE-Y
factor I-GENE-Y
expression O
induced O
by O
all O
three O
challenging O
agents. O
Iloprost B-CHEMICAL
was O
the O
most O
potent: O
50% O
inhibition O
occurred O
at O
5 O
nM, O
a O
concentration O
close O
to O
the O
reported O
dissociation O
constant O
for O
iloprost B-CHEMICAL
binding O
to O
the O
platelet O
prostacyclin B-GENE-Y
receptor. I-GENE-Y
An O
orally O
active O
analogue, O
cicaprost, B-CHEMICAL
was O
equally O
effective O
against O
endotoxin-induced O
tissue B-GENE-Y
factor I-GENE-Y
expression. O
Carbacyclin B-CHEMICAL
and O
ciprostene B-CHEMICAL
were O
100 O
times O
less O
potent. O
Iloprost O
prevented O
the O
endotoxin-induced O
expression O
of O
tissue B-GENE-Y
factor I-GENE-Y
antigen O
on O
the O
surface O
of O

THP-1 O
cells, O
as O
determined O
by O
flow O
cytometry. O
Iloprost B-CHEMICAL
(500 O
pM-50 O
nM) O
increased O
intracellular O
levels O
of O
cyclic B-CHEMICAL
AMP. I-CHEMICAL
This O
effect O
was O
potentiated O
by O
isobutylmethylxanthine, B-CHEMICAL
an O
inhibitor O
of O
phosphodiesterase. B-GENE-N
The O
inhibitory O
effects O
of O
iloprost O
on O
tissue B-GENE-Y
factor I-GENE-Y
expression O
were O
also O
potentiated O
by O
isobutylmethylxanthine B-CHEMICAL
and O
mimicked O
by O
forskolin B-CHEMICAL
and O
dibutyryl B-CHEMICAL
cyclic I-CHEMICAL
AMP I-CHEMICAL
but O
not O
dibutyryl B-CHEMICAL
cyclic I-CHEMICAL
GMP. I-CHEMICAL
These O
results O
suggest O
that O

prostacyclin B-CHEMICAL
may O
play O
a O
role O
in O
downregulating O
tissue B-GENE-Y
factor I-GENE-Y
expression O
in O
monocytes, O
at O
least O
in O
part O
via O
elevation O
of O
intracellular O
levels O
of O
cyclic B-CHEMICAL
AMP. I-CHEMICAL
Amphetamine-type B-CHEMICAL
central O
nervous O
system O
stimulants O
release O
norepinephrine B-CHEMICAL
more O
potently O
than O
they O
release O
dopamine B-CHEMICAL
and O
serotonin. B-CHEMICAL
A O
large O
body O
of O
evidence O
supports O
the O
hypothesis O
that O
mesolimbic O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
mediates, O
in O
animal O
models, O
the O
reinforcing O
effects O
of O
central O
nervous O
system O
stimulants O
such O
as O
cocaine B-CHEMICAL
and O
amphetamine. B-CHEMICAL
The O
role O
DA B-CHEMICAL
plays O
in O

mediating O
amphetamine-type B-CHEMICAL
subjective O
effects O
of O
stimulants O
in O
humans O
remains O
to O
be O
established. O
Both O
amphetamine B-CHEMICAL
and O
cocaine B-CHEMICAL
increase O
norepinephrine B-CHEMICAL
(NE) B-CHEMICAL
via O
stimulation O
of O
release O
and O
inhibition O
of O
reuptake, O
respectively. O
If O
increases O
in O
NE B-CHEMICAL
mediate O
amphetamine-type B-CHEMICAL
subjective O
effects O
of O
stimulants O
in O
humans, O
then O
one O
would O
predict O
that O
stimulant O
medications O
that O
produce O
amphetamine-type B-CHEMICAL
subjective O
effects O
in O
humans O
should O
share O
the O
ability O
to O
increase O
NE. B-CHEMICAL
To O
test O
this O
hypothesis, O
we O
determined, O
using O
in O
vitro O
methods, O
the O
neurochemical O
mechanism O
of O
action O
of O

amphetamine, B-CHEMICAL
3,4-methylenedioxymethamphetamine B-CHEMICAL
(MDMA), B-CHEMICAL
(+)-methamphetamine, B-CHEMICAL
ephedrine, B-CHEMICAL
phentermine, B-CHEMICAL
and O
aminorex. B-CHEMICAL
As O
expected, O
their O
rank O
order O
of O
potency O
for O
DA B-CHEMICAL
release O
was O
similar O
to O
their O
rank O
order O
of O
potency O
in O
published O
self-administration O
studies. O
Interestingly, O
the O
results O
demonstrated O
that O
the O
most O
potent O
effect O
of O
these O
stimulants O
is O
to O
release O
NE. B-CHEMICAL
Importantly, O
the O
oral O
dose O
of O
these O
stimulants, O
which O
produce O
amphetamine-type B-CHEMICAL
subjective O
effects O
in O
humans, O
correlated O
with O
the O
their O

potency O
in O
releasing O
NE, B-CHEMICAL
not O
DA, B-CHEMICAL
and O
did O
not O
decrease O
plasma O
prolactin, B-GENE-Y
an O
effect O
mediated O
by O
DA B-CHEMICAL
release. O
These O
results O
suggest O
that O
NE B-CHEMICAL
may O
contribute O
to O
the O
amphetamine-type B-CHEMICAL
subjective O
effects O
of O
stimulants O
in O
humans. O
Genetic O
risk O
factors O
for O
infection O
in O
patients O
with O
early O
rheumatoid O
arthritis. O
We O
analyzed O
clinical O
and O
genetic O
factors O
contributing O
to O
infections O
in O
457 O
subjects O
with O
early O
rheumatoid O
arthritis O
(RA) O
enrolled O
in O
a O
prospective, O
1-year O
clinical O
trial O
of O
methotrexate B-CHEMICAL
and O
the O
TNF B-GENE-Y
inhibitor O
etanercept. O
Subjects O
were O

genotyped O
for O
the O
following O
single O
nucleotide B-CHEMICAL
polymorphisms O
(SNPs): O
(TNF B-GENE-Y
-308, O
-238, O
and O
+ O
488); O
lymphotoxin-alpha B-GENE-Y
(LTA) B-GENE-Y
(LTA B-GENE-Y
+ O
249, O
+ O
365, O
and O
+ O
720); O
and O
Fc B-GENE-N
gamma I-GENE-N
receptors I-GENE-N
FCGR2A B-GENE-Y
131 O
H/R; O
FCGR3A B-GENE-Y
176 O
F/V; O
and O
FCGR3B B-GENE-Y
NA O
1/2 O
and O
genotypes O
were O
correlated O
with O
infections. O
At O
least O
one O
URI O
was O
noted O
in O
52% O
of O
subjects O
(99/191) O
with O
the O

NA2/NA2 O
genotype O
of O
the O
neutrophil-specific O
FCGR3B B-GENE-Y
gene, O
compared O
to O
42% O
(77/181) O
of O
those O
with O
the O
NA1/NA2 O
genotype O
and O
39% O
(23/59) O
of O
those O
with O
the O
NA1/NA1 O
genotype O
(P O
= O
0.038). O
Urinary O
tract O
infection O
(UTI) O
was O
associated O
with O
the O
TNF B-GENE-Y
-238 O
A O
(odds O
ratio(OR) O
2.56, O
95% O
confidence O
interval O
(CI) O
1.05-6.25) O
and O
LTA B-GENE-Y

+365 O
C O
(OR O
1.73, O
95% O
CI O
1.07-2.79) O
alleles, O
and O
marginally O
with O
the O
FCGR3A B-GENE-Y
F O
allele O
(OR O
1.72, O
95% O
CI O
0.99-3.00). O
There O
was O
a O
striking O
linear O
correlation O
between O
UTI O
and O
the O
number O
of O
risk O
alleles O
defined O
by O
these O
three O
SNPs O
(P O
< O
0.001), O
suggesting O
an O
additive O
effect O
on O
susceptibility. O
These O
findings O
have O
important O
implications O
for O
the O
role O
of O
genetics O
in O
susceptibility O
to O
bacterial O
and O
viral O
infections. O
Design, O

synthesis, O
and O
structure-activity O
relationship O
studies O
of O
tryptanthrins B-CHEMICAL
as O
antitubercular O
agents. O
The O
natural O
product O
tryptanthrin B-CHEMICAL
(1a) O
represents O
a O
potential O
lead O
for O
new O
tuberculosis O
(TB) O
drugs O
since O
tryptanthrin B-CHEMICAL
and O
its O
synthetic O
analogues O
possess O
potent O
in O
vitro O
activity O
against O
Mycobacterium O
tuberculosis O
(Mtb). O
However, O
in O
spite O
of O
their O
in O
vitro O
activity, O
none O
of O
these O
agents O
have O
been O
shown O
to O
be O
efficacious O
in O
vivo O
against O
animal O
models O
of O
TB. O
Described O
herein O
are O
syntheses O
of O
new O
tryptanthrin B-CHEMICAL

analogues O
together O
with O
a O
systematic O
investigation O
of O
their O
in O
vitro O
antitubercular O
activity O
and O
ADME O
properties O
followed O
by O
pharmacokinetic O
characterization O
in O
rodents O
for O
the O
most O
promising O
compounds. O
Those O
with O
the O
best O
potency O
and O
oral O
bioavailability O
were O
progressed O
to O
evaluations O
of O
efficacy O
against O
acute O
murine O
TB. O
The O
work O
aimed O
to O
prove O
the O
concept O
that O
this O
compound O
class O
can O
limit O
growth O
of O
Mtb O
during O
infection O
as O
well O
as O
to O
establish O
the O
SAR O
for O
in O
vitro O
activity O
against O
Mtb O
and O
the O
range O
of O
in O
vitro O
ADME O
parameters O
for O
this O
class O
of O
natural O
products. O
Novel O

C-11-deoxy O
(5b) O
and O
A-ring-saturated O
(6) O
tryptanthrin B-CHEMICAL
analogues O
were O
discovered O
that O
maintained O
activity O
against O
Mtb O
and O
showed O
improved O
solubility O
compared O
to O
tryptanthrin B-CHEMICAL
as O
well O
as O
evidence O
of O
oral O
bioavailability O
in O
rodents. O
However, O
neither O
5b O
nor O
6 O
demonstrated O
efficacy O
against O
acute O
murine O
TB O
following O
administration O
at O
doses O
up O
to O
400 O
mg/kg O
daily O
for O
4 O
weeks. O
Although O
5b O
and O
6 O
failed O
to O
inhibit O
replication O
or O
kill O
Mtb O
in O
vivo, O
they O
illuminate O
a O
path O
to O
new O
structural O
variations O
of O
the O

tryptanthrin B-CHEMICAL
scaffold O
that O
may O
maximize O
the O
potential O
of O
this O
class O
of O
compounds O
against O
TB. O
Serotonin-glutamate B-CHEMICAL
and O
serotonin-dopamine B-CHEMICAL
reciprocal O
interactions O
as O
putative O
molecular O
targets O
for O
novel O
antipsychotic O
treatments: O
from O
receptor O
heterodimers O
to O
postsynaptic O
scaffolding O
and O
effector O
proteins. O
The O
physical O
and O
functional O
interactions O
between O
serotonin-glutamate B-CHEMICAL
and O
serotonin-dopamine B-CHEMICAL
signaling O
have O
been O
suggested O
to O
be O
involved O
in O
psychosis O
pathophysiology O
and O
are O
supposed O
to O
be O

relevant O
for O
antipsychotic O
treatment. O
Type B-GENE-Y
II I-GENE-Y
metabotropic I-GENE-Y
glutamate I-GENE-Y
receptors I-GENE-Y
(mGluRs) B-GENE-N
and O
serotonin B-CHEMICAL
5-HT(2A) B-GENE-Y
receptors O
have O
been O
reported O
to O
form O
heterodimers O
that O
modulate O
G-protein-mediated B-GENE-N
intracellular O
signaling O
differentially O
compared O
to O
mGluR2 B-GENE-Y
and O
5-HT(2A) B-GENE-Y
homomers. O
Additionally, O
direct O
evidence O
has O
been O
provided O
that O
D(2) B-GENE-N
and I-GENE-N
5-HT(2A) I-GENE-N
receptors I-GENE-N
form O
physical O
heterocomplexes O
which O
exert O
a O
functional O
cross-talk, O
as O
demonstrated O
by O
studies O
on O

hallucinogen-induced O
signaling. O
Moving O
from O
receptors O
to O
postsynaptic O
density O
(PSD) O
scenario, O
the O
scaffolding O
protein O
PSD-95 O
is O
known O
to O
interact O
with O
N-methyl-D-aspartate B-GENE-N
(NMDA), I-GENE-N
D(2) I-GENE-N
and I-GENE-N
5-HT(2) I-GENE-N
receptors, I-GENE-N
regulating O
their O
activation O
state. O
Homer1a, O
the O
inducible O
member O
of O
the O
Homer B-GENE-N
family O
of O
PSD O
proteins O
that O
is O
implicated O
in O
glutamatergic O
signal O
transduction, O
is O
induced O
in O
striatum O
by O
antipsychotics O
with O
high O
dopamine B-CHEMICAL
receptor O
affinity O
and O
in O
the O
cortex O

by O
antipsychotics O
with O
mixed O
serotonergic/dopaminergic O
profile. O
Signaling O
molecules, O
such O
as O
Akt B-GENE-N
and O
glycogen-synthase-kinase-3 B-GENE-N
(GSK-3), B-GENE-N
could O
be O
involved O
in O
the O
mechanism O
of O
action O
of O
antipsychotics, O
targeting O
dopamine, B-CHEMICAL
serotonin, B-CHEMICAL
and O
glutamate B-CHEMICAL
neurotransmission. O
Altogether, O
these O
proteins O
stand O
at O
the O
crossroad O
of O
glutamate-dopamine-serotonin B-CHEMICAL
signaling O
pathways O
and O
may O
be O
considered O
as O
valuable O
molecular O
targets O
for O
current O
and O
new O

antipsychotics. O
The O
aim O
of O
this O
review O
is O
to O
provide O
a O
critical O
appraisal O
on O
serotonin-glutamate B-CHEMICAL
and O
serotonin-dopamine B-CHEMICAL
interplay O
to O
support O
the O
idea O
that O
next O
generation O
schizophrenia O
pharmacotherapy O
should O
not O
exclusively O
rely O
on O
receptor O
targeting O
strategies. O
The O
serotonin B-GENE-Y
transporter I-GENE-Y
polymorphism, O
5HTTLPR, B-GENE-Y
is O
associated O
with O
a O
faster O
response O
time O
to O
sertraline B-CHEMICAL
in O
an O
elderly O
population O
with O
major O
depressive O
disorder. O
RATIONALE: O
A O
common O
polymorphism O
(5HTTLPR) B-GENE-Y
within O
the O
promoter O
region O

of O
the O
serotonin B-GENE-Y
transporter I-GENE-Y
gene O
(LSC6A4) B-GENE-Y
has O
been O
shown O
to O
influence O
response O
time O
as O
well O
as O
overall O
response O
to O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors O
(SSRIs) O
in O
subjects O
with O
major O
depressive O
disorder. O
We O
hypothesized O
that O
a O
similar O
effect O
in O
response O
time O
to O
sertraline B-CHEMICAL
would O
be O
observed O
and O
that O
no O
effect O
on O
response O
time O
would O
be O
seen O
in O
a O
placebo O
arm. O
OBJECTIVES: O
We O
tested O
the O
hypothesis O
that O
subjects O
homozygous O
for O
the O
long O
allele O
at O
the O
5HTTLPR B-GENE-Y
polymorphism O
would O
respond O
more O

rapidly O
to O
sertraline B-CHEMICAL
than O
subjects O
carrying O
one O
or O
two O
copies O
of O
the O
short O
allele. O
METHODS: O
HAM-D O
and O
CGI-I O
responses O
to O
sertraline B-CHEMICAL
and O
placebo O
were O
measured O
weekly O
in O
the O
context O
of O
an O
8-week, O
placebo-controlled O
study O
in O
elderly O
depressed O
subjects. O
Genotyping O
of O
the O
5HTTLPR B-GENE-Y
polymorphism O
was O
performed O
to O
test O
for O
correlations O
with O
response O
at O
each O
week O
in O
the O
sertraline B-CHEMICAL
and O
placebo O
groups O
( O
n=206). O
RESULTS: O
Subjects O
homozygous O
for O
the O
long O
allele O
of O

5HTTLPR B-GENE-Y
showed O
a O
significant O
increase O
in O
response O
at O
week O
1 O
and O
week O
2, O
as O
assessed O
by O
the O
CGI-I O
scale O
compared O
with O
subjects O
carrying O
one O
or O
two O
copies O
of O
the O
short O
allele O
( O
P=0.01 O
at O
both O
weeks). O
No O
significant O
difference O
was O
observed O
in O
the O
placebo O
group. O
CONCLUSIONS: O
These O
results O
suggest O
that O
genetic O
variation O
in O
the O
serotonin B-GENE-Y
transporter I-GENE-Y
gene O
effects O
the O
response O
time O
to O
sertraline B-CHEMICAL
and O
provides O
complementing O
evidence O
to O
previous O
reports O
that O
this O
polymorphism O
affects O
response O
time O
to O
other O
SSRIs. O
Histone B-GENE-Y
deacetylase I-GENE-Y
3 I-GENE-Y
is O
required O
for O
maintenance O

of O
bone O
mass O
during O
aging. O
Histone B-GENE-Y
deacetylase I-GENE-Y
3 I-GENE-Y
(Hdac3) B-GENE-Y
is O
a O
nuclear O
enzyme O
that O
removes O
acetyl B-CHEMICAL
groups O
from O
lysine B-CHEMICAL
residues O
in O
histones B-GENE-N
and O
other O
proteins O
to O
epigenetically O
regulate O
gene O
expression. O
Hdac3 B-GENE-Y
interacts O
with O
bone-related O
transcription O
factors O
and O
co-factors O
such O
as O
Runx2 B-GENE-Y
and O
Zfp521, B-GENE-Y
and O
thus O
is O
poised O
to O
play O
a O
key O
role O
in O
the O
skeletal O
system. O
To O
understand O
the O
role O
of O
Hdac3 B-GENE-Y
in O
osteoblasts O
and O
osteocytes, O
Hdac3 B-GENE-Y
conditional O
knockout O
(CKO) O
mice O
were O
created O
with O
the O

osteocalcin B-GENE-N
(OCN) I-GENE-N
promoter I-GENE-N
driving O
Cre B-GENE-N
expression. O
Hdac3 B-GENE-Y
CKO(OCN) B-GENE-Y
mice O
were O
of O
normal O
size O
and O
weight, O
but O
progressively O
lost O
trabecular O
and O
cortical O
bone O
mass O
with O
age. O
The O
Hdac3 B-GENE-Y
CKO(OCN) B-GENE-Y
mice O
exhibited O
reduced O
cortical O
bone O
mineralization O
and O
material O
properties O
and O
suffered O
frequent O
fractures. O
Bone O
resorption O
was O
lower, O
not O
higher, O
in O
the O
Hdac3 B-GENE-Y
CKO(OCN) B-GENE-Y
mice, O
suggesting O
that O
primary O
defects O
in O
osteoblasts O
caused O
the O
reduced O
bone O
mass. O
Indeed, O
reductions O

in O
bone O
formation O
were O
observed. O
Osteoblasts O
and O
osteocytes O
from O
Hdac3 B-GENE-Y
CKO(OCN) B-GENE-Y
mice O
showed O
increased O
DNA O
damage O
and O
reduced O
functional O
activity O
in O
vivo O
and O
in O
vitro. O
Thus, O
Hdac3 B-GENE-Y
expression O
in O
osteoblasts O
and O
osteocytes O
is O
essential O
for O
bone O
maintenance O
during O
aging. O
Enzyme O
expression O
profiles O
suggest O
the O
novel O
tumor-activated O
fluoropyrimidine B-CHEMICAL
carbamate I-CHEMICAL
capecitabine B-CHEMICAL
(Xeloda) B-CHEMICAL
might O
be O
effective O
against O
papillary O
thyroid O
cancers O
of O
children O
and O
young O
adults. O
PURPOSE: O
The O

fluoropyrimidine B-CHEMICAL
carbamate I-CHEMICAL
(capecitabine) B-CHEMICAL
is O
converted O
to O
5-fluorouracil B-CHEMICAL
(5-FU) B-CHEMICAL
by O
thymidine B-GENE-Y
phosphorylase I-GENE-Y
(TP) B-GENE-Y
inside O
target O
tissues. O
5-FU B-CHEMICAL
interferes O
with O
DNA O
synthesis O
by O
blocking O
thymidylate B-GENE-Y
synthase I-GENE-Y
(TS) B-GENE-Y
but O
is O
inactivated O
by O
dihydropyrimidine B-GENE-Y
dehydrogenase I-GENE-Y
(DPD). B-GENE-Y
Favorable O
enzyme O
profiles O
(high O
TP B-GENE-Y
and O
low O
DPD) B-GENE-Y
generate O
high O
intratumor O
levels O
of O
5-FU B-CHEMICAL
that O
are O
effective O
against O
many O
tumors, O
especially O

those O
with O
low O
TS. B-GENE-Y
Capecitabine B-CHEMICAL
has O
not O
been O
tested O
against O
thyroid O
cancers, O
and O
it O
is O
not O
known O
to O
what O
extent O
thyroid O
cancers O
express O
TP, B-GENE-Y
TS B-GENE-Y
or O
DPD. B-GENE-Y
METHODS: O
To O
test O
this, O
we O
determined O
TP, B-GENE-Y
TS B-GENE-Y
and O
DPD B-GENE-Y
in O
19 O
thyroid O
cancers O
from O
young O
patients O
(14 O
papillary, O
4 O
follicular, O
1 O
medullary) O
by O
immunohistochemistry. O
After O
approval O
by O
the O
Human O
Use O
Committee, O
the O
intensity O
of O
TP, B-GENE-Y
TS, B-GENE-Y
and O
DPD B-GENE-Y
staining O
was O
determined O
by O
two O
independent O
examiners O
and O

graded O
(absent=0 O
to O
intense=3) O
with O
>90% O
concordance. O
RESULTS: O
TS B-GENE-Y
was O
detected O
in O
7/19 O
cancers O
(37%), O
TP B-GENE-Y
in O
14/19 O
cancers O
(74%) O
and O
DPD B-GENE-Y
in O
14/19 O
cancers O
(74%). O
In O
six O
tumors, O
TP B-GENE-Y
was O
more O
intense O
that O
DPD, B-GENE-Y
suggesting O
capecitabine O
sensitivity. O
Only O
five O
tumors O
failed O
to O
express O
TP B-GENE-Y
but O
four O
of O
these O
expressed O
DPD, B-GENE-Y
suggesting O
capecitabine B-CHEMICAL
resistance. O
Overall, O
6/19 O
tumors O
(32% O
of O
the O
total) O
had O
a O
favorable O
expression O

profile, O
and O
all O
of O
them O
were O
papillary O
cancers. O
CONCLUSIONS: O
We O
conclude O
that O
the O
majority O
of O
differentiated O
thyroid O
cancers O
(74%) O
express O
TP B-GENE-Y
and O
low O
levels O
of O
TS B-GENE-Y
(63% O
undetectable). O
The O
results O
support O
the O
hypothesis O
that O
capecitabine B-CHEMICAL
is O
activated O
in O
the O
majority O
of O
differentiated O
thyroid O
cancers O
and O
that O
32% O
have O
favorable O
expression O
of O
all O
three O
enzymes O
(TP, B-GENE-Y
TS, B-GENE-Y
and O
DPD). B-GENE-Y
Nonsteroidal O
anti-inflammatory O
drugs O
activate O
carbonic B-GENE-N
anhydrase I-GENE-N
by O
a O
direct O
mechanism O
of O
action. O
Previous O
studies O
by O
this O
research O
team O

proved O
that O
vasodilating O
prostaglandins B-CHEMICAL
(PGs) B-CHEMICAL
E1, O
E2 O
and O
I2 O
inhibit O
carbonic B-GENE-N
anhydrase I-GENE-N
(CA) B-GENE-N
in O
vitro O
and O
in O
vivo, O
which O
suggested O
involvement O
of O
CA B-GENE-N
in O
gastric O
acid O
secretion O
inhibition O
and O
the O
increase O
of O
gastric O
mucosa O
blood O
flow O
produced O
by O
this O
group O
of O
PGs. B-CHEMICAL
Relying O
on O
these O
findings, O
as O
well O
as O
on O
our O
clinical O
observations, O
we O
studied O
in O
vitro O
and O
in O
vivo O
the O
effects O
of O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
on O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II. I-GENE-Y
We O

also O
followed O
in O
vitro O
the O
effects O
on O
these O
isozymes O
of O
NSAIDs O
associated O
to O
histamine, B-CHEMICAL
Ca, B-CHEMICAL
PGE2 O
and O
acetazolamide. B-CHEMICAL
The O
results O
show O
that O
the O
NSAIDs O
used O
here, O
which O
reduce O
the O
activity O
of O
cyclooxygenase B-GENE-N
and O
PG B-CHEMICAL
production, O
activated O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II I-GENE-Y
in O
a O
dose-dependent O
manner O
by O
a O
mechanism O
of O
the O
noncompetitive O
type. O
Histamine B-CHEMICAL
and O
Ca B-CHEMICAL
added O
to O
NSAIDs O
amplified O
the O
activating O
effect O
of O
the O
latter O
on O
CA B-GENE-Y
II. I-GENE-Y
Association O
of O
PGE2 O
or O
acetazolamide B-CHEMICAL
to O
NSAIDs O

reduced O
NSAID-induced O
activation O
of O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II. I-GENE-Y
Indomethacin B-CHEMICAL
abolished O
the O
inhibitory O
effect O
of O
acetazolamide B-CHEMICAL
on O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II. I-GENE-Y
Our O
data O
imply O
that O
between O
CA B-GENE-N
and O
cyclooxygenase B-GENE-N
there O
is O
an O
inverse O
relationship, O
CA B-GENE-N
activation O
being O
accompanied O
by O
reduction O
of O
cyclooxygenase B-GENE-N
activity, O
a O
reduction O
achieved O
by O
the O
pH O
modifications O
induced O
by O
CA B-GENE-N
activation. O
In O
this O
way, O
cyclooxygenase, B-GENE-N
inhibition O
occurs O
"via O
CA," B-GENE-N
with O
the O
pH O
variations O
it O
brings O
about. O
Surface-modified O
HK:siRNA O
nanoplexes O
with O

enhanced O
pharmacokinetics O
and O
tumor O
growth O
inhibition. O
We O
characterized O
in O
this O
study O
the O
pharmacokinetics O
and O
antitumor O
efficacy O
of O
histidine-lysine B-CHEMICAL
(HK):siRNA O
nanoplexes O
modified O
with O
PEG B-CHEMICAL
and O
a O
cyclic O
RGD B-GENE-N
(cRGD) B-GENE-N
ligand O
targeting O
αvβ3 B-GENE-Y
and O
αvβ5 B-GENE-Y
integrins. I-GENE-Y
With O
noninvasive O
imaging, O
systemically O
administered O
surface-modified O
HK:siRNA O
nanoplexes O
showed O
nearly O
4-fold O
greater O
blood O
levels, O
40% O
higher O
accumulation O
in O
tumor O
tissue, O
and O
60% O
lower O

luciferase O
activity O
than O
unmodified O
HK:siRNA O
nanoplexes. O
We O
then O
determined O
whether O
the O
surface-modified O
HK:siRNA O
nanoplex O
carrier O
was O
more O
effective O
in O
reducing O
MDA-MB-435 O
tumor O
growth O
with O
an O
siRNA O
targeting O
Raf-1. B-GENE-Y
Repeated O
systemic O
administration O
of O
the O
selected O
surface O
modified O
HK:siRNA O
nanoplexes O
targeting O
Raf-1 B-GENE-Y
showed O
35% O
greater O
inhibition O
of O
tumor O
growth O
than O
unmodified O
HK:siRNA O
nanoplexes O
and O
60% O
greater O
inhibition O
of O
tumor O
growth O
than O
untreated O
mice. O
The O
improved O
blood O
pharmacokinetic O
results O

and O
tumor O
localization O
observed O
with O
the O
integrin-targeting B-GENE-N
surface O
modification O
of O
HK:siRNA O
nanoplexes O
correlated O
with O
greater O
tumor O
growth O
inhibition. O
This O
investigation O
reveals O
that O
through O
control O
of O
targeting O
ligand O
surface O
display O
in O
association O
with O
a O
steric O
PEG B-CHEMICAL
layer, O
modified O
HK: O
siRNA O
nanoplexes O
show O
promise O
to O
advance O
RNAi O
therapeutics O
in O
oncology O
and O
potentially O
other O
critical O
diseases. O
Inhibition O
of O
platelet B-GENE-N
receptors I-GENE-N
involved O
in O
neutrophil-platelet O
interaction O
in O
model O
cardiopulmonary O
bypass. O
We O
investigated O
the O
interactions O
between O
neutrophils, O
platelets, O
and O
artificial O
surfaces, O

and O
whether O
blocking O
of O
relevant O
receptors O
on O
platelets O
reduced O
unwanted O
activation O
responses O
in O
model O
cardiopulmonary O
bypass. O
Isolated O
neutrophils O
and O
platelets O
resuspended O
in O
heparin-anticoagulated O
plasma O
were O
recirculated O
with O
and O
without O
blocking O
antibodies O
to O
CD62P, B-GENE-Y
CD42b, B-GENE-Y
or O
junctional B-GENE-Y
adhesion I-GENE-Y
molecule I-GENE-Y
C I-GENE-Y
(JAM-C) B-GENE-Y
in O
polyvinyl B-CHEMICAL
chloride I-CHEMICAL
tubing O
using O
a O
roller O
pump. O
Platelet O
adhesion O
to O
the O
tubing O
was O
inhibited O
by O
anti-CD42b B-GENE-Y
and O
anti-CD62P, B-GENE-Y
and O
adhesion O
of O

neutrophils O
by O
anti-JAM-C. B-GENE-Y
Formation O
of O
platelet-neutrophil O
and O
platelet O
aggregates O
was O
reduced O
by O
anti-CD62P. B-GENE-Y
Anti-JAM-C B-GENE-Y
decreased O
platelet-neutrophil O
aggregation O
at O
low O
concentrations O
and O
platelet O
macroaggregates O
at O
high O
concentrations. O
Anti-CD62P B-GENE-Y
increased O
neutrophil O
CD11b B-GENE-Y
expression O
but O
not O
degranulation. O
Anti-JAM-C B-GENE-Y
substantially O
increased O
neutrophil O
degranulation O
and O
slightly O
increased O
CD11b B-GENE-Y
expression. O
Platelet O
activation O
increased O
when O
CD62P B-GENE-Y
was O

blocked O
and O
decreased O
with O
anti-CD42b B-GENE-Y
antibody. O
High-dose O
anti-JAM-C B-GENE-Y
reduced O
platelet O
activation. O
In O
conclusion, O
inhibiting O
platelet O
and O
neutrophil-platelet O
interactions O
had O
useful O
effects O
but O
no O
single O
blocking O
antibody O
seemed O
capable O
of O
inducing O
only O
beneficial O
effects. O
A O
comparison O
of O
the O
effects O
of O
nabumetone B-CHEMICAL
vs O
meloxicam B-CHEMICAL
on O
serum O
thromboxane B-CHEMICAL
B2 I-CHEMICAL
and O
platelet O
function O
in O
healthy O
volunteers. O
AIMS: O
To O
compare O
the O
effects O
of O
nabumetone B-CHEMICAL
and O
meloxicam, B-CHEMICAL
two O
cyclo-oxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y

preferential O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs), O
on O
platelet O
COX-1 B-GENE-Y
activity O
and O
platelet O
function. O
METHODS: O
Twelve O
healthy O
volunteers O
(3 O
male, O
9 O
female, O
median O
age O
22 O
years) O
participated O
in O
an O
open, O
randomized, O
cross-over O
trial O
of O
nabumetone B-CHEMICAL
1000 O
mg O
twice O
daily O
vs O
meloxicam B-CHEMICAL
7.5 O
mg O
twice O
daily O
during O
1 O
week O
with O
2 O
weeks O
wash-out. O
After O
a O
second O
2 O
week O
wash-out O
period, O
one O
dose O
of O
indomethacin B-CHEMICAL
50 O
mg O
was O
given O
as O
a O
positive O
control O
to O
check O
for O
NSAID O
induced O
inhibition O
of O

platelet O
function. O
COX-1 B-GENE-Y
inhibition O
was O
measured O
as O
percentage O
inhibition O
of O
serum O
TXB2 B-CHEMICAL
generation O
in O
clotting O
whole O
blood, O
and O
as O
closure O
time O
with O
use O
of O
the O
platelet O
function O
analyser O
PFA-100. O
Data O
are O
reported O
as O
median O
with O
range. O
Paired O
variables O
were O
analysed O
using O
Wilcoxons O
signed O
rank O
test. O
RESULTS: O
TXB2 B-CHEMICAL
levels O
decreased O
significantly O
after O
all O
three O
medications, O
but O
percentage O
inhibition O
after O
nabumetone B-CHEMICAL
and O
indomethacin B-CHEMICAL
(88% O
and O
97%, O
respectively) O
was O
significantly O
higher O
than O
after O
meloxicam B-CHEMICAL
(63%) O

(P<0.05). O
Closure O
times O
increased O
significantly O
after O
administration O
of O
all O
three O
medications O
(P<0.05). O
Increases O
in O
closure O
time O
after O
administration O
did O
not O
differ O
between O
nabumetone B-CHEMICAL
and O
meloxicam B-CHEMICAL
(24% O
and O
14%, O
respectively), O
but O
were O
significantly O
larger O
after O
indomethacin B-CHEMICAL
administration O
(63%) O
(P<0.01). O
CONCLUSIONS: O
In O
the O
maximum O
registered O
dosage, O
nabumetone B-CHEMICAL
inhibits O
thromboxane B-CHEMICAL
production O
much O
more O
than O
meloxicam, O
signifying O
less O
COX-2 B-GENE-Y
selectivity O
of O
the O

former. O
However, O
both O
nabumetone B-CHEMICAL
and O
meloxicam B-CHEMICAL
cause O
only O
minor O
impairment O
in O
platelet O
function O
in O
comparison O
with O
indomethacin B-CHEMICAL
and O
the O
difference O
between O
them O
is O
not O
significant. O
Diclofenac B-CHEMICAL
inhibits O
proliferation O
and O
differentiation O
of O
neural O
stem O
cells. O
Nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
are O
widely O
used O
in O
clinical O
situations O
as O
anti-inflammatory, O
analgesic O
and O
antipyretic O
drugs. O
However, O
it O
is O
still O
unknown O
whether O
NSAIDs O
have O
effects O
on O
the O
development O
of O
the O
central O
nervous O
system. O
In O
the O
present O
study, O
we O
investigated O
the O
effects O
of O
NSAIDs O
on O

neural O
stem O
cell O
(NSC) O
proliferation O
and O
differentiation O
into O
neurons. O
In O
contrast O
to O
aspirin, B-CHEMICAL
naproxen, B-CHEMICAL
indomethacin B-CHEMICAL
and O
ibuprofen, B-CHEMICAL
treatment O
with O
diclofenac B-CHEMICAL
(10 O
microM) O
for O
2 O
days O
induced O
the O
death O
of O
NSCs O
in O
a O
concentration-dependent O
manner. O
Diclofenac B-CHEMICAL
also O
inhibited O
the O
proliferation O
of O
NSCs O
and O
their O
differentiation O
into O
neurons. O
Treatment O
with O
diclofenac B-CHEMICAL
resulted O
in O
nuclear O
condensation O
(a O
morphological O
change O
due O
to O
apoptosis O
of O
NSCs) O
24hr O
after O
the O
treatment O
and O
activated O

caspase-3 B-GENE-Y
after O
6 O
hr, O
indicating O
that O
diclofenac B-CHEMICAL
may O
cause O
apoptosis O
of O
neuronal O
cells O
via O
activation O
of O
the O
caspase B-GENE-N
cascade. O
These O
results O
suggest O
that O
diclofenac B-CHEMICAL
may O
affect O
the O
development O
of O
the O
central O
nervous O
system. O
Correlation O
between O
activation O
of O
PPARγ B-GENE-Y
and O
resistin B-GENE-Y
downregulation O
in O
a O
mouse O
adipocyte O
cell O
line O
by O
a O
series O
of O
thiazolidinediones. B-CHEMICAL
The O
present O
study O
shows O
significant O
correlations O
between O
the O
EC50 O
for O
PPARγ B-GENE-Y
activation O
in O
a O
reporter O
gene O
cell O
line O
and O
resistin B-GENE-Y
downregulation O
in O
mouse O

adipocytes, O
and O
between O
the O
IC50 O
for O
resistin B-GENE-Y
downregulation O
and O
the O
already O
published O
minimum O
effective O
dose O
for O
antihyperglycemic O
activity O
in O
a O
mouse O
model. O
These O
correlations O
indicate O
that O
PPARγ B-GENE-Y
mediated O
downregulation O
of O
resistin O
might O
promote O
insulin B-GENE-N
sensitivity O
and O
that O
downregulation O
of O
resistin B-GENE-Y
in O
mouse O
adipocytes O
provides O
an O
adequate O
and O
possibly O
more O
direct O
bioassay O
for O
screening O
of O
newly O
developed O
antihyperglycemic O
compounds. O
Because O
of O
the O
higher O
throughput O
of O
the O
PPARγ B-GENE-Y
the O
resistin B-GENE-Y
downregulation O
assays O
seems O
most O
suitable O
to O
be O
used O
as O
a O
second O
tier O
in O
a O

tiered O
screening O
strategy. O
Identification O
of O
aldo-keto B-GENE-N
reductases I-GENE-N
as O
NRF2-target B-GENE-Y
marker O
genes O
in O
human O
cells. O
Transcription O
factor O
NF-E2-related B-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(NRF2) B-GENE-Y
plays O
a O
crucial O
role O
in O
the O
cellular O
defense O
against O
oxidative/electrophilic O
stress O
by O
up-regulating O
multiple O
antioxidant O
genes. O
Numerous O
studies O
with O
genetically O
modified O
animals O
have O
demonstrated O
that O
Nrf2 B-GENE-Y
is O
a O
sensitivity O
determining O
factor O
upon O
the O
exposure O
to O
environmental O
chemicals O
including O
carcinogens. O
Moreover, O
recent O
studies O
have O
demonstrated O
that O
polymorphism O
in O
the O
human B-GENE-N
NRF2 I-GENE-N
promoter I-GENE-N

is O
associated O
with O
higher O
risks O
for O
developing O
acute O
lung O
injury, O
gastric O
mucosal O
inflammation, O
and O
nephritis. O
Therefore, O
the O
identification O
of O
reliable O
and O
effective O
human O
target O
genes O
of O
NRF2 B-GENE-Y
may O
allow O
the O
monitoring O
of O
NRF2 B-GENE-Y
activity O
and O
to O
predict O
individual O
sensitivity O
to O
environmental O
stress-induced O
damage. O
For O
this O
purpose, O
we O
investigated O
genes O
that O
are O
tightly O
controlled O
by O
NRF2 B-GENE-Y
to O
establish O
markers O
for O
NRF2 B-GENE-Y
activity O
in O
human O
cells. O
Firstly, O
in O
the O
normal O
human O
renal O
epithelial O
HK-2 O
cells, O
the O
measurement O
of O
the O
expression O
of O
30 O
previously O
reported O
NRF2 B-GENE-Y
target O
genes O
in O

response O
to O
NRF2 B-GENE-Y
inducers O
(sulforaphane, B-CHEMICAL
tert-butylhydroquinone, B-CHEMICAL
cinnamic B-CHEMICAL
aldehyde, I-CHEMICAL
and O
hydrogen B-CHEMICAL
peroxide) I-CHEMICAL
showed O
that O
the O
aldo-keto B-GENE-Y
reductase I-GENE-Y
(AKR) I-GENE-Y
1C1 I-GENE-Y
is O
highly O
inducible O
by O
all O
treatments. O
Accordantly, O
the O
basal O
and O
inducible O
expressions O
of O
AKRs B-GENE-N
were O
significantly O
attenuated O
in O
NRF2-silenced B-GENE-Y
HK-2 O
cells. O
Whereas, O
cells O
with O
stable O
KEAP1 B-GENE-Y
knockdown, O
which O
causes O
a O
modest O
NRF2 B-GENE-Y
activation, O
demonstrated O
substantially O
increased O

levels O
of O
AKR1A1, B-GENE-N
1B1, I-GENE-N
1B10, I-GENE-N
1C1, I-GENE-N
1C2, I-GENE-N
and I-GENE-N
1C3. I-GENE-N
Secondly, O
the O
linkage O
between O
NRF2 B-GENE-Y
and O
the O
AKRs B-GENE-N
was O
confirmed O
in O
human O
monocytic O
leukemia O
cell O
line O
U937, O
which O
can O
be O
a O
model O
of O
peripherally O
available O
blood O
cells. O
The O
treatment O
of O
U937 O
cells O
with O
NRF2 B-GENE-Y
inducers O
including O
sulforaphane B-CHEMICAL
effectively O
elevated O
the O
expression O
of O
AKR1B1, B-GENE-N
1B10, I-GENE-N
1C1, I-GENE-N
1C2, I-GENE-N
and I-GENE-N
1C3. I-GENE-N
Whereas, O
the O
levels O
of O

both O
the O
basal O
and O
sulforaphane-inducible B-CHEMICAL
expression O
of O
AKR1C1 B-GENE-Y
were O
significantly O
reduced O
in O
NRF2-silenced B-GENE-Y
stable O
U937 O
cells O
compared O
to O
the O
control O
cells. O
Similarly, O
the O
inducible O
expression O
of O
AKR1C1 B-GENE-Y
was O
observed O
in O
another O
human O
monocytic O
leukemia O
cell O
line O
THP-1 O
as O
well O
as O
in O
human O
primary O
blood O
CD14(+) O
monocytes. O
In O
conclusion, O
together O
with O
the O
high O
inducibility O
and O
NRF2 B-GENE-Y
dependency O
shown O
in O
renal O
epithelial O
cells O
as O
well O
as O
in O
peripherally O
available O
blood O
cells, O
current O
findings O

suggest O
that O
AKRs B-GENE-N
can O
be O
utilized O
as O
a O
marker O
of O
NRF2 B-GENE-Y
activity O
in O
human O
cells. O
Cellular O
mechanisms O
of O
insulin B-GENE-Y
resistance: O
role O
of O
stress-regulated B-GENE-N
serine I-GENE-N
kinases I-GENE-N
and O
insulin B-GENE-N
receptor I-GENE-N
substrates I-GENE-N
(IRS) B-GENE-N
serine B-CHEMICAL
phosphorylation. O
Insulin B-GENE-N
receptor I-GENE-N
substrates I-GENE-N
(IRS) B-GENE-N
serine B-CHEMICAL
phosphorylation O
is O
a O
time-controlled O
physiological O
feedback O
mechanism O
in O
insulin B-GENE-Y
signaling O
that O
is O
hijacked O
by O
metabolic O
and O
inflammatory O
stresses O
to O
promote O
insulin B-GENE-Y
resistance. O
Kinases, B-GENE-N
including O
IKKbeta, B-GENE-Y
JNK, B-GENE-N
ERK, B-GENE-N
mTOR, B-GENE-Y
and O
S6K, B-GENE-N
activated O
by O
the O

inducers O
of O
insulin B-GENE-Y
resistance O
induce O
uncontrolled O
IRS B-GENE-N
serine B-CHEMICAL
phosphorylation. O
Studies O
with O
genetically O
modified O
mice O
reveal O
that O
these O
kinases B-GENE-N
integrate O
signals O
from O
metabolic O
and O
inflammatory O
stresses O
in O
adipose O
tissue, O
liver, O
and O
hypothalamus O
leading O
to O
peripheral O
and O
central O
insulin B-GENE-N
resistance. O
Moreover, O
IKKbeta/NF-kappaB B-GENE-Y
and O
JNK1 B-GENE-Y
pathways O
in O
myeloid O
cells O
represent O
a O
core O
mechanism O
involved O
in O
inflammation O
linked O
to O
obesity. O
These O
kinases B-GENE-N
are O
thus O
potential O
drug O
targets O
against O
insulin B-GENE-N
resistance O
and O
the O
targeting O
of O
the O
IKKbeta/NF-kappaB B-GENE-Y
or O
the O

JNK B-GENE-N
pathway O
may O
evolve O
into O
future O
diabetes O
medication. O
Angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
inhibition O
and O
AT1 B-GENE-N
receptor O
blockade O
modify O
the O
pressure-natriuresis O
relationship O
by O
additive O
mechanisms O
in O
rats O
with O
human B-GENE-Y
renin I-GENE-Y
and O
angiotensinogen B-GENE-Y
genes. O
The O
intrarenal O
factors O
responsible O
for O
hypertension O
in O
double-transgenic O
rats O
(dTGR) O
harboring O
human B-GENE-Y
renin I-GENE-Y
and O
human B-GENE-Y
angiotensinogen I-GENE-Y
genes O
are O
unclear. O
The O
pressure-natriuresis O
and O
-diuresis O
relationships O
in O
response O
to O
chronic O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibition O
and O
AT1 B-GENE-N
receptor O
blockade O

were O
evaluated. O
Renal B-GENE-Y
renin-angiotensin I-GENE-Y
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
system O
gene O
expression O
was O
also O
investigated. O
Six-week-old O
dTGR O
were O
treated O
for O
3 O
wk O
with O
submaximal O
doses O
of O
cilazapril B-CHEMICAL
(10 O
mg/kg, O
orally) O
or O
losartan B-CHEMICAL
(10 O
mg/kg, O
orally) O
or O
with O
the O
drug O
combination. O
In O
untreated O
dTGR, O
pressure-natriuresis O
relationships O
were O
maximally O
shifted O
rightward O
by O
approximately O
70 O
to O
80 O
mmHg, O
and O
both O
renal O
blood O
flow O
(RBF) O
and O
GFR O
were O

markedly O
decreased. O
Submaximal O
cilazapril B-CHEMICAL
and O
losartan B-CHEMICAL
dosages O
both O
decreased O
systolic O
BP O
by O
30 O
mmHg O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
by O
25 O
to O
30 O
mmHg. O
Cilazapril B-CHEMICAL
increased O
RBF O
and O
GFR O
to O
values O
observed O
in O
normotensive O
control O
animals O
but O
did O
not O
significantly O
affect O
fractional O
sodium B-CHEMICAL
excretion O
(FENa) O
or O
fractional O
water O
excretion O
(FEH2O) O
curves. O
In O
contrast, O
losartan B-CHEMICAL
had O
no O
significant O
effect O
on O
RBF O
or O
GFR O
but O
shifted O
the O

FENa O
and O
FEH2O O
curves O
leftward. O
The O
cilazapril B-CHEMICAL
and O
losartan B-CHEMICAL
combination O
completely O
normalized O
BP O
and O
shifted O
the O
pressure-natriuresis O
curves O
leftward O
more O
than O
did O
either O
drug O
alone. O
When O
cilazapril B-CHEMICAL
and O
losartan B-CHEMICAL
were O
administered O
at O
higher O
doses O
(30 O
mg/kg, O
orally), O
the O
two O
drugs O
equally O
shifted O
the O
pressure-natriuresis O
curves O
leftward, O
by O
50 O
mmHg. O
Both O
drugs O
increased O
RBF O
and O
GFR; O
however, O
only O
losartan B-CHEMICAL
shifted O
FENa O
and O
FEH2O O
curves O
leftward. O
Human B-GENE-N
and I-GENE-N

rat I-GENE-N
renin I-GENE-N
and O
angiotensinogen B-GENE-N
genes O
were O
downregulated O
in O
dTGR O
and O
were O
increased O
by O
losartan B-CHEMICAL
and O
cilazapril B-CHEMICAL
treatments, O
whereas O
no O
changes O
in O
the O
expression O
of O
rat B-GENE-Y
ACE I-GENE-Y
and O
AT1A B-GENE-Y
receptor O
genes O
were O
observed. O
Endothelial B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
expression O
was O
increased O
by O
cilazapril B-CHEMICAL
but O
not O
by O
losartan. B-CHEMICAL
Neither O
inducible B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
nor O
neural B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
gene O
expression O
was O
affected O
by O
drug O
treatments. O
Therefore, O
submaximal O
ACE B-GENE-Y
inhibition O
enhanced O
sodium B-CHEMICAL
excretion O
mainly O
by O
increasing O
RBF O
and O
GFR, O
whereas O

submaximal O
AT1 B-GENE-N
receptor O
blockade O
decreased O
tubular O
sodium B-CHEMICAL
and O
water O
reabsorption. O
The O
combination O
of O
the O
two O
drugs O
produced O
an O
additive O
effect. O
The O
ACE B-GENE-Y
inhibitor O
effects O
may O
involve O
increased O
endothelial B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
expression, O
perhaps O
related O
to O
the O
inhibition O
of O
bradykinin B-GENE-Y
degradation. O
A O
novel O
SCN5A B-GENE-Y
arrhythmia O
mutation, O
M1766L, B-GENE-N
with O
expression O
defect O
rescued O
by O
mexiletine. B-CHEMICAL
OBJECTIVE: O
Mutations O
in O
the O
cardiac O
sodium B-CHEMICAL
channel O
gene, O
SCN5A, B-GENE-Y
cause O
congenital O
long O
QT O
syndrome O

(LQT3), O
Brugada O
syndrome, O
idiopathic O
ventricular O
fibrillation, O
and O
conduction O
disease O
by O
distinct O
cellular O
and O
clinical O
electrophysiological O
phenotypes. O
METHODS: O
Postmortem O
molecular O
analysis O
of O
SCN5A B-GENE-Y
was O
conducted O
on O
an O
infant O
who O
presented O
shortly O
after O
birth O
with O
self-terminating O
torsades O
de O
pointes. O
The O
infant O
was O
treated O
with O
lidocaine, B-CHEMICAL
propranolol, B-CHEMICAL
and O
mexiletine B-CHEMICAL
and O
was O
stable O
for O
16 O
months O
manifesting O
only O
a O
prolonged O
QT O
interval. O
The O
infant O
collapsed O
suddenly O
following O
presumed O
viral O
gastroenteritis, O
was O
found O
in O

2:1 O
AV O
block, O
and O
was O
subsequently O
declared O
brain O
dead. O
Genomic O
DNA O
was O
subjected O
to O
SCN5A B-GENE-Y
mutational O
analyses O
and O
DNA O
sequencing O
revealing O
a O
novel, O
spontaneous O
germline O
missense O
mutation, O
M1766L. B-GENE-N
The O
M1766L B-GENE-N
mutation O
was O
engineered O
into O
the O
hH1a O
clone O
by O
site-directed O
mutagenesis, O
transfected O
into O
embryonic O
kidney O
cells O
(HEK-293), O
and O
studied O
by O
voltage O
clamp. O
RESULTS: O
The O
M1766L B-GENE-N
mutation O
caused O
a O
significant O
decrease O
in O
the O
sodium B-CHEMICAL
channel O
expression. O
Co-expression O
with O

beta1 O
subunit, O
incubation O
at O
low O
temperature, O
and O
most O
effectively O
incubation O
with O
mexiletine B-CHEMICAL
partially O
'rescued' O
the O
defective O
expression. O
In O
addition O
to O
this O
pronounced O
loss O
of O
function, O
M1766L B-GENE-N
also O
showed O
a O
10-fold O
increase O
in O
the O
persistent O
late O
sodium B-CHEMICAL
current. O
CONCLUSIONS: O
These O
findings O
suggest O
that O
M1766L-SCN5A B-GENE-N
channel O
dysfunction O
may O
contribute O
to O
the O
basis O
of O
lethal O
arrhythmias, O
displays O
an O
overlapping O
electrophysiological O
phenotype, O
and O
represents O
the O
first O
sodium B-CHEMICAL
channelopathy O
rescued O
by O
drug. O
Neuroprotective O

effects O
of O
oxymatrine B-CHEMICAL
against O
excitotoxicity O
partially O
through O
down-regulation O
of O
NR2B-containing B-GENE-Y
NMDA B-GENE-N
receptors. I-GENE-N
Oxymatrine B-CHEMICAL
(OMT) B-CHEMICAL
is O
a O
major O
bioactive O
component O
derived O
from O
Sophora O
flavescens O
Ait O
(kushen), O
which O
is O
widely O
used O
in O
Chinese O
medicine. O
Recent O
studies O
have O
shown O
that O
it O
has O
neuroprotective O
effects; O
however, O
its O
underlying O
mechanisms O
remain O
unclear. O
We O
focus O
on O
the O
mechanisms O
of O
pharmacologic O
action O
in O
OMT B-CHEMICAL
by O
detecting O
its O
pharmacological O
properties O
against O
focal O
cerebral O
ischemia O
in O
vivo O
and O

NMDA-induced B-CHEMICAL
neurotoxicity O
in O
vitro. O
OMT B-CHEMICAL
prevented O
cerebral O
ischemic O
injury O
in O
mice O
induced O
via O
a O
2 O
h O
middle O
cerebral O
artery O
occlusion O
and O
a O
24 O
h O
reperfusion, O
in O
vivo. O
In O
vitro O
cultured O
neurons O
challenged O
with O
N-methyl-D-aspartate B-CHEMICAL
(NMDA, B-CHEMICAL
200 O
μM) O
for O
30 O
min O
showed O
significant O
decrease O
in O
the O
viability O
of O
neurons; O
however, O
OMT B-CHEMICAL
was O
able O
to O
protect O
neurons O
against O
induced O
neurotoxicity O
via O
NMDA B-CHEMICAL
exposure. O
Western O
blot O
analysis O
revealed O
that O
OMT B-CHEMICAL
decreased O
the O
expression O
of O
Bax B-GENE-Y
and O

repaired O
the O
balance O
of O
pro- O
and O
anti-apoptotic O
proteins. O
Furthermore, O
OMT B-CHEMICAL
significantly O
reversed O
the O
up-regulation O
of O
NR2B B-GENE-Y
and O
inhibited O
the O
calcium B-CHEMICAL
overload O
in O
the O
cultured O
neurons O
after O
challenging O
the O
NMDA. B-CHEMICAL
OMT B-CHEMICAL
showed O
partial O
protection O
in O
the O
cortical O
neurons O
via O
down-regulation O
of O
NR2B B-GENE-Y
containing O
NMDA B-GENE-N
receptors I-GENE-N
and O
up-regulation O
of O
Bcl-2 B-GENE-Y
family. O
Our O
results O
provide O
new O
insights O
into O
the O
development O
of O
natural O
therapeutic O
anti-oxidants O
against O
ischemia. O
Phenotypic O
analysis O
of O
ovine O
antigen O
presenting O
cells O
loaded O
with O

nanoparticles O
migrating O
from O
the O
site O
of O
vaccination. O
Virus-sized O
particulate O
adjuvants O
such O
as O
ISCOMs, O
polystyrene B-CHEMICAL
nanoparticles O
and O
virus-like O
particles O
have O
been O
shown O
to O
target O
dendritic O
cells, O
resulting O
in O
the O
activation O
of O
T O
and O
B O
cells O
in O
vivo. O
Using O
an O
ovine O
pseudo-afferent O
lymph O
cannulation O
model O
to O
capture O
APC O
that O
traffic O
from O
the O
site O
of O
injection O
to O
the O
local O
lymph O
node, O
we O
show O
that O
40-50nm O
nanoparticles O
are O
taken O
up O
at O
the O
site O
of O
injection O
by O

dendritic O
cells O
(DCs) O
migrating O
to O
the O
draining O
lymph O
node. O
These O
DCs O
can O
express O
CD11c, B-GENE-Y
CD1b, B-GENE-Y
CD5, B-GENE-Y
MHC B-GENE-N
class I-GENE-N
II I-GENE-N
and O
CD8. B-GENE-N
Nanoparticles O
transported O
by O
DCs O
migrating O
from O
the O
site O
of O
injection O
to O
the O
local O
lymph O
node O
therefore O
needs O
to O
be O
considered O
as O
a O
new O
mechanism O
underlying O
the O
immunogenicity O
of O
virus-sized O
vaccine O
delivery O
systems. O
Emodin-6-O-β-D-glucoside B-CHEMICAL
inhibits O
HMGB1-induced B-GENE-Y
inflammatory O
responses O
in O
vitro O
and O
in O
vivo. O
High B-GENE-Y
mobility I-GENE-Y
group I-GENE-Y
box I-GENE-Y
1 I-GENE-Y

(HMGB1) B-GENE-Y
protein O
acts O
as O
a O
potent O
proinflammatory O
cytokine B-GENE-N
and O
is O
involved O
in O
the O
pathogenesis O
of O
several O
vascular O
diseases, O
such O
as, O
systemic O
vasculitis O
and O
sepsis. O
Emodin-6-O-β-D-glucoside B-CHEMICAL
(EG) O
is O
a O
new O
active O
compound O
from O
Reynoutria O
japonica, O
and O
its O
biologic O
activities O
have O
not O
been O
previously O
investigated. O
In O
this O
study, O
we O
first O
investigated O
the O
antiinflammatory O
activities O
of O
EG O
on O
HMGB1-mediated B-GENE-Y
proinflammatory O
responses O
in O
human O

umbilical O
vein O
endothelial O
cells O
(HUVECs) O
and O
in O
a O
murine O
cecal O
ligation O
and O
puncture O
(CLP)-model O
of O
sepsis O
in O
mice. O
EG O
was O
found O
to O
suppress O
the O
release O
of O
HMGB1, B-GENE-Y
the O
production O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-α, I-GENE-Y
and O
the O
activation O
of O
nuclear B-GENE-N
factor-κB I-GENE-N
(NF-κB) B-GENE-N
by O
HMGB1 B-GENE-Y
in O
HUVECs, O
and O
to O
inhibit O
HMGB1-mediated B-GENE-Y
hyperpermeability O
and O
leukocyte O
migration O
in O
mice. O
In O
the O
CLP O
model, O

HMGB1 B-GENE-Y
was O
highly O
released, O
but O
this O
release O
was O
prevented O
by O
EG. O
Furthermore, O
EG O
also O
increased O
the O
survival O
times O
of O
CLP O
administered O
mice. O
Collectively, O
this O
study O
shows O
EG O
can O
protect O
barrier O
integrity O
and O
inhibit O
HMGB1-mediated B-GENE-Y
inflammatory O
responses, O
which O
suggests O
a O
potential O
use O
as O
a O
therapy O
for O
sepsis O
or O
septic O
shock. O
Copy O
number O
variations O
of O
the O
human B-GENE-Y
histamine I-GENE-Y
H4 I-GENE-Y
receptor I-GENE-Y
gene O
are O
associated O
with O
systemic O
lupus O
erythematosus. O
BACKGROUND: O
Systemic O
lupus O
erythematosus O
(SLE) O
is O
a O
complex O
genetic O
disease; O
the O

histamine B-GENE-Y
H4 I-GENE-Y
receptor I-GENE-Y
(HRH4) B-GENE-Y
has O
been O
shown O
to O
be O
related O
to O
different O
kinds O
of O
autoimmune O
disorders; O
and O
copy O
number O
variations O
(CNVs) O
have O
been O
found O
to O
be O
associated O
with O
various O
types O
of O
diseases. O
OBJECTIVES: O
To O
explore O
a O
possible O
association O
between O
HRH4 B-GENE-Y
(formerly O
H4R) B-GENE-Y
CNVs O
and O
the O
risk O
of O
SLE. O
METHODS: O
Genomic O
DNA O
and O
RNA O
from O
340 O
patients O
with O
SLE O
and O
392 O
healthy O
controls O
were O
extracted, O
and O
CNVs O
and O
mRNA O
levels O
of O
HRH4 B-GENE-Y
were O
examined. O

RESULTS: O
The O
expression O
of O
HRH4 B-GENE-Y
mRNA O
was O
significantly O
increased O
in O
patients O
with O
SLE O
compared O
with O
controls. O
Amplification O
of O
HRH4 B-GENE-Y
copy O
numbers O
significantly O
increased O
the O
risk O
of O
SLE O
[P O
< O
0.001, O
odds O
ratio O
(OR) O
2.26, O
95% O
confidence O
interval O
(CI) O
1.50-3.40]. O
HRH4 B-GENE-Y
amplifications O
also O
positively O
correlated O
with O
the O
incidence O
of O
arthritis O
(P O
= O
0.019, O
OR O
1.96, O
95% O
CI O
1.11-3.47), O
and O
proteinuria O

(P O
< O
0.001, O
OR O
2.95, O
95% O
CI O
1.73-5.00) O
and O
antinuclear O
antibody O
abnormalities O
(P O
< O
0.001, O
OR O
2.97, O
95% O
CI O
1.66-5.33). O
Deletions O
of O
HRH4 B-GENE-Y
copy O
numbers O
were O
protective O
against O
proteinuria O
(P O
= O
0.03, O
OR O
0.50, O
95% O
CI O
0.26-0.94). O
CONCLUSION: O
CNVs O
of O
the O
HRH4 B-GENE-Y
gene O
are O
associated O
with O
SLE. O
Pharmacology O
of O

ramelteon, B-CHEMICAL
a O
selective O
MT1/MT2 B-GENE-Y
receptor O
agonist: O
a O
novel O
therapeutic O
drug O
for O
sleep O
disorders. O
An O
estimated O
one-third O
of O
the O
general O
population O
is O
affected O
by O
insomnia, O
and O
this O
number O
is O
increasing O
due O
to O
more O
stressful O
working O
conditions O
and O
the O
progressive O
aging O
of O
society. O
However, O
current O
treatment O
of O
insomnia O
with O
hypnotics, O
gamma-aminobutyric B-GENE-N
acid I-GENE-N
A I-GENE-N
(GABA(A)) I-GENE-N
receptor I-GENE-N
modulators, O
induces O
various O
side O
effects, O
including O
cognitive O
impairment, O
motor O
disturbance, O
dependence, O
tolerance, O
hangover, O
and O
rebound O
insomnia. O

Ramelteon B-CHEMICAL
(Rozerem; B-CHEMICAL
Takeda O
Pharmaceutical O
Company O
Limited, O
Osaka, O
Japan) O
is O
an O
orally O
active, O
highly O
selective O
melatonin B-CHEMICAL
MT(1)/MT(2) B-GENE-Y
receptor O
agonist. O
Unlike O
the O
sedative O
hypnotics O
that O
target O
GABA(A) B-GENE-N
receptor I-GENE-N
complexes, O
ramelteon B-CHEMICAL
is O
a O
chronohypnotic O
that O
acts O
on O
the O
melatonin B-CHEMICAL
MT(1) B-GENE-Y
and O
MT(2) B-GENE-Y
receptors, O
which O
are O
primarily O
located O
in O
the O
suprachiasmatic O
nucleus, O
the O
body's O
"master O
clock." O
As O

such, O
ramelteon B-CHEMICAL
possesses O
the O
first O
new O
therapeutic O
mechanism O
of O
action O
for O
a O
prescription O
insomnia O
medication O
in O
over O
three O
decades. O
Ramelteon B-CHEMICAL
has O
demonstrated O
sleep-promoting O
effects O
in O
clinical O
trials, O
and O
coupled O
with O
its O
favorable O
safety O
profile O
and O
lack O
of O
abuse O
potential O
or O
dependence, O
this O
chronohypnotic O
provides O
an O
important O
treatment O
option O
for O
insomnia. O
Antimyeloma O
effects O
of O
a O
novel O
synthetic O
retinoid B-CHEMICAL
Am80 B-CHEMICAL
(Tamibarotene) B-CHEMICAL
through O
inhibition O
of O
angiogenesis. O
In O
multiple O
myeloma O
(MM), O
the O
interaction O
between O
myeloma O
cells O
and O
bone O
marrow O

microenvironment O
has O
an O
important O
role O
in O
the O
pathogenesis O
of O
MM. O
We O
first O
examined O
the O
inducing O
effect O
of O
myeloma O
cells O
on O
migration O
of O
human O
umbilical O
vein O
vascular O
endothelial O
cells O
(HUVECs). O
Five O
myeloma O
cell O
lines O
produced O
varying O
amounts O
of O
VEGF, B-GENE-Y
and O
migration O
of O
HUVECs O
was O
induced O
by O
coculture O
with O
myeloma O
cells. O
We O
next O
examined O
the O
inhibitory O
effect O
of O
a O
novel O
synthetic O
retinoid B-CHEMICAL
Am80 B-CHEMICAL
(Tamibarotene) B-CHEMICAL
on O
both O
myeloma O
cells O
and O
HUVECs. O
Am80 B-CHEMICAL
is O
specific O
for O
the O

retinoic-acid B-GENE-N
receptor-alpha/beta, I-GENE-N
and O
has O
therapeutic O
effects O
in O
all-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
resistant O
acute O
promyelocytic O
leukemia. O
Am80 B-CHEMICAL
slightly O
inhibited O
the O
growth O
of O
both O
myeloma O
cells O
and O
HUVECs, O
and O
remarkably O
inhibited O
the O
growth O
of O
HUVECs O
stimulated O
by O
VEGF. B-GENE-Y
Am80 B-CHEMICAL
showed O
little O
growth O
inhibition O
of O
bone O
marrow O
stromal O
cells O
(BMSCs), O
but O
it O
markedly O
inhibited O
migration O
of O
HUVECs O
by O
cocultured O
myeloma O
cells. O
Am80 B-CHEMICAL
inhibited O
VEGF-induced B-GENE-Y

phosphorylation O
of O
VEGF B-GENE-N
receptor. I-GENE-N
In O
addition, O
VEGF-induced B-GENE-Y
formation O
of O
tube-like O
structures O
in O
vitro O
and O
neovascularization O
in O
mouse O
corneas O
were O
significantly O
inhibited O
by O
Am80. B-CHEMICAL
These O
findings O
clearly O
demonstrate O
that O
Am80 B-CHEMICAL
is O
a O
potential O
inhibitor O
of O
angiogenesis O
caused O
by O
the O
interaction O
between O
vascular O
endothelial O
cells O
and O
myeloma O
cells, O
and O
might O
be O
a O
useful O
therapeutic O
agent O
against O
MM. O
Mechanisms O
of O
inhibition O
of O
calmodulin-stimulated B-GENE-N
cyclic I-GENE-N
nucleotide I-GENE-N
phosphodiesterase I-GENE-N
by O
dihydropyridine O
calcium O
antagonists. O

Calmodulin-dependent B-GENE-N
cyclic I-GENE-N
nucleotide I-GENE-N
phosphodiesterase I-GENE-N
(CaMPDE) B-GENE-N
is O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
complex O
interaction O
between O
the O
cyclic O
nucleotide B-CHEMICAL
and O
Ca2+ B-CHEMICAL
second-messenger O
systems. O
CaMPDE B-GENE-N
exists O
as O
tissue-specific O
isozymes, O
and O
initially O
these O
isozymes O
were O
designated O
according O
to O
their O
respective O
subunit O
molecular O
mass. O
A O
variety O
of O
pharmacological O
agents O
have O
been O
used O
to O
inhibit O
CaMPDE, B-GENE-N
and O
this O
inhibition O
occurs O
mostly O
via O
Ca2+-dependent B-CHEMICAL
association O
with O
the O
proteins. O
We O
have O
examined O
the O
effect O

of O
dihydropyridine B-CHEMICAL
Ca2+-channel B-GENE-N
blockers O
felodipine B-CHEMICAL
and O
nicardipine B-CHEMICAL
on O
CaMPDE. B-GENE-N
The O
results O
suggest O
that O
the O
63-kDa O
(PDE B-GENE-Y
1B1) I-GENE-Y
and O
60-kDa O
(PDE B-GENE-Y
1A2) I-GENE-Y
CaMPDE B-GENE-N
isozymes O
are O
inhibited O
by O
felodipine B-CHEMICAL
and O
nicardipine B-CHEMICAL
by O
partial O
competitive O
inhibition O
and O
that O
these O
two O
Ca2+ B-CHEMICAL
antagonists O
appear O
to O
counteract O
each O
other. O
This O
study O
further O
demonstrates O
the O
existence O
of O
a O
specific O
site, O
distinct O
from O
the O
active O
site O
on O
CaMPDE, B-GENE-N
that O

exhibits O
high-affinity O
binding O
of O
these O
drugs. O
Felodipine B-CHEMICAL
and O
nicardipine B-CHEMICAL
have O
similar O
affinities O
for O
60-kDa O
CaMPDE B-GENE-N
isozymes O
but O
bring O
about O
different O
levels O
of O
enzyme O
inhibition, O
suggesting O
the O
possibility O
of O
designing O
specific O
drugs O
that O
can O
protect O
the O
enzyme O
from O
inhibition O
by O
dihydropyridine B-CHEMICAL
Ca2+-channel B-GENE-N
blockers. O
Efficient O
MRI O
labeling O
of O
endothelial O
progenitor O
cells: O
Design O
of O
thiolated O
surface O
stabilized O
superparamagnetic O
iron B-CHEMICAL
oxide I-CHEMICAL
nanoparticles. O
The O
aim O
of O
this O
study O
was O
to O
design O
thiolated O

surface O
stabilized O
superparamagnetic O
iron B-CHEMICAL
oxide I-CHEMICAL
nanoparticles O
(TSS-SPIONs) O
for O
efficient O
internalization O
with O
high O
MRI O
sensitivity. O
TSS-SPIONs O
were O
developed O
by O
chelation O
between O
thiolated O
chitosan-thioglycolic B-CHEMICAL
acid I-CHEMICAL
(chitosan-TGA) B-CHEMICAL
hydrogel O
and O
iron B-CHEMICAL
ions O
(Fe(2+)/Fe(3+)). B-CHEMICAL
Likely, O
unmodified O
chitosan O
hydrogel O
SPIONs O
(UC-SPIONs) O
and O
uncoated O
SPIONs O
were O
used O
as O
control. O
Moreover, O

TSS-SPIONs O
were O
investigated O
regarding O
to O
their O
iron B-CHEMICAL
core O
size, O
hydrodynamic O
diameter, O
zeta O
potential, O
iron B-CHEMICAL
contents, O
molar O
relaxivities O
(r1 O
and O
r2), O
and O
cellular O
internalization. O
TSS-SPIONs O
demonstrated O
an O
iron B-CHEMICAL
oxide I-CHEMICAL
core O
diameter O
(crystallite O
size O
by O
XRD) O
of O
3.1±0.02nm, O
a O
hydrodynamic O
diameter O
of O
94±20nm, O
a O
zeta O
potential O
of O
+21±5mV, O
and O
an O
iron B-CHEMICAL
content O
of O
3.6±0.9mg/mL. O
In O
addition, O
internalization O
of O

TSS-SPIONs O
into O
human O
endothelial O
progenitor O
cells O
(EPC) O
from O
umbilical O
cord O
blood O
was O
more O
than O
threefold O
and O
17-fold O
higher O
in O
contrast O
to O
UC-SPIONs O
and O
SPIONs, O
respectively. O
With O
twofold O
lower O
incubation O
iron B-CHEMICAL
concentration O
of O
TSS-SPIONs, O
more O
than O
threefold O
higher O
internalization O
was O
achieved O
as O
compared O
to O
Resovist®. O
Also, O
cell O
viability O
of O
more O
than O
90% O
was O
observed O
in O
the O
presence O
of O
TSS-SPIONs O
after O
24h. O
The O
molar O
MR O
relaxivities O
(r2) O
value O
at O

1.5T O
was O
threefold O
higher O
than O
that O
of O
Resovist® O
and O
demonstrated O
that O
TSS-SPIONs O
have O
the O
potential O
as O
very O
effective O
T2 O
contrast-enhancement O
agent. O
According O
to O
these O
findings, O
TSS-SPIONs O
with O
efficient O
internalization, O
lower O
cytotoxicity, O
and O
high O
MRI O
sensitivity O
seem O
to O
be O
promising O
for O
cell O
tracking. O
Selective O
inhibitors O
and O
tailored O
activity O
probes O
for O
lipoprotein-associated B-GENE-Y
phospholipase I-GENE-Y
A(2). I-GENE-Y
Lipoprotein-associated B-GENE-Y
phospholipase I-GENE-Y
A(2) I-GENE-Y
(Lp-PLA(2) B-GENE-Y

or O
PLA(2)G7) B-GENE-Y
binds O
to O
low-density B-GENE-N
lipoprotein I-GENE-N
(LDL) B-GENE-N
particles, O
where O
it O
is O
thought O
to O
hydrolyze O
oxidatively O
truncated O
phospholipids. O
Lp-PLA(2) B-GENE-Y
has O
also O
been O
implicated O
as O
a O
pro-tumorigenic O
enzyme O
in O
human O
prostate O
cancer. O
Several O
inhibitors O
of O
Lp-PLA(2) B-GENE-Y
have O
been O
described, O
including O
darapladib, B-CHEMICAL
which O
is O
currently O
in O
phase O
3 O
clinical O
development O
for O
the O
treatment O
of O
atherosclerosis. O
The O
selectivity O
that O
darapladib B-CHEMICAL
and O
other O

Lp-PLA(2) B-GENE-Y
inhibitors O
display O
across O
the O
larger O
serine B-GENE-N
hydrolase I-GENE-N
family O
has O
not, O
however, O
been O
reported. O
Here, O
we O
describe O
the O
use O
of O
both O
general O
and O
tailored O
activity-based O
probes O
for O
profiling O
Lp-PLA(2) B-GENE-Y
and O
inhibitors O
of O
this O
enzyme O
in O
native O
biological O
systems. O
We O
show O
that O
both O
darapladib B-CHEMICAL
and O
a O
novel O
class O
of O
structurally O
distinct O
carbamate B-CHEMICAL
inhibitors O
inactivate O
Lp-PLA(2) B-GENE-Y
in O
mouse O
tissues O
and O
human O
cell O
lines O
with O
high O
selectivity. O
Our O
findings O
thus O
identify O
both O
inhibitors O
and O
chemoproteomic O

probes O
that O
are O
suitable O
for O
investigating O
Lp-PLA(2) B-GENE-Y
function O
in O
biological O
systems. O
Arformoterol: B-CHEMICAL
(R,R)-eformoterol, B-CHEMICAL
(R,R)-formoterol, B-CHEMICAL
arformoterol B-CHEMICAL
tartrate, I-CHEMICAL
eformoterol-sepracor, B-CHEMICAL
formoterol-sepracor, B-CHEMICAL
R,R-eformoterol, B-CHEMICAL
R,R-formoterol. B-CHEMICAL
Sepracor O
in O
the O
US O
is O
developing O
arformoterol B-CHEMICAL
[R,R-formoterol], B-CHEMICAL
a O
single O
isomer O
form O
of O
the O

beta(2)-adrenoceptor B-GENE-Y
agonist O
formoterol B-CHEMICAL
[eformoterol]. B-CHEMICAL
This O
isomer O
contains O
two O
chiral O
centres O
and O
is O
being O
developed O
as O
an O
inhaled O
preparation O
for O
the O
treatment O
of O
respiratory O
disorders. O
Sepracor O
believes O
that O
arformoterol B-CHEMICAL
has O
the O
potential O
to O
be O
a O
once-daily O
therapy O
with O
a O
rapid O
onset O
of O
action O
and O
a O
duration O
of O
effect O
exceeding O
12 O
hours. O
In O
1995, O
Sepracor O
acquired O
New O
England O
Pharmaceuticals, O
a O
manufacturer O
of O
metered-dose O
and O
dry O
powder O
inhalers, O
for O
the O
purpose O
of O
preparing O
formulations O
of O
levosalbutamol B-CHEMICAL
and O

arformoterol. B-CHEMICAL
Phase O
II O
dose-ranging O
clinical O
studies O
of O
arformoterol B-CHEMICAL
as O
a O
longer-acting, O
complementary O
bronchodilator O
were O
completed O
successfully O
in O
the O
fourth O
quarter O
of O
2000. O
Phase O
III O
trials O
of O
arformoterol B-CHEMICAL
began O
in O
September O
2001. O
The O
indications O
for O
the O
drug O
appeared O
to O
be O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
(COPD). O
However, O
an O
update O
of O
the O
pharmaceutical O
product O
information O
on O
the O
Sepracor O
website O
in O
September O
2003 O
listed O
COPD O
maintenance O
therapy O
as O
the O
only O
indication O
for O
arformoterol. B-CHEMICAL
In O
October O
2002, O
Sepracor O
stated O
that O
two O
pivotal O
phase O

III O
studies O
were O
ongoing O
in O
1600 O
patients. O
Sepracor O
estimates O
that O
its O
NDA O
submission O
for O
arformoterol, B-CHEMICAL
which O
is O
projected O
for O
the O
first O
half O
of O
2004, O
will O
include O
approximately O
3000 O
adult O
subjects. O
Sepracor O
stated O
in O
July O
2003 O
that O
it O
had O
completed O
more O
than O
100 O
preclinical O
studies O
and O
initiated O
or O
completed O
15 O
clinical O
studies O
for O
arformoterol B-CHEMICAL
inhalation O
solution O
for O
the O
treatment O
of O
bronchospasm O
in O
patients O
with O
COPD. O
In O
addition, O
Sepracor O
stated O
that O
the O
two O
pivotal O
phase O
III O
studies O
in O
1600 O
patients O
were O
still O
progressing. O
In O
1995, O
European O
patents O
were O
granted O
to O
Sepracor O

for O
the O
use O
of O
arformoterol B-CHEMICAL
in O
the O
treatment O
of O
asthma, O
and O
the O
US O
patent O
application O
was O
pending. O
Role O
of O
nitric B-CHEMICAL
oxide I-CHEMICAL
in O
the O
chemistry O
and O
anticancer O
activity O
of O
etoposide B-CHEMICAL
(VP-16,213). B-CHEMICAL
Originally O
identified O
as O
an O
innate O
cytotoxin, O
nitric B-CHEMICAL
oxide I-CHEMICAL
((·)NO) B-CHEMICAL
formation O
in O
tumors O
can O
influence O
chemotherapy O
and O
exacerbate O
cancer O
progression. O
Here, O
we O
examined O
the O
hypothesis O
that O
(·)NO B-CHEMICAL
generation O
contributes O
to O
cancer O
cell O
drug O
resistance O
toward O
the O
widely O
used O
anticancer O
drug O
Etoposide B-CHEMICAL
(VP-16). B-CHEMICAL
The O

UV-vis O
spectrum O
of O
VP-16 B-CHEMICAL
was O
not O
changed O
by O
exposure O
of O
VP-16 B-CHEMICAL
to O
(·)NO B-CHEMICAL
in O
aqueous O
buffer. O
In O
contrast, O
reddish-orange O
compound(s) O
characteristic O
of O
o-quinone- B-CHEMICAL
and I-CHEMICAL
nitroso-VP-16 I-CHEMICAL
were O
readily O
generated O
in O
a O
hydrophobic O
medium O
(chloroform) B-CHEMICAL
in O
an O
oxygen-dependent B-CHEMICAL
manner. O
Similar O
products O
were O
also O
formed O
when O
the O
VP-16 B-CHEMICAL
radical, O
generated O
from O
VP-16 B-CHEMICAL
and O
horseradish O
peroxidase/H2O2, B-CHEMICAL
was O
exposed O
directly O
to O
(·)NO B-CHEMICAL
in O
chloroform B-CHEMICAL
in O
the O
presence O
of O

oxygen. B-CHEMICAL
Separation O
and O
spectral O
analysis O
of O
VP-16 B-CHEMICAL
reaction O
extracts O
by O
electron O
spin O
resonance O
and O
UV-vis O
indicated O
the O
generation O
of O
the O
phenoxy B-CHEMICAL
radical O
and O
the O
o-quinone B-CHEMICAL
of O
VP-16, B-CHEMICAL
as O
well O
as O
putative O
nitroxide, B-CHEMICAL
iminoxyl, B-CHEMICAL
and O
other O
nitrogen B-CHEMICAL
oxide I-CHEMICAL
intermediates. O
Nitric B-CHEMICAL
oxide I-CHEMICAL
products O
of O
VP-16 B-CHEMICAL
displayed O
significantly O
diminished O
topoisomerase B-GENE-Y
II-dependent I-GENE-Y
cleavage O
of O
DNA O
and O
cytotoxicity O
to O
human O
HL-60 O
leukemia O
cells. O
LPS-mediated O
induction O
of O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N
in O
murine O

macrophages O
resulted O
in O
VP-16 B-CHEMICAL
resistance O
compared O
to O
Raw O
cells. O
Furthermore, O
(·)NO B-CHEMICAL
products O
derived O
from O
iNOS B-GENE-Y
rapidly O
reacted O
with O
VP-16 B-CHEMICAL
leading O
to O
decreased O
DNA O
damage O
and O
cytotoxicity. O
Together, O
these O
observations O
suggest O
that O
the O
formation O
of O
(·)NO B-CHEMICAL
in O
tumors O
(associated O
macrophages) O
can O
contribute O
to O
VP-16 B-CHEMICAL
resistance O
via O
the O
detoxification O
of O
VP-16. B-CHEMICAL
Acyl-CoA B-GENE-N
synthetase I-GENE-N
isoforms I-GENE-N
1, I-GENE-N
4, I-GENE-N
and I-GENE-N
5 I-GENE-N
are O
present O
in O
different O
subcellular O
membranes O
in O
rat O
liver O
and O
can O
be O
inhibited O
independently. O
Inhibition O
studies O

have O
suggested O
that O
acyl-CoA B-GENE-N
synthetase I-GENE-N
(ACS, B-GENE-N
EC O
) O
isoforms O
might O
regulate O
the O
use O
of O
acyl-CoAs B-CHEMICAL
by O
different O
metabolic O
pathways. O
In O
order O
to O
determine O
whether O
the O
subcellular O
locations O
differed O
for O
each O
of O
the O
three O
ACSs B-GENE-N
present O
in O
liver O
and O
whether O
these O
isoforms O
were O
regulated O
independently, O
non-cross-reacting O
peptide O
antibodies O
were O
raised O
against O
ACS1, B-GENE-Y
ACS4, B-GENE-Y
and O
ACS5. B-GENE-Y
ACS1 B-GENE-Y
was O
identified O
in O
endoplasmic O
reticulum, O
mitochondria-associated O
membrane O
(MAM), O
and O
cytosol, O

but O
not O
in O
mitochondria. O
ACS4 B-GENE-Y
was O
present O
primarily O
in O
MAM, O
and O
the O
76-kDa O
ACS5 B-GENE-Y
protein O
was O
located O
in O
mitochondrial O
membrane. O
Consistent O
with O
these O
locations, O
N-ethylmaleimide, B-CHEMICAL
an O
inhibitor O
of O
ACS4, B-GENE-Y
inhibited O
ACS B-GENE-N
activity O
47% O
in O
MAM O
and O
28% O
in O
endoplasmic O
reticulum. O
Troglitazone, B-CHEMICAL
a O
second O
ACS4 B-GENE-Y
inhibitor, O
inhibited O
ACS B-GENE-N
activity O
<10% O
in O
microsomes O
and O
mitochondria O
and O
45% O
in O
MAM. O
Triacsin B-CHEMICAL
C, I-CHEMICAL
a O
competitive O
inhibitor O

of O
both O
ACS1 B-GENE-Y
and O
ACS4, B-GENE-Y
inhibited O
ACS B-GENE-N
activity O
similarly O
in O
endoplasmic O
reticulum, O
MAM, O
and O
mitochondria, O
suggesting O
that O
a O
hitherto O
unidentified O
triacsin-sensitive B-CHEMICAL
ACS B-GENE-N
is O
present O
in O
mitochondria. O
ACS1, B-GENE-Y
ACS4, B-GENE-Y
and O
ACS5 B-GENE-Y
were O
regulated O
independently O
by O
fasting O
and O
re-feeding. O
Fasting O
rats O
for O
48 O
h O
resulted O
in O
a O
decrease O
in O
ACS4 B-GENE-Y
protein, O
and O
an O
increase O
in O
ACS5. B-GENE-Y
Re-feeding O
normal O
chow O
or O
a O
high O
sucrose B-CHEMICAL
diet O
for O
24 O
h O
after O
a O
48-h O

fast O
increased O
both O
ACS1 B-GENE-Y
and O
ACS4 B-GENE-Y
protein O
expression O
1.5-2.0-fold, O
consistent O
with O
inhibition O
studies. O
These O
results O
suggest O
that O
ACS1 B-GENE-Y
and O
ACS4 B-GENE-Y
may O
be O
linked O
to O
triacylglycerol B-CHEMICAL
synthesis. O
Taken O
together, O
the O
data O
suggest O
that O
acyl-CoAs B-CHEMICAL
may O
be O
functionally O
channeled O
to O
specific O
metabolic O
pathways O
through O
different O
ACS B-GENE-N
isoforms O
in O
unique O
subcellular O
locations. O
The O
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor O
ZD1839 B-CHEMICAL
("Iressa") B-CHEMICAL
inhibits O
HER2-driven B-GENE-Y
signaling O
and O
suppresses O
the O
growth O
of O

HER2-overexpressing B-GENE-Y
tumor O
cells. O
The O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
is O
commonly O
overexpressed O
in O
many O
human O
tumors O
and O
provides O
a O
new O
target O
for O
anticancer O
drug O
development. O
ZD1839 B-CHEMICAL
("Iressa"), B-CHEMICAL
a O
quinazoline B-CHEMICAL
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor O
selective O
for O
the O
EGFR, B-GENE-Y
has O
shown O
good O
activity O
in O
preclinical O
studies O
and O
in O
the O
early O
phase O
of O
clinical O
trials. O
However, O
because O
it O
remains O
unclear O
which O
tumor O
types O
are O
the O
best O
targets O
for O
treatment O
with O
this O
agent, O
the O
molecular O
characteristics O
that O
correlate O
with O
tumor O
sensitivity O
to O

ZD1839 B-CHEMICAL
have O
been O
studied. O
In O
a O
panel O
of O
human O
breast O
cancer O
and O
other O
epithelial O
tumor O
cell O
lines, O
HER2-overexpressing B-GENE-Y
tumors O
were O
particularly O
sensitive O
to O
ZD1839. B-CHEMICAL
Growth O
inhibition O
of O
these O
tumor O
cell O
lines O
was O
associated O
with O
the O
dephosphorylation O
of O
EGFR, B-GENE-Y
HER2, B-GENE-Y
and O
HER3, B-GENE-Y
accompanied O
by O
the O
loss O
of O
association O
of O
HER3 O
with O
phosphatidylinositol B-GENE-N
3-kinase, I-GENE-N
and O
down-regulation O
of O
Akt B-GENE-N
activity. O
These O
studies O
suggest O
that O
HER2-overexpressing B-GENE-Y
tumors O
are O
particularly O
susceptible O
to O
the O

inhibition O
of O
HER B-GENE-N
family O
tyrosine B-GENE-N
kinase I-GENE-N
signaling O
and O
suggest O
novel O
strategies O
to O
treat O
these O
particularly O
aggressive O
tumors. O
Integrated O
chemical O
and O
biological O
analysis O
to O
explain O
estrogenic O
potency O
in O
bile O
extracts O
of O
red O
mullet O
(Mullus O
barbatus). O
A O
biological O
screening O
was O
performed O
to O
establish O
the O
total O
exposure O
to O
estrogenic O
compounds O
of O
red O
mullet O
(Mullus O
barbatus) O
collected O
at O
several O
sites O
along O
the O
Spanish O
Mediterranean O
coast O
by O
testing O
male O
fish O
bile O
extracts O
using O
the O
in O
vitro O
ER-LUC B-GENE-Y
reporter O
gene O
assay. O
In O
addition, O
major O
metabolites O
were O
identified O
and O
measurements O
of O

OH-PAHs B-CHEMICAL
(1-naphthol, B-CHEMICAL
9-phenantrol, B-CHEMICAL
9-fluorenol, B-CHEMICAL
1-pyrenol, B-CHEMICAL
1OH-BaP B-CHEMICAL
and O
3OH-BaP) B-CHEMICAL
and O
alkylphenols B-CHEMICAL
(4-n-nonylphenol B-CHEMICAL
(4-n-NP) B-CHEMICAL
and O
4-tertoctylphenol B-CHEMICAL
(4-tert-OP)) B-CHEMICAL
in O
the O
same O
fish O
bile O
extracts O
were O
taken O
by O
gas O
chromatography-mass O
spectrometry O
in O
electron O
ionization O
mode O

(GC-EI-MS). O
Relative O
in O
vitro O
estrogenic O
potencies O
of O
the O
chemically O
quantified O
compounds O
were O
also O
tested. O
The O
highest O
biliary O
concentrations O
of O
1-pyrenol, B-CHEMICAL
9-fluorenol B-CHEMICAL
and O
4-n-NP B-CHEMICAL
were O
found O
in O
fish O
from O
Barcelona O
and O
from O
the O
Mar O
Menor O
coastal O
lagoon. O
However, O
these O
concentrations O
can O
be O
considered O
relatively O
low O
compared O
to O
values O
reported O
in O
red O
mullet O
from O
other O
polluted O
waters O
in O
the O
Mediterranean O
Sea. O
The O
contribution O
of O
1-pyrenol, B-CHEMICAL
4-n-NP B-CHEMICAL
and O

4-tert-OP B-CHEMICAL
to O
the O
total O
estrogenic O
potency O
measured O
in O
male O
fish O
bile O
was O
found O
to O
be O
negligible, O
indicating O
the O
presence O
of O
other O
estrogenic O
compounds O
in O
red O
mullet O
bile. O
Estrogenic O
potency O
in O
bile O
from O
male O
fish O
was O
markedly O
elevated O
in O
Mar O
Menor O
lagoon O
(234.8±5.7pgE2EQ/μl), O
and O
further O
research O
will O
be O
necessary O
to O
explain O
whether O
the O
presence O
of O
natural O
and O
synthetic-hormones O
in O
the O
lagoon O
contributed O
to O
this O
finding. O
Values O
of O
approximately O
15-16E2EQpg/mg O

bile O
can O
be O
regarded O
as O
preliminary O
baseline O
levels O
of O
bile O
estrogenicity O
in O
male O
red O
mullet O
from O
the O
western O
Mediterranean O
Sea. O
[Pharmacological O
effects O
of O
a O
mu-opioid B-GENE-Y
receptor I-GENE-Y
antagonist O
naltrexone B-CHEMICAL
on O
alcohol B-CHEMICAL
dependence]. O
Alcohol B-CHEMICAL
is O
one O
of O
the O
most O
commonly O
abused O
substances, O
and O
its O
chronic O
intake O
leads O
to O
the O
development O
of O
ethanol B-CHEMICAL
dependence O
in O
both O
humans O
and O
laboratory O
animals. O
In O
many O
countries, O
a O
mu-opioid B-GENE-Y
receptor I-GENE-Y
antagonist O
naltrexone B-CHEMICAL
has O
been O
used O
in O
the O
treatment O
of O
alcohol B-CHEMICAL
dependence. O
The O
introduction O
of O
naltrexone B-CHEMICAL
for O
the O
treatment O
of O
alcohol B-CHEMICAL
dependence O

has O
been O
mainly O
based O
on O
behavioral O
animal O
models O
that O
provide O
evidence O
of O
the O
involvement O
of O
the O
endogenous O
opioid O
system O
in O
alcohol B-CHEMICAL
drinking O
and O
dependence. O
It O
has O
been O
well O
known O
that O
alcohol B-CHEMICAL
leads O
to O
the O
activation O
of O
the O
endogenous O
opioid O
system. O
The O
endogenous O
opioid O
agonists, O
such O
as O
beta-endorphin, B-GENE-Y
increase O
the O
activity O
of O
the O
mesolimbic O
dopaminergic O
system O
through O
the O
inhibition O
of O
the O
gamma-aminobutyric B-CHEMICAL
acid I-CHEMICAL
(GABA)-containing B-CHEMICAL
inhibitory O
interneurons O
in O
the O
ventral O
tegmental O
area, O
resulting O
in O
the O
expression O
of O
alcohol B-CHEMICAL
reinforcement O

and/or O
rewarding O
effect. O
Therefore, O
naltrexone, B-CHEMICAL
which O
is O
useful O
for O
alcohol B-CHEMICAL
dependence O
therapy, O
may O
attenuate O
the O
rewarding O
effect O
of O
ethanol B-CHEMICAL
by O
interfering O
with O
the O
ethanol-induced B-CHEMICAL
stimulation O
of O
the O
mesolimbic O
dopaminergic O
system. O
The O
following O
review O
provides O
a O
summary O
of O
the O
interactions O
between O
endogenous O
opioid O
system O
and O
mesolimbic O
dopaminergic O
system O
in O
alcohol B-CHEMICAL
dependence. O
Re-evaluation O
of O
lisuride B-CHEMICAL
pharmacology: O
5-hydroxytryptamine1A B-GENE-Y
receptor-mediated I-GENE-Y
behavioral O
effects O
overlap O
its O
other O
properties O
in O
rats. O

RATIONALE: O
There O
is O
substantial O
evidence O
that O
lisuride B-CHEMICAL
can O
produce O
effects O
linked O
to O
5-HT(1A) B-GENE-Y
receptor O
occupancy. O
Nevertheless, O
this O
action O
has O
generally O
been O
ignored O
in O
the O
mechanism O
of O
action O
of O
lisuride, B-CHEMICAL
in O
favor O
of O
an O
exclusive O
role O
for O
dopamine B-GENE-N
receptors I-GENE-N
in O
considering O
its O
antiparkinsonian O
effects, O
or O
an O
exclusive O
role O
of O
5-HT(2A/2C) B-GENE-N
receptor O
activation O
in O
hallucinogenesis. O
These O
conclusions O
are O
surprising O
when O
one O
considers O
that O
the O
potent O
interaction O
of O
lisuride B-CHEMICAL
with O
5-HT(1A) B-GENE-Y
receptors O
has O
been O
demonstrated O
in O

several O
different O
laboratories O
and O
that O
activation O
of O
5-HT(1A) B-GENE-Y
and O
5-HT(1B) B-GENE-Y
receptors O
can O
modulate O
dopaminergically O
mediated O
responses. O
OBJECTIVE: O
The O
lack O
of O
full O
substitution O
of O
lisuride B-CHEMICAL
for O
lysergic B-CHEMICAL
acid I-CHEMICAL
diethylamide I-CHEMICAL
(LSD) B-CHEMICAL
in O
drug O
discrimination O
experiments O
and O
induction O
of O
a O
pronounced O
5-HT B-CHEMICAL
syndrome O
by O
this O
compound O
at O
relatively O
low O
doses O
convinced O
us O
to O
execute O
two O
series O
of O
experiments O
that O
might O
explain O
the O
primary O
mechanism O
responsible O
for O
lisuride-mediated B-CHEMICAL
biological O
effects O
and O
its O
paradoxical O
classification O
as O
a O
dopamine B-CHEMICAL
agonist O
in O
the O

literature. O
RESULTS: O
In O
drug O
discrimination O
studies, O
lisuride B-CHEMICAL
fully O
mimicked O
the O
5-HT(1A) B-GENE-Y
agonist O
LY B-CHEMICAL
293284, I-CHEMICAL
only O
partially O
substituted O
for O
LSD B-CHEMICAL
and O
DOI, B-CHEMICAL
and O
failed O
to O
substitute O
for O
(+)-amphetamine. B-CHEMICAL
Lisuride B-CHEMICAL
produced O
a O
significant O
dose-related O
increase O
in O
flat O
body O
posture, O
forepaw O
treading, O
and O
lower-lip O
retraction O
which O
reflect O
a O
modulation O
of O
behavior O
by O
action O
at O
central O
5-HT(1A) B-GENE-Y
receptors. O
Only O
pMPPI O

[4-iodo-N-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridynyl-benzamide B-CHEMICAL
hydrochloride], I-CHEMICAL
a O
selective O
5-HT(1A) B-GENE-Y
antagonist, O
was O
effective O
in O
inhibiting O
all O
5-HT B-CHEMICAL
syndrome O
behaviors O
produced O
by O
lisuride, B-CHEMICAL
whereas O
pMPPI O
was O
without O
effect O
on O
any O
behavior O
induced O
by O
LSD. B-CHEMICAL
Lisuride O
dose O
dependently O
decreased O
body O
temperature O
in O
rats O
with O
a O
potency O
similar O
to O
that O
of O
the O
selective O

5-HT(1A) B-GENE-Y
agonist O
LY B-CHEMICAL
293284. I-CHEMICAL
The O
hypothermic O
effect O
of O
lisuride B-CHEMICAL
was O
prevented O
by O
pre-injection O
of O
pMPPI, O
but O
not O
by O
ketanserin B-CHEMICAL
or O
haloperidol. B-CHEMICAL
CONCLUSION: O
We O
have O
demonstrated O
that O
the O
behavioral O
effects O
of O
low O
doses O
of O
lisuride B-CHEMICAL
are O
clearly O
mediated O
by O
stimulation O
of O
5-HT(1A) B-GENE-Y
receptors. O
Bupropion B-CHEMICAL
inhibits O
nicotine-evoked B-CHEMICAL
[(3)H]overflow B-CHEMICAL
from O
rat O
striatal O
slices O
preloaded O
with O

[(3)H]dopamine B-CHEMICAL
and O
from O
rat O
hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine. B-CHEMICAL
Bupropion, B-CHEMICAL
an O
efficacious O
antidepressant O
and O
smoking O
cessation O
agent, O
inhibits O
dopamine B-GENE-N
and I-GENE-N
norepinephrine I-GENE-N
transporters I-GENE-N
(DAT B-GENE-Y
and O
NET, B-GENE-Y
respectively). O
Recently, O
bupropion B-CHEMICAL
has O
been O
reported O
to O
noncompetitively O
inhibit O
alpha3beta2, B-GENE-N
alpha3beta4, I-GENE-N
and I-GENE-N
alpha4beta2 I-GENE-N
nicotinic I-GENE-N
acetylcholine I-GENE-N
receptors I-GENE-N

(nAChRs) I-GENE-N
expressed O
in O
Xenopus O
oocytes O
or O
established O
cell O
lines. O
The O
present O
study O
evaluated O
bupropion-induced B-CHEMICAL
inhibition O
of O
native O
alpha3beta2* B-GENE-N
and I-GENE-N
alpha3beta4* I-GENE-N
nAChRs I-GENE-N
using O
functional O
neurotransmitter O
release O
assays, O
nicotine-evoked B-CHEMICAL
[(3)H]overflow B-CHEMICAL
from O
superfused O
rat O
striatal O
slices O
preloaded O
with O
[(3)H]dopamine B-CHEMICAL
([(3)H]DA), B-CHEMICAL
and O
nicotine-evoked B-CHEMICAL
[(3)H]overflow B-CHEMICAL
from O

hippocampal O
slices O
preloaded O
with O
[(3)H]norepinephrine B-CHEMICAL
([(3)H]NE). B-CHEMICAL
The O
mechanism O
of O
inhibition O
was O
evaluated O
using O
Schild O
analysis. O
To O
eliminate O
the O
interaction O
of O
bupropion B-CHEMICAL
with O
DAT B-GENE-Y
or O
NET, B-GENE-Y
nomifensine B-CHEMICAL
or O
desipramine, B-CHEMICAL
respectively, O
was O
included O
in O
the O
superfusion O
buffer. O
A O
high O
bupropion B-CHEMICAL
concentration O
(100 O
microM) O
elicited O
intrinsic O
activity O
in O
the O
[(3)H]DA B-CHEMICAL
release O
assay. O
However, O
none O
of O
the O
concentrations O
(1 O
nM-100 O
microM) O

examined O
evoked O
[(3)H]NE B-CHEMICAL
overflow O
and, O
thus, O
were O
without O
intrinsic O
activity O
in O
this O
assay. O
Moreover, O
bupropion B-CHEMICAL
inhibited O
both O
nicotine-evoked B-CHEMICAL
[(3)H]DA B-CHEMICAL
overflow O
(IC(50) O
= O
1.27 O
microM) O
and O
nicotine-evoked B-CHEMICAL
[(3)H]NE B-CHEMICAL
overflow O
(IC(50) O
= O
323 O
nM) O
at O
bupropion B-CHEMICAL
concentrations O
well O
below O
those O
eliciting O
intrinsic O
activity. O
Results O
from O
Schild O
analyses O
suggest O
that O
bupropion B-CHEMICAL
competitively O
inhibits O

nicotine-evoked B-CHEMICAL
[(3)H]DA B-CHEMICAL
overflow, O
whereas O
evidence O
for O
receptor O
reserve O
was O
obtained O
upon O
assessment O
of O
bupropion B-CHEMICAL
inhibition O
of O
nicotine-evoked B-CHEMICAL
[(3)H]NE B-CHEMICAL
overflow. O
Thus, O
bupropion B-CHEMICAL
acts O
as O
an O
antagonist O
at O
alpha3beta2* B-GENE-N
and I-GENE-N
alpha3beta4* I-GENE-N
nAChRs I-GENE-N
in O
rat O
striatum O
and O
hippocampus, O
respectively, O
across O
the O
same O
concentration O
range O
that O
inhibits O
DAT B-GENE-Y
and O
NET B-GENE-Y
function. O
The O
combination O
of O
nAChR B-GENE-N
and O
transporter O
inhibition O
produced O
by O

bupropion B-CHEMICAL
may O
contribute O
to O
its O
clinical O
efficacy O
as O
a O
smoking O
cessation O
agent. O
Nitrogen-containing B-CHEMICAL
bisphosphonates B-CHEMICAL
induce O
apoptosis O
of O
hematopoietic O
tumor O
cells O
via O
inhibition O
of O
Ras B-GENE-N
signaling O
pathways O
and O
Bim-mediated B-GENE-Y
activation O
of O
the O
intrinsic O
apoptotic O
pathway. O
Nitrogen-containing B-CHEMICAL
bisphosphonates B-CHEMICAL
(N-BPs) B-CHEMICAL
induce O
apoptosis O
in O
tumor O
cells O
by O
inhibiting O
the O
prenylation O
of O
small O
G-proteins. B-GENE-N
However, O
the O
details O
of O
the O
apoptosis-inducing O
mechanism O
remain O
obscure. O
The O
present O
study O
showed O
that O
the O
induction O
of O

apoptosis O
by O
N-BPs B-CHEMICAL
in O
hematopoietic O
tumor O
cells O
is O
mediated O
by O
mitochondrial O
apoptotic O
signaling O
pathways, O
which O
are O
activated O
by O
the O
suppression O
of O
geranylgeranyl B-CHEMICAL
pyrophosphate I-CHEMICAL
(GGPP) B-CHEMICAL
biosynthesis. O
Furthermore, O
N-BPs B-CHEMICAL
decreased O
the O
levels O
of O
phosphorylated B-GENE-N
extracellular I-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
and O
mTOR B-GENE-Y
via O
suppression O
of O
Ras B-GENE-N
prenylation O
and O
enhanced O
Bim B-GENE-Y
expression. O
The O
present O
results O
indicated O
that O
N-BPs B-CHEMICAL
induce O
apoptosis O
by O
decreasing O
the O
mitochondrial O
transmembrane O
potential, O
increasing O
the O
activation O
of O

caspase-9 B-GENE-Y
and O
caspase-3, B-GENE-Y
and O
enhancing O
Bim B-GENE-Y
expression O
through O
inhibition O
of O
the O
Ras/MEK/ERK B-GENE-N
and O
Ras/mTOR B-GENE-N
pathways. O
The O
accumulation O
of O
N-BPs B-CHEMICAL
in O
bones O
suggests O
that O
they O
may O
act O
more O
effectively O
on O
tumors O
that O
have O
spread O
to O
bones O
or O
on O
Ras-variable B-GENE-N
tumors. O
This O
is O
the O
first O
study O
to O
show O
that O
the O
specific O
molecular O
pathways O
of O
N-BP-induced B-CHEMICAL
apoptosis. O
CASK B-GENE-Y
is O
a O
new O
intracellular O
modulator O
of O
P2X3 B-GENE-Y
receptors. I-GENE-Y
ATP-gated B-GENE-Y
P2X3 I-GENE-Y
receptors I-GENE-Y
of O
sensory O
ganglion O
neurons O
are O

important O
transducers O
of O
painful O
stimuli O
and O
are O
modulated O
by O
extracellular O
algogenic O
substances, O
via O
changes O
in O
the O
receptor O
phosphorylation O
state. O
The O
present O
study O
investigated O
the O
role O
of O
calcium/calmodulin-dependent B-GENE-Y
serine I-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
CASK B-GENE-Y
in O
interacting O
and O
controlling O
P2X3 B-GENE-Y
receptor I-GENE-Y
expression O
and O
function O
in O
mouse O
trigeminal O
ganglia. O
Most O
ganglion O
neurons O
in O
situ O
or O
in O
culture O
co-expressed O
P2X3 B-GENE-Y
and O
CASK. B-GENE-Y
CASK B-GENE-Y
was O
immunoprecipitated O
with O
P2X3 B-GENE-Y
receptors O
from O
trigeminal O
ganglia O
and O
from O

P2X3/CASK-cotransfected B-GENE-Y
HEK O
cells. O
Recombinant O
P2X3/CASK B-GENE-Y
expression O
in O
HEK O
cells O
increased O
serine B-CHEMICAL
phosphorylation O
of O
P2X3 B-GENE-Y
receptors, O
typically O
associated O
with O
receptor O
upregulation. O
CASK B-GENE-Y
deletion O
mutants O
also O
enhanced O
P2X3 B-GENE-Y
subunit O
expression. O
After O
silencing O
CASK, B-GENE-Y
cell O
surface O
P2X3 B-GENE-Y
receptor O
expression O
was O
decreased, O
which O
is O
consistent O
with O
depressed O
P2X3 B-GENE-Y
currents. O
The O
reduction O
of O
P2X3 B-GENE-Y
expression O
levels O
was O
reversed O
by O
the O
proteasomal O
inhibitor O

MG-132. B-CHEMICAL
Moreover, O
neuronal O
CASK/P2X3 B-GENE-Y
interaction O
was O
upregulated O
by O
NGF B-GENE-Y
signaling O
and O
downregulated O
by O
P2X3 B-GENE-Y
agonist-induced O
desensitization. O
These O
data O
suggest O
a O
novel O
interaction O
between O
CASK B-GENE-Y
and O
P2X3 B-GENE-Y
receptors O
with O
positive O
outcome O
for O
receptor O
stability O
and O
function. O
As O
CASK-mediated B-GENE-Y
control O
of O
P2X3 B-GENE-Y
receptors O
was O
dependent O
on O
the O
receptor O
activation O
state, O
CASK B-GENE-Y
represents O
an O
intracellular O
gateway O
to O
regulate O
purinergic O
nociceptive O
signaling. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Bile O

acids O
induce O
cdx2 B-GENE-Y
expression O
through O
the O
farnesoid B-GENE-Y
x I-GENE-Y
receptor I-GENE-Y
in O
gastric O
epithelial O
cells. O
Clinical O
and O
experimental O
studies O
showed O
that O
the O
reflux O
of O
bile O
into O
the O
stomach O
contributes O
to O
the O
induction O
of O
intestinal O
metaplasia O
of O
the O
stomach O
and O
gastric O
carcinogenesis. O
Caudal-type B-GENE-Y
homeobox I-GENE-Y
2 I-GENE-Y
(Cdx2) B-GENE-Y
plays O
a O
key O
role O
in O
the O
exhibition O
of O
intestinal O
phenotypes O
by O
regulating O
the O
expression O
of O
intestine-specific O
genes O
such O
as O
goblet-specific O
gene O
mucin B-GENE-Y
2 I-GENE-Y
(MUC2). B-GENE-Y
We O
investigated O
the O
involvement O
of O
the O

farnesoid B-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
(FXR), B-GENE-Y
a O
nuclear B-GENE-N
receptor I-GENE-N
for O
bile O
acids, O
in O
the O
chenodeoxycholic B-CHEMICAL
acid I-CHEMICAL
(CDCA)-induced B-CHEMICAL
expression O
of O
Cdx2 B-GENE-Y
and O
MUC2 B-GENE-Y
in O
normal O
rat O
gastric O
epithelial O
cells O
(RGM-1 O
cells). O
RGM-1 O
cells O
were O
treated O
with O
CDCA B-CHEMICAL
or O
GW4064, B-CHEMICAL
an O
FXR B-GENE-Y
agonist, O
in O
the O
presence O
or O
absence O
of O
guggulsterone, B-CHEMICAL
an O
FXR B-GENE-Y
antagonist. O
CDCA B-CHEMICAL
induced O
dose-dependent O
expression O
of O
Cdx2 B-GENE-Y
and O
MUC2 B-GENE-Y
at O
both O
the O
mRNA O
and O
protein O
levels. O

The O
maximum O
stimulation O
of O
Cdx2 B-GENE-Y
and O
MUC2 B-GENE-Y
mRNA O
induced O
by O
CDCA B-CHEMICAL
was O
observed O
at O
3 O
h O
and O
by O
6 O
h, O
respectively. O
GW4064 B-CHEMICAL
also O
induced O
expression O
of O
these O
molecules. O
The O
effects O
of O
CDCA B-CHEMICAL
and O
GW4064 B-CHEMICAL
on O
expression O
of O
Cdx2 B-GENE-Y
and O
MUC2 B-GENE-Y
were O
abolished O
by O
guggulsterone. B-CHEMICAL
These O
findings O
suggest O
that O
bile O
acids O
may O
induce O
gastric O
intestinal O
metaplasia O
and O
carcinogenesis O
through O
the O
FXR. B-GENE-Y
Mazindol B-CHEMICAL
analogues O
as O
potential O
inhibitors O
of O
the O
cocaine B-GENE-N
binding I-GENE-N
site I-GENE-N
at O
the O
dopamine B-GENE-Y
transporter. I-GENE-Y
A O
series O
of O

mazindol B-CHEMICAL
(2) O
and O
homomazindol B-CHEMICAL
(3) O
analogues O
with O
a O
variety O
of O
electron-donating O
and O
electron-withdrawing O
groups O
in O
the O
pendant O
aryl B-CHEMICAL
group O
and O
the O
benzo B-CHEMICAL
ring O
C, O
as O
well O
as O
H, O
methoxy, B-CHEMICAL
and O
alkyl B-CHEMICAL
groups O
replacing O
the O
hydroxyl B-CHEMICAL
group O
were O
synthesized, O
and O
their O
binding O
affinities O
at O
the O
dopamine B-GENE-N
transporter I-GENE-N
(DAT) B-GENE-N
on O
rat O
or O
guinea O
pig O
striatal O
membranes O
were O
determined. O
Several O
active O
analogues O
were O
also O
evaluated O
for O
their O
ability O
to O
block O
uptake O
of O
DA, B-CHEMICAL
5-HT, B-CHEMICAL
and O

NE B-CHEMICAL
and O
inhibit O
binding O
of O
[(125)I] B-CHEMICAL
RTI-55 I-CHEMICAL
at O
HEK-hDAT, B-GENE-Y
HEK-hSERT, B-GENE-Y
and O
HEK-hNET B-GENE-Y
cells. O
Mazindane B-CHEMICAL
(26) O
was O
found O
to O
be O
a O
pro-drug, O
oxidizing O
(5-H B-CHEMICAL
--> O
5-OH) B-CHEMICAL
to O
mazindol B-CHEMICAL
on O
rat O
striatal O
membranes O
and O
HEK-hDAT B-GENE-Y
cells. O
The O
4',7,8-trichloro B-CHEMICAL
analogue O
(38) O
of O
mazindol B-CHEMICAL
was O
the O
most O
potent O
and O
selective O

ligand O
for O
HEK-hDAT B-GENE-Y
cells O
(DAT B-GENE-Y
K(i) O
= O
1.1 O
nM; O
SERT/DAT B-GENE-Y
= O
1283 O
and O
NET/DAT B-GENE-Y
= O
38). O
Experimental O
results O
strongly O
favor O
the O
cyclic O
or O
ol O
tautomers O
of O
2 O
and O
3 O
to O
bind O
more O
tightly O
at O
the O
DAT B-GENE-Y
than O
the O
corresponding O
keto O
tautomers. O
Herbicidal O
inhibitors O
of O
amino B-CHEMICAL
acid I-CHEMICAL
biosynthesis O
and O
herbicide-tolerant O
crops. O
Acetohydroxyacid B-GENE-N
synthase I-GENE-N
(AHAS) B-GENE-N
inhibitors O
interfere O
with O
branched-chain B-CHEMICAL
amino I-CHEMICAL
acid I-CHEMICAL
biosynthesis O
by O

inhibiting O
AHAS. B-GENE-N
Glyphosate B-CHEMICAL
affects O
aromatic B-CHEMICAL
amino I-CHEMICAL
acid I-CHEMICAL
biosynthesis O
by O
inhibiting O
5-enolpyruvylshikimate-3-phosphate B-GENE-N
synthase I-GENE-N
(EPSPS). B-GENE-N
Glufosinate B-CHEMICAL
inhibits O
glutamine B-GENE-N
synthetase I-GENE-N
and O
blocks O
biosynthesis O
of O
glutamine. B-CHEMICAL
AHAS B-GENE-N
gene O
variants O
that O
confer O
tolerance O
to O
AHAS B-GENE-N
inhibitors O
have O
been O
discovered O
in O
plants O
through O
selection O
or O
mutagenesis. O
Imidazolinone-tolerant B-CHEMICAL
crops O
have O
been O
commercialized O
based O
on O
these O
AHAS B-GENE-N
gene O
variants. O
A O
modified O

maize B-GENE-Y
EPSPS I-GENE-Y
gene O
and O
CP4-EPSPS B-GENE-Y
gene O
from O
Agrobacterium O
sp. O
have O
been O
used O
to O
transform O
plants O
for O
target-based O
tolerance O
to O
glyphosate. B-CHEMICAL
A O
gox B-GENE-N
gene O
isolated O
from O
Ochrobactrum O
anthropi O
has O
also O
been O
employed O
to O
encode O
glyphosate B-GENE-N
oxidoreductase I-GENE-N
to O
detoxify O
glyphosate B-CHEMICAL
in O
plants. O
Glyphosate-tolerant B-CHEMICAL
crops O
with O
EPSPS B-GENE-N
transgene O
alone O
or O
both O
EPSPS B-GENE-N
and O
gox B-GENE-N
transgenes O
have O
been O
commercialized. O
Similarly, O
bar B-GENE-Y
and O
pat B-GENE-Y
genes O
isolated O
from O

Streptomyces O
hygroscopicus O
and O
S. O
viridochromogenes, O
respectively, O
have O
been O
inserted O
into O
plants O
to O
encode O
phosphinothricin B-GENE-N
N-acetyltransferase I-GENE-N
to O
detoxify O
glufosinate. B-CHEMICAL
Glufosinate-tolerant B-CHEMICAL
crops O
have O
been O
commercialized O
using O
one O
of O
these O
two O
transgenes. O
Mechanisms O
of O
Glucose B-CHEMICAL
Lowering O
of O
Dipeptidyl B-GENE-Y
Peptidase-4 I-GENE-Y
Inhibitor O
Sitagliptin B-CHEMICAL
When O
Used O
Alone O
or O
With O
Metformin B-CHEMICAL
in O
Type O
2 O
Diabetes: O
A O

double-tracer O
study. O
OBJECTIVETo O
assess O
glucose-lowering B-CHEMICAL
mechanisms O
of O
sitagliptin B-CHEMICAL
(S), O
metformin B-CHEMICAL
(M), O
and O
the O
two O
combined O
(M+S).RESEARCH O
DESIGN O
AND O
METHODSWe O
randomized O
16 O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
to O
four O
6-week O
treatments O
with O
placebo O
(P), O
M, O
S, O
and O
M+S. O
After O
each O
period, O
subjects O
received O
a O
6-h O
meal O
tolerance O
test O
(MTT) B-CHEMICAL
with O
[(14)C]glucose B-CHEMICAL
to O
calculate O

glucose B-CHEMICAL
kinetics. O
Fasting O
plasma O
glucose B-CHEMICAL
(FPG), O
fasting O
plasma O
insulin, B-GENE-Y
C-peptide B-GENE-Y
(insulin B-GENE-Y
secretory O
rate O
[ISR]), O
fasting O
plasma O
glucagon, B-GENE-Y
and O
bioactive O
glucagon-like B-GENE-Y
peptide I-GENE-Y
(GLP-1) B-GENE-Y
and O
gastrointestinal B-GENE-Y
insulinotropic I-GENE-Y
peptide I-GENE-Y
(GIP) B-GENE-Y
was O
measured.RESULTSFPG O
decreased O
from O
P, O
160 O
± O
4 O
to O
M, O
150 O
± O
4; O
S, O
154 O
± O
4; O
and O
M+S, O
125 O
± O
3 O
mg/dL. O
Mean O
post-MTT B-CHEMICAL
PG O
decreased O
from O

P, O
207 O
± O
5 O
to O
M, O
191 O
± O
4; O
S, O
195 O
± O
4; O
and O
M+S, O
161 O
± O
3 O
mg/dL O
(P O
< O
0.01]. O
The O
increase O
in O
mean O
post-MTT B-CHEMICAL
plasma O
insulin B-GENE-Y
and O
in O
ISR O
was O
similar O
in O
P, O
M, O
and O
S O
and O
slightly O
greater O
in O
M+S. O
Fasting O
plasma O
glucagon B-GENE-Y
was O
equal O
(∼65-75 O
pg/mL) O
with O
all O
treatments, O
but O
there O
was O
a O
significant O
drop O
during O
the O
initial O
120 O
min O
with O
S O
24% O
and O
M+S O
34% O
(both O
P O
< O
0.05) O
vs. O
P O
17% O

and O
M O
16%. O
Fasting O
and O
mean O
post-MTT B-CHEMICAL
plasma O
bioactive O
GLP-1 B-GENE-Y
were O
higher O
(P O
< O
0.01) O
after O
S O
and O
M+S O
vs. O
M O
and O
P. O
Basal O
endogenous O
glucose B-CHEMICAL
production O
(EGP) O
fell O
from O
P O
2.0 O
± O
0.1 O
to O
S O
1.8 O
± O
0.1 O
mg/kg O
⋅ O
min, O
M O
1.8 O
± O
0.2 O
mg/kg O
⋅ O
min O
[both O
P O
< O
0.05 O
vs. O
P), O
and O
M+S O
1.5 O
± O
0.1 O
mg/kg O
⋅ O
min O
(P O
< O
0.01 O
vs. O

P). O
Although O
the O
EGP O
slope O
of O
decline O
was O
faster O
in O
M O
and O
M+S O
vs. O
S, O
all O
had O
comparable O
greater O
post-MTT O
EGP O
inhibition O
vs. O
P O
(P O
< O
0.05).CONCLUSIONSM+S O
combined O
produce O
additive O
effects O
to O
1) O
reduce O
FPG O
and O
postmeal O
PG, O
2) O
augment O
GLP-1 B-GENE-Y
secretion O
and O
β-cell O
function, O
3) O
decrease O
plasma O
glucagon, B-GENE-Y
and O
4) O
inhibit O
fasting O
and O
postmeal O
EGP O
compared O
with O
M O
or O
S O
monotherapy. O
Modulation O
of O
cytochrome B-GENE-N

P450 I-GENE-N
1 I-GENE-N
(Cyp1) B-GENE-N
by O
vanadium B-CHEMICAL
in O
hepatic O
tissue O
and O
isolated O
hepatocyte O
of O
C57BL/6 O
mice. O
The O
objective O
of O
the O
current O
study O
was O
to O
investigate O
the O
effect O
of O
vanadium B-CHEMICAL
(V(5+)) B-CHEMICAL
on O
Cyp1 B-GENE-N
expression O
and O
activity O
in O
C57BL/6 O
mice O
liver O
and O
isolated O
hepatocytes. O
For O
this O
purpose, O
C57BL6 O
mice O
were O
injected O
intraperitoneally O
with O
V(5+) B-CHEMICAL
(5 O
mg/kg) O
in O
the O
absence O
and O
presence O
of O

2,3,7,8-tetrachlorodibenzo-p-dioxin B-CHEMICAL
(TCDD) B-CHEMICAL
(15 O
μg/kg) O
for O
6 O
and O
24 O
h. O
Furthermore, O
isolated O
hepatocytes O
from O
C57BL6 O
mice O
were O
treated O
with O
V(5+) B-CHEMICAL
(5, O
10, O
and O
20 O
μM) O
in O
the O
absence O
and O
presence O
of O
TCDD B-CHEMICAL
(1 O
nM) O
for O
3, O
6, O
12, O
and O
24 O
h. O
In O
vivo, O
V(5+) B-CHEMICAL
alone O
did O
not O
significantly O
alter O
Cyp1a1, B-GENE-Y
Cyp1a2, B-GENE-Y
or O

Cyp1b1 B-GENE-Y
mRNA, O
protein, O
or O
catalytic O
activity O
levels. O
Upon O
co-exposure O
to O
V(5+) B-CHEMICAL
and O
TCDD, B-CHEMICAL
V(5+) B-CHEMICAL
significantly O
potentiated O
the O
TCDD-mediated B-CHEMICAL
induction O
of O
the O
Cyp1a1, B-GENE-Y
Cyp1a2, B-GENE-Y
and O
Cyp1b1 B-GENE-Y
mRNA, O
protein, O
and O
catalytic O
activity O
levels O
at O
24 O
h. O
In O
vitro, O
V(5+) B-CHEMICAL
decreased O
the O
TCDD-mediated B-CHEMICAL
induction O
of O
Cyp1a1 B-GENE-Y
mRNA, O
protein, O
and O
catalytic O
activity O
levels. O
Furthermore, O
V(5+) B-CHEMICAL
significantly O
inhibited O

the O
TCDD-induced B-CHEMICAL
AhR-dependent B-GENE-Y
luciferase O
activity. O
V(5+) B-CHEMICAL
also O
increased O
serum B-GENE-N
hemoglobin I-GENE-N
(Hb) B-GENE-N
levels O
in O
animals O
treated O
for O
24 O
h. O
Upon O
treatment O
of O
isolated O
hepatocytes O
with O
Hb B-GENE-N
alone O
or O
in O
the O
presence O
of O
TCDD, B-CHEMICAL
there O
was O
an O
increase O
in O
the O
AhR-dependent B-GENE-Y
luciferase O
activity. O
When O
isolated O
hepatocytes O
were O
treated O
for O
2 O
h O
with O
V(5+) B-CHEMICAL
in O
the O
presence O
of O
TCDD, B-CHEMICAL
followed O
by O
replacement O
of O
the O
medium O
with O
new O
medium O
containing O
Hb, B-GENE-N
there O
was O
further O
potentiation O
to O
the O

TCDD-mediated B-CHEMICAL
effect. O
The O
present O
study O
demonstrates O
that O
there O
is O
a O
differential O
modulation O
of O
Cyp1a1 B-GENE-Y
by O
V(5+) B-CHEMICAL
in O
C57BL/6 O
mice O
livers O
and O
isolated O
hepatocytes O
and O
demonstrates O
Hb B-GENE-N
as O
an O
in O
vivo O
specific O
modulator. O
Glucocorticosteroids O
affect O
functions O
of O
airway- O
and O
blood-derived O
human O
T-cell O
clones, O
favoring O
the O
Th1 O
profile O
through O
two O
mechanisms. O
Glucocorticosteroids O
(GCS) B-CHEMICAL
are O
beneficial O
in O
allergic O
asthma. O
GCS B-CHEMICAL
therapy O
results O
in O
reduced O

mRNA O
expression O
of O
interleukin-4 B-GENE-Y
(IL-4) B-GENE-Y
and O
IL-5 B-GENE-Y
in O
cells O
from O
bronchoalveolar O
lavage O
(BAL) O
but O
not O
of O
IFN-gamma. B-GENE-Y
In O
vitro O
studies O
with O
blood-derived O
T O
cells, O
however, O
show O
inhibition O
of O
all O
three O
cytokines B-GENE-N
by O
GCS. B-CHEMICAL
We O
studied O
the O
effects O
of O
GCS B-CHEMICAL
on O
T O
cells O
from O
BAL O
in O
vitro, O
namely O
Th0-, O
Th1, O
and O
Th2-like O
clones; O
and O
we O
compared O
BAL- O
with O
blood-derived O
clones. O
Dexamethasone B-CHEMICAL

(DEX) B-CHEMICAL
inhibited O
the O
anti-CD3-induced B-GENE-N
production O
of O
IL-4, B-GENE-Y
IL-5 B-GENE-Y
and O
IFN-gamma B-GENE-Y
in O
all O
20 O
clones O
tested. O
IFN-gamma B-GENE-Y
production O
was O
inhibited O
significantly O
less O
than O
IL-4 B-GENE-Y
and O
IL-5. B-GENE-Y
DEX B-CHEMICAL
enhanced O
the O
ratio O
IFN-gamma/IL-4 B-GENE-Y
(mean O
+/- O
SEM: O
control, O
28.7 O
+/- O
17.6; O
with O
10-7 O
M O
DEX, O
55.0 O
+/- O
27.5, O
P<0.005). O
Interestingly, O
two O
categories O
of O
clones O
were O
distinguished O
based O
on O

the O
effects O
of O
GCS B-CHEMICAL
on O
IL-2 B-GENE-Y
production O
and O
IL-2R B-GENE-Y
alpha I-GENE-Y
expression O
and O
proliferation; O
1) O
In O
low O
IL-2 B-GENE-Y
producers O
DEX B-CHEMICAL
blocked O
IL-2 B-GENE-Y
production O
and O
decreased O
IL-2R B-GENE-Y
alpha I-GENE-Y
expression O
and O
proliferation; O
2) O
In O
high O
IL-2 B-GENE-Y
producers O
DEX B-CHEMICAL
inhibited O
IL-2 B-GENE-Y
production O
partially O
and O
enhanced O
IL-2R B-GENE-Y
alpha I-GENE-Y
expression O
and O
proliferation. O
Anti-IL-2 B-GENE-Y
and O
anti-IL2R B-GENE-Y
alpha I-GENE-Y
blocked O
the O
DEX-induced B-CHEMICAL
increase O
in O
proliferation. O
High O
levels O
of O
added O
IL-2 B-GENE-Y
induced O
the O
second O
type O
of O
response. O
In O
conclusion, O
the O
production O
of O
IL-4 B-GENE-Y
and O
IL-5 B-GENE-Y
by O

T-cell O
clones O
(derived O
either O
from O
BAL O
or O
blood) O
was O
more O
sensitive O
to O
inhibition O
by O
DEX B-CHEMICAL
than O
that O
of O
IFN-gamma, B-GENE-Y
which O
may O
account O
for O
the O
therapeutic O
effects O
of O
glucocorticosteroids O
in O
patients O
with O
asthma. O
The O
differential O
effects O
of O
DEX B-CHEMICAL
on O
the O
proliferation O
of O
high O
and O
low O
IL-2 B-GENE-Y
producers O
in O
vitro O
may O
implicate O
a O
selective O
outgrowth O
of O
Th1-like O
T O
cells O
in O
vivo O
in O
patients O
treated O
with O
steroids. B-CHEMICAL
Pregnane B-GENE-Y
X I-GENE-Y
Receptor I-GENE-Y
Mediates O
Dyslipidemia O
Induced O
by O
the O
HIV B-GENE-N
Protease I-GENE-N

Inhibitor O
Amprenavir B-CHEMICAL
in O
Mice. O
HIV B-GENE-Y
protease I-GENE-Y
inhibitors O
(PIs) O
have O
been O
used O
successfully O
in O
extending O
the O
lifespan O
of O
people O
infected O
with O
HIV. O
The O
use O
of O
PIs O
has O
also O
been O
associated O
with O
dyslipidemia O
and O
an O
increased O
risk O
of O
cardiovascular O
disease O
but O
the O
underlying O
mechanisms O
remain O
elusive. O
Several O
PIs O
have O
been O
implicated O
to O
activate O
the O
nuclear O
receptor O
pregnane B-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
(PXR), B-GENE-Y
which O
acts O
as O
a O
xenobiotic O
sensor O
to O
regulate O
xenobiotic O
metabolism O
in O
the O
liver O
and O
intestine. O
Recent O
studies O
indicate O
that O
PXR B-GENE-Y
may O
also O
play O
an O
important O

role O
in O
the O
regulation O
of O
lipid O
homeostasis. O
In O
the O
present O
study, O
we O
identified O
amprenavir, B-CHEMICAL
a O
widely O
used O
HIV O
PI, O
as O
a O
potent O
PXR-selective B-GENE-Y
agonist. O
Computational O
docking O
studies O
combined O
with O
site-direct O
mutagenesis O
identified O
several O
key O
residues O
within O
the O
ligand O
binding O
pocket O
of O
PXR B-GENE-Y
that O
constitute O
points O
of O
interaction O
with O
amprenavir. B-CHEMICAL
Amprenavir B-CHEMICAL
efficiently O
activated O
PXR B-GENE-Y
and O
induced O
PXR B-GENE-Y
target O
gene O
expression O
in O
vitro O
and O
in O
vivo. O
Short-term O
exposure O
to O
amprenavir B-CHEMICAL
significantly O
increased O
plasma O
total O
cholesterol B-CHEMICAL
and O

atherogenic O
low-density O
lipoprotein O
cholesterol B-CHEMICAL
levels O
in O
wild-type O
mice, O
but O
not O
in O
PXR-deficient B-GENE-Y
mice. O
Amprenavir-mediated B-CHEMICAL
PXR B-GENE-Y
activation O
stimulated O
the O
expression O
of O
several O
key O
intestinal O
genes O
involved O
in O
lipid O
homeostasis. O
These O
findings O
provide O
critical O
mechanistic O
insight O
for O
understanding O
the O
impact O
of O
PIs O
on O
cardiovascular O
disease O
and O
demonstrate O
a O
potential O
role O
of O
PXR B-GENE-Y
in O
mediating O
adverse O
effects O
of O
HIV O
PIs O
in O
humans. O
Charge O
screening O
between O
anionic O
and O
cationic O
surfactants O
in O
ionic O
liquids. O
The O
aggregation O

and O
interfacial O
behavior O
of O
mixtures O
of O
anionic O
(sodium B-CHEMICAL
dodecylsulfate, I-CHEMICAL
SDS) B-CHEMICAL
and O
cationic O
(dodecylammonium B-CHEMICAL
bromide, I-CHEMICAL
DTAB) B-CHEMICAL
surfactants O
were O
investigated. O
A O
room-temperature O
ionic O
liquid O
(IL) O
was O
explored O
as O
a O
solvent O
for O
the O
SDS/DTAB B-CHEMICAL
system O
and O
compared O
to O
water. O
The O
critical O
micelle O
concentration O
(cmc) O
and O
composition O
in O
mixed O
micelles O
were O
determined O
for O
both O
solvents. O
Our O
experiments O
showed O
nearly O
ideal O
mixing O
of O
SDS/DTAB B-CHEMICAL
over O
the O
entire O
composition O
range O
and O
suggest O
that O
charge O
screening O
is O
prominent O
in O

ILs. O
This O
behavior O
is O
in O
sharp O
contrast O
to O
the O
strong O
electrostatic O
attraction O
and O
a O
multiphase O
composition O
gap O
in O
water. O
Two O
models O
by O
Clint O
and O
Rubingh, O
which O
describe O
ideal O
and O
nonideal O
micellar O
behavior, O
respectively, O
are O
discussed O
on O
the O
basis O
of O
our O
results. O
According O
to O
Rubingh's O
model, O
the O
composition O
of O
mixed O
micelles O
is O
gradually O
changing O
with O
the O
bulk O
composition O
in O
ILs O
but O
tends O
to O
be O
a O
1:1 O
ratio O
in O
water. O
The O
results O
here O
are O
further O
support O
of O
the O
strong O
charge O
screening O
in O
ionic O
liquids. O
Anti-diabetic O
Activity O
of O
Swertiamarin B-CHEMICAL
is O
due O
to O
an O
Active O

Metabolite, O
Gentianine, B-CHEMICAL
that O
Upregulates O
PPAR-γ B-GENE-Y
Gene O
Expression O
in O
3T3-L1 O
cells. O
We O
have O
previously O
shown O
the O
anti-diabetic O
effects O
of O
swertiamarin; B-CHEMICAL
however, O
pharmacokinetic O
analysis O
showed O
that O
swertiamarin B-CHEMICAL
had O
a O
plasma O
half-life O
of O
1.3 O
h. O
Gentianine B-CHEMICAL
is O
an O
active O
metabolite O
of O
swertiamarin B-CHEMICAL
that O
possesses O
a O
pharmacophoric O
moiety. O
The O
aim O
of O
this O
study O
was O
to O
explore O
the O
possibility O
whether O
the O
anti-diabetic O
effect O
of O

swertiamarin B-CHEMICAL
is O
due O
to O
gentianine. B-CHEMICAL
Swertiamarin B-CHEMICAL
treatment O
had O
no O
significant O
effect O
on O
adipogenesis, O
or O
the O
mRNA O
expression O
of O
PPAR-γ B-GENE-Y
and O
GLUT-4; B-GENE-Y
however, O
there O
was O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
adiponectin. B-GENE-Y
On O
the O
other O
hand, O
treatment O
with O
gentianine B-CHEMICAL
significantly O
increased O
adipogenesis, O
which O
was O
associated O
with O
a O
significant O
increase O
in O
the O
mRNA O
expression O
of O
PPAR-γ, B-GENE-Y
GLUT-4 B-GENE-Y
and O
adiponectin. B-GENE-Y
These O
findings O
suggest, O
for O
the O
first O
time, O
that O
the O

anti-diabetic O
effect O
of O
swertiamarin B-CHEMICAL
is O
due O
to O
gentianine, B-CHEMICAL
an O
active O
metabolite O
of O
swertiamarin. B-CHEMICAL
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons, O
Ltd. O
[Brugada O
syndrome]. O
In O
1992 O
we O
described O
a O
new O
syndrome O
consisting O
of O
syncopal O
episodes O
and/or O
sudden O
death O
in O
patients O
with O
a O
structurally O
normal O
heart O
and O
a O
characteristic O
electrocardiogram O
displaying O
a O
pattern O
resembling O
right O
bundle O
branch O
block O
with O
an O
ST O
segment O
elevation O
in O
leads O
V1 O
to O
V3. O
In O
1998 O
it O
was O
described O
that O
the O
disease O
is O
genetically O
determined O
with O
an O
autosomal O
dominant O
pattern O
of O
transmission. O
Three O

different O
mutations O
have O
been O
identified. O
All O
three O
mutations O
affect O
the O
structure O
and O
the O
function O
of O
the O
sodium B-GENE-N
channel I-GENE-N
SCN5A. B-GENE-Y
Two O
mutations O
result O
in O
total O
loss O
of O
function O
of O
the O
sodium B-GENE-N
channel. I-GENE-N
The O
other O
mutation O
results O
in O
acceleration O
of O
the O
recovery O
of O
the O
sodium B-GENE-N
channel I-GENE-N
from O
inactivation. O
The O
disease O
causes O
4 O
to O
10 O
sudden O
deaths O
per O
10,000 O
inhabitants O
per O
year O
in O
areas O
like O
Thailand O
and O
Laos. O
Up O
to O
50% O
of O
the O
yearly O
sudden O
deaths O
in O
patients O
with O
a O
normal O
heart O
might O
be O
caused O
by O
this O
syndrome. O
The O
diagnosis O
is O
easily O
made O
by O
means O
of O
the O
electrocardiogram O
(ECG). O
The O
presence O
of O
concealed O
and O
intermittent O
forms, O

however, O
makes O
the O
diagnosis O
difficult O
in O
some O
patients. O
The O
ECG O
can O
be O
modulated O
by O
changes O
in O
autonomic O
balance O
and O
the O
administration O
of O
antiarrhythmic O
drugs. O
Beta-adrenergic O
stimulation O
normalises O
the O
ECG, O
while O
i.v. O
ajmaline, B-CHEMICAL
flecainide B-CHEMICAL
or O
procainamide B-CHEMICAL
accentuate O
the O
ST O
segment O
elevation O
and O
are O
capable O
of O
unmasking O
concealed O
and O
intermittent O
forms O
of O
the O
disease. O
The O
prognosis O
is O
poor O
for O
patients O
who O
do O
not O
receive O
an O
implantable O
cardioverter-defibrillator. O
Antiarrhythmic O
drugs O
like O

amiodarone B-CHEMICAL
or O
beta-blockers O
do O
not O
prevent O
sudden O
death O
in O
symptomatic O
or O
asymptomatic O
individuals. O
The O
effects O
of O
jaspamide B-CHEMICAL
on O
human O
cardiomyocyte O
function O
and O
cardiac B-GENE-N
ion I-GENE-N
channel I-GENE-N
activity. O
Jaspamide B-CHEMICAL
(jasplakinolide; B-CHEMICAL
NSC-613009) B-CHEMICAL
is O
a O
cyclodepsipeptide B-CHEMICAL
that O
has O
antitumor O
activity. O
A O
narrow O
margin O
of O
safety O
was O
observed O
between O
doses O
required O
for O
efficacy O
in O
mouse O
tumor O
models O
and O
doses O
that O
caused O
severe O
acute O
toxicity O
in O
rats O
and O
dogs. O
We O
explored O
the O
hypothesis O
that O
the O
observed O
toxicity O
was O
due O

to O
cardiotoxicity. O
Jaspamide B-CHEMICAL
was O
tested O
in O
a O
patch O
clamp O
assay O
to O
determine O
its O
effect O
on O
selected O
cardiac B-GENE-N
ion I-GENE-N
channels. I-GENE-N
Jaspamide B-CHEMICAL
(10 O
μM) O
inhibited O
Kv1.5 O
activity O
by O
98.5%. O
Jaspamide B-CHEMICAL
also O
inhibited O
other O
channels O
including O
Cav1.2, B-GENE-N
Cav3.2, B-GENE-N
and O
HCN2; B-GENE-N
however, O
the O
Kv11.1 B-GENE-Y
(hERG) B-GENE-Y
channel O
was O
minimally O
affected. O
Using O
spontaneously O
contracting O
human O
cardiomyocytes O
derived O
from O
induced O
pluripotent O
stem O
cells, O
effects O
on O

cardiomyocyte O
contraction O
and O
viability O
were O
also O
examined. O
Jaspamide B-CHEMICAL
(30 O
nM O
to O
30 O
μM) O
decreased O
cardiomyocyte O
cell O
indices O
and O
beat O
amplitude, O
putative O
measurements O
of O
cell O
viability O
and O
cardiac O
contractility, O
respectively. O
Concentration-dependent O
increases O
in O
rhythmic O
beating O
rate O
were O
noted O
at O
≤ O
6 O
h O
of O
treatment, O
followed O
by O
dose-dependent O
decreases O
after O
6 O
and O
72 O
h O
exposure. O
The O
toxic O
effects O
of O
jaspamide B-CHEMICAL
were O
compared O
with O
that O
of O
the O
known O
cardiotoxicant O
mitoxantrone, B-CHEMICAL
and O
confirmed O
by O
multiparameter O
fluorescence O
imaging O
analysis. O
These O

results O
support O
the O
hypothesis O
that O
the O
toxicity O
observed O
in O
rats O
and O
dogs O
is O
due O
to O
toxic O
effects O
of O
jaspamide B-CHEMICAL
on O
cardiomyocytes. O
Carvedilol B-CHEMICAL
modulates O
the O
expression O
of O
hypoxia-inducible B-GENE-Y
factor-1alpha I-GENE-Y
and O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
in O
a O
rat O
model O
of O
volume-overload O
heart O
failure. O
BACKGROUND: O
The O
use O
of O
beta-blockers O
has O
emerged O
as O
a O
beneficial O
treatment O
for O
congestive O
heart O
failure. O
Hypoxia-inducible B-GENE-Y
factor-1alpha I-GENE-Y
(HIF-1alpha) B-GENE-Y
is O
tightly O
regulated O
in O
the O

ventricular O
myocardium. O
However, O
the O
expression O
of O
HIF-1alpha B-GENE-Y
in O
chronic O
heart O
failure O
resulting O
from O
volume O
overload O
and O
after O
treatment O
with O
beta-blocker O
is O
little O
known. O
METHODS O
AND O
RESULTS: O
To O
test O
the O
hypothesis O
that O
HIF-1alpha B-GENE-Y
plays O
a O
role O
in O
the O
failing O
myocardium O
because O
of O
volume O
overload, O
an O
aorta-caval O
shunt O
was O
created O
for O
4 O
weeks O
in O
adult O
Sprague-Dawley O
rats O
to O
induce O
volume-overload O
heart O
failure. O
Carvedilol B-CHEMICAL
at O
50 O
mg/kg O
body O
weight O
per O
day O
after O
surgery O

was O
given. O
The O
heart O
weight O
and O
body O
weight O
ratio O
increased O
from O
2.6 O
+/- O
0.3 O
in O
the O
sham O
group O
to O
3.9 O
+/- O
0.7 O
(P O
< O
.001) O
in O
the O
shunt O
group. O
Left O
ventricular O
end-diastolic O
dimension O
increased O
from O
6.5 O
+/- O
0.5 O
mm O
to O
8.7 O
+/- O
0.6 O
mm O
(P O
< O
.001). O
Treatment O
with O
carvedilol B-CHEMICAL
in O
the O
shunt O
group O
reversed O
the O
heart O
weight O
and O
ventricular O
dimension O
to O
the O
baseline O
values. O
Western O
blot O
showed O
that O

HIF-1alpha, B-GENE-Y
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF), B-GENE-Y
and O
brain B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(BNP) B-GENE-Y
proteins O
were O
upregulated O
and O
nerve B-GENE-Y
growth I-GENE-Y
factor-beta I-GENE-Y
(NGF-beta) B-GENE-Y
downregulated O
in O
the O
shunt O
group. O
Real-time O
polymerase O
chain O
reaction O
showed O
that O
mRNA O
of O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
and O
BNP B-GENE-Y
increased O
and O
mRNA O
of O
NGF-beta B-GENE-Y
decreased O
in O
the O
shunt O
group. O
Treatment O
with O
carvedilol B-CHEMICAL
reversed O
both O
protein O
and O
mRNA O
of O
HIF-1alpha, B-GENE-Y

VEGF, B-GENE-Y
BNP, B-GENE-Y
and O
NGF-beta B-GENE-Y
to O
the O
baseline O
values. O
Increased O
immunohistochemical O
labeling O
of O
HIF-1alpha, B-GENE-Y
VEGF, B-GENE-Y
and O
BNP B-GENE-Y
in O
the O
ventricular O
myocardium O
was O
observed O
in O
the O
shunt O
group O
and O
carvedilol B-CHEMICAL
again O
normalized O
the O
labeling. O
CONCLUSION: O
HIF-1alpha B-GENE-Y
and O
VEGF B-GENE-Y
mRNA O
and O
protein O
expression O
were O
upregulated O
in O
the O
rat O
model O
of O
volume-overload O
heart O
failure. O
Treatment O
with O
carvedilol B-CHEMICAL
is O
associated O
with O
a O
reversal O
of O
abnormal O
regulation O
of O

HIF-1alpha B-GENE-Y
and O
VEGF B-GENE-Y
in O
the O
failing O
ventricular O
myocardium. O
Apoptosis O
induced O
by O
oxidized O
lipids O
is O
associated O
with O
up-regulation O
of O
p66Shc B-GENE-Y
in O
intestinal O
Caco-2 O
cells: O
protective O
effects O
of O
phenolic B-CHEMICAL
compounds. O
In O
this O
study, O
we O
investigated O
the O
alterations O
of O
the O
redox O
balance O
induced O
by O
the O
lipid O
fraction O
of O
oxLDL B-GENE-N
in O
Caco-2 O
intestinal O
cells, O
and O
the O
effects O
of O
tyrosol B-CHEMICAL
and O
protocatechuic B-CHEMICAL
acid, I-CHEMICAL
two O
dietary O
phenolic B-CHEMICAL
compounds. O
We O
found O
that O
oxidized O

lipids O
extracted O
from O
oxLDL B-GENE-N
(LipE) B-GENE-Y
induced O
oxidative O
stress O
by O
determining, O
6 O
h O
after O
treatment, O
ROS O
overproduction O
(about O
a O
100% O
and O
a O
43% O
increase O
of O
O*2 B-CHEMICAL
and O
H2O2 B-CHEMICAL
production, O
respectively, O
P<.05: O
LipE B-GENE-Y
vs. O
control) O
and, O
12 O
h O
after O
treatment, O
GSH O
depletion O
(about O
a O
26% O
decrease, O
P<.05: O
LipE B-GENE-Y
vs. O
control), O
and O
by O
impairing O
the O
activities O
of O
superoxide B-GENE-N
dismutase, I-GENE-N
catalase B-GENE-Y
and O
glutathione B-GENE-N

peroxidase. I-GENE-N
In O
response O
to O
the O
induced O
oxidative O
stress, O
we O
observed O
significant O
overexpression O
of O
glutathione B-GENE-N
peroxidase I-GENE-N
(6 O
h O
after O
treatment: O
P<.05), O
glutathione B-GENE-N
reductase I-GENE-N
and O
gamma-glutamylcysteine B-GENE-Y
synthetase I-GENE-Y
(12 O
h O
after O
treatment: O
P<.05). O
Notably, O
when O
GSH O
depletion O
occurred, O
p66Shc B-GENE-Y
protein O
expression O
increased O
by O
about O
300% O
with O
respect O
to O
control O
(P<.001; O
LipE B-GENE-Y
vs. O
control). O
These O
effects O
were O
fully O

counteracted O
by O
dietary O
phenolics B-CHEMICAL
which O
inhibited O
ROS O
overproduction O
and O
GSH O
consumption, O
rendered O
the O
reactive O
transcription O
of O
glutathione-associated B-CHEMICAL
enzymes O
unnecessary O
and O
blocked O
the O
intracellular O
signals O
leading O
to O
the O
overexpression O
and O
rearrangement O
of O
p66Shc B-GENE-Y
signalling O
molecule. O
Altogether, O
these O
results O
suggest O
that O
the O
impairment O
of O
the O
antioxidant O
system O
hijacks O
intestinal O
cells O
towards O
an O
apoptotic-prone O
phenotype O
via O
the O
activation O
of O
p66Shc B-GENE-Y
molecule. O
They O
also O
propose O
a O
reappraisal O
of O

dietary O
polyphenols B-CHEMICAL
as O
intestinal O
protecting O
agents, O
indicating O
the O
antiapoptotic O
effect O
as O
a O
further O
mechanism O
of O
action O
of O
these O
antioxidant O
compounds. O
Serine B-GENE-N
racemases I-GENE-N
from O
barley, O
Hordeum O
vulgare O
L., O
and O
other O
plant O
species O
represent O
a O
distinct O
eukaryotic O
group: O
gene O
cloning O
and O
recombinant O
protein O
characterization. O
Several O
d-amino B-CHEMICAL
acids I-CHEMICAL
have O
been O
identified O
in O
plants. O
However, O
the O
biosynthetic O
pathway O
to O
them O
is O
unclear. O
In O
this O
study, O
we O
cloned O
and O
sequenced O
a O
cDNA O
encoding O
a O
serine B-GENE-Y
racemase I-GENE-Y
from O

barley O
which O
contained O
an O
open O
reading O
frame O
encoding O
337 O
amino B-CHEMICAL
acid I-CHEMICAL
residues. O
The O
deduced O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
showed O
significant O
identity O
to O
plant O
and O
mammalian O
serine B-GENE-N
racemases I-GENE-N
and O
contained O
conserved O
pyridoxal B-CHEMICAL
5-phosphate I-CHEMICAL
(PLP)-binding B-CHEMICAL
lysine B-CHEMICAL
and O
PLP-interacting B-CHEMICAL
amino B-CHEMICAL
acid I-CHEMICAL
residues. O
The O
purified O
gene O
product O
catalyzed O
not O
only O
racemization O
of O
serine B-CHEMICAL
but O
also O
dehydration O
of O
serine B-CHEMICAL
to O
pyruvate. B-CHEMICAL
The O
enzyme O
requires O
PLP B-CHEMICAL
and O
divalent O
cations O
such O
as O
Ca(2+), B-CHEMICAL
Mg(2+), B-CHEMICAL
or O

Mn(2+), B-CHEMICAL
but O
not O
ATP, B-CHEMICAL
whereas O
mammalian O
serine B-GENE-N
racemase I-GENE-N
activity O
is O
increased O
by O
ATP. B-CHEMICAL
In O
addition O
to O
the O
results O
regarding O
the O
effect O
of O
ATP B-CHEMICAL
on O
enzyme O
activity O
and O
the O
phylogenetic O
analysis O
of O
eukaryotic O
serine B-GENE-N
racemases, I-GENE-N
the O
antiserum O
against O
Arabidopsis B-GENE-Y
serine I-GENE-Y
racemase I-GENE-Y
did O
not O
form O
a O
precipitate O
with O
barley O
and O
rice O
serine B-GENE-N
racemases. I-GENE-N
This O
suggests O
that O
plant O
serine B-GENE-N
racemases I-GENE-N
represent O
a O
distinct O
group O
in O
the O
eukaryotic O
serine B-GENE-N
racemase I-GENE-N
family O
and O
can O
be O
clustered O
into O
monocot O
and O
dicot O
types. O

Characterization O
of O
renal O
ecto-phosphodiesterase. B-GENE-N
In O
kidneys, O
stimulation O
of O
adenylyl B-GENE-N
cyclase I-GENE-N
causes O
egress O
of O
cAMP, B-CHEMICAL
conversion O
of O
cAMP B-CHEMICAL
to O
AMP B-CHEMICAL
by O
ecto-phosphodiesterase, B-GENE-N
and O
metabolism O
of O
AMP B-CHEMICAL
to O
adenosine B-CHEMICAL
by O
ecto-5'-nucleotidase. B-GENE-Y
Although O
much O
is O
known O
about O
ecto-5'-nucleotidase, B-GENE-Y
the O
renal O
ecto-phosphodiesterase B-GENE-N
remains O
uncharacterized. O
We O
administered O

cAMP B-CHEMICAL
(10 O
microM O
in O
the O
perfusate) O
to O
12 O
different O
groups O
of O
perfused O
kidneys. O
AMP B-CHEMICAL
was O
measured O
in O
perfusate O
using O
ion O
trap O
mass O
spectrometry. O
In O
control O
kidneys O
(n=19), O
basal O
renal O
secretion O
rate O
of O
AMP B-CHEMICAL
was O
0.49+/-0.08 O
and O
increased O
to O
3.0+/-0.2 O
nmol O
AMP/g B-CHEMICAL
kidney O
weight/min O
during O
administration O
of O
cAMP. B-CHEMICAL
A O
broad-spectrum O
phosphodiesterase B-GENE-N
(PDE) B-GENE-N
inhibitor O

(1,3-isobutyl-1-methylxanthine, B-CHEMICAL
300 O
microM, O
n=6) O
and O
an O
ecto-phosphodiesterase O
inhibitor O
(1,3-dipropyl-8-p-sulfophenylxanthine, B-CHEMICAL
1 O
mM, O
n=6) O
significantly O
attenuated O
cAMP-induced B-CHEMICAL
AMP B-CHEMICAL
secretion O
by O
60 O
and O
74%, O
respectively. O
Blockade O
of O
PDE1 B-GENE-N
(8-methoxymethyl-3-isobutyl-1-methylxanthine, B-CHEMICAL
100 O
microM), O

PDE2 B-GENE-N
[erythro-9-(2-hydroxy-3-nonyl)adenine, B-CHEMICAL
30 O
microM], O
PDE3 B-GENE-N
(milrinone, B-CHEMICAL
10 O
microM; O
cGMP, O
10 O
microM), O
PDE4 B-GENE-N
(Ro O
20-1724 O
[4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], B-CHEMICAL
100 O
microM), O
PDE5 B-GENE-Y
and O
PDE6 B-GENE-N
(zaprinast, B-CHEMICAL
30 O
microM), O
and O
PDE7 B-GENE-N

[BRL-50481 B-CHEMICAL
(5-nitro-2,N,N-trimethylbenzenesulfonamide), B-CHEMICAL
10 O
microM] O
did O
not O
alter O
renal O
ecto-phosphodiesterase B-GENE-N
activity. O
Administration O
of O
a O
concentration O
(100 O
microM) O
of O
dipyridamole B-CHEMICAL
that O
blocks O
PDE8 B-GENE-N
inhibited O
ecto-phosphodiesterase B-GENE-N
activity O
(by O
44%). O
However, O
a O
lower O
concentration O
of O
dipyridamole B-CHEMICAL
(3 O
microM) O
that O
blocks O
PDE9, B-GENE-N
PDE10, B-GENE-Y
and O
PDE11, B-GENE-Y
but O
not O

PDE8, B-GENE-N
did O
not O
inhibit O
ecto-phosphodiesterase B-GENE-N
activity. O
These O
data O
support O
the O
conclusion O
that O
renal O
ecto-phosphodiesterase B-GENE-N
activity O
is O
not O
mediated O
by O
PDE1, B-GENE-N
PDE2, B-GENE-N
PDE3, B-GENE-N
PDE4, B-GENE-N
PDE5, B-GENE-Y
PDE6, B-GENE-N
PDE7, B-GENE-N
PDE9, B-GENE-N
PDE10, B-GENE-Y
or O
PDE11 B-GENE-Y
and O
is O
inhibited O
by O
high O
concentrations O
of O
dipyridamole. B-CHEMICAL
Ecto-phosphodiesterase B-GENE-N
has O
some O
pharmacological O
characteristics O
similar O
to O
PDE8. O
Hyperglycemia O

slows O
embryonic O
growth O
and O
suppresses O
cell O
cycle O
via O
cyclin B-GENE-Y
D1 I-GENE-Y
and O
p21. B-GENE-Y
In O
pregnant O
women, O
the O
diabetic O
condition O
results O
in O
a O
three- O
to O
fivefold O
increased O
risk O
for O
fetal O
cardiac O
malformations O
as O
a O
result O
of O
elevated O
glucose B-CHEMICAL
concentrations O
and O
the O
resultant O
osmotic O
stress O
in O
the O
developing O
embryo O
and O
fetus. O
Heart O
development O
before O
septation O
in O
the O
chick O
embryo O
was O
studied O
under O
two O
hyperglycemic O
conditions. O
Pulsed O
hyperglycemia O
induced O
by O
daily O
administration O
of O
glucose B-CHEMICAL
during O
3 O
days O
of O
development O
caused O
daily O
spikes O
in O
plasma O
glucose B-CHEMICAL
concentration. O
In O

a O
second O
model, O
sustained O
hyperglycemia O
was O
induced O
with O
a O
single O
injection O
of O
glucose B-CHEMICAL
into O
the O
yolk O
on O
day O
0. O
The O
sustained O
model O
raised O
the O
average O
plasma O
glucose B-CHEMICAL
concentration O
from O
70 O
mg/dL O
to O
180 O
mg/dL O
and O
led O
to O
decreased O
gene O
expression O
of O
glucose B-GENE-N
transporter I-GENE-N
GLUT1. B-GENE-Y
Both O
models O
of O
hyperglycemia O
reduced O
embryo O
size, O
increased O
mortality, O
and O
delayed O
development. O
Within O
the O
heart O
outflow O
tract, O
reduced O
proliferation O
of O
myocardial O
and O
endocardial O
cells O
resulted O
from O
the O
sustained O
hyperglycemia O
and O
hyperosmolarity. O
The O
cell O
cycle O
inhibitor O
p21 B-GENE-Y

was O
significantly O
increased, O
whereas O
cyclin B-GENE-Y
D1, I-GENE-Y
a O
cell O
cycle O
promoter, O
decreased O
in O
sustained O
hyperglycemia O
compared O
with O
controls. O
The O
evidence O
suggests O
that O
hyperglycemia-induced O
developmental O
delays O
are O
associated O
with O
slowed O
cell O
cycle O
progression, O
leading O
to O
reduced O
cellular O
proliferation. O
The O
suppression O
of O
critical O
developmental O
steps O
may O
underlie O
the O
cardiac O
defects O
observed O
during O
late O
gestation O
under O
hyperglycemic O
conditions. O
Effect O
of O
ketoconazole B-CHEMICAL
on O
the O
pharmacokinetic O
profile O
of O
ambrisentan. B-CHEMICAL
Ambrisentan B-CHEMICAL
is O
an O
endothelin B-GENE-Y
type I-GENE-Y
A I-GENE-Y
(ET(A))-selective I-GENE-Y
receptor I-GENE-Y
antagonist O
that O

is O
metabolized O
primarily O
by O
glucuronidation O
but O
also O
undergoes O
oxidative O
metabolism O
by O
CYP3A4. B-GENE-Y
The O
potential O
for O
ketoconazole, B-CHEMICAL
the O
archetypal O
strong O
inhibitor O
of O
CYP3A4, B-GENE-Y
to O
alter O
the O
pharmacokinetic O
profile O
of O
ambrisentan B-CHEMICAL
and O
its O
oxidative O
metabolite, O
4-hydroxymethyl B-CHEMICAL
ambrisentan, I-CHEMICAL
was O
assessed O
in O
an O
open-label, O
nonrandomized, O
2-period, O
single-sequence O
study O
in O
16 O
healthy O
men. O
Participants O
received O
a O
single O
dose O
of O
ambrisentan B-CHEMICAL
10 O

mg O
alone O
and O
after O
4 O
days O
of O
ketoconazole B-CHEMICAL
400 O
mg O
administered O
once O
daily. O
In O
the O
presence O
of O
multiple O
doses O
of O
ketoconazole, B-CHEMICAL
single-dose O
ambrisentan B-CHEMICAL
AUC(0-infinity) O
estimate O
was O
increased O
by O
35.3%, O
whereas O
C(max) O
was O
increased O
by O
20.0%. O
For O
the O
4-hydroxymethyl B-CHEMICAL
ambrisentan I-CHEMICAL
metabolite, O
AUC(0-infinity) O
estimate O
was O
decreased O
by O
4.0%, O
whereas O
C(max) O
was O
decreased O
by O
16.5%. O
Concomitant O
administration O
of O

ambrisentan B-CHEMICAL
and O
ketoconazole B-CHEMICAL
was O
well O
tolerated. O
In O
summary, O
ketoconazole B-CHEMICAL
had O
no O
clinically O
significant O
effect O
on O
the O
pharmacokinetics O
or O
safety O
profile O
of O
ambrisentan; B-CHEMICAL
therefore, O
no O
changes O
in O
ambrisentan B-CHEMICAL
dose O
should O
be O
necessary O
when O
the O
drug O
is O
administered O
concomitantly O
with O
known O
CYP3A4 B-GENE-Y
inhibitors. O
A O
Model-Based O
Approach O
to O
Predict O
Longitudinal O
HbA1c, B-GENE-Y
Using O
Early O
Phase O
Glucose B-CHEMICAL
Data O
From O
Type O
2 O
Diabetes O
Mellitus O
Patients O
After O
Anti-Diabetic O
Treatment. O

Predicting O
late O
phase O
outcomes O
from O
early-phase O
findings O
can O
help O
inform O
decisions O
in O
drug O
development. O
If O
the O
measurements O
in O
early-phase O
differ O
from O
those O
in O
late O
phase, O
forecasting O
is O
more O
challenging. O
In O
this O
paper, O
we O
present O
a O
model-based O
approach O
for O
predicting O
glycosylated B-GENE-Y
hemoglobin I-GENE-Y
(HbA1c) B-GENE-Y
in O
late O
phase O
using O
glucose B-CHEMICAL
and O
insulin B-GENE-Y
concentrations O
from O
an O
early-phase O
study, O
investigating O
an O
anti-diabetic O
treatment. O
Two O
previously O
published O
models O
were O
used; O
an O
integrated O
glucose B-CHEMICAL
and O
insulin B-GENE-Y
(IGI) O
model O
for O
meal O
tolerance O
tests O
and O
an O
integrated O
glucose-red B-CHEMICAL
blood O

cell-HbA1c B-GENE-Y
(IGRH) O
model O
predicting O
the O
formation O
of O
HbA1c B-GENE-Y
from O
the O
average O
glucose B-CHEMICAL
concentration O
(Cg,av O
). O
Output O
from O
the O
IGI O
model O
was O
used O
as O
input O
to O
the O
IGRH O
model. O
Parameters O
of O
the O
IGI O
model O
and O
drug O
effects O
were O
estimated O
using O
data O
from O
a O
phase1 O
study O
in O
59 O
diabetic O
patients O
receiving O
various O
doses O
of O
a O
glucokinase B-GENE-Y
activator. O
Cg,av O
values O
were O
simulated O
according O
to O
a O
Phase O
2 O
study O
design O
and O
used O
in O
the O
IGRH O
model O
for O
predictions O
of O
HbA1c. B-GENE-Y

The O
performance O
of O
the O
model-based O
approach O
was O
assessed O
by O
comparing O
the O
predicted O
to O
the O
actual O
outcome O
of O
the O
Phase O
2 O
study. O
We O
have O
shown O
that O
this O
approach O
well O
predicts O
the O
longitudinal O
HbA1c B-GENE-Y
response O
in O
a O
12-week O
study O
using O
only O
information O
from O
a O
1-week O
study O
where O
glucose B-CHEMICAL
and O
insulin B-GENE-Y
concentrations O
were O
measured. O
Reduction O
of O
dimethylarsinic B-CHEMICAL
acid I-CHEMICAL
to O
the O
highly O
toxic O
dimethylarsinous B-CHEMICAL
acid I-CHEMICAL
by O
rats O
and O
rat O
liver O
cytosol. O
Dimethylarsinic B-CHEMICAL
acid I-CHEMICAL
(DMAs(V)), B-CHEMICAL
the O
major O
urinary O
metabolite O
of O
inorganic O

arsenic, B-CHEMICAL
is O
weakly O
cytotoxic, O
whereas O
its O
reduced O
form, O
dimethylarsinous B-CHEMICAL
acid I-CHEMICAL
(DMAs(III)), B-CHEMICAL
is O
highly O
toxic. O
Although O
glutathione B-GENE-Y
S-transferase I-GENE-Y
omega I-GENE-Y
1 I-GENE-Y
(GSTO1) B-GENE-Y
and O
arsenic B-GENE-Y
methyltransferase I-GENE-Y
have O
been O
shown O
or O
thought O
to O
catalyze O
DMAs(V) B-CHEMICAL
reduction, O
their O
role O
in O
DMAs(V) B-CHEMICAL
reduction O
in O
vivo, O
or O
in O
cell O
extracts O
is O
uncertain. O
Therefore, O
the O
reduction O
of O
DMAs(V) B-CHEMICAL
to O
DMAs(III) B-CHEMICAL
in O
rats O
and O

in O
rat O
liver O
cytosol O
was O
studied O
to O
better O
understand O
its O
mechanism. O
To O
assess O
DMAs(V) B-CHEMICAL
reduction O
in O
rats, O
a O
novel O
procedure O
was O
devised O
based O
on O
following O
the O
accumulation O
of O
red O
blood O
cell O
(RBC)-bound O
dimethylarsenic B-CHEMICAL
(DMAs), B-CHEMICAL
which O
represents O
DMAs(III), B-CHEMICAL
in O
the O
blood O
of O
DMAs(V)-injected B-CHEMICAL
anesthetized O
rats. O
These O
studies O
indicated O
that O
rats O
reduced O
DMAs(V) B-CHEMICAL
to O
DMAs(III) B-CHEMICAL
to O
a O
significant O
extent, O
as O
in O
90 O
min O
31% O
of O
the O
injected O
50 O
μmol/kg O

DMAs(V) B-CHEMICAL
dose O
was O
converted O
to O
DMAs(III) B-CHEMICAL
that O
was O
sequestered O
by O
the O
circulating O
erythrocytes. O
Pretreatment O
of O
rats O
with O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
depletors O
(phorone B-CHEMICAL
or O
BSO) B-CHEMICAL
delayed O
the O
elimination O
of O
DMAs(V) B-CHEMICAL
and O
the O
accumulation O
of O
RBC-bound O
DMAs, B-CHEMICAL
whereas O
the O
indirect O
methyltransferase B-GENE-N
inhibitor O
periodate-oxidized B-CHEMICAL
adenosine B-CHEMICAL
was O
without O
effect. O
Assessment O
of O
DMAs(V)-reducing B-CHEMICAL
activity O
of O
rat O
liver O
cytosol O
revealed O
that O
reduction O
of O

DMAs(V) B-CHEMICAL
required O
cytosolic O
protein O
and O
GSH B-CHEMICAL
and O
was O
inhibited O
by O
thiol B-CHEMICAL
reagents, O
GSSG B-CHEMICAL
and O
dehydroascorbate. B-CHEMICAL
Although O
thioredoxin B-GENE-N
reductase I-GENE-N
(TRR) B-GENE-N
inhibitors O
(aurothioglucose B-CHEMICAL
and O
Sb(III)) B-CHEMICAL
inhibited O
cytosolic O
DMAs(V) B-CHEMICAL
reduction, O
recombinant O
rat B-GENE-N
TRR I-GENE-N
plus O
NADPH, B-CHEMICAL
alone O
or O
when O
added O
to O
the O
cytosol, O
failed O
to O
support O
DMAs(V) B-CHEMICAL
reduction. O
On O
ultrafiltration O

of O
the O
cytosol O
through O
a O
3 O
kDa O
filter, O
the O
reducing O
activity O
in O
the O
retentate O
was O
lost O
but O
was O
largely O
restored O
by O
NADPH. B-CHEMICAL
Such O
experiments O
also O
suggested O
that O
the O
reducing O
enzyme O
was O
larger O
than O
100 O
kDa O
and O
was O
not O
GSTO1. B-GENE-Y
In O
summary, O
reduction O
of O
DMAs(V) B-CHEMICAL
to O
the O
highly O
toxic O
DMAs(III) B-CHEMICAL
in O
rats O
and O
rat O
liver O
cytosol O
is O
a O
GSH-dependent B-CHEMICAL
enzymatic O
process, O
yet O
its O
mechanism O
remains O
uncertain. O
Effect O
of O
thiazinotrienomycin B-CHEMICAL
B, I-CHEMICAL
an O
ansamycin B-CHEMICAL
antibiotic, O
on O
the O

function O
of O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
in O
human O
stomach O
tumor O
cells. O
Thiazinotrienomycin B-CHEMICAL
B I-CHEMICAL
(TT-B), B-CHEMICAL
an O
ansamycin B-CHEMICAL
isolated O
from O
fermentation O
broths O
of O
Streptomyces O
sp. O
MJ672-m3, O
inhibited O
the O
growth O
in O
vitro O
of O
human O
stomach O
tumor O
SC-6 O
cells O
over O
10 O
times O
more O
strongly O
than O
the O
growth O
of O
other O
human O
tumor O
cells, O
such O
as O
HeLa O
(cervix), O
T24 O
(bladder) O
and O
LX-1 O
(lung). O
The O
extent O
of O
growth O
inhibition O
by O

TT-B O
of O
SC-6, O
but O
not O
of O
LX-1 O
nor O
T24, O
was O
lowered O
in O
a O
competitive O
manner O
by O
raising O
serum O
concentrations O
in O
the O
culture O
medium. O
TT-B B-CHEMICAL
inhibited O
the O
cell O
cycle O
progression O
of O
SC-6 O
at O
an O
early O
stage O
of O
the O
progression O
from O
G0/G1 O
to O
S. O
The O
inhibition O
was O
again O
competitive O
with O
serum O
concentrations O
in O
the O
culture O
medium. O
No O
direct O
inhibition O
of O
DNA O
synthesis O
was O
observed O
at O
the O
concentration O
range O
which O
caused O
the O
cell O
cycle O
arrest. O
TT-B B-CHEMICAL
and O
anti-epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(anti-EGFR) B-GENE-Y
were O
antagonistic O
to O

each O
other O
in O
inhibiting O
the O
cell O
cycle O
progression O
of O
SC-6 O
from O
G0/G1 O
to O
S, O
suggesting O
that O
the O
two O
compounds O
share O
the O
same O
target, O
EGFR. B-GENE-Y
The O
kinase B-GENE-N
activity O
of O
EGFR B-GENE-Y
was O
little O
inhibited O
by O
TT-B B-CHEMICAL
in O
a O
cell-free O
system. O
Vapreotide: B-CHEMICAL
a O
somatostatin B-GENE-Y
analog O
for O
the O
treatment O
of O
acute O
variceal O
bleeding. O
BACKGROUND: O
Portal O
hypertension O
is O
a O
clinically O
important O
consequence O
of O
cirrhosis O
that O
can O
lead O
to O
morbidities O
such O
as O
variceal O
bleeding, O

hepatic O
encephalopathy O
and O
ascites. O
All O
of O
these O
outcomes O
carry O
high O
mortality O
rates. O
There O
have O
been O
several O
drugs O
created O
to O
assist O
with O
endoscopic O
therapy O
for O
the O
treatment O
of O
acute O
variceal O
bleeding. O
Recently, O
vapreotide B-CHEMICAL
has O
been O
studied O
in O
patients O
to O
evaluate O
its O
efficacy O
as O
treatment O
for O
acute O
variceal O
hemorrhage. O
Although O
no O
comparisons O
have O
been O
made O
between O
vapreotide B-CHEMICAL
and O
other O
somatostatin B-GENE-Y
analogues, O
this O
drug O
has O
been O
shown O
to O
have O
efficacy O
in O
the O
control O
of O
acute O
variceal O
bleeding O
as O
well O
as O
reducing O
the O
risk O
of O
recurrent O
bleeding O
and O
death, O
especially O

when O
started O
prior O
to O
endoscopy. O
OBJECTIVE: O
This O
paper O
reviews O
the O
literature O
regarding O
the O
basic O
science O
and O
clinical O
efficacy O
of O
vapreotide B-CHEMICAL
in O
acute O
variceal O
bleeding. O
METHODS: O
We O
used O
a O
PubMed/Medline O
search O
in O
order O
to O
review O
the O
literature O
regarding O
the O
drug, O
vapreotide. B-CHEMICAL
RESULTS/CONCLUSIONS: O
Vapreotide B-CHEMICAL
appears O
to O
have O
benefit O
in O
the O
control O
of O
acute O
variceal O
bleeding. O
It O
is O
easy O
to O
administer O
and O
has O
few O
side O
effects, O
which O
are O
minor. O
These O
findings O
endorse O
the O
need O
for O

future O
trials O
to O
evaluate O
vapreotide B-CHEMICAL
and O
its O
use O
in O
acute O
variceal O
hemorrhage, O
a O
morbidity O
among O
patients O
with O
cirrhosis. O
Sorafenib B-CHEMICAL
(BAY B-CHEMICAL
43-9006, I-CHEMICAL
Nexavar), B-CHEMICAL
a O
dual-action O
inhibitor O
that O
targets O
RAF/MEK/ERK B-GENE-N
pathway O
in O
tumor O
cells O
and O
tyrosine B-GENE-N
kinases I-GENE-N
VEGFR/PDGFR B-GENE-N
in O
tumor O
vasculature. O
Activating O
mutations O
in O
Ras B-GENE-N
and O
B-RAF B-GENE-Y
were O
identified O
in O
several O
human O
cancers. O
In O
addition, O
several O
receptor B-GENE-N
tyrosine I-GENE-N
kinases, I-GENE-N
acting O

upstream O
of O
Ras, B-GENE-N
were O
found O
either O
mutated O
or O
overexpressed O
in O
human O
tumors. O
Because O
oncogenic O
activation O
of O
the O
Ras/RAF B-GENE-N
pathway O
may O
lead O
to O
a O
sustained O
proliferative O
signal O
resulting O
in O
tumor O
growth O
and O
progression, O
inhibition O
of O
this O
pathway O
represents O
an O
attractive O
approach O
for O
cancer O
drug O
discovery. O
A O
novel O
class O
of O
biaryl B-CHEMICAL
urea I-CHEMICAL
that O
inhibits O
C-RAF B-GENE-Y
kinase B-GENE-N
was O
discovered O
using O
a O
combination O
of O
medicinal O
and O
combinatorial O
chemistry O
approaches. O
This O
effort O
culminated O
in O
the O
identification O
of O
the O
clinical O
candidate O
BAY B-CHEMICAL
43-9006 I-CHEMICAL
(Sorafenib, B-CHEMICAL
Nexavar), B-CHEMICAL
which O
has O
recently O
been O
approved O
by O

the O
FDA O
for O
advanced O
renal O
cell O
carcinoma O
in O
phase O
III O
clinical O
trials. O
Sorafenib B-CHEMICAL
inhibited O
the O
kinase B-GENE-N
activity O
of O
both O
C-RAF B-GENE-Y
and O
B-RAF B-GENE-Y
(wild O
type O
and O
V600E B-GENE-N
mutant). O
It O
inhibited O
MEK B-GENE-N
and O
ERK B-GENE-N
phosphorylation O
in O
various O
cancer O
cell O
lines O
and O
tumor O
xenografts O
and O
exhibited O
potent O
oral O
antitumor O
activity O
in O
a O
broad O
spectrum O
of O
human O
tumor O
xenograft O
models. O
Further O
characterization O
of O
sorafenib B-CHEMICAL
revealed O
that O
this O
molecule O
was O
a O
multikinase O
inhibitor O
that O
targeted O
the O
vascular B-GENE-N
endothelial I-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
family O

(VEGFR-2 B-GENE-Y
and O
VEGFR-3) B-GENE-Y
and O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
family O
(PDGFR-beta B-GENE-Y
and O
Kit), B-GENE-Y
which O
play O
key O
roles O
in O
tumor O
progression O
and O
angiogenesis. O
Thus, O
sorafenib B-CHEMICAL
may O
inhibit O
tumor O
growth O
by O
a O
dual O
mechanism, O
acting O
either O
directly O
on O
the O
tumor O
(through O
inhibition O
of O
Raf B-GENE-N
and O
Kit B-GENE-Y
signaling) O
and/or O
on O
tumor O
angiogenesis O
(through O
inhibition O
of O
VEGFR B-GENE-N
and O
PDGFR B-GENE-N
signaling). O
In O
phase O
I O
and O
phase O
II O
clinical O
trials, O
sorafenib B-CHEMICAL
showed O
limited O
side O
effects O
and, O
more O

importantly, O
disease O
stabilization. O
This O
agent O
is O
currently O
being O
evaluated O
in O
phase O
III O
clinical O
trials O
in O
renal O
cell O
and O
hepatocellular O
carcinomas. O
Treatment-related O
osteoporosis O
in O
men O
with O
prostate O
cancer. O
The O
intended O
therapeutic O
effect O
of O
gonadotropin-releasing B-GENE-Y
hormone I-GENE-Y
(GnRH) B-GENE-Y
agonists O
is O
hypogonadism, O
a O
major O
cause O
of O
acquired O
osteoporosis O
in O
men. O
Consistent O
with O
this O
observation, O
GnRH B-GENE-Y
agonists O
increase O
bone O
turnover O
and O
decrease O
bone O
mineral O
density, O
a O
surrogate O
for O
fracture O
risk. O
Large O
claims-based O
analyses O
and O
other O
retrospective O

studies O
provide O
compelling O
evidence O
that O
GnRH B-GENE-Y
agonists O
increase O
risk O
of O
clinical O
fractures. O
Estrogens B-CHEMICAL
play O
a O
central O
role O
in O
homeostasis O
of O
the O
normal O
male O
skeleton, O
and O
estrogen B-CHEMICAL
deficiency O
rather O
than O
testosterone B-CHEMICAL
deficiency O
seems O
to O
be O
primarily O
responsible O
for O
the O
adverse O
skeletal O
effects O
of O
GnRH B-GENE-Y
agonists. O
In O
randomized O
controlled O
trials, O
bisphosphonates B-CHEMICAL
(pamidronate B-CHEMICAL
and O
zoledronic B-CHEMICAL
acid) I-CHEMICAL
and O
selective O
estrogen B-GENE-Y
receptor I-GENE-Y
modulators O
(raloxifene B-CHEMICAL
and O
toremifene) B-CHEMICAL
increased O
bone O
mineral O
density O
in O
GnRH B-GENE-Y
agonist-treated O
men. O
Two O
ongoing O
large O

randomized O
placebo-controlled O
studies O
will O
prospectively O
define O
fracture O
outcomes O
in O
men O
with O
prostate O
cancer O
and O
assess O
the O
efficacy O
of O
novel O
pharmacologic O
interventions O
(AMG162, O
toremifene) B-CHEMICAL
during O
GnRH B-GENE-Y
agonist O
treatment. O
Rapamycin B-CHEMICAL
allosterically O
inhibits O
the O
proteasome. B-GENE-N
Rapamycin B-CHEMICAL
is O
a O
canonical O
allosteric O
inhibitor O
of O
the O
mTOR B-GENE-Y
kinase B-GENE-N
with O
immunosuppressive O
and O
pro-apoptotic O
activities. O
We O
found O
that O
in O
vitro O
rapamycin B-CHEMICAL
also O
regulates O
the O
proteasome, B-GENE-N
an O
essential O
intracellular O

protease O
of O
the O
ubiquitin-proteasome B-GENE-N
pathway. O
Rapamycin B-CHEMICAL
inhibits O
proteinase B-GENE-N
and O
selected O
peptidase B-GENE-N
activities O
of O
the O
catalytic O
core O
proteasome B-GENE-N
at O
low O
micromolar O
concentrations. O
Moreover, O
the O
drug O
interferes O
with O
binding O
of O
the O
19S O
cap O
essential O
for O
processing O
of O
polyubiquitinylated O
substrates, O
and O
the O
PA200 B-GENE-Y
activator O
to O
the O
20S B-GENE-N
catalytic I-GENE-N
core I-GENE-N
proteasome. I-GENE-N
These O
protein O
complexes O
are O
known O
to O
bind O
to O
specific O
grooves O
on O
the O
α O
face O
region O
of O
the O
20S O
core. O
A O
treatment O
with O
rapamycin B-CHEMICAL
affects O
conformational O

dynamics O
of O
the O
proteasomal O
gate, O
a O
centrally O
positioned O
within O
the O
α O
face O
and O
allosterically O
regulated O
element O
responsible O
for O
the O
intake O
of O
substrates. O
Interestingly, O
we O
showed O
that O
rapamycin B-CHEMICAL
shares O
all O
the O
proteasome B-GENE-N
targeting O
properties O
not O
only O
with O
other O
two-domain, O
closed-ring O
analogs O
(rapalogs), O
but O
also O
with O
its O
single O
domain O
mimics, O
and O
with O
seco-rapamycin. B-CHEMICAL
The O
latter O
is O
the O
first O
in O
vivo O
open-ring O
metabolite O
of O
rapamycin B-CHEMICAL
that O
does O
not O
affect O
mTOR. B-GENE-Y
We O
hypothesize O
that O
the O

rapamycin B-CHEMICAL
and O
related O
compounds O
bind O
to O
the O
α O
face O
and O
allosterically O
impact O
the O
proteasome B-GENE-N
function. O
The O
implications O
of O
our O
finding O
for O
mechanism O
of O
in O
vivo O
actions O
of O
rapamycin B-CHEMICAL
and O
for O
design O
of O
novel O
allosteric O
drugs O
targeting O
the O
proteasome B-GENE-N
are O
discussed. O
Effect O
of O
MELANOTAN, B-CHEMICAL
[Nle(4), B-CHEMICAL
D-Phe(7)]-alpha-MSH, I-CHEMICAL
on O
melanin O
synthesis O
in O
humans O
with O
MC1R B-GENE-Y
variant O
alleles. O
MELANOTAN B-CHEMICAL
(NDP-MSH) B-CHEMICAL
binds O
the O
MC1 B-GENE-Y
receptor I-GENE-Y
to O
significantly O
increase O
the O

eumelanin O
content O
of O
human O
skin O
cells. O
In O
this O
study O
of O
77 O
Caucasian O
individuals, O
we O
investigated O
the O
effects O
of O
MELANOTAN B-CHEMICAL
in O
individuals O
with O
variant O
MC1R B-GENE-Y
genotypes, O
as O
it O
has O
been O
suggested O
through O
in O
vitro O
studies O
that O
variant O
alleles O
decrease O
MELANOTAN B-CHEMICAL
binding O
efficacy, O
which O
would O
subsequently O
affect O
the O
synthesis O
of O
melanin. O
Administration O
of O
MELANOTAN B-CHEMICAL
produced O
a O
significant O
(p<0.001) O
increase O
in O
melanin O
density O
in O
treated, O
compared O
to O
placebo, O
individuals. O
Importantly, O
MELANOTAN B-CHEMICAL
increased O
the O
melanin O
density O
to O
a O

greater O
extent O
in O
individuals O
carrying O
the O
variant O
alleles O
Val60Leu, O
Asp84Glu, O
Val92Met, O
Arg142His, O
Arg151Cys, O
and O
Arg160Trp O
than O
in O
individuals O
with O
no O
variant O
alleles. O
This O
study O
demonstrates O
that O
MELANOTAN B-CHEMICAL
effectively O
increases O
the O
melanin O
content O
of O
skin O
in O
those O
individuals O
with O
MC1R B-GENE-Y
variant O
alleles O
and O
therefore, O
those O
most O
in O
need O
of O
photoprotection. O
In O
vitro O
simulation O
of O
therapeutic O
plasmatic O
fibrinolysis. O
One O
type O
of O
therapy O
for O
thromboembolism O

is O
plasmatic O
thrombolysis. O
Several O
plasminogen B-GENE-N
activators I-GENE-N
(PA) B-GENE-N
are O
clinically O
available, O
including O
urokinase B-GENE-N
(u-PA), B-GENE-Y
tissue B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(t-PA), B-GENE-Y
streptokinase B-GENE-N
(SK), B-GENE-N
plasminogen-streptokinase-activator-complex B-GENE-N
(PSAC), B-GENE-N
or O
mutants O
of O
t-PA B-GENE-Y
such O
as O
reteplase O
(RP) O
or O
tenecteplase O
(TP). O
Therapeutic O
plasmatic O
fibrinolysis O
was O
simulated, O
using O
the O
PA B-GENE-N
at O
relevant O

plasma O
concentrations, O
and O
plasmin B-GENE-Y
(Pli) B-GENE-Y
and O
PA B-GENE-N
activities O
were O
determined. O
Normal O
citrated O
plasma O
was O
supplemented O
with O
31 O
to O
1,000 O
IU/mL O
u-PA, O
0.31 O
to O
20 O
microg/mL O
t-PA, B-GENE-N
125 O
to O
4,000 O
IU/mL O
SK, B-GENE-N
12.5 O
to O
400 O
U/mL O
PSAC, B-GENE-N
125 O
to O
4,000 O
U/mL O
RP, O
or O
0.31 O
to O
10 O
microg/mL O
TP. O
Ten O
IU/mL O
urokinase B-GENE-N
was O
also O
incubated O
with O
pooled O
plasma O
of O
stroke O

patients, O
that O
was O
previously O
oxidized O
with O
the O
singlet B-CHEMICAL
oxygen I-CHEMICAL
(1O2) B-CHEMICAL
donor O
chloramine B-CHEMICAL
T I-CHEMICAL
(CT), B-CHEMICAL
to O
destroy O
plasmatic B-GENE-Y
PAI-1 I-GENE-Y
and O
alpha2-antiplasmin. B-GENE-Y
After O
0 O
to O
80 O
minutes O
(37 O
degrees O
C), O
50-microL O
samples O
were O
withdrawn O
and O
added O
to O
100 O
microL O
1.5 O
M O
arginine, B-CHEMICAL
pH O
8.7, O
and O
oxidized O
with O
50 O
microL O
of O
20 O
mM O
CT. B-CHEMICAL
For O
determination O
of O
plasmin B-GENE-Y
activity, O
10 O
microL O
thereof O
was O
incubated O
with O
150 O
microL O
1.5 O
M O
arginine, B-CHEMICAL

pH O
8.7, O
and O
100 O
microL O
20 O
mM O
CT B-CHEMICAL
preoxidized O
(15 O
minutes O
37 O
degrees O
C) O
pooled O
normal O
citrate B-CHEMICAL
buffered O
EDTA-plasma B-CHEMICAL
for O
30 O
minutes O
(37 O
degrees O
C). O
For O
determination O
of O
[PA+Pli]-activity, B-GENE-N
arginine B-CHEMICAL
was O
added O
after O
this O
incubation. O
25-microL O
6 O
mM O
Val-Leu-Lys-pNA B-CHEMICAL
were O
added O
and O
deltaA/h O
at O
room O
temperature O
(RT) O
was O
monitored, O
using O
a O
microtiterplate O
reader. O
[PA+Pli]-Pli B-GENE-N
= O
PA. B-GENE-N
The O
PA B-GENE-N

concentration O
required O
to O
induce O
25% O
[ED25] O
of O
the O
maximally O
inducible O
Pli-activity B-GENE-Y
in O
plasma O
(= O
1 O
U/mL O
= O
45 O
mg/L O
= O
0.53 O
micromol/L O
active O
Pli; B-GENE-Y
deltaA O
= O
363 O
+/- O
8 O
mA/h O
RT) O
after O
10 O
minutes O
(37 O
degrees O
C) O
were O
320 O
IU/mL O
u-PA, B-GENE-Y
8 O
microg/mL O
t-PA, B-GENE-Y
140 O
U/mL O
PSAC, O
6,000 O
IU/mL O
SK, O
720 O
U/mL O
RP, O
and O
approximately O
150 O

microg/mL O
TP. O
The O
approximate O
activity O
half-lives O
of O
the O
PA B-GENE-N
in O
plasma O
were O
30 O
minutes O
for O
u-PA, B-GENE-Y
30 O
minutes O
for O
t-PA, B-GENE-Y
greater O
than O
80 O
minutes O
for O
SK, B-GENE-N
greater O
than O
80 O
minutes O
for O
PSAC, B-GENE-N
50 O
minutes O
for O
RP, O
and O
80 O
minutes O
for O
TP. O
The O
present O
study O
shows--for O
the O
first O
time--a O
combined O
kinetic O
in O
vitro O
simulation O
of O
the O
plasmatic O
activity O
of O
six O
different O
PAs. B-GENE-N
At O
clinically O
used O
concentrations, O
RP O
induces O
the O
highest O
plasmatic B-GENE-Y
Pli I-GENE-Y
activity. O
Due O
to O
unselective O
generation O
of O
plasmin B-GENE-Y
in O
plasma, O
all O

PA B-GENE-N
are O
of O
some O
danger O
in O
inducing O
severe O
hemorrhagias. O
Clinical O
thrombolysis O
might O
be O
improved O
by O
usage O
of O
more O
physiologic O
activators O
of O
thrombolysis, O
such O
as O
activators O
of O
polymorphonuclear O
neutrophils. O
Novel O
assays O
for O
detection O
of O
urinary O
KIM-1 B-GENE-Y
in O
mouse O
models O
of O
kidney O
injury. O
Kidney B-GENE-Y
injury I-GENE-Y
molecule-1 I-GENE-Y
(KIM-1) B-GENE-Y
has O
been O
qualified O
by O
the O
Food O
and O
Drug O
Administration O
and O
European O
Medicines O
Agency O
as O
a O
urinary O
biomarker O
to O
monitor O
preclinical O

nephrotoxicity O
in O
rats O
and O
on O
a O
case-by-case O
basis O
for O
the O
translation O
of O
potentially O
nephrotoxic O
drugs O
into O
first-in O
human O
studies. O
Although O
mouse O
models O
are O
widely O
employed O
in O
preclinical O
studies, O
few O
urinary O
biomarker O
studies O
have O
been O
performed O
in O
mice O
due O
to O
limited O
urine O
availability O
and O
lack O
of O
sensitive O
assays. O
Here, O
we O
report O
the O
development O
and O
validation O
of O
two O
different O
assays O
for O
quantitative O
assessment O
of O
mouse B-GENE-Y
urinary I-GENE-Y
KIM-1 I-GENE-Y
(uKIM-1) B-GENE-Y
and O
compare O
the O
sensitivity O
of O
KIM-1 B-GENE-Y
relative O
to O
other O
standard O
markers O
in O
ischemia O

reperfusion O
and O
aristolochic B-CHEMICAL
acid I-CHEMICAL
(AA)-induced O
kidney O
injury O
in O
mice. O
A O
sensitive, O
reproducible, O
and O
quantitative O
microbead-based O
KIM-1 B-GENE-Y
ELISA O
was O
established, O
which O
requires O
only O
10 O
μl O
urine O
for O
triplicate O
determination O
with O
an O
assay O
range O
of O
12.21 O
pg/ml O
to O
50 O
ng/ml. O
The O
second O
assay O
is O
a O
laminar O
flow O
dipstick O
assay, O
which O
has O
an O
assay O
range O
of O
195 O
pg/ml O
to O
50 O
ng/ml O
and O
provides O
quantitative O
assessment O
of O
KIM-1 B-GENE-Y
in O
15 O
min. O

uKIM-1 B-GENE-Y
levels O
increased O
with O
increasing O
time O
of O
ischemia O
or O
time O
after O
AA O
administration. O
After O
only O
10-min O
ischemia O
followed O
by O
24-h O
reperfusion, O
uKIM-1 B-GENE-Y
was O
significantly O
elevated O
by O
13-fold, O
whereas O
serum O
creatinine B-CHEMICAL
(sCr), O
blood O
urea B-CHEMICAL
nitrogen, B-CHEMICAL
N-acetyl-β-glucosaminidase B-GENE-Y
(NAG), B-GENE-Y
and O
proteinuria O
levels O
did O
not O
change. O
After O
AA O
administration, O
uKIM-1 B-GENE-Y
levels O
were O
significantly O
upregulated O
by O
greater O
than O
threefold O
within O
12 O
h, O
whereas O
sCr O
and O

NAG B-GENE-Y
levels O
were O
unchanged. O
Mouse B-GENE-Y
KIM-1 I-GENE-Y
was O
stable O
for O
multiple O
freeze-thaw O
cycles, O
for O
up O
to O
5 O
days O
at O
room O
temperature O
and O
up O
to O
at O
least O
an O
year O
when O
stored O
at O
-80°C. O
Impaired O
antibody O
synthesis O
after O
spinal O
cord O
injury O
is O
level O
dependent O
and O
is O
due O
to O
sympathetic O
nervous O
system O
dysregulation. O
Individuals O
with O
spinal O
cord O
injury O
(SCI) O
are O
highly O
susceptible O
to O
infection. O
This O
post-traumatic O
immune O
suppression O
is O
thought O
to O
occur O
via O
alterations O
in O
sympathetic O
nervous O
system O
(SNS) O
or O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O

function. O
Normally, O
the O
HPA O
axis O
and O
SNS O
help O
coordinate O
proper O
immune O
function. O
After O
SCI, O
the O
HPA O
axis O
becomes O
activated O
and O
descending O
input O
to O
sympathetic O
preganglionic O
neurons O
(SPNs) O
is O
impaired. O
Because O
lymphoid O
organs O
are O
innervated O
by O
SPNs O
distributed O
throughout O
the O
thoracolumbar O
spinal O
cord, O
we O
predicted O
level-dependent O
immune O
suppression O
after O
SCI O
due O
to O
activation O
of O
the O
HPA O
axis O
and O
loss O
of O
descending O
input O
to O
SPNs. O
We O
tested O
this O
hypothesis O
by O
measuring O
indices O
of O
HPA O
(circulating O
corticosterone; B-CHEMICAL
CORT) B-CHEMICAL
and O
SNS O
function O

(norepinephrine B-CHEMICAL
(NE) B-CHEMICAL
in O
spleen) O
as O
well O
as O
antigen-specific O
antibody O
synthesis O
against O
an O
exogenous O
non-self O
protein O
following O
high- O
or O
low-level O
SCI. O
Using O
a O
mid-thoracic O
(T9) O
spinal O
contusion O
injury O
model, O
we O
found O
that O
CORT B-CHEMICAL
was O
elevated O
after O
SCI O
with O
aberrant O
patterns O
of O
diurnal O
CORT B-CHEMICAL
synthesis O
evident O
through O
at O
least O
the O
first O
24 O
h O
post-injury. O
However, O
splenic O
NE B-CHEMICAL
and O
antibody O
synthesis O
were O
similar O
to O
uninjured O
controls. O
Injury O
severity O
did O
not O
change O
these O
parameters. O
Indeed, O

CORT, B-CHEMICAL
NE B-CHEMICAL
and O
antibody O
synthesis O
were O
similar O
after O
T9 O
contusion O
or O
transection O
SCI. O
In O
contrast, O
high-level O
SCI O
(T3) O
caused O
sustained O
increases O
in O
CORT B-CHEMICAL
and O
splenic O
NE B-CHEMICAL
along O
with O
impaired O
antibody O
synthesis O
and O
elevated O
splenocyte O
apoptosis. O
The O
immunosuppressive O
effects O
of O
T3 O
SCI O
were O
caused O
by O
NE B-CHEMICAL
acting O
at O
beta2-adrenergic B-GENE-Y
receptors I-GENE-Y
(beta2AR) B-GENE-Y
and O
could O
be O
reversed O
using O
beta2AR B-GENE-Y
blockers. O
Interestingly, O
impaired O
antibody O
after O
T3 O
SCI O
could O
be O
mimicked O
after O
T9 O
SCI O
with O

a O
beta2AR B-GENE-Y
agonist. O
These O
data O
illustrate O
the O
immunosuppressive O
effects O
of O
the O
SNS O
after O
high-level O
SCI O
and O
indicate O
that O
immune O
deficits O
may O
be O
overcome O
using O
beta-blockers. O
Zuclopenthixol B-CHEMICAL
facilitates O
memory O
retrieval O
in O
rats: O
possible O
involvement O
of O
noradrenergic O
and O
serotonergic O
mechanisms. O
Although O
disturbed O
memory O
function O
often O
coexists O
with O
psychosis, O
the O
cognitive O
effects O
of O
antipsychotic O
medications O
with O
diverse O
pharmacodynamic O
properties O
are O
rarely O
investigated. O
The O
neurocognitive O
profile O
of O
zuclopenthixol, B-CHEMICAL
a O

thioxanthene B-CHEMICAL
dopaminergic O
antagonist O
and O
a O
conventional O
neuroleptic O
agent, O
has O
yet O
to O
be O
investigated O
despite O
the O
effect O
of O
the O
drug O
on O
a O
variety O
of O
neurotransmitter O
systems O
involved O
in O
mediation O
of O
learning O
and O
memory O
processes. O
In O
this O
study, O
the O
effect O
of O
zuclopenthixol B-CHEMICAL
was O
tested O
on O
memory O
retrieval O
24 O
h O
after O
training O
using O
an O
inhibitory O
avoidance O
task O
in O
rats. O
Acute O
administration O
of O
zuclopenthixol B-CHEMICAL
(0.7 O
and O
1.4 O
mg/kg O
i.p.) O
before O
retrieval O
testing O
increased O
step-through O
latency O

during O
the O
test O
session. O
The O
same O
doses O
of O
zuclopenthixol B-CHEMICAL
did O
not O
affect O
the O
ambulatory O
activity O
of O
rats O
in O
the O
openfield O
test O
and O
therefore O
the O
facilitatory O
effect O
of O
the O
drug O
on O
memory O
function O
could O
not O
be O
confounded O
with O
any O
motoric O
properties. O
This O
study O
also O
investigated O
the O
effect O
of O
zuclopenthixol B-CHEMICAL
on O
cortical O
and O
hippocampal O
monoaminergic O
neurotransmitters' O
levels O
together O
with O
acetylcholinesterase B-GENE-Y
enzyme O
(AChE) B-GENE-Y
activity, O
both O
of O
which O
are O
known O
to O
be O
important O
in O
control O
of O
cognitive O
function. O
Administration O
of O

zuclopenthixol B-CHEMICAL
(0.7 O
and O
1.4 O
mg/kg O
i.p.) O
neither O
affected O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
level O
nor O
AChE B-GENE-Y
activity O
in O
rat O
cortex O
and O
hippocampus. O
On O
the O
other O
hand, O
the O
lower O
dose O
of O
zuclopenthixol B-CHEMICAL
elevated O
cortical O
norepinephrine B-CHEMICAL
(NE) B-CHEMICAL
level, O
while O
the O
higher O
dose O
elevated O
both O
cortical O
and O
hippocampal O
NE B-CHEMICAL
level O
together O
with O
hippocampal O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
level. O
These O
results O
may O
suggest O
the O
involvement O
of O
adrenergic O
and O

serotonergic O
mechanisms O
in O
the O
facilitatory O
effect O
of O
zuclopenthixol B-CHEMICAL
on O
retrieval O
memory. O
Zuclopenthixol B-CHEMICAL
may O
therefore O
be O
a O
better O
alternative O
than O
other O
commonly O
used O
antipsychotic O
medications O
reported O
to O
impair O
cognitive O
function O
of O
schizophrenic O
patients. O
Selective O
Bisubstrate O
Inhibitors O
with O
Sub-nanomolar O
Affinity O
for O
Protein B-GENE-N
Kinase I-GENE-N
Pim-1. B-GENE-Y
Potent O
and O
selective: O
The O
unique O
nature O
of O
the O
ATP B-CHEMICAL
binding O
pocket O
structure O
of O
Pim B-GENE-N
family O
protein B-GENE-N
kinases I-GENE-N
(PKs) B-GENE-N
was O
used O
for O

the O
development O
of O
bisubstrate O
inhibitors O
and O
a O
fluorescent O
probe O
with O
sub-nanomolar O
affinity. O
Conjugates O
of O
arginine-rich B-CHEMICAL
peptides O
with O
two O
ATP B-CHEMICAL
mimetic O
scaffolds O
were O
synthesized O
and O
tested O
as O
inhibitors O
of O
Pim-1. B-GENE-Y
Against O
a O
panel O
of O
124 O
protein B-GENE-N
kinases, I-GENE-N
a O
novel O
ARC-PIM B-GENE-N
conjugate O
selectively O
inhibited O
PKs B-GENE-N
of O
the O
Pim B-GENE-N
family. O
Nuclear B-GENE-N
receptor I-GENE-N
CAR B-GENE-Y
specifically O
activates O
the O
two-pore O
K+ B-GENE-N
channel I-GENE-N
Kcnk1 B-GENE-Y
gene O
in O
male O
mouse O
livers, O
which O
attenuates O

phenobarbital-induced B-CHEMICAL
hepatic O
hyperplasia. O
KCNK1, B-GENE-Y
a O
member O
of O
the O
family O
of O
two-pore O
K(+) B-GENE-N
ion I-GENE-N
channels, I-GENE-N
is O
specifically O
induced O
in O
the O
livers O
of O
male O
mice O
after O
phenobarbital B-CHEMICAL
treatment. O
Here, O
we O
have O
determined O
the O
molecular O
mechanism O
of O
this O
male-specific O
activation O
of O
the O
Kcnk1 B-GENE-Y
gene O
and O
characterized O
KCNK1 B-GENE-Y
as O
a O
phenobarbital-inducible B-CHEMICAL
antihyperplasia O
factor. O
Upon O
activation O
by O
phenobarbital, B-CHEMICAL
nuclear B-GENE-N
receptor I-GENE-N
CAR B-GENE-Y
binds O
the O
97-bp O
response O
element O

(-2441/-2345) O
within O
the O
Kcnk1 B-GENE-N
promoter. I-GENE-N
This O
binding O
is O
observed O
in O
the O
livers O
of O
male O
mice, O
but O
not O
in O
the O
livers O
of O
female O
mice O
and O
requires O
the O
pituitary O
gland, O
because O
hypophysectomy O
abrogates O
it. O
Hyperplasia O
further O
progressed O
in O
the O
livers O
of O
Kcnk1 B-GENE-Y
( O
-/- O
) O
male O
mice O
compared O
with O
those O
of O
Kcnk1 B-GENE-Y
( O
+/+ O
) O
males O
after O
phenobarbital B-CHEMICAL
treatment. O
Thus, O
KCNK1 B-GENE-Y
suppresses O
phenobarbital-induced B-CHEMICAL
hyperplasia. O

These O
results O
indicate O
that O
phenobarbital B-CHEMICAL
treatment O
induces O
KCNK1 B-GENE-Y
to O
elicit O
a O
male-specific O
and O
growth-suppressing O
signal. O
Thus, O
KCNK1 B-GENE-Y
and O
Kcnk1 B-GENE-Y
( O
-/- O
) O
mice O
provide O
an O
experimental O
tool O
for O
further O
investigation O
into O
the O
molecular O
mechanism O
of O
CAR-mediated B-GENE-Y
promotion O
of O
the O
development O
of O
hepatocellular O
carcinoma O
in O
mice. O
Development O
of O
new O
cyclic O
plasmin B-GENE-Y
inhibitors O
with O
excellent O
potency O
and O
selectivity. O
The O
trypsin-like B-GENE-N
serine B-GENE-N
protease I-GENE-N
plasmin B-GENE-Y
is O
a O
target O
for O
the O
development O
of O
antifibrinolytic O
drugs O
for O

use O
in O
cardiac O
surgery O
with O
cardiopulmonary O
bypass O
or O
organ O
transplantations O
to O
reduce O
excessive O
blood O
loss. O
The O
optimization O
of O
our O
recently O
described O
substrate-analogue O
plasmin B-GENE-Y
inhibitors, O
which O
were O
cyclized O
between O
their O
P3 O
and O
P2 O
side O
chains, O
provided O
a O
new O
series O
with O
improved O
efficacy O
and O
excellent O
selectivity. O
The O
most O
potent O
inhibitor O
8 O
binds O
to O
plasmin B-GENE-Y
with O
an O
inhibition O
constant O
of O
0.2 O
nM, O
whereas O
K(i) O
values O
>1 O
μM O
were O
determined O
for O
nearly O
all O
other O
tested O
trypsin-like B-GENE-N
serine I-GENE-N
proteases, I-GENE-N
with O
the O
exception O
of O
trypsin, B-GENE-N
which O
is O

also O
inhibited O
in O
the O
nanomolar O
range. O
Docking O
studies O
revealed O
a O
potential O
binding O
mode O
in O
the O
widely O
open O
active O
site O
of O
plasmin B-GENE-Y
that O
explains O
the O
strong O
potency O
and O
selectivity O
profile O
of O
these O
inhibitors. O
The O
dialkylated O
piperazine-linker B-CHEMICAL
segment O
contributes O
to O
an O
excellent O
solubility O
of O
all O
analogues. O
Based O
on O
their O
overall O
profile O
the O
presented O
inhibitors O
are O
well O
suited O
for O
further O
development O
as O
injectable O
antifibrinolytic O
drugs. O
Different O
responses O
to O
dexamethasone B-CHEMICAL
and O
prednisolone B-CHEMICAL
in O
the O
same O
depressed O
patients. O
RATIONALE: O
Patients O
with O
major O
depression O

show O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
hyperactivity, O
but O
the O
mechanisms O
underlying O
this O
abnormality O
are O
still O
unclear. O
OBJECTIVES: O
We O
have O
compared O
two O
synthetic O
glucorticoids, O
dexamethasone B-CHEMICAL
and O
prednisolone, B-CHEMICAL
in O
their O
ability O
to O
suppress O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis O
in O
depressed O
patients. O
Dexamethasone B-CHEMICAL
probes O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
(GR) B-GENE-Y
function, O
while O
prednisolone B-CHEMICAL
probes O
both O
GR B-GENE-Y
and O

mineralocorticoid B-GENE-Y
receptor I-GENE-Y
(MR) B-GENE-Y
function. O
MATERIALS O
AND O
METHODS: O
We O
used O
a O
single-blind, O
repeated-measure O
design. O
We O
administered O
placebo, O
prednisolone B-CHEMICAL
(5 O
mg) O
or O
dexamethasone B-CHEMICAL
(0.5 O
mg), O
at O
22:00, O
to O
18 O
severe, O
treatment-resistant O
depressed O
inpatients O
(15 O
of O
them O
with O
a O
history O
of O
childhood O
trauma) O
and O
14 O
healthy O
volunteers. O
On O
the O
following O
days, O
we O
collected O
salivary O
cortisol B-CHEMICAL
from O
9:00 O
to O
22:00. O
RESULTS: O
Depressed O
patients O
had O

higher O
salivary O
cortisol B-CHEMICAL
levels O
compared O
with O
controls, O
at O
baseline O
and O
after O
both O
prednisolone B-CHEMICAL
and O
dexamethasone B-CHEMICAL
(p<0.001). O
Consistent O
with O
previous O
studies, O
depressed O
inpatients O
showed O
impaired O
suppression O
by O
dexamethasone: B-CHEMICAL
based O
on O
the O
analysis O
of O
the O
areas O
under O
the O
curve O
(AUCs), O
suppression O
by O
dexamethasone B-CHEMICAL
(0.5 O
mg) O
was O
-85% O
in O
controls O
vs O
-46% O
in O
depressed O
patients O
(p=0.018). O
However, O
the O
same O
depressed O
patients O
showed O
normal O
suppression O
by O
prednisolone B-CHEMICAL

(5 O
mg): O
suppression O
was O
-41% O
in O
controls O
and O
-36% O
in O
depressed O
patients O
(p=0.6). O
CONCLUSIONS: O
We O
suggest O
that O
the O
additional O
effects O
of O
prednisolone B-CHEMICAL
on O
the O
MR B-GENE-Y
explain O
the O
different O
responses O
to O
these O
glucocorticoids O
in O
the O
same O
depressed O
patients. O
Adolescence O
methylphenidate B-CHEMICAL
treatment O
in O
a O
rodent O
model O
of O
attention O
deficit/hyperactivity O
disorder: O
Dopamine B-GENE-Y
transporter I-GENE-Y
function O
and O
cellular O
distribution O
in O
adulthood. O
Attention O
deficit/hyperactivity O
disorder O
(ADHD) O
is O
attributed O
to O
dysfunction O
of O
the O

prefrontal O
cortex. O
Methylphenidate, B-CHEMICAL
an O
inhibitor O
of O
dopamine B-GENE-N
and I-GENE-N
norepinephrine I-GENE-N
transporters I-GENE-N
(DAT B-GENE-Y
and O
NET, B-GENE-Y
respectively), O
is O
a O
standard O
treatment O
for O
ADHD. O
The O
Spontaneously O
Hypertensive O
Rat O
(SHR) O
is O
a O
well-established O
animal O
model O
of O
ADHD. O
Our O
previous O
results O
showed O
that O
methylphenidate B-CHEMICAL
treatment O
in O
adolescent O
SHR O
enhanced O
cocaine B-CHEMICAL
self-administration O
during O
adulthood, O
and O
alterations O
in O
DAT B-GENE-Y
function O
in O
prefrontal O
cortex O
play O
a O
role O
in O
this O
response. O
Importantly, O
prefrontal O
cortex O
subregions, O
orbitofrontal O
cortex O

(OFC) O
and O
medial O
prefrontal O
cortex O
(mPFC), O
have O
been O
shown O
to O
have O
distinct O
roles O
in O
ADHD O
and O
cocaine B-CHEMICAL
self-administration. O
In O
the O
current O
study, O
SHR, O
Wistar-Kyoto O
(WKY) O
and O
Wistar O
(WIS) O
rats O
received O
a O
therapeutically O
relevant O
dose O
of O
methylphenidate B-CHEMICAL
(1.5mg/kg, O
p.o.) O
or O
vehicle O
during O
adolescence O
and O
then O
OFC O
and O
mPFC O
DAT B-GENE-Y
function O
and O
cellular O
expression O
were O
assessed O
during O
adulthood. O
In O
both O
OFC O
and O
mPFC, O
no O
strain O
differences O
in O
Vmax O
or O

Km O
for O
dopamine B-CHEMICAL
uptake O
into O
synaptosomes O
were O
found O
between O
vehicle-treated O
SHR, O
WKY O
and O
WIS. O
Methylphenidate B-CHEMICAL
increased O
DAT B-GENE-Y
Vmax O
in O
SHR O
mPFC O
and O
decreased O
DAT B-GENE-Y
Vmax O
in O
WKY O
OFC. O
Also, O
methylphenidate B-CHEMICAL
decreased O
DAT B-GENE-Y
Km O
in O
WIS O
OFC. O
Further, O
methylphenidate B-CHEMICAL
did O
not O
alter O
DAT B-GENE-Y
cellular O
localization, O
indicating O
that O
methylphenidate B-CHEMICAL
treatment O
during O
adolescence O
regulated O
DAT B-GENE-Y
function O
in O
SHR O
mPFC O
in O
a O
trafficking-independent O
manner. O
Thus, O
the O
increase O

in O
mPFC O
DAT B-GENE-Y
function O
was O
an O
SHR-specific O
long O
term O
consequence O
of O
methylphenidate B-CHEMICAL
treatment O
during O
adolescence, O
which O
may O
be O
responsible O
for O
the O
treatment-induced O
alterations O
in O
behavior O
including O
the O
observed O
increases O
in O
cocaine B-CHEMICAL
self-administration. O
Dual O
inhibitor O
of O
PDE7 B-GENE-N
and O
GSK-3-VP1.15 B-GENE-N
acts O
as O
antipsychotic O
and O
cognitive O
enhancer O
in O
C57BL/6J O
mice. O
Cognitive O
deficit O
is O
a O
core O
of O
schizophrenia O
and O
it O
is O
not O
effectively O
treated O
by O
the O
available O
antipsychotic O
drugs, O
hence O
new O
and O
more O
effective O
therapy O
is O
needed. O
Schizophrenia O
is O

considered O
as O
a O
pathway O
disorder O
where O
Disrupted-In-Schizophrenia-1 B-GENE-Y
(DISC1) B-GENE-Y
is O
important O
molecular O
player O
that O
regulates O
multiple O
cellular O
cascades. O
We O
recently O
reported O
synergistic O
action O
between O
phosphodiesterase-4 B-GENE-N
(PDE4) B-GENE-N
and O
glycogen B-GENE-N
synthase I-GENE-N
kinase-3 I-GENE-N
(GSK-3) B-GENE-N
as O
DISC1 B-GENE-Y
interacting O
proteins. O
In O
the O
current O
study O
we O
characterized O
behavioural O
effects O
of O
a O
newly O
developed O
compound, O
VP1.15 O
that O
inhibits O
both O
PDE7 B-GENE-N
and O
GSK-3 B-GENE-N
with O
main O
focus O
on O
its O

antipsychotic O
and O
cognitive O
capacities. O
VP1.15 O
reduced O
ambulation O
in O
C57BL/6J O
mice O
in O
a O
dose-dependent O
manner O
(7.5 O
mg/kg O
and O
3 O
mg/kg, O
respectively) O
and, O
hence, O
lower O
dose O
was O
chosen O
for O
the O
further O
analysis. O
VP1.1.5 O
facilitated O
pre-pulse O
inhibition O
(PPI), O
reversed O
amphetamine- B-CHEMICAL
but O
not O
MK-801-induced B-CHEMICAL
PPI O
deficit. O
The O
drug O
was O
able O
to O
ameliorate O
the O
disrupted O
latent O
inhibition O
(LI) O
induced O
by O
the O
increased O
number O
of O
conditioning O
trials O
and O
reversed O

amphetamine-induced B-CHEMICAL
LI O
deficit, O
supporting O
further O
its O
antipsychotic O
effects. O
The O
drug O
also O
significantly O
improved O
episodic O
memory O
in O
the O
spatial O
object O
recognition O
test, O
facilitated O
working O
memory O
in O
Y-maze O
and O
enhanced O
cued O
fear O
memory, O
but O
had O
no O
effect O
on O
executive O
function O
in O
the O
Puzzle O
box O
and O
contextual O
fear O
conditioning. O
Taken O
together, O
VP1.15 O
elicited O
antipsychotic O
effects O
and O
also O
facilitated O
cognitive O
domains O
in O
mice, O
suggesting O
that O
multitarget O
drugs, O
affecting O
molecular O
substrates O
from O
the O
same O
pathway, O
perhaps O
could O
be O
antipsychotics O
of O
new-generation O
that O
open O
a O
new O
possibilities O
in O
drug O

discoveries. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Cognitive O
Enhancers'. O
Comparison O
of O
inhibitory O
effects O
of O
meloxicam B-CHEMICAL
and O
diclofenac B-CHEMICAL
on O
human O
thromboxane B-CHEMICAL
biosynthesis O
after O
single O
doses O
and O
at O
steady O
state. O
OBJECTIVE: O
To O
evaluate O
the O
extent O
of O
human B-GENE-Y
cyclooxygenase-1 I-GENE-Y
(COX-1) B-GENE-Y
inhibition O
by O
meloxicam, B-CHEMICAL
which O
has O
been O
reported O
to O
preferentially O
inhibit O
cyclooxygenase-2 B-GENE-Y
(COX-2). B-GENE-Y
The O
effects O
of O

meloxicam B-CHEMICAL
were O
compared O
with O
those O
of O
diclofenac, B-CHEMICAL
a O
nonselective O
COX B-GENE-N
inhibitor. O
METHODS: O
COX-1 B-GENE-Y
inhibition O
was O
determined O
by O
measuring O
thromboxane B-CHEMICAL
B2 I-CHEMICAL
(TXB2)-generation B-CHEMICAL
from O
clotting O
whole O
blood O
ex O
vivo O
after O
single O
oral O
doses O
of O
7.5 O
and O
15 O
mg O
meloxicam B-CHEMICAL
and O
75 O
mg O
diclofenac B-CHEMICAL
and O
at O
steady O
state O
(15 O
mg O
meloxicam B-CHEMICAL
daily O
and O
150 O
mg O
diclofenac B-CHEMICAL
daily). O
The O
effect O
was O
expressed O
as O
percentage O
inhibition O
of O
serum O
TXB2 B-CHEMICAL
generation O
and O
was O
directly O
related O
to O

the O
serum O
drug O
concentration O
with O
use O
of O
a O
standard O
sigmoidal O
E(max) O
model. O
RESULTS: O
In O
terms O
of O
inhibition O
of O
TXB2 B-CHEMICAL
generation, O
diclofenac B-CHEMICAL
was O
about O
1 O
order O
of O
magnitude O
more O
potent O
than O
meloxicam, B-CHEMICAL
indicated O
by O
a O
diclofenac B-CHEMICAL
EC50 O
(concentration O
of O
drug O
required O
to O
cause O
50% O
of O
maximum O
effect) O
that O
was O
about O
10 O
times O
lower O
than O
that O
of O
meloxicam B-CHEMICAL
(EC50 O
diclofenac B-CHEMICAL
single O
doses: O
37.50+/-29.64; O
EC50 O
meloxicam B-CHEMICAL
single O
doses: O

677.50+/-189.08). O
However, O
serum O
concentrations O
of O
meloxicam B-CHEMICAL
after O
administration O
of O
15 O
mg O
were O
approximately O
10-fold O
higher O
than O
those O
of O
diclofenac. B-CHEMICAL
Therefore O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
area O
under O
the O
effect O
time O
curve O
(P O
= O
.115) O
and O
the O
mean O
effect O
(P O
= O
.424) O
between O
meloxicam B-CHEMICAL
and O
diclofenac. B-CHEMICAL
The O
EC50 O
of O
both O
drugs O
was O
significantly O
higher O
at O
steady O
state O
(diclofenac B-CHEMICAL
steady O
state: O
87.07+/-55.24 O
ng/mL; O
meloxicam B-CHEMICAL
steady O

state: O
1850.12+/-829.93 O
ng/mL) O
than O
after O
a O
single O
dose O
(P O
< O
.001). O
CONCLUSION: O
These O
data O
show O
that O
meloxicam B-CHEMICAL
inhibits O
TXB2 B-CHEMICAL
generation O
at O
clinically O
relevant O
doses, O
although O
less O
potently O
than O
diclofenac. B-CHEMICAL
Thus O
our O
data O
suggest O
that O
the O
COX-2 B-GENE-Y
preference O
of O
meloxicam B-CHEMICAL
observed O
in O
vitro O
may O
not O
result O
in O
clinical O
advantages O
when O
the O
higher O
dose O
of O
15 O
mg O
is O
needed. O
Because O
of O
the O
increase O
in O
EC50 O
at O
steady O
state, O
COX-1 B-GENE-Y
is O
relatively O
spared O
when O
the O
lower O

dose O
of O
7.5 O
mg O
is O
administered. O
Interleukin B-GENE-Y
2 I-GENE-Y
toxin: O
a O
step O
toward O
selective O
immunomodulation. O
We O
have O
used O
protein O
engineering O
and O
recombinant O
DNA O
methodologies O
to O
genetically O
replace O
the O
eukaryotic B-GENE-N
cell I-GENE-N
receptor I-GENE-N
binding I-GENE-N
domain I-GENE-N
of O
diphtheria O
toxin O
with O
interleukin B-GENE-Y
2 I-GENE-Y
(IL-2). B-GENE-Y
The O
toxin-related O
T B-GENE-N
cell I-GENE-N
growth I-GENE-N
factor I-GENE-N
fusion O
gene O
has O
been O
cloned O
in O
Escherichia O
coli O
K12. O
Recombinant O
strains O
of O
E O
coli O
produce O
a O
68,086 O
K O
hybrid O
toxin, O
IL-2 B-GENE-Y
toxin O
that O
retains O

immunologic O
properties O
intrinsic O
to O
both O
its O
diphtheria O
toxin O
and O
IL-2 B-GENE-Y
components. O
IL-2 B-GENE-N
toxin O
has O
been O
found O
to O
selectively O
inhibit O
protein O
synthesis O
in O
both O
human O
and O
murine O
T O
cell O
lines O
that O
bear O
high O
affinity O
IL-2 B-GENE-N
receptors, I-GENE-N
whereas O
the O
hybrid O
toxin O
is O
not O
active O
against O
cells O
that O
do O
not O
bear O
this O
receptor. O
The O
cytotoxic O
action O
of O
IL-2 B-GENE-Y
toxin O
is O
specifically O
blocked O
by O
free O
IL-2 B-GENE-Y
and O
monoclonal O
antibodies O
that O
bind O
to O
the O
p55 B-GENE-Y
(Tac B-GENE-N
antigen) O
subunit O
of O
the O
high O
affinity O
IL-2 B-GENE-N
receptor. I-GENE-N
In O
addition, O

IL-2 B-GENE-Y
toxin, O
like O
diphtheria O
toxin O
itself, O
must O
pass O
through O
an O
acidic O
compartment O
in O
order O
to O
deliver O
its O
adenosine B-GENE-N
diphosphate I-GENE-N
ribosyl I-GENE-N
transferase I-GENE-N
activity O
to O
the O
cytosol O
of O
target O
T O
cells. O
In O
a O
murine O
delayed O
type O
hypersensitivity O
(DTH) O
model O
system, O
we O
have O
shown O
that O
IL-2 B-GENE-Y
toxin O
treatment O
induces O
a O
marked O
immunosuppression. O
3D O
Organotypic O
Cultures O
of O
Human O
HepaRG O
Cells: O
A O
Tool O
for O
In O
Vitro O
Toxicity O
Studies. O
Drug-induced O
human O

hepatotoxicity O
is O
difficult O
to O
predict O
using O
the O
current O
in O
vitro O
systems. O
In O
this O
study, O
long-term O
3D O
organotypic O
cultures O
of O
the O
human O
hepatoma O
HepaRG O
cell O
line O
were O
prepared O
using O
a O
high-throughput O
hanging O
drop O
method. O
The O
organotypic O
cultures O
were O
maintained O
for O
3 O
weeks O
and O
assessed O
for O
(1) O
liver O
specific O
functions, O
including O
phase O
I O
enzyme O
and O
transporter O
activities, O
(2) O
expression O
of O
liver-specific O
proteins, O
and O
(3) O
responses O
to O
three O
drugs O
(acetaminophen, B-CHEMICAL
troglitazone, B-CHEMICAL
and O
rosiglitazone). B-CHEMICAL
Our O
results O
show O

that O
the O
organotypic O
cultures O
maintain O
high O
liver-specific O
functionality O
during O
3 O
weeks O
of O
culture. O
The O
immunohistochemistry O
analyses O
illustrate O
that O
the O
organotypic O
cultures O
express O
liver-specific O
markers O
such O
as O
albumin, B-GENE-Y
CYP3A4, B-GENE-Y
CYP2E1, B-GENE-Y
and O
MRP-2 B-GENE-Y
throughout O
the O
cultivation O
period. O
Accordingly, O
the O
production O
rates O
of O
albumin B-GENE-Y
and O
glucose, B-CHEMICAL
as O
well O
as O
CYP2E1 B-GENE-Y
activity, O
were O
significantly O
higher O
in O
the O
3D O
versus O
the O
2D O
cultures. O
Toxicity O
studies O
show O
that O
the O
organotypic O
cultures O
are O
more O
sensitive O
to O
acetaminophen- B-CHEMICAL
and O
rosiglitazone-induced B-CHEMICAL
toxicity O
but O

less O
sensitive O
to O
troglitazone-induced B-CHEMICAL
toxicity O
than O
the O
2D O
cultures. O
Furthermore, O
the O
EC50 O
value O
(2.7mM) O
for O
acetaminophen B-CHEMICAL
on O
the O
3D O
cultures O
was O
similar O
to O
in O
vivo O
toxicity. O
In O
summary, O
the O
results O
from O
our O
study O
suggest O
that O
the O
3D O
organotypic O
HepaRG O
culture O
is O
a O
promising O
in O
vitro O
tool O
for O
more O
accurate O
assessment O
of O
acute O
and O
also O
possibly O
for O
chronic O
drug-induced O
hepatotoxicity. O
Inhibition O
of O
angiogenesis O
and O
invasion O
by O
DMBT B-CHEMICAL
is O
mediated O
by O
downregulation O
of O
VEGF B-GENE-N
and O
MMP-9 B-GENE-Y
through O
Akt B-GENE-N

pathway O
in O
MDA-MB-231 O
breast O
cancer O
cells. O
Invasion, O
either O
directly O
or O
via O
metastasis O
formation, O
is O
the O
main O
cause O
of O
death O
in O
cancer O
patients, O
development O
of O
efficient O
anti-invasive O
agents O
is O
an O
important O
research O
challenge. O
In O
order O
to O
obtain O
more O
potent O
inhibitors, O
a O
series O
of O
brartemicin B-CHEMICAL
analogs O
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
activity O
against O
invasion. O
Among O
the O
synthetic O
analogs O
tested, O
DMBT, B-CHEMICAL
6,6'-bis B-CHEMICAL
(2,3-dimethoxybenzoyl)-a,a-d-trehalose, I-CHEMICAL
was O
found O
to O
be O
the O
most O
potent O

anti-invasive O
agent. O
But O
the O
effects O
of O
DMBT B-CHEMICAL
on O
breast O
cancer O
cells O
were O
not O
known. O
In O
this O
study, O
the O
effects O
of O
DMBT B-CHEMICAL
on O
invasion O
and O
metastasis O
in O
MDA-MB-231 O
cells O
were O
investigated. O
MTT B-CHEMICAL
assay O
showed O
that O
no O
obvious O
inhibitory O
or O
cytotoxic O
effect O
of O
DMBT B-CHEMICAL
was O
found. O
DMBT B-CHEMICAL
could O
inhibit O
invasion, O
migration O
and O
tube O
formation O
of O
HUVECs. O
Gelatin O
zymography O
showed O
that O
DMBT B-CHEMICAL
inhibited O
secretion O
and O
activity O
of O
MMP-9. B-GENE-Y
Western O
blotting O
demonstrated O
that O
DMBT B-CHEMICAL
effectively O
suppressed O
the O
expression O

of O
VEGF, B-GENE-N
p-VEGFR-2, B-GENE-Y
p-EGFR, B-GENE-Y
and O
p-Akt. B-GENE-N
These O
results O
suggested O
that O
DMBT B-CHEMICAL
could O
inhibit O
invasion O
and O
angiogenesis O
by O
downregulation O
of O
VEGFand B-GENE-N
MMP-9, B-GENE-Y
resulting O
from O
the O
inhibition O
of O
Akt B-GENE-N
pathway. O
DMBT B-CHEMICAL
might O
be O
a O
promising O
lead O
molecule O
for O
the O
anti-metastasis O
and O
serve O
as O
a O
therapeutic O
agent O
to O
inhibit O
breast O
cancer O
cell O
invasion O
and O
metastasis. O
Quantitative O
determination O
of O
fatty B-CHEMICAL
acid I-CHEMICAL
chain O
composition O
in O
pork O
meat O
products O
by O
high O
resolution O
1H B-CHEMICAL
NMR O
spectroscopy. O

High O
resolution O
(1)H B-CHEMICAL
NMR O
spectroscopy O
was O
proposed O
for O
the O
determination O
of O
the O
fatty B-CHEMICAL
acid I-CHEMICAL
chain O
profile O
of O
lipids O
in O
pork O
meat O
products O
during O
ripening. O
Two O
typical O
Mediterranean O
PDO O
salami O
produced O
in O
Calabria, O
a O
region O
in O
the O
Southern O
Italy, O
were O
chosen O
as O
a O
case O
of O
study. O
Quantitative O
NMR O
analysis O
provided O
the O
fatty B-CHEMICAL
acid I-CHEMICAL
chain O
profiles O
of O
total O
lipid O
extracts. O
The O
transesterification O
of O
total O
lipid O
extracts O
furnished O
FAME B-CHEMICAL
mixtures O
that O
enabled O
quantitation O
of O
fatty B-CHEMICAL
acid I-CHEMICAL
acyl I-CHEMICAL
chains O
in O
the O
acylglycerol B-CHEMICAL
and O
FFA O
portions. O
In O
all O
cases, O

oleyl B-CHEMICAL
chains O
were O
predominant, O
and O
high O
amounts O
of O
polyunsaturated B-CHEMICAL
fatty I-CHEMICAL
acid I-CHEMICAL
chains O
were O
observed. O
The O
proposed O
spectroscopic O
method O
allowed O
also O
the O
estimation O
of O
the O
most O
important O
nutritional O
parameters O
of O
dry O
fermented O
meat O
products. O
Identification O
of O
the O
regulatory O
region O
of O
the O
L-type B-GENE-Y
pyruvate I-GENE-Y
kinase I-GENE-Y
gene O
in O
mouse O
liver O
by O
hydrodynamics-based O
gene O
transfection. O
Expression O
of O
L-type B-GENE-Y
pyruvate I-GENE-Y
kinase I-GENE-Y
(L-PK) B-GENE-Y
is O
upregulated O
in O
the O
liver O
by O
dietary O
carbohydrate. B-CHEMICAL
Previously, O
3 O

carbohydrate/insulin B-GENE-N
response I-GENE-N
elements I-GENE-N
were O
identified O
in O
the O
5'-flanking O
region O
of O
the O
L-PK B-GENE-Y
gene O
up O
to O
bp O
-170. O
Studies O
of O
the O
5'-flanking O
region O
beyond O
bp O
-183 O
in O
transgenic O
mice O
suggested O
that O
other O
regulatory O
elements O
may O
be O
present O
upstream O
of O
bp O
-183, O
but O
the O
positions O
of O
these O
elements O
were O
uncertain. O
In O
the O
present O
study, O
the O
existence O
of O
regulatory O
regions O
of O
the O
L-PK B-GENE-Y
gene O
responding O
to O
stimulation O
by O
feeding O
was O
examined O
using O
in O
vivo O
hydrodynamics-based O
gene O
transfection O
(HT) O
in O
mouse O
liver. O
The O

firefly-luciferase O
(FL) O
gene, O
fused O
with O
various O
lengths O
of O
the O
5'-flanking O
region O
of O
the O
L-PK B-GENE-Y
gene, O
was O
introduced O
into O
mouse O
liver O
by O
HT. O
The O
mice O
had O
free O
access O
to O
a O
high-carbohydrate B-CHEMICAL
diet. O
In O
liver O
homogenate, O
luciferase O
activity O
of O
pL-PK(-1467)-FL B-GENE-Y
(which O
included O
the O
5'-flanking O
region O
from O
bp O
-1467 O
to O
+17), O
was O
markedly O
stimulated O
by O
feeding. O
5'-Deletion O
up O
to O
bp O
-1065 O
caused O
only O

minor O
changes O
in O
luciferase O
activity, O
but O
further O
deletion O
up O
to O
bp O
-690 O
and O
bp O
-203 O
caused O
significant, O
gradual O
decreases O
in O
activity. O
Further O
analyses O
utilizing O
5'-deletion O
mutants O
indicated O
the O
existence O
of O
positive O
regulatory O
regions O
that O
respond O
to O
stimulation O
by O
feeding O
between O
bp O
-1065 O
and O
-945, O
and O
between O
-300 O
and O
-203 O
on O
the O
L-PK B-GENE-Y
gene. O
These O
results O
suggest O
that O
unidentified O
cis-acting B-GENE-N
DNA I-GENE-N
elements I-GENE-N
exist O
in O
the O
upstream O
region O
of O
the O
L-PK B-GENE-Y
gene, O
and O
that O
HT O
is O
a O
useful O
approach O
for O
detecting O
regulatory O
regions O
of O
genes O
expressed O
in O
the O

liver. O
The O
Ras-GTPase B-GENE-N
activity O
of O
neurofibromin B-GENE-Y
restrains O
ERK-dependent B-GENE-N
FGFR B-GENE-N
signaling O
during O
endochondral O
bone O
formation. O
The O
severe O
defects O
in O
growth O
plate O
development O
caused O
by O
chondrocyte O
extracellular B-GENE-N
signal-regulated I-GENE-N
protein I-GENE-N
kinases I-GENE-N
1 I-GENE-N
and I-GENE-N
2 I-GENE-N
(ERK1/2) B-GENE-N
gain O
or O
loss-of-function O
suggest O
that O
tight O
spatial O
and O
temporal O
regulation O
of O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
signaling O
is O
necessary O
to O
achieve O
harmonious O
growth O
plate O
elongation O
and O
structure. O
We O
provide O
here O
evidence O
that O
neurofibromin, B-GENE-Y
via O
its O
Ras B-GENE-N
guanosine B-GENE-N

triphosphatase I-GENE-N
-activating O
activity, O
controls O
ERK1/2-dependent B-GENE-N
fibroblast B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
(FGFR) B-GENE-N
signaling O
in O
chondrocytes. O
We O
show O
first O
that O
neurofibromin B-GENE-Y
is O
expressed O
in O
FGFR-positive B-GENE-N
prehypertrophic O
and O
hypertrophic O
chondrocytes O
during O
growth O
plate O
endochondral O
ossification. O
Using O
mice O
lacking O
neurofibromin B-GENE-Y
1 I-GENE-Y
(Nf1) B-GENE-Y
in O
type B-GENE-N
II I-GENE-N
collagen-expressing I-GENE-N
cells, O
(Nf1col2(-/-) B-GENE-Y
mutant O
mice), O
we O
then O
show O
that O
lack O

of O
neurofibromin B-GENE-Y
in O
post-mitotic O
chondrocytes O
triggers O
a O
number O
of O
phenotypes O
reminiscent O
of O
the O
ones O
observed O
in O
mice O
characterized O
by O
FGFR B-GENE-N
gain-of-function O
mutations. O
Those O
include O
dwarfism, O
constitutive O
ERK1/2 B-GENE-N
activation, O
strongly O
reduced O
Ihh B-GENE-Y
expression O
and O
decreased O
chondrocyte O
proliferation O
and O
maturation, O
increased O
chondrocytic O
expression O
of O
Rankl, B-GENE-Y
matrix B-GENE-Y
metalloproteinase I-GENE-Y
9 I-GENE-Y
(Mmp9) B-GENE-Y
and O
Mmp13 B-GENE-Y
and O
enhanced O
growth O
plate O
osteoclastogenesis, O
as O
well O
as O
increased O
sensitivity O
to O

caspase-9 B-GENE-Y
mediated O
apoptosis. O
Using O
wildtype O
(WT) O
and O
Nf1(-/-) B-GENE-Y
chondrocyte O
cultures O
in O
vitro, O
we O
show O
that O
FGF2 B-GENE-Y
pulse-stimulation O
triggers O
rapid O
ERK1/2 B-GENE-N
phosphorylation O
in O
both O
genotypes, O
but O
that O
return O
to O
the O
basal O
level O
is O
delayed O
in O
Nf1(-/-) B-GENE-Y
chondrocytes. O
Importantly, O
in O
vivo O
ERK1/2 B-GENE-N
inhibition O
by O
daily O
injection O
of O
a O
recombinant O
form O
of O
C-type B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
to O

post-natal O
pups O
for O
18 O
days O
was O
able O
to O
correct O
the O
short O
stature O
of O
Nf1col2(-/-) B-GENE-Y
mice. O
Together, O
these O
results O
underscore O
the O
requirement O
of O
neurofibromin O
and O
ERK1/2 B-GENE-N
for O
normal O
endochondral O
bone O
formation O
and O
support O
the O
notion O
that O
neurofibromin, O
by O
restraining O
RAS-ERK1/2 B-GENE-N
signaling, O
is O
a O
negative O
regulator O
of O
FGFR B-GENE-N
signaling O
in O
differentiating O
chondrocytes. O
Felbamate B-CHEMICAL
block O
of O
recombinant O
N-methyl-D-aspartate B-GENE-N
receptors: I-GENE-N

selectivity O
for O
the O
NR2B B-GENE-Y
subunit. O
The O
anticonvulsant O
felbamate B-CHEMICAL
blocks O
N-methyl-D-asparate B-GENE-N
(NMDA) I-GENE-N
receptors I-GENE-N
but O
fails O
to O
exhibit O
the O
neurobehavioral O
toxicity O
characteristic O
of O
other O
NMDA B-GENE-N
receptor I-GENE-N
antagonists. O
To O
investigate O
the O
possibility O
that O
felbamate's O
favorable O
toxicity O
profile O
could O
be O
related O
to O
NMDA B-GENE-N
receptor I-GENE-N
subtype O
selectivity, O
we O
examined O
the O
specificity O
of O
felbamate B-CHEMICAL
block O
of O
recombinant O
NMDA B-GENE-N
receptors I-GENE-N
composed O
of O
the O
NR1a B-GENE-Y
subunit O
and O
various O
NR2 B-GENE-N
subunits. O
Felbamate B-CHEMICAL

produced O
a O
rapid, O
concentration-dependent O
block O
of O
currents O
evoked O
by O
50 O
microM O
NMDA B-CHEMICAL
and O
10 O
microM O
glycine B-CHEMICAL
in O
human O
embryonic O
kidney O
293 O
cells O
expressing O
the O
rat B-GENE-Y
NR1a I-GENE-Y
subunit, O
and O
either O
the O
NR2A, B-GENE-Y
NR2B B-GENE-Y
or O
NR2C B-GENE-Y
subunits; O
the O
IC50 O
values O
for O
block O
were O
2.6, O
0.52 O
and O
2.4 O
mM, O
respectively O
(holding O
potential, O
- O
60 O
mV). O
The O
Hill O
coefficient O
values O
were O
< O
1 O
and, O
in O
kinetic O
analyses, O
onset O
and O
recovery O
from O
block O
were O
well O
fit O
by O
double O
exponential O

functions, O
indicating O
binding O
to O
more O
than O
one O
blocking O
site O
on O
the O
NMDA B-GENE-N
receptor I-GENE-N
channel O
complex. O
The O
higher O
affinity O
of O
felbamate B-CHEMICAL
block O
of O
NMDA B-GENE-N
receptors I-GENE-N
containing O
the O
NR2B B-GENE-Y
subunit O
could O
be O
accounted O
for O
by O
more O
rapid O
association O
and O
slower O
dissociation O
from O
these O
sites. O
We O
conclude O
that O
felbamate B-CHEMICAL
exhibits O
modest O
selectivity O
for O
NMDA B-GENE-N
receptors I-GENE-N
composed O
of O
NR1a/NR2B B-GENE-Y
subunits. O
This O
selectivity O
could, O
in O
part, O
account O
for O
the O
more O
favorable O
clinical O
profile O
of O
felbamate B-CHEMICAL
in O
comparison O
with O
NMDA B-GENE-N
receptor I-GENE-N
antagonists O
that O
do O
not O
show O
subunit O
selectivity. O

Adrenocortical O
reserves O
in O
hyperthyroidism. O
Explicit O
data O
regarding O
the O
changes O
in O
adrenocortical O
reserves O
during O
hyperthyroidism O
do O
not O
exist. O
We O
aimed O
to O
document O
the O
capability O
(response) O
of O
adrenal O
gland O
to O
secrete O
cortisol B-CHEMICAL
and O
DHEA-S B-CHEMICAL
during O
hyperthyroidism O
compared O
to O
euthyroidism, O
and O
to O
describe O
factors O
associated O
with O
these O
responses. O
A O
standard-dose O
(0.25 O
mg/i.v.) O
ACTH B-GENE-Y
stimulation O
test O
was O
performed O
to O
the O
same O
patients O
before O
hyperthyroidism O
treatment, O
and O
after O
attainment O
of O

euthyroidism. O
Baseline O
cortisol B-CHEMICAL
(Cor0), O
DHEA-S B-CHEMICAL
(DHEA-S0), B-CHEMICAL
cortisol B-GENE-Y
binding I-GENE-Y
globulin I-GENE-Y
(CBG), B-GENE-Y
ACTH, B-GENE-Y
calculated O
free O
cortisol B-CHEMICAL
(by O
Coolen's O
equation O
= O
CFC), O
free O
cortisol B-CHEMICAL
index O
(FCI), O
60-min O
cortisol B-CHEMICAL
(Cor60), O
and O
DHEA-S B-CHEMICAL
(DHEA-S60), B-CHEMICAL
delta B-CHEMICAL
cortisol I-CHEMICAL
(ΔCor), B-CHEMICAL
delta B-CHEMICAL
DHEA-S I-CHEMICAL

(ΔDHEA-S) B-CHEMICAL
responses O
were O
evaluated. O
Forty-one O
patients O
[22 O
females, O
49.5 O
± O
15.2 O
years O
old, O
32 O
Graves O
disease, O
nine O
toxic O
nodular O
goiter] O
had O
similar O
Cor0, O
DHEA-S0, B-CHEMICAL
CFC, O
FCI, O
and O
DHEA-S60 B-CHEMICAL
in O
hyperthyroid O
and O
euthyroid O
states. O
Cor60, O
ΔCor, B-CHEMICAL
and O
ΔDHEA-S B-CHEMICAL
were O
lower O
in O
hyperthyroidism. O
In O
four O
(10 O
%) O
patients O
the O
peak O
ACTH-stimulated B-GENE-Y
cortisol B-CHEMICAL
values O
were O
lower O
than O
18 O

μg/dL. O
When O
the O
test O
repeated O
after O
attainment O
of O
euthyroidism, O
all O
of O
the O
patients O
had O
normal O
cortisol B-CHEMICAL
response. O
Regression O
analysis O
demonstrated O
an O
independent O
association O
of O
Cor60 O
with O
free O
T3 O
in O
hyperthyroidism. O
However, O
the O
predictors O
of O
CFC, O
FCI, O
and O
DHEA-S B-CHEMICAL
levels O
were O
serum O
creatinine B-CHEMICAL
levels O
in O
hyperthyroidism, O
and O
both O
creatinine B-CHEMICAL
and O
transaminase B-GENE-N
levels O
in O
euthyroidism. O
ACTH-stimulated B-GENE-Y
peak O
cortisol, B-CHEMICAL
delta B-CHEMICAL
cortisol, I-CHEMICAL
and O
delta B-CHEMICAL

DHEA-S I-CHEMICAL
levels O
are O
decreased O
during O
hyperthyroidism, O
probably O
due O
to O
increased O
turnover. O
Since O
about O
10 O
% O
of O
the O
subjects O
with O
hyperthyroidism O
are O
at O
risk O
for O
adrenal O
insufficiency, O
clinicians O
dealing O
with O
Graves' O
disease O
should O
be O
alert O
to O
the O
possibility O
of O
adrenal O
insufficiency O
during O
hyperthyroid O
stage. O
Mechanisms O
of O
agonist-induced O
down-regulation O
of O
the O
human B-GENE-Y
kappa-opioid I-GENE-Y
receptor: I-GENE-Y
internalization O
is O
required O
for O
down-regulation. O
Previously, O
we O
showed O
that O
the O
human B-GENE-Y
kappa-opioid I-GENE-Y
receptor I-GENE-Y
(hkor) B-GENE-Y
stably O
expressed O
in O
Chinese O

hamster O
ovary O
(CHO) O
cells O
underwent O
down-regulation O
after O
prolonged O
U50,488H B-CHEMICAL
treatment. O
In O
the O
present O
study, O
we O
determined O
the O
mechanisms O
underlying O
this O
process. O
U50, B-CHEMICAL
488H I-CHEMICAL
caused O
a O
significant O
down-regulation O
of O
the O
hkor, B-GENE-Y
although O
etorphine B-CHEMICAL
did O
not. O
Neither O
U50,488H B-CHEMICAL
nor O
etorphine B-CHEMICAL
caused O
down-regulation O
of O
the O
rat B-GENE-Y
kappa-opioid I-GENE-Y
receptor. I-GENE-Y
Thus, O
similar O
to O
internalization, O
there O
are O
agonist O
and O
species O
differences O
in O
down-regulation O
of O
kappa-opioid B-GENE-Y
receptors. I-GENE-Y
Expression O
of O
the O
dominant O
negative O
mutants O

arrestin-2(319-418) B-GENE-Y
or O
dynamin B-GENE-Y
I-K44A I-GENE-Y
significantly O
reduced O
U50,488H-induced B-CHEMICAL
down-regulation O
of O
the O
hkor. B-GENE-Y
Coexpression O
of O
GRK2 B-GENE-Y
or O
GRK2 B-GENE-Y
and O
arrestin-2 B-GENE-Y
permitted O
etorphine B-CHEMICAL
to O
induce O
down-regulation O
of O
the O
hkor, B-GENE-Y
although O
expression O
of O
arrestin-2 B-GENE-Y
or O
dynamin B-GENE-Y
I I-GENE-Y
alone O
did O
not. O
Expression O
of O
the O
dominant O
negative O
mutants O
rab5A-N133I B-GENE-Y
or O
rab7-N125I B-GENE-N
blunted O
U50,488H-induced B-CHEMICAL

down-regulation. O
Pretreatment O
with O
lysosomal O
enzyme O
inhibitors O
[(2S, B-CHEMICAL
3S)trans-epoxysuccinyl-L-leucylamido-3-methylbutane I-CHEMICAL
ethyl I-CHEMICAL
ester I-CHEMICAL
or I-CHEMICAL
chloroquine] I-CHEMICAL
or O
proteasome B-GENE-N
inhibitors O
(proteasome B-GENE-N
inhibitor O
I, O
MG-132, B-CHEMICAL
or O
lactacystin) B-CHEMICAL
decreased O
the O
extent O
of O
U50,488H-induced B-CHEMICAL
down-regulation. O
A O
combination O
of O
chloroquine B-CHEMICAL
and O
proteasome B-GENE-N
inhibitor O
I O
abolished O
U50,488H-induced B-CHEMICAL

down-regulation. O
These O
results O
indicate O
that O
U50,488H-induced B-CHEMICAL
down-regulation O
of O
the O
hkor B-GENE-Y
involves O
GRK-, B-GENE-N
arrestin-2-, B-GENE-Y
dynamin-, B-GENE-N
rab5-, B-GENE-N
and O
rab7-dependent B-GENE-N
mechanisms O
and O
receptors O
seem O
to O
be O
trafficked O
to O
lysosomes O
and O
proteasomes B-GENE-N
for O
degradation. O
Thus, O
U50,488H-induced B-CHEMICAL
internalization O
and O
down-regulation O
of O
the O
hkor B-GENE-Y
share O
initial O
common O
mechanisms. O
To O
the O
best O
of O
our O
knowledge, O
these O
results O
represent O
the O
first O
report O
on O
the O
involvement O
of O
both O
rab5 B-GENE-N
and O
rab7 B-GENE-N
in O

agonist-induced O
down-regulation O
of O
a O
G B-GENE-N
protein-coupled I-GENE-N
receptor. I-GENE-N
In O
addition, O
this O
study O
is O
among O
the O
first O
to O
show O
the O
involvement O
of O
proteasomes B-GENE-N
in O
agonist-induced O
down-regulation O
of O
a O
G B-GENE-N
protein-coupled I-GENE-N
receptor. I-GENE-N
Dose-dependent O
release O
of O
endogenous O
tissue B-GENE-Y
factor I-GENE-Y
pathway O
inhibitor O
by O
different O
low O
molecular O
weight O
heparins. O
Tissue B-GENE-Y
factor I-GENE-Y
pathway O
inhibitor O
(TFPI) O
is O
released O
to O
circulating O
blood O
after O
intravenous O
and O
subcutaneous O
injections O
of O
heparins, O
and O
may O
thus O
contribute O
to O
the O
antithrombotic O
effect O
of O
heparins. O
A O
previous O
study O
suggested O
different O

abilities O
of O
various O
low O
molecular O
weight O
heparins O
(LMWH) O
to O
release O
endogenous O
TFPI, O
but O
the O
dose-response O
relationship O
was O
not O
determined. O
In O
the O
present O
study, O
the O
dose-response O
relationship O
for O
escalating O
doses O
of O
two O
LMWHs, O
dalteparin O
and O
enoxaparin, O
on O
the O
release O
of O
endogenous O
TFPI O
was O
investigated. O
Six O
healthy O
male O
participants O
were O
given O
50, O
100 O
and O
200 O
U/kg O
dalteparin O
and O
0.5, O
1.0 O
and O
2.0 O
mg/kg O
enoxaparin O
as O
a O
single O
subcutaneous O

injection. O
The O
study O
was O
a O
randomized, O
cross-over O
design O
with O
a O
1-week O
wash-out O
period O
between O
each O
injection. O
Peak O
free O
TFPI O
antigen O
and O
TFPI O
activity O
were O
detected O
after O
only O
1 O
h, O
whereas O
anti-activated O
factor B-GENE-Y
X I-GENE-Y
(anti-FXa) B-GENE-Y
and O
anti-activated O
factor B-GENE-N
II I-GENE-N
(anti-FIIa) B-GENE-Y
activities O
were O
detected O
after O
2-6 O
h. O
Putative O
therapeutic O
equivalent O
doses O
of O
dalteparin O
and O
enoxaparin O
gave O
similar O
release O
of O
endogenous O
TFPI, O
but O
dissimilar O
effects O
on O
anti-FXa B-GENE-Y
and O
anti-FIIa B-GENE-Y
activities. O

Life-threatening O
hypoglycemia O
associated O
with O
intentional O
insulin B-GENE-Y
ingestion. O
There O
are O
reports O
of O
insulin B-GENE-Y
overdose O
by O
injection, O
yet O
little O
is O
known O
regarding O
the O
potential O
harms O
of O
intentional O
oral O
ingestion O
of O
insulin. B-GENE-Y
In O
this O
report, O
we O
describe O
a O
case O
of O
massive O
insulin B-GENE-Y
ingestion O
and O
ensuing O
hypoglycemia. O
To O
our O
knowledge, O
there O
are O
no O
previously O
published O
cases O
of O
hypoglycemia O
caused O
by O
intentional O
insulin B-GENE-Y
ingestion. O
A O
51-year-old O
man O
intentionally O
ingested O
three O
10-ml O
vials O
(total O
of O
3000 O
units) O
of O
various O
insulins: B-GENE-Y
one O
vial O
each O

of O
insulin B-GENE-Y
aspart, O
lispro, O
and O
glargine. O
Four O
symptomatic O
hypoglycemic O
episodes, O
with O
blood O
glucose B-CHEMICAL
levels O
of O
48, O
25, O
34, O
and O
40 O
mg/dl, O
occurred O
approximately O
1, O
3, O
4, O
and O
5 O
hours, O
respectively, O
after O
ingestion. O
The O
hypoglycemia O
could O
not O
be O
explained O
other O
than O
the O
ingestion O
of O
the O
insulins. B-GENE-Y
The O
patient O
was O
admitted O
for O
observation, O
and O
euglycemia O
occurred O
within O
24 O
hours O
without O
any O
additional O
hypoglycemic O
episodes. O
Hypoglycemia O
treatment O
is O

reviewed O
in O
this O
case O
report, O
and O
factors O
that O
may O
affect O
systemic O
response O
of O
orally O
ingested O
insulin, B-GENE-Y
including O
gastrointestinal O
absorption O
and O
insulin B-GENE-Y
sensitivity, O
are O
discussed. O
In O
addition, O
the O
findings O
of O
our O
case O
report O
may O
provide O
useful O
insight O
into O
the O
development O
of O
novel O
oral O
insulin B-GENE-Y
products O
that O
are O
currently O
in O
research. O
Despite O
poor O
bioavailability O
(1%) O
when O
taken O
orally, O
insulin B-GENE-Y
may O
produce O
symptomatic O
hypoglycemia O
with O
a O
massive O
ingestion. O
Vigilant O
blood O
glucose B-CHEMICAL
monitoring, O
supportive O
care O
with O
glucose B-CHEMICAL
replacement O
therapy, O
and O
admission O
to O
the O
hospital O
for O
observation O
may O
be O
required. O
Effect O
of O
water O

extracts O
from O
edible O
myrtaceae O
plants O
on O
uptake O
of O
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose B-CHEMICAL
in O
TNF-α-treated B-GENE-Y
FL83B O
mouse O
hepatocytes. O
This O
study O
investigated O
the O
glucose B-CHEMICAL
uptake O
activity O
of O
the O
water O
extracts O
from O
the O
leaves O
and O
fruit O
of O
edible O
Myrtaceae O
plants, O
including O
guava O
(Psidium O
guajava O
Linn.), O
wax O
apples O
[Syzygium O

samarangense O
(Blume) O
Merr. O
and O
L.M. O
Perry], O
Pu-Tau O
[Syzygium O
jambo O
(L.) O
Alston], O
and O
Kan-Shi O
Pu-Tau O
(Syzygium O
cumini O
Linn.) O
in O
FL83B O
mouse O
hepatocytes. O
The O
fluorescent O
dye O
2-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose B-CHEMICAL
was O
used O
to O
estimate O
the O
uptake O
ability O

of O
the O
cells. O
Glucose B-CHEMICAL
uptake O
test O
showed O
that O
pink O
wax O
apple O
fruit O
extract O
(PWFE) O
exhibits O
the O
highest O
glucose B-CHEMICAL
uptake O
activity, O
at O
an O
increment O
of O
21% O
in O
the O
insulin-resistant B-GENE-N
FL83B O
mouse O
hepatocytes O
as O
compared O
with O
the O
TNF-α-treated B-GENE-Y
control O
group. O
Vescalagin B-CHEMICAL
was O
isolated O
using O
column O
chromatography O
of O
PWFE. O
This O
compound, O
at O
the O
concentration O
of O
6.25 O
µg/mL, O
exhibits O
the O
same O
glucose B-CHEMICAL
uptake O
improvement O
in O
insulin-resistant B-GENE-N
cells O
as O
PWFE O
at O
a O

100-µg/mL O
dose. O
We O
postulate O
that O
vescalagin B-CHEMICAL
is O
an O
active O
component O
in O
PWFE O
that O
may O
alleviate O
the O
insulin B-GENE-N
resistance O
in O
mouse O
hepatocytes. O
FXR-dependent B-GENE-Y
and O
-independent O
interaction O
of O
glucocorticoids O
with O
the O
regulatory O
pathways O
involved O
in O
the O
control O
of O
bile B-CHEMICAL
acid I-CHEMICAL
handling O
by O
the O
liver. O
Treatment O
with O
glucocorticoids O
(GCs) O
may O
cause O
adverse O
effects, O
including O
cholestasis. O
The O
ability O
of O
dexamethasone, B-CHEMICAL
prednisolone B-CHEMICAL
and O
budesonide B-CHEMICAL
to O
affect O
the O
liver O
handling O
of O
bile B-CHEMICAL
acids I-CHEMICAL

(BAs) O
has O
been O
investigated. O
In O
rats O
treated O
with O
GCs O
for O
4 O
days, O
altered O
serum O
and O
bile O
BA O
levels, O
changed O
conjugation O
pattern, O
and O
delayed O
and O
decreased O
ability O
to O
conjugate/secrete O
exogenously O
administered O
deoxycholate, B-CHEMICAL
were O
found O
using O
HPLC-MS/MS. O
RT-QPCR O
analyses O
revealed O
that O
GC O
treatment O
also O
induced O
a O
down-regulation O
of O
liver B-GENE-N
nuclear I-GENE-N
receptors I-GENE-N
(Fxr, B-GENE-Y
Gr B-GENE-Y
and O
Shp), B-GENE-Y
transporters O
(Ntcp, B-GENE-Y
Mrp4 B-GENE-Y
and O
Bcrp) B-GENE-Y
and O
enzymes O
(Cyp7a1 B-GENE-Y
and O
Baat), B-GENE-Y

whereas O
Bsep, B-GENE-Y
Mrp2 B-GENE-Y
and O
Cyp27a1 B-GENE-Y
were O
up-regulated. O
Human O
HepG2 O
and O
Alexander O
cell O
lines O
were O
used O
as O
in O
vitro O
models O
of O
liver O
cells O
with O
and O
without O
constitutive O
FXR B-GENE-Y
expression, O
respectively. O
In O
HepG2 O
cells, O
GCs O
induced O
a O
decreased O
expression O
of O
FXR B-GENE-Y
and O
SHP, B-GENE-Y
and O
inhibited O
the O
regulatory O
effect O
of O
GW4064 B-CHEMICAL
on O
FXR-target B-GENE-Y
genes. O
In O
Alexander O
cells, O
only O
when O
they O
were O
transfected O
with O
FXR+RXR, B-GENE-Y
GW4064 B-CHEMICAL
caused O
up-regulation O
of O
SHP B-GENE-Y
and O
OSTβ, B-GENE-Y
and O

a O
down-regulation O
of O
CYP27A1. B-GENE-Y
GCs O
had O
the O
opposite O
effect O
on O
these O
genes, O
both O
in O
the O
absence O
and O
in O
the O
presence O
of O
FXR B-GENE-Y
expression. O
Co-transfection O
of O
Alexander O
cells O
with O
IR-1-Luc O
and O
FXR+RXR B-GENE-Y
revealed O
that O
GCs O
did O
not O
inhibit O
but O
moderately O
enhanced O
FXR B-GENE-Y
activity. O
Moreover, O
GCs O
have O
a O
synergistic O
effect O
on O
GW4064-induced B-CHEMICAL
FXR B-GENE-Y
activation, O
whereas O
chenodeoxycholate B-CHEMICAL
and O
GW4064 B-CHEMICAL
have O
an O
additive O
effect. O
In O
conclusion, O
GCs O
are O
able O
to O
directly O
or O
indirectly O
activate O
FXR B-GENE-Y
but O

they O
also O
antagonize, O
through O
FXR-independent B-GENE-Y
mechanisms, O
the O
expression O
of O
FXR B-GENE-Y
and O
FXR B-GENE-Y
target O
genes O
involved O
in O
the O
hepatic O
handling O
of O
BAs. O
Ethanol B-CHEMICAL
extract O
of O
Adiantum O
capillus-veneris O
L. O
suppresses O
the O
production O
of O
inflammatory O
mediators O
by O
inhibiting O
NF-κB B-GENE-N
activation. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Adiantum O
capillus-veneris O
L. O
is O
a O
wildly O
distributed O
plant O
species O
and O
has O
been O
extensively O
used O
in O
south O
of O
China O
as O
traditional O
folk O
medicine O
for O
the O
treatment O
of O
inflammatory O

diseases. O
AIM O
OF O
THE O
STUDY: O
To O
investigate O
the O
anti-inflammatory O
effect O
of O
ethanolic O
extracts O
of O
Adiantum O
capillus-veneris O
L. O
and O
the O
involvement O
of O
NF-κB B-GENE-N
signaling O
in O
the O
regulation O
of O
inflammation. O
MATERIALS O
AND O
METHODS: O
The O
plant O
ethanolic O
extracts O
were O
initially O
tested O
against O
lipopolysaccharide O
(LPS)-induced O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
production O
in O
RAW264.7 O
mouse O
macrophages, O
and O
interleukin B-GENE-Y
6 I-GENE-Y
(IL-6) B-GENE-Y
and O
tumor B-GENE-Y

necrosis I-GENE-Y
factor I-GENE-Y
(TNF) B-GENE-Y
production O
in O
human O
U937 O
monocytes. O
The O
effect O
of O
the O
plant O
extracts O
on O
the O
transcription O
factor O
nuclear B-GENE-N
factor I-GENE-N
kappa I-GENE-N
B I-GENE-N
(NF-κB) B-GENE-N
pathway O
was O
evaluated O
in O
TNF-α B-GENE-Y
stimulated O
HepG2 O
cells O
by O
luciferase O
gene O
reporter O
assay O
and O
Western O
blotting O
at O
the O
transcriptional O
and O
translational O
levels. O
Subsequently, O
the O
inhibition O
of O
NF-κB B-GENE-N
downstream O
gene O
expression O
(IL-8 B-GENE-Y
and O
ICAM-1) B-GENE-Y
by O
the O
plant O
extracts O
was O
assessed O
via O
quantitative O
real O
time O
polymerase O
chain O
reaction O
(qPCR). O

Lastly, O
the O
anti-inflammatory O
activities O
of O
the O
plant O
extracts O
in O
vivo O
were O
evaluated O
by O
testing O
spleen O
index O
and O
NF-κB B-GENE-N
related O
protein O
expression O
in O
LPS-stimulated O
CD1 O
mice. O
RESULTS: O
The O
plant O
ethanolic O
extracts O
effectively O
suppressed O
PGE2, B-CHEMICAL
IL-6 B-GENE-Y
and O
TNF B-GENE-Y
release O
with O
an O
IC50 O
less O
than O
50μg/ml. O
Moreover, O
luciferase O
expression O
could O
be O
specifically O
blocked O
in O
HepG2 O
cells, O
not O
in O
HEK293 O
cells, O
showing O
that O
the O
plant O
extracts O
displayed O
a O
cell-specific O
pattern O
on O

NF-κB B-GENE-N
gene O
transcription. O
The O
assayed O
biological O
activity O
also O
depended O
on O
the O
order O
of O
adding O
TNF-α B-GENE-Y
and O
the O
plant O
extracts O
because O
the O
plant O
extracts O
could O
only O
block O
the O
NF-κB B-GENE-N
activation O
if O
added O
earlier O
but O
were O
unable O
to O
stop O
the O
signal O
when O
added O
after O
TNF-α. B-GENE-Y
However, O
the O
plant O
extracts O
did O
not O
exert O
any O
effect O
on O
ubiquitination O
which O
regulates O
several O
steps O
in O
the O
NF-κB B-GENE-N
pathway. O
Additionally, O
the O
plant O
extracts O
down-regulated O
phosphorylation O
of O
IKKα/β B-GENE-N
at O
S176/180, O
p38 B-GENE-N
at O

T180/Y182 O
and O
p65 B-GENE-Y
at O
S536, O
but O
not O
p65 B-GENE-Y
at O
S276. O
This O
was O
confirmed O
by O
their O
ability O
to O
selectively O
abrogate O
the O
induction O
of O
IL-8 B-GENE-Y
transcription, O
whereas O
the O
ICAM-1 B-GENE-Y
gene, O
which O
is O
not O
transcribed O
selectively O
by O
an O
NF-κB B-GENE-N
complex O
containing O
a O
form O
of O
p65 B-GENE-Y
phosphorylated O
on O
Ser536, B-CHEMICAL
did O
not O
change. O
Finally, O
the O
plant O
extracts O
at O
200μg/mg O
could O
normalize O
the O
LPS-induced O
elevation O
of O
spleen O
index O
as O
well O
as O
NF-κB B-GENE-N
and O
p38 B-GENE-N

activations O
in O
CD1 O
mice. O
CONCLUSION: O
The O
present O
studies O
presents O
the O
potential O
utilization O
of O
this O
plant O
extracts, O
as O
a O
natural O
resources O
for O
the O
development O
of O
an O
anti-inflammatory O
medicine. O
Robust O
autoactivation, O
chymotrypsin B-GENE-Y
C I-GENE-Y
independence O
and O
diminished O
secretion O
define O
a O
subset O
of O
hereditary O
pancreatitis O
associated O
cationic B-GENE-Y
trypsinogen I-GENE-Y
mutants. O
Mutations O
in O
human B-GENE-Y
cationic I-GENE-Y
trypsinogen I-GENE-Y
cause O
hereditary O
pancreatitis O
by O
altering O
its O
proteolytic O
regulation O
of O
activation O
and O
degradation O
by O
chymotrypsin B-GENE-Y
C I-GENE-Y
(CTRC). B-GENE-Y
CTRC B-GENE-Y
stimulates O

trypsinogen O
autoactivation O
by O
processing O
the O
activation O
peptide O
to O
a O
shorter O
form O
but O
also O
promotes O
degradation O
by O
cleaving O
the O
calcium B-GENE-N
binding I-GENE-N
loop I-GENE-N
in O
trypsinogen. O
Mutations O
render O
trypsinogen O
resistant O
to O
CTRC-mediated B-GENE-Y
degradation O
and/or O
increase O
processing O
of O
the O
activation O
peptide O
by O
CTRC. B-GENE-N
Here O
we O
demonstrate O
that O
activation O
peptide O
mutations O
D19A, B-GENE-N
D22G, B-GENE-N
K23R B-GENE-N
and O
K23_I24insIDK B-GENE-N
robustly O
increased O
the O
rate O
of O
trypsinogen O
autoactivation, O
both O
in O
the O
presence O
and O
absence O
of O
CTRC. B-GENE-Y
Degradation O
of O
the O
mutants O
by O
CTRC B-GENE-Y
was O

unchanged O
and O
processing O
of O
the O
activation O
peptide O
was O
increased O
only O
in O
the O
D19A B-GENE-N
mutant O
by O
4-fold. O
Surprisingly, O
however, O
this O
increased O
processing O
had O
only O
a O
minimal O
effect O
on O
autoactivation. O
The O
tetra-aspartate B-GENE-N
motif I-GENE-N
in O
the O
trypsinogen O
activation O
peptide O
binds O
calcium B-CHEMICAL
(KD O
~1.6 O
mM), O
which O
stimulates O
autoactivation. O
Unexpectedly, O
calcium B-CHEMICAL
binding O
was O
not O
compromised O
by O
any O
of O
the O
activation O
peptide O
mutations. O
Despite O
normal O
binding, O
autoactivation O
of O
mutants O
D22G B-GENE-N
and O
K23_I24insIDK B-GENE-N
was O
not O
stimulated O
by O

calcium. B-CHEMICAL
Finally, O
the O
activation O
peptide O
mutants O
exhibited O
reduced O
secretion O
from O
transfected O
cells, O
and O
secreted O
trypsinogen O
levels O
were O
inversely O
proportional O
with O
autoactivation O
rates. O
We O
conclude O
that O
D19A, B-GENE-N
D22G, B-GENE-N
K23R B-GENE-N
and O
K23_I24insIDK B-GENE-N
form O
a O
mechanistically O
distinct O
subset O
of O
hereditary O
pancreatitis O
associated O
mutations, O
which O
exert O
their O
effect O
primarily O
through O
direct O
stimulation O
of O
autoactivation, O
independently O
of O
CTRC. B-GENE-Y
The O
potentially O
severe O
clinical O
impact O
of O
the O
markedly O
increased O
autoactivation O
is O
offset O
by O
diminished O
secretion, O
resulting O
in O
a O
clinical O
phenotype O

indistinguishable O
from O
typical O
hereditary O
pancreatitis. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Small O
molecule O
mediated O
proliferation O
of O
primary O
retinal B-CHEMICAL
pigment O
epithelial O
cells. O
Retinal B-CHEMICAL
pigment O
epithelial O
(RPE) O
cells O
form O
a O
monolayer O
adjacent O
to O
the O
retina O
and O
play O
a O
critical O
role O
in O
the O
visual O
light O
cycle. O
Degeneration O
of O
this O
layer O
results O
in O
vision O
loss, O
causing O
retinal O
disorders O
such O
as O
age-related O
macular O
degeneration. O
Cell O
transplant O
therapies O
exist O
to O
restore O
vision O
loss; O
however, O
risks O
associated O
with O
and O
an O
inadequate O
supply O
of O

donor O
cells O
have O
limited O
their O
therapeutic O
success. O
The O
identification O
of O
factors O
that O
proliferate O
RPE O
cells O
ex O
vivo O
could O
provide O
a O
renewable O
source O
of O
cells O
for O
the O
treatment O
of O
such O
disorders. O
We O
show O
that O
a O
small O
molecule O
(WS3) O
can O
reversibly O
proliferate O
primary O
RPE O
cells O
isolated O
from O
fetal O
and O
adult O
human O
donors. O
Following O
withdrawal O
of O
WS3, O
RPE O
cells O
differentiate O
into O
a O
functional O
monolayer, O
as O
exhibited O
by O
their O
expression O
of O
mature O
RPE O
genes O
and O
phagocytosis O
of O
photoreceptor O
outer O
segments. O
Furthermore, O
chemically O
expanded O
RPE O
cells O
preserve O
vision O
when O
transplanted O

into O
dystrophic O
Royal O
College O
of O
Surgeons O
(RCS) O
rats, O
a O
well-established O
model O
of O
retinal O
degeneration. O
Murine O
chromosomal O
location O
of O
the O
mu B-GENE-N
and I-GENE-N
kappa I-GENE-N
opioid I-GENE-N
receptor I-GENE-N
genes. O
Opioid B-GENE-N
receptors I-GENE-N
are O
the O
membrane O
proteins O
that O
mediate O
the O
pain-relieving O
effect O
of O
opioid O
drugs, O
such O
as O
morphine B-CHEMICAL
and O
fentanyl B-CHEMICAL
as O
well O
as O
endogenous B-GENE-N
opioid I-GENE-N
peptides I-GENE-N
enkephalins B-GENE-Y
and O
endorphins. B-GENE-N
Using O
cDNAs O
for O
the O
mu B-GENE-N
and I-GENE-N
the I-GENE-N
kappa I-GENE-N
opioid I-GENE-N
receptors, I-GENE-N
we O
mapped O
the O

chromosomal O
locations O
of O
their O
genes O
in O
mouse. O
Multilocus O
cross O
analysis O
located O
the O
mu B-GENE-Y
receptor I-GENE-Y
gene O
Oprm B-GENE-Y
on O
Chr O
10 O
and O
the O
kappa B-GENE-Y
receptor I-GENE-Y
gene O
Oprk1 B-GENE-Y
on O
Chr O
1. O
Both O
genes O
are O
near O
centromere, O
with O
no O
markers O
more O
centromeric. O
These O
data O
indicate O
that O
the O
two O
opioid B-GENE-N
receptors I-GENE-N
are O
different O
gene O
products, O
ruling O
out O
the O
possibility O
that O
they O
may O
be O
differential O
splicing O
products O
from O
the O
same O
gene. O
The O
exposure O
of O
highly O
toxic O
aconitine B-CHEMICAL
does O
not O
significantly O
impact O
the O
activity O
and O
expression O
of O
cytochrome B-GENE-N
P450 I-GENE-N
3A I-GENE-N
in O
rats O
determined O
by O
a O
novel O
ultra O
performance O

liquid O
chromatography-tandem O
mass O
spectrometric O
method O
of O
a O
specific O
probe O
buspirone. B-CHEMICAL
Aconitum O
species O
are O
widely O
used O
to O
treat O
rheumatism, O
cardiovascular O
diseases, O
and O
tumors O
in O
China O
and O
other O
Asian O
countries. O
The O
herbs O
are O
always O
used O
with O
drugs O
such O
as O
paclitaxel. B-CHEMICAL
Aconitine B-CHEMICAL
(AC) O
is O
one O
of O
the O
main O
bioactive/high-toxic O
alkaloids O
of O
Aconitum O
roots. O
AC O
is O
metabolized O
by O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) I-GENE-N
3A. I-GENE-N
However, O
whether O
AC O
inhibits/induces O
CYP3A, B-GENE-N

which O
causes O
drug-drug O
interaction O
(DDI) O
is O
unclear. O
Our O
study O
aims O
to O
explore O
the O
potent O
effects O
of O
AC, O
as O
a O
marker O
component O
of O
Aconitum, O
on O
CYP3A B-GENE-N
using O
the O
probe O
buspirone B-CHEMICAL
in O
rats. O
The O
effects O
of O
oral O
AC O
on O
pharmacokinetics O
of O
buspirone B-CHEMICAL
were O
evaluated. O
CYP3A B-GENE-N
activity O
and O
protein O
levels O
in O
rat O
liver O
microsomes O
pretreated O
with O
oral O
AC O
were O
also O
measured O
using O
in O
vitro O
buspirone B-CHEMICAL
metabolism O
and O
Western O
blot. O
Buspirone B-CHEMICAL
and O
its O
major O
metabolites O

1-(2-pyrimidinyl)piperazine B-CHEMICAL
and O
6'-hydroxybuspirone B-CHEMICAL
were O
determined O
using O
a O
newly O
validated O
UPLC-MS/MS O
method. O
Single O
dose O
and O
7-day O
AC O
administration O
at O
0.125mg/kg O
had O
no O
effect O
on O
CYP3A B-GENE-N
activity O
since O
no O
change O
in O
the O
formation O
of O
1-(2-pyrimidinyl)piperazine B-CHEMICAL
and O
6'-hydroxybuspirone. B-CHEMICAL
CYP3A B-GENE-N
activity O
and O
protein O
levels O
in O
liver O
microsomes O
were O
also O
not O
affected O
by O
7-day O
AC O
pretreatment O
at O

0.125mg/kg. O
Therefore, O
AC O
neither O
inhibits O
nor O
induces O
CYP3A B-GENE-N
in O
rats, O
indicating O
AC O
does O
not O
cause O
CYP3A-related B-GENE-N
DDI O
in O
the O
liver. O
The O
yeast B-GENE-N
cap I-GENE-N
binding I-GENE-N
complex I-GENE-N
modulates O
transcription O
factor O
recruitment O
and O
establishes O
proper O
histone B-GENE-N
H3K36 I-GENE-N
trimethylation O
during O
active O
transcription. O
Recent O
studies O
have O
revealed O
a O
close O
relationship O
between O
transcription, O
histone B-GENE-N
modification, O
and O
RNA O
processing. O
In O
fact, O
genome-wide O
analyses O
that O
correlate O
histone O
marks O
with O
RNA O
processing O
signals O
raise O
the O
possibility O
that O
specific O
RNA O
processing O
factors O
may O
modulate O
transcription O
and O
help O
to O
"write" O

chromatin O
marks. O
Here O
we O
show O
that O
the O
nuclear B-GENE-N
cap I-GENE-N
binding I-GENE-N
complex I-GENE-N
(CBC) B-GENE-N
directs O
recruitment O
of O
transcription O
elongation O
factors O
and O
establishes O
proper O
histone B-GENE-N
marks O
during O
active O
transcription. O
A O
directed O
genetic O
screen O
revealed O
that O
deletion O
of O
either O
subunit O
of O
the O
CBC B-GENE-N
confers O
a O
synthetic O
growth O
defect O
when O
combined O
with O
deletion O
of O
genes O
encoding O
either O
Ctk2 B-GENE-Y
or O
Bur2, B-GENE-Y
a O
component O
of O
the O
Saccharomyces O
cerevisiae O
ortholog O
of O
P-TEFb. B-GENE-N
The O
CBC B-GENE-N
physically O
associates O
with O
these O
complexes O
to O
recruit O
them O
during O
transcription O
and O
mediates O
phosphorylation O
at O
Ser-2 B-CHEMICAL
of O
the O

C-terminal B-CHEMICAL
domain O
(CTD) O
of O
RNA B-GENE-N
polymerase I-GENE-N
II. I-GENE-N
To O
understand O
how O
these O
interactions O
influence O
downstream O
events, O
histone B-GENE-N
H3K36me3 I-GENE-N
was O
examined, O
and O
we O
demonstrate O
that O
CBCΔ B-GENE-N
affects O
proper O
Set2-dependent B-GENE-Y
H3K36me3. B-GENE-N
Consistent O
with O
this, O
the O
CBC B-GENE-N
and O
Set2 B-GENE-Y
have O
similar O
effects O
on O
the O
ability O
to O
rapidly O
induce O
and O
sustain O
activated O
gene O
expression, O
and O
these O
effects O
are O
distinct O
from O
other O
histone B-GENE-N
methyltransferases. O
This O
work O
provides O
evidence O
for O
an O
emerging O
model O
that O
RNA O
processing O
factors O
can O
modulate O
the O
recruitment O
of O
transcription O
factors O
and O
influence O
histone B-GENE-N
modification O
during O
elongation. O

Kinetic O
and O
stereochemical O
studies O
on O
novel O
inactivators O
of O
C-terminal B-CHEMICAL
amidation. O
C-terminal B-CHEMICAL
amidation, O
a O
required O
post-translational O
modification O
for O
the O
bioactivation O
of O
many O
neuropeptides, O
entails O
sequential O
enzymic O
action O
by O
peptidylglycine B-GENE-Y
alpha-mono-oxygenase I-GENE-Y
(PAM, B-GENE-Y
EC B-GENE-Y
1.14.17.3) I-GENE-Y
and O
peptidylamidoglycolate B-GENE-Y
lyase I-GENE-Y
(PGL, B-GENE-Y
EC B-GENE-Y
4.3.2.5). I-GENE-Y
Here O
we O
introduce O
novel O
compounds O
in O
which O
an O
olefinic O
functionality O
is O
incorporated O
into O
peptide O

analogues O
as O
the O
most O
potent O
turnover-dependent O
inactivators O
of O
PAM. B-GENE-Y
Kinetic O
parameters O
for O
PAM B-GENE-Y
inactivation O
by O
4-oxo-5-acetamido-6-phenyl-hex-2-enoic B-CHEMICAL
acid I-CHEMICAL
and I-CHEMICAL
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic I-CHEMICAL
acid I-CHEMICAL
were O
obtained O
by O
using O
both O
the O
conventional O
dilution O
assay O
method O
and O
the O
more O
complex O
progress O
curve O
method. O
The O
results O
obtained O
from O
the O
progress O
curve O
method O
establish O
that O
these O
compounds O
exhibit O
the O
kinetic O
characteristics O
of O
pure O
competitive O

inactivators O
(i.e. O
no O
ESI O
complex O
forms O
during O
inactivation). O
On O
the O
basis O
of O
k(inact)/K(i) O
values, O
4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic B-CHEMICAL
acid I-CHEMICAL
is O
almost O
two O
orders O
of O
magnitude O
more O
potent O
than O
benzoylacrylate, B-CHEMICAL
a O
chemically O
analogous O
olefinic O
inactivator O
that O
lacks O
the O
peptide O
moiety. O
Stereochemical O
studies O
established O
that O
PAM B-GENE-Y
inactivation O
by O

4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic B-CHEMICAL
acid I-CHEMICAL
is O
stereospecific O
with O
respect O
to O
the O
moiety O
at O
the O
P(2) O
position, O
which O
is O
consistent O
with O
previous O
results O
with O
substrates O
and O
reversible O
inhibitors. O
In O
contrast, O
2, B-CHEMICAL
4-dioxo-5-acetamido-6-phenylhexanoic I-CHEMICAL
acid, I-CHEMICAL
which O
is O
a O
competitive O
inhibitor O
with O
respect O
to O
ascorbate, B-CHEMICAL
exhibits O
a O
low O
degree O
of O
stereospecificity O
in O
binding O
to O
the O
ascorbate B-CHEMICAL
sites O
of O
both O

PAM B-GENE-Y
and O
dopamine-beta-hydroxylase. B-GENE-Y
Chalcogenopyrylium B-CHEMICAL
Dyes O
as O
Differential O
Modulators O
of O
Organic O
Anion O
Transport O
by O
MRP1, B-GENE-Y
MRP2 B-GENE-Y
and O
MRP4. B-GENE-Y
Multidrug B-GENE-N
resistance I-GENE-N
proteins I-GENE-N
(MRPs) B-GENE-N
mediate O
the O
ATP-dependent B-CHEMICAL
efflux O
of O
structurally O
diverse O
compounds, O
including O
anticancer O
drugs O
and O
physiological O
organic O
anions. O
Five O
classes O
of O
chalcogenopyrylium B-CHEMICAL
dyes O
(CGPs) B-CHEMICAL
were O
examined O
for O
their O
ability O
to O
modulate O
transport O
of O
[(3)H]estradiol B-CHEMICAL
glucuronide I-CHEMICAL

(E217βG) B-CHEMICAL
(a O
prototypical O
MRP B-GENE-N
substrate) O
into O
MRP-enriched B-GENE-N
inside-out O
membrane O
vesicles. O
Additionally, O
some O
CGPs B-CHEMICAL
were O
tested O
in O
intact O
transfected O
cells O
using O
a O
calcein B-CHEMICAL
efflux O
assay. O
Sixteen O
of O
34 O
CGPs B-CHEMICAL
inhibited O
MRP1-mediated B-GENE-Y
E217βG B-CHEMICAL
uptake O
by O
>50% O
(IC50's O
0.7-7.6 O
μM). O
Of O
9 O
CGPs B-CHEMICAL
with O
IC50's O
≤2 O
μM, O
two O
belonged O
to O
Class O
I, O
two O
to O
Class O
III O
and O

five O
to O
Class O
V. O
When O
tested O
in O
the O
intact O
cells, O
only O
4 O
of O
16 O
CGPs B-CHEMICAL
(at O
10 O
μM) O
inhibited O
MRP1-mediated B-GENE-Y
calcein B-CHEMICAL
efflux O
by O
>50% O
(III-1, O
V-3, O
-4, O
-6) O
while O
a O
fifth O
(I-5) O
inhibited O
efflux O
by O
just O
23%. O
These O
five O
CGPs B-CHEMICAL
also O
inhibited O
[(3)H]E217βG B-CHEMICAL
uptake O
by O
MRP4. B-GENE-Y
In O
contrast, O
their O
effects O
on O
MRP2 B-GENE-Y
varied O
with O
two O
(V-4, O
V-6) O

inhibiting O
E217βG B-CHEMICAL
transport O
(IC50's O
2.0, O
9.2 O
μM), O
two O
(V-3, O
III-1) O
stimulating O
transport O
(>2-fold), O
while O
CGP B-CHEMICAL
I-5 O
had O
no O
effect. O
Strikingly, O
although O
V-3 O
and O
V-4 O
had O
opposite O
effects O
on O
MRP2 B-GENE-Y
activity, O
they O
are O
structurally O
identical O
except O
for O
their O
chalcogen B-CHEMICAL
atom O
(Se B-CHEMICAL
versus O
Te). B-CHEMICAL
This O
study O
is O
the O
first O
to O
identify O
Class O
V O
CGPs O
with O
their O
distinctive O
methine B-CHEMICAL
or O
trimethine B-CHEMICAL
linkage O
between O
two O

disubstituted O
pyrylium B-CHEMICAL
moieties O
as O
a O
particularly O
potent O
class O
of O
MRP B-GENE-N
modulators O
and O
also O
show O
that O
within O
this O
core O
structure, O
differences O
in O
the O
electronegativity O
associated O
with O
a O
chalcogen B-CHEMICAL
atom O
can O
be O
the O
sole O
determinant O
of O
whether O
a O
compound O
will O
stimulate O
or O
inhibit O
MRP2. B-GENE-Y
Zinc B-CHEMICAL
drives O
a O
tertiary O
fold O
in O
the O
prion B-GENE-N
protein I-GENE-N
with O
familial O
disease O
mutation O
sites O
at O
the O
interface. O
The O
cellular O
prion B-GENE-Y
protein I-GENE-Y
PrP(C) I-GENE-Y
consists O
of O
two O
domains--a O
flexible O
N-terminal B-CHEMICAL
domain, O
which O
participates O
in O
copper B-CHEMICAL
and O
zinc B-CHEMICAL
regulation, O

and O
a O
largely O
helical O
C-terminal B-CHEMICAL
domain O
that O
converts O
to O
β O
sheet O
in O
the O
course O
of O
prion O
disease. O
These O
two O
domains O
are O
thought O
to O
be O
fully O
independent O
and O
noninteracting. O
Compelling O
cellular O
and O
biophysical O
studies, O
however, O
suggest O
a O
higher O
order O
structure O
that O
is O
relevant O
to O
both O
PrP(C) B-GENE-Y
function O
and O
misfolding O
in O
disease. O
Here, O
we O
identify O
a O
Zn²⁺-driven B-CHEMICAL
N-terminal B-CHEMICAL
to O
C-terminal B-CHEMICAL
tertiary O
interaction O
in O
PrP(C). B-GENE-Y
The O
C-terminal B-CHEMICAL
surface O
participating O
in O
this O
interaction O
carries O
the O
majority O
of O
the O
point O
mutations O
that O
confer O
familial O
prion O

disease. O
Investigation O
of O
mutant O
PrPs B-GENE-N
finds O
a O
systematic O
relationship O
between O
the O
type O
of O
mutation O
and O
the O
apparent O
strength O
of O
this O
domain O
structure. O
The O
structural O
features O
identified O
here O
suggest O
mechanisms O
by O
which O
physiologic O
metal O
ions O
trigger O
PrP(C) B-GENE-Y
trafficking O
and O
control O
prion O
disease. O
IFNα B-GENE-N
converts O
IL-22 B-GENE-Y
into O
a O
cytokine B-GENE-N
efficiently O
activating O
STAT1 B-GENE-Y
and O
its O
downstream O
targets. O
Besides O
their O
antiviral O
activity, O
type B-GENE-N
I I-GENE-N
Interferons I-GENE-N
(IFN) B-GENE-N
display O
context-specific O
immunomodulation. O
In O
contrast O
to O
long-known O
IFNα/β, B-GENE-N
Interleukin B-GENE-Y

(IL)-22 I-GENE-Y
is O
an O
anti-bacterial, O
largely O
tissue O
protective O
cytokine B-GENE-N
that O
recently O
gained O
attention. O
Herein, O
cellular O
IFNα/IL-22 B-GENE-N
interactions O
are O
investigated. O
We O
report O
that O
pre-conditioning O
of O
epithelial O
cells O
with O
IFNα B-GENE-N
initiated O
dramatic O
changes O
in O
IL-22 B-GENE-Y
signaling O
normally O
dominated O
by O
signal B-GENE-Y
transducer I-GENE-Y
and I-GENE-Y
activator I-GENE-Y
of I-GENE-Y
transcription I-GENE-Y
(STAT)-3. I-GENE-Y
Specifically, O
by O
using O
human O
DLD1 O
colon O
epithelial/carcinoma O
cells O
we O
demonstrate O
that, O
upon O
IFNα, B-GENE-N
IL-22 B-GENE-Y
converts O
into O
a O
cytokine B-GENE-N
robustly O
activating O

STAT1 B-GENE-Y
and O
its O
downstream O
pro-inflammatory O
targets O
CXCL9, B-GENE-Y
CXCL10, B-GENE-Y
and O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS). B-GENE-Y
Accordingly, O
only O
after O
IFNα B-GENE-N
pre-incubation O
was O
IL-22-induced B-GENE-Y
STAT1 B-GENE-Y
binding O
to O
the O
CXCL10 B-GENE-N
promoter I-GENE-N
detectable. O
Using O
the O
viral O
mimic O
polyinosinic:polycytidylic B-CHEMICAL
acid I-CHEMICAL
and O
the O
IFNα/β B-GENE-N
antagonist O
B18R O
we O
furthermore O
demonstrate O
the O
capability O
of O
endogenous O
IFN B-GENE-N
to O
promote O
IL-22-induced B-GENE-Y
STAT1 B-GENE-Y
activation O
and O
expression O
of O

CXCL10. B-GENE-Y
IL-22-induced B-GENE-Y
STAT1 B-GENE-Y
activation O
subsequent O
to O
IFNα B-GENE-N
priming O
became O
likewise O
apparent O
in O
human O
Caco2 O
colon O
epithelial/carcinoma O
cells, O
HepG2 O
hepatoma O
cells, O
and O
primary O
keratinocytes. O
Current O
observations O
may O
relate O
to O
characteristics O
of O
IFNα/β B-GENE-N
in O
clinical O
therapy O
and O
expose O
margins O
of O
tissue O
protection O
by O
IL-22 B-GENE-Y
application. O
Gemfibrozil, B-CHEMICAL
a O
lipid-lowering O
drug, O
inhibits O
the O
induction O
of O
nitric-oxide B-GENE-N
synthase I-GENE-N
in O
human O
astrocytes. O

Gemfibrozil, B-CHEMICAL
a O
lipid-lowering O
drug, O
inhibited O
cytokine-induced B-GENE-N
production O
of O
NO B-CHEMICAL
and O
the O
expression O
of O
inducible B-GENE-Y
nitric-oxide I-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
in O
human O
U373MG O
astroglial O
cells O
and O
primary O
astrocytes. O
Similar O
to O
gemfibrozil, B-CHEMICAL
clofibrate, B-CHEMICAL
another O
fibrate B-CHEMICAL
drug, O
also O
inhibited O
the O
expression O
of O
iNOS. B-GENE-Y
Inhibition O
of O
human B-GENE-N
iNOS I-GENE-N
promoter-driven I-GENE-N
luciferase O
activity O
by O
gemfibrozil B-CHEMICAL
in O
cytokine-stimulated B-GENE-N

U373MG O
astroglial O
cells O
suggests O
that O
this O
compound O
inhibits O
the O
transcription O
of O
iNOS. B-GENE-Y
Since O
gemfibrozil B-CHEMICAL
is O
known O
to O
activate O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor-alpha I-GENE-Y
(PPAR-alpha), B-GENE-Y
we O
investigated O
the O
role O
of O
PPAR-alpha B-GENE-Y
in O
gemfibrozil-mediated B-CHEMICAL
inhibition O
of O
iNOS. B-GENE-Y
Gemfibrozil B-CHEMICAL
induced O
peroxisome B-GENE-N
proliferator-responsive I-GENE-N
element I-GENE-N
(PPRE)-dependent B-GENE-N
luciferase O
activity, O
which O
was O
inhibited O
by O
the O
expression O
of O
DeltahPPAR-alpha, B-GENE-Y

the O
dominant-negative O
mutant O
of O
human B-GENE-Y
PPAR-alpha. I-GENE-Y
However, O
DeltahPPAR-alpha B-GENE-Y
was O
unable O
to O
abrogate O
gemfibrozil-mediated B-CHEMICAL
inhibition O
of O
iNOS B-GENE-Y
suggesting O
that O
gemfibrozil B-CHEMICAL
inhibits O
iNOS B-GENE-Y
independent O
of O
PPAR-alpha. B-GENE-Y
The O
human B-GENE-N
iNOS I-GENE-N
promoter I-GENE-N
contains O
consensus O
sequences O
for O
the O
binding O
of O
transcription O
factors, O
including O
interferon-gamma B-GENE-Y
(IFN-gamma) I-GENE-Y
regulatory I-GENE-Y
factor-1 I-GENE-Y
(IRF-1) B-GENE-Y
binding O
to O
interferon-stimulated B-GENE-N
responsive I-GENE-N
element I-GENE-N
(ISRE), B-GENE-N
signal B-GENE-N
transducer I-GENE-N
and I-GENE-N
activator I-GENE-N

of I-GENE-N
transcription I-GENE-N
(STAT) B-GENE-N
binding O
to O
gamma-activation O
site O
(GAS), O
nuclear B-GENE-N
factor-kappaB I-GENE-N
(NF-kappaB), B-GENE-N
activator B-GENE-Y
protein-1 I-GENE-Y
(AP-1), B-GENE-Y
and O
CCAAT/enhancer-binding B-GENE-Y
protein I-GENE-Y
beta I-GENE-Y
(C/EBPbeta); B-GENE-Y
therefore, O
we O
investigated O
the O
effect O
of O
gemfibrozil B-CHEMICAL
on O
the O
activation O
of O
these O
transcription O
factors. O
The O
combination O
of O
interleukin B-GENE-Y
(IL)-1beta I-GENE-Y
and O
IFN-gamma B-GENE-Y
induced O
the O
activation O
of O
NF-kappaB, B-GENE-N
AP-1, B-GENE-Y

C/EBPbeta, B-GENE-Y
and O
GAS O
but O
not O
that O
of O
ISRE, B-GENE-N
suggesting O
that O
IRF-1 B-GENE-Y
may O
not O
be O
involved O
in O
cytokine-induced B-GENE-N
expression O
of O
iNOS B-GENE-Y
in O
human O
astrocytes. O
Interestingly, O
gemfibrozil B-CHEMICAL
strongly O
inhibited O
the O
activation O
of O
NF-kappaB, B-GENE-N
AP-1, B-GENE-Y
and O
C/EBPbeta B-GENE-Y
but O
not O
that O
of O
GAS O
in O
cytokine-stimulated B-GENE-N
astroglial O
cells. O
These O
results O
suggest O
that O
gemfibrozil B-CHEMICAL
inhibits O
the O
induction O
of O
iNOS B-GENE-Y
probably O
by O

inhibiting O
the O
activation O
of O
NF-kappaB, B-GENE-N
AP-1, B-GENE-Y
and O
C/EBPbeta B-GENE-Y
and O
that O
gemfibrozil, B-CHEMICAL
a O
prescribed O
drug O
for O
humans, O
may O
further O
find O
its O
therapeutic O
use O
in O
neuroinflammatory O
diseases. O
Central O
sympatholysis O
as O
a O
novel O
countermeasure O
for O
cocaine-induced B-CHEMICAL
sympathetic O
activation O
and O
vasoconstriction O
in O
humans. O
OBJECTIVES: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
cocaine's O
sympathomimetic O
actions O
can O
be O
reversed O
by O
a O
potent O
centrally O
acting O
alpha2 B-GENE-N

adrenergic I-GENE-N
receptor I-GENE-N
(AR) B-GENE-N
agonist O
(dexmedetomidine). B-CHEMICAL
BACKGROUND: O
We O
recently O
showed O
that O
cocaine B-CHEMICAL
stimulates O
the O
human O
cardiovascular O
system O
primarily O
by O
acting O
in O
the O
brain O
to O
increase O
sympathetic O
nerve O
activity O
(SNA), O
the O
neural O
stimulus O
to O
norepinephrine B-CHEMICAL
release. O
Thus, O
SNA O
constitutes O
a O
putative O
new O
drug O
target O
to O
block O
cocaine's O
adverse O
cardiovascular O
effects O
at O
their O
origin. O
METHODS: O
In O
22 O
healthy O
cocaine-naive B-CHEMICAL
humans, O
we O
measured O
skin O
SNA O
(microneurography) O
and O
skin O
blood O
flow O
(laser O
Doppler O

velocimetry) O
as O
well O
as O
heart O
rate O
and O
blood O
pressure O
before O
and O
after O
intranasal O
cocaine B-CHEMICAL
(2 O
mg/kg) O
alone O
and O
in O
combination O
with O
dexmedetomidine B-CHEMICAL
or O
saline. O
RESULTS: O
During O
intranasal O
cocaine B-CHEMICAL
alone, O
SNA O
increased O
by O
2-fold O
and O
skin O
vascular O
resistance O
increased O
from O
13.2 O
+/- O
2.3 O
to O
20.1 O
+/- O
2.2 O
resistance O
units O
while O
mean O
arterial O
pressure O
increased O
by O
14 O
+/- O
3 O
mm O
Hg O
and O
heart O
rate O
by O
18 O
+/- O
3 O
beats/min O
(p O
< O
0.01). O

Dexmedetomidine B-CHEMICAL
abolished O
these O
increases, O
whereas O
intravenous O
saline O
was O
without O
effect. O
Dexmedetomidine B-CHEMICAL
was O
effective O
in O
blocking O
these O
sympathomimetic O
actions O
of O
cocaine B-CHEMICAL
even O
in O
all O
7 O
subjects O
who O
were O
homozygous O
for O
the O
Del322-325 O
polymorphism O
in O
the O
alpha2C B-GENE-Y
AR, I-GENE-Y
a O
loss-of-function O
mutation O
that O
is O
highly O
enriched O
in O
blacks. O
CONCLUSIONS: O
The O
data O
advance O
the O
novel O
hypothesis O
that O
central O
sympatholysis O
with O
dexmedetomidine B-CHEMICAL
constitutes O
a O
highly O
effective O
countermeasure O
for O
cocaine's O

sympathomimetic O
actions O
on O
the O
human O
cardiovascular O
system, O
even O
in O
individuals O
carrying O
the O
alpha2CDel322-325 B-GENE-Y
polymorphism. O
(Study O
to O
Improve O
Scientific O
Understanding O
of O
the O
Cardiovascular O
Actions O
of O
Cocaine; B-CHEMICAL
http://clinicaltrials.gov/ct/show/NCT00338546?order=1; O
NCT00338546). O
The O
inhibitory O
effect O
of O
sodium B-CHEMICAL
nitroprusside I-CHEMICAL
on O
HIF-1 B-GENE-N
activation O
is O
not O
dependent O
on O
nitric B-CHEMICAL
oxide-soluble I-CHEMICAL
guanylyl I-GENE-N
cyclase I-GENE-N
pathway. O
Adaptation O

to O
hypoxia O
and O
maintenance O
of O
O(2) B-CHEMICAL
homeostasis O
involve O
a O
wide O
range O
of O
responses O
that O
occur O
at O
different O
organizational O
levels O
in O
the O
body. O
One O
of O
the O
most O
important O
transcription O
factors O
that O
activate O
the O
expression O
of O
O(2)-regulated B-CHEMICAL
genes O
is O
hypoxia-inducible B-GENE-N
factor I-GENE-N
1 I-GENE-N
(HIF-1). B-GENE-N
Nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
mediates O
a O
variety O
of O
biological O
effects O
including O
relaxation O
of O
blood O
vessels O
and O
cytotoxicity O
of O
activated O
macrophages. O
We O
investigated O
the O
effect O
of O
the O
clinically O
used O
nitrates O
nitroglycerin B-CHEMICAL
(NTG), B-CHEMICAL
isosorbide B-CHEMICAL

dinitrate I-CHEMICAL
(ISDN), B-CHEMICAL
and O
sodium B-CHEMICAL
nitroprusside I-CHEMICAL
(SNP) B-CHEMICAL
on O
HIF-1-mediated B-GENE-N
transcriptional O
responses O
to O
hypoxia. O
We O
demonstrate O
that O
among O
the O
three O
nitrates, O
only O
SNP B-CHEMICAL
inhibits O
HIF-1 B-GENE-N
activation O
in O
response O
to O
hypoxia. O
In O
contrast, O
NTG B-CHEMICAL
or O
ISDN B-CHEMICAL
does O
not O
affect O
HIF-1 B-GENE-N
activity. O
SNP B-CHEMICAL
inhibits O
the O
accumulation O
of O
HIF-1alpha, B-GENE-Y
the O
regulatory O
subunit O
of O
HIF-1, B-GENE-N
and O
the O
transcriptional O
activation O
of O
HIF-1alpha B-GENE-Y
via O
a O
mechanism O
that O
is O
not O

dependent O
on O
either O
NO B-CHEMICAL
or O
soluble B-GENE-N
guanylate I-GENE-N
cyclase. I-GENE-N
Indomethacin B-CHEMICAL
activates O
carbonic B-GENE-N
anhydrase I-GENE-N
and O
antagonizes O
the O
effect O
of O
the O
specific O
carbonic B-GENE-N
anhydrase I-GENE-N
inhibitor O
acetazolamide, B-CHEMICAL
by O
a O
direct O
mechanism O
of O
action. O
OBJECTIVES: O
In O
this O
paper O
we O
investigated O
the O
effect O
of O
indomethacin, B-CHEMICAL
acetazolamide B-CHEMICAL
and O
their O
combination O
in O
vitro O
and O
in O
vivo O
on O
carbonic B-GENE-N
anhydrase I-GENE-N
(CA) B-GENE-N
isozymes. O
METHOD: O
In O
vitro O
experiments O
followed O
the O
effect O
of O
the O
two O
substances O
at O

concentrations O
between O
10(-8)-10(-4) O
M O
on O
purified O
human B-GENE-N
red I-GENE-N
cell I-GENE-N
CA I-GENE-N
I I-GENE-N
and I-GENE-N
II I-GENE-N
as O
well O
as O
on O
human B-GENE-Y
gastric I-GENE-Y
mucosa I-GENE-Y
CA I-GENE-Y
IV I-GENE-Y
using O
dose-response O
relationships. O
Kinetic O
studies O
were O
also O
performed. O
The O
effects O
of O
single O
and O
combined O
administration O
of O
indomethacin B-CHEMICAL
and O
acetazolamide B-CHEMICAL
on O
red O
cell O
CA B-GENE-N
and O
on O
gastric O
acid O
secretion O
were O
studied O
in O
vivo. O
RESULTS: O
Indomethacin, B-CHEMICAL
in O
vitro O
and O
in O
vivo. O
induces O
an O
increase O
in O
erythorcyte O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II I-GENE-Y
activity. O

Acetazolamide, B-CHEMICAL
a O
specific O
inhibitor O
of O
CA, B-GENE-N
reduces O
the O
activity O
of O
CA B-GENE-Y
I I-GENE-Y
and O
CA B-GENE-Y
II I-GENE-Y
from O
red O
cells. O
Indomethacin B-CHEMICAL
completely O
antagonizes O
CA B-GENE-N
activity, O
i.e. O
abolishes O
the O
inhibitory O
effect O
of O
acetazolamide B-CHEMICAL
on O
CA. B-GENE-N
In O
humans, O
an O
increase O
or O
decrease O
in O
erythrocyte O
CA B-GENE-Y
II I-GENE-Y
activity O
is O
correlated O
with O
an O
increase O
or O
decrease O
in O
gastric O
acid O
secretion. O
CONCLUSIONS: O
Our O
results O
show O
that O
indomethacin, B-CHEMICAL
a O
known O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
inhibitor, O
is O
also O
an O
activator O
of O

CA. B-GENE-N
Our O
data O
also O
prove O
that O
indomethacin B-CHEMICAL
is O
not O
only O
an O
activator O
of O
CA B-GENE-N
but O
also O
antagonizes O
the O
effect O
of O
acetazolamide, B-CHEMICAL
a O
specific O
inhibitor O
of O
this O
enzyme. O
In O
view O
of O
the O
role O
of O
CA B-GENE-N
in O
acid-base O
balance O
as O
well O
as O
the O
fact O
that O
an O
increase O
or O
decrease O
in O
its O
activity O
is O
accompanied O
by O
an O
increase O
or O
decrease O
in O
intra- O
and O
extracellular O
pH, O
our O
results O
suggest O
that: O
firstly, O
CA B-GENE-N
activation O
induced O
by O
indomethacin B-CHEMICAL
might O
cause O
changes O
in O
COX B-GENE-N
activity; O
secondly, O
PGs O
are O
synthetized O
as O
a O
consequence O
of O
the O
changes O
in O
COX B-GENE-N

activity, O
a O
hypothesis O
that O
requires O
further O
study. O
Recent O
developments O
in O
the O
synthesis O
of O
acetylcholinesterase B-GENE-Y
inhibitors. O
The O
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
and O
butyrylcholinesterase B-GENE-Y
(BuChE) B-GENE-Y
inhibitory O
activities O
of O
a O
series O
of O
pyrano[2,3-b]quinolines B-CHEMICAL
(2, O
3), O
[1,8]naphthyridines B-CHEMICAL
(5, O
6), O

4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines B-CHEMICAL
(11-13)/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine B-CHEMICAL
(14), O

4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline B-CHEMICAL
(15)/ O
4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine B-CHEMICAL
(16) O
are O
described. O
These O
compounds O
are O
tacrine B-CHEMICAL
analogues O
that O
have O
been O
prepared O
from O
readily O
available O
polyfunctionalized O
ethyl B-CHEMICAL

[6-amino-5-cyano-4H-pyran]-3-carboxylates I-CHEMICAL
(9, O
10), O
ethyl B-CHEMICAL
[6-amino-5-cyanopyridine]-3-carboxylates I-CHEMICAL
(7, O
8), O
2-amino-3-cyano-4,5-diarylfurans B-CHEMICAL
(17-19) O
and O
2-amino-3-cyano-4,5-diphenylthiophene B-CHEMICAL
(20) O
via O
Friedlander O
condensation O
with O
selected O
ketones. B-CHEMICAL
These O
compounds O
are O
competitive O
and, O

in O
a O
few O
cases, O
non-competitive O
inhibitors O
for O
AChE, B-GENE-Y
the O
most O
potent O
being O
compound O
(14), O
though O
three-fold O
less O
active O
than O
tacrine. B-CHEMICAL
The O
BuChE B-GENE-Y
inhibitory O
activity O
is O
only O
significant O
in O
compounds O
11 O
and O
14, O
ten-fold O
less O
active O
than O
tacrine. B-CHEMICAL
Furthermore, O
the O
products O
12 O
and O
13 O
are O
selective O
and O
moderate O
AChE B-GENE-Y
inhibitors. O
Development O
and O
validation O
of O
NIR-chemometric O
methods O
for O
chemical O
and O
pharmaceutical O
characterization O
of O
meloxicam B-CHEMICAL
tablets. O
Abstract O
Context: O
Near-Infrared O
(NIR) O
spectroscopy O
is O
an O
important O

component O
of O
a O
Process O
Analytical O
Technology O
(PAT) O
toolbox O
and O
is O
a O
key O
technology O
for O
enabling O
the O
rapid O
analysis O
of O
pharmaceutical O
tablets. O
Objective: O
The O
aim O
of O
this O
research O
work O
was O
to O
develop O
and O
validate O
NIR-chemometric O
methods O
not O
only O
for O
the O
determination O
of O
active O
pharmaceutical O
ingredients O
content O
but O
also O
pharmaceutical O
properties O
(crushing O
strength, O
disintegration O
time) O
of O
meloxicam B-CHEMICAL
tablets. O
Materials O
and O
methods: O
The O
development O
of O
the O
method O
for O
active O
content O
assay O
was O
performed O
on O
samples O
corresponding O
to O
80%, O
90%, O
100%, O
110% O
and O
120% O
of O
meloxicam B-CHEMICAL
content O
and O
the O
development O
of O

the O
methods O
for O
pharmaceutical O
characterization O
was O
performed O
on O
samples O
prepared O
at O
seven O
different O
compression O
forces O
(ranging O
from O
7 O
to O
45 O
kN) O
using O
NIR O
transmission O
spectra O
of O
intact O
tablets O
and O
PLS O
as O
a O
regression O
method. O
Results: O
The O
results O
show O
that O
the O
developed O
methods O
have O
good O
trueness, O
precision O
and O
accuracy O
and O
are O
appropriate O
for O
direct O
active O
content O
assay O
in O
tablets O
(ranging O
from O
12 O
to O
18 O
mg/tablet) O
and O
also O
for O
predicting O
crushing O
strength O
and O
disintegration O
time O
of O
intact O
meloxicam B-CHEMICAL
tablets. O
Discussion: O
The O
comparative O
data O
show O
that O
the O
proposed O
methods O
are O
in O
good O
agreement O
with O
the O
reference O
methods O
currently O
used O
for O
the O

characterization O
of O
meloxicam B-CHEMICAL
tablets O
(HPLC-UV O
methods O
for O
the O
assay O
and O
European O
Pharmacopeia O
methods O
for O
determining O
the O
crushing O
strength O
and O
disintegration O
time). O
Conclusion: O
The O
results O
show O
the O
possibility O
to O
predict O
both O
chemical O
properties O
(active O
content) O
and O
physical/pharmaceutical O
properties O
(crushing O
strength O
and O
disintegration O
time) O
directly, O
without O
any O
sample O
preparation, O
from O
the O
same O
NIR O
transmission O
spectrum O
of O
meloxicam B-CHEMICAL
tablets. O
Juglone, B-CHEMICAL
isolated O
from O
Juglans O
mandshurica O
Maxim, O
induces O
apoptosis O
via O
down-regulation O
of O
AR B-GENE-Y
expression O
in O
human O
prostate O
cancer O

LNCaP O
cells. O
Juglone B-CHEMICAL
is O
a O
natural O
compound O
which O
has O
been O
isolated O
from O
Juglans O
mandshurica O
Maxim. O
Recent O
studies O
have O
shown O
that O
juglone B-CHEMICAL
had O
various O
pharmacological O
effects O
such O
as O
anti-viral, O
anti-bacterial O
and O
anti-cancer. O
However, O
its O
anti-cancer O
activity O
on O
human O
prostate O
cancer O
LNCaP O
cell O
has O
not O
been O
examined. O
Thus, O
the O
current O
study O
was O
designed O
to O
elucidate O
the O
molecular O
mechanism O
of O
apoptosis O
induced O
by O
juglone B-CHEMICAL
in O
androgen-sensitive B-CHEMICAL
prostate O
cancer O
LNCaP O
cells. O
MTT B-CHEMICAL
assay O
was O
performed O
to O
examine O
the O

anti-proliferative O
effect O
of O
juglone. B-CHEMICAL
Occurrence O
of O
apoptosis O
was O
detected O
by O
Hoechst B-CHEMICAL
33342 I-CHEMICAL
staining O
and O
flow O
cytometry O
in O
LNCaP O
cells O
treated O
with O
juglone B-CHEMICAL
for O
24h. O
The O
result O
shown O
that O
juglone B-CHEMICAL
inhibited O
the O
growth O
of O
LNCaP O
cells O
in O
a O
dose-dependent O
manner. O
Morphological O
changes O
of O
apoptotic O
body O
formation O
after O
juglone B-CHEMICAL
treatment O
were O
observed O
by O
Hoechst B-CHEMICAL
33342 I-CHEMICAL
staining. O
This O
apoptotic O
induction O
was O
associated O
with O
loss O
of O
mitochondrial O
membrane O
potential, O
and O
caspase-3, B-GENE-N

-9 I-GENE-N
activation. O
Moreover, O
we O
found O
that O
juglone B-CHEMICAL
significantly O
inhibited O
the O
expression O
levels O
of O
androgen B-GENE-Y
receptor I-GENE-Y
(AR) B-GENE-Y
and O
prostate-specific B-GENE-Y
antigen I-GENE-Y
(PSA) B-GENE-Y
in O
a O
dose-dependent O
manner, O
as O
well O
as O
abrogated O
up-regulation O
of O
AR B-GENE-Y
and O
PSA B-GENE-Y
genes O
with O
and/or O
without O
dihydrotestosterone B-CHEMICAL
(DHT). B-CHEMICAL
Take O
together, O
our O
results O
demonstrated O
that O
juglone B-CHEMICAL
might O
induce O
the O
apoptosis O
in O
LNCaP O
cell O
via O
down-regulation O
of O
AR B-GENE-Y
expression. O
Therefore, O
our O
results O
indicated O
that O
juglone B-CHEMICAL
may O
be O
a O
potential O
candidate O
of O
drug O
for O

androgen-sensitive B-CHEMICAL
prostate O
cancer. O
Anticancer O
activity O
of O
novel O
hybrid O
molecules O
containing O
5-benzylidene B-CHEMICAL
thiazolidine-2,4-dione. I-CHEMICAL
Hybridization O
of O
two O
different O
bioactive O
molecules O
with O
different O
mechanism O
of O
action O
is O
one O
of O
the O
methods O
that O
are O
being O
adopted O
to O
treat O
cancer. O
Molecules O
bearing O
a O
thiazolidine-2,4-dione B-CHEMICAL
scaffold O
have O
been O
recognized O
as O
antineoplastic O
agents O
with O
a O
broad O
spectrum O
of O
activity O
against O
many O
cancer O
cell O
lines. O
In O
this O
manuscript O
we O
have O
described O
the O
synthesis O
and O
biological O
evaluation O
of O
two O
series O
of O

N-3-substituted-5-arylidene B-CHEMICAL
thiazolidine-2,4-diones, I-CHEMICAL
bearing O
the O
α-bromoacryloylamido B-CHEMICAL
moiety O
at O
the O
para- O
or O
meta-position O
on O
the O
phenyl B-CHEMICAL
of O
the O
arylidene B-CHEMICAL
portion. O
We O
have O
observed O
that O
selected O
compounds O
5a, O
5c O
and O
5g O
suppress O
proliferation O
of O
human O
myeloid O
leukaemia O
HL-60 O
and O
U937 O
cells O
by O
triggering O
morphological O
changes O
and O
internucleosomal O
DNA O
fragmentation, O
which O
are O
well-known O
features O
of O
apoptosis. O
Finally, O
our O
results O
indicated O

that O
the O
investigated O
compounds O
induced O
apoptotic O
cell O
death O
through O
a O
mechanism O
that O
involved O
activation O
of O
multiple O
caspases B-GENE-N
and O
was O
also O
associated O
with O
the O
release O
of O
cytochrome B-GENE-Y
c I-GENE-Y
from O
the O
mitochondria. O
Methylation O
damage O
to O
RNA O
induced O
in O
vivo O
in O
Escherichia O
coli O
is O
repaired O
by O
endogenous O
AlkB B-GENE-Y
as O
part O
of O
the O
adaptive O
response. O
Cytotoxic O
1-methyladenine B-CHEMICAL
(1-meA) B-CHEMICAL
and O
3-methylcytosine B-CHEMICAL
(3-meC) B-CHEMICAL
lesions O
induced O
in O
DNA O
and O
RNA O
in O
vitro O
and O
in O
pre-damaged O
DNA O
and O
RNA O

bacteriophages O
in O
vivo O
are O
repaired O
by O
the O
Escherichia B-GENE-Y
coli I-GENE-Y
(E. I-GENE-Y
coli) I-GENE-Y
protein I-GENE-Y
AlkB I-GENE-Y
and O
a O
human B-GENE-Y
homolog, I-GENE-Y
ALKBH3. I-GENE-Y
However, O
it O
is O
not O
known O
whether O
endogenous O
RNA O
is O
repaired O
in O
vivo O
by O
repair O
proteins O
present O
at O
physiological O
concentrations. O
The O
concept O
of O
RNA O
repair O
as O
a O
biologically O
relevant O
process O
has O
therefore O
remained O
elusive. O
Here, O
we O
demonstrate O
AlkB-mediated B-GENE-Y
repair O
of O
endogenous O
RNA O
in O
vivo O
by O
measuring O
differences O
in O
lesion-accumulation O
in O
two O
independent O
AlkB-proficient B-GENE-Y
and O
deficient O
E. O
coli O
strains O

during O
exposure O
to O
methyl B-CHEMICAL
methanesulfonate I-CHEMICAL
(MMS). B-CHEMICAL
Repair O
was O
observed O
both O
in O
AlkB-overproducing B-GENE-Y
strains O
and O
in O
the O
wild-type O
strains O
after O
AlkB B-GENE-Y
induction. O
RNA O
repair O
appeared O
to O
be O
highest O
in O
RNA O
species O
below O
200 O
nucleotides B-CHEMICAL
in O
size, O
mainly O
comprising O
tRNAs. O
Strikingly, O
at O
least O
10-fold O
more O
lesions O
were O
repaired O
in O
RNA O
than O
in O
DNA. O
This O
may O
be O
a O
consequence O
of O
some O
30-fold O
higher O
levels O
of O
aberrant O
methylation O
in O
RNA O
than O
in O
DNA O
after O
exposure O
to O
MMS. B-CHEMICAL
A O
high O
primary O
kinetic O
isotope O
effect O

(>10) O
was O
measured O
using O
a O
deuterated O
methylated O
RNA O
substrate, O
D3-1me(rA), O
demonstrating O
that O
it O
is O
the O
catalytic O
step, O
and O
not O
the O
search O
step O
that O
is O
rate-limiting. O
Our O
results O
demonstrate O
that O
RNA O
repair O
by O
AlkB B-GENE-Y
takes O
place O
in O
endogenous O
RNA O
as O
part O
of O
an O
adaptive O
response O
in O
wild-type O
E. O
coli O
cells. O
Association O
of O
serum B-GENE-Y
proprotein I-GENE-Y
convertase I-GENE-Y
subtilisin/kexin I-GENE-Y
type I-GENE-Y
9 I-GENE-Y
with O
carotid O
intima O
media O
thickness O
in O
hypertensive O
subjects. O
OBJECTIVE: O
The O
clinical O
significance O
of O
the O
measurement O

of O
serum B-GENE-Y
PCSK9 I-GENE-Y
(proprotein B-GENE-Y
subtilisin I-GENE-Y
kexin I-GENE-Y
type I-GENE-Y
9) I-GENE-Y
is O
not O
well O
defined. O
This O
study O
investigated O
the O
association O
between O
serum B-GENE-Y
PCSK9 I-GENE-Y
levels O
and O
atherosclerosis O
assessed O
by O
carotid O
intima O
media O
thickness O
(IMT) O
in O
hypertensive O
patients. O
METHODS: O
A O
total O
of O
126 O
hypertensive O
patients O
over O
the O
age O
of O
45 O
were O
enrolled. O
The O
maximum O
carotid O
IMT O
(max-IMT) O
and O
the O
mean O
carotid O
IMT O
(mean-IMT) O
were O
measured O
at O
the O
time O
of O
enrollment. O
Clinical O
and O
laboratory O
parameters O
including O
serum B-GENE-Y

PCSK9 I-GENE-Y
were O
analyzed. O
RESULTS: O
Patients O
were O
divided O
into O
tertiles O
based O
on O
serum B-GENE-Y
PCSK9 I-GENE-Y
levels. O
After O
adjusting O
for O
age, O
sex, O
total O
cholesterol, B-CHEMICAL
HDL-cholesterol B-GENE-N
and O
triglyceride, B-CHEMICAL
max-IMT O
was O
significantly O
increased O
in O
the O
highest O
tertile O
of O
serum B-GENE-Y
PCSK9 I-GENE-Y
(0.969±0.033 O
vs O
0.959±0.033 O
vs O
1.077±0.033mm, O
respectively; O
P=0.026). O
Mean-IMT O
showed O
a O
tendency O

to O
increase O
across O
the O
tertile O
groups O
(0.773±0.025 O
vs O
0.790±0.026 O
vs O
0.856±0.025mm, O
respectively; O
P=0.059). O
Multivariate O
regression O
analysis O
revealed O
that O
serum B-GENE-Y
PCSK9 I-GENE-Y
was O
independently O
associated O
with O
carotid O
IMT O
(max-IMT: O
β=0.212, O
P=0.016; O
mean-IMT: O
β=0.184, O
P=0.04). O
CONCLUSION: O
The O
present O
study O
is O
the O
first O
to O
report O
the O
association O

between O
serum B-GENE-Y
PCSK9 I-GENE-Y
levels O
and O
carotid O
IMT O
in O
hypertensive O
patients. O
These O
results O
suggest O
that O
serum B-GENE-Y
PCSK9 I-GENE-Y
may O
have O
a O
certain O
role O
in O
early O
pathogenesis O
of O
atherosclerosis. O
Astemizole, B-CHEMICAL
a O
potent O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonist: O
effect O
in O
allergic O
rhinoconjunctivitis, O
on O
antigen O
and O
histamine B-CHEMICAL
induced O
skin O
weal O
responses O
and O
relationship O
to O
serum O
levels. O
The O
efficacy O
of O
astemizole, B-CHEMICAL
a O
new, O
long O
acting, O
oral O
histamine B-GENE-Y
H1-receptor I-GENE-Y
antagonist O
was O
compared O
to O
placebo O
for O
the O
treatment O
of O
allergic O
rhinitis O
and O

conjunctivitis O
during O
the O
grass O
pollen O
season O
of O
1982. O
Sixty-three O
patients O
with O
a O
positive O
skin O
prick O
test O
to O
grass O
pollen O
and O
current O
symptoms O
participated O
in O
an O
8 O
week, O
double-blind, O
randomized O
study. O
Astemizole, B-CHEMICAL
10 O
mg, O
was O
significantly O
better O
than O
placebo O
in O
alleviating O
both O
nose O
(P O
less O
than O
0.05) O
and O
eye O
(P O
less O
than O
0.01) O
symptoms O
despite O
significantly O
greater O
use O
of O
the O
reserve O
medication, O
clemastine, B-CHEMICAL
by O
the O
placebo O
group O
(P O
less O
than O
0.003). O
There O
was O
a O
lag O
period O
of O
5 O
days O
after O
initiation O
of O
therapy O
before O

treatment O
benefit O
became O
manifest. O
Subdivision O
of O
nasal O
symptoms O
indicated O
significant O
improvement O
compared O
to O
placebo O
over O
the O
8 O
weeks O
for O
sneezing O
(P O
less O
than O
0.05) O
and O
runny O
nose O
(P O
less O
than O
0.05) O
but O
not O
blocked O
nose. O
The O
absence O
of O
effect O
on O
nasal O
blockage O
was O
confirmed O
by O
parallel O
measurement O
of O
nasal O
calibre O
by O
body O
plethysmography. O
The O
antihistaminic O
potency O
of O
astemizole B-CHEMICAL
was O
indicated O
by O
an O
80% O
inhibition O
of O
the O
histamine B-CHEMICAL
induced O
skin O
weal O
response O
after O
8 O
weeks O
therapy. O
A O
positive O
correlation O
was O
found O
between O
serum O
drug O
levels O
and O
% O
inhibition O
of O

histamine B-CHEMICAL
skin O
weal O
(r O
= O
0.64, O
P O
less O
than O
0.001). O
Astemizole B-CHEMICAL
was O
free O
from O
adverse O
sedative O
or O
anticholinergic O
effects O
but O
did O
cause O
a O
mean O
increase O
in O
weight O
of O
1.3 O
kg O
(P O
less O
than O
0.01) O
after O
8 O
weeks O
therapy, O
not O
found O
with O
placebo. O
Rivastigmine B-CHEMICAL
for O
Alzheimer's O
disease. O
BACKGROUND: O
Alzheimer's O
disease O
(AD) O
is O
the O
commonest O
cause O
of O
dementia O
affecting O
older O
people. O
One O
of O
the O
therapeutic O
strategies O
aimed O
at O
ameliorating O
the O
clinical O
manifestations O
of O

Alzheimer's O
disease O
is O
to O
enhance O
cholinergic O
neurotransmission O
in O
relevant O
parts O
of O
the O
brain O
by O
the O
use O
of O
cholinesterase B-GENE-Y
inhibitors O
to O
delay O
the O
breakdown O
of O
acetylcholine B-CHEMICAL
released O
into O
synaptic O
clefts. O
Tacrine, B-CHEMICAL
the O
first O
of O
the O
cholinesterase B-GENE-Y
inhibitors O
to O
undergo O
extensive O
trials O
for O
this O
purpose, O
was O
associated O
with O
significant O
adverse O
effects O
including O
hepatotoxicity. O
Other O
cholinesterase B-GENE-Y
inhibitors, O
including O
rivastigmine, B-CHEMICAL
with O
superior O
properties O
in O
terms O
of O
specificity O
of O
action O
and O
low O
risk O
of O
adverse O
effects, O
have O
now O
been O
introduced. O

Rivastigmine B-CHEMICAL
has O
received O
approval O
for O
use O
in O
60 O
countries O
including O
all O
member O
states O
of O
the O
European O
Union O
and O
the O
USA. O
OBJECTIVES: O
To O
determine O
the O
clinical O
efficacy O
and O
safety O
of O
rivastigmine B-CHEMICAL
for O
patients O
with O
dementia O
of O
Alzheimer's O
type. O
SEARCH O
STRATEGY: O
The O
Specialized O
Register O
of O
the O
Cochrane O
Dementia O
and O
Cognitive O
Improvement O
Group O
(CDCIG), O
The O
Cochrane O
Library, O
MEDLINE, O
EMBASE, O
PsycINFO, O
CINAHL O
and O
LILACS O
were O
searched O
on O
27 O
March O
2008 O

using O
the O
terms: O
Rivastigmine B-CHEMICAL
OR O
exelon B-CHEMICAL
OR O
ENA B-CHEMICAL
OR O
"SDZ B-CHEMICAL
ENA I-CHEMICAL
713" I-CHEMICAL
. O
The O
CDCIG O
Specialized O
Register O
contains O
records O
from O
all O
major O
health O
care O
databases O
(The O
Cochrane O
Library, O
MEDLINE, O
EMBASE, O
PsycINFO, O
CINAHL, O
LILACS) O
as O
well O
as O
from O
many O
clinical O
trials O
registries O
and O
grey O
literature O
sources. O
SELECTION O
CRITERIA: O
All O
unconfounded, O
double-blind, O
randomized O
trials O
in O
which O
treatment O
with O
rivastigmine B-CHEMICAL
was O
administered O
to O
patients O
with O

dementia O
of O
the O
Alzheimer's O
type O
for O
more O
than O
two O
weeks O
and O
its O
effects O
compared O
with O
those O
of O
placebo O
in O
a O
parallel O
group O
of O
patients. O
DATA O
COLLECTION O
AND O
ANALYSIS: O
One O
reviewer O
(JSB) O
applied O
study O
selection O
criteria, O
assessed O
the O
quality O
of O
studies O
and O
extracted O
data. O
MAIN O
RESULTS: O
Nine O
trials, O
involving O
4775 O
participants, O
were O
included O
in O
the O
analyses. O
Use O
of O
rivastigmine B-CHEMICAL
in O
high O
doses O
was O
associated O
with O
statistically O
significant O
benefits O
on O
several O
measures. O
High-dose O
rivastigmine B-CHEMICAL
(6 O
to O
12 O
mg O
daily) O
was O
associated O
with O

a O
two-point O
improvement O
in O
cognitive O
function O
on O
the O
ADAS-Cog O
score O
compared O
with O
placebo O
(weighted O
mean O
difference O
-1.99, O
95% O
confidence O
interval O
-2.49 O
to O
-1.50, O
on O
an O
intention-to-treat O
basis) O
and O
a O
2.2 O
point O
improvement O
in O
activities O
of O
daily O
living O
assessed O
on O
the O
Progressive O
Deterioration O
Scale O
(weighted O
mean O
difference O
-2.15, O
95% O
confidence O
interval O
-3.16 O
to O
-1.13, O
on O
an O
intention-to-treat O
basis) O
at O
26 O
weeks. O
At O
lower O
doses O
(4 O
mg O
daily O
or O
lower) O
differences O
were O
in O
the O
same O
direction O
but O
were O

statistically O
significant O
only O
for O
cognitive O
function. O
There O
were O
statistically O
significantly O
higher O
numbers O
of O
events O
of O
nausea, O
vomiting, O
diarrhoea, O
anorexia, O
headache, O
syncope, O
abdominal O
pain O
and O
dizziness O
among O
patients O
taking O
high-dose O
rivastigmine B-CHEMICAL
than O
among O
those O
taking O
placebo. O
There O
was O
some O
evidence O
that O
adverse O
events O
might O
be O
less O
common O
with O
more O
frequent, O
smaller O
doses O
of O
rivastigmine. B-CHEMICAL
The O
2008 O
update O
includes O
a O
new O
study O
testing O
two O
types O
of O
rivastigmine B-CHEMICAL
transdermal O
patch, O
one O
delivering O
a O
higher O
dose O
than O
previously O
tested O
(17.4 O
mg/day) O
and O
a O

smaller O
patch O
delivering O
9.6 O
mg/day. O
The O
efficacy O
of O
the O
smaller O
patch O
was O
not O
significantly O
different O
compared O
with O
the O
capsules O
of O
similar O
daily O
dose, O
but O
was O
associated O
with O
significantly O
fewer O
adverse O
events O
of O
nausea, O
vomiting, O
dizziness O
and O
asthenia. O
The O
efficacy O
of O
the O
larger O
patch O
was O
not O
significantly O
different O
compared O
with O
the O
smaller O
patch, O
but O
the O
smaller O
patch O
was O
associated O
with O
significantly O
fewer O
adverse O
events O
of O
nausea, O
vomiting, O
weight O
loss O
and O
dizziness. O
There O
appears O
to O
be O
advantages O
associated O
with O
the O
smaller O
patch O
compared O
with O
both O
the O
higher O
dose O
patch O
and O
the O
6-12 O
mg/day O
capsules. O
AUTHORS' O

CONCLUSIONS: O
Rivastigmine B-CHEMICAL
appears O
to O
be O
beneficial O
for O
people O
with O
mild O
to O
moderate O
Alzheimer's O
disease. O
In O
comparisons O
with O
placebo, O
improvements O
were O
seen O
in O
the O
rate O
of O
decline O
of O
cognitive O
function, O
activities O
of O
daily O
living, O
and O
severity O
of O
dementia O
with O
daily O
doses O
of O
6 O
to O
12 O
mg. O
Adverse O
events O
were O
consistent O
with O
the O
cholinergic O
actions O
of O
the O
drug. O
A O
transdermal O
patch O
has O
been O
tested O
in O
one O
trial, O
and O
there O
is O
evidence O
that O
the O
lower O
dose O
smaller O
patch O
is O
associated O
with O
fewer O
side O
effects O
than O
the O
capsules O
or O
the O
higher O
dose O
larger O
patch O
and O
has O
comparable O
efficacy O
to O
both. O
This O

review O
has O
not O
examined O
economic O
data. O
NHE3 B-GENE-Y
inhibition O
activates O
duodenal O
bicarbonate O
secretion O
in O
the O
rat. O
We O
examined O
the O
effect O
of O
inhibition O
of O
Na+/H+ B-GENE-N
exchange I-GENE-N
(NHE) B-GENE-N
on O
duodenal O
bicarbonate O
secretion O
(DBS) O
in O
rats O
to O
further O
understand O
DBS O
regulation. O
DBS O
was O
measured O
by O
using O
the O
pH-stat O
method O
and O
by O
using O
CO2-sensitive B-CHEMICAL
electrodes. O
5-(N,N-dimethyl)-amiloride B-CHEMICAL
(50 O
microM; O
DMA), B-CHEMICAL
a O
concentration O
that O
selectively O
inhibits O
the O
NHE B-GENE-N

isoforms O
NHE1 B-GENE-Y
and O
NHE2, B-GENE-Y
but O
not O
NHE3, B-GENE-Y
did O
not O
affect O
DBS. O
Nevertheless, O
3 O
mM O
DMA, B-CHEMICAL
a O
higher O
concentration O
that O
inhibits O
NHE1, B-GENE-Y
NHE2, B-GENE-Y
and O
NHE3, B-GENE-Y
significantly O
increased O
DBS. O
Moreover, O
S1611 B-CHEMICAL
and O
S3226, B-CHEMICAL
both O
specific O
inhibitors O
of O
NHE3 B-GENE-Y
only, O
or O
perfusion O
with O
Na+-free B-CHEMICAL
solutions, O
dose O
dependently O
increased O
DBS, O
as O
measured O
by O
pH-stat O
and O
CO2-sensitive B-CHEMICAL
electrode, O
without O
affecting O
intracellular O
pH. O
Coperfusion O
with O
0.1 O
microM O

indomethacin, B-CHEMICAL
0.5 O
mM O
DIDS, O
or O
1 O
mM O
methazolamide B-CHEMICAL
did O
not O
affect O
S3226-induced B-CHEMICAL
DBS. O
Nevertheless, O
coperfusion O
with O
0.1 O
and O
0.3 O
mM O
5-nitro-2-(3-phenylpropylamino) B-CHEMICAL
benzoic I-CHEMICAL
acid, I-CHEMICAL
which O
inhibits O
the O
cystic B-GENE-Y
fibrosis I-GENE-Y
transmembrane I-GENE-Y
conductor I-GENE-Y
regulator I-GENE-Y
(CFTR), B-GENE-Y
dose O
dependently O
inhibited O
S3226-induced B-CHEMICAL
DBS. O
In O
conclusion, O
only O
specific O
apical O
NHE3 B-GENE-Y
inhibition O
increased O
DBS, O
whereas O

prostaglandin B-CHEMICAL
synthesis, O
Na+-HCO3- B-GENE-Y
cotransporter I-GENE-Y
activation, O
or O
intracellular O
HCO3- B-CHEMICAL
formation O
by O
carbonic B-GENE-N
anhydrase I-GENE-N
was O
not O
involved. O
Because O
NHE3 B-GENE-Y
inhibition-increased O
DBS O
was O
inhibited O
by O
an O
anion B-GENE-N
channel I-GENE-N
inhibitor O
and O
because O
reciprocal O
CFTR B-GENE-Y
regulation O
has O
been O
previously O
shown O
between O
NHE3 B-GENE-Y
and O
apical B-GENE-N
membrane I-GENE-N
anion I-GENE-N
transporters, I-GENE-N
we O
speculate O
that O
NHE3 B-GENE-Y
inhibition O
increased O
DBS O
by O
altering O
anion B-GENE-N
transporter I-GENE-N
function. O
The O
Prevalence O
of O
Meeting O
A1C, B-GENE-Y
Blood O
Pressure, O
and O
LDL B-GENE-N
Goals O

Among O
People O
With O
Diabetes, O
1988-2010. O
OBJECTIVETo O
determine O
the O
prevalence O
of O
people O
with O
diabetes O
who O
meet O
hemoglobin B-GENE-Y
A(1c) I-GENE-Y
(A1C), B-GENE-Y
blood O
pressure O
(BP), O
and O
LDL B-GENE-N
cholesterol B-CHEMICAL
(ABC) O
recommendations, O
and O
their O
current O
statin O
use, O
factors O
associated O
with O
goal O
achievement, O
and O
changes O
in O
the O
proportion O
achieving O
goals O
between O
1988 O
and O
2010.RESEARCH O
AND O
DESIGN O
METHODSData O
were O
cross-sectional O
from O
the O
National O
Health O
and O
Nutrition O
Examination O
Surveys O
(NHANES) O
from O

1988-1994, O
1999-2002, O
2003-2006, O
and O
2007-2010. O
Participants O
were O
4,926 O
adults O
aged O
≥20 O
years O
who O
self-reported O
a O
previous O
diagnosis O
of O
diabetes O
and O
completed O
the O
household O
interview O
and O
physical O
examination O
(n O
= O
1,558 O
for O
valid O
LDL O
levels). O
Main O
outcome O
measures O
were O
A1C, B-GENE-Y
BP, O
and O
LDL B-GENE-N
cholesterol, B-CHEMICAL
in O
accordance O
with O
the O
American O
Diabetes O
Association O
recommendations, O
and O
current O
use O
of O
statins.RESULTSIn O
2007-2010, O
52.5% O
of O
people O
with O
diabetes O
achieved O
A1C B-GENE-Y
<7.0% O

(<53 O
mmol/mol), O
51.1% O
achieved O
BP O
<130/80 O
mmHg, O
56.2% O
achieved O
LDL B-GENE-N
<100 O
mg/dL, O
and O
18.8% O
achieved O
all O
three O
ABCs. O
These O
levels O
of O
control O
were O
significant O
improvements O
from O
1988 O
to O
1994 O
(all O
P O
< O
0.05). O
Statin O
use O
significantly O
increased O
between O
1988-1994 O
(4.2%) O
and O
2007-2010 O
(51.4%, O
P O
< O
0.01). O
Compared O
with O
non-Hispanic O
whites, O
Mexican O
Americans O
were O
less O
likely O
to O
meet O
A1C B-GENE-Y
and O
LDL B-GENE-N
goals O
(P O

< O
0.03), O
and O
non-Hispanic O
blacks O
were O
less O
likely O
to O
meet O
BP O
and O
LDL B-GENE-N
goals O
(P O
< O
0.02). O
Compared O
with O
non-Hispanic O
blacks, O
Mexican O
Americans O
were O
less O
likely O
to O
meet O
A1C B-GENE-Y
goals O
(P O
< O
0.01). O
Younger O
individuals O
were O
less O
likely O
to O
meet O
A1C B-GENE-Y
and O
LDL B-GENE-N
goals.CONCLUSIONSDespite O
significant O
improvement O
during O
the O
past O
decade, O
achieving O
the O
ABC O
goals O
remains O
suboptimal O
among O
adults O
with O
diabetes, O
particularly O
in O
some O
minority O
groups. O
Substantial O
opportunity O
exists O
to O
further O
improve O
diabetes O
control O
and, O
thus, O
to O
reduce O
diabetes-related O

morbidity O
and O
mortality. O
EphB1 B-GENE-Y
null O
mice O
exhibit O
neuronal O
loss O
in O
substantia O
nigra O
pars O
reticulata O
and O
spontaneous O
locomotor O
hyperactivity. O
The O
molecular O
mechanisms O
that O
regulate O
basal O
ganglia O
development O
are O
largely O
unknown. O
Eph B-GENE-N
receptor I-GENE-N
tyrosine B-GENE-N
kinases I-GENE-N
are O
potential O
participants O
in O
this O
process O
as O
they O
regulate O
development O
of O
other O
CNS O
regions O
and O
are O
expressed O
in O
basal O
ganglia O
nuclei, O
such O
as O
the O
substantia O
nigra O
(SN) O
and O
striatum. O
To O
address O
the O
role O
of O
Eph B-GENE-N
receptors I-GENE-N
in O
the O
development O
of O
these O
nuclei, O
we O
analysed O

anatomical O
changes O
in O
the O
SN O
and O
striatum O
of O
mice O
with O
null O
mutations O
for O
EphB1. B-GENE-Y
These O
mice O
express O
beta-galactosidase O
as O
a O
marker O
for O
cells O
normally O
expressing O
EphB1. B-GENE-Y
In O
situ O
hybridization O
data O
and O
a O
direct O
comparison O
of O
SN O
neurons O
expressing O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
(TH) B-GENE-Y
and/or O
the O
beta-gal O
marker O
for O
EphB1 B-GENE-Y
revealed O
that O
EphB1 B-GENE-Y
is O
not O
expressed O
in O
TH+ B-GENE-Y
neurons O
of O
pars O
compacta O
(SNc), O
but O
is O
restricted O
to O
neurons O
in O
pars O
reticulata O

(SNr). O
Consistent O
with O
this, O
we O
find O
that O
EphB1 B-GENE-Y
null O
mice O
exhibit O
a O
significant O
decrease O
in O
the O
volume O
and O
number O
of O
neurons O
(40% O
decrease) O
in O
SNr, O
whereas O
the O
volume O
and O
number O
of O
TH+ B-GENE-Y
neurons O
in O
SNc O
is O
not O
significantly O
affected O
nor O
are O
there O
changes O
in O
the O
distribution O
of O
nigrostriatal O
dopamine B-CHEMICAL
neurons. O
Although O
EphB1 B-GENE-Y
is O
expressed O
in O
the O
striatum, O
EphB1-/- B-GENE-Y
mice O
exhibit O
no O
significant O
changes O
in O
striatal O
volume O
and O
TH B-GENE-Y
fiber O
density, O
and O
have O
no O
obvious O
alterations O
in O
striatal O

patch/matrix O
organization. O
Behavioral O
evaluation O
of O
EphB1 B-GENE-Y
null O
mice O
in O
an O
open-field O
environment O
revealed O
that O
these O
mice O
exhibited O
spontaneous O
locomotor O
hyperactivity. O
These O
results O
suggest O
that O
EphB1 B-GENE-Y
is O
necessary O
for O
the O
proper O
formation O
of O
SNr, O
and O
that O
neuronal O
loss O
in O
SNr O
is O
associated O
with O
altered O
locomotor O
functions. O
pH-responsive O
composite O
microspheres O
based O
on O
magnetic O
mesoporous O
silica B-CHEMICAL
nanoparticle O
for O
drug O
delivery. O
pH-responsive O
composite O
microspheres, O
consisting O
of O
a O
core O
of O

Fe3O4 B-CHEMICAL
nanoparticle, O
a O
sandwiched O
layer O
of O
mesoporous O
silica B-CHEMICAL
and O
a O
shell O
of O
crosslinked O
poly B-CHEMICAL
(methacrylic I-CHEMICAL
acid) I-CHEMICAL
(PMAA), B-CHEMICAL
were O
successfully O
synthesized O
via O
distillation O
precipitation O
polymerization. O
The O
pKa O
of O
the O
composite O
microsphere O
increased O
with O
the O
increase O
in O
the O
crosslinking O
density. O
Doxorubicin B-CHEMICAL
hydrochloride I-CHEMICAL
(DOX) B-CHEMICAL
was O
applied O
as O
a O
model O
drug, O
and O
the O
behavior O
of O
drug O
storage/release O
was O
investigated. O
The O
cumulative O
release O
of O
DOX-loaded B-CHEMICAL
composite O
microsphere O
in O
vitro O
showed O
that O

the O
drug O
release O
rate O
was O
much O
faster O
below O
its O
pKa O
than O
that O
of O
above O
its O
pKa. O
Because O
pH O
of O
most O
tumor O
tissues O
was O
lower O
than O
that O
of O
normal O
tissues, O
the O
pH-responsive O
composite O
microspheres O
are O
promising O
drug O
delivery O
system O
especially O
for O
cancer O
therapy. O
Novel O
therapeutic O
targets O
in O
non-small O
cell O
lung O
cancer. O
Oncogenic O
driver O
mutations O
frequently O
occur O
in O
lung O
cancer O
and O
play O
role O
in O
carcinogenesis. O
These O
mutations O
are O
usually O
associated O
with O
distinct O
clinical O
and O
histological O
features O
and O
are O
attractive O
targets O
for O
anticancer O
therapy. O
Recently, O
several O
molecularly O
distinct O
phenotypes O
of O
NSCLC O
based O
on O

specific O
and O
mutually O
exclusive O
genetic O
derangements O
have O
been O
described. O
Few O
targets O
like O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
mutations O
and O
anaplastic B-GENE-Y
lymphoma I-GENE-Y
kinase I-GENE-Y
(ALK) B-GENE-Y
gene O
rearrangements O
have O
successfully O
been O
targeted O
with O
EGFR B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
inhibitors O
(TKIs) O
and O
crizotinib, B-CHEMICAL
respectively. O
Many O
more O
inhibitors O
of O
specific O
driver O
mutations O
involving O
genes O
like O
ROS, B-GENE-Y
c-MET, B-GENE-Y
FGFR, B-GENE-N
mTOR, B-GENE-Y
IGFR B-GENE-Y
and O
RET B-GENE-Y
are O
currently O
under O
development. O
However, O
efforts O
to O
target O
some O

mutated O
genes O
like O
K-RAS B-GENE-Y
have O
been O
unsuccessful. O
Moreover, O
the O
emerging O
challenge O
of O
acquired O
resistance O
to O
initially O
effective O
therapy O
is O
becoming O
another O
major O
concern. O
In O
this O
review O
recent O
data O
on O
novel O
molecular O
targets O
and O
their O
future O
prospects O
are O
discussed. O
Mechanisms O
limiting O
distribution O
of O
the O
threonine-protein B-GENE-Y
kinase I-GENE-Y
B-RaF(V600E) I-GENE-Y
inhibitor O
dabrafenib B-CHEMICAL
to O
the O
brain: O
implications O
for O
the O
treatment O
of O
melanoma O
brain O
metastases. O
Brain O
metastases O
are O
a O
common O
cause O
of O
death O
in O
stage O
IV O
metastatic O
melanoma. O
Dabrafenib O
is O
a O
BRAF B-GENE-Y
(gene O
encoding O

serine/threonine-protein B-GENE-Y
kinase I-GENE-Y
B-Raf) I-GENE-Y
inhibitor O
that O
has O
been O
developed O
to O
selectively O
target O
the O
valine B-GENE-N
600 I-GENE-N
to I-GENE-N
glutamic I-GENE-N
acid I-GENE-N
substitution O
(BRAF(V600E)), B-GENE-Y
which O
is O
commonly O
found O
in O
metastatic O
melanoma. O
Clinical O
trials O
with O
dabrafenib B-CHEMICAL
have O
shown O
encouraging O
results; O
however, O
the O
central O
nervous O
system O
distribution O
of O
dabrafenib B-CHEMICAL
remains O
unknown. O
Thus, O
the O
objective O
of O
the O
current O
study O
was O
to O
evaluate O
the O
brain O
distribution O
of O
dabrafenib B-CHEMICAL
in O
mice, O
and O
to O
see O
whether O
active O
efflux O
by O
P-glycoprotein B-GENE-N

(P-gp) B-GENE-N
and O
breast B-GENE-Y
cancer I-GENE-Y
resistance I-GENE-Y
protein I-GENE-Y
(BCRP) B-GENE-Y
restricts O
its O
delivery O
across O
the O
blood-brain O
barrier O
(BBB). O
In O
vitro O
accumulation O
studies O
conducted O
in O
Madin-Darby O
canine O
kidney O
II O
cells O
indicate O
that O
dabrafenib B-CHEMICAL
is O
an O
avid O
substrate O
for O
both O
P-gp B-GENE-N
and O
BCRP. B-GENE-Y
Directional O
flux O
studies O
revealed O
greater O
transport O
in O
the O
basolateral O
to O
apical O
direction O
with O
corrected O
efflux O
ratios O
greater O
than O
2 O
for O
both O
P-gp B-GENE-N
and O
Bcrp1 B-GENE-Y
transfected O
cell O
lines. O
In O
vivo, O
the O
ratio O
of O
area O
under O
the O
concentration-time O
curve O

(AUC)(brain) O
to O
AUC(plasma) O
(K(p)) O
of O
dabrafenib B-CHEMICAL
after O
an O
i.v. O
dose O
(2.5 O
mg/kg) O
was O
0.023, O
which O
increased O
by O
18-fold O
in O
Mdr1 B-GENE-N
a/b(-/-)Bcrp1(-/-) I-GENE-N
mice O
to O
0.42. O
Dabrafenib B-CHEMICAL
plasma O
exposure O
was O
∼2-fold O
greater O
in O
Mdr1 B-GENE-N
a/b(-/-)Bcrp1(-/-) I-GENE-N
mice O
as O
compared O
with O
wild-type O
with O
an O
oral O
dose O
(25 O

mg/kg); O
however, O
the O
brain O
distribution O
was O
increased O
by O
~10-fold O
with O
a O
resulting O
K(p) O
of O
0.25. O
Further, O
compared O
with O
vemurafenib, B-CHEMICAL
another O
BRAF(V600E) B-GENE-Y
inhibitor, O
dabrafenib B-CHEMICAL
showed O
greater O
brain O
penetration O
with O
a O
similar O
dose. O
In O
conclusion, O
the O
dabrafenib B-CHEMICAL
brain O
distribution O
is O
limited O
in O
an O
intact O
BBB O
model, O
and O
the O
data O
presented O
herein O
may O
have O
clinical O
implications O
in O
the O
prevention O
and O
treatment O
of O
melanoma O
brain O
metastases. O
PXR B-GENE-Y
antagonists O
and O
implication O
in O
drug O
metabolism. O
Adopted O
orphan B-GENE-N
nuclear I-GENE-N
receptor I-GENE-N

(NR), B-GENE-N
pregnane B-GENE-Y
X I-GENE-Y
receptor I-GENE-Y
(PXR), B-GENE-Y
plays O
a O
central O
role O
in O
the O
regulation O
of O
xeno- O
and O
endobiotic O
metabolism. O
Since O
the O
discovery O
of O
the O
functional O
role O
of O
PXR B-GENE-Y
in O
1998, O
there O
is O
evolving O
evidence O
for O
the O
role O
of O
PXR B-GENE-Y
agonists O
in O
abrogating O
metabolic O
pathophysiology O
(e.g., O
cholestasis, O
hypercholesterolemia, O
and O
inflammation). O
However, O
more O
recently, O
it O
is O
clear O
that O
PXR B-GENE-Y
is O
also O
an O
important O
mediator O
of O
adverse O
xeno- O
(e.g., O
enhances O

acetaminophen B-CHEMICAL
toxicity) O
and O
endobiotic O
(e.g., O
hepatic O
steatosis) O
metabolic O
phenotypes. O
Moreover, O
in O
cancer O
therapeutics, O
PXR B-GENE-Y
activation O
can O
induce O
drug O
resistance, O
and O
there O
is O
growing O
evidence O
for O
tissue-specific O
enhancement O
of O
the O
malignant O
phenotype. O
Thus, O
in O
these O
instances, O
there O
may O
be O
a O
role O
for O
PXR B-GENE-Y
antagonists. O
However, O
as O
opposed O
to O
the O
discovery O
efforts O
for O
PXR B-GENE-Y
agonists, O
there O
are O
only O
a O
few O
antagonists O
described. O
The O
mode O
of O
action O
of O
these O
antagonists O
(e.g., O

sulforaphane) B-CHEMICAL
remains O
less O
clear. O
Our O
laboratory O
efforts O
have O
focused O
on O
this O
question. O
Since O
the O
original O
discovery O
of O
azoles B-CHEMICAL
analogs O
as O
PXR B-GENE-Y
antagonists, O
we O
have O
preliminarily O
defined O
an O
important O
PXR B-GENE-Y
antagonist O
pharmacophore O
and O
developed O
less-toxic O
PXR B-GENE-Y
antagonists. O
In O
this O
review, O
we O
describe O
our O
published O
and O
unpublished O
findings O
on O
recent O
structure-function O
studies O
involving O
the O
azole B-CHEMICAL
chemical O
scaffold. O
Further O
work O
in O
the O
future O
is O
needed O
to O
fully O
define O
potent, O
more-selective O
PXR B-GENE-Y
antagonists O
that O
may O
be O
useful O
in O
clinical O
application. O
Biophysical O

properties, O
pharmacology, O
and O
modulation O
of O
human, O
neuronal O
L-type O
(alpha(1D), B-GENE-Y
Ca(V)1.3) B-GENE-Y
voltage-dependent O
calcium B-CHEMICAL
currents. O
Voltage-dependent B-GENE-N
calcium I-GENE-N
channels I-GENE-N
(VDCCs) O
are O
multimeric O
complexes O
composed O
of O
a O
pore-forming O
alpha(1) O
subunit O
together O
with O
several O
accessory O
subunits, O
including O
alpha(2)delta, O
beta, O
and, O
in O
some O
cases, O
gamma O
subunits. O
A O
family O
of O
VDCCs B-GENE-N
known O
as O
the O
L-type B-GENE-N
channels I-GENE-N
are O
formed O
specifically O
from O
alpha(1S) O
(skeletal O
muscle), O

alpha(1C) O
(in O
heart O
and O
brain), O
alpha(1D) O
(mainly O
in O
brain, O
heart, O
and O
endocrine O
tissue), O
and O
alpha(1F) O
(retina). O
Neuroendocrine O
L-type O
currents O
have O
a O
significant O
role O
in O
the O
control O
of O
neurosecretion O
and O
can O
be O
inhibited O
by O
GTP-binding B-GENE-N
(G-) I-GENE-N
proteins. I-GENE-N
However, O
the O
subunit O
composition O
of O
the O
VDCCs B-GENE-N
underlying O
these O
G-protein-regulated B-GENE-N
neuroendocrine O
L-type O
currents O
is O
unknown. O
To O
investigate O
the O
biophysical O
and O
pharmacological O
properties O
and O
role O
of O

G-protein B-GENE-N
modulation O
of O
alpha(1D) B-GENE-Y
calcium I-GENE-Y
channels, I-GENE-Y
we O
have O
examined O
calcium B-GENE-N
channel I-GENE-N
currents O
formed O
by O
the O
human B-GENE-Y
neuronal I-GENE-Y
L-type I-GENE-Y
alpha(1D) I-GENE-Y
subunit, O
co-expressed O
with O
alpha(2)delta-1 O
and O
beta(3a), O
stably O
expressed O
in O
a O
human O
embryonic O
kidney O
(HEK) O
293 O
cell O
line, O
using O
whole O
cell O
and O
perforated O
patch-clamp O
techniques. O
The O
alpha(1D)-expressing O
cell O
line O
exhibited O
L-type O
currents O
with O
typical O
characteristics. O
The O
currents O
were O
high-voltage O
activated O
(peak O
at O
+20 O
mV O
in O
20 O

mM O
Ba2+) B-CHEMICAL
and O
showed O
little O
inactivation O
in O
external O
Ba2+, B-CHEMICAL
while O
displaying O
rapid O
inactivation O
kinetics O
in O
external O
Ca2+. B-CHEMICAL
The O
L-type O
currents O
were O
inhibited O
by O
the O
1,4 B-CHEMICAL
dihydropyridine I-CHEMICAL
(DHP) B-CHEMICAL
antagonists O
nifedipine B-CHEMICAL
and O
nicardipine B-CHEMICAL
and O
were O
enhanced O
by O
the O
DHP B-CHEMICAL
agonist O
BayK B-CHEMICAL
S-(-)8644. I-CHEMICAL
However, O
alpha(1D) B-GENE-Y
L-type O
currents O
were O
not O
modulated O
by O
activation O
of O
a O
number O
of O
G-protein B-GENE-N
pathways. O
Activation O
of O
endogenous O
somatostatin B-GENE-Y
receptor I-GENE-Y

subtype I-GENE-Y
2 I-GENE-Y
(sst2) B-GENE-Y
by O
somatostatin-14 B-CHEMICAL
or O
activation O
of O
transiently O
transfected O
rat B-GENE-N
D2 I-GENE-N
dopamine I-GENE-N
receptors I-GENE-N
(rD2(long)) B-GENE-N
by O
quinpirole B-CHEMICAL
had O
no O
effect. O
Direct O
activation O
of O
G-proteins O
by O
the O
nonhydrolyzable O
GTP B-CHEMICAL
analogue, O
guanosine B-CHEMICAL
5'-0-(3-thiotriphospate) I-CHEMICAL
also O
had O
no O
effect O
on O
the O
alpha(1D) O
currents. O
In O
contrast, O
in O
the O
same O
system, O
N-type B-CHEMICAL
currents, O
formed O
from O
transiently O
transfected O

alpha(1B)/alpha(2)delta-1/beta(3), O
showed O
strong O
G-protein-mediated B-GENE-N
inhibition. O
Furthermore, O
the O
I-II O
loop O
from O
the O
alpha(1D) O
clone, O
expressed O
as O
a O
glutathione-S-transferase B-GENE-N
(GST) B-GENE-N
fusion O
protein, O
did O
not O
bind O
Gbetagamma, O
unlike O
the O
alpha(1B) B-GENE-N
I-II I-GENE-N
loop I-GENE-N
fusion O
protein. O
These O
data O
show O
that O
the O
biophysical O
and O
pharmacological O
properties O
of O
recombinant O
human O
alpha(1D) O
L-type O
currents O
are O
similar O
to O
alpha(1C) O
currents, O
and O
these O

currents O
are O
also O
resistant O
to O
modulation O
by O
G(i/o)-linked B-GENE-N
G-protein-coupled B-GENE-N
receptors. I-GENE-N
Antofine-induced B-CHEMICAL
connexin43 B-GENE-Y
gap O
junction O
disassembly O
in O
rat O
astrocytes O
involves O
protein B-GENE-Y
kinase I-GENE-Y
Cβ. I-GENE-Y
Antofine, B-CHEMICAL
a O
phenanthroindolizidine B-CHEMICAL
alkaloid I-CHEMICAL
derived O
from O
Cryptocaryachinensis O
and O
Ficusseptica O
in O
the O
Asclepiadaceae O
milkweed O
family, O
is O
cytotoxic O
for O
various O
cancer O
cell O
lines. O
In O
this O
study, O
we O
demonstrated O
that O
treatment O
of O
rat O
primary O
astrocytes O
with O
antofine B-CHEMICAL

induced O
dose-dependent O
inhibition O
of O
gap O
junction O
intercellular O
communication O
(GJIC), O
as O
assessed O
by O
scrape-loading O
6-carboxyfluorescein B-CHEMICAL
dye O
transfer. O
Levels O
of O
Cx43 B-GENE-Y
protein O
were O
also O
decreased O
in O
a O
dose- O
and O
time-dependent O
manner O
following O
antofine B-CHEMICAL
treatment. O
Double-labeling O
immunofluorescence O
microscopy O
showed O
that O
antofine B-CHEMICAL
(10ng/ml) O
induced O
endocytosis O
of O
surface O
gap O
junctions O
into O
the O
cytoplasm, O
where O
Cx43 B-GENE-Y
was O
co-localized O
with O
the O
early O
endosome O
marker O
EEA1. B-GENE-N

Inhibition O
of O
lysosomes O
or O
proteasomes O
by O
co-treatment O
with O
antofine B-CHEMICAL
and O
their O
respective O
specific O
inhibitors, O
NH4Cl B-CHEMICAL
or O
MG132, B-CHEMICAL
partially O
inhibited O
the O
antofine-induced O
decrease O
in O
Cx43 B-GENE-Y
protein O
levels, O
but O
did O
not O
inhibit O
the O
antofine-induced O
inhibition O
of O
GJIC. O
After O
30min O
of O
treatment, O
antofine O
induced O
a O
rapid O
increase O
in O
the O
intracellular O
Ca(2+) B-CHEMICAL
concentration O
and O
activation O
of O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC)α/βII, I-GENE-N
which O
was O
maintained O
for O
at O
least O
6h. O
Co-treatment O

of O
astrocytes O
with O
antofine B-CHEMICAL
and O
the O
intracellular O
Ca(2+) B-CHEMICAL
chelator O
BAPTA-AM B-CHEMICAL
prevented O
downregulation O
of O
Cx43 B-GENE-Y
and O
inhibition O
of O
GJIC. O
Moreover, O
co-treatment O
with O
antofine B-CHEMICAL
and O
a O
specific O
PKCβ B-GENE-Y
inhibitor O
prevented O
endocytosis O
of O
gap O
junctions, O
downregulation O
of O
Cx43, B-GENE-Y
and O
inhibition O
of O
GJIC. O
Taken O
together, O
these O
findings O
indicate O
that O
antofine B-CHEMICAL
induces O
Cx43 B-GENE-Y
gap O
junction O
disassembly O
by O
the O
PKCβ B-GENE-Y
signaling O
pathway. O
Inhibition O
of O

GJIC O
by O
antofine B-CHEMICAL
may O
undermine O
the O
neuroprotective O
effect O
of O
astrocytes O
in O
CNS. O
Torasemide B-CHEMICAL
inhibits O
angiotensin B-GENE-Y
II-induced I-GENE-Y
vasoconstriction O
and O
intracellular O
calcium B-CHEMICAL
increase O
in O
the O
aorta O
of O
spontaneously O
hypertensive O
rats. O
Torasemide B-CHEMICAL
is O
a O
loop O
diuretic O
that O
is O
effective O
at O
low O
once-daily O
doses O
in O
the O
treatment O
of O
arterial O
hypertension. O
Because O
its O
antihypertensive O
mechanism O
of O
action O
may O
not O
be O
based O
entirely O
on O
the O
elimination O
of O
salt O
and O
water O
from O
the O
body, O
a O

vasodilator O
effect O
of O
this O
drug O
can O
be O
considered. O
In O
the O
present O
study, O
the O
ability O
of O
different O
concentrations O
of O
torasemide B-CHEMICAL
to O
modify O
angiotensin B-GENE-Y
II I-GENE-Y
(Ang B-GENE-Y
II)-induced I-GENE-Y
vascular O
responses O
was O
examined, O
with O
the O
use O
of O
an O
organ O
bath O
system, O
in O
endothelium-denuded O
aortic O
rings O
from O
spontaneously O
hypertensive O
rats. O
Ang B-GENE-Y
II-induced I-GENE-Y
increases O
of O
intracellular O
free O
calcium B-CHEMICAL
concentration O
([Ca(2+)](i)) B-CHEMICAL
were O
also O
examined O
by O
image O
analysis O
in O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs) O
from O
spontaneously O
hypertensive O
rats. O

A O
dose-response O
curve O
to O
Ang B-GENE-Y
II I-GENE-Y
was O
plotted O
for O
cumulative O
concentrations O
(from O
10(-9) O
to O
10(-6) O
mol/L) O
in O
endothelium-denuded O
aortic O
rings O
(pD(2)=7.5+/-0.3). O
Isometric O
contraction O
induced O
by O
a O
submaximal O
concentration O
of O
Ang B-GENE-Y
II I-GENE-Y
(10(-7) O
mol/L) O
was O
reduced O
in O
a O
dose-dependent O
way O
by O
torasemide B-CHEMICAL
(IC(50)=0.5+/-0.04 O
micromol/L). O
Incubation O

of O
VSMCs O
with O
different O
concentrations O
of O
Ang B-GENE-Y
II I-GENE-Y
(from O
10(-10) O
to O
10(-6) O
mol/L) O
resulted O
in O
a O
dose-dependent O
rise O
of O
[Ca(2+)](i) B-CHEMICAL
(pD(2)=7.5+/-0.3). O
The O
stimulatory O
effect O
of O
[Ca(2+)](i) B-CHEMICAL
induced O
by O
a O
submaximal O
concentration O
of O
Ang B-GENE-Y
II I-GENE-Y
(10(-7) O
mol/L) O
was O
blocked O
by O
torasemide B-CHEMICAL

(IC(50)=0.5+/-0.3 O
nmol/L). O
Our O
findings O
suggest O
that O
torasemide B-CHEMICAL
blocks O
the O
vasoconstrictor O
action O
of O
Ang B-GENE-Y
II I-GENE-Y
in O
vitro. O
This O
action O
can O
be O
related O
to O
the O
ability O
of O
torasemide B-CHEMICAL
to O
block O
the O
increase O
of O
[Ca(2+)](i) B-CHEMICAL
induced O
by O
Ang B-GENE-Y
II I-GENE-Y
in O
VSMCs. O
It O
is O
proposed O
that O
these O
actions O
might O
be O
involved O
in O
the O
antihypertensive O
effect O
of O
torasemide B-CHEMICAL
observed O
in O
vivo. O
Characterization O
of O
tyrosinase B-GENE-Y
inhibitors O
in O
the O

twigs O
of O
Cudrania O
tricuspidata O
and O
their O
structure-activity O
relationship O
study. O
The O
twigs O
of O
Cudrania O
tricuspidata O
were O
found O
to O
show O
strong O
tyrosinase B-GENE-Y
inhibitory O
activity, O
and O
further O
detailed O
component O
analysis O
resulted O
in O
the O
isolation O
of O
a O
new O
flavanol B-CHEMICAL
glucoside, I-CHEMICAL
(2S,3S)-2,3-trans-dihydromorin-7-O-β-d-glucoside B-CHEMICAL
(1), O
plus O
twenty-seven O
known O
compounds O
(2-28). O
Their O
structures O
were O
elucidated O
on O
the O
basis O

of O
ESI-MS O
and O
NMR O
spectral O
data. O
Among O
the O
isolated O
compounds, O
trans-dihydromorin B-CHEMICAL
(8), O
oxyresveratrol B-CHEMICAL
(9), O
and O
steppogenin B-CHEMICAL
(12) O
were O
found O
to O
exhibit O
significant O
tyrosinase B-GENE-Y
inhibition O
activities. O
Moreover, O
the O
structure-activity O
relationship O
of O
these O
isolated O
compounds O
was O
also O
discussed. O
Pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
may O
be O
curative O
in O
early-onset O
epileptic O
encephalopathy. O
Neonatal O
epileptic O
encephalopathy O
can O
be O
caused O
by O
inborn O
errors O
of O
metabolism. O
These O
conditions O
are O
often O

unresponsive O
to O
treatment O
with O
conventional O
antiepileptic O
drugs. O
Six O
children O
with O
pyridox(am)ine-5'-phosphate B-GENE-Y
oxidase I-GENE-Y
(PNPO) B-GENE-Y
deficiency O
presented O
with O
neonatal O
epileptic O
encephalopathy. O
Two O
were O
treated O
with O
pyridoxal B-CHEMICAL
5'-phosphate I-CHEMICAL
(PLP) B-CHEMICAL
within O
the O
first O
month O
of O
life O
and O
showed O
normal O
development O
or O
moderate O
psychomotor O
retardation O
thereafter. O
Four O
children O
with O
late O
or O
no O
treatment O
died O
or O
showed O
severe O
mental O
handicap. O
All O
of O
the O
children O
showed O
atypical O
biochemical O
findings. O
Prompt O
treatment O
with O

PLP B-CHEMICAL
in O
all O
neonates O
and O
infants O
with O
epileptic O
encephalopathy O
should O
become O
mandatory, O
permitting O
normal O
development O
in O
at O
least O
some O
of O
those O
affected O
with O
PNPO B-GENE-Y
deficiency. O
The O
prostaglandin B-CHEMICAL
E I-CHEMICAL
series O
modulates O
high-voltage-activated B-GENE-N
calcium I-GENE-N
channels I-GENE-N
probably O
through O
the O
EP3 B-GENE-Y
receptor I-GENE-Y
in O
rat O
paratracheal O
ganglia. O
The O
modulation O
of O
high-voltage-activated B-GENE-N
(HVA) I-GENE-N
Ca2+ I-GENE-N
channels I-GENE-N
by O
the O
prostaglandin B-CHEMICAL
E I-CHEMICAL
series O
(PGE1 B-CHEMICAL
and O
PGE2) B-CHEMICAL
was O
studied O
in O
the O
paratracheal O
ganglion O
cells. O
Prostaglandin B-CHEMICAL

E1, I-CHEMICAL
E2, I-CHEMICAL
STA2 B-CHEMICAL
(a O
stable O
analogue O
of O
thromboxane B-CHEMICAL
A2), I-CHEMICAL
17-phenyl-trinor-PGE2 B-CHEMICAL
(an O
EP1-selective B-GENE-Y
agonist) O
and O
sulprostone B-CHEMICAL
(an O
EP3-selective B-GENE-Y
agonist) O
inhibited O
the O
HVA O
Ca2+ B-CHEMICAL
current O
(HVA O
ICa) O
dose-dependently, O
and O
the O
rank O
order O
of O
potency O
to O
inhibit O
HVA B-GENE-N
Ca2+ I-GENE-N
channels I-GENE-N
was O
sulprostone>PGE2, B-CHEMICAL

PGE1>STA2>>17-phenyl-trinor-PGE2. B-CHEMICAL
SC-51089 B-CHEMICAL
(10(-5) O
M), O
a O
selective O
EP1-receptor B-GENE-Y
antagonist, O
showed O
no O
effect O
on O
the O
PGE1- B-CHEMICAL
or O
PGE2-induced B-CHEMICAL
inhibition O
of O
the O
HVA O
ICa, O
thereby O
indicating O
that O
PGE1- B-CHEMICAL
and O
PGE2-induced B-CHEMICAL
inhibition O
of O
the O
HVA B-GENE-N
Ca2+ I-GENE-N
channels I-GENE-N
is O
possibly O
mediated O
by O
the O
EP3 B-GENE-Y
receptor. I-GENE-Y
The O
PGE1-sensitive B-CHEMICAL
component O
of O
the O
current O
was O
markedly O
reduced O
in O
the O
presence O
of O

omega-conotoxin-GVIA O
(3x10(-6) O
M), O
but O
not O
with O
nifedipine B-CHEMICAL
(3x10(-6) O
M). O
PGE1 B-CHEMICAL
and O
PGE2 B-CHEMICAL
also O
inhibited O
the O
remaining O
ICa O
in O
a O
saturating O
concentration O
of O
nifedipine, B-CHEMICAL
omega-conotoxin-GVIA O
and O
omega-conotoxin-MVIIC, O
suggesting O
that O
R-type B-GENE-N
Ca2+ I-GENE-N
channels I-GENE-N
are O
involved. O
The O
inhibitory O
effect O
of O
PGE1 B-CHEMICAL
or O
sulprostone B-CHEMICAL
was O
prevented O
by O
pretreatment O

with O
pertussis B-GENE-N
toxin I-GENE-N
[islet B-GENE-N
activating I-GENE-N
protein I-GENE-N
(IAP)] B-GENE-N
or O
phorbol-12-myristate-13-acetate B-CHEMICAL
(PMA), B-CHEMICAL
and O
the O
protein B-GENE-N
kinase I-GENE-N
C I-GENE-N
(PKC) B-GENE-N
inhibitor O
chelerythrine B-CHEMICAL
blocked O
the O
action O
of O
PMA. B-CHEMICAL
It O
was O
concluded O
that O
PGE1 B-CHEMICAL
selectively O
reduces O
both O
N- O
and O
R-type O
Ca2+ B-CHEMICAL
currents O
by O
activating O
a O
G-protein B-GENE-N
probably O
through O
the O
EP3 B-GENE-Y
receptor I-GENE-Y
in O
paratracheal O
ganglion O
cells. O
Inhibition O
of O
MCP-1 B-GENE-Y
and O
MIP-2 B-GENE-Y
transcription O
and O
translation O
by O
mimosine B-CHEMICAL
in O
muscle O
tissue O

infected O
with O
the O
parasite O
Trichinella O
spiralis. O
Mimosine B-CHEMICAL
is O
a O
non-toxic O
plant O
aminoacid B-CHEMICAL
which O
is O
an O
effective O
inhibitor O
of O
DNA O
replication O
by O
acting O
at O
the O
S-phase. O
In O
this O
study O
we O
infected O
mice O
with O
T. O
spiralis, O
a O
nematode O
parasite, O
and O
studied O
the O
inflammatory O
response O
through O
the O
determination O
of O
MIP-2, B-GENE-Y
a O
C-X-C B-GENE-N
chemokine I-GENE-N
and O
MCP-1, B-GENE-Y
a O
C-C B-GENE-N
chemokine I-GENE-N
in O
the O
inflamed O
area O
around O
the O
parasitic O
cyst. O
The O
animals O
were O
infected O
and O
their O
diaphragms O
were O
tested O
for O
inflammatory O
response. O

MCP-1 B-GENE-Y
and O
MIP-2 B-GENE-Y
was O
tested O
after O
1, O
10, O
20, O
30, O
and O
40 O
days O
post O
inoculation, O
before O
and O
after O
mimosine B-CHEMICAL
treatment. O
The O
inflammatory O
index O
was O
calculated O
by O
counting O
the O
white O
blood O
cells O
around O
the O
nematode O
cysts, O
while O
expression O
of O
MIP-2 B-GENE-Y
and O
MCP-1 B-GENE-Y
was O
calculated O
by O
ELISA O
method O
and O
transcription O
by O
Northern O
blot O
and O
RT-PCR. O
Here O
we O
found O
that O
mimosine B-CHEMICAL
strongly O
inhibited O
the O
inflammatory O
index O
in O
the O
diaphragmatic O
tissue O
at O
10, O
20, O
30 O
and O
40 O
days O
post-treatment. O
In O
these O

experiments, O
mimosine B-CHEMICAL
had O
no O
effect O
on O
the O
number O
of O
cysts O
produced. O
In O
addition, O
we O
found O
that O
MCP-1 B-GENE-Y
transcription O
and O
translation O
was O
completely O
inhibited O
by O
mimosine, B-CHEMICAL
while O
MIP-2 B-GENE-Y
transcription O
and O
translation O
was O
partially O
inhibited O
at O
30 O
and O
40 O
days; O
yet O
it O
was O
totally O
inhibited O
after O
10 O
and O
20 O
days O
in O
encysted O
diaphragm O
tissue O
infected O
by O
T. O
spiralis. O
Our O
studies O
suggest O
that O
mimosine B-CHEMICAL
has O
an O
inhibitory O
effect O
through O
the O
inhibition O
of O
cytoplasmatic O
serine O
hydroxymethyltransferase O
altering O
the O
cell O
cycle O
of O
white O

blood O
cells. O
This O
study O
suggests O
for O
the O
first O
time O
the O
premise O
that O
mimosine B-CHEMICAL
acts O
as O
an O
anti-inflammatory O
compound. O
Balancing O
societal O
needs O
and O
regulatory O
certainty: O
the O
case O
study O
of O
peramivir B-CHEMICAL
in O
Japan. O
Regulators O
must O
balance O
societal O
and O
medical O
requirements O
against O
the O
need O
for O
certainty O
about O
benefit O
and O
risk O
for O
new O
medicines. O
This O
is O
described O
in O
a O
case O
study O
of O
the O
expedited O
review O
and O
approval O
of O
peramivir, B-CHEMICAL
a O
novel O
neuraminidase B-GENE-N
inhibitor, O
in O
Japan O
in O
the O
context O
of O
the O
emergence O
of O
new O
strain O
of O
influenza O
in O
2009. O
The O
case O
illustrates O
the O
importance O
of O
regulatory O
science O
and O
transparency O
in O
supporting O
such O
decision O

making. O
The O
influence O
of O
sex, O
ethnicity, O
and O
CYP2B6 B-GENE-Y
genotype O
on O
bupropion B-CHEMICAL
metabolism O
as O
an O
index O
of O
hepatic O
CYP2B6 B-GENE-Y
activity O
in O
humans. O
The O
effects O
of O
sex, O
ethnicity, O
and O
genetic O
polymorphism O
on O
hepatic O
CYP2B6 B-GENE-Y
(cytochrome B-GENE-Y
P450 I-GENE-Y
2B6) I-GENE-Y
expression O
and O
activity O
were O
previously O
demonstrated O
in O
vitro. O
Race/ethnic O
differences O
in O
CYP2B6 B-GENE-Y
genotype O
and O
phenotype O
were O
observed O
only O
in O
women. O
To O
identify O
important O
covariates O
associated O
with O
interindividual O
variation O
in O

CYP2B6 B-GENE-Y
activity O
in O
vivo, O
we O
evaluated O
these O
effects O
in O
healthy O
volunteers O
using O
bupropion B-CHEMICAL
(Wellbutrin B-CHEMICAL
SR I-CHEMICAL
GlaxoSmithKline, O
Research O
Triangle O
Park, O
NC) O
as O
a O
CYP2B6 B-GENE-Y
probe O
substrate. O
A O
fixed O
150-mg O
oral O
sustained-release O
dose O
of O
bupropion B-CHEMICAL
was O
administered O
to O
100 O
healthy O
volunteers O
comprising O
four O
sex/ethnicity O
cohorts O
(n O
= O
25 O
each): O
Caucasian O
men O
and O
Caucasian, O
African O
American, O
and O
Hispanic O
women. O
Blood O
samples O
were O
obtained O
at O
0 O
and O
6 O
hours O
postdose O
for O
the O
measurement O
of O
serum O
bupropion B-CHEMICAL
(BU) O
and O

hydroxybupropion B-CHEMICAL
(HB) O
concentrations. O
Whole O
blood O
was O
obtained O
at O
baseline O
for O
CYP2B6 B-GENE-Y
genotyping. O
To O
characterize O
the O
relationship O
between O
CYP2B6 B-GENE-Y
activity O
and O
ethnicity, O
sex, O
and O
genotype O
when O
accounting O
for O
serum O
BU O
concentrations O
(dose-adjusted O
log(10)-transformed), O
analysis O
of O
covariance O
model O
was O
fitted O
in O
which O
the O
dependent O
variable O
was O
CYP2B6 B-GENE-Y
activity O
represented O
as O
the O
log(10)-transformed, O
metabolic O
ratio O
of O
HB O
to O
BU O
concentrations. O
Several O
CYP2B6 B-GENE-Y
polymorphisms O
were O
associated O
with O

CYP2B6 B-GENE-Y
activity. O
Evidence O
of O
dependence O
of O
CYP2B6 B-GENE-Y
activity O
on O
ethnicity O
or O
genotype-by-ethnicity O
interactions O
was O
not O
detected O
in O
women. O
These O
results O
suggest O
that O
CYP2B6 B-GENE-Y
genotype O
is O
the O
most O
important O
patient O
variable O
for O
predicting O
the O
level O
of O
CYP2B6 B-GENE-Y
activity O
in O
women, O
when O
measured O
by O
the O
metabolism O
of O
bupropion. B-CHEMICAL
The O
bupropion B-CHEMICAL
metabolic O
ratio O
appears O
to O
detect O
known O
differences O
in O
CYP2B6 B-GENE-Y
activity O
associated O
with O
genetic O
polymorphism, O
across O
different O
ethnic O
groups. O
Prospective O
studies O
will O
be O
needed O
to O
validate O
the O
use O
of O
bupropion B-CHEMICAL

as O
a O
probe O
substrate O
for O
clinical O
use. O
Alpha-2 B-GENE-N
adrenoceptor I-GENE-N
subtype O
causing O
nitric B-CHEMICAL
oxide-mediated I-CHEMICAL
vascular O
relaxation O
in O
rats. O
The O
alpha-2 B-GENE-N
adrenoceptor I-GENE-N
subtype O
and O
its O
signal O
transduction O
pathway O
mediating O
vascular O
relaxation O
in O
rats O
were O
studied O
in O
vitro O
using O
rings O
of O
superior O
mesenteric O
arteries. O
Removal O
of O
endothelium O
or O
incubation O
with O
NG-nitro-L-arginine B-CHEMICAL
completely O
blocked O
relaxant O
responses O
to O
UK14,304, B-CHEMICAL
suggesting O
endothelium-derived O
nitric B-CHEMICAL
oxide I-CHEMICAL
mediates O
relaxation. O
The O
order O
of O
potency O
for O
full O

(F) O
or O
partial O
(P) O
agonists O
causing O
relaxation O
was O
guanabenz B-CHEMICAL
(P) O
> O
UK14,304 B-CHEMICAL
(F) O
> O
clonidine B-CHEMICAL
(P) O
> O
epinephrine B-CHEMICAL
(F) O
> O
norepinephrine B-CHEMICAL
(F). O
Affinities O
(Ka) O
of O
alpha-2 B-GENE-N
adrenoceptor I-GENE-N
subtype-selective O
drugs O
for O
blocking O
relaxation O
were O
obtained O
in O
side-by-side O
experiments O
comparing O
rat O
mesenteric O
arteries O
with O
pig O
coronary O
arteries. O
Relaxation O
of O
pig O
coronary O
arteries O
is O
known O
to O
be O
mediated O
by O
the O
alpha-2A B-GENE-Y

adrenoceptor I-GENE-Y
subtype. O
Ka O
values O
in O
nM O
for O
rauwolscine B-CHEMICAL
(19), O
WB-4101 B-CHEMICAL
(265), O
SKF-104078 B-CHEMICAL
(197), O
spiroxatrine B-CHEMICAL
(128), O
and O
prazosin B-CHEMICAL
(1531) O
for O
blocking O
relaxation O
in O
rat O
arteries O
were O
consistent O
with O
their O
affinities O
for O
binding O
at O
the O
alpha-2D B-GENE-Y
adrenoceptor I-GENE-Y
subtype. O
Ka O
values O
for O
rauwolscine B-CHEMICAL
and O
WB-4101, B-CHEMICAL
drugs O
distinguishing O
the O
alpha-2D O
from O
the O
alpha-2A B-GENE-Y
adrenoceptor I-GENE-Y
subtype, O
were O

significantly O
higher O
in O
blocking O
relaxation O
of O
rat O
arteries O
compared O
with O
pig O
arteries, O
suggesting O
the O
alpha-2D B-GENE-Y
adrenoceptor I-GENE-Y
subtype O
mediates O
NO-induced B-CHEMICAL
relaxation O
in O
rat O
arteries. O
We O
used O
forskolin B-CHEMICAL
to O
oppose O
alpha-2 B-GENE-N
adrenoceptor-mediated I-GENE-N
inhibition O
of O
cAMP B-CHEMICAL
formation O
by O
directly O
stimulating O
cAMP B-CHEMICAL
formation O
in O
endothelium. O
Forskolin B-CHEMICAL
did O
not O
affect O
the O
relaxant O
response O
to O
UK14,304, B-CHEMICAL
suggesting O
that O
cAMP B-CHEMICAL
is O
not O
involved O
in O
the O
coupling O
of O
alpha-2 B-GENE-N
adrenoceptors I-GENE-N
to O
nitric B-CHEMICAL
oxide-induced I-CHEMICAL
vascular O
relaxation. O
Determination O
of O

paralytic O
shellfish O
poisoning O
toxins O
by O
HILIC-MS/MS O
coupled O
with O
dispersive O
solid O
phase O
extraction. O
This O
paper O
describes O
the O
use O
of O
QuEChERS O
(Quick, O
Easy, O
Cheap, O
Effective, O
Rugged O
and O
Safe) O
for O
the O
extraction, O
cleanup O
and O
detection O
of O
10 O
paralytic O
shellfish O
toxins O
(PSP) O
in O
sea O
food O
by O
HILIC-MS/MS O
with O
positive O
ESI. O
Matrix O
matched O
calibration O
standards O
were O
used O
to O
compensate O
for O
matrix O
effects. O
The O
toxins O
were O
extracted O
with O
acetonitrile/water B-CHEMICAL

(90:10, O
v/v) O
containing O
0.1% O
formic B-CHEMICAL
acid I-CHEMICAL
and O
cleaned O
by O
HLB O
and O
GCB B-CHEMICAL
sorbents. O
Qualitative O
and O
quantitative O
detection O
for O
the O
analytes O
were O
carried O
out O
under O
the O
multiple O
reaction O
monitoring O
(MRM) O
in O
positive O
ionization O
mode O
after O
chromatography O
separation O
on O
a O
TSK-gel O
Amide-80® B-CHEMICAL
column O
(150 O
mm×2.0 O
mm×3 O
μm). O
Studies O
at O
three O
fortification O
levels O
for O
the O
toxins O
in O
the O
range O
of O
8.1-225.5 O
μg/kg O
gave O
mean O
recoveries O
from O
71.3% O
to O

104.6% O
with O
relative O
standard O
deviation O
(RSD) O
≤ O
15.8%. O
The O
limit O
of O
detection O
(LOD) O
was O
below O
the O
recommended O
regulatory O
limit O
of O
170 O
μgSTX(equ.)/kg B-CHEMICAL
and O
the O
proposed O
method O
fully O
meets O
the O
needs O
of O
daily O
monitoring. O
Comparative O
gene O
expression O
profiling O
of O
in O
vitro O
differentiated O
megakaryocytes O
and O
erythroblasts O
identifies O
novel O
activatory O
and O
inhibitory O
platelet O
membrane O
proteins. O
To O
identify O
previously O
unknown O
platelet B-GENE-N
receptors I-GENE-N
we O
compared O
the O
transcriptomes O
of O
in O
vitro O
differentiated O
megakaryocytes O

(MKs) O
and O
erythroblasts O
(EBs). O
RNA O
was O
obtained O
from O
purified, O
biologically O
paired O
MK O
and O
EB O
cultures O
and O
compared O
using O
cDNA O
microarrays. O
Bioinformatical O
analysis O
of O
MK-up-regulated O
genes O
identified O
151 O
transcripts O
encoding O
transmembrane O
domain-containing O
proteins. O
Although O
many O
of O
these O
were O
known O
platelet O
genes, O
a O
number O
of O
previously O
unidentified O
or O
poorly O
characterized O
transcripts O
were O
also O
detected. O
Many O
of O
these O
transcripts, O
including O
G6b, B-GENE-Y
G6f, B-GENE-Y
LRRC32, B-GENE-Y
LAT2, B-GENE-Y
and O
the O
G B-GENE-N

protein-coupled I-GENE-N
receptor I-GENE-N
SUCNR1, B-GENE-Y
encode O
proteins O
with O
structural O
features O
or O
functions O
that O
suggest O
they O
may O
be O
involved O
in O
the O
modulation O
of O
platelet O
function. O
Immunoblotting O
on O
platelets O
confirmed O
the O
presence O
of O
the O
encoded O
proteins, O
and O
flow O
cytometric O
analysis O
confirmed O
the O
expression O
of O
G6b, B-GENE-Y
G6f, B-GENE-Y
and O
LRRC32 B-GENE-Y
on O
the O
surface O
of O
platelets. O
Through O
comparative O
analysis O
of O
expression O
in O
platelets O
and O
other O
blood O
cells O
we O
demonstrated O
that O
G6b, B-GENE-Y
G6f, B-GENE-Y
and O
LRRC32 B-GENE-Y
are O
restricted O
to O
the O
platelet O
lineage, O
whereas O
LAT2 B-GENE-Y
and O
SUCNR1 B-GENE-Y
were O

also O
detected O
in O
other O
blood O
cells. O
The O
identification O
of O
the O
succinate B-GENE-N
receptor I-GENE-N
SUCNR1 B-GENE-Y
in O
platelets O
is O
of O
particular O
interest, O
because O
physiologically O
relevant O
concentrations O
of O
succinate B-CHEMICAL
were O
shown O
to O
potentiate O
the O
effect O
of O
low O
doses O
of O
a O
variety O
of O
platelet O
agonists. O
Neostigmine: B-CHEMICAL
safe O
and O
effective O
treatment O
for O
acute O
colonic O
pseudo-obstruction. O
BACKGROUND: O
Ogilvie's O
syndrome, O
or O
acute O
colonic O
pseudo-obstruction, O
is O
a O
common O
and O
relatively O
dangerous O
condition. O
If O
left O
untreated, O
it O
may O
cause O
ischemic O
necrosis O

and O
colonic O
perforation, O
with O
a O
mortality O
rate O
as O
high O
as O
50 O
percent. O
Neostigmine B-CHEMICAL
enhances O
excitatory O
parasympathetic O
activity O
by O
competing O
with O
acetylcholine B-CHEMICAL
for O
attachment O
to O
acetylcholinesterase B-GENE-Y
at O
sites O
of O
cholinergic O
transmission O
and O
enhancing O
cholinergic O
action. O
We O
hypothesized O
that O
neostigmine B-CHEMICAL
would O
restore O
peristalsis O
in O
patients O
with O
acute O
colonic O
pseudo-obstruction. O
METHODS: O
Twenty-eight O
patients O
at O
Fletcher O
Allen O
Health O
Care O
and O
The O
Cleveland O
Clinic O
Foundation O
were O
treated O
for O
acute O
colonic O

pseudo-obstruction O
with O
neostigmine B-CHEMICAL
2.5 O
mg O
IV O
over O
3 O
minutes O
while O
being O
monitored O
with O
telemetry. O
Mechanical O
obstruction O
had O
been O
excluded. O
RESULTS: O
Complete O
clinical O
resolution O
of O
large O
bowel O
distention O
occurred O
in O
26 O
of O
the O
28 O
patients. O
Time O
to O
pass O
flatus O
varied O
from O
30 O
seconds O
to O
10 O
minutes O
after O
administration O
of O
neostigmine. B-CHEMICAL
No O
adverse O
effects O
or O
complications O
were O
noted. O
Of O
the O
two O
patients O
who O
did O
not O
resolve, O
one O
had O
a O
sigmoid O
cancer O
that O
required O
resection O
and O
one O
patient O
died O
from O
multiorgan O
failure. O
CONCLUSION: O
This O
study O

supports O
the O
theory O
that O
acute O
colonic O
pseudo-obstruction O
is O
the O
result O
of O
excessive O
parasympathetic O
suppression O
rather O
than O
sympathetic O
overactivity. O
We O
have O
shown O
that O
neostigmine B-CHEMICAL
is O
a O
safe O
and O
effective O
treatment O
for O
acute O
colonic O
pseudo-obstruction. O
Apoptosis O
initiation O
of O
β-ionone B-CHEMICAL
in O
SGC-7901 O
gastric O
carcinoma O
cancer O
cells O
via O
a O
PI3K-AKT B-GENE-N
pathway. O
β-ionone B-CHEMICAL
has O
been O
shown O
to O
hold O
potent O
anti-proliferative O
and O
apoptosis O
induction O
properties O
in O
vitro O
and O
in O
vivo. O
To O
investigate O
the O
effects O
of O

β-ionone B-CHEMICAL
on O
apoptosis O
initiation O
and O
its O
possible O
mechanisms O
of O
action, O
we O
qualified O
cell O
apoptosis, O
proteins O
related O
to O
apoptosis O
and O
a O
phosphatidylinositol B-GENE-N
3-kinase I-GENE-N
(PI3K)-AKT B-GENE-N
pathway O
in O
human O
gastric O
adenocarcinoma O
cancer O
SGC-7901 O
cells. O
The O
results O
demonstrated O
that O
β-ionone-induced B-CHEMICAL
apoptosis O
in O
a O
dose-dependent O
manner O
in O
SGC-7901 O
cells O
treated O
with O
β-ionone B-CHEMICAL
(25, O
50, O
100 O
and O
200 O
μmol/L) O
for O
24 O
h. O
β-ionone B-CHEMICAL
was O
also O

shown O
to O
induce O
the O
expression O
of O
cleaved-caspase-3 B-GENE-Y
and O
inhibit O
bcl-2 B-GENE-Y
expression O
in O
SGC-7901 O
cells O
in O
a O
dose-dependent O
manner. O
The O
significantly O
decreased O
levels O
of O
p-PI3K B-GENE-N
and O
p-AKT B-GENE-N
expression O
were O
observed O
in O
SGC-7901 O
cells O
after O
β-ionone B-CHEMICAL
treatments O
in O
a O
time- O
and O
dose-dependent O
manner O
(P O
< O
0.01). O
Thus, O
the O
apoptosis O
induction O
in O
SGC-7901 O
cells O
by O
β-ionone B-CHEMICAL
may O
be O
regulated O
through O
a O
PI3K-AKT B-GENE-N
pathway. O
These O
results O
demonstrate O
a O
potential O
mechanism O

by O
which O
β-ionone B-CHEMICAL
to O
induce O
apoptosis O
initiation O
in O
SGC-7901 O
cells. O
Eprosartan B-CHEMICAL
for O
the O
treatment O
of O
hypertension. O
Antihypertensive O
agents O
are O
proven O
to O
reduce O
the O
cardiovascular O
risk O
of O
stroke, O
coronary O
heart O
disease O
and O
cardiac O
failure. O
The O
ideal O
antihypertensive O
agent O
should O
control O
all O
grades O
of O
hypertension O
and O
have O
a O
placebo-like O
side O
effect O
profile. O
Angiotensin B-GENE-N
II I-GENE-N
(AII) I-GENE-N
receptor I-GENE-N
antagonists O
are O
a O
relatively O
new O
class O
of O
antihypertensive O
agent O
that O
block O
AII B-GENE-Y
Type I-GENE-Y
1 I-GENE-Y
(AT(1)) I-GENE-Y
receptors, I-GENE-Y

and O
reduce O
the O
pressor O
effects O
of O
AII B-GENE-Y
in O
the O
vasculature. O
By O
this O
mechanism, O
they O
induce O
similar O
pharmacological O
effects O
compared O
with O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitors, O
resulting O
in O
a O
lowering O
of O
blood O
pressure. O
However, O
AII B-GENE-N
receptor I-GENE-N
blockers O
differ O
from O
ACE B-GENE-Y
inhibitors O
with O
respect O
to O
side O
effects, O
and O
induce O
less O
cough, O
a O
side O
effect O
which O
may O
be O
related O
to O
bradykinin B-GENE-Y
or O
other O
mediators O
such O
as O
substance B-CHEMICAL
P. I-GENE-Y
Within O
the O
class O
of O
AII B-GENE-Y
blockers, O
eprosartan B-CHEMICAL
differs O
from O
other O
currently O
available O
agents O
in O
terms O
of O
chemical O
structure, O
as O
it O
is O

a O
non-biphenyl, B-CHEMICAL
non-tetrazole, B-CHEMICAL
non-peptide O
antagonist O
with O
a O
dual O
pharmacological O
mode O
of O
action. O
Eprosartan B-CHEMICAL
acts O
at O
vascular O
AT(1) B-GENE-Y
receptors I-GENE-Y
(postsynaptically) O
and O
at O
presynaptic O
AT(1) B-GENE-Y
receptors, I-GENE-Y
where O
it O
inhibits O
sympathetically O
stimulated O
noradrenaline B-CHEMICAL
release. O
Its O
lack O
of O
metabolism O
by O
cytochrome B-GENE-N
P450 I-GENE-N
enzymes O
confers O
a O
low O
potential O
for O
metabolic O
drug O
interactions O
and O
may O
be O
of O
importance O
when O
treating O
elderly O
patients O
and O
those O
on O
multiple O
drugs. O
In O
clinical O
trials, O
eprosartan B-CHEMICAL
has O
been O
demonstrated O

to O
be O
at O
least O
as O
effective O
in O
reducing O
blood O
pressure O
as O
the O
ACE B-GENE-Y
inhibitor O
enalapril, B-CHEMICAL
and O
has O
significantly O
lower O
side O
effects. O
Eprosartan B-CHEMICAL
is O
safe, O
effective O
and O
well-tolerated O
in O
long-term O
treatment, O
either O
as O
a O
monotherapy O
or O
in O
combination O
with O
other O
antihypertensive O
drugs O
such O
as O
hydrochlorothiazide. B-CHEMICAL
Reductive O
detoxification O
of O
arylhydroxylamine B-CHEMICAL
carcinogens O
by O
human B-GENE-Y
NADH I-GENE-Y
cytochrome I-GENE-Y
b5 I-GENE-Y
reductase I-GENE-Y
and O
cytochrome B-GENE-Y
b5. I-GENE-Y
Heterocyclic B-CHEMICAL
and I-CHEMICAL
aromatic I-CHEMICAL
amine I-CHEMICAL

carcinogens O
are O
thought O
to O
lead O
to O
tumor O
initiation O
via O
the O
formation O
of O
DNA O
adducts, O
and O
bioactivation O
to O
arylhydroxylamine B-CHEMICAL
metabolites O
is O
necessary O
for O
reactivity O
with O
DNA. O
Carcinogenic O
arylhydroxylamine B-CHEMICAL
metabolites O
are O
cleared O
by O
a O
microsomal, O
NADH-dependent, B-CHEMICAL
oxygen-insensitive B-CHEMICAL
reduction O
pathway O
in O
humans, O
which O
may O
be O
a O
source O
of O
interindividual O
variability O
in O
response O
to O
aromatic B-CHEMICAL
amine I-CHEMICAL
carcinogens. O
The O
purpose O
of O
this O
study O
was O
to O
characterize O
the O
identity O
of O
this O
reduction O
pathway O
in O
human O
liver. O
On O
the O

basis O
of O
our O
findings O
with O
structurally O
similar O
arylhydroxylamine B-CHEMICAL
metabolites O
of O
therapeutic O
drugs, O
we O
hypothesized O
that O
the O
reductive O
detoxification O
of O
arylhydroxylamine B-CHEMICAL
carcinogens O
was O
catalyzed O
by O
NADH B-GENE-Y
cytochrome I-GENE-Y
b5 I-GENE-Y
reductase I-GENE-Y
(b5R) B-GENE-Y
and O
cytochrome B-GENE-Y
b5 I-GENE-Y
(cyt B-GENE-Y
b5). I-GENE-Y
We O
found O
that O
reduction O
of O
the O
carcinogenic O
hydroxylamines B-CHEMICAL
of O
the O
aromatic B-CHEMICAL
amine I-CHEMICAL
4-aminobiphenyl B-CHEMICAL
(4-ABP; B-CHEMICAL
found O
in O
cigarette O
smoke) O
and O
the O

heterocyclic B-CHEMICAL
amine I-CHEMICAL
2-amino-1-methyl-6-phenylimidazo B-CHEMICAL
[4,5-b] I-CHEMICAL
pyridine I-CHEMICAL
(PhIP; B-CHEMICAL
found O
in O
grilled O
meats) O
was O
indeed O
catalyzed O
by O
a O
purified O
system O
containing O
only O
human B-GENE-Y
b5R I-GENE-Y
and O
cyt B-GENE-Y
b5. I-GENE-Y
Specific O
activities O
were O
56-346-fold O
higher O
in O
the O
purified O
system O
as O
compared O
to O
human O
liver O
microsomes O
(HLM), O
with O
similar O
Michaelis-Menten O
constants O
(K(m) O
values) O
in O
both O
systems. O
The O
stoichiometry O
for O

b5R B-GENE-Y
and O
cyt B-GENE-Y
b5 I-GENE-Y
that O
yielded O
the O
highest O
activity O
in O
the O
purified O
system O
was O
also O
similar O
to O
that O
found O
in O
native O
HLM O
( O
approximately O
1:8 O
to O
1:10). O
Polyclonal O
antisera O
to O
either O
b5R B-GENE-Y
or O
cyt B-GENE-Y
b5 I-GENE-Y
significantly O
inhibited O
N-hydroxy-4-aminobiphenyl B-CHEMICAL
(NHOH-4-ABP) B-CHEMICAL
reduction O
by O
95 O
and O
89%, O
respectively, O
and O
immunoreactive O
cyt O
b5 O
protein O
content O
in O
individual O
HLM O
was O
significantly O
correlated O
with O
individual O
reduction O
of O
both O
NHOH-4-ABP B-CHEMICAL
and O

N-hydroxy-PhIP B-CHEMICAL
(NHOH-PhIP). B-CHEMICAL
Finally, O
titration O
of O
HLM O
into O
the O
purified O
b5R/cyt B-GENE-Y
b5 I-GENE-Y
system O
did O
not O
enhance O
the O
efficiency O
of O
reduction O
activity. O
We O
conclude O
that O
b5R B-GENE-Y
and O
cyt B-GENE-Y
b5 I-GENE-Y
are O
together O
solely O
capable O
of O
the O
reduction O
of O
arylhydroxylamine B-CHEMICAL
carcinogens, O
and O
we O
further O
hypothesize O
that O
this O
pathway O
may O
be O
a O
source O
of O
individual O
variability O
with O
respect O
to O
cancer O
susceptibility O
following O
4-ABP B-CHEMICAL
or O
PhIP B-CHEMICAL
exposure. O
Conformation O
Guides O
Molecular O
Efficacy O
in O

Docking O
Screens O
of O
Activated O
β-2 B-GENE-Y
Adrenergic I-GENE-Y
G I-GENE-Y
Protein I-GENE-Y
Coupled I-GENE-Y
Receptor. I-GENE-Y
A O
prospective, O
large O
library O
virtual O
screen O
against O
an O
activated O
β2-adrenergic B-GENE-Y
receptor I-GENE-Y
(β2AR) B-GENE-Y
structure O
returned O
potent O
agonists O
to O
the O
exclusion O
of O
inverse-agonists, O
providing O
the O
first O
complement O
to O
the O
previous O
virtual O
screening O
campaigns O
against O
inverse-agonist-bound O
G B-GENE-N
protein I-GENE-N
coupled I-GENE-N
receptor I-GENE-N
(GPCR) B-GENE-N
structures, O
which O
predicted O
only O
inverse-agonists. O
In O
addition, O
two O
hits O
recapitulated O
the O
signaling O
profile O
of O
the O
co-crystal O
ligand O
with O
respect O
to O
the O
G B-GENE-N
protein I-GENE-N
and O

arrestin B-GENE-N
mediated O
signaling. O
This O
functional O
fidelity O
has O
important O
implications O
in O
drug O
design, O
as O
the O
ability O
to O
predict O
ligands O
with O
predefined O
signaling O
properties O
is O
highly O
desirable. O
However, O
the O
agonist-bound O
state O
provides O
an O
uncertain O
template O
for O
modeling O
the O
activated O
conformation O
of O
other O
GPCRs, B-GENE-N
as O
a O
dopamine B-GENE-N
D2 I-GENE-N
receptor I-GENE-N
(DRD2) B-GENE-Y
activated O
model O
templated O
on O
the O
activated O
β2AR B-GENE-Y
structure O
returned O
few O
hits O
of O
only O
marginal O
potency. O
Conformational O
transitions O
linked O
to O
active O
site O
ligation O
in O
human B-GENE-Y
thrombin: I-GENE-Y
effect O
on O
the O
interaction O
with O
fibrinogen B-GENE-N
and O
the O
cleavable B-GENE-N
platelet I-GENE-N

receptor. I-GENE-N
An O
experimental O
strategy O
based O
on O
solution O
viscosity O
perturbation O
allowed O
us O
to O
study O
the O
energetics O
of O
amide-substrates, B-CHEMICAL
p-aminobenzamidine B-CHEMICAL
(p-ABZ) B-CHEMICAL
and O
proflavin B-CHEMICAL
binding O
to O
the O
catalytic O
site O
of O
two O
proteolyzed O
forms O
of O
alpha-thrombin, B-GENE-Y
i.e. O
zeta- B-GENE-N
and I-GENE-N
gamma I-GENE-N
T-thrombin. I-GENE-N
These O
thrombin B-GENE-Y
derivatives O
are O
cleaved O
at O
the O
Leu144-Gly150 O
loop O
and O
at O
the O
fibrinogen B-GENE-N
recognition I-GENE-N
exosite I-GENE-N
(FRS), B-GENE-N
respectively. O
A O
phenomenological O
analysis O
of O

thermodynamic O
data O
showed O
that O
the O
amide B-CHEMICAL
substrates O
and O
p-ABZ B-CHEMICAL
interactions O
with O
zeta-thrombin B-GENE-Y
were O
respectively, O
associated O
with O
a O
chemical O
compensation O
(i.e. O
the O
linear O
relationship O
between O
entropy O
and O
enthalpy O
of O
binding) O
and O
a O
hydrophobic O
phenomenon O
(i.e. O
a O
change O
in O
the O
standard O
heat O
capacity). O
The O
latter O
was O
slightly O
lower O
than O
that O
previously O
observed O
for O
a O
alpha-thrombin B-GENE-Y
(0.78 O
+/- O
0.25 O
versus O
1.01 O
+/- O
0.17 O
kcal/mol O
K). O
Both O
phenomenon O
were O
absent O
in O
gamma O

T-thrombin. O
The O
interaction O
of O
a O
alpha-, B-GENE-N
zeta- I-GENE-N
and I-GENE-N
gamma I-GENE-N
T-thrombin I-GENE-N
with O
macromolecular O
substrates O
that O
"bridge-bind" O
to O
both O
the O
catalytic O
site O
(CS) O
and O
fibrinogen B-GENE-N
recognition I-GENE-N
exosite I-GENE-N
(FRS), B-GENE-N
such O
as O
fibrinogen B-GENE-N
and O
the O
cleavable B-GENE-N
platelet I-GENE-N
receptor I-GENE-N
(CPR), B-GENE-N
was O
also O
evaluated. O
These O
interactions O
were O
studied O
by O
following O
fibrinopeptide B-GENE-Y
A I-GENE-Y
(FpA) B-GENE-Y
release O
and O
by O
measuring O
intraplatelet O
Ca2+ B-CHEMICAL
changes O
induced O
by O
thrombin-CPR B-GENE-Y
interaction. O
It O
was O
found O
that O

the O
free O
energy O
of O
activation O
(RT O
ln O
Kcat/Km) O
for O
both O
fibrinogen B-GENE-N
and O
CPR B-GENE-N
hydrolysis O
followed O
the O
same O
hierarchy, O
i.e. O
alpha O
> O
zeta O
> O
gamma. O
Moreover, O
the O
values O
of O
delta O
Cp O
for O
alpha-, B-GENE-N
zeta- I-GENE-N
and I-GENE-N
gamma I-GENE-N
T-thrombin I-GENE-N
interaction O
with O
p-ABZ B-CHEMICAL
were O
found O
to O
be O
linearly O
correlated O
to O
the O
free O
energy O
of O
activation O
for O
both O
fibrinogen B-GENE-N
and O
CPR B-GENE-N
cleavage. O
In O
conclusion, O
these O
data O
demonstrate O
that: O
(1) O
the O
Leu144-Gly150 O
loop O
and O
the O
FRS B-GENE-N
are O
both O

involved O
in O
the O
conformational O
transition O
linked O
to O
the O
binding O
of O
p-aminobenzamidine B-CHEMICAL
to O
the O
thrombin B-GENE-Y
active O
site; O
(2) O
the O
extent O
of O
thrombin's B-GENE-Y
capacity O
to O
undergo O
conformational O
transitions O
in O
alpha-, O
zeta- O
and O
gamma O
T O
forms O
is O
positively O
correlated O
to O
the O
free O
energy O
of O
activation O
for O
hydrolysis O
of O
macromolecular O
substrates O
interacting O
with O
both O
the O
catalytic O
domain O
and O
the O
FRS. B-GENE-N
Neuropsychological O
and O
conditioned O
blocking O
performance O
in O
patients O
with O
schizophrenia: O
assessment O
of O
the O
contribution O
of O
neuroleptic O
dose, O
serum O
levels O
and O
dopamine B-GENE-Y
D2-receptor I-GENE-Y

occupancy. O
Patients O
with O
schizophrenia O
show O
impairments O
of O
attention O
and O
neuropsychological O
performance, O
but O
the O
extent O
to O
which O
this O
is O
attributable O
to O
antipsychotic O
medication O
remains O
largely O
unexplored. O
We O
describe O
here O
the O
putative O
influence O
of O
the O
dose O
of O
antipsychotic O
medication O
(chlorpromazine B-CHEMICAL
equivalents, O
CPZ), B-CHEMICAL
the O
antipsychotic O
serum O
concentration O
of O
dopamine B-GENE-Y
(DA) I-GENE-Y
D2-blocking I-GENE-Y
activity O
and O
the O
approximated O
central O
dopamine B-CHEMICAL
D2-receptor B-GENE-Y
occupancy O
(DA B-CHEMICAL

D2-occupancy), B-GENE-Y
on O
conditioned O
blocking O
(CB) O
measures O
of O
attention O
and O
performance O
on O
a O
neuropsychological O
battery, O
in O
108 O
patients O
with O
schizophrenia O
(compared O
with O
62 O
healthy O
controls). O
Antipsychotic O
serum O
concentration O
and O
D2-occupancy B-GENE-Y
were O
higher O
in O
patients O
with O
a O
paranoid O
versus O
non-paranoid O
diagnosis, O
and O
in O
female O
versus O
male O
patients O
(independent O
of O
symptom O
severity). O
Controlling O
for O
D2-occupancy B-GENE-Y
removed O
the O
difference O
between O
high O
CB O
in O
paranoid O
and O
impaired O
low O
CB O
in O
non-paranoid O
patients. O
Similar O
partial O
correlations O
for O
antipsychotic O
drug O
dose O

and O
serum O
levels O
of O
DA B-CHEMICAL
D2-blocking B-GENE-Y
activity O
with O
performance O
of O
the O
trail-making O
and O
picture O
completion O
tests O
(negative) O
and O
the O
block-design O
task O
(positive) O
showed O
the O
functional O
importance O
of O
DA-related B-CHEMICAL
activity. O
High O
estimates O
of O
central O
DA B-CHEMICAL
D2-occupancy B-GENE-Y
were O
related O
to O
impaired O
verbal O
fluency O
but O
were O
associated O
with O
improved O
recall O
of O
stories, O
especially O
in O
paranoid O
patients. O
This, O
the O
first O
study O
of O
its O
kind, O
tentatively O
imputes O
a O
role O
for O
DA B-CHEMICAL
D2-related B-GENE-Y
activity O
in O
left O
frontal O
(e.g. O
CB, O
verbal O
fluency) O
and O
temporal O
lobe O
functions O
(verbal O
recall) O
as O
well O
as O

in O
some O
non-verbal O
abilities O
mediated O
more O
in O
the O
right O
hemisphere O
in O
patients O
with O
schizophrenia. O
Clinical O
effects O
of O
pranlukast, B-CHEMICAL
an O
oral O
leukotriene B-GENE-N
receptor I-GENE-N
antagonist, O
in O
mild-to-moderate O
asthma: O
a O
4 O
week O
randomized O
multicentre O
controlled O
trial. O
OBJECTIVE: O
Leukotriene B-CHEMICAL
antagonists O
are O
increasingly O
used O
in O
asthma O
management. O
Pranlukast B-CHEMICAL
is O
a O
new, O
orally O
active, O
selective O
inhibitor O
of O
CysLt1 B-GENE-Y
leukotriene B-GENE-N
receptor. I-GENE-N
The O
present O
clinical O
trial O
was O
performed O
to O
study O
the O
effect O
and O
safety O
of O
pranlukast B-CHEMICAL
in O

mild-to-moderate O
asthma. O
METHODOLOGY: O
A O
randomized, O
double-blind, O
placebo-controlled, O
parallel O
group O
study O
was O
performed O
in O
eight O
medical O
centres O
in O
Korea. O
Mild-to-moderate O
asthma O
patients O
who O
had O
been O
treated O
with O
beta2-agonists O
and/or O
inhaled O
corticosteroids B-CHEMICAL
were O
studied. O
The O
patients' O
symptoms O
were O
evaluated O
by O
asthma O
diary O
and O
twice-daily O
peak O
flow O
monitoring. O
RESULTS: O
Of O
the O
206 O
patients O
enrolled, O
197 O
were O
eligible O
for O
analysis. O
The O
pranlukast B-CHEMICAL
group O
(n O
= O
98) O
showed O
statistically O

significant O
improvement O
in O
asthma O
symptoms, O
including O
asthma O
attack O
rate, O
daily O
living O
score, O
and O
morning O
and O
evening O
asthma O
scores. O
Pranlukast B-CHEMICAL
significantly O
reduced O
the O
consumption O
of O
beta2-agonist. O
Compared O
with O
the O
placebo O
group, O
forced O
vital O
capacity O
(FVC) O
and O
forced O
expiratory O
volume O
in O
1 O
s O
(FEV1) O
were O
not O
significantly O
higher O
in O
the O
pranlukast B-CHEMICAL
group. O
Morning O
and O
evening O
peak O
expiratory O
flow O
(PEF) O
were O
significantly O
increased O
after O
pranlukast B-CHEMICAL
treatment O
at O
weeks O
2 O
and O
4 O
(380.8 O
+/- O
10.1 O
L/min O
at O

baseline, O
394.5 O
+/- O
10.1 O
at O
week O
2, O
396.3 O
+/- O
10.4 O
at O
week O
4). O
There O
were O
no O
serious O
adverse O
reactions. O
CONCLUSION: O
Pranlukast, B-CHEMICAL
an O
oral O
leukotriene B-CHEMICAL
antagonist, O
was O
well O
tolerated O
and O
was O
effective O
for O
the O
management O
of O
mild-to-moderate O
asthma. O
Physicochemical O
parameters O
that O
influence O
carotenoids O
bioaccessibility O
from O
a O
tomato O
juice. O
In O
vitro O
digestion O
models O
have O
been O
developed O
to O
estimate O
carotenoid O
bioavailability O
but O
most O
do O
not O
consider O
that O

their O
diffusion O
from O
fruit O
matrix O
to O
the O
lipid O
phase O
of O
the O
bolus O
could O
be O
a O
limiting O
step. O
Therefore O
we O
designed O
a O
model O
in O
which O
tomato O
juice O
is O
mixed O
with O
oil O
or O
oil/water O
emulsions, O
and O
the O
carotenoids O
diffusing O
to O
oil O
are O
measured O
by O
spectrometry. O
Temperature, O
pH O
and O
tomato O
juice/peanut O
oil O
ratio O
were O
evaluated O
for O
their O
influence O
on O
carotenoid O
diffusion. O
When O
oil/tomato O
ratio O
was O
between O
0.11 O
and O
1, O
extraction O
of O
lycopene B-CHEMICAL
was O
limited O
by O
the O
saturation O
of O
the O
oil O
phase. O
With O
a O
large O
excess O
of O
oil, O
diffusion O
was O
also O

limited, O
as O
only O
31 O
± O
1% O
of O
lycopene B-CHEMICAL
could O
be O
extracted O
from O
the O
juice. O
Diffusion O
did O
not O
vary O
significantly O
with O
pH O
but O
doubled O
when O
temperature O
rose O
from O
10°C O
to O
37°C. O
When O
the O
juice O
was O
mixed O
in O
an O
emulsion O
stabilised O
with O
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
or O
phospholipids O
the O
maximum O
extraction O
decreased O
to O
14.5 O
± O
0.2% O
and O
18.5 O
± O
1.5% O
respectively, O
indicating O
that O
in O
addition O
to O
the O
saturation O
of O
the O
oil O
phase O
at O
low O
oil/tomato O
ratio O
and O
in O
addition O
to O
intrinsic O
properties O
of O
the O
tomato O
juice O
in O

non-saturating O
conditions, O
lycopene B-CHEMICAL
diffusion O
was O
limited O
by O
the O
structure O
of O
the O
interface O
in O
emulsions. O
Acute O
and O
chronic O
interference O
with O
BDNF/TrkB-signaling B-GENE-Y
impair O
LTP O
selectively O
at O
mossy O
fiber O
synapses O
in O
the O
CA3 O
region O
of O
mouse O
hippocampus. O
Brain-derived B-GENE-Y
neurotrophic I-GENE-Y
factor I-GENE-Y
(BDNF) B-GENE-Y
signaling O
via O
TrkB B-GENE-Y
crucially O
regulates O
synaptic O
plasticity O
in O
the O
brain. O
Although O
BDNF B-GENE-Y
is O
abundant O
at O
hippocampal O
mossy O
fiber O
(MF) O
synapses, O
which O
critically O
contribute O
to O

hippocampus O
dependent O
memory, O
its O
role O
in O
MF O
synaptic O
plasticity O
(long-term O
potentiation, O
LTP) O
remained O
largely O
unclear. O
Using O
field O
potential O
recordings O
in O
CA3 O
of O
adult O
heterozygous O
BDNF B-GENE-Y
knockout O
(ko, O
BDNF+/-) B-GENE-Y
mice O
we O
observed O
impaired O
(∼50%) O
NMDAR-independent B-GENE-N
MF-LTP. O
In O
contrast O
to O
MF O
synapses, O
LTP O
at O
neighboring O
associative/commissural O
(A/C) O
fiber O
synapses O
remained O
unaffected. O
To O
exclude O
that O
impaired O
MF-LTP O

in O
BDNF+/- B-GENE-Y
mice O
was O
due O
to O
developmental O
changes O
in O
response O
to O
chronically O
reduced O
BDNF B-GENE-Y
levels, O
and O
to O
prove O
the O
importance O
of O
acute O
availability O
of O
BDNF B-GENE-Y
in O
MF-LTP, O
we O
also O
tested O
effects O
of O
acute O
interference O
with O
BDNF/TrkB B-GENE-Y
signaling. O
Inhibition O
of O
TrkB B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
signaling O
with O
k252a, O
or O
with O
the O
selective O
BDNF B-GENE-Y
scavenger O
TrkB-Fc, B-GENE-Y
both O
inhibited O
MF-LTP O
to O
the O
same O
extent O
as O
observed O
in O
BDNF+/- B-GENE-Y
mice. O
Basal O
synaptic O

transmission, O
short-term O
plasticity, O
and O
synaptic O
fatigue O
during O
LTP O
induction O
were O
not O
significantly O
altered O
by O
treatment O
with O
k252a O
or O
TrkB-Fc, B-GENE-Y
or O
by O
chronic O
BDNF B-GENE-Y
reduction O
in O
BDNF+/- B-GENE-Y
mice. O
Since O
the O
acute O
interference O
with O
BDNF-signaling B-GENE-Y
did O
not O
completely O
block O
MF-LTP, O
our O
results O
provide O
evidence O
that O
an O
additional O
mechanism O
besides O
BDNF B-GENE-Y
induced O
TrkB B-GENE-Y
signaling O
contributes O
to O
this O
type O
of O
LTP. O
Our O
results O
prove O
for O
the O
first O
time O
a O
mechanistic O
action O
of O
acute O
BDNF/TrkB B-GENE-Y
signaling O
in O
presynaptic O
expression O
of O

MF-LTP O
in O
adult O
hippocampus. O
Drug O
binding O
interactions O
in O
the O
inner O
cavity O
of O
HERG B-GENE-Y
channels: O
molecular O
insights O
from O
structure-activity O
relationships O
of O
clofilium B-CHEMICAL
and O
ibutilide B-CHEMICAL
analogs. O
Block O
of O
human B-GENE-Y
ether-a-go-go I-GENE-Y
related I-GENE-Y
gene I-GENE-Y
(hERG) I-GENE-Y
K(+) I-GENE-Y
channels I-GENE-Y
by O
otherwise O
useful O
drugs O
is O
the O
most O
common O
cause O
of O
long O
QT O
syndrome, O
a O
disorder O
of O
cardiac O
repolarization O
that O
predisposes O
patients O
to O
potentially O
fatal O
arrhythmias. O
This O
undesirable O
long O
QT O
side O
effect O
has O
been O
a O
major O
reason O
for O
the O
withdrawal O
of O
medications O

from O
the O
pharmaceutical O
market. O
Understanding O
the O
molecular O
basis O
of O
hERG B-GENE-Y
block O
is O
therefore O
essential O
to O
facilitate O
the O
design O
of O
safe O
drugs. O
Binding O
sites O
for O
hERG B-GENE-Y
blockers O
have O
been O
mapped O
within O
the O
inner O
cavity O
of O
the O
channel O
and O
include O
aromatic O
residues O
in O
the O
S6 O
helix O
(Tyr-652, B-CHEMICAL
Phe-656) B-CHEMICAL
and O
residues O
in O
the O
pore O
helix O
(Thr-623, B-CHEMICAL
Ser-624, B-CHEMICAL
Val-625). B-CHEMICAL
We O
used O
mutagenesis O
of O
these O
residues, O
combined O
with O
an O
investigation O
of O
hERG B-GENE-Y
block O
by O
close O
analogs O
of O
clofilium B-CHEMICAL
and O
ibutilide, B-CHEMICAL

to O
assess O
how O
specific O
alterations O
in O
drug O
structure O
affected O
potency O
and O
binding O
interactions. O
Although O
changing O
the O
basic O
nitrogen B-CHEMICAL
from O
quaternary O
to O
tertiary O
accelerated O
the O
onset O
of O
block, O
the O
IC(50) O
and O
kinetics O
for O
recovery O
from O
block O
were O
similar. O
In O
contrast, O
analogs O
with O
different O
para-substituents O
on O
the O
phenyl B-CHEMICAL
ring O
had O
significantly O
different O
potencies O
for O
wild-type O
hERG B-GENE-Y
block. O
The O
highest O
potency O
was O
achieved O
with O
polar O
or O
electronegative O
para-substituents, O
whereas O
neutral O
para-substituents O
had O
potencies O
more O
than O
100-fold O
lower. O
Results O
from O

mutagenesis O
and O
molecular O
modeling O
studies O
suggest O
that O
phenyl B-CHEMICAL
ring O
para-substituents O
influence O
drug O
interactions O
with O
Thr-623, B-CHEMICAL
Ser-624, B-CHEMICAL
and O
Tyr-652 B-CHEMICAL
and O
strongly O
affect O
binding O
affinity. O
Together, O
these O
findings O
suggest O
that O
modifying O
the O
para-substituent O
could O
be O
a O
useful O
strategy O
for O
reducing O
hERG O
potency O
and O
increasing O
the O
safety O
margin O
of O
compounds O
in O
development. O
Iron B-CHEMICAL
overload O
inhibits O
osteoblast O
biological O
activity O
through O
oxidative O
stress. O
Iron B-CHEMICAL
overload O
has O
recently O
been O
connected O
with O
bone O
mineral O
density O
in O
osteoporosis. O
However, O
to O

date, O
the O
effect O
of O
iron B-CHEMICAL
overload O
on O
osteoblasts O
remains O
poorly O
understood. O
The O
purpose O
of O
this O
study O
is O
to O
examine O
osteoblast O
biological O
activity O
under O
iron B-CHEMICAL
overload. O
The O
osteoblast O
cells O
(hFOB1.19) O
were O
cultured O
in O
a O
medium O
supplemented O
with O
different O
concentrations O
(50, O
100, O
and O
200 O
μM) O
of O
ferric B-CHEMICAL
ammonium I-CHEMICAL
citrate I-CHEMICAL
as O
a O
donor O
of O
ferric B-CHEMICAL
ion. O
Intracellular O
iron B-CHEMICAL
was O
measured O
with O
a O
confocal O
laser O
scanning O
microscope. O
Reactive O
oxygen B-CHEMICAL
species O
(ROS) O
were O
detected O
by O

2,7-dichlorofluorescin B-CHEMICAL
diacetate I-CHEMICAL
fluorophotometry. O
Osteoblast O
biological O
activities O
were O
evaluated O
by O
measuring O
the O
activity O
of O
alkaline B-GENE-N
phosphatase I-GENE-N
(ALP) B-GENE-N
and O
mineralization O
function. O
Results O
indicated O
that O
iron B-CHEMICAL
overload O
could O
consequently O
increase O
intracellular O
iron B-CHEMICAL
concentration O
and O
intracellular O
ROS O
levels O
in O
a O
concentration-dependent O
manner. O
Additionally, O
ALP B-GENE-N
activity O
was O
suppressed, O
and O
a O
decline O
in O
the O
number O
of O
mineralized O
nodules O
was O
observed O
in O
in O
vitro O
cultured O
osteoblast O
cells. O
According O
to O
these O
results, O
it O
seems O
that O
iron B-CHEMICAL
overload O
probably O
inhibits O

osteoblast O
function O
through O
higher O
oxidative O
stress O
following O
increased O
intracellular O
iron B-CHEMICAL
concentrations. O
Adrenergic O
agonists O
suppress O
the O
proliferation O
of O
microglia O
through O
beta B-GENE-Y
2-adrenergic I-GENE-Y
receptor. I-GENE-Y
The O
effects O
of O
several O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate I-CHEMICAL
(cAMP)-elevating B-CHEMICAL
agents O
on O
the O
proliferation O
of O
cultured O
rat O
microglia O
were O
investigated O
by O
immunocytochemical O
staining O
with O
an O
antibody O
against O
proliferating B-GENE-Y
cell I-GENE-Y
nuclear I-GENE-Y
antigen I-GENE-Y
(PCNA). B-GENE-Y
Epinephrine, B-CHEMICAL
isoproterenol, B-CHEMICAL
forskolin B-CHEMICAL
and O
8Br-cAMP B-CHEMICAL

suppressed O
the O
microglial O
proliferation. O
A O
beta2-selective O
agonist O
terbutaline B-CHEMICAL
but O
not O
a O
beta1-selective O
agonist O
dobutamine B-CHEMICAL
mimicked O
the O
effect O
of O
the O
above O
cAMP-elevating B-CHEMICAL
agents. O
Furthermore, O
a O
non-selective O
beta-receptor O
antagonist O
oxprenolol B-CHEMICAL
and O
a O
beta2-selective O
antagonist O
acebutalol, B-CHEMICAL
but O
not O
a O
beta1-selective O
antagonist O
butoxamine, B-CHEMICAL
counteracted O
the O
suppressive O
effects O
of O
the O
beta-agonists O
on O
microglial O
proliferation. O
These O
findings O
suggest O
that O
the O
beta-agonists O
suppress O
the O
proliferation O
of O
microglia O
by O
elevating O

intracellular O
cAMP B-CHEMICAL
level O
through O
an O
action O
on O
beta2-adrenergic B-GENE-Y
receptor. I-GENE-Y
Copper B-CHEMICAL
induced O
upregulation O
of O
apoptosis O
related O
genes O
in O
zebrafish O
(Danio O
rerio) O
gill. O
Copper B-CHEMICAL
(Cu) B-CHEMICAL
is O
an O
essential O
micronutrient O
that, O
when O
present O
in O
high O
concentrations, O
becomes O
toxic O
to O
aquatic O
organisms. O
It O
is O
known O
that O
Cu B-CHEMICAL
toxicity O
may O
induce O
apoptotic O
cell O
death. O
However, O
the O
precise O
mechanism O
and O
the O
pathways O
that O
are O
activated, O
in O
fish, O
are O
still O
unclear. O
Thus, O
this O
study O
aimed O
to O
assess O
which O
apoptotic O
pathways O
are O
triggered O
by O
Cu, B-CHEMICAL
in O

zebrafish O
(Danio O
rerio) O
gill, O
the O
main O
target O
of O
waterborne O
pollutants. O
Fish O
where O
exposed O
to O
12.5 O
and O
100 O
μg/L O
of O
Cu B-CHEMICAL
during O
6, O
12, O
24 O
and O
48 O
h. O
Fish O
gills O
were O
collected O
to O
TUNEL O
assay O
and O
mRNA O
expression O
analysis O
of O
selected O
genes O
by O
real O
time O
PCR. O
An O
approach O
to O
different O
apoptosis O
pathways O
was O
done O
selecting O
p53, B-GENE-Y
caspase-8, B-GENE-Y
caspase-9 B-GENE-Y
and O
apoptosis B-GENE-Y
inducing I-GENE-Y
factor I-GENE-Y
(AIF) B-GENE-Y
genes. O
The O
higher O
incidence O
of O
TUNEL-positive O
cells, O
in O

gill O
epithelia O
of O
the O
exposed O
fish, O
proved O
that O
Cu B-CHEMICAL
induced O
apoptosis. O
The O
results O
suggest O
that O
different O
apoptosis O
pathways O
are O
triggered O
by O
Cu B-CHEMICAL
at O
different O
time O
points O
of O
the O
exposure O
period, O
as O
the O
increase O
in O
transcripts O
was O
sequential, O
instead O
of O
simultaneous. O
Apoptosis O
seems O
to O
be O
initiated O
via O
intrinsic O
pathway O
(caspase-9), B-GENE-Y
through O
p53 B-GENE-Y
activation; O
then O
followed O
by O
the O
extrinsic O
pathway O
(caspase-8) B-GENE-Y
and O
finally O
by O
the O
caspase-independent B-GENE-N
pathway O
(AIF). B-GENE-Y
A O
possible O
model O
for O
Cu-induce B-CHEMICAL
apoptosis O
pathways O
is O
proposed. O

Gene O
expression O
signature O
of O
parathion-transformed B-CHEMICAL
human O
breast O
epithelial O
cells. O
Environmental O
substances O
seem O
to O
be O
involved O
in O
the O
etiology O
of O
breast O
cancers. O
Many O
studies O
have O
found O
an O
association O
between O
human O
cancer O
and O
exposure O
to O
agricultural O
pesticides O
such O
as O
the O
organophosphorous B-CHEMICAL
pesticides. O
Parathion B-CHEMICAL
is O
a O
cholinesterase B-GENE-N
inhibitor O
that O
induces O
the O
hydrolysis O
of O
body O
choline B-CHEMICAL
esters, I-CHEMICAL
including O
acetylcholine B-CHEMICAL
at O
cholinergic O
synapses. O
The O
primary O
target O
of O
action O
in O
insects O
is O
the O
nervous O
system O
whereby O
pesticides O
inhibit O
the O
release O
of O
the O
enzyme O

acetylcholinesterase B-GENE-N
at O
the O
synaptic O
junction. O
Atropine O
is O
a O
parasympatholytic O
alkaloid O
used O
as O
an O
antidote O
to O
acetylcholinesterase B-GENE-N
inhibitors. O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
parathion B-CHEMICAL
and O
atropine B-CHEMICAL
on O
cell O
transformation O
of O
human O
breast O
epithelial O
cells O
in O
vitro. O
These O
studies O
showed O
that O
parathion B-CHEMICAL
alone O
was O
able O
to O
induce O
malignant O
transformation O
of O
an O
immortalized O
human O
breast O
epithelial O
cell O
line, O
MCF-10F O
as O
indicated O
by O
increased O
cell O
proliferation, O
anchorage O
independency O

and O
invasive O
capabilities. O
There O
was O
also O
an O
increase O
in O
c-kit, B-GENE-Y
Trio, B-GENE-Y
Rho-A, B-GENE-Y
Rac-3, B-GENE-Y
EGFR, B-GENE-Y
Notch-4, B-GENE-Y
Dvl-2, B-GENE-Y
Ezrin, B-GENE-Y
beta B-GENE-Y
catenin I-GENE-Y
and O
mutant O
p53 B-GENE-Y
protein O
expression O
in O
the O
parathion-treated B-CHEMICAL
cells. O
However, O
atropine B-CHEMICAL
significantly O
inhibited O
this O
increase. O
In O
a O
human O
cell O
cycle O
array O
of O
96 O
genes, O
13 O
of O
them O
were O
altered O
by O
parathion B-CHEMICAL
treatment. O
Among O
the O
genes O
affected O
were O
the O
cyclins, B-GENE-N
such O
as O
cyclin B-GENE-Y
D3, I-GENE-Y
the O
cyclin-dependent B-GENE-N

kinases I-GENE-N
(CDKs) B-GENE-N
such O
as O
CDK41 B-GENE-Y
and O
the O
minichromosome B-GENE-Y
maintenance I-GENE-Y
deficient I-GENE-Y
(MCM) I-GENE-Y
MCM2 I-GENE-Y
and O
MCM3. B-GENE-Y
It O
is O
suggested O
that O
parathion B-CHEMICAL
influences O
human O
breast O
epithelial O
cell O
transformation O
and O
is O
an O
initiator O
factor O
in O
the O
transformation O
process O
in O
breast O
cancer. O
Purification O
and O
multimeric O
structure O
of O
bovine O
N-acetylglucosamine-1-phosphodiester B-GENE-Y
alpha-N-acetylglucosaminidase. I-GENE-Y
N-Acetylglucosamine-1-phosphodiester B-GENE-Y

alpha-N-Acetylglucosaminidase I-GENE-Y
(EC B-GENE-Y
3.1.4.45; I-GENE-Y
phosphodiester B-GENE-Y
alpha-GlcNAcase) I-GENE-Y
catalyzes O
the O
second O
step O
in O
the O
synthesis O
of O
the O
mannose B-CHEMICAL
6-phosphate I-CHEMICAL
determinant O
required O
for O
efficient O
intracellular O
targeting O
of O
newly O
synthesized O
lysosomal O
hydrolases O
to O
the O
lysosome. O
A O
partially O
purified O
preparation O
of O
phosphodiester B-GENE-Y
alpha-GlcNAcase I-GENE-Y
from O
bovine O
pancreas O
was O
used O
to O
generate O
a O
panel O
of O
murine O
monoclonal O
antibodies. O
The O

anti-phosphodiester B-GENE-Y
alpha-GlcNAcase I-GENE-Y
monoclonal O
antibody O
UC1 O
was O
coupled O
to O
a O
solid O
support O
and O
used O
to O
immunopurify O
the O
bovine O
liver O
enzyme O
670,000-fold O
in O
two O
steps O
to O
apparent O
homogeneity O
with O
an O
overall O
yield O
of O
14%. O
The O
purified O
phosphodiester B-GENE-Y
alpha-GlcNAcase I-GENE-Y
has O
a O
specific O
activity O
of O
498 O
micromol O
of O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl B-CHEMICAL
cleaved O
per O
h O
per O
mg O
of O
protein O
using O
0.5 O

mM O
[3H]GlcNAc-alpha-phosphomannose-alpha-methyl B-CHEMICAL
as O
substrate. O
The O
subunit O
structure O
of O
the O
enzyme O
was O
determined O
using O
a O
combination O
of O
analytical O
gel O
filtration O
chromatography, O
SDS-polyacrylamide B-CHEMICAL
gel O
electrophoresis, O
and O
amino-terminal O
sequencing. O
The O
data O
indicate O
that O
bovine O
phosphodiester B-GENE-Y
alpha-GlcNAcase I-GENE-Y
is O
a O
272,000-Da O
complex O
of O
four O
identical O
68,000-Da O
glycoprotein O
subunits O
arranged O
as O
two O
disulfide-linked B-CHEMICAL
homodimers. O

A O
soluble O
form O
of O
the O
enzyme, O
isolated O
from O
fetal O
bovine O
serum, O
showed O
the O
same O
subunit O
structure. O
Both O
forms O
of O
the O
enzyme O
reacted O
with O
a O
rabbit O
antibody O
raised O
to O
the O
amino-terminal B-CHEMICAL
peptide O
of O
the O
liver O
enzyme, O
suggesting O
that O
phosphodiester B-GENE-Y
alpha-GlcNAcase I-GENE-Y
is O
a O
type B-GENE-N
I I-GENE-N
membrane-spanning I-GENE-N
glycoprotein I-GENE-N
with O
its O
amino B-CHEMICAL
terminus O
in O
the O
lumen O
of O
the O
Golgi O
apparatus. O
Impact O
of O
ketorolac B-CHEMICAL
administration O
around O
ovarian O
stimulation O
on O
in O
vivo O
and O
in O
vitro O
fertilization O
and O
subsequent O
embryo O
development. O
Abstract O
We O
performed O
this O

study O
to O
investigate O
the O
effect O
of O
ketorolac B-CHEMICAL
(a O
non-steroidal O
anti-inflammatory O
drug) O
administration O
around O
ovarian O
stimulation O
on O
in O
vivo O
and O
in O
vitro O
fertilization O
process. O
Sixty-four O
female O
mice O
(ICR) O
were O
injected O
with O
ketorolac B-CHEMICAL
(0, O
7.5, O
15 O
and O
30 O
µg/d) O
for O
3 O
d O
starting O
from O
the O
day O
of O
eCG B-GENE-N
treatment. O
In O
experiment O
1, O
41 O
mice O
were O
triggered O
by O
hCG B-GENE-N
and O
then O
mated; O
two-cell O
embryos O
were O
obtained O
and O
in O
vitro O
development O
up O
to O
blastocyst O
was O

observed. O
In O
experiment O
2, O
23 O
mice O
were O
triggered O
by O
hCG B-GENE-N
and O
mature O
oocytes O
were O
collected; O
in O
vitro O
fertilization O
rate O
and O
subsequent O
embryo O
development O
up O
to O
blastocyst O
was O
recorded. O
In O
experiment O
1, O
the O
blastocyst-forming O
rates O
per O
in O
vivo O
fertilized O
two-cell O
embryo O
showed O
an O
inverse O
relationship O
with O
a O
dosage O
of O
ketorolac B-CHEMICAL
(97.6%, O
64.2%, O
35.4% O
and O
25.9%). O
In O
experiment O
2, O
degenerated O
oocytes O
were O
frequently O
observed O
in O
a O
dose-dependent O
manner O

(4.3%, O
22.9%, O
22.4% O
and O
75.0%). O
Lower O
fertilization O
rates O
were O
noted O
in O
all O
the O
three O
ketorolac-treating B-CHEMICAL
groups; O
blastocyst-forming O
rate O
was O
significantly O
lower O
in O
30-µg-treating O
group O
when O
compared O
with O
the O
control O
group. O
Administration O
of O
ketorolac B-CHEMICAL
around O
ovarian O
stimulation O
significantly O
affects O
the O
development O
of O
in O
vivo O
fertilized O
embryo O
in O
a O
dose-dependent O
manner. O
High-dose O
ketorolac B-CHEMICAL
could O
result O
in O
a O
poor O
oocyte O
quality O
and O
decreased O
embryo O
developmental O
competence. O
Passive O
stiffness O

of O
airway O
smooth O
muscle: O
the O
next O
target O
for O
improving O
airway O
distensibility O
and O
treatment O
for O
asthma? O
Reduced O
airway O
distensibility O
due O
to O
increased O
airway O
stiffness O
is O
a O
characteristic O
of O
asthma. O
Airway O
stiffness O
is O
determined O
by O
the O
property O
and O
structural O
organization O
of O
the O
various O
elements O
of O
the O
airway O
wall, O
and O
is O
often O
divided O
into O
active O
and O
passive O
components. O
Active O
stiffness O
is O
thought O
to O
be O
associated O
with O
activation O
of O
muscle O
cells O
in O
the O
airway O
wall. O
This O
component O
of O
stiffness O
can O
be O
inhibited O
when O
active O
force O
produced O
by O
the O
muscle O
is O
abolished. O
Passive O
stiffness, O
on O
the O

other O
hand, O
is O
thought O
to O
stem O
from O
non-muscle O
component O
of O
the O
airway O
wall, O
especially O
the O
collagen/elastin B-GENE-N
fibrous O
network O
of O
the O
extracellular O
matrix O
within O
which O
the O
muscle O
cells O
are O
embedded. O
In O
this O
brief O
review, O
the O
notion O
that O
passive O
stiffness O
is O
exclusively O
extracellular O
in O
origin O
is O
challenged. O
Recent O
evidence O
suggests O
that O
a O
substantial O
portion O
of O
the O
passive O
stiffness O
of O
an O
in O
vitro O
preparation O
of O
tracheal O
smooth O
muscle O
is O
calcium B-CHEMICAL
sensitive O
and O
is O
regulated O
by O
Rho-kinase, B-GENE-N
although O
the O
underlying O
mechanism O
and O
the O
details O
of O
regulation O
for O
the O
development O
of O
this O
intracellular O
passive O
stiffness O
are O
still O
largely O

unknown. O
To O
reduce O
airway O
stiffness O
different O
lines O
of O
attack O
must O
be O
tailored O
to O
different O
components O
of O
the O
stiffness. O
The O
regulatable O
passive O
stiffness O
is O
distinct O
from O
the O
relatively O
permanent O
stiffness O
of O
the O
extracellular O
matrix O
and O
the O
stiffness O
associated O
with O
active O
muscle O
contraction. O
To O
improve O
airway O
distensibility O
during O
asthma O
exacerbation, O
a O
comprehensive O
approach O
to O
reduce O
overall O
airway O
stiffness O
should O
therefore O
include O
a O
strategy O
for O
targeting O
the O
regulatable O
passive O
stiffness. O
The O
vascular O
protective O
properties O
of O
kinsenoside B-CHEMICAL
isolated O
from O
Anoectochilus O
roxburghii O
under O
high O
glucose B-CHEMICAL
condition. O

Anoectochilus O
roxburghii O
is O
a O
traditional O
Chinese O
herb O
used O
for O
the O
treatment O
of O
diabetes O
and O
some O
other O
diseases. O
The O
vascular O
protective O
effect O
of O
its O
major O
active O
ingredient, O
kinsenoside, B-CHEMICAL
in O
high O
glucose B-CHEMICAL
conditions O
was O
investigated O
in O
in O
vivo O
and O
in O
vitro O
experiments. O
In O
in O
vivo O
tests, O
kinsenoside B-CHEMICAL
(50 O
and O
100mg/kg) O
efficiently O
lowered O
blood O
glucose B-CHEMICAL
and O
cholesterol B-CHEMICAL
levels O
and O
it O
enhanced O
the O
oxidation O
resistance O
of O
diabetic O
mice O
induced O
by O
streptozotocin. B-CHEMICAL
In O
the O
in O
vitro O
assay, O
kinsenoside B-CHEMICAL
(20 O
and O

50μg/mL) O
markedly O
inhibited O
changes O
in O
various O
biochemical O
substances O
(nitric B-CHEMICAL
oxide I-CHEMICAL
(NO), B-CHEMICAL
lactic B-GENE-N
dehydrogenase I-GENE-N
(LDH), B-GENE-N
superoxide B-GENE-N
dismutase I-GENE-N
(SOD), B-GENE-N
and O
catalase B-GENE-Y
(CAT)) B-GENE-Y
in O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs) O
damaged O
by O
high O
glucose B-CHEMICAL
(35mM) O
and O
restored O
vascular O
endothelial O
structure O
by O
balancing O
the O
matrix B-GENE-N
metalloproteinases-the I-GENE-N
tissue B-GENE-N
inhibitors I-GENE-N
of I-GENE-N
matrix I-GENE-N
metalloproteinases I-GENE-N
(MMP-TIMP) B-GENE-N
system. O
The O
vascular O

protective O
effects O
of O
kinsenoside B-CHEMICAL
were O
speculated O
to O
be O
attributed O
to O
oxidative O
stress O
inhibition O
and O
the O
reduction O
of O
nuclear B-GENE-N
factor I-GENE-N
kappa I-GENE-N
B I-GENE-N
(NF-κB) B-GENE-N
mRNA O
expression O
levels O
in O
high O
glucose B-CHEMICAL
conditions. O
Moreover, O
histological O
examination, O
including O
hematoxylin-eosin B-CHEMICAL
(H&E) O
staining, O
masson O
trichrome O
(Masson) O
staining, O
and O
periodic O
Schiff-methenamine B-CHEMICAL
(PASM) O
staining, O
greatly O
supported O
the O
morphological O
and O
functional O
amelioration O
of O
diabetes-related O
changes O
in O
mice O
aortas O
after O
kinsenoside B-CHEMICAL
(20 O
and O

50μg/mL) O
treatment. O
These O
results O
indicated O
that O
kinsenoside B-CHEMICAL
might O
be O
a O
promising O
agent O
for O
the O
treatment O
of O
diabetic O
vascular O
disease. O
Prenatal O
exposure O
to O
bisphenol B-CHEMICAL
A I-CHEMICAL
impacts O
midbrain O
dopamine B-CHEMICAL
neurons O
and O
hippocampal O
spine O
synapses O
in O
non-human O
primates. O
Prevalent O
use O
of O
bisphenol-A B-CHEMICAL
(BPA) B-CHEMICAL
in O
the O
manufacture O
of O
resins, O
plastics O
and O
paper O
products O
has O
led O
to O
frequent O
exposure O
of O
most O
people O
to O
this O
endocrine O
disruptor. O
Some O
rodent O
studies O
have O
suggested O
that O
BPA B-CHEMICAL
can O
exert O
detrimental O

effects O
on O
brain O
development. O
However O
as O
rodent O
models O
cannot O
be O
relied O
on O
to O
predict O
consequences O
of O
human O
exposure O
to O
BPA B-CHEMICAL
during O
development, O
it O
is O
important O
to O
investigate O
the O
effects O
of O
BPA B-CHEMICAL
on O
non-human O
primate O
brain O
development. O
Previous O
research O
suggests O
that O
BPA B-CHEMICAL
preferentially O
targets O
dopamine B-CHEMICAL
neurons O
in O
ventral O
mesencephalon O
and O
glutamatergic O
neurons O
in O
hippocampus, O
so O
the O
present O
work O
examined O
the O
susceptibility O
of O
these O
systems O
to O
low O
dose O
BPA B-CHEMICAL
exposure O
at O
the O
fetal O
and O
juvenile O
stages O
of O
development O
in O
non-human O
primates. O
Exposure O
of O
pregnant O
rhesus O
monkeys O
to O

relatively O
low O
levels O
of O
BPA B-CHEMICAL
during O
the O
final O
2 O
months O
of O
gestation, O
induced O
abnormalities O
in O
fetal O
ventral O
mesencephalon O
and O
hippocampus. O
Specifically, O
light O
microscopy O
revealed O
a O
decrease O
in O
tyrosine B-GENE-N
hydroxylase-expressing I-GENE-N
(dopamine) B-CHEMICAL
neurons O
in O
the O
midbrain O
of O
BPA-exposed B-CHEMICAL
fetuses O
and O
electron O
microscopy O
identified O
a O
reduction O
in O
spine O
synapses O
in O
the O
CA1 O
region O
of O
hippocampus. O
In O
contrast, O
administration O
of O
BPA B-CHEMICAL
to O
juvenile O
vervet O
monkeys O
(14-18 O
months O
of O
age) O
was O
without O
effect O
on O
these O

indices, O
or O
on O
dopamine B-CHEMICAL
and O
serotonin B-CHEMICAL
concentrations O
in O
striatum O
and O
prefrontal O
cortex, O
or O
on O
performance O
of O
a O
cognitive O
task O
that O
tests O
working O
memory O
capacity. O
These O
data O
indicate O
that O
BPA B-CHEMICAL
exerts O
an O
age-dependent O
detrimental O
impact O
on O
primate O
brain O
development, O
at O
blood O
levels O
within O
the O
range O
measured O
in O
humans O
having O
only O
environmental O
contact O
with O
BPA. B-CHEMICAL
Potentiation O
of O
sulfonylurea B-CHEMICAL
action O
by O
an O
EPAC-selective B-GENE-Y
cAMP B-CHEMICAL
analog O
in O
INS-1 O
cells: O
comparison O
of O
tolbutamide B-CHEMICAL
and O
gliclazide B-CHEMICAL
and O
a O
potential O
role O
for O

EPAC B-GENE-Y
activation O
of O
a O
2-APB-sensitive O
Ca2+ O
influx. O
Tolbutamide B-CHEMICAL
and O
gliclazide O
block O
the O
K(ATP) B-GENE-N
channel I-GENE-N
K(ir)6.2/Sur1, B-GENE-Y
causing O
membrane O
depolarization O
and O
stimulating O
insulin B-GENE-Y
secretion O
in O
pancreatic O
beta O
cells. O
We O
examined O
the O
ability O
of O
the O
EPAC-selective B-GENE-Y
cAMP B-CHEMICAL
analog O
8-pCPT-2'-O-Me-cAMP-AM B-CHEMICAL
to O
potentiate O
the O
action O
of O
these O
drugs O
and O
the O
mechanism O
that O
might O
account O
for O
it. O
Insulin B-GENE-N
secretion O
stimulated O
by O
both O
200 O

μM O
tolbutamide B-CHEMICAL
and O
20 O
μM O
gliclazide, B-CHEMICAL
concentrations O
that O
had O
equivalent O
effects O
on O
membrane O
potential, O
was O
inhibited O
by O
thapsigargin B-CHEMICAL
(1 O
μM) O
or O
the O
L-type B-GENE-N
Ca(2+) I-GENE-N
channel I-GENE-N
blocker O
nicardipine B-CHEMICAL
(2 O
μM) O
and O
was O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM B-CHEMICAL
at O
concentrations O
≥2 O
μM O
in O
INS-1 O
cells. O
Ca(2+) B-CHEMICAL
transients O
stimulated O
by O
either O
tolbutamide B-CHEMICAL
or O
gliclazide B-CHEMICAL
were O

inhibited O
by O
thapsigargin B-CHEMICAL
or O
nicardipine B-CHEMICAL
and O
were O
significantly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM O
at O
5 O
μM O
but O
not O
1 O
μM. O
Both O
tolbutamide B-CHEMICAL
and O
gliclazide B-CHEMICAL
stimulated O
phospholipase B-GENE-N
C I-GENE-N
activity; O
however, O
only O
gliclazide B-CHEMICAL
did O
so O
independently O
of O
its O
activity O
at O
K(ATP) B-GENE-N
channels, I-GENE-N
and O
this O
activity O
was O
partially O
inhibited O
by O
pertussis B-GENE-N
toxin. I-GENE-N
8-pCPT-2'-O-Me-cAMP-AM B-CHEMICAL
alone O

(5 O
μM) O
did O
not O
stimulate O
insulin B-GENE-N
secretion, O
but O
did O
increase O
intracellular O
Ca(2+) B-CHEMICAL
concentration O
significantly, O
and O
this O
activity O
was O
inhibited O
by O
25 O
μM O
2-aminoethoxydiphenylborate B-CHEMICAL
(2-APB) B-CHEMICAL
or O
the O
removal O
of O
extracellular O
Ca(2+). B-CHEMICAL
8-pCPT-2'-O-Me-cAMP-AM B-CHEMICAL
potentiation O
of O
insulin B-GENE-N
secretion O
stimulated O
by O
tolbutamide B-CHEMICAL
was O
markedly O
inhibited O
by O
2-APB B-CHEMICAL
(25 O
μM) O
and O
enhanced O
by O
the O
PKC B-GENE-N
inhibitor O

bisindolylmaleimide B-CHEMICAL
I I-CHEMICAL
(1 O
μM). O
Our O
data O
demonstrate O
that O
the O
actions O
of O
both O
tolbutamide B-CHEMICAL
and O
gliclazide B-CHEMICAL
are O
strongly O
potentiated O
by O
8-pCPT-2'-O-Me-cAMP-AM, B-CHEMICAL
that O
gliclazide B-CHEMICAL
can O
stimulate O
phospholipase B-GENE-N
C I-GENE-N
activity O
via O
a O
partially O
pertussis B-GENE-N
toxin-sensitive I-GENE-N
mechanism, O
and O
that O
8-pCPT-2'-O-Me-cAMP-AM B-CHEMICAL
potentiation O
of O
tolbutamide O
action O
may O
involve O
activation O
of O
a O
2-APB-sensitive B-CHEMICAL

Ca(2+) B-CHEMICAL
influx. O
Energy O
depletion O
of O
bovine O
mammary O
epithelial O
cells O
activates O
AMPK B-GENE-N
and O
suppresses O
protein O
synthesis O
through O
inhibition O
of O
mTORC1 B-GENE-N
signaling. O
The O
molecular O
mechanisms O
by O
which O
cellular O
energy O
status O
regulates O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
have O
not O
been O
characterized. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effect O
of O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
activation O
by O
2-deoxyglucose B-CHEMICAL
on O
protein O
synthesis O
and O
the O
mammalian B-GENE-N
target I-GENE-N
of I-GENE-N
rapamycin I-GENE-N
complex I-GENE-N
1 I-GENE-N
(mTORC1) B-GENE-N

signaling O
pathway O
in O
bovine O
mammary O
epithelial O
cells. O
Phosphorylation O
of O
AMPK B-GENE-N
at O
Thr172 B-CHEMICAL
increased O
by O
1.4-fold O
within O
5 O
min, O
and O
remained O
elevated O
throughout O
a O
30-min O
time O
course, O
in O
response O
to O
2-deoxyglucose. B-CHEMICAL
Global O
rates O
of O
protein O
synthesis O
declined O
by O
78% O
of O
control O
values. O
The O
decline O
in O
protein O
synthesis O
was O
associated O
with O
repression O
of O
mTORC1 B-GENE-N
signaling, O
as O
indicated O
by O
reduced O
phosphorylation O
of O
ribosomal B-GENE-Y
protein I-GENE-Y
S6 I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
and O
eIF4E B-GENE-Y
binding I-GENE-Y
protein-1 I-GENE-Y

(4E-BP1). B-GENE-Y
Phosphorylation O
of O
ER-stress O
marker O
eIF2α B-GENE-Y
was O
also O
increased O
but O
only O
at O
30 O
min O
of O
2-deoxyglucose B-CHEMICAL
exposure. O
2-Deoxyglucose B-CHEMICAL
increased O
phosphorylation O
of O
tuberous B-GENE-Y
sclerosis I-GENE-Y
complex I-GENE-Y
2 I-GENE-Y
(TSC2) B-GENE-Y
on O
AMPK B-GENE-N
consensus O
sites O
but O
did O
not O
change O
the O
amount O
of O
TSC1 B-GENE-Y
bound O
to O
TSC2. B-GENE-Y
Activation O
of O
AMPK B-GENE-N
did O
not O
result O
in O
changes O
in O
the O
amount O
of O
raptor O
bound O
to O
mTOR. B-GENE-Y
The O
inhibitory O
effects O
of O
AMPK B-GENE-N
activation O
on O

mTORC1 B-GENE-N
signaling O
were O
associated O
with O
a O
marked O
increase O
in O
Ser792 B-CHEMICAL
phosphorylation O
on O
raptor. O
Collectively, O
the O
results O
suggest O
that O
activation O
of O
AMPK B-GENE-N
represses O
global O
protein O
synthesis O
in O
mammary O
epithelial O
cells O
through O
inhibition O
of O
mTORC1 B-GENE-N
signaling. O
Conivaptan: B-CHEMICAL
a O
dual O
vasopressin B-GENE-N
receptor I-GENE-N
v1a/v2 I-GENE-N
antagonist O
[corrected]. O
Several O
fluid O
retentive O
states O
such O
as O
heart O
failure, O
cirrhosis O
of O
the O
liver, O
and O
syndrome O
of O
inappropriate O
antidiuretic O
hormone O
secretion O
are O
associated O
with O
inappropriate O
elevation O
in O
plasma O
levels O
of O

arginine B-GENE-Y
vasopressin I-GENE-Y
(AVP), B-GENE-Y
a O
neuropeptide O
that O
is O
secreted O
by O
the O
hypothalamus O
and O
plays O
a O
critical O
role O
in O
the O
regulation O
of O
serum O
osmolality O
and O
in O
circulatory O
homeostasis. O
The O
actions O
of O
AVP B-GENE-Y
are O
mediated O
by O
three O
receptor O
subtypes O
V1a, O
V2, O
and O
V1b. O
The O
V1a B-GENE-Y
receptor I-GENE-Y
regulates O
vasodilation O
and O
cellular O
hypertrophy O
while O
the O
V2 B-GENE-Y
receptor I-GENE-Y
regulates O
free O
water O
excretion. O
The O
V1b B-GENE-Y
receptor I-GENE-Y
regulates O
adrenocorticotropin B-GENE-Y
hormone I-GENE-Y

release. O
Conivaptan B-CHEMICAL
is O
a O
nonpeptide O
dual O
V1a/V2 B-GENE-N
AVP I-GENE-N
receptor I-GENE-N
antagonist. O
It O
binds O
with O
high O
affinity, O
competitively, O
and O
reversibly O
to O
the O
V1a/V2 B-GENE-N
receptor I-GENE-N
subtypes; O
its O
antagonistic O
effect O
is O
concentration O
dependent. O
It O
inhibits O
CYP3A4 B-GENE-Y
liver O
enzyme O
and O
elevates O
plasma O
levels O
of O
other O
drugs O
metabolized O
by O
this O
enzyme. O
It O
is O
approved O
only O
for O
short-term O
intravenous O
use. O
Infusion O
site O
reaction O
is O
the O
most O
common O
reason O
for O
discontinuation O
of O
the O
drug. O
In O
animals O
conivaptan O
increased O
urine O
volume O
and O

free O
water O
clearance. O
In O
heart O
failure O
models O
it O
improved O
hemodynamic O
parameters O
and O
free O
water O
excretion. O
Conivaptan B-CHEMICAL
has O
been O
shown O
to O
correct O
hyponatremia O
in O
euvolemic O
or O
hypervolemic O
patients. O
Its O
efficacy O
and O
safety O
for O
short-term O
use O
have O
led O
to O
the O
Food O
and O
Drug O
Administration O
(FDA) O
approval O
of O
its O
intravenous O
form O
for O
the O
correction O
of O
hyponatremia O
in O
euvolemic O
and O
hypervolemic O
states. O
Despite O
its O
ability O
to O
block O
the O
action O
of O
AVP B-GENE-Y
on O
V1a B-GENE-Y
receptors, I-GENE-Y
no O
demonstrable O
benefit O
from O
this O

action O
was O
noted O
in O
patients O
with O
chronic O
compensated O
heart O
failure O
and O
it O
is O
not O
approved O
for O
this O
indication. O
Consideration O
should O
be O
given O
to O
further O
evaluation O
of O
its O
potential O
benefits O
in O
patients O
with O
acute O
decompensated O
heart O
failure. O
Histamine B-CHEMICAL
and O
asthma: O
an O
appraisal O
based O
on O
specific O
H1-receptor B-GENE-Y
antagonism. O
H1-receptor B-GENE-Y
antagonists O
have O
been O
utilized, O
following O
their O
initial O
chemical O
synthesis O
in O
1933, O
both O
in O
the O
treatment O
of O
conditions O
in O
which O
histamine B-CHEMICAL
is O
considered O
to O
be O
of O
pathogenic O
importance O
and O
conversely O
to O
help O
elucidate O
the O
role O
of O
histamine B-CHEMICAL
in O
disease, O
through O
an O
evaluation O
of O
their O
influence O

on O
disease O
expression. O
While O
there O
is O
considerable O
indirect O
evidence O
to O
implicate O
histamine B-CHEMICAL
in O
the O
pathogenesis O
of O
asthma, O
a O
critical O
evaluation O
of O
H1-receptor B-GENE-Y
antagonism O
in O
this O
condition O
has, O
until O
recently, O
proved O
difficult, O
as O
many O
of O
the O
early O
H1-receptor B-GENE-Y
antagonists O
possessed O
additional O
actions, O
such O
as O
anti-cholinergic, O
local O
anaesthetic, O
alpha-adrenoceptor B-GENE-N
antagonistic O
and O
anti-serotonin O
activity. O
In O
addition, O
H1-receptor B-GENE-Y
antagonists O
have O
been O
shown O
to O
have O
effects O
on O
mast O
cell O
function. O
In O
low O
concentrations O
in O
vitro, O

antihistamines O
have O
been O
found O
to O
inhibit O
immunologically O
stimulated O
mast O
cell O
mediator O
release, O
with O
the O
IC50 O
in O
the O
nanomolar O
to O
micromolar O
range, O
while O
at O
higher O
concentrations O
they O
induce O
histamine B-CHEMICAL
release. O
The O
potency O
of O
these O
drugs O
in O
producing O
such O
effects O
is O
unrelated O
to O
their O
H1-receptor B-GENE-Y
blocking O
activity. O
Furthermore O
the O
sedative O
effects O
of O
these O
therapeutic O
agents O
limit O
the O
tolerable O
administrable O
dose O
and O
thus O
the O
degree O
of O
H1-receptor B-GENE-Y
blockade O
achievable O
within O
the O
airways. O
The O
recent O
development O
of O
H1-receptor B-GENE-Y
antagonists O
devoid O
of O
clinical O
sedative O
effects O

has O
enabled O
the O
administration O
of O
doses O
of O
H1-antihistamines B-GENE-Y
which O
achieve O
a O
greater O
degree O
of O
H1-receptor B-GENE-Y
blockade O
within O
the O
airways, O
thus O
permitting O
a O
better O
appraisal O
of O
the O
role O
of O
histamine B-CHEMICAL
in O
this O
condition. O
Furthermore, O
the O
receptor O
specificity O
of O
many O
of O
these O
agents O
has O
been O
focused O
such O
that O
terfenadine, B-CHEMICAL
astemizole, B-CHEMICAL
loratadine B-CHEMICAL
and O
cetirizine B-CHEMICAL
are O
devoid O
of O
anticholinergic O
activity O
and O
exhibit O
little O
alpha-antagonistic O
or O
anti-serotonin B-CHEMICAL
activity O
of O
clinical O
relevance. O
However, O
of O
these O
agents O
both O
loratadine B-CHEMICAL
and O
cetirizine B-CHEMICAL
possess O
additional O
actions O
likely O

to O
be O
of O
relevance O
to O
asthma. O
Pretreatment O
with O
loratadine B-CHEMICAL
has O
been O
shown O
to O
reduce O
the O
recovery O
of O
both O
histamine B-CHEMICAL
and O
prostaglandin B-CHEMICAL
D2 I-CHEMICAL
(PGD2) B-CHEMICAL
in O
nasal O
lavage O
fluid O
following O
nasal O
allergen O
challenge, O
a O
finding O
interpreted O
as O
indicative O
of O
in O
vivo O
mast O
cell O
stabilization, O
and O
cetirizine B-CHEMICAL
has O
been O
shown O
in O
vivo O
at O
therapeutic O
doses O
to O
inhibit O
allergen-induced O
eosinophil O
chemotaxis. O
Thus O
while O
both O
these O
agents O
offer O
the O
potential O
of O
an O
oral O
therapy O
for O
asthma O
based O
on O
an O
H1-receptor B-GENE-Y

antagonist, O
their O
additional O
actions O
do O
not O
make O
them O
ideally O
suited O
to O
the O
exploration O
of O
the O
role O
of O
histamine B-CHEMICAL
in O
asthma.(ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS) O
Identification O
of O
novel O
FLT3 B-GENE-Y
kinase B-GENE-N
inhibitors. O
FLT3 B-GENE-Y
and O
PDGFR B-GENE-N
tyrosine B-GENE-N
kinases I-GENE-N
are O
important O
targets O
for O
therapy O
of O
different O
types O
of O
leukemia. O
Several O
FLT3/PDGFR B-GENE-Y
inhibitors O
are O
currently O
under O
clinical O
investigation O
for O
combination O
with O
standard O
therapy O
for O
treatment O
of O
acute O
myeloid O
leukemia O
(AML), O
however O
these O
agents O
only O
induce O
partial O
remission O

and O
development O
of O
resistance O
has O
been O
reported. O
In O
this O
work O
we O
describe O
the O
identification O
of O
potent O
and O
novel O
dual O
FLT3/PDGFR B-GENE-Y
inhibitors O
that O
resulted O
from O
our O
efforts O
to O
screen O
a O
library O
of O
25,607 O
small O
molecules O
against O
the O
FLT3 B-GENE-Y
dependent O
cell O
line O
MOLM-13 O
and O
the O
PDGFR B-GENE-N
dependent O
cell O
line O
EOL-1. O
This O
effort O
led O
to O
the O
identification O
of O
five O
compounds O
that O
were O
confirmed O
to O
be O
active O
on O
additional O
FLT3 B-GENE-Y
dependent O
cell O
lines O
(cellular O
EC50 O
values O
between O
35 O
and O
700 O
nM), O
while O
having O
no O
significant O
effect O
on O
24 O
other O
tyrosine B-GENE-N
kinases. I-GENE-N

Enzyme-responsive O
surface O
erosion O
of O
poly(ethylene B-CHEMICAL
carbonate) I-CHEMICAL
for O
controlled O
drug O
release. O
Cholesterol B-GENE-Y
esterase I-GENE-Y
(CE) B-GENE-Y
induced O
surface O
erosion O
of O
poly(ethylene B-CHEMICAL
carbonate) I-CHEMICAL
(PEC) B-CHEMICAL
and O
drug O
release O
from O
PEC B-CHEMICAL
under O
mild O
physiological O
environment O
was O
investigated. O
The O
degradation O
process O
was O
monitored O
by O
changes O
of O
mass O
and O
molecular O
weight O
(MW) O
and O
surface O
morphology O
of O
polymer O
films. O
During O
the O
whole O
period O
of O
degradation, O
MW O
of O
PEC B-CHEMICAL
was O
unchanged. O
Water O
uptake O
of O
the O
polymer O
was O
only O
2.8 O
and O
0.2% O
for O
PEC B-CHEMICAL
with O
the O
MW O
of O
200 O

kDa O
(PEC200) B-CHEMICAL
and O
PEC B-CHEMICAL
with O
the O
MW O
of O
41 O
kDa O
(PEC41), B-CHEMICAL
respectively. O
Degradation O
of O
less O
hydrophilic O
PEC41 B-CHEMICAL
with O
higher O
density O
was O
slower O
than O
that O
of O
PEC200. B-CHEMICAL
By O
this O
mechanism, O
CE-responsive B-GENE-Y
drug O
in O
vitro O
release O
from O
PEC B-CHEMICAL
in O
situ O
forming O
depots O
(ISFD) O
was O
conducted O
successfully. O
As O
expected, O
less O
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
(BSA) B-GENE-Y
was O
released O
from O
PEC41 B-CHEMICAL
compared O
with O
that O
of O
PEC200 B-CHEMICAL
in O
the O
same O
time O
period. O
In O
conclusion, O
this O
work O

enabled O
the O
in O
vitro O
drug O
release O
evaluation O
of O
existing O
PEC B-CHEMICAL
devices O
and O
implied O
a O
new O
candidate O
for O
the O
development O
of O
enzyme-responsive O
systems. O
Genome-wide O
integrated O
analyses O
of O
androgen B-GENE-Y
receptor I-GENE-Y
signaling O
in O
prostate O
cancer O
based O
on O
high-throughput O
technology. O
The O
androgen B-GENE-Y
receptor I-GENE-Y
(AR) B-GENE-Y
is O
a O
steroid B-GENE-N
hormone I-GENE-N
receptor I-GENE-N
that O
functions O
as O
a O
ligand-dependent O
transcriptional O
factor, O
which O
plays O
a O
key O
role O
in O
the O
development O
and O
progression O
of O
prostate O
cancer. O
Recent O
advancement O
in O
high O
throughput O
technologies O
including O
microarrays O
and O
deep-sequencing O
provides O
unbiased O
genome-wide O
knowledge O
on O
the O
AR B-GENE-Y
signaling O
including O

datasets O
for O
androgen-regulated B-CHEMICAL
gene O
expression O
and O
genomic O
binding O
sites O
for O
AR. B-GENE-Y
In O
the O
present O
review, O
we O
will O
briefly O
summarize O
the O
main O
features O
of O
the O
AR B-GENE-Y
signaling O
as O
well O
as O
the O
individual O
AR B-GENE-Y
target O
genes O
identified O
by O
the O
integration O
of O
multiple O
datasets O
in O
prostate O
cancer. O
Cap O
analysis O
gene O
expression O
(CAGE) O
is O
also O
featured O
as O
a O
unique O
transcriptome O
method, O
which O
particularly O
determines O
the O
androgen-dependent B-CHEMICAL
transcription O
start O
points O
in O
prostate O
cancer. O
Glucagon B-GENE-Y
receptor I-GENE-Y
antagonism O
improves O
islet O
function O
in O
mice O
with O
insulin B-GENE-N
resistance O
induced O
by O
a O
high-fat O
diet. O

AIMS/HYPOTHESIS: O
Increased O
glucagon B-GENE-Y
secretion O
predicts O
deterioration O
of O
glucose B-CHEMICAL
tolerance, O
and O
high O
glucagon B-GENE-Y
levels O
contribute O
to O
hyperglycaemia O
in O
type O
2 O
diabetes. O
Inhibition O
of O
glucagon O
action O
may O
therefore O
be O
a O
potential O
novel O
target O
to O
reduce O
hyperglycaemia. O
Here, O
we O
investigated O
whether O
chronic O
treatment O
with O
a O
glucagon B-GENE-Y
receptor I-GENE-Y
antagonist O
(GRA) O
improves O
islet O
dysfunction O
in O
female O
mice O
on O
a O
high-fat O
diet O
(HFD). O
MATERIALS O
AND O
METHODS: O
After O
8 O
weeks O
of O

HFD, O
mice O
were O
treated O
with O
a O
small O
molecule O
GRA O
(300 O
mg/kg, O
gavage O
once O
daily) O
for O
up O
to O
30 O
days. O
Insulin B-GENE-N
secretion O
was O
studied O
after O
oral O
and O
intravenous O
administration O
of O
glucose B-CHEMICAL
and O
glucagon B-GENE-Y
secretion O
after O
intravenous O
arginine. B-CHEMICAL
Islet O
morphology O
was O
examined O
and O
insulin B-GENE-N
secretion O
and O
glucose B-CHEMICAL
oxidation O
were O
measured O
in O
isolated O
islets. O
RESULTS: O
Fasting O
plasma O
glucose B-CHEMICAL
levels O
were O
reduced O
by O
GRA O
(6.0 O
+/- O
0.2 O
vs O
7.4 O
+/- O
0.5 O
mmol/l; O
p O

= O
0.017). O
The O
acute O
insulin B-GENE-N
response O
to O
intravenous O
glucose B-CHEMICAL
was O
augmented O
(1,300 O
+/- O
110 O
vs O
790 O
+/- O
64 O
pmol/l; O
p O
< O
0.001). O
The O
early O
insulin B-GENE-N
response O
to O
oral O
glucose B-CHEMICAL
was O
reduced O
in O
mice O
on O
HFD O
+ O
GRA O
(1,890 O
+/- O
160 O
vs O
3,040 O
+/- O
420 O
pmol/l; O
p O
= O
0.012), O
but O
glucose B-CHEMICAL
excursions O
were O
improved. O
Intravenous O
arginine B-CHEMICAL
significantly O
increased O
the O
acute O
glucagon B-GENE-Y
response O
(129 O
+/- O
12 O

vs O
36 O
+/- O
6 O
ng/l O
in O
controls; O
p O
< O
0.01), O
notably O
without O
affecting O
plasma O
glucose. B-CHEMICAL
GRA O
caused O
a O
modest O
increase O
in O
alpha O
cell O
mass, O
while O
beta O
cell O
mass O
was O
similar O
to O
that O
in O
mice O
on O
HFD O
+ O
vehicle. O
Isolated O
islets O
displayed O
improved O
glucose-stimulated B-CHEMICAL
insulin B-GENE-N
secretion O
after O
GRA O
treatment O
(0.061 O
+/- O
0.007 O
vs O
0.030 O
+/- O
0.004 O
pmol O
islet(-1) O
h(-1) O
at O
16.7 O
mmol/l O
glucose; B-CHEMICAL
p O
< O
0.001), O

without O
affecting O
islet O
glucose B-CHEMICAL
oxidation. O
CONCLUSIONS/INTERPRETATION: O
Chronic O
glucagon B-GENE-Y
receptor I-GENE-Y
antagonism O
in O
HFD-fed O
mice O
improves O
islet O
sensitivity O
to O
glucose B-CHEMICAL
and O
increases O
insulin B-GENE-N
secretion, O
suggesting O
improvement O
of O
key O
defects O
underlying O
impaired O
glucose B-CHEMICAL
tolerance O
and O
type O
2 O
diabetes. O
Cis-silencing O
of O
PIP5K1B B-GENE-Y
evidenced O
in O
Friedreich's O
ataxia O
patient O
cells O
results O
in O
cytoskeleton O
anomalies. O
Friedreich's O
ataxia O
(FRDA) O
is O
a O
progressive O
neurodegenerative O
disease O

characterized O
by O
ataxia, O
variously O
associating O
heart O
disease, O
diabetes O
mellitus O
and/or O
glucose B-CHEMICAL
intolerance. O
It O
results O
from O
intronic O
expansion O
of O
GAA B-GENE-N
triplet I-GENE-N
repeats I-GENE-N
at O
the O
FXN B-GENE-Y
locus. O
Homozygous O
expansions O
cause O
silencing O
of O
the O
FXN B-GENE-Y
gene O
and O
subsequent O
decreased O
expression O
of O
the O
encoded O
mitochondrial O
frataxin. B-GENE-Y
Detailed O
analyses O
in O
fibroblasts O
and O
neuronal O
tissues O
from O
FRDA O
patients O
have O
revealed O
profound O
cytoskeleton O
anomalies. O
So O
far, O
however, O
the O
molecular O
mechanism O
underlying O
these O
cytoskeleton O
defects O
remains O
unknown. O
We O
show O
here O
that O
gene O

silencing O
spreads O
in O
cis O
over O
the O
PIP5K1B B-GENE-Y
gene O
in O
cells O
from O
FRDA O
patients O
(circulating O
lymphocytes O
and O
primary O
fibroblasts), O
correlating O
with O
expanded O
GAA O
repeat O
size. O
PIP5K1B B-GENE-Y
encodes O
phosphatidylinositol B-GENE-Y
4-phosphate I-GENE-Y
5-kinase I-GENE-Y
β I-GENE-Y
type I-GENE-Y
I I-GENE-Y
(pip5k1β), B-GENE-Y
an O
enzyme O
functionally O
linked O
to O
actin B-GENE-N
cytoskeleton O
dynamics O
that O
phosphorylates O
phosphatidylinositol B-CHEMICAL
4-phosphate I-CHEMICAL
[PI(4)P] B-CHEMICAL
to O
generate O

phosphatidylinositol-4,5-bisphosphate B-CHEMICAL
[PI(4,5)P2]. B-CHEMICAL
Accordingly, O
loss O
of O
pip5k1β B-GENE-Y
function O
in O
FRDA O
cells O
was O
accompanied O
by O
decreased O
PI(4,5)P2 B-CHEMICAL
levels O
and O
was O
shown O
instrumental O
for O
destabilization O
of O
the O
actin O
network O
and O
delayed O
cell O
spreading. O
Knockdown O
of O
PIP5K1B B-GENE-Y
in O
control O
fibroblasts O
using O
shRNA O
reproduced O
abnormal O
actin B-GENE-N
cytoskeleton O
remodeling, O
whereas O
over-expression O
of O
PIP5K1B, B-GENE-Y
but O

not O
FXN, B-GENE-Y
suppressed O
this O
phenotype O
in O
FRDA O
cells. O
In O
addition O
to O
provide O
new O
insights O
into O
the O
consequences O
of O
the O
FXN B-GENE-Y
gene O
expansion, O
these O
findings O
raise O
the O
question O
whether O
PIP5K1B B-GENE-Y
silencing O
may O
contribute O
to O
the O
variable O
manifestation O
of O
this O
complex O
disease. O
Involvement O
of O
regucalcin B-GENE-Y
in O
lipid O
metabolism O
and O
diabetes. O
Regucalcin B-GENE-Y
(RGN/SMP30) B-GENE-Y
was O
originally O
discovered O
in O
1978 O
as O
a O
unique O
calcium-binding B-CHEMICAL
protein O
that O
does O
not O
contain O
the O
EF-hand B-GENE-N
motif I-GENE-N
of O
calcium-binding B-GENE-N
domain. I-GENE-N
The O
regucalcin B-GENE-Y
gene O
(rgn) B-GENE-Y
is O

localized O
on O
the O
X O
chromosome O
and O
is O
identified O
in O
over O
15 O
species O
consisting O
the O
regucalcin B-GENE-Y
family. O
Regucalcin B-GENE-Y
has O
been O
shown O
to O
play O
a O
multifunctional O
role O
in O
cell O
regulation; O
maintaining O
of O
intracellular O
calcium B-CHEMICAL
homeostasis O
and O
suppressing O
of O
signal O
transduction, O
translational O
protein O
synthesis, O
nuclear O
deoxyribonucleic O
acid O
(DNA) O
and O
ribonucleic O
acid O
(RNA) O
synthesis, O
proliferation, O
and O
apoptosis O
in O
many O
cell O
types. O
Moreover, O
regucalcin B-GENE-Y
may O
play O
a O
pathophysiological O
role O
in O
metabolic O
disorder. O
The O
expression O
of O
regucalcin B-GENE-Y
is O
stimulated O
through O

the O
action O
of O
insulin B-GENE-Y
in O
liver O
cells O
in O
vitro O
and O
in O
vivo O
and O
it O
is O
decreased O
in O
the O
liver O
of O
rats O
with O
type O
I O
diabetes O
induced O
by O
streptozotocin B-CHEMICAL
administration O
in O
vivo. O
Overexpression O
of O
endogenous O
regucalcin B-GENE-Y
stimulates O
glucose B-CHEMICAL
utilization O
and O
lipid O
production O
in O
liver O
cells O
with O
glucose B-CHEMICAL
supplementation O
in O
vitro. O
Regucalcin B-GENE-Y
reveals O
insulin B-GENE-Y
resistance O
in O
liver O
cells. O
Deficiency O
of O
regucalcin B-GENE-Y
induces O
an O
impairment O
of O
glucose B-CHEMICAL
tolerance O
and O
lipid O
accumulation O
in O
the O
liver O
of O
mice O
in O
vivo. O
Overexpression O
of O
endogenous O

regucalcin B-GENE-Y
has O
been O
shown O
to O
decrease O
triglyceride, B-CHEMICAL
total O
cholesterol B-CHEMICAL
and O
glycogen O
contents O
in O
the O
liver O
of O
rats, O
inducing O
hyperlipidemia. O
Leptin B-GENE-Y
and O
adiponectin B-GENE-Y
mRNA O
expressions O
in O
the O
liver O
tissues O
are O
decreased O
in O
regucalcin B-GENE-Y
transgenic O
rats. O
Decrease O
in O
hepatic O
regucalcin B-GENE-Y
is O
associated O
with O
the O
development O
and O
progression O
of O
nonalcoholic O
fatty O
liver O
disease O
and O
fibrosis O
in O
human O
patients. O
Regucalcin O
may O
be O
a O
key O
molecule O
in O
lipid O
metabolic O
disorder O
and O
diabetes. O
AMP-activated B-GENE-N
protein I-GENE-N
kinase-dependent I-GENE-N

and O
-independent O
mechanisms O
underlying O
in O
vitro O
antiglioma O
action O
of O
compound O
C. O
We O
investigated O
the O
effect O
of O
compound O
C, O
a O
well-known O
inhibitor O
of O
the O
intracellular O
energy O
sensor O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK), B-GENE-N
on O
proliferation O
and O
viability O
of O
human O
U251 O
and O
rat O
C6 O
glioma O
cell O
lines. O
Compound O
C O
caused O
G(2)/M O
cell O
cycle O
block, O
accompanied O
by O
apoptotic O
glioma O
cell O
death O
characterized O
by O
caspase B-GENE-N
activation, O
phosphatidylserine B-CHEMICAL
exposure O
and O
DNA O
fragmentation. O
The O
mechanisms O
underlying O
the O
pro-apoptotic O
action O

of O
compound O
C O
involved O
induction O
of O
oxidative O
stress O
and O
downregulation O
of O
antiapoptotic O
molecule O
Bcl-2, B-GENE-N
while O
no O
alteration O
of O
pro-apoptotic O
Bax B-GENE-N
was O
observed. O
Compound O
C O
diminished O
AMPK B-GENE-N
phosphorylation O
and O
enzymatic O
activity, O
resulting O
in O
reduced O
phosphorylation O
of O
its O
target O
acetyl B-GENE-N
CoA I-GENE-N
carboxylase. I-GENE-N
AMPK B-GENE-N
activators O
metformin B-CHEMICAL
and O
AICAR B-CHEMICAL
partly O
prevented O
the O
cell O
cycle O
block, O
oxidative O
stress O
and O
apoptosis O
induced O
by O
compound O
C. O
The O
small O
interfering O
RNA O

(siRNA) O
targeting O
of O
human B-GENE-Y
AMPK I-GENE-Y
mimicked O
compound O
C-induced O
G(2)/M O
cell O
cycle O
arrest, O
but O
failed O
to O
induce O
oxidative O
stress O
and O
apoptosis O
in O
U251 O
glioma O
cells. O
In O
conclusion, O
our O
data O
indicate O
that O
AMPK B-GENE-N
inhibition O
is O
required, O
but O
not O
sufficient O
for O
compound O
C-mediated O
apoptotic O
death O
of O
glioma O
cells. O
Evidence O
that O
the O
granulocyte B-GENE-Y
colony-stimulating I-GENE-Y
factor I-GENE-Y
(G-CSF) I-GENE-Y
receptor I-GENE-Y
plays O
a O
role O
in O
the O
pharmacokinetics O
of O
G-CSF B-GENE-Y
and O
PegG-CSF O
using O

a O
G-CSF-R B-GENE-Y
KO O
model. O
The O
covalent O
attachment O
of O
polyethylene O
glycol O
to O
filgrastim O
results O
in O
a O
new O
molecule O
pegfilgrastim, O
which O
has O
a O
significantly O
longer O
half-life O
than O
filgrastim. O
It O
is O
likely O
that O
the O
clearance O
of O
both O
filgrastim O
and O
pegfilgrastim O
involves O
granulocyte B-GENE-Y
colony I-GENE-Y
simulating I-GENE-Y
factor I-GENE-Y
(G-CSF) I-GENE-Y
receptor I-GENE-Y
binding, O
but O
the O
pharmacokinetics O
of O
these O
drugs O
have O
not O
been O
compared O
in O
mice O
with O
and O
without O
a O
functional O
G-CSF B-GENE-Y

receptor. I-GENE-Y
We O
sought O
to O
clarify O
the O
role O
of O
receptor-mediated O
clearance O
of O
filgrastim O
and O
pegfilgrastim O
using O
wild-type O
(WT) O
mice O
or O
mice O
with O
a O
non-functional O
G-CSF-R B-GENE-Y
(knockout, O
KO). O
We O
administered O
single O
doses O
of O
filgrastim O
or O
pegfilgrastim O
(10 O
or O
100 O
microg O
kg(-1)) O
intravenously O
to O
WT O
and O
KO O
mice. O
Plasma O
levels O
of O
protein O
were O
measured O
by O
enzyme-linked O
immunosorbent O
assay O
(ELISA) O
at O

preset O
time O
points, O
and O
AUC, O
MRT, O
CL, O
V(d), O
and O
T(1/2) O
were O
calculated. O
When O
compared O
with O
WT O
mice, O
the O
G-CSF-R B-GENE-Y
KO O
mice O
had O
significantly O
greater O
AUC, O
longer O
MRT, O
longer O
T(1/2), O
and O
lower O
clearance. O
This O
was O
the O
case O
whether O
animals O
received O
10 O
or O
100 O
microg O
kg(-1) O
and O
whether O
they O
received O
filgrastim O
or O
pegfilgrastim. O
The O
volume O
of O
protein O
distribution O
was O
identical O
among O
WT O
and O
KO O
mice. O
However, O
the O
V(d) O

was O
larger O
after O
pegfilgrastim O
dosing O
than O
after O
filgrastim O
dosing. O
In O
both O
WT O
and O
KO O
mice, O
increasing O
the O
dose O
of O
figrastim O
or O
pegfilgrastim O
resulted O
in O
a O
proportional O
increase O
in O
the O
AUC. O
A O
functional O
G-CSF-R B-GENE-Y
is O
an O
important O
mechanism O
in O
the O
plasma O
clearance O
of O
both O
filgrastim O
and O
pegfilgrastim. O
Duloxetine B-CHEMICAL
hydrochloride: I-CHEMICAL
a O
new O
dual-acting O
medication O
for O
the O
treatment O
of O
major O
depressive O
disorder. O
BACKGROUND: O
Duloxetine B-CHEMICAL

hydrochloride I-CHEMICAL
has O
recently O
been O
approved O
by O
the O
US O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
major O
depressive O
disorder O
(MDD). O
Duloxetine B-CHEMICAL
is O
a O
potent O
inhibitor O
of O
serotonin B-CHEMICAL
and O
norepinephrine B-CHEMICAL
reuptake, O
with O
weak O
effects O
on O
dopamine B-CHEMICAL
reuptake. O
OBJECTIVE: O
This O
article O
reviews O
the O
literature O
on O
duloxetine B-CHEMICAL
with O
regard O
to O
its O
pharmacodynamics, O
pharmacokinetics, O
clinical O
efficacy, O
and O
tolerability. O
METHODS: O
A O
comprehensive O
search O
of O
MEDLINE O
was O
performed O
using O
the O
terms O

duloxetine, B-CHEMICAL
Cymbalta, B-CHEMICAL
and O
major O
depressive O
disorder, O
with O
no O
restriction O
on O
year. O
The O
Eli O
Lilly O
and O
Company O
clinical O
trial O
registry, O
and O
abstracts O
and O
posters O
from O
recent O
American O
Psychiatric O
Association O
meetings O
were O
also O
reviewed. O
RESULTS: O
Duloxetine B-CHEMICAL
exhibits O
linear, O
dose-dependent O
pharmacokinetics O
across O
the O
approved O
oral O
dosage O
range O
of O
40 O
to O
60 O
mg/d. O
No O
dose O
adjustment O
appears O
to O
be O
needed O
based O
on O
age. O
Duloxetine B-CHEMICAL
has O
shown O
efficacy O
in O
reducing O
depressive O
symptoms O
compared O
with O
placebo, O
and O
duloxetine O
recipients O
have O
shown O
significant O
improvements O
in O
global O
functioning O

compared O
with O
placebo O
(both, O
P O
< O
0.05). O
Response O
and O
remission O
rates O
have O
been O
comparable O
to O
or O
greater O
than O
those O
seen O
with O
fluoxetine B-CHEMICAL
or O
paroxetine. B-CHEMICAL
Duloxetine B-CHEMICAL
is O
generally O
well O
tolerated, O
with O
nausea, O
dry O
mouth, O
and O
fatigue O
being O
the O
most O
common O
treatment-emergent O
adverse O
effects. O
Cardiovascular O
adverse O
effects O
do O
not O
appear O
to O
result O
in O
sustained O
blood O
pressure O
elevations, O
QTc-interval O
prolongation, O
or O
other O
electrocardiographic O
changes. O
CONCLUSIONS: O
Based O
on O
the O
available O
evidence, O
duloxetine B-CHEMICAL
is O
a O
well-tolerated O
and O
effective O
treatment O

for O
MDD O
in O
adults. O
Randomized O
head-to-head O
comparisons O
against O
established O
antidepressants O
are O
needed O
to O
determine O
the O
relative O
safety O
and O
efficacy O
of O
duloxetine. B-CHEMICAL
In O
vivo O
effects O
of O
amtolmetin B-CHEMICAL
guacyl I-CHEMICAL
on O
lipid O
peroxidation O
and O
antioxidant O
defence O
systems. O
Comparison O
with O
non-selective O
and O
COX-2 B-GENE-Y
selective O
NSAIDs. O
1. O
The O
in O
vivo O
effects O
of O
the O
non-steroid B-CHEMICAL
anti-inflammatory O
drug O
(NSAID) O
amtolmetin B-CHEMICAL
guacyl, I-CHEMICAL
a O
pro-drug O
of O
the O
NSAID O

tolmetin, B-CHEMICAL
on O
lipid O
peroxidation, O
glutathione B-CHEMICAL
levels O
and O
activity O
of O
antioxidant O
enzymes O
(superoxide B-GENE-N
dismutase, I-GENE-N
catalase, B-GENE-Y
glutathione B-GENE-N
peroxidase I-GENE-N
and O
glutathione B-GENE-N
reductase) I-GENE-N
in O
rat O
gastric O
mucosa, O
colon O
mucosa O
and O
liver, O
were O
compared O
with O
the O
effects O
of O
non-selective O
(indomethacin, B-CHEMICAL
diclofenac) B-CHEMICAL
and O
COX-2 B-GENE-Y
selective O
(celecoxib) B-CHEMICAL
NSAIDs. O
2. O
Indomethacin B-CHEMICAL
treatment O
led O
to O
an O
increase O
in O
lipid O

peroxidation, O
glutathione B-GENE-N
peroxidase I-GENE-N
and O
glucose-6-phosphate B-GENE-Y
dehydrogenase I-GENE-Y
activities O
and O
to O
a O
decrease O
in O
catalase B-GENE-Y
activity O
and O
glutathione B-CHEMICAL
levels O
in O
gastric O
mucosa. O
In O
contrast, O
amtolmetin B-CHEMICAL
guacyl I-CHEMICAL
treatment O
was O
without O
effects O
in O
gastric O
and O
colon O
mucosa, O
or O
liver O
from O
control O
animals. O
Like O
amtolmetin B-CHEMICAL
guacyl, I-CHEMICAL
celecoxib B-CHEMICAL
had O
no O
effect O
on O
the O
lipid O
peroxidation, O
or O
on O
enzyme O
and O
non-enzyme O
antioxidant O
defence O
systems O
in O
gastric O

mucosa. O
3. O
It O
is O
suggested O
that O
the O
lack O
of O
pro-oxidant O
effects O
in O
vivo O
associated O
with O
amtolmetin B-CHEMICAL
guacyl I-CHEMICAL
treatment O
contribute O
improved O
gastric O
tolerability. O
Reversible O
inhibition O
of O
human B-GENE-N
carboxylesterases I-GENE-N
by O
acyl B-CHEMICAL
glucuronides. I-CHEMICAL
Carboxylesterases B-GENE-N
hydrolyze O
esters, B-CHEMICAL
amides, B-CHEMICAL
and O
thioesters B-CHEMICAL
to O
produce O
carboxylic B-CHEMICAL
acids I-CHEMICAL
and O
resulting O
alcohols, B-CHEMICAL
amines, B-CHEMICAL
and O
thiols, B-CHEMICAL
respectively. O
Uridine B-GENE-N
5'-diphosphate- I-GENE-N
glucuronosyltransferases I-GENE-N

are O
colocalized O
with O
carboxylesterases B-GENE-N
and O
have O
the O
potential O
to O
further O
metabolize O
carboxylic B-CHEMICAL
acids I-CHEMICAL
to O
acyl B-CHEMICAL
glucuronides, I-CHEMICAL
but O
it O
is O
currently O
unknown O
if O
acyl B-CHEMICAL
glucuronides, I-CHEMICAL
being O
esters, B-CHEMICAL
also O
interact O
with O
carboxylesterases. B-GENE-N
Objective: O
This O
study O
explores O
the O
ability O
of O
acyl B-CHEMICAL
glucuronides I-CHEMICAL
to O
act O
as O
substrates O
or O
inhibitors O
of O
human B-GENE-Y
carboxylesterases I-GENE-Y
1 I-GENE-Y
(hCES1) B-GENE-Y
and O
2 O
(hCES2). B-GENE-Y
Methods: O
The O
stability O
of O
six O
acyl B-CHEMICAL
glucuronides I-CHEMICAL

in O
the O
presence O
of O
hCES1, B-GENE-Y
hCES2, B-GENE-Y
and O
buffer O
alone O
(100 O
mM O
potassium B-CHEMICAL
phosphate, I-CHEMICAL
pH O
7.4, O
37°C) O
were O
investigated. O
Reversible O
inhibition O
of O
4-nitrophenyl B-CHEMICAL
acetate I-CHEMICAL
hydrolysis O
by O
the O
acyl B-CHEMICAL
glucuronides I-CHEMICAL
was O
also O
studied. O
Diclofenac-β-d-glucuronide B-CHEMICAL
was O
used O
to O
explore O
potential O
time-dependent O
inactivation. O
Results: O
The O
chemical O
stability O
half-life O
values O
for O
CGP B-CHEMICAL
47292-β-d-glucuronide, I-CHEMICAL

diclofenac-β-d-glucuronide, B-CHEMICAL
(R)-naproxen-β-d-glucuronide, B-CHEMICAL
(S)-naproxen-β-d-glucuronide, B-CHEMICAL
ibuprofen-β-d-glucuronide B-CHEMICAL
(racemic), I-CHEMICAL
clopidogrel-β-d-glucuronide, B-CHEMICAL
and O
valproate-β-d-glucuronide B-CHEMICAL
were O
found O
to O
be O
0.252, O
0.537, O
0.996, O
1.77, O

3.67, O
5.02, O
and O
15.2 O
hours, O
respectively. O
Diclofenac-β-d-glucuronide, B-CHEMICAL
clopidogrel-β-d-glucuronide, B-CHEMICAL
ibuprofen-β-d-glucuronide, B-CHEMICAL
(R)-naproxen-β-d-glucuronide, B-CHEMICAL
and O
(S)-naproxen-β-d-glucuronide B-CHEMICAL
selectively O
inhibited O
hCES1, B-GENE-Y
with O
Ki O
values O
of O
4.32 O
± O
0.47, O
24.8 O
± O

4.2, O
355 O
± O
38, O
468 O
± O
21, O
707 O
± O
64 O
µM, O
respectively, O
but O
did O
not O
significantly O
inhibit O
hCES2. B-GENE-Y
Valproate-β-d-glucuronide B-CHEMICAL
and O
CGP B-CHEMICAL
47292-β-d-glucuronide I-CHEMICAL
did O
not O
inhibit O
either O
hCES. B-GENE-N
Time-dependent O
inactivation O
of O
hCES1 B-GENE-Y
by O
diclofenac-β-d-glucuronide B-CHEMICAL
was O
not O
observed. O
Lastly, O
both O
hCES1 B-GENE-Y
and O
hCES2 B-GENE-Y
were O
shown O
not O
to O
catalyze O
the O

hydrolysis O
of O
the O
acyl B-CHEMICAL
glucuronides I-CHEMICAL
studied. O
Conclusion: O
Drug-drug O
interaction O
studies O
may O
be O
warranted O
for O
drugs O
that O
metabolize O
to O
acyl B-CHEMICAL
glucuronides I-CHEMICAL
due O
to O
the O
potential O
inhibition O
of O
hCESs. B-GENE-N
NF-κB-associated B-GENE-N
mechanisms O
underlying O
the O
response O
of O
embryonic O
cells O
to O
Doxorubicin. B-CHEMICAL
The O
involvement O
of O
NF-κB B-GENE-N
in O
the O
regulation O
of O
teratogen-induced O
apoptosis O
has O
not O
been O
established O
yet. O
Therefore, O
we O
tried O
to O
assess O
the O
involvement O
of O
the O
p65 B-GENE-Y
subunit O
of O
NF-κB B-GENE-N
in O
the O

embryonic O
response O
to O
the O
anti-cancer O
drug O
Doxorubicin B-CHEMICAL
(DOX). B-CHEMICAL
Thus, O
exposure O
of O
p65 B-GENE-Y
knockout O
(p65(-/-)) B-GENE-Y
or O
wild O
type O
(WT) O
mouse O
embryonic O
fibroblasts O
(MEFs) O
to O
DOX B-CHEMICAL
resulted O
in O
a O
decrease O
in O
cell O
survival, O
culture O
density O
and O
cell O
proliferation, O
which O
was O
found O
to O
be O
more O
prominent O
in O
p65(-/-) B-GENE-Y
MEFs. O
Those O
phenomena O
were O
accompanied O
by O
a O
DOX-induced B-CHEMICAL
increase O
in O
the O
proportion O
of O
apoptotic O
cells, O
which O
was O
demonstrated O
only O
in O

p65(-/-) B-GENE-Y
cells O
and O
a O
G2/M O
arrest, O
which O
was O
found O
to O
be O
more O
prominent O
in O
WT O
cells. O
Furthermore, O
DOX-treated B-CHEMICAL
WT O
and O
p65(-/-) B-GENE-Y
MEFs O
differed O
in O
their O
expression O
of O
various O
apoptosis-associated O
molecules, O
when O
the O
former O
demonstrated O
a O
decrease O
in O
the O
percentage O
of O
p65-positive B-GENE-Y
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
p53-positive B-GENE-Y
cells, O
while O
a O
decreased O
percentage O
of O
IκBα-positive B-GENE-Y
and O
a O
more O
prominent O
decrease O
in O
the O
percentage O
of O
bcl-2-positive B-GENE-Y
cells O
was O
detected O
among O
the O
latter. O
The O
fact O
that O

the O
response O
of O
the O
cells O
to O
the O
teratogen O
was O
clearly O
p65-dependent B-GENE-Y
implicates O
this O
molecule O
to O
be O
involved O
in O
the O
response O
of O
the O
embryonic O
cells O
to O
DOX. B-CHEMICAL
Protective O
effect O
of O
crocin B-CHEMICAL
on O
diazinon B-CHEMICAL
induced O
cardiotoxicity O
in O
rats O
in O
subchronic O
exposure. O
This O
study O
was O
designed O
to O
evaluate O
the O
effectiveness O
of O
crocin, B-CHEMICAL
main O
component O
of O
Crocus O
sativus O
L. O
(Saffron) O
against O
subchronic O
diazinon B-CHEMICAL
(DZN) B-CHEMICAL
induced O
cardiotoxicity O
in O
rats. O
METHODS: O
Rats O
were O
divided O
into O
7 O

groups; O
control O
(corn O
oil, O
gavage), O
DZN O
(15mg/kg/day, O
gavage,), O
crocin B-CHEMICAL
(12.5, O
25 O
or O
50mg/kg/day, O
i.p) O
plus O
DZN, B-CHEMICAL
vitamin B-CHEMICAL
E I-CHEMICAL
(200IU/kg, O
i.p, O
three O
times O
per O
week) O
plus O
DZN B-CHEMICAL
and O
crocin B-CHEMICAL
(50mg/kg/day, O
i.p) O
groups. O
Treatments O
were O
continued O
for O
4weeks. O
Creatine B-GENE-N
phosphokinase I-GENE-N
MB I-GENE-N
(CK-MB), B-GENE-N

malondealdehyde B-CHEMICAL
(MDA) B-CHEMICAL
and O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
levels O
were O
evaluated O
in O
heart O
tissue O
at O
the O
end O
of O
treatments. O
Levels O
of O
apoptotic O
proteins O
(Bax, B-GENE-Y
Bcl2, B-GENE-Y
caspase B-GENE-Y
3) I-GENE-Y
and O
cytosolic B-GENE-Y
cytochrome I-GENE-Y
c I-GENE-Y
were O
analyzed O
by O
Western O
blotting. O
Transcript O
levels O
of O
Bax B-GENE-Y
and O
Bcl2 B-GENE-Y
were O
also O
determined O
using O
qRT O
PCR. O
RESULTS: O
DZN B-CHEMICAL
induced O
histophatological O
damages O
and O
elevated O
the O
level O
of O
cardiac O
marker O
CK-MB. B-GENE-N
These O
effects O
were O
associated O
with O
increased O

MDA B-CHEMICAL
level, O
lower O
level O
of O
reduced O
GSH B-CHEMICAL
and O
induction O
of O
apoptosis O
through O
elevation O
of O
Bax/Bcl2 B-GENE-Y
ratio O
(both O
protein O
and O
mRNA O
levels), O
cytochrome B-GENE-Y
c I-GENE-Y
release O
to O
the O
cytosol O
and O
activation O
caspase B-GENE-Y
3 I-GENE-Y
in O
cardiac O
tissue. O
Crocin B-CHEMICAL
(25 O
and O
50mg/kg) O
or O
vitamin B-CHEMICAL
E I-CHEMICAL
improved O
histopathological O
damages, O
decreased O
MDA B-CHEMICAL
and O
CK-MB, B-GENE-N
increased O
GSH B-CHEMICAL
content O
and O
attenuated O
the O
increase O
of O
Bax/Bcl2 B-GENE-Y
ratio, O
activation O
of O
caspase B-GENE-Y
3 I-GENE-Y
and O
release O
of O
cytochrome B-GENE-Y
c I-GENE-Y
to O

the O
cytosol O
induced O
by O
DZN. B-CHEMICAL
In O
summary, O
DZN B-CHEMICAL
induced O
mitochondrial-mediated O
apoptosis O
in O
heart O
tissue O
of O
rat O
following O
subchronic O
exposure. O
Crocin, B-CHEMICAL
as O
an O
antioxidant, O
showed O
protective O
effects O
against O
DZN B-CHEMICAL
cardiotoxicity O
by O
reducing O
lipid O
peroxidation O
and O
alleviating O
apoptosis. O
Nutrients O
and O
bioactive O
compounds O
of O
Thai O
indigenous O
fruits. O
This O
study O
determined O
the O
nutritional O
potential O
of O
Thai O
indigenous O
fruits O
in O
terms O
of O
nutrients, O
bioactive O
compounds, O
and O
antioxidant O
activities. O
Three O
indigenous O
fruits O
were O
collected O
at O
two O
conservation O
areas O
in O

Kanchanaburi O
province, O
Thailand. O
The O
results O
showed O
that O
Phyllanthus O
emblica O
L. O
exhibited O
the O
highest O
levels O
of O
vitamin B-CHEMICAL
C I-CHEMICAL
(575±452mg/100g), O
total O
phenolics B-CHEMICAL
(TP) O
(3703±1244mGAE/100g), O
and O
antioxidant O
activities, O
as O
measured O
by O
DPPH, B-CHEMICAL
FRAP O
and O
ORAC O
assays. O
Compared O
to O
the O
other O
two O
fruits, O
Antidesma O
velutinosum O
Blume O
contained O
higher O
levels O
of O
most O
nutrients O
and O
dietary O
fibre O

(15.6±5.9g/100g), O
as O
well O
as O
carotenoids O
(335±98μg/100g) O
and O
phytosterols B-CHEMICAL
(22.1±3.9mg/100g). O
Spondias O
pinnata O
(L.f.) O
Kurz O
was O
high O
in O
total O
phenolics B-CHEMICAL
(3178±887mGAE/100g) O
and O
antioxidant O
activity. O
Moreover, O
high O
correlations O
were O
found O
between O
TP O
and O
antioxidant O
activities O
(r>0.9). O
These O
Thai O
indigenous O
fruits O

are O
potentially O
good O
sources O
of O
nutrients, O
bioactive O
compounds, O
and O
antioxidant O
activities. O
Conservation O
and O
utilisation O
should O
be O
promoted O
for O
food O
security O
and O
consumption O
as O
part O
of O
a O
healthy O
diet. O
A O
genetic O
program O
promotes O
C. O
elegans O
longevity O
at O
cold O
temperatures O
via O
a O
thermosensitive O
TRP B-GENE-N
channel. I-GENE-N
Both O
poikilotherms O
and O
homeotherms O
live O
longer O
at O
lower O
body O
temperatures, O
highlighting O
a O
general O
role O
of O
temperature O
reduction O
in O
lifespan O
extension. O
However, O
the O
underlying O
mechanisms O
remain O
unclear. O
One O
prominent O
model O
is O
that O
cold O
temperatures O
reduce O
the O
rate O
of O
chemical O
reactions, O
thereby O
slowing O
the O
rate O
of O
aging. O
This O
view O
suggests O

that O
cold-dependent O
lifespan O
extension O
is O
simply O
a O
passive O
thermodynamic O
process. O
Here, O
we O
challenge O
this O
view O
in O
C. O
elegans O
by O
showing O
that O
genetic O
programs O
actively O
promote O
longevity O
at O
cold O
temperatures. O
We O
find O
that O
TRPA-1, B-GENE-Y
a O
cold-sensitive O
TRP B-GENE-N
channel, I-GENE-N
detects O
temperature O
drop O
in O
the O
environment O
to O
extend O
lifespan. O
This O
effect O
requires O
cold-induced, O
TRPA-1-mediated B-GENE-Y
calcium B-CHEMICAL
influx O
and O
a O
calcium-sensitive B-CHEMICAL
PKC B-GENE-N
that O
signals O
to O
the O
transcription O
factor O
DAF-16/FOXO. B-GENE-Y
Human B-GENE-Y
TRPA1 I-GENE-Y
can O
functionally O
substitute O
for O
worm B-GENE-N

TRPA-1 I-GENE-N
in O
promoting O
longevity. O
Our O
results O
reveal O
a O
previously O
unrecognized O
function O
for O
TRP B-GENE-N
channels, I-GENE-N
link O
calcium B-CHEMICAL
signaling O
to O
longevity, O
and, O
importantly, O
demonstrate O
that O
genetic O
programs O
contribute O
to O
lifespan O
extension O
at O
cold O
temperatures. O
Effect O
of O
fenoterol-induced B-CHEMICAL
constitutive O
beta(2)-adrenoceptor B-GENE-Y
activity O
on O
contractile O
receptor O
function O
in O
airway O
smooth O
muscle. O
In O
the O
present O
study, O
we O
investigated O
the O
effect O
of O
fenoterol-induced B-CHEMICAL
constitutive O
beta(2)-adrenoceptor B-GENE-Y
activity O
on O
muscarinic B-GENE-N
receptor I-GENE-N
agonist- O
and O

histamine-induced B-CHEMICAL
bovine O
tracheal O
smooth O
muscle O
contractions. O
Bovine O
tracheal O
smooth O
muscle O
strips O
were O
incubated O
with O
10 O
microM O
fenoterol B-CHEMICAL
or O
vehicle O
for O
various O
periods O
of O
time O
(5, O
30 O
min, O
18 O
h) O
at O
37 O
degrees O
C. O
After O
extensive O
washout O
(3 O
h, O
37 O
degrees O
C), O
isometric O
contractions O
were O
measured O
to O
the O
full O
muscarinic B-GENE-N
receptor I-GENE-N
agonist O
methacholine, B-CHEMICAL
the O
partial O
muscarinic B-GENE-N
receptor I-GENE-N
agonist O

4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium B-CHEMICAL
(McN-A-343) B-CHEMICAL
and O
histamine. B-CHEMICAL
Fenoterol B-CHEMICAL
treatment O
significantly O
reduced O
the O
sensitivity O
(pEC(50)) O
to O
methacholine B-CHEMICAL
in O
a O
time-dependent O
manner, O
without O
affecting O
maximal O
contraction O
(E(max)). O
Fenoterol B-CHEMICAL
treatment O
similarly O
reduced O
the O
pEC(50) O
of O
McN-A-343 B-CHEMICAL
and O
histamine; B-CHEMICAL
however, O
E(max) O
values O
were O
also O
reduced, O
to O
approximately O
70% O
of O

control O
after O
18-h O
treatment. O
The O
inverse O
agonist O
timolol, B-CHEMICAL
having O
no O
effect O
on O
control O
preparations, O
consistently O
restored O
the O
reduced O
pEC(50) O
and O
E(max) O
values O
of O
the O
contractile O
agonists. O
Remarkably, O
in O
the O
presence O
of O
timolol O
the O
pEC(50) O
values O
of O
McN-A-343 B-CHEMICAL
and O
histamine B-CHEMICAL
in O
fenoterol-treated B-CHEMICAL
airways O
were O
significantly O
enhanced O
compared O
to O
controls. O
In O
conclusion, O
fenoterol-induced B-CHEMICAL
constitutive O
beta(2)-adrenoceptor B-GENE-Y
activity O
reduces O
muscarinic B-GENE-N
receptor I-GENE-N

agonist- O
and O
histamine-induced B-CHEMICAL
contractions O
of O
bovine O
tracheal O
smooth O
muscle, O
which O
can O
be O
reversed O
by O
the O
inverse O
agonist O
timolol. B-CHEMICAL
Moreover, O
after O
beta(2)-adrenoceptor B-GENE-Y
agonist O
treatment, O
inverse O
agonism O
by O
beta-adrenoceptor B-GENE-N
antagonists O
may O
cause O
enhanced O
airway O
reactivity O
to O
contractile O
mediators. O
Beta-glucogallin B-CHEMICAL
reduces O
the O
expression O
of O
lipopolysaccharide-induced O
inflammatory O
markers O
by O
inhibition O
of O
aldose B-GENE-Y
reductase I-GENE-Y
in O
murine O
macrophages O
and O
ocular O
tissues. O

Aldose B-GENE-Y
reductase I-GENE-Y
(AR) B-GENE-Y
catalyzes O
the O
reduction O
of O
toxic O
lipid O
aldehydes B-CHEMICAL
to O
their O
alcohol B-CHEMICAL
products O
and O
mediates O
inflammatory O
signals O
triggered O
by O
lipopolysaccharide O
(LPS). O
Beta-glucogallin B-CHEMICAL
(BGG), B-CHEMICAL
a O
recently O
described O
AR B-GENE-Y
inhibitor, O
was O
purified O
from O
extracts O
of O
the O
Indian O
gooseberry O
(Emblica O
officinalis). O
In O
this O
study, O
we O
found O
that O
BGG B-CHEMICAL
showed O
low O
cytotoxicity O
in O
Raw264.7 O
murine O
macrophages O
and O
effectively O
inhibited O
AR B-GENE-Y
activity O
as O
measured O
by O
a O

decrease O
in O
sorbitol B-CHEMICAL
accumulation. O
In O
addition, O
BGG-mediated B-CHEMICAL
inhibition O
of O
AR B-GENE-Y
prevented O
LPS-induced O
activation O
of O
JNK B-GENE-N
and O
p38 B-GENE-N
and O
lowered O
ROS O
levels, O
which O
could O
inhibit O
LPS-induced O
apoptosis. O
Uveitis O
is O
a O
disease O
of O
the O
eye O
associated O
with O
chronic O
inflammation. O
In O
this O
study, O
we O
also O
demonstrated O
that O
treatment O
with O
BGG B-CHEMICAL
decreased O
the O
number O
of O
inflammatory O
cells O
that O
infiltrate O
the O
ocular O
media O
of O
mice O
with O
experimental O
uveitis. O
Accordingly, O
these O
results O
suggest O
BGG B-CHEMICAL
is O
a O
potential O
therapy O
for O
inflammatory O
diseases. O
Differential O
phosphoproteome O
of O

the O
striatum O
from O
pleiotrophin B-GENE-Y
knockout O
and O
midkine B-GENE-Y
knockout O
mice O
treated O
with O
amphetamine: B-CHEMICAL
Correlations O
with O
amphetamine-induced B-CHEMICAL
neurotoxicity. O
The O
neurotrophic O
factors O
pleiotrophin B-GENE-Y
(PTN) B-GENE-Y
and O
midkine B-GENE-Y
(MK) B-GENE-Y
have O
been O
shown O
to O
modulate O
amphetamine-induced B-CHEMICAL
neurotoxicity. O
Accordingly, O
PTN-/- B-GENE-Y
and O
MK-/- B-GENE-Y
mice O
show O
an O
increased O
vulnerability O
to O
amphetamine-induced B-CHEMICAL
neurotoxic O
effects. O
In O
an O
effort O
to O
uncover O
new O
pharmacological O
targets O
to O
prevent O

amphetamine B-CHEMICAL
neurotoxic O
effects, O
we O
have O
now O
used O
a O
proteomic O
approach O
to O
study O
protein O
phosphorylation, O
in O
which O
we O
combined O
phosphoprotein O
enrichment, O
by O
immobilized O
metal O
affinity O
chromatography O
(IMAC), O
with O
two-dimensional O
gel O
electrophoresis O
and O
mass O
spectrometry, O
in O
order O
to O
identify O
the O
phosphoproteins O
regulated O
in O
the O
striatum O
of O
PTN-/-, B-GENE-Y
MK-/- B-GENE-Y
and O
wild O
type O
(WT) O
mice O
treated O
with O
amphetamine. B-CHEMICAL
We O
identified O
13 O
differentially O
expressed O

phosphoproteins O
that O
are O
judged O
to O
be O
relevant O
in O
the O
neuroprotective O
roles O
of O
PTN B-GENE-Y
and O
MK B-GENE-Y
against O
amphetamine-induced B-CHEMICAL
neurotoxicity. O
It O
is O
very O
interesting O
to O
note O
that O
4 O
of O
these O
phosphoproteins, O
annexin B-GENE-Y
A7 I-GENE-Y
(ANXA7), B-GENE-Y
COP9 B-GENE-Y
signalosome I-GENE-Y
subunit I-GENE-Y
5 I-GENE-Y
(COPS5), B-GENE-Y
aldehyde B-GENE-Y
dehydrogenase I-GENE-Y
family I-GENE-Y
1 I-GENE-Y
member I-GENE-Y
A1 I-GENE-Y
(ALDH1A1) B-GENE-Y
and O
creatine B-GENE-Y
kinase I-GENE-Y
U-type I-GENE-Y
(CKMT1), B-GENE-Y
are O
known O
to O
be O
involved O
in O
Parkinson's O

disease, O
a O
result O
of O
significant O
importance O
since O
PTN B-GENE-Y
and O
MK B-GENE-Y
have O
been O
also O
demonstrated O
to O
limit O
Parkinson's O
disease O
(PD) O
progress O
and O
have O
been O
suggested O
to O
be O
among O
the O
important O
genetic O
factors O
possibly O
preventing O
the O
development O
of O
PD O
in O
methamphetamine B-CHEMICAL
abusers. O
The O
data O
identify O
phosphoproteins O
differentially O
regulated O
by O
amphetamine B-CHEMICAL
treatment O
and/or O
the O
presence O
of O
endogenous O
PTN/MK B-GENE-Y
which O
may O
be O
relevant O
mediators O
of O
PTN/MK B-GENE-Y
neuroprotective O
effects O
against O
amphetamine-induced B-CHEMICAL
neurotoxicity. O
The O
data O
support O
further O
studies O
to O
validate O
the O

phosphoproteins O
here O
identified O
as O
possible O
new O
pharmacological O
targets O
to O
prevent O
amphetamine B-CHEMICAL
neurotoxic O
effects. O
Universal O
rule O
on O
chirality-dependent O
bandgaps O
in O
graphene B-CHEMICAL
antidot O
lattices. O
Graphene B-CHEMICAL
with O
periodically O
patterned O
antidots O
has O
attracted O
intense O
research O
attention O
as O
it O
represents O
a O
facile O
route O
to O
open O
a O
bandgap O
for O
graphene B-CHEMICAL
electronics. O
However, O
not O
all O
graphene B-CHEMICAL
antidot O
lattices O
(GALs) O
can O
open O
a O
bandgap O
and O
a O
guiding O
rule O
is O
missing. O
Here, O
through O
systematic O
first-principles O
calculations, O
it O
is O
found O
that O

bandgaps O
in O
triangular O
GALs O
are O
surprisingly O
well O
defined O
by O
a O
chirality O
vector O
R O
= O
n O
a1 O
+ O
ma2 O
connecting O
two O
neighboring O
antidots, O
where O
a1 O
and O
a2 O
are O
the O
basis O
vectors O
of O
graphene. B-CHEMICAL
The O
bandgap O
opens O
in O
the O
GALs O
with O
(n-m)mod3 O
= O
0 O
but O
remains O
closed O
in O
those O
with O
(n-m)mod3 O
= O
±1, O
reminiscent O
of O
the O
gap-chirality O
rule O
in O
carbon B-CHEMICAL
nanotubes. O
Remarkably, O
the O
gap O
value O
in O
GALs O
allows O
ample O
modulation O
by O
adjusting O
the O
length O
of O
chirality O

vectors, O
shape O
and O
size O
of O
the O
antidots. O
The O
gap-chirality O
relation O
in O
GALs O
stems O
from O
the O
chirality-dependent O
atomic O
structures O
of O
GALs O
as O
revealed O
by O
a O
super-atom O
model O
as O
well O
as O
Clar O
sextet O
analyses. O
This O
chirality-dependent O
bandgap O
is O
further O
shown O
to O
be O
a O
generic O
behavior O
in O
any O
parallelogram O
GAL O
and O
thus O
serves O
as O
an O
essential O
stepping O
stone O
for O
experimenters O
to O
realize O
graphene B-CHEMICAL
devices O
by O
antidot O
engineering. O
Exogenous O
C2-ceramide B-CHEMICAL
activates O
c-fos B-GENE-N
serum I-GENE-N
response I-GENE-N
element I-GENE-N
via O
Rac-dependent B-GENE-N
signalling O
pathway. O

Ceramide B-CHEMICAL
is O
an O
important O
regulatory O
molecule O
implicated O
in O
a O
variety O
of O
biological O
processes O
in O
response O
to O
stress O
and O
cytokines. B-GENE-N
To O
understand O
the O
signal O
transduction O
pathway O
of O
ceramide B-CHEMICAL
to O
the O
nucleus, O
in O
the O
present O
study, O
we O
examined O
whether O
C2-ceramide, B-CHEMICAL
a O
cell O
permeable O
ceramide, B-CHEMICAL
activates O
c-fos B-GENE-N
serum I-GENE-N
response I-GENE-N
element I-GENE-N
(SRE). B-GENE-N
Treatment O
of O
Rat-2 O
fibroblast O
cells O
with O
C2-ceramide B-CHEMICAL
caused O
the O
stimulation O
of O
c-fos B-GENE-N
SRE-dependent I-GENE-N
reporter O
gene O
activity O
in O
a O
dose- O
and O
time-dependent O
manner O
by O
transient O

transfection O
analysis. O
Next, O
we O
examined O
the O
role O
of O
Rho B-GENE-N
family O
GTPases B-GENE-N
in O
the O
ceramide-induced B-CHEMICAL
signalling O
to O
SRE B-GENE-N
activation. O
By O
reporter O
gene O
analysis O
following O
transient O
transfections O
with O
various O
plasmids O
expressing O
a O
dominant O
negative O
mutant O
form O
of O
Cdc42, B-GENE-Y
Rac1 B-GENE-Y
or O
RhoA, B-GENE-Y
C2-ceramide-induced B-CHEMICAL
SRE B-GENE-N
activation O
was O
shown O
to O
be O
selectively O
repressed O
by O
pEXV-RacN17 O
encoding O
a O
dominant O
negative O
mutant O
of O
Rac1, B-GENE-Y
suggesting O
that O
Rac B-GENE-N
activity O
is O
essential O
for O
the O
signalling O
cascade O
of O
ceramide B-CHEMICAL
to O

the O
nucleus. O
In O
a O
further O
study O
to O
analyse O
the O
downstream O
mediator O
of O
Rac B-GENE-N
in O
the O
ceramide-signalling B-CHEMICAL
pathway, O
we O
observed O
that O
either O
pretreatment O
with O
mepacrine, B-CHEMICAL
a O
potent O
and O
specific O
inhibitor O
of O
phospholipase O
A2, O
or O
co-transfection O
with O
antisense O
cytosolic B-GENE-Y
phospholipase I-GENE-Y
A2 I-GENE-Y
(cPLA2) B-GENE-Y
oligonucleotide O
repressed O
the O
C2-ceramide-induced B-CHEMICAL
SRE B-GENE-N
activation O
selectively, O
implying O
a O
critical O
role O
of O
cPLA2 B-GENE-Y
in O
C2-ceramide-induced B-CHEMICAL

signalling O
to O
nucleus. O
Consistent O
with O
these O
results, O
the O
translocation O
of O
cPLA2 B-GENE-Y
protein O
as O
well O
as O
the O
release O
of O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
a O
principal O
product O
of O
phospholipase B-GENE-Y
A2, I-GENE-Y
was O
rapidly O
induced O
by O
the O
addition O
of O
C2-ceramide B-CHEMICAL
in O
a O
Rac-dependent B-GENE-N
manner. O
Together, O
our O
findings O
suggest O
the O
critical O
role O
of O
'Rac B-GENE-N
and O
subsequent O
activation O
of O
phospholipase B-GENE-Y
A2' I-GENE-Y
in O
ceramide-signalling B-CHEMICAL
to O
nucleus. O
Effect O
of O
ramelteon B-CHEMICAL
(TAK-375), B-CHEMICAL
a O
selective O
MT1/MT2 B-GENE-N
receptor I-GENE-N

agonist, O
on O
motor O
performance O
in O
mice. O
Effect O
of O
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide B-CHEMICAL
(ramelteon, B-CHEMICAL
TAK-375), B-CHEMICAL
a O
selective O
MT1/MT2 B-GENE-N
receptor I-GENE-N
agonist, O
on O
motor O
coordination O
was O
studied O
using O
rota-rod O
performance O
in O
mice. O
Ramelteon B-CHEMICAL
did O
not O
impair O
rota-rod O
performance O
at O
doses O
of O
3, O
10 O
and O
30 O

mg/kg, O
p.o. O
Melatonin B-CHEMICAL
and O
N-acetyl-5-hydroxytryptamine B-CHEMICAL
(N-acetyl-5-HT), B-CHEMICAL
a O
ligand O
of O
MT3 B-GENE-N
biding O
site, O
also O
had O
no O
impairment O
on O
the O
performance, O
per O
se. O
However, O
in O
combination O
with O
a O
low O
dose O
of O
diazepam B-CHEMICAL
(3mg/kg, O
p.o.), O
treatment O
with O
melatonin B-CHEMICAL
and O
N-acetyl-5-HT B-CHEMICAL
exacerbated O
the O
impairment O
by O
diazepam. B-CHEMICAL
Ramelteon B-CHEMICAL
had O

no O
significant O
effect O
on O
the O
diazepam-induced B-CHEMICAL
impairment O
of O
motor O
coordination. O
The O
role O
of O
platelet/lymphocyte O
serotonin B-GENE-Y
transporter I-GENE-Y
in O
depression O
and O
beyond. O
A O
large O
amount O
of O
the O
data O
gathered O
in O
the O
last O
50 O
years O
support O
the O
hypothesis O
that O
alterations O
of O
the O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
neurotransmission O
play O
a O
crucial O
role O
in O
the O
pathophysiology O
of O
not O
only O
major O
depression O
(MD), O
but O
also O
of O
different O
neuropsychiatric O
disorders. O
Research O
in O
this O
field O
has O
been O
substantially O
promoted O
by O
the O
evidence O
that O
the O
reuptake O
protein O
(SERT), B-GENE-Y

present O
in O
presynaptic O
neurons, O
is O
a O
key O
element O
in O
terminating O
the O
activity O
of O
the O
neurotransmitter O
in O
the O
synaptic O
cleft. O
For O
this O
reason, O
it O
was O
specifically O
targeted O
for O
the O
development O
of O
second-generation O
antidepressants, O
in O
particular O
of O
selective O
5-HT B-CHEMICAL
reuptake O
inhibitors O
(SSRIs), O
with O
the O
aim O
of O
increasing O
the O
intrasynaptic O
5-HT B-CHEMICAL
concentrations. O
Moreover, O
since O
a O
lot O
of O
studies O
showed O
that O
circulating O
platelets O
and, O
more O
recently, O
lymphocytes O
possess O
functional O
SERT B-GENE-Y
proteins, O
they O
have O
been O
widely O
used O
as O
peripheral O
mirrors O
of O
the O
same O
structures O

located O
in O
the O
central O
nervous O
system. O
The O
presence O
of O
functional O
SERT B-GENE-Y
in O
blood O
cells O
suggests O
strict O
relationships O
between O
the O
nervous O
and O
the O
immune O
system O
that O
need O
to O
be O
better O
clarified O
in O
MD, O
as O
well O
as O
the O
possibility O
of O
reciprocal O
modulation O
of O
the O
two O
systems O
by O
different O
drugs. O
This O
paper O
aims O
to O
review O
briefly O
the O
literature O
on O
the O
5-HT B-CHEMICAL
hypothesis O
of O
depression O
with O
a O
major O
focus O
on O
the O
possible O
role O
of O
SERT B-GENE-Y
in O
this O
disorder, O
while O
highlighting O
how O
recent O
data O
are O
more O
oriented O
on O
dimensional O
rather O
than O
nosological O
involvement O
of O
this O
structure O
in O
different O
conditions O
spanning O
from O
normality O
to O
pathology. O
Synthesis O
and O
cancer O
stem O

cell-based O
activity O
of O
substituted O
5-morpholino-7H-thieno[3,2-b]pyran-7-ones B-CHEMICAL
designed O
as O
next O
generation O
PI3K B-GENE-N
inhibitors. O
Dysregulation O
of O
the O
phosphatidylinositol-3-kinase B-GENE-N
(PI3K) B-GENE-N
pathway O
in O
a O
wide O
range O
of O
tumors O
has O
made O
PI3K B-GENE-N
a O
consensus O
target O
to O
inhibit O
as O
illustrated O
by O
more O
than O
15 O
inhibitors O
now O
in O
clinical O
trials. O
Our O
previous O
work, O
built O
on O
the O
early O
pioneering O
multikinase O
inhibitor O
LY294002, B-CHEMICAL
resulted O
in O
the O

only O
PI3K B-GENE-N
vascular-targeted O
PI3K B-GENE-N
inhibitor O
prodrug, O
SF1126, B-CHEMICAL
which O
has O
now O
completed O
Phase O
I O
clinical O
trials. O
This O
inhibitor O
has O
properties O
that O
impart O
more O
in O
vivo O
activity O
than O
should O
be O
warranted O
by O
its O
enzymatic O
potency, O
which O
in O
general O
is O
much O
lower O
than O
other O
clinical O
stage O
PI3K B-GENE-N
inhibitors. O
We O
embarked O
on O
the O
exploration O
of O
scaffolds O
that O
retained O
such O
properties O
while O
simultaneously O
exhibiting O
an O
increased O
potency O
toward O
PI3K. B-GENE-N
This O
work O
resulted O
in O
the O
discovery O
of O
the O

5-morpholino-7H-thieno[3,2-b]pyran-7-one B-CHEMICAL
system O
as O
the O
foundation O
of O
a O
new O
compound O
class O
of O
potential O
PI3K B-GENE-N
inhibitors O
having O
improved O
potency O
toward O
PI3K. B-GENE-N
The O
synthesis O
and O
cancer O
stem O
cell-based O
activity O
of O
these O
compounds O
are O
reported O
herein. O
Heterobivalent O
dual-target O
probe O
for O
targeting O
GRP B-GENE-Y
and O
Y1 B-GENE-Y
receptors I-GENE-Y
on O
tumor O
cells. O
Receptor O
targeting O
ligands O
for O
imaging O
and/or O
therapy O
of O
cancer O
are O
limited O
by O
heterogeneity O
of O
receptor O
expression O
by O
tumor O
cells, O
both O
inter-patient O
and O

intra-patient. O
It O
is O
often O
more O
important O
for O
imaging O
agents O
to O
identify O
local O
and O
distant O
spread O
of O
disease O
than O
it O
is O
to O
identify O
a O
specific O
receptor O
presence. O
Two O
natural O
hormone O
peptide O
receptors, O
GRPR B-GENE-Y
and O
Y1, B-GENE-Y
are O
specifically O
interesting O
because O
expression O
of O
GRPR, B-GENE-Y
Y1 B-GENE-Y
or O
both O
is O
up-regulated O
in O
most O
breast O
cancers. O
We O
describe O
here O
the O
design O
and O
development O
of O
a O
new O
heterobivalent O
peptide O
ligand, O
truncated B-GENE-N
bombesin I-GENE-N
(t-BBN)/BVD15-DO3A, B-GENE-N
for O
dual-targeting O
of O
GRPR B-GENE-Y
and O
Y1, B-GENE-Y
and O
validation O

of O
its O
dual O
binding O
capability. O
Such O
a O
probe O
should O
be O
useful O
in O
imaging O
cells, O
tissues O
and O
tumors O
that O
are O
GRPR B-GENE-Y
and/or O
Y1 B-GENE-Y
positive O
and O
should O
target O
radioisotopes, O
for O
example, O
(68)Ga O
and/or O
(177)Lu, O
to O
more O
tumors O
cells O
than O
single O
GRPR B-GENE-Y
or O
Y1 B-GENE-Y
targeted O
probes. O
A O
GRP B-GENE-Y
targeting O
ligand, O
J-G-Abz4-QWAVGHLM-NH(2) O
(J-G-Abz4-t-BBN), O
and O
an O
Y1 B-GENE-Y
targeting O
ligand, O

INP-K[ε-J-(α-DO3A-ε-DGa)-K]-YRLRY-NH(2)([ε-J-(α-DO3A-ε-DGa)-K]-BVD-15), O
were O
synthesized O
and O
coupled O
to O
produce O
the O
heterobivalent O
ligand, O
t-BBN/BVD15-DO3A. B-GENE-N
Competitive O
displacement O
binding O
assays O
using O
t-BBN/BVD15-DO3A B-GENE-N
against O

(125)I-Tyr(4)-BBN B-GENE-N
yielded O
an O
IC(50) O
value O
of O
18 O
± O
0.7 O
nM O
for O
GRPR B-GENE-Y
in O
T-47D O
cells, O
a O
human O
breast O
cancer O
cell O
line. O
A O
similar O
assay O
using O
t-BBN/BVD15-DO3A B-GENE-N
against O
porcine B-GENE-Y
(125)I-NPY I-GENE-Y
showed O
IC(50) O
values O
of O
80 O
± O
11 O
nM O
for O
Y1 B-GENE-Y
receptor I-GENE-Y
in O
MCF7 O
cells, O
another O
human O
breast O
cancer O
cell O
line. O
In O
conclusion, O
it O
is O
possible O
to O
construct O
a O
single O
DO3A O
chelate O

containing O
probe O
that O
can O
target O
both O
GRPR B-GENE-Y
and O
Y1 B-GENE-Y
on O
human O
tumor O
cells. O
Induction O
of O
the O
metabolic O
regulator O
Txnip B-GENE-Y
in O
fasting-induced O
and O
natural O
torpor. O
Torpor O
is O
a O
physiological O
state O
characterised O
by O
controlled O
lowering O
of O
metabolic O
rate O
and O
core O
body O
temperature, O
allowing O
substantial O
energy O
savings O
during O
periods O
of O
reduced O
food O
availability O
or O
harsh O
environmental O
conditions. O
The O
hypothalamus O
coordinates O
energy O
homeostasis O
and O
thermoregulation, O
and O
plays O
a O
key O
role O
in O
directing O
torpor. O
We O
recently O
showed O
that O
mice O
lacking O
the O
orphan B-GENE-N
G I-GENE-N
protein I-GENE-N
coupled I-GENE-N
receptor I-GENE-N
Gpr50 B-GENE-Y
readily O
enter O
torpor O
in O
response O
to O

fasting, O
and O
have O
now O
used O
these O
mice O
to O
conduct O
a O
microarray O
analysis O
of O
hypothalamic O
gene O
expression O
changes O
related O
to O
the O
torpor O
state. O
This O
revealed O
a O
strong O
induction O
of O
thioredoxin B-GENE-Y
interacting I-GENE-Y
protein I-GENE-Y
(Txnip) B-GENE-Y
in O
the O
hypothalamus O
of O
torpid O
mice, O
which O
was O
confirmed O
by O
quantitative O
RT-PCR O
and O
Western O
blot O
analyses. O
In O
situ O
hybridisation O
identified O
the O
ependyma O
lining O
the O
third O
ventricle O
as O
the O
principal O
site O
of O
torpor-related O
expression O
of O
Txnip. B-GENE-Y
To O
characterise O
further O
the O
relationship O
between O
Txnip B-GENE-Y

and O
torpor, O
we O
profiled O
Txnip B-GENE-Y
expression O
in O
mice O
during O
prolonged O
fasting, O
cold O
exposure, O
and O
2-deoxyglucose-induced B-CHEMICAL
hypometabolism, O
as O
well O
as O
in O
naturally O
occurring O
torpor O
bouts O
in O
the O
Siberian O
hamster. O
Strikingly, O
pronounced O
upregulation O
of O
Txnip B-GENE-Y
expression O
was O
only O
observed O
in O
WT O
mice O
when O
driven O
into O
torpor, O
and O
during O
torpor O
in O
the O
Siberian O
hamster. O
Increase O
of O
Txnip B-GENE-Y
was O
not O
limited O
to O
the O
hypothalamus, O
with O
exaggerated O
expression O
in O
white O

adipose O
tissue, O
brown O
adipose O
tissue, O
and O
liver O
also O
demonstrated O
in O
torpid O
mice. O
Given O
the O
recent O
identification O
of O
Txnip B-GENE-Y
as O
a O
molecular O
nutrient O
sensor O
important O
in O
the O
regulation O
of O
energy O
metabolism, O
our O
data O
suggest O
that O
elevated O
Txnip B-GENE-Y
expression O
is O
critical O
to O
regulating O
energy O
expenditure O
and O
fuel O
utilisation O
during O
the O
extreme O
hypometabolic O
state O
of O
torpor. O
Design, O
synthesis O
and O
antiproliferative O
properties O
of O
some O
new O
5-substituted-2-iminobenzimidazole B-CHEMICAL
derivatives. O
Some O
new O

1,3,5-substituted-2,3-dihydro-2-imino-benzimidazoles B-CHEMICAL
were O
synthesized O
under O
solid-liquid O
phase O
transfer O
catalysis O
conditions O
using O
5-substituted-2-aminobenzimidazoles B-CHEMICAL
as O
precursors O
in O
order O
to O
assess O
their O
cytotoxicity O
respectively O
proliferative O
activity. O
The O
structures O
of O
the O
compounds O
were O
confirmed O
by O
IR, O
(1)H B-CHEMICAL
NMR, O
(13)C B-CHEMICAL
NMR O
and O
elemental O
analysis. O
Compounds O
9-10, O
12 O
and O
16-17 O
were O
evaluated O
for O
their O
cytotoxical O
effect O
on O
four O
cancer O

cell O
lines: O
HT-29, O
breast O
cancer O
cells O
MDA-MB-231, O
HeLa, O
HepG2 O
and O
as O
well O
as O
human O
diploid O
cell O
line O
Lep-3. O
Significant O
cytotoxicity O
of O
hydrazone B-CHEMICAL
16 O
against O
MDA-MB-231 O
was O
established O
by O
biologically O
study, O
the O
IC50 O
was O
6.2 O
nM O
while O
the O
EC50 O
value O
to O
Lep O
3 O
is O
0.21 O
nM. O
Relative O
high O
antiproliferative O
effects O
of O
the O
acetate B-CHEMICAL
12 O
and O
compound O
16 O
against O
HT-29 O
were O
ascertained O
and O
the O
calculated O

IC50 O
values O
were O
IC50 O
- O
0.85 O
nM O
and O
IC50 O
- O
2.83 O
nM O
respectively. O
Cytotoxic O
activity O
against O
HeLa O
and O
HepG2 O
cells O
was O
demonstrated O
by O
hydrazone B-CHEMICAL
17, O
IC50 O
was O
7.2 O
nM O
and O
117 O
nM O
respectively. O
All O
tested O
compounds O
revealed O
proliferative O
activities O
to O
human O
diploid O
cell O
line O
Lep-3. O
The O
EC50 O
values O
were O
in O
the O
range O
from O
0.05 O
to O
16.91 O
nM. O
The O
obtained O
results O
prove O
the O
selective O
cytotoxicity O
of O
the O
tested O
compounds O
and O
are O
promising O
for O
further O
evaluation O

of O
the O
investigated O
compounds O
in O
vivo O
experiments O
using O
experimentally O
induced O
tumors O
in O
laboratory O
animals. O
Immunomodulatory O
properties O
of O
multi-walled O
carbon B-CHEMICAL
nanotubes O
in O
peripheral O
blood O
mononuclear O
cells O
from O
healthy O
subjects O
and O
allergic O
patients. O
In O
the O
present O
study, O
we O
investigated O
the O
immunomodulatory O
activity O
of O
multi-walled O
carbon B-CHEMICAL
nanotubes O
(MWCNTs) O
in O
peripheral O
blood O
mononuclear O
cells O
(PBMCs) O
from O
healthy O
donors O
and O
mite-allergic O
subjects. O
Freshly O
prepared O
PBMCs, O
stimulated O
or O
not O
with O
Toll-like B-GENE-N
receptor I-GENE-N

(TLR)1-9 I-GENE-N
agonists, O
a O
T B-GENE-N
cell I-GENE-N
mitogen I-GENE-N
(phytohemagglutinin B-GENE-N
A) I-GENE-N
or O
mite O
allergen O
extract O
were O
cultured O
in O
the O
presence O
or O
absence O
of O
MWCNTs. O
Secretion O
of O
TNF-α, B-GENE-Y
IL-2, B-GENE-Y
IL-5, B-GENE-Y
IL-6, B-GENE-Y
IL-12/23p40 B-GENE-N
or O
IFN-γ B-GENE-Y
was O
quantified O
in O
the O
culture O
supernatants O
by O
ELISA. O
Basal O
secretion O
of O
all O
the O
cytokines B-GENE-N
was O
not O
altered O
by O
MWCNTs O
in O
PBMCs O
from O
both O
healthy O
donors O
and O

allergic O
subjects. O
In O
PBMCs O
from O
healthy O
donors, O
TNF-α, B-GENE-Y
IL-6 B-GENE-Y
and O
IL-12/23p40 B-GENE-N
secretion O
in O
response O
to O
the O
TLR4 B-GENE-Y
agonist, O
lipopolysaccharide O
was O
however O
increased O
in O
a O
dose-dependent O
manner O
by O
MWCNTs. O
Significant O
increases O
in O
the O
release O
of O
these O
cytokines B-GENE-N
were O
also O
observed O
in O
PBMCs O
stimulated O
with O
a O
TLR2 B-GENE-Y
or O
TLR3 B-GENE-Y
agonist. O
MWCNTs O
also O
increased O
the O
release O
of O
IL-2 B-GENE-Y
and O
IFN-γ B-GENE-Y
by O
PBMCs O
stimulated O
with O
a O
T B-GENE-N
cell I-GENE-N
mitogen. I-GENE-N
In O

contrast, O
MWCNTs O
inhibited O
allergen-induced O
IL-5 B-GENE-Y
secretion O
by O
PBMCs O
from O
mite-allergic O
subjects. O
As O
well, O
MWCNTs O
altered O
the O
capacity O
of O
PBMC-derived O
monocytes O
to O
differentiate O
into O
functional O
dendritic O
cells. O
All O
together, O
our O
data O
suggest O
that O
according O
to O
its O
immune O
cell O
target, O
MWCNTs O
may O
either O
promote O
or O
suppress O
immune O
responses O
in O
humans. O
Further O
investigations O
are O
necessary O
to O
fully O
understand O
the O
complexity O
behind O
interactions O
of O
engineered O
nanoparticles O
with O
the O
immune O
system. O
2-aminothiazoles B-CHEMICAL
with O
improved O
pharmacotherapeutic O

properties O
for O
treatment O
of O
prion O
disease. O
Recently, O
we O
described O
the O
aminothiazole B-CHEMICAL
lead O
(4-biphenyl-4-ylthiazol-2-yl)-(6-methylpyridin-2-yl)-amine B-CHEMICAL
(1), O
which O
exhibits O
many O
desirable O
properties, O
including O
excellent O
stability O
in O
liver O
microsomes, O
oral O
bioavailability O
of O
∼40 O
%, O
and O
high O
exposure O
in O
the O
brains O
of O
mice. O
Despite O
its O
good O
pharmacokinetic O
properties, O
compound O
1 O
exhibited O
only O
modest O
potency O
in O
mouse O
neuroblastoma O
cells O
overexpressing O
the O
disease-causing O

prion B-GENE-Y
protein I-GENE-Y
PrP(Sc) I-GENE-Y
. O
Accordingly, O
we O
sought O
to O
identify O
analogues O
of O
1 O
with O
improved O
antiprion O
potency O
in O
ScN2a-cl3 O
cells O
while O
retaining O
similar O
or O
superior O
properties. O
Herein O
we O
report O
the O
discovery O
of O
improved O
lead O
compounds O
such O
as O
(6-methylpyridin-2-yl)-[4-(4-pyridin-3-yl-phenyl)thiazol-2-yl]amine B-CHEMICAL
and O
cyclopropanecarboxylic B-CHEMICAL
acid I-CHEMICAL

(4-biphenylthiazol-2-yl)amide, I-CHEMICAL
which O
exhibit O
brain O
exposure/EC50 O
ratios O
at O
least O
tenfold O
greater O
than O
that O
of O
compound O
1. O
Immunotherapy O
for O
De O
Novo O
renal O
transplantation: O
what's O
in O
the O
pipeline? O
Immunosuppressive O
drugs O
have O
been O
traditionally O
developed O
to O
prevent O
acute O
rejection O
and O
to O
improve O
short-term O
kidney O
transplant O
outcomes. O
There O
is O
still O
a O
medical O
need O
to O
improve O
outcomes O
among O
subgroups O
of O
patients O
at O
higher O
risk O
for O
graft O
loss O
and O
to O
reduce O
cardiovascular, O
infectious O
and O
malignancy-associated O
morbidity O
and O

mortality, O
and O
improve O
long-term O
adherence. O
Several O
new O
immunosuppressive O
agents O
and O
formulations O
are O
undergoing O
clinical O
investigation O
and O
are O
discussed O
in O
this O
review.A O
modified O
release O
tacrolimus B-CHEMICAL
formulation O
(MR4) O
for O
once-daily O
administration O
is O
undergoing O
phase O
III O
trials. O
It O
has O
been O
developed O
to O
be O
administered O
de O
novo O
or O
for O
maintenance O
using O
the O
same O
therapeutic O
target O
tacrolimus B-CHEMICAL
trough O
concentrations O
as O
for O
the O
original O
formulation. O
Belatacept O
(LEA29Y), O
a O
second O
generation O
cytotoxic-T-lymphocyte-associated B-GENE-Y
antigen I-GENE-Y
immunoglobulin B-GENE-N

(CTLA4-Ig), B-GENE-Y
blocks O
the O
interaction O
between O
CD80/86 B-GENE-N
and O
CD28 B-GENE-Y
costimulatory O
pathways. O
In O
phase O
II O
trials, O
belatacept O
was O
as O
effective O
as O
ciclosporin B-CHEMICAL
(cyclosporine) B-CHEMICAL
when O
administered O
in O
combination O
with O
basiliximab, O
mycophenolate B-CHEMICAL
mofetil I-CHEMICAL
(MMF) B-CHEMICAL
and O
corticosteroids. O
Currently, O
belatacept O
is O
undergoing O
phase O
III O
trials O
including O
one O
study O
in O
recipients O
of O
organs O
from O
expanded O
criteria O
donors. O
Inhibitors O
of O
the O
Janus B-GENE-Y
protein I-GENE-Y
tyrosine I-GENE-Y
kinase I-GENE-Y
(JAK)-3 I-GENE-Y
show O

some O
selectivity O
for O
cells O
of O
the O
lymphoid O
lineage O
and O
have O
been O
shown O
to O
be O
effective O
in O
late O
preclinical O
transplant O
models. O
The O
most O
frequent O
adverse O
effects O
have O
been O
related O
to O
nonspecific O
binding O
to O
JAK2 B-GENE-Y
kinases. B-GENE-N
CP-690550, B-CHEMICAL
a O
JAK3 B-GENE-Y
inhibitor O
is O
currently O
in O
phase O
II O
clinical O
trials.FK778, B-CHEMICAL
is O
a O
synthetic O
malononitrilamide B-CHEMICAL
that O
targets O
the O
critical O
enzyme O
of O
the O
de O
novo O
pyrimidine B-CHEMICAL
synthesis, O
dihydroorotic B-GENE-Y
acid I-GENE-Y
dehydrogenase, I-GENE-Y
and O
receptor-associated B-GENE-N
tyrosine I-GENE-N
kinases I-GENE-N
has O
completed O
phase O

II O
trials. O
FK778 B-CHEMICAL
also O
shows O
antiviral O
activities O
that O
have O
been O
tested O
in O
patients O
with O
polyomavirus O
nephropathy. O
Fingolimod B-CHEMICAL
(FTY720), B-CHEMICAL
a O
synthetic O
sphingosine B-GENE-N
phosphate I-GENE-N
receptor I-GENE-N
modulator O
that O
reduces O
the O
recirculation O
of O
lymphocytes O
to O
blood O
and O
peripheral O
tissues O
including O
inflammatory O
lesions O
and O
graft O
sites O
is O
undergoing O
phase O
III O
trials. O
Although O
the O
efficacy O
of O
fingolimod B-CHEMICAL
is O
similar O
to O
MMF B-CHEMICAL
in O
patients O
receiving O
full O
doses O
of O
ciclosporin, B-CHEMICAL
safety O
issues O
such O
as O
a O
negative O
chronotropic O
effect, O
macular O
oedema, O
pulmonary O
adverse O

reactions O
and O
graft O
function O
resulted O
in O
premature O
discontinuation O
of O
the O
development O
programme O
for O
kidney O
transplantation. O
Because O
there O
was O
no O
clear O
clinical O
benefit O
over O
treatment O
options, O
the O
clinical O
development O
programme O
of O
FK778 B-CHEMICAL
was O
discontinued.Finally, O
a O
new O
evolving O
strategy O
with O
powerful O
induction-induced O
prolonged O
T-cell O
depletion O
followed O
by O
low-dose O
immunosuppressive O
monotherapy O
is O
showing O
promising O
results. O
Effect O
of O
apocalmodulin B-GENE-Y
on O
recombinant O
human B-GENE-Y
brain I-GENE-Y
glutamic I-GENE-Y
acid I-GENE-Y
decarboxylase. I-GENE-Y
In O
this O
work, O
we O
report O
that O
the O
recombinant O
glutathione B-GENE-N
S-transferase I-GENE-N

(GST)-human B-GENE-N
L-glutamic I-GENE-Y
acid I-GENE-Y
decarboxylase I-GENE-Y
(HGAD) B-GENE-Y
isoforms, O
65-kDa B-GENE-Y
L-glutamic I-GENE-Y
acid I-GENE-Y
decarboxylase I-GENE-Y
(GAD) B-GENE-Y
(GST-HGAD65) B-GENE-N
fusion O
protein O
or O
free O
truncated O
HGAD65, B-GENE-Y
were O
activated O
by O
apocalmodulin B-GENE-Y
(ApoCaM) B-GENE-Y
to O
an O
extent O
of O
60%. O
Both O
truncated O
forms O
of O
GAD67 B-GENE-Y
(tGAD67), B-GENE-Y
HGAD67(Delta1-70) B-GENE-Y
and O

HGAD67(Delta1-90), B-GENE-Y
were O
markedly O
activated O
by O
ApoCaM B-GENE-Y
to O
an O
extent O
of O
141 O
and O
85%, O
respectively, O
while O
GST-HGAD67 B-GENE-N
was O
not O
significantly O
affected. O
The O
activation O
appears O
to O
be O
due O
to O
an O
increase O
of O
GAD B-GENE-Y
affinity O
for O
its O
cofactor, O
pyridoxal B-CHEMICAL
phosphate I-CHEMICAL
(PLP). B-CHEMICAL
This O
conclusion O
is O
based O
on O
the O
following O
observations. O
Firstly, O
the O
V(max) O
of O
GAD B-GENE-Y
was O
increased O
when O
ApoCaM B-GENE-Y
was O
present O
whereas O
the O
affinity O
for O
the O
substrate, O
glutamate, B-CHEMICAL
was O
not O
affected. O

Secondly, O
the O
affinity O
of O
GAD B-GENE-Y
for O
PLP B-CHEMICAL
was O
increased O
in O
the O
presence O
of O
ApoCaM. B-GENE-Y
Thirdly, O
results O
from O
calmodulin-agarose B-GENE-Y
affinity O
column O
chromatography O
studies O
indicated O
a O
direct O
interaction O
or O
binding O
between O
ApoCaM B-GENE-Y
and O
GAD. B-GENE-Y
Fourthly, O
ApoCaM B-GENE-Y
was O
found O
to O
be O
copurified O
with O
GAD65/GAD67 B-GENE-Y
by O
anti-GAD65/67 B-GENE-N
immunoaffinity O
column O
using O
rat O
brain O
extract. O
Hence, O
it O
is O
proposed O
that O
a O
conformational O
change O
is O
induced O
when O
ApoCaM B-GENE-Y
interacts O
with O
GAD65 B-GENE-Y
or O

tGAD67, B-GENE-Y
resulting O
in O
an O
increase O
of O
GAD B-GENE-Y
affinity O
for O
PLP B-CHEMICAL
and O
the O
activation O
of O
GAD. B-GENE-Y
The O
physiological O
significance O
of O
the O
interaction O
between O
GAD B-GENE-Y
and O
ApoCaM B-GENE-Y
is O
discussed. O
Hydrogen B-CHEMICAL
sulfide I-CHEMICAL
acts O
as O
a O
mediator O
of O
inflammation O
in O
acute O
pancreatitis: O
in O
vitro O
studies O
using O
isolated O
mouse O
pancreatic O
acinar O
cells. O
Hydrogen B-CHEMICAL
sulphide I-CHEMICAL
(H(2)S) B-CHEMICAL
is O
synthesized O
from O
L-cysteine B-CHEMICAL
via O
the O
action O
of O
cystathionine-gamma-lyase B-GENE-Y
(CSE) B-GENE-Y
and O

cystathionine-beta-synthase B-GENE-Y
(CBS). B-GENE-Y
We O
have O
earlier O
shown O
that O
H(2)S B-CHEMICAL
acts O
as O
a O
mediator O
of O
inflammation. O
However O
the O
mechanism O
remains O
unclear. O
In O
this O
study, O
we O
investigated O
the O
presence O
of O
H(2)S B-CHEMICAL
and O
the O
expression O
of O
H(2)S B-CHEMICAL
synthesizing O
enzymes, O
CSE B-GENE-Y
and O
CBS, B-GENE-Y
in O
isolated O
mouse O
pancreatic O
acini. O
Pancreatic O
acinar O
cells O
from O
mice O
were O
incubated O
with O
or O
without O
caerulein B-CHEMICAL
(10(-7) O
M O
for O
30 O
and O
60 O
min). O
Caerulein B-CHEMICAL
increased O
the O
levels O
of O

H(2)S B-CHEMICAL
and O
CSE B-GENE-Y
mRNA O
expression O
while O
CBS B-GENE-Y
mRNA O
expression O
was O
decreased. O
In O
addition, O
cells O
pre-treated O
with O
DL-propargylglycine B-CHEMICAL
(PAG, B-CHEMICAL
3 O
mM), O
a O
CSE B-GENE-Y
inhibitor, O
reduced O
the O
formation O
of O
H(2)S B-CHEMICAL
in O
caerulein B-CHEMICAL
treated O
cells, O
suggesting O
that O
CSE B-GENE-Y
may O
be O
the O
main O
enzyme O
involved O
in O
H(2)S B-CHEMICAL
formation O
in O
mouse O
acinar O
cells. O
Furthermore, O
substance B-GENE-Y
P I-GENE-Y
(SP) B-GENE-Y
concentration O
in O
the O
acini O
and O
expression O
of O
SP B-GENE-Y
gene O
(preprotachykinin-A, B-GENE-Y
PPT-A) B-GENE-Y
and O

neurokinin-1 B-GENE-Y
receptor I-GENE-Y
(NK-1R), B-GENE-Y
the O
primary O
receptor O
for O
SP, B-GENE-Y
are O
increased O
in O
secretagogue O
caerulein-treated B-CHEMICAL
acinar O
cells. O
Inhibition O
of O
endogenous O
production O
of O
H(2)S B-CHEMICAL
by O
PAG B-CHEMICAL
significantly O
suppressed O
SP B-GENE-Y
concentration, O
PPT-A B-GENE-Y
expression O
and O
NK1-R B-GENE-Y
expression O
in O
the O
acini. O
To O
determine O
whether O
H(2)S B-CHEMICAL
itself O
provoked O
inflammation O
in O
acinar O
cells, O
the O
cells O
were O
treated O
with O
H(2)S B-CHEMICAL
donor O
drug, O
sodium B-CHEMICAL
hydrosulphide I-CHEMICAL
(NaHS), B-CHEMICAL
(10, O
50 O
and O
100 O

muM), O
that O
resulted O
in O
a O
significant O
increase O
in O
SP B-GENE-Y
concentration O
and O
expression O
of O
PPT-A B-GENE-Y
and O
NK1-R B-GENE-Y
in O
acinar O
cells. O
These O
results O
suggest O
that O
the O
pro-inflammatory O
effect O
of O
H(2)S B-CHEMICAL
may O
be O
mediated O
by O
SP-NK-1R B-GENE-Y
related O
pathway O
in O
mouse O
pancreatic O
acinar O
cells. O
Thermodynamic O
determination O
of O
the O
binding O
constants O
of O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
inhibitors O
by O
a O
displacement O
method. O
Somatic O
angiotensin B-GENE-Y
I-converting I-GENE-Y
enzyme I-GENE-Y
(s-ACE) B-GENE-Y
plays O
a O
central O
role O
in O
blood O
pressure O
regulation O
and O
has O
been O
the O
target O

of O
most O
antihypertensive O
drugs. O
A O
displacement O
isothermal O
titration O
calorimetry O
method O
has O
been O
used O
to O
accurately O
determine O
the O
binding O
constant O
of O
three O
strong O
s-ACE B-GENE-Y
inhibitors. O
Under O
the O
experimental O
conditions O
studied O
in O
this O
work, O
the O
relative O
potency O
of O
the O
inhibitors O
was O
determined O
to O
be O
enalaprilat>lisinopril>captopril. B-CHEMICAL
We O
analyze O
the O
thermodynamic O
behaviour O
of O
the O
binding O
process O
using O
the O
new O
structural O
information O
provided O
by O
the O
ACE B-GENE-Y
structures, O
as O
well O
as O
the O
conformational O
changes O
that O
occur O
upon O
binding. O
Antiaggressive O
activity O
of O
central O

oxytocin B-GENE-Y
in O
male O
rats. O
RATIONALE: O
A O
substantial O
body O
of O
research O
suggests O
that O
the O
neuropeptide O
oxytocin B-GENE-Y
promotes O
social O
affiliative O
behaviors O
in O
a O
wide O
range O
of O
animals O
including O
humans. O
However, O
its O
antiaggressive O
action O
has O
not O
been O
unequivocally O
demonstrated O
in O
male O
laboratory O
rodents. O
OBJECTIVE: O
Our O
primary O
goal O
was O
to O
examine O
the O
putative O
serenic O
effect O
of O
oxytocin B-GENE-Y
in O
a O
feral O
strain O
(wild O
type O
Groningen, O
WTG) O
of O
rats O
that O
generally O
show O
a O
much O
broader O
variation O
and O
higher O
levels O
of O
intermale O

aggression O
than O
commonly O
used O
laboratory O
strains O
of O
rats. O
METHODS: O
Resident O
animals O
were O
intracerebroventricularly O
(icv) O
administered O
with O
different O
doses O
of O
synthetic O
oxytocin B-GENE-Y
and O
oxytocin B-GENE-Y
receptor I-GENE-Y
antagonist, O
alone O
and O
in O
combination, O
in O
order O
to O
manipulate O
brain O
oxytocin B-GENE-Y
functioning O
and O
to O
assess O
their O
behavioral O
response O
to O
an O
intruder. O
RESULTS: O
Our O
data O
clearly O
demonstrate O
that O
acute O
icv O
administered O
oxytocin B-GENE-Y
produces O
dose-dependent O
and O
receptor-selective O
changes O
in O
social O
behavior, O
reducing O
aggression O
and O
potentiating O
social O
exploration. O
These O
antiaggressive O
effects O
are O
stronger O
in O

the O
more O
offensive O
rats. O
On O
the O
other O
hand, O
administration O
of O
an O
oxytocin B-GENE-Y
receptor I-GENE-Y
antagonist O
tends O
to O
increase O
(nonsignificantly) O
aggression O
only O
in O
low-medium O
aggressive O
animals. O
CONCLUSIONS: O
These O
results O
suggest O
that O
transiently O
enhancing O
brain O
oxytocin B-GENE-Y
function O
has O
potent O
antiaggressive O
effects, O
whereas O
its O
attenuation O
tends O
to O
enhance O
aggressiveness. O
In O
addition, O
a O
possible O
inverse O
relationship O
between O
trait O
aggression O
and O
endogenous O
oxytocinergic O
signaling O
is O
revealed. O
Overall, O
this O
study O
emphasizes O
the O
importance O
of O
brain O
oxytocinergic O
signaling O
for O
regulating O
intermale O
offensive O
aggression. O

This O
study O
supports O
the O
suggestion O
that O
oxytocin B-GENE-Y
receptor I-GENE-Y
agonists O
could O
clinically O
be O
useful O
for O
curbing O
heightened O
aggression O
seen O
in O
a O
range O
of O
neuropsychiatric O
disorders O
like O
antisocial O
personality O
disorder, O
autism, O
and O
addiction. O
Possible O
Therapeutic O
Uses O
of O
Salvia O
triloba O
and O
Piper O
nigrum O
in O
Alzheimer's O
Disease-Induced O
Rats. O
Abstract O
This O
study O
aimed O
to O
investigate O
the O
role O
of O
Salvia O
triloba O
L. O
and O
Piper O
nigrum O
extracts O
in O
ameliorating O
neuroinflammatory O
insults O
characteristic O
of O
Alzheimer's O
disease O

(AD) O
in O
an O
experimentally O
induced O
rat O
model. O
Adult O
male O
Sprague-Dawley O
rats O
were O
classified O
into O
Group O
1 O
(n=10): O
normal O
healthy O
animals O
serving O
as O
the O
negative O
control O
group; O
Group O
2 O
(n=60): O
the O
AD-induced O
group. O
After O
AD O
induction, O
animals O
in O
the O
AD-induced O
group O
were O
divided O
randomly O
and O
equally O
into O
6 O
subgroups. O
The O
first O
subgroup O
served O
as O
AD O
control; O
the O
second O
one, O
which O
served O
as O
positive O
control, O
was O
treated O
orally O
with O
the O
conventional O
therapy O
for O
AD O
(rivastigmine) B-CHEMICAL
at O
a O
dose O
of O
0.3 O
mg/kg O
body O
weight O

(b.w.) O
daily O
for O
3 O
months. O
The O
third O
and O
fourth O
subgroups O
were, O
respectively, O
treated O
orally O
with O
the O
S. O
triloba O
extract O
at O
a O
dose O
of O
750 O
and O
375 O
mg/kg O
b.w. O
daily O
for O
3 O
months. O
The O
fifth O
and O
sixth O
subgroups O
were, O
respectively, O
treated O
orally O
with O
the O
P. O
nigrum O
extract O
at O
a O
dose O
of O
187.5 O
and O
93.75 O
mg/kg O
b.w. O
daily O
for O
3 O
months. O
Levels O
of O
brain O
acetylcholine B-CHEMICAL
(Ach), O
serum O
and O
brain O
acetylcholinesterase B-GENE-Y
(AchE) B-GENE-Y

activity, O
C-reactive B-GENE-Y
protein I-GENE-Y
(CRP), B-GENE-Y
total O
nuclear B-GENE-N
factor I-GENE-N
kappa-B I-GENE-N
(NF-κB), B-GENE-N
and O
monocyte B-GENE-Y
chemoattractant I-GENE-Y
protein-1 I-GENE-Y
(MCP-1) B-GENE-Y
were O
estimated. O
The O
results O
showed O
that O
administration O
of O
AlCl3 B-CHEMICAL
resulted O
in O
a O
significant O
elevation O
in O
the O
levels O
of O
AchE B-GENE-Y
activity, O
CRP, B-GENE-Y
NF-κB, B-GENE-N
and O
MCP-1 B-GENE-Y
accompanied O
with O
a O
significant O
depletion O
in O
the O
Ach O
level. O
Treatment O
of O
AD O
rats O
with O
each O
of O
the O
selected O
medicinal O
plant O
extracts O
caused O
marked O
improvement O
in O
the O
measured O
biochemical O
parameters. O
In O
conclusion, O
S. O

triloba O
and O
P. O
nigrum O
methanolic O
extracts O
have O
potent O
anti-inflammatory O
effects O
against O
neuroinflammation O
characterizing O
AD. O
Glutathione B-CHEMICAL
conjugation O
attenuates O
biological O
activities O
of O
6-dehydroshogaol B-CHEMICAL
from O
ginger. O
6-Dehydroshogaol B-CHEMICAL
(6-DHSG) B-CHEMICAL
is O
a O
bioactive O
α,β-unsaturated B-CHEMICAL
carbonyl I-CHEMICAL
compound O
isolated O
from O
fresh O
ginger O
with O
anti-inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities. O
Here O
we O
describe O
the O
glutathione B-CHEMICAL
(GSH)-dependent B-CHEMICAL
metabolism O
and O
the O
effect O
of O
this O

metabolic O
transformation O
on O
the O
biological O
activities O
of O
6-DHSG. B-CHEMICAL
Compared O
with O
other O
ginger O
compounds, O
such O
as O
6-gingerol B-CHEMICAL
and O
6-shogaol, B-CHEMICAL
6-DHSG B-CHEMICAL
showed O
the O
most O
potent O
anti-inflammatory O
effect O
in O
lipopolysaccharide O
(LPS)-stimulated O
RAW O
264.7 O
cells. O
The O
biological O
activities O
of O
6-DHSG B-CHEMICAL
were O
attenuated O
by O
sulfhydryl B-CHEMICAL
antioxidants O
such O
as O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
or O
N-acetyl B-CHEMICAL
cysteine I-CHEMICAL
(NAC), B-CHEMICAL
but O
not O
ascorbic B-CHEMICAL
acid I-CHEMICAL

(ASC). B-CHEMICAL
6-DHSG B-CHEMICAL
was O
metabolised O
by O
GSH B-CHEMICAL
to O
form O
a O
GSH B-CHEMICAL
conjugate O
(GS-6-DHSG) B-CHEMICAL
in O
RAW O
264.7 O
cells, O
via O
a O
potential O
mechanism O
involving O
the O
catalytic O
activity O
of O
glutathione-S-transferase B-GENE-N
(GST). B-GENE-N
GS-6-DHSG B-CHEMICAL
showed O
reduced O
biological O
activities O
compared O
with O
6-DHSG B-CHEMICAL
in O
multiple O
biological O
assays. O
Together, O
these O
results O
indicate O
that O
GSH B-CHEMICAL
conjugation O
attenuates O
the O
biological O
activities O
of O
6-DHSG B-CHEMICAL
and O
other O

α,β-unsaturated B-CHEMICAL
carbonyl I-CHEMICAL
compounds. O
Hydrogen B-CHEMICAL
sulfide I-CHEMICAL
as O
an O
allosteric O
modulator O
of O
ATP-sensitive B-GENE-N
potassium I-GENE-N
channels I-GENE-N
in O
colonic O
inflammation. O
The O
ATP-sensitive B-GENE-N
potassium I-GENE-N
channel I-GENE-N
(K(ATP)) B-GENE-N
in O
mouse O
colonic O
smooth O
muscle O
cell O
is O
a O
complex O
containing O
a O
pore-forming O
subunit O
(Kir6.1) B-GENE-Y
and O
a O
sulfonylurea B-GENE-N
receptor I-GENE-N
subunit O
(SUR2B). B-GENE-Y
These O
channels O
contribute O
to O
the O
cellular O
excitability O
of O
smooth O
muscle O
cells O
and O
hence O
regulate O
the O
motility O
patterns O
in O
the O
colon. O
Whole-cell O
voltage-clamp O
techniques O

were O
used O
to O
study O
the O
alterations O
in O
K(ATP) B-GENE-N
channels I-GENE-N
in O
smooth O
muscle O
cells O
in O
experimental O
colitis. O
Colonic O
inflammation O
was O
induced O
in O
BALB/C O
mice O
after O
intracolonic O
administration O
of O
trinitrobenzene B-CHEMICAL
sulfonic I-CHEMICAL
acid. I-CHEMICAL
K(ATP) B-CHEMICAL
currents O
were O
measured O
at O
a O
holding O
potential O
of O
-60 O
mV O
in O
high O
K(+) B-CHEMICAL
external O
solution. O
The O
concentration O
response O
to O
levcromakalim B-CHEMICAL
(LEVC), B-CHEMICAL
a O
K(ATP) B-GENE-N
channel I-GENE-N
opener, O
was O
significantly O
shifted O
to O
the O
left O
in O
the O
inflamed O
smooth-muscle O
cells. O
Both O
the O
potency O
and O
maximal O

currents O
induced O
by O
LEVC B-CHEMICAL
were O
enhanced O
in O
inflammation. O
The O
EC(50) O
values O
in O
control O
were O
6259 O
nM O
(n O
= O
10) O
and O
422 O
nM O
(n O
= O
8) O
in O
inflamed O
colon, O
and O
the O
maximal O
currents O
were O
9.9 O
± O
0.71 O
pA/pF O
(60 O
μM) O
in O
control O
and O
39.7 O
± O
8.8 O
pA/pF O
(3 O
μM) O
after O
inflammation. O
As O
was O
seen O
with O
LEVC, B-CHEMICAL
the O
potency O
and O
efficacy O
of O
sodium B-CHEMICAL
hydrogen I-CHEMICAL
sulfide I-CHEMICAL
(NaHS) B-CHEMICAL
(10-1000 O
μM) O
on O

K(ATP) B-CHEMICAL
currents O
were O
significantly O
greater O
in O
inflamed O
colon O
compared O
with O
controls. O
In O
control O
cells, O
pretreatment O
with O
100 O
µM O
NaHS B-CHEMICAL
shifted O
the O
EC(50) O
for O
LEV-induced O
currents O
from O
2838 O
(n O
= O
6) O
to O
154 O
(n O
= O
8) O
nM. O
Sulfhydration O
of O
sulfonylurea B-GENE-Y
receptor I-GENE-Y
2B I-GENE-Y
(SUR2B) B-GENE-Y
was O
induced O
by O
NaHS B-CHEMICAL
and O
colonic O
inflammation. O
These O
data O
suggest O
that O
sulfhydration O
of O
SUR2B B-GENE-Y
induces O
allosteric O
modulation O
of O
K(ATP) B-CHEMICAL
currents O
in O

colonic O
inflammation. O
[Short O
QT O
syndrome]. O
Short O
QT O
syndrome O
is O
a O
new O
genetic O
disorder O
associated O
with O
familial O
atrial O
fibrillation O
and/or O
sudden O
death O
or O
syncope. O
To O
date, O
different O
mutations O
in O
genes O
encoding O
for O
cardiac B-GENE-N
ion I-GENE-N
channels I-GENE-N
(KCNH2, B-GENE-Y
KCNQ1, B-GENE-Y
and O
KCNJ2) B-GENE-Y
have O
been O
identified O
to O
cause O
the O
short O
QT O
syndrome. O
The O
mutations O
lead O
to O
a O
gain O
of O
function O
of O
the O
affected O
current O
(IKr, B-GENE-Y
IKs, B-GENE-Y
and O
IK1). B-GENE-Y
The O
phenotype O
is O
characterized O
by O
a O
shortened O
QT O
interval<335 O
ms O
after O

correction O
for O
heart O
rate O
at O
rates<80 O
beats/min. O
Furthermore, O
the O
QT O
interval O
poorly O
adapts O
to O
heart O
rate. O
Patients O
exhibit O
shortened O
atrial O
and O
ventricular O
effective O
refractory O
periods O
and, O
in O
the O
majority, O
inducibility O
of O
ventricular O
fibrillation. O
Death O
occurs O
already O
in O
newborns. O
Therapy O
of O
choice O
seems O
to O
be O
the O
implantable O
cardioverter O
defibrillator O
because O
of O
the O
high O
incidence O
of O
sudden O
death. O
Pharmacological O
treatment O
has O
been O
studied O
and O
it O
could O
be O
demonstrated, O
that O
some O
mutant O
currents O
may O
be O
insufficiently O
suppressed O
by O
drugs O
targeted O
to O
block O
the O
specific O
current O
such O

as, O
e.g., O
sotalol B-CHEMICAL
or O
ibutilide B-CHEMICAL
in O
patients O
with O
a O
mutation O
in O
the O
IKr-coding B-GENE-Y
gene O
KCNH2 B-GENE-Y
(HERG). B-GENE-Y
Quinidine B-CHEMICAL
proved O
to O
be O
efficient O
in O
prolonging O
the O
QT O
interval O
and O
normalizing O
the O
effective O
refractory O
periods O
in O
some O
patients. O
The O
pure O
antiandrogen O
RU B-CHEMICAL
23908 I-CHEMICAL
(Anandron), B-CHEMICAL
a O
candidate O
of O
choice O
for O
the O
combined O
antihormonal O
treatment O
of O
prostatic O
cancer: O
a O
review. O
The O
nonsteroidal O
antiandrogen O
RU B-CHEMICAL
23908 I-CHEMICAL
( O
Anandron B-CHEMICAL
) O
weakly O
interacts O
with O
the O

prostatic O
cytosolic O
androgen B-GENE-Y
receptor I-GENE-Y
and O
shows O
a O
fast O
dissociation O
rate. O
When O
administered O
to O
immature O
castrated O
rats O
up O
to O
the O
daily O
dose O
of O
100 O
mg/kg, O
it O
is O
devoid O
of O
any O
androgenic O
activity O
but O
efficiently O
blocks O
the O
growth-promoting O
activity O
of O
androgens B-CHEMICAL
on O
ventral O
prostate O
and O
seminal O
vesicle O
weight, O
thus O
showing O
the O
characteristics O
of O
a O
pure O
antiandrogen. O
In O
intact O
animals, O
on O
the O
other O
hand, O
the O
antiandrogen O
administered O
alone O
exerts O
only O
a O
partial O
inhibition O
of O
prostate O
and O
seminal O
vesicle O
weight. O
This O
is O
due O
to O
the O
property O
of O
the O
pure O
antiandrogen O

to O
neutralize O
the O
inhibitory O
feedback O
effect O
of O
androgens B-CHEMICAL
at O
the O
pituitary O
level O
on O
the O
LH B-GENE-N
responsiveness O
to O
LHRH, B-GENE-Y
as O
illustrated O
in O
vitro O
in O
rat O
anterior O
pituitary O
cells O
in O
culture O
as O
well O
as O
in O
vivo O
in O
intact O
and O
castrated O
animals. O
In O
intact O
animals, O
neutralization O
of O
the O
inhibitory O
feedback O
action O
of O
endogenous O
androgens B-CHEMICAL
leads O
to O
an O
increased O
LH B-GENE-N
and O
testosterone B-CHEMICAL
secretion, O
which O
partly O
overcomes O
the O
direct O
action O
of O
the O
antiandrogen O
at O
the O
level O
of O
the O
prostate O
and O
seminal O
vesicles. O
In O
fact, O
the O
plasma O
testosterone B-CHEMICAL
concentration O
is O

more O
than O
doubled O
6 O
hr O
after O
the O
administration O
of O
10 O
mg O
of O
RU B-CHEMICAL
23908 I-CHEMICAL
while O
plasma O
LH B-GENE-N
and O
testosterone B-CHEMICAL
levels O
are O
increased O
by O
7- O
and O
17-fold, O
respectively, O
after O
14 O
days O
of O
similar O
daily O
treatment. O
Efficient O
neutralization O
of O
the O
androgenic O
action O
at O
the O
prostatic O
level O
in O
intact O
animals O
thus O
requires O
prevention O
of O
this O
escape O
phenomenon O
through O
inhibition O
of O
LH B-GENE-N
secretion. O
Although O
inhibition O
of O
LH B-GENE-N
release O
can O
be O
achieved O
by O
estrogen B-CHEMICAL
and O
progestins, B-CHEMICAL
an O
optimal O
inhibitory O
effect O
on O
the O
prostate O
is O
obtained O
by O
the O
combined O
administration O
of O
the O
antiandrogen O
with O
an O
LHRH B-GENE-Y

agonist O
that O
causes O
a O
specific O
blockage O
of O
testicular O
androgen B-CHEMICAL
biosynthesis O
as O
well O
as O
an O
inhibition O
of O
the O
LH B-GENE-N
responsiveness O
to O
LHRH. B-GENE-Y
Cytochrome B-GENE-N
P450-mediated I-GENE-N
herb-drug O
interaction O
potential O
of O
Galgeun-tang. O
We O
evaluated O
the O
herb-drug O
interaction O
potential O
of O
Galgeun-tang O
(GGT) O
extracts, O
mediated O
by O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) B-GENE-N
inhibition/induction. O
Further, O
the O
effects O
of O
fermentation O
on O
the O
CYP-mediated B-GENE-N
herb-drug O
interaction O
potential O
of O
GGT O

extracts O
were O
determined. O
As O
measured O
by O
LC-ESI/MS/MS, O
GGT O
extracts O
(0-300μg/mL) O
showed O
no O
inhibitory O
activity O
toward O
eight O
CYP B-GENE-N
isoforms O
(1A2, B-GENE-N
2A6, I-GENE-N
2B6, I-GENE-N
2C9, I-GENE-N
2C19, I-GENE-N
2D6, I-GENE-N
2E1, I-GENE-N
and I-GENE-N
3A4) I-GENE-N
in O
pooled O
human O
liver O
microsomes, O
suggesting O
that O
GGT O
may O
have O
low O
potential O
for O
herb-drug O
interactions O
mediated O
by O
CYP B-GENE-N
inhibition. O
Hepatic O
CYP B-GENE-N
expression O
and O
activity O
in O
rats O
treated O
with O
GGT O
extracts O
twice O
per O

day O
for O
1week O
was O
examined. O
Among O
the O
tested O
CYP B-GENE-N
isoforms O
(1A1, B-GENE-N
1A2, I-GENE-N
1B1, I-GENE-N
2B1, I-GENE-N
2C11, I-GENE-N
2E1, I-GENE-N
3A1, I-GENE-N
3A2, I-GENE-N
and I-GENE-N
4A1), I-GENE-N
CYP1B1 B-GENE-N
and I-GENE-N
4A1 I-GENE-N
were O
increased O
by O
GGT O
extracts. O
Hepatic O
activities O
of O
7-ethoxyresorufin-O-deethylase, B-GENE-Y
7-pentoxyresorufin-O-depentylase, B-GENE-Y
and O
chlorzoxazone B-GENE-Y
6-hydroxylase, I-GENE-Y
but O
not O

midazolam B-GENE-N
hydroxylase I-GENE-N
were O
also O
elevated. O
These O
results O
raise O
the O
possibility O
that O
GGT O
extracts O
may O
increase O
the O
toxicity O
of O
environmental O
toxicants O
through O
the O
elevating O
CYP-dependent B-GENE-N
metabolic O
activation. O
Interestingly, O
the O
increases O
in O
CYP1B1 B-GENE-Y
and O
CYP4A1 B-GENE-Y
levels, O
and O
7-ethoxyresorufin-O-deethylase, B-GENE-Y
7-pentoxyresorufin-O-depentylase, B-GENE-Y
and O
chlorzoxazone B-GENE-Y
6-hydroxylase I-GENE-Y
activities O
were O
attenuated O
by O
fermentation O
of O
GGT O
extract O
using O

Lactobacillus O
plantarum O
KFRI O
402, O
but O
not O
144. O
Further O
studies O
are O
needed O
to O
identify O
the O
CYP B-GENE-N
regulatory O
component(s) O
from O
GGT O
and O
determination O
its O
metabolism. O
Mechanisms O
of O
cefadroxil B-CHEMICAL
uptake O
in O
the O
choroid O
plexus: O
studies O
in O
wild-type O
and O
PEPT2 B-GENE-Y
knockout O
mice. O
The O
choroid O
plexus O
uptake O
of O
[(3)H]cefadroxil B-CHEMICAL
was O
studied O
in O
peptide B-GENE-Y
transporter I-GENE-Y
2 I-GENE-Y
(PEPT2) B-GENE-Y
wild-type O
and O
null O
mice O
as O
a O
function O
of O
temperature, O
transport O

inhibitors, O
pH, O
and O
saturability. O
At O
normal O
pH O
(7.4) O
and O
temperature O
(37 O
degrees O
C), O
the O
uptake O
of O
1 O
microM O
cefadroxil B-CHEMICAL
was O
reduced O
by O
83% O
in O
PEPT2(-/-) B-GENE-Y
mice O
as O
compared O
with O
PEPT2(+/+) B-GENE-Y
mice O
(p O
< O
0.001). O
A O
further O
reduction O
was O
achieved O
in O
null O
animals O
by O
reducing O
the O
temperature O
to O
4 O
degrees O
C, O
or O
by O
adding O
saturating O
concentrations O
of O
unlabeled O
cefadroxil B-CHEMICAL
or O
p-aminohippurate B-CHEMICAL
(p O
< O

0.05). O
Glycylsarcosine B-CHEMICAL
coadministration O
could O
inhibit O
the O
uptake O
of O
cefadroxil B-CHEMICAL
in O
PEPT2(+/+) B-GENE-Y
mice O
(p O
< O
0.01) O
but O
not O
PEPT2(-/-) B-GENE-Y
mice. O
Although O
a O
proton-stimulated O
uptake O
of O
cefadroxil B-CHEMICAL
was O
demonstrated O
in O
PEPT2(+/+) B-GENE-Y
mice O
(pH O
6.5 O
versus O
pH O
7.4; O
p O
< O
0.01), O
no O
pH O
dependence O
was O
observed O
in O
PEPT2(-/-) B-GENE-Y
mice. O

Kinetic O
parameters O
for O
cefadroxil B-CHEMICAL
(without O
p-aminohippurate) B-CHEMICAL
in O
wild-type O
mice O
were: O
V(max) O
= O
5.4 O
pmol/mg/min, O
K(m) O
= O
34 O
microM, O
and O
K(d) O
= O
0.0069 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate, B-CHEMICAL
the O
parameters O
were: O
V(max) O
= O
4.1 O
pmol/mg/min, O
K(m) O
= O
27 O
microM, O
and O
K(d) O
= O
0.0064 O

microl/mg/min. O
In O
null O
animals, O
the O
kinetic O
parameters O
of O
cefadroxil B-CHEMICAL
(without O
p-aminohippurate) B-CHEMICAL
were: O
V(max) O
= O
2.7 O
pmol/mg/min, O
K(m) O
= O
110 O
microM, O
and O
K(d) O
= O
0.0084 O
microl/mg/min; O
in O
the O
presence O
of O
p-aminohippurate, B-CHEMICAL
only O
a O
K(d) O
= O
0.010 O
microl/mg/min O
was O
observed. O
Based O
on O
kinetic O
and O
inhibitor O
analyses, O
it O
was O
determined O
that O
(under O
linear O
conditions), O
80 O
to O

85% O
of O
cefadroxil's O
uptake O
in O
choroid O
plexus O
is O
mediated O
by O
PEPT2, B-GENE-Y
10 O
to O
15% O
by O
organic B-GENE-Y
anion I-GENE-Y
transporter(s), I-GENE-Y
and O
5% O
by O
nonspecific O
mechanisms. O
These O
findings O
demonstrate O
that O
PEPT2 B-GENE-Y
is O
the O
primary O
transporter O
responsible O
for O
cefadroxil B-CHEMICAL
uptake O
in O
the O
choroid O
plexus. O
Moreover, O
the O
data O
suggest O
a O
role O
for O
PEPT2 B-GENE-Y
in O
the O
clearance O
of O
peptidomimetics O
from O
cerebrospinal O
fluid. O
Comparative O
proteomics O
of O
ovarian O

epithelial O
tumors. O
We O
analyzed O
12 O
ovarian O
epithelial O
tumors O
using O
2D O
PAGE-based O
comparative O
proteomics O
to O
construct O
intra- O
and O
inter-tumoral O
distance O
map O
trees O
and O
to O
discover O
surrogate O
biomarkers O
indicative O
of O
an O
ovarian O
tumor. O
The O
analysis O
was O
performed O
after O
laser O
microdissection O
of O
12 O
fresh-frozen O
tissue O
samples, O
including O
4 O
serous, O
5 O
mucinous, O
and O
3 O
endometrioid O
tumors, O
with O
correlation O
with O
their O
histopathological O
characteristics. O
Ovarian O
epithelial O
tumors O
and O
normal O
tissues O
showed O
an O
apparent O
separation O
on O
the O
distance O
map O
tree. O

Mucinous O
carcinomas O
were O
closest O
to O
the O
normal O
group, O
whereas O
serous O
carcinomas O
were O
located O
furthest O
from O
the O
normal O
group. O
All O
mucinous O
tumors O
with O
aggressive O
histology O
were O
separated O
from O
the O
low O
malignant O
potential O
(LMP) O
group. O
The O
benign-looking O
cysts O
adjacent O
to O
the O
intraepithelial O
carcinoma O
(IEC) O
showed O
an O
expression O
pattern O
identical O
to O
that O
of O
the O
IEC O
area. O
The O
extent O
of O
change O
on O
the O
lineages O
leading O
to O
the O
mucinous O
and O
serous O
carcinoma O
was O
1.98-fold O
different. O
The O
overall O
gene O
expression O
profiles O

of O
serous O
or O
endometrioid O
carcinomas O
appeared O
to O
be O
less O
affected O
by O
grade O
or O
stage O
than O
by O
histologic O
type. O
The O
potential O
candidate O
biomarkers O
screened O
in O
ovarian O
tumors O
and O
found O
to O
be O
significantly O
up-regulated O
in O
comparison O
to O
normal O
tissues O
were O
as O
follows: O
NM23, B-GENE-Y
annexin-1, B-GENE-Y
protein B-GENE-N
phosphatase-1, I-GENE-N
ferritin B-GENE-Y
light I-GENE-Y
chain, I-GENE-Y
proteasome B-GENE-Y
alpha-6, I-GENE-Y
and O
NAGK B-GENE-Y
(N-acetyl B-GENE-Y
glucosamine I-GENE-Y
kinase). I-GENE-Y
In O
conclusion, O
ovarian O
mucinous O
tumors O
are O
distinct O
from O
other O
ovarian O

epithelial O
tumors. O
LMP O
mucinous O
tumors O
showing O
histologically O
aggressive O
features O
belong O
to O
mucinous O
carcinoma O
on O
the O
proteomic O
basis. O
The O
effects O
of O
the O
adenosine B-GENE-Y
A3 I-GENE-Y
receptor I-GENE-Y
agonist O
IB-MECA B-CHEMICAL
on O
sodium B-CHEMICAL
taurocholate-induced I-CHEMICAL
experimental O
acute O
pancreatitis. O
The O
role O
of O
adenosine B-GENE-Y
A3 I-GENE-Y
receptors I-GENE-Y
and O
their O
distribution O
in O
the O
gastrointestinal O
tract O
have O
been O
widely O
investigated. O
Most O
of O
the O
reports O
discuss O
their O
role O
in O
intestinal O
inflammations. O
However, O
the O
role O
of O
adenosine B-GENE-Y
A3 I-GENE-Y
receptor I-GENE-Y
agonist O
in O

pancreatitis O
has O
not O
been O
well O
established. O
The O
aim O
of O
this O
study O
is O
(Ed O
note: O
Purpose O
statements O
should O
be O
in O
present O
tense) O
to O
evaluate O
the O
effects O
of O
the O
adenosine B-GENE-Y
A3 I-GENE-Y
receptor I-GENE-Y
agonist O
on O
the O
course O
of O
sodium B-CHEMICAL
taurocholate-induced I-CHEMICAL
experimental O
acute O
pancreatitis O
(EAP). O
The O
experiments O
were O
performed O
on O
80 O
male O
Wistar O
rats, O
58 O
of O
which O
survived, O
subdivided O
into O
3 O
groups: O
C-control O
rats, O
I-EAP O
group, O
and O
II-EAP O
group O
treated O
with O
the O
adenosine B-GENE-Y
A3 I-GENE-Y
receptor I-GENE-Y
agonist O
IB-MECA B-CHEMICAL

(1-deoxy-1-6[[(3-iodophenyl) B-CHEMICAL
methyl]amino]-9H-purin-9-yl)-N-methyl-B-D-ribofuronamide I-CHEMICAL
at O
a O
dose O
of O
0.75 O
mg/kg O
b.w. O
i.p. O
at O
48, O
24, O
12 O
and O
1 O
h O
before O
and O
1 O
h O
after O
the O
injection O
of O
5 O
% O
sodium B-CHEMICAL
taurocholate I-CHEMICAL
solution O
into O
the O
biliary-pancreatic O
duct. O
Serum O
for O
α-amylase B-GENE-N
and O
lipase B-GENE-N
determinations O
and O
tissue O
samples O
for O

morphological O
examinations O
were O
collected O
at O
2, O
6, O
and O
24 O
h O
of O
the O
experiment. O
In O
the O
IB-MECA B-CHEMICAL
group, O
α-amylase B-GENE-N
activity O
was O
decreased O
with O
statistically O
high O
significance O
compared O
to O
group O
I. O
The O
activity O
of O
lipase B-GENE-N
was O
not O
significantly O
different O
among O
the O
experimental O
groups O
but O
higher O
than O
in O
the O
control O
group. O
The O
administration O
of O
IB-MECA B-CHEMICAL
attenuated O
the O
histological O
parameters O
of O
inflammation O
as O
compared O
to O
untreated O
animals. O
The O
use O
of O
A3 B-GENE-Y
receptor I-GENE-Y
agonist O
IB-MECA B-CHEMICAL
attenuates O
EAP. O
Our O
findings O
suggest O
that O
stimulation O
of O
adenosine B-GENE-Y
A3 I-GENE-Y
receptors I-GENE-Y
plays O

a O
positive O
role O
in O
the O
sodium B-CHEMICAL
taurocholate-induced I-CHEMICAL
EAP O
in O
rats. O
Pyrrolopyrazines B-CHEMICAL
as O
Selective O
Spleen B-GENE-Y
Tyrosine I-GENE-Y
Kinase I-GENE-Y
Inhibitors. O
We O
describe O
the O
discovery O
of O
several O
pyrrolopyrazines B-CHEMICAL
as O
potent O
and O
selective O
Syk B-GENE-Y
inhibitors O
and O
the O
efforts O
that O
eventually O
led O
to O
the O
desired O
improvements O
in O
physicochemical O
properties O
and O
human O
whole O
blood O
potencies. O
Ultimately, O
our O
mouse O
model O
revealed O
unexpected O
toxicity O
that O
precluded O
us O
from O
further O
advancing O
this O
series. O
Bioactive O
microconstituents O
and O
antioxidant O
properties O
of O
wild O
edible O
mushrooms O
from O
the O
island O
of O

Lesvos, O
Greece. O
Crude O
composition, O
fatty B-CHEMICAL
acids, I-CHEMICAL
sterols, B-CHEMICAL
total O
phenolic O
content O
(TPC), O
individual O
polyphenols B-CHEMICAL
and O
terpenic B-CHEMICAL
acids I-CHEMICAL
were O
determined O
in O
five O
wild O
edible O
mushrooms O
species O
(Lactarius O
deliciosus, O
Lactarius O
sanguifluus, O
Lactarius O
semisanguifluus, O
Russula O
delica, O
Suillus O
bellinii) O
from O
Lesvos O
Island, O
Greece. O
In O
addition, O
the O
DPPH B-CHEMICAL
scavenging O
capacity, O
the O
ferric B-CHEMICAL
ion O
reducing O
power O
(FRAP) O
and O
the O
ferrous B-CHEMICAL
ion O

chelating O
activity O
of O
mushroom O
methanolic O
extracts O
were O
assessed. O
Among O
sterols, B-CHEMICAL
ergosterol B-CHEMICAL
predominated O
at O
concentrations O
9.2-18.0mg/100g O
fw. O
Total O
phenolic O
content O
of O
mushroom O
extracts O
ranged O
from O
6.0 O
to O
20.8mg O
GAE/100g O
fw. O
Up O
to O
19 O
simple O
polyphenols B-CHEMICAL
were O
determined O
in O
mushrooms O
extracts, O
the O
more O
abundant O
being O
p-OH-benzoic B-CHEMICAL
acid, I-CHEMICAL
p-OH-phenylacetic B-CHEMICAL
acid, I-CHEMICAL
o-coumaric B-CHEMICAL
acid, I-CHEMICAL
ferulic B-CHEMICAL
acid I-CHEMICAL
and O

chrysin. B-CHEMICAL
In O
addition, O
the O
triterpenic B-CHEMICAL
acids I-CHEMICAL
oleanolic B-CHEMICAL
and O
ursolic B-CHEMICAL
were O
detected O
for O
the O
first O
time O
in O
mushrooms. O
All O
species O
exerted O
antioxidant O
activity O
and O
ferrous B-CHEMICAL
ion O
chelating O
capacity. O
Principal O
component O
analysis O
revealed O
good O
correlations O
between O
TPC, O
DPPH B-CHEMICAL
and O
FRAP O
but O
not O
with O
metal O
chelating O
activity. O
It O
seems O
that O
mushrooms O
polyphenols B-CHEMICAL
exert O
antiradical O
and O
reducing O
activities, O
but O
they O
are O
not O
strong O
metal O
chelators, O
the O
observed O
chelating O
ability O
being O
probably O
due O
to O
other O
classes O
of O
compounds. O
To O
our O
knowledge, O

this O
is O
the O
first O
report O
on O
the O
bioactive O
microconstituents O
and O
antioxidant O
activity O
of O
wild O
Greek O
edible O
mushrooms. O
Optimization O
of O
taxane B-CHEMICAL
binding O
to O
microtubules: B-GENE-N
binding O
affinity O
dissection O
and O
incremental O
construction O
of O
a O
high-affinity O
analog O
of O
paclitaxel. B-CHEMICAL
The O
microtubule B-GENE-N
binding O
affinities O
of O
a O
series O
of O
synthetic O
taxanes B-CHEMICAL
have O
been O
measured O
with O
the O
aims O
of O
dissecting O
individual O
group O
contributions O
and O
obtaining O
a O
rationale O
for O
the O
design O
of O
novel O
compounds O
with O
the O
ability O
to O
overcome O
drug O
resistance. O
As O
previously O
observed O
for O
epothilones, B-CHEMICAL
the O
positive O
and O
negative O
contributions O
of O

the O
different O
substituents O
to O
the O
binding O
free O
energies O
are O
cumulative. O
By O
combining O
the O
most O
favorable O
substitutions O
we O
increased O
the O
binding O
affinity O
of O
paclitaxel B-CHEMICAL
500-fold. O
Insight O
into O
the O
structural O
basis O
for O
this O
improvement O
was O
gained O
with O
molecular O
modeling O
and O
NMR O
data O
obtained O
for O
microtubule-bound B-GENE-N
docetaxel. B-CHEMICAL
Taxanes B-CHEMICAL
with O
affinities O
for O
microtubules B-GENE-N
well O
above O
their O
affinities O
for O
P-glycoprotein B-GENE-N
are O
shown O
not O
to O
be O
affected O
by O
multidrug O
resistance. O
This O
finding O
strongly O
indicates O
that O
optimization O
of O
the O
ligand-target O
interaction O
is O
a O
good O
strategy O
to O
overcome O

multidrug O
resistance O
mediated O
by O
efflux B-GENE-N
pumps. I-GENE-N
Effects O
of O
ozone B-CHEMICAL
and O
fine O
particulate O
matter O
(PM(2.5)) O
on O
rat O
system O
inflammation O
and O
cardiac O
function. O
In O
order O
to O
understand O
the O
toxic O
mechanisms O
of O
cardiovascular O
system O
injuries O
induced O
by O
ambient O
PM(2.5) O
and/or O
ozone, B-CHEMICAL
a O
subacute O
toxicological O
animal O
experiment O
was O
designed O
with O
exposure O
twice O
a O
week O
for O
3 O
continuous O
weeks. O
Wistar O
rats O
were O
randomly O
categorized O
into O
8 O
groups O
(n=6): O
1 O
control O
group, O
3 O
groups O
exposed O
to O
fine O
particulate O
matters O
(PM(2.5)) O
alone O
at O
3 O
doses O

(0.2, O
0.8, O
or O
3.2 O
mg/rat), O
1 O
group O
to O
ozone B-CHEMICAL
(0.81 O
ppm) O
alone O
and O
3 O
groups O
to O
ozone B-CHEMICAL
plus O
PM(2.5) O
at O
3 O
doses O
(0.2, O
0.8, O
or O
3.2 O
mg/rat). O
Heart O
rate O
(HR) O
and O
electrocardiogram O
(ECG) O
was O
monitored O
at O
approximately O
24-h O
both O
after O
the O
3rd O
exposure O
and O
the O
last O
(6th) O
exposure, O
and O
systolic O
blood O
pressure O
(SBP) O
was O
monitored O
at O
approximately O
24-h O
after O
the O
6th O
exposure. O

Biomarkers O
of O
systemic O
inflammation O
and O
injuries O
(CRP, B-GENE-Y
IL-6, B-GENE-Y
LDH, B-GENE-N
CK), B-GENE-N
heart O
oxidative O
stress O
(MDA, B-CHEMICAL
SOD) B-GENE-N
and O
endothelial O
function O
(ET-1, B-GENE-Y
VEGF) B-GENE-Y
were O
analyzed O
after O
the O
6th O
exposure. O
Additionally, O
myocardial O
ultrastructural O
alterations O
were O
observed O
under O
transmission O
electron O
microscopy O
(TEM) O
for O
histopathological O
analyses. O
Results O
showed O
that O
PM(2.5) O
alone O
exposure O
could O
trigger O
the O
significant O
increase O
of O
CRP, B-GENE-Y
MDA, B-CHEMICAL
CK, B-GENE-N
ET-1 B-GENE-Y
and O
SBP O
and O
decrease O
of O
heart O

rate O
variability O
(HRV), O
a O
marker O
of O
cardiac O
autonomic O
nervous O
system O
(ANS) O
function. O
Ozone B-CHEMICAL
alone O
exposure O
in O
rats O
did O
not O
show O
significant O
alterations O
in O
any O
indicators. O
Ozone B-CHEMICAL
plus O
PM(2.5) O
exposure, O
however, O
induced O
CRP, B-GENE-Y
IL-6, B-GENE-Y
CK, B-GENE-N
LDH B-GENE-N
and O
MDA B-CHEMICAL
increase, O
SOD B-GENE-N
and O
HRV O
decrease O
significantly O
in O
a O
dose-response O
way. O
Meanwhile, O
abnormal O
ECG O
types O
were O
monitored O
in O
rats O
exposed O
to O
PM(2.5) O
with O
and O
without O
ozone B-CHEMICAL
and O
obvious O
myocardial O
ultrastructural O
changes O
were O
observed O
by O
TEM. O
In O

conclusion, O
PM(2.5) O
alone O
exposure O
could O
cause O
inflammation, O
endothelial O
function O
and O
ANS O
injuries, O
and O
ozone B-CHEMICAL
potentiated O
these O
effects O
induced O
by O
PM(2.5). O
Flavopiridol B-CHEMICAL
Hoechst O
AG. O
Hoechst O
is O
developing O
flavopiridol, B-CHEMICAL
a O
synthetic O
flavonoid B-CHEMICAL
based O
on O
an O
extract O
from O
an O
Indian O
plant, O
for O
the O
potential O
treatment O
of O
cancer. O
Flavopiridol, B-CHEMICAL
a O
cyclin-dependent B-GENE-N
kinase I-GENE-N
inhibitor, O
arrests O
cell O
division O
and O
causes O
apoptosis O
in O
non-small O
lung O
cancer O
cells O
[283660]. O
A O
phase O
II O

trial, O
in O
collaboration O
with O
the O
National O
Cancer O
Institute, O
has O
commenced O
at O
the O
University O
of O
Chicago O
Medical O
Center, O
which O
involves O
patients O
with O
high O
or O
intermediate-grade O
lymphoma O
or O
multiple O
myeloma O
[272937], O
[277372]. O
In O
ex O
vivo O
experiments O
with O
tumor O
cells O
from O
refractory O
chronic O
lymphoblastic O
leukemia, O
dose-dependent O
CDK2 B-GENE-Y
inhibition O
associated O
with O
apoptotic O
changes O
was O
seen O
at O
concentrations O
greater O
than O
100 O
nM O
of O
flavopiridol. B-CHEMICAL
In O
vitro O
pharmacokinetic O
studies O
have O
shown O
that O
flavopiridol B-CHEMICAL
undergoes O

hepatic O
biotransformation O
to O
its O
corresponding O
glucoronide B-CHEMICAL
by O
uridine B-CHEMICAL
diphosphate I-CHEMICAL
glucoronosyltransferases O
[283791]. O
Flavopiridol B-CHEMICAL
inhibits O
CDK B-GENE-N
with O
an O
IC50 O
value O
of O
0.4 O
mM O
[285707]. O
Preclinical O
toxicology O
studies O
in O
rats O
and O
dogs O
demonstrated O
dose-related O
leukopenia O
and O
drug-related O
lesions O
in O
the O
thymus, O
spleen O
and O
bone O
marrow. O
The O
gastrointestinal O
and O
bone O
marrow O
toxicity O
was O
dose-limiting O
[178579]. O

Hoechst O
Marion O
Roussel O
expects O
to O
launch O
flavopiridol B-CHEMICAL
in O
the O
year O
2001, O
with O
potential O
sales O
in O
excess O
of O
DM O
750 O
million O
[288651]. O
Carbonic B-GENE-N
anhydrase I-GENE-N
inhibitors: O
aromatic B-CHEMICAL
and I-CHEMICAL
heterocyclic I-CHEMICAL
sulfonamides I-CHEMICAL
incorporating O
adamantyl B-CHEMICAL
moieties O
with O
strong O
anticonvulsant O
activity. O
A O
series O
of O
aromatic/heterocyclic B-CHEMICAL
sulfonamides I-CHEMICAL
incorporating O
adamantyl B-CHEMICAL
moieties O
were O
prepared O
by O
reaction O
of O
aromatic/heterocyclic B-CHEMICAL
aminosulfonamides I-CHEMICAL
with O
the O
acyl B-CHEMICAL

chlorides I-CHEMICAL
derived O
from O
adamantyl-1-carboxylic B-CHEMICAL
acid I-CHEMICAL
and O
1-adamantyl-acetic B-CHEMICAL
acid. I-CHEMICAL
Related O
derivatives O
were O
obtained O
from O
the O
above-mentioned O
aminosulfonamides B-CHEMICAL
with O
adamantyl B-CHEMICAL
isocyanate I-CHEMICAL
and O
adamantyl B-CHEMICAL
isothiocyanate, I-CHEMICAL
respectively. O
Some O
of O
these O
derivatives O
showed O
good O
inhibitory O
potency O
against O
two O
human B-GENE-N
CA I-GENE-N
isozymes O
involved O
in O
important O
physiological O
processes, O
CA B-GENE-Y
I, I-GENE-Y
and O
CA B-GENE-Y
II, I-GENE-Y
of O
the O
same O
order O
of O
magnitude O
as O
the O
clinically O
used O
drugs O
acetazolamide B-CHEMICAL
and O
methazolamide. B-CHEMICAL
The O

lipophilicity O
of O
the O
best O
CA B-GENE-N
inhibitors O
was O
determined O
and O
expressed O
as O
their O
experimental O
log O
k' O
IAM O
and O
theoretical O
ClogP O
value. O
Their O
lipophilicity O
was O
propitious O
with O
the O
crossing O
of O
the O
blood-brain O
barrier O
(log O
k' O
> O
IAM O
> O
1.35). O
The O
anticonvulsant O
activity O
of O
some O
of O
the O
best O
CA B-GENE-N
inhibitors O
reported O
here O
has O
been O
evaluated O
in O
a O
MES O
test O
in O
mice. O
After O
intraperitoneal O
injection O
(30 O
mg O
kg(-1)), O
compounds O
A8 O
and O
A9 O
exhibited O
a O
high O
protection O
against O
electrically O
induced O
convulsions O

(> O
90%). O
Their O
ED50 O
was O
3.5 O
and O
2.6 O
mg O
kg(-1), O
respectively. O
Enzymatic O
characterization O
of O
a O
recombinant O
isoform O
hybrid O
of O
glutamic B-GENE-N
acid I-GENE-N
decarboxylase I-GENE-N
(rGAD67/65) B-GENE-N
expressed O
in O
yeast. O
BACKGROUND O
AND O
AIMS: O
Glutamic B-GENE-N
acid I-GENE-N
decarboxylase I-GENE-N
(GAD, B-GENE-N
EC B-GENE-Y
4.1.1.15) I-GENE-Y
catalyses O
the O
conversion O
of O
glutamate B-CHEMICAL
to O
gamma-aminobutyric B-CHEMICAL
acid I-CHEMICAL
(GABA). B-CHEMICAL
The O
65 O
kDa O

isoform, O
GAD65 B-GENE-Y
is O
a O
potent O
autoantigen O
in O
type O
1 O
diabetes, O
whereas O
GAD67 B-GENE-Y
is O
not. O
A O
hybrid O
cDNA O
was O
created O
by O
fusing O
a O
human O
cDNA O
for O
amino B-CHEMICAL
acids I-CHEMICAL
1-101 O
of O
GAD67 B-GENE-Y
to O
a O
human O
cDNA O
for O
amino B-CHEMICAL
acids I-CHEMICAL
96-585 O
of O
GAD65; B-GENE-Y
the O
recombinant O
(r) O
protein O
was O
expressed O
in O
yeast O
and O
was O
shown O
to O
have O
equivalent O
immunoreactivity O
to O
mammalian B-GENE-N
brain I-GENE-N
GAD I-GENE-N
with O
diabetes O
sera. O
We O
here O
report O
on O
enzymatic O
and O
molecular O
properties O
of O
rGAD67/65. B-GENE-N

METHODS: O
Studies O
were O
performed O
on O
enzymatic O
activity O
of O
rGAD67/65 B-GENE-N
by O
production O
of O
3H-GABA B-CHEMICAL
from O
3H-glutamate, B-CHEMICAL
enzyme O
kinetics, O
binding O
to O
the O
enzyme O
cofactor O
pyridoxal B-CHEMICAL
phosphate I-CHEMICAL
(PLP), B-CHEMICAL
stability O
according O
to O
differences O
in O
pH, O
temperature O
and O
duration O
of O
storage, O
and O
antigenic O
reactivity O
with O
various O
GAD-specific B-GENE-N
antisera. O
RESULTS: O
The O
properties O
of O
rGAD67/65 B-GENE-N
were O
compared O
with O
published O
data O
for O
mammalian B-GENE-N
brain I-GENE-N
GAD I-GENE-N
(brackets). O
These O
included O
a O
specific O
enzyme O
activity O

of O
22.7 O
(16.7) O
nKat, O
optimal O
pH O
for O
enzymatic O
activity O
7.4 O
(6.8), O
K(m) O
of O
1.3 O
(1.3) O
mM, O
efficient O
non-covalent O
binding O
to O
the O
cofactor O
PLP, B-CHEMICAL
and O
high O
autoantigenic O
potency. O
The O
stability O
of O
rGAD67/65 B-GENE-N
was O
optimal O
over O
3 O
months O
at O
-80 O
degrees O
C, O
or O
in O
lyophilized O
form O
at O
-20 O
degrees O
C. O
CONCLUSIONS: O
Hybrid O
rGAD67/65 B-GENE-N
has O
enzymatic O
and O
other O
properties O
similar O
to O

those O
of O
the O
mixed O
isoforms O
of O
GAD B-GENE-N
in O
preparations O
from O
mammalian O
brain O
as O
described O
elsewhere, O
in O
addition O
to O
its O
previously O
described O
similar O
immunoreactivity. O
Bioactive O
phenolics B-CHEMICAL
from O
Seriphidium O
stenocephalum. O
Chromatographic O
separation O
of O
the O
ethyl B-CHEMICAL
acetate I-CHEMICAL
soluble O
part O
of O
the O
methanolic O
extract O
from O
Seriphidium O
stenocephalum O
yielded O
three O
new O
compounds: O
stenocepflavone B-CHEMICAL
(1), O
stenocepflavan B-CHEMICAL
(2), O
and O
stenocephol B-CHEMICAL
(3), O
together O
with O

cirsimaritin B-CHEMICAL
(4), O
5,7,5'-trihydroxy-3',4',6-trimethoxyflavone B-CHEMICAL
(5), O
5,6,7,5'-tetrahydroxy-4'-methoxyflavone B-CHEMICAL
(6), O
and O
axillaroside B-CHEMICAL
(7). O
All O
isolates O
were O
characterized O
with O
the O
help O
of O
spectroscopic O
data O
including O
1D, O
2D O
NMR, O
and O
high O
resolution O
mass O
spectrometry O
and/or O
in O
comparison O
with O
the O
related O
compounds O
in O
literature. O
All O
compounds O

were O
tested O
for O
in O
vitro O
enzyme O
inhibitory O
activities O
against O
acetylcholinesterase, B-GENE-Y
butyrylcholinesterase, B-GENE-Y
and O
lipoxygenase. B-GENE-N
Compounds O
1 O
and O
4-7 O
exhibited O
significant O
activity O
against O
all O
the O
tested O
enzymes, O
whereas O
compounds O
2 O
and O
3 O
were O
found O
inactive. O
Anti-inflammatory O
effect O
of O
essential O
oil O
and O
its O
constituents O
from O
fingered O
citron O
(Citrus O
medica O
L. O
var. O
sarcodactylis) O
through O
blocking O
JNK, B-GENE-N
ERK B-GENE-N
and O
NF-κB B-GENE-N
signaling O
pathways O
in O
LPS-activated O
RAW O
264.7 O
cells. O
We O
investigated O
the O
composition O

of O
essential O
oil O
from O
fingered O
citron O
(Citrus O
medica O
L. O
var. O
sarcodactylis) O
(FCEO) O
peels O
by O
GC-MS O
and O
its O
anti-inflammatory O
effects O
on O
lipopolysaccharide O
(LPS) O
- O
stimulated O
mouse O
macrophage O
(RAW O
264.7) O
cells. O
Fifteen O
compounds, O
representing O
98.97% O
of O
the O
essential O
oil, O
were O
tentatively O
identified; O
the O
main O
constituents O
were O
limonene B-CHEMICAL
(52.44%) O
and O
γ-terpinene B-CHEMICAL
(28.41%). O
FCEO O
significantly O
inhibited O
nitric B-CHEMICAL

oxide I-CHEMICAL
(NO) B-CHEMICAL
and O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
by O
suppressing O
the O
protein O
expression O
of O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
and O
cyclooxygenase B-GENE-Y
(COX)-2, I-GENE-Y
respectively. O
Additionally, O
FCEO O
suppressed O
the O
production O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α), B-GENE-Y
interleukin B-GENE-Y
(IL)-1β, I-GENE-Y
and O
IL-6. B-GENE-Y
FCEO O
attenuated O
LPS-induced O
nuclear B-GENE-N
factor-κB I-GENE-N
(NF-κB) B-GENE-N
activation O
via O
inhibition O
of O
inhibitor B-GENE-Y

κB-α I-GENE-Y
phosphorylation. O
Furthermore, O
FCEO O
blocked O
activation O
of O
c-Jun B-GENE-N
N-terminal I-GENE-N
kinase I-GENE-N
(JNK) B-GENE-N
and O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
but O
not O
that O
of O
p38 B-GENE-N
mitogen-activated I-GENE-N
protein I-GENE-N
kinase. I-GENE-N
These O
results O
indicate O
that O
FCEO O
inhibits O
LPS-stimulated O
inflammation O
by O
blocking O
the O
NF-κB, B-GENE-N
JNK, B-GENE-N
and O
ERK B-GENE-N
pathways O
in O
macrophages, O
and O
demonstrate O
that O
FCEO O
possesses O
anti-inflammatory O
properties. O
Modulation O
of O
TNF B-GENE-Y
and O
GM-CSF B-GENE-Y
release O
from O
dispersed O
human O
nasal O
polyp O
cells O
and O

human O
whole O
blood O
by O
inhibitors O
of O
different O
PDE B-GENE-N
isoenzymes O
and O
glucocorticoids. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
role O
of O
the O
inhibitors O
of O
different O
PDE B-GENE-N
isoenzymes O
(PDE B-GENE-N
1-5) I-GENE-N
on O
the O
production O
of O
two O
pro-inflammatory O
cytokines B-GENE-N
- O
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TNF) B-GENE-Y
and O
granulocyte-macrophage B-GENE-Y
colony-stimulating I-GENE-Y
factor I-GENE-Y
(GM-CSF). B-GENE-Y
Two O
in O
vitro O
models O
were O
used O
to O
compare O
the O
antiinflammatory O
properties O
of O
PDE B-GENE-N
inhibitors O
with O
that O
of O

glucocorticoids. O
The O
effect O
on O
TNF B-GENE-Y
release O
from O
diluted O
human O
blood O
following O
lipopolysaccharide O
(LPS O
from O
Salmonella O
abortus O
equi) O
stimulation O
as O
well O
as O
the O
GM-CSF B-GENE-Y
and O
TNF B-GENE-Y
release O
from O
human O
nasal O
polyp O
cells O
following O
allergic O
stimulation O
were O
investigated. O
Both O
models O
proofed O
to O
be O
well O
suited O
for O
the O
characterisation O
of O
the O
antiinflammatory O
properties O
of O
new O
chemical O
entities. O
In O
diluted O
human O
blood O
and O
dispersed O
human O
nasal O
polyp O
cells O
the O
induced O
TNF B-GENE-Y
release O
was O
most O
potently O
suppressed O
by O
selective O
PDE4 B-GENE-N
inhibitors. O

Amrinone B-CHEMICAL
and O
milrinone, B-CHEMICAL
selective O
PDE3 B-GENE-N
inhibitors, O
suppressed O
TNF B-GENE-Y
secretion O
to O
a O
lesser O
extent. O
The O
effects O
of O
theophylline B-CHEMICAL
(unspecific O
PDE B-GENE-N
inhibitor), O
vinpocetine B-CHEMICAL
(PDE1 B-GENE-N
inhibitor), O
EHNA O
(PDE2 B-GENE-Y
inhibitor) O
and O
the O
PDE5 B-GENE-Y
inhibitors O
zaprinast B-CHEMICAL
and O
E B-CHEMICAL
4021 I-CHEMICAL
were O
weak. O
In O
human O
blood, O
the O
tested O
glucocorticoids O
beclomethasone, B-CHEMICAL
dexamethasone B-CHEMICAL
and O
fluticasone B-CHEMICAL
inhibited O
the O
LPS O
induced O
TNF B-GENE-Y
release O
potently O
in O
a O
concentration O

dependent O
manner, O
whereas O
in O
dispersed O
human O
nasal O
polyp O
cells, O
the O
effect O
of O
the O
glucocorticoids O
on O
allergically O
induced O
TNF B-GENE-Y
release, O
with O
the O
exception O
of O
dexamethasone, B-CHEMICAL
was O
much O
less O
pronounced. O
Glucocorticoids O
were O
the O
most O
potent O
inhibitors O
of O
GM-CSF B-GENE-Y
release O
and O
the O
effect O
correlates O
well O
with O
the O
affinity O
to O
the O
glucocorticoid B-GENE-Y
receptor. I-GENE-Y
The O
selective O
PDE B-GENE-N
4 I-GENE-N
inhibitors, O
and O
to O
a O
certain O
extent O
the O
PDE3 B-GENE-N
inhibitors O
amrinone B-CHEMICAL
and O
milrinone, B-CHEMICAL
reduced O
the O
GM-CSF B-GENE-Y
release O
in O
a O
concentration O
dependent O
manner. O

In O
all O
investigations O
selective O
PDE4 B-GENE-N
inhibitors O
reduced O
TNF B-GENE-Y
release O
to O
a O
much O
higher O
degree O
(4-10 O
fold) O
than O
GM-CSF B-GENE-Y
release. O
Activating O
glucocorticoid B-GENE-Y
receptor-ERK I-GENE-Y
signaling O
pathway O
contributes O
to O
ginsenoside B-CHEMICAL
Rg1 I-CHEMICAL
protection O
against O
β-amyloid B-GENE-Y
peptide-induced I-GENE-Y
human O
endothelial O
cells O
apoptosis. O
The O
deposition O
of O
β-amyloid B-GENE-Y
(Aβ) B-GENE-Y
in O
neurons O
and O
vascular O
cells O
of O
the O
brain O
has O
been O
characterized O
in O
Alzheimer's O
disease. O
Ginsenoside B-CHEMICAL
Rg1 I-CHEMICAL
(Rg1) B-CHEMICAL
is O
an O
active O
components O
in O
Panax O

ginseng, O
a O
famous O
traditional O
Chinese O
medicines O
recorded O
in O
Compendium O
of O
Materia O
Medica. O
Present O
study O
attempted O
to O
evaluate O
the O
potential O
mechanisms O
of O
Aβ-mediated B-GENE-Y
insult O
and O
the O
protective O
effects O
of O
Rg1 B-CHEMICAL
on O
human O
endothelial O
cells. O
Rg1 B-CHEMICAL
attenuated O
the O
Aβ25-35-associated B-GENE-Y
mitochondrial O
apoptotic O
events, O
accompanied O
by O
inhibiting O
HIF-1α B-GENE-Y
expression O
followed O
by O
intracellular O
reactive O
nitrogen B-CHEMICAL
species O
generation, O
and O
protein O
nitrotyrosination. O
These O
protective O
effects O
were O
abolished O
by O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
(GR) B-GENE-Y
antagonist O
RU486 B-CHEMICAL
or O

p-ERK B-GENE-N
inhibitor O
U0126 B-CHEMICAL
rather O
than O
estrogen B-GENE-Y
receptor I-GENE-Y
α I-GENE-Y
antagonist O
ICI B-CHEMICAL
82,780. I-CHEMICAL
Taken O
together, O
our O
results O
suggested O
that O
Rg1 B-CHEMICAL
protected O
against O
Aβ25-35-induced B-GENE-Y
apoptosis O
at O
least O
in O
part O
by O
two O
complementary O
GR-dependent B-GENE-Y
ERK B-GENE-N
phosphorylation O
pathways: O
(1) O
down-regulating O
HIF-1α B-GENE-Y
initiated O
protein O
nitrotyrosination, O
and O
(2) O
inhibiting O
mitochondrial O
apoptotic O
cascades. O
These O
data O
provided O
a O
novel O
insight O
to O
the O
mechanisms O
of O
Rg1protective B-CHEMICAL
effects O
on O
Aβ25-35-induced B-GENE-Y

endothelial O
cells O
apoptosis, O
suggesting O
that O
GR-ERK B-GENE-Y
signaling O
pathway O
might O
play O
an O
important O
role O
in O
it. O
Aberrant O
transcription O
of O
the O
LHCGR B-GENE-Y
gene O
caused O
by O
a O
mutation O
in O
exon O
6A O
leads O
to O
Leydig O
cell O
hypoplasia O
type O
II. O
The O
luteinizing B-GENE-Y
hormone/chorionic I-GENE-Y
gonadotropin I-GENE-Y
receptor I-GENE-Y
(LHCGR) B-GENE-Y
is O
essential O
for O
normal O
male O
sex O
differentiation. O
Recently, O
the O
additional O
primate-specific O
exon O
6A O
of O
the O
LHCGR B-GENE-Y
was O
discovered O
and O
it O
was O
shown O
to O
act O
as O
regulatory O
element O
at O
the O
transcriptional O
level. O
Compound O

heterozygous O
mutations O
in O
exon O
6A O
(c.580 B-GENE-N
A>G) I-GENE-N
and O
exon O
11 O
(c.1244T>C) B-GENE-N
were O
identified O
in O
the O
LHCGR B-GENE-Y
of O
a O
male O
46,XY O
patient O
with O
genital O
malformation. O
Analysis O
revealed O
that O
mutation O
c.580A>G B-GENE-N
in O
exon O
6A O
affects O
the O
splicing O
pattern O
resulting O
in O
an O
increase O
of O
transcripts O
containing O
the O
internal O
variants O
of O
exon O
6A O
prone O
to O
nonsense-mediated O
decay. O
In O
contrast, O
mutation O
c.1244T>C B-GENE-N
results O
in O
an O
amino B-CHEMICAL
acid I-CHEMICAL
substitution O
(Ile415Thr), B-GENE-N

which O
abolishes O
signal O
transduction O
due O
to O
structural O
changes. O
When O
inherited O
in O
a O
compound O
heterozygous O
fashion O
these O
mutations O
result O
in O
Leydig O
cell O
hypoplasia O
(LCH) O
type O
II. O
Thus O
this O
study O
provides O
proof O
that O
mutations O
causing O
aberrant O
transcription O
can O
impair O
receptor O
function O
and O
thereby O
be O
causative O
of O
LCH. O
Effectiveness O
of O
endopeptidase B-GENE-N
inhibition O
(candoxatril) B-CHEMICAL
in O
congestive O
heart O
failure. O
Candoxatril B-CHEMICAL
is O
a O
novel, O
orally O
active O
inhibitor O
of O
neutral B-GENE-Y
endopeptidase I-GENE-Y
EC B-GENE-Y
3.4.24.11, I-GENE-Y
the O
enzyme O
that O

degrades O
atrial B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(ANP). B-GENE-Y
The O
acute O
and O
chronic O
(10 O
days O
treatment) O
hemodynamic O
and O
hormonal O
effects O
of O
candoxatril B-CHEMICAL
(150 O
mg O
twice O
daily) O
in O
12 O
patients O
with O
moderately O
severe O
congestive O
heart O
failure O
were O
investigated O
in O
a O
randomized, O
placebo-controlled, O
double-blind O
study. O
On O
study O
day O
1, O
candoxatril B-CHEMICAL
acutely O
increased O
plasma O
ANP B-GENE-Y
levels, O
suppressed O
aldosterone B-CHEMICAL
and O
decreased O
right O
atrial O
and O
pulmonary O
capillary O
wedge O
pressures. O
After O
10 O
days O
of O
treatment, O
basal O
ANP B-GENE-Y
was O
increased O
and O
basal O
aldosterone B-CHEMICAL
was O

decreased. O
Body O
weight O
was O
reduced, O
most O
likely O
reflecting O
chronic O
natriuretic O
or O
diuretic O
effects, O
or O
both, O
and O
there O
was O
a O
trend O
toward O
increased O
cardiac O
index O
and O
reduced O
preload O
values. O
On O
study O
day O
10, O
the O
acute O
effects O
of O
candoxatril B-CHEMICAL
were O
similar O
to O
those O
on O
day O
1 O
(i.e., O
ANP B-GENE-Y
was O
further O
increased, O
aldosterone B-CHEMICAL
was O
suppressed, O
and O
right O
and O
left O
ventricular O
filling O
pressures O
were O
decreased). O
Thus, O
candoxatril B-CHEMICAL
may O
offer O
a O
new O
and O
effective O
therapeutic O
approach O
in O
the O
treatment O
of O
heart O
failure. O
Longer O
HSD11B2 B-GENE-Y
CA-repeat B-GENE-N
in O
impaired O
glucose B-CHEMICAL
tolerance O

and O
type O
2 O
diabetes. O
Type B-GENE-Y
2 I-GENE-Y
11β-hydroxysteroid I-GENE-Y
dehydrogenase I-GENE-Y
encoded O
by O
the O
HSD11B2 B-GENE-Y
gene O
converts O
cortisol B-CHEMICAL
to O
inactive O
cortisone, B-CHEMICAL
and O
alteration O
in O
this O
enzymatic O
activity O
might O
affect O
glucose B-CHEMICAL
homeostasis O
by O
affecting O
circulating O
levels O
or O
tissue O
availability O
of O
glucocorticoids. O
We O
investigated O
the O
association O
of O
HSD11B2 B-GENE-Y
variant O
with O
glucose B-CHEMICAL
homeostasis. O
Subjects O
with O
normal O
glucose B-CHEMICAL
tolerance O
(n=585), O
impaired O
glucose B-CHEMICAL
tolerance O
(n=202) O
and O
type O
2 O
diabetes O
(n=355) O
were O
genotyped O
for O
a O

highly O
polymorphic O
CA-repeat B-GENE-N
polymorphism O
in O
the O
first O
intron O
of O
HSD11B2. B-GENE-Y
Allele O
and O
genotype O
frequencies O
differed O
between O
normal O
and O
impaired O
glucose B-CHEMICAL
tolerance O
(P O
= O
0.0014 O
and O
0.0407, O
respectively; O
4DF) O
or O
type O
2 O
diabetes O
(P O
= O
0.0053 O
and O
0.0078), O
with O
significant O
linear O
trends O
between O
the O
repeat O
length O
and O
the O
phenotype O
fraction. O
In O
normal O
subjects, O
total O
CA-repeat B-GENE-N
length O
was O
negatively O
correlated O
with O
fasting O
insulin B-GENE-Y
and O
HOMA-β. O
Thus, O
subjects O
having O
more O
CA B-GENE-N
repeats I-GENE-N
are O
susceptible O
to O
developing O
abnormal O
glucose B-CHEMICAL

tolerance, O
whereas O
normal O
subjects O
carrying O
more O
CA B-GENE-N
repeats I-GENE-N
appeared O
to O
have O
frugal O
characteristics O
in O
insulin B-GENE-Y
secretion. O
Efficacy O
and O
safety O
of O
tamsulosin B-CHEMICAL
in O
the O
treatment O
of O
urological O
diseases. O
The O
alpha(1)-adrenoceptor B-GENE-N
antagonist, O
tamsulosin, B-CHEMICAL
is O
selective O
for O
alpha(1A)- B-GENE-N
and I-GENE-N
alpha(1D)- I-GENE-N
over I-GENE-N
alpha(1B)-adrenoceptors. I-GENE-N
Both O
placebo-controlled O
and O
comparative O
studies O
with O
other O
agents O
have O
demonstrated O
tamsulosin B-CHEMICAL
to O
be O
an O
effective O
treatment O
for O
patients O
with O
lower O
urinary O
symptoms O
suggestive O
of O
benign O
prostatic O

hyperplasia. O
Its O
effectiveness O
appears O
to O
be O
maintained O
over O
many O
years. O
Tamsulosin B-CHEMICAL
may O
also O
effectively O
reduce O
lower O
urinary O
tract O
symptoms O
in O
other O
urological O
diseases. O
A O
dose O
of O
tamsulosin B-CHEMICAL
0.4 O
mg/day O
has O
a O
tolerability O
close O
to O
that O
of O
placebo O
and O
has O
little, O
if O
any, O
blood O
pressure O
lowering O
effects. O
Tolerability O
and O
lack O
of O
blood O
pressure O
lowering O
are O
maintained O
even O
in O
high-risk O
patients O
such O
as O
those O
with O
cardiovascular O
comorbidity O
and/or O
comedication. O
Apart O
from O
adrenoceptor B-GENE-N
subtype-selectivity, O
a O
smooth O
pharmacokinetic O

profile O
of O
its O
modified-release O
formulation O
and O
a O
selective O
accumulation O
in O
target O
tissues O
may O
contribute O
to O
an O
excellent O
efficacy:tolerability O
ratio. O
Pioglitazone B-CHEMICAL
protects O
against O
cisplatin B-CHEMICAL
induced O
nephrotoxicity O
in O
rats O
and O
potentiates O
its O
anticancer O
activity O
against O
human O
renal O
adenocarcinoma O
cell O
lines. O
Cisplatin-induced B-CHEMICAL
nephrotoxicity O
is O
a O
serious O
problem O
that O
limits O
its O
use O
in O
cancer O
treatment. O
The O
present O
study O
aimed O
to O
investigate O
the O
renal O
protective O
capacity O
of O
pioglitazone B-CHEMICAL
to O
reduce O
the O
cisplatin- B-CHEMICAL
induced O

nephrotoxicity. O
The O
underlying O
suggested O
mechanism(s) O
and O
whether O
this O
nephroprotective O
effect O
(if O
any) O
interferes O
with O
the O
cytotoxic O
effect O
of O
cisplatin B-CHEMICAL
on O
cancer O
cells O
were O
also O
investigated. O
Pioglitazone, B-CHEMICAL
Bisphenol B-CHEMICAL
A I-CHEMICAL
diglycidyl I-CHEMICAL
ether, I-CHEMICAL
BADGE, B-CHEMICAL
IP O
injected O
(Peroxisome B-GENE-Y
proliferator- I-GENE-Y
activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
(PPAR-γ) B-GENE-Y
antagonist), O
or O
their O
combination O
were O
administered O
to O
rats O
one O
hour O
before O
cisplatin B-CHEMICAL
injection. O
Moreover, O
their O
effects O
on O
the O
cell O
viability O
of O
human O
renal O

adenocarcinoma O
cell O
models O
(ACHN) O
were O
studied. O
The O
obtained O
results O
showed O
that O
pioglitazone B-CHEMICAL
improved O
the O
renal O
function, O
structural O
changes, O
renal O
malondialdehyde B-CHEMICAL
(MDA), B-CHEMICAL
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TNF-α), B-GENE-Y
nuclear B-GENE-N
factor I-GENE-N
kappa I-GENE-N
B I-GENE-N
(NF-κB) B-GENE-N
genes O
expression O
in O
cisplatin B-CHEMICAL
injected O
rats. O
It O
increased O
both O
renal O
reduced O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
content O
and O
PPAR-γ B-GENE-Y
gene O
expression. O
In O
contrast O
to O
the O
data O
obtained O
by O
prior O
administration O
of O
BADGE. B-CHEMICAL
Pioglitazone B-CHEMICAL

also O
potentiated O
the O
cytotoxic O
effect O
of O
cisplatin B-CHEMICAL
on O
human O
renal O
adenocarcinoma O
cells O
and O
this O
effect O
was O
abolished O
by O
BADGE B-CHEMICAL
co O
administration. O
In O
conclusion, O
these O
results O
suggested O
that O
pioglitazone B-CHEMICAL
protected O
against O
cisplatin- B-CHEMICAL
induced O
nephrotoxicity O
through O
its O
interaction O
with O
PPAR-γ B-GENE-Y
receptors O
and O
antioxidant O
effects. O
Furthermore, O
pioglitazone B-CHEMICAL
did O
not O
interfere O
but O
rather O
potentiated O
the O
cytotoxic O
effects O
of O
cisplatin B-CHEMICAL
on O
human O
renal O
adenocarcinoma O
cells. O
A O
structural O
and O
functional O
perspective O
into O
the O

mechanism O
of O
Ca2+-sensitizers B-CHEMICAL
that O
target O
the O
cardiac O
troponin B-GENE-N
complex. I-GENE-N
The O
Ca(2+) B-CHEMICAL
dependent O
interaction O
between O
troponin B-GENE-N
I I-GENE-N
(cTnI) B-GENE-N
and O
troponin B-GENE-N
C I-GENE-N
(cTnC) B-GENE-N
triggers O
contraction O
in O
heart O
muscle. O
Heart O
failure O
is O
characterized O
by O
a O
decrease O
in O
cardiac O
output, O
and O
compounds O
that O
increase O
the O
sensitivity O
of O
cardiac O
muscle O
to O
Ca(2+) B-CHEMICAL
have O
therapeutic O
potential. O
The O
Ca(2+)-sensitizer, B-CHEMICAL
levosimendan, B-CHEMICAL
targets O
cTnC; O
however, O
detailed O
understanding O
of O
its O
mechanism O
has O
been O

obscured O
by O
its O
instability. O
In O
order O
to O
understand O
how O
this O
class O
of O
positive O
inotropes O
function, O
we O
investigated O
the O
mode O
of O
action O
of O
two O
fluorine B-CHEMICAL
containing O
novel O
analogs O
of O
levosimendan; B-CHEMICAL
2',4'-difluoro(1,1'-biphenyl)-4-yloxy B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
(dfbp-o) B-CHEMICAL
and O
2',4'-difluoro(1,1'-biphenyl)-4-yl B-CHEMICAL
acetic I-CHEMICAL
acid I-CHEMICAL
(dfbp). B-CHEMICAL
The O
affinities O
of O
dfbp B-CHEMICAL

and O
dfbp-o B-CHEMICAL
for O
the O
regulatory O
domain O
of O
cTnC B-GENE-N
were O
measured O
in O
the O
absence O
and O
presence O
of O
cTnI O
by O
NMR O
spectroscopy, O
and O
dfbp-o B-CHEMICAL
was O
found O
to O
bind O
more O
strongly O
than O
dfbp. B-CHEMICAL
Dfbp-o B-CHEMICAL
also O
increased O
the O
affinity O
of O
cTnI B-GENE-N
for O
cTnC. B-GENE-N
Dfbp-o B-CHEMICAL
increased O
the O
Ca(2+)-sensitivity B-CHEMICAL
of O
demembranated O
cardiac O
trabeculae O
in O
a O
manner O
similar O
to O
levosimendan. B-CHEMICAL
The O
high O
resolution O
NMR O
solution O
structure O
of O
the O

cTnC-cTnI-dfbp-o B-GENE-N
ternary O
complex O
showed O
that O
dfbp-o B-CHEMICAL
bound O
at O
the O
hydrophobic O
interface O
formed O
by O
cTnC B-GENE-N
and O
cTnI B-GENE-N
making O
critical O
interactions O
with O
residues O
such O
as O
Arg147 O
of O
cTnI. B-GENE-N
In O
the O
absence O
of O
cTnI, B-GENE-N
docking O
localized O
dfbp-o B-CHEMICAL
to O
the O
same O
position O
in O
the O
hydrophobic O
groove O
of O
cTnC. B-GENE-N
The O
structural O
and O
functional O
data O
reveal O
that O
the O
levosimendan B-CHEMICAL
class O
of O
Ca(2+)-sensitizers B-CHEMICAL
work O
by O
binding O

to O
the O
regulatory O
domain O
of O
cTnC B-GENE-N
and O
stabilizing O
the O
pivotal O
cTnC-cTnI B-GENE-N
regulatory O
unit O
via O
a O
network O
of O
hydrophobic O
and O
electrostatic O
interactions, O
in O
contrast O
to O
the O
destabilizing O
effects O
of O
antagonists O
such O
as O
W7 O
at O
the O
same O
interface. O
Induction O
of O
cyp1a1 B-GENE-Y
is O
a O
nonspecific O
biomarker O
of O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
activation: O
results O
of O
large O
scale O
screening O
of O
pharmaceuticals O
and O
toxicants O
in O
vivo O
and O
in O
vitro. O
Expression O
of O
Cyp1a1 B-GENE-Y
and O
its O
related O
enzyme O
activity O
have O
long O
been O
used O
as O
a O

biomarker O
for O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AhR) B-GENE-Y
activation O
and O
a O
warning O
of O
dioxin-like B-CHEMICAL
toxicity. O
As O
a O
result, O
induction O
of O
Cyp1a1 B-GENE-Y
by O
pharmaceutical O
drug O
candidates O
or O
environmental O
contaminants O
raises O
significant O
concern O
in O
risk O
assessment. O
The O
current O
study O
evaluates O
the O
specificity O
of O
Cyp1a1 B-GENE-Y
induction O
as O
a O
marker O
for O
AhR B-GENE-Y
affinity O
and O
activation O
and O
provides O
context O
to O
assess O
the O
relevancy O
of O
AhR B-GENE-Y
activation O
to O
risk O
assessment. O
In O
vivo O
experiments O
examined O
the O
expression O
of O
Cyp1a1 B-GENE-Y
and O
other O
AhR-regulated B-GENE-Y
genes O
in O
liver, O
kidney, O
and O
heart O
in O
response O
to O

596 O
compounds. O
From O
this O
data O
set, O
a O
subset O
of O
147 O
compounds O
was O
then O
evaluated O
for O
their O
ability O
to O
activate O
or O
bind O
to O
the O
AhR B-GENE-Y
using O
a O
combination O
of O
gel O
shift, O
reporter O
gene, O
and O
competitive O
receptor O
binding O
assays. O
Whereas O
in O
vivo O
Cyp1a1 B-GENE-Y
mRNA O
expression O
is O
a O
sensitive O
marker O
for O
AhR B-GENE-Y
activation, O
it O
lacks O
specificity, O
because O
81 O
(59%) O
of O
137 O
compounds O
were O
found O
to O
significantly O
induce O
Cyp1a1 B-GENE-Y
in O
vivo O
but O
were O
not O
verified O
to O
bind O
or O
activate O
the O
AhR B-GENE-Y
in O
vitro. O
Combining O
in O
vivo O
and O
in O
vitro O
findings, O
we O
identified O
nine O

AhR B-GENE-Y
agonists, O
six O
of O
which O
are O
marketed O
therapeutics O
and O
have O
been O
approved O
by O
the O
U.S. O
Food O
and O
Drug O
Administration, O
including O
leflunomide, B-CHEMICAL
flutamide, B-CHEMICAL
and O
nimodipine. B-CHEMICAL
These O
drugs O
do O
not O
produce O
dioxin-like B-CHEMICAL
toxicity O
in O
rats O
or O
in O
humans. O
These O
data O
demonstrate O
that O
induction O
of O
Cyp1a1 B-GENE-Y
is O
a O
nonspecific O
biomarker O
of O
direct O
AhR B-GENE-Y
affinity O
and O
activation O
and O
lend O
further O
support O
to O
the O
hypothesis O
that O
Cyp1a1 B-GENE-Y
induction O
and/or O
AhR B-GENE-Y
activation O
is O
not O
synonymous O
with O
dioxin-like B-CHEMICAL
toxicity. O
No O
mutations O
in O
the O

serotonin B-CHEMICAL
related O
TPH1 B-GENE-Y
and O
HTR1B B-GENE-Y
genes O
in O
patients O
with O
monogenic O
sclerosing O
bone O
disorders. O
Since O
the O
identification O
of O
LRP5 B-GENE-Y
as O
the O
causative O
gene O
for O
the O
osteoporosis O
pseudoglioma O
syndrome O
(OPPG) O
as O
well O
as O
the O
high O
bone O
mass O
(HBM) O
phenotype, O
LRP5 B-GENE-Y
and O
the O
Wnt/β-catenin B-GENE-N
signaling O
have O
been O
extensively O
studied O
for O
their O
role O
in O
the O
differentiation O
and O
proliferation O
of O
osteoblasts, O
in O
the O
apoptosis O
of O
osteoblasts O
and O
osteocytes O
and O
in O
the O
response O
of O
bone O
to O
mechanical O

loading. O
However, O
more O
recently O
the O
direct O
effect O
of O
LRP5 B-GENE-Y
on O
osteoblasts O
and O
bone O
formation O
has O
been O
questioned. O
Gene O
expression O
studies O
showed O
that O
mice O
lacking O
lrp5 B-GENE-Y
have O
increased O
expression O
of O
tph1, B-GENE-Y
the O
rate O
limiting O
enzyme O
for O
the O
production O
of O
serotonin B-CHEMICAL
in O
the O
gut. O
Furthermore O
mice O
lacking O
either O
tph1 B-GENE-Y
or O
htr1B, B-GENE-Y
the O
receptor O
for O
serotonin B-CHEMICAL
on O
the O
osteoblasts, O
were O
reported O
to O
have O
an O
increased O
bone O
mass O
due O
to O
increased O
bone O
formation. O
This O
led O
to O
the O
still O
controversial O
hypothesis O
that O
LRP5 B-GENE-Y
influences O
bone O
formation O
indirectly O
by O
regulating O
the O
expression O
of O
thp1 B-GENE-Y
and O

as O
a O
consequence O
influencing O
the O
production O
of O
serotonin B-CHEMICAL
in O
the O
gut. O
Based O
on O
these O
data O
we O
decided O
to O
evaluate O
the O
role O
of O
TPH1 B-GENE-Y
and O
HTR1B B-GENE-Y
in O
the O
development O
of O
craniotubular O
hyperostoses, O
a O
group O
of O
monogenic O
sclerosing O
bone O
dysplasias. O
We O
screened O
the O
coding O
regions O
of O
both O
genes O
in O
53 O
patients O
lacking O
a O
mutation O
in O
the O
known O
causative O
genes O
LRP5, B-GENE-Y
LRP4 B-GENE-Y
and O
SOST. B-GENE-Y
We O
could O
not O
find O
disease-causing O
coding O
variants O
in O
neither O
of O
the O
tested O
genes O
and O
therefore, O
we O
cannot O
provide O
support O
for O
an O
important O

function O
of O
TPH1 B-GENE-Y
and O
HTR1B B-GENE-Y
in O
the O
pathogenesis O
of O
sclerosing O
bone O
dysplasias O
in O
our O
tested O
patient O
cohort. O
Grb10-mediated B-GENE-Y
Negative O
Regulation O
of O
IGF1R-Activated B-GENE-Y
Signalling O
Pathway O
Results O
in O
Cognitive O
Disorder O
in O
Diabetic O
Rats. O
Growth B-GENE-Y
factor I-GENE-Y
receptor-bound I-GENE-Y
protein I-GENE-Y
10(Grb10)is I-GENE-Y
a O
Src B-GENE-N
homology I-GENE-N
2 I-GENE-N
(SH2) I-GENE-N
domain-containing I-GENE-N
protein O
and O
one O
of O
the O
binding O
partners O
for O
several O
trans-membrane O
tyrosine-kinase B-GENE-N
receptors, I-GENE-N
including O
insulin B-GENE-Y
receptor I-GENE-Y
(IR) B-GENE-Y
and O

insulin-like B-GENE-Y
growth I-GENE-Y
factor-1 I-GENE-Y
receptor I-GENE-Y
(IGF1-R). B-GENE-Y
The O
hippocampus, O
which O
is O
critical O
for O
cognitive O
functions, O
is O
one O
of O
the O
main O
distribution O
areas O
of O
Grb10 B-GENE-Y
in O
the O
central O
nervous O
system. O
In O
recent O
years, O
diabetic O
encephalopathy O
has O
been O
defined O
as O
a O
third O
type O
of O
diabetes O
and O
the O
IGF1-IR B-GENE-Y
pathway O
has O
been O
shown O
to O
be O
critical O
for O
the O
neuropathogenic O
process O
of O
cognitive O
disorder O
in O
diabetes. O
However, O
the O
role O
of O
endogenous O
Grb10 B-GENE-Y
in O
regulating O
the O
IGF1-IR B-GENE-Y
pathway O
and O
neurobehavioral O

changes O
is O
not O
explicit. O
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
in O
vivo O
function O
of O
endogenous O
Grb10 B-GENE-Y
in O
diabetic O
encephalopathy O
and O
the O
underlying O
mechanisms. O
Using O
stereotaxic O
surgical O
techniques O
and O
lentiviral O
vectors O
expressing O
specific O
short O
hairpin O
RNA O
(shRNA), O
we O
could O
steadily O
knock O
down O
Grb10 B-GENE-Y
expression O
in O
the O
hippocampus. O
More O
importantly, O
we O
demonstrated O
that O
hippocampus-specific O
modulation O
of O
Grb10 B-GENE-Y
protein O
levels O
led O
to O
a O
prominent O
remission O
of O
cognitive O
disorder, O
including O
improvements O
in O
both O
ultrastructural O
pathology O
and O
abnormal O

neurobehavioural O
changes. O
Our O
findings O
indicate O
that O
endogenous O
overexpression O
of O
Grb10 B-GENE-Y
functions O
as O
a O
suppressor O
of O
the O
IGF1-IR B-GENE-Y
pathway, O
which O
may O
represent O
an O
important O
mechanism O
that O
regulates O
cognitive O
disorder O
in O
diabetes. O
This O
article O
is O
protected O
by O
copyright. O
All O
rights O
reserved. O
Drug O
cocktail O
interaction O
study O
on O
the O
effect O
of O
the O
orally O
administered O
lavender O
oil O
preparation O
silexan O
on O
cytochrome B-GENE-N
p450 I-GENE-N
enzymes O
in O
healthy O
volunteers. O
This O
cocktail O
study O
evaluated O
the O
interaction O
potential O
of O
the O
oral O
lavender O
oil O
preparation O
silexan O
with O
major O
P450 B-GENE-N
(cytochrome B-GENE-N

P450) I-GENE-N
enzymes. O
Subjects O
and O
Methods: O
Sixteen O
healthy O
male O
or O
female O
Caucasians O
completed O
this O
double-blind, O
randomized, O
2-fold O
crossover O
study. O
Silexan O
(160 O
mg) O
or O
placebo O
were O
administered O
once O
daily O
for O
11 O
days. O
Additionally, O
on O
day O
11 O
of O
both O
study O
periods, O
150 O
mg O
caffeine B-CHEMICAL
(CYP1A2), B-GENE-Y
125 O
mg O
tolbutamide B-CHEMICAL
(CYP2C9), B-GENE-Y
20 O
mg O
omeprazole B-CHEMICAL
(CYP2C19), B-GENE-Y
30 O
mg O
dextromethorphan-HBr B-CHEMICAL
(CYP2D6), B-GENE-Y

and O
2 O
mg O
midazolam B-CHEMICAL
(CYP3A4) B-GENE-Y
were O
administered O
orally. O
Formal O
interaction O
was O
excluded O
if O
the O
90% O
confidence O
interval O
(CI) O
for O
the O
silexan O
over O
placebo O
ratios O
for O
phenotyping O
metrics O
(primary: O
AUC0-t) O
was O
within O
a O
0.70-1.43 O
range. O
Results: O
According O
to O
the O
AUC0-t O
comparisons, O
silexan O
had O
no O
relevant O
effect O
on O
CYP1A2, B-GENE-N
2C9, I-GENE-N
2D6, I-GENE-N
and I-GENE-N
3A4 I-GENE-N
activity. O
Secondary O
phenotyping O
metrics O
confirmed O
this O
result. O
Mean O
ratios O
for O

all O
omeprazole-derived B-CHEMICAL
metrics O
were O
close O
to O
unity. O
The O
90% O
CI O
for O
the O
AUC0-t O
ratio O
of O
omeprazole B-CHEMICAL
but O
not O
for O
omeprazole/5-OH-omeprazole B-CHEMICAL
plasma O
ratio O
3 O
hours O
post-dose O
or O
omeprazole/5-OH-omeprazole B-CHEMICAL
AUC0-t O
ratio O
(secondary O
CYP2C19 B-GENE-Y
metrics) O
was O
above O
the O
predefined O
threshold O
of O
1.43, O
probably O
caused O
by O
the O
inherent O
high O
variability O
of O
omeprazole B-CHEMICAL
pharmacokinetics. O

Silexan O
and O
the O
phenotyping O
drugs O
were O
well O
tolerated. O
Repeated O
silexan O
(160 O
mg/day) O
administration O
has O
no O
clinically O
relevant O
inhibitory O
or O
inducing O
effects O
on O
the O
CYP1A2, B-GENE-N
2C9, I-GENE-N
2C19, I-GENE-N
2D6, I-GENE-N
and I-GENE-N
3A4 I-GENE-N
enzymes O
in O
vivo. O
Sulindac B-CHEMICAL
independently O
modulates O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
1/2 I-GENE-N
and O
cyclic B-GENE-N
GMP-dependent I-GENE-N
protein I-GENE-N
kinase I-GENE-N
signaling O
pathways. O
Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
mortality O
in O
the O
United O
States. O
Substantial O
human O
and O
animal O
data O
support O
the O
ability O
of O

nonsteroidal O
anti-inflammatory O
drugs O
to O
cause O
regression O
of O
existing O
colon O
tumors O
and O
prevent O
new O
tumor O
formation. O
The O
mechanism O
by O
which O
the O
nonsteroidal O
anti-inflammatory O
drug O
sulindac B-CHEMICAL
prevents O
tumor O
growth O
is O
poorly O
understood O
and O
seems O
complex O
as O
sulindac B-CHEMICAL
can O
modulate O
several O
growth-related O
signaling O
pathways. O
Sulindac B-CHEMICAL
metabolites O
simultaneously O
(a) O
increase O
cellular O
cyclic B-CHEMICAL
GMP I-CHEMICAL
and O
subsequently O
activate O
cyclic B-GENE-N
GMP-dependent I-GENE-N
protein I-GENE-N
kinase I-GENE-N
(PKG); B-GENE-N
(b) O
activate O
c-jun B-GENE-N
NH2-terminal I-GENE-N
kinase I-GENE-N
(JNK); B-GENE-N
(c) O
inhibit O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N

1/2 I-GENE-N
(ERK1/2); B-GENE-N
and O
(d) O
decrease O
beta-catenin B-GENE-Y
protein O
expression O
at O
times O
and O
doses O
consistent O
with O
apoptosis. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PKG, B-GENE-N
ERK1/2, B-GENE-N
JNK, B-GENE-N
and O
beta-catenin B-GENE-Y
are O
independent O
targets O
for O
sulindac B-CHEMICAL
in O
vitro. O
Pharmacologic O
activation O
of O
PKG B-GENE-N
with O
YC-1 B-CHEMICAL
increases O
JNK B-GENE-N
phosphorylation O
and O
induces O
apoptosis O
in O
colon O
cancer O
cells O
without O
modulating O
ERK1/2 B-GENE-N
phosphorylation O
or O

beta-catenin B-GENE-Y
protein O
expression. O
Inhibition O
of O
ERK1/2 B-GENE-N
with O
U0126 B-CHEMICAL
induces O
apoptosis O
but O
fails O
to O
activate O
JNK B-GENE-N
phosphorylation O
or O
down-regulate O
beta-catenin B-GENE-Y
protein O
expression. O
Cotreatment O
with O
U0126 B-CHEMICAL
and O
YC-1 B-CHEMICAL
synergistically O
increases O
apoptosis O
in O
colorectal O
cancer O
cells O
and O
recapitulates O
the O
effects O
of O
sulindac B-CHEMICAL
treatment O
on O
ERK1/2, B-GENE-N
JNK, B-GENE-N
and O
beta-catenin. B-GENE-Y
These O
results O
indicate O
that O
sulindac B-CHEMICAL
metabolites O
modulate O
ERK1/2 B-GENE-N
and O

PKG B-GENE-N
pathways O
independently O
in O
colon O
cancer O
cells O
and O
suggest O
that O
the O
full O
apoptotic O
effect O
of O
sulindac B-CHEMICAL
is O
mediated O
by O
more O
than O
one O
pathway. O
Using O
similar O
combinatorial O
approaches O
in O
vivo O
may O
provide O
more O
effective, O
less O
toxic O
chemopreventive O
and O
chemotherapeutic O
strategies. O
Such O
therapies O
could O
dramatically O
reduce O
the O
incidence O
and O
death O
rate O
from O
colorectal O
cancer. O
Synthesis O
and O
antagonistic O
activity O
at O
muscarinic B-GENE-N
receptor I-GENE-N
subtypes O
of O
some O
2-carbonyl B-CHEMICAL
derivatives O
of O
diphenidol. B-CHEMICAL
A O
series O
of O
2-carbonyl B-CHEMICAL
analogues O
of O
the O

muscarinic O
antagonist O
diphenidol B-CHEMICAL
bearing O
1-substituents O
of O
different O
lipophilic, O
electronic, O
and O
steric O
properties O
was O
synthesized O
and O
their O
affinity O
for O
the O
M2 B-GENE-N
and I-GENE-N
M3 I-GENE-N
muscarinic I-GENE-N
receptor I-GENE-N
subtypes O
was O
evaluated O
by O
functional O
tests. O
Two O
derivatives O
(2g O
and O
2d) O
showed O
an O
M2-selective B-GENE-Y
profile O
which O
was O
confirmed O
by O
functional O
tests O
on O
the O
M1 B-GENE-N
and I-GENE-N
M4 I-GENE-N
receptors. I-GENE-N
A O
possible O
relationship O
between O
M2 B-GENE-Y
selectivity O
and O
lipophilicity O
of O
the O
1-substituent O
was O
suggested O
by O
structure-activity O
analysis. O
This O
work O
showed O
that O
appropriate O
structural O
modification O

of O
diphenidol B-CHEMICAL
can O
lead O
to O
M2-selective B-GENE-Y
muscarinic O
antagonists O
of O
possible O
interest O
in O
the O
field O
of O
Alzheimer's O
disease. O
Activation O
of O
an O
apoptotic O
signal O
transduction O
pathway O
involved O
in O
the O
upregulation O
of O
calpain B-GENE-N
and O
apoptosis-inducing B-GENE-Y
factor I-GENE-Y
in O
aldosterone-induced B-CHEMICAL
primary O
cultured O
cardiomyocytes. O
In O
this O
study, O
aldosterone B-CHEMICAL
(ALD)-induced B-CHEMICAL
apoptosis O
of O
cardiomyocyte O
was O
evaluated O
based O
on O
the O
previous O
studies, O
and O
the O
roles O
of O
calpain B-GENE-N
signaling O
were O
clarified. O
Primary O
cultured O
rat O

cardiomyocytes O
were O
injured O
by O
ALD B-CHEMICAL
(0.01-10 O
μM) O
for O
varying O
time O
periods. O
Then, O
the O
effects O
of O
ethylene B-CHEMICAL
glycol I-CHEMICAL
tetraacetic I-CHEMICAL
acid I-CHEMICAL
(EGTA) B-CHEMICAL
(0.5 O
mM), O
calpeptin B-CHEMICAL
(2.5 O
μM), O
and O
spironoclactone B-CHEMICAL
(10 O
μM) O
were O
evaluated O
on O
cardiomyocytes O
activated O
by O
ALD. B-CHEMICAL
Cardiomyocytes O
that O
were O
injured O
by O
ALD B-CHEMICAL
were O
assayed O
by O
the O
MTT B-CHEMICAL
and O
LDH B-GENE-N
leakage O
ratio. O
Apoptosis O
was O
evaluated O
by O
a O

TUNEL O
assay, O
annexin O
V/PI O
staining, O
and O
caspase-3 B-GENE-Y
activity. O
The O
expression O
of O
cleavage O
of O
Bid B-GENE-Y
(tBid), B-GENE-Y
calpain B-GENE-N
and O
apoptosis-inducing B-GENE-Y
factor I-GENE-Y
(AIF) B-GENE-Y
was O
evaluated O
by O
western O
blot O
analysis. O
ALD B-CHEMICAL
increased O
calpain B-GENE-N
expression O
and O
caspase-3 B-GENE-Y
activity O
and O
promoted O
Bid O
cleavage. O
It O
also O
induced O
the O
release O
of O
AIF B-GENE-Y
from O
mitochondria O
into O
the O
cytosol. O
The O
upregulation O
of O
calpain, B-GENE-N
tBid B-GENE-Y
and O
caspase-3 B-GENE-Y

activity O
were O
further O
inhibited O
by O
treatment O
with O
EGTA B-CHEMICAL
in O
the O
presence O
of O
ALD. B-CHEMICAL
Additionally, O
AIF B-GENE-Y
levels O
in O
the O
cytosol O
decreased O
due O
to O
EGTA B-CHEMICAL
but O
not O
due O
to O
calpeptin. B-CHEMICAL
This O
was O
also O
accompanied O
by O
a O
significant O
decrease O
in O
apoptosis. O
Furthermore, O
treatment O
with O
spironoclactone B-CHEMICAL
not O
only O
attenuated O
the O
pro-apoptotic O
effect O
of O
ALD B-CHEMICAL
but O
reversed O
the O
ALD-induced B-CHEMICAL
increase O
of O
calpain B-GENE-N
and O
AIF B-GENE-Y
levels. O
Loperamide, B-CHEMICAL
an O
opiate O
analog, O
differently O
modifies O
the O
adrenocorticotropin B-GENE-Y

responses O
to O
corticotropin-releasing B-GENE-Y
hormone I-GENE-Y
and O
lysine B-GENE-Y
vasopressin I-GENE-Y
in O
patients O
with O
Addison's O
disease. O
Loperamide B-CHEMICAL
is O
a O
peripheral O
opiate O
agonist O
able O
to O
inhibit O
ACTH B-GENE-Y
secretion. O
In O
this O
work, O
the O
interactions O
between O
loperamide B-CHEMICAL
and O
two O
ACTH B-GENE-Y
secretagogues, O
lysine B-GENE-Y
vasopressin I-GENE-Y
(LVP) B-GENE-Y
and O
corticotropin-releasing B-GENE-Y
hormone I-GENE-Y
(CRH), B-GENE-Y
were O
investigated O
in O
patients O
with O
Addison's O
disease. O
After O
loperamide B-CHEMICAL
(16 O
mg O
orally) O
or O
placebo O
administration, O
5 O
patients O
received O
LVP B-GENE-Y

(0.06 O
IU/kg O
i.v. O
over O
1 O
h) O
and O
6 O
patients O
received O
oCRH B-GENE-Y
(1 O
micrograms/kg O
i.v. O
as O
bolus). O
In O
all O
patients O
loperamide B-CHEMICAL
induced O
a O
significant O
fall O
in O
plasma O
ACTH B-GENE-Y
levels. O
LVP B-GENE-Y
increased O
ACTH B-GENE-Y
levels O
after O
both O
loperamide B-CHEMICAL
(from O
48 O
+/- O
17.3 O
to O
a O
peak O
of O
95 O
+/- O
21 O
pmol/l) O
and O
placebo O
(from O
231 O
+/- O
59.5 O
to O
365 O
+/- O
86.6 O
pmol/l): O
the O
interaction O
between O
treatments O
and O
time O
was O
not O

significant. O
CRH B-GENE-Y
caused O
a O
rise O
in O
plasma O
ACTH B-GENE-Y
after O
both O
loperamide B-CHEMICAL
(from O
30 O
+/- O
16.6 O
to O
a O
peak O
of O
108 O
+/- O
31 O
pmol/l) O
and O
placebo O
(from O
98.5 O
+/- O
47 O
to O
211 O
+/- O
61.7 O
pmol/l): O
the O
interaction O
between O
treatments O
and O
time O
was O
significant, O
and O
the O
first O
phase O
of O
CRH-induced B-GENE-Y
ACTH B-GENE-Y
secretion O
was O
significantly O
lower O
after O
loperamide. B-CHEMICAL
These O
data O
demonstrate O
that O
loperamide B-CHEMICAL
differently O
modifies O
the O
stimulatory O
action O
of O
LVP B-GENE-Y
and O
CRH B-GENE-Y
on O
ACTH B-GENE-Y

secretion: O
namely, O
LVP B-GENE-Y
and O
loperamide B-CHEMICAL
act O
in O
an O
additive O
manner, O
while O
CRH B-GENE-Y
and O
loperamide B-CHEMICAL
interact O
in O
a O
non O
additive O
way. O
Although O
these O
findings O
might O
be O
explained O
by O
the O
involvement O
of O
different O
intracellular O
ACTH-secreting B-GENE-Y
mechanisms, O
an O
influence O
of O
loperamide B-CHEMICAL
on O
some O
suprapituitary O
factors O
modulating O
the O
ACTH B-GENE-Y
response O
is O
suggested. O
Comparisons O
of O
beta-adrenergic O
blocking O
properties O
of O
S- B-CHEMICAL
and I-CHEMICAL
R-timolol I-CHEMICAL
in O
humans. O
In O
animals, O
the O
R-enantiomer B-CHEMICAL
of I-CHEMICAL
timolol I-CHEMICAL
causes O
a O
significant O
reduction O
in O

intraocular O
pressure O
but O
had O
only O
1/80 O
the O
activity O
of O
the O
S-enantiomer O
at O
extraocular B-GENE-N
receptors. I-GENE-N
The O
beta B-GENE-N
1- I-GENE-N
and I-GENE-N
beta I-GENE-N
2-adrenoceptor I-GENE-N
blocking O
properties O
of O
orally O
administered O
R- B-CHEMICAL
and I-CHEMICAL
S-timolol I-CHEMICAL
were O
compared O
in O
a O
double-blind O
placebo O
controlled O
trial O
in O
two O
groups O
of O
healthy O
men. O
Each O
subject O
in O
group O
A O
(n O
= O
6) O
received O
placebo, O
1 O
and O
3 O
mg O
S-timolol B-CHEMICAL
and O
25 O
and O
75 O
mg O
R-timolol B-CHEMICAL
in O
random O
order, O
group O
B O
(n O
= O
5) O
received O
placebo, O
0.5, O

and O
1 O
mg O
S-timolol B-CHEMICAL
and O
3 O
and O
10 O
mg O
R-timolol. B-CHEMICAL
In O
both O
groups, O
R- B-CHEMICAL
and I-CHEMICAL
S-timolol I-CHEMICAL
comparably O
inhibited O
isoproterenol-induced B-CHEMICAL
increases O
in O
heart O
rate O
(P O
< O
.05), O
forearm O
blood O
flow O
(P O
< O
.05, O
except O
at O
3 O
micrograms/minute O
of O
isoproterenol B-CHEMICAL
after O
the O
R-doses O
in O
group O
B), O
and O
finger O
tremor O
(P O
< O
.05) O
in O
comparison O
with O
placebo. O
The O
findings O
for O
the O
R-enantiomer O
in O
this O
study O
were O
unexpected O
based O
on O
the O
animal O

studies O
and O
previous O
studies O
that O
demonstrated O
marked O
differences O
in O
beta O
blocking O
effects O
of O
other O
beta-blockers O
in O
which O
the O
R-enantiomers O
were O
less O
inhibitory. O
Rosmarinic B-CHEMICAL
acid I-CHEMICAL
ameliorates O
acute O
liver O
damage O
and O
fibrogenesis O
in O
carbon B-CHEMICAL
tetrachloride-intoxicated I-CHEMICAL
mice. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
therapeutic O
potential O
of O
rosmarinic B-CHEMICAL
acid I-CHEMICAL
(RA), O
a O
natural O
phenolic, O
in O
the O
treatment O
of O
acute O
liver O
toxicity. O
RA O
at O
10, O
25 O
and O
50mg/kg O
was O
administered O
by O
gavage O
once O
daily O
for O
2 O
consecutive O
days, O
6h O
after O

CCl(4) B-CHEMICAL
intoxication. O
CCl(4) B-CHEMICAL
intoxication O
caused O
hepatic O
necrosis O
and O
increased O
serum O
ALT B-GENE-N
activity. O
In O
the O
livers, O
oxidative/nitrosative O
stress O
was O
evidenced O
by O
increased O
3-nitrotyrosine B-CHEMICAL
(3-NT) B-CHEMICAL
and O
thiobarbituric B-CHEMICAL
acid I-CHEMICAL
reactive O
substances O
(TBARS) O
formation O
and O
a O
significant O
decrease O
in O
Cu/Zn B-GENE-Y
superoxide I-GENE-Y
dismutase I-GENE-Y
(SOD) B-GENE-N
activity. O
CCl(4) B-CHEMICAL
administration O
triggered O
inflammatory O
response O
in O
mice O
livers O
by O
activating O
nuclear B-GENE-N
factor-kappaB I-GENE-N

(NF-κB), B-GENE-N
which O
coincided O
with O
the O
induction O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-α) B-GENE-Y
and O
cyclooxygenase-2 B-GENE-Y
(COX-2). B-GENE-Y
RA O
improved O
histological O
and O
serum O
markers O
of O
liver O
damage O
and O
significantly O
ameliorated O
oxidative/nitrosative O
stress O
and O
inflammatory O
response O
in O
liver O
tissue. O
Additionally, O
RA O
prevented O
transforming B-GENE-Y
growth I-GENE-Y
factor-beta1 I-GENE-Y
(TGF-β1) B-GENE-Y
and O
alpha-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
(α-SMA) B-GENE-Y
expression, O
suggesting O
suppression O
of O
profibrotic O
response. O
Furthermore, O
RA O
significantly O

inhibited O
the O
CCl(4)-induced B-CHEMICAL
apoptosis, O
which O
was O
evident O
from O
decreased O
cleavage O
of O
caspase-3. B-GENE-Y
The O
hepatoprotective O
activity O
of O
RA O
coincided O
with O
enhanced O
NF-E2-related B-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2) B-GENE-Y
and O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
expression. O
The O
results O
of O
this O
study O
indicates O
that O
RA O
possesses O
antioxidant, O
anti-inflammatory, O
antiapoptotic O
and O
antifibrotic O
activity O
against O
acute O
liver O
toxicity. O
Pre-clinical O
pharmacology O
of O
zolmitriptan B-CHEMICAL
(Zomig; B-CHEMICAL
formerly B-CHEMICAL

311C90), B-CHEMICAL
a O
centrally O
and O
peripherally O
acting O
5HT1B/1D B-GENE-N
agonist O
for O
migraine. O
Zolmitriptan B-CHEMICAL
(Zomig; B-CHEMICAL
formerly B-CHEMICAL
311C90) B-CHEMICAL
is O
a O
novel O
5-hydroxytryptamine B-GENE-N
(5HT)1B/1D I-GENE-N
receptor O
agonist O
with O
proven O
efficacy O
in O
the O
acute O
treatment O
of O
migraine O
with O
or O
without O
preceding O
aura. O
The O
drug O
differs O
from O
presently O
available O
members O
of O
this O
drug O
class O
in O
that O
it O
combines O
5HT1B/1D B-GENE-N
receptor O
partial O
agonist O
activity O
with O
robust O
oral O
pharmacokinetics O
and O
an O
ability O
to O
inhibit O

trigeminovascular O
activation O
centrally O
as O
well O
as O
peripherally O
in O
preclinical O
studies. O
Consistent O
with O
its O
selectivity O
for O
5HT1B/1D B-GENE-N
receptors, O
zolmitriptan B-CHEMICAL
produces O
constriction O
of O
various O
isolated O
blood O
vessels, O
most O
notably O
cranial O
arteries. O
In O
anaesthetized O
animals, O
these O
vascular O
effects O
manifest O
as O
a O
selective O
constriction O
of O
cranial O
arterio-venous O
anastomoses O
resulting O
in O
a O
redistribution O
of O
carotid O
arterial O
blood O
flow. O
This O
effect O
is O
produced O
without O
significant O
effects O
on O
heart O
rate, O
blood O
pressure O
or O

blood O
flow O
to O
the O
brain, O
heart O
or O
lungs. O
Zolmitriptan B-CHEMICAL
also O
inhibits O
trigeminal-evoked O
increases O
in O
cerebral O
blood O
flow O
in O
anaesthetized O
cats O
and O
blocks O
trigeminal-evoked O
plasma O
protein O
extravasation O
in O
the O
dura O
of O
guinea-pigs. O
These O
actions O
are O
consistent O
with O
a O
pre-junctional O
inhibition O
of O
neuropeptide O
release O
from O
perivascular O
afferents O
of O
the O
trigeminal O
nerve, O
as O
confirmed O
by O
independent O
studies O
showing O
that O
zolmitriptan B-CHEMICAL
blocks O
elevations O
of O
calcitonin-gene-related B-GENE-N
peptide I-GENE-N
in O

jugular O
venous O
blood O
during O
electrical O
stimulation O
of O
the O
trigeminal O
ganglion. O
In O
all O
of O
these O
effects, O
zolmitriptan B-CHEMICAL
is O
three O
to O
four O
times O
more O
potent O
than O
sumatriptan, B-CHEMICAL
but O
produces O
the O
same O
maximum O
response. O
Zolmitriptan B-CHEMICAL
crosses O
the O
intact O
blood-brain O
barrier O
to O
inhibit O
trigeminovascular O
activation O
in O
the O
brainstem. O
This O
was O
shown O
initially O
by O
the O
ability O
of O
the O
drug O
to O
block O
a O
brainstem O
reflex O
provoking O
vasoactive O
intestinal O
peptide O
release O
from O
the O
VIIth O
cranial O
(facial) O
nerve O
during O
trigeminal O
stimulation. O
Subsequent O
ex O
vivo O

autoradiography O
confirmed O
that O
intravenously O
injected O
[3H]zolmitriptan B-CHEMICAL
labels O
a O
discrete O
population O
of O
cells O
in O
the O
trigeminal O
nucleus O
caudalis O
(TNC) O
and O
nucleus O
tractus O
solitarius. O
Direct O
evidence O
for O
a O
central O
neuromodulatory O
effect O
of O
zolmitriptan B-CHEMICAL
was O
provided O
by O
electrophysiological O
experiments O
which O
clearly O
demonstrated O
that O
the O
drug O
inhibits O
the O
excitability O
of O
cells O
in O
the O
TNC O
after O
systemic O
administration. O
This O
novel O
pre-clinical O
profile O
not O
only O
distinguishes O
zolmitriptan B-CHEMICAL
from O
sumatriptan, B-CHEMICAL
but O
raises O
intriguing O
questions O
about O
the O

clinical O
relevance O
of O
a O
dual O
action. O
Studies O
to O
date O
show O
that O
zolmitriptan B-CHEMICAL
indeed O
modulates O
cranial O
sensory O
processing O
in O
humans, O
yet O
central O
side-effects O
are O
no O
different O
from O
sumatriptan. B-CHEMICAL
This O
property O
may O
account O
for O
the O
remarkable O
consistency O
in O
clinical O
efficacy O
observed O
in O
clinical O
trials. O
Oligomeric O
procyanidins B-CHEMICAL
of O
lotus O
seedpod O
inhibits O
the O
formation O
of O
advanced O
glycation O
end-products O
by O
scavenging O
reactive O
carbonyls. B-CHEMICAL
It O
has O
been O
reported O
that O
oligomeric O
procyanidins B-CHEMICAL
of O
lotus O
seedpod O
(LSOPC) O
is O
effective O

in O
the O
alleviation O
of O
Alzheimer's O
disease O
and O
diabetes O
through O
its O
antioxidant O
and O
insulin-potentiating B-GENE-Y
activities. O
This O
study O
investigated O
the O
anti-glycative O
activity O
of O
LSOPC O
in O
a O
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
(BSA)-glucose B-GENE-Y
model. O
The O
level O
of O
glycation O
and O
conformational O
alterations O
were O
assessed O
by O
specific O
fluorescence, O
Congo O
red O
binding O
assay O
and O
circular O
dichroism. O
The O
results O
show O
that O
LSOPC O
has O
a O
significant O
anti-glycative O
activity O
in O
vitro O
and O
it O
can O
also O
effectively O
protect O
the O
secondary O
structure O
of O
BSA B-GENE-Y
during O
glycation. O

LSOPC O
or O
catechin B-CHEMICAL
(a O
major O
constituent O
unit O
of O
LSOPC), O
were O
used O
to O
react O
with O
methylglyoxal. B-CHEMICAL
The O
structures O
of O
their O
carbonyl B-CHEMICAL
adducts O
were O
tentatively O
identified O
using O
HPLC-MS(2). O
Their O
capacity O
to O
scavenge O
methylglyoxal B-CHEMICAL
suggested O
carbonyl B-CHEMICAL
scavenging O
as O
a O
major O
mechanism O
of O
antiglycation. O
Therefore, O
LSOPC O
could O
be O
helpful O
to O
prevent O
AGEs-associated O
diseases, O
and O
with O
the O
potential O
to O
be O
used O
as O
functional O
food O
ingredients. O
Pegylated B-GENE-N
recombinant I-GENE-N
human I-GENE-N
arginase I-GENE-N

(rhArg-peg5,000mw) B-GENE-N
inhibits O
the O
in O
vitro O
and O
in O
vivo O
proliferation O
of O
human O
hepatocellular O
carcinoma O
through O
arginine B-CHEMICAL
depletion. O
Hepatocellular O
carcinoma O
(HCC) O
is O
believed O
to O
be O
auxotrophic O
for O
arginine B-CHEMICAL
through O
the O
lack O
of O
expression O
of O
argininosuccinate B-GENE-Y
synthetase I-GENE-Y
(ASS). B-GENE-Y
The O
successful O
use O
of O
the O
arginine-depleting B-GENE-N
enzyme I-GENE-N
arginine B-GENE-N
deiminase I-GENE-N
(ADI) B-GENE-N
to O
treat O
ASS-deficient B-GENE-Y
tumors O
has O
opened O
up O

new O
possibilities O
for O
effective O
cancer O
therapy. O
Nevertheless, O
many O
ASS-positive B-GENE-Y
HCC O
cell O
lines O
are O
found O
to O
be O
resistant O
to O
ADI B-GENE-N
treatment, O
although O
most O
require O
arginine B-CHEMICAL
for O
proliferation. O
Thus O
far, O
an O
arginine-depleting B-GENE-N
enzyme I-GENE-N
for O
killing O
ASS-positive B-GENE-Y
tumors O
has O
not O
been O
reported. O
Here, O
we O
provide O
direct O
evidence O
that O
recombinant O
human B-GENE-N
arginase I-GENE-N
(rhArg) B-GENE-N
inhibits O
ASS-positive B-GENE-Y
HCCs. O
All O
the O
five O
human O
HCC O
cell O
lines O
we O
used O
were O
sensitive O
to O
rhArg B-GENE-N
but O
ADI B-GENE-N
had O
virtually O
no O
effect O
on O
these O
cells. O
They O
all O
expressed O

ASS, B-GENE-Y
but O
not O
ornithine B-GENE-Y
transcarbamylase I-GENE-Y
(OTC), B-GENE-Y
the O
enzyme O
that O
converts O
ornithine, B-CHEMICAL
the O
product O
of O
degradation O
of O
arginine B-CHEMICAL
with O
rhArg, B-GENE-N
to O
citrulline, B-CHEMICAL
which O
is O
converted O
back O
to O
arginine B-CHEMICAL
via O
ASS. B-GENE-Y
Transfection O
of O
HCC O
cells O
with O
OTC B-GENE-Y
resulted O
in O
resistance O
to O
rhArg. B-GENE-N
Thus, O
OTC B-GENE-Y
expression O
alone O
may O
be O
sufficient O
to O
induce O
rhArg B-GENE-N
resistance O
in O
ASS-positive B-GENE-Y
HCC O
cells. O
This O
surprising O
correlation O
between O
the O
lack O
of O
OTC B-GENE-Y
expression O
and O
sensitivity O
of O
ASS-positive B-GENE-Y
HCC O

cells O
shows O
that O
OTC-deficient B-GENE-Y
HCCs O
are O
sensitive O
to O
rhArg-mediated B-GENE-N
arginine B-CHEMICAL
depletion. O
Therefore, O
pretreatment O
tumor O
gene O
expression O
profiling O
of O
ASS B-GENE-Y
and O
OTC B-GENE-Y
could O
aid O
in O
predicting O
tumor O
response O
to O
arginine B-CHEMICAL
depletion O
with O
arginine-depleting B-GENE-N
enzymes. I-GENE-N
We O
have O
also O
shown O
that O
the O
rhArg B-GENE-N
native O
enzyme O
and O
the O
pegylated B-GENE-N
rhArg I-GENE-N
(rhArg-peg(5,000mw)) B-GENE-N
gave O
similar O
anticancer O
efficacy O
in O
vitro. O
Furthermore, O
the O
growth O
of O
the O

OTC-deficient B-GENE-Y
Hep3B O
tumor O
cells O
(ASS-positive B-GENE-Y
and O
ADI-resistant) B-GENE-N
in O
mice O
was O
inhibited O
by O
treatment O
with O
rhArg-peg(5,000mw), B-GENE-N
which O
is O
active O
alone O
and O
is O
synergistic O
in O
combination O
with O
5-fluorouracil. B-CHEMICAL
Thus, O
our O
data O
suggest O
that O
rhArg-peg(5,000mw) B-GENE-N
is O
a O
novel O
agent O
for O
effective O
cancer O
therapy. O
Visualization O
and O
virtual O
screening O
of O
the O
chemical O
universe O
database O
GDB-17. O
The O
chemical O
universe O
database O
GDB-17 O
contains O
166.4 O
billion O

molecules O
of O
up O
to O
17 O
atoms O
of O
C, B-CHEMICAL
N, B-CHEMICAL
O, B-CHEMICAL
S, B-CHEMICAL
and O
halogens B-CHEMICAL
obeying O
rules O
for O
chemical O
stability, O
synthetic O
feasibility, O
and O
medicinal O
chemistry. O
GDB-17 O
was O
analyzed O
using O
42 O
integer O
value O
descriptors O
of O
molecular O
structure O
which O
we O
term O
"Molecular O
Quantum O
Numbers" O
(MQN). O
Principal O
component O
analysis O
and O
representation O
of O
the O
(PC1, O
PC2)-plane O
provided O
a O
graphical O
overview O
of O
the O
GDB-17 O
chemical O
space. O
Rapid O
ligand-based O
virtual O
screening O
(LBVS) O
of O
GDB-17 O
using O
the O
city-block O
distance O

CBD(MQN) O
as O
a O
similarity O
search O
measure O
was O
enabled O
by O
a O
hashed O
MQN-fingerprint. O
LBVS O
of O
the O
entire O
GDB-17 O
and O
of O
selected O
subsets O
identified O
shape O
similar, O
scaffold O
hopping O
analogs O
(ROCS O
> O
1.6 O
and O
T(SF) O
< O
0.5) O
of O
15 O
drugs. O
Over O
97% O
of O
these O
analogs O
occurred O
within O
CBD(MQN) O
≤ O
12 O
from O
each O
drug, O
a O
constraint O
which O
might O
help O
focus O
advanced O
virtual O
screening. O
An O
MQN-searchable O
50 O
million O
subset O
of O
GDB-17 O
is O

publicly O
available O
at O
www.gdb.unibe.ch O
. O
Both O
5-HT1B B-GENE-Y
and O
5-HT1F B-GENE-Y
receptors O
modulate O
c-fos B-GENE-Y
expression O
within O
rat O
trigeminal O
nucleus O
caudalis. O
A O
possible O
mechanism O
of O
action O
of O
antimigraine O
drugs O
such O
as O
sumatriptan B-CHEMICAL
is O
inhibition O
of O
the O
trigeminovascular O
pathway. O
Sumatriptan's O
effects O
might O
be O
mediated O
by O
5-HT1B, B-GENE-Y
5-HT1D B-GENE-Y
or O
5-HT1F B-GENE-Y
receptors. O
To O
establish O
the O
relative O
importance O
of O
these O
subtypes, O
we O
compared O
the O
effects O

of O
sumatriptan B-CHEMICAL
with O
those O
of O
a O
selective O
5-HT1F B-GENE-Y
receptor O
agonist O
(LY B-CHEMICAL
344864) I-CHEMICAL
on O
c-fos B-GENE-Y
protein O
expression O
in O
the O
trigeminal O
nucleus O
caudalis. O
c-fos B-GENE-Y
expression O
was O
induced O
in O
urethane-anaesthetized B-CHEMICAL
rats O
by O
intracisternal O
capsaicin B-CHEMICAL
administration. O
Sumatriptan B-CHEMICAL
and O
LY B-CHEMICAL
344864 I-CHEMICAL
decreased O
the O
number O
of O
capsaicin-induced B-CHEMICAL
c-fos-like B-GENE-Y
immunoreactive O
cells O
within O
trigeminal O
nucleus O
caudalis O
(ID50 O
= O
0.04 O
and O
0.6 O
mg O

kg(-1)). O
The O
effect O
of O
sumatriptan, B-CHEMICAL
but O
not O
of O
LY B-CHEMICAL
344864, I-CHEMICAL
was O
prevented O
by O
pretreatment O
with O
the O
antagonist O
SDZ B-CHEMICAL
21-009, I-CHEMICAL
which O
displays O
high O
affinity O
for O
rat B-GENE-Y
5-HT1B I-GENE-Y
receptors. O
LY B-CHEMICAL
344864 I-CHEMICAL
appears O
to O
attenuate O
c-fos-like O
immunoreactivity O
via O
5-HT1F B-GENE-Y
receptors, O
while O
sumatriptan B-CHEMICAL
acts O
via O
5-HT1B B-GENE-Y
receptors. O
The O
fact O
that O
activation O
of O
5-HT1F B-GENE-Y
receptors O
is O
sufficient O
to O
modulate O
the O
activity O
of O
the O

trigeminal O
system O
suggests O
that O
this O
receptor O
may O
be O
a O
target O
for O
antimigraine O
drugs O
with O
improved O
safety O
profile. O
Disruption O
of O
the O
cereblon B-GENE-Y
gene O
enhances O
hepatic O
AMPK B-GENE-N
activity O
and O
prevents O
high O
fat O
diet-induced O
obesity O
and O
insulin B-GENE-N
resistance O
in O
mice. O
A O
nonsense O
mutation O
in O
cereblon B-GENE-Y
(CRBN) B-GENE-Y
causes O
a O
mild O
type O
of O
mental O
retardation O
in O
humans. O
An O
earlier O
study O
showed O
that O
CRBN B-GENE-Y
negatively O
regulates O
the O
functional O
activity O
of O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
in O
vitro O
by O
binding O
directly O
to O
the O
α1 B-GENE-Y
subunit I-GENE-Y
of I-GENE-Y
the I-GENE-Y

AMPK I-GENE-Y
complex. O
However, O
the O
in O
vivo O
role O
of O
CRBN B-GENE-Y
was O
not O
studied. O
To O
elucidate O
the O
physiological O
functions O
of O
Crbn, B-GENE-Y
a O
mouse O
strain O
was O
generated O
in O
which O
the O
Crbn B-GENE-Y
gene O
was O
deleted O
throughout O
the O
whole O
body. O
In O
Crbn-deficient B-GENE-Y
mice O
fed O
a O
normal O
diet, O
AMPK B-GENE-N
in O
the O
liver O
showed O
hyper-phosphorylation, O
which O
indicated O
the O
constitutive O
activation O
of O
AMPK. B-GENE-N
Since O
Crbn-deficient B-GENE-Y
mice O
showed O
significantly O
less O
weight O
gain O
when O
fed O
a O
high O
fat O
diet O
and O
their O
insulin O
sensitivity O
was O
considerably O
improved, O
the O
functions O
of O

Crbn B-GENE-Y
in O
the O
liver O
were O
primarily O
investigated. O
These O
results O
provide O
the O
first O
in O
vivo O
evidence O
that O
Crbn B-GENE-Y
is O
a O
negative O
modulator O
of O
AMPK, B-GENE-N
which O
suggests O
that O
Crbn B-GENE-Y
may O
be O
a O
potential O
target O
for O
metabolic O
disorders O
of O
the O
liver. O
Involvement O
of O
EP1 B-GENE-Y
and O
EP2 B-GENE-Y
receptors I-GENE-Y
in O
the O
regulation O
of O
the O
Na,K-ATPase B-GENE-N
by O
prostaglandins B-CHEMICAL
in O
MDCK O
cells. O
Prostaglandins B-CHEMICAL
are O
key O
regulators O
of O
ion O
transport O
in O
the O
kidney. O
In O
MDCK O
cells, O
which O
model O
distal O
tubule O
cells, O
the O
transcription O
of O
the O
Na,K-ATPase B-GENE-N

beta1 I-GENE-N
subunit O
is O
regulated O
by O
PGE1 O
and O
PGE2. O
To O
identify O
the O
EP B-GENE-N
receptors I-GENE-N
that O
mediate O
transcriptional O
regulation, O
transient O
transfection O
studies O
are O
conducted O
using O
the O
human O
beta1promoter/luciferase O
construct, O
pHbeta1-1141 O
Luc. O
The O
involvement O
of O
EP1 B-GENE-Y
and O
EP2 B-GENE-Y
receptors I-GENE-Y
is O
indicated O
by O
studies O
with O
the O
EP1 B-GENE-Y
selective O
agonist O
17-phenyl B-CHEMICAL
trinor I-CHEMICAL
PGE2, I-CHEMICAL
and O
the O
EP2 B-GENE-Y
selective O
agonist O
butaprost B-CHEMICAL
(which O
stimulate), O
as O
well O
as O
by O
studies O
with O
the O
antagonists O
SC-51089 B-CHEMICAL
(EP1 O
specific) O
and O

AH B-CHEMICAL
6809 I-CHEMICAL
(EP1 B-GENE-Y
and O
EP2 B-GENE-Y
specific). O
Consistent O
with O
the O
involvement O
of O
Gs B-GENE-N
coupled O
EP2 B-GENE-Y
receptors, I-GENE-Y
is O
that O
the O
PGE1 B-CHEMICAL
stimulation O
is O
inhibited O
by O
the O
PKAI B-GENE-N
expression O
vector O
(encoding O
the O
protein B-GENE-N
kinase I-GENE-N
A I-GENE-N
(PKA) I-GENE-N
inhibitory I-GENE-N
protein), I-GENE-N
as O
well O
as O
by O
the O
myristolated B-GENE-N
PKA I-GENE-N
inhibitory I-GENE-N
peptide I-GENE-N
PKI. O
In O
addition O
to O
this O
evidence O
(for O
the O
involvement O
of O
EP2 B-GENE-Y
receptors), I-GENE-Y
evidence O
for O
the O
involvement O
of O
EP1 B-GENE-Y
receptors I-GENE-Y
in O
the O
PGE1 B-CHEMICAL
mediated O
stimulation O
of O
Na,K-ATPase B-GENE-N
beta I-GENE-N
subunit O
gene O
transcription O
includes O
the O
stimulatory O

effect O
of O
17-phenyl B-CHEMICAL
trinor I-CHEMICAL
PGE2, I-CHEMICAL
as O
well O
as O
the O
inhibitory O
effects O
of O
SC-51089. B-CHEMICAL
Also O
consistent O
with O
the O
involvement O
of O
Gq B-GENE-N
coupled O
EP1 B-GENE-Y
receptors, I-GENE-Y
the O
PGE1 B-CHEMICAL
stimulation O
is O
inhibited O
by O
the O
PKCI B-GENE-N
vector O
(encoding O
the O
PKC B-GENE-N
inhibitory I-GENE-N
domain), I-GENE-N
the O
PKC B-GENE-N
inhibitor O
Go B-CHEMICAL
6976, I-CHEMICAL
thapsigargin, B-CHEMICAL
as O
well O
as O
the O
calmodulin B-GENE-N
antagonists O
W7 B-CHEMICAL
and O
W13. B-CHEMICAL
VMAT2: B-GENE-Y
a O
dynamic O
regulator O
of O
brain O
monoaminergic O
neuronal O
function O
interacting O
with O
drugs O
of O
abuse. O
The O

monoaminergic O
neuron, O
in O
particular O
the O
dopaminergic O
neuron, O
is O
central O
to O
mediating O
the O
hedonic O
and O
addictive O
properties O
of O
drugs O
of O
abuse. O
The O
effects O
of O
amphetamine B-CHEMICAL
(AMPH) B-CHEMICAL
and O
cocaine B-CHEMICAL
(COC), B-CHEMICAL
for O
example, O
depend O
on O
the O
ability O
to O
increase O
dopamine B-CHEMICAL
in O
the O
synapse, O
by O
effects O
on O
either O
the O
plasma O
membrane O
transporter O
DAT B-GENE-Y
or O
the O
vesicular O
transporter O
for O
monoamine B-CHEMICAL
storage, O
VMAT2. B-GENE-Y
The O
potential O
role O
of O
DAT B-GENE-Y
as O
a O
target O
for O
AMPH B-CHEMICAL
and O
COC B-CHEMICAL
has O
been O
reviewed O
extensively. O
Here, O
we O

present O
VMAT2 B-GENE-Y
as O
a O
target O
that O
enables O
the O
rewarding O
and O
addictive O
actions O
of O
these O
drugs, O
based O
on O
imaging, O
neurochemical, O
biochemical, O
cell O
biological, O
genetic, O
and O
immunohistochemical O
evidence. O
The O
presence O
of O
VMAT2 B-GENE-Y
in O
noradrenergic, O
serotoninergic, O
histaminergic, O
and O
potentially O
trace O
aminergic O
neurons O
invites O
consideration O
of O
a O
wider O
role O
for O
aminergic O
neurotransmission O
in O
AMPH B-CHEMICAL
and O
COC B-CHEMICAL
abuse O
and O
addiction. O
Spiro O
heterocycles O
as O
potential O
inhibitors O
of O
SIRT1: B-GENE-Y

Pd/C-mediated B-CHEMICAL
synthesis O
of O
novel O
N-indolylmethyl B-CHEMICAL
spiroindoline-3,2'-quinazolines. I-CHEMICAL
Novel O
N-indolylmethyl B-CHEMICAL
substituted I-CHEMICAL
spiroindoline-3,2'-quinazolines I-CHEMICAL
were O
designed O
as O
potential O
inhibitiors O
of O
SIRT1. B-GENE-Y
These O
compounds O
were O
synthesized O
in O
good O
yields O
by O
using O
Pd/C-Cu B-CHEMICAL
mediated O
coupling-cyclization O
strategy O
as O
a O
key O
step O
involving O
the O
reaction O
of O

1-(prop-2-ynyl)-1'H-spiro[indoline-3,2'-quinazoline]-2,4'(3'H)-dione B-CHEMICAL
with O
2-iodoanilides. B-CHEMICAL
Some O
of O
the O
compounds O
synthesized O
have O
shown O
encouraging O
inhibition O
of O
Sir B-GENE-Y
2 I-GENE-Y
protein O
(a O
yeast O
homologue O
of O
mammalian B-GENE-N
SIRT1) I-GENE-N
in O
vitro O
and O
three O
of O
them O
showed O
dose O
dependent O
inhibition O
of O
Sir B-GENE-Y
2. I-GENE-Y
The O
docking O
results O
suggested O
that O
the O
benzene B-CHEMICAL
ring O
of O

1,2,3,4-tetrahydroquinazolin B-CHEMICAL
ring O
system O
of O
these O
molecules O
occupied O
the O
deep O
hydrophobic O
pocket O
of O
the O
protein O
and O
one O
of O
the O
NH B-CHEMICAL
along O
with O
the O
sulfonyl B-CHEMICAL
group O
participated O
in O
strong O
H-bonding B-CHEMICAL
interaction O
with O
the O
amino B-CHEMICAL
acid I-CHEMICAL
residues. O
Cyclopentenone B-CHEMICAL
prostaglandins I-CHEMICAL
suppress O
activation O
of O
microglia: O
down-regulation O
of O
inducible B-GENE-Y
nitric-oxide I-GENE-Y
synthase I-GENE-Y
by O
15-deoxy-Delta12,14-prostaglandin B-CHEMICAL
J2. I-CHEMICAL
Mechanisms O
leading O
to O
down-regulation O
of O
activated O
microglia O
and O
astrocytes O
are O

poorly O
understood, O
in O
spite O
of O
the O
potentially O
detrimental O
role O
of O
activated O
glia O
in O
neurodegeneration. O
Prostaglandins, B-CHEMICAL
produced O
both O
by O
neurons O
and O
glia, O
may O
serve O
as O
mediators O
of O
glial O
and O
neuronal O
functions. O
We O
examined O
the O
influence O
of O
cyclopentenone B-CHEMICAL
prostaglandins I-CHEMICAL
and O
their O
precursors O
on O
activated O
glia. O
As O
models O
of O
glial O
activation, O
production O
of O
inducible B-GENE-Y
nitric-oxide I-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
was O
studied O
in O
lipopolysaccharide-stimulated O
rat O
microglia, O
a O
murine O
microglial O
cell O

line O
BV-2, O
and O
IL-1beta-stimulated B-GENE-Y
rat O
astrocytes. O
Cyclopentenone B-CHEMICAL
prostaglandins I-CHEMICAL
were O
potent O
inhibitors O
of O
iNOS B-GENE-Y
induction O
and O
were O
more O
effective O
than O
their O
precursors, O
prostaglandins B-CHEMICAL
E2 I-CHEMICAL
and I-CHEMICAL
D2. I-CHEMICAL
15-Deoxy-Delta12,14-prostaglandin B-CHEMICAL
J2 I-CHEMICAL
(15d-PGJ2) B-CHEMICAL
was O
the O
most O
potent O
prostaglandin B-CHEMICAL
among O
those O
tested. O
In O
activated O
microglia, O
15d-PGJ2 B-CHEMICAL
suppressed O
iNOS B-GENE-N
promoter I-GENE-N
activity, O
iNOS B-GENE-Y
mRNA, O

and O
protein O
levels. O
The O
action O
of O
15d-PGJ2 B-CHEMICAL
does O
not O
appear O
to O
involve O
its O
nuclear O
receptor O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y
(PPARgamma) B-GENE-Y
because O
troglitazone, B-CHEMICAL
a O
specific O
ligand O
of O
PPARgamma, B-GENE-Y
was O
unable O
to O
inhibit O
iNOS B-GENE-Y
induction, O
and O
neither O
troglitazone B-CHEMICAL
nor O
15d-PGJ2 B-CHEMICAL
could O
stimulate O
the O
activity O
of O
a O
PPAR-dependent B-GENE-N
promoter O
in O
the O
absence O
of O
cotransfected O
PPARgamma. B-GENE-Y
15d-PGJ2 B-CHEMICAL
did O
not O
block O
nuclear O
translocation O
or O
DNA-binding O
activity O
of O
the O

transcription O
factor O
NFkappaB, B-GENE-N
but O
it O
did O
inhibit O
the O
activity O
of O
an O
NFkappaB B-GENE-N
reporter O
construct, O
suggesting O
that O
the O
mechanism O
of O
suppression O
of O
microglial O
iNOS B-GENE-Y
by O
15d-PGJ2 B-CHEMICAL
may O
involve O
interference O
with O
NFkappaB B-GENE-N
transcriptional O
activity O
in O
the O
nucleus. O
Thus, O
our O
data O
suggest O
the O
existence O
of O
a O
novel O
pathway O
mediated O
by O
cyclopentenone B-CHEMICAL
prostaglandins, I-CHEMICAL
which O
may O
represent O
part O
of O
a O
feedback O
mechanism O
leading O
to O
the O
cessation O
of O
inflammatory O
glial O
responses O
in O
the O
brain. O
Mechanism O
of O
the O
haemostatic O
effect O
of O
ethanolamine B-CHEMICAL

oleate I-CHEMICAL
in O
the O
injection O
sclerotherapy O
for O
oesophageal O
varices. O
Changes O
in O
coagulation O
and O
fibrinolysis O
were O
investigated O
in O
20 O
patients O
with O
oesophageal O
varices, O
who O
underwent O
endoscopic O
injection O
sclerotherapy O
(EIS) O
with O
5 O
per O
cent O
ethanolamine B-CHEMICAL
oleate I-CHEMICAL
(EO), B-CHEMICAL
by O
means O
of O
serial O
determination O
of O
plasma O
fibrinopeptide B-GENE-Y
A I-GENE-Y
(FPA) B-GENE-Y
and O
fibrinopeptide B-GENE-Y
B I-GENE-Y
beta I-GENE-Y
15-42 I-GENE-Y
(B B-GENE-Y
beta I-GENE-Y
15-42). I-GENE-Y
One O
hour O
after O
the O
completion O
of O
EIS, O
the O
value O
of O
FPA B-GENE-Y
was O
significantly O
increased O

to O
38.1 O
+/- O
11.1 O
ng/ml O
(mean O
+/- O
s.e.m.) O
from O
a O
pre-EIS O
value O
of O
7.1 O
+/- O
1.4 O
ng/ml O
(P O
less O
than O
0.01) O
and O
it O
gradually O
returned O
to O
normal O
range O
by O
48 O
h O
after O
EIS. O
A O
very O
similar O
change O
was O
observed O
in O
the O
value O
of O
B B-GENE-Y
beta I-GENE-Y
15-42 I-GENE-Y
(P O
less O
than O
0.01). O
These O
observations O
indicated O
that O
EIS O
provokes O
transient O
activation O
of O
coagulation O
and O
fibrinolysis. O
In O
vitro O
studies, O
however, O
revealed O
that O

EO B-CHEMICAL
inhibits O
fibrin B-GENE-N
clot O
formation O
because O
of O
the O
Ca2+-chelating B-CHEMICAL
ability O
of O
its O
constituent O
ethanolamine, B-CHEMICAL
although O
oleate B-CHEMICAL
or O
benzyl B-CHEMICAL
alcohol I-CHEMICAL
exhibited O
procoagulant O
activity O
in O
FPA B-GENE-Y
formation O
in O
vitro. O
Nevertheless, O
an O
external O
application O
of O
EO B-CHEMICAL
or O
oleate B-CHEMICAL
over O
decapsulized O
kidney O
of O
rat O
resulted O
in O
a O
significant O
accumulation O
of O
125I-labelled B-CHEMICAL
fibrin(ogen). B-GENE-N
From O
these O
results O
it O
was O
suggested O
that O
intravascular O
injection O
of O
EO, B-CHEMICAL
which O
exerts O
an O
inhibitory O
effect O
on O
coagulation O
in O
vitro, O
activates O

the O
local O
coagulation O
system. O
The O
activation O
may O
be O
accelerated O
by O
an O
acute O
inflammatory O
process O
provoked O
by O
oleate, B-CHEMICAL
which O
is O
supported O
by O
such O
clinical O
manifestations O
as O
mild O
fever, O
retrosternal O
pain O
leukocytosis O
and O
an O
increase O
in O
plasma O
fibrinogen B-GENE-N
level O
which O
was O
observed O
in O
all O
during O
the O
period. O
Renal O
failure O
associated O
with O
the O
use O
of O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
OBJECTIVE: O
Celecoxib B-CHEMICAL
and O
rofecoxib B-CHEMICAL
are O
two O
relatively O
new O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O
that O
selectively O
inhibit O
the O

cyclo-oxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
isoenzyme O
at O
therapeutic O
concentrations. O
The O
nephrotoxic O
potential O
of O
selective O
COX-2 B-GENE-Y
inhibitors O
has O
not O
been O
clearly O
established. O
This O
study O
was O
conducted O
in O
order O
to O
understand O
the O
association O
between O
acute O
renal O
failure O
and O
the O
two O
COX-2 B-GENE-Y
inhibitors O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
METHODS: O
A O
search O
was O
performed O
in O
the O
US O
Food O
and O
Drug O
Administration's O
(FDA) O
Adverse O
Event O
Reporting O
System O
(AERS) O
to O
identify O
cases O
of O
renal O
failure O
submitted O
to O
the O
FDA. O
A O

MEDLINE O
search O
of O
the O
English O
language O
literature O
was O
also O
performed O
to O
identify O
published O
cases O
of O
renal O
failure O
associated O
with O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
RESULTS: O
One O
hundred O
twenty-two O
and O
142 O
domestic O
US O
cases O
of O
celecoxib B-CHEMICAL
and O
rofecoxib-associated B-CHEMICAL
renal O
failure, O
respectively, O
were O
identified O
in O
the O
AERS O
database. O
The O
literature O
search O
identified O
19 O
cases O
of O
acute O
renal O
impairment O
in O
association O
with O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
In O
addition, O
drug O
regulatory O
authorities O
in O
the O
UK, O
Canada, O
and O
Australia O
have O
received O
about O

50 O
reports O
of O
renal O
failure O
with O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
Descriptive O
statistics O
of O
the O
AERS O
cases O
have O
been O
summarised O
in O
this O
report. O
CONCLUSIONS: O
Data O
from O
AERS O
and O
published O
case O
reports O
suggest O
that O
use O
of O
both O
these O
drugs O
is O
associated O
with O
renal O
effects O
similar O
to O
that O
of O
conventional O
nonselective O
NSAIDs. O
Physicians O
should O
be O
aware O
that O
serious O
or O
life-threatening O
renal O
failure O
has O
been O
reported O
in O
patients O
with O
normal O
or O
impaired O
renal O
function O
after O
short-term O
therapy O
with O
celecoxib B-CHEMICAL
and O
rofecoxib. B-CHEMICAL
Patients O
at O

greatest O
risk O
for O
renal O
injury O
are O
those O
with O
pre-existing O
renal O
impairment, O
heart O
failure, O
liver O
dysfunction, O
those O
taking O
diuretics O
and/or O
ACE B-GENE-Y
inhibitors, O
and O
the O
elderly. O
Kidney O
function O
should O
be O
monitored O
closely O
for O
any O
signs O
of O
potential O
renal O
injuries O
soon O
after O
initiating O
treatment O
with O
these O
agents, O
especially O
in O
high-risk O
populations. O
In O
addition, O
healthcare O
practitioners O
should O
adequately O
warn O
patients O
of O
the O
signs O
and O
symptoms O
of O
serious O
renal O
toxicity, O
and O
of O
the O
need O
for O
them O
to O
see O
their O
physician O
promptly O
if O
they O
occur. O
Celecoxib B-CHEMICAL
and O
rofecoxib B-CHEMICAL
are O
not O
recommended O
for O
use O

in O
patients O
with O
advanced O
renal O
disease. O
Evaluation O
of O
the O
pharmacological O
selectivity O
profile O
of O
alpha B-GENE-N
1 I-GENE-N
adrenoceptor I-GENE-N
antagonists O
at O
prostatic O
alpha B-GENE-N
1 I-GENE-N
adrenoceptors: I-GENE-N
binding, O
functional O
and O
in O
vivo O
studies. O
1. O
The O
profile O
of O
a O
range O
of O
alpha B-GENE-N
1 I-GENE-N
adrenoceptor I-GENE-N
antagonists O
was O
determined O
in O
vitro O
against O
cloned O
human B-GENE-N
alpha I-GENE-N
1A, I-GENE-N
alpha I-GENE-N
1B I-GENE-N
and I-GENE-N
alpha I-GENE-N
1D I-GENE-N
adrenoceptors I-GENE-N
and O
against O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta O
and O
human O
prostate. O
The O
in O
vivo O
profile O
of O
compounds O
was O
determined O
in O
an O
anaesthetized O

dog O
model O
which O
allowed O
the O
simultaneous O
assessment O
of O
antagonist O
potency O
against O
phenylephrine-mediated B-CHEMICAL
increases O
in O
blood O
pressure O
and O
prostatic O
pressure. O
2. O
The O
quinazoline B-CHEMICAL
antagonists, O
prazosin, B-CHEMICAL
doxazosin B-CHEMICAL
and O
alfuzosin B-CHEMICAL
displayed O
high O
affinity O
but O
were O
non O
selective O
for O
the O
three O
cloned O
human B-GENE-N
alpha I-GENE-N
1 I-GENE-N
adrenoceptors. I-GENE-N
Indoramin B-CHEMICAL
and O
SNAP B-CHEMICAL
1069 I-CHEMICAL
showed O
selectivity O
for O
alpha B-GENE-N
1A I-GENE-N
and I-GENE-N
alpha I-GENE-N
1B I-GENE-N
adrenoceptors I-GENE-N
relative O
to O
the O
alpha B-GENE-Y
1D I-GENE-Y
subtype. I-GENE-Y
Rec B-CHEMICAL
15/2739, I-CHEMICAL
WB B-CHEMICAL
4101, I-CHEMICAL
SL B-CHEMICAL
89,0591, I-CHEMICAL

(+)- B-CHEMICAL
and I-CHEMICAL
(-)- I-CHEMICAL
tamsulosin I-CHEMICAL
showed O
selectivity O
for O
alpha B-GENE-N
1A I-GENE-N
and I-GENE-N
alpha I-GENE-N
1D I-GENE-N
adrenoceptors I-GENE-N
relative O
to O
the O
alpha B-GENE-Y
1B I-GENE-Y
subtype. I-GENE-Y
RS B-CHEMICAL
17053 I-CHEMICAL
showed O
high O
affinity O
and O
selectivity O
for O
alpha B-GENE-Y
1A I-GENE-Y
adrenoceptors I-GENE-Y
(pKi O
8.6) O
relative O
to O
alpha B-GENE-Y
1B I-GENE-Y
(pKi O
= O
7.3) O
and O
alpha B-GENE-Y
1D I-GENE-Y
(pKi O
= O
7.1) O
subtypes. O
3. O
(+)-Tamsulosin, B-CHEMICAL
(-)-tamsulosin, B-CHEMICAL
SL B-CHEMICAL
89,0591, I-CHEMICAL
Rec B-CHEMICAL

15/2739, I-CHEMICAL
SNAP B-CHEMICAL
1069 I-CHEMICAL
and O
RS B-CHEMICAL
17053 I-CHEMICAL
appeared O
to O
act O
as O
competitive O
antagonists O
of O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta O
yielding O
pA2 O
affinity O
estimates O
which O
were O
similar O
to O
binding O
affinities O
at O
cloned O
human B-GENE-Y
alpha I-GENE-Y
1D I-GENE-Y
adrenoceptors. I-GENE-Y
The O
following O
rank O
order O
was O
obtained: O
prazosin B-CHEMICAL
= O
(-)-tamsulosin B-CHEMICAL
> O
doxazosin B-CHEMICAL
> O
SL B-CHEMICAL
89,0591 I-CHEMICAL
= O
(+)-tamsulosin B-CHEMICAL
> O
Rec B-CHEMICAL
15/2739 I-CHEMICAL
> O
RS B-CHEMICAL
17053 I-CHEMICAL
= O
SNAP B-CHEMICAL
1069. I-CHEMICAL
4. O

(-)-Tamsulosin B-CHEMICAL
was O
a O
very O
potent, O
insurmountable O
antagonist O
of O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
human O
prostate, O
yielding O
an O
approximate O
pA2 O
estimate O
of O
9.8 O
at O
1 O
nM. O
The O
corresponding O
(+)-enantiomer O
was O
30 O
fold O
weaker. O
SL O
89,0591, O
SNAP O
1069 O
and O
Rec O
15/2739 O
yielded O
pA2 O
estimates O
which O
compared O
well O
with O
their O
alpha B-GENE-Y
1A I-GENE-Y
binding O
affinities. O
The O
affinity O
estimate O
for O
prazosin B-CHEMICAL
on O
human O
prostate O
was O
lower O
than O
the O
corresponding O
binding O
affinity O
determined O
at O
alpha B-GENE-Y
1A I-GENE-Y
adrenoceptors I-GENE-Y

and O
RS B-CHEMICAL
17053 I-CHEMICAL
was O
a O
very O
weak O
antagonist O
on O
human O
prostate O
(pA2 O
= O
6.0) O
relative O
to O
the O
high O
affinity O
(pKi O
= O
8.6) O
determined O
at O
cloned O
human B-GENE-Y
alpha I-GENE-Y
1A I-GENE-Y
adrenoceptors. I-GENE-Y
5. O
In O
the O
anaesthetized O
dog, O
in O
vivo O
pseudo O
"pA2' O
values O
showed O
that O
doxazosin, B-CHEMICAL
(+)- B-CHEMICAL
and I-CHEMICAL
(-)-tamsulosin I-CHEMICAL
inhibited O
phenylephrine-induced B-CHEMICAL
increases O
in O
prostatic O
and O
blood O
pressure O
with O
similar O
affinity, O
implying O
that O
these O
agents O
show O
little O
or O
no O
selectivity O
for O
prostatic O
responses O
in O

this O
model. O
SL O
89,0591 O
and O
SNAP O
1069 O
were O
moderately O
selective O
(3 O
and O
6 O
fold O
respectively) O
for O
prostatic O
pressure O
relative O
to O
blood O
pressure. O
Rec B-CHEMICAL
15/2739 I-CHEMICAL
was O
a O
more O
potent O
antagonist O
of O
phenylephrine-mediated B-CHEMICAL
increases O
in O
prostatic O
pressure O
("pA2' O
= O
8.74) O
compared O
to O
blood O
pressure O
("pA2' O
= O
7.51). O
6. O
Data O
in O
this O
study O
suggest O
that O
the O
alpha B-GENE-N
1 I-GENE-N
adrenoceptor I-GENE-N
mediating O
noradrenaline-induced B-CHEMICAL
contractions O
of O
human O
prostate, O
whilst O
having O
some O
of O
the O
characteristics O
of O
an O
alpha B-GENE-Y
1A I-GENE-Y

adrenoceptor, I-GENE-Y
cannot O
be O
satisfactorily O
aligned O
with O
cloned O
alpha B-GENE-N
1A, I-GENE-N
alpha I-GENE-N
1B I-GENE-N
or I-GENE-N
alpha I-GENE-N
1D I-GENE-N
adrenoceptors. I-GENE-N
In O
addition, O
studies O
in O
the O
anaesthetized O
dog O
have O
shown O
that O
agents O
having O
high O
affinity O
and O
selectivity O
for O
prostatic O
alpha B-GENE-N
1 I-GENE-N
adrenoceptors, I-GENE-N
particularly O
over O
the O
alpha B-GENE-Y
1D I-GENE-Y
subtype, I-GENE-Y
appear O
to O
inhibit O
phenylephrine-induced B-CHEMICAL
increases O
in O
prostatic O
pressure O
selectively O
compared O
to O
blood O
pressure. O
In O
functional O
experiments, O
risperidone B-CHEMICAL
is O
selective, O
not O
for O
the O
B, O
but O
for O
the O
A O
subtype O
of O
alpha B-GENE-N

1-adrenoceptors. I-GENE-N
The O
potency O
of O
the O
antipsychotic O
drug, O
risperidone, B-CHEMICAL
to O
antagonize O
alpha B-GENE-Y
1A-adrenoceptor-mediated I-GENE-Y
contraction O
in O
rat O
vas O
deferens O
and O
vasoconstriction O
in O
rat O
perfused O
kidney, O
and O
alpha B-GENE-Y
1B-adrenoceptor-mediated I-GENE-Y
contractions O
in O
spleen O
from O
guinea-pig O
and O
mouse O
was O
evaluated O
and O
compared O
to O
that O
of O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
subtype-discriminating O
antagonists. O
Prazosin B-CHEMICAL
was O
found O
to O
be O
unselective; O

2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane B-CHEMICAL
(WB B-CHEMICAL
4101), I-CHEMICAL
5-methyl-urapidil, B-CHEMICAL
indoramin B-CHEMICAL
and O
(+)-niguldipine B-CHEMICAL
were O
confirmed O
as O
selective O
for O
the O
alpha B-GENE-Y
1A-adrenoceptor, I-GENE-Y
whereas O
spiperone B-CHEMICAL
was O
weakly O
alpha O
1B-selective. O
Risperidone B-CHEMICAL
was O
equipotent O
to O
prazosin B-CHEMICAL
at O
alpha B-GENE-Y
1A-adrenoceptors I-GENE-Y
in O
rat O
vas O
deferens O
and O
kidney. O
However, O
at O

guinea-pig B-GENE-N
and I-GENE-N
mouse I-GENE-N
splenic I-GENE-N
alpha I-GENE-N
1B-adrenoceptors, I-GENE-N
the O
affinity O
values O
of O
risperidone B-CHEMICAL
were O
10-fold O
lower O
than O
those O
of O
prazosin. B-CHEMICAL
Thus, O
in O
functional O
experiments O
the O
presumed O
high O
selectivity O
of O
risperidone B-CHEMICAL
for O
the O
B O
subtype O
of O
alpha B-GENE-N
1-adrenoceptors I-GENE-N
could O
not O
be O
confirmed, O
the O
drug O
instead O
appears O
to O
be O
moderately O
selective O
(10-fold) O
for O
the O
A O
subtype. O
New O
assignments O
for O
multitasking O
signal O
transduction O
inhibitors. O
An O
article O
presented O
in O
this O
issue O
of O
Molecular O
Pharmacology O
(p. O
1527) O
provides O

an O
intriguing O
example O
of O
how O
tyrosine B-GENE-N
kinase I-GENE-N
inhibitors O
can O
be O
put O
to O
many O
uses. O
In O
this O
article, O
the O
action O
of O
dasatinib B-CHEMICAL
(BMS-354825) B-CHEMICAL
is O
contrasted O
with O
that O
of O
imatinib, B-CHEMICAL
a O
kinase B-GENE-N
inhibitor O
that O
is O
currently O
being O
used O
to O
treat O
chronic O
myelogenous O
leukemia O
and O
other O
disorders. O
Both O
pharmacologic O
inhibitors O
target O
several O
tyrosine B-GENE-N
kinases, I-GENE-N
including O
Bcr-Abl B-GENE-Y
and O
the O
platelet-derived B-GENE-N
growth I-GENE-N
factor I-GENE-N
receptor I-GENE-N
(PDGFR). B-GENE-N
Up O
to O
this O
point, O
the O
PDGFR B-GENE-N
has O
not O
been O
a O

primary O
therapeutic O
target O
for O
this O
class O
of O
agents. O
The O
work O
of O
Chen O
and O
colleagues O
shows O
that O
dasatinib B-CHEMICAL
is O
a O
particularly O
potent O
inhibitor O
of O
PDGFR B-GENE-N
and O
that O
the O
compound O
also O
targets O
Src B-GENE-Y
kinase. I-GENE-Y
The O
authors O
suggest O
that O
this O
combination O
of O
activities O
could O
be O
useful O
in O
the O
treatment O
of O
vascular O
obstructive O
diseases. O
Although O
a O
lack O
of O
absolute O
specificity O
has O
typically O
been O
regarded O
as O
a O
pharmacologic O
drawback, O
this O
study O
exemplifies O
how O
drugs O
with O
multiple O
molecular O
targets O
can O
potentially O
provide O
a O
very O
beneficial O
spectrum O
of O
therapeutic O
activities O
in O
multiple O
disease O
states. O
Serotonin B-GENE-Y
transporter I-GENE-Y
function O
in O
vivo: O
assessment O
by O

chronoamperometry. O
Local O
application O
of O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors, O
fluvoxamine B-CHEMICAL
and O
citalopram, B-CHEMICAL
prolonged O
the O
clearance O
of O
exogenously O
administered O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
in O
both O
the O
dentate O
gyrus O
and O
CA3 O
region O
of O
the O
dorsal O
hippocampus, O
as O
measured O
using O
in O
vivo O
chronoamperometry. O
These O
effects O
were O
abolished O
in O
rats O
pretreated O
with O
5,7-dihydroxytryptamine. B-CHEMICAL
The O
NE B-CHEMICAL
uptake O
inhibitors, O
desipramine B-CHEMICAL
and O
protriptyline, B-CHEMICAL
did O
not O
alter O

the O
5-HT B-CHEMICAL
signal O
in O
the O
CA3 O
region, O
but O
prolonged O
the O
clearance O
of O
5-HT B-CHEMICAL
in O
the O
dentate O
gyrus; O
this O
effect O
was O
absent O
in O
rats O
pretreated O
with O
6-hydroxydopamine. B-CHEMICAL
From O
these O
data, O
it O
is O
inferred O
that O
both O
the O
SERT B-GENE-Y
and O
NET B-GENE-Y
contribute O
to O
the O
active O
clearance O
of O
exogenously O
applied O
5-HT B-CHEMICAL
in O
the O
dentate O
gyrus. O
In O
another O
experiment, O
cyanopindolol, B-CHEMICAL
an O
antagonist O
of O
the O
serotonin B-GENE-N
terminal I-GENE-N
autoreceptor, I-GENE-N
also O
prolonged O
the O
clearance O
of O
5-HT B-CHEMICAL
from O
the O
CA3 O
region. O
These O

and O
other O
data O
have O
generated O
a O
working O
hypothesis O
that O
activation O
of O
the O
terminal O
serotonin B-GENE-N
autoreceptor I-GENE-N
enhances O
the O
kinetics O
of O
5-HT B-CHEMICAL
uptake O
through O
an O
effect O
on O
the O
serotonin B-GENE-Y
transporter. I-GENE-Y
Effect O
of O
minaprine B-CHEMICAL
on O
cycloheximide-induced B-CHEMICAL
amnesia O
in O
mice. O
The O
effects O
of O
minaprine B-CHEMICAL
on O
cycloheximide-induced B-CHEMICAL
amnesia O
were O
investigated O
in O
a O
step-down O
passive O
avoidance O
task O
in O
mice. O
Minaprine B-CHEMICAL
significantly O
improved O
cycloheximide-induced B-CHEMICAL
amnesia. O
This O
effect O
was O
inhibited O
by O

scopolamine, B-CHEMICAL
but O
was O
potentiated O
by O
physostigmine. B-CHEMICAL
The O
anti-amnesic O
effect O
of O
minaprine B-CHEMICAL
on O
the O
cycloheximide-induced B-CHEMICAL
memory O
impairment O
was O
also O
antagonized O
by O
a O
serotonin B-CHEMICAL
(5-HT) B-CHEMICAL
releaser, O
p-chloroamphetamine, B-CHEMICAL
and O
by O
a O
5-HT B-CHEMICAL
precursor, O
5-hydroxytryptophan, B-CHEMICAL
whereas O
a O
5-HT1A-selective B-GENE-Y
agonist, O
8-hydroxy-2-(di-n-propylamino)tetralin, B-CHEMICAL

was O
inactive. O
The O
memory-improving O
effect O
of O
minaprine B-CHEMICAL
on O
cycloheximide-induced B-CHEMICAL
amnesia O
was O
potentiated O
by O
a O
selective O
5-HT2 B-GENE-N
antagonist, O
ritanserin. B-CHEMICAL
These O
results O
suggest O
that O
the O
beneficial O
effect O
of O
minaprine B-CHEMICAL
on O
cycloheximide-induced B-CHEMICAL
amnesia O
may O
be O
related O
not O
only O
to O
cholinergic O
but O
also O
serotonergic O
neuronal O
systems O
(5-HT2 B-GENE-N
receptors). I-GENE-N
Extracts O
of O
Scutellaria O
baicalensis O
reduced O
body O
weight O
and O
blood O
triglyceride B-CHEMICAL
in O
db/db O
Mice. O

Scutellaria O
baicalensis O
has O
been O
extensively O
employed O
for O
the O
clinical O
treatment O
of O
hyperlipidemia, O
atherosclerosis, O
hypertension, O
dysentery, O
inflammatory O
diseases, O
and O
the O
common O
cold. O
The O
present O
study O
was O
performed O
to O
investigate O
the O
anti-obesity O
and O
anti-dyslipidemia O
effect O
of O
Scutellaria O
baicalensis O
extracts O
(SBE) O
in O
type O
2 O
diabetic O
db/db O
mice. O
Male O
db/db O
mice O
were O
divided O
into O
three O
groups O
(n O
= O
5) O
and O
orally O
administrated O
vehicle O
(control), O

SBE O
10, O
and O
100 O
mg/kg O
body O
weight/day O
for O
4 O
weeks O
everyday. O
Administration O
of O
SBE O
improves O
weight O
gain, O
hypertriglyceridemia, O
and O
hyperinsulinemia O
in O
db/db O
mice. O
In O
obese O
db/db O
mice, O
SBE O
treatment O
also O
reduced O
plasma O
alanine B-GENE-N
aminotransferase I-GENE-N
levels. O
In O
the O
livers O
of O
db/db O
mice, O
SBE O
promoted O
5' B-GENE-N
AMP-activated I-GENE-N
protein I-GENE-N
kinase I-GENE-N
activity O
and O
restored O
metabolic O
process O
and O
insulin B-GENE-N
signaling O
pathways. O
Our O
data O
demonstrate O
that O
SBE O
exerts O
potent O
anti-obesity O
and O

anti-hypertriglyceride O
effects O
suggesting O
its O
useful O
potential O
function O
as O
adjuvant O
therapeutic O
agent O
for O
the O
treatment O
of O
weight O
gain O
and O
hypertriglyceridemia. O
Altered O
methionine B-CHEMICAL
metabolism O
in O
long O
living O
Ames O
dwarf O
mice. O
Ames O
dwarf O
mice O
(df/df) O
are O
deficient O
in O
growth B-GENE-Y
hormone, I-GENE-Y
prolactin, B-GENE-Y
and O
thyroid-stimulating B-GENE-N
hormone I-GENE-N
and O
live O
significantly O
longer O
than O
their O
normal O
siblings. O
In O
the O
current O
study, O
we O
found O
that O
the O
hormone O
deficiencies O
affect O
methionine B-CHEMICAL
metabolism. O
We O
previously O
reported O
that O
the O
dwarf O
mice O
exhibit O
enzyme O
activities O
and O
levels O
that O
combat O
oxidative O

stress O
more O
efficiently O
than O
those O
of O
normal O
mice. O
Moreover, O
methionine B-CHEMICAL
or O
metabolites O
of O
methionine B-CHEMICAL
are O
involved O
in O
antioxidative O
processes. O
Thus, O
we O
performed O
an O
experiment O
that O
compared O
various O
parameters O
of O
methionine B-CHEMICAL
metabolism O
between O
18-month O
old O
male O
dwarf O
(N=6) O
and O
wild O
type O
(N=5) O
mice. O
The O
specific O
activity O
of O
liver B-GENE-N
methionine I-GENE-N
adenosyltransferase I-GENE-N
(MAT) B-GENE-N
was O
significantly O
elevated O
(205%, O
p<0.0001) O
in O
the O
dwarf O
mice, O
as O
were O
cystathionine B-GENE-N
synthase I-GENE-N
(50%, O

p<0.01), O
cystathionase B-GENE-Y
(83%, O
p<0.001), O
and O
glycine B-GENE-Y
N-methyltransferase I-GENE-Y
(GNMT, B-GENE-Y
91%, O
p<0.001) O
activities. O
Even O
though O
the O
activities O
of O
MAT B-GENE-N
and O
GNMT B-GENE-Y
were O
elevated, O
the O
concentration O
of O
liver O
S-adenosylmethionine B-CHEMICAL
was O
decreased O
(24%, O
p<0.001) O
and O
S-adenosylhomocysteine B-CHEMICAL
increased O
(113%, O
p<0.001) O
in O
the O
dwarf O
mice. O
These O
data O
indicate O

that O
dwarf O
mice, O
compared O
to O
wild O
type O
mice, O
have O
a O
markedly O
different O
metabolism O
of O
methionine. B-CHEMICAL
Altered O
methionine B-CHEMICAL
metabolism O
may O
partially O
explain O
earlier O
reports O
indicating O
less O
oxidative O
damage O
to O
proteins O
in O
dwarf O
mice. O
Taken O
together, O
the O
data O
suggest O
that O
methionine B-CHEMICAL
metabolism O
may O
play O
a O
role O
in O
oxidative O
defense O
in O
the O
dwarf O
mouse O
and O
should O
be O
studied O
as O
a O
potential O
mechanism O
of O
extended O
lifespan. O
The O
potential O
of O
nicotinic O
enhancement O
of O
cognitive O
remediation O
training O
in O
schizophrenia. O
Cognitive O
deficits O
in O
schizophrenia O
are O
critically O
important O
predictors O
of O
long-term O

psychosocial O
outcome O
and O
are O
not O
significantly O
ameliorated O
by O
currently O
available O
medications. O
Cognitive O
remediation O
training O
has O
shown O
promise O
for O
alleviating O
cognitive O
symptoms O
of O
schizophrenia, O
but O
the O
clinical O
significance O
has O
often O
been O
limited O
by O
small O
effect O
sizes. O
Approaches O
that O
achieve O
larger O
improvement O
involve O
time O
requirements O
that O
can O
be O
cost-prohibitive O
within O
the O
current O
clinical O
care O
system. O
This O
mini-review O
evaluates O
the O
theoretical O
potential O
of O
a O
pharmacological O
enhancement O
strategy O
of O
cognitive O
remediation O
training O
with O
nicotinic B-GENE-N
acetylcholine I-GENE-N
receptor I-GENE-N
(nAChR) B-GENE-N
agonists. O
nAChR B-GENE-N

agonists O
can O
facilitate O
sensory O
processing, O
alertness, O
attention, O
learning O
and O
memory. O
While O
these O
effects O
may O
be O
too O
subtle O
and O
short-lasting O
to O
be O
of O
clinical O
relevance O
as O
a O
primary O
treatment O
of O
cognitive O
deficits, O
they O
constitute O
an O
ideal O
effects O
profile O
for O
enhancing O
training O
benefits. O
Several O
mechanisms O
are O
described O
through O
which O
repeated O
coupling O
of O
cognitive O
training O
challenges O
with O
nAChR B-GENE-N
stimulation O
may O
enhance O
and O
accelerate O
cognitive O
remediation O
training O
effects, O
advancing O
such O
interventions O
into O
more O
effective O
and O
practicable O
treatments O
of O
some O
of O
the O
most O
debilitating O
symptoms O
of O
schizophrenia. O
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Cognitive O

Enhancers'. O
Activation O
of O
alpha B-GENE-Y
2B-adrenoceptors I-GENE-Y
mediates O
the O
cardiovascular O
effects O
of O
etomidate. B-CHEMICAL
BACKGROUND: O
The O
intravenous O
anesthetic O
etomidate B-CHEMICAL
exhibits O
structural O
similarities O
to O
specific O
alpha2-adrenoceptor B-GENE-N
agonists O
of O
the O
type O
such O
as O
dexmedetomidine. B-CHEMICAL
The O
current O
study O
was O
performed O
to O
elucidate O
the O
possible O
interaction O
of O
etomidate B-CHEMICAL
with O
alpha2-adrenoceptors B-GENE-N
in O
mice O
lacking O
individual O
alpha2-adrenoceptor B-GENE-N
subtypes O
(alpha2-KO). O

METHODS: O
Sedative O
and O
cardiovascular O
responses O
to O
etomidate B-CHEMICAL
and O
the O
alpha2-agonist, O
dexmedetomidine, B-CHEMICAL
were O
determined O
in O
mice O
deficient O
in O
alpha2-receptor B-GENE-N
subtypes. O
Inhibition O
of O
binding O
of O
the O
alpha2-receptor B-GENE-N
antagonist O
[3H]RX821002 B-CHEMICAL
to O
recombinant O
alpha2-receptors B-GENE-N
by O
etomidate B-CHEMICAL
was O
tested O
in O
human O
embryonic O
kidney O
(HEK293) O
cells O
in O
vitro. O
RESULTS: O
In O
vivo, O
loss O
and O
recovery O
of O
the O
righting O
reflex O
required O
similar O
times O
after O

intraperitoneal O
injection O
of O
etomidate B-CHEMICAL
in O
wild-type O
and O
in O
alpha2A-receptor-deficient B-GENE-Y
mice, O
indicating O
that O
the O
hypnotic O
effect O
of O
etomidate B-CHEMICAL
in O
mice O
does O
not O
require O
the O
alpha2A-receptor B-GENE-Y
subtype. O
Intravenous O
injection O
of O
etomidate B-CHEMICAL
resulted O
in O
a O
transient O
increase O
(duration O
2.4 O
+/- O
0.2 O
min) O
in O
arterial O
blood O
pressure O
in O
wild-type O
mice O
(17 O
+/- O
3 O
mmHg). O
Etomidate B-CHEMICAL
did O
not O
affect O
blood O
pressure O
in O
alpha2B-KO O
or O
alpha2AB-KO O

mice. O
In O
membranes O
from O
HEK293 O
cells O
transfected O
with O
alpha2-receptors, B-GENE-N
etomidate B-CHEMICAL
inhibited O
binding O
of O
the O
alpha2-antagonist, O
[3H]RX821002, B-CHEMICAL
with O
higher O
potency O
from O
alpha2B- B-GENE-N
and I-GENE-N
alpha2C-receptors I-GENE-N
than O
from O
alpha2A-receptors B-GENE-Y
(Ki O
alpha2A O
208 O
microm, O
alpha2B O
26 O
microm, O
alpha2C O
56 O
microm). O
In O
alpha2B-receptor-expressing B-GENE-Y
HEK293 O
cells, O
etomidate B-CHEMICAL
rapidly O
increased O
phosphorylation O
of O
the O
extracellular B-GENE-N
signal-related I-GENE-N
kinases I-GENE-N

ERK1/2. B-GENE-N
CONCLUSIONS: O
These O
results O
indicate O
that O
etomidate B-CHEMICAL
acts O
as O
an O
agonist O
at O
alpha2-adrenoceptors, B-GENE-N
which O
appears O
in O
vivo O
primarily O
as O
an O
alpha2B-receptor-mediated B-GENE-Y
increase O
in O
blood O
pressure. O
This O
effect O
of O
etomidate B-CHEMICAL
may O
contribute O
to O
the O
cardiovascular O
stability O
of O
patients O
after O
induction O
of O
anesthesia O
with O
etomidate. B-CHEMICAL
Silica B-CHEMICAL
nanoparticles-induced O
cytotoxicity, O
oxidative O
stress O
and O
apoptosis O
in O
cultured O
A431 O
and O
A549 O
cells. O
In O
medicine, O
the O
use O
of O
silica B-CHEMICAL

nanoparticles O
(SiO(2) B-CHEMICAL
NPs) O
offers O
new O
perspectives O
in O
biosensor, O
drug O
delivery O
and O
cancer O
therapy. O
However, O
questions O
about O
potential O
toxic O
and O
deleterious O
effects O
of O
SiO(2) B-CHEMICAL
NPs O
have O
also O
been O
raised. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
induction O
of O
cytotoxicity, O
oxidative O
stress O
and O
apoptosis O
by O
SiO(2) B-CHEMICAL
NPs O
(size O
15 O
nm) O
in O
human O
skin O
epithelial O
(A431) O
and O
human O
lung O
epithelial O
(A549) O
cells. O
SiO(2) B-CHEMICAL
NPs O

(concentration O
range O
25-200 O
µg/ml) O
induced O
dose-dependent O
cytotoxicity O
in O
both O
types O
of O
cells, O
which O
was O
demonstrated O
by O
cell O
viability O
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) B-CHEMICAL
and O
lactate B-GENE-N
dehydrogenase I-GENE-N
leakage O
assays. O
SiO(2) B-CHEMICAL
NPs O
were O
also O
found O
to O
induce O
oxidative O
stress O
in O
a O
dose-dependent O
manner, O
indicated O
by O
depletion O
of O
glutathione B-CHEMICAL
and O
induction O
of O
reactive O
oxygen B-CHEMICAL
species O

(ROS) O
generation O
and O
lipid O
peroxidation. O
Quantitative O
real-time O
polymerase O
chain O
reaction O
analysis O
showed O
that O
following O
the O
exposure O
of O
cells O
to O
SiO(2) B-CHEMICAL
NPs, O
the O
messenger O
RNA O
level O
of O
apoptotic O
genes O
(caspase-3 B-GENE-Y
and O
caspase-9) B-GENE-Y
were O
upregulated O
in O
a O
dose-dependent O
manner. O
Moreover, O
activities O
of O
caspase-3 B-GENE-Y
and O
caspase-9 B-GENE-Y
enzymes O
were O
also O
significantly O
higher O
in O
both O
kinds O
of O
cells O
exposed O
to O
SiO(2) B-CHEMICAL
NPs. O
This O
study O
suggested O
that O
SiO(2) B-CHEMICAL
NPs O
induce O

cytotoxicity O
and O
apoptosis O
in O
A431 O
and O
A549 O
cells, O
which O
is O
likely O
to O
be O
mediated O
through O
ROS O
generation O
and O
oxidative O
stress. O
The O
CYP2B6*6 B-GENE-Y
Allele O
Significantly O
Alters O
the O
N-demethylation O
of O
Ketamine B-CHEMICAL
Enantiomers O
In O
Vitro. O
Ketamine B-CHEMICAL
is O
primarily O
metabolized O
to O
norketamine B-CHEMICAL
by O
hepatic O
cytochrome B-GENE-Y
P450 I-GENE-Y
(CYP) I-GENE-Y
2B6 I-GENE-Y
and O
CYP3A4-mediated B-GENE-Y
N-demethylation. O
However, O
the O
relative O
contribution O
from O
each O
enzyme O
remains O
controversial. O

The O
CYP2B6*6 B-GENE-Y
allele O
is O
associated O
with O
reduced O
enzyme O
expression O
and O
activity O
that O
may O
lead O
to O
interindividual O
variability O
in O
ketamine B-CHEMICAL
metabolism. O
We O
examined O
the O
N-demethylation O
of O
individual O
ketamine B-CHEMICAL
enantiomers O
using O
human O
liver O
microsomes O
(HLMs) O
genotyped O
for O
the O
CYP2B6*6 B-GENE-Y
allele, O
insect O
cell O
expressed O
recombinant O
CYP2B6 B-GENE-Y
and O
CYP3A4 B-GENE-Y
enzymes O
and O
COS-1 O
cell O
expressed O
recombinant O
CYP2B6.1 B-GENE-Y
and O
CYP2B6.6 B-GENE-Y
protein O

variant. O
Effects O
of O
CYP-selective B-GENE-N
inhibitors O
on O
norketamine B-CHEMICAL
formation O
were O
also O
determined O
in O
HLMs. O
The O
two-enzyme O
Michaelis-Menten O
model O
best O
fitted O
the O
HLM O
kinetic O
data. O
The O
Km O
value O
for O
the O
high O
affinity O
enzyme O
and O
the O
low O
affinity O
enzyme O
were O
similar O
to O
those O
for O
the O
expressed O
CYP2B6 B-GENE-Y
and O
CYP3A4, B-GENE-Y
respectively. O
The O
intrinsic O
clearance O
for O
both O
ketamine B-CHEMICAL
enantiomers O
by O
the O
high O
affinity O
enzyme O
in O
HLMs O
with O
CYP2B6*1/*1 B-GENE-Y
genotype O
were O
at O
least O
2-fold O
and O
6-fold O
higher, O
respectively, O
than O

those O
for O
CYP2B6*1/*6 B-GENE-Y
genotype O
and O
CYP2B6*6/*6 B-GENE-Y
genotype. O
The O
Vmax O
and O
Km O
values O
for O
CYP2B6.1 B-GENE-Y
were O
approximately O
160% O
and O
70% O
of O
those O
for O
CYP2B6.6, B-GENE-Y
respectively. O
ThioTEPA B-CHEMICAL
(CYP2B6 B-GENE-Y
inhibitor, O
25 O
μM) O
and O
the O
monoclonal O
antibody O
against O
CYP2B6 B-GENE-Y
but O
not O
troleandomycin B-CHEMICAL
(CYP3A4 B-GENE-Y
inhibitor, O
25 O
μM) O
or O
the O
monoclonal O
antibody O
against O

CYP3A4 B-GENE-Y
inhibited O
ketamine B-CHEMICAL
N-demethylation O
at O
clinically O
relevant O
concentrations. O
The O
degree O
of O
inhibition O
was O
significantly O
reduced O
in O
HLMs O
with O
the O
CYP2B6*6 B-GENE-Y
allele O
(gene-dose O
P<0.05). O
These O
results O
indicate O
a O
major O
role O
of O
CYP2B6 B-GENE-Y
in O
ketamine B-CHEMICAL
N-demethylation O
in O
vitro O
and O
a O
significant O
impact O
of O
the O
CYP2B6*6 B-GENE-Y
allele O
on O
enzyme-ketamine B-CHEMICAL
binding O
and O
catalytic O
activity. O
A O
Role O
for O
Cargo B-GENE-N
in O
the O
Activation O
of O

ADP-Ribosylation B-GENE-N
Factors I-GENE-N
(Arf) B-GENE-N
and O
Adaptor B-GENE-N
Recruitment. O
Membrane O
traffic O
requires O
the O
specific O
concentration O
of O
protein B-GENE-N
cargos I-GENE-N
and O
exclusion O
of O
other O
proteins O
into O
nascent O
carriers. O
Critical O
components O
of O
this O
selectivity O
are O
the O
protein B-GENE-N
adaptors I-GENE-N
that O
bind O
to O
short, O
linear O
motifs O
in O
the O
cytoplasmic O
tails O
of O
transmembrane O
protein B-GENE-N
cargos I-GENE-N
and O
sequester O
them O
into O
nascent O
carriers. O
The O
recruitment O
of O
the O
adaptors O
is O
mediated O
by O
activated O
Arf B-GENE-N
GTPases B-GENE-N
and O
the O
Arf-adaptor B-GENE-N
complexes O
mark O
sites O
of O
carrier O
formation. O
However, O
the O
nature O
of O
the O

signal(s) O
that O
initiate O
carrier O
biogenesis O
remains O
unknown. O
We O
examined O
the O
specificity O
and O
initial O
sites O
of O
recruitment O
of O
Arf-dependent B-GENE-N
adaptors B-GENE-N
(AP-1 B-GENE-N
and O
GGAs) B-GENE-N
in O
response O
to O
the O
Golgi O
or O
endosomal O
localization O
of O
specific O
cargo B-GENE-N
proteins I-GENE-N
(furin, B-GENE-Y
mannose-6-phosphate B-GENE-Y
receptor I-GENE-Y
(M6PR) B-GENE-Y
and O
M6PR B-GENE-Y
lacking O
a O
C-terminal B-CHEMICAL
domain O
M6PRΔC). B-GENE-Y
We O
find O
that O
cargo B-GENE-N
promotes O
the O
recruitment O
of O
specific O
adaptors, B-GENE-N
suggesting O
that O
it O
is O
part O
of O
an O
upstream O
signaling O
event. O
Cargos B-GENE-N
do O
not O
promote O
adaptor B-GENE-N
recruitment O
to O
all O
compartments O
in O
which O
they O

reside O
and O
thus O
additional O
factors O
regulate O
the O
cargo's B-GENE-N
ability O
to O
promote O
Arf B-GENE-N
activation O
and O
adaptor B-GENE-N
recruitment. O
We O
document O
that O
within O
a O
given O
compartment O
different O
cargos B-GENE-N
recruit O
different O
adaptors B-GENE-N
suggesting O
that O
there O
is O
little O
or O
no O
free, O
activated O
Arf B-GENE-N
at O
the O
membrane O
and O
that O
Arf B-GENE-N
activation O
is O
spatially O
and O
temporally O
coupled O
to O
the O
cargo B-GENE-N
and O
the O
adaptor. B-GENE-N
Using O
temperature O
block, O
Brefeldin B-CHEMICAL
A, I-CHEMICAL
and O
recovery O
from O
each, O
we O
found O
that O
the O
cytoplasmic O
tail O
of O
M6PR B-GENE-Y
causes O
the O
recruitment O
of O
AP-1 B-GENE-N
and O
GGAs B-GENE-N
to O
recycling O
endosomes O
and O
not O
at O
the O
Golgi, O
as O
predicted O
by O

steady O
state O
staining O
profiles. O
These O
results O
are O
discussed O
with O
respect O
to O
the O
generation O
of O
novel O
models O
for O
cargo-dependent B-GENE-N
regulation O
of O
membrane O
traffic. O
Aromatase B-GENE-Y
inhibitors O
for O
male O
infertility. O
PURPOSE: O
Testosterone-to-estradiol B-CHEMICAL
ratio O
levels O
in O
infertile O
men O
improve O
during O
treatment O
with O
the O
aromatase B-GENE-Y
inhibitor, O
testolactone, B-CHEMICAL
and O
resulting O
changes O
in O
semen O
parameters. O
We O
evaluated O
the O
effect O
of O
anastrozole, B-CHEMICAL
a O
more O
selective O
aromatase B-GENE-Y
inhibitor, O
on O
the O
hormonal O
and O
semen O
profiles O
of O
infertile O
men O
with O
abnormal O
baseline O
testosterone-to-estradiol B-CHEMICAL

ratios. O
MATERIALS O
AND O
METHODS: O
A O
total O
of O
140 O
subfertile O
men O
with O
abnormal O
testosterone-to-estradiol B-CHEMICAL
ratios O
were O
treated O
with O
100 O
to O
200 O
mg. O
testolactone B-CHEMICAL
daily O
or O
1 O
mg. O
anastrozole B-CHEMICAL
daily. O
Changes O
in O
testosterone, B-CHEMICAL
estradiol, B-CHEMICAL
testosterone-to-estradiol B-CHEMICAL
ratios O
and O
semen O
parameters O
were O
evaluated O
during O
therapy. O
The O
effect O
of O
obesity, O
diagnosis O
of O
the O
Klinefelter O
syndrome, O
and O
presence O
of O
varicocele O
and/or O
history O
of O
varicocele O
repair O
on O
treatment O
results O
was O
studied. O

RESULTS: O
Men O
treated O
with O
testolactone B-CHEMICAL
had O
an O
increase O
in O
testosterone-to-estradiol B-CHEMICAL
ratios O
during O
therapy O
(mean O
plus O
or O
minus O
standard O
error O
of O
the O
mean O
5.3 O
+/- O
0.2 O
versus O
12.4 O
+/- O
1.1, O
p O
<0.001). O
This O
change O
was O
confirmed O
in O
subgroups O
of O
men O
with O
the O
Klinefelter O
syndrome, O
a O
history O
of O
varicocele O
repair O
and O
those O
with O
varicocele. O
A O
total O
of O
12 O
oligospermic O
men O
had O
semen O
analysis O
before O
and O
during O
testolactone B-CHEMICAL
treatment O
with O
an O
increase O
in O
sperm O

concentration O
(5.5 O
versus O
11.2 O
million O
sperm O
per O
ml., O
p O
<0.01), O
motility O
(14.7% O
versus O
21.0%, O
p O
<0.05), O
morphology O
(6.5% O
versus O
12.8%, O
p O
= O
0.05), O
and O
motility O
index O
(606.3 O
versus O
1685.2 O
million O
motile O
sperm O
per O
ejaculate, O
respectively, O
p O
<0.05) O
appreciated. O
During O
anastrozole B-CHEMICAL
treatment, O
similar O
changes O
in O
the O
testosterone-to-estradiol B-CHEMICAL
ratios O
were O
seen O
(7.2 O

+/- O
0.3 O
versus O
18.1 O
+/- O
1.0, O
respectively, O
p O
<0.001). O
This O
improvement O
of O
hormonal O
parameters O
was O
noted O
for O
all O
subgroups O
except O
those O
patients O
with O
the O
Klinefelter O
syndrome. O
A O
total O
of O
25 O
oligospermic O
men O
with O
semen O
analysis O
before O
and O
during O
anastrozole B-CHEMICAL
treatment O
had O
an O
increase O
in O
semen O
volume O
(2.9 O
versus O
3.5 O
ml., O
p O
<0.05), O
sperm O
concentration O
(5.5 O
versus O
15.6 O
million O
sperm O
per O
ml., O
p O
<0.001) O
and O

motility O
index O
(832.8 O
versus O
2930.8 O
million O
motile O
sperm O
per O
ejaculate, O
respectively, O
p O
<0.005). O
These O
changes O
were O
similar O
to O
those O
observed O
in O
men O
treated O
with O
testolactone. B-CHEMICAL
No O
significant O
difference O
in O
serum O
testosterone B-CHEMICAL
levels O
during O
treatment O
with O
testolactone B-CHEMICAL
and O
anastrozole B-CHEMICAL
was O
observed. O
However, O
the O
anastrozole B-CHEMICAL
treatment O
group O
did O
have O
a O
statistically O
better O
improvement O
of O
serum O
estradiol B-CHEMICAL
concentration O
and O
testosterone-to-estradiol B-CHEMICAL
ratios O
(p O
<0.001). O
CONCLUSIONS: O
Men O
who O
are O

infertile O
with O
a O
low O
serum O
testosterone-to-estradiol B-CHEMICAL
ratio O
can O
be O
treated O
with O
an O
aromatase B-GENE-Y
inhibitor. O
With O
treatment, O
an O
increase O
in O
testosterone-to-estradiol B-CHEMICAL
ratio O
occurred O
in O
association O
with O
increased O
semen O
parameters. O
Anastrozole B-CHEMICAL
and O
testolactone B-CHEMICAL
have O
similar O
effects O
on O
hormonal O
profiles O
and O
semen O
analysis. O
Anastrazole B-CHEMICAL
appears O
to O
be O
at O
least O
as O
effective O
as O
testolactone B-CHEMICAL
for O
treating O
men O
with O
abnormal O
testosterone-to-estradiol B-CHEMICAL
ratios, O
except O
for O
the O
subset O
with O
the O
Klinefelter O
syndrome, O
who O
appeared O
to O
be O
more O
effectively O
treated O
with O

testolactone. B-CHEMICAL
Interactions O
between O
CYP2E1 B-GENE-Y
and O
CYP2B4: B-GENE-Y
effects O
on O
affinity O
for O
NADPH-cytochrome B-GENE-Y
P450 I-GENE-Y
reductase I-GENE-Y
and O
substrate O
metabolism. O
Studies O
in O
microsomal O
and O
reconstituted O
systems O
have O
shown O
that O
the O
presence O
of O
one O
cytochrome B-GENE-N
P450 I-GENE-N
isoform O
can O
significantly O
influence O
the O
catalytic O
activity O
of O
another O
isoform. O
In O
this O
study, O
we O
assessed O
whether O
CYP2E1 B-GENE-Y
could O
influence O
the O
catalytic O
activity O
of O
CYP2B4 B-GENE-Y
under O
steady-state O
turnover O
conditions. O
The O
results O
show O
that O
CYP2E1 B-GENE-Y
inhibits O

CYP2B4-mediated B-GENE-Y
metabolism O
of O
benzphetamine B-CHEMICAL
(BNZ) B-CHEMICAL
with O
a O
K(i) O
of O
0.04 O
µM. O
However, O
CYP2B4 B-GENE-Y
is O
not O
an O
inhibitor O
of O
CYP2E1-mediated B-GENE-Y
p-nitrophenol B-CHEMICAL
hydroxylation. O
When O
these O
inhibition O
studies O
were O
performed O
with O
the O
artificial O
oxidant O
tert-butyl B-CHEMICAL
hydroperoxide, I-CHEMICAL
CYP2E1 B-GENE-Y
did O
not O
significantly O
inhibit O
CYP2B4 B-GENE-Y
activity. O
Determinations O
of O
the O
apparent O
K(M) O
and O
k(cat) O
of O
CYP2B4 B-GENE-Y
for O

CPR B-GENE-Y
in O
the O
presence O
of O
increasing O
concentrations O
of O
CYP2E1 B-GENE-Y
revealed O
a O
mixed O
inhibition O
of O
CYP2B4 B-GENE-Y
by O
CYP2E1. B-GENE-Y
At O
low O
concentrations O
of O
CYP2E1, B-GENE-Y
the O
apparent O
K(M) O
of O
CYP2B4 B-GENE-Y
for O
CPR B-GENE-Y
increased O
up O
to O
23-fold O
with O
virtually O
no O
change O
in O
the O
k(cat) O
for O
the O
reaction, O
however, O
at O
higher O
concentrations O
of O
CYP2E1, B-GENE-Y
the O
apparent O
K(M) O
of O
CYP2B4 B-GENE-Y
for O
CPR B-GENE-Y
decreased O
to O
levels O
similar O
to O
those O
observed O
in O
the O
absence O
of O
CYP2E1 B-GENE-Y
and O
the O
k(cat) O

also O
decreased O
by O
11-fold. O
Additionally, O
CYP2E1 B-GENE-Y
increased O
the O
apparent O
K(M) O
of O
CYP2B4 B-GENE-Y
for O
BNZ B-CHEMICAL
by O
8-fold O
and O
the O
apparent O
K(M) O
did O
not O
decrease O
to O
its O
original O
value O
when O
saturating O
concentrations O
of O
CPR B-GENE-Y
were O
used. O
While O
the O
individual O
apparent O
K(M) O
values O
of O
CYP2B4 B-GENE-Y
and O
CYP2E1 B-GENE-Y
for O
CPR B-GENE-Y
are O
similar, O
the O
apparent O
K(M) O
of O
CYP2E1 B-GENE-Y
for O
CPR B-GENE-Y
in O
the O
presence O
of O
CYP2B4 B-GENE-N
decreased O
significantly, O
thus O
suggesting O
that O
CYP2B4 B-GENE-Y
enhances O
the O
affinity O

of O
CYP2E1 B-GENE-Y
for O
CPR B-GENE-Y
and O
this O
may O
allow O
CYP2E1 B-GENE-Y
to O
out-compete O
CYP2B4 B-GENE-Y
for O
CPR. B-GENE-Y
Prosocial O
effects O
of O
oxytocin B-GENE-Y
in O
two O
mouse O
models O
of O
autism O
spectrum O
disorders. O
Clinical O
evidence O
suggests O
that O
oxytocin B-GENE-Y
treatment O
improves O
social O
deficits O
and O
repetitive O
behavior O
in O
autism O
spectrum O
disorders O
(ASDs). O
However, O
the O
neuropeptide B-GENE-N
has O
a O
short O
plasma O
half-life O
and O
poor O
ability O
to O
penetrate O
the O
blood-brain O
barrier. O
In O
order O
to O
facilitate O
the O
development O
of O
more O
bioavailable O
oxytocinergic O
compounds O
as O
therapeutics O
to O
treat O
core O

ASD O
symptoms, O
small O
animal O
models O
must O
be O
validated O
for O
preclinical O
screens. O
This O
study O
examined O
the O
preclinical O
utility O
of O
two O
inbred O
mouse O
strains, O
BALB/cByJ O
and O
C58/J, O
that O
exhibit O
phenotypes O
relevant O
to O
core O
ASD O
symptoms. O
Mice O
from O
both O
strains O
were O
intraperitoneally O
administered O
oxytocin, B-GENE-Y
using O
either O
acute O
or O
sub-chronic O
regimens. O
Acute O
oxytocin B-GENE-Y
did O
not O
increase O
sociability O
in O
BALB/cByJ; O
however, O
sub-chronic O
oxytocin B-GENE-Y
had O
significant O
prosocial O

effects O
in O
both O
BALB/cByJ O
and O
C58/J. O
Increased O
sociability O
was O
observed O
24 O
hours O
following O
the O
final O
oxytocin B-GENE-Y
dose O
in O
BALB/cByJ, O
while O
prosocial O
effects O
of O
oxytocin B-CHEMICAL
emerged O
1-2 O
weeks O
post-treatment O
in O
C58/J. O
Furthermore, O
acute O
oxytocin B-GENE-Y
decreased O
motor O
stereotypy O
in O
C58/J O
and O
did O
not O
induce O
hypoactivity O
or O
anxiolytic-like O
effects O
in O
an O
open O
field O
test. O
This O
study O
demonstrates O
that O
oxytocin B-GENE-Y
administration O
can O
attenuate O
social O

deficits O
and O
repetitive O
behavior O
in O
mouse O
models O
of O
ASD, O
dependent O
on O
dose O
regimen O
and O
genotype. O
These O
findings O
provide O
validation O
of O
the O
BALB/cByJ O
and O
C58/J O
models O
as O
useful O
platforms O
for O
screening O
novel O
drugs O
for O
intervention O
in O
ASDs O
and O
for O
elucidating O
the O
mechanisms O
contributing O
to O
the O
prosocial O
effects O
of O
oxytocin. B-GENE-Y
Probing O
for O
a O
hydrophobic O
a O
binding O
register O
in O
prostate-specific B-GENE-Y
membrane I-GENE-Y
antigen I-GENE-Y
with O
phenylalkylphosphonamidates. B-CHEMICAL
To O
explore O
for O
the O
existence O
of O
an O
auxiliary O
hydrophobic O
binding O
register O
remote O
from O
the O
active O
site O
of O

PSMA B-GENE-Y
a O
series O
of O
phenylalkylphosphonamidate B-CHEMICAL
derivatives O
of O
glutamic B-CHEMICAL
acid I-CHEMICAL
were O
synthesized O
and O
evaluated O
for O
their O
inhibitory O
potencies O
against O
PSMA. B-GENE-Y
Both O
the O
phenyl- B-CHEMICAL
and I-CHEMICAL
benzylphosphonamidates I-CHEMICAL
(1a O
and O
1b) O
exhibited O
only O
modest O
inhibitory O
potency O
against. O
The O
phenethyl B-CHEMICAL
analog O
1c O
was O
intermediate O
in O
inhibitory O
potency O
while O
inhibitors O
possessing O
a O
longer O
alkyl B-CHEMICAL
tether O
from O
the O
phenyl O
ring, O
resulted O
in O
markedly O
improved O
K(i) O
values. O
The O
greatest O
inhibitory O
potency O
was O
obtained O
for O
the O
inhibitors O
in O
which O
the O

phenyl O
ring O
was O
extended O
furthest O
from O
the O
central O
phosphorus B-CHEMICAL
(1f, O
n=5 O
and O
1g, O
n=6). O
The O
slightly O
serrated O
pattern O
that O
emerged O
as O
the O
alkyl B-CHEMICAL
tether O
increased O
from O
three O
to O
six O
methylene O
units O
suggests O
that O
inhibitory O
potency O
is O
not O
simply O
correlated O
to O
increased O
hydrophobicity O
imparted O
by O
the O
phenylalkyl B-CHEMICAL
chain, O
but O
rather O
that O
one O
or O
more O
hydrophobic O
binding O
registers O
may O
exist O
remote O
from O
the O
substrate O
recognition O
architecture O
in O
the O
active O
site O
of O
PSMA. B-GENE-Y
Deficits O
in O
male O
sexual O
behavior O
in O
adulthood O
after O
social O
instability O
stress O
in O
adolescence O

in O
rats. O
There O
is O
increasing O
evidence O
that O
exposure O
to O
stressors O
in O
adolescence O
has O
long-lasting O
effects O
on O
emotional O
and O
cognitive O
behavior, O
but O
little O
is O
known O
as O
to O
whether O
reproductive O
functions O
are O
affected. O
We O
investigated O
appetitive O
and O
consummatory O
aspects O
of O
sexual O
behavior O
in O
male O
rats O
that O
were O
exposed O
to O
chronic O
social O
instability O
stress O
(SS, O
n=24) O
for O
16 O
days O
in O
mid-adolescence O
compared O
to O
control O
rats O
(CTL, O
n=24). O
Over O
five O
sexual O
behavior O
test O
sessions O
with O
a O
receptive O
female, O
SS O
rats O
made O
fewer O
ejaculations O
(p=0.02) O
and O
had O
longer O
latencies O
to O

ejaculation O
(p=0.03). O
When O
only O
data O
from O
rats O
that O
ejaculated O
in O
the O
fifth O
session O
were O
analyzed, O
SS O
rats O
(n=18) O
had O
reduced O
copulatory O
efficiency O
(more O
mounts O
and O
intromissions O
before O
ejaculation) O
compared O
to O
CTL O
rats O
(n=19) O
(p=0.004), O
and O
CTL O
rats O
were O
twice O
as O
likely O
as O
SS O
rats O
to O
make O
more O
than O
one O
ejaculation O
in O
the O
fifth O
session O
(p=0.05). O
Further, O
more O
CTL O
(14/24) O
than O
SS O
(5/25) O
rats O

ejaculated O
in O
four O
or O
more O
sessions O
(p=0.05). O
SS O
rats O
had O
lower O
plasma O
testosterone B-CHEMICAL
concentrations O
than O
CTL O
rats O
(p=0.05), O
but O
did O
not O
differ O
in O
androgen B-GENE-Y
receptor, I-GENE-Y
estrogen B-GENE-Y
receptor I-GENE-Y
alpha, I-GENE-Y
or O
Fos B-GENE-Y
immunoreactive O
cell O
counts O
in O
the O
medial O
preoptic O
area. O
The O
groups O
did O
not O
differ O
in O
a O
partner O
preference O
test O
administered O
between O
the O
fourth O
and O
fifth O
sexual O
behavior O
session. O
The O
results O
suggest O
that O
developmental O
history O
contributes O
to O
individual O
differences O
in O
reproductive O
behavior, O
and O
that O
stress O
exposures O
in O
adolescence O
may O
be O
a O
factor O
in O
sexual O
sluggishness. O

Low-Dose O
Dexamethasone B-CHEMICAL
Treatment O
Promotes O
Pro-Survival O
Signalling O
Pathway O
In O
Adult O
Rat O
Prefrontal O
Cortex. O
Synthetic O
glucocorticoid O
dexamethasone B-CHEMICAL
(DEX), B-CHEMICAL
a O
highly O
potent O
anti-inflammatory O
and O
immunosuppressive O
agent, O
is O
widely O
used O
in O
treatments O
of O
brain O
cancer, O
inflammatory O
and O
autoimmune O
diseases. O
The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low-dose O
subchronic O
DEX B-CHEMICAL
treatment O
(100 O
μg/kg O
for O
8 O
consecutive O
days) O
exerts O
long-term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O

prefrontal O
cortex O
(PFC) O
by O
examining O
the O
expression O
of O
cell O
death-promoting O
molecules O
(poly B-GENE-N
(ADP-ribose) I-GENE-N
polymerase I-GENE-N
(PARP), B-GENE-N
p53, B-GENE-Y
procaspase B-GENE-Y
3, I-GENE-Y
cleaved O
caspase B-GENE-Y
3, I-GENE-Y
Bax) B-GENE-Y
and O
cell-survival O
molecules O
(AKT, B-GENE-N
Bcl-2). B-GENE-Y
Our O
results O
revealed O
that O
body, O
thymus O
and O
adrenal O
weight O
as O
well O
corticosterone B-CHEMICAL
level O
in O
the O
serum O
and O
PFC O
were O
reduced O
a O
day O
following O
last O
DEX B-CHEMICAL
injection. O
In O
PFC, O
DEX B-CHEMICAL
caused O
activation O
of O
AKT, B-GENE-N
augmentation O
of O

pro-survival O
Bcl-2 B-GENE-Y
protein O
and O
enhanced O
Bcl-2/Bax B-GENE-Y
protein O
ratio, O
as O
well O
Bcl-2 B-GENE-Y
translocation O
to O
mitochondria. O
The O
unaltered O
profile O
in O
the O
protein O
expression O
of O
apoptotic O
molecules O
PARP, B-GENE-N
procaspase B-GENE-Y
3 I-GENE-Y
and O
Bax B-GENE-Y
was O
detected, O
while O
the O
p53 B-GENE-Y
protein O
was O
decreased. O
Results O
of O
RT-PCR O
analysis O
showed O
decrease O
of O
p53 B-GENE-Y
mRNA O
level O
and O
no O
significant O
difference O
in O
Bcl-2 B-GENE-Y
and O
Bax B-GENE-Y
mRNA O
expressions O
in O
DEX-treated B-CHEMICAL
rats. O
Finally, O
the O
DNA O
fragmentation O
assay O
and O
Fluoro-Jade O

staining O
demonstrated O
no O
considerable O
changes O
in O
the O
apoptosis O
in O
rat O
PFC. O
Our O
findings O
support O
the O
concept O
that O
a O
low-dose O
DEX B-CHEMICAL
creates O
the O
hypocorticoid O
state O
in O
the O
brain O
and O
indicate O
that O
subchronic O
DEX B-CHEMICAL
treatment O
activates O
pro-survival O
signalling O
pathway O
but O
does O
not O
change O
apoptotic O
markers O
in O
rat O
PFC. O
This O
mechanism O
might O
be O
relevant O
for O
DEX-induced B-CHEMICAL
apoptosis O
resistance O
observed O
during O
and O
after O
chemotherapy O
of O
patients O
with O
brain O
tumours. O
© O
2013 O
British O
Society O
for O
Neuroendocrinology. O
Crystal O
structure O
of O
the O
IL-2 B-GENE-Y
signaling O
complex: O
paradigm O
for O
a O

heterotrimeric O
cytokine B-GENE-N
receptor. I-GENE-N
IL-2 B-GENE-Y
is O
a O
cytokine B-GENE-N
that O
functions O
as O
a O
growth O
factor O
and O
central O
regulator O
in O
the O
immune O
system O
and O
mediates O
its O
effects O
through O
ligand-induced O
hetero-trimerization O
of O
the O
receptor O
subunits O
IL-2R B-GENE-Y
alpha, I-GENE-Y
IL-2R B-GENE-N
beta, I-GENE-N
and I-GENE-N
gamma(c). I-GENE-N
Here, O
we O
describe O
the O
crystal O
structure O
of O
the O
trimeric O
assembly O
of O
the O
human B-GENE-N
IL-2 I-GENE-N
receptor I-GENE-N
ectodomains O
in O
complex O
with O
IL-2 B-GENE-Y
at O
3.0 O
A O
resolution. O
The O
quaternary O
structure O
is O
consistent O
with O
a O
stepwise O
assembly O
from O

IL-2/IL-2R B-GENE-Y
alpha I-GENE-Y
to O
IL-2/IL-2R B-GENE-Y
alpha/IL-2R I-GENE-Y
beta I-GENE-Y
to O
IL-2/IL-2R B-GENE-Y
alpha/IL-2R I-GENE-Y
beta/gamma(c). I-GENE-N
The O
IL-2R B-GENE-Y
alpha I-GENE-Y
subunit O
forms O
the O
largest O
of O
the O
three O
IL-2/IL-2R B-GENE-Y
interfaces, O
which, O
together O
with O
the O
high O
abundance O
of O
charge-charge O
interactions, O
correlates O
well O
with O
the O
rapid O
association O
rate O
and O
high-affinity O
interaction O
of O
IL-2R B-GENE-Y
alpha I-GENE-Y
with O
IL-2 B-GENE-Y
at O
the O
cell O
surface. O
Surprisingly, O
IL-2R B-GENE-Y
alpha I-GENE-Y
makes O
no O
contacts O
with O

IL-2R B-GENE-N
beta I-GENE-N
or I-GENE-N
gamma(c), I-GENE-N
and O
only O
minor O
changes O
are O
observed O
in O
the O
IL-2 B-GENE-Y
structure O
in O
response O
to O
receptor O
binding. O
These O
findings O
support O
the O
principal O
role O
of O
IL-2R B-GENE-Y
alpha I-GENE-Y
to O
deliver O
IL-2 B-GENE-Y
to O
the O
signaling O
complex O
and O
act O
as O
regulator O
of O
signal O
transduction. O
Cooperativity O
in O
assembly O
of O
the O
final O
quaternary O
complex O
is O
easily O
explained O
by O
the O
extraordinarily O
extensive O
set O
of O
interfaces O
found O
within O
the O
fully O
assembled O
IL-2 B-GENE-Y
signaling O
complex, O
which O
nearly O
span O
the O
entire O
length O
of O
the O
IL-2R B-GENE-N
beta I-GENE-N
and I-GENE-N
gamma(c) I-GENE-N
subunits. O
Helix O
A O
of O
IL-2 B-GENE-Y
wedges O

tightly O
between O
IL-2R B-GENE-N
beta I-GENE-N
and I-GENE-N
gamma(c) I-GENE-N
to O
form O
a O
three-way O
junction O
that O
coalesces O
into O
a O
composite O
binding O
site O
for O
the O
final O
gamma(c) O
recruitment. O
The O
IL-2/gamma(c) B-GENE-Y
interface O
itself O
exhibits O
the O
smallest O
buried O
surface O
and O
the O
fewest O
hydrogen B-CHEMICAL
bonds O
in O
the O
complex, O
which O
is O
consistent O
with O
its O
promiscuous O
use O
in O
other O
cytokine B-GENE-N
receptor I-GENE-N
complexes. O
Antitumor O
activity O
of O
sorafenib B-CHEMICAL
in O
FLT3-driven B-GENE-Y
leukemic O
cells. O
Activating O
internal O
tandem O
duplication O
(ITD) O
insertions O
in O
the O
juxtamembrane B-GENE-N
domain I-GENE-N
of O
the O

FLT3 B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
are O
found O
in O
about O
one O
fourth O
of O
patients O
with O
acute O
myeloid O
leukemia O
and O
have O
been O
shown O
to O
be O
an O
independent O
negative O
prognostic O
factor O
for O
survival. O
We O
show O
that O
sorafenib B-CHEMICAL
(BAY B-CHEMICAL
43-9006, I-CHEMICAL
Nexavar) B-CHEMICAL
potently O
inhibits O
FLT3 B-GENE-Y
enzymatic O
and O
signaling O
activities. O
In O
HEK293 O
cells O
stably O
transfected O
with O
FLT3-WT B-GENE-Y
or O
FLT3-ITD, B-GENE-Y
sorafenib B-CHEMICAL
blocked O
basal O
and O
ligand O
dependent O
FLT3-mediated B-GENE-Y
tyrosine B-CHEMICAL

autophosphorylation O
as O
well O
as O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase1/2 I-GENE-N
and O
Stat5 B-GENE-Y
phosphorylation. O
In O
leukemia O
cell O
lines O
MV4-11 O
and O
EOL-1, O
sorafenib B-CHEMICAL
treatment O
resulted O
in O
decreased O
cell O
proliferation O
and O
inhibition O
of O
FLT3 B-GENE-Y
signaling. O
The O
growth O
of O
the O
FLT3-independent B-GENE-Y
RS4-11 O
cell O
line O
was O
only O
weakly O
inhibited O
by O
sorafenib. B-CHEMICAL
Cell O
cycle O
arrest O
and O
induction O
of O
apoptosis O
were O
observed O
upon O
treatment O
with O
sorafenib B-CHEMICAL
in O
MV4-11 O
and O
EOL-1 O
cells. O
The O
antitumor O
efficacy O
of O

sorafenib B-CHEMICAL
was O
evaluated O
against O
the O
MV4-11 O
leukemia O
grown O
subcutaneously O
in O
NCr O
nu/nu O
mice. O
Doses O
of O
3 O
and O
10 O
mg/kg O
administered O
orally O
for O
14 O
days O
resulted O
in O
six O
and O
nine O
out O
of O
10 O
animals O
with O
complete O
responses, O
respectively. O
The O
demonstration O
that O
sorafenib B-CHEMICAL
exhibits O
potent O
target O
inhibition O
and O
efficacy O
in O
FLT3-driven B-GENE-Y
models O
suggests O
that O
this O
compound O
may O
have O
a O
therapeutic O
benefit O
for O
patients O
with O
FLT3-driven B-GENE-Y
leukemias. O
Apoptosis O
induced O
neurotoxicity O
of O

Di-n-butyl-di-(4-chlorobenzohydroxamato) B-CHEMICAL
Tin I-CHEMICAL
(IV) I-CHEMICAL
via O
mitochondria-mediated O
pathway O
in O
PC12 O
cells. O
The O
severe O
toxicity O
of O
antitumor O
organotin B-CHEMICAL
(IV) I-CHEMICAL
compounds O
limits O
their O
application O
in O
clinic, O
however, O
the O
toxic O
mechanism O
is O
still O
unclear. O
Di-n-butyl-di-(4-chlorobenzohydroxamato) B-CHEMICAL
Tin I-CHEMICAL
(IV) I-CHEMICAL
(DBDCT), B-CHEMICAL
an O
antitumor O
agent O
with O
high O
activity O
and O
obvious O
neurotoxicity O
was O
chosen O
as O
a O
typical O
diorganotin B-CHEMICAL

(IV) I-CHEMICAL
compound O
to O
investigate O
its O
neurotoxic O
mechanism O
using O
PC12 O
cells O
and O
comprehensive O
methods. O
Treatment O
with O
DBDCT B-CHEMICAL
resulted O
in O
a O
dose- O
and O
time-dependent O
growth O
inhibition O
of O
PC12 O
cells. O
The O
changes O
in O
cell O
morphology O
were O
observed O
using O
light O
microscopy, O
fluorescence O
microscopy O
and O
transmission O
electron O
microscopy. O
PC12 O
cell O
apoptosis O
induced O
by O
DBDCT B-CHEMICAL
was O
confirmed O
by O
annexin O
V/propidium B-CHEMICAL
iodide I-CHEMICAL
staining, O
and O
characterized O
by O
cleavage O
of O
caspase-9 B-GENE-Y
and O
caspase-3 B-GENE-Y
proteins. O
DBDCT B-CHEMICAL
induced O
the O
release O
of O

cytochrome B-GENE-Y
c I-GENE-Y
from O
the O
mitochondria O
to O
the O
cytosol O
and O
the O
generation O
of O
reactive O
oxygen B-CHEMICAL
species. O
DBDCT B-CHEMICAL
up-regulated O
the O
expression O
of O
Bax, B-GENE-Y
down-regulated O
the O
expression O
of O
Bcl-2, B-GENE-Y
and O
significantly O
increased O
the O
ratio O
of O
Bax/Bcl-2. B-GENE-Y
DBDCT B-CHEMICAL
also O
caused O
the O
phosphorylation O
of O
JNK B-GENE-N
and O
p38(MAPK). B-GENE-N
In O
rats O
exposed O
to O
DBDCT, B-CHEMICAL
apoptosis O
was O
also O
observed O
in O
brain, O
as O
shown O
by O
the O
detection O
of O
cleaved O
caspase-9 B-GENE-Y
and O
caspase-3 B-GENE-Y
proteins O

and O
increased O
TUNEL O
positive O
staining. O
In O
conclusion, O
the O
results O
demonstrated O
that O
DBDCT B-CHEMICAL
caused O
the O
neurotoxicity O
by O
inducing O
apoptosis O
via O
mitochondria-mediated O
pathway. O
Structure-based O
design O
of O
aliskiren, B-CHEMICAL
a O
novel O
orally O
effective O
renin B-GENE-Y
inhibitor. O
Hypertension O
is O
a O
major O
risk O
factor O
for O
cardiovascular O
diseases O
such O
as O
stroke, O
myocardial O
infarction, O
and O
heart O
failure, O
the O
leading O
causes O
of O
death O
in O
the O
Western O
world. O
Inhibitors O
of O
the O
renin-angiotensin B-GENE-Y
system O
(RAS) O
have O
proven O
to O
be O
successful O
treatments O
for O

hypertension. O
As O
renin B-GENE-Y
specifically O
catalyses O
the O
rate-limiting O
step O
of O
the O
RAS, O
it O
represents O
the O
optimal O
target O
for O
RAS O
inhibition. O
Several O
peptide-like O
renin B-GENE-Y
inhibitors O
have O
been O
synthesized O
previously, O
but O
poor O
pharmacokinetic O
properties O
meant O
that O
these O
compounds O
were O
not O
clinically O
useful. O
We O
employed O
a O
combination O
of O
molecular O
modelling O
and O
crystallographic O
structure O
analysis O
to O
design O
renin B-GENE-Y
inhibitors O
lacking O
the O
extended O
peptide-like O
backbone O
of O
earlier O
inhibitors, O
for O
improved O
pharmacokinetic O
properties. O
This O
led O
to O
the O
discovery O
of O
aliskiren, B-CHEMICAL
a O
highly O
potent O
and O
selective O
inhibitor O
of O

human B-GENE-Y
renin I-GENE-Y
in O
vitro, O
and O
in O
vivo; O
once-daily O
oral O
doses O
of O
aliskiren B-CHEMICAL
inhibit O
renin B-GENE-Y
and O
lower O
blood O
pressure O
in O
sodium-depleted B-CHEMICAL
marmosets O
and O
hypertensive O
human O
patients. O
Aliskiren B-CHEMICAL
represents O
the O
first O
in O
a O
novel O
class O
of O
renin B-GENE-Y
inhibitors O
with O
the O
potential O
for O
treatment O
of O
hypertension O
and O
related O
cardiovascular O
diseases. O
Functional O
divergence O
of O
a O
unique O
C-terminal B-CHEMICAL
domain O
of O
leucyl-tRNA B-GENE-N
synthetase I-GENE-N
to O
accommodate O
its O
splicing O
and O
aminoacylation O
roles. O
Leucyl-tRNA B-GENE-Y
synthetase I-GENE-Y
(LeuRS) B-GENE-Y

performs O
dual O
essential O
roles O
in O
group O
I O
intron O
RNA O
splicing O
as O
well O
as O
protein O
synthesis O
within O
the O
yeast O
mitochondria. O
Deletions O
of O
the O
C B-CHEMICAL
terminus O
differentially O
impact O
the O
two O
functions O
of O
the O
enzyme O
in O
splicing O
and O
aminoacylation O
in O
vivo. O
Herein, O
we O
determined O
that O
a O
fiveamino B-CHEMICAL
acid I-CHEMICAL
C-terminal B-CHEMICAL
deletion O
of O
LeuRS, B-GENE-Y
which O
does O
not O
complement O
a O
null O
strain, O
can O
form O
a O
ternary O
complex O
with O
the O
bI4 O
intron O
and O
its O
maturase O
splicing O
partner. O
However, O
the O
complex O
fails O
to O
stimulate O
splicing O
activity. O
The O
x-ray O

co-crystal O
structure O
of O
LeuRS B-GENE-Y
showed O
that O
a O
C-terminal B-CHEMICAL
extension O
of O
about O
60 O
amino B-CHEMICAL
acids I-CHEMICAL
forms O
a O
discrete O
domain, O
which O
is O
unique O
among O
the O
LeuRSs B-GENE-Y
and O
interacts O
with O
the O
corner O
of O
the O
L-shaped O
tRNALeu. O
Interestingly, O
deletion O
of O
the O
entire O
yeast B-GENE-Y
mitochondrial I-GENE-Y
LeuRS I-GENE-Y
C-terminal B-CHEMICAL
domain O
enhanced O
its O
aminoacylation O
and O
amino B-CHEMICAL
acid I-CHEMICAL
editing O
activities. O
In O
striking O
contrast, O
deletion O
of O
the O
corresponding O
C-terminal B-CHEMICAL
domain O
of O
Escherichia B-GENE-Y
coli I-GENE-Y
LeuRS I-GENE-Y
abolished O
aminoacylation O
of O
tRNALeu O
and O
also O
amino B-CHEMICAL
acid I-CHEMICAL
editing O
of O
mischarged O
tRNA O
molecules. O

These O
results O
suggest O
that O
the O
role O
of O
the O
leucine-specific B-CHEMICAL
C-terminal B-CHEMICAL
domain O
in O
tRNA O
recognition O
for O
aminoacylation O
and O
amino B-CHEMICAL
acid I-CHEMICAL
editing O
has O
adapted O
differentially O
and O
with O
surprisingly O
opposite O
effects. O
We O
propose O
that O
the O
secondary O
role O
of O
yeast B-GENE-Y
mitochondrial I-GENE-Y
LeuRS I-GENE-Y
in O
RNA O
splicing O
has O
impacted O
the O
functional O
evolution O
of O
this O
critical O
C-terminal B-CHEMICAL
domain. O
Everolimus: B-CHEMICAL
the O
first O
approved O
product O
for O
patients O
with O
advanced O
renal O
cell O
cancer O
after O
sunitinib B-CHEMICAL
and/or O
sorafenib. B-CHEMICAL
Everolimus B-CHEMICAL
(RAD001, B-CHEMICAL
Afinitor((R)) B-CHEMICAL
Novartis) I-CHEMICAL
is O
the O
first O
oral O
inhibitor O
of O

mTOR B-GENE-Y
(mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin) I-GENE-Y
to O
reach O
the O
oncology O
clinic. O
Everolimus B-CHEMICAL
10 O
mg O
daily O
achieves O
complete O
inhibition O
of O
its O
target O
at O
below O
the O
maximum O
tolerable O
dose O
for O
most O
patients. O
A O
phase O
III O
randomized O
placebo-controlled O
trial O
has O
examined O
the O
impact O
of O
everolimus B-CHEMICAL
in O
patients O
with O
clear O
cell O
renal O
cancers O
and O
progressive O
disease O
on O
or O
within O
6 O
months O
of O
the O
VEGFR B-GENE-N
tyrosine B-GENE-N
kinase I-GENE-N
inhibitors O
sunitinib B-CHEMICAL
and/or O
sorafenib. B-CHEMICAL
The O
primary O
endpoint O
of O
progression-free O
survival O
was O
increased O
from O
median O
1.9 O
to O

4.9 O
months O
(hazard O
ratio O
0.33, O
P O
< O
0.001) O
and O
25% O
were O
still O
progression-free O
after O
10 O
months O
of O
everolimus B-CHEMICAL
therapy. O
There O
was O
a O
delay O
in O
time O
to O
decline O
of O
performance O
status O
and O
trends O
to O
improvement O
in O
quality O
of O
life, O
disease-related O
symptoms, O
and O
overall O
survival O
despite O
crossover O
of O
the O
majority O
of O
patients O
assigned O
to O
placebo. O
In O
2009, O
everolimus B-CHEMICAL
was O
approved O
in O
the O
US O
and O
Europe O
as O
the O
only O
validated O
option O
for O
this O
indication. O
Toxicities O
are O
usually O
mild O
to O
moderate O
and O
can O
be O
managed O
with O
dose O
reduction O
or O
interruption O
if O
necessary. O
Opportunistic O
infections O
and O

non-infectious O
pneumonitis O
are O
seen O
as O
a O
class O
effect. O
Management O
of O
common O
practical O
management O
issues O
are O
discussed. O
Clinical O
trials O
are O
in O
progress O
to O
examine O
additional O
roles O
for O
everolimus B-CHEMICAL
in O
renal O
cancer, O
alone O
and O
in O
combination O
with O
other O
agents. O
Anti-aging O
molecule, O
Sirt1: B-GENE-Y
a O
novel O
therapeutic O
target O
for O
diabetic O
nephropathy. O
Caloric O
restriction O
prolongs O
the O
lifespan O
of O
many O
species. O
Therefore, O
investigators O
have O
researched O
the O
usefulness O
of O
caloric O
restriction O
for O
healthy O
lifespan O
extension. O
Sirt1, B-GENE-Y
an O
NAD(+)-dependent B-GENE-N
deacetylase, I-GENE-N
was O
identified O
as O
a O

molecule O
necessary O
for O
caloric O
restriction-related O
anti-aging O
strategies. O
Sirt1 B-GENE-Y
functions O
as O
an O
intracellular O
energy O
sensor O
to O
detect O
the O
concentration O
of O
NAD(+), B-CHEMICAL
and O
controls O
in O
vivo O
metabolic O
changes O
under O
caloric O
restriction O
and O
starvation O
through O
its O
deacetylase B-GENE-N
activity O
to O
many O
targets O
including O
histones, B-GENE-N
nuclear O
transcriptional O
factors, O
and O
enzymes. O
During O
the O
past O
decade, O
investigators O
have O
reported O
the O
relationship O
between O
disturbance O
of O
Sirt1 B-GENE-Y
activation O
and O
the O
onset O
of O
aging- O
and O
obesity-associated O
diseases O
such O
as O
diabetes, O
cardiovascular O
disease O
and O
neurodegenerative O
disorders. O
Consequently, O
a O
calorie O

restriction-mimetic O
action O
of O
Sirt1 B-GENE-Y
is O
now O
expected O
as O
a O
new O
therapy O
for O
these O
diseases. O
In O
addition, O
recent O
studies O
have O
gradually O
clarified O
the O
role O
of O
Sirt1 B-GENE-Y
in O
the O
onset O
of O
kidney O
disease. O
Its O
activation O
may O
also O
become O
a O
new O
target O
of O
treatment O
in O
the O
patients O
with O
chronic O
kidney O
disease O
including O
diabetic O
nephropathy. O
In O
this O
article, O
we O
would O
like O
to O
review O
the O
role O
of O
Sirt1 B-GENE-Y
in O
the O
onset O
of O
kidney O
disease O
based O
on O
previous O
studies, O
and O
discuss O
its O
possibility O
as O
the O
target O
of O
treatment O
in O
diabetic O
nephropathy. O
Sucralfate: B-CHEMICAL
the O
Bangkok O
review. O

Sucralfate B-CHEMICAL
is O
a O
site-protective O
ulcer O
healing O
drug O
with O
a O
remarkable O
range O
of O
mechanisms O
of O
action. O
Recent O
studies O
highlight O
the O
capacity O
of O
sucralfate B-CHEMICAL
to O
bind O
basic B-GENE-Y
fibroblast I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(bFGF) B-GENE-Y
and O
deliver O
it O
in O
high O
concentration O
to O
the O
ulcer. O
Basic B-GENE-Y
fibroblast I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
stimulates O
the O
production O
of O
granulation O
tissue, O
angiogenesis O
and O
re-epithelization, O
thus O
improving O
the O
quality O
of O
ulcer O
healing. O
The O
effect O
of O
sucralfate B-CHEMICAL
in O
reducing O
parietal O
cell O
sensitivity O
may O
be O
another O
factor O
important O
in O
the O
lower O
relapse O
rate O
demonstrated O
after O

duodenal O
ulcer O
healing. O
Sucralfate B-CHEMICAL
has O
been O
demonstrated O
to O
be O
efficacious O
in O
healing O
both O
duodenal O
and O
gastric O
ulcers O
together O
with O
mild O
oesophagitis, O
and O
it O
is O
safe O
for O
both O
short-term O
use O
and O
maintenance. O
In O
stress O
ulcer O
prophylaxis O
it O
is O
as O
effective O
as O
acid O
suppression O
or O
neutralization O
and O
has O
the O
advantage O
of O
lesser O
rates O
of O
nosocomial O
pneumonia O
than O
are O
demonstrated O
with O
antacids O
or O
H2 O
antagonists. O
The O
potential O
advantages O
of O
sucralfate B-CHEMICAL
lie O
in O
the O
better O
quality O
of O
ulcer O
healing O
associated O
with O
longer O
duration O
of O
remission. O

Synthesis O
and O
structure-activity O
relationship O
of O
pyripyropene B-CHEMICAL
A I-CHEMICAL
derivatives O
as O
potent O
and O
selective O
acyl-CoA:cholesterol B-GENE-Y
acyltransferase I-GENE-Y
2 I-GENE-Y
(ACAT2) B-GENE-Y
inhibitors: O
Part O
2. O
Synthesis O
and O
structure-activity O
relationships O
of O
7-O-p-cyanobenzoyl B-CHEMICAL
pyripyropene I-CHEMICAL
A I-CHEMICAL
derivatives O
with O
modification O
at O
C1 O
and O
11 O
are O
described. O
Regioselective O
mono-deprotection O
of O
di-tert-butylsilylene B-CHEMICAL
acetal I-CHEMICAL
was O
critical O
in O
their O
synthesis. O
Involvement O
of O

pertussis B-GENE-N
toxin-sensitive I-GENE-N
G-proteins B-GENE-N
in O
the O
hormonal O
inhibition O
of O
dihydropyridine-sensitive B-CHEMICAL
Ca2+ B-CHEMICAL
currents O
in O
an O
insulin-secreting B-GENE-Y
cell O
line O
(RINm5F). O
Adrenaline B-CHEMICAL
inhibits O
insulin B-GENE-Y
secretion O
via O
pertussis O
toxin-sensitive O
mechanisms. O
Since O
voltage-dependent O
Ca2+ B-CHEMICAL
currents O
play O
a O
key O
role O
in O
insulin B-GENE-Y
secretion, O
we O
examined O
whether O
adrenaline B-CHEMICAL
modulates O
voltage-dependent O
Ca2+ B-CHEMICAL
currents O
of O
the O
rat O
insulinoma O
cell O
line, O
RINm5F. O
In O
the O
whole-cell O
configuration O
of O
the O
patch-clamp O

technique, O
dihydropyridine- B-CHEMICAL
but O
not O
omega-conotoxin-sensitive O
Ca2+ B-CHEMICAL
currents O
were O
identified. O
Adrenaline B-CHEMICAL
via O
alpha B-GENE-N
2-adrenoceptors I-GENE-N
inhibited O
the O
Ca2+ B-CHEMICAL
currents O
by O
about O
50%. O
Somatostatin B-GENE-Y
which O
also O
inhibits O
insulin B-GENE-Y
secretion O
was O
less O
efficient O
(inhibition O
by O
20%). O
The O
hormonal O
inhibition O
of O
Ca2+ B-CHEMICAL
currents O
was O
not O
affected O
by O
intracellularly O
applied O
cAMP B-CHEMICAL
but O
blocked O
by O
the O
intracellularly O
applied O
GDP B-CHEMICAL
analog O
guanosine B-CHEMICAL

5'-O-(2-thiodiphosphate) I-CHEMICAL
and O
by O
pretreatment O
of O
cells O
with O
pertussis B-GENE-N
toxin. I-GENE-N
In O
contrast O
to O
adrenaline B-CHEMICAL
and O
somatostatin, B-GENE-Y
galanin, B-GENE-Y
another O
inhibitor O
of O
insulin B-GENE-Y
secretion, O
reduced O
Ca2+ B-CHEMICAL
currents O
by O
about O
40% O
in O
a O
pertussis B-GENE-N
toxin-insensitive I-GENE-N
manner. O
Immunoblot O
experiments O
performed O
with O
antibodies O
generated O
against O
synthetic O
peptides O
revealed O
that O
membranes O
of O
RINm5F O
cells O
possess O
four O
pertussis B-GENE-N
toxin-sensitive I-GENE-N
G-proteins B-GENE-N
including O
Gi1, B-GENE-Y
Gi2, B-GENE-Y
Go2, B-GENE-Y
and O

another O
Go B-GENE-N
subtype, O
most O
likely O
representing O
Go1. B-GENE-Y
In O
membranes O
of O
control O
but O
not O
of O
pertussis B-GENE-N
toxin-treated I-GENE-N
cells, O
adrenaline B-CHEMICAL
via O
alpha B-GENE-N
2-adrenoceptors I-GENE-N
stimulated O
incorporation O
of O
the O
photo-reactive O
GTP B-CHEMICAL
analog O
[alpha-32P]GTP B-CHEMICAL
azidoanilide I-CHEMICAL
into O
pertussis O
toxin O
substrates O
comigrating O
with O
the O
alpha-subunits O
of O
Gi2, B-GENE-Y
Go2, B-GENE-Y
and O
the O
not O
further O
identified O
Go B-GENE-N
subtype. O
The O
present O
findings O
indicate O
that O
activated O
alpha B-GENE-N
2-adrenoceptors I-GENE-N
of O
RINm5F O
cells O
interact O
with O
multiple O
G-proteins, B-GENE-N

i.e. O
two O
forms O
of O
Go B-GENE-N
and O
with O
Gi2. B-GENE-Y
These O
G-proteins B-GENE-N
are O
likely O
to O
be O
involved O
in O
the O
adrenaline-induced B-CHEMICAL
inhibition O
of O
dihydropyridine-sensitive B-CHEMICAL
Ca2+ B-CHEMICAL
currents O
and O
in O
other O
signal O
transduction O
pathways O
contributing O
to O
the O
adrenaline-induced B-CHEMICAL
inhibition O
of O
insulin B-GENE-Y
secretion. O
Synthesis O
and O
in O
Vitro O
Characterisation O
of O
Ifenprodil-Based B-CHEMICAL
Fluorescein B-CHEMICAL
Conjugates O
as O
GluN1/GluN2B B-GENE-Y
N-Methyl-D-aspartate B-GENE-N
Receptor I-GENE-N
Antagonists. O
GluN2B-containing B-GENE-Y

NMDA B-GENE-N
receptors I-GENE-N
are O
involved O
in O
many O
important O
physiological O
functions O
and O
play O
a O
pivotal O
role O
in O
mediating O
pain O
as O
well O
as O
in O
several O
neurodegenerative O
disorders. O
We O
aimed O
to O
develop O
fluorescent O
probes O
to O
target O
the O
GluN2B B-GENE-Y
subunit O
selectively O
in O
order O
to O
allow O
better O
understanding O
of O
the O
relationships O
between O
receptor O
localisation O
and O
physiological O
importance. O
Ifenprodil, B-CHEMICAL
known O
as O
the O
GluNR2B B-GENE-Y
antagonist O
of O
reference, O
was O
chosen O
as O
the O
template O
for O
the O
elaboration O
of O
probes. O
We O
had O
previously O
reported O
a O
fluorescein B-CHEMICAL
conjugate O
that O
was O
shown O
(by O
confocal O
microscopy O
imaging O
of O

DS-red-labelled O
cortical O
neurons) O
to O
bind O
specifically O
to O
GluN2B. B-GENE-Y
To O
elaborate O
this O
probe, O
we O
explored O
the O
influence O
of O
both O
the O
nature O
and O
the O
attachment O
point O
of O
the O
spacer O
between O
the O
fluorophore O
and O
the O
parent O
compound, O
ifenprodil. B-CHEMICAL
We O
performed O
chemical O
modifications O
of O
ifenprodil B-CHEMICAL
at O
the O
benzylic B-CHEMICAL
position O
and O
on O
the O
phenol B-CHEMICAL
ring O
by O
introducing O
secondary B-CHEMICAL
amine I-CHEMICAL
or I-CHEMICAL
amide I-CHEMICAL
functions O
and O
evaluated O
alkyl O
chains O
from O
two O
to O
20 O
bonds O
either O
including O
or O
not O
including O
secondary B-CHEMICAL
amide I-CHEMICAL
functions O
as O
spacers. O
The O
previously O
developed O
probe O
was O
found O
to O
display O
the O
greatest O
activity O
in O

the O
inhibition O
of O
NMDA-induced B-CHEMICAL
Ca(2+) B-CHEMICAL
influx O
by O
calcium B-CHEMICAL
imaging O
experiments O
on O
HEK293 O
cells O
transfected O
with O
the O
cDNA O
encoding O
for O
GluN1-1A B-GENE-Y
and O
GluN2B. B-GENE-Y
Further O
investigations O
revealed O
that O
this O
probe O
had O
a O
neuroprotective O
effect O
equivalent O
to O
that O
of O
ifenprodil B-CHEMICAL
in O
a O
standard O
test O
for O
neurotoxicity. O
Despite O
effects O
of O
lesser O
amplitude O
with O
these O
probes O
relative O
to O
ifenprodil, B-CHEMICAL
we O
demonstrated O
that O
they O
displaced O
[(3) B-CHEMICAL
H]ifenprodil I-CHEMICAL
in O
mouse O
brain O
slices O
in O
a O
similar O
manner. O

Conformational O
epitopes O
on O
the O
diabetes O
autoantigen O
GAD65 B-GENE-Y
identified O
by O
peptide O
phage O
display O
and O
molecular O
modeling. O
The O
major B-GENE-N
diabetes I-GENE-N
autoantigen, I-GENE-N
glutamic B-GENE-N
acid I-GENE-N
decarboxylase I-GENE-N
(GAD65), B-GENE-Y
contains O
a O
region O
of O
sequence O
similarity, O
including O
six O
identical O
residues O
PEVKEK, B-GENE-N
to O
the O
P2C B-GENE-Y
protein I-GENE-Y
of O
coxsackie O
B O
virus, O
suggesting O
that O
cross-reactivity O
between O
coxsackie O
B O
virus O
and O
GAD65 B-GENE-Y
can O
initiate O
autoimmune O
diabetes. O
We O
used O
the O
human O
islet O
cell O
mAbs O
MICA3 O
and O
MICA4 O
to O

identify O
the O
Ab O
epitopes O
of O
GAD65 B-GENE-Y
by O
screening O
phage-displayed O
random O
peptide O
libraries. O
The O
identified O
peptide O
sequences O
could O
be O
mapped O
to O
a O
homology O
model O
of O
the O
pyridoxal B-GENE-N
phosphate I-GENE-N
(PLP) I-GENE-N
binding I-GENE-N
domain I-GENE-N
of O
GAD65. B-GENE-Y
For O
MICA3, O
a O
surface O
loop O
containing O
the O
sequence O
PEVKEK B-GENE-N
and O
two O
adjacent O
exposed O
helixes O
were O
identified O
in O
the O
PLP B-GENE-N
binding I-GENE-N
domain I-GENE-N
as O
well O
as O
a O
region O
of O
the O
C B-CHEMICAL
terminus O
of O
GAD65 B-GENE-Y
that O
has O
previously O
been O
identified O
as O
critical O
for O
MICA3 O
binding. O
To O
confirm O
that O
the O
loop O
containing O
the O
PEVKEK B-GENE-N
sequence O
contributes O

to O
the O
MICA3 O
epitope, O
this O
loop O
was O
deleted O
by O
mutagenesis. O
This O
reduced O
binding O
of O
MICA3 O
by O
70%. O
Peptide O
sequences O
selected O
using O
MICA4 O
were O
rich O
in O
basic O
or O
hydroxyl-containing B-CHEMICAL
amino B-CHEMICAL
acids, I-CHEMICAL
and O
the O
surface O
of O
the O
GAD65 B-GENE-N
PLP-binding I-GENE-N
domain I-GENE-N
surrounding O
Lys358, O
which O
is O
known O
to O
be O
critical O
for O
MICA4 O
binding, O
was O
likewise O
rich O
in O
these O
amino B-CHEMICAL
acids. I-CHEMICAL
Also, O
the O
two O
phage O
most O
reactive O
with O
MICA4 O
encoded O
the O
motif O
VALxG, B-GENE-N
and O
the O
reverse O
of O
this O
sequence, O
LAV, B-GENE-N
was O
located O
in O
this O
same O

region. O
Thus, O
we O
have O
defined O
the O
MICA3 O
and O
MICA4 O
epitopes O
on O
GAD65 B-GENE-Y
using O
the O
combination O
of O
phage O
display, O
molecular O
modeling, O
and O
mutagenesis O
and O
have O
provided O
compelling O
evidence O
for O
the O
involvement O
of O
the O
PEVKEK B-GENE-N
loop O
in O
the O
MICA3 O
epitope. O
Molecular O
determinants O
for O
the O
selective O
inhibition O
of O
cyclooxygenase-2 B-GENE-Y
by O
lumiracoxib. B-CHEMICAL
Lumiracoxib B-CHEMICAL
is O
the O
first O
example O
of O
a O
marketed O
COX-2 B-GENE-Y
inhibitor O
of O
the O
arylacetic B-CHEMICAL
acid I-CHEMICAL
class, O
and O
it O
is O
reported O
to O
be O
the O
most O
selective O

COXIB O
in O
vivo. O
However, O
the O
molecular O
basis O
of O
its O
COX-2 B-GENE-Y
inhibition O
has O
not O
been O
completely O
defined. O
Using O
standard O
assays, O
lumiracoxib B-CHEMICAL
was O
found O
to O
be O
a O
poor O
inhibitor O
of O
purified O
ovine B-GENE-Y
COX-1 I-GENE-Y
and O
a O
relatively O
weak O
inhibitor O
of O
purified O
human B-GENE-Y
COX-2. I-GENE-Y
The O
extent O
of O
COX-2 B-GENE-Y
inhibition O
plateaued O
at O
around O
50% O
and O
suggested O
that O
the O
inhibitor O
may O
be O
reversibly O
bound O
to O
the O
enzyme. O
Kinetic O
studies O
with O
lumiracoxib B-CHEMICAL
demonstrated O
that O
it O
was O
a O
time-dependent O
and O
slowly O
reversible O
inhibitor O
of O
human B-GENE-Y
COX-2 I-GENE-Y

that O
exhibited O
at O
least O
two O
binding O
steps O
during O
inhibition. O
Derivatives O
of O
lumiracoxib B-CHEMICAL
were O
synthesized O
with O
or O
without O
the O
methyl B-CHEMICAL
group O
on O
the O
phenylacetic B-CHEMICAL
acid I-CHEMICAL
ring O
and O
with O
various O
substitutions O
on O
the O
lower O
aniline B-CHEMICAL
ring. O
Inhibition O
studies O
demonstrated O
that O
the O
methyl B-CHEMICAL
group O
on O
the O
phenylacetic B-CHEMICAL
acid I-CHEMICAL
ring O
is O
required O
for O
COX-2 B-GENE-Y
selectivity. O
The O
chemical O
identity O
and O
position O
of O
the O
substituents O
on O
the O
lower O
aniline B-CHEMICAL
ring O
were O
important O
in O
determining O
the O
potency O
and O
extent O
of O
COX B-GENE-N
inhibition O
as O
well O
as O
COX-2 B-GENE-Y
selectivity. O
Mutation O
of O

Ser-530 B-GENE-N
to I-GENE-N
Ala I-GENE-N
or O
Val-349 B-GENE-N
to I-GENE-N
Ala I-GENE-N
or I-GENE-N
Leu I-GENE-N
abolished O
the O
potent O
inhibition O
observed O
with O
wild-type O
human B-GENE-Y
COX-2 I-GENE-Y
and O
key O
lumiracoxib B-CHEMICAL
analogs. O
Interestingly, O
a O
Val-349 B-GENE-N
to I-GENE-N
Ile I-GENE-N
mutant O
was O
inhibited O
with O
equal O
potency O
to O
human B-GENE-Y
COX-2 I-GENE-Y
with O
2,6-dichloro-, B-CHEMICAL
2,6-dimethyl-, B-CHEMICAL
or O
2-chloro-6-methyl-substituted B-CHEMICAL
inhibitors O
and, O
in O
the O
case O
of O
lumiracoxib, B-CHEMICAL
actually O
showed O
an O
increase O
in O
potency. O
Taken O
together O

with O
a O
recent O
crystal O
structure O
of O
a O
lumiracoxib-COX-2 B-CHEMICAL
complex, O
the O
kinetic O
analyses O
presented O
herein O
of O
the O
inhibition O
of O
mutant O
COX-2s B-GENE-Y
by O
lumiracoxib B-CHEMICAL
allows O
the O
definition O
of O
the O
molecular O
basis O
of O
COX-2 B-GENE-Y
inhibition. O
Cerebral O
D2 B-GENE-N
and I-GENE-N
5-HT2 I-GENE-N
receptor I-GENE-N
occupancy O
in O
Schizophrenic O
patients O
treated O
with O
olanzapine B-CHEMICAL
or O
clozapine. B-CHEMICAL
We O
report O
the O
results O
of O
a O
double-blind, O
randomized O
prospective O
trial O
on O
D2 B-GENE-N
and I-GENE-N
5-HT2 I-GENE-N
receptor I-GENE-N
occupancy O
and O
the O
clinical O
effects O

of O
olanzapine B-CHEMICAL
versus O
clozapine B-CHEMICAL
in O
a O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients. O
Receptor O
occupancy O
was O
evaluated O
in O
different O
cortical O
areas O
and O
in O
basal O
ganglia O
using O
[18F] B-CHEMICAL
fluoro-ethyl-spiperone I-CHEMICAL
([18F] B-CHEMICAL
FESP) I-CHEMICAL
and O
positron O
emission O
tomography O
(PET). O
A O
total O
of O
15 O
neuroleptic-free O
patients O
completed O
the O
study O
undergoing O
a O
baseline O
and O
a O
post-treatment O
PET O
scan O
(olanzapine, B-CHEMICAL
nine O
patients, O
one O
female; O

clozapine, B-CHEMICAL
six O
patients, O
three O
female) O
8 O
weeks O
after O
starting O
treatment. O
PET O
data O
were O
analysed O
both O
by O
regions O
of O
interest O
and O
on O
a O
voxel-by-voxel O
basis O
using O
Statistical O
Parametric O
Mapping O
(SPM96). O
Olanzapine B-CHEMICAL
and O
clozapine B-CHEMICAL
induced O
a O
similar O
and O
significant O
inhibition O
of O
[18F] B-CHEMICAL
FESP I-CHEMICAL
binding O
index O
in O
the O
cortex. O
In O
the O
basal O
ganglia, O
receptor O
occupancy O
was O
significantly O
higher O
with O
olanzapine B-CHEMICAL
than O
with O
clozapine B-CHEMICAL
(p=0.0018). O
By O
contrast, O
no O
differences O
in O
receptor O

occupancy O
were O
detected O
at O
the O
level O
of O
the O
pituitary O
gland. O
Clinical O
outcomes, O
in O
particular O
a O
full O
extra O
pyramidal O
tolerability, O
were O
similar. O
In O
this O
sample O
of O
neuroleptic-refractory O
schizophrenic O
patients, O
olanzapine B-CHEMICAL
and O
clozapine B-CHEMICAL
showed O
a O
different O
pattern O
of O
occupancy O
of O
D2-like B-GENE-Y
receptor I-GENE-Y
despite O
a O
common O
lack O
of O
extrapyramidal O
side-effects. O
Inhibitory O
effect O
of O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors O
on O
the O
vesicular B-GENE-Y
monoamine I-GENE-Y
transporter I-GENE-Y
2. I-GENE-Y
The O
neuronal B-GENE-Y
vesicular I-GENE-Y

monoamine I-GENE-Y
transporter I-GENE-Y
(VMAT2) B-GENE-Y
is O
the O
target O
molecule O
of O
action O
of O
some O
psychostimulants, O
such O
as O
methamphetamine B-CHEMICAL
and O
3,4-methylenedioxymethamphetamine B-CHEMICAL
(MDMA). B-CHEMICAL
The O
present O
study O
examined O
the O
effect O
of O
antidepressants, O
such O
as O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitors O
(SSRIs), O
on O
VMAT2 B-GENE-Y
activity O
by O
measuring O
adenosine B-CHEMICAL
triphosphate-dependent I-CHEMICAL
[(3)H]dopamine B-CHEMICAL
uptake O
into O
synaptic O
vesicles O
prepared O
from O
rat O
striatum. O

SSRIs, O
fluoxetine, B-CHEMICAL
paroxetine, B-CHEMICAL
and O
fluvoxamine, B-CHEMICAL
inhibited O
vesicular O
[(3)H]dopamine B-CHEMICAL
uptake O
in O
vitro. O
The O
rank O
order O
of O
potency O
was O
reserpine>>fluoxetine, B-CHEMICAL
paroxetine>fluvoxamine, B-CHEMICAL
methamphetamine>MDMA. B-CHEMICAL
Moreover, O
kinetic O
analysis O
revealed O
that O
inhibition O
by O
reserpine, B-CHEMICAL
a O
typical O
VMAT2 B-GENE-Y
inhibitor, O
was O
uncompetitive, O
decreasing O
maximum O
velocity O
and O
affinity O
for O
dopamine. B-CHEMICAL
Inhibition O
by O
fluoxetine B-CHEMICAL
was O

noncompetitive, O
only O
decreasing O
maximum O
velocity O
for O
dopamine. B-CHEMICAL
These O
results O
suggest O
that O
fluoxetine B-CHEMICAL
inhibited O
the O
activity O
of O
VMAT2 B-GENE-Y
by O
a O
mechanism O
different O
from O
that O
of O
reserpine B-CHEMICAL
and O
did O
not O
directly O
interact O
with O
the O
active O
site O
of O
VMAT2. B-GENE-Y
Anti-inflammatory O
effects O
of O
an O
aqueous O
extract O
of O
Welsh O
onion O
green O
leaves O
in O
mice. O
The O
anti-inflammatory O
effects O
of O
an O
aqueous O
extract O
of O
Welsh O
onion O
green O
leaves O
(WOE) O
in O
mice O
was O
investigated. O
Administration O
of O
WOE, O
in O
the O
range O
of O
0.25-1g/kg, O
showed O
a O
concentration O
dependent O
inhibition O

on O
paw O
edema O
development O
after O
carrageenan O
treatment O
in O
mice. O
The O
anti-inflammatory O
effects O
of O
WOE O
were O
closely O
attributed O
to O
decreased O
levels O
of O
tissue O
NO B-CHEMICAL
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α). B-GENE-Y
Further O
evidence O
for O
WOE's O
protection O
is O
shown O
in O
the O
reduction O
of O
lipid O
oxidation O
and O
the O
increase O
of O
antioxidant O
enzyme O
activities, O
including O
catalase B-GENE-Y
(CAT), B-GENE-Y
superoxide B-GENE-N
dismutase I-GENE-N
(SOD), B-GENE-N
and O
glutathione B-GENE-N
peroxidase I-GENE-N
(GPX) B-GENE-N
in O
vivo. O
Further, O
WOE O
also O
decreased O
the O
number O
of O
acetic B-CHEMICAL
acid-induced I-CHEMICAL

writhing O
responses O
and O
formalin-induced B-CHEMICAL
pain O
in O
the O
late O
phase O
in O
mice. O
Overall, O
the O
results O
showed O
that O
WOE O
might O
serve O
as O
a O
natural O
source O
of O
anti-inflammatory O
compounds. O
Application O
of O
the O
bradford O
hill O
criteria O
to O
assess O
the O
causality O
of O
cisapride-induced B-CHEMICAL
arrhythmia: O
a O
model O
for O
assessing O
causal O
association O
in O
pharmacovigilance. O
INTRODUCTION: O
The O
Bradford O
Hill O
criteria O
are O
a O
widely O
used, O
useful O
tool O
for O
the O
assessment O
of O
biomedical O
causation. O
We O
have O
examined O
their O
application O
to O
pharmacovigilance O
using O
the O
example O
of O

cisapride-induced B-CHEMICAL
QTc O
interval O
prolongation/arrhythmia. O
METHODS: O
A O
literature O
search O
was O
conducted O
using O
MEDLINE, O
EMBASE, O
Reactions O
Weekly O
and O
regulatory O
websites O
to O
identify O
evidence O
for O
the O
association O
between O
cisapride B-CHEMICAL
and O
QTc O
interval O
prolongation/arrhythmia O
that O
had O
been O
published O
in O
the O
English O
language. O
Two O
hundred O
and O
five O
publications O
were O
identified O
as O
being O
potentially O
suitable O
for O
the O
study. O
After O
excluding O
irrelevant O
articles, O
studies O
on O
high-risk O
populations O
and O
review O
articles, O
70 O
publications O
were O
assessed O
using O
the O
Bradford O
Hill O
criteria. O
These O
included O
24 O
case O

reports, O
case O
series O
or O
spontaneous O
report O
summaries; O
eight O
epidemiological O
studies; O
22 O
clinical O
studies; O
and O
16 O
experimental O
(in O
vivo O
and O
in O
vitro) O
publications. O
RESULTS: O
The O
most O
compelling O
evidence O
for O
an O
association O
between O
cisapride B-CHEMICAL
use O
and O
QTc O
interval O
prolongation/arrhythmia O
came O
from O
case/spontaneous O
reports O
and O
biological O
plausibility. O
Considering O
the O
rare O
incidence O
of O
serious O
cardiac O
events, O
these O
criteria O
formed O
the O
basis O
for O
the O
strength O
of O
the O
association. O
The O
number O
of O
reports O
from O
different O
populations O
showed O
consistency. O
Specificity O
was O
supported O
by O
clinical O
and O
cardiographic O

characterisation O
of O
the O
events. O
There O
were O
temporal O
relationships O
between O
the O
events O
and O
the O
initiation O
of O
cisapride B-CHEMICAL
treatment, O
increases O
in O
the O
dosage O
and O
the O
receipt O
of O
interacting O
medications. O
The O
relationships O
between O
the O
adverse O
events O
and O
the O
latter O
two O
factors O
exhibited O
biological O
gradients. O
Experimental O
evidence O
could O
be O
found O
from O
biological O
models, O
as O
well O
as O
reports O
of O
positive O
dechallenge O
and/or O
rechallenge O
found O
in O
individual O
patients. O
Cisapride B-CHEMICAL
was O
found O
to O
bind O
the O
human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene I-GENE-Y
(HERG) I-GENE-Y
potassium I-GENE-Y
channel, I-GENE-Y
which O
provides O
a O
plausible O
mechanism O
for O
QTc O
interval O

prolongation/arrhythmia. O
Other O
QTc O
interval-prolonging/arrhythmic O
drugs O
that O
also O
bind O
to O
HERG B-GENE-Y
provided O
an O
analogy O
for O
cisapride B-CHEMICAL
causing O
QTc O
interval O
prolongation/arrhythmia O
via O
this O
mechanism. O
The O
evidence O
provided O
by O
clinical O
studies O
was O
inconsistent, O
and O
epidemiological O
studies O
failed O
to O
demonstrate O
an O
association. O
Nevertheless, O
this O
did O
not O
prevent O
the O
assessment O
of O
causation. O
DISCUSSION: O
This O
study O
showed O
how O
different O
types O
of O
evidence O
found O
in O
pharmacovigilance O
can O
be O
evaluated O
using O
the O
Bradford O
Hill O
criteria. O

Further O
work O
is O
required O
to O
examine O
how O
the O
criteria O
can O
be O
applied O
to O
different O
types O
of O
adverse O
events O
and O
how O
they O
may O
be O
applied O
to O
pharmacovigilance. O
Betaxolol, B-CHEMICAL
a O
beta(1)-adrenoceptor B-GENE-Y
antagonist, O
reduces O
Na(+) B-CHEMICAL
influx O
into O
cortical O
synaptosomes O
by O
direct O
interaction O
with O
Na(+) B-GENE-N
channels: I-GENE-N
comparison O
with O
other O
beta-adrenoceptor B-GENE-N
antagonists. O
Betaxolol, B-CHEMICAL
a O
beta(1)-adrenoceptor B-GENE-Y
antagonist O
used O
for O
the O
treatment O
of O
glaucoma, O
is O
known O
to O
be O
neuroprotective O
in O

paradigms O
of O
ischaemia/excitotoxicity. O
In O
this O
study, O
we O
examined O
whether O
betaxolol B-CHEMICAL
and O
other O
beta-adrenoceptor B-GENE-N
antagonists O
interact O
directly O
with O
neurotoxin O
binding O
to O
sites O
1 O
and O
2 O
of O
the O
voltage-sensitive B-GENE-N
sodium I-GENE-N
channel I-GENE-N
(Na(+) B-GENE-N
channel) I-GENE-N
in O
rat O
cerebrocortical O
synaptosomes. O
Betaxolol B-CHEMICAL
inhibited O
specific O
[(3)H]-batrachotoxinin-A B-CHEMICAL
20-alpha-benzoate I-CHEMICAL
([(3)H]-BTX-B) B-CHEMICAL
binding O
to O
neurotoxin B-GENE-N
site I-GENE-N

2 I-GENE-N
in O
a O
concentration-dependent O
manner O
with O
an O
IC(50) O
value O
of O
9.8 O
microM. O
Comparison O
of O
all O
the O
beta-adrenoceptor B-GENE-N
antagonists O
tested O
revealed O
a O
potency O
order O
of O
propranolol>betaxolol B-CHEMICAL
approximately O
levobetaxolol>levobunolol B-CHEMICAL
approximately O
carteolol>/=timolol>atenolol. B-CHEMICAL
None O
of O
the O
drugs O
caused O
a O
significant O
inhibition O
of O
[(3)H]-saxitoxin B-CHEMICAL
binding O
to O
neurotoxin B-GENE-N
receptor I-GENE-N
site I-GENE-N
1, I-GENE-N
even O
at O
concentrations O
as O
high O
as O
250 O

microM. O
Saturation O
experiments O
showed O
that O
betaxolol B-CHEMICAL
increased O
the O
K(D) O
of O
[(3)H]-BTX-B B-CHEMICAL
binding O
but O
had O
no O
effect O
on O
the O
B(max). O
The O
association O
kinetics O
of O
[(3)H]-BTX-B B-CHEMICAL
were O
unaffected O
by O
betaxolol, B-CHEMICAL
but O
the O
drug O
significantly O
accelerated O
the O
dissociation O
rate O
of O
the O
radioligand. O
These O
findings O
argue O
for O
a O
competitive, O
indirect, O
allosteric O
mode O
of O
inhibition O
of O
[(3)H]-BTX-B B-CHEMICAL
binding O
by O
betaxolol. B-CHEMICAL
Betaxolol B-CHEMICAL

inhibited O
veratridine-stimulated B-CHEMICAL
Na(+) B-CHEMICAL
influx O
in O
rat O
cortical O
synaptosomes O
with O
an O
IC(50) O
value O
of O
28. O
3 O
microM. O
Carteolol, B-CHEMICAL
levobunolol, B-CHEMICAL
timolol B-CHEMICAL
and O
atenolol B-CHEMICAL
were O
significantly O
less O
effective O
than O
betaxolol B-CHEMICAL
at O
reducing O
veratridine-evoked B-CHEMICAL
Na(+) B-CHEMICAL
influx. O
The O
ability O
of O
betaxolol B-CHEMICAL
to O
interact O
with O
neurotoxin O
site O
2 O
of O
the O
Na(+) B-GENE-N
channel I-GENE-N
and O
inhibit O
Na(+) B-CHEMICAL
influx O
may O
have O
a O
role O
in O
its O

neuroprotective O
action O
in O
paradigms O
of O
excitotoxicity/ischaemia O
and O
in O
its O
therapeutic O
effect O
in O
glaucoma. O
Synthesis O
of O
novel O
1,3,4-trisubstituted B-CHEMICAL
pyrazoles I-CHEMICAL
as O
anti-inflammatory O
and O
analgesic O
agents. O
Some O
novel O
1,3,4-trisubstituted B-CHEMICAL
pyrazoles I-CHEMICAL
were O
synthesized O
and O
screened O
for O
their O
anti-inflammatory O
and O
analgesic O
activities O
as O
well O
as O
their O
ulcerogenic O
liability. O
They O
showed O
anti-inflammatory O
and O
analgesic O
activities O
with O
better O
GIT O
tolerance O
than O
the O
standard O
drug O
phenylbutazone. B-CHEMICAL
In O

addition, O
IC50 O
values O
for O
5e O
and O
8e O
were O
recorded. O
Compound O
5e O
was O
found O
to O
be O
the O
most O
active O
one O
as O
anti-inflammatory O
and O
analgesic O
agent. O
On O
the O
other O
hand, O
COX-1/COX-2 B-GENE-Y
isozyme O
selectivity O
was O
also O
done O
which O
showed O
equal O
inhibition O
to O
both O
isoforms. O
Leukotriene B-CHEMICAL
D4 I-CHEMICAL
induces O
cognitive O
impairment O
through O
enhancement O
of O
CysLT₁ B-GENE-Y
R-mediated I-GENE-Y
amyloid-β B-GENE-Y
generation O
in O
mice. O
Amyloid B-GENE-Y
plaques O
in O
the O
extracellular O
parenchyma O
mainly O
consist O
of O
amyloid-β B-GENE-Y

peptides I-GENE-Y
(Aβ), B-GENE-Y
one O
of O
the O
pathological O
hallmarks O
in O
Alzheimer's O
disease O
(AD). O
In O
the O
present O
study, O
we O
examined O
neuroinflammation, O
amyloidogenesis, O
and O
memory O
performance O
following O
intracerebral O
infusions O
of O
leukotriene B-CHEMICAL
D4 I-CHEMICAL
(LTD4) B-CHEMICAL
in O
mice. O
The O
results O
demonstrated O
that O
intracerebral O
infusions O
of O
LTD4 B-CHEMICAL
(1 O
ng/mouse) O
produced O
memory O
impairment O
as O
determined O
by O
Morris O
water O
maze O
test O
and O
Y-maze O
test O
in O
mice, O
and O
caused O
the O
accumulation O
of O
Aβ1-40 B-GENE-Y

and O
Aβ1-42 B-GENE-Y
in O
the O
hippocampus O
and O
cortex O
through O
increased O
activity O
of O
β- O
and O
γ-secretases O
accompanied O
with O
increased O
expression O
of O
amyloid B-GENE-Y
precursor I-GENE-Y
protein I-GENE-Y
(APP). B-GENE-Y
LTD4 B-CHEMICAL
also O
induced O
expression O
of O
cysteinyl B-GENE-Y
leukotriene I-GENE-Y
receptor I-GENE-Y
1 I-GENE-Y
(CysLT(1)R) B-GENE-Y
and O
NF-κB B-GENE-N
p65 B-GENE-Y
in O
the O
hippocampus O
and O
cortex. O
Pretreatment O
with O
pranlukast B-CHEMICAL
(1.5 O
ng/mouse, O
intracerebroventricularly), O
a O
CysLT(1)R B-GENE-Y
antagonist, O
blocked O

LTD4-induced B-CHEMICAL
amyloidogenesis, O
memory O
deficits. O
Pranlukast B-CHEMICAL
(0.6 O
μM) O
also O
prevented O
LTD4 B-CHEMICAL
(20 O
nM)-induced O
amyloidogenesis O
in O
the O
cultured O
neurons O
in O
vitro. O
Moreover, O
LTD4-induced B-CHEMICAL
increases O
in O
CysLT(1)R B-GENE-Y
and O
NF-κB B-GENE-N
p65 B-GENE-Y
in O
the O
brain O
were O
also O
attenuated O
by O
pranlukast. B-CHEMICAL
These O
results O
suggest O
that O
LTD4 B-CHEMICAL
increases O
Aβ B-GENE-Y
peptide I-GENE-Y
burden O
via O
activation O
of O
CysLT(1)R, B-GENE-Y
which O
further O
affects O
APP B-GENE-Y
levels O
and O

activity O
of O
β- O
and O
γ-secretases O
via O
the O
NF-κB B-GENE-N
pathway. O
Our O
findings O
identify O
CysLT(1)R B-GENE-Y
signaling O
as O
a O
novel O
proinflammatory O
and O
proamyloidogenic O
pathway, O
and O
suggest O
a O
rationale O
for O
development O
of O
therapeutics O
targeting O
the O
CysLT(1)R B-GENE-Y
in O
neuroinflammatory O
diseases O
such O
as O
AD. O
Predicting O
cardiomyopathic O
phenotypes O
by O
altering O
Ca2+ B-CHEMICAL
affinity O
of O
cardiac B-GENE-Y
troponin I-GENE-Y
C. I-GENE-Y
Cardiac O
diseases O
associated O
with O
mutations O
in O
troponin B-GENE-N
subunits O
include O
hypertrophic O

cardiomyopathy O
(HCM), O
dilated O
cardiomyopathy O
(DCM), O
and O
restrictive O
cardiomyopathy O
(RCM). O
Altered O
calcium O
handling O
in O
these O
diseases O
is O
evidenced O
by O
changes O
in O
the O
Ca(2+) B-CHEMICAL
sensitivity O
of O
contraction. O
Mutations O
in O
the O
Ca(2+) B-CHEMICAL
sensor, O
troponin B-GENE-Y
C I-GENE-Y
(TnC), B-GENE-Y
were O
generated O
to O
increase/decrease O
the O
Ca(2+) B-CHEMICAL
sensitivity O
of O
cardiac O
skinned O
fibers O
to O
create O
the O
characteristic O
effects O
of O
DCM, O
HCM, O
and O
RCM. O
We O
also O
used O
a O
reconstituted O
assay O
to O
determine O

the O
mutation O
effects O
on O
ATPase B-GENE-N
activation O
and O
inhibition. O
One O
mutant O
(A23Q) B-GENE-N
was O
found O
with O
HCM-like O
properties O
(increased O
Ca(2+) B-CHEMICAL
sensitivity O
of O
force O
and O
normal O
levels O
of O
ATPase B-GENE-N
inhibition). O
Three O
mutants O
(S37G, B-GENE-N
V44Q, B-GENE-N
and O
L48Q) B-GENE-N
were O
identified O
with O
RCM-like O
properties O
(a O
large O
increase O
in O
Ca(2+) B-CHEMICAL
sensitivity, O
partial O
loss O
of O
ATPase B-GENE-N
inhibition, O
and O
increased O
basal O
force). O
Two O
mutations O
were O
identified O
(E40A B-GENE-N
and O
I61Q) B-GENE-N
with O
DCM O
properties O
(decreased O
Ca(2+) B-CHEMICAL

sensitivity, O
maximal O
force O
recovery, O
and O
activation O
of O
the O
ATPase B-GENE-N
at O
high O
[Ca(2+)]). B-CHEMICAL
Steady-state O
fluorescence O
was O
utilized O
to O
assess O
Ca(2+) B-CHEMICAL
affinity O
in O
isolated O
cardiac B-GENE-Y
(c)TnCs I-GENE-Y
containing O
F27W B-GENE-N
and O
did O
not O
necessarily O
mirror O
the O
fiber O
Ca(2+) B-CHEMICAL
sensitivity. O
Circular O
dichroism O
of O
mutant O
cTnCs B-GENE-Y
revealed O
a O
trend O
where O
increased O
alpha-helical O
content O
correlated O
with O
increased O
Ca(2+) B-CHEMICAL
sensitivity O
in O
skinned O
fibers O
and O
vice O
versa. O
The O
main O
findings O
from O
this O
study O
were O
as O
follows: O
1) O

cTnC B-GENE-Y
mutants O
demonstrated O
distinct O
functional O
phenotypes O
reminiscent O
of O
bona O
fide O
HCM, O
RCM, O
and O
DCM O
mutations; O
2) O
a O
region O
in O
cTnC B-GENE-Y
associated O
with O
increased O
Ca(2+) B-CHEMICAL
sensitivity O
in O
skinned O
fibers O
was O
identified; O
and O
3) O
the O
F27W B-GENE-N
reporter O
mutation O
affected O
Ca(2+) B-CHEMICAL
sensitivity, O
maximal O
force, O
and O
ATPase B-GENE-N
activation O
of O
some O
mutants. O
DNA O
methylation O
and O
histone B-GENE-N
modification O
profiles O
of O
mouse B-GENE-N
organic I-GENE-N
anion I-GENE-N
transporting I-GENE-N
polypeptides. I-GENE-N
Organic B-GENE-N
anion I-GENE-N
transporting I-GENE-N
polypeptides I-GENE-N
(rodents, O
Oatps; B-GENE-N
human, O

OATPs) B-GENE-N
are O
primarily O
involved O
in O
the O
transmembrane O
transportation O
of O
a O
wide O
range O
of O
endogenous O
and O
exogenous O
compounds. O
Multiple O
mouse B-GENE-Y
Oatp1 I-GENE-Y
isoforms O
are O
closely O
located O
on O
chromosome O
6, O
where O
each O
isoform O
shows O
distinct O
tissue O
distribution; O
Oatp1b2, B-GENE-Y
Oatp1a6, B-GENE-N
and O
Oatp1c1 B-GENE-Y
are O
expressed O
exclusively O
in O
the O
liver, O
kidney, O
and O
cerebrum, O
respectively; O
Oatp1a1 B-GENE-Y
in O
the O
liver O
and O
kidney; O
and O
Oatp1a4 B-GENE-Y
in O
the O
liver O
and O
cerebrum. O
We O
have O
identified O
tissue-dependent B-GENE-N

differentially I-GENE-N
methylated I-GENE-N
region I-GENE-N
(T-DMR) B-GENE-N
around O
the O
transcriptional B-GENE-N
start I-GENE-N
site I-GENE-N
(TSS) B-GENE-N
of O
Oatp1b2, B-GENE-Y
which O
correlates O
with O
its O
liver-specific O
expression. O
Bisulfite B-CHEMICAL
sequencing O
also O
demonstrated O
the O
presence O
of O
T-DMRs B-GENE-N
around O
the O
TSS B-GENE-N
in O
other O
Oatp1 B-GENE-Y
genes: O
CpG O
dinucleotides O
at O
+149 O
relative O
to O
the O
TSS B-GENE-N
for O
Oatp1c1; B-GENE-Y
-48, O
+101, O
and O
+356 O
for O
Oatp1a4; B-GENE-Y
-572 O
and O
-550 O
for O
Oatp1a1; B-GENE-Y
and O

-122 O
and O
+216 O
for O
Oatp1a6 B-GENE-N
were O
differentially O
methylated O
among O
the O
liver, O
kidney, O
and O
cerebrum. O
These O
methylation O
profiles O
were O
largely O
consistent O
with O
the O
tissue O
distribution O
of O
Oatp1 B-GENE-Y
mRNAs. O
Chromatin O
immunoprecipitation O
assay O
revealed O
that O
the O
mRNA O
expression O
of O
Oatp1 B-GENE-Y
genes O
was O
accompanied O
by O
acetylated O
histone B-GENE-N
H3. I-GENE-N
Human B-GENE-Y
OATP1B1 I-GENE-Y
and O
OATP1B3 B-GENE-Y
are O
located O
on O
chromosome O
12p12 O
in O
the O
OATP1 B-GENE-Y
cluster; O
both O
show O
predominant O
expression O
in O
the O
liver. O
These O
genes O

also O
contained O
T-DMRs B-GENE-N
that O
were O
hypomethylated O
in O
the O
liver, O
compared O
with O
kidney O
cortex: O
-511, O
-411, O
and O
+92 O
relative O
to O
the O
TSS B-GENE-N
for O
OATP1B1 B-GENE-Y
and O
-331, O
+70, O
and O
+73 O
for O
OATP1B3. B-GENE-Y
These O
results O
suggest O
that O
the O
difference O
in O
epigenetic O
profiles O
comprising O
DNA O
methylation O
and O
histone B-GENE-N
acetylation O
determines O
the O
distinct O
tissue O
distribution O
of O
Oatp/OATP B-GENE-N
mRNAs. O
Escitalopram. B-CHEMICAL
Escitalopram B-CHEMICAL
oxalate I-CHEMICAL

(S-citalopram, B-CHEMICAL
Lexapro), B-CHEMICAL
a O
selective O
serotonin B-CHEMICAL
re-uptake O
inhibitor O
antidepressant O
which O
is O
the O
S-enantiomer B-CHEMICAL
of I-CHEMICAL
citalopram, I-CHEMICAL
is O
in O
clinical O
development O
worldwide O
for O
the O
treatment O
of O
depression O
and O
anxiety O
disorders. O
Preclinical O
studies O
demonstrate O
that O
the O
therapeutic O
activity O
of O
citalopram B-CHEMICAL
resides O
in O
the O
S-isomer O
and O
that O
escitalopram B-CHEMICAL
binds O
with O
high O
affinity O
to O
the O
human B-GENE-Y
serotonin I-GENE-Y
transporter. I-GENE-Y
Conversely, O
R-citalopram B-CHEMICAL
is O
approximately O
30-fold O
less O
potent O
than O
escitalopram B-CHEMICAL
at O
this O
transporter. O

Escitalopram B-CHEMICAL
has O
linear O
pharmacokinetics, O
so O
that O
plasma O
levels O
increase O
proportionately O
and O
predictably O
with O
increased O
doses O
and O
its O
half-life O
of O
27 O
- O
32 O
h O
is O
consistent O
with O
once-daily O
dosing. O
In O
addition, O
escitalopram B-CHEMICAL
has O
negligible O
effects O
on O
cytochrome B-GENE-N
P450 I-GENE-N
drug-metabolising O
enzymes O
in O
vitro, O
suggesting O
a O
low O
potential O
for O
drug-drug O
interactions. O
The O
efficacy O
of O
escitalopram B-CHEMICAL
in O
patients O
with O
major O
depressive O
disorder O
has O
been O
demonstrated O
in O
multiple O
short-term, O
placebo-controlled O
clinical O
trials, O
three O
of O
which O
included O

citalopram B-CHEMICAL
as O
an O
active O
control, O
as O
well O
as O
in O
a O
36-week O
study O
evaluating O
efficacy O
in O
the O
prevention O
of O
depression O
relapse. O
In O
these O
studies, O
escitalopram B-CHEMICAL
was O
shown O
to O
have O
robust O
efficacy O
in O
the O
treatment O
of O
depression O
and O
associated O
symptoms O
of O
anxiety O
relative O
to O
placebo. O
Efficacy O
has O
also O
been O
shown O
in O
treating O
generalised O
anxiety O
disorder, O
panic O
disorder O
and O
social O
anxiety O
disorder. O
Results O
also O
suggest O
that, O
at O
comparable O
doses, O
escitalopram B-CHEMICAL
demonstrates O
clinically O
relevant O
and O
statistically O
significant O
superiority O
to O
placebo O
treatment O
earlier O
than O
citalopram. B-CHEMICAL
Analysis O
of O
the O
safety O
database O
shows O
a O
low O
rate O
of O

discontinuation O
due O
to O
adverse O
events, O
and O
there O
was O
no O
statistically O
significant O
difference O
between O
escitalopram B-CHEMICAL
10 O
mg/day O
and O
placebo O
in O
the O
proportion O
of O
patients O
who O
discontinued O
treatment O
early O
because O
of O
adverse O
events. O
The O
most O
common O
adverse O
events O
associated O
with O
escitalopram B-CHEMICAL
which O
occurred O
at O
a O
rate O
greater O
than O
placebo O
include O
nausea, O
insomnia, O
ejaculation O
disorder, O
diarrhoea, O
dry O
mouth O
and O
somnolence. O
Only O
nausea O
occurred O
in O
> O
10% O
of O
escitalopram-treated B-CHEMICAL
patients. O
Statins B-CHEMICAL
increase O
p21 B-GENE-Y
through O
inhibition O
of O
histone B-GENE-N
deacetylase I-GENE-N
activity O

and O
release O
of O
promoter-associated O
HDAC1/2. B-GENE-N
Statins B-CHEMICAL
are O
3-hydroxy-3-methylglutaryl-CoA B-GENE-Y
reductase I-GENE-Y
inhibitors O
broadly O
used O
for O
the O
control O
of O
hypercholesterolemia. O
Recently, O
they O
are O
reported O
to O
have O
beneficial O
effects O
on O
certain O
cancers. O
In O
this O
study, O
we O
show O
that O
statins O
inhibited O
the O
histone B-GENE-N
deacetylase I-GENE-N
(HDAC) B-GENE-N
activity O
and O
increased O
the O
accumulation O
of O
acetylated B-GENE-N
histone-H3 I-GENE-N
and O
the O
expression O
of O
p21(WAF/CIP) B-GENE-Y
in O
human O
cancer O
cells. O
Computational O

modeling O
showed O
the O
direct O
interaction O
of O
the O
carboxylic B-CHEMICAL
acid I-CHEMICAL
moiety O
of O
statins O
with O
the O
catalytic O
site O
of O
HDAC2. B-GENE-Y
In O
the O
subsequent O
enzymatic O
assay, O
it O
was O
shown O
that O
lovastatin B-CHEMICAL
inhibited O
HDAC2 B-GENE-Y
activity O
competitively O
with O
a O
K(i) O
value O
of O
31.6 O
micromol/L. O
Sp1 B-GENE-Y
but O
not O
p53 B-GENE-Y
sites O
were O
found O
to O
be O
the O
statins-responsive B-GENE-N
element I-GENE-N
shown O
by O
p21 B-GENE-Y
luciferase-promoter O
assays. O
DNA O
affinity O
protein O
binding O
assay O
and O
chromatin O
immunoprecipitation O

assay O
showed O
the O
dissociation O
of O
HDAC1/2 B-GENE-N
and O
association O
of O
CBP, B-GENE-Y
leading O
to O
the O
histone-H3 B-GENE-N
acetylation O
on O
the O
Sp1 B-GENE-Y
sites O
of O
p21 B-GENE-N
promoter. I-GENE-N
In O
vitro O
cell O
proliferation O
and O
in O
vivo O
tumor O
growth O
were O
both O
inhibited O
by O
statins. O
These O
results O
suggest O
a O
novel O
mechanism O
for O
statins O
through O
abrogation O
of O
the O
HDAC B-GENE-N
activity O
and O
promoter O
histone-H3 B-GENE-N
acetylation O
to O
regulate O
p21 B-GENE-Y
expression. O
Therefore, O
statins O
might O
serve O
as O
novel O
HDAC B-GENE-N
inhibitors O
for O
cancer O
therapy O
and O
chemoprevention. O
Imatinib B-CHEMICAL

mesylate I-CHEMICAL
(Gleevec) B-CHEMICAL
enhances O
mature O
osteoclast O
apoptosis O
and O
suppresses O
osteoclast O
bone O
resorbing O
activity. O
Recent O
studies O
have O
reported O
that O
imatinib B-CHEMICAL
mesylate, I-CHEMICAL
a O
kinase B-GENE-N
inhibitor O
that O
targets O
the O
intracellular O
tyrosine B-GENE-N
kinase I-GENE-N
BCR-ABL B-GENE-Y
and O
the O
platelet B-GENE-N
derived I-GENE-N
growth I-GENE-N
factor I-GENE-N
(PDGF) I-GENE-N
receptor, I-GENE-N
is O
an O
effective O
inhibitor O
of O
the O
macrophage B-GENE-Y
colony I-GENE-Y
stimulating I-GENE-Y
factor I-GENE-Y
(M-CSF) I-GENE-Y
receptor, I-GENE-Y
c-FMS. B-GENE-Y
Given O
that O
M-CSF B-GENE-Y
signalling O
through O
c-FMS B-GENE-Y
plays O
an O
important O
role O
in O
osteoclast O

biology, O
we O
speculated O
that O
blocking O
such O
a O
pathway O
with O
imatinib B-CHEMICAL
may O
modulate O
osteoclast O
activity. O
Using O
a O
cell O
model O
of O
mature O
rabbit O
osteoclasts, O
we O
thus O
investigated O
the O
effect O
of O
imatinib B-CHEMICAL
on O
in O
vitro O
osteoclast O
apoptosis O
and O
bone O
resorbing O
activity. O
Our O
findings O
demonstrate O
that O
imatinib B-CHEMICAL
dose-dependently O
stimulates O
osteoclast O
apoptosis, O
a O
phenomenon O
which O
is O
blocked O
by O
the O
caspase B-GENE-Y
I I-GENE-Y
inhibitor O
Z-VAD-fmk. O
The O
ability O
of O
imatinib B-CHEMICAL
to O
enhance O
osteoclast O
cell O
death O
was O
accompanied O

by O
a O
dose-dependent O
inhibition O
of O
osteoclast O
bone O
resorbing O
activity. O
Imatinib B-CHEMICAL
was O
also O
found O
to O
inhibit O
M-CSF-induced B-GENE-Y
osteoclast O
survival O
as O
well O
as O
M-CSF-induced B-GENE-Y
osteoclast O
bone O
resorbing O
activity, O
but O
was O
without O
effect O
on O
interleukin B-GENE-Y
1alpha I-GENE-Y
(IL-1alpha) B-GENE-Y
and O
receptor B-GENE-Y
activator I-GENE-Y
of I-GENE-Y
nuclear I-GENE-Y
factor I-GENE-Y
kappa I-GENE-Y
B I-GENE-Y
ligand I-GENE-Y
(RANKL)-induced B-GENE-Y
inhibition O
of O
osteoclasts O
apoptosis, O
further O
supporting O
the O
hypothesis O
that O
imatinib B-CHEMICAL
may O
affect O
mature O

osteoclasts O
through O
the O
inhibition O
of O
c-FMS. B-GENE-Y
Taken O
together, O
these O
results O
suggest O
that O
imatinib B-CHEMICAL
could O
be O
of O
clinical O
value O
in O
treating O
diseases O
where O
bone O
destruction O
can O
occur O
due O
to O
excessive O
M-CSF B-GENE-Y
production O
such O
as O
osteoporosis, O
inflammatory-and O
tumor-induced O
osteolysis. O
Structural O
basis O
for O
LFA-1 B-GENE-Y
inhibition O
upon O
lovastatin B-CHEMICAL
binding O
to O
the O
CD11a B-GENE-N
I-domain. I-GENE-N
The O
lymphocyte B-GENE-Y
function-associated I-GENE-Y
antigen I-GENE-Y
(LFA-1) B-GENE-Y
belongs O
to O
the O
family O
of O
beta2-integrins B-GENE-Y
and O
plays O
an O
important O
role O

in O
T-cell O
activation O
and O
leukocyte O
migration O
to O
sites O
of O
inflammation. O
We O
report O
here O
that O
lovastatin, B-CHEMICAL
a O
drug O
clinically O
used O
for O
lowering O
cholesterol B-CHEMICAL
levels, O
inhibits O
the O
interaction O
of O
human B-GENE-Y
LFA-1 I-GENE-Y
with O
its O
counter-receptor O
intercellular B-GENE-Y
adhesion I-GENE-Y
molecule-1. I-GENE-Y
Using O
nuclear O
magnetic O
resonance O
spectroscopy O
and O
X-ray O
crystallography O
we O
show O
that O
the O
inhibitor O
binds O
to O
a O
highly O
conserved O
domain O
of O
the O
LFA-1 B-GENE-Y
alpha-chain I-GENE-Y
called O
the O
I-domain. B-GENE-N
The O
first O
three-dimensional O
structure O
of O
an O
integrin B-GENE-N
inhibitor O
bound O
to O
its O
receptor O
reveals O
atomic O
details O
for O
a O

hitherto O
unknown O
mode O
of O
LFA-1 B-GENE-Y
inhibition. O
It O
also O
sheds O
light O
into O
possible O
mechanisms O
of O
LFA-1 B-GENE-Y
mediated O
signalling O
and O
will O
support O
the O
design O
of O
novel O
anti-adhesive O
and O
immunosuppressive O
drugs. O
Inhibition O
of O
matrix B-GENE-N
metalloproteinases I-GENE-N
(MMPs) B-GENE-N
as O
a O
potential O
strategy O
to O
ameliorate O
hypertension-induced O
cardiovascular O
alterations. O
A O
group O
of O
proteases, O
the O
matrix B-GENE-N
metalloproteinases I-GENE-N
(MMPs) B-GENE-N
are O
well O
known O
for O
their O
capacity O
to O
degrade O
extracellular B-GENE-N
matrix I-GENE-N
(ECM) I-GENE-N
proteins. I-GENE-N
Particularly O
MMP-2 B-GENE-Y
and O

MMP-9 B-GENE-Y
contribute O
to O
the O
degradation O
and O
reorganization O
of O
the O
ECM O
components O
and O
are O
involved O
in O
the O
pathophysiology O
of O
cardiovascular O
remodeling. O
Imbalanced O
MMP B-GENE-N
activity O
promotes O
vascular O
smooth O
muscle O
cells O
and O
migration O
and O
proliferation O
and O
endothelial O
dysfunction, O
thus O
resulting O
in O
increased O
cardiovascular O
stiffness O
and O
hypertrophy. O
Furthermore, O
MMP-2 B-GENE-Y
cleaves O
non-ECM O
protein O
substrates O
including O
cellular O
receptors O
and O
intracellular O
proteins, O
thus O
causing O
cardiac O
and O
vascular O
dysfunction. O
It O
is O
now O
becoming O
clear O
that O
increased O
MMP B-GENE-N
activity O
promotes O
long-lasting O
cardiovascular O
structural O
and O
functional O
alterations O
in O

both O
experimental O
and O
clinical O
hypertension, O
and O
this O
alteration O
may O
contribute O
to O
sustained O
hypertension O
and O
its O
complications. O
Other O
pathogenic O
mechanisms O
including O
activation O
of O
the O
renin-angiotensin-aldosterone B-GENE-Y
system O
and O
oxidative O
stress O
activate O
and O
upregulate O
MMPs. B-GENE-N
Therefore, O
MMP B-GENE-N
inhibition O
may O
prevent O
the O
deleterious O
consequences O
of O
hypertension O
to O
the O
cardiovascular O
system. O
This O
review O
article O
will O
focus O
on O
growing O
evidence O
supporting O
the O
relevance O
of O
MMPs B-GENE-N
in O
hypertension O
and O
the O
effects O
of O
MMP B-GENE-N
inhibitors. O
Particularly, O
the O
effects O
of O
doxycycline B-CHEMICAL

used O
as O
a O
non O
selective O
MMP B-GENE-N
inhibitor O
in O
experimental O
and O
clinical O
studies O
will O
be O
discussed. O
Time-dependent O
changes O
in O
hepatic O
and O
intestinal O
induction O
of O
cytochrome B-GENE-N
P450 I-GENE-N
3A I-GENE-N
after O
administration O
of O
dexamethasone B-CHEMICAL
to O
rats. O
Abstract O
1. O
We O
investigated O
the O
effects O
of O
the O
dose O
of O
and O
the O
number O
of O
times O
an O
inducer O
was O
administered O
and O
the O
duration O
of O
induction O
of O
hepatic O
and O
intestinal O
cytochrome B-GENE-N
P450 I-GENE-N
3A I-GENE-N
(CYP3A) B-GENE-N
in O
rats O
using O
dexamethasone B-CHEMICAL
21-phosphate I-CHEMICAL
(DEX-P) B-CHEMICAL
and O
midazolam B-CHEMICAL

(MDZ) B-CHEMICAL
as O
an O
inducer O
and O
a O
substrate O
to O
CYP3A, B-GENE-N
respectively. O
2. O
The O
number O
of O
times O
DEX-P B-CHEMICAL
was O
administered O
was O
not O
a O
significant O
factor O
in O
the O
induction O
of O
either O
hepatic O
or O
intestinal O
CYP3A; B-GENE-N
however, O
administration O
of O
DEX-P B-CHEMICAL
multiple O
times O
markedly O
decreased O
the O
bioavailability O
of O
DEX-P B-CHEMICAL
by O
self-induction O
of O
CYP3A. B-GENE-N
3. O
CYP3A B-GENE-N
induction O
in O
the O
liver O
increased O
depending O
on O
the O
dose O
of O
DEX-P, B-CHEMICAL
whereas O
that O
in O
intestine O
showed O
a O
mild O
increase, O
but O
the O
induction O
level O
was O
almost O
constant O
regardless O

of O
the O
dose O
of O
DEX-P. B-CHEMICAL
4. O
Administration O
of O
a O
single O
dose O
of O
DEX-P B-CHEMICAL
showed O
a O
temporal O
increase O
in O
CYP3A B-GENE-N
activity O
in O
both O
tissues O
and O
the O
induction O
ratios O
reached O
maximum O
values O
at O
12 O
h O
after O
DEX-P B-CHEMICAL
administration. O
On O
the O
other O
hand, O
a O
mild O
increase O
of O
CYP3A B-GENE-N
activity, O
which O
lasted O
for O
at O
least O
48 O
h, O
was O
observed O
in O
both O
tissues O
after O
administration O
of O
multiple O
doses. O
5. O
Some O
physiological O
compounds O
such O
as O
cytokines B-GENE-N
might O
be O
involved O
in O
decreasing O
the O
CYP3A B-GENE-N
activity O
to O
maintain O
homeostasis O
of O
the O
body. O
Autoradiographic O
study O
of O
serotonin B-GENE-Y

transporter I-GENE-Y
during O
memory O
formation. O
Serotonin B-GENE-Y
transporter I-GENE-Y
(SERT) B-GENE-Y
has O
been O
associated O
with O
drugs O
of O
abuse O
like O
d-methamphetamine B-CHEMICAL
(METH). B-CHEMICAL
METH B-CHEMICAL
is O
well O
known O
to O
produce O
effects O
on O
the O
monoamine B-CHEMICAL
systems O
but O
it O
is O
unclear O
how O
METH B-CHEMICAL
affects O
SERT B-GENE-Y
and O
memory. O
Here O
the O
effects O
of O
METH B-CHEMICAL
and O
the O
serotonin B-CHEMICAL
reuptake O
inhibitor O
fluoxetine B-CHEMICAL
(FLX) B-CHEMICAL
on O
autoshaping O
and O
novel O
object O
recognition O
(NOR) O
were O
investigated. O
Notably, O
both O
memory O
tasks O
recruit O
different O
behavioral, O
neural O
and O
cognitive O
demand. O
In O
autoshaping O
task O
a O
dose-response O
curve O
for O

METH B-CHEMICAL
was O
determined. O
METH B-CHEMICAL
(1.0mg/kg) O
impaired O
short-term O
memory O
(STM; O
lasting O
less O
of O
90min) O
in O
NOR O
and O
impaired O
both O
STM O
and O
long-term O
memory O
(LTM; O
lasting O
24 O
and O
48h) O
in O
autoshaping, O
indicating O
that O
METH B-CHEMICAL
had O
long-lasting O
effects O
in O
the O
latter O
task. O
A O
comparative O
autoradiography O
study O
of O
the O
relationship O
between O
the O
binding O
pattern O
of O
SERT B-GENE-Y
in O
autoshaping O
new O
untrained O
vs. O
trained O
treated O
(METH, B-CHEMICAL
FLX, B-CHEMICAL
or O
both) O
animals O
was O
made. O
Considering O
that O
hemispheric O
dominance O
is O
important O
for O

LTM, O
hence O
right O
vs. O
left O
hemisphere O
of O
the O
brain O
was O
compared. O
Results O
showed O
that O
trained O
animals O
decreased O
cortical O
SERT B-GENE-Y
binding O
relative O
to O
untrained O
ones. O
In O
untrained O
and O
trained O
treated O
animals O
with O
the O
amnesic O
dose O
(1.0mg/kg) O
of O
METH B-CHEMICAL
SERT B-GENE-Y
binding O
in O
several O
areas O
including O
hippocampus O
and O
cortex O
decreased, O
more O
remarkably O
in O
the O
trained O
animals. O
In O
contrast, O
FLX O
improved O
memory, O
increased O
SERT B-GENE-Y
binding, O
prevented O
the O
METH B-CHEMICAL
amnesic O
effect O
and O
re-established O
the O
SERT B-GENE-Y
binding. O
In O
general, O
memory O
and O
amnesia O
seemed O
to O
make O
SERT B-GENE-Y
more O
vulnerable O

to O
drugs O
effects. O
Hypoxia O
and O
lactate B-CHEMICAL
production O
in O
trophoblast O
cells. O
The O
etiology O
of O
preeclampsia O
is O
unknown O
but O
is O
thought O
to O
be O
related O
to O
hypoxia O
in O
the O
placenta. O
We O
previously O
reported O
that O
the O
enzyme O
lactate B-GENE-N
dehydrogenase I-GENE-N
(LDH) B-GENE-N
has O
increased O
activity O
and O
gene O
expression O
in O
placentas O
from O
preeclamptic O
pregnancies O
[Tsoi O
SCM, O
Zheng O
J, O
Xu O
F, O
Kay O
HH. O
Differential O
expression O
of O
lactate B-GENE-N
dehydrogenase I-GENE-N
isozymes O
(LDH) B-GENE-N
in O
human O
placenta O
with O

high O
expression O
of O
LDH-A(4) B-GENE-Y
isozyme O
in O
the O
endothelial O
cells O
of O
pre-eclampsia O
villi. O
Placenta O
2001;22:317-22]. O
LDH B-GENE-N
is O
responsible O
for O
pyruvate B-CHEMICAL
conversion O
to O
lactate B-CHEMICAL
through O
glycolysis. O
In O
this O
study, O
we O
further O
investigated O
the O
role O
of O
hypoxia O
in O
primary O
trophoblast O
cells O
and O
a O
cultured O
cell O
line, O
JEG3 O
cells, O
to O
obtain O
a O
better O
understanding O
of O
how O
it O
affects O
the O
activities O
of O
lactate B-GENE-N
dehydrogenase, I-GENE-N
lactate B-CHEMICAL
production O
and O
regulatory O

genes, O
as O
a O
possible O
model O
for O
preeclampsia. O
Primary O
trophoblast O
cells O
and O
JEG3 O
cells O
were O
cultured O
under O
1% O
oxygen. B-CHEMICAL
At O
6, O
12 O
and O
24h, O
cells O
were O
analyzed O
for O
LDHA B-GENE-Y
and O
LDHB B-GENE-Y
isozyme O
activities, O
mRNA O
and O
protein O
expression O
compared O
to O
standard O
culture O
conditions. O
Lactate B-CHEMICAL
was O
measured O
from O
cell O
medium. O
The O
hypoxia B-GENE-N
inducible I-GENE-N
transcription I-GENE-N
factor I-GENE-N
(HIF-1alpha) B-GENE-Y
protein O
expression O
was O
confirmed O
by O
western O
blot. O
Two O
lactate B-GENE-N
transporters I-GENE-N
(MCT1 B-GENE-Y
and O
MCT4) B-GENE-Y
mRNA O
and O
protein O
expression O
were O
also O
studied O
under O

hypoxia. O
Finally, O
lactate B-CHEMICAL
was O
measured O
in O
plasma O
obtained O
from O
patients O
with O
severe O
preeclampsia. O
Under O
hypoxic O
conditions, O
LDHA B-GENE-Y
mRNA O
is O
increased O
in O
primary O
trophoblast O
cells O
and O
JEG3 O
cells. O
The O
HIF-1alpha B-GENE-Y
protein O
expression O
is O
higher O
in O
hypoxia-treated O
JEG3 O
cells O
than O
control. O
LDHA B-GENE-Y
isozyme O
activity O
and O
its O
protein O
expression O
are O
increased O
most O
significantly O
at O
24h O
of O
culture O
under O
hypoxia. O
However, O
LDHB B-GENE-Y
protein O
is O
unchanged O
while O
its O
mRNA O
is O
decreased. O
Lactate B-CHEMICAL
secretion O
from O
JEG3 O

cells O
under O
hypoxia O
is O
increased, O
as O
is O
the O
lactate B-CHEMICAL
levels O
in O
the O
plasma O
from O
preeclampsia O
patients. O
Of O
the O
two O
lactate B-CHEMICAL
transporters O
studied, O
MCT4 B-GENE-Y
mRNA O
and O
protein O
level O
are O
increased O
under O
hypoxia. O
Our O
findings O
support O
the O
role O
of O
hypoxia O
in O
inducing O
HIF-1alpha B-GENE-Y
activity O
in O
trophoblasts O
and O
increasing O
LDH B-GENE-N
transcription O
as O
well O
as O
its O
activity. O
Higher O
levels O
of O
lactate B-CHEMICAL
are O
produced O
and O
secreted O
which O
may O
contribute O
to O
the O
higher O
lactate B-CHEMICAL
levels O
in O
plasma O
of O
preeclamptic O
patients. O
These O
mechanisms O
may O
be O
important O
in O

the O
pathophysiology O
of O
preeclampsia. O
Preclinical O
pharmacokinetics O
and O
in O
vitro O
metabolism O
of O
dasatinib B-CHEMICAL
(BMS-354825): B-CHEMICAL
a O
potent O
oral O
multi-targeted O
kinase B-GENE-N
inhibitor O
against O
SRC B-GENE-Y
and O
BCR-ABL. B-GENE-Y
PURPOSE: O
Dasatinib B-CHEMICAL
(BMS-354825), B-CHEMICAL
a O
potent O
oral O
multi-targeted O
kinase B-GENE-N
inhibitor O
against O
SRC B-GENE-Y
and O
BCR-ABL, B-GENE-Y
has O
recently O
been O
approved O
for O
the O
treatment O
of O
chronic O
myelogenous O
leukaemia O
(CML) O
in O
imatinib-acquired B-CHEMICAL
resistance O
and O

intolerance. O
In O
vitro O
and O
in O
vivo O
studies O
were O
conducted O
to O
characterize O
the O
pharmacokinetics O
and O
metabolism O
of O
dasatinib B-CHEMICAL
in O
mouse, O
rat, O
dog, O
and O
monkey. O
Possible O
mechanisms O
contributing O
to O
the O
incomplete O
oral O
bioavailability O
of O
dasatinib B-CHEMICAL
in O
animals O
were O
investigated. O
METHODS: O
Metabolic O
stability O
of O
dasatinib B-CHEMICAL
was O
measured O
after O
incubation O
with O
liver O
microsomes O
(either O
NADPH- B-CHEMICAL
or O
UDPGA-fortified) B-CHEMICAL
and O
isolated O
hepatocytes O
obtained O
from O
mouse, O
rat, O
dog, O
monkey, O
and O
human. O
In O
all O

cases, O
substrate O
depletion O
over O
time O
was O
measured, O
and O
appropriate O
scaling O
factors O
were O
used O
to O
predict O
in O
vivo O
clearance. O
Pharmacokinetics O
of O
dasatinib B-CHEMICAL
were O
determined O
in O
mice, O
rats, O
dogs, O
and O
monkeys O
after O
administration O
of O
single O
intravenous O
or O
oral O
doses. O
In O
addition, O
the O
routes O
of O
excretion O
were O
investigated O
after O
administration O
of O
dasatinib B-CHEMICAL
to O
bile O
duct O
cannulated O
(BDC) O
rats. O
Absorption O
and O
first-pass O
metabolism O
were O
evaluated O
as O
possible O
reasons O
for O
the O
incomplete O
oral O
bioavailability O
using O
various O
in O
vitro O
and O
in O
vivo O
models O
like O

Caco-2 O
cells, O
P-glycoprotein B-GENE-N
(P-gp) B-GENE-N
knockout O
mice, O
and O
intra-portal O
dosing O
in O
rats. O
RESULTS: O
In O
vivo O
systemic O
plasma O
clearance O
values O
of O
dasatinib B-CHEMICAL
were O
62, O
26, O
25, O
and O
34 O
ml/min/kg O
in O
mouse, O
rat, O
dog, O
and O
monkey, O
respectively. O
Scaling O
of O
in O
vitro O
hepatocyte O
and O
liver O
microsomal O
data O
gave O
reasonably O
good O
predictions O
of O
in O
vivo O
clearances O
across O
all O
species. O
Percent O
distribution O
in O
blood O
cells O
ranged O
from O
43% O
in O
mouse O
to O
57% O
in O

dog. O
Dasatinib B-CHEMICAL
showed O
high O
volumes O
of O
distribution O
(>3 O
l/kg) O
and O
high O
serum O
protein O
binding O
values O
(>90%) O
in O
all O
four O
species O
tested. O
Oral O
bioavailability O
of O
dasatinib B-CHEMICAL
ranged O
from O
14% O
in O
the O
mouse O
to O
34% O
in O
the O
dog. O
In O
rats, O
bioavailability O
after O
an O
intraportal O
dose O
was O
comparable O
to O
that O
after O
intra-arterial O
administration. O
In O
BDC O
rats, O
less O
than O
15% O
of O
an O
intravenous O
dose O
was O
excreted O
unchanged O
in O
urine, O
bile, O
and O
the O
gastrointestinal O
tract, O
suggesting O
that O

dasatinib B-CHEMICAL
is O
cleared O
primarily O
via O
metabolism. O
Dasatinib B-CHEMICAL
has O
high O
intrinsic O
permeability O
in O
Caco-2 O
cells, O
however, O
the O
efflux O
ratio O
was O
approximately O
two-fold O
indicating O
that O
it O
may O
be O
a O
substrate O
for O
an O
intestinal O
efflux O
transporter. O
However, O
in O
vivo O
studies O
in O
P-gp B-GENE-N
knockout O
mice O
versus O
wild-type O
mice O
showed O
no O
difference O
in O
the O
amount O
of O
dasatinib B-CHEMICAL
remaining O
unabsorbed O
in O
the O
gastrointestinal O
tract, O
suggesting O
that O
P-gp B-GENE-N
may O
not O
be O
responsible O
for O
the O
incomplete O
bioavailability. O
CONCLUSIONS: O

Dasatinib B-CHEMICAL
shows O
intermediate O
clearance O
in O
mouse, O
rat, O
dog, O
and O
monkey, O
and O
distributes O
extensively O
in O
those O
species. O
Oxidative O
metabolism O
appears O
to O
be O
the O
predominant O
clearance O
pathway. O
The O
incomplete O
oral O
bioavailability O
may O
be O
due O
to O
both O
incomplete O
absorption O
and O
high O
first-pass O
metabolism. O
However, O
the O
efflux B-GENE-N
transporter, I-GENE-N
P-glycoprotein B-GENE-N
does O
not O
appear O
to O
be O
limiting O
oral O
absorption. O
Genetic O
linkage O
of O
Fc B-GENE-Y
gamma I-GENE-Y
RIIa I-GENE-Y
and O
Fc B-GENE-Y
gamma I-GENE-Y
RIIIa I-GENE-Y
and O
implications O
for O
their O
use O
in O
predicting O
clinical O
responses O
to O
CD20-directed B-GENE-Y
monoclonal O
antibody O

therapy. O
BACKGROUND: O
Polymorphisms O
in O
FcgammaRIIa B-GENE-Y
and O
FcgammaRIIIa B-GENE-Y
receptors O
are O
associated O
with O
responses O
to O
the O
CD20-directed B-GENE-Y
immunoglobulin B-GENE-Y
G1 I-GENE-Y
(IgG1) B-GENE-Y
monoclonal O
antibody O
rituximab O
among O
patients O
with O
indolent O
lymphoma. O
At O
odds O
with O
the O
aforementioned O
clinical O
observations O
has O
been O
the O
finding O
that O
IgG1 B-GENE-Y
binding O
is O
impacted O
by O
polymorphisms O
in O
FcgammaRIIIa B-GENE-Y
but O
not O
FcgammaRIIa. B-GENE-Y
One O
possibility O
for O
this O

discrepancy O
might O
involve O
linkage O
of O
polymorphisms O
between O
FcgammaRIIa B-GENE-Y
and O
FcgammaRIIIa. B-GENE-Y
MATERIALS O
AND O
METHODS: O
As O
such, O
we O
performed O
allelespecific O
polymerase O
chain O
reaction O
and O
directed O
sequencing O
of O
the O
genomic O
DNA O
coding O
region O
of O
FcgammaRIIA B-GENE-Y
and O
FcgammaRIIIA B-GENE-Y
for O
52 O
healthy O
individuals. O
RESULTS: O
Two O
common O
polymorphisms O
were O
observed O
for O
FcgammaRIIA B-GENE-Y
(at O
positions O
27 O
and O
131) O
and O
FcgammaRIIIA B-GENE-Y

(at O
positions O
48 O
and O
158). O
Importantly, O
we O
observed O
linkage O
among O
polymorphisms O
within O
and O
between O
FcgammaRIIa B-GENE-Y
and O
FcgammaRIIIa, B-GENE-Y
including O
the O
expression O
of O
histidine O
at O
FcgammaRIIa-131 B-GENE-Y
and O
valine O
at O
FcgammaRIIIa, B-GENE-Y
both O
of O
which O
are O
associated O
with O
enhanced O
responses O
to O
rituximab. O
The O
results O
of O
these O
studies O
demonstrate O
that O
there O
is O
wide O
linkage O
within O
and O
between O
polymorphisms O
in O
FcgammaRIIa B-GENE-Y
and O
FcgammaRIIIa B-GENE-Y
and O
might O
provide O
an O
explanation O

for O
why O
polymorphisms O
at O
FcgammaRIIa B-GENE-Y
are O
associated O
with O
rituximab O
responses O
despite O
a O
lack O
of O
impact O
on O
IgG1 B-GENE-Y
binding. O
CONCLUSION: O
Knowledge O
of O
such O
linkages O
could O
facilitate O
the O
development O
of O
diagnostic O
tests O
aimed O
at O
identifying O
patients O
who O
might O
be O
more O
suitable O
for O
treatment O
with O
rituximab O
and O
possibly O
other O
therapeutic O
antibodies. O
Characterization O
of O
an O
alpha B-GENE-Y
1D-adrenoceptor I-GENE-Y
mediating O
the O
contractile O
response O
of O
rat O
aorta O
to O
noradrenaline. B-CHEMICAL
1. O
The O
affinities O
of O
a O
number O
of O
alpha B-GENE-N
1-adrenoceptor I-GENE-N

antagonists O
were O
determined O
by O
displacement O
of O
[3H]-prazosin B-CHEMICAL
binding O
from O
cloned O
human B-GENE-Y
alpha I-GENE-Y
1A-adrenoceptors I-GENE-Y
(previously O
designated O
cloned O
alpha O
1c O
subtype), O
alpha O
1B O
alpha O
1D O
and O
rat B-GENE-Y
alpha I-GENE-Y
1D-adrenoceptors, I-GENE-Y
stably O
expressed O
in O
rat-1 O
fibroblasts. O
Functional O
affinity O
estimates O
for O
these O
compounds O
were O
also O
determined O
from O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta. O
2. O
BMY B-CHEMICAL
7378 I-CHEMICAL
displayed O
high O
affinity O
for O
cloned O
human B-GENE-Y
alpha I-GENE-Y
1D-adrenoceptors I-GENE-Y
(pKi O
= O

8.2 O
+/- O
0.10) O
and O
was O
selective O
over O
alpha O
1A O
(pKi O
= O
6.2 O
+/- O
0.10) O
and O
alpha O
1B O
subtypes O
(6.7 O
+/- O
0.11). O
WB O
4101, O
benoxathian B-CHEMICAL
and O
phentolamine B-CHEMICAL
displayed O
high O
affinity O
for O
alpha B-GENE-N
1A I-GENE-N
and I-GENE-N
alpha I-GENE-N
1D I-GENE-N
adrenoceptors I-GENE-N
compared O
to O
the O
alpha O
1B O
subtype. O
Spiperone B-CHEMICAL
displayed O
high O
affinity O
and O
selectivity O
for O
alpha B-GENE-Y
1B I-GENE-Y
adrenoceptors I-GENE-Y
(pKi O
8.8 O
+/- O
0.16). O

5-Methyl-urapidil B-CHEMICAL
was O
selective O
for O
cloned O
alpha B-GENE-Y
1A I-GENE-Y
adrenoceptors. I-GENE-Y
3. O
Comparative O
binding O
affinities O
(pKi) O
for O
compounds O
at O
cloned O
human B-GENE-N
and I-GENE-N
rat1D I-GENE-N
adrenoceptors I-GENE-N
were O
almost O
identical O
(r O
= O
0.99, O
slope O
= O
1.08). O
4. O
Prazosin, B-CHEMICAL
doxazosin B-CHEMICAL
and O
5-methyl-urapidil B-CHEMICAL
were O
potent, O
competitive O
antagonists O
of O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta O
(pA2 O
values O
of O
9.8, O
8.8 O
and O
7.8 O

respectively). O
The O
selective O
alpha O
1D O
antagonist O
BMY B-CHEMICAL
7378 I-CHEMICAL
was O
also O
a O
potent O
antagonist O
on O
rat O
aorta O
(pKB O
= O
8.3 O
+/- O
0.1) O
but O
the O
interaction O
of O
this O
compound O
was O
not O
consistent O
with O
competitive O
antagonism O
at O
a O
single O
population O
of O
receptors. O
5. O
Functional O
affinities O
for O
compounds O
determined O
against O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta O
correlated O
well O
with O
binding O
affinities O
at O
cloned O
alpha B-GENE-Y
1D-adrenoceptors I-GENE-Y
(r O
= O
0.96), O
but O
not O
with O
alpha O
1A O
(r O
= O
0.61) O
or O
alpha O

1B O
(r O
= O
0.46) O
subtypes. O
6. O
Noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
aorta O
were O
sensitive O
to O
the O
alkylating O
effects O
of O
chlorethylclonidine B-CHEMICAL
(CEC). B-CHEMICAL
CEC O
(10 O
microM) O
caused O
a O
small O
rightward O
shift O
in O
the O
noradrenaline B-CHEMICAL
concentration-response O
curve. O
CEC B-CHEMICAL
at O
100 O
microM O
caused O
a O
further O
shift O
and O
suppression O
of O
the O
maximum O
response O
to O
noradrenaline.7. B-CHEMICAL
The O
results O
of O
this O
study O
suggest O
that O
noradrenaline B-CHEMICAL
predominantly, O
but O
not O
exclusively, O
mediates O
contraction O
of O
rat O
aorta O
through O
the O
activation O

of O
an O
alphalD-adrenoceptor. B-GENE-Y
Display O
of O
amino B-CHEMICAL
groups O
on O
substrate O
surfaces O
by O
simple O
dip-coating O
of O
methacrylate-based B-CHEMICAL
polymers O
and O
its O
application O
to O
DNA O
immobilization. O
The O
implementation O
of O
a O
reactive O
functional O
group O
onto O
a O
material O
surface O
is O
of O
great O
importance. O
Reactive O
functional O
groups O
(e.g., O
an O
amino B-CHEMICAL
group O
and O
a O
hydroxyl B-CHEMICAL
group) O
are O
usually O
hydrophilic, O
which O
makes O
it O
difficult O
to O
display O
them O
on O
a O
dry O
polymer O
surface. O
We O
here O
propose O
a O
novel O
method O
for O
displaying O
amino B-CHEMICAL
groups O
on O
the O
surfaces O
of O
polymeric O
substrates O
through O
dip-coating O
of O
a O

methacrylate-based B-CHEMICAL
copolymer. O
We O
synthesized O
copolymers O
composed O
of O
methyl B-CHEMICAL
methacrylate I-CHEMICAL
and O
2-aminoethyl B-CHEMICAL
methacrylate I-CHEMICAL
with O
different O
protecting O
groups O
or O
ion-complexes O
on O
their O
amino B-CHEMICAL
groups, O
then O
dip-coated O
the O
copolymers O
onto O
a O
poly(methyl B-CHEMICAL
methacrylate) I-CHEMICAL
(PMMA) B-CHEMICAL
substrate. O
Evaluation O
using O
a O
cleavable O
fluorescent O
compound, O
which O
was O
synthesized O
in O
the O
present O
study O
to O
quantify O
a O
small O
amount O
(pmol/cm(2)) O
of O
amino B-CHEMICAL
groups O
on O
a O
solid O
surface, O
revealed O
that O
the O
protection O
of O
amino B-CHEMICAL
groups O
affected O
their O
surface O

segregation O
in O
the O
copolymer O
coating. O
p-Toluenesulfonate B-CHEMICAL
ion-complex O
and O
tert-butoxycarbonyl B-CHEMICAL
(Boc) B-CHEMICAL
protection O
of O
amino B-CHEMICAL
groups O
were O
found O
to O
effectively O
display O
amino B-CHEMICAL
groups O
on O
the O
surface O
(more O
than O
70 O
pmol/cm(2)). O
The O
density O
of O
amino B-CHEMICAL
groups O
displayed O
on O
a O
surface O
can O
be O
easily O
controlled O
by O
mixing O
the O
copolymer O
and O
PMMA B-CHEMICAL
before O
dip-coating. O
Dip-coating O
of O
the O
copolymer O
with O
Boc B-CHEMICAL
protection O
on O
various O
polymeric O
substrates O
also O
successfully O
displayed O
amino B-CHEMICAL
groups O
on O
their O
surfaces. O
Finally, O
we O
demonstrated O
that O
the O
amino B-CHEMICAL
groups O
displayed O
can O
be O
utilized O

for O
the O
immobilization O
of O
a O
DNA O
oligonucleotide O
on O
a O
substrate O
surface. O
Neuroprotective O
role O
of O
ATP-sensitive B-GENE-N
potassium I-GENE-N
channels I-GENE-N
in O
cerebral O
ischemia. O
ATP-sensitive B-GENE-N
potassium I-GENE-N
(K(ATP)) I-GENE-N
channels I-GENE-N
are O
weak, O
inward O
rectifiers O
that O
couple O
metabolic O
status O
to O
cell O
membrane O
electrical O
activity, O
thus O
modulating O
many O
cellular O
functions. O
An O
increase O
in O
the O
ADP/ATP B-CHEMICAL
ratio O
opens O
K(ATP) B-GENE-N
channels, I-GENE-N
leading O
to O
membrane O
hyperpolarization. O
K(ATP) B-GENE-N
channels I-GENE-N
are O
ubiquitously O
expressed O
in O
neurons O
located O
in O
different O
regions O
of O
the O
brain, O
including O
the O

hippocampus O
and O
cortex. O
Brief O
hypoxia O
triggers O
membrane O
hyperpolarization O
in O
these O
central O
neurons. O
In O
vivo O
animal O
studies O
confirmed O
that O
knocking O
out O
the O
Kir6.2 B-GENE-N
subunit O
of O
the O
K(ATP) B-GENE-N
channels I-GENE-N
increases O
ischemic O
infarction, O
and O
overexpression O
of O
the O
Kir6.2 B-GENE-N
subunit O
reduces O
neuronal O
injury O
from O
ischemic O
insults. O
These O
findings O
provide O
the O
basis O
for O
a O
practical O
strategy O
whereby O
activation O
of O
endogenous O
K(ATP) B-GENE-N
channels I-GENE-N
reduces O
cellular O
damage O
resulting O
from O
cerebral O
ischemic O
stroke. O
K(ATP) B-GENE-N
channel I-GENE-N
modulators O
may O
prove O
to O
be O

clinically O
useful O
as O
part O
of O
a O
combination O
therapy O
for O
stroke O
management O
in O
the O
future. O
Comparison O
of O
the O
effect O
of O
rofecoxib B-CHEMICAL
(a O
cyclooxygenase B-GENE-Y
2 I-GENE-Y
inhibitor), O
ibuprofen, B-CHEMICAL
and O
placebo O
on O
the O
gastroduodenal O
mucosa O
of O
patients O
with O
osteoarthritis: O
a O
randomized, O
double-blind, O
placebo-controlled O
trial. O
The O
Rofecoxib B-CHEMICAL
Osteoarthritis O
Endoscopy O
Multinational O
Study O
Group. O
OBJECTIVE: O
This O
randomized, O
double-blind O
study O
tested O
the O
hypothesis O
that O

rofecoxib, B-CHEMICAL
a O
drug O
that O
specifically O
inhibits O
cyclooxygenase B-GENE-Y
2, I-GENE-Y
would O
cause O
fewer O
gastroduodenal O
ulcers O
than O
ibuprofen B-CHEMICAL
(in O
a O
multicenter O
trial), O
and O
its O
side O
effects O
would O
be O
equivalent O
to O
those O
of O
placebo O
(in O
a O
prespecified O
analysis O
combining O
the O
results O
with O
another O
trial O
of O
identical O
design). O
METHODS: O
Seven O
hundred O
seventy-five O
patients O
with O
osteoarthritis O
were O
randomized O
to O
receive O
rofecoxib B-CHEMICAL
at O
a O
dosage O
of O
25 O
mg O
or O
50 O
mg O
once O
daily, O
ibuprofen O

800 O
mg O
3 O
times O
daily, O
or O
placebo. O
Gastroduodenal O
ulceration O
was O
assessed O
by O
endoscopy O
at O
6, O
12, O
and O
(for O
active O
treatment) O
24 O
weeks. O
The O
primary O
and O
secondary O
end O
points O
were O
the O
incidence O
of O
gastroduodenal O
ulcers O
at O
12 O
and O
24 O
weeks, O
respectively. O
RESULTS: O
Ulcers O
were O
significantly O
less O
common O
(P O
< O
0.001) O
following O
treatment O
with O
rofecoxib B-CHEMICAL
(25 O
mg O
or O
50 O
mg) O
than O
with O
ibuprofen B-CHEMICAL
after O
12 O
weeks O
(5.3% O
and O
8.8% O
versus O

29.2%, O
respectively) O
or O
24 O
weeks O
(9.9% O
and O
12.4% O
versus O
46.8%, O
respectively). O
In O
the O
combined O
analysis, O
the O
12-week O
ulcer O
incidence O
with O
25 O
mg O
rofecoxib B-CHEMICAL
(4.7%) O
and O
with O
placebo O
(7.3%) O
satisfied O
prespecified O
criteria O
for O
equivalence. O
CONCLUSION: O
At O
2-4 O
times O
the O
therapeutically O
effective O
dose, O
rofecoxib B-CHEMICAL
caused O
fewer O
endoscopically O
detected O
ulcers O
than O
did O
ibuprofen. B-CHEMICAL
Rofecoxib O
at O
a O
dose O
of O
25 O

mg O
(the O
highest O
dose O
recommended O
for O
osteoarthritis) O
satisfied O
prespecified O
criteria O
for O
equivalence O
to O
placebo. O
Profiling O
976 O
ToxCast O
chemicals O
across O
331 O
enzymatic O
and O
receptor O
signaling O
assays. O
Understanding O
potential O
health O
risks O
is O
a O
significant O
challenge O
due O
to O
large O
numbers O
of O
diverse O
chemicals O
with O
poorly O
characterized O
exposures O
and O
mechanisms O
of O
toxicities. O
The O
present O
study O
analyzes O
976 O
chemicals O
(including O
failed O
pharmaceuticals, O
alternative O
plasticizers, O
food O
additives, O
and O
pesticides) O
in O
Phase O
I O
and O
II O
of O
the O
U.S. O
EPA's O
ToxCast™ O
project O
across O
331 O
cell-free O

enzymatic O
and O
ligand-binding O
high-throughput O
screening O
(HTS) O
assays. O
Half-maximal O
activity O
concentrations O
(AC50) O
were O
identified O
for O
729 O
chemicals O
in O
256 O
assays O
(7,135 O
chemical-assay O
pairs). O
Some O
of O
the O
most O
commonly O
affected O
assays O
were O
CYPs B-GENE-N
(CYP2C9, B-GENE-Y
CYP2C19), B-GENE-Y
transporters O
(mitochondrial O
TSPO, O
norepinephrine, B-CHEMICAL
dopaminergic), O
and O
GPCRs B-GENE-N
(aminergic). O
Heavy O
metals, O
surfactants, O
and O
dithiocarbamate B-CHEMICAL
fungicides O

showed O
promiscuous, O
but O
distinctly O
different O
patterns O
of O
activity O
whereas O
many O
of O
the O
pharma O
compounds O
showed O
promiscuous O
activity O
across O
GPCRs. B-GENE-N
Literature O
analysis O
confirmed O
>50% O
of O
the O
activities O
for O
the O
most O
potent O
chemical-assay O
pairs O
(56), O
but O
also O
revealed O
10 O
missed O
interactions. O
Twenty-two O
chemicals O
with O
known O
estrogenic O
activity O
were O
correctly O
identified O
for O
the O
majority O
(77%), O
missing O
only O
the O
weaker O
interactions. O
In O
many O
cases, O
novel O
findings O
for O
previously O
unreported O
chemical-target O
combinations O
clustered O
with O
known O
chemical-target O
interactions. O
Results O
from O
this O
large O
inventory O
of O
chemical-biological O
interactions O
can O
inform O

read-across O
methods O
as O
well O
as O
to O
link O
potential O
targets O
to O
molecular O
initiating O
events O
in O
adverse O
outcome O
pathways O
for O
diverse O
toxicities. O
This O
abstract O
does O
not O
necessarily O
reflect O
U.S. O
EPA O
policy. O
A O
combination O
of O
[+] B-CHEMICAL
and I-CHEMICAL
[-]-Huperzine I-CHEMICAL
A I-CHEMICAL
improves O
protection O
against O
soman O
toxicity O
compared O
to O
[+]-Huperzine B-CHEMICAL
A I-CHEMICAL
in O
guinea O
pigs. O
The O
neuropathologic O
mechanisms O
after O
exposure O
to O
lethal O
doses O
of O
nerve O
agent O
are O
complex O
and O
involve O
multiple O
biochemical O
pathways. O
Effective O
treatment O
requires O
drugs O
that O
can O
simultaneously O
protect O
by O
reversible O
binding O
to O
the O
acetylcholinesterase B-GENE-Y

(AChE) B-GENE-Y
and O
blocking O
cascades O
of O
seizure O
related O
brain O
damage, O
inflammation, O
neuronal O
degeneration O
as O
well O
as O
promoting O
induction O
of O
neuroregeneration. O
[-]-Huperzine B-CHEMICAL
A I-CHEMICAL
([-]-Hup B-CHEMICAL
A), I-CHEMICAL
is O
a O
naturally O
occurring O
potent O
reversible O
AChE B-GENE-Y
inhibitor O
that O
penetrates O
the O
blood-brain O
barrier. O
It O
also O
has O
several O
neuroprotective O
effects O
including O
modification O
of O
beta-amyloid B-GENE-Y
peptide, I-GENE-Y
reduction O
of O
oxidative O
stress, O
anti-inflammatory, O
anti-apoptotic O
and O
induction O
and O
regulation O
of O
nerve B-GENE-Y
growth I-GENE-Y
factor. I-GENE-Y
Toxicities O

at O
higher O
doses O
restrict O
the O
neuroporotective O
ability O
of O
[-]-Hup B-CHEMICAL
A I-CHEMICAL
for O
treatment. O
The O
synthetic O
stereoisomer, O
[+]-Hup B-CHEMICAL
A, I-CHEMICAL
is O
less O
toxic O
due O
to O
poor O
AChE B-GENE-Y
inhibition O
and O
is O
suitable O
for O
both O
pre-/post-exposure O
treatments O
of O
nerve O
agent O
toxicity. O
[+]-Hup B-CHEMICAL
A I-CHEMICAL
block O
the O
N-methyl-d-aspartate B-CHEMICAL
(NMDA)-induced B-CHEMICAL
seizure O
in O
rats, O
reduce O
excitatory O
amino B-CHEMICAL
acid I-CHEMICAL
induced O
neurotoxicity O
and O
also O
prevent O
soman O
induced O
toxicity O
with O
minimum O
performance O
decrement. O
Unique O
combinations O
of O
two O

stereo-isomers O
of O
Hup B-CHEMICAL
A I-CHEMICAL
may O
provide O
an O
excellent O
pre/post-treatment O
drug O
for O
the O
nerve O
agent O
induced O
seizure/status O
epilepticus. O
We O
investigated O
a O
combination O
of O
[+]-Hup B-CHEMICAL
A I-CHEMICAL
with O
a O
small O
dose O
of O
[-]-Hup B-CHEMICAL
A I-CHEMICAL
([+] B-CHEMICAL
and I-CHEMICAL
[-]-Hup I-CHEMICAL
A) I-CHEMICAL
against O
soman B-CHEMICAL
toxicity. O
Our O
data O
showed O
that O
pretreatment O
with O
a O
combination O
[+] B-CHEMICAL
and I-CHEMICAL
[-]-Hup I-CHEMICAL
A I-CHEMICAL
significantly O
increased O
the O
survival O
rate O
and O
reduced O
behavioral O
abnormalities O
after O
exposure O
to O
1.2×LD50 O
soman O
compared O
to O
[+]-Hup B-CHEMICAL
A I-CHEMICAL

in O
guinea O
pigs. O
In O
addition, O
[+] B-CHEMICAL
and I-CHEMICAL
[-]-Hup I-CHEMICAL
A I-CHEMICAL
pretreatment O
inhibited O
the O
development O
of O
high O
power O
of O
EEG O
better O
than O
[+]-Hup B-CHEMICAL
A I-CHEMICAL
pretreatment O
alone. O
These O
data O
suggest O
that O
a O
combination O
of O
[+] B-CHEMICAL
and I-CHEMICAL
[-]-Hup I-CHEMICAL
A I-CHEMICAL
offers O
better O
protection O
than O
[+]-Hup B-CHEMICAL
A I-CHEMICAL
and O
serves O
as O
a O
potent O
medical O
countermeasure O
against O
lethal O
dose O
nerve O
agent O
toxicity O
in O
guinea O
pigs. O
Vinblastine-induced B-CHEMICAL
apoptosis O
of O
melanoma O
cells O
is O
mediated O
by O
Ras B-GENE-Y
homologous I-GENE-Y
A I-GENE-Y
protein I-GENE-Y

(Rho B-GENE-Y
A) I-GENE-Y
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms. O
Despite O
the O
availability O
of O
melanoma O
treatment O
at O
the O
primary O
site, O
the O
recurrence O
of O
local O
melanoma O
can O
metastasize O
to O
any O
distant O
organ. O
Currently, O
the O
available O
therapies O
for O
the O
treatment O
of O
metastatic O
melanoma O
are O
of O
limited O
benefit. O
Thus, O
the O
functional O
analysis O
of O
conventional O
therapies O
may O
help O
to O
improve O
their O
efficiency O
in O
the O
treatment O
of O
metastatic O
melanoma. O
In O
the O
present O
study, O
the O
exposure O
of O
melanoma O
cells O
to O
vinblastine B-CHEMICAL
was O
found O
to O
trigger O
apoptosis O
as O
evidenced O
by O
the O
loss O
of O
mitochondrial O
membrane O

potential, O
the O
release O
of O
both O
cytochrome B-GENE-Y
c I-GENE-Y
and O
apoptosis B-GENE-Y
inducing I-GENE-Y
factor, I-GENE-Y
activation O
of O
caspase-9 B-GENE-N
and I-GENE-N
3, I-GENE-N
and O
cleavage O
of O
Poly B-GENE-N
(ADP-ribose)-Polymerase. I-GENE-N
Also, O
vinblastine B-CHEMICAL
enhances O
the O
phosphorylation O
of O
Ras B-GENE-Y
homologous I-GENE-Y
protein I-GENE-Y
A, I-GENE-Y
the O
accumulation O
of O
reactive O
oxygen B-CHEMICAL
species, O
the O
release O
of O
intracellular O
Ca(2+), B-CHEMICAL
as O
well O
as O
the O
activation O
of O
apoptosis B-GENE-Y
signal-regulating I-GENE-Y
kinase I-GENE-Y
1, I-GENE-Y
c-jun-N-terminal B-GENE-N
kinase, I-GENE-N
p38, B-GENE-N
inhibitor B-GENE-Y
of I-GENE-Y
kappaBα I-GENE-Y

(IκBα) B-GENE-Y
kinase, B-GENE-N
and O
inositol B-GENE-Y
requiring I-GENE-Y
enzyme I-GENE-Y
1α. I-GENE-Y
In O
addition, O
vinblastine B-CHEMICAL
induces O
the O
DNA-binding O
activities O
of O
the O
transcription O
factor O
NF-κB, B-GENE-N
HSF1, B-GENE-Y
AP-1, B-GENE-Y
and O
ATF-2, B-GENE-Y
together O
with O
the O
expression O
of O
HSP70 B-GENE-N
and O
Bax B-GENE-Y
proteins. O
Moreover, O
inhibitory O
experiments O
addressed O
a O
central O
role O
for O
Rho B-GENE-Y
A I-GENE-Y
in O
the O
regulation O
of O
vinblastine-induced B-CHEMICAL
apoptosis O
of O
melanoma O
cells O
via O
mitochondrial O
and O
non-mitochondrial-dependent O
mechanisms. O
In O
conclusion, O
the O
present O
study O
addresses O
for O
the O
first O
time O
a O
central O
role O
for O

Rho B-GENE-Y
A I-GENE-Y
in O
the O
modulation O
of O
vinblastine-induced B-CHEMICAL
apoptosis O
of O
melanoma O
cells O
and O
thereby O
provides O
an O
insight O
into O
the O
molecular O
action O
of O
vinblastine B-CHEMICAL
in O
melanoma O
treatment. O
Cloning O
and O
characterization O
of O
a O
novel O
human B-GENE-N
phosphodiesterase I-GENE-N
that O
hydrolyzes O
both O
cAMP B-CHEMICAL
and O
cGMP B-CHEMICAL
(PDE10A). B-GENE-Y
cDNA O
encoding O
a O
novel O
phosphodiesterase B-GENE-N
(PDE) B-GENE-N
was O
isolated O
from O
a O
human O
fetal O
lung O
cDNA O
library O
and O
designated O
PDE10A. B-GENE-Y
The O
deduced O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
contains O
779 O
amino B-CHEMICAL
acids, I-CHEMICAL
including O

a O
putative O
cGMP B-GENE-N
binding I-GENE-N
sequence I-GENE-N
in O
the O
amino-terminal B-CHEMICAL
portion O
of O
the O
molecule O
and O
a O
catalytic O
domain O
that O
is O
16-47% O
identical O
in O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
to O
those O
of O
other O
PDE B-GENE-N
families. O
Recombinant O
PDE10A B-GENE-Y
transfected O
and O
expressed O
in O
COS-7 O
cells O
hydrolyzed O
cAMP B-CHEMICAL
and O
cGMP B-CHEMICAL
with O
Km O
values O
of O
0.26 O
and O
7.2 O
microM, O
respectively, O
and O
Vmax O
with O
cGMP B-CHEMICAL
was O
almost O
twice O
that O
with O
cAMP. B-CHEMICAL
Of O
the O
PDE B-GENE-N
inhibitors O
tested, O
dipyridamole B-CHEMICAL
was O
most O
effective, O
with O
IC50 O
values O
of O

1.2 O
and O
0.45 O
microM O
for O
inhibition O
of O
cAMP B-CHEMICAL
and O
cGMP B-CHEMICAL
hydrolysis, O
respectively. O
cGMP B-CHEMICAL
inhibited O
hydrolysis O
of O
cAMP, B-CHEMICAL
and O
cAMP B-CHEMICAL
inhibited O
cGMP B-CHEMICAL
hydrolysis O
with O
IC50 O
values O
of O
14 O
and O
0.39 O
microM, O
respectively. O
Thus, O
PDE10A B-GENE-Y
exhibited O
properties O
of O
a O
cAMP B-GENE-N
PDE I-GENE-N
and O
a O
cAMP-inhibited B-GENE-N
cGMP I-GENE-N
PDE. I-GENE-N
PDE10A B-GENE-Y
transcripts O
were O
particularly O
abundant O
in O
the O
putamen O
and O
caudate O
nucleus O
regions O
of O
brain O
and O
in O
thyroid O
and O

testis, O
and O
in O
much O
lower O
amounts O
in O
other O
tissues. O
The O
PDE10A B-GENE-Y
gene O
was O
located O
on O
chromosome O
6q26 O
by O
fluorescent O
in O
situ O
hybridization O
analysis. O
PDE10A B-GENE-Y
represents O
a O
new O
member O
of O
the O
PDE B-GENE-N
superfamily, O
exhibiting O
unique O
kinetic O
properties O
and O
inhibitor O
sensitivity. O
Effects O
of O
5-aza-2'-deoxycytidine B-CHEMICAL
on O
fetal B-GENE-N
hemoglobin I-GENE-N
levels, O
red O
cell O
adhesion, O
and O
hematopoietic O
differentiation O
in O
patients O
with O
sickle O
cell O
disease. O
Fetal B-GENE-N
hemoglobin I-GENE-N
(HbF) B-GENE-N
decreases O
polymerization O
of O
sickle B-GENE-N
hemoglobin I-GENE-N

(HbS) B-GENE-N
and O
improves O
outcomes O
in O
sickle O
cell O
disease O
(SSD). O
Therefore, O
a O
therapeutic O
goal O
in O
SSD O
is O
pharmacologic O
reactivation O
of O
HbF. B-GENE-N
Silencing O
of O
the O
gamma-globin B-GENE-N
(HbF) B-GENE-N
gene O
is O
associated O
with O
DNA O
methylation. O
The O
cytosine B-CHEMICAL
analog O
5-aza-2'-deoxycytidine B-CHEMICAL
(decitabine) B-CHEMICAL
hypomethylates O
DNA O
by O
inhibiting O
DNA B-GENE-N
methyltransferase. I-GENE-N
We O
examined O
if O
subcutaneous O
decitabine B-CHEMICAL
could O
increase O
HbF B-GENE-N
levels O

and O
improve O
SSD O
pathophysiology O
without O
cytotoxicity. O
Eight O
symptomatic O
SSD O
patients O
resistant O
or O
intolerant O
of O
standard O
treatment O
with O
hydroxyurea B-CHEMICAL
received O
decitabine B-CHEMICAL
0.2 O
mg/kg O
subcutaneously O
1 O
to O
3 O
times O
per O
week O
in O
2 O
cycles O
of O
6-week O
duration. O
Treatment O
decreased O
neutrophils O
and O
increased O
mean O
HbF B-GENE-N
(6.5% O
to O
20.4%, O
P O
<.0001) O
and O
mean O
total O
hemoglobin B-GENE-N
(76 O
to O
96 O
g/L O
[7.6 O
to O
9.6 O

g/dL], O
P O
<.001). O
Features O
of O
vaso-occlusive O
crisis O
pathophysiology O
such O
as O
red O
cell O
adhesion, O
endothelial O
damage, O
and O
coagulation O
pathway O
activity O
significantly O
improved. O
gamma-Globin B-GENE-N
gene I-GENE-N
promoter I-GENE-N
methylation O
decreased, O
and O
platelets O
and O
the O
proportion O
of O
megakaryocytes O
and O
erythroid O
cells O
in O
the O
marrow O
increased O
without O
a O
decrease O
in O
marrow O
cellularity, O
consistent O
with O
a O
DNA O
hypomethylating, O
noncytotoxic O
mechanism O
of O
action. O
Weekly O
subcutaneous O
decitabine B-CHEMICAL
produces O

cumulative O
increases O
in O
HbF B-GENE-N
and O
total O
hemoglobin B-GENE-N
through O
a O
noncytotoxic O
mechanism O
of O
action. O
Chronic O
dosing O
and O
sustained O
increases O
in O
hemoglobin B-GENE-N
F I-GENE-N
and O
total O
hemoglobin B-GENE-N
levels O
may O
be O
possible. O
Further O
studies O
in O
SSD O
and O
thalassemia O
are O
indicated. O
Quinone B-CHEMICAL
compounds O
regulate O
the O
level O
of O
ROS O
production O
by O
the O
NADPH B-GENE-N
oxidase I-GENE-N
Nox4. B-GENE-Y
NADPH B-GENE-N
oxidase I-GENE-N
Nox4 B-GENE-Y
is O
expressed O
in O
a O
wide O
range O
of O
tissues O
and O
plays O
a O
role O
in O
cellular O
signaling O
by O
providing O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
as O
intracellular O

messengers. O
Nox4 B-GENE-Y
oxidase B-GENE-N
activity O
is O
thought O
to O
be O
constitutive O
and O
regulated O
at O
the O
transcriptional O
level; O
however, O
we O
challenge O
this O
point O
of O
view O
and O
suggest O
that O
specific O
quinone B-CHEMICAL
derivatives O
could O
modulate O
this O
activity. O
In O
fact, O
we O
demonstrated O
a O
significant O
stimulation O
of O
Nox4 B-GENE-Y
activity O
by O
4 O
quinone B-CHEMICAL
derivatives O
(AA-861, B-CHEMICAL
tBuBHQ, B-CHEMICAL
tBuBQ, B-CHEMICAL
and O
duroquinone) B-CHEMICAL
observed O
in O
3 O
different O
cellular O
models, O
HEK293E, O
T-REx™, O
and O
chondrocyte O
cell O
lines. O
Our O
results O
indicate O
that O
the O

effect O
is O
specific O
toward O
Nox4 B-GENE-Y
versus O
Nox2. B-GENE-Y
Furthermore, O
we O
showed O
that O
NAD(P)H:quinone B-GENE-Y
oxidoreductase I-GENE-Y
(NQO1) B-GENE-Y
may O
participate O
in O
this O
stimulation. O
Interestingly, O
Nox4 B-GENE-Y
activity O
is O
also O
stimulated O
by O
reducing O
agents O
that O
possibly O
act O
by O
reducing O
the O
disulfide B-CHEMICAL
bridge O
(Cys226, B-CHEMICAL
Cys270) B-CHEMICAL
located O
in O
the O
extracellular B-GENE-N
E-loop I-GENE-N
of O
Nox4. B-GENE-Y
Such O
model O
of O
Nox4 B-GENE-Y
activity O
regulation O
could O
provide O
new O
insight O
into O
the O
understanding O
of O
the O
molecular O
mechanism O
of O
the O
electron O
transfer O
through O
the O
enzyme, O
i.e., O

its O
potential O
redox O
regulation, O
and O
could O
also O
define O
new O
therapeutic O
targets O
in O
diseases O
in O
which O
quinones B-CHEMICAL
and O
Nox4 B-GENE-Y
are O
implicated. O
Does O
aspirin B-CHEMICAL
acetylate O
multiple O
cellular O
proteins? O
(Review). O
Aspirin B-CHEMICAL
is O
a O
salicylate B-CHEMICAL
drug O
that O
is O
extensively O
used O
for O
its O
anti-inflammatory, O
antipyretic, O
analgesic O
and O
anti-thrombotic O
effects. O
More O
recently, O
it O
has O
been O
shown O
to O
decrease O
the O
incidence O
of O
cancers O
of O
epithelial O
origin. O
In O
most O
cases, O
aspirin B-CHEMICAL
is O
relatively O
safe. O
However, O
it O
does O
cause O
a O
host O
of O
adverse O
effects O
and O
toxicities, O
including O

gastrointestinal O
bleeding, O
ulcerations, O
nephrotoxicity O
and O
hypersensitivity O
reactions. O
Although O
the O
inhibition O
of O
cyclooxygenases B-GENE-N
by O
aspirin, B-CHEMICAL
which O
leads O
to O
its O
anti-inflammatory/analgesic O
properties, O
has O
been O
well O
studied, O
the O
mechanisms O
involved O
in O
its O
chemopreventive O
effects O
as O
well O
as O
some O
of O
its O
adverse O
effects O
are O
as O
yet O
ill-defined. O
Studies O
over O
the O
past O
decades O
suggest O
that, O
besides O
cyclooxygenases, B-GENE-N
aspirin B-CHEMICAL
acetylates O
other O
cellular O
proteins. O
These O
studies O
used O
radiolabeled O
3H B-CHEMICAL

or O
14C B-CHEMICAL
aspirin, B-CHEMICAL
the O
only O
approach O
used O
to O
date O
for O
the O
detection O
of O
proteins O
acetylated O
by O
aspirin. B-CHEMICAL
In O
a O
recent O
study O
using O
protein-specific O
anti-acetyl O
lysine B-CHEMICAL
antibodies O
and O
immunological O
methods, O
we O
demonstrated O
the O
ability O
of O
aspirin B-CHEMICAL
to O
acetylate O
the O
tumor B-GENE-Y
suppressor I-GENE-Y
protein I-GENE-Y
p53. I-GENE-Y
In O
this O
review, O
we O
present O
current O
research O
from O
the O
literature O
on O
the O
aspirin-induced B-CHEMICAL
acetylation O
of O
proteins. O
We O
also O
describe O
an O
immunological O
approach O
to O
detecting O
acetylated O
proteins O
in O
aspirin-treated B-CHEMICAL
cells, O
and O
demonstrate O
that O
multiple O
proteins O
are O
acetylated. O

Since O
post-translational O
modification O
of O
proteins, O
such O
as O
acetylation, O
may O
lead O
to O
the O
alteration O
of O
their O
function, O
it O
is O
possible O
that O
some O
of O
the O
hitherto O
unexplained O
beneficial O
or O
adverse O
effects O
of O
aspirin B-CHEMICAL
could O
occur O
as O
a O
result O
of O
these O
modifications. O
The O
identification O
of O
these O
novel O
acetylation O
targets O
of O
aspirin B-CHEMICAL
represents O
a O
new O
area O
for O
investigation. O
Topoisomerase B-GENE-Y
IIβ I-GENE-Y
deficiency O
enhances O
camptothecin-induced B-CHEMICAL
apoptosis. O
Camptothecin B-CHEMICAL
(CPT), B-CHEMICAL
a O
topoisomerase B-GENE-Y
(Top) I-GENE-Y
I-targeting I-GENE-Y
drug O
that O
stabilizes O
Top1-DNA B-GENE-Y
covalent O

adducts, O
can O
induce O
S-phase-specific O
cytotoxicity O
due O
to O
the O
arrest O
of O
progressing O
replication O
forks. O
However, O
CPT-induced B-CHEMICAL
non-S-phase O
cytotoxicity O
is O
less O
well O
characterized. O
In O
this O
study, O
we O
have O
identified O
topoisomerase B-GENE-Y
IIβ I-GENE-Y
(Top2β) B-GENE-Y
as O
a O
specific O
determinant O
for O
CPT B-CHEMICAL
sensitivity, O
but O
not O
for O
many O
other O
cytotoxic O
agents, O
in O
non-S-phase O
cells. O
First, O
quiescent O
mouse O
embryonic O
fibroblasts O
(MEFs) O
lacking O
Top2β B-GENE-Y
were O
shown O
to O
be O

hypersensitive O
to O
CPT B-CHEMICAL
with O
prominent O
induction O
of O
apoptosis. O
Second, O
ICRF-187, B-CHEMICAL
a O
Top2 B-GENE-Y
catalytic O
inhibitor O
known O
to O
deplete O
Top2β, B-GENE-Y
specifically O
sensitized O
MEFs O
to O
CPT. B-CHEMICAL
To O
explore O
the O
molecular O
basis O
for O
CPT B-CHEMICAL
hypersensitivity O
in O
Top2β-deficient B-GENE-Y
cells, O
we O
found O
that O
upon O
CPT B-CHEMICAL
exposure, O
the O
RNA B-GENE-N
polymerase I-GENE-N
II I-GENE-N
large I-GENE-N
subunit I-GENE-N
(RNAP B-GENE-N
LS) I-GENE-N
became O
progressively O
depleted, O
followed O
by O
recovery O
to O
nearly O
the O
original O
level O
in O
wild-type O
MEFs, O
whereas O
RNAP B-GENE-N
LS I-GENE-N
remained O
depleted O
without O
recovery O
in O

Top2β-deficient B-GENE-Y
cells. O
Concomitant O
with O
the O
reduction O
of O
the O
RNAP B-GENE-N
LS I-GENE-N
level, O
the O
p53 B-GENE-Y
protein O
level O
was O
greatly O
induced. O
Interestingly, O
RNAP B-GENE-N
LS I-GENE-N
depletion O
has O
been O
well O
documented O
to O
lead O
to O
p53-dependent B-GENE-Y
apoptosis. O
Altogether, O
our O
findings O
support O
a O
model O
in O
which O
Top2β B-GENE-Y
deficiency O
promotes O
CPT-induced B-CHEMICAL
apoptosis O
in O
quiescent O
non-S-phase O
cells, O
possibly O
due O
to O
RNAP B-GENE-N
LS I-GENE-N
depletion O
and O
p53 B-GENE-Y
accumulation. O
Effects O
of O
felodipine B-CHEMICAL
(a O
dihydropyridine B-CHEMICAL
calcium B-GENE-N
channel I-GENE-N
blocker) O

and O
analogues O
on O
calmodulin-dependent B-GENE-N
enzymes. I-GENE-N
We O
have O
examined O
the O
effects O
on O
the O
activities O
of O
three O
calmodulin-dependent B-GENE-N
enzymes I-GENE-N
(cAMP B-GENE-N
phosphodiesterase, I-GENE-N
caldesmon B-GENE-N
kinase I-GENE-N
and O
myosin B-GENE-Y
light I-GENE-Y
chain I-GENE-Y
kinase) I-GENE-Y
of O
the O
dihydropyridine B-CHEMICAL
Ca2+ B-GENE-N
channel I-GENE-N
blocker O
felodipine B-CHEMICAL
and O
three O
analogues O
(p-chloro, B-CHEMICAL
oxidized O
and O
t-butyl) B-CHEMICAL
exhibiting O
different O
pharmacological O
potencies. O
The O
cAMP B-GENE-N
phosphodiesterase I-GENE-N
was O
inhibited O
completely O
by O
felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL

analogue O
with O
IC50 O
values O
of O
3.7 O
and O
1.5 O
microM O
respectively. O
The O
oxidized O
and O
t-butyl B-CHEMICAL
analogues O
were O
relatively O
ineffective O
in O
inhibiting O
cAMP B-GENE-N
phosphodiesterase. I-GENE-N
Felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
inhibited O
the O
basal O
(Ca2+/calmodulin-independent) B-CHEMICAL
activity O
of O
cAMP B-GENE-N
phosphodiesterase I-GENE-N
as O
well O
as O
the O
calmodulin-stimulated B-GENE-Y
activity. O
Calmodulin B-GENE-Y
was O
relatively O
ineffective O
in O
preventing O
inhibition O
of O
cAMP B-GENE-N
phosphodiesterase I-GENE-N
by O
felodipine B-CHEMICAL
and O
the O

p-chloro B-CHEMICAL
analogue. O
These O
observations O
suggest O
that O
felodipine B-CHEMICAL
may O
act O
directly O
on O
the O
phosphodiesterase B-GENE-N
as O
well O
as O
through O
calmodulin. B-GENE-Y
Felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
inhibited O
Ca2+/calmodulin-dependent B-CHEMICAL
caldesmon B-GENE-N
kinase I-GENE-N
with O
similar O
potencies O
(IC50 O
= O
17.4 O
microM), O
whereas O
the O
oxidized O
and O
t-butyl B-CHEMICAL
analogues O
caused O
no O
inhibition. O
Similarly, O
felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
inhibited O
myosin B-GENE-Y
light I-GENE-Y
chain I-GENE-Y
kinase I-GENE-Y
activity O
whether O
the O
isolated O
20 O

kD O
light O
chain O
(IC50 O
= O
12.6 O
microM) O
or O
intact O
myosin B-GENE-N
(IC50 O
= O
11.0 O
microM) O
was O
used O
as O
substrate. O
Inhibition O
in O
each O
case O
was O
prevented O
by O
excess O
calmodulin. B-GENE-Y
The O
oxidized O
and O
t-butyl B-CHEMICAL
derivatives O
caused O
little O
or O
no O
inhibition. O
Finally, O
the O
effects O
of O
felodipine B-CHEMICAL
and O
the O
three O
analogues O
on O
two O
processes O
which O
are O
dependent O
on O
myosin B-GENE-N
phosphorylation O
were O
examined, O
namely O
the O
actin-activated B-GENE-N
Mg2+-ATPase B-GENE-N
activity O
of O
myosin B-GENE-N
and O
the O
assembly O
of O
myosin B-GENE-N

filaments. O
Felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
inhibited O
the O
actin-activated B-GENE-N
Mg2+-ATPase B-GENE-N
activity O
of O
smooth O
muscle O
myosin B-GENE-N
(IC50 O
= O
25.1 O
microM). O
The O
oxidized O
and O
t-butyl B-CHEMICAL
analogues O
exhibited O
no O
inhibition. O
Similarly, O
felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
blocked O
myosin B-GENE-N
filament O
assembly O
induced O
by O
low O
concentrations O
of O
calmodulin, B-GENE-Y
whereas O
the O
oxidized O
and O
t-butyl B-CHEMICAL
analogues O
did O
not. O
Again, O
inhibition O
of O
the O
actin-activated B-GENE-N
myosin B-GENE-N

Mg2+-ATPase B-GENE-N
and O
myosin B-GENE-N
filament O
assembly O
by O
felodipine B-CHEMICAL
and O
the O
p-chloro B-CHEMICAL
analogue O
could O
be O
reversed O
by O
raising O
the O
calmodulin B-GENE-Y
concentration. O
These O
observations O
suggest O
that O
some O
of O
the O
pharmacological O
actions O
of O
felodipine B-CHEMICAL
on O
smooth O
muscle O
may O
involve O
inhibition O
of O
calmodulin-dependent B-GENE-N
enzymes I-GENE-N
which O
are O
functionally O
involved O
in O
the O
regulation O
of O
smooth O
muscle O
contraction. O
Aldosterone-induced B-CHEMICAL
ENaC B-GENE-N
and O
basal O
Na(+)/K(+)-ATPase B-GENE-N
trafficking O
via O
protein B-GENE-Y
kinase I-GENE-Y
D1-phosphatidylinositol I-GENE-Y

4-kinaseIIIβ I-GENE-Y
trans O
Golgi O
signalling O
in O
M1 O
cortical O
collecting O
duct O
cells. O
Aldosterone B-CHEMICAL
regulates O
Na(+) B-CHEMICAL
transport O
in O
the O
distal O
nephron O
through O
multiple O
mechanisms O
that O
include O
the O
transcriptional O
control O
of O
epithelial O
sodium B-GENE-N
channel I-GENE-N
(ENaC) B-GENE-N
and O
Na(+)/K(+)-ATPase B-GENE-N
subunits. O
Aldosterone B-CHEMICAL
also O
induces O
the O
rapid O
phosphorylation O
of O
Protein B-GENE-Y
Kinase I-GENE-Y
D1 I-GENE-Y
(PKD1). B-GENE-Y
PKD B-GENE-Y
isoforms O
regulate O
protein O
trafficking, O
by O
the O
control O
of O
vesicle O
fission O
from O
the O

trans O
Golgi O
network O
(TGN) O
through O
activation O
of O
phosphatidylinositol B-GENE-Y
4-kinaseIIIβ I-GENE-Y
(PI4KIIIβ). B-GENE-Y
We O
report O
rapid O
ENaCγ B-GENE-Y
translocation O
to O
the O
plasma O
membrane O
after O
30min O
aldosterone O
treatment O
in O
polarized O
M1 O
cortical O
collecting O
duct O
cells, O
which O
was O
significantly O
impaired O
in O
PKD1 B-GENE-Y
shRNA-mediated O
knockdown O
cells. O
In O
PKD1-deficient B-GENE-Y
cells, O
the O
ouabain-sensitive B-CHEMICAL
current O
was O
significantly O
reduced O
and O
Na(+)/K(+)-ATPase B-GENE-N
α I-GENE-N
and I-GENE-N
β I-GENE-N

subunits O
showed O
aberrant O
localization. O
PKD1 B-GENE-Y
and O
PI4KIIIβ B-GENE-Y
localize O
to O
the O
TGN, O
and O
aldosterone B-CHEMICAL
induced O
an O
interaction O
between O
PKD1 B-GENE-Y
and O
PI4KIIIβ B-GENE-Y
following O
aldosterone B-CHEMICAL
treatment. O
This O
study O
reveals O
a O
novel O
mechanism O
for O
rapid O
regulation O
of O
ENaC B-GENE-N
and O
the O
Na(+)/K(+)-ATPase, B-GENE-N
via O
directed O
trafficking O
through O
PKD1-PI4KIIIβ B-GENE-Y
signalling O
at O
the O
level O
of O
the O
TGN. O
The O
role O
of O
5-HT(1A) B-GENE-Y
and O

5-HT(1B/1D) B-GENE-N
receptors I-GENE-N
on O
the O
modulation O
of O
acute O
fluoxetine-induced B-CHEMICAL
changes O
in O
extracellular O
5-HT: B-CHEMICAL
the O
mechanism O
of O
action O
of O
(+/-)pindolol. B-CHEMICAL
Some O
clinical O
evidence O
has O
suggested O
that O
(+/-)pindolol B-CHEMICAL
can O
be O
effective O
at O
producing O
a O
shortened O
time O
to O
onset O
of O
antidepressant O
activity O
when O
co-administered O
with O
a O
serotonin B-CHEMICAL
specific O
reuptake O
inhibitor O
(SSRI). O
This O
effect O
has O
been O
attributed O
to O
the O
antagonist O
effects O
of O
pindolol B-CHEMICAL
at O
the O
5-HT(1A) B-GENE-Y
receptor. O
In O

the O
present O
study, O
we O
compared O
the O
pharmacology O
of O
(+/-)pindolol, B-CHEMICAL
WAY-100635 B-CHEMICAL
(a O
5-HT(1A) B-GENE-Y
antagonist), O
GR127935 B-CHEMICAL
(a O
5-HT(1B/1D) B-GENE-N
antagonist), O
and O
isamoltane B-CHEMICAL
(a O
5-HT(1B) B-GENE-Y
antagonist), O
when O
given O
acutely O
in O
combination O
with O
fluoxetine, B-CHEMICAL
using O
in O
vivo O
microdialysis O
in O
the O
frontal O
cortex O
of O
the O
freely O
moving O
rat. O
We O
have O
determined O
that O
the O
acute O
fluoxetine-induced B-CHEMICAL
increases O
in O
extracellular O

5-HT B-CHEMICAL
can O
be O
augmented O
by O
(+/-)pindolol, B-CHEMICAL
WAY100635, B-CHEMICAL
GR127935 B-CHEMICAL
and O
isamoltane B-CHEMICAL
with O
maximum O
increases O
of O
216+/-32%, O
235+/-49%, O
240+/-18% O
and O
171+/-47% O
of O
preinjection O
control O
levels, O
respectively. O
Combination O
of O
both O
5-HT(1A) B-GENE-Y
and O
5-HT(1B/1D) B-GENE-N
autoreceptor O
antagonists O
with O
fluoxetine B-CHEMICAL
produced O
additive O
increases O
in O
extracellular O
5-HT B-CHEMICAL
(i.e. O

WAY100635+GR127935+fluoxetine B-CHEMICAL
and O
WAY100635+isamoltane+fluoxetine B-CHEMICAL
produced O
a O
four- O
and O
five-fold O
potentiation, O
respectively), O
suggesting O
that O
this O
strategy O
may O
be O
useful O
in O
further O
augmenting O
the O
action O
of O
a O
SSRI O
in O
the O
treatment O
of O
depression. O
In O
addition, O
by O
comparing O
the O
combined O
administration O
of O
(+/-)pindolol B-CHEMICAL
with O
either O
WAY100635, B-CHEMICAL
GR127935 B-CHEMICAL
or O
isamoltane, B-CHEMICAL
we O
have O
determined O
that O
(+/-)pindolol B-CHEMICAL
produces O
much O
of O
its O

acute O
potentiation O
of O
fluoxetine-induced B-CHEMICAL
increases O
in O
extracellular O
5-HT B-CHEMICAL
via O
its O
action O
at O
the O
5-HT(1B/D) B-GENE-N
receptor I-GENE-N
in O
addition O
to O
any O
activity O
it O
has O
at O
the O
presynaptic O
5-HT(1A) B-GENE-Y
receptor. O
Design, O
synthesis O
and O
biological O
evaluation O
of O
novel O
hybrid O
compounds O
of O
imidazole B-CHEMICAL
scaffold-based O
2-benzylbenzofuran B-CHEMICAL
as O
potent O
anticancer O
agents. O
A O
series O
of O
novel O
hybrid O
compounds O
between O
2-benzylbenzofuran B-CHEMICAL
and O
imidazole B-CHEMICAL
has O
been O
prepared O
and O
evaluated O
in O
vitro O
against O
a O
panel O

of O
human O
tumor O
cell O
lines. O
The O
results O
suggest O
that O
the O
existence O
of O
benzimidazole B-CHEMICAL
ring O
and O
substitution O
of O
the O
imidazolyl-3-position B-CHEMICAL
with O
a O
naphthylacyl B-CHEMICAL
or O
4-methoxyphenacyl B-CHEMICAL
group O
were O
vital O
for O
modulating O
cytotoxic O
activity. O
In O
particular, O
hybrid O
compounds O
46 O
and O
47 O
were O
found O
to O
be O
the O
most O
potent O
derivatives O
against O
5 O
strains O
human O
tumor O
cell O
lines O
and O
more O
active O
than O
cisplatin B-CHEMICAL
(DDP), B-CHEMICAL
and O
exhibited O
cytotoxic O
activities O
selectively O
against O
breast O
carcinoma O
(MCF-7) O
and O
myeloid O
liver O

carcinoma O
(SMMC-7721), O
respectively. O
Involvement O
of O
serotonin B-CHEMICAL
5-HT3 B-GENE-Y
receptors O
in O
the O
modulation O
of O
noradrenergic O
transmission O
by O
serotonin B-CHEMICAL
reuptake O
inhibitors: O
a O
microdialysis O
study O
in O
rat O
brain. O
RATIONALE: O
Selective O
serotonin B-CHEMICAL
reuptake O
inhibitors O
(SSRIs), O
in O
addition O
to O
being O
able O
to O
enhance O
serotonergic O
neurotransmission, O
are O
able O
to O
modulate O
other O
brain O
systems O
involved O
in O
depression. O
OBJECTIVES: O
This O
study O

evaluates O
the O
neurochemical O
effect O
of O
the O
SSRI O
citalopram O
on O
brain O
noradrenergic O
activity O
and O
the O
serotonin B-GENE-N
receptor I-GENE-N
involved O
in O
this O
effect. O
METHODS: O
Dual-probe O
microdialysis O
in O
the O
locus O
coeruleus O
(LC) O
and O
prefrontal O
cortex O
(PFC) O
was O
performed O
in O
freely O
awake O
rats. O
RESULTS: O
Systemic O
citalopram B-CHEMICAL
(10 O
mg/kg, O
i.p.) O
increased O
noradrenaline B-CHEMICAL
(NA) O
in O
the O
LC O
(E O
max O
= O
141 O
± O
13 O
%) O
and O
simultaneously O
decreased O
NA O

in O
the O
PFC O
(Emax O
= O
-46 O
± O
7 O
%). O
In O
the O
local O
presence O
into O
the O
LC O
of O
the O
α2-adrenoceptor B-GENE-N
antagonist O
RS79948 B-CHEMICAL
(1 O
μM), O
systemic O
citalopram B-CHEMICAL
increased O
NA O
in O
the O
LC O
(Emax O
= O
157 O
± O
25 O
%) O
and O
PFC O
(Emax O
= O
175 O
± O
24 O
%). O
Local O
citalopram B-CHEMICAL
(0.1-100 O
μM) O
into O
the O
LC O
induced O
NA O
increase O
in O
the O
LC O
(Emax O
= O
210 O
± O
25 O
%) O
and O
decrease O
in O
the O
PFC O
(Emax O
= O
-38 O

± O
9 O
%). O
Local O
LC O
citalopram B-CHEMICAL
effect O
was O
abolished O
by O
LC O
presence O
of O
the O
5-HT3 B-GENE-Y
receptor O
antagonist O
MDL72222 B-CHEMICAL
(1 O
μM) O
but O
not O
the O
5-HT1/2 B-GENE-N
receptor O
antagonist O
methiothepin B-CHEMICAL
(1 O
μM). O
Systemic O
citalopram B-CHEMICAL
in O
the O
LC O
presence O
of O
MDL72222 B-CHEMICAL
did O
not O
modify O
NA O
in O
the O
LC O
but O
increased O
NA O
in O
the O
PFC O
(Emax O
= O
158 O
± O
26 O
%). O
Local O
citalopram B-CHEMICAL
into O
the O
PFC O
enhanced O
NA O
(Emax O
= O
376 O
± O
18 O

%) O
in O
the O
area, O
which O
was O
prevented O
by O
MDL72222. B-CHEMICAL
CONCLUSIONS: O
The O
SSRI O
citalopram B-CHEMICAL
modulates O
central O
noradrenergic O
neurotransmission O
by O
activation, O
through O
endogenous O
serotonin, B-CHEMICAL
of O
5-HT3 B-GENE-Y
receptors O
expressed O
in O
the O
somatodendritic O
(LC) O
and O
terminal O
(PFC) O
areas, O
which O
subsequently O
promote O
an O
enhancement O
of O
local O
NA. O
Therefore, O
5-HT3 B-GENE-Y
receptors O
and O
somatodendritic O
α2-adrenoceptors B-GENE-N
in O
the O
LC O
play O
an O
important O
role O
in O
the O

global O
effect O
of O
SSRIs. O
Expressions O
and O
mechanical O
functions O
of O
alpha1-adrenoceptor B-GENE-N
subtypes O
in O
hamster O
ureter. O
We O
characterized O
the O
alpha(1)-adrenoceptor B-GENE-N
subtypes O
in O
hamster O
ureters O
according O
to O
gene O
and O
protein O
expressions O
and O
contractile O
function. O
Real-time O
quantitative O
reverse-transcription O
polymerase O
chain O
reaction O
and O
immunohistochemical O
analysis O
were O
performed O
to O
determine O
mRNA O
levels O
and O
receptor O
protein O
expressions O
respectively, O
for O
alpha(1A)-, B-GENE-N
alpha(1B)- I-GENE-N
and I-GENE-N
alpha(1D)-adrenoceptors I-GENE-N
in O

hamster O
ureteral O
smooth O
muscle. O
alpha(1)-Adrenoceptor B-GENE-N
antagonists O
were O
tested O
against O
the O
phenylephrine B-CHEMICAL
(alpha(1)-adrenoceptor B-GENE-N
agonist)-induced O
contraction O
in O
isolated O
hamster O
ureteral O
preparations O
using O
a O
functional O
experimental O
approach. O
In O
the O
smooth O
muscle, O
relative O
mRNA O
expression O
levels O
for O
alpha(1a)-, B-GENE-N
alpha(1b)- I-GENE-N
and I-GENE-N
alpha(1d)-adrenoceptors I-GENE-N
were O
10.7%, O
1.2% O
and O
88.1%, O
respectively, O
and O
protein O
expressions O
were O
identified O
for O

alpha(1A)- B-GENE-N
and I-GENE-N
alpha(1D)-adrenoceptors I-GENE-N
immunohistochemically. O
Noradrenaline B-CHEMICAL
and O
phenylephrine B-CHEMICAL
(alpha(1)-adrenoceptor B-GENE-N
agonist) O
each O
produced O
a O
concentration-dependent O
tonic O
contraction, O
their O
pD(2) O
values O
being O
6.87+/-0.08 O
and O
6.10+/-0.05, O
respectively. O
Prazosin B-CHEMICAL
(nonselective O
alpha(1)-adrenoceptor B-GENE-N
antagonist), O
silodosin B-CHEMICAL
(selective O

alpha(1A)-adrenoceptor B-GENE-N
antagonist) O
and O
BMY-7378 B-CHEMICAL
(8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione B-CHEMICAL
dihydrochloride) I-CHEMICAL
(selective O
alpha(1D)-adrenoceptor B-GENE-N
antagonist) O
competitively O
antagonized O
the O
phenylephrine-induced B-CHEMICAL
contraction O
(pA(2) O
values, O
8.60+/-0.07, O

9.44+/-0.06 O
and O
5.75+/-0.07, O
respectively). O
Chloroethylclonidine B-CHEMICAL
(3x10(-6) O
mol/L O
or O
more) O
produced O
a O
rightward O
shift O
in O
the O
concentration-response O
curve O
for O
phenylephrine. B-CHEMICAL
Thus, O
in O
hamster O
ureters, O
alpha(1A)- B-GENE-N
and I-GENE-N
alpha(1D)-adrenoceptors I-GENE-N
were O
more O
prevalent O
than O
the O
alpha(1B)-adrenoceptor, B-GENE-Y
with O
contraction O
being O
mediated O
mainly O
via O
alpha(1A)-adrenoceptors. B-GENE-N

If O
these O
findings O
hold O
true O
for O
humans, O
alpha(1A)-adrenoceptor B-GENE-N
antagonists O
could O
become O
useful O
medication O
for O
stone O
passage O
in O
urolithiasis O
patients. O
Amylin B-GENE-Y
receptors: O
molecular O
composition O
and O
pharmacology. O
Several O
receptors O
which O
bind O
the O
hormone O
AMY B-GENE-Y
(amylin) B-GENE-Y
with O
high O
affinity O
have O
now O
been O
identified. O
The O
minimum O
binding O
unit O
is O
composed O
of O
the O
CT B-GENE-Y
(calcitonin) I-GENE-Y
receptor I-GENE-Y
at O
its O
core, O
plus O
a O
RAMP B-GENE-N
(receptor B-GENE-N
activity I-GENE-N
modifying I-GENE-N
protein). I-GENE-N
The O
receptors O
have O
been O
named O
AMY(1(a)), B-GENE-N
AMY(2(a)) B-GENE-N
and O

AMY(3(a)) B-GENE-N
in O
accordance O
with O
the O
association O
of O
the O
CT B-GENE-Y
receptor I-GENE-Y
(CT((a))) B-GENE-Y
with O
RAMP1, B-GENE-Y
RAMP2 B-GENE-Y
and O
RAMP3 B-GENE-Y
respectively. O
The O
challenge O
is O
now O
to O
determine O
the O
localization O
and O
pharmacological O
nature O
of O
each O
of O
these O
receptors. O
Recent O
attempts O
to O
achieve O
these O
aims O
will O
be O
briefly O
discussed. O
Hospitalized O
osteoporotic O
vertebral O
fracture O
increases O
the O
risk O
of O
stroke: O
a O
population-based O
cohort O
study. O
The O
association O
between O
osteoporosis O
and O
cardiovascular O
diseases O
has O
been O
demonstrated. O
Higher O
cardiovascular O
risk O
has O
also O
been O
correlated O
with O

vertebral O
fractures. O
However, O
the O
association O
between O
osteoporotic O
vertebral O
fracture O
and O
the O
possibly O
higher O
risk O
of O
stroke O
remains O
uncertain. O
This O
study O
aimed O
to O
evaluate O
the O
incidence, O
risk, O
and O
type O
of O
stroke O
in O
patients O
with O
osteoporotic O
vertebral O
fracture. O
Patients O
with O
osteoporotic O
vertebral O
fracture O
were O
identified O
(n O
= O
380) O
and O
10 O
age- O
and O
sex-matched O
controls O
per O
case O
(comparison O
group, O
n O
= O
3795) O
were O
chosen O
from O
a O
nationwide O
representative O
cohort O
of O
999,997 O
people O
from O
1998 O
to O
2005. O
Both O
groups O
were O

followed-up O
for O
stroke O
events O
for O
3 O
years, O
matched O
by O
propensity O
scores O
with O
adjustments O
for O
covariates O
such O
as O
comorbidities O
(ie, O
hypertension, O
diabetes, O
arrhythmia, O
or O
coronary O
heart O
diseases) O
and O
exposure O
to O
medications O
(ie, O
aspirin, B-CHEMICAL
lipid O
lowering O
drug, O
or O
nitrates), B-CHEMICAL
and O
assessed O
by O
Kaplan-Meier O
and O
Cox O
regression O
analyses. O
The O
incidence O
rate O
of O
stroke O
in O
the O
osteoporotic O
vertebral O
fracture O
group O
(37.5 O
per O
1000 O
person-years; O
95% O
confidence O
interval O
[CI], O

27.5-51.2) O
was O
significantly O
higher O
than O
in O
the O
comparison O
group O
(14.0 O
per O
1000 O
person-years; O
95% O
CI, O
12.0-16.4, O
p O
< O
0.001). O
Stroke O
was O
more O
likely O
to O
occur O
in O
the O
osteoporotic O
vertebral O
fracture O
patients O
than O
in O
the O
normal O
controls O
(crude O
hazard O
ratio O
[HR] O
2.68, O
95% O
CI O
1.89-3.79, O
p O
< O
0.001; O
adjusted O
HR O
2.71, O
95% O
CI O
1.90-3.86, O
p O
< O

0.001). O
In O
conclusion, O
patients O
with O
osteoporotic O
vertebral O
fracture O
have O
a O
higher O
risk O
of O
stroke O
(ie, O
both O
ischemic O
and O
hemorrhagic) O
and O
require O
stroke O
prevention O
strategies. O
Inhibition O
of O
recombinant O
L-type B-GENE-N
voltage-gated I-GENE-N
calcium I-GENE-N
channels I-GENE-N
by O
positive O
allosteric O
modulators O
of O
GABAA B-GENE-N
receptors. I-GENE-N
Benzodiazepines B-CHEMICAL
(BDZs) B-CHEMICAL
depress O
neuronal O
excitability O
via O
positive O
allosteric O
modulation O
of O
inhibitory O
GABA(A) B-GENE-N
receptors I-GENE-N
(GABA(A)R). B-GENE-N

BDZs B-CHEMICAL
and O
other O
positive O
GABA(A)R B-GENE-N
modulators, O
including O
barbiturates, B-CHEMICAL
ethanol, B-CHEMICAL
and O
neurosteroids, B-CHEMICAL
can O
also O
inhibit O
L-type B-GENE-N
voltage-gated I-GENE-N
calcium I-GENE-N
channels I-GENE-N
(L-VGCCs), B-GENE-N
which O
could O
contribute O
to O
reduced O
neuronal O
excitability. O
Because O
neuronal O
L-VGCC B-GENE-N
function O
is O
up-regulated O
after O
long-term O
GABA(A)R B-GENE-N
modulator O
exposure, O
an O
interaction O
with O
L-VGCCs B-GENE-N
may O
also O
play O
a O
role O
in O
physical O
dependence. O
The O
current O
studies O
assessed O
the O
effects O
of O
BDZs B-CHEMICAL

(diazepam, B-CHEMICAL
flurazepam, B-CHEMICAL
and O
desalkylflurazepam), B-CHEMICAL
allopregnanolone, B-CHEMICAL
pentobarbital, B-CHEMICAL
and O
ethanol B-CHEMICAL
on O
whole-cell O
Ba(2+) B-CHEMICAL
currents O
through O
recombinant O
neuronal O
Ca(v)1.2 B-GENE-Y
and O
Ca(v)1.3 B-GENE-Y
L-VGCCs B-GENE-N
expressed O
with O
beta(3) O
and O
alpha(2)delta-1 O
in O
HEK293T O
cells. O
Allopregnanolone B-CHEMICAL
was O
the O
most O
potent O
inhibitor O
(IC(50), O
approximately O
10 O
muM), O
followed O

by O
BDZs B-CHEMICAL
(IC(50), O
approximately O
50 O
muM), O
pentobarbital B-CHEMICAL
(IC(50), O
0.3-1 O
mM), O
and O
ethanol B-CHEMICAL
(IC(50), O
approximately O
300 O
mM). O
Ca(v)1.3 B-GENE-Y
channels O
were O
less O
sensitive O
to O
pentobarbital B-CHEMICAL
inhibition O
than O
Ca(v)1.2 B-GENE-Y
channels, O
similar O
to O
dihydropyridine B-CHEMICAL
(DHP) B-CHEMICAL
L-VGCC B-GENE-N
antagonists. O
All O
GABA(A)R B-GENE-N
modulators O
induced O
a O
negative O
shift O
in O
the O
steady-state O

inactivation O
curve O
of O
Ca(v)1.3 B-GENE-Y
channels, O
but O
only O
BDZs B-CHEMICAL
and O
pentobarbital B-CHEMICAL
induced O
a O
negative O
shift O
in O
Ca(v)1.2 B-GENE-Y
channel O
inactivation. O
Mutation O
of O
the O
high-affinity B-GENE-N
DHP I-GENE-N
binding I-GENE-N
site I-GENE-N
(T1039Y B-GENE-N
and O
Q1043M) B-GENE-N
in O
Ca(v)1.2 B-GENE-Y
channels O
reduced O
pentobarbital B-CHEMICAL
potency. O
Despite O
the O
structural O
similarity O
between O
benzothiazepines B-CHEMICAL
and O
BDZs, B-CHEMICAL
mutation O
of O
an O
amino B-CHEMICAL
acid I-CHEMICAL
important O
for O
diltiazem B-CHEMICAL
potency O
(I1150A) B-GENE-N
did O
not O
affect O

diazepam B-CHEMICAL
potency. O
Although O
L-VGCC B-GENE-N
inhibition O
by O
BDZs B-CHEMICAL
occurred O
at O
concentrations O
that O
are O
possibly O
too O
high O
to O
be O
clinically O
relevant O
and O
is O
not O
likely O
to O
play O
a O
role O
in O
the O
up-regulation O
of O
L-VGCCs B-GENE-N
during O
long-term O
treatment, O
pentobarbital B-CHEMICAL
and O
ethanol O
inhibited O
L-VGCCs B-GENE-N
at O
clinically O
relevant O
concentrations. O
5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone B-CHEMICAL
inhibits O
nitric B-CHEMICAL
oxide I-CHEMICAL
production O
in O
lipopolysaccharide-stimulated O

BV2 O
microglia O
via O
NF-κB B-GENE-N
suppression O
and O
Nrf-2-dependent B-GENE-Y
heme B-GENE-Y
oxygenase-1 I-GENE-Y
induction. O
In O
this O
study, O
we O
found O
that O
5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone B-CHEMICAL
(5HHMF) B-CHEMICAL
from O
Hizikia O
fusiforme O
considerably O
inhibits O
lipopolysaccharide O
(LPS)-stimulated O
NO B-CHEMICAL
production O
by O
suppressing O
the O
expression O
of O
inducible B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
(iNOS) B-GENE-Y
in O
BV2 O
microglia. O
In O
addition, O

5HHMF B-CHEMICAL
blocked O
LPS-induced O
phosphorylation O
of O
IκB, B-GENE-N
resulting O
in O
suppression O
of O
the O
nuclear O
translocation O
of O
nuclear B-GENE-N
factor-κB I-GENE-N
(NF-κB) B-GENE-N
subunits, O
namely O
p65 B-GENE-Y
and O
p50, B-GENE-Y
which O
are O
important O
molecules O
involved O
in O
the O
regulation O
of O
iNOS B-GENE-Y
expression. O
Pyrrolidine B-CHEMICAL
dithiocarbamate I-CHEMICAL
(PDTC), B-CHEMICAL
a O
specific O
NF-κB B-GENE-N
inhibitor, O
along O
with O
20S B-GENE-N
proteasome I-GENE-N
inhibitor O
(PSI) O
significantly O
inhibited O
LPS-induced O
iNOS B-GENE-Y
expression, O
which O
indirectly O
suggested O
that O
5HHMF B-CHEMICAL

downregulated O
iNOS B-GENE-Y
expression O
by O
suppressing O
NF-κB B-GENE-N
activity. O
Thus, O
we O
found O
that O
5HHMF B-CHEMICAL
enhances O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1) B-GENE-Y
expression O
via O
nuclear B-GENE-Y
factor-erythroid I-GENE-Y
2-related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2) B-GENE-Y
activation. O
In O
addition, O
cobalt B-CHEMICAL
protoporphyrin I-CHEMICAL
(CoPP), B-CHEMICAL
a O
specific O
HO-1 B-GENE-Y
inducer, O
predominantly O
suppressed O
LPS-induced O
NO B-CHEMICAL
production. O
In O
contrast, O
zinc B-CHEMICAL
protoporphyrin I-CHEMICAL
(ZnPP), B-CHEMICAL
a O
specific O
HO-1 B-GENE-Y
inhibitor, O
showed O
a O
partial O
suppressive O
effect O
of O

5HHMF B-CHEMICAL
on O
LPS-induced O
NO B-CHEMICAL
production. O
Further, O
5HHMF B-CHEMICAL
increased O
specific O
DNA-binding O
activity O
of O
Nrf2, B-GENE-Y
and O
transient O
knockdown O
with O
Nrf2 B-GENE-Y
siRNA O
subsequently O
reversed O
5HHMF-induced B-CHEMICAL
NO B-CHEMICAL
inhibition, O
which O
was O
followed O
by O
suppression O
of O
HO-1 B-GENE-Y
activity. O
Taken O
together, O
our O
findings O
indicate O
that O
5HHMF B-CHEMICAL
suppresses O
NO B-CHEMICAL
production O
through O
modulation O
of O
iNOS, B-GENE-Y
consequently O
suppressing O
NF-κB B-GENE-N
activity O
and O
induction O
of O
Nrf2-dependent B-GENE-Y
HO-1 B-GENE-Y
activity. O
Synthesis O
and O
antitumor O
activity O
of O

1,3,4-oxadiazole B-CHEMICAL
possessing O
1,4-benzodioxan B-CHEMICAL
moiety O
as O
a O
novel O
class O
of O
potent O
methionine B-GENE-Y
aminopeptidase I-GENE-Y
type I-GENE-Y
II I-GENE-Y
inhibitors. O
A O
series O
of O
1,3,4-oxadiazole B-CHEMICAL
derivatives O
containing O
1,4-benzodioxan B-CHEMICAL
moiety O
(7a-7q) O
have O
been O
designed, O
synthesized O
and O
evaluated O
for O
their O
antitumor O
activity. O
Most O
of O
the O
synthesized O
compounds O
were O
proved O
to O
have O
potent O
antitumor O
activity O
and O
low O
toxicity. O
Among O
them, O
compound O
7a O
showed O
the O
most O
potent O
biological O
activity O
against O
Human O

Umbilical O
Vein O
Endothelial O
cells, O
which O
was O
comparable O
to O
the O
positive O
control. O
The O
results O
of O
apoptosis O
and O
flow O
cytometry O
(FCM) O
demonstrated O
that O
compound O
7a O
induce O
cell O
apoptosis O
by O
the O
inhibition O
of O
MetAP2 B-GENE-Y
pathway. O
Molecular O
docking O
was O
performed O
to O
position O
compound O
7a O
into O
MetAP2 B-GENE-Y
binding O
site O
in O
order O
to O
explore O
the O
potential O
target. O
Discovery O
of O
novel O
cannabinoid B-GENE-N
receptor I-GENE-N
ligands O
by O
a O
virtual O
screening O
approach: O
further O
development O
of O
2,4,6-trisubstituted B-CHEMICAL
1,3,5-triazines I-CHEMICAL
as O
CB2 B-GENE-Y
agonists. O

3D O
ligand-based O
virtual O
screening O
was O
employed O
to O
identify O
novel O
scaffolds O
for O
cannabinoid B-GENE-N
receptor I-GENE-N
ligand O
development. O
A O
total O
of O
112 O
compounds O
with O
diverse O
structures O
were O
purchased O
from O
commercial O
vendors. O
12 O
CB1 B-GENE-Y
receptor O
antagonists/inverse O
agonists O
and O
10 O
CB2 B-GENE-Y
receptor O
agonists O
were O
identified O
in O
vitro. O
One O
of O
the O
CB2 B-GENE-Y
agonists, O
N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine B-CHEMICAL

(19, O
-logEC(50)=7.5, O
E(max)=255%) O
was O
selected O
for O
further O
development. O
As O
far O
as O
we O
are O
aware, O
the O
compound's O
1,3,5-triazine B-CHEMICAL
scaffold O
represents O
a O
new O
core O
structure O
for O
CB2 B-GENE-Y
agonists. O
A O
library O
of O
fifty-seven O
2,4,6-trisubstituted-1,3,5-triazines B-CHEMICAL
was O
created O
to O
clarify O
the O
structure-activity O
relationship O
study O
of O
the O
analogs. O
Inborn O
errors O
in O
the O
metabolism O
of O
glutathione. B-CHEMICAL
Glutathione B-CHEMICAL
is O

a O
tripeptide B-CHEMICAL
composed O
of O
glutamate, B-CHEMICAL
cysteine B-CHEMICAL
and O
glycine. B-CHEMICAL
Glutathione B-CHEMICAL
is O
present O
in O
millimolar O
concentrations O
in O
most O
mammalian O
cells O
and O
it O
is O
involved O
in O
several O
fundamental O
biological O
functions, O
including O
free O
radical O
scavenging, O
detoxification O
of O
xenobiotics O
and O
carcinogens, O
redox O
reactions, O
biosynthesis O
of O
DNA, O
proteins O
and O
leukotrienes, B-CHEMICAL
as O
well O
as O
neurotransmission/neuromodulation. O
Glutathione B-CHEMICAL
is O
metabolised O
via O
the O
gamma-glutamyl B-CHEMICAL
cycle, O
which O
is O
catalyzed O
by O

six O
enzymes. O
In O
man, O
hereditary O
deficiencies O
have O
been O
found O
in O
five O
of O
the O
six O
enzymes. O
Glutathione B-GENE-Y
synthetase I-GENE-Y
deficiency O
is O
the O
most O
frequently O
recognized O
disorder O
and, O
in O
its O
severe O
form, O
it O
is O
associated O
with O
hemolytic O
anemia, O
metabolic O
acidosis, O
5-oxoprolinuria, O
central O
nervous O
system O
(CNS) O
damage O
and O
recurrent O
bacterial O
infections. O
Gamma-glutamylcysteine B-GENE-Y
synthetase I-GENE-Y
deficiency O
is O
also O
associated O
with O
hemolytic O
anemia, O
and O
some O
patients O
with O
this O
disorder O
show O
defects O
of O
neuromuscular O
function O
and O
generalized O
aminoaciduria. O

Gamma-glutamyl B-GENE-Y
transpeptidase I-GENE-Y
deficiency O
has O
been O
found O
in O
patients O
with O
CNS O
involvement O
and O
glutathionuria. O
5-Oxoprolinase B-GENE-Y
deficiency O
is O
associated O
with O
5-oxoprolinuria O
but O
without O
a O
clear O
association O
with O
other O
symptoms. O
Dipeptidase B-GENE-N
deficiency O
has O
been O
described O
in O
one O
patient. O
All O
disorders O
are O
very O
rare O
and O
inherited O
in O
an O
autosomal O
recessive O
manner. O
Most O
of O
the O
mutations O
are O
leaky O
so O
that O
many O
patients O
have O
residual O
enzyme O
activity. O
Diagnosis O
is O
made O
by O
measuring O
the O
concentration O
of O
different O
metabolites O
in O
the O
gamma-glutamyl B-CHEMICAL

cycle, O
enzyme O
activity O
and O
in O
glutathione B-GENE-Y
synthetase I-GENE-Y
and O
gamma-glutamylcysteine B-GENE-Y
synthetase I-GENE-Y
deficiency, O
also O
by O
mutation O
analysis. O
Prenatal O
diagnosis O
has O
been O
preformed O
in O
glutathione B-CHEMICAL
synthetase O
deficiency. O
The O
prognosis O
is O
difficult O
to O
predict, O
as O
few O
patients O
are O
known, O
but O
seems O
to O
vary O
significantly O
between O
different O
patients. O
The O
aims O
of O
the O
treatment O
of O
glutathione B-CHEMICAL
synthesis O
defects O
are O
to O
avoid O
hemolytic O
crises O
and O
to O
increase O
the O
defense O
against O
reactive O
oxygen B-CHEMICAL
species. O
No O
treatment O
has O
been O
recommended O
for O
gamma-glutamyl B-GENE-Y
transpeptidase, I-GENE-Y

5-oxoprolinase B-GENE-Y
and O
dipeptidase B-GENE-N
deficiency. O
Properties O
of O
purified O
recombinant O
human B-GENE-N
polyamine I-GENE-N
oxidase, I-GENE-N
PAOh1/SMO. B-GENE-Y
The O
discovery O
of O
an O
inducible O
oxidase B-GENE-N
whose O
apparent O
substrate O
preference O
is O
spermine B-CHEMICAL
indicates O
that O
polyamine B-CHEMICAL
catabolism O
is O
more O
complex O
than O
that O
originally O
proposed. O
To O
facilitate O
the O
study O
of O
this O
enzyme, O
the O
purification O
and O
characterization O
of O
the O
recombinant O
human B-GENE-Y
PAOh1/SMO I-GENE-Y
polyamine B-GENE-N
oxidase I-GENE-N
are O
reported. O
Purified O
PAOh1/SMO B-GENE-Y
oxidizes O

both O
spermine B-CHEMICAL
(K(m)=1.6 O
microM) O
and O
N(1)-acetylspermine B-CHEMICAL
(K(m)=51 O
microM), O
but O
does O
not O
oxidize O
spermidine. B-CHEMICAL
The O
purified O
human O
enzyme O
also O
does O
not O
oxidize O
eight O
representative O
antitumor O
polyamine B-CHEMICAL
analogues; O
however, O
specific O
oligamine O
analogues O
were O
found O
to O
be O
potent O
inhibitors O
of O
the O
oxidation O
of O
spermine B-CHEMICAL
by O
PAOh1/SMO. B-GENE-Y
The O
results O
of O
these O
studies O
are O
consistent O
with O
the O
hypothesis O
that O
PAOh1/SMO B-GENE-Y
represents O
a O
new O
addition O
to O
the O

polyamine B-CHEMICAL
metabolic O
pathway O
that O
may O
represent O
a O
new O
target O
for O
antineoplastic O
drug O
development. O
Effects O
of O
serine/threonine B-GENE-N
protein I-GENE-N
phosphatase I-GENE-N
inhibitors O
on O
morphine-induced B-CHEMICAL
antinociception O
in O
the O
tail O
flick O
test O
in O
mice. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
serine/threonine B-GENE-N
protein I-GENE-N
phosphatase I-GENE-N
(PP) B-GENE-N
inhibitors O
on O
morphine-induced B-CHEMICAL
antinociception O
in O
the O
tail O
flick O
test O
in O
mice, O
and O
on O
[3H]naloxone B-CHEMICAL
binding O
to O
the O
forebrain O
crude O
synaptosome O
fraction. O
Neither O

okadaic B-CHEMICAL
acid I-CHEMICAL
nor O
cantharidin B-CHEMICAL
(1-10000 O
nM) O
displaced O
[3H]naloxone B-CHEMICAL
from O
its O
specific O
binding O
sites, O
which O
indicates O
that O
they O
do O
not O
interact O
at O
the O
opioid B-GENE-N
receptor I-GENE-N
level. O
The O
i.c.v. O
administration O
of O
very O
low O
doses O
of O
okadaic B-CHEMICAL
acid I-CHEMICAL
(0.001-1 O
pg/mouse) O
and O
cantharidin B-CHEMICAL
(0.001-1 O
ng/mouse), O
which O
inhibit O
PP2A, B-GENE-N
produced O
a O
dose-dependent O
antagonism O
of O
the O
antinociception O
induced O
by O
morphine B-CHEMICAL
(s.c.). O

However, O
L-nor-okadaone B-CHEMICAL
(0.001 O
pg/mouse-1 O
ng/mouse, O
i.c.v.), O
an O
analogue O
of O
okadaic B-CHEMICAL
acid I-CHEMICAL
lacking O
activity O
against O
protein B-GENE-N
phosphatases, I-GENE-N
did O
not O
affect O
the O
antinociceptive O
effect O
of O
morphine. B-CHEMICAL
On O
the O
other O
hand, O
high O
doses O
of O
okadaic B-CHEMICAL
acid I-CHEMICAL
(10 O
ng/mouse, O
i.c.v.) O
and O
cantharidin B-CHEMICAL
(1 O
microg/mouse, O
i.c.v.), O
which O
also O
block O
PP1, B-GENE-N
and O
calyculin-A B-CHEMICAL
(0.1 O

fg/mouse-1 O
ng/mouse, O
i.c.v.), O
which O
inhibits O
equally O
both O
PP1 B-GENE-N
and O
PP2A, B-GENE-N
did O
not O
modify O
the O
morphine-induced B-CHEMICAL
antinociception. O
These O
results O
suggest O
that O
the O
activation O
of O
type B-GENE-N
2A I-GENE-N
serine/threonine I-GENE-N
protein I-GENE-N
phosphatases I-GENE-N
may O
play O
a O
role O
in O
the O
antinociceptive O
effect O
of O
morphine, B-CHEMICAL
and O
that O
PP1 B-GENE-N
might O
counterbalace O
this O
activity. O
Carbonic B-GENE-N
anhydrase I-GENE-N
inhibitors. O
Inhibition O
of O
mammalian B-GENE-N
isoforms I-GENE-N
I-XIV I-GENE-N
with O
a O
series O
of O
natural O
product O

polyphenols B-CHEMICAL
and O
phenolic B-CHEMICAL
acids. I-CHEMICAL
A O
series O
of O
phenolic B-CHEMICAL
acids I-CHEMICAL
and O
phenol B-CHEMICAL
natural O
products, O
such O
as O
p-hydroxybenzoic B-CHEMICAL
acid, I-CHEMICAL
p-coumaric B-CHEMICAL
acid, I-CHEMICAL
caffeic B-CHEMICAL
acid, I-CHEMICAL
ferulic B-CHEMICAL
acid, I-CHEMICAL
gallic B-CHEMICAL
acid, I-CHEMICAL
syringic B-CHEMICAL
acid, I-CHEMICAL
quercetin, B-CHEMICAL
and O
ellagic B-CHEMICAL
acid, I-CHEMICAL
were O
investigated O
for O
their O
inhibitory O
effects O
against O
the O
metalloenzyme B-GENE-N
carbonic B-GENE-N
anhydrase I-GENE-N
(CA, B-GENE-N
EC B-GENE-Y
4.2.1.1). I-GENE-Y
All O
mammalian O
isozymes O
of O
human O
(h) O
or O
murine O

(m) O
origin O
hCA B-GENE-Y
I-hCA I-GENE-Y
XII, I-GENE-Y
mCA B-GENE-Y
XIII I-GENE-Y
and O
hCA B-GENE-Y
XIV I-GENE-Y
were O
inhibited O
in O
the O
low O
micromolar O
or O
submicromolar O
range O
by O
these O
(poly)phenols O
(K(I)s O
in O
the O
range O
of O
0.87-7.79 O
microM). O
p-Hydroxybenzoic B-CHEMICAL
acid I-CHEMICAL
was O
the O
best O
inhibitor O
of O
all O
isozymes O
(K(I)s O
of O
0.87-35.4 O
microM) O
and O
the O
different O
isozymes O
showed O
very O
variable O
inhibition O
profiles O
with O
these O
derivatives. O
Phenols B-CHEMICAL
like O
the O
ones O
investigated O
here O
possess O

a O
CA B-GENE-N
inhibition O
mechanism O
distinct O
of O
that O
of O
the O
sulfonamides/sulfamates B-CHEMICAL
used O
clinically O
or O
the O
coumarins. B-CHEMICAL
Unlike O
the O
sulfonamides, B-CHEMICAL
which O
bind O
to O
the O
catalytic O
zinc B-CHEMICAL
ion, O
phenols B-CHEMICAL
are O
anchored O
at O
the O
Zn(II)-coordinated B-CHEMICAL
water O
molecule O
and O
bind O
more O
externally O
within O
the O
active O
site O
cavity, O
making O
contacts O
with O
various O
amino B-CHEMICAL
acid I-CHEMICAL
residues. O
As O
this O
is O
the O
region O
with O
the O
highest O
variability O
between O
the O
many O
CA B-GENE-N
isozymes O
found O
in O
mammals, O
this O
class O
of O
compounds O
may O
lead O
to O
isoform-selective O
inhibitors O
targeting O
just O
one O
or O
few O
of O
the O

medicinally O
relevant O
CAs. B-GENE-N
Crystal O
structure O
of O
the O
pyridoxal-5'-phosphate-dependent B-CHEMICAL
serine B-GENE-Y
dehydratase I-GENE-Y
from O
human O
liver. O
L-serine B-GENE-Y
dehydratase I-GENE-Y
(SDH), B-GENE-Y
a O
member O
of O
the O
beta-family O
of O
pyridoxal B-CHEMICAL
phosphate-dependent I-CHEMICAL
(PLP) O
enzymes, O
catalyzes O
the O
deamination O
of O
L-serine B-CHEMICAL
and O
L-threonine B-CHEMICAL
to O
yield O
pyruvate B-CHEMICAL
or O
2-oxobutyrate. B-CHEMICAL
The O
crystal O
structure O
of O
L-serine B-GENE-Y
dehydratase I-GENE-Y
from O
human O
liver O
(hSDH) B-GENE-Y
has O
been O
solved O
at O

2.5 O
A-resolution O
by O
molecular O
replacement. O
The O
structure O
is O
a O
homodimer O
and O
reveals O
a O
fold O
typical O
for O
beta-family O
PLP-dependent O
enzymes. O
Each O
monomer O
serves O
as O
an O
active O
unit O
and O
is O
subdivided O
into O
two O
distinct O
domains: O
a O
small O
domain O
and O
a O
PLP-binding B-GENE-N
domain I-GENE-N
that O
covalently O
anchors O
the O
cofactor. O
Both O
domains O
show O
the O
typical O
open O
alpha/beta O
architecture O
of O
PLP O
enzymes. O
Comparison O
with O
the O
rSDH-(PLP-OMS) B-GENE-Y
holo-enzyme O
reveals O
a O
large O
structural O
difference O
in O
active O
sites O
caused O
by O
the O
artifical O

O-methylserine. B-CHEMICAL
Furthermore, O
the O
activity O
of O
hSDH-PLP B-GENE-Y
was O
assayed O
and O
it O
proved O
to O
show O
catalytic O
activity. O
That O
suggests O
that O
the O
structure O
of O
hSDH-PLP B-GENE-Y
is O
the O
first O
structure O
of O
the O
active O
natural O
holo-SDH. B-GENE-Y
Synthesis O
and O
evaluation O
of O
carbamoylmethylene B-CHEMICAL
linked O
prodrugs O
of O
BMS-582949, B-CHEMICAL
a O
clinical O
p38α B-GENE-Y
inhibitor. O
A O
series O
of O
carbamoylmethylene B-CHEMICAL
linked O
prodrugs O
of O
1 O
(BMS-582949), B-CHEMICAL
a O
clinical O
p38α B-GENE-Y
inhibitor, O
were O
synthesized O
and O

evaluated. O
Though O
the O
phosphoryloxymethylene B-CHEMICAL
carbamates I-CHEMICAL
(3, O
4, O
and O
5) O
and O
α-aminoacyloxymethylene B-CHEMICAL
carbamates I-CHEMICAL
(22, O
23, O
and O
26) O
were O
found O
unstable O
at O
neutral O
pH O
values, O
fumaric B-CHEMICAL
acid I-CHEMICAL
derived O
acyloxymethylene B-CHEMICAL
carbamates I-CHEMICAL
(2, O
28, O
and O
31) O
were O
highly O
stable O
under O
both O
acidic O
and O
neutral O
conditions. O
Prodrugs O
2 O
and O
31 O
were O
also O
highly O
soluble O
at O
both O
acidic O
and O
neutral O
pH O
values. O
At O
a O
solution O
dose O
of O
14.2mpk O
(equivalent O
to O
10mpk O
of O
1), O
2 O
gave O

essentially O
the O
same O
exposure O
of O
1 O
compared O
to O
dosing O
10mpk O
of O
1 O
itself. O
At O
a O
suspension O
dose O
of O
142mpk O
(equivalent O
to O
100mpk O
of O
1), O
2 O
demonstrated O
that O
it O
could O
overcome O
the O
solubility O
issue O
associated O
with O
1 O
and O
provide O
a O
much O
higher O
exposure O
of O
1. O
To O
our O
knowledge, O
the O
unique O
type O
of O
prodrugs O
like O
2, O
28, O
and O
31 O
was O
not O
reported O
in O
the O
past O
and O
could O
represent O
a O
novel O
prodrug O
approach O
for O
secondary B-CHEMICAL
amides, I-CHEMICAL
a O
class O
of O
molecules O
frequently O
identified O
as O
drug O
candidates. O
Iron B-CHEMICAL
and O
diabetes O
risk. O
Iron B-CHEMICAL
overload O
is O
a O
risk O
factor O
for O
diabetes. O
The O
link O
between O
iron B-CHEMICAL
and O

diabetes O
was O
first O
recognized O
in O
pathologic O
conditions-hereditary O
hemochromatosis O
and O
thalassemia-but O
high O
levels O
of O
dietary O
iron B-CHEMICAL
also O
impart O
diabetes O
risk. O
Iron B-CHEMICAL
plays O
a O
direct O
and O
causal O
role O
in O
diabetes O
pathogenesis O
mediated O
both O
by O
β O
cell O
failure O
and O
insulin B-GENE-Y
resistance. O
Iron B-CHEMICAL
also O
regulates O
metabolism O
in O
most O
tissues O
involved O
in O
fuel O
homeostasis, O
with O
the O
adipocyte O
in O
particular O
serving O
an O
iron-sensing B-CHEMICAL
role. O
The O
underlying O
molecular O
mechanisms O
mediating O
these O
effects O
are O
numerous O
and O
incompletely O
understood O
but O
include O
oxidant O
stress O
and O
modulation O
of O
adipokines B-GENE-N
and O
intracellular O
signal O
transduction O
pathways. O
Changes O

of O
phosphorylation O
of O
cAMP B-GENE-N
response I-GENE-N
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
in O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol B-CHEMICAL
intake: O
naloxone B-CHEMICAL
reversal. O
AIM: O
To O
study O
the O
changes O
in O
the O
expression O
and O
phosphorylation O
of O
cAMP B-GENE-N
response I-GENE-N
element I-GENE-N
binding I-GENE-N
protein I-GENE-N
(CREB) B-GENE-N
in O
the O
rat O
nucleus O
accumbens O
after O
chronic O
ethanol B-CHEMICAL
intake O
and O
its O
withdrawal. O
METHODS: O
Ethanol B-CHEMICAL
was O
given O
in O
drinking O
water O
at O
the O
concentration O
of O
6 O
% O
(v/v), O
for O
one O
month. O
Changes O
in O
the O
levels O
of O
CREB B-GENE-N
and O
phospho-CREB B-GENE-N

(p-CREB) B-GENE-N
protein O
in O
the O
nucleus O
accumbens O
were O
measured O
by O
immunohistochemistry O
methods. O
RESULTS: O
Ethanol B-CHEMICAL
given O
to O
rats O
in O
drinking O
water O
decreased O
the O
level O
of O
p-CREB B-GENE-N
protein O
in O
the O
nucleus O
accumbens O
(-75 O
%) O
at O
the O
time O
of O
exposure O
to O
ethanol. B-CHEMICAL
The O
decrement O
of O
p-CREB B-GENE-N
protein O
in O
the O
nucleus O
accumbens O
remained O
at O
24 O
h O
(-35 O
%) O
and O
72 O
h O
(-28 O
%) O
of O
ethanol B-CHEMICAL
withdrawal, O
which O
recovered O
toward O
control O
level O
after O
7 O
d O
of O
ethanol B-CHEMICAL
withdrawal. O
However, O

chronic O
ethanol, B-CHEMICAL
as O
well O
as O
ethanol B-CHEMICAL
withdrawal O
failed O
to O
produce O
any O
significant O
alteration O
in O
the O
level O
of O
CREB B-GENE-N
protein O
in O
the O
nucleus O
accumbens. O
Naloxone B-CHEMICAL
(alone) O
treatment O
of O
rats O
had O
no O
effect O
on O
the O
levels O
of O
CREB B-GENE-N
and O
p-CREB B-GENE-N
protein O
in O
the O
nucleus O
accumbens. O
However, O
when O
naloxone O
was O
administered O
concurrently O
with O
ethanol B-CHEMICAL
treatment, O
it O
antagonized O
the O
down-regulation O
of O
p-CREB B-GENE-N
protein O
in O
the O
nucleus O
accumbens O
(142 O
%) O
of O
rats O
exposed O
to O
ethanol. B-CHEMICAL
CONCLUSION: O
A O
long-term O
intake O

of O
ethanol B-CHEMICAL
solution O
down-regulates O
the O
phosphorylation O
of O
CREB B-GENE-N
in O
the O
nucleus O
accumbens, O
and O
those O
changes O
can O
be O
reversed O
by O
naloxone, B-CHEMICAL
which O
may O
be O
one O
kind O
of O
the O
molecular O
mechanisms O
associated O
with O
ethanol B-CHEMICAL
dependence. O
Impaired O
function O
of O
prejunctional O
adenosine B-GENE-Y
A1 I-GENE-Y
receptors I-GENE-Y
expressed O
by O
perivascular O
sympathetic O
nerves O
in O
DOCA-salt B-CHEMICAL
hypertensive O
rats. O
Increased O
sympathetic O
nervous O
system O
activity O
contributes O
to O
deoxycorticosterone B-CHEMICAL
acetate I-CHEMICAL
(DOCA)-salt B-CHEMICAL
hypertension O
in O
rats. O
ATP B-CHEMICAL
and O
norepinephrine B-CHEMICAL
(NE) O

are O
coreleased O
from O
perivascular O
sympathetic O
nerves. O
NE O
acts O
at O
prejunctional O
α2-adrenergic B-GENE-N
receptors I-GENE-N
(α2ARs) B-GENE-N
to O
inhibit O
NE O
release, O
and O
α2AR B-GENE-N
function O
is O
impaired O
in O
DOCA-salt B-CHEMICAL
rats. O
Adenosine, B-CHEMICAL
an O
enzymatic O
ATP B-CHEMICAL
degradation O
product, O
acts O
at O
prejunctional O
A1 B-GENE-Y
adenosine I-GENE-Y
receptors I-GENE-Y
(A1Rs) B-GENE-Y
to O
inhibit O
NE O
release. O
We O
tested O
the O
hypothesis O
that O
prejunctional O
A1R B-GENE-Y
function O
is O
impaired O
in O
sympathetic O
nerves O
supplying O
mesenteric O
arteries O
(MAs) O
and O
veins O
(MVs) O
of O
DOCA-salt B-CHEMICAL

rats. O
Electrically O
evoked O
NE O
release O
and O
constrictions O
of O
blood O
vessels O
were O
studied O
in O
vitro O
with O
use O
of O
amperometry O
to O
measure O
NE O
oxidation O
currents O
and O
video O
microscopy, O
respectively. O
Immunohistochemical O
methods O
were O
used O
to O
localize O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
(TH) B-GENE-Y
and O
A1Rs B-GENE-Y
in O
perivascular O
sympathetic O
nerves. O
TH B-GENE-Y
and O
A1Rs B-GENE-Y
colocalized O
to O
perivascular O
sympathetic O
nerves. O
Adenosine B-CHEMICAL
and O
N(6)-cyclopentyl-adenosine B-CHEMICAL
(CPA, B-CHEMICAL
A1R B-GENE-Y
agonist) O

constricted O
MVs O
but O
not O
MAs. O
Adenosine B-CHEMICAL
and O
CPA B-CHEMICAL
(0.001-10 O
µM) O
inhibited O
neurogenic O
constrictions O
and O
NE O
release O
in O
MAs O
and O
MVs. O
DOCA-salt B-CHEMICAL
arteries O
were O
resistant O
to O
adenosine B-CHEMICAL
and O
CPA-mediated B-CHEMICAL
inhibition O
of O
NE O
release O
and O
constriction. O
The O
A2A B-GENE-Y
adenosine I-GENE-Y
receptor I-GENE-Y
agonist O
CGS21680 B-CHEMICAL
(C23H29N7O6.HCl.xH2O) B-CHEMICAL
(0.001-0.1 O
μM) O
did O
not O
alter O
NE O
oxidation O

currents. O
We O
conclude O
that O
there O
are O
prejunctional O
A1Rs B-GENE-Y
in O
arteries O
and O
both O
pre- O
and O
postjunctional O
A1Rs B-GENE-Y
in O
veins; O
thus, O
adenosine B-CHEMICAL
selectively O
constricts O
the O
veins. O
Prejunctional O
A1R B-GENE-Y
function O
is O
impaired O
in O
arteries, O
but O
not O
veins, O
from O
DOCA-salt B-CHEMICAL
rats. O
Sympathetic O
autoreceptor O
dysfunction O
is O
not O
specific O
to O
α2ARs, B-GENE-N
but O
there O
is O
a O
more O
general O
disruption O
of O
prejunctional O
mechanisms O
controlling O
sympathetic O
neurotransmitter O
release O
in O
DOCA-salt B-CHEMICAL
hypertension. O
Functional O
consequences O
of O
the O

arrhythmogenic O
G306R B-GENE-N
KvLQT1 B-GENE-Y
K+ B-GENE-N
channel I-GENE-N
mutant O
probed O
by O
viral O
gene O
transfer O
in O
cardiomyocytes. O
IKs, O
the O
slow O
component O
of O
the O
delayed O
rectifier O
potassium B-CHEMICAL
current, O
figures O
prominently O
in O
the O
repolarization O
of O
heart O
cells. O
The O
K+ B-GENE-N
channel I-GENE-N
gene O
KvLQT1 B-GENE-Y
is O
mutated O
in O
the O
heritable O
long O
QT O
(LQT) O
syndrome. O
Heterologous O
coexpression O
of O
KvLQT1 B-GENE-Y
and O
the O
accessory O
protein O
minK B-GENE-Y
yields O
an O
IKs-like O
current. O
Nevertheless, O
the O
links O
between O

KvLQT1 B-GENE-Y
and O
cardiac O
IKs O
are O
largely O
inferential. O
Since O
the O
LQT O
syndrome O
mutant O
KvLQT1-G306R B-GENE-Y
suppresses O
channel O
activity O
when O
coexpressed O
with O
wild-type O
KvLQT1 B-GENE-Y
in O
a O
heterologous O
system, O
overexpression O
of O
this O
mutant O
in O
cardiomyocytes O
should O
reduce O
or O
eliminate O
native O
IKs O
if O
KvLQT1 B-GENE-Y
is O
indeed O
the O
major O
molecular O
component O
of O
this O
current. O
To O
test O
this O
idea, O
we O
created O
the O
adenovirus O
AdRMGI-KvLQT1-G306R, B-GENE-Y

which O
overexpresses O
KvLQT1-G306R B-GENE-Y
channels. O
In O
> O
60 O
% O
of O
neonatal O
mouse O
myocytes, O
a O
sizable O
IKs O
could O
be O
measured O
using O
perforated-patch O
recordings O
(8.0 O
+/- O
1.6 O
pA O
pF-1, O
n O
= O
13). O
IKs O
was O
increased O
by O
forskolin B-CHEMICAL
and O
blocked O
by O
clofilium B-CHEMICAL
or O
indapamide B-CHEMICAL
but O
not O
by O
E-4031. B-CHEMICAL
While O
cells O
infected O
with O
a O
reporter O
virus O
expressing O
only O
green O
fluorescent O
protein O
(GFP) O
displayed O
IKs O
similar O
to O
that O
in O
uninfected O

cells, O
AdRMGI-KvLQT1-G306R-infected B-GENE-Y
cells O
showed O
a O
significantly O
reduced O
IKs O
(2.4 O
+/- O
1.1 O
pA O
pF-1, O
n O
= O
10, O
P O
< O
0.01) O
when O
measured O
60-72 O
h O
after O
infection. O
Similar O
results O
were O
observed O
in O
adult O
guinea-pig O
myocytes O
(5.9 O
+/- O
1.2 O
pA O
pF-1, O
n O
= O
9, O
for O
control O
vs. O
0.1 O
+/- O
0.1 O
pA O
pF-1, O
n O
= O
5, O
for O

AdRMGI-KvLQT1-G306R-infected B-GENE-Y
cells). O
We O
conclude O
that O
KvLQT1 B-GENE-Y
is O
the O
major O
molecular O
component O
of O
IKs. O
Our O
results O
further O
establish O
a O
dominant-negative O
mechanism O
for O
the O
G306R B-GENE-N
LQT O
syndrome O
mutation. O
Pasireotide: B-CHEMICAL
A O
Review O
of O
Its O
Use O
in O
Cushing's O
Disease. O
Pasireotide B-CHEMICAL
(Signifor(®)) B-CHEMICAL
is O
a O
new O
subcutaneous O
somatostatin B-GENE-Y
analogue O
that O
acts O
via O
somatostatin B-GENE-N
receptors I-GENE-N
to O
inhibit O
the O
secretion O
of O
corticotropin B-GENE-Y
from O
the O

pituitary O
adenoma O
in O
patients O
with O
Cushing's O
disease. O
Pasireotide B-CHEMICAL
has O
a O
receptor O
binding O
profile O
that O
is O
distinct O
from O
that O
of O
other O
somatostatin B-GENE-Y
analogues, O
binding O
with O
high O
affinity O
to O
somatostatin B-GENE-Y
receptor I-GENE-Y
subtype I-GENE-Y
5, I-GENE-Y
which O
is O
strongly O
over O
expressed O
in O
corticotroph O
adenoma O
cells. O
Pasireotide B-CHEMICAL
is O
the O
first O
pituitary-directed O
agent O
to O
be O
approved O
for O
use O
in O
Cushing's O
disease. O
In O
a O
phase O
III O
clinical O
trial O
in O
patients O
with O
Cushing's O
disease, O
twice-daily O
pasireotide B-CHEMICAL
600 O
or O
900 O
μg O
for O
6 O
months O

led O
to O
normalization O
of O
urinary O
free O
cortisol B-CHEMICAL
(UFC) O
levels O
in O
up O
to O
a O
quarter O
of O
all O
patients O
(primary O
endpoint) O
and O
significantly O
reduced O
mean O
UFC O
levels. O
The O
reduction O
in O
UFC O
levels O
is O
rapid O
(within O
one O
to O
two O
months) O
and O
sustained O
(up O
to O
24 O
months). O
Most O
patients O
who O
do O
not O
have O
an O
early O
response O
to O
pasireotide B-CHEMICAL
do O
not O
respond O
at O
a O
later O
time O
point. O
Decreases O
in O
UFC O
levels O
achieved O
during O
pasireotide B-CHEMICAL
treatment O
are O
accompanied O
by O
decreases O
in O
serum O
and O
salivary O
cortisol B-CHEMICAL
levels, O
as O
well O
as O
improvements O
in O
clinical O
signs O
and O
symptoms, O
including O
body O

weight, O
blood O
pressure O
and O
health-related O
quality-of-life. O
Pasireotide B-CHEMICAL
has O
a O
generally O
similar O
tolerability O
profile O
to O
that O
of O
other O
somatostatin B-GENE-Y
analogues, O
but O
is O
associated O
with O
a O
relatively O
high O
incidence O
of O
hyperglycaemia, O
requiring O
the O
addition O
or O
intensification O
of O
glucose-lowering B-CHEMICAL
medication O
in O
a O
substantial O
proportion O
of O
patients. O
Thus, O
pasireotide, B-CHEMICAL
together O
with O
on-going O
patient O
monitoring, O
provides O
a O
promising O
new O
option O
for O
the O
medical O
management O
of O
Cushing's O
disease. O
SB365, B-CHEMICAL
Pulsatilla B-CHEMICAL
saponin I-CHEMICAL
D I-CHEMICAL
suppresses O
the O
proliferation O
of O
human O
colon O
cancer O

cells O
and O
induces O
apoptosis O
by O
modulating O
the O
AKT/mTOR B-GENE-N
signalling O
pathway. O
Pulsatilla O
koreana O
has O
been O
used O
as O
a O
traditional O
medicine O
for O
the O
treatment O
of O
several O
diseases. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
SB365, B-CHEMICAL
Pulsatilla B-CHEMICAL
saponin I-CHEMICAL
D I-CHEMICAL
isolated O
from O
the O
root O
of O
P. O
koreana O
inhibits O
the O
progression O
of O
colon O
cancer. O
We O
found O
that O
SB365 B-CHEMICAL
strongly O
suppressed O
the O
growth O
and O
proliferation O
of O
colon O
cancer O
cells O
and O
induced O
their O
apoptosis. O
Also, O
SB365 B-CHEMICAL
showed O
anti-angiogenic O
activity O
by O
decreasing O
the O
expression O

of O
HIF-1α B-GENE-Y
and O
VEGF. B-GENE-Y
These O
results O
were O
confirmed O
by O
an O
in O
vivo O
study O
showing O
that O
SB365 B-CHEMICAL
significantly O
inhibited O
tumor O
growth O
by O
the O
induction O
of O
apoptosis O
and O
inhibition O
of O
angiogenesis O
with O
stronger O
anticancer O
activity O
than O
5-FU. B-CHEMICAL
When O
further O
examined O
for O
its O
anticancer O
mechanism, O
SB365 B-CHEMICAL
effectively O
suppressed O
the O
AKT/mTOR B-GENE-N
pathway O
both O
in O
vitro O
and O
in O
vivo. O
Taken O
together, O
our O
study O
demonstrated O
that O
SB365 B-CHEMICAL
inhibits O
the O
AKT/mTOR B-GENE-N
pathway, O
leading O
to O
the O
suppression O
of O
tumor O
growth O
and O

angiogenesis O
together O
with O
induction O
of O
apoptosis. O
Therefore, O
SB365 B-CHEMICAL
is O
a O
good O
candidate O
as O
a O
natural O
product O
for O
use O
in O
the O
treatment O
of O
colon O
cancer. O
Apolipoprotein B-GENE-Y
E3 I-GENE-Y
(apoE3) B-GENE-Y
safeguards O
pig O
proximal O
tubular O
LLC-PK1 O
cells O
against O
reduction O
in O
SGLT1 B-GENE-Y
activity O
induced O
by O
gentamicin B-CHEMICAL
C. I-CHEMICAL
Megalin, O
a O
family O
of O
endocytic B-GENE-N
receptors I-GENE-N
related O
to O
the O
low-density B-GENE-N
lipoprotein I-GENE-N
(LDL) I-GENE-N
receptor, I-GENE-N
is O
a O
major O
pathway O
for O
proximal O
tubular O
aminoglycoside B-CHEMICAL
accumulation. O
We O
previously O
reported O
that O

aminoglycoside B-CHEMICAL
antibiotics O
reduce O
SGLT1-dependent B-GENE-Y
glucose B-CHEMICAL
transport O
in O
pig O
proximal O
tubular O
epithelial O
LLC-PK1 O
cells O
in O
parallel O
with O
the O
order O
of O
their O
nephrotoxicity. O
In O
this O
study, O
using O
a O
model O
of O
gentamicin B-CHEMICAL
C I-CHEMICAL
(GMC)-induced B-CHEMICAL
reduction O
in O
SGLT1 B-GENE-Y
activity, O
we O
examined O
whether O
ligands O
for O
megalin O
protect O
LLC-PK1 O
cells O
from O
the O
GMC-induced B-CHEMICAL
reduction O
in O
SGLT1 B-GENE-Y
activity. O
We O
employed O
apolipoprotein B-GENE-Y
E3 I-GENE-Y
(apoE3) B-GENE-Y
and O
lactoferrin B-GENE-Y
as O

ligands O
for O
megalin. O
Then O
the O
cells O
were O
treated O
with O
various O
concentrations O
of O
apoE3, B-GENE-Y
lactoferrin B-GENE-Y
and O
bovine B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
with O
or O
without O
100 O
microg/ml O
of O
GMC, B-CHEMICAL
and O
the O
SGLT1-dependent B-GENE-Y
methyl B-CHEMICAL
alpha-D-glucopyranoside I-CHEMICAL
(AMG) B-CHEMICAL
uptake O
and O
levels O
of O
SGLT1 B-GENE-Y
expression O
were O
determined. O
As O
a O
result, O
we O
demonstrated O
that O
the O
apoE3 B-GENE-Y
significantly O
protects O
these O
cells O
from O
GMC-induced B-CHEMICAL
reduction O
in O
AMG B-CHEMICAL
uptake, O
but O
neither O
lactoferrin B-GENE-Y
nor O
albumin B-GENE-Y
does. O
In O
accord O
with O

a O
rise O
in O
AMG B-CHEMICAL
uptake O
activity, O
the O
mRNA O
and O
protein O
levels O
of O
SGLT1 B-GENE-Y
were O
apparently O
up-regulated O
in O
the O
presence O
of O
apoE3. B-GENE-Y
Furthermore, O
we O
found O
that O
the O
uptake O
of O
[3H] B-CHEMICAL
gentamicin I-CHEMICAL
is O
decreased O
by O
apoE3, B-GENE-Y
and O
that O
apoE3 B-GENE-Y
showed O
obvious O
protection O
against O
the O
GMC-dependent B-CHEMICAL
N-acetyl-beta-D-glucosamidase B-GENE-N
(NAG) B-GENE-N
release O
from O
LLC-PK1 O
cells. O
Thus, O
these O
results O
indicate O
that O
apoE3 B-GENE-Y
could O
be O
a O
valuable O
tool O
for O
the O
prevention O
of O
aminoglycoside B-CHEMICAL

nephrotoxicity. O
Actions O
of O
nizatidine, B-CHEMICAL
a O
selective O
histamine B-GENE-N
H2-receptor I-GENE-N
antagonist, O
on O
gastric O
acid O
secretion O
in O
dogs, O
rats O
and O
frogs. O
Nizatidine B-CHEMICAL
(LY139037), B-CHEMICAL
a O
selective O
histamine B-GENE-N
H2-receptor I-GENE-N
antagonist, O
is O
a O
potent O
inhibitor O
of O
gastric O
acid O
secretion. O
It O
was O
17.8 O
times O
as O
active O
as O
cimetidine B-CHEMICAL
on O
histamine B-CHEMICAL
(10(-5) O
M)-induced O
secretion O
from O
the O
isolated O
gastric O
mucosa O
of O
the O
bullfrog. O
Nizatidine B-CHEMICAL
was O
8.9 O
times O
as O
active O
as O

cimetidine B-CHEMICAL
on O
basal O
acid O
secretion O
of O
the O
chronic O
gastric O
fistula O
rats O
after O
s.c. O
administration. O
Against O
acid O
secretion O
from O
the O
vagally O
innervated O
gastric O
fistula O
and O
Heidenhain O
pouch O
of O
dogs O
stimulated O
with O
submaximal O
doses O
of O
histamine, B-CHEMICAL
methacholine B-CHEMICAL
and O
gastrin, B-GENE-Y
nizatidine B-CHEMICAL
was, O
respectively, O
6.5, O
5 O
and O
4.7 O
times O
as O
active O
as O
cimetidine B-CHEMICAL
by O
i.v. O
administration. O
Nizatidine B-CHEMICAL
was O
very O
well O
absorbed O
from O
the O
gut O
and O
was O
5 O
to O
10 O
times O
as O
active O
as O
cimetidine B-CHEMICAL
on O

gastric O
acid O
secretion O
of O
dogs O
induced O
by O
submaximal O
and O
maximal O
doses O
of O
histamine B-CHEMICAL
when O
given O
p.o. O
Equal O
molar O
doses O
of O
nizatidine B-CHEMICAL
showed O
equal O
peak O
effects O
when O
given O
i.v., O
s.c. O
or O
i.m. O
Pharmacological O
data O
indicate O
that O
nizatidine B-CHEMICAL
is O
safe O
and O
effective O
as O
an O
agent O
for O
the O
control O
of O
excessive O
gastric O
acid O
secretion. O
3D-QSAR-assisted O
drug O
design: O
identification O
of O
a O
potent O
quinazoline-based B-CHEMICAL
Aurora B-GENE-N
kinase I-GENE-N
inhibitor. O
We O
describe O
the O
3D-QSAR-assisted O
design O
of O
an O
Aurora B-GENE-Y
kinase I-GENE-Y
A I-GENE-Y
inhibitor O
with O

improved O
physicochemical O
properties, O
in O
vitro O
activity, O
and O
in O
vivo O
pharmacokinetic O
profiles O
over O
those O
of O
the O
initial O
lead. O
Three O
different O
3D-QSAR O
models O
were O
built O
and O
validated O
by O
using O
a O
set O
of O
66 O
pyrazole B-CHEMICAL
(Model O
I) O
and O
furanopyrimidine B-CHEMICAL
(Model O
II) O
compounds O
with O
IC(50) O
values O
toward O
Aurora B-GENE-Y
kinase I-GENE-Y
A I-GENE-Y
ranging O
from O
33 O
nM O
to O
10.5 O
μM. O
The O
best O
3D-QSAR O
model, O
Model O
III, O
constructed O
with O
24 O
training O
set O
compounds O
from O
both O
series, O
showed O
robustness O
(r(2) O

(CV) O
=0.54 O
and O
0.52 O
for O
CoMFA O
and O
CoMSIA, O
respectively) O
and O
superior O
predictive O
capacity O
for O
42 O
test O
set O
compounds O
(R(2) O
(pred) O
=0.52 O
and O
0.67, O
CoMFA O
and O
CoMSIA). O
Superimposition O
of O
CoMFA O
and O
CoMSIA O
Model O
III O
over O
the O
crystal O
structure O
of O
Aurora B-GENE-Y
kinase I-GENE-Y
A I-GENE-Y
suggests O
the O
potential O
to O
improve O
the O
activity O
of O
the O
ligands O
by O
decreasing O
the O
steric O
clash O
with O
Val147 O
and O
Leu139 O
and O
by O
increasing O
hydrophobic O
contact O
with O
Leu139 O
and O
Gly216 O

residues O
in O
the O
solvent-exposed O
region O
of O
the O
enzyme. O
Based O
on O
these O
suggestions, O
the O
rational O
redesign O
of O
furanopyrimidine B-CHEMICAL
24 O
(clog O
P=7.41; O
Aurora B-GENE-Y
A I-GENE-Y
IC(50) O
=43 O
nM; O
HCT-116 O
IC(50) O
=400 O
nM) O
led O
to O
the O
identification O
of O
quinazoline B-CHEMICAL
67 O
(clog O
P=5.28; O
Aurora B-GENE-Y
A I-GENE-Y
IC(50) O
=25 O
nM; O
HCT-116 O
IC(50) O
=23 O
nM). O
Rat O
in O
vivo O
pharmacokinetic O
studies O
showed O
that O
67 O
has O
better O

systemic O
exposure O
after O
i.v. O
administration O
than O
24, O
and O
holds O
potential O
for O
further O
development. O
NMDA B-GENE-N
Receptor I-GENE-N
Activation O
Down-Regulates O
Expression O
of O
δ B-GENE-Y
Subunit-Containing I-GENE-Y
GABA-A I-GENE-Y
Receptors I-GENE-Y
in O
Cultured O
Hippocampal O
Neurons. O
Neurosteroids O
are O
endogenous O
allosteric O
modulators O
of O
γ B-GENE-N
amino-butyric I-GENE-N
acid I-GENE-N
type I-GENE-N
A I-GENE-N
receptors I-GENE-N
(GABARs), B-GENE-N
and O
enhance O
GABAR-mediated B-GENE-N
inhibition. O
However, O
GABARs B-GENE-N
expressed O
on O
hippocampal O
dentate O
granule O
neurons O
of O
epileptic O
animals O
are O
modified O
such O

that O
their O
neurosteroid O
sensitivity O
is O
reduced O
and O
δ O
subunit O
expression O
is O
diminished. O
The O
molecular O
mechanisms O
triggering O
this O
GABAR B-GENE-N
plasticity O
were O
explored. O
In O
the O
cultured O
hippocampal O
neurons O
treatment O
with O
NMDA B-CHEMICAL
(10 O
μM) O
for O
48 O
hrs O
reduced O
surface O
expression O
of O
δ O
and O
α4 O
subunits, O
but O
did O
not O
increase O
expression O
of O
γ2 O
subunits. O
The O
tonic O
current O
recorded O
from O
neurons O
in O
NMDA-treated B-CHEMICAL
cultures O
was O
reduced, O
and O
its O
neurosteroid O
modulation O
was O
also O
diminished. O
In O
contrast, O
synaptic O
inhibition O
and O
its O
modulation O
by O
neurosteroids O
were O
preserved O
in O

these O
neurons. O
The O
time O
course O
of O
NMDA B-CHEMICAL
effects O
on O
surface O
and O
total O
δ O
subunit O
expression O
were O
distinct; O
shorter O
(6 O
hrs) O
treatment O
decreased O
surface O
expression, O
whereas O
longer O
treatment O
reduced O
both O
surface O
and O
total O
expression. O
APV B-CHEMICAL
blocked O
NMDA B-CHEMICAL
effects O
on O
δ O
subunit O
expression. O
Chelation O
of O
calcium B-CHEMICAL
ions O
by O
BAPTA-AM B-CHEMICAL
or O
blockade O
of O
ERK1/2 B-GENE-N
activation O
by O
UO126 B-CHEMICAL
also O
prevented O
the O
NMDA B-CHEMICAL
effects. O
Thus O
prolonged O
activation O
of O
NMDA B-GENE-N
receptors I-GENE-N
in O
hippocampal O
neurons O
reduced O
GABAR B-GENE-Y
δ I-GENE-Y
subunit I-GENE-Y
expression O
through O
Ca2+ B-CHEMICAL
entry O
and O
at O
least O
in O
part O
by O
ERK1/2 B-GENE-N

activation. O
Conjugated O
linoleic B-CHEMICAL
acid I-CHEMICAL
and O
calcium B-CHEMICAL
co-supplementation O
improves O
bone O
health O
in O
ovariectomised O
mice. O
Osteoporosis O
is O
a O
significant O
health O
concern O
for O
the O
elderly; O
conjugated O
linoleic B-CHEMICAL
acid I-CHEMICAL
(CLA) O
has O
been O
shown O
to O
improve O
overall O
bone O
mass O
when O
calcium B-CHEMICAL
is O
included O
as O
a O
co-supplement. O
However, O
potential O
effects O
of O
CLA O
and O
calcium B-CHEMICAL
on O
bone O
mass O
during O
a O
period O
of O
bone O
loss O
have O
not O
been O
reported. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
how O
dietary O
calcium B-CHEMICAL
modulates O
the O
effects O
of O
conjugated O
linoleic B-CHEMICAL
acid I-CHEMICAL
(CLA) O

in O
preventing O
bone O
loss, O
using O
an O
ovariectomised O
mouse O
model. O
CLA O
supplementation O
significantly O
prevented O
ovariectomy-associated O
weight O
and O
fat O
mass O
gain, O
compared O
to O
non-supplemented O
controls. O
CLA O
significantly O
increased O
bone O
markers O
without O
major O
changes O
in O
bone O
mineral O
composition O
in O
the O
femur O
compared O
to O
respective O
controls. O
CLA O
treatment O
increased O
serum O
parathyroid B-GENE-Y
hormone I-GENE-Y
(PTH) B-GENE-Y
significantly O
(p=0.0172), O
while O
serum O
1,25-dihydroxyvitamin B-CHEMICAL
D3 I-CHEMICAL
concentration O
was O
not O
changed O
by O
CLA. O
Meanwhile, O
CLA O
significantly O
reduced O
femur O
tartrate B-GENE-Y
resistant I-GENE-Y

acid I-GENE-Y
phosphatase I-GENE-Y
(TRAP) B-GENE-Y
activity, O
suggesting O
potential O
reduction O
of O
osteoclastogenesis. O
The O
data O
suggest O
that O
CLA, O
along O
with O
dietary O
calcium, B-CHEMICAL
has O
great O
potential O
to O
be O
used O
to O
prevent O
bone O
loss O
and O
weight O
gain O
associated O
with O
menopause. O
Testosterone B-CHEMICAL
deficiency O
induces O
markedly O
decreased O
serum O
triglycerides, B-CHEMICAL
increased O
small O
dense O
LDL, B-GENE-N
and O
hepatic O
steatosis O
mediated O
by O
dysregulation O
of O
lipid O
assembly O
and O
secretion O
in O
mice O
fed O
a O
high-fat O
diet. O
OBJECTIVE: O
Although O
low O
serum O
testosterone B-CHEMICAL
(T) O
is O
associated O

with O
metabolic O
disorders, O
the O
mechanism O
of O
this O
association O
is O
unclear. O
The O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
combined O
effects O
of O
T O
deficiency O
and O
a O
high-fat O
diet O
(HFD) O
on O
hepatic O
lipid O
homeostasis O
in O
mice. O
MATERIALS/METHODS: O
Orchiectomized O
(ORX) O
mice O
and O
sham-operated O
(SHAM) O
mice O
were O
randomly O
divided O
into O
five O
groups: O
SHAM O
mice O
fed O
a O
standard O
diet O
(SD), O
SHAM O
mice O
fed O
HFD, O
ORX O
mice O
fed O
SD, O
ORX O
mice O
fed O
HFD, O
and O
ORX O
mice O
fed O

HFD O
with O
T O
supplementation. O
After O
4weeks O
of O
treatment, O
we O
investigated O
the O
synthesis O
and O
secretion O
of O
lipids O
in O
the O
liver O
and O
detailed O
serum O
lipoprotein O
profiles O
in O
each O
group. O
RESULTS: O
ORX O
mice O
fed O
HFD O
showed O
increased O
hepatic O
steatosis, O
markedly O
decreased O
serum O
triglyceride B-CHEMICAL
(TG) O
and O
TG-VLDL B-GENE-N
content, O
and O
increased O
serum O
very O
small-LDL B-GENE-N
content. O
Gene O
expression O
analysis O
revealed O
that O
ORX O
mice O
fed O
HFD O
showed O
significantly O
decreased O
expression O
of O
microsomal B-GENE-Y
triglyceride I-GENE-Y
transfer I-GENE-Y
protein, I-GENE-Y

lipin-1, B-GENE-Y
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR)-α I-GENE-Y
and O
PPAR-γ B-GENE-Y
coactivator I-GENE-Y
1-α, I-GENE-Y
and O
significantly O
increased O
sterol B-GENE-Y
regulatory I-GENE-Y
element-binding I-GENE-Y
protein-1, I-GENE-Y
diacylglycerol B-GENE-Y
acyltransferase-2 I-GENE-Y
and O
fatty B-GENE-Y
acid I-GENE-Y
synthase. I-GENE-Y
Reduction O
of O
hepatic O
AMPK B-GENE-N
phosphorylation O
was O
observed O
in O
ORX O
mice O
fed O
HFD. O
These O
perturbations O
in O
ORX O
mice O
fed O
HFD O
were O
normalized O
to O
the O
levels O
of O
SHAM O
mice O
fed O
HFD O
by O
T O

supplementation. O
CONCLUSION: O
T O
deficiency O
is O
associated O
with O
failure O
of O
lipid O
homeostasis O
mediated O
by O
altered O
expression O
of O
genes O
involved O
in O
hepatic O
assembly O
and O
secretion O
of O
lipids. O
Two O
distinct O
mechanisms O
of O
Topoisomerase B-GENE-Y
1-dependent I-GENE-Y
mutagenesis O
in O
yeast. O
Topoisomerase B-GENE-Y
1 I-GENE-Y
(Top1) B-GENE-Y
resolves O
transcription-associated O
supercoils O
by O
generating O
transient O
single-strand O
breaks O
in O
DNA. O
Top1 B-GENE-Y
activity O
in O
yeast O
is O
a O
major O
source O
of O
transcription-associated O
mutagenesis, O
generating O
a O
distinctive O
mutation O
signature O
characterized O
by O
deletions O
in O
short, O
tandem O
repeats. O
A O
similar O
signature O
is O
associated O
with O
the O

persistence O
of O
ribonucleoside B-CHEMICAL
monophosphates I-CHEMICAL
(rNMPs) B-CHEMICAL
in O
DNA, O
and O
it O
also O
depends O
on O
Top1 B-GENE-Y
activity. O
There O
is O
only O
partial O
overlap, O
however, O
between O
Top1-dependent B-GENE-Y
deletion O
hotspots O
identified O
in O
highly O
transcribed O
DNA O
and O
those O
associated O
with O
rNMPs, B-CHEMICAL
suggesting O
the O
existence O
of O
both O
rNMP-dependent B-CHEMICAL
and O
rNMP-independent B-CHEMICAL
events. O
Here, O
we O
present O
genetic O
studies O
confirming O
that O
there O
are O
two O
distinct O
types O
of O
hotspots. O
Data O
suggest O
a O
novel O
model O
in O
which O
rNMP-dependent B-CHEMICAL
hotspots O
are O
generated O
by O
sequential O
Top1 B-GENE-Y
reactions O
and O
are O

consistent O
with O
rNMP-independent B-CHEMICAL
hotspots O
reflecting O
processing O
of O
a O
trapped O
Top1 B-GENE-Y
cleavage O
complex. O
Covalent O
modification O
of O
stathmin B-GENE-Y
by O
CCNU O
determined O
by O
FTMS O
analysis O
of O
modified O
proteins O
and O
tryptic O
peptides. O
Chemical O
modification O
of O
proteins O
is O
often O
carried O
out O
to O
generate O
protein-small O
molecule O
conjugates O
for O
various O
applications. O
The O
high O
resolution O
and O
mass O
accuracy O
of O
a O
Fourier O
transform O
mass O
spectrometer O
is O
particularly O
useful O
for O
assessing O
the O
extent O
or O
sites O
of O
covalent O
modifications. O
As O
protein-small O
molecule O
reactions O
often O
produce O
products O
with O
variable O
numbers O
of O
the O
compound O
incorporated O
at O
different O
sites, O
a O
direct O
mass O
analysis O
of O

the O
reaction O
products O
at O
times O
yields O
mass O
spectra O
hard O
to O
interpret. O
Chromatographic O
separation O
at O
protein O
level O
could O
reduce O
the O
complexity O
of O
a O
sample, O
thus O
allowing O
more O
accurate O
mass O
spectrometric O
analysis. O
In O
this O
report, O
we O
demonstrate O
the O
utility O
of O
reversed-phase O
protein O
chromatography O
and O
FT-ICR O
mass O
spectrometry O
in O
analyzing O
CCNU O
(lomustine, B-CHEMICAL
1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea, B-CHEMICAL
MW: O
233.7Da) O
modification O
of O
stathmin. B-GENE-Y
With O
this O
combined O

approach, O
we O
determined O
the O
stoichiometry O
as O
well O
as O
sites O
of O
CCNU O
incorporation O
into O
the O
protein, O
demonstrating O
differential O
reactivity O
of O
several O
lysyl O
residues O
to O
CCNU O
alkylation. O
Amitriptyline B-CHEMICAL
is O
a O
TrkA B-GENE-Y
and O
TrkB B-GENE-Y
receptor O
agonist O
that O
promotes O
TrkA/TrkB B-GENE-Y
heterodimerization O
and O
has O
potent O
neurotrophic O
activity. O
Neurotrophins, B-GENE-N
the O
cognate O
ligands O
for O
the O
Trk B-GENE-N
receptors, I-GENE-N
are O
homodimers O
and O
induce O
Trk B-GENE-N
dimerization O
through O
a O
symmetric O
bivalent O
mechanism. O
We O
report O
here O
that O

amitriptyline, B-CHEMICAL
an O
antidepressant O
drug, O
directly O
binds O
TrkA B-GENE-Y
and O
TrkB B-GENE-Y
and O
triggers O
their O
dimerization O
and O
activation. O
Amitriptyline, B-CHEMICAL
but O
not O
any O
other O
tricyclic B-CHEMICAL
or O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitor O
antidepressants, O
promotes O
TrkA B-GENE-Y
autophosphorylation O
in O
primary O
neurons O
and O
induces O
neurite O
outgrowth O
in O
PC12 O
cells. O
Amitriptyline B-CHEMICAL
binds O
the O
extracellular O
domain O
of O
both O
TrkA B-GENE-Y
and O
TrkB B-GENE-Y
and O
promotes O
TrkA-TrkB B-GENE-Y
receptor O
heterodimerization. O
Truncation O
of O

amitriptyline B-CHEMICAL
binding O
motif O
on O
TrkA B-GENE-Y
abrogates O
the O
receptor O
dimerization O
by O
amitriptyline. B-CHEMICAL
Administration O
of O
amitriptyline B-CHEMICAL
to O
mice O
activates O
both O
receptors O
and O
significantly O
reduces O
kainic B-CHEMICAL
acid-triggered I-CHEMICAL
neuronal O
cell O
death. O
Inhibition O
of O
TrkA, B-GENE-Y
but O
not O
TrkB, B-GENE-Y
abolishes O
amitriptyline's O
neuroprotective O
effect O
without O
impairing O
its O
antidepressant O
activity. O
Thus, O
amitriptyline B-CHEMICAL
acts O
as O
a O
TrkA B-GENE-Y
and O
TrkB B-GENE-Y
agonist O
and O
possesses O
marked O
neurotrophic O
activity. O
Truncated O

ErbB2 B-GENE-Y
receptor O
(p95ErbB2) B-GENE-Y
is O
regulated O
by O
heregulin B-GENE-Y
through O
heterodimer O
formation O
with O
ErbB3 B-GENE-Y
yet O
remains O
sensitive O
to O
the O
dual O
EGFR/ErbB2 B-GENE-Y
kinase O
inhibitor O
GW572016. B-CHEMICAL
The O
expression O
of O
the O
NH2 B-CHEMICAL
terminally O
truncated O
ErbB2 B-GENE-Y
receptor O
(p95ErbB2) B-GENE-Y
in O
breast O
cancer O
correlates O
with O
metastatic O
disease O
progression O
compared O
with O
the O
expression O
of O
full-length O
p185ErbB2. B-GENE-Y
We O
now O
show O
that O
heregulin B-GENE-Y
(HRG), B-GENE-Y
but O
not O
EGF, B-GENE-Y

stimulates O
p95ErbB2 B-GENE-Y
phosphorylation O
in O
BT474 O
breast O
cancer O
cells. O
Furthermore, O
phospho-p95ErbB2 B-GENE-Y
forms O
heterodimers O
with O
ErbB3, B-GENE-Y
but O
not O
EGFR, B-GENE-Y
while O
p185ErbB2 B-GENE-Y
heterodimerizes O
with O
both O
EGFR B-GENE-Y
and O
ErbB3. B-GENE-Y
The O
predilection O
of O
p95ErbB2 B-GENE-Y
to O
heterodimerize O
with O
ErbB3 B-GENE-Y
provides O
an O
explanation O
for O
its O
regulation O
by O
HRG, B-GENE-Y
an O
ErbB3 B-GENE-Y
ligand. O

GW572016, B-CHEMICAL
a O
reversible O
small O
molecule O
inhibitor O
of O
EGFR B-GENE-Y
and O
ErbB2 B-GENE-Y
tyrosine B-GENE-N
kinases, I-GENE-N
inhibits O
baseline O
p95ErbB2 B-GENE-Y
phosphorylation O
in O
BT474 O
cells O
and O
tumor O
xenografts. O
Inhibition O
of O
p95ErbB2, B-GENE-Y
p185ErbB2, B-GENE-Y
and O
EGFR B-GENE-Y
phosphorylation O
by O
GW572016 B-CHEMICAL
resulted O
in O
the O
inhibition O
of O
downstream O
phospho-Erk1/2, B-GENE-N
phospho-AKT, B-GENE-N
and O
cyclin B-GENE-N

D I-GENE-N
steady-state O
protein O
levels. O
Increased O
phosphorylation O
of O
p95ErbB2 B-GENE-Y
and O
AKT B-GENE-N
in O
response O
to O
HRG B-GENE-N
was O
abrogated O
to O
varying O
degrees O
by O
GW572016. B-CHEMICAL
In O
contrast, O
trastuzumab O
did O
not O
inhibit O
p95ErbB2 B-GENE-Y
phosphorylation O
or O
the O
expression O
of O
downstream O
phospho-Erk1/2, B-GENE-N
phospho-AKT, B-GENE-N
or O
cyclin B-GENE-N
D. I-GENE-N
It O
is O
tempting O
to O
speculate O
that O
trastuzumab O
resistance O
may O
be O
mediated O
in O
part O
by O
the O
selection O
of O

p95ErbB2-expressing B-GENE-Y
breast O
cancer O
cells O
capable O
of O
exerting O
potent O
growth O
and O
prosurvival O
signals O
through O
p95ErbB2-ErbB3 B-GENE-Y
heterodimers. O
Thus, O
p95ErbB2 B-GENE-Y
represents O
a O
target O
for O
therapeutic O
intervention, O
and O
one O
that O
is O
sensitive O
to O
GW572016 B-CHEMICAL
therapy. O
Nonsteroidal O
anti-inflammatory O
drugs O
induce O
colorectal O
cancer O
cell O
apoptosis O
by O
suppressing O
14-3-3epsilon. B-GENE-Y
To O
determine O
the O
role O
of O
14-3-3 B-GENE-N
in O
colorectal O
cancer O
apoptosis O
induced O
by O

nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs), O
we O
evaluated O
the O
effects O
of O
sulindac B-CHEMICAL
on O
14-3-3epsilon B-GENE-Y
protein I-GENE-Y
expression O
in O
colorectal O
cancer O
cells. O
Sulindac B-CHEMICAL
sulfide I-CHEMICAL
inhibited O
14-3-3epsilon B-GENE-Y
proteins I-GENE-Y
in O
HT-29 O
and O
DLD-1 O
cells O
in O
a O
time- O
and O
concentration-dependent O
manner. O
Sulindac B-CHEMICAL
sulfone I-CHEMICAL
at O
600 O
mumol/L O
inhibited O
14-3-3epsilon O
protein O
expression O
in O
HT-29. O
Indomethacin B-CHEMICAL
and O
SC-236, B-CHEMICAL
a O
selective O

cyclooxygenase-2 B-GENE-Y
(COX-2) B-GENE-Y
inhibitor, O
exerted O
a O
similar O
effect O
as O
sulindac. B-CHEMICAL
Sulindac B-CHEMICAL
suppressed O
14-3-3epsilon O
promoter O
activity. O
As O
14-3-3epsilon B-GENE-N
promoter I-GENE-N
activation O
is O
mediated O
by O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
delta I-GENE-Y
(PPARdelta), B-GENE-Y
we O
determined O
the O
correlation O
between O
14-3-3epsilon B-GENE-Y
inhibition O
and O
PPARdelta B-GENE-Y
suppression O
by O
NSAIDs. O
Sulindac B-CHEMICAL
sulfide I-CHEMICAL
inhibited O
PPARdelta B-GENE-Y
protein O
expression O
and O
PPARdelta B-GENE-Y
transcriptional O
activity. O

Overexpression O
of O
PPARdelta B-GENE-Y
by O
adenoviral O
transfer O
rescued O
14-3-3epsilon B-GENE-Y
proteins O
from O
elimination O
by O
sulindac B-CHEMICAL
or O
indomethacin. B-CHEMICAL
NSAID-induced O
14-3-3epsilon B-GENE-Y
suppression O
was O
associated O
with O
reduced O
cytosolic B-GENE-Y
Bad I-GENE-Y
with O
elevation O
of O
mitochondrial B-GENE-Y
Bad I-GENE-Y
and O
increase O
in O
apoptosis O
which O
was O
rescued O
by O
Ad-PPARdelta B-GENE-Y
transduction. O
Stable O
expression O
of O
14-3-3epsilon B-GENE-Y
in O
HT-29 O
significantly O
protected O
cells O
from O
apoptosis. O
Our O
findings O
shed O
light O
on O
a O
novel O
mechanism O
by O
which O
NSAIDs O
induce O
colorectal O

cancer O
apoptosis O
via O
the O
PPARdelta/14-3-3epsilon B-GENE-Y
transcriptional O
pathway. O
These O
results O
suggest O
that O
14-3-3epsilon B-GENE-Y
is O
a O
target O
for O
the O
prevention O
and O
therapy O
of O
colorectal O
cancer. O
Cellular O
and O
pharmacogenetics O
foundation O
of O
synergistic O
interaction O
of O
pemetrexed B-CHEMICAL
and O
gemcitabine B-CHEMICAL
in O
human O
non-small-cell O
lung O
cancer O
cells. O
Gemcitabine B-CHEMICAL
and O
pemetrexed B-CHEMICAL
are O
effective O
agents O
in O
the O
treatment O
of O
non-small-cell O
lung O
cancer O
(NSCLC), O
and O
the O
present O
study O
investigates O
cellular O

and O
genetic O
aspects O
of O
their O
interaction O
against O
A549, O
Calu-1, O
and O
Calu-6 O
cells. O
Cells O
were O
treated O
with O
pemetrexed B-CHEMICAL
and O
gemcitabine, B-CHEMICAL
and O
their O
interaction O
was O
assessed O
using O
the O
combination O
index. O
The O
role O
of O
drug O
metabolism O
in O
gemcitabine B-CHEMICAL
cytotoxicity O
was O
examined O
with O
inhibitors O
of O
deoxycytidine B-GENE-Y
kinase I-GENE-Y
(dCK), B-GENE-Y
5'-nucleotidase, B-GENE-Y
and O
cytidine B-GENE-Y
deaminase, I-GENE-Y
whereas O
the O
role O
of O
pemetrexed O
targets, O
thymidylate B-GENE-Y
synthase I-GENE-Y

(TS), B-GENE-Y
dihydrofolate B-GENE-Y
reductase I-GENE-Y
(DHFR), B-GENE-Y
and O
glycinamide B-GENE-Y
ribonucleotide I-GENE-Y
formyltransferase I-GENE-Y
(GARFT) B-GENE-Y
in O
drug O
chemosensitivity O
was O
analyzed O
in O
cytotoxicity O
rescue O
studies. O
The O
effect O
of O
gemcitabine B-CHEMICAL
and O
pemetrexed O
on O
Akt B-GENE-N
phosphorylation O
was O
investigated O
with O
enzyme-linked O
immunosorbent O
assay, O
whereas O
quantitative O
polymerase O
chain O
reaction O
(PCR) O
was O
used O
to O
study O
target O
gene-expression O
profiles O
and O
its O
modulation O
by O
each O
drug. O

Synergistic O
cytotoxicity O
was O
demonstrated, O
and O
pemetrexed B-CHEMICAL
significantly O
decreased O
the O
amount O
of O
phosphorylated B-GENE-N
Akt, I-GENE-N
enhanced O
apoptosis, O
and O
increased O
the O
expression O
of O
dCK B-GENE-Y
in O
A549 O
and O
Calu-6 O
cells, O
as O
well O
as O
the O
expression O
of O
the O
human B-GENE-Y
nucleoside I-GENE-Y
equilibrative I-GENE-Y
transporter I-GENE-Y
1 I-GENE-Y
(hENT1) B-GENE-Y
in O
all O
cell O
lines. O
PCR O
demonstrated O
a O
correlation O
between O
dCK B-GENE-Y
expression O
and O
gemcitabine B-CHEMICAL
sensitivity, O
whereas O
expression O
of O
TS, B-GENE-Y
DHFR, B-GENE-Y
and O
GARFT B-GENE-Y
was O
predictive O
of O

pemetrexed B-CHEMICAL
chemosensitivity. O
These O
data O
demonstrated O
that O
1) O
gemcitabine B-CHEMICAL
and O
pemetrexed B-CHEMICAL
synergistically O
interact O
against O
NSCLC O
cells O
through O
the O
suppression O
of O
Akt B-GENE-N
phosphorylation O
and O
induction O
of O
apoptosis; O
2) O
the O
gene O
expression O
profile O
of O
critical O
genes O
may O
predict O
for O
drug O
chemosensitivity; O
and O
3) O
pemetrexed B-CHEMICAL
enhances O
dCK B-GENE-Y
and O
hENT1 B-GENE-Y
expression, O
thus O
suggesting O
the O
role O
of O
gene-expression O
modulation O
for O
rational O
development O
of O
chemotherapy O
combinations. O
Tissue O
expression O
and O
translational O
control O

of O
rat B-GENE-Y
kynurenine I-GENE-Y
aminotransferase/glutamine I-GENE-Y
transaminase I-GENE-Y
K I-GENE-Y
mRNAs. O
Kynurenic B-CHEMICAL
acid I-CHEMICAL
(KA) B-CHEMICAL
is O
an O
endogenous O
glutamate B-GENE-N
receptor I-GENE-N
antagonist O
at O
the O
level O
of O
the O
different O
ionotropic B-GENE-N
glutamate I-GENE-N
receptors. I-GENE-N
One O
of O
the O
enzymes O
responsible O
for O
the O
production O
of O
KA, B-CHEMICAL
kynurenine B-GENE-Y
aminotransferase I-GENE-Y
I I-GENE-Y
(KATI), B-GENE-Y
also O
catalyses O
the O
reversible O
transamination O
of O
glutamine B-CHEMICAL
to O
oxoglutaramic B-CHEMICAL
acid I-CHEMICAL
(GTK, B-GENE-Y
EC B-GENE-Y
2.6.1.15). I-GENE-Y
The O
enzyme O
exists O

in O
a O
cytosolic O
and O
in O
a O
mitochondrial O
form O
because O
of O
the O
presence O
of O
two O
different O
KATI B-GENE-Y
mRNAs O
coding O
for O
a O
protein O
respectively O
with O
and O
without O
leader B-GENE-N
sequence I-GENE-N
targeting O
the O
protein O
into O
mitochondria. O
We O
have O
cloned O
from O
a O
phage O
library O
of O
rat O
kidney O
cDNA O
four O
new O
KATI B-GENE-Y
cDNAs O
containing O
different O
5' B-GENE-N
untranslated I-GENE-N
regions I-GENE-N
(UTRs). B-GENE-N
One O
of O
the O
transcripts O
(+14KATI B-GENE-Y
cDNA) O
contains O
an O
alternative O
site O
of O
initiation O
of O
translation. O
The O
tissue O
distribution O
of O
the O
different O
transcripts O
was O
studied O
by O
RT-PCR. O
The O
study O
demonstrated O
that O

several O
KATI B-GENE-Y
mRNAs O
are O
constitutively O
expressed O
in O
ubiquitous O
manner, O
while O
+14KATI B-GENE-Y
mRNA O
is O
present O
only O
in O
kidney. O
The O
translational O
efficiency O
of O
the O
different O
transcripts O
was O
studied O
in O
vitro O
and O
enzymatic O
activities O
were O
measured O
in O
transiently O
transfected O
Cos-1 O
cells. O
Each O
KATI B-GENE-Y
mRNA O
exhibits O
a O
different O
in O
vitro O
translational O
efficiency, O
which O
corresponds O
to O
different O
levels O
of O
KAT B-GENE-Y
enzymatic O
activity O
in O
transfected O
cells. O
Both O
findings O
correlate O
with O
the O
predicted O
accessibility O
of O
the O
ribosomal O
binding O
sites O
of O
the O
different O
mRNAs. O

The O
structure O
of O
the O
rat B-GENE-Y
KATI/GTK I-GENE-Y
gene O
was O
also O
studied. O
The O
expression O
of O
several O
KATI B-GENE-Y
mRNAs O
with O
different O
5'UTRs B-GENE-N
represents O
an O
interesting O
example O
of O
transcriptional/translational O
control O
on O
the O
expression O
of O
pyridoxal B-GENE-N
phosphate I-GENE-N
(PLP)-dependent I-GENE-N
aminotransferases. I-GENE-N
Down-regulation O
of O
LRRK2 B-GENE-Y
in O
control O
and O
DAT B-GENE-Y
transfected O
HEK O
cells O
increases O
manganese-induced B-CHEMICAL
oxidative O
stress O
and O
cell O
toxicity. O
The O
extra-pyramidal O
symptoms O
associated O
with O
manganism B-CHEMICAL
often O
overlap O
with O
that O
seen O
in O
Parkinsonism O
suggesting O
a O
common O
link O
between O
the O
two O

disorders. O
Since O
wide O
deviations O
are O
observed O
in O
susceptibility O
and O
characteristics O
of O
the O
symptoms O
observed O
in O
manganism, B-CHEMICAL
these O
differences O
may O
be O
due O
to O
underlying O
genetic O
variability. O
Genes O
linked O
to O
early O
onset O
of O
Parkinsonism O
which O
includes O
ATP13A2 B-GENE-Y
and O
parkin B-GENE-Y
have O
already O
been O
suggested O
to O
promote O
development O
of O
Mn B-CHEMICAL
toxicity. O
Of O
the O
other O
Parkinson-linked O
genes, O
mutations O
in O
LRRK2, B-GENE-Y
an O
autosomal O
dominant O
gene, O
represent O
another O
likely O
candidate O
involved O
in O
the O
development O
of O
manganism. B-CHEMICAL
In O
this O
paper O
the O
effect O
of O
shRNA O
LRRK2 B-GENE-Y
knock-down O
on O
Mn B-CHEMICAL
toxicity O
was O
examined O

in O
control O
and O
DAT B-GENE-Y
transfected O
HEK293 O
cells. O
Results O
demonstrate O
that O
LRRK2 B-GENE-Y
down-regulation O
potentiates O
Mn B-CHEMICAL
toxicity O
in O
both O
control O
and O
DAT-transfected B-GENE-Y
cell O
as O
well O
as O
potentiates O
DA O
toxicity. O
Combined O
treatment O
of O
Mn B-CHEMICAL
and O
DA O
further O
augments O
cell O
toxicity, O
ROS O
production O
and O
JNK B-GENE-N
phosphorylation O
in O
LRRK2 B-GENE-Y
deficient O
cells O
compared O
to O
controls. O
Consistent O
with O
studies O
demonstrating O
that O
LRRK2 B-GENE-N
plays O
a O
role O
in O
the O
phosphorylation O
of O
p38, B-GENE-N
our O
results O
similarly O
demonstrate O
a O
decrease O
in O
p38 B-GENE-N

activation O
in O
LRRK2 B-GENE-Y
knock-down O
cells. O
Our O
findings O
suggest O
that O
null O
mutations O
in O
LRRK2 B-GENE-Y
which O
cause O
Parkinsonism O
potentiate O
Mn B-CHEMICAL
toxicity O
and O
increase O
susceptibility O
to O
develop O
manganism. B-CHEMICAL
Swim O
training O
of O
monosodium B-CHEMICAL
L-glutamate-obese I-CHEMICAL
mice O
improves O
the O
impaired O
insulin B-GENE-Y
receptor I-GENE-Y
tyrosine B-CHEMICAL
phosphorylation O
in O
pancreatic O
islets. O
The O
goal O
of O
the O
present O
study O
was O
to O
investigate O
changes O
on O
glucose B-CHEMICAL
homoeostasis O
and O
of O
the O
insulin B-GENE-Y
receptor I-GENE-Y
(IR) B-GENE-Y
and O
insulin B-GENE-Y
receptor I-GENE-Y
substrate-1 I-GENE-Y
(IRS-1) B-GENE-Y
signalling O

in O
pancreatic O
islets O
from O
MSG-obese B-CHEMICAL
mice O
submitted O
to O
or O
not O
submitted O
to O
swim O
training. O
Swim O
training O
of O
90-day-old O
MSG B-CHEMICAL
mice O
was O
used O
to O
evaluate O
whether O
signalling O
pathways O
of O
the O
IR B-GENE-Y
and O
IRS-1 B-GENE-Y
in O
islets O
are O
involved O
with O
the O
insulin B-GENE-N
resistance O
and O
glucose B-CHEMICAL
intolerance O
observed O
in O
this O
obese O
animal O
model. O
The O
results O
showed O
that O
IR B-GENE-Y
tyrosine B-CHEMICAL
phosphorylation O
(pIR) B-GENE-Y
was O
reduced O
by O
42 O
% O
in O
MSG-obese B-CHEMICAL
mice O
(MSG, B-CHEMICAL
6.7 O
± O
0.2 O
arbitrary O
units O

(a.u.); O
control, O
11.5 O
± O
0.4 O
a.u.); O
on O
the O
other O
hand, O
exercise O
training O
increased O
pIR B-GENE-Y
by O
76 O
% O
in O
MSG B-CHEMICAL
mice O
without O
affecting O
control O
mice O
(MSG, B-CHEMICAL
11.8 O
± O
0.3; O
control, O
12.8 O
± O
0.2 O
a.u.). O
Although O
the O
treatment O
with O
MSG B-CHEMICAL
increased O
IRS-1 B-GENE-Y
tyrosine B-CHEMICAL
phosphorylation O
(pIRS-1) B-GENE-Y
by O
96 O
% O
(MSG, B-CHEMICAL
17.02 O
± O
0.6; O
control, O
8.7 O
± O
0.2 O

a.u.), O
exercise O
training O
also O
increased O
it O
in O
both O
groups O
(control, O
13.6 O
± O
0.1; O
MSG, B-CHEMICAL
22.2 O
± O
1.1 O
a.u.). O
Current O
research O
shows O
that O
the O
practice O
of O
swim O
training O
increases O
the O
tyrosine B-CHEMICAL
phosphorylation O
of O
IRS-1 B-GENE-Y
which O
can O
modulate O
the O
effect O
caused O
by O
obesity O
in O
insulin B-GENE-Y
receptors. I-GENE-Y
Long-term O
use O
of O
sildenafil. B-CHEMICAL
The O
treatment O
of O
erectile O
dysfunction O
(ED) O
has O
been O
revolutionised O
by O
new O
agents O
to O
inhibit O
the O
enzyme O
PDE5. B-GENE-Y
The O
scientific O
basis O
of O
this O
treatment O

of O
ED O
includes O
relaxation O
of O
the O
corpus O
cavernosum O
smooth O
muscle O
tissue O
by O
inhibition O
of O
PDE5 B-GENE-Y
that O
breaks O
down O
cGMP, B-CHEMICAL
the O
key O
pathway O
for O
the O
production O
of O
erectile O
function O
in O
humans. O
Many O
clinical O
studies, O
both O
pre- O
and O
post-marketing, O
have O
demonstrated O
the O
clinical O
efficacy O
and O
safety O
of O
sildenafil B-CHEMICAL
(Viagra, B-CHEMICAL
Pfizer) O
- O
the O
first O
approved O
selective O
PDE B-GENE-N
inhibitor O
for O
the O
treatment O
of O
ED. O
Sildenafil B-CHEMICAL
is O
inhibitory O
of O
PDE5 B-GENE-Y
at O
a O
rate O
tenfold O
higher O
than O
for O
the O
next O
PDE B-GENE-N
(PDE6), B-GENE-N
which O
produces O
visual O
changes O
through O
the O

retinal O
rods. O
Its O
clinical O
effectiveness O
has O
been O
well O
documented O
in O
the O
majority O
of O
men O
with O
ED O
irrespective O
of O
aetiology. O
The O
aetiology O
of O
ED, O
also, O
does O
not O
appear O
to O
effect O
the O
function O
of O
sildenafil B-CHEMICAL
in O
relaxing O
corpus O
cavernosum O
smooth O
muscle O
tissue. O
Adverse O
events O
are O
usually O
associated O
with O
the O
vascular O
changes O
from O
PDE5 B-GENE-Y
inhibition. O
These O
include O
headache O
and O
flushing. O
Each O
of O
these O
adverse O
events, O
however, O
declines O
with O
medication O
use. O
With O
the O
use O
of O
sildenafil, B-CHEMICAL
it O
has O
been O
clearly, O
clinically O
demonstrated O
that O
the O
selective O
inhibition O
of O
PDE5 B-GENE-Y

is O
an O
appropriate, O
effective, O
safe O
method O
for O
the O
treatment O
of O
ED O
of O
all O
aetiologies O
and O
severities. O
Cytosolic B-GENE-Y
aspartate I-GENE-Y
aminotransferase, I-GENE-Y
a O
new O
partner O
in O
adipocyte O
glyceroneogenesis O
and O
an O
atypical O
target O
of O
thiazolidinedione. B-CHEMICAL
We O
show O
that O
cytosolic B-GENE-Y
aspartate I-GENE-Y
aminotransferase I-GENE-Y
(cAspAT) B-GENE-Y
is O
involved O
in O
adipocyte O
glyceroneogenesis, O
a O
regulated O
pathway O
that O
controls O
fatty B-CHEMICAL
acid I-CHEMICAL
homeostasis O
by O
promoting O
glycerol B-CHEMICAL
3-phosphate I-CHEMICAL
formation O
for O
fatty B-CHEMICAL
acid I-CHEMICAL

re-esterification O
during O
fasting. O
cAspAT B-GENE-Y
activity, O
as O
well O
as O
the O
incorporation O
of O
[(14)C]aspartate B-CHEMICAL
into O
the O
neutral O
lipid O
fraction O
of O
3T3-F442A B-GENE-N
adipocytes O
was O
stimulated O
by O
the O
thiazolidinedione B-CHEMICAL
(TZD) B-CHEMICAL
rosiglitazone. B-CHEMICAL
Conversely, O
the O
ratio O
of O
fatty B-CHEMICAL
acid I-CHEMICAL
to O
glycerol B-CHEMICAL
released O
into O
the O
medium O
decreased. O
Regulation O
of O
cAspAT B-GENE-Y
gene O
expression O
was O
specific O
to O
differentiated O
adipocytes O
and O
did O
not O
require O
any O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
gamma I-GENE-Y

(PPARgamma)/retinoid B-GENE-Y
X I-GENE-Y
receptor-alpha I-GENE-Y
direct O
binding. O
Nevertheless, O
PPARgamma B-GENE-Y
is O
indirectly O
necessary O
for O
both O
cAspAT B-GENE-Y
basal O
expression O
and O
TZD B-CHEMICAL
responsiveness O
because O
they O
are, O
respectively, O
diminished O
and O
abolished O
by O
ectopic O
overexpression O
of O
a O
dominant O
negative O
PPARgamma. B-GENE-Y
The O
cAspAT B-GENE-Y
TZD-responsive B-CHEMICAL
site O
was O
restricted O
to O
a O
single O
AGGACA B-CHEMICAL
hexanucleotide B-CHEMICAL
located O
at O
-381 O
to O
-376 O
bp O
whose O
mutation O
impaired O
the O
specific O
RORalpha B-GENE-Y
binding. O
RORalpha B-GENE-Y

ectopic O
expression O
activated O
the O
cAspAT B-GENE-Y
gene O
transcription O
in O
absence O
of O
rosiglitazone, B-CHEMICAL
and O
its O
protein O
amount O
in O
nuclear O
extracts O
is O
1.8-fold O
increased O
by O
rosiglitazone B-CHEMICAL
treatment O
of O
adipocytes. O
Finally, O
the O
amounts O
of O
RORalpha B-GENE-Y
and O
cAspAT B-GENE-Y
mRNAs O
were O
similarly O
increased O
by O
TZD B-CHEMICAL
treatment O
of O
human O
adipose O
tissue O
explants, O
confirming O
coordinated O
regulation. O
Our O
data O
identify O
cAspAT B-GENE-Y
as O
a O
new O
member O
of O
glyceroneogenesis, O
transcriptionally O
regulated O
by O
TZD B-CHEMICAL
via O
the O
control O
of O
RORalpha B-GENE-Y
expression O
by O

PPARgamma B-GENE-Y
in O
adipocytes. O
ABT-199, B-CHEMICAL
a O
potent O
and O
selective O
BCL-2 B-GENE-Y
inhibitor, O
achieves O
antitumor O
activity O
while O
sparing O
platelets. O
Proteins O
in O
the O
B B-GENE-Y
cell I-GENE-Y
CLL/lymphoma I-GENE-Y
2 I-GENE-Y
(BCL-2) B-GENE-Y
family O
are O
key O
regulators O
of O
the O
apoptotic O
process. O
This O
family O
comprises O
proapoptotic O
and O
prosurvival O
proteins, O
and O
shifting O
the O
balance O
toward O
the O
latter O
is O
an O
established O
mechanism O
whereby O
cancer O
cells O
evade O
apoptosis. O
The O
therapeutic O
potential O
of O
directly O
inhibiting O
prosurvival O
proteins O
was O
unveiled O
with O
the O
development O
of O

navitoclax, B-CHEMICAL
a O
selective O
inhibitor O
of O
both O
BCL-2 B-GENE-Y
and O
BCL-2-like B-GENE-Y
1 I-GENE-Y
(BCL-X(L)), B-GENE-Y
which O
has O
shown O
clinical O
efficacy O
in O
some O
BCL-2-dependent B-GENE-Y
hematological O
cancers. O
However, O
concomitant O
on-target O
thrombocytopenia O
caused O
by O
BCL-X(L) B-GENE-Y
inhibition O
limits O
the O
efficacy O
achievable O
with O
this O
agent. O
Here O
we O
report O
the O
re-engineering O
of O
navitoclax B-CHEMICAL
to O
create O
a O
highly O
potent, O
orally O
bioavailable O
and O
BCL-2-selective B-GENE-Y
inhibitor, O

ABT-199. B-CHEMICAL
This O
compound O
inhibits O
the O
growth O
of O
BCL-2-dependent B-GENE-Y
tumors O
in O
vivo O
and O
spares O
human O
platelets. O
A O
single O
dose O
of O
ABT-199 B-CHEMICAL
in O
three O
patients O
with O
refractory O
chronic O
lymphocytic O
leukemia O
resulted O
in O
tumor O
lysis O
within O
24 O
h. O
These O
data O
indicate O
that O
selective O
pharmacological O
inhibition O
of O
BCL-2 B-GENE-Y
shows O
promise O
for O
the O
treatment O
of O
BCL-2-dependent B-GENE-Y
hematological O
cancers. O
Smad3 B-GENE-Y
mediates O
cigarette O
smoke O
extract O
(CSE) O
induction O
of O
VEGF B-GENE-Y
release O
by O
human O
fetal O
lung O
fibroblasts. O

Cigarette O
smoke O
is O
the O
major O
cause O
of O
chronic O
obstructive O
pulmonary O
disease O
(COPD), O
yet O
pathogenic O
mechanisms O
are O
not O
fully O
understood. O
Vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF) B-GENE-Y
is O
one O
of O
the O
major O
regulators O
of O
endothelial O
cell O
survival O
and O
is O
believed O
to O
play O
a O
role O
in O
the O
pathogenesis O
of O
COPD. O
Fibroblasts O
are O
a O
significant O
source O
of O
VEGF B-GENE-Y
in O
the O
lungs; O
however O
the O
effect O
of O
cigarette O
smoke O
exposure O
on O
VEGF B-GENE-Y
release O
by O
fibroblasts O
is O
not O
fully O
understood. O
We O
hypothesized O
that O
cigarette O
smoke-induced O
disturbed O

VEGF B-GENE-Y
release O
by O
human O
lung O
fibroblasts O
is O
a O
potential O
pathogenic O
mechanism O
that O
could O
contribute O
to O
COPD. O
Cigarette O
smoke O
extract O
(CSE) O
was O
prepared O
by O
modification O
of O
the O
methods O
of O
Carp O
and O
Janoff O
(American O
Review O
of O
Respiratory O
Disease, O
1978). O
Human O
fetal O
lung O
fibroblasts O
(HFL-1) O
were O
exposed O
to O
different O
concentrations O
of O
CSE O
and O
for O
different O
durations. O
VEGF B-GENE-Y
release O
into O
the O
media O
was O
measured O
using O
ELISA. O
TGF-β1 B-GENE-Y
receptor I-GENE-Y
(TβR1)/Smad3 B-GENE-Y
as O
a O
potential O
pathway O
for O

CSE O
modulated O
VEGF B-GENE-Y
release O
was O
also O
investigated O
using O
biochemical O
analyses O
and O
siRNA O
inhibition O
of O
Smad3 B-GENE-Y
and O
siRNA O
and O
pharmacologic O
inhibition O
of O
TβR1. B-GENE-Y
CSE O
induced O
VEGF B-GENE-Y
release O
by O
HFL-1 O
in O
concentration O
and O
time O
dependent O
manner. O
This O
was O
confirmed O
in O
two O
additional O
types O
of O
primary O
human O
fetal O
lung O
fibroblasts. O
CSE O
induced O
Smad3 B-GENE-Y
phosphorylation O
and O
nuclear O
translocation O
in O
HFL-1 O
cells. O
Silencing O
of O
Smad3 B-GENE-Y
by O
siRNA O
not O
only O
eliminated O
the O
stimulatory O
effect O
of O
CSE O
on O

VEGF B-GENE-Y
release O
but O
also O
inhibited O
baseline O
VEGF B-GENE-Y
production. O
Suppression O
of O
TβR1 B-GENE-Y
by O
the O
pharmacological O
inhibitor O
(SB431542) B-CHEMICAL
markedly O
reduced O
VEGF B-GENE-Y
release O
by O
HFL-1 O
in O
response O
to O
CSE O
and O
this O
effect O
was O
confirmed O
by O
TβR1 B-GENE-Y
siRNA. O
In O
contrast, O
nicotine O
inhibited O
VEGF B-GENE-Y
release O
by O
HFL-1 O
in O
a O
dose O
and O
time O
dependent O
manner. O
Our O
findings O
indicate O
that O
CSE O
stimulates O
Smad3-mediated B-GENE-Y
VEGF B-GENE-Y
release O
by O
lung O
fibroblasts. O
Nicotine B-CHEMICAL
does O
not O
account O
for O
the O

CSE O
stimulation O
of O
VEGF B-GENE-Y
in O
HFL-1. O
The O
ability O
of O
lung O
fibroblasts O
to O
produce O
VEGF B-GENE-Y
may O
play O
a O
role O
in O
pathogenesis O
of O
cigarette O
smoke O
induced O
lung O
disease. O
A O
novel O
metabotropic B-GENE-Y
glutamate I-GENE-Y
receptor I-GENE-Y
5 I-GENE-Y
positive O
allosteric O
modulator O
acts O
at O
a O
unique O
site O
and O
confers O
stimulus O
bias O
to O
mGlu5 B-GENE-Y
signaling. O
Metabotropic B-GENE-Y
glutamate I-GENE-Y
receptor I-GENE-Y
5 I-GENE-Y
(mGlu5) B-GENE-Y
is O
a O
target O
for O
the O
treatment O
of O
central O
nervous O
system O
(CNS) O
disorders, O
such O
as O
schizophrenia O
and O
Alzheimer's O
disease. O
Furthermore, O
mGlu5 B-GENE-Y
has O

been O
shown O
to O
play O
an O
important O
role O
in O
hippocampal O
synaptic O
plasticity, O
specifically O
in O
long-term O
depression O
(LTD) O
and O
long-term O
potentiation O
(LTP), O
which O
is O
thought O
to O
be O
involved O
in O
cognition. O
Multiple O
mGlu5-positive B-GENE-Y
allosteric O
modulators O
(PAMs) O
have O
been O
developed O
from O
a O
variety O
of O
different O
scaffolds. O
Previous O
work O
has O
extensively O
characterized O
a O
common O
allosteric O
site O
on O
mGlu5, B-GENE-Y
termed O
the O
MPEP B-CHEMICAL
(2-Methyl-6-(phenylethynyl)pyridine) B-CHEMICAL
binding O

site. O
However, O
one O
mGlu5 B-GENE-Y
PAM, O
CPPHA B-CHEMICAL
(N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), B-CHEMICAL
interacts O
with O
a O
separate O
allosteric O
site O
on O
mGlu5. B-GENE-Y
Using O
cell-based O
assays O
and O
brain O
slice O
preparations, O
we O
characterized O
the O
interaction O
of O
a O
potent O
and O
efficacious O
mGlu5 B-GENE-Y
PAM O
from O
the O
CPPHA B-CHEMICAL

series O
termed O
NCFP B-CHEMICAL
(N-(4-chloro-2-((4-fluoro-1,3-dioxoisoindolin-2-yl)methyl)phenyl)picolinamide). B-CHEMICAL
NCFP B-CHEMICAL
binds O
to O
the O
CPPHA B-CHEMICAL
site O
on O
mGlu5 B-GENE-Y
and O
potentiates O
mGlu5-mediated B-GENE-Y
responses O
in O
both O
recombinant O
and O
native O
systems. O
However, O
NCFP B-CHEMICAL
provides O
greater O
mGlu5 B-GENE-Y
subtype O
selectivity O
than O
does O
CPPHA, B-CHEMICAL
making O
it O
more O
suitable O
for O
studies O
of O
effects O
on O
mGlu5 B-GENE-Y
in O
CNS O
preparations. O

Of O
interest, O
NCFP B-CHEMICAL
does O
not O
potentiate O
responses O
involved O
in O
hippocampal O
synaptic O
plasticity O
(LTD/LTP), O
setting O
it O
apart O
from O
other O
previously O
characterized O
MPEP B-CHEMICAL
site O
PAMs. O
This O
suggests O
that O
although O
mGlu5 B-GENE-Y
PAMs O
may O
have O
similar O
responses O
in O
some O
systems, O
they O
can O
induce O
differential O
effects O
on O
mGlu5-mediated B-GENE-Y
physiologic O
responses O
in O
the O
CNS. O
Such O
stimulus O
bias O
by O
mGlu5 B-GENE-Y
PAMs O
may O
complicate O
drug O
discovery O
efforts O
but O
would O
also O
allow O
for O
specifically O
tailored O
therapies, O
if O
pharmacological O
biases O
can O
be O
attributed O
to O
different O
therapeutic O
outcomes. O

G B-GENE-N
protein-coupled I-GENE-N
receptors I-GENE-N
as O
direct O
targets O
of O
inhaled O
anesthetics. O
The O
molecular O
pharmacology O
of O
inhalational O
anesthetics O
remains O
poorly O
understood. O
Despite O
accumulating O
evidence O
suggesting O
that O
neuronal O
membrane O
proteins O
are O
potential O
targets O
of O
inhaled O
anesthetics, O
most O
currently O
favored O
membrane O
protein O
targets O
lack O
any O
direct O
evidence O
for O
anesthetic O
binding. O
We O
report O
herein O
the O
location O
of O
the O
binding O
site O
for O
the O
inhaled O
anesthetic O
halothane B-CHEMICAL
at O
the O
amino B-CHEMICAL
acid I-CHEMICAL
residue O
level O
of O
resolution O
in O
the O
ligand O
binding O
cavity O
in O
a O
prototypical O
G B-GENE-N
protein-coupled I-GENE-N
receptor, I-GENE-N
bovine B-GENE-Y

rhodopsin. I-GENE-Y
Tryptophan B-CHEMICAL
fluorescence O
quenching O
and O
direct O
photoaffinity O
labeling O
with O
[(14)C]halothane B-CHEMICAL
suggested O
an O
interhelical O
location O
of O
halothane B-CHEMICAL
with O
a O
stoichiometry O
of O
1 O
(halothane/rhodopsin B-CHEMICAL
molar O
ratio). O
Radiosequence O
analysis O
of O
[(14)C]halothane-labeled B-CHEMICAL
rhodopsin B-GENE-Y
revealed O
that O
halothane B-CHEMICAL
contacts O
an O
amino B-CHEMICAL
acid I-CHEMICAL
residue O
(Trp265) O
lining O
the O
ligand O
binding O
cavity O
in O
the O
transmembrane O
core O
of O
the O
receptor. O
The O
predicted O
functional O

consequence, O
competition O
between O
halothane B-CHEMICAL
and O
the O
ligand O
retinal, O
was O
shown O
here O
by O
spectroscopy O
and O
is O
known O
to O
exist O
in O
vivo. O
These O
data O
suggest O
that O
competition O
with O
endogenous O
ligands O
may O
be O
a O
general O
mechanism O
of O
the O
action O
of O
halothane B-CHEMICAL
at O
this O
large O
family O
of O
signaling O
proteins. O
Effects O
of O
venlafaxine B-CHEMICAL
on O
extracellular O
concentrations O
of O
5-HT B-CHEMICAL
and O
noradrenaline B-CHEMICAL
in O
the O
rat O
frontal O
cortex: O
augmentation O
via O
5-HT1A B-GENE-Y
receptor O
antagonism. O
Venlafaxine B-CHEMICAL
is O
a O
novel O
serotonin/noradrenaline B-CHEMICAL

reuptake O
inhibitor O
(SNRI) O
which O
has O
been O
shown O
clinically O
to O
be O
an O
effective O
antidepressant O
(AD) O
with O
a O
faster O
onset O
of O
action O
than O
serotonin B-CHEMICAL
specific O
reuptake O
inhibitors O
(SSRI). O
Preclinically, O
venlafaxine B-CHEMICAL
has O
been O
shown O
to O
potently O
inhibit O
dorsal O
raphe O
neuronal O
(DRN) O
firing O
through O
a O
5-HT1A B-GENE-Y
mediated O
mechanism, O
in O
a O
similar O
manner O
to O
SSRIs. O
Here O
we O
demonstrate O
the O
acute O
neurochemical O
effects O
of O
venlafaxine B-CHEMICAL
on O
extracellular O
concentrations O
of O
5-HT B-CHEMICAL
and O

noradrenaline B-CHEMICAL
(NA) B-CHEMICAL
from O
the O
rat O
frontal O
cortex O
using O
in O
vivo O
microdialysis. O
Administration O
of O
venlafaxine B-CHEMICAL
(3-50 O
mg/kg O
s.c.) O
resulted O
in O
a O
significant O
dose-dependent O
increase O
in O
extracellular O
NA, B-CHEMICAL
but O
produced O
no O
significant O
increase O
in O
5-HT B-CHEMICAL
concentrations. O
Combination O
treatment O
with O
the O
selective O
5-HT1A B-GENE-Y
antagonist O
WAY100635 B-CHEMICAL
produced O
a O
dose-dependent O
augmentation O
of O
venlafaxine-induced B-CHEMICAL
(3-30 O
mg/kg O
s.c) O
extracellular O
5-HT B-CHEMICAL
concentrations, O
but O
had O
no O

further O
effect O
on O
NA B-CHEMICAL
above O
that O
produced O
by O
venlafaxine B-CHEMICAL
alone. O
WAY100635, B-CHEMICAL
at O
doses O
as O
low O
as O
0.03 O
mg/kg O
s.c., O
maintained O
this O
potentiation O
effect. O
The O
beta-adrenergic/5-HT1A B-GENE-Y
receptor O
antagonist O
(+/-)pindolol B-CHEMICAL
and O
the O
selective O
5-HT1B/D B-GENE-N
antagonist O
GR127935 B-CHEMICAL
produced O
no O
significant O
augmentation O
of O
venlafaxine-induced B-CHEMICAL
changes O
in O
either O
5-HT B-CHEMICAL
or O
NA. B-CHEMICAL
Using O
the O
alpha1 B-GENE-N
and I-GENE-N

alpha2-adrenoceptor I-GENE-N
antagonists, O
prazosin B-CHEMICAL
and O
idazoxane, B-CHEMICAL
we O
also O
demonstrate O
the O
role O
of O
the O
alpha-adrenoceptors B-GENE-N
in O
the O
augmentation O
of O
venlafaxine-induced B-CHEMICAL
changes. O
The O
possible O
mechanisms O
underlying O
venlafaxines B-CHEMICAL
improved O
clinical O
AD O
action O
and O
the O
potential O
for O
further O
enhancement O
of O
this O
SNRIs O
clinical O
effects O
are O
discussed. O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors, I-GENE-N
seizures, O
and O
the O
amygdala. O
The O
amygdala O
is O
a O
critical O
brain O
region O
for O
limbic O
seizure O
activity, O
but O
the O
mechanisms O
underlying O
its O

epileptic O
susceptibility O
are O
obscure. O
Several O
lines O
of O
evidence O
implicate O
GluR5 B-GENE-Y
(GLU(K5)) B-GENE-Y
kainate B-GENE-N
receptors, I-GENE-N
a O
type O
of O
ionotropic B-GENE-N
glutamate I-GENE-N
receptor, I-GENE-N
in O
the O
amygdala's O
vulnerability O
to O
seizures O
and O
epileptogenesis. O
GluR5 B-GENE-Y
mRNA O
is O
abundant O
in O
temporal O
lobe O
structures O
including O
the O
amygdala. O
Brain O
slice O
recordings O
indicate O
that O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
mediate O
a O
portion O
of O
the O
synaptic O
excitation O
of O
neurons O
in O
the O
rat O
basolateral O
amygdala. O

Whole-cell O
voltage-clamp O
studies O
demonstrate O
that O
GluR5 B-GENE-Y
kainate B-GENE-N
receptor-mediated I-GENE-N
synaptic O
currents O
are O
inwardly O
rectifying O
and O
are O
likely O
to O
be O
calcium B-CHEMICAL
permeable. O
Prolonged O
activation O
of O
basolateral O
amygdala O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
results O
in O
enduring O
synaptic O
facilitation O
through O
a O
calcium-dependent B-CHEMICAL
process. O
The O
selective O
GluR5 B-GENE-Y
kainate B-GENE-N
receptor I-GENE-N
agonist O
ATPA O
induces O
spontaneous O
epileptiform O
bursting O
that O
is O
sensitive O
to O
the O
GluR5 B-GENE-Y
kainate B-GENE-N
receptor I-GENE-N
antagonist O
LY293558. B-CHEMICAL
Intra-amygdala O

infusion O
of O
ATPA O
in O
the O
rat O
induces O
limbic O
status O
epilepticus; O
in O
some O
animals, O
recurrent O
spontaneous O
seizures O
occur O
for O
months O
after O
the O
ATPA O
treatment. O
Together, O
these O
observations O
indicate O
that O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
have O
a O
unique O
role O
in O
triggering O
epileptiform O
activity O
in O
the O
amygdala O
and O
could O
participate O
in O
long-term O
plasticity O
mechanisms O
that O
underlie O
some O
forms O
of O
epileptogenesis. O
Accordingly, O
GluR5 B-GENE-Y
kainate B-GENE-N
receptors I-GENE-N
represent O
a O
potential O
target O
for O
antiepileptic O
and O
antiepileptogenic O
drug O
treatments. O
Most O
antiepileptic O
drugs O
do O
not O
act O

through O
effects O
on O
glutamate B-GENE-N
receptors. I-GENE-N
However, O
topiramate B-CHEMICAL
at O
low O
concentrations O
causes O
slow O
inhibition O
of O
GluR5 B-GENE-Y
kainate B-GENE-N
receptor-mediated I-GENE-N
synaptic O
currents O
in O
the O
basolateral O
amygdala, O
indicating O
that O
it O
may O
protect O
against O
seizures, O
at O
least O
in O
part, O
through O
suppression O
of O
GluR5 B-GENE-Y
kainate B-GENE-N
receptor I-GENE-N
responses. O
Multidrug B-GENE-N
resistance-associated I-GENE-N
proteins I-GENE-N
are O
involved O
in O
the O
transport O
of O
the O
glutathione B-CHEMICAL
conjugates O
of O
the O
ultimate O
carcinogen O
of O
benzo[a]pyrene B-CHEMICAL
in O
human O
Caco-2 O
cells. O
A O
wide O
variety O
of O
contaminants O

are O
ingested O
through O
food, O
among O
them O
the O
pro-carcinogenic O
polycyclic O
aromatic O
hydrocarbon O
benzo[a]pyrene B-CHEMICAL
(BP) O
that O
is O
resorbed O
and O
partially O
metabolized O
in O
the O
enterocytes O
of O
the O
small O
intestine. O
Previous O
in O
vitro O
studies O
have O
revealed O
that O
BP B-CHEMICAL
phenols I-CHEMICAL
are O
excreted O
as O
Phase O
II O
metabolites O
including O
glucuronides O
and O
sulfates. B-CHEMICAL
This O
export O
is O
mediated O
by O
the O
breast B-GENE-Y
cancer I-GENE-Y
resistance I-GENE-Y
protein I-GENE-Y
(ABCG2). B-GENE-Y
The O
ultimate O
carcinogenic O
Phase O
I O
BP O
metabolite O

anti-BP-7,8-dihydrodiol-9,10-epoxide B-CHEMICAL
(BPDE) B-CHEMICAL
can O
be O
detoxified O
by O
glutathione B-CHEMICAL
conjugate O
formation O
catalyzed O
by O
glutathione B-GENE-N
S-transferases. I-GENE-N
In O
the O
present O
study, O
differentiated O
human O
intestinal O
Caco-2 O
cells O
were O
used O
as O
a O
model O
for O
the O
human O
small O
intestine O
to O
investigate O
the O
detoxification O
of O
BPDE B-CHEMICAL
and O
excretion O
of O
stereoisomeric O
glutathione B-CHEMICAL
conjugates O
in O
the O
presence O
of O
an O
inhibitor O
of O
the O
glutathione-cleaving B-GENE-N
enzyme I-GENE-N

γ-glutamyl B-GENE-N
transpeptidase I-GENE-N
at O
the O
cell O
surface. O
The O
results O
indicate O
that O
the O
glutathione B-CHEMICAL
conjugates O
of O
BPDE B-CHEMICAL
are O
formed O
and O
excreted O
mainly O
to O
the O
apical O
and O
to O
a O
minor O
extent O
to O
the O
basolateral O
side O
of O
polarized O
Caco-2 O
monolayers. O
Inhibition O
studies O
revealed O
that O
the O
multidrug B-GENE-N
resistance-associated I-GENE-N
proteins I-GENE-N
(ABCCs) B-GENE-N
are O
involved O
in O
the O
transport O
of O
BPDE B-CHEMICAL
glutathione I-CHEMICAL
conjugates. O
Stable O
ABCC1, B-GENE-Y
ABCC2 B-GENE-Y
and O
ABCC3 B-GENE-Y
knockdown O
cell O
lines O
were O
generated, O
thus O
making O
it O
possible O
to O
demonstrate O

that O
ABCC1 B-GENE-Y
mediates O
the O
basolateral O
and O
ABCC2 B-GENE-Y
the O
apical O
excretion O
of O
BPDE B-CHEMICAL
glutathione I-CHEMICAL
conjugates. O
In O
conclusion, O
the O
ultimate O
carcinogen O
BPDE B-CHEMICAL
is O
detoxified O
via O
glutathione B-CHEMICAL
conjugation O
and O
subsequently O
excreted O
by O
Caco-2 O
cells O
in O
both O
apical O
and O
basolateral O
directions. O
This O
finding O
is O
equivalent O
to O
a O
transport O
into O
feces O
as O
well O
as O
blood O
system O
in O
the O
in O
vivo O
situation. O
Evaluation O
of O
biological O
activities O
of O
a O
groundnut O
(Apios O
americana O
Medik) O
extract O
containing O
a O
novel O

isoflavone. B-CHEMICAL
Groundnut O
(Apios O
americana O
Medik) O
contains O
a O
novel O
isoflavone, B-CHEMICAL
genistein-7-O-gentiobioside. B-CHEMICAL
In O
the O
present O
study, O
we O
examined O
the O
biological O
activities O
of O
an O
alcohol B-CHEMICAL
extract O
of O
groundnut O
containing O
genistein-7-O-gentiobioside B-CHEMICAL
as O
the O
main O
component. O
Although O
the O
groundnut O
extract O
by O
itself O
did O
not O
show O
antioxidative O
activity, O
it O
drove O
the O
antioxidative O
system O
in O
cells. O
Pretreatment O
of O
human O
breast O
carcinoma O
MCF-7 O
cells O
for O
24 O
h O
with O
the O
groundnut O
extract O

and O
soybean O
isoflavone B-CHEMICAL
increased O
gene O
expression O
of O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1), B-GENE-Y
a O
major O
antioxidative O
stress O
enzyme. O
These O
groundnut O
extract-treated O
cells O
showed O
antioxidative O
activity O
against O
free O
radicals O
derived O
from O
a O
radical O
initiator. O
Pretreatment O
of O
cells O
with O
100 O
μg/mL O
groundnut O
extract O
prevented O
the O
depletion O
of O
glutathione B-CHEMICAL
by O
the O
radical O
initiator; O
however, O
treatment O
with O
100 O
μg/mL O
of O
soybean O
isoflavone B-CHEMICAL
injured O
the O
cell O
membrane, O
indicating O
that O
glutathione B-CHEMICAL
might O
be O
released O

to O
the O
extracellular O
environment. O
These O
results O
suggest O
that O
the O
groundnut O
extract O
had O
isoflavone-like B-CHEMICAL
activity. O
Like O
soybean, O
groundnuts O
are O
a O
good O
source O
of O
isoflavones. B-CHEMICAL
Comparison O
of O
cyclooxygenase B-GENE-N
inhibitory O
activity O
and O
ocular O
anti-inflammatory O
effects O
of O
ketorolac B-CHEMICAL
tromethamine I-CHEMICAL
and O
bromfenac B-CHEMICAL
sodium. I-CHEMICAL
OBJECTIVE: O
To O
compare O
the O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
activity O
and O
anti-inflammatory O
effects O
of O
the O
nonsteroidal O
anti-inflammatory O
drugs O
(NSAIDs) O

ketorolac B-CHEMICAL
tromethamine I-CHEMICAL
(ketorolac) B-CHEMICAL
and O
bromfenac B-CHEMICAL
sodium I-CHEMICAL
(bromfenac). B-CHEMICAL
METHODS: O
Cyclooxygenase B-GENE-N
activity O
and O
selectivity O
was O
determined O
in O
vitro O
by O
measuring O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
(PGE(2)) B-CHEMICAL
production O
following O
incubation O
of O
varying O
concentrations O
of O
NSAID O
with O
human B-GENE-Y
recombinant I-GENE-Y
COX-1 I-GENE-Y
or O
COX-2 B-GENE-Y
and O
arachidonic B-CHEMICAL
acid. I-CHEMICAL
Anti-inflammatory O
effects O
were O
evaluated O
in O
a O
rabbit O
model O
in O
which O
an O
ocular O
inflammatory O
response O
was O
induced O
by O
intravenous O
injection O

of O
10 O
microg/kg O
lipopolysaccharide O
(LPS). O
In O
study O
animals, O
one O
eye O
was O
treated O
with O
50 O
microL O
(+/-) B-CHEMICAL
ketorolac I-CHEMICAL
0.4% O
(Acular B-CHEMICAL
LS) I-CHEMICAL
or O
bromfenac B-CHEMICAL
0.09% O
(Xibrom) B-CHEMICAL
and O
the O
other O
eye O
with O
50 O
microL O
buffered O
saline. O
In O
control O
animals, O
both O
eyes O
were O
treated O
with O
vehicle. O
All O
animals O
were O
treated O
twice: O
2 O
hours O
and O
1 O
hour O
before O
LPS. O
MAIN O
OUTCOME O
MEASURES: O
PGE(2) B-CHEMICAL
production O
in O
vitro, O
measured O
by O

enzyme O
immunoassay; O
fluorescein B-CHEMICAL
isothiocyanate I-CHEMICAL
(FITC)-dextran B-CHEMICAL
leakage O
into O
the O
anterior O
chamber, O
measured O
by O
fluorophotometry; O
aqueous O
PGE(2) B-CHEMICAL
levels O
in O
vivo, O
measured O
by O
ELISA O
immunoassay. O
RESULTS: O
Ketorolac B-CHEMICAL
was O
six O
times O
more O
active O
against O
COX-1 B-GENE-Y
(IC(50) O
= O
0.02 O
microM) O
than O
COX-2 B-GENE-Y
(IC(50) O
= O
0.12 O
microM) O
while O
bromfenac B-CHEMICAL
was O
approximately O
32 O

times O
more O
active O
against O
COX-2 B-GENE-Y
(IC(50) O
= O
0.0066 O
microM) O
than O
COX-1 B-GENE-Y
(IC(50) O
= O
0.210 O
microM). O
In O
the O
animal O
model, O
both O
drugs O
resulted O
in O
nearly O
complete O
inhibition O
of O
FITC-dextran B-CHEMICAL
leakage O
and O
PGE(2) B-CHEMICAL
production O
in O
the O
anterior O
chamber O
of O
treated O
eyes. O
There O
was O
also O
a O
79% O
inhibition O
(p O
< O
0.001) O
of O
FITC-dextran B-CHEMICAL
leakage O
in O
the O
contralateral O
eyes O
of O
bromfenac-treated B-CHEMICAL
rabbits, O
and O
a O

22.5% O
inhibition O
(not O
statistically O
significant) O
in O
the O
contralateral O
eyes O
of O
ketorolac-treated B-CHEMICAL
rabbits. O
CONCLUSIONS: O
Ketorolac B-CHEMICAL
is O
relatively O
COX-1 B-GENE-Y
selective O
while O
bromfenac B-CHEMICAL
is O
potently O
selective O
for O
COX-2 B-GENE-Y
over O
COX-1. B-GENE-Y
In O
the O
animal O
model, O
both O
ketorolac B-CHEMICAL
0.4% O
and O
bromfenac B-CHEMICAL
0.09% O
demonstrated O
maximal O
anti-inflammatory O
activity O
in O
treated O
eyes. O
Only O
bromfenac B-CHEMICAL
0.09% O
had O
a O
significant O
effect O
on O
the O
contralateral O
eye, O
suggesting O
possible O
systemic O
absorption O
of O

this O
drug. O
Tumor-growth-promoting O
cyclooxygenase-2 B-GENE-Y
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
pathway O
provides O
medulloblastoma O
therapeutic O
targets. O
Prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
(PGE(2)) B-CHEMICAL
has O
been O
shown O
to O
play O
important O
roles O
in O
several O
aspects O
of O
tumor O
development O
and O
progression. O
PGE(2) B-CHEMICAL
is O
synthesized O
from O
arachidonic B-CHEMICAL
acid I-CHEMICAL
by O
cyclooxygenases B-GENE-N
(COX) B-GENE-N
and O
prostaglandin B-GENE-N
E I-GENE-N
synthases I-GENE-N
(PGES) B-GENE-N
and O
mediates O
its O
biological O
activity O
through O
binding O
to O
the O
four O
prostanoid B-GENE-Y
receptors I-GENE-Y

EP(1) I-GENE-Y
through O
EP(4). B-GENE-Y
In O
this O
study, O
we O
show O
for O
the O
first O
time O
that O
medulloblastoma O
(MB), O
the O
most O
common O
malignant O
childhood O
brain O
tumor, O
expresses O
high O
levels O
of O
COX-2, B-GENE-Y
microsomal B-GENE-Y
prostaglandin I-GENE-Y
E I-GENE-Y
synthase-1, I-GENE-Y
and O
EP(1) B-GENE-Y
through O
EP(4) B-GENE-Y
and O
secretes O
PGE(2). B-CHEMICAL
PGE(2) B-CHEMICAL
and O
the O
EP(2) B-GENE-Y
receptor I-GENE-Y
agonist O
butaprost O
stimulated O
MB O
cell O
proliferation. O
Treatment O
of O
MB O
cells O
with O
COX B-GENE-N
inhibitors O
suppressed O
PGE(2) B-CHEMICAL
production O
and O
induced O

caspase-dependent B-GENE-N
apoptosis. O
Similarly, O
specific O
COX-2 B-GENE-Y
silencing O
by O
small O
interfering O
RNA O
inhibited O
MB O
cell O
growth. O
EP(1) B-GENE-Y
and O
EP(3) B-GENE-Y
receptor I-GENE-Y
antagonists O
ONO-8713 B-CHEMICAL
and O
ONO-AE3-240, B-CHEMICAL
but O
not O
the O
EP(4) B-GENE-Y
antagonists O
ONO-AE3-208 B-CHEMICAL
and O
AH B-CHEMICAL
23848, I-CHEMICAL
inhibited O
tumor O
cell O
proliferation, O
indicating O
the O
significance O
of O
EP(1) B-GENE-Y
and O
EP(3) B-GENE-Y
but O
not O
EP(4) B-GENE-Y
for O
MB O
growth. O
Administration O
of O
COX B-GENE-N
inhibitors O
at O
clinically O
achievable O

nontoxic O
concentrations O
significantly O
inhibited O
growth O
of O
established O
human O
MB O
xenografts. O
Apoptosis O
was O
increased, O
proliferation O
was O
reduced, O
and O
angiogenesis O
was O
inhibited O
in O
MBs O
treated O
with O
COX B-GENE-N
inhibitors. O
This O
study O
suggests O
that O
PGE(2) B-CHEMICAL
is O
important O
for O
MB O
growth O
and O
that O
therapies O
targeting O
the O
prostanoid O
metabolic O
pathway O
are O
potentially O
beneficial O
and O
should O
be O
tested O
in O
clinical O
settings O
for O
treatment O
of O
children O
with O
MB. O
Fluticasone B-CHEMICAL
propionate: I-CHEMICAL
safety O
profile. O
Fluticasone B-CHEMICAL
propionate I-CHEMICAL
is O
a O
potent O
fluorinated O
corticosteroid O
used O
for O
the O
topical O

therapy O
of O
dermatoses O
and O
as O
inhalation O
therapy O
for O
bronchial O
asthma O
and O
allergic O
rhinitis. O
This O
agent O
has O
a O
good O
safety O
profile O
with O
a O
low O
propensity O
for O
systemic O
side O
effects, O
such O
as O
suppression O
of O
the O
hypothalamic-pituitary-adrenal O
(HPA) O
axis, O
and O
a O
low O
incidence O
of O
local O
side O
effects O
such O
as O
pruritus, O
burning, O
or O
skin O
atrophy. O
The O
pharmacologic O
properties O
of O
fluticasone B-CHEMICAL
propionate-including I-CHEMICAL
high O
lipophilicity, O
high O
selectivity O
and O
affinity O
for O
the O

glucocorticoid B-GENE-Y
receptor, I-GENE-Y
low O
systemic O
absorption, O
and O
rapid O
metabolism O
and O
clearance-combine O
to O
give O
fluticasone B-CHEMICAL
propionate I-CHEMICAL
a O
high O
therapeutic O
index. O
Bioreducible O
polymers O
as O
a O
determining O
factor O
for O
polyplex B-CHEMICAL
decomplexation O
rate O
and O
transfection. O
Polyplex B-CHEMICAL
formation O
(complexation) O
and O
gene O
release O
from O
the O
polyplexes B-CHEMICAL
(decomplexation) O
are O
major O
events O
in O
polymeric O
gene O
delivery; O
however, O
the O
effect O
of O
the O
decomplexation O
rate O
on O
transfection O
has O
been O
rarely O
investigated. O
This O
study O
employed O
mixed O
polymers O
of O

poly((L)-lysine) B-CHEMICAL
(PLL: B-CHEMICAL
MW O
~7.4 O
kDa) O
and O
reducible O
PLL B-CHEMICAL
(RPLL) O
(MW O
~6.7 O
kDa) O
to O
design O
decomplexation O
rate-controllable O
PLL(100-x)RPLL(x)/pDNA B-CHEMICAL
complexes O
(PRL(x) O
polyplexes). B-CHEMICAL
The O
transfection O
efficiency O
of O
a O
model O
gene O
(luciferase) O
in O
MCF7 O
and O
HEK293 O
cell O
lines O
increased O
with O
increasing O
x O
(RPLL O
content) O
in O
the O

PRL(x) O
polyplexes B-CHEMICAL
until O
peaking O
at O
x O
= O
2.5 O
and O
10, O
respectively, O
after O
which O
point O
transfection O
efficiency O
declined O
rapidly. O
In O
MCF7 O
cells, O
PRL(2.5) O
polyplex B-CHEMICAL
produced O
3 O
or O
223 O
times O
higher O
gene O
expression O
than O
PLL B-CHEMICAL
or O
RPLL O
polyplexes, B-CHEMICAL
respectively. O
Similarly, O
the O
transfection O
efficiency O
of O
PRL(10) O
polyplex-transfected B-CHEMICAL
HEK293 O
cells O
was O
3.8 O
or O
67 O
times O
higher O
than O
that O
of O
PLL B-CHEMICAL
or O
RPLL O
polyplexes, B-CHEMICAL
respectively. O
The O
transfection O
results O
were O
not O

apparently O
related O
to O
the O
particle O
size, O
surface O
charge, O
complexation/compactness, O
cellular O
uptake, O
or O
cytotoxicity O
of O
the O
tested O
polyplexes. B-CHEMICAL
However, O
the O
decomplexation O
rate O
varied O
by O
RPLL O
content O
in O
the O
polyplexes, B-CHEMICAL
which O
in O
turn O
influenced O
the O
gene O
transfection. O
The O
nuclear O
localization O
of O
pDNA O
delivered O
by O
PRL(x) O
polyplexes B-CHEMICAL
showed O
a O
similar O
trend O
to O
their O
transfection O
efficiencies. O
This O
study O
suggests O
that O
an O
optimum O
decomplexation O
rate O
may O
result O
in O
high O
nuclear O
localization O
of O
pDNA O
and O

transfection. O
Understanding O
in O
decomplexation O
and O
intracellular O
localization O
of O
pDNA O
may O
help O
develop O
more O
effective O
polyplexes. B-CHEMICAL
Phosphodiesterase B-GENE-N
4 I-GENE-N
inhibitors O
delay O
human O
eosinophil O
and O
neutrophil O
apoptosis O
in O
the O
absence O
and O
presence O
of O
salbutamol. B-CHEMICAL
In O
asthma O
and O
chronic O
obstructive O
pulmonary O
disease O
(COPD), O
the O
number O
of O
eosinophils O
and O
neutrophils O
in O
the O
lung O
is O
increased. O
One O
described O
mechanism O
leading O
to O
the O
impaired O
clearance O
of O
these O
cells O
from O
the O
lung O
is O
the O
delay O
in O
their O
programmed O
cell O
death O

(apoptosis). O
Selective O
inhibitors O
of O
phosphodiesterases B-GENE-N
(PDEs) B-GENE-N
are O
under O
development O
for O
the O
treatment O
of O
lung O
diseases O
because O
of O
their O
anti-inflammatory O
and O
bronchodilator O
activity. O
The O
aim O
of O
the O
present O
study O
was O
to O
establish O
whether O
inhibitors O
of O
PDE3, B-GENE-N
PDE4 B-GENE-N
and O
PDE5 B-GENE-Y
modulate O
human O
eosinophil O
or O
neutrophil O
apoptosis O
or O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonist- O
or O
cytokine-afforded B-GENE-N
survival. O
We O
also O
evaluated O
whether O
a O
PDE4 B-GENE-N
inhibitor O
could O
modulate O
the O
effect O
of O
a O

corticosteroid B-CHEMICAL
on O
eosinophil O
and O
neutrophil O
apoptosis. O
Apoptosis O
was O
measured O
by O
using O
the O
relative O
DNA O
fragmentation O
assay O
and O
Annexin-V O
binding. O
Inhibitors O
of O
PDE4 B-GENE-N
(rolipram; B-CHEMICAL
0.1-10 O
microM) O
and O
PDE3 B-GENE-N
(cilostazol; B-CHEMICAL
0.1-10 O
microM) O
delayed O
spontaneous O
eosinophil O
apoptosis O
maximally O
by O
25% O
and O
15%, O
respectively. O
A O
combination O
of O
a O
PDE4 B-GENE-N
or O
PDE3 B-GENE-N
inhibitor O
(10 O
microM) O
with O
salbutamol B-CHEMICAL

(100 O
nM) O
further O
delayed O
eosinophil O
apoptosis O
maximally O
by O
42-49%. O
In O
neutrophils, O
rolipram B-CHEMICAL
(10 O
microM) O
also O
decreased O
apoptosis O
with O
a O
maximal O
inhibition O
of O
13%. O
The O
combination O
of O
rolipram B-CHEMICAL
(10 O
microM) O
and O
salbutamol B-CHEMICAL
(100 O
nM) O
produced O
a O
27% O
inhibition O
of O
neutrophil O
apoptosis. O
Inhibitor O
of O
cGMP-specific B-GENE-Y
PDE5 I-GENE-Y
(zaprinast; B-CHEMICAL
0.1-10 O
microM) O
did O
not O
affect O

eosinophil O
apoptosis O
and O
only O
slightly O
increased O
spontaneous O
neutrophil O
apoptosis. O
The O
effect O
of O
budesonide B-CHEMICAL
on O
apoptosis O
was O
not O
significantly O
modulated O
by O
a O
PDE4 B-GENE-N
inhibitor O
in O
eosinophils O
or O
neutrophils. O
The O
present O
results O
show O
that O
selective O
inhibitors O
of O
cAMP-hydrolyzing B-GENE-N
PDEs I-GENE-N
(PDE3 B-GENE-N
and O
PDE4) B-GENE-N
delay O
eosinophil O
apoptosis O
and, O
thus, O
increase O
their O
survival O
in O
vitro. O
Furthermore, O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonists O
enhance O
the O

anti-apoptotic O
effects O
of O
PDE3 B-GENE-N
and O
PDE4 B-GENE-N
inhibitors, O
suggesting O
that O
such O
drug O
combinations O
may O
prolong O
eosinophil O
and O
neutrophil O
longevity O
in O
the O
lung. O
Significance O
of O
the O
transient B-GENE-Y
receptor I-GENE-Y
potential I-GENE-Y
canonical I-GENE-Y
2 I-GENE-Y
(TRPC2) B-GENE-Y
channel O
in O
the O
regulation O
of O
rat O
thyroid O
FRTL-5 O
cell O
proliferation, O
migration, O
adhesion O
and O
invasion. O
Mammalian B-GENE-N
transient I-GENE-N
receptor I-GENE-N
potential I-GENE-N
(TRP) I-GENE-N
channels I-GENE-N
are O
involved O
in O
many O
physiologically O
important O
processes. O
Here, O
we O
have O
studied O
the O
significance O
of O
the O
TRPC2 B-GENE-Y
channel O
in O
the O
regulation O
of O
rat O
thyroid O

FRTL-5 O
cell O
proliferation, O
migration, O
adhesion O
and O
invasion, O
using O
stable O
TRPC2 B-GENE-Y
(shTRPC2) B-GENE-Y
knock-down O
cells. O
In O
the O
shTRPC2 B-GENE-Y
cells, O
proliferation O
was O
decreased O
due O
to O
a O
prolonged O
G1/S O
cell O
cycle O
phase. O
The O
tumor B-GENE-Y
suppressor I-GENE-Y
p53 I-GENE-Y
and O
the O
cyclin-dependant B-GENE-Y
kinase I-GENE-Y
inhibitors I-GENE-Y
p27 I-GENE-Y
and O
p21 B-GENE-Y
were O
upregulated. O
Cell O
invasion, O
adhesion O
and O
migration O
were O
also O
attenuated O
in O
shTRPC2 B-GENE-Y
cells, O
probably O
due O
to O
decreased O
activity O
of O
both O
Rac B-GENE-N
and O
calpain, B-GENE-N
and O
a O
decreased O
secretion O

and O
activity O
of O
matrix B-GENE-Y
metalloproteinase I-GENE-Y
2. I-GENE-Y
The O
attenuated O
proliferation, O
migration, O
invasion O
and O
ATP-evoked B-CHEMICAL
calcium B-CHEMICAL
entry O
was O
mimicked O
by O
overexpressing O
a O
non-conducting, O
truncated O
TRPC2 B-GENE-Y
(TRPC2-DN) B-GENE-Y
in O
wild O
type O
cells, O
and O
was O
reversed O
by O
overexpression O
of O
TRPC2-GFP B-GENE-Y
in O
shTRPC2 B-GENE-Y
cells. O
In O
conclusion, O
TRPC2 B-GENE-Y
is O
an O
important O
regulator O
of O
rat O
thyroid O
cell O
function. O
Lutein O
and O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
interact O
to O
modify O
iNOS B-GENE-Y
mRNA O
levels O
through O
the O

PPARgamma/RXR B-GENE-Y
pathway O
in O
chickens O
and O
HD11 O
cell O
lines. O
Two O
experiments O
were O
conducted O
to O
investigate O
the O
effect O
of O
lutein O
and O
fat O
or O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
interaction O
on O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS), B-GENE-Y
PPARs B-GENE-N
alpha, I-GENE-N
beta, I-GENE-N
and I-GENE-N
gamma, I-GENE-N
and O
retinoic B-GENE-N
acid I-GENE-N
X I-GENE-N
receptor I-GENE-N
(RXR) I-GENE-N
alpha I-GENE-N
and I-GENE-N
gamma I-GENE-N
mRNA O
levels. O
In O
Expt. O
1, O
macrophages O
were O
collected O
from O
broiler O
chicks O
fed O
3 O
or O
6% O
dietary O
fat O
(g/100 O
g) O
with O
0, O
25, O

and O
50 O
mg O
lutein/kg O
feed O
for O
23 O
d. O
In O
Expt. O
2, O
using O
a O
3 O
x O
3 O
factorial, O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
at O
0, O
15 O
and O
50 O
micromol/L O
and O
lutein O
at O
0, O
10 O
and O
100 O
micromol/L O
were O
applied O
to O
HD11 O
cell O
culture O
for O
24 O
h. O
In O
both O
experiments, O
cells O
were O
stimulated O
with O
lipopolysaccharide O
before O
RNA O
isolation. O
Lutein O
interacted O
with O
fat O
in O
Expt. O
1 O
and O
with O
EPA O
in O
Expt. O
2 O
to O
affect O
mRNA O
levels O
of O
iNOS, B-GENE-Y

PPARgamma, B-GENE-Y
and O
RXRalpha B-GENE-Y
in O
chicken O
macrophages O
and O
HD11 O
cells, O
respectively O
(P O
< O
0.05). O
At O
3% O
dietary O
fat O
or O
up O
to O
15 O
micromol/L O
EPA O
in O
the O
medium, O
increasing O
lutein O
increased O
the O
iNOS B-GENE-Y
mRNA. O
However, O
at O
6% O
dietary O
fat O
or O
50 O
micromol/L O
EPA, O
lutein O
did O
not O
cause O
a O
rise O
in O
iNOS B-GENE-Y
mRNA. O
Increasing O
lutein O
in O
the O
medium O
from O
0 O
to O
100 O
micromol/L O
decreased O
iNOS B-GENE-Y
mRNA. O
Increasing O
lutein O

with O
high O
fat O
(6%) O
or O
EPA O
(15 O
micromol/L O
EPA) O
increased O
PPARgamma B-GENE-Y
and O
RXRalpha B-GENE-Y
mRNA O
levels. O
Lutein O
increased O
PPARalpha B-GENE-Y
mRNA O
levels O
in O
both O
macrophages O
(P O
< O
0.01) O
and O
HD11 O
(P O
= O
0.01) O
cells O
and O
RXRgamma B-GENE-Y
(P O
< O
0.01) O
mRNA O
levels O
in O
macrophages. O
GW9662, B-CHEMICAL
a O
PPARgamma B-GENE-Y
antagonist, O
prevented O
(P O
< O
0.01) O
the O
lutein-induced O
iNOS B-GENE-Y
mRNA O
downregulation O

in O
HD11 O
cells. O
LG101208, O
a O
RXR B-GENE-N
antagonist, O
prevented O
(P O
< O
0.01) O
iNOS B-GENE-Y
upregulation O
induced O
by O
10 O
micromol/L O
lutein O
and O
iNOS B-GENE-Y
mRNA O
downregulation O
induced O
by O
100 O
micromol/L O
lutein. O
We O
conclude O
that O
lutein O
and O
EPA B-CHEMICAL
interact O
through O
the O
PPARgamma B-GENE-Y
and O
RXR B-GENE-N
pathways O
to O
modulate O
iNOS B-GENE-Y
mRNA. O
Occupancy O
of O
dopamine B-CHEMICAL
D(1), B-GENE-Y
D B-GENE-Y
(2) I-GENE-Y
and O
serotonin B-GENE-Y
(2A) I-GENE-Y
receptors I-GENE-Y
in O

schizophrenic O
patients O
treated O
with O
flupentixol B-CHEMICAL
in O
comparison O
with O
risperidone B-CHEMICAL
and O
haloperidol. B-CHEMICAL
RATIONALE: O
Flupentixol B-CHEMICAL
(FLX) B-CHEMICAL
has O
been O
used O
as O
a O
neuroleptic O
for O
nearly O
4 O
decades. O
In O
vitro O
data O
show O
comparable O
affinity O
to O
dopamine B-GENE-Y
D(2), I-GENE-Y
D(1) B-GENE-Y
and O
5-HT(2A) B-GENE-Y
receptors I-GENE-Y
and O
recently, O
FLX B-CHEMICAL
showed O
to O
be O
not O
inferior O
to O
risperidone B-CHEMICAL
in O
schizophrenic O
patients O
with O
predominant O
negative O
symptomatology, O
which O
was O
implicated O
with O

flupentixol's O
interaction O
with O
5-HT(2A) B-GENE-Y
and/or O
D(1) B-GENE-Y
receptors. I-GENE-Y
OBJECTIVES: O
To O
assess O
in O
vivo O
receptor O
occupancy O
(RO) O
in O
patients O
clinically O
treated O
with O
FLX O
(n O
= O
13, O
5.7 O
+/- O
1.4 O
mg/day) O
in O
comparison O
with O
risperidone B-CHEMICAL
(RIS, O
n O
= O
11, O
3.6 O
+/- O
1.3 O
mg/day) O
and O
haloperidol B-CHEMICAL
(HAL, O
n O
= O
11, O
8.5 O
+/- O
5.5 O

mg/day). O
MATERIALS O
AND O
METHODS: O
Each O
patient O
underwent O
two O
PET O
scans O
with O
3-N-[(11)C]methylspiperone B-CHEMICAL
(target: O
frontal O
5-HT(2A)), B-GENE-Y
[(11)C]SCH23390 B-CHEMICAL
(striatal O
D(1)) B-GENE-Y
or O
[(11)C]raclopride B-CHEMICAL
(striatal O
D(2)). B-GENE-Y
RO O
was O
calculated O
as O
the O
percentage O
reduction O
of O
specific O
binding O
in O
comparison O
with O
healthy O
controls. O
RESULTS: O

D(2)-RO B-GENE-Y
under O
FLX O
was O
between O
50% O
and O
70%, O
indicating O
an O
ED(50) O
of O
about O
0.7 O
ng/ml O
serum. O
5-HT(2A) B-GENE-Y
and O
D(1)-RO B-GENE-Y
was O
20 O
+/- O
10% O
and O
20 O
+/- O
5% O
(mean, O
SEM). O
Under O
HAL, O
D(1)-RO B-GENE-Y
was O
14 O
+/- O
6% O
and O
under O
RIS O
not O
significantly O
different O
from O
zero. O
CONCLUSIONS: O
We O
were O
able O
to O
demonstrate O
a O
moderate O
5-HT(2A) B-GENE-Y
and O

D(1) B-GENE-Y
occupancy O
under O
clinically O
relevant O
doses O
of O
flupentixol, B-CHEMICAL
albeit O
lower O
than O
expected O
from O
in O
vitro O
data O
and O
clearly O
below O
saturation. O
Therefore, O
if O
flupentixol's O
efficacy O
on O
negative O
symptoms O
is O
based O
on O
its O
interaction O
with O
5-HT(2A) B-GENE-Y
and/or O
D(1) B-GENE-Y
receptors, I-GENE-Y
it O
should O
be O
highly O
dependent O
on O
serum O
concentration O
and O
thus O
on O
dosage O
and O
metabolism. O
However, O
these O
data O
suggest O
that O
mechanisms O
other O
than O
D(1) B-GENE-Y
or O
5-HT(2A) B-GENE-Y
antagonism O
may O
contribute O
to O
flupentixol's O
efficacy O
on O
negative O
symptoms. O

Stereospecific O
inhibition O
of O
monoamine B-GENE-N
uptake I-GENE-N
transporters I-GENE-N
by O
meta-hydroxyephedrine B-CHEMICAL
isomers. O
Meta-hydroxyephedrine B-CHEMICAL
(HED) B-CHEMICAL
comprises O
four O
stereoisomers O
consisting O
of O
two O
enantiomeric O
pairs O
related O
to O
ephedrine B-CHEMICAL
and O
pseudoephedrine. B-CHEMICAL
HED B-CHEMICAL
is O
transported O
into O
adrenergic O
neurons O
and O
radiolabeled O
HED B-CHEMICAL
has O
been O
employed O
in O
positron O
emission O
tomography O
(PET) O
to O
image O
adrenergic O
neurons O
in O
vivo. O
To O
extend O
structure-activity O
analyses O
of O
binding O
sites O
within O
monoamine B-GENE-N
transporters I-GENE-N
and O

to O
determine O
which O
stereoisomer O
displayed O
the O
best O
selectivity O
for O
PET O
imaging O
applications, O
we O
tested O
the O
HED B-CHEMICAL
compounds O
for O
their O
abilities O
to O
inhibit O
[(3)H]neurotransmitter B-CHEMICAL
uptake O
into O
platelets, O
transfected O
cells, O
and O
chromaffin O
vesicles. O
We O
hypothesized O
that O
the O
HED B-CHEMICAL
compounds O
would O
be O
most O
potent O
at O
the O
norepinephrine B-GENE-Y
transporter I-GENE-Y
(NET) B-GENE-Y
compared O
to O
the O
serotonin B-GENE-N
or I-GENE-N
dopamine I-GENE-N
transporters I-GENE-N
and O
that O
the O
1R O
diastereomers O
would O
be O
more O
effective O
than O
1S O
diastereomers. O
Supporting O
the O

hypotheses, O
all O
stereoisomers O
were O
most O
potent O
at O
the O
NET B-GENE-Y
and O
the O
1R,2S O
stereoisomer O
was O
the O
most O
potent O
inhibitor O
overall. O
However, O
the O
1S,2R O
isomer O
may O
be O
preferred O
for O
PET O
applications O
because O
of O
better O
selectivity O
among O
the O
transporters O
and O
reduced O
neuronal O
recycling. O
TCDD B-CHEMICAL
inhibition O
of O
canonical O
wnt B-GENE-N
signaling O
disrupts O
prostatic O
bud O
formation O
in O
mouse O
urogenital O
sinus. O
In O
mice, O
in O
utero O
exposure O
to O
2,3,7,8-tetrachlorodibenzo-p- B-CHEMICAL
dioxin I-CHEMICAL

(TCDD) B-CHEMICAL
reduces O
the O
number O
of O
dorsolateral O
prostatic O
buds O
resulting O
in O
a O
smaller O
dorsolateral O
prostate O
and O
prevents O
formation O
of O
ventral O
buds O
culminating O
in O
ventral O
prostate O
agenesis. O
The O
genes O
and O
signaling O
pathways O
affected O
by O
TCDD B-CHEMICAL
that O
are O
responsible O
for O
disrupting O
prostate O
development O
are O
largely O
unknown. O
Here O
we O
show O
that O
treatment O
of O
urogenital O
sinus O
(UGS) O
organ O
cultures O
with O
known O
inhibitors O
of O
canonical O
Wnt B-GENE-N
signaling O
also O
inhibits O
prostatic O
bud O
formation. O
In O
support O
of O
the O
hypothesis O
that O
TCDD B-CHEMICAL
decreases O
canonical O
Wnt B-GENE-N
signaling, O
we O
identify O
inhibitory O
effects O
of O
TCDD B-CHEMICAL

on O
multiple O
components O
of O
the O
canonical O
Wnt B-GENE-N
signaling O
pathway O
in O
the O
UGS O
that O
temporally O
coincide O
with O
the O
inhibitory O
effect O
of O
TCDD B-CHEMICAL
on O
prostatic O
bud O
formation: O
(1) O
expression O
of O
R-spondins B-GENE-N
(Rspo2 B-GENE-Y
and O
Rspo3) B-GENE-Y
that O
promote O
canonical O
Wnt B-GENE-N
signaling O
is O
reduced; O
(2) O
expression O
of O
Lef1, B-GENE-Y
Tcf1, B-GENE-Y
and O
Wif1, B-GENE-Y
established O
canonical O
Wnt B-GENE-N
target O
genes, O
is O
decreased; O
(3) O
expression O
of O
Lgr5, B-GENE-Y
a O
RSPO B-GENE-Y
receptor I-GENE-Y
that O
activates O
canonical O
Wnt B-GENE-N
signaling, O
is O
reduced; O
and O
(4) O
expression O
of O

Dickkopfs B-GENE-N
(Dkks), B-GENE-N
inhibitors O
of O
canonical O
Wnt B-GENE-N
signaling, O
is O
not O
increased O
by O
TCDD. B-CHEMICAL
Thus, O
the O
TCDD-induced B-CHEMICAL
reduction O
in O
canonical O
Wnt B-GENE-N
signaling O
is O
associated O
with O
a O
decrease O
in O
activators O
(Rspo2 B-GENE-Y
and O
Rspo3) B-GENE-Y
rather O
than O
an O
increase O
in O
inhibitors O
(Dkk1 B-GENE-Y
and O
Dkk2) B-GENE-Y
of O
the O
pathway. O
This O
study O
focuses O
on O
determining O
whether O
treatment O
of O
TCDD-exposed B-CHEMICAL
UGS O
organ O
cultures O
with O
RSPO2 B-GENE-Y
and/or O
RSPO3 B-GENE-Y
is O
capable O
of O
rescuing O
the O
inhibitory O
effects O
of O
TCDD B-CHEMICAL
on O
canonical O
Wnt B-GENE-N
signaling O
and O

prostatic O
bud O
formation. O
We O
discovered O
that O
each O
RSPO B-GENE-N
alone O
or O
in O
combination O
partially O
rescues O
TCDD B-CHEMICAL
inhibition O
of O
both O
canonical O
Wnt B-GENE-N
signaling O
and O
prostatic O
bud O
formation. O
CYP2J2 B-GENE-Y
overexpression O
increases O
EETs B-CHEMICAL
and O
protects O
against O
angiotensin B-GENE-Y
II-induced I-GENE-Y
abdominal O
aortic O
aneurysm O
in O
mice. O
Cytochrome B-GENE-Y
P450 I-GENE-Y
epoxygenase I-GENE-Y
2J2 I-GENE-Y
(CYP2J2) B-GENE-Y
metabolizes O
arachidonic B-CHEMICAL
acids I-CHEMICAL
to O
form O
epoxyeicosatrienoic B-CHEMICAL
acids I-CHEMICAL
(EETs), B-CHEMICAL
which O
possess O
various O
beneficial O
effects O
on O
the O

cardiovascular O
system. O
However, O
whether O
increasing O
EETs B-CHEMICAL
production O
by O
CYP2J2 B-GENE-Y
overexpression O
in O
vivo O
could O
prevent O
abdominal O
aortic O
aneurysm O
(AAA) O
remains O
unknown. O
Here O
we O
investigated O
the O
effects O
of O
recombinant O
adeno-associated O
virus O
(rAAV)-mediated O
CYP2J2 B-GENE-Y
overexpression O
on O
angiotensin B-GENE-Y
(Ang) I-GENE-Y
II-induced I-GENE-Y
AAA O
in O
apoE-deficient O
mice. O
rAAV-CYP2J2 B-GENE-Y
delivery O
led O
to O
an O
abundant O
aortic O
CYP2J2 B-GENE-Y
expression O
and O
increased O
EETs B-CHEMICAL
generation. O
It O
was O
shown O

that O
CYP2J2 B-GENE-Y
overexpression O
attenuated O
matrix B-GENE-N
metalloproteinase I-GENE-N
expression O
and O
activity, O
elastin B-GENE-Y
degradation, O
and O
AAA O
formation, O
which O
was O
associated O
with O
reduced O
aortic O
inflammation O
and O
macrophage O
infiltration. O
In O
cultured O
vascular O
smooth O
muscle O
cells O
(VSMCs), O
rAAV-mediated O
CYP2J2 B-GENE-Y
overexpression O
and O
EETs B-CHEMICAL
markedly O
suppressed O
Ang B-GENE-Y
II-induced I-GENE-Y
inflammatory O
cytokine B-GENE-N
expression. O
Moreover, O
overexpressed O
CYP2J2 B-GENE-Y
and O
EETs B-CHEMICAL
inhibited O
Ang B-GENE-Y
II-induced I-GENE-Y
macrophage O
migration O
in O
a O

VSMC-macrophage O
coculture O
system. O
We O
further O
indicated O
that O
these O
protective O
effects O
were O
mediated O
by O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
(PPAR)γ I-GENE-Y
activation. O
Taken O
together, O
these O
results O
provide O
evidence O
that O
rAAV-mediated O
CYP2J2 B-GENE-Y
overexpression O
prevents O
AAA O
development O
which O
is O
likely O
via O
PPARγ B-GENE-Y
activation O
and O
anti-inflammatory O
action, O
suggesting O
that O
increasing O
EETs B-CHEMICAL
levels O
could O
be O
considered O
as O
a O
potential O
strategy O
to O
prevent O
and O
treat O
AAA. O
Differential O
effects O
of O
organic O
and O
inorganic O
selenium B-CHEMICAL
compounds O
on O
adenosine B-GENE-Y
deaminase I-GENE-Y
activity O
and O

scavenger O
capacity O
in O
cerebral O
cortex O
slices O
of O
young O
rats. O
Selenium B-CHEMICAL
(Se) B-CHEMICAL
has O
anti-inflammatory O
and O
antioxidant O
properties O
and O
is O
necessary O
for O
the O
development O
and O
normal O
function O
of O
the O
central O
nervous O
system. O
This O
study O
was O
aimed O
to O
compare O
the O
in O
vitro O
effects O
of O
3-methyl-1-phenyl-2-(phenylseleno)oct-2-en-1-one B-CHEMICAL
(C21H2HOSe; B-CHEMICAL
organoselenium) B-CHEMICAL
and O
sodium B-CHEMICAL
selenate I-CHEMICAL
(inorganic O
Se) B-CHEMICAL
on O
adenosine B-GENE-Y
deaminase I-GENE-Y

(ADA) B-GENE-Y
activity, O
cell O
viability, O
lipid O
peroxidation, O
scavenger O
of O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
and O
nonprotein O
thiols B-CHEMICAL
(NP-SH) B-CHEMICAL
content O
in O
the O
cerebral O
cortex O
slices O
of O
the O
young O
rats. O
A O
decrease O
in O
ADA B-GENE-Y
activity O
was O
observed O
when O
the O
slices O
were O
exposed O
to O
organoselenium B-CHEMICAL
at O
the O
concentrations O
of O
1, O
10 O
and O
30 O
µM. O
The O
same O
compound O
showed O
higher O
scavenger O
capacity O
of O
NO B-CHEMICAL
than O
the O
inorganic O
compound. O
Inorganic O
Se B-CHEMICAL
was O
able O
to O
protect O
against O
sodium B-CHEMICAL
nitroprusside-induced I-CHEMICAL

oxidative O
damage O
and O
increased O
the O
NP-SH B-CHEMICAL
content. O
Both O
the O
compounds O
displayed O
distinctive O
antioxidant O
capacities O
and O
were O
not O
cytotoxic O
for O
the O
cerebral O
cortex O
slices O
in O
the O
conditions O
tested. O
These O
findings O
are O
likely O
to O
be O
related O
to O
immunomodulatory O
and O
antioxidant O
properties O
of O
this O
compound. O
Antigenotoxic O
potencies O
of O
a O
lichen O
species, O
Evernia O
prunastri. O
In O
this O
article, O
the O
genotoxic O
and O
antigenotoxic O
effects O
of O
methanol B-CHEMICAL
extract O
of O
Evernia O
prunastri O
(Huds.) O
Willd. O

(MEP) O
were O
studied O
using O
WP2, O
Ames O
(TA1535 O
and O
TA1537) O
and O
sister O
chromatid O
exchange O
(SCE) O
test O
systems. O
The O
results O
obtained O
from O
bacterial O
test O
systems O
demonstrated O
that O
MEP O
has O
strong O
antimutagenic O
potencies O
on O
TA1537 O
and O
WP2 O
strains. O
The O
highest O
inhibition O
rates O
for O
MEP O
on O
TA1537 O
and O
WP2 O
strains O
were O
37.70% O
and O
69.70%, O
respectively. O
According O
to O
the O
SCE O
test O
system, O
MEP O
reduced O
the O
genotoxic O
effects O
of O
aflatoxin. B-CHEMICAL
In O
order O
to O

clarify O
the O
mechanism O
underlying O
the O
antigenotoxic O
effects O
of O
MEP, O
the O
antioxidants O
were O
determined. O
Cotreatments O
of O
5, O
10 O
and O
20 O
µg/mL O
concentrations O
of O
MEP O
with O
aflatoxin B-CHEMICAL
B(1) I-CHEMICAL
decreased O
the O
frequencies O
of O
SCE O
and O
the O
malondialdehyde B-CHEMICAL
level O
and O
increased O
amount O
of O
superoxide B-GENE-N
dismutase, I-GENE-N
glutathione B-CHEMICAL
and O
glutathione B-GENE-N
peroxidase I-GENE-N
which O
were O
decreased O
by O
aflatoxin. B-CHEMICAL
The O
data O
obtained O
from O
this O
work O
have O
clearly O
shown O
that O
MEP O
has O
significant O
antigenotoxic O
effects O
which O
are O
thought O

to O
be O
partly O
due O
to O
the O
antioxidant O
activities O
and O
antioxidant O
inducing O
capability O
of O
MEP. O
This O
is O
the O
first O
report O
indicating O
the O
antigenotoxic O
activities O
of O
MEP O
against O
several O
mutagen O
agents O
such O
as O
N-methyl-N'-nitro-N-nitrosoguanidine, B-CHEMICAL
acridin B-CHEMICAL
and O
aflatoxin. B-CHEMICAL
Cross-talk O
between O
constitutive B-GENE-Y
androstane I-GENE-Y
receptor I-GENE-Y
and O
hypoxia-inducible B-GENE-N
factor I-GENE-N
in O
the O
regulation O
of O
gene O
expression. O
Hypoxia B-GENE-N
inducible I-GENE-N
factor I-GENE-N
(HIF) B-GENE-N
and O

5'-AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
are O
often O
activated O
under O
similar O
physiological O
conditions. O
Constitutive B-GENE-Y
androstane I-GENE-Y
receptor I-GENE-Y
(CAR) B-GENE-Y
translocates O
into O
the O
nucleus O
in O
accordance O
with O
5'-AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
and O
thus O
confers O
transactivation. O
The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
a O
possible O
link O
between O
CAR B-GENE-Y
and O
HIFα. B-GENE-Y
Phenobarbital B-CHEMICAL
(PB), O
a O
typical O
CAR B-GENE-Y
activator, O
increased O
the O
gene O
expression O
of O
HIF-target B-GENE-N
genes O
in O
the O
livers O
of O
mice, O
including O
erythropoietin, B-GENE-Y
heme B-GENE-Y
oxygenase-1 I-GENE-Y

and O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor-a. I-GENE-Y
PB O
induced O
an O
accumulation O
of O
nuclear O
HIF-1α B-GENE-Y
and O
an O
increase O
in O
the O
HIF-responsive B-GENE-N
element-mediated I-GENE-N
transactivation O
in O
HepG2 O
cells. O
Cobalt B-CHEMICAL
chloride, I-CHEMICAL
a O
typical O
HIF B-GENE-N
activator, O
induced O
the O
gene O
expression O
of O
CAR-target B-GENE-Y
genes, O
including O
cyp2b9 B-GENE-Y
and O
cyp2b10, B-GENE-Y
an O
accumulation O
of O
nuclear O
CAR B-GENE-Y
and O
an O
increase O
in O
the O
PB-responsive B-GENE-N
enhancer I-GENE-N
module-mediated I-GENE-N
transactivation O
in O
the O
mouse O
liver. O

Immunoprecipitation-immunoblot O
and O
chromatin O
immunoprecipitation O
analyses O
suggest O
that O
CAR B-GENE-Y
binds O
to O
the O
PB-responsive B-GENE-N
enhancer I-GENE-N
module I-GENE-N
with O
HIF-1α B-GENE-Y
in O
the O
liver O
of O
untreated O
mice O
and O
that O
the O
complex O
dissociates O
upon O
PB O
treatment. O
Taken O
together O
these O
results O
suggest O
that O
CAR B-GENE-Y
and O
HIF-α B-GENE-Y
interact O
and O
reciprocally O
modulate O
the O
functions O
of O
each O
other. O
Methionine B-GENE-Y
adenosyltransferase I-GENE-Y
II I-GENE-Y
beta I-GENE-Y
subunit O
gene O
expression O
provides O
a O
proliferative O
advantage O
in O
human O

hepatoma. O
BACKGROUND O
& O
AIMS: O
Of O
the O
2 O
genes O
(MAT1A, B-GENE-Y
MAT2A) B-GENE-Y
encoding O
methionine B-GENE-N
adenosyltransferase, I-GENE-N
the O
enzyme O
that O
synthesizes O
S-adenosylmethionine, B-CHEMICAL
MAT1A, B-GENE-Y
is O
expressed O
in O
liver, O
whereas O
MAT2A B-GENE-Y
is O
expressed O
in O
extrahepatic O
tissues. O
In O
liver, O
MAT2A B-GENE-Y
expression O
associates O
with O
growth, O
dedifferentiation, O
and O
cancer. O
Here, O
we O
identified O
the O
beta O
subunit O
as O
a O
regulator O
of O
proliferation O
in O
human O
hepatoma O
cell O
lines. O

The O
beta O
subunit O
has O
been O
cloned O
and O
shown O
to O
lower O
the O
K(m) O
of O
methionine B-GENE-Y
adenosyltransferase I-GENE-Y
II I-GENE-Y
alpha2 I-GENE-Y
(the O
MAT2A B-GENE-Y
product) O
for O
methionine B-CHEMICAL
and O
to O
render O
the O
enzyme O
more O
susceptible O
to O
S-adenosylmethionine B-CHEMICAL
inhibition. O
METHODS: O
Methionine B-GENE-N
adenosyltransferase I-GENE-N
II I-GENE-N
alpha2 I-GENE-N
and I-GENE-N
beta I-GENE-N
subunit O
expression O
was O
analyzed O
in O
human O
and O
rat O
liver O
and O
hepatoma O
cell O
lines O
and O
their O
interaction O
studied O
in O
HuH7 O
cells. O
beta O
Subunit O
expression O
was O
up- O
and O
down-regulated O
in O

human O
hepatoma O
cell O
lines O
and O
the O
effect O
on O
DNA O
synthesis O
determined. O
RESULTS: O
We O
found O
that O
beta O
subunit O
is O
expressed O
in O
rat O
extrahepatic O
tissues O
but O
not O
in O
normal O
liver. O
In O
human O
liver, O
beta O
subunit O
expression O
associates O
with O
cirrhosis O
and O
hepatoma. O
beta O
Subunit O
is O
expressed O
in O
most O
(HepG2, O
PLC, O
and O
Hep3B) O
but O
not O
all O
(HuH7) O
hepatoma O
cell O
lines. O
Transfection O
of O
beta O
subunit O
reduced O
S-adenosylmethionine B-CHEMICAL
content O
and O
stimulated O
DNA O
synthesis O
in O
HuH7 O

cells, O
whereas O
down-regulation O
of O
beta O
subunit O
expression O
diminished O
DNA O
synthesis O
in O
HepG2. O
The O
interaction O
between O
methionine B-GENE-N
adenosyltransferase I-GENE-N
II I-GENE-N
alpha2 I-GENE-N
and I-GENE-N
beta I-GENE-N
subunit O
was O
demonstrated O
in O
HuH7 O
cells. O
CONCLUSIONS: O
Our O
findings O
indicate O
that O
beta O
subunit O
associates O
with O
cirrhosis O
and O
cancer O
providing O
a O
proliferative O
advantage O
in O
hepatoma O
cells O
through O
its O
interaction O
with O
methionine B-GENE-Y
adenosyltransferase I-GENE-Y
II I-GENE-Y
alpha2 I-GENE-Y
and O
down-regulation O
of O
S-adenosylmethionine B-CHEMICAL
levels. O
Temporal O
profile O
of O
brain O
and O

pituitary O
GnRHs, B-GENE-N
GnRH-R B-GENE-Y
and O
gonadotropin B-GENE-N
mRNA O
expression O
and O
content O
during O
early O
development O
in O
European O
sea O
bass O
(Dicentrarchus O
labrax O
L.). O
A O
likely O
endocrine O
control O
mechanism O
for O
sexual O
differentiation O
in O
size-graded O
populations O
of O
European O
sea O
bass O
(Dicentrarchus O
labrax) O
is O
proposed O
by O
evaluating O
the O
brain O
expression O
and O
pituitary O
content O
of O
two O
forms O
of O
gonadotropin-releasing B-GENE-N
hormone I-GENE-N
(GnRH), B-GENE-N
namely O
sea O
bream O
(sbGnRH) B-GENE-N
and O
salmon O
(sGnRH), B-GENE-N
the O

pituitary O
expression O
of O
one O
subtype O
of O
GnRH B-GENE-Y
receptor I-GENE-Y
(dlGnRH-R-2A) B-GENE-N
and O
the O
three O
gonadotropin B-GENE-N
(GtH) B-GENE-N
subunits, O
namely O
glycoprotein B-GENE-N
alpha I-GENE-N
(GPalpha), B-GENE-N
follicle-stimulating B-GENE-N
hormone I-GENE-N
beta I-GENE-N
(FSHbeta) B-GENE-N
and O
luteinizing B-GENE-N
hormone I-GENE-N
beta I-GENE-N
(LHbeta), B-GENE-N
as O
well O
as O
the O
pituitary O
and O
plasma O
LH B-GENE-N
levels O
between O
50 O
and O
300 O
days O
post-hatching O
(dph). O
Four O
gradings O
were O
conducted O
between O
2 O
and O
8 O
months O
after O

hatching, O
resulting O
in O
a O
population O
of O
large O
and O
small O
individuals, O
having O
96.5% O
females O
(female-dominant O
population) O
and O
69.2% O
males O
(male-dominant O
population), O
respectively, O
after O
the O
last O
grading. O
The O
onset O
of O
gonadal O
differentiation O
was O
different O
in O
the O
two O
sexes, O
and O
coincided O
with O
a O
peak O
of O
expression O
of O
sbGnRH B-GENE-N
or O
sGnRH. B-GENE-N
Furthermore, O
the O
expression O
of O
these O
GnRHs B-GENE-N
was O
correlated O
with O
the O
expression O
of O
dlGnRH-R-2A. B-GENE-N
Sex-related O
differences O
in O
the O
brain O
and O
pituitary O
content O
of O

sbGnRH B-GENE-N
were O
also O
found O
at O
the O
time O
of O
sexual O
differentiation. O
Moreover, O
the O
observed O
sexual O
dimorphism O
at O
the O
transcriptional O
or O
synthesis O
level O
of O
these O
GnRH B-GENE-N
forms O
suggests O
that O
a O
different O
neuro-hormonal O
regulation O
is O
operating O
according O
to O
sex. O
At O
the O
onset O
of O
sex O
differentiation, O
FSHbeta B-GENE-N
transcriptional O
activity O
reached O
maximal O
values, O
which O
were O
maintained O
until O
the O
completion O
of O
the O
process. O
The O
present O
study O
suggests O
a O
role O
for O
sbGnRH, B-GENE-N
sGnRH B-GENE-N
and O
the O
dlGnRH-R-2A B-GENE-N
during O
gonadal O
differentiation, O
possibly O
through O

enhancement O
of O
FSHbeta B-GENE-N
gene O
expression. O
In O
males, O
a O
different O
endocrine O
regulation O
seems O
to O
exist O
also O
during O
spermiogenesis O
and O
spermiation, O
when O
gene O
transcription, O
peptide O
synthesis O
and O
release O
of O
LH B-GENE-N
are O
of O
greater O
importance. O
Linking O
GABA(A) B-GENE-N
receptor I-GENE-N
subunits O
to O
alcohol-induced B-CHEMICAL
conditioned O
taste O
aversion O
and O
recovery O
from O
acute O
alcohol B-CHEMICAL
intoxication. O
GABA B-GENE-N
type I-GENE-N
A I-GENE-N
receptors I-GENE-N
(GABA(A)-R) B-GENE-N
are O
important O
for O
ethanol B-CHEMICAL
actions O
and O
it O
is O
of O
interest O
to O
link O
individual O
subunits O
with O
specific O
ethanol B-CHEMICAL
behaviors. O
We O
studied O
null O
mutant O
mice O
for O
six O
different O
GABA(A)-R B-GENE-N

subunits I-GENE-N
(α1, I-GENE-N
α2, I-GENE-N
α3, I-GENE-N
α4, I-GENE-N
α5 I-GENE-N
and I-GENE-N
δ). I-GENE-N
Only O
mice O
lacking O
the O
α2 O
subunit O
showed O
reduction O
of O
conditioned O
taste O
aversion O
(CTA) O
to O
ethanol. B-CHEMICAL
These O
results O
are O
in O
agreement O
with O
data O
from O
knock-in O
mice O
with O
mutation O
of O
the O
ethanol-sensitive B-CHEMICAL
site O
in O
the O
α2-subunit O
(Blednov O
et O
al., O
2011). O
All O
together, O
they O
indicate O
that O
aversive O
property O
of O
ethanol B-CHEMICAL
is O
dependent O
on O
ethanol B-CHEMICAL
action O
on O
α2-containing B-GENE-Y
GABA(A)-R. I-GENE-Y
Deletion O
of O
the O
α2-subunit O
led O
to O
faster O
recovery O
whereas O
absence O
of O
the O

α3-subunit O
slowed O
recovery O
from O
ethanol-induced B-CHEMICAL
incoordination O
(rotarod). O
Deletion O
of O
the O
other O
four O
subunits O
did O
not O
affect O
this O
behavior. O
Similar O
changes O
in O
this O
behavior O
for O
the O
α2 O
and O
α3 O
null O
mutants O
were O
found O
for O
flurazepam B-CHEMICAL
motor O
incoordination. O
However, O
no O
differences O
in O
recovery O
were O
found O
in O
motor-incoordinating O
effects O
of O
an O
α1-selective O
modulator O
(zolpidem) B-CHEMICAL
or O
an O
α4-selective O
agonist O
(gaboxadol). B-CHEMICAL
Therefore, O
recovery O
of O
rotarod O
incoordination O
is O
under O
control O
of O
two O

GABA(A)-R B-GENE-N
subunits: I-GENE-N
α2 I-GENE-N
and I-GENE-N
α3. I-GENE-N
For O
motor O
activity, O
α3 O
null O
mice O
demonstrated O
higher O
activation O
by O
ethanol B-CHEMICAL
(1 O
g/kg) O
whereas O
both O
α2 O
(-/-) O
and O
α3 O
(-/Y) O
knockout O
mice O
were O
less O
sensitive O
to O
ethanol-induced B-CHEMICAL
reduction O
of O
motor O
activity O
(1.5 O
g/kg). O
These O
studies O
demonstrate O
that O
the O
effects O
of O
ethanol B-CHEMICAL
at O
GABAergic O
synapses O
containing O
α2 O
subunit O
are O
important O
for O
specific O
behavioral O
effects O
of O
ethanol B-CHEMICAL
which O
may O
be O
relevant O
to O
the O
genetic O
linkage O
of O
the O
α2 O
subunit O
with O
human O
alcoholism. O
Pancreatic O

β-Cell O
Dysfunction O
and O
Risk O
of O
New-Onset O
Diabetes O
After O
Kidney O
Transplantation. O
OBJECTIVEChronic O
exposure O
to O
calcineurin B-GENE-N
inhibitors O
and O
corticosteroids O
poses O
renal O
transplant O
recipients O
(RTR) O
at O
high O
risk O
for O
development O
of O
new-onset O
diabetes O
after O
transplantation O
(NODAT). O
Pancreatic O
β-cell O
dysfunction O
may O
be O
crucial O
to O
the O
pathophysiology O
of O
NODAT O
and O
specific O
markers O
for O
β-cell O
dysfunction O
may O
have O
additive O
value O
for O
predicting O
NODAT O
in O
this O
population. O
Therefore, O

we O
prospectively O
investigated O
whether O
proinsulin, B-GENE-Y
as O
a O
marker O
of O
pancreatic O
β-cell O
dysfunction, O
is O
associated O
with O
future O
development O
of O
NODAT O
and O
improves O
prediction O
of O
it.RESEARCH O
DESIGN O
AND O
METHODSAll O
RTR O
between O
2001 O
and O
2003 O
with O
a O
functioning O
graft O
for O
≥1 O
year O
were O
considered O
eligible O
for O
inclusion, O
except O
for O
subjects O
with O
diabetes O
at O
baseline O
who O
were O
excluded. O
We O
recorded O
incidence O
of O
NODAT O
until O
April O
2012.RESULTSA O
total O
of O
487 O
RTR O
(age O
50 O
± O
12 O
years, O
55% O
men) O
participated O
at O
a O
median O
time O
of O

6.0 O
(interquartile O
range O
[IQR], O
2.6-11.5) O
years O
after O
transplantation. O
Median O
fasting O
proinsulin B-GENE-Y
levels O
were O
16.6 O
(IQR, O
11.0-24.2) O
pmol/L. O
During O
median O
follow-up O
for O
10.1 O
(IQR, O
9.1-10.4) O
years, O
42 O
(35%) O
RTR O
had O
development O
of O
NODAT O
in O
the O
highest O
quartile O
of O
the O
distribution O
of O
proinsulin B-GENE-Y
versus O
34 O
(9%) O
in O
the O
lowest O
three O
quartiles O
(P O
< O

0.001). O
In O
Cox O
regression O
analyses, O
proinsulin B-GENE-Y
(hazard O
ratio, O
2.29; O
95% O
confidence O
interval, O
1.85-2.83; O
P O
< O
0.001) O
was O
strongly O
associated O
with O
NODAT O
development. O
This O
was O
independent O
of O
age, O
sex, O
calcineurine B-GENE-N
inhibitors, O
prednisolone B-CHEMICAL
use, O
components O
of O
the O
metabolic O
syndrome, O
or O
homeostasis O
model O
assessment.CONCLUSIONSIn O
conclusion, O
fasting O
proinsulin B-GENE-Y
is O
strongly O
associated O
with O
NODAT O
development O
in O
RTR. O
Our O
results O
highlight O
the O
role O
of O
β-cell O
dysfunction O

in O
the O
pathophysiology O
of O
NODAT O
and O
indicate O
the O
potential O
value O
of O
proinsulin B-GENE-Y
for O
identification O
of O
RTR O
at O
increased O
risk O
for O
NODAT. O
Resveratrol B-CHEMICAL
attenuates O
hepatotoxicity O
of O
rats O
exposed O
to O
arsenic B-CHEMICAL
trioxide. I-CHEMICAL
Arsenic B-CHEMICAL
trioxide I-CHEMICAL
(As(2)O(3)) B-CHEMICAL
is O
an O
environmental O
pollutant O
and O
potent O
toxicant O
to O
humans. O
However, O
it O
also O
shows O
substantial O
anti-cancer O
activity O
in O
individuals O
with O
acute O
promyelocytic O
leukemia O
(APL). O
Unfortunately, O

As(2)O(3)-treated B-CHEMICAL
leukemia O
patients O
suffer O
hepatotoxicity. O
Resveratrol B-CHEMICAL
has O
been O
demonstrated O
to O
have O
efficient O
antioxidant O
and O
antineoplastic O
activities. O
The O
study O
that O
how O
As(2)O(3) B-CHEMICAL
in O
combination O
with O
resveratrol B-CHEMICAL
affects O
hepatotoxicity O
and O
arsenic B-CHEMICAL
accumulation O
in O
the O
liver O
is O
lacking, O
and O
the O
present O
study O
tackles O
this O
question. O
Wistar O
rats O
were O
injected O
with O
3mg/kg O
As(2)O(3) B-CHEMICAL
on O
alternate O
days; O
resveratrol B-CHEMICAL
(8mg/kg) O

was O
administered O
1h O
before O
As(2)O(3). B-CHEMICAL
Rats O
were O
killed O
on O
the O
8th O
day O
to O
determine O
histological O
liver O
damage, O
the O
antioxidant O
enzymes O
in O
serum, O
the O
ratio O
of O
reduced B-CHEMICAL
glutathione I-CHEMICAL
(GSH) B-CHEMICAL
to O
oxidized B-CHEMICAL
glutathione I-CHEMICAL
(GSSG), B-CHEMICAL
and O
arsenic B-CHEMICAL
accumulation O
in O
the O
liver. O
In O
the O
resveratrol+As(2)O(3) B-CHEMICAL
group, O
activities O
of O
superoxide B-GENE-N
dismutase, I-GENE-N
catalase B-GENE-Y
in O
serum O
and O
GSH/GSSG B-CHEMICAL
were O
significantly O
increased, O
histopathological O
effects O
were O

reduced, O
and O
arsenic B-CHEMICAL
accumulation O
markedly O
decreased O
in O
the O
liver, O
compared O
with O
the O
As(2)O(3)-treated B-CHEMICAL
group. O
Thus, O
resveratrol B-CHEMICAL
attenuated O
As(2)O(3)-induced B-CHEMICAL
hepatotoxicity O
by O
decreasing O
oxidative O
stress O
and O
arsenic B-CHEMICAL
accumulation O
in O
the O
liver. O
These O
data O
suggest O
that O
use O
of O
resveratrol B-CHEMICAL
as O
post-remission O
therapy O
of O
APL O
and O
adjunctive O
therapy O
in O
patients O
with O
chronic O
exposure O
to O
arsenic B-CHEMICAL
may O
decrease O
arsenic B-CHEMICAL
hepatotoxicity. O
Influence O
of O

stimulant-induced O
hyperactivity O
on O
social O
approach O
in O
the O
BTBR O
mouse O
model O
of O
autism. O
Translational O
research O
is O
needed O
to O
discover O
pharmacological O
targets O
and O
treatments O
for O
the O
diagnostic O
behavioral O
domains O
of O
autism O
spectrum O
disorders. O
Animal O
models O
with O
phenotypic O
relevance O
to O
diagnostic O
criteria O
offer O
clear O
experimental O
strategies O
to O
test O
the O
efficacy O
and O
safety O
of O
novel O
treatments. O
Antagonists O
of O
mGluR5 B-GENE-Y
receptors O
are O
in O
clinical O
trials O
for O
Fragile O
X O
syndrome O
and O
under O
investigation O
for O
the O
treatment O
of O
autism O
spectrum O
disorders. O
However, O
in O
preclinical O
studies O
of O
mGluR5 B-GENE-Y
compounds O
tested O
in O
our O
laboratory O
and O
others, O
increased O

locomotion O
following O
mGluR5 B-GENE-Y
modulation O
has O
been O
observed. O
Understanding O
the O
influence O
of O
general O
activity O
on O
sociability O
and O
repetitive O
behaviors O
will O
increase O
the O
accuracy O
of O
interpretations O
of O
positive O
outcomes O
measured O
from O
pharmacological O
treatment O
that O
produces O
locomotor O
activating O
or O
sedating O
effects. O
In O
the O
present O
studies, O
dose-response O
curves O
for O
d-amphetamine B-CHEMICAL
(AMPH)-induced B-CHEMICAL
hyperlocomotion O
were O
similar O
in O
standard O
B6 O
mice O
and O
in O
the O
BTBR O
mouse O
model O
of O
autism. O
AMPH B-CHEMICAL
produced O
significant, O
robust O
reductions O
in O
the O
high O
level O
of O
repetitive O
self-grooming O
that O
characterizes O

BTBR, O
and O
also O
reduced O
the O
low O
baseline O
grooming O
in O
B6, O
indicating O
that O
AMPH-induced B-CHEMICAL
hyperlocomotion O
competes O
with O
time O
spent O
engaged O
in O
self-grooming. O
We O
then O
tested O
AMPH B-CHEMICAL
in O
B6 O
and O
BTBR O
on O
the O
3-chambered O
social O
approach O
task. O
One O
component O
of O
sociability, O
the O
time O
spent O
in O
the O
chamber O
with O
the O
novel O
mouse, O
in O
B6 O
mice O
was O
reduced, O
while O
the O
sniffing O
time O
component O
of O
sociability O
in O
BTBR O
mice O
was O
enhanced. O
This O
finding O
replicated O
across O
multiple O
cohorts O
treated O
with O
AMPH B-CHEMICAL
and O
saline O
vehicle. O
In-depth O

analysis O
revealed O
that O
AMPH B-CHEMICAL
increased O
the O
number O
and O
decreased O
the O
duration O
of O
sniffing O
bouts O
in O
BTBR, O
suggesting O
BTBR O
treated O
with O
AMPH B-CHEMICAL
mostly O
engaged O
in O
brief O
sniffs O
rather O
than O
true O
social O
interactions O
with O
the O
novel O
mouse O
during O
the O
social O
approach O
task. O
Our O
data O
suggest O
that O
compounds O
with O
stimulant O
properties O
may O
have O
some O
direct O
benefits O
on O
reducing O
repetitive O
behaviors O
in O
autism O
spectrum O
disorders, O
particularly O
in O
the O
subset O
of O
autistic O
individuals O
with O
hyperactivity. O
This O
article O
is O
part O
of O
the O
Special O
Issue O
entitled O
'Neurodevelopmental O
Disorders'. O
Decreased O
serum O
concentrations O
of O

25-hydroxycholecalciferol B-CHEMICAL
are O
associated O
with O
increased O
risk O
of O
progression O
to O
impaired O
fasting O
glucose B-CHEMICAL
and O
diabetes. O
OBJECTIVE O
To O
study O
the O
association O
between O
vitamin B-CHEMICAL
D I-CHEMICAL
status O
and O
the O
risk O
of O
incident O
impaired O
fasting O
glucose B-CHEMICAL
(IFG) O
and O
diabetes O
in O
a O
population-based O
cohort O
of O
diabetes-free O
subjects. O
RESEARCH O
DESIGN O
AND O
METHODS O
In O
a O
historical O
prospective O
cohort O
study O
of O
subjects O
from O
the O
Clalit O
Health O
Services O
database, O
which O
includes O
information O
on O
nearly O
4 O
million O
people, O
diabetes-free O
subjects O
aged O
40-70 O
years O
with O
serum O

25-hydroxycholecalciferol B-CHEMICAL
(25-OHD) B-CHEMICAL
measurements O
available O
were O
followed O
for O
2 O
years O
to O
assess O
the O
development O
of O
IFG O
and O
diabetes O
in O
five O
25-OHD B-CHEMICAL
subgroups: O
≥25, O
25.1-37.5, O
37.6-50, O
50.1-75, O
and O
>75 O
nmol/L. O
RESULTS O
The O
baseline O
cohort O
included O
117,960 O
adults: O
83,526 O
normoglycemic O
subjects O
and O
34,434 O
subjects O
with O
IFG. O
During O
follow-up, O
8,629 O
subjects O
(10.3% O

of O
the O
normoglycemic O
group) O
developed O
IFG, O
and O
2,162 O
subjects O
(1.8% O
of O
the O
total O
cohort) O
progressed O
to O
diabetes. O
A O
multivariable O
model O
adjusted O
for O
age, O
sex, O
population O
group, O
immigrant O
status, O
BMI, O
season O
of O
vitamin B-CHEMICAL
D I-CHEMICAL
measurement, O
LDL B-GENE-N
and O
HDL B-GENE-N
cholesterol, B-CHEMICAL
triglycerides, B-CHEMICAL
estimated O
glomerular O
filtration O
rate, O
history O
of O
hypertension O
or O
cardiovascular O
disease, O
Charlson O
comorbidity O
index, O
smoking, O
and O
socioeconomic O
status O
revealed O
an O
inverse O
association O
between O
25-OHD B-CHEMICAL
and O
the O
risk O
of O
progression O

to O
IFG O
and O
diabetes. O
The O
odds O
of O
transitioning O
from O
normoglycemia O
to O
IFG, O
from O
normoglycemia O
to O
diabetes, O
and O
from O
IFG O
to O
diabetes O
in O
subjects O
with O
a O
25-OHD B-CHEMICAL
level O
≤25 O
nmol/L O
were O
greater O
than O
those O
of O
subjects O
with O
a O
25-OHD B-CHEMICAL
level O
>75 O
nmol/L O
[odds O
ratio O
1.13 O
(95% O
CI O
1.03-1.24), O
1.77 O
(1.11-2.83), O
and O
1.43 O
(1.16-1.76), O
respectively]. O
CONCLUSIONS O

Vitamin B-CHEMICAL
D I-CHEMICAL
deficiency O
appears O
to O
be O
an O
independent O
risk O
factor O
for O
the O
development O
of O
IFG O
and O
diabetes. O
Structural O
features O
of O
the O
central O
cannabinoid B-CHEMICAL
CB1 B-GENE-Y
receptor O
involved O
in O
the O
binding O
of O
the O
specific O
CB1 B-GENE-Y
antagonist O
SR B-CHEMICAL
141716A. I-CHEMICAL
The O
antagonist O
SR B-CHEMICAL
141716A I-CHEMICAL
has O
a O
high O
specificity O
for O
the O
central O
CB1 B-GENE-Y
cannabinoid B-GENE-N
receptor I-GENE-N
and O
negligeable O
affinity O
for O
the O
peripheral O
CB2 B-GENE-Y
receptor, O
making O
it O
an O
excellent O
tool O
for O
probing O
receptor O
structure-activity O
relationships. O
From O
binding O
experiments O
with O
mutated O
CB1 B-GENE-Y
and O
with O
chimeric O
CB1/CB2 B-GENE-Y
receptors O
we O
have O
begun O
to O
identify O
the O
domains O
of O

CB1 B-GENE-Y
implicated O
in O
the O
recognition O
of O
SR B-CHEMICAL
141716A. I-CHEMICAL
Receptors O
were O
transiently O
expressed O
in O
COS-3 O
cells, O
and O
their O
binding O
characteristics O
were O
studied O
with O
SR B-CHEMICAL
141716A I-CHEMICAL
and O
with O
CP B-CHEMICAL
55,940, I-CHEMICAL
an O
agonist O
recognized O
equally O
well O
by O
the O
two O
receptors. O
The O
region O
delineated O
by O
the O
fourth O
and O
fifth O
transmembrane O
helices O
of O
CB1 B-GENE-Y
proved O
to O
be O
crucial O
for O
high O
affinity O
binding O
of O
SR B-CHEMICAL
141716A. I-CHEMICAL
The O
CB1 B-GENE-Y
and O
CB2 B-GENE-Y
second O
extracellular O
loops, O
e2, O
were O
exchanged, O
modifications O
that O
had O
no O
effect O
on O
SR B-CHEMICAL
141716A I-CHEMICAL
binding O
in O
the O

CB1 B-GENE-Y
variant O
but O
that O
eliminated O
CP B-CHEMICAL
55,940 I-CHEMICAL
binding O
in O
both O
mutants. O
The O
replacement O
of O
the O
conserved O
cysteine B-CHEMICAL
residues O
in O
e2 O
of O
CB2 B-GENE-Y
by O
serine B-CHEMICAL
also O
eliminated O
CP B-CHEMICAL
55,940 I-CHEMICAL
binding, O
but O
replacement O
of O
those O
in O
CB1 B-GENE-Y
resulted O
in O
the O
sequestration O
of O
the O
mutated O
receptors O
in O
the O
cell O
cytoplasm. O
The O
e2 B-GENE-N
domain I-GENE-N
thus O
plays O
some O
role O
in O
CP B-CHEMICAL
55,940 I-CHEMICAL
binding O
but O
none O
in O
SR B-CHEMICAL
141716A I-CHEMICAL
recognition, O
binding O
of O
the O
latter O
clearly O
implicating O
residues O
in O
the O
adjoining O
transmembrane O
helices. O
Drosophila B-GENE-N

GABA-gated I-GENE-N
chloride I-GENE-N
channel: I-GENE-N
modified O
[3H]EBOB B-CHEMICAL
binding O
site O
associated O
with O
Ala-->Ser B-CHEMICAL
or O
Gly B-CHEMICAL
mutants O
of O
Rdl B-GENE-Y
subunit. O
The O
non-competitive O
blocker O
site O
of O
the O
GABA-gated B-GENE-N
chloride I-GENE-N
ion I-GENE-N
channel I-GENE-N
in O
normal O
susceptible O
strains O
of O
Drosophila O
melanogaster O
and O
simulans O
binds O
4-n-[3H]propyl-4'-ethynylbicycloorthobenzoate B-CHEMICAL
([3H]EBOB) B-CHEMICAL
at O
specific O
sites O
with O
KdS O
of O
1.6-1.9 O
nM O
and O

BmaxS O
of O
171-181 O
fmol/mg O
protein. O
This O
specific O
binding O
of O
[3H]EBOB B-CHEMICAL
is O
strongly O
inhibited O
by: O
a O
large O
number O
and O
variety O
of O
insecticidal O
channel O
blockers O
at O
20 O
nM O
(lindane, B-CHEMICAL
alpha-endosulfan, B-CHEMICAL
dieldrin, B-CHEMICAL
12-ketoendrin, B-CHEMICAL
fipronil, B-CHEMICAL
and O
a O
representative O
bicycloorthobenzoate B-CHEMICAL
and O
dithiane) B-CHEMICAL
or O
200 O
nM O
(picrotoxinin); B-CHEMICAL
the O
insecticidal O
channel O
activators O
avermectin B-CHEMICAL
and O
moxidectin B-CHEMICAL
at O
20 O

nM; O
muscimol B-CHEMICAL
at O
30 O
microM O
and O
GABA B-CHEMICAL
at O
300 O
microM. O
Cyclodiene B-CHEMICAL
resistance O
in O
D. O
melanogaster O
has O
been O
attributed O
to O
a O
mutation O
resulting O
in O
an O
Ala302-->Ser B-GENE-N
replacement O
in O
the O
Rdl B-GENE-Y
GABA I-GENE-Y
receptor I-GENE-Y
subunit O
and O
in O
D. O
simulans O
to O
an O
homologous O
Ala-->Ser B-CHEMICAL
or O
Gly B-CHEMICAL
replacement. O
These O
mutations O
are O
shown O
here O
to O
greatly O
reduce O
[3H]EBOB B-CHEMICAL
binding, O
i.e. O
lower O
affinity O
and O
apparent O
number O
of O
binding O
sites. O
The O
Ala-->Ser B-CHEMICAL
replacement O
with O
both O

melanogaster O
and O
simulans O
almost O
always O
reduces O
the O
potency O
in O
inhibiting O
[3H]EBOB B-CHEMICAL
binding O
of O
each O
of O
eight O
channel O
blockers O
and O
of O
muscimol B-CHEMICAL
and O
GABA. B-CHEMICAL
The O
Ala-->Gly B-CHEMICAL
replacement O
in O
D. O
simulans O
is O
generally O
less O
effective O
than O
the O
Ala-->Ser B-CHEMICAL
modification O
in O
reducing O
sensitivity O
to O
the O
channel O
blockers O
and O
to O
muscimol B-CHEMICAL
and O
GABA. B-CHEMICAL
The O
channel O
activators O
avermectin B-CHEMICAL
and O
moxidectin B-CHEMICAL
usually O
retain O
their O
inhibitory O
potency O
in O
the O
Rdl B-GENE-Y
subunit O
mutants. O
Thus, O
it O

appears O
that O
replacement O
of O
Ala B-CHEMICAL
by O
Ser B-CHEMICAL
generally O
modifies O
the O
non-competitive O
blocker O
site O
and O
its O
coupling O
to O
the O
GABA-recognition B-CHEMICAL
site O
with O
less O
effect O
on O
the O
channel O
activator O
site. O
In O
contrast, O
the O
Ala-->Gly B-CHEMICAL
replacement O
has O
less O
impact O
in O
protecting O
the O
chloride B-GENE-N
channel I-GENE-N
from O
the O
action O
of O
insecticidal O
blockers. O
Each O
of O
the O
resistant O
strains O
has O
the O
same O
level O
of O
resistance O
to O
the O
lethal O
action O
of O
the O
five O
channel O
blockers O
examined O
but O
none O
to O
avermectins B-CHEMICAL
and O
muscimol. B-CHEMICAL
In O
vitro O
antiprogestational/antiglucocorticoid O
activity O
and O

progestin B-GENE-N
and O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
binding O
of O
the O
putative O
metabolites O
and O
synthetic O
derivatives O
of O
CDB-2914, B-CHEMICAL
CDB-4124, B-CHEMICAL
and O
mifepristone. B-CHEMICAL
In O
determining O
the O
biological O
profiles O
of O
various O
antiprogestins, O
it O
is O
important O
to O
assess O
the O
hormonal O
and O
antihormonal O
activity, O
selectivity, O
and O
potency O
of O
their O
proximal O
metabolites. O
The O
early O
metabolism O
of O
mifepristone B-CHEMICAL
is O
characterized O
by O
rapid O
demethylation O
and O
hydroxylation. O
Similar O
initial O
metabolic O
pathways O
have O
been O
proposed O
for O
CDB-2914 B-CHEMICAL
(CDB: O

Contraceptive O
Development O
Branch O
of O
NICHD) O
and O
CDB-4124, B-CHEMICAL
and O
their O
putative O
metabolites O
have O
been O
synthesized. O
We O
have O
examined O
the O
functional O
activities O
and O
potencies, O
in O
various O
cell-based O
assays, O
and O
relative O
binding O
affinities O
(RBAs) O
for O
progesterone B-GENE-N
receptors I-GENE-N
(PR) B-GENE-N
and O
glucocorticoid B-GENE-Y
receptors I-GENE-Y
(GR) B-GENE-Y
of O
the O
putative O
mono- O
and O
didemethylated O
metabolites O
of O
CDB-2914, B-CHEMICAL
CDB-4124, B-CHEMICAL
and O
mifepristone B-CHEMICAL
and O
of O
the O
17alpha-hydroxy B-CHEMICAL
and O
aromatic O

A-ring O
derivatives O
of O
CDB-2914 B-CHEMICAL
and O
CDB-4124. B-CHEMICAL
The O
binding O
affinities O
of O
the O
monodemethylated O
metabolites O
for O
rabbit B-GENE-Y
uterine I-GENE-Y
PR I-GENE-Y
and O
human B-GENE-Y
PR-A I-GENE-Y
and O
PR-B B-GENE-Y
were O
similar O
to O
those O
of O
the O
parent O
compounds. O
Monodemethylated O
mifepristone B-CHEMICAL
bound O
to O
rabbit B-GENE-Y
thymic I-GENE-Y
GR I-GENE-Y
with O
higher O
affinity O
than O
monodemethylated O
CDB-2914 B-CHEMICAL
or O
CDB-4124. B-CHEMICAL
T47D-CO O
cells O
were O
used O
to O
assess O
inhibition O
of O
R5020-stimulated O
endogenous O
alkaline B-GENE-N
phosphatase I-GENE-N
activity O
and O

transactivation O
of O
the O
PRE(2)-thymidine B-GENE-N
kinase I-GENE-N
(tk)-luciferase B-GENE-N
(LUC) O
reporter O
plasmid O
in O
transient O
transfections. O
The O
antiprogestational O
potency O
was O
as O
follows: O
mifepristone/CDB-2914/CDB-4124/monodemethylated B-CHEMICAL
metabolites O
(IC(50)'s O
approximately O
10(-9)M) O
> O
aromatic O
A-ring O
derivatives O
(IC(50)'s O
approximately O
10(-8)M) O
> O

didemethylated/17alpha-hydroxy B-CHEMICAL
derivatives O
(IC(50)'s O
approximately O
10(-7)M). O
Antiglucocorticoid O
activity O
was O
determined O
by O
inhibition O
of O
dexamethasone-stimulated B-CHEMICAL
transcriptional O
activity O
in O
HepG2 O
cells. O
The O
mono- O
and O
didemethylated O
metabolites O
of O
CDB-2914 B-CHEMICAL
and O
CDB-4124 B-CHEMICAL
had O
less O
antiglucocorticoid O
activity O
(IC(50)'s O
approximately O
10(-6)M) O
than O
monodemethylated O
mifepristone B-CHEMICAL

(IC(50) O
approximately O
10(-8)M) O
or O
the O
other O
test O
compounds. O
At O
10(-6)M O
in O
transcription O
assays, O
none O
of O
these O
compounds O
showed O
progestin B-GENE-Y
agonist O
activity, O
whereas O
mifepristone B-CHEMICAL
and O
its O
monodemethylated O
metabolite O
manifested O
slight O
glucocorticoid B-GENE-Y
agonist O
activity. O
The O
reduced O
antiglucocorticoid O
activity O
of O
monodemethylated O
CDB-2914 B-CHEMICAL
and O
CDB-4124 B-CHEMICAL
was O
confirmed O
in O
vivo O
by O
the O
thymus O
involution O
assay O
in O
adrenalectomized O
male O
rats. O
The O
aromatic O

A-ring O
derivatives-stimulated O
transcription O
of O
an O
estrogen-responsive B-CHEMICAL
reporter O
plasmid O
in O
MCF-7 O
and O
T47D-CO O
human O
breast O
cancer O
cells O
but O
were O
much O
less O
potent O
than O
estradiol. B-CHEMICAL
Taken O
together, O
these O
data O
suggest O
that O
the O
proximal O
metabolites O
of O
mifepristone, B-CHEMICAL
CDB-2914, B-CHEMICAL
and O
CDB-4124 B-CHEMICAL
contribute O
significantly O
to O
the O
antiprogestational O
activity O
of O
the O
parent O
compounds O
in O
vivo. O
Furthermore, O
the O
reduced O
antiglucocorticoid O
activity O
of O
CDB-2914 B-CHEMICAL
and O
CDB-4124 B-CHEMICAL
compared O
to O

mifepristone B-CHEMICAL
in O
vivo O
may O
be O
due O
in O
part O
to O
decreased O
activity O
of O
their O
putative O
proximal O
metabolites. O
Different O
mechanisms O
of O
acquired O
resistance O
to O
fluorinated B-CHEMICAL
pyrimidines I-CHEMICAL
in O
human O
colorectal O
cancer O
cells. O
5-Fluorouracil B-CHEMICAL
(5-FU), B-CHEMICAL
5-fluoro-2'-deoxyuridine B-CHEMICAL
(FdUrd) B-CHEMICAL
and O
5-trifluorothymidine B-CHEMICAL
(F3(d)Thd) B-CHEMICAL
are O
antimetabolites O
which O
are O
metabolized O
to O
their O
corresponding O
active O
forms O
which O
inhibit O
DNA O
synthesis O
via O

inhibition O
of O
thymidylate B-GENE-Y
synthase I-GENE-Y
(TS). B-GENE-Y
To O
investigate O
ways O
of O
overcoming O
5-FU-resistance, B-CHEMICAL
we O
established O
acquired-resistant O
colorectal O
cancer O
cell O
lines O
against O
these O
three O
drugs O
by O
continuous O
and O
step-wise O
escalation O
of O
drugs, O
and O
analyzed O
the O
cytotoxicity O
and O
the O
mechanism O
of O
resistance O
to O
the O
drugs. O
When O
cells O
were O
incubated O
with O
the O
3 O
drugs O
for O
72 O
h, O
the O
resistance O
ratio O
to O
parental O
DLD-1 O
human O
colorectal O
tumor O
cells O
was O
65.2 O
for O
DLD-1/5-FU, O
9.7 O
for O

DLD-1/FdUrd B-CHEMICAL
and O
448.6 O
for O
DLD-1/F3(d)Thd B-CHEMICAL
cells. O
DLD-1/5-FU B-CHEMICAL
cells O
did O
not O
show O
any O
cross-resistance O
against O
FdUrd B-CHEMICAL
and O
F(3)dThd. B-CHEMICAL
However, O
DLD-1/FdUrd B-CHEMICAL
cells O
showed O
3- O
and O
9-fold O
increased O
resistance O
to O
5-FU B-CHEMICAL
and O
F3(d)Thd, B-CHEMICAL
respectively, O
and O
DLD-1/F3(d)Thd B-CHEMICAL
cells O
also O
showed O
about O
90-fold O
resistance O
to O

FdUrd. B-CHEMICAL
Analysis O
of O
enzyme O
activities O
and O
gene O
expression O
associated O
with O
pyrimidine B-CHEMICAL
metabolism O
indicated O
that O
a O
significant O
decrease O
in O
orotate B-GENE-Y
phosphoribosyltransferase I-GENE-Y
activity O
in O
DLD-1/5-FU B-CHEMICAL
cells, O
a O
7-fold O
increase O
of O
TS B-GENE-Y
mRNA O
in O
DLD-1/FdUrd B-CHEMICAL
cells, O
and O
a O
37-fold O
decrease O
in O
thymidine B-GENE-Y
kinase I-GENE-Y
activity O
of O
DLD-1/F3(d)Thd B-CHEMICAL
cells O
were O
the O
major O
mechanisms O
of O
drug O
resistance. O
These O
findings O
were O
closely O
associated O
with O
the O
cytotoxicity O
of O

5-FU, B-CHEMICAL
FdUrd B-CHEMICAL
and O
F3(d)Thd B-CHEMICAL
against O
the O
established O
5-FU-, B-CHEMICAL
FdUrd- B-CHEMICAL
or O
F3(d)Thd-resistant B-CHEMICAL
cells. O
When O
DLD-1/FdUrd B-CHEMICAL
cells O
expressing O
increased O
TS B-GENE-Y
mRNA O
were O
treated O
with O
FdUrd B-CHEMICAL
and O
F3(d)Thd B-CHEMICAL
for O
only O
4 O
h, O
the O
resistance O
ratios O
of O
DLD-1/FdUrd B-CHEMICAL
cells O
to O
parental O
DLD-1 O
cells O
were O
markedly O
different O
for O
FdUrd B-CHEMICAL
and O
F3(d)Thd, B-CHEMICAL
suggesting O
that O
the O

cytotoxicity O
with O
short-time O
exposure O
to O
F3(d)Thd B-CHEMICAL
is O
due O
to O
a O
mechanism O
other O
than O
TS B-GENE-Y
inhibition, O
although O
the O
cytotoxicity O
of O
F3(d)Thd B-CHEMICAL
in O
the O
short-time O
is O
low O
compared O
to O
that O
of O
long-time O
exposure. O
In O
conclusion, O
F3(d)Thd, B-CHEMICAL
an O
antimetabolite O
that O
inhibits O
TS B-GENE-Y
activity, O
may O
be O
effective O
against O
5-FU B-CHEMICAL
and/or O
FdUrd-resistance B-CHEMICAL
in O
colorectal O
cancer O
cells O
caused O
by O
amplification O
of O
TS B-GENE-N
and/or O
deletion O

of O
orotate B-GENE-Y
phosphoribosyltransferase. I-GENE-Y
Failure O
of O
ritodrine B-CHEMICAL
to O
prevent O
preterm O
labor O
in O
the O
sheep. O
OBJECTIVES: O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
continuous O
infusion O
of O
ritodrine B-CHEMICAL
could O
prevent O
preterm O
delivery O
in O
sheep. O
STUDY O
DESIGN: O
Sheep O
in O
preterm O
labor O
induced O
by O
RU B-CHEMICAL
486 I-CHEMICAL
(mifepristone) B-CHEMICAL
received O
infusions O
of O
either O
ritodrine B-CHEMICAL
(n O
= O
5) O
or O
saline O
solution O
(n O
= O
5), O
and O
the O
progress O
of O
labor O

was O
monitored. O
beta B-GENE-Y
2-Adrenergic I-GENE-Y
receptor I-GENE-Y
density O
and O
function O
(agonist-induced O
cyclic B-CHEMICAL
adenosine I-CHEMICAL
monophosphate I-CHEMICAL
production) O
was O
measured O
in O
myometrial O
samples O
from O
both O
groups. O
RESULTS: O
Ritodrine B-CHEMICAL
initially O
inhibited O
labor O
contractions. O
This O
inhibition O
was O
only O
maintained O
for O
16 O
hours, O
after O
which O
both O
the O
amplitude O
and O
frequency O
of O
electromyographic O
bursts O
and O
contractions O
returned. O
The O
failure O
of O
the O
myometrium O
to O
respond O
to O
ritodrine B-CHEMICAL
(desensitization) O
was O
associated O
with O
significant O
reductions O
in O
agonist-induced O
cyclic B-CHEMICAL
adenosine I-CHEMICAL

monophosphate I-CHEMICAL
production O
and O
beta B-GENE-Y
2-adrenergic I-GENE-Y
receptor I-GENE-Y
concentration O
in O
myometrial O
tissue O
collected O
from O
these O
animals O
compared O
with O
the O
saline O
solution-treated O
controls. O
CONCLUSIONS: O
Continuous O
infusion O
of O
ritodrine B-CHEMICAL
to O
sheep O
in O
preterm O
labor O
produces O
only O
a O
transient O
inhibition O
of O
contractions. O
This O
desensitization O
is O
caused O
by O
a O
down-regulation O
of O
myometrial O
beta B-GENE-Y
2-adrenergic I-GENE-Y
receptors. I-GENE-Y
Smoothened B-GENE-Y
is O
a O
fully O
competent O
activator O
of O
the O
heterotrimeric O
G B-GENE-N
protein I-GENE-N
G(i). B-GENE-N
Smoothened B-GENE-Y

(Smo) B-GENE-Y
is O
a O
7-transmembrane O
protein O
essential O
to O
the O
activation O
of O
Gli B-GENE-Y
transcription O
factors O
(Gli) B-GENE-Y
by O
hedgehog O
morphogens. O
The O
structure O
of O
Smo B-GENE-Y
implies O
interactions O
with O
heterotrimeric O
G B-GENE-N
proteins, I-GENE-N
but O
the O
degree O
to O
which O
G B-GENE-N
proteins I-GENE-N
participate O
in O
the O
actions O
of O
hedgehogs O
remains O
controversial. O
We O
posit O
that O
the O
G(i) B-GENE-N
family O
of O
G B-GENE-N
proteins I-GENE-N
provides O
to O
hedgehogs O
the O
ability O
to O
expand O
well O
beyond O
the O
bounds O
of O
Gli. B-GENE-Y
In O
this O
regard, O
we O
evaluate O
here O
the O
efficacy O
of O
Smo B-GENE-Y
as O
it O
relates O
to O
the O
activation O
of O
G(i), B-GENE-N
by O
comparing O

Smo B-GENE-Y
with O
the O
5-hydroxytryptamine(1A) B-GENE-Y
(5-HT(1A)) B-GENE-Y
receptor, O
a O
quintessential O
G(i)-coupled B-GENE-N
receptor. I-GENE-N
We O
find O
that O
with O
use O
of O
[(35)S]guanosine B-CHEMICAL
5'-(3-O-thio)triphosphate, I-CHEMICAL
first, O
with O
forms O
of O
G(i) B-GENE-N
endogenous O
to O
human O
embryonic O
kidney O
(HEK)-293 O
cells O
made O
to O
express O
epitope-tagged O
receptors O
and, O
second, O
with O
individual O
forms O
of O
Gα(i) B-GENE-N
fused O
to O
the O
C O

terminus O
of O
each O
receptor, O
Smo B-GENE-Y
is O
equivalent O
to O
the O
5-HT(1A) B-GENE-Y
receptor O
in O
the O
assay O
as O
it O
relates O
to O
capacity O
to O
activate O
G(i). B-GENE-N
This O
finding O
is O
true O
regardless O
of O
subtype O
of O
G(i) B-GENE-N
(e.g., O
G(i2), B-GENE-Y
G(o), B-GENE-Y
and O
G(z)) B-GENE-Y
tested. O
We O
also O
find O
that O
Smo B-GENE-Y
endogenous O
to O
HEK-293 O
cells, O
ostensibly O
through O
inhibition O
of O
adenylyl B-GENE-N
cyclase, I-GENE-N
decreases O
intracellular O
levels O
of O
cAMP. B-CHEMICAL
The O
results O
indicate O
that O
Smo B-GENE-Y
is O
a O
receptor O
that O
can O

engage O
not O
only O
Gli B-GENE-Y
but O
also O
other O
more O
immediate O
effectors. O
Antiarrhythmic O
effects O
of O
(-)-epicatechin-3-gallate, B-CHEMICAL
a O
novel O
sodium B-GENE-N
channel I-GENE-N
agonist O
in O
cultured O
neonatal O
rat O
ventricular O
myocytes. O
(-)-Epicatechin-3-gallate B-CHEMICAL
(ECG), B-CHEMICAL
a O
polyphenol B-CHEMICAL
extracted O
from O
green O
tea, O
has O
been O
proposed O
as O
an O
effective O
compound O
for O
improving O
cardiac O
contractility. O
However, O
the O
therapeutic O
potential O
of O
ECG B-CHEMICAL
on O
the O
treatment O
of O
arrhythmia O
remains O
unknown. O
We O
investigated O
the O
direct O
actions O
of O
ECG B-CHEMICAL
on O
the O

modulation O
of O
ion O
currents O
and O
cardiac O
cell O
excitability O
in O
the O
primary O
culture O
of O
neonatal O
rat O
ventricular O
myocyte O
(NRVM), O
which O
is O
considered O
a O
hypertrophic O
model O
for O
analysis O
of O
myocardial O
arrhythmias. O
By O
using O
the O
whole-cell O
patch-clamp O
configurations, O
we O
found O
ECG B-CHEMICAL
enhanced O
the O
slowly O
inactivating O
component O
of O
voltage-gated O
Na(+) B-CHEMICAL
currents O
(I(Na)) B-CHEMICAL
in O
a O
concentration-dependent O
manner O
(0.1-100 O
μM) O
with O
an O
EC(50) O
value O
of O
3.8 O
μM. O

ECG B-CHEMICAL
not O
only O
shifted O
the O
current-voltage O
relationship O
of O
peak O
I(Na) B-CHEMICAL
to O
the O
hyperpolarizing O
direction O
but O
also O
accelerated O
I(Na) B-CHEMICAL
recovery O
kinetics. O
Working O
at O
a O
concentration O
level O
of O
I(Na) B-CHEMICAL
enhancement, O
ECG B-CHEMICAL
has O
no O
notable O
effect O
on O
voltage-gated O
K(+) B-CHEMICAL
currents O
and O
L-type O
Ca(2+) B-CHEMICAL
currents. O
With O
culture O
time O
increment, O
the O
firing O
rate O
of O
spontaneous O
action O
potential O
(sAP) O
in O
NRVMs O
was O
gradually O
decreased O
until O
spontaneous O
early O
after-depolarization O
(EAD) O
was O
observed O
after O
about O
one O
week O
culture. O
ECG B-CHEMICAL
increased O

the O
firing O
rate O
of O
normal O
sAP O
about O
two-fold O
without O
waveform O
alteration. O
Interestingly, O
the O
bradycardia-dependent O
EAD O
could O
be O
significantly O
restored O
by O
ECG B-CHEMICAL
in O
fast O
firing O
rate O
to O
normal O
sAP O
waveform. O
The O
expression O
of O
dominant O
cardiac O
sodium B-GENE-N
channel I-GENE-N
subunit, O
Nav1.5, B-GENE-Y
was O
consistently O
detected O
throughout O
the O
culture O
periods. O
Our O
results O
reveal O
how O
ECG, B-CHEMICAL
the O
novel O
I(Na) B-CHEMICAL
agonist, O
may O
act O
as O
a O
promising O
candidate O
in O
clinical O
applications O
on O
cardiac O
arrhythmias. O
Liver O
choline B-GENE-Y
dehydrogenase I-GENE-Y
and O
kidney O
betaine-homocysteine B-GENE-N

methyltransferase I-GENE-N
expression O
are O
not O
affected O
by O
methionine B-CHEMICAL
or O
choline B-CHEMICAL
intake O
in O
growing O
rats. O
Choline B-GENE-Y
dehydrogenase I-GENE-Y
(CHDH) B-GENE-Y
and O
betaine-homocysteine B-GENE-N
methyltransferase I-GENE-N
(BHMT) B-GENE-N
are O
2 O
enzymes O
involved O
in O
choline B-CHEMICAL
oxidation. O
BHMT B-GENE-N
is O
expressed O
at O
high O
levels O
in O
rat O
liver O
and O
its O
expression O
is O
regulated O
by O
dietary O
Met B-CHEMICAL
and O
choline. B-CHEMICAL
BHMT B-GENE-N
is O
also O
found O
in O
rat O
kidney, O
albeit O
in O
substantially O
lower O
amounts, O
but O
it O
is O
not O
known O
whether O
kidney O
BHMT B-GENE-N
expression O
is O
regulated O
by O
dietary O
Met B-CHEMICAL
or O

choline. B-CHEMICAL
Similarly, O
CHDH B-GENE-Y
activity O
is O
highest O
in O
the O
liver O
and O
kidney, O
but O
the O
regulation O
of O
its O
expression O
by O
diet O
has O
not O
been O
thoroughly O
investigated. O
Sprague O
Dawley O
rats O
( O
approximately O
50 O
g) O
were O
fed, O
for O
9 O
d O
in O
2 O
x O
3 O
factorial O
design O
(n O
= O
8), O
an O
l-amino B-CHEMICAL
acid-defined I-CHEMICAL
diet O
varying O
in O
l-Met B-CHEMICAL
(0.125, O
0.3, O
or O
0.8%) O
and O
choline B-CHEMICAL
(0 O
or O
25 O
mmol/kg O
diet). O
Liver O
and O
kidney O
BHMT B-GENE-N
and O
CHDH B-GENE-Y
were O
assessed O
using O
enzymatic, O
Western O

blot, O
and O
real-time O
PCR O
analyses. O
Liver O
samples O
were O
also O
fixed O
for O
histological O
analysis. O
Liver O
BHMT B-GENE-N
activity O
was O
1.3-fold O
higher O
in O
rats O
fed O
the O
Met B-CHEMICAL
deficient O
diet O
containing O
choline, B-CHEMICAL
which O
was O
reflected O
in O
corresponding O
increases O
in O
mRNA O
content O
and O
immunodetectable O
protein. O
Independent O
of O
dietary O
choline, B-CHEMICAL
supplemental O
Met B-CHEMICAL
increased O
hepatic O
BHMT B-GENE-N
activity O
approximately O
30%. O
Kidney O
BHMT B-GENE-N
and O
liver O
CHDH B-GENE-Y
expression O
were O
refractory O
to O
these O
diets. O
Some O
degree O
of O
fatty O
liver O
developed O
in O
all O
rats O
fed O
a O

choline-devoid B-CHEMICAL
diet, O
indicating O
that O
supplemental O
Met B-CHEMICAL
cannot O
completely O
compensate O
for O
the O
lack O
of O
dietary O
choline B-CHEMICAL
in O
growing O
rats. O
Identification O
of O
a O
new O
interaction O
mode O
between O
the O
Src B-GENE-N
homology I-GENE-N
2 I-GENE-N
(SH2) I-GENE-N
domain I-GENE-N
of O
C-terminal B-GENE-Y
Src I-GENE-Y
kinase I-GENE-Y
(Csk) B-GENE-Y
and O
Csk-binding B-GENE-Y
protein I-GENE-Y
(Cbp)/phosphoprotein B-GENE-Y
associated I-GENE-Y
with I-GENE-Y
glycosphingolipid I-GENE-Y
microdomains I-GENE-Y
(PAG). B-GENE-Y
Proteins O
with O
Src B-GENE-N
homology I-GENE-N
2 I-GENE-N
(SH2) I-GENE-N
domains I-GENE-N
play O
major O
roles O
in O
tyrosine B-GENE-N
kinase I-GENE-N
signaling. O
Structures O
of O
many O
SH2 B-GENE-N

domains I-GENE-N
have O
been O
studied, O
and O
the O
regions O
involved O
in O
their O
interactions O
with O
ligands O
have O
been O
elucidated. O
However, O
these O
analyses O
have O
been O
performed O
using O
short O
peptides O
comprising O
phosphotyrosine B-CHEMICAL
followed O
by O
a O
few O
amino B-CHEMICAL
acids, I-CHEMICAL
which O
are O
described O
as O
the O
canonical O
recognition O
sites. O
Here O
we O
report O
the O
solution O
structure O
of O
the O
SH2 B-GENE-N
domain I-GENE-N
of O
C-terminal B-GENE-Y
Src I-GENE-Y
kinase I-GENE-Y
(Csk) B-GENE-Y
in O
complex O
with O
a O
longer O
phosphopeptide O
from O
Csk-binding B-GENE-Y
protein I-GENE-Y
(Cbp). B-GENE-Y
This O
structure, O
together O
with O
biochemical O
experiments, O
revealed O
the O
existence O
of O
a O
novel O
binding O
region O
in O
addition O
to O
the O
canonical O

phosphotyrosine-314 B-CHEMICAL
binding O
site O
of O
Cbp. B-GENE-Y
Mutational O
analysis O
of O
this O
second O
region O
in O
cells O
showed O
that O
both O
canonical O
and O
novel O
binding O
sites O
are O
required O
for O
tumor O
suppression O
through O
the O
Cbp-Csk B-GENE-Y
interaction. O
Furthermore, O
the O
data O
indicate O
an O
allosteric O
connection O
between O
Cbp B-GENE-Y
binding O
and O
Csk B-GENE-Y
activation O
that O
arises O
from O
residues O
in O
the O
βB/βC O
loop O
of O
the O
SH2 B-GENE-N
domain. I-GENE-N
Protective O
effects O
of O
protein O
transduction O
domain-metallothionein B-GENE-N
fusion O
proteins O
against O
hypoxia- O
and O
oxidative O
stress-induced O
apoptosis O
in O
an O

ischemia/reperfusion O
rat O
model. O
Ischemic O
heart O
diseases O
caused O
by O
insufficient O
oxygen B-CHEMICAL
supply O
to O
the O
cardiac O
muscle O
require O
pharmaceutical O
agents O
for O
the O
prevention O
of O
the O
progress O
and O
recurrence. O
Metallothionein B-GENE-N
(MT) B-GENE-N
has O
a O
potential O
as O
a O
protein O
therapeutic O
for O
the O
treatment O
of O
this O
disease O
due O
to O
its O
anti-oxidative O
effects O
under O
stressful O
conditions. O
In O
spite O
of O
its O
therapeutic O
potential, O
efficient O
delivery O
systems O
need O
to O
be O
developed O
to O
overcome O
limitations O
such O
as O
low O
transduction O
efficiency, O
instability O
and O
short O
half-life O
in O
the O
body. O
To O
enhance O
intra-cellular O
transduction O
efficiency, O
Tat O
sequence O
as O
a O
protein O

transduction O
domain O
(PTD) O
was O
fused O
with O
MT B-GENE-N
in O
a O
recombinant O
method. O
Anti-apoptotic O
and O
anti-oxidative O
effects O
of O
Tat-MT B-GENE-N
fusion O
protein O
were O
evaluated O
under O
hyperglycemia O
and O
hypoxia O
stress O
conditions O
in O
cultured O
H9c2 O
cells. O
Recovery O
of O
cardiac O
functions O
by O
anti-apoptotic O
and O
anti-fibrotic O
effects O
of O
Tat-MT B-GENE-N
was O
confirmed O
in O
an O
ischemia/reperfusion O
(I/R) O
rat O
myocardial O
infarction O
model. O
Tat-MT B-GENE-N
fusion O
protein O
effectively O
protected O

H9c2 O
cells O
under O
stressful O
conditions O
by O
reducing O
intracellular O
ROS O
production O
and O
inhibiting O
caspase-3 O
activation. O
Tat-MT B-GENE-N
fusion O
protein O
inhibited O
apoptosis, O
reduced O
fibrosis O
area O
and O
enhanced O
cardiac O
functions O
in O
I/R. O
Tat-MT B-GENE-N
fusion O
protein O
could O
be O
a O
promising O
therapeutic O
for O
the O
treatment O
of O
ischemic O
heart O
diseases. O
Lifelong O
exposure O
to O
bisphenol B-CHEMICAL
a I-CHEMICAL
alters O
cardiac O
structure/function, O
protein O
expression, O
and O
DNA O
methylation O
in O
adult O
mice. O
Bisphenol B-CHEMICAL
A I-CHEMICAL
(BPA) B-CHEMICAL
is O
an O
estrogenizing O
endocrine O
disruptor O

compound O
of O
concern. O
Our O
objective O
was O
to O
test O
whether O
lifelong O
BPA B-CHEMICAL
would O
impact O
cardiac O
structure/function, O
calcium B-CHEMICAL
homeostasis O
protein O
expression, O
and O
the O
DNA O
methylation O
of O
cardiac O
genes. O
We O
delivered O
0.5 O
and O
5.0 O
µg/kg/day O
BPA B-CHEMICAL
lifelong O
from O
gestation O
day O
11 O
or O
200 O
µg/kg/day O
from O
gestation O
day O
11 O
to O
postnatal O
day O
21 O
via O
the O
drinking O
water O
to O
C57bl/6n O
mice. O
BPA B-CHEMICAL
5.0 O
males O
and O
females O
had O
increased O
body O
weight, O
body O
mass O
index, O
body O
surface O
area, O
and O
adiposity. O

Echocardiography O
identified O
concentric O
remodeling O
in O
all O
BPA-treated B-CHEMICAL
males. O
Systolic O
and O
diastolic O
cardiac O
functions O
were O
essentially O
similar, O
but O
lifelong O
BPA B-CHEMICAL
enhanced O
male O
and O
reduced O
female O
sex-specific O
differences O
in O
velocity O
of O
circumferential O
shortening O
and O
ascending O
aorta O
velocity O
time O
integral. O
Diastolic O
blood O
pressure O
was O
increased O
in O
all O
BPA B-CHEMICAL
females. O
The O
calcium B-CHEMICAL
homeostasis O
proteins O
sarcoendoplasmic B-GENE-Y
reticulum I-GENE-Y
ATPase I-GENE-Y
2a I-GENE-Y
(SERCA2a), B-GENE-Y
sodium B-GENE-Y
calcium I-GENE-Y
exchanger-1, I-GENE-Y
phospholamban B-GENE-Y
(PLB), B-GENE-Y

phospho-PLB, B-GENE-Y
and O
calsequestrin B-GENE-Y
2 I-GENE-Y
are O
important O
for O
contraction O
and O
relaxation. O
Changes O
in O
their O
expression O
suggest O
increased O
calcium B-CHEMICAL
mobility O
in O
males O
and O
reduced O
calcium B-CHEMICAL
mobility O
in O
females O
supporting O
the O
cardiac O
function O
changes. O
DNA B-GENE-Y
methyltransferase I-GENE-Y
3a I-GENE-Y
expression O
was O
increased O
in O
all O
BPA B-CHEMICAL
males O
and O
BPA B-CHEMICAL
0.5 O
females O
and O
reduced O
in O
BPA B-CHEMICAL
200 O
females. O
Global O
DNA O
methylation O
was O
increased O
in O
BPA B-CHEMICAL
0.5 O
males O
and O
reduced O
in O
BPA B-CHEMICAL
0.5 O
females. O
BPA B-CHEMICAL
induced O
sex-specific O
altered O
DNA O
methylation O
in O
specific O
CpG B-CHEMICAL
pairs O
in O
the O
calsequestrin B-GENE-Y
2 I-GENE-Y

CpG O
island. O
These O
results O
suggest O
that O
continual O
exposure O
to O
BPA B-CHEMICAL
impacts O
cardiac O
structure/function, O
protein O
expression, O
and O
epigenetic O
DNA O
methylation O
marks O
in O
males O
and O
females. O
Wogonoside B-CHEMICAL
induces O
autophagy O
in O
MDA-MB-231 O
cells O
by O
regulating O
MAPK-mTOR B-GENE-N
pathway. O
Previous O
studies O
have O
demonstrated O
that O
wogonoside, B-CHEMICAL
a O
bioactive O
flavonoid B-CHEMICAL
extracted O
from O
the O
root O
of O
Scutellaria O
baicalensis O
Gerogi, O
has O
anti-inflammatory O
and O
anti-angiogenic O
activities. O
In O
this O
study, O
we O
evaluated O
wogonoside-induced B-CHEMICAL

autophagy O
on O
human O
breast O
MDA-MB-231 O
cells. O
We O
report O
that O
wogonoside B-CHEMICAL
triggered O
the O
formation O
of O
microtubule-associated B-GENE-N
protein-light I-GENE-N
chain I-GENE-N
3 I-GENE-N
(MAP-LC3) B-GENE-N
positive O
autophagosomes O
and O
the O
accumulation O
of O
acidic O
vesicular O
and O
autolysosomes O
in O
MDA-MB-231 O
cells. O
In O
addition, O
cells O
treated O
by O
wogonoside B-CHEMICAL
developed O
autophagosome-like O
characteristics, O
including O
single O
and O
double O
membrane O
vacuoles O
containing O
intact O
and O
degraded O
cellular O
debris. O
The O
results O
showed O
that O
wogonoside B-CHEMICAL
promotes O
the O
expression O
of O
LC3-II B-GENE-Y
and O

Beclin-1. B-GENE-Y
Furthermore, O
wogonoside B-CHEMICAL
inhibited O
cell O
growth O
of O
MDA-MB-231 O
cells O
in O
a O
concentration- O
and O
time-dependent O
manner, O
which O
was O
associated O
with O
wogonoside-induced B-CHEMICAL
autophagy. O
Wogonoside B-CHEMICAL
also O
suppressed O
the O
activation O
of O
mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
(mTOR) B-GENE-Y
and O
p70-S6 B-GENE-N
kinase I-GENE-N
(p70S6K) B-GENE-N
by O
regulating O
the O
expression O
of O
the O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK1/2) B-GENE-N
and O
p38 B-GENE-N
involved O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK) B-GENE-N
signaling O
pathway. O
Taken O

together, O
these O
results O
suggest O
that O
wogonoside B-CHEMICAL
partially O
inhibits O
MDA-MB-231 O
cell O
growth O
by O
inducing O
autophagy O
through O
the O
MAPK-mTOR B-GENE-N
pathway O
and O
may O
be O
a O
promising O
anti-tumor O
agent. O
A O
mutation O
in O
the O
FAM36A B-GENE-Y
gene, O
the O
human O
ortholog O
of O
COX20, B-GENE-N
impairs O
cytochrome B-GENE-N
c I-GENE-N
oxidase I-GENE-N
assembly O
and O
is O
associated O
with O
ataxia O
and O
muscle O
hypotonia. O
The O
mitochondrial B-GENE-N
respiratory I-GENE-N
chain I-GENE-N
complex I-GENE-N
IV I-GENE-N
(cytochrome B-GENE-N
c I-GENE-N
oxidase) I-GENE-N
is O
a O
multi-subunit O
enzyme O
that O
transfers O
electrons O
from O

cytochrome B-GENE-Y
c I-GENE-Y
to O
molecular O
oxygen, B-CHEMICAL
yielding O
water. O
Its O
biogenesis O
requires O
concerted O
expression O
of O
mitochondria- O
and O
nuclear-encoded O
subunits O
and O
assembly O
factors. O
In O
this O
report, O
we O
describe O
a O
homozygous O
missense O
mutation O
in O
FAM36A B-GENE-Y
from O
a O
patient O
who O
displays O
ataxia O
and O
muscle O
hypotonia. O
The O
FAM36A B-GENE-Y
gene O
is O
a O
remote, O
putative O
ortholog O
of O
the O
fungal B-GENE-N
complex I-GENE-N
IV I-GENE-N
assembly I-GENE-N
factor I-GENE-N
COX20. B-GENE-N
Messenger O
RNA O
(mRNA) O
and O
protein O
co-expression O
analyses O
support O
the O
involvement O
of O
FAM36A B-GENE-Y
in O
complex B-GENE-N
IV I-GENE-N
function O
in O
mammals. O
The O

c.154A>C B-GENE-N
mutation O
in O
the O
FAM36A B-GENE-Y
gene, O
a O
mutation O
that O
is O
absent O
in O
sequenced O
exomes, O
leads O
to O
a O
reduced O
activity O
and O
lower O
levels O
of O
complex B-GENE-N
IV I-GENE-N
and O
its O
protein O
subunits. O
The O
FAM36A B-GENE-Y
protein O
is O
nearly O
absent O
in O
patient's O
fibroblasts. O
Cells O
affected O
by O
the O
mutation O
accumulate O
subassemblies O
of O
complex B-GENE-N
IV I-GENE-N
that O
contain O
COX1 B-GENE-Y
but O
are O
almost O
devoid O
of O
COX2 B-GENE-Y
protein. O
We O
observe O
co-purification O
of O
FAM36A B-GENE-Y
and O
COX2 B-GENE-Y
proteins, O
supporting O
that O
the O
FAM36A B-GENE-Y
defect O
hampers O
the O
early O
step O

of O
complex B-GENE-N
IV I-GENE-N
assembly O
at O
the O
incorporation O
of O
the O
COX2 B-GENE-Y
subunit. O
Lentiviral O
complementation O
of O
patient's O
fibroblasts O
with O
wild-type O
FAM36A B-GENE-Y
increases O
the O
complex B-GENE-N
IV I-GENE-N
activity O
as O
well O
as O
the O
amount O
of O
holocomplex B-GENE-N
IV I-GENE-N
and O
of O
individual O
subunits. O
These O
results O
establish O
the O
function O
of O
the O
human B-GENE-Y
gene I-GENE-Y
FAM36A/COX20 I-GENE-Y
in O
complex B-GENE-N
IV I-GENE-N
assembly O
and O
support O
a O
causal O
role O
of O
the O
gene O
in O
complex B-GENE-N
IV I-GENE-N
deficiency. O
Deduced O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
from O
the O
bovine B-GENE-Y
oxytocin-neurophysin I-GENE-Y
I I-GENE-Y
precursor I-GENE-Y
cDNA. O
The O
nonapeptide O
hormone O

oxytocin-like B-GENE-Y
arginine-vasopressin B-GENE-Y
(AVP) B-GENE-Y
is O
synthesized O
as O
part O
of O
a O
larger O
precursor O
polypeptide. O
The O
precursor O
also O
includes O
the O
neurophysin B-GENE-N
molecule O
with O
which O
the O
hormone O
is O
associated O
in O
the O
neurosecretory O
granules O
of O
the O
hypothalamo-pituitary O
tract. O
A O
protein O
of O
molecular O
weight O
(Mr) O
approximately O
20,000 O
has O
been O
isolated O
from O
supraoptic O
nuclei O
of O
rat O
hypothalami O
which, O
after O
tryptic O
cleavage, O
released O
a O
neurophysin-like B-GENE-N
molecule O
of O
Mr O
approximately O
10,000 O
and O

an O
oligopeptide O
related O
to O
oxytocin. B-GENE-Y
This O
result O
was O
complemented O
by O
in O
vitro O
translation O
of O
bovine O
hypothalamic O
mRNA. O
Among O
the O
primary O
translation O
products O
a O
single O
polypeptide O
of O
Mr O
approximately O
16,500 O
was O
shown O
to O
contain O
antigenic O
determinants O
recognized O
by O
specific O
antisera O
against O
bovine B-GENE-Y
neurophysin I-GENE-Y
I I-GENE-Y
and O
oxytocin. B-GENE-Y
Here O
we O
report O
the O
amino B-CHEMICAL
acid I-CHEMICAL
sequence O
of O
the O
bovine B-GENE-Y
oxytocin-neurophysin I-GENE-Y
I I-GENE-Y
(OT-NpI) I-GENE-Y
precursor I-GENE-Y
which O
was O
derived O
from O
sequence O
analysis O
of O
the O

cloned O
cDNA. O
As O
is O
the O
case O
for O
the O
bovine B-GENE-Y
arginine-vasopressin-neurophysin I-GENE-Y
II I-GENE-Y
(AVP-NpII) I-GENE-Y
precursor, I-GENE-Y
the O
signal O
sequence O
of O
the O
OT-NpI B-GENE-Y
precursor O
is O
immediately O
followed O
by O
the O
nonapeptide O
hormone O
which O
is O
connected O
to O
neurophysin B-GENE-Y
I I-GENE-Y
by O
a O
Gly-Lys-Arg B-GENE-N
sequence. O
A O
striking O
feature O
of O
the O
nucleic O
acid O
sequence O
is O
the O
197-nucleotide O
long O
perfect O
homology O
with O
the O
AVP-NpII B-GENE-Y
precursor I-GENE-Y
mRNA O
sequence O
encoding O
the O
conserved O
middle O
part O
of O

neurophysins B-GENE-N
I I-GENE-N
and I-GENE-N
II. I-GENE-N
Pelargonidin B-CHEMICAL
activates O
the O
AhR B-GENE-Y
and O
induces O
CYP1A1 B-GENE-Y
in O
primary O
human O
hepatocytes O
and O
human O
cancer O
cell O
lines O
HepG2 O
and O
LS174T. O
We O
examined O
the O
effects O
of O
anthocyanidins B-CHEMICAL
(cyanidin, B-CHEMICAL
delphinidin, B-CHEMICAL
malvidin, B-CHEMICAL
peonidin, B-CHEMICAL
petunidin, B-CHEMICAL
pelargonidin) B-CHEMICAL
on O
the O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AhR)-CYP1A1 B-GENE-Y
signaling O
pathway O
in O
human O
hepatocytes, O
hepatic O

HepG2 O
and O
intestinal O
LS174T O
cancer O
cells. O
AhR-dependent B-GENE-Y
reporter O
gene O
expression O
in O
transfected O
HepG2 O
cells O
was O
increased O
by O
pelargonidin B-CHEMICAL
in O
a O
concentration-dependent O
manner O
at O
24h. O
Similarly, O
pelargonidin B-CHEMICAL
induced O
the O
expression O
of O
CYP1A1 B-GENE-Y
mRNA O
up O
to O
5-fold O
in O
HepG2 O
and O
LS174T O
cells O
relative O
to O
the O
induction O
by O
5 O
nM O
2,3,7,8-tetrachlorodibenzodioxin B-CHEMICAL
(TCDD), B-CHEMICAL
the O
most O
potent O
activator O
of O
AhR. B-GENE-Y

CYP1A1 B-GENE-Y
and O
CYP1A2 B-GENE-Y
mRNAs O
were O
also O
increased O
by O
pelargonidin B-CHEMICAL
in O
three O
primary O
human O
hepatocytes O
cultures O
(approximately O
5% O
of O
TCDD B-CHEMICAL
potency) O
and O
the O
increase O
in O
CYP1A1 B-GENE-Y
protein O
in O
HepG2 O
and O
LS174T O
cells O
was O
comparable O
to O
the O
increase O
in O
catalytic O
activity O
of O
CYP1A1 B-GENE-Y
enzyme. O
Ligand O
binding O
analysis O
demonstrated O
that O
pelargonidin B-CHEMICAL
was O
a O
weak O
ligand O
of O
AhR. B-GENE-Y
Enzyme O
kinetic O
analyses O
using O
human O
liver O
microsomes O
revealed O
inhibition O
of O
CYP1A1 B-GENE-Y
activity O
by O

delphinidin B-CHEMICAL
(IC50 O
78 O
μM) O
and O
pelargonidin B-CHEMICAL
(IC50 O
33 O
μM). O
Overall, O
although O
most O
anthocyanidins B-CHEMICAL
had O
no O
effects O
on O
AhR-CYP1A1 B-GENE-Y
signaling, O
pelargonidin B-CHEMICAL
can O
bind O
to O
and O
activate O
the O
AhR B-GENE-Y
and O
AhR-dependent B-GENE-Y
gene O
expression, O
and O
pelargonidin B-CHEMICAL
and O
delphinidin B-CHEMICAL
inhibit O
the O
CYP1A1 B-GENE-Y
catalytic O
activity. O
Cloning O
and O
expression O
of O
a O
novel O
serotonin B-GENE-N
receptor I-GENE-N
with O
high O
affinity O
for O
tricyclic B-CHEMICAL
psychotropic O
drugs. O
We O
have O
used O
the O

polymerase O
chain O
reaction O
technique O
to O
selectively O
amplify O
a O
guanine B-GENE-N
nucleotide-binding I-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
cDNA O
sequence O
from O
rat O
striatal O
mRNA O
that O
exhibits O
high O
homology O
to O
previously O
cloned O
serotonin B-GENE-N
receptors. I-GENE-N
Sequencing O
of O
a O
full O
length O
clone O
isolated O
from O
a O
rat O
striatal O
cDNA O
library O
revealed O
an O
open O
reading O
frame O
of O
1311 O
base O
pairs, O
encoding O
a O
437-residue O
protein O
with O
seven O
hydrophobic O
regions. O
Within O
these O
hydrophobic O
regions, O
this O
receptor O
was O
found O
to O
be O
41-36% O
identical O
to O
the O
following O
serotonin B-GENE-N

[5-hydroxytryptamine I-GENE-N
(5-HT)] I-GENE-N
receptors: I-GENE-N
5-HT2 B-GENE-Y
> O
5-HT1D B-GENE-Y
> O
5-HT1C B-GENE-Y
> O
5-HT1B B-GENE-Y
> O
5-HT1A B-GENE-Y
> O
5-HT1E. B-GENE-Y
Northern O
blots O
revealed O
a O
approximately O
4.2-kilobase O
transcript O
localized O
in O
various O
brain O
regions, O
with O
the O
following O
rank O
order O
of O
abundance: O
striatum O
>> O
olfactory O
tubercle O
> O
cerebral O
cortex O
> O
hippocampus. O
Expression O
of O
this O
clone O
in O
COS-7 O
cells O
resulted O
in O
the O
appearance O
of O

high O
affinity, O
saturable O
binding O
of O
(+)-[2-125I] B-CHEMICAL
iodolysergic I-CHEMICAL
acid I-CHEMICAL
diethylamide I-CHEMICAL
([125I]LSD) B-CHEMICAL
with O
a O
Kd O
of O
1.26 O
nM. O
Among O
endogenous O
biogenic O
amines, O
only O
5-HT B-CHEMICAL
completely O
inhibited O
[125I]LSD B-CHEMICAL
binding O
(Ki O
= O
150 O
nM). O
The O
inhibition O
of O
[125I]LSD B-CHEMICAL
binding O
by O
other O
serotonergic O
agonists O
and O
antagonists O
revealed O
a O
pharmacological O
profile O
that O
does O
not O
correlate O
with O
that O
of O
any O
previously O
described O
serotonin B-GENE-N

receptor I-GENE-N
subtype. O
In O
addition, O
this O
receptor O
exhibits O
high O
affinity O
for O
a O
number O
of O
tricyclic B-CHEMICAL
antipsychotic O
and O
antidepressant O
drugs, O
including O
clozapine, B-CHEMICAL
amoxipine, B-CHEMICAL
and O
amitriptyline. B-CHEMICAL
In O
HEK-293 O
cells O
stably O
transfected O
with O
this O
receptor, O
serotonin B-CHEMICAL
elicits O
a O
potent O
stimulation O
of O
adenylyl B-GENE-N
cyclase I-GENE-N
activity, O
which O
is O
blocked O
by O
antipsychotic O
and O
antidepressant O
drugs. O
The O
distinct O
structural O
and O
pharmacological O
properties O
of O
this O
receptor O
site O
indicate O
that O
it O
represents O
a O
completely O
novel O
subtype O
of O

serotonin B-GENE-N
receptor. I-GENE-N
Based O
on O
its O
affinity O
for O
tricyclic B-CHEMICAL
psychotropic O
drugs O
and O
its O
localization O
to O
limbic O
and O
cortical O
regions O
of O
the O
brain, O
it O
is O
likely O
that O
this O
receptor O
may O
play O
a O
role O
in O
several O
neuropsychiatric O
disorders O
that O
involve O
serotonergic O
systems. O
The O
use O
of O
insulin B-GENE-Y
analogues O
in O
pregnancy. O
Excellent O
glycaemic O
control O
is O
essential O
in O
pregnancy O
to O
optimise O
maternal O
and O
foetal O
outcomes. O
The O
aim O
of O
this O
review O
is O
to O
assess O
the O
efficacy O
and O
safety O
of O
insulin B-GENE-Y
analogues O
in O
pregnancy. O
Insulin B-GENE-Y
lispro O
and O
insulin B-GENE-Y
aspart O
are O
safe O
in O

pregnancy O
and O
may O
improve O
post-prandial O
glycaemic O
control O
in O
women O
with O
type O
1 O
diabetes. O
However, O
a O
lack O
of O
data O
indicating O
improved O
foetal O
outcomes O
would O
suggest O
that O
there O
is O
no O
imperative O
to O
switch O
to O
a O
short-acting O
analogue O
where O
the O
woman's O
diabetes O
is O
well O
controlled O
with O
human B-GENE-Y
insulin. I-GENE-Y
There O
are O
no O
reports O
of O
the O
use O
of O
insulin B-GENE-Y
glulisine O
in O
pregnancy O
and O
so O
its O
use O
cannot O
be O
recommended. O
Most O
studies O
of O
insulin B-GENE-Y
glargine O
in O
pregnancy O
are O
small, O
retrospective O
and O
include O
women O
with O
pre-existing O
diabetes O
and O
gestational O
diabetes. O
There O
appear O
to O
be O
no O
major O
safety O
concerns O
and O
so O
it O
seems O
reasonable O

to O
continue O
insulin B-GENE-Y
glargine O
if O
required O
to O
achieve O
excellent O
glycaemic O
control. O
A O
head-to-head O
comparison O
between O
insulin B-GENE-Y
detemir O
and O
NPH O
insulin B-GENE-Y
in O
women O
with O
type O
1 O
diabetes O
showed O
that O
while O
foetal O
outcomes O
did O
not O
differ, O
fasting O
plasma O
glucose B-CHEMICAL
improved O
with O
insulin B-GENE-Y
detemir O
without O
an O
increased O
incidence O
of O
hypoglycaemia. O
The O
greater O
evidence O
base O
supports O
the O
use O
of O
insulin B-GENE-Y
detemir O
as O
the O
first O
line O
long-acting O
analogue O
in O
pregnancy O
but O
the O
lack O
of O
definitive O
foetal O
benefits O
means O
that O
there O
is O
no O
strong O
need O
to O
switch O
a O
woman O
who O
is O
well O
controlled O
on O
NPH O
insulin. B-GENE-Y
There O

seems O
little O
justification O
in O
using O
long O
acting O
insulin B-GENE-Y
analogues O
in O
women O
with O
gestational O
diabetes O
or O
type O
2 O
diabetes O
where O
the O
risk O
of O
hypoglycaemia O
is O
low. O
alpha-Linolenic B-CHEMICAL
acid, I-CHEMICAL
Delta6-desaturase B-GENE-Y
gene O
polymorphism, O
and O
the O
risk O
of O
nonfatal O
myocardial O
infarction. O
BACKGROUND: O
Delta(6)-Desaturase B-GENE-Y
(FADS2) B-GENE-Y
is O
the O
rate-limiting O
step O
in O
the O
polyunsaturated B-CHEMICAL
fatty I-CHEMICAL
acid I-CHEMICAL
(PUFA) B-CHEMICAL
biosynthetic O
pathway. O
OBJECTIVE: O
The O

aim O
was O
to O
test O
whether O
the O
common O
deletion O
[T/-] O
in O
the O
promoter O
of O
FADS2 B-GENE-Y
affects O
the O
PUFA B-CHEMICAL
biosynthetic O
pathway O
and O
consequently O
modifies O
the O
effect O
of O
alpha-linolenic B-CHEMICAL
acid I-CHEMICAL
(ALA) B-CHEMICAL
on O
myocardial O
infarction O
(MI). O
DESIGN: O
Case O
subjects O
(n O
=1694) O
with O
a O
first O
nonfatal O
acute O
MI O
were O
matched O
by O
age, O
sex, O
and O
area O
of O
residence O
to O
1694 O
population-based O
control O
subjects O
in O
Costa O
Rica. O
PUFAs B-CHEMICAL
were O
quantified O
by O
gas-liquid O
chromatography O
from O
plasma O
and O

adipose O
tissue O
samples. O
Least-squares O
means O
from O
generalized O
linear O
models O
and O
odds O
ratios O
(ORs) O
and O
95% O
CIs O
from O
multiple O
conditional O
logistic O
regression O
models O
were O
estimated. O
RESULTS: O
The O
prevalence O
of O
the O
variant O
T/- O
allele O
was O
48%. O
Eicosapentaenoic B-CHEMICAL
acid, I-CHEMICAL
gamma-linolenic B-CHEMICAL
acid, I-CHEMICAL
and O
arachidonic B-CHEMICAL
acid I-CHEMICAL
decreased O
in O
adipose O
tissue O
and O
plasma O
with O
increasing O
number O
of O
copies O
of O
the O
variant O
allele O
with O
a O
monotonic O
trend O
(P O
< O
0.05 O
for O
all). O
Fasting O
plasma O

triacylglycerols B-CHEMICAL
by O
genotype O
were O
2.08 O
mmol/L O
for O
TT, O
2.16 O
mmol/L O
for O
T-, O
and O
2.26 O
mmol/L O
for O
- O
- O
[ie, O
homozygous O
for O
the O
variant O
(deletion) O
allele] O
(P O
= O
0.03). O
The O
FADS2 B-GENE-Y
deletion O
was O
not O
associated O
with O
MI O
and O
did O
not O
significantly O
modify O
the O
association O
between O
adipose O
tissue O
ALA B-CHEMICAL
and O
the O
risk O
of O
MI. O
CONCLUSIONS: O
The O
FADS2 B-GENE-Y
deletion O
may O
prevent O
the O
conversion O
of O
ALA B-CHEMICAL

into O
very-long-chain B-CHEMICAL
PUFAs. I-CHEMICAL
However, O
this O
metabolic O
effect O
is O
not O
translated O
into O
an O
attenuated O
risk O
between O
ALA B-CHEMICAL
and O
MI O
among O
carriers O
of O
the O
variant. O
It O
is O
possible O
that, O
at O
current O
intakes O
of O
ALA, B-CHEMICAL
any O
potential O
defect O
in O
the O
transcription O
of O
the O
gene O
is O
masked O
by O
the O
availability O
of O
substrate. O
Further O
research O
in O
populations O
deficient O
in O
ALA B-CHEMICAL
intake O
is O
warranted. O
Altered O
vasoreactivity O
to O
angiotensin B-GENE-Y
II I-GENE-Y
in O
experimental O
diabetic O
neuropathy: O
role O
of O
nitric B-CHEMICAL
oxide. I-CHEMICAL
We O
evaluated O
the O
effects O
of O
angiotensin B-GENE-Y
II I-GENE-Y
and O
an O
angiotensin-converting B-GENE-Y

enzyme I-GENE-Y
inhibitor O
(cilazapril) B-CHEMICAL
on O
nerve O
blood O
flow O
(NBF) O
and O
electrophysiology O
in O
control O
and O
diabetic O
rats. O
When O
applied O
locally O
to O
the O
sciatic O
nerve, O
the O
dose-response O
curve O
of O
angiotensin B-GENE-Y
II I-GENE-Y
was O
more O
potent O
in O
experimental O
diabetic O
neuropathy O
(EDN) O
than O
control O
rats. O
No O
difference O
existed O
in O
plasma O
angiotensin B-GENE-Y
II I-GENE-Y
levels O
between O
EDN O
and O
controls. O
The O
rats O
were O
given O
typical O
rat O
pellets O
or O
pellets O
treated O
with O
10 O
mg/kg O
per O
day O
cilazapril B-CHEMICAL
for O
4 O
weeks. O
Diabetes O
caused O
a O
significant O
reduction O

in O
NBF, O
nerve O
conduction O
velocity, O
and O
compound O
muscle O
action O
potential O
(CMAP) O
amplitudes. O
NBF O
was O
significantly O
increased O
in O
diabetic O
rats O
supplemented O
with O
cilazapril B-CHEMICAL
diet, O
and O
nerve O
conduction O
velocity O
and O
amplitudes O
of O
the O
CMAP O
were O
also O
improved O
after O
4 O
weeks O
on O
this O
diet. O
Direct O
application O
10(-3) O
mol/L O
cilazapril B-CHEMICAL
on O
sciatic O
nerve O
did O
not O
increase O
NBF O
in O
normal O
and O
EDN O
rats. O
We O
topically O
applied O
the O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N
(NOS) B-GENE-N
inhibitor, O

NG-nitro-L-arginine, B-CHEMICAL
on O
sciatic O
nerve O
and O
observed O
reduced O
inhibition O
of O
NBF O
in O
EDN, O
which O
was O
correctable O
with O
a O
cilazapril B-CHEMICAL
diet. O
These O
results O
suggest O
that O
diabetic O
neuropathy O
may O
have O
an O
increasing O
vasopressor O
action O
with O
angiotensin B-GENE-Y
II I-GENE-Y
and O
this O
is O
likely O
to O
be O
the O
mechanism O
of O
NOS B-GENE-N
inhibition. O
Angiotensin B-GENE-Y
II-converting I-GENE-Y
enzyme I-GENE-Y
inhibitors O
may O
have O
potential O
in O
the O
treatment O
of O
diabetic O
neuropathy. O
Effect O
of O
the O
R(-) B-CHEMICAL
and I-CHEMICAL
S(+) I-CHEMICAL
isomers I-CHEMICAL
of I-CHEMICAL
MDA I-CHEMICAL

and O
MDMA B-CHEMICAL
on O
phosphatidyl B-CHEMICAL
inositol I-CHEMICAL
turnover O
in O
cultured O
cells O
expressing O
5-HT2A B-GENE-Y
or O
5-HT2C B-GENE-Y
receptors. O
The O
effect O
of O
the O
R(-) B-CHEMICAL
and I-CHEMICAL
S(+) I-CHEMICAL
isomers I-CHEMICAL
of I-CHEMICAL
3,4-methylenedioxyamphetamine I-CHEMICAL
(MDA) B-CHEMICAL
and O
its O
N-methyl B-CHEMICAL
analog I-CHEMICAL
3,4-methylenedioxymethamphetamine I-CHEMICAL
(MDMA) B-CHEMICAL
on O
[3H]inositol B-CHEMICAL
monophosphate I-CHEMICAL
accumulation O
was O
studied O
in O
cells O
expressing O
either O
5-HT2A B-GENE-Y
or O
5-HT2C B-GENE-Y

receptors. O
The O
isomers O
of O
MDA B-CHEMICAL
produced O
a O
concentration O
dependent O
increase O
in O
phosphatidyl B-CHEMICAL
inositol I-CHEMICAL
(PI) B-CHEMICAL
hydrolysis O
at O
the O
5-HT2A B-GENE-Y
receptors, O
with O
the O
R(-) B-CHEMICAL
isomer I-CHEMICAL
of I-CHEMICAL
MDA I-CHEMICAL
being O
more O
potent O
than O
the O
S(+) O
at O
the O
5-HT2A B-GENE-Y
receptor. O
The O
R(-) B-CHEMICAL
and I-CHEMICAL
S(+) I-CHEMICAL
isomers I-CHEMICAL
of I-CHEMICAL
MDMA I-CHEMICAL
were O
significantly O
less O
efficacious O
at O
the O
5-HT2A B-GENE-Y
receptor O
as O
compared O
to O
MDA; B-CHEMICAL
S(+)MDMA B-CHEMICAL
had O
no O
effect. O
At O
the O

5-HT2C B-GENE-Y
receptor, O
both O
R(-) B-CHEMICAL
and I-CHEMICAL
S(+)MDA I-CHEMICAL
were O
equipotent O
at O
stimulating O
PI B-CHEMICAL
hydrolysis, O
with O
the O
S(+) B-CHEMICAL
isomer I-CHEMICAL
of I-CHEMICAL
MDMA I-CHEMICAL
being O
more O
efficacious O
at O
the O
5-HT2C B-GENE-Y
receptor O
compared O
with O
the O
R(-) O
isomer. O
In O
all O
cases O
at O
both O
the O
5-HT2A B-GENE-Y
and O
5-HT2C B-GENE-Y
receptors, O
the O
affinities O
of O
the O
isomers O
of O
MDMA B-CHEMICAL
and O
MDA B-CHEMICAL
were O
at O
least O
2-3 O
orders O
of O
magnitude O
less O
than O
5-HT. B-CHEMICAL
Despite O
the O
weak O

effect O
of O
these O
compounds O
at O
the O
5-HT2A B-GENE-Y
and O
5-HT2C B-GENE-Y
receptors, O
these O
substituted O
amphetamines B-CHEMICAL
do O
possess O
intrinsic O
activity O
which O
may O
contribute O
to O
their O
neurotoxic O
effects O
when O
administered O
at O
high O
doses. O
Hepatocytes O
display O
a O
compensatory O
survival O
response O
against O
cadmium B-CHEMICAL
toxicity O
by O
a O
mechanism O
mediated O
by O
EGFR B-GENE-Y
and O
Src. B-GENE-Y
Although O
the O
liver O
is O
a O
cadmium-target B-CHEMICAL
organ, O
hepatocyte O
response O
involved O
in O
its O
toxicity O
is O
not O
yet O
elucidated. O
A O
link O
between O
this O
heavy O
metal O
treatment O
and O
Stat3 B-GENE-Y
signaling O
pathways O
was O
examined O
in O
primary O
mouse O

hepatocytes. O
We O
provided O
evidence O
of O
a O
novel O
link O
among O
NADPH B-GENE-N
oxidase I-GENE-N
and O
Stat3 B-GENE-Y
signaling, O
mediated O
by O
Src, B-GENE-Y
EGFR, B-GENE-Y
and O
Erk1/2. B-GENE-N
Cadmium B-CHEMICAL
activates O
NADPH B-GENE-N
oxidase. I-GENE-N
ROS O
produced O
by O
this O
oxidase B-GENE-N
activates O
Src, B-GENE-Y
enable O
that O
in O
turn, O
transactivates O
EGFR B-GENE-Y
that O
activates O
Stat3 B-GENE-Y
in O
tyrosine, B-CHEMICAL
allowing O
its O
dimerization. O
Also, O
ROS O
from O
NADPH B-GENE-N
oxidase I-GENE-N
favors O
ERK1/2 B-GENE-N
activation O
that O

phosphorylates O
Stat3 B-GENE-Y
in O
serine, B-CHEMICAL
resulting O
in O
a O
compensatory O
or O
adaptive O
survival O
response O
such O
as O
production O
of O
metallothionein-II B-GENE-Y
in O
short O
Cd B-CHEMICAL
exposure O
times. O
However, O
after O
12h O
CdCl2 B-CHEMICAL
treatment, O
cell O
viability O
diminished O
in O
50%, O
accompanied O
by O
a O
drastic O
decrease O
of O
metallothionein-II B-GENE-Y
production, O
and O
an O
increase O
in O
p53 B-GENE-Y
activation O
and O
the O
pro-apoptotic O
protein O
Bax. B-GENE-Y
[Screening O
of O
short O
peptides O
binding O
to O
cell O
surface O
interleukin-2 B-GENE-Y
receptor I-GENE-Y
alpha I-GENE-Y
chain]. I-GENE-Y
OBJECTIVE: O
To O

screen O
and O
characterize O
the O
short O
peptides O
which O
bind O
specifically O
to O
interleukin-2 B-GENE-Y
(IL-2) I-GENE-Y
receptor I-GENE-Y
alpha I-GENE-Y
chain I-GENE-Y
(IL-2Ralpha) B-GENE-Y
for O
acquisition O
of O
small O
antagonists O
for O
blocking O
the O
binding O
of O
IL-2 B-GENE-Y
with O
IL-2Ralpha. B-GENE-Y
METHODS: O
12-mer O
phage O
displayed O
peptide O
library O
was O
screened O
with O
the O
target O
cells O
of O
MT-2 O
cells O
which O
expressed O
IL-2Ralpha B-GENE-Y
at O
high O
levels. O
The O
binding O
phage O
clones O
were O
eluted O
by O
anti-IL-2Ralpha B-GENE-Y
monoclonal O
antibody. O
After O
3 O
rounds O
of O

screening, O
the O
positive O
phage O
clones O
were O
identified O
by O
enzyme-linked O
immunosorbent O
assay O
(ELISA) O
and O
immunohistochemistry, O
and O
the O
amino B-CHEMICAL
acid I-CHEMICAL
sequences O
of O
the O
positive O
clones O
were O
deduced O
from O
the O
DNA O
sequences. O
RESULTS: O
Seven O
positive O
clones O
were O
screened O
out O
of O
the O
17 O
phage O
clones O
bound O
to O
MT-2 O
cells. O
The O
positive O
clone O
M15 O
could O
bind O
specifically O
to O
MT-2 O
cell O
and O
PHA-activated O
peripheral O
blood O
monouclear O
cells. O
Amino B-CHEMICAL
acid I-CHEMICAL
sequence O
analysis O
identified O
6 O
sequences, O
all O
of O
which O
contained O
hydrophilic O

residues, O
and O
5 O
of O
these O
6 O
sequences O
included O
Tyr, B-CHEMICAL
Phe B-CHEMICAL
and O
Leu B-CHEMICAL
conservative O
residues. O
CONCLUSION: O
The O
peptide O
sequences O
containing O
Tyr, B-CHEMICAL
Phe B-CHEMICAL
conservative O
residues O
identified O
in O
this O
study O
can O
bind O
to O
cell O
surface O
IL-2Ralpha. B-GENE-Y
Peyer's O
patch-mediated O
intestinal O
immune O
system O
modulating O
activity O
of O
pectic-type O
polysaccharide O
from O
peel O
of O
Citrus O
unshiu. O
An O
intestinal O
immune O
system O
modulating O
polysaccharide O
(CUI-3IIb-3-2, O
18kDa) O
was O

purified O
from O
Citrus O
unshiu O
peel. O
CUI-3IIb-3-2 O
mainly O
comprised O
GalA, B-CHEMICAL
GlcA, B-CHEMICAL
Ara, B-CHEMICAL
Gal B-CHEMICAL
and O
Rha, B-CHEMICAL
and O
it O
consisted O
of O
4-linked O
GalA, B-CHEMICAL
terminal O
Araf, B-CHEMICAL
4- O
or O
5-linked/3,4- O
or O
3,5-branched O
Ara, B-CHEMICAL
terminal O
Gal, B-CHEMICAL
and O
2-linked/2,4-branched O
Rha. B-CHEMICAL
After O
CUI-3IIb-3-2 O
digestion O
by O
endo-α-d-(1→4)-polygalacturonase, B-GENE-N

its O
hydrolysate O
was O
fractionated O
into O
PG-1 O
and O
PG-2. O
Methylation O
analyses O
of O
PG-1 O
and O
PG-2 O
using O
base-catalysed O
β-elimination O
suggested O
that O
CUI-3IIb-3-2 O
be O
assumed O
as O
pectic-type O
polysaccharide. O
Since O
the O
activities O
of O
PG-1 O
and O
PG-2 O
were O
potently O
decreased, O
the O
whole O
polysaccharide O
structure O
of O
CUI-3IIb-3-2 O
would O
be O
essential O
to O
maintain O
the O
activity. O
Meanwhile, O
when O
CUI-3IIb O
was O

orally O
administered O
in O
mice, O
bone O
marrow O
cell O
proliferation O
and O
GM-CSF/IL-6 B-GENE-Y
production O
from O
Peyer's O
patch O
cell O
were O
significantly O
higher O
(1.76- O
and O
2.03/2.51-fold, O
respectively) O
than O
a O
saline. O
Therefore, O
a O
pectic-type O
polysaccharide O
from O
citrus O
peel O
could O
stimulate O
Peyer's O
patches O
and O
produce O
hematopoietic O
growth O
factors O
resulted O
in O
bone O
marrow O
cell O
proliferation. O
An O
Indian O
butyrylcholinesterase B-GENE-Y
variant O
L307P B-GENE-N
is O
not O
structurally O
stable: O
A O
molecular O
dynamics O
simulation O
study. O
The O
human B-GENE-Y

butyrylcholinesterase I-GENE-Y
(BChE) B-GENE-Y
activity O
is O
less O
than O
1% O
in O
the O
serum O
of O
silent O
variant O
individuals O
of O
Vysya O
community O
in O
India. O
They O
are O
homozygous O
for O
a O
point O
mutation O
at O
codon O
307 O
(CTT→CCT) B-GENE-N
resulting O
in O
the O
substitution O
of O
leucine B-GENE-N
307 I-GENE-N
by I-GENE-N
proline. I-GENE-N
The O
reason O
for O
the O
disappearance O
of O
the O
protein O
in O
the O
serum O
has O
not O
been O
explicated O
till O
date. O
Based O
on O
this O
background, O
we O
performed O
molecular O
dynamics O
simulation O
to O
probe O
the O
structural O
stability O
of O
Indian O
variant O
(L307P) B-GENE-N
in O
comparison O
with O
wild O
and O
other O
BChE B-GENE-Y
variants O

(D70G, B-GENE-N
E497V, B-GENE-N
V142M) B-GENE-N
having O
differential O
esterase B-GENE-N
activity. O
The O
simulation O
of O
all O
the O
mutants O
except O
D70G B-GENE-N
showed O
a O
much O
larger O
Cα O
root O
mean O
square O
deviation O
from O
the O
wild O
BChE B-GENE-Y
crystal O
structure, O
showing O
the O
overall O
conformational O
disturbance. O
Further O
analysis O
revealed O
that O
secondary O
structure O
of O
the O
mutant O
proteins O
was O
not O
stable. O
The O
orientation O
of O
the O
catalytic O
triad O
is O
also O
distorted O
in O
all O
the O
mutants. O
The O
distance O
between O
δ O
nitrogen B-CHEMICAL
of O
His438 B-CHEMICAL
to O
ε O
oxygen B-CHEMICAL
of O
Glu325 B-CHEMICAL
and O
ε O
nitrogen B-CHEMICAL
of O
His438 B-CHEMICAL
to O
γ O
oxygen B-CHEMICAL
of O
Ser198 B-CHEMICAL
were O
highly O
altered O

in O
L307P B-GENE-N
mutant O
than O
the O
wild O
and O
other O
three O
variants O
throughout O
the O
simulation. O
Such O
disparity O
of O
distances O
between O
the O
catalytic O
residues O
may O
be O
due O
to O
the O
change O
in O
the O
protein O
conformation O
attributing O
to O
their O
differential O
catalytic O
activity. O
Our O
studies O
thus O
prove O
that O
the O
Indian O
BChE B-GENE-Y
L307P B-GENE-N
mutant O
with O
negligible O
activity O
is O
possibly O
due O
to O
its O
structural O
instability O
when O
compared O
to O
other O
BChE B-GENE-Y
variants. O
The O
inhibitory O
effect O
of O
ginseng B-CHEMICAL
saponins I-CHEMICAL
on O
the O
stress-induced O
plasma O
interleukin-6 B-GENE-Y
level O
in O
mice. O
The O
effect O
of O
ginseng B-CHEMICAL
saponins I-CHEMICAL
on O
plasma O

interleukin-6 B-GENE-Y
(IL-6) B-GENE-Y
in O
non-stressed O
and O
immobilization-stressed O
mice O
were O
investigated. O
Ginseng O
total O
saponins, B-CHEMICAL
ginsenosides B-CHEMICAL
Rb2, I-CHEMICAL
Rg1 I-CHEMICAL
and I-CHEMICAL
Rd I-CHEMICAL
administered O
intraperitoneally O
attenuated O
the O
immobilization O
stress-induced O
increase O
in O
plasma O
IL-6 B-GENE-Y
level. O
But, O
intracerebroventricular O
injection O
of O
each O
ginsenoside B-CHEMICAL
did O
not O
affect O
plasma O
IL-6 B-GENE-Y
level O
induced O
by O
immobilization O
stress. O
Ginsenosides B-CHEMICAL
Rb2, I-CHEMICAL
Rd I-CHEMICAL
and I-CHEMICAL
Rg1 I-CHEMICAL
significantly O
decreased O

norepinephrine B-CHEMICAL
and/or O
epinephrine-induced B-CHEMICAL
increase O
of O
IL-6 B-GENE-Y
level O
in O
macrophage O
cell O
line O
(RAW O
264.7). O
Thus, O
it O
can O
be O
suggested O
that O
the O
inhibitory O
action O
of O
ginseng B-CHEMICAL
saponins I-CHEMICAL
against O
the O
immobilization O
stress-induced O
increase O
of O
plasma O
IL-6 B-GENE-Y
level O
would O
be O
in O
periphery; O
at O
least O
in O
part, O
mediated O
by O
blocking O
norepinephrine- B-CHEMICAL
and/or O
epinephrine-induced B-CHEMICAL
increase O
of O
IL-6 B-GENE-Y
level O
in O
macrophage O
rather O
than O
in O
the O
brain. O
Ginseng B-CHEMICAL
saponins I-CHEMICAL
might O
be O
proposed O
as O
a O
possible O

candidate O
in O
the O
research O
or O
therapeutic O
modulation O
of O
stress-related O
disorders. O
Sitagliptin. B-CHEMICAL
Sitagliptin, B-CHEMICAL
an O
oral O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
(DPP-4) B-GENE-Y
inhibitor, O
improves O
glycaemic O
control O
by O
inhibiting O
DPP-4 B-GENE-Y
inactivation O
of O
the O
incretin B-GENE-N
hormones I-GENE-N
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
and O
glucose-dependent B-GENE-Y
insulinotropic I-GENE-Y
polypeptide. I-GENE-Y
This O
increases O
active O
incretin B-GENE-N
and O
insulin B-GENE-Y
levels, O
and O
decreases O
glucagon B-GENE-Y
levels O
and O
post-glucose-load B-CHEMICAL
glucose B-CHEMICAL
excursion. O
In O
large, O
well O
designed O
phase O

III O
trials O
in O
patients O
with O
type O
2 O
diabetes O
mellitus, O
sitagliptin B-CHEMICAL
100 O
or O
200mg O
once O
daily O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics O
was O
associated O
with O
significant O
improvements O
relative O
to O
placebo O
in O
overall O
glycaemic O
control O
and O
indices O
for O
insulin B-GENE-Y
response O
and O
beta-cell O
function. O
Improvements O
from O
baseline O
in O
mean O
glycosylated B-GENE-Y
haemoglobin I-GENE-Y
(HbA(1c)) B-GENE-Y
were O
significantly O
greater O
with O
sitagliptin B-CHEMICAL
monotherapy O
than O
with O
placebo O
in O
patients O
with O
type O
2 O
diabetes. O
As O
add-on O
therapy O
in O
patients O
with O
suboptimal O

glycaemic O
control O
despite O
oral O
antihyperglycaemic O
treatment, O
sitagliptin B-CHEMICAL
improved O
HbA(1c) B-GENE-Y
to O
a O
significantly O
greater O
extent O
than O
placebo O
when O
added O
to O
metformin B-CHEMICAL
or O
pioglitazone B-CHEMICAL
and O
was O
noninferior O
to O
glipizide B-CHEMICAL
when O
added O
to O
metformin. B-CHEMICAL
Sitagliptin B-CHEMICAL
was O
well O
tolerated O
when O
administered O
alone O
or O
in O
combination O
with O
other O
antihyperglycaemics, O
with O
an O
adverse O
event O
profile O
similar O
to O
that O
shown O
with O
placebo. O
The O
incidence O
of O
hypoglycaemia O
with O
sitagliptin B-CHEMICAL
was O
similar O
to O
that O
with O
placebo O

and, O
in O
combination O
with O
metformin, B-CHEMICAL
lower O
than O
that O
with O
glipizide. B-CHEMICAL
Sitagliptin B-CHEMICAL
had O
a O
generally O
neutral O
effect O
on O
bodyweight. O
Streptococcus B-GENE-Y
pneumoniae I-GENE-Y
ClpP I-GENE-Y
protease B-GENE-N
induces O
apoptosis O
via O
caspase-independent B-GENE-N
pathway O
in O
human O
neuroblastoma O
cells: O
cytoplasmic O
relocalization O
of O
p53. B-GENE-Y
Streptococcus O
pneumoniae O
causes O
the O
most O
severe O
form O
of O
the O
bacterial O
meningitis O
which O
is O
the O
major O
cause O
of O
bacterial O
meningitis. O
Virulence O
factors O
produced O
by O
S. O
pneumoniae O
have O
been O
known O
to O
contribute O
significantly O

to O
the O
disease O
process. O
ClpP B-GENE-Y
protease B-GENE-N
(ClpP) B-GENE-Y
which O
is O
essential O
for O
virulence O
and O
survival O
under O
stress O
conditions O
in O
S. O
pneumonia O
was O
examined O
for O
the O
ability O
to O
induce O
apoptosis O
and O
the O
mechanism O
of O
the O
induction O
of O
apoptosis O
in O
human O
neuron-like O
cells, O
SK-N-SH O
neuroblastoma O
cells. O
ClpP B-GENE-Y
inhibited O
cell O
growth O
and O
induced O
apoptosis O
in O
SK-N-SH O
cells. O
Treatment O
with O
ClpP B-GENE-Y
resulted O
in O
hypodiploid O
DNA O
contents, O
increased O
Bax/ B-GENE-Y
Bcl-2 B-GENE-Y
ratio O
and O
induction O

of O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
production. O
The O
release O
of O
cytochrome B-GENE-Y
c I-GENE-Y
from O
mitochondria O
into O
the O
cytosol, O
which O
is O
an O
initiator O
of O
the O
activation O
of O
caspase B-GENE-N
cascades, O
was O
not O
observed O
in O
ClpP-treated B-GENE-Y
cells. O
In O
addition, O
pretreatment O
with O
Z-Val-Ala-Asp-fluoromethylketone B-CHEMICAL
(Z-VAD-fmk), B-CHEMICAL
a O
broad O
spectrum O
of O
caspase B-GENE-N
inhibitor, O
could O
not O
rescue O
apoptotic O
cells O
from O
ClpP B-GENE-Y
toxicity. O
Coincidently, O

caspase-3 B-GENE-N
and I-GENE-N
-8 I-GENE-N
activation O
and O
cleavage O
of O
PARP B-GENE-N
were O
not O
detected. O
Moreover, O
caspase B-GENE-N
independent O
apoptosis-inducing B-GENE-Y
factor I-GENE-Y
(AIF) B-GENE-Y
was O
released O
from O
mitochondria O
and O
translocated O
to O
the O
nucleus O
in O
response O
to O
ClpP. B-GENE-Y
We O
also O
found O
that O
ClpP B-GENE-Y
treatment O
resulted O
in O
the O
increase O
of O
p53 B-GENE-Y
activity O
and O
cytoplasmic O
p53 B-GENE-Y
levels O
were O
increased O
by O
ClpP, B-GENE-Y
suggesting O
that O
functional O
activation O
of O
p53 B-GENE-Y
is O
intact O
despite O
increased O
cytoplasmic O
accumulation. O
Taken O
together, O
these O
data O
suggest O
that O
ClpP B-GENE-Y
contributes O
to O

neuronal O
damage O
in O
meningitis O
and O
provide O
further O
insight O
into O
the O
mechanisms O
underlying O
action O
of O
pneumococcal O
virulence O
factors O
during O
bacterial O
pathogenesis. O
New O
aspects O
in O
the O
management O
of O
obesity: O
operation O
and O
the O
impact O
of O
lipase B-GENE-N
inhibitors. O
Obesity O
is O
an O
increasing O
health O
problem O
in O
most O
developed O
countries O
and O
its O
prevalence O
is O
also O
increasing O
in O
developing O
countries. O
There O
has O
been O
no O
great O
success O
with O
dietary O
means O
and O
life O
style O
modification O
for O
permanent O
weight O
loss. O
Various O
surgical O
treatment O
methods O
for O
obesity O
are O
now O
available. O
They O
are O
aimed O
at O
limiting O
oral O
energy O
intake O
with O
or O
without O
causing O
dumping O
or O
inducing O
selective O

maldigestion O
and O
malabsorption. O
Based O
on O
current O
literature, O
up O
to O
75% O
of O
excess O
weight O
is O
lost O
by O
surgical O
treatment O
with O
concomitant O
disappearance O
of O
hyperlipidaemias, O
type O
2 O
diabetes, O
hypertension O
or O
sleep O
apnoea. O
The O
main O
indication O
for O
operative O
treatment O
is O
morbid O
obesity O
(body O
mass O
index O
greater O
than O
40 O
kg/m2) O
or O
severe O
obesity O
(body O
mass O
index O
> O
35 O
kg/m2) O
with O
comorbidities O
of O
obesity. O
Orlistat B-CHEMICAL
is O
a O
new O
inhibitor O
of O
pancreatic B-GENE-Y
lipase I-GENE-Y
enzyme. O
At O
doses O
of O
120 O
mg O

three O
times O
per O
day O
with O
meals O
it O
results O
in O
a O
30% O
reduction O
in O
dietary O
fat O
absorption, O
which O
equals O
approximately O
200 O
kcal O
daily O
energy O
deficit. O
In O
the O
long O
term, O
orlistat B-CHEMICAL
has O
been O
shown O
to O
be O
more O
effective O
than O
placebo O
in O
reducing O
body O
weight O
and O
serum O
total O
and O
low-density B-GENE-N
lipoprotein I-GENE-N
cholesterol B-CHEMICAL
levels. O
Orlistat B-CHEMICAL
has O
a O
lowering O
effect O
on O
serum O
cholesterol B-CHEMICAL
independent O
of O
weight O
loss. O
Along O
with O
weight O
loss, O
orlistat B-CHEMICAL
also O
favourably O
affects O
blood O
pressure O
and O
glucose B-CHEMICAL
and O
insulin B-GENE-Y
levels O
in O
obese O
individuals O
and O
in O
obese O
type O
2 O
diabetic O
patients. O
The O
characteristics O
of O

genistin-induced B-CHEMICAL
inhibitory O
effects O
on O
intestinal O
motility. O
Genistin B-CHEMICAL
belongs O
to O
isoflavones. B-CHEMICAL
Based O
on O
the O
facts O
that O
genistin B-CHEMICAL
exerts O
inhibitory O
effects O
on O
the O
contractility O
of O
vascular O
smooth O
muscle,the O
present O
study O
was O
designed O
to O
characterize O
the O
effects O
of O
genistin B-CHEMICAL
on O
intestinal O
contractility O
and O
evaluate O
its O
potential O
clinical O
implication. O
Ex O
vivo O
[isolated O
jejunal O
segment O
(IJS) O
of O
rat], O
in O
vitro, O
and O
in O
vivo O
assays O
were O
used O
in O
the O
study. O
The O
results O
indicated O
that O
genistin B-CHEMICAL

(5-80 O
μmol/L) O
inhibited O
the O
contraction O
of O
IJS O
in O
a O
dose-dependent O
manner O
and O
inhibited O
the O
increased-contractility O
of O
IJS O
induced O
by O
acetylcholine B-CHEMICAL
(ACh), B-CHEMICAL
histamine, B-CHEMICAL
high O
Ca(2+), B-CHEMICAL
and O
erythromycin, B-CHEMICAL
respectively. O
The O
inhibitory O
effects O
of O
genistin B-CHEMICAL
were O
correlated O
with O
the O
stimulation O
of O
alpha B-GENE-N
adrenergic I-GENE-N
and I-GENE-N
beta I-GENE-N
adrenergic I-GENE-N
receptors I-GENE-N
since O
these O
inhibitory O
effects O
were O
significantly O
blocked O
in O
the O
presence O
of O
phentolamine B-CHEMICAL
and O
propranolol B-CHEMICAL
respectively. O
No O
further O
inhibitory O
effects O

of O
genistin B-CHEMICAL
were O
observed O
in O
the O
presence O
of O
verapamil B-CHEMICAL
or O
in O
Ca(2+)-free B-CHEMICAL
condition, O
indicating O
genistin-induced B-CHEMICAL
inhibitory O
effects O
are O
Ca(2+)-dependent. B-CHEMICAL
Genistin B-CHEMICAL
decreased O
myosin B-GENE-Y
light I-GENE-Y
chain I-GENE-Y
kinase I-GENE-Y
(MLCK) B-GENE-Y
protein O
contents O
and O
MLCK B-GENE-Y
mRNA O
expression O
in O
IJS, O
and O
inhibited O
both O
phosphorylation O
and O
Mg(2+)-ATPase B-CHEMICAL
activity O
of O
purified O
myosin, O
implicating O
that O
the O
decrease O
of O
MLCK B-GENE-Y
contents O
and O
inhibition O
of O
MLCK B-GENE-Y
activity O
are O
involved O
in O

the O
genistin-induced B-CHEMICAL
inhibitory O
effects. O
The O
study O
suggests O
the O
potential O
clinical O
implications O
of O
genistin B-CHEMICAL
in O
relieving O
intestinal O
hypercontractility. O
Contribution O
of O
single-minded B-GENE-Y
2 I-GENE-Y
to O
hyperglycaemia-induced O
neurotoxicity. O
Diabetes O
mellitus O
is O
associated O
to O
central O
nervous O
system O
damage, O
which O
results O
in O
impairment O
of O
brain O
functions O
and O
cognitive O
deficits O
and O
decline O
in O
memory. O
However, O
the O
mechanisms O
mediating O
the O
actions O
of O
glucose B-CHEMICAL
on O
the O
neurons O
remained O
elusive. O
Single-minded B-GENE-Y
2 I-GENE-Y
(Sim2), B-GENE-Y
a O
basic B-GENE-N
helix-loop-helix I-GENE-N

(bHLH)-PAS B-GENE-N
transcriptional O
repressor, O
is O
thought O
to O
be O
involved O
in O
some O
symptoms O
of O
Down O
syndrome. O
We O
hypothesized O
that O
Sim2 B-GENE-Y
mediated O
hyperglycaemia-induced O
neuronal O
injury O
and O
impairment O
of O
learning O
and O
memory. O
It O
was O
found O
that O
expression O
of O
Sim2 B-GENE-Y
protein O
in O
cortical O
neurons O
was O
increased O
in O
streptozotocin-induced B-CHEMICAL
diabetes O
mellitus O
rat O
model. O
Drebrin, B-GENE-Y
down-regulated O
by O
Sim2, B-GENE-Y
was O
subsequently O
decreased O
as O
detected O
by O
confocal O
laser O
scanning O
microscopy O
and O
Western O
blot O
analysis. O
The O
expression O
pattern O
of O

Sim2 B-GENE-Y
and O
Drebrin B-GENE-Y
correspond O
to O
50mmol/L O
glucose B-CHEMICAL
(hyperglycaemia) O
was O
also O
found O
in O
primary O
cultured O
neurons. O
Curcumin, B-CHEMICAL
one O
neuroprotective O
agent, O
inhibited O
hyperglycaemia-induced O
neurotoxicity. O
Moreover, O
curcumin B-CHEMICAL
alleviated O
Sim2 B-GENE-Y
expression, O
and O
reversely O
raised O
Drebrin B-GENE-Y
expression O
in O
neurons O
treated O
with O
hyperglycaemia. O
Finally, O
we O
found O
that O
silencing O
Sim2 B-GENE-Y
expression O
decreased O
hyperglycaemia-induced O
neuronal O
injury. O
In O
conclusion, O
Sim2 B-GENE-Y
may O
mediate O

neurotoxicity O
during O
hyperglycaemia O
and O
thereby O
play O
a O
critical O
role O
in O
the O
development O
of O
hyperglycaemia-induced O
cognitive O
deficits. O
Global O
analysis O
of O
Drosophila B-GENE-N
Cys2-His2 I-GENE-N
zinc I-GENE-N
finger I-GENE-N
proteins I-GENE-N
reveals O
a O
multitude O
of O
novel O
recognition O
motifs O
and O
binding O
determinants. O
Cys2-His2 B-GENE-N
zinc I-GENE-N
finger I-GENE-N
proteins I-GENE-N
(ZFPs) B-GENE-N
are O
the O
largest O
group O
of O
transcription O
factors O
in O
higher O
metazoans. O
A O
complete O
characterization O
of O
these O
ZFPs B-GENE-N
and O
their O
associated O
target O
sequences O
is O
pivotal O
to O
fully O
annotate O
transcriptional O
regulatory O
networks O
in O
metazoan O
genomes. O
As O
a O
first O
step O
in O
this O

process, O
we O
have O
characterized O
the O
DNA-binding O
specificities O
of O
129 O
zinc B-GENE-N
finger I-GENE-N
sets O
from O
Drosophila O
using O
a O
bacterial O
one-hybrid O
system. O
This O
data O
set O
contains O
the O
DNA-binding O
specificities O
for O
at O
least O
one O
encoded O
ZFP B-GENE-N
from O
70 O
unique O
genes O
and O
23 O
alternate O
splice O
isoforms O
representing O
the O
largest O
set O
of O
characterized O
ZFPs B-GENE-N
from O
any O
organism O
described O
to O
date. O
These O
recognition O
motifs O
can O
be O
used O
to O
predict O
genomic O
binding O
sites O
for O
these O
factors O
within O
the O
fruit O
fly O
genome. O
Subsets O
of O
fingers O
from O
these O
ZFPs B-GENE-N
were O
characterized O
to O
define O
their O
orientation O
and O
register O
on O
their O
recognition O
sequences, O
thereby O
allowing O
us O
to O
define O
the O
recognition O

diversity O
within O
this O
finger O
set. O
We O
find O
that O
the O
characterized O
fingers O
can O
specify O
47 O
of O
the O
64 O
possible O
DNA O
triplets. O
To O
confirm O
the O
utility O
of O
our O
finger O
recognition O
models, O
we O
employed O
subsets O
of O
Drosophila O
fingers O
in O
combination O
with O
an O
existing O
archive O
of O
artificial O
zinc B-GENE-N
finger I-GENE-N
modules O
to O
create O
ZFPs B-GENE-N
with O
novel O
DNA-binding O
specificity. O
These O
hybrids O
of O
natural O
and O
artificial O
fingers O
can O
be O
used O
to O
create O
functional O
zinc B-GENE-N
finger I-GENE-N
nucleases I-GENE-N
for O
editing O
vertebrate O
genomes. O
Polymorphisms O
in O
dopamine B-GENE-Y
transporter I-GENE-Y
(SLC6A3) B-GENE-Y
are O
associated O
with O
stimulant O
effects O
of O

D-amphetamine: B-CHEMICAL
an O
exploratory O
pharmacogenetic O
study O
using O
healthy O
volunteers. O
Individuals O
vary O
in O
their O
subjective O
responses O
to O
stimulant O
drugs, O
and O
these O
differences O
are O
believed O
to O
be O
partially O
genetic O
in O
origin. O
We O
evaluated O
associations O
between O
mood, O
cognitive O
and O
cardiovascular O
responses O
to O
d-amphetamine B-CHEMICAL
and O
four O
polymorphisms O
in O
the O
dopamine B-GENE-Y
transporter I-GENE-Y
(SLC6A3): B-GENE-Y
rs460000, O
rs3756450, O
rs37022 O
and O
rs6869645. O
Healthy O
Caucasian O
male O
and O
female O
volunteers O
(N O
= O
152) O
participated O

in O
a O
double-blind, O
crossover O
design O
study O
in O
which O
they O
received O
placebo, O
10 O
and O
20 O
mg O
of O
d-amphetamine. B-CHEMICAL
We O
measured O
self-reported O
rating O
of O
mood, O
performance O
on O
the O
Digit O
Symbol O
Substitution O
Task, O
blood O
pressure O
and O
heart O
rate. O
Individuals O
with O
the O
C/C O
genotype O
at O
rs460000 O
(N O
= O
83) O
reported O
approximately O
twofold O
higher O
ratings O
of O
stimulation O
and O
euphoria O
relative O
to O
the O
A/A+A/C O
(N O
= O
69) O
genotype O
group, O
at O
both O
the O
10 O
and O
20 O
mg O
doses. O
No O
other O
responses O
or O
SNPs O
showed O
significant O

effects. O
rs460000 O
is O
in O
perfect O
LD O
with O
rs463379 O
(CEU: O
D' O
= O
1; O
r O
(2) O
= O
1), O
which O
was O
not O
studied O
here, O
but O
has O
been O
associated O
with O
etiology O
of O
Attention O
Deficit O
Hyperactivity O
Disorder O
(ADHD). O
These O
findings O
suggest O
a O
pleiotropic O
effect O
of O
this O
polymorphic O
locus O
on O
both O
ADHD O
and O
sensitivity O
to O
the O
subjective O
effects O
of O
amphetamine. B-CHEMICAL
The O
structure O
and O
properties O
of O
septin B-GENE-Y
3: I-GENE-Y
a O
possible O
missing O
link O
in O
septin B-GENE-N
filament O
formation. O
The O
human O
genome O
codes O

for O
13 O
members O
of O
a O
family O
of O
filament-forming O
GTP-binding B-GENE-N
proteins I-GENE-N
known O
as O
septins. B-GENE-N
These O
have O
been O
divided O
into O
four O
different O
subgroups O
on O
the O
basis O
of O
sequence O
similarity. O
The O
differences O
between O
the O
subgroups O
are O
believed O
to O
control O
their O
correct O
assembly O
into O
heterofilaments O
which O
have O
specific O
roles O
in O
membrane O
remodelling O
events. O
Many O
different O
combinations O
of O
the O
13 O
proteins O
are O
theoretically O
possible O
and O
it O
is O
therefore O
important O
to O
understand O
the O
structural O
basis O
of O
specific O
filament O
assembly. O
However, O
three-dimensional O
structures O
are O
currently O
available O
for O
only O
three O
of O
the O
four O
subgroups. O
In O
the O
present O
study O
we O
describe O
the O
crystal O
structure O
of O

a O
construct O
of O
human B-GENE-Y
SEPT3 I-GENE-Y
which O
belongs O
to O
the O
outstanding O
subgroup. O
This O
construct O
(SEPT3-GC), B-GENE-Y
which O
includes O
the O
GTP-binding B-GENE-N
and I-GENE-N
C-terminal I-GENE-N
domains, I-GENE-N
purifies O
as O
a O
nucleotide-free B-CHEMICAL
monomer, O
allowing O
for O
its O
characterization O
in O
terms O
of O
GTP-binding B-CHEMICAL
and O
hydrolysis. O
In O
the O
crystal O
structure, O
SEPT3-GC B-GENE-Y
forms O
foreshortened O
filaments O
which O
employ O
the O
same O
NC O
and O
G O
interfaces O
observed O
in O
the O
heterotrimeric O
complex O
of O
human B-GENE-N
septins I-GENE-N
2, I-GENE-N
6 I-GENE-N
and I-GENE-N
7, I-GENE-N
reinforcing O
the O
notion O
of O

'promiscuous' O
interactions O
described O
previously. O
In O
the O
present O
study O
we O
describe O
these O
two O
interfaces O
and O
relate O
the O
structure O
to O
its O
tendency O
to O
form O
monomers O
and O
its O
efficiency O
in O
the O
hydrolysis O
of O
GTP. B-CHEMICAL
The O
relevance O
of O
these O
results O
is O
emphasized O
by O
the O
fact O
that O
septins O
from O
the O
SEPT3 B-GENE-Y
subgroup O
may O
be O
important O
determinants O
of O
polymerization O
by O
occupying O
the O
terminal O
position O
in O
octameric O
units O
which O
themselves O
form O
the O
building O
blocks O
of O
at O
least O
some O
heterofilaments. O
The O
effect O
of O
inorganic O
arsenic B-CHEMICAL
on O
endothelium-dependent O
relaxation: O
Role O
of O
NADPH B-GENE-N

oxidase I-GENE-N
and O
hydrogen B-CHEMICAL
peroxide. I-CHEMICAL
Chronic O
arsenic B-CHEMICAL
ingestion O
predisposes O
to O
vascular O
disease, O
but O
underlying O
mechanisms O
are O
poorly O
understood. O
In O
the O
present O
study O
we O
have O
analyzed O
the O
effects O
of O
short-term O
arsenite B-CHEMICAL
exposure O
on O
vascular O
function O
and O
endothelium-dependent O
relaxation. O
Endothelium-dependent O
relaxations, O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
and O
endothelium O
derived O
hyperpolarizing O
factor O
(EDHF)-type, O
were O
studied O
in O
rabbit O
iliac O
artery O
and O
aortic O
rings O
using O
the O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
agonist O
acetylcholine B-CHEMICAL
(ACh) B-CHEMICAL

and O
by O
cyclopiazonic B-CHEMICAL
acid I-CHEMICAL
(CPA), B-CHEMICAL
which O
promotes O
store-operated O
Ca(2+) B-CHEMICAL
entry O
by O
inhibiting O
the O
endothelial O
SERCA B-GENE-N
pump. O
Production O
of O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
in O
the O
endothelium O
of O
rabbit O
aortic O
valve O
leaflets O
and O
endothelium-denuded O
RIA O
and O
aortic O
rings O
was O
assessed O
by O
imaging O
of O
dihydroethidium. B-CHEMICAL
In O
the O
iliac O
artery, O
exposure O
to O
100μM O
arsenite B-CHEMICAL
for O
30min O
potentiated O
EDHF-type O
relaxations O
evoked O
by O
both O
CPA B-CHEMICAL
and O

ACh. B-CHEMICAL
Potentiation O
was O
prevented O
by O
catalase, B-GENE-Y
the O
catalase/superoxide B-GENE-Y
dismutase I-GENE-N
mimetic O
manganese B-CHEMICAL
porphyrin I-CHEMICAL
and O
the O
NADPH B-GENE-N
oxidase I-GENE-N
inhibitor O
apocynin. B-CHEMICAL
By O
contrast O
in O
aortic O
rings, O
that O
exhibited O
negligible O
EDHF-type O
responses, O
endothelium-dependent O
NO-mediated B-CHEMICAL
relaxations O
evoked O
by O
CPA B-CHEMICAL
and O
ACh B-CHEMICAL
were O
unaffected O
by O
arsenite. B-CHEMICAL
Arsenite B-CHEMICAL
induced O
apocynin-sensitive B-CHEMICAL
increases O
in O
ROS O
production O
in O
the O
aortic O
valve O
endothelium, O
but O
not O

in O
the O
media O
and O
adventitia O
of O
the O
iliac O
artery O
and O
aorta. O
Our O
results O
suggest O
that O
arsenite B-CHEMICAL
can O
potentiate O
EDHF-type O
relaxations O
via O
a O
mechanism O
that O
is O
dependent O
on O
hydrogen B-CHEMICAL
peroxide, I-CHEMICAL
thus O
demonstrating O
that O
dismutation O
of O
the O
superoxide B-CHEMICAL
anion O
generated O
by O
NADPH B-GENE-N
oxidase I-GENE-N
can O
potentially O
offset O
loss O
of O
NO B-CHEMICAL
bioavailability O
under O
conditions O
of O
reduced O
eNOS B-GENE-Y
activity. O
By O
contrast, O
selective O
increases O
in O
endothelial O
ROS O
production O
following O
exposure O
to O
arsenite B-CHEMICAL
failed O
to O
modify O
relaxations O
mediated O
by O
endogenous O
NO. B-CHEMICAL
Anthocyanin, B-CHEMICAL

antioxidant O
activity O
and O
stress-induced O
gene O
expression O
in O
high O
CO2-treated B-CHEMICAL
table O
grapes O
stored O
at O
low O
temperature. O
A O
pretreatment O
with O
20kPa O
CO2+20 B-CHEMICAL
kPa O
O2+60 O
kPa O
N2 B-CHEMICAL
for O
3 O
days O
proved O
effective O
in O
maintaining O
the O
fruit O
quality O
and O
controlling O
decay O
in O
table O
grapes O
(Vitis O
vinifera O
cv. O
Cardinal) O
stored O
at O
0 O
degrees O
C. O
In O
the O
present O
work, O
we O
analyzed O
whether O
total O
anthocyanin B-CHEMICAL
content, O
the O
molecular O
mechanism O
implicated O
in O
their O
biosynthesis O
and O
antioxidant O
activity O
is O
related O
to O
the O
beneficial O
effect O
of O
this O
gaseous O

treatment. O
We O
isolated O
partial O
cDNAs O
that O
codified O
for O
enzymes O
implicated O
in O
the O
anthocyanin B-CHEMICAL
biosynthesis O
such O
as O
l-phenylalanine B-GENE-Y
ammonia-lyase I-GENE-Y
(PAL) B-GENE-Y
and O
chalcone B-GENE-Y
synthase I-GENE-Y
(CHS), B-GENE-Y
and O
an O
antioxidant O
enzyme O
such O
as O
ascorbate B-GENE-Y
peroxidase I-GENE-Y
(APX). B-GENE-Y
Low O
temperatures O
induced O
an O
accumulation O
of O
total O
anthocyanin B-CHEMICAL
content O
in O
the O
skin O
of O
both O
treated O
and O
non-treated O
grapes, O
although O
levels O
were O
lower O
in O
CO2-treated B-CHEMICAL
fruit. O
By O
contrast, O
antioxidant O
activity O
decreased O
during O
storage O

at O
0 O
degrees O
C O
in O
non-treated O
grapes O
but O
did O
not O
change O
in O
CO2-treated B-CHEMICAL
grapes. O
The O
up-regulation O
of O
anthocyanin B-CHEMICAL
biosynthesis O
gene O
expression O
and O
VcAPX B-GENE-Y
mRNA O
observed O
in O
non-treated O
grape O
is O
not O
enhanced O
in O
CO2-treated B-CHEMICAL
grapes, O
which O
presented O
low O
total O
decay. O
These O
results O
point O
out O
the O
ability O
of O
CO2-treated B-CHEMICAL
grapes O
to O
prevent O
the O
generation O
of O
reactive O
oxygen B-CHEMICAL
species O
rather O
than O
their O
inactivation O
by O
means O
of O
induction O
of O
studied O
defense O
systems. O
MUC1-C B-GENE-Y
oncoprotein O
as O
a O
target O
in O
breast O
cancer: O
activation O
of O
signaling O
pathways O
and O
therapeutic O
approaches. O

Mucin B-GENE-Y
1 I-GENE-Y
(MUC1) B-GENE-Y
is O
a O
heterodimeric O
protein O
formed O
by O
two O
subunits O
that O
is O
aberrantly O
overexpressed O
in O
human O
breast O
cancer O
and O
other O
cancers. O
Historically, O
much O
of O
the O
early O
work O
on O
MUC1 B-GENE-Y
focused O
on O
the O
shed O
mucin B-GENE-N
subunit. O
However, O
more O
recent O
studies O
have O
been O
directed O
at O
the O
transmembrane O
MUC1-C-terminal B-GENE-Y
subunit I-GENE-Y
(MUC1-C) B-GENE-Y
that O
functions O
as O
an O
oncoprotein. O
MUC1-C B-GENE-Y
interacts O
with O
EGFR B-GENE-Y
(epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor), I-GENE-Y
ErbB2 B-GENE-Y
and O
other O

receptor B-GENE-N
tyrosine I-GENE-N
kinases I-GENE-N
at O
the O
cell O
membrane O
and O
contributes O
to O
activation O
of O
the O
PI3KAKT B-GENE-N
and O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
kinase I-GENE-N
(MEK)extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
pathways. O
MUC1-C B-GENE-Y
also O
localizes O
to O
the O
nucleus O
where O
it O
activates O
the O
Wnt/β-catenin, B-GENE-N
signal B-GENE-N
transducer I-GENE-N
and I-GENE-N
activator I-GENE-N
of I-GENE-N
transcription I-GENE-N
(STAT) B-GENE-N
and O
NF B-GENE-N
(nuclear B-GENE-N
factor)-κB I-GENE-N
RelA B-GENE-Y
pathways. O
These O
findings O
and O
the O
demonstration O
that O
MUC1-C B-GENE-Y
is O
a O
druggable O
target O
have O
provided O
the O
experimental O
basis O
for O
designing O
agents O
that O

block O
MUC1-C B-GENE-Y
function. O
Notably, O
inhibitors O
of O
the O
MUC1-C B-GENE-Y
subunit O
have O
been O
developed O
that O
directly O
block O
its O
oncogenic O
function O
and O
induce O
death O
of O
breast O
cancer O
cells O
in O
vitro O
and O
in O
xenograft O
models. O
On O
the O
basis O
of O
these O
findings, O
a O
first-in-class O
MUC1-C B-GENE-Y
inhibitor O
has O
entered O
phase O
I O
evaluation O
as O
a O
potential O
agent O
for O
the O
treatment O
of O
patients O
with O
breast O
cancers O
who O
express O
this O
oncoprotein. O
Synthesis, O
crystal O
structure O
and O
antidiabetic O
activity O
of O
substituted O
(E)-3-(Benzo B-CHEMICAL

[d]thiazol-2-ylamino) I-CHEMICAL
phenylprop-2-en-1-one. I-CHEMICAL
A O
novel O
series O
of O
substituted O
(E)-3-(Benzo B-CHEMICAL
[d]thiazol-2-ylamino)phenylprop-2-en-1-onewere I-CHEMICAL
synthesized O
starting O
from O
2-aminobenzothiazole B-CHEMICAL
and O
1-aryl-3,3-bis- B-CHEMICAL
(methylsulfanyl)-2-propen-1-onesin I-CHEMICAL
the O
presence O
of O
a O
catalytic O
amount O
of O
sodium B-CHEMICAL
hydride I-CHEMICAL
in O

THF. B-CHEMICAL
The O
synthesised O
compounds' O
structures O
were O
confirmed O
by O
IR, O
Mass O
spectrometry, O
(1)H B-CHEMICAL
NMR, O
(13)C B-CHEMICAL
NMR O
and O
HRMS O
spectral O
data. O
These O
compounds O
were O
evaluated O
for O
their O
antidiabetic O
activity, O
and O
most O
of O
the O
derivatives O
of O
(E)-3-(Benzo B-CHEMICAL
[d]thiazol-2-ylamino)phenylprop-2-en-1-one I-CHEMICAL
displayed O
significant O
antidiabetic O
activity. O
Acetaminophen B-CHEMICAL
(paracetamol) B-CHEMICAL
is O
a O
selective O

cyclooxygenase-2 B-GENE-Y
inhibitor O
in O
man. O
For O
more O
than O
three O
decades, O
acetaminophen B-CHEMICAL
(INN, B-CHEMICAL
paracetamol) B-CHEMICAL
has O
been O
claimed O
to O
be O
devoid O
of O
significant O
inhibition O
of O
peripheral O
prostanoids. B-CHEMICAL
Meanwhile, O
attempts O
to O
explain O
its O
action O
by O
inhibition O
of O
a O
central O
cyclooxygenase B-GENE-N
(COX)-3 I-GENE-N
have O
been O
rejected. O
The O
fact O
that O
acetaminophen B-CHEMICAL
acts O
functionally O
as O
a O
selective O
COX-2 B-GENE-Y
inhibitor O
led O
us O
to O
investigate O
the O
hypothesis O
of O
whether O
it O
works O
via O
preferential O
COX-2 B-GENE-Y
blockade. O
Ex O
vivo O
COX B-GENE-N
inhibition O

and O
pharmacokinetics O
of O
acetaminophen B-CHEMICAL
were O
assessed O
in O
5 O
volunteers O
receiving O
single O
1000 O
mg O
doses O
orally. O
Coagulation-induced O
thromboxane B-CHEMICAL
B(2) I-CHEMICAL
and O
lipopolysaccharide-induced O
prostaglandin B-CHEMICAL
E(2) I-CHEMICAL
were O
measured O
ex O
vivo O
and O
in O
vitro O
in O
human O
whole O
blood O
as O
indices O
of O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
activity. O
In O
vitro, O
acetaminophen B-CHEMICAL
elicited O
a O
4.4-fold O
selectivity O
toward O
COX-2 B-GENE-Y
inhibition O
(IC(50)=113.7 O

micromol/L O
for O
COX-1; B-GENE-Y
IC(50)=25.8 O
micromol/L O
for O
COX-2). B-GENE-Y
Following O
oral O
administration O
of O
the O
drug, O
maximal O
ex O
vivo O
inhibitions O
were O
56% O
(COX-1) B-GENE-Y
and O
83% O
(COX-2). B-GENE-Y
Acetaminophen B-CHEMICAL
plasma O
concentrations O
remained O
above O
the O
in O
vitro O
IC(50) O
for O
COX-2 B-GENE-Y
for O
at O
least O
5 O
h O
postadministration. O
Ex O
vivo O
IC(50) O
values O
(COX-1: B-GENE-Y
105.2 O
micromol/L; O

COX-2: B-GENE-Y
26.3 O
micromol/L) O
of O
acetaminophen B-CHEMICAL
compared O
favorably O
with O
its O
in O
vitro O
IC(50) O
values. O
In O
contrast O
to O
previous O
concepts, O
acetaminophen B-CHEMICAL
inhibited O
COX-2 B-GENE-Y
by O
more O
than O
80%, O
i.e., O
to O
a O
degree O
comparable O
to O
nonsteroidal O
antiinflammatory O
drugs O
(NSAIDs) O
and O
selective O
COX-2 B-GENE-Y
inhibitors. O
However, O
a O
>95% O
COX-1 B-GENE-Y
blockade O
relevant O
for O
suppression O
of O
platelet O
function O
was O
not O
achieved. O
Our O
data O
may O
explain O

acetaminophen's O
analgesic O
and O
antiinflammatory O
action O
as O
well O
as O
its O
superior O
overall O
gastrointestinal O
safety O
profile O
compared O
with O
NSAIDs. O
In O
view O
of O
its O
substantial O
COX-2 B-GENE-Y
inhibition, O
recently O
defined O
cardiovascular O
warnings O
for O
use O
of O
COX-2 B-GENE-Y
inhibitors O
should O
also O
be O
considered O
for O
acetaminophen. B-CHEMICAL
Effect O
of O
galantamine B-CHEMICAL
on O
acetylcholinesterase B-GENE-Y
and O
butyrylcholinesterase B-GENE-Y
activities O
in O
the O
presence O
of O
L-carnitine B-CHEMICAL
in O
rat O
selected O
brain O
and O
peripheral O
tissues. O
OBJECTIVES: O
The O
alkaloid O

galantamine B-CHEMICAL
(GAL), B-CHEMICAL
which O
exhibits O
a O
combined O
anticholinesterase B-GENE-Y
and O
direct O
parasympathomimetic O
mechanism O
of O
action, O
is O
employed O
in O
conjunction O
with O
therapeutic O
interventions O
in O
the O
stimulation O
of O
central O
cholinergic O
transfer O
in O
cognitive O
diseases. O
We O
attempted O
to O
achieve O
pharmacologically-induced O
enhancement O
of O
the O
parasympathomimetic O
activity O
of O
GAL B-CHEMICAL
in O
the O
key O
areas O
of O
rat O
brain, O
using O
an O
interactive O
combination O
of O
the O
alkaloid O
with O
the O
transmembrane O
enhancer O
L-carnitine B-CHEMICAL
(CAR). B-CHEMICAL
METHODS: O
We O
investigated O
activities O
of O

acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
in O
brain O
areas O
(frontal O
cortex, O
basal O
ganglia, O
septum O
and O
hippocampus) O
and O
the O
hypophysis, O
and O
that O
of O
butyrylcholinesterase B-GENE-Y
(BuChE) B-GENE-Y
in O
plasma O
and O
liver. O
RESULTS: O
Following O
administration O
of O
the O
highest O
of O
the O
GAL B-CHEMICAL
doses O
used O
(2.5; O
5; O
10 O
mg/kg O
i.m.), O
AChE B-GENE-Y
activity O
decreased O
mainly O
in O
the O
frontal O
cortex, O
hippocampus O
and O
hypophysis. O
In O
the O
interaction O
of O
GAL B-CHEMICAL
and O

CAR, B-GENE-N
AChE B-GENE-Y
inhibition O
was O
stronger O
but O
without O
any O
statistical O
significance. O
The O
peripheral O
inhibition O
of O
BuChE B-GENE-Y
was O
found O
to O
be O
dose-dependent. O
Premedication O
by O
CAR B-CHEMICAL
led O
to O
a O
slight O
change O
in O
the O
values O
of O
the O
activities O
monitored. O
CONCLUSIONS: O
CAR B-CHEMICAL
in O
terms O
of O
positive O
modulation O
of O
GAL B-CHEMICAL
targeting O
to O
the O
central O
nervous O
system O
had O
no O
statistically O
significant O
effect. O
Inhibition O
of O
neurite O
outgrowth O
and O
alteration O
of O
cytoskeletal O
gene O
expression O
by O
sodium B-CHEMICAL
arsenite. I-CHEMICAL
Arsenic B-CHEMICAL
compounds O
that O
are O
often O
found O
in O
drinking O
water O
increase O
the O
risk O

of O
developmental O
brain O
disorders. O
In O
this O
study, O
we O
performed O
live O
imaging O
analyses O
of O
Neuro-2a O
cells O
expressing O
SCAT3, O
a O
caspase-3 B-GENE-Y
cleavage O
peptide O
sequence O
linking O
two O
fluorescent O
proteins; O
enhanced O
cyan O
fluorescence O
protein O
(ECFP) O
and O
Venus, O
to O
determine O
whether O
sodium B-CHEMICAL
arsenite I-CHEMICAL
(NaAsO(2); B-CHEMICAL
0, O
1, O
5, O
or O
10 O
μM) O
affects O
both O
neurite O
outgrowth O
and/or O
induces O
apoptosis O
with O
the O
same O
doses O
and O
in O
the O
same O
cell O
cultures. O
We O
observed O
that O
the O
area O
ratio O
of O
neurite O
to O
cell O
body O
in O

SCAT3-expressing O
cells O
was O
significantly O
reduced O
by O
5 O
and O
10 O
μM O
NaAsO(2), B-CHEMICAL
but O
not O
by O
1 O
μM, O
although O
the O
emission O
ratio O
of O
ECFP O
to O
Venus, O
an O
endpoint O
of O
caspase-3 B-GENE-Y
activity, O
was O
not O
changed. O
However, O
cytological O
assay O
using O
apoptotic O
and O
necrotic O
markers O
resulted O
in O
that O
apoptosis, O
but O
not O
necrosis, O
was O
significantly O
induced O
in O
Neuro-2a O
cells O
when O
NaAsO(2) B-CHEMICAL
exposure O
continued O
after O
the O
significant O
effects O
of O
NaAsO(2) B-CHEMICAL
on O
neurite O
outgrowth O
were O
found O
by O

live O
imaging. O
These O
results O
suggested O
that O
neurite O
outgrowth O
was O
suppressed O
by O
NaAsO(2) B-CHEMICAL
prior O
to O
NaAsO(2)-induced B-CHEMICAL
apoptosis. O
Next, O
we O
examined O
the O
effects O
of O
NaAsO(2) B-CHEMICAL
on O
cytoskeletal O
gene O
expression O
in O
Neuro-2a O
cells. O
NaAsO(2) B-CHEMICAL
increased O
the O
mRNA O
levels O
of O
the O
light B-GENE-N
and I-GENE-N
medium I-GENE-N
subunits I-GENE-N
of I-GENE-N
neurofilament I-GENE-N
and O
decreased O
the O
mRNA O
levels O
of O
tau B-GENE-Y
and O
tubulin B-GENE-N
in O
a O
dose-dependent O
manner; O
no O
significant O
effect O
was O
found O
in O
the O
mRNA O
levels O
of O
the O
heavy B-GENE-Y
subunit I-GENE-Y
of I-GENE-Y

neurofilament, I-GENE-Y
microtubule-associated B-GENE-Y
protein I-GENE-Y
2, I-GENE-Y
or O
actin. B-GENE-N
The O
changes O
in O
cytoskeletal O
gene O
expression O
are O
likely O
responsible O
for O
the O
inhibitory O
effects O
of O
NaAsO(2) B-CHEMICAL
on O
neurite O
outgrowth. O
A O
naloxone-steroid B-CHEMICAL
hybrid I-CHEMICAL
azine I-CHEMICAL
with O
selective O
and O
long-acting O
opioid O
antagonism O
at O
delta B-GENE-Y
receptors I-GENE-Y
in O
vitro. O
The O
interaction O
of O
naloxone B-CHEMICAL
estrone I-CHEMICAL
azine I-CHEMICAL
(N-EH) B-CHEMICAL
with O
various O
opioid B-GENE-N
receptor I-GENE-N
types O
was O
studied O
in O
vitro. O
Its O
potency O
as O
an O
antagonist O
of O
opioid O
effects O
was O

compared O
to O
that O
of O
naloxone B-CHEMICAL
on O
the O
electrically O
evoked O
contractions O
of O
mouse O
vas O
deferens O
(Mvd) O
and O
guinea O
pig O
ileum O
myenteric O
plexus O
longitudinal O
muscle O
(Gpi) O
preparations. O
N-EH B-CHEMICAL
was O
found O
to O
be O
9-fold O
more O
potent O
than O
naloxone B-CHEMICAL
in O
antagonizing O
the O
effects O
of O
D-Ala2-Leu5-enkephalin B-CHEMICAL
in O
the O
Mvd O
and O
22-fold O
less O
potent O
in O
antagonizing O
normorphine B-CHEMICAL
in O
the O
Gpi. O
In O
the O
Mvd, O
the O
recovery O
half-time O
for O

N-EH B-CHEMICAL
was O
longer O
than O
1000 O
min. O
Neither O
compound O
showed O
agonism. O
The O
two O
compounds O
were O
also O
compared O
for O
their O
capacity O
to O
displace O
the O
binding O
of O
3H-D-Ala2-Leu5-enkephalin, B-CHEMICAL
3H-dihydromorphine, B-CHEMICAL
and O
3H-ethylketocyclazocine B-CHEMICAL
to O
rat O
brain O
membranes O
under O
conditions O
where O
delta, O
mu, O
and O
kappa O
sites O
were O
labeled. O
The O
relative O
affinities O
were O
0.70, O
0.16, O
and O
0.14 O
for O
N-EH B-CHEMICAL
and O
0.05, O
0.87, O

and O
0.08 O
for O
naloxone, B-CHEMICAL
respectively. O
Thus, O
compared O
to O
naloxone, B-CHEMICAL
which O
is O
mu O
selective, O
N-EH B-CHEMICAL
is O
a O
delta-selective O
antagonist. O
Inhibition O
of O
dipeptidyl B-GENE-Y
peptidase-IV I-GENE-Y
(DPP-IV) B-GENE-Y
by O
atorvastatin. B-CHEMICAL
Dipeptidyl B-GENE-Y
peptidase-IV I-GENE-Y
(DPP-IV) B-GENE-Y
is O
an O
enzyme O
responsible O
for O
the O
inactivation O
of O
the O
glucoregulatory O
incretin B-GENE-N
hormones I-GENE-N
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1) B-GENE-Y
and O
glucose-dependent B-GENE-Y
insulinotropic I-GENE-Y

polypeptide I-GENE-Y
(GIP). B-GENE-Y
In O
this O
report, O
we O
show O
that O
the O
hypolipidemic O
agent O
atorvastatin B-CHEMICAL
is O
a O
competitive O
inhibitor O
of O
porcine B-GENE-Y
DPP-IV I-GENE-Y
in O
vitro, O
with O
K(i)=57.8+/-2.3 O
microM. O
These O
results O
may O
have O
implications O
in O
the O
development O
of O
novel O
DPP-IV B-GENE-Y
inhibitors O
based O
on O
the O
use O
of O
atorvastatin B-CHEMICAL
as O
a O
lead O
compound O
for O
the O
treatment O
of O
type O
2 O
diabetes. O
Neoechinulin B-CHEMICAL
A I-CHEMICAL
suppresses O
amyloid-β B-GENE-Y
oligomer-induced O
microglia O
activation O
and O
thereby O

protects O
PC-12 O
cells O
from O
inflammation-mediated O
toxicity. O
A O
pathological O
hallmark O
of O
Alzheimer's O
disease O
(AD), O
aggregation O
and O
deposition O
of O
amyloid-β B-GENE-Y
peptides, I-GENE-Y
has O
been O
recognized O
as O
a O
potent O
activator O
of O
microglia-mediated O
neuroinflammation O
and O
neuronal O
dysfunction. O
Therefore, O
downregulation O
of O
microglial O
activation O
has O
a O
significant O
therapeutic O
demand. O
In O
this O
study, O
focus O
was O
given O
to O
evaluate O
the O
ability O
of O
neoechinulin B-CHEMICAL
A, I-CHEMICAL
an O
indole B-CHEMICAL
alkaloid O
isolated O
from O
marine-derived O
Microsporum O
sp., O
to O
attenuate O

microglial O
activation O
by O
oligomeric O
amyloid-β B-GENE-Y
1-42 I-GENE-Y
(Aβ42). B-GENE-Y
Neoechinulin B-CHEMICAL
A I-CHEMICAL
treatment O
significantly O
inhibited O
the O
generation O
of O
reactive O
oxygen B-CHEMICAL
and O
nitrogen B-CHEMICAL
species O
in O
Aβ42-activated B-GENE-Y
BV-2 O
microglia O
cells. O
In O
addition, O
we O
found O
that O
neoechinulin B-CHEMICAL
A I-CHEMICAL
significantly O
suppressed O
the O
production O
of O
neurotoxic O
inflammatory O
mediator O
tumour B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α), B-GENE-Y
interleukin-1β B-GENE-Y
(IL-1β), B-GENE-Y
interleukin-6 B-GENE-Y
(IL-6), B-GENE-Y
and O

prostaglandin B-CHEMICAL
E2 I-CHEMICAL
(PGE2) B-CHEMICAL
in O
activated O
BV-2 O
cells. O
Moreover, O
the O
treatment O
downregulated O
the O
protein O
and O
gene O
expressions O
of O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS), B-GENE-Y
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
TNF-α, B-GENE-Y
IL-1β B-GENE-Y
and O
IL-6. B-GENE-Y
Further, O
activated O
microglia-mediated O
apoptosis O
of O
PC-12 O
pheochromocytoma O
cells O
was O
significantly O
repressed O
by O
neoechinulin B-CHEMICAL
A. I-CHEMICAL
The O
molecular O
mechanism O
studies O
suggested O
that O
neoechinulin B-CHEMICAL
A I-CHEMICAL
may O
block O

the O
phosphorylation O
of O
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK) B-GENE-N
molecule O
p38, B-GENE-N
apoptosis B-GENE-Y
signal-regulating I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(ASK-1) B-GENE-Y
and O
nuclear O
translocation O
of O
nuclear B-GENE-N
factor-κB I-GENE-N
(NF-κB) B-GENE-N
p65 B-GENE-Y
and O
p50 B-GENE-Y
subunits. O
Regulation O
of O
these O
signalling O
pathways O
have O
most O
probably O
contributed O
to O
the O
anti-inflammatory O
activity O
of O
neoechinulin B-CHEMICAL
A. I-CHEMICAL
Collectively, O
these O
results O
suggest O
that O
with O
further O
studies O
neoechinulin B-CHEMICAL
A I-CHEMICAL
have O
a O
potential O
to O
be O
developed O
as O
a O
modulator O
of O
neuroinflammatory O
process O
in O
AD. O
WNT6 B-GENE-Y
is O
a O

novel O
target O
gene O
of O
caveolin-1 B-GENE-Y
promoting O
chemoresistance O
to O
epirubicin B-CHEMICAL
in O
human O
gastric O
cancer O
cells. O
Resistance O
to O
chemotherapy O
is O
a O
major O
obstacle O
for O
curative O
treatment O
of O
human O
gastric O
cancer O
(GC). O
However, O
the O
underlying O
molecular O
mechanisms O
are O
largely O
unknown. O
Wingless-type B-GENE-N
MMTV I-GENE-N
integration I-GENE-N
site I-GENE-N
family I-GENE-N
members I-GENE-N
(WNTs) B-GENE-N
are O
secreted O
glycoproteins O
involved O
in O
embryogenesis O
and, O
on O
inappropriate O
expression O
in O
the O
adult, O
in O
cancer. O
Here, O
we O
show O
expression O
of O
WNT6 B-GENE-Y
in O
GC O
patient O
specimens, O
human O
GC O
cell O
lines O
and O
in O
a O

mouse O
model O
of O
GC. O
In O
human O
GC O
cells, O
WNT6 B-GENE-Y
expression O
was O
enhanced O
by O
caveolin-1 B-GENE-Y
(Cav1), B-GENE-Y
a O
scaffold O
protein O
of O
plasma O
membrane O
caveolae. O
WNT6 B-GENE-Y
knock-down O
and O
overexpression O
experiments O
demonstrated O
that O
WNT6 B-GENE-Y
increased O
the O
resistance O
to O
apoptotic O
cell O
death O
induced O
by O
the O
anthracycline B-CHEMICAL
chemotherapeutics O
epirubicin B-CHEMICAL
(Epi) B-CHEMICAL
and O
doxorubicin B-CHEMICAL
(Dox). B-CHEMICAL
Epi B-CHEMICAL
increased O
the O
activity O
of O
the O
human B-GENE-N
WNT6 I-GENE-N
promoter I-GENE-N
through O
Cav1-dependent B-GENE-Y
binding O
of O

β-catenin B-GENE-Y
to O
the O
proximal O
WNT6 B-GENE-N
promoter. I-GENE-N
Epi B-CHEMICAL
increased O
both O
WNT6/Wnt6 B-GENE-Y
and O
Cav1 B-GENE-Y
expression O
in O
human O
GC O
cells O
and O
within O
the O
tumor O
area O
of O
a O
murine O
model O
of O
GC O
(CEA424-SV40 O
TAg). O
In O
GC O
patients, O
WNT6 B-GENE-Y
expression O
was O
positively O
associated O
with O
the O
tumor O
stage O
and O
the O
nodal O
status, O
and O
inversely O
correlated O
with O
the O
response O
to O
ECF O
(Epi, B-CHEMICAL
cisplatin, B-CHEMICAL
5-fluorouracil) B-CHEMICAL
chemotherapy. O
These O
results O
showed O
that O
WNT6 B-GENE-Y
and O

Cav1 B-GENE-Y
are O
upregulated O
by O
chemotherapeutics O
and O
enhance O
the O
resistance O
of O
GC O
cells O
to O
anthracycline B-CHEMICAL
drugs. O
Understanding O
the O
molecular O
mechanisms O
driving O
WNT6/Cav1-induced B-GENE-Y
drug O
resistance O
will O
provide O
benefits O
in O
developing O
new O
therapies O
for O
GC. O
2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced B-CHEMICAL
inflammatory O
activation O
is O
mediated O
by O
intracellular O
free O
calcium B-CHEMICAL
in O
microglial O
cells. O
2,3,7,8-Tetrachlorodibenzo-p-dioxin B-CHEMICAL

(TCDD) B-CHEMICAL
has O
been O
known O
to O
induce O
inflammatory O
signaling O
in O
a O
number O
of O
cell O
types O
and O
tissues. O
However, O
the O
adverse O
effects O
of O
TCDD B-CHEMICAL
on O
the O
central O
nervous O
system O
(CNS) O
have O
not O
been O
entirely O
elucidated. O
In O
this O
study, O
using O
reverse O
transcriptase O
PCR O
(RT-PCR) O
and O
ELISA, O
we O
showed O
that O
TCDD B-CHEMICAL
up-regulated O
the O
expression O
and O
secretion O
of O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-α) B-GENE-Y
in O
a O
time-dependent O
manner O
in O
cultured O
HAPI O
microglial O
cells. O
TCDD B-CHEMICAL
also O
caused O
a O
fast O
(within O

30min O
as O
judged O
by O
the O
increase O
in O
its O
mRNA O
level) O
activation O
of O
cytosolic B-GENE-Y
phospholipase I-GENE-Y
A2 I-GENE-Y
(cPLA2). B-GENE-Y
This O
initial O
action O
was O
accompanied O
by O
up-regulation O
of O
cyclooxygenase-2 B-GENE-Y
(COX-2), B-GENE-Y
an O
important O
inflammation O
marker O
within O
1h O
after O
TCDD B-CHEMICAL
treatment. O
These O
pro-inflammatory O
responses O
were O
inhibited O
by O
two O
types O
of O
Ca(2+) B-CHEMICAL
blockers, O
bis-(o-aminophenoxy) B-CHEMICAL
ethane-N,N,N',N'-tetra-acetic I-CHEMICAL
acid I-CHEMICAL

acetoxymethyl I-CHEMICAL
ester I-CHEMICAL
(BAPTA-AM) B-CHEMICAL
and O
nifedipine, B-CHEMICAL
thus, O
indicating O
that O
the O
effects O
are O
triggered O
by O
initial O
increase O
in O
the O
intracellular O
concentration O
of O
free O
Ca(2+) B-CHEMICAL
([Ca(2+)]i). B-CHEMICAL
Further, O
TCDD B-CHEMICAL
exposure O
could O
induce O
phosphorylation- O
and O
ubiquitination-dependent O
degradation O
of O
IкBα, B-GENE-Y
and O
the O
translocation O
of O
NF-κB B-GENE-Y
p65 I-GENE-Y
from O
the O
cytosol O
to O
the O
nucleus O
in O
this O
microglial O
cell O
line. O
Thus, O
the O
NF-κB B-GENE-N
signaling O
pathway O
can O

be O
activated O
after O
TCDD B-CHEMICAL
treatment. O
However, O
Ca(2+) B-CHEMICAL
blockers O
also O
obviously O
attenuated O
NF-κB B-GENE-N
activation O
and O
transnuclear O
transport O
induced O
by O
TCDD. B-CHEMICAL
In O
concert O
with O
these O
results, O
we O
highlighted O
that O
the O
secretion O
of O
pro-inflammatory O
cytokine B-GENE-N
and O
NF-κB B-GENE-N
activation O
induced O
by O
TCDD B-CHEMICAL
can O
be O
mediated O
by O
elevation O
of O
[Ca(2+)]i B-CHEMICAL
in O
HAPI O
microglial O
cells. O
Introduction: O
The O
pharmacological O
profile O
of O
eprosartan--implications B-CHEMICAL
for O
cerebrovascular O
and O
cardiovascular O
risk O
reduction. O

Moderate O
elevations O
in O
blood O
pressure O
translate O
to O
significant O
increases O
in O
cardiovascular O
and O
cerebro O
vascular O
risk. O
Beneficially, O
this O
relationship O
allows O
small O
decreases O
in O
blood O
pressure O
to O
be O
associated O
with O
risk O
reduction. O
Both O
the O
renin-angiotensin B-GENE-Y
system O
and O
the O
sympathetic O
nervous O
system O
are O
involved O
in O
hypertension, O
hence O
targeting O
these O
systems O
is O
likely O
to O
be O
of O
benefit O
in O
the O
treatment O
of O
hypertension. O
Angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
blockers O
(ARBs) O
are O
used O
for O
controlling O
blood O
pressure O
and O
treating O
heart O
failure O
in O
a O
broad O
range O
of O
patients, O
including O
those O
with O
diabetes O
and O
the O
elderly. O
Not O
only O
have O

ARBs O
shown O
good O
efficacy O
and O
tolerability, O
they O
also O
appear O
to O
have O
a O
protective O
effect O
that O
goes O
beyond O
that O
expected O
from O
the O
reduction O
of O
blood O
pressure. O
The O
ARB O
eprosartan B-CHEMICAL
is O
a O
nonbiphenyl O
nontetrazole O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
(AT1) B-GENE-Y
antagonist, O
which O
acts O
to O
decrease O
total O
peripheral O
resistance. O
Eprosartan B-CHEMICAL
acts O
at O
vascular O
AT1 B-GENE-Y
receptors I-GENE-Y
(postsynaptically) O
and O
at O
presynaptic O
AT1 B-GENE-Y
receptors, I-GENE-Y
where O
it O
inhibits O
noradrenaline B-CHEMICAL
release. O
In O
clinical O
studies, O
eprosartan B-CHEMICAL
has O
been O
shown O
to O
significantly O
reduce O

cardiovascular O
and O
cerebrovascular O
events, O
whilst O
avoiding O
the O
persistent O
cough O
that O
commonly O
occurs O
with O
the O
use O
of O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
inhibitors. O
Eprosartan B-CHEMICAL
can O
also O
be O
differentiated O
from O
other O
ARBs O
due O
to O
its O
noradrenergic O
effects, O
which O
other O
ARBs O
used O
at O
therapeutic O
doses O
do O
not O
possess. O
Eprosartan, B-CHEMICAL
therefore, O
represents O
a O
useful O
therapeutic O
option O
in O
the O
management O
of O
patients O
with O
hypertension, O
including O
those O
with O
a O
history O
of O
stroke O
or O
with O
co-morbid O
type O
2 O
diabetes O
mellitus. O
Analysis O
of O
alpha B-GENE-N
1L-adrenoceptor I-GENE-N

pharmacology O
in O
rat O
small O
mesenteric O
artery. O
1. O
To O
illuminate O
the O
controversy O
on O
alpha B-GENE-Y
1A- I-GENE-Y
or O
alpha B-GENE-N
1L-adrenoceptor I-GENE-N
involvement O
in O
noradrenaline-mediated B-CHEMICAL
contractions O
of O
rat O
small O
mesenteric O
artery O
(SMA), O
we O
have O
studied O
the O
effects O
of O
subtype-selective O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
agonists O
and O
antagonists O
under O
different O
experimental O
conditions. O
2. O
The O
agonist O
potency O
order O
in O
rat O
SMA O
was: O
A61603 B-CHEMICAL
>> O
SKF89748-A B-CHEMICAL
> O
cirazoline B-CHEMICAL
> O
noradrenaline B-CHEMICAL
> O

ST-587 B-CHEMICAL
> O
methoxamine. B-CHEMICAL
Prazosin B-CHEMICAL
antagonized O
all O
agonists O
with O
a O
low O
potency O
(pA2: O
8.29-8.80) O
indicating O
the O
involvement O
of O
alpha B-GENE-N
1L-rather I-GENE-N
than O
alpha B-GENE-Y
1A-adrenoceptors. I-GENE-Y
3. O
The O
putative O
alpha B-GENE-N
1L-adrenoceptor I-GENE-N
antagonist O
JTH-601, B-CHEMICAL
but O
not O
the O
alpha B-GENE-Y
1B-adrenoceptor I-GENE-Y
antagonist O
chloroethylclonidine B-CHEMICAL
(10 O
microM) O
antagonized O
noradrenaline-induced B-CHEMICAL
contractions O
of O
SMA. O
The O
potency O
of O
the O

selective O
alpha B-GENE-Y
1D-adrenoceptor I-GENE-Y
antagonist O
BMY B-CHEMICAL
7378 I-CHEMICAL
against O
noradrenaline B-CHEMICAL
(pA2 O
= O
6.16 O
+/- O
0.13) O
and O
of O
the O
selective O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
antagonist O
RS-17053 B-CHEMICAL
against O
noradrenaline B-CHEMICAL
(pKB O
= O
8.35 O
+/- O
0.10) O
and O
against O
the O
selective O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
agonist O
A-61603 B-CHEMICAL
(pKB O
= O
8.40 O
+/- O
0.09) O
were O
too O
low O
to O
account O
for O
alpha B-GENE-Y
1D- I-GENE-Y
and O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y

involvement. O
4. O
The O
potency O
of O
RS-17053 B-CHEMICAL
(pKB/pA2's O
= O
7.72-8.46) O
was O
not O
affected O
by O
lowering O
temperature, O
changing O
experimental O
protocol O
or O
inducing O
myogenic O
tone O
via O
KCl B-CHEMICAL
or O
U46619. B-CHEMICAL
5. O
Selective O
protection O
of O
a O
putative O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
population O
against O
the O
irreversible O
action O
of O
phenoxybenzamine B-CHEMICAL
also O
failed O
to O
increase O
the O
potency O
of O
RS-17053 B-CHEMICAL
(pA2 O
= O
8.25 O
+/- O
0.06 O
against O
A61603). O
6. O
Combined O

concentration-ratio O
analysis O
demonstrated O
that O
tamsulosin, B-CHEMICAL
which O
does O
not O
discriminate O
between O
alpha B-GENE-Y
1A- I-GENE-Y
and O
alpha B-GENE-N
1L-adrenoceptors, I-GENE-N
and O
RS-17053 B-CHEMICAL
competed O
for O
binding O
at O
the O
same O
site O
in O
the O
SMA. O
7. O
In O
summary, O
data O
obtained O
in O
our O
experiments O
in O
rat O
SMA O
indicate O
that O
the O
alpha B-GENE-N
1-adrenoceptor I-GENE-N
mediating O
noradrenaline-induced B-CHEMICAL
contraction O
displays O
a O
distinct O
alpha B-GENE-N
1L-adrenoceptor I-GENE-N
pharmacology. O
This O
study O
does O
not O
provide O
evidence O
for O
the O
hypothesis O
that O
alpha B-GENE-N
1L-adrenoceptors I-GENE-N
represent O
an O
affinity O
state O
of O
the O
alpha B-GENE-Y

1A-adrenoceptor I-GENE-Y
in O
functional O
assays. O
Furthermore, O
there O
is O
no O
co-existing O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
in O
the O
SMA. O
Discriminative O
stimulus O
effects O
of O
esteratic O
local O
anesthetics O
in O
squirrel O
monkeys. O
A O
number O
of O
esteratic O
local O
anesthetics O
serve O
as O
positive O
reinforcers O
and O
produce O
cocaine-like B-CHEMICAL
discriminative O
stimulus O
effects O
in O
animals. O
It O
has O
been O
suggested O
that O
the O
affinity O
of O
these O
compounds O
for O
a O
site O
on O
the O
dopamine B-GENE-Y
transporter, I-GENE-Y
and O
not O
their O
local O
anesthetic O
actions, O
is O
responsible O
for O
these O
abuse-related O
behavioral O
effects. O
In O
the O
present O

study, O
three O
local O
anesthetics O
previously O
shown O
to O
be O
self-administered O
in O
animals O
were O
examined O
in O
squirrel O
monkeys O
trained O
to O
discriminate O
cocaine B-CHEMICAL
(0.3 O
mg/kg) O
from O
saline O
in O
a O
two-lever, O
food-reinforced O
procedure. O
Dimethocaine B-CHEMICAL
(0.1-3.0 O
mg/kg) O
fully O
and O
dose-dependently O
substituted O
for O
cocaine. B-CHEMICAL
Doses O
of O
dimethocaine B-CHEMICAL
(1.7 O
mg/kg) O
and O
cocaine B-CHEMICAL
(0.3 O
mg/kg) O
which O
produced O
full O
(> O
80%) O
substitution O
for O
cocaine B-CHEMICAL
were O
administered O
in O
combination O
with O
the O
dopamine B-GENE-Y
D1 I-GENE-Y
receptor I-GENE-Y
antagonist O

SCH B-CHEMICAL
39166 I-CHEMICAL
((-)-trans-6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H B-CHEMICAL
-benzo I-CHEMICAL
[d]naphtho-(2,1-b)azepine) I-CHEMICAL
and O
the O
dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y
antagonist O
raclopride B-CHEMICAL
(both O
at O
0.003-0.03 O
mg/kg). O
SCH B-CHEMICAL
39166 I-CHEMICAL
fully O
blocked O
the O
cocaine-like B-CHEMICAL
discriminative O
stimulus O
effects O
of O
dimethocaine B-CHEMICAL
and O
cocaine, B-CHEMICAL

but O
raclopride B-CHEMICAL
produced O
only O
partial O
antagonism O
of O
cocaine-lever B-CHEMICAL
selection. O
In O
addition, O
there O
was O
some O
evidence O
that O
raclopride B-CHEMICAL
blocked O
cocaine-lever B-CHEMICAL
responding O
produced O
by O
a O
lower O
dose O
of O
dimethocaine. B-CHEMICAL
In O
substitution O
studies, O
neither O
procaine B-CHEMICAL
(1-10 O
mg/kg) O
nor O
chloroprocaine B-CHEMICAL
(1-30 O
mg/kg) O
produced O
cocaine-like B-CHEMICAL
effects. O
These O
results O
support O
a O
role O
for O
dopamine B-CHEMICAL
in O
the O
behavioral O
effects O
of O
some O
local O
anesthetics. O
Plasma O
N-terminal B-GENE-Y
pro-brain I-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
and O
adrenomedullin: B-GENE-Y

prognostic O
utility O
and O
prediction O
of O
benefit O
from O
carvedilol B-CHEMICAL
in O
chronic O
ischemic O
left O
ventricular O
dysfunction. O
Australia-New O
Zealand O
Heart O
Failure O
Group. O
OBJECTIVES: O
We O
sought O
to O
assess O
plasma O
concentrations O
of O
the O
amino B-GENE-Y
(N)-terminal I-GENE-Y
portion I-GENE-Y
of I-GENE-Y
pro-brain I-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(N-BNP) B-GENE-Y
and O
adrenomedullin B-GENE-Y
for O
prediction O
of O
adverse O
outcomes O
and O
responses O
to O
treatment O
in O
297 O
patients O
with O
ischemic O
left O
ventricular O
(LV) O
dysfunction O
who O
were O
randomly O
assigned O
to O
receive O
carvedilol B-CHEMICAL
or O
placebo. O

BACKGROUND: O
Although O
neurohormonal O
status O
has O
known O
prognostic O
significance O
in O
heart O
failure, O
the O
predictive O
power O
of O
either O
N-BNP B-GENE-Y
or O
adrenomedullin B-GENE-Y
in O
chronic O
ischemic O
LV O
dysfunction O
has O
not O
been O
previously O
reported. O
METHODS: O
Plasma O
N-BNP B-GENE-Y
and O
adrenomedullin B-GENE-Y
were O
measured O
in O
297 O
patients O
with O
chronic O
ischemic O
(LV) O
dysfunction O
before O
randomization O
to O
carvedilol B-CHEMICAL
or O
placebo, O
added O
to O
established O
treatment O
with O
a O
converting O
enzyme O
inhibitor O
and O
loop O
diuretic O
(with O
or O
without O

digoxin). O
The O
patients' O
clinical O
outcomes, O
induding O
mortality O
and O
heart O
failure O
events, O
were O
recorded O
for O
18 O
months. O
RESULTS: O
Above-median O
N-BNP B-GENE-Y
and O
adrenomedullin B-GENE-Y
levels O
conferred O
increased O
risks O
(all O
p O
< O
0.001) O
of O
mortality O
(risk O
ratios O
[95% O
confidence O
intervals]: O
4.67 O
[2-10.9] O
and O
3.92 O
[1.76-8.7], O
respectively) O
and O
hospital O
admission O
with O
heart O
failure O
(4.7 O
[2.2-10.3] O
and O
2.4 O

[1.3-4.5], O
respectively). O
Both O
of O
these O
predicted O
death O
or O
heart O
failure O
independent O
of O
age, O
New O
York O
Heart O
Association O
functional O
class, O
LV O
ejection O
fraction, O
previous O
myocardial O
infarction O
or O
previous O
admission O
with O
heart O
failure. O
Carvedilol B-CHEMICAL
reduced O
the O
risk O
of O
death O
or O
heart O
failure O
in O
patients O
with O
above-median O
levels O
of O
N-BNP B-GENE-Y
or O
adrenomedullin, B-GENE-Y
or O
both, O
to O
rates O
not O
significantly O
different O
from O
those O
observed O
in O
patients O
with O
levels O
below O
the O
median O
value. O
CONCLUSIONS: O
In O
patients O
with O
established O
ischemic O
LV O
dysfunction, O
plasma O

N-BNP B-GENE-Y
and O
adrenomedullin B-GENE-Y
are O
independent O
predictors O
of O
mortality O
and O
heart O
failure. O
Carvedilol B-CHEMICAL
reduced O
mortality O
and O
heart O
failure O
in O
patients O
with O
higher O
pre-treatment O
plasma O
N-BNP B-GENE-Y
and O
adrenomedullin. B-GENE-Y
Synergistic O
anti-cancer O
effects O
of O
resveratrol B-CHEMICAL
and O
chemotherapeutic O
agent O
clofarabine B-CHEMICAL
against O
human O
malignant O
mesothelioma O
MSTO-211H O
cells. O
Dietary O
phytochemicals O
as O
adjuvants O
have O
been O
suggested O
to O
play O
important O
roles O
in O
enhancing O
chemotherapeutic O
potential O
owing O
to O

multitargeted O
chemopreventive O
properties O
and O
lack O
of O
substantial O
toxicity. O
Here, O
we O
investigated O
the O
efficacy O
of O
the O
combined O
treatment O
of O
various O
phytochemicals O
with O
the O
anticancer O
drug O
clofarabine B-CHEMICAL
in O
malignant O
mesothelioma O
MSTO-211H O
cells O
and O
normal O
mesothelial O
MeT-5A O
cells. O
The O
combined O
treatment O
of O
resveratrol B-CHEMICAL
and O
clofarabine B-CHEMICAL
produced O
a O
synergistic O
antiproliferative O
effect O
in O
MSTO-211H O
cells, O
but O
not O
in O
MeT-5A O
cells. O
In O
MSTO-211H O
cells, O

the O
nuclear O
accumulation O
of O
Sp1 B-GENE-Y
and O
the O
levels O
of O
p-Akt, B-GENE-N
Sp1, B-GENE-Y
c-Met, B-GENE-Y
cyclin B-GENE-Y
D1, I-GENE-Y
and O
p21 B-GENE-Y
were O
effectively O
decreased O
by O
the O
combined O
treatment O
of O
them. O
In O
combination O
with O
clofarabine, B-CHEMICAL
the O
ability O
of O
resveratrol B-CHEMICAL
to O
reduce O
the O
contents O
of O
Sp1 B-GENE-Y
and O
its O
target O
gene O
products O
was O
also O
evident O
in O
a O
time- O
and O
dose-dependent O
experiment. O
The O
inhibition O
of O
phosphoinositide B-GENE-N
3-kinase I-GENE-N
using O
Ly294002 B-CHEMICAL
augmented O
a O
decrease O
in O
the O
p21 B-GENE-Y
level O
induced O
by O
their O
combination, O
but O
it O
showed O
no O
significant O

effects O
on O
expression O
of O
Sp1 B-GENE-Y
and O
cyclin B-GENE-Y
D1. I-GENE-Y
Taken O
together, O
the O
data O
provide O
evidence O
that O
the O
synergistic O
antiproliferative O
effect O
of O
resveratrol B-CHEMICAL
and O
clofarabine B-CHEMICAL
is O
linked O
to O
the O
inhibition O
of O
Akt B-GENE-N
and O
Sp1 B-GENE-Y
activities, O
and O
suggest O
that O
this O
combination O
may O
have O
therapeutic O
value O
in O
treatment O
of O
malignant O
mesothelioma. O
Phillyrin B-CHEMICAL
attenuates O
high O
glucose-induced B-CHEMICAL
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes O
through O
the O
activation O
of O
LKB1/AMP-activated B-GENE-Y
protein I-GENE-N
kinase-dependent I-GENE-N

signalling. O
Phillyrin, B-CHEMICAL
an O
active O
constituent O
found O
in O
many O
medicinal O
plants O
and O
certain O
functional O
foods, O
has O
anti-obesity O
activity O
in O
vivo. O
The O
aim O
of O
our O
study O
was O
to O
provide O
new O
data O
on O
the O
molecular O
mechanism(s) O
underlying O
the O
role O
of O
phillyrin B-CHEMICAL
in O
the O
prevention O
of O
high O
glucose-induced B-CHEMICAL
lipid O
accumulation O
in O
human O
HepG2 O
hepatocytes. O
We O
found O
that O
phillyrin B-CHEMICAL
suppressed O
high O
glucose-induced B-CHEMICAL
lipid O
accumulation O
in O
HepG2 O
cells. O
Phillyrin B-CHEMICAL
strongly O
inhibited O
high O
glucose-induced B-CHEMICAL
fatty B-GENE-Y
acid I-GENE-Y
synthase I-GENE-Y
(FAS) B-GENE-Y
expression O
by O
modulating O

sterol B-GENE-Y
regulatory I-GENE-Y
element-binding I-GENE-Y
protein-1c I-GENE-Y
(SREBP-1c) B-GENE-Y
activation. O
Moreover, O
use O
of O
the O
pharmacological O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
inhibitor O
compound B-CHEMICAL
C I-CHEMICAL
revealed O
that O
AMPK B-GENE-N
is O
essential O
for O
suppressing O
SREBP-1c B-GENE-Y
expression O
in O
phillyrin-treated B-CHEMICAL
cells. O
Finally, O
we O
found O
that O
liver B-GENE-Y
kinase I-GENE-Y
B1 I-GENE-Y
(LKB1) B-GENE-Y
phosphorylation O
is O
required O
for O
the O
phillyrin-enhanced B-CHEMICAL
activation O
of O
AMPK B-GENE-N
in O
HepG2 O
hepatocytes. O
These O
results O
indicate O
that O
phillyrin B-CHEMICAL

prevents O
lipid O
accumulation O
in O
HepG2 O
cells O
by O
blocking O
the O
expression O
of O
SREBP-1c B-GENE-Y
and O
FAS B-GENE-Y
through O
LKB1/AMPK B-GENE-Y
activation, O
suggesting O
that O
phillyrin B-CHEMICAL
is O
a O
novel O
AMPK B-GENE-N
activator O
with O
a O
role O
in O
the O
prevention O
and O
treatment O
of O
obesity. O
Structural, O
kinetic, O
and O
thermodynamic O
analysis O
of O
the O
binding O
of O
the O
40 O
kDa O
PEG-interferon-alpha2a B-CHEMICAL
and O
its O
individual O
positional O
isomers O
to O
the O
extracellular O
domain O
of O
the O
receptor O
IFNAR2. B-GENE-Y
Type-I B-GENE-N
Interferons I-GENE-N
exert O
antiviral O

and O
antiproliferative O
activities O
through O
the O
binding O
to O
a O
common O
cell O
surface O
receptor O
comprising O
two O
subunits, O
IFNAR1 B-GENE-Y
and O
IFNAR2. B-GENE-Y
Human B-GENE-Y
recombinant I-GENE-Y
Interferon-alpha(2a) I-GENE-Y
(IFNalpha(2a)) B-GENE-Y
is O
a O
potent O
drug O
(Roferon-A) O
used O
to O
treat O
various O
cancers O
and O
viral O
diseases O
including O
Hepatitis O
B/C O
infections. O
To O
significantly O
improve O
the O
pharmacological O
properties O
of O
the O
drug, O
a O
pegylated O
form O
of O
IFNalpha(2a) B-GENE-Y
was O
developed O
(PEGASYS). O
This O
40 O

kDa O
PEG-conjugated B-CHEMICAL
IFNalpha(2a) B-GENE-Y
((40)PEG-IFNalpha(2a)) B-GENE-Y
is O
obtained O
by O
the O
covalent O
binding O
of O
one O
40 O
kDa O
branched O
PEG-polymer O
to O
a O
lysine B-CHEMICAL
side-chain O
of O
IFNalpha(2a). B-GENE-Y
Here, O
we O
report O
the O
detailed O
structural, O
kinetic, O
and O
thermodynamic O
analysis O
of O
the O
binding O
to O
the O
extracellular O
domain O
of O
the O
receptor O
IFNAR2 B-GENE-Y
of O
(40)PEG-IFNalpha(2a) B-GENE-Y
and O
its O
isolated O
positional O
isomers O
modified O
at O

K31, O
K134, O
K131, O
K121, O
K164, O
and O
K70, O
respectively, O
in O
comparison O
with O
unmodified O
IFNalpha(2a). B-GENE-Y
Our O
binding O
studies, O
using O
the O
surface O
plasmon O
resonance O
technique, O
show O
that O
the O
pegylation O
does O
not O
abolish O
the O
binding O
to O
the O
receptor, O
but O
significantly O
reduces O
the O
affinity O
mainly O
due O
to O
a O
change O
of O
the O
association O
rate. O
The O
results O
are O
supported O
by O
modeling O
and O
simulation O
of O
the O
binding, O
using O
Self-Avoiding-Walk O
calculations O
for O
the O
polymer O
conformations. O
A O
correlation O
between O
the O
structural O
parameters O
and O
the O
kinetic O
and O

thermodynamic O
parameters O
of O
the O
binding O
of O
the O
positional O
isomers O
could O
be O
established. O
For O
the O
Isomer-K31 O
and O
-K164, O
the O
PEG-polymer O
attachment O
point O
is O
located O
in O
proximity O
to O
the O
binding O
interface, O
and O
the O
isomers O
display O
affinity O
in O
the O
range O
150-520 O
nM O
in O
an O
enthalpy-driven O
binding O
process. O
In O
contrast O
for O
the O
Isomer-K134, O
-K131, O
-K121, O
and O
-K70, O
the O
PEG-polymer B-CHEMICAL
is O
attached O
remotely O
from O
the O
binding O
interface, O
and O
the O
isomers O
exhibit O
a O
higher O
affinity O
(32-76 O

nM) O
in O
an O
entropy-driven O
binding O
process. O
This O
study O
constitutes O
an O
essential O
collection O
of O
knowledge O
on O
which O
the O
interaction O
of O
(40)PEG-IFNalpha(2a) B-GENE-Y
and O
its O
positional O
isomers O
with O
its O
cellular O
receptors O
can O
be O
better O
understood. O
Noncanonical O
control O
of O
C. O
elegans O
germline O
apoptosis O
by O
the O
insulin/IGF-1 B-GENE-N
and O
Ras/MAPK B-GENE-N
signaling O
pathways. O
The O
insulin/IGF-1 B-GENE-N
pathway O
controls O
a O
number O
of O
physiological O
processes O
in O
the O
nematode O
worm O
Caenorhabditis O
elegans, O
including O
development, O
aging O

and O
stress O
response. O
We O
previously O
found O
that O
the O
Akt/PKB B-GENE-Y
ortholog O
AKT-1 B-GENE-Y
dampens O
the O
apoptotic O
response O
to O
genotoxic O
stress O
in O
the O
germline O
by O
negatively O
regulating O
the O
p53-like B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
CEP-1. B-GENE-Y
Here, O
we O
report O
unexpected O
rearrangements O
to O
the O
insulin/IGF-1 B-GENE-N
pathway, O
whereby O
the O
insulin-like B-GENE-Y
receptor I-GENE-Y
DAF-2 B-GENE-Y
and O
3-phosphoinositide-dependent B-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
PDK-1 I-GENE-Y
oppose O
AKT-1 B-GENE-Y
to O
promote O
DNA O
damage-induced O
apoptosis. O
While O
DNA O
damage O
does O

not O
affect O
phosphorylation O
at O
the O
PDK-1 B-GENE-Y
site O
Thr350/Thr308 B-GENE-N
of O
AKT-1, B-GENE-Y
it O
increased O
phosphorylation O
at O
Ser517/Ser473. B-GENE-N
Although O
ablation O
of O
daf-2 B-GENE-Y
or O
pdk-1 B-GENE-Y
completely O
suppressed O
akt-1-dependent B-GENE-Y
apoptosis, O
the O
transcriptional O
activation O
of O
CEP-1 B-GENE-Y
was O
unaffected, O
suggesting O
that O
daf-2 B-GENE-Y
and O
pdk-1 B-GENE-Y
act O
independently O
or O
downstream O
of O
cep-1 B-GENE-Y
and O
akt-1. B-GENE-Y
Ablation O
of O
the O
akt-1 B-GENE-Y
paralog O

akt-2 B-GENE-Y
or O
the O
downstream O
target O
of O
the O
insulin/IGF-1 B-GENE-N
pathway O
daf-16 B-GENE-Y
(a O
FOXO B-GENE-Y
transcription O
factor) O
restored O
sensitivity O
to O
damage-induced O
apoptosis O
in O
daf-2 B-GENE-Y
and O
pdk-1 B-GENE-Y
mutants. O
In O
addition, O
daf-2 B-GENE-Y
and O
pdk-1 B-GENE-Y
mutants O
have O
reduced O
levels O
of O
phospho-MPK-1/ERK B-GENE-Y
in O
their O
germ O
cells, O
indicating O
that O
the O
insulin/IGF-1 B-GENE-N
pathway O
promotes O
Ras B-GENE-N
signaling O
in O
the O
germline. O
Ablation O
of O
the O
Ras B-GENE-N
effector O

gla-3, B-GENE-Y
a O
negative O
regulator O
of O
mpk-1, B-GENE-Y
restored O
sensitivity O
to O
apoptosis O
in O
daf-2 B-GENE-Y
mutants, O
suggesting O
that O
gla-3 B-GENE-Y
acts O
downstream O
of O
daf-2. B-GENE-Y
In O
addition, O
the O
hypersensitivity O
of O
let-60/Ras B-GENE-Y
gain-of-function O
mutants O
to O
damage-induced O
apoptosis O
was O
suppressed O
to O
wild-type O
levels O
by O
ablation O
of O
daf-2. B-GENE-Y
Thus, O
insulin/IGF-1 B-GENE-N
signaling O
selectively O
engages O
AKT-2/DAF-16 B-GENE-Y
to O
promote O
DNA O
damage-induced O
germ O
cell O
apoptosis O

downstream O
of O
CEP-1 B-GENE-Y
through O
the O
Ras B-GENE-N
pathway. O
Carbonic B-GENE-N
anhydrase I-GENE-N
inhibitors. O
Benzenesulfonamides B-CHEMICAL
incorporating O
cyanoacrylamide B-CHEMICAL
moieties O
strongly O
inhibit O
Saccharomyces B-GENE-Y
cerevisiae I-GENE-Y
β-carbonic I-GENE-Y
anhydrase. I-GENE-Y
A O
series O
of O
benzenesulfonamides B-CHEMICAL
incorporating O
cyanoacrylamide B-CHEMICAL
moieties O
(tyrphostine B-CHEMICAL
analogs) O
were O
assayed O
as O
inhibitors O
of O
the O
β-carbonic B-GENE-Y
anhydrase I-GENE-Y
(CA, B-GENE-N
EC B-GENE-Y
4.2.1.1) I-GENE-Y
from O
Saccharomyces O

cerevisiae, O
ScCA. B-GENE-Y
Some O
of O
these O
compounds O
were O
low O
nanomolar O
or O
subnanomolar O
ScCA B-GENE-Y
inhibitors O
and O
showed O
selectivity O
ratios O
in O
the O
range O
of O
4.91-69.86 O
for O
inhibiting O
the O
yeast O
enzyme O
over O
the O
offtarget O
human O
(h) O
isoforms O
hCA B-GENE-Y
I I-GENE-Y
and O
of O
6.46-13.52 O
for O
inhibiting O
ScCA B-GENE-Y
over O
hCA B-GENE-Y
II. I-GENE-Y
The O
model O
organism O
S. O
cerevisiae O
and O
this O
particular O
enzyme O
may O
be O
useful O
for O
detecting O
antifungals O
with O
a O
novel O
mechanism O
of O
action O
compared O
to O
the O
classical O
azole B-CHEMICAL
drugs O
to O
which O
significant O
drug O

resistance O
emerged. O
Indeed, O
some O
of O
these O
sulfonamides B-CHEMICAL
inhibited O
the O
growth O
of O
the O
yeast O
with O
CC50-s O
in O
the O
range O
of O
0.73-6.54μM. O
Artemisinic B-CHEMICAL
acid I-CHEMICAL
inhibits O
melanogenesis O
through O
downregulation O
of O
C/EBP B-GENE-Y
α-dependent I-GENE-Y
expression O
of O
HMG-CoA B-GENE-Y
reductase I-GENE-Y
gene. O
Cholesterol B-CHEMICAL
is O
associated O
with O
the O
regulation O
of O
melanogenesis O
which O
is O
the O
major O
physiological O
defense O
against O
solar O
irradiation. O
The O
present O
study O
was O
designed O
to O
determine O
the O
effects O
of O
artemisinic B-CHEMICAL
acid I-CHEMICAL
on O
melanogenesis O
and O
its O
mechanisms O

of O
action O
in O
human O
epidermal O
melanocytes. O
In O
this O
study, O
we O
found O
that O
artemisinic B-CHEMICAL
acid I-CHEMICAL
inhibited O
melanin O
content. O
The O
mRNA O
levels O
of O
microphthalmia-associated B-GENE-Y
transcription I-GENE-Y
factor I-GENE-Y
(MITF) B-GENE-Y
and O
its O
downstream O
genes O
tyrosinase, B-GENE-Y
tyrosinase-related B-GENE-Y
protein I-GENE-Y
(TRP)-1, I-GENE-Y
and O
TRP-2 B-GENE-Y
were O
reduced O
by O
artemisinic B-CHEMICAL
acid I-CHEMICAL
treatment. O
Additionally, O
the O
mRNA O
levels O
of O
melanogenesis-related O
genes O
(c-KIT, B-GENE-Y
stem B-GENE-Y
cell I-GENE-Y
factor I-GENE-Y
(SCF), B-GENE-Y
and O
macrophage B-GENE-Y
migration I-GENE-Y
inhibitory I-GENE-Y
factor I-GENE-Y

(MIF)) B-GENE-Y
were O
down-regulated O
by O
artemisinic B-CHEMICAL
acid. I-CHEMICAL
Furthermore, O
cAMP B-CHEMICAL
production O
and O
protein B-GENE-N
kinase I-GENE-N
A I-GENE-N
(PKA) B-GENE-N
activity O
were O
suppressed O
by O
artemisinic B-CHEMICAL
acid. I-CHEMICAL
Moreover, O
attempts O
to O
elucidate O
a O
possible O
mechanism O
underlying O
the O
artemisinic B-CHEMICAL
acid-mediated I-CHEMICAL
effects O
revealed O
that O
artemisinic B-CHEMICAL
acid I-CHEMICAL
regulated O
melanogenesis O
by O
inhibiting O
cholesterol B-CHEMICAL
synthesis O
through O
downregulation O
of O
the O
hydroxymethylglutaryl B-GENE-Y
CoA I-GENE-Y
(HMG I-GENE-Y
CoA) I-GENE-Y
reductase I-GENE-Y
gene, O
which O
was O
mediated O
through O
reduced O
expression O
of O
the O

CCAAT/enhancer-binding B-GENE-Y
protein I-GENE-Y
(C/EBP) I-GENE-Y
α I-GENE-Y
gene. O
Taken O
together, O
these O
findings O
indicate O
that O
the O
inhibition O
of O
melanogenesis O
by O
artemisinic B-CHEMICAL
acid I-CHEMICAL
occurs O
through O
reduced O
expression O
of O
the O
HMG B-GENE-Y
CoA I-GENE-Y
reductase I-GENE-Y
gene, O
which O
is O
mediated O
by O
C/EBP B-GENE-Y
α I-GENE-Y
inhibition O
and O
suggest O
that O
artemisinic B-CHEMICAL
acid I-CHEMICAL
may O
be O
useful O
as O
a O
hyperpigmentation O
inhibitor. O
Norethisterone B-CHEMICAL
metabolites O
modulate O
the O
uteroglobin B-GENE-Y
and O
progesterone B-GENE-Y
receptor I-GENE-Y
gene O
expression O
in O
prepubertal O
rabbits. O
Norethisterone B-CHEMICAL

(NET) B-CHEMICAL
is O
a O
synthetic O
progestin, B-CHEMICAL
used O
as O
a O
contraceptive O
agent, O
that O
is O
biotransformed O
at O
target O
tissues O
into O
5 B-CHEMICAL
alpha-NET I-CHEMICAL
and O
3 B-CHEMICAL
beta,5 I-CHEMICAL
alpha-NET, I-CHEMICAL
which O
possess O
different O
pharmacological O
properties. O
The O
effects O
of O
these O
metabolites O
on O
the O
expression O
of O
uteroglobin B-GENE-Y
(UG) B-GENE-Y
and O
progesterone B-GENE-N
receptor I-GENE-N
(PR) B-GENE-N
genes, O
both O
regulated O
by O
progesterone B-CHEMICAL
(P4), I-CHEMICAL
were O
evaluated O
in O
the O
uterus O
of O
prepubertal O
female O
rabbits O
that O
were O
simultaneously O
treated O
with O
P4 O
(1.0 O
mg) O
for O
5 O
consecutive O

days. O
As O
determined O
by O
Western O
and O
Northern O
blot O
analyses, O
5 B-CHEMICAL
alpha-NET I-CHEMICAL
inhibited O
the O
P4-induced O
UG B-GENE-Y
gene O
expression O
in O
a O
dose-dependent O
manner. O
A O
similar O
inhibition O
was O
observed O
with O
the O
administration O
of O
RU-486. B-CHEMICAL
The O
estrogenic O
agent O
3 B-CHEMICAL
beta,5 I-CHEMICAL
alpha-NET I-CHEMICAL
and O
estradiol B-CHEMICAL
at O
a O
dose O
of O
1.0 O
mg O
also O
inhibited O
the O
UG B-GENE-Y
gene O
expression O
induced O
by O
P4. O
Both O
5 B-CHEMICAL
alpha-NET I-CHEMICAL
and O
3 B-CHEMICAL
beta,5 I-CHEMICAL
alpha-NET I-CHEMICAL
blocked O
the O
PR B-GENE-Y
down-regulation O
induced O
by O
P4 O
as O
assessed O
by O
Western O
and O
Northern O
blot O
methods. O

The O
inhibition O
of O
UG B-GENE-Y
synthesis O
and O
PR B-GENE-Y
down-regulation O
by O
5 B-CHEMICAL
alpha-NET I-CHEMICAL
and O
3 B-CHEMICAL
beta,5 I-CHEMICAL
alpha-NET I-CHEMICAL
indicates O
that O
these O
NET B-CHEMICAL
metabolites O
possess O
antiprogestational O
properties. O
Dioscin-induced B-CHEMICAL
autophagy O
mitigates O
cell O
apoptosis O
through O
modulation O
of O
PI3K/Akt B-GENE-N
and O
ERK B-GENE-N
and O
JNK B-GENE-N
signaling O
pathways O
in O
human O
lung O
cancer O
cell O
lines. O
Our O
previous O
study O
has O
revealed O
that O
dioscin, B-CHEMICAL
a O
compound O
with O
anti-inflammatory, O
lipid-lowering, O
anticancer O
and O
hepatoprotective O
effects, O
may O
induce O
autophagy O
in O

hepatoma O
cells. O
Autophagy O
is O
a O
lysosomal O
degradation O
pathway O
that O
is O
essential O
for O
cell O
survival O
and O
tissue O
homeostasis. O
In O
this O
study, O
the O
role O
of O
autophagy O
and O
related O
signaling O
pathways O
during O
dioscin-induced B-CHEMICAL
apoptosis O
in O
human O
lung O
cancer O
cells O
was O
investigated. O
Results O
from O
4'-6-diamidino-2-phenylindole B-CHEMICAL
and O
annexin-V/PI O
double-staining O
assay O
showed O
that O
caspase-3- B-GENE-Y
and O
caspase-8-dependent, B-GENE-Y
and O
dose-dependent O
apoptoses O
were O
detected O
after O
a O
24-h O

dioscin B-CHEMICAL
treatment. O
Meanwhile, O
autophagy O
was O
detected O
as O
early O
as O
12 O
h O
after O
an O
exposure O
to O
low-dose O
dioscin, B-CHEMICAL
as O
indicated O
by O
an O
up-regulated O
expression O
of O
LC3-II B-GENE-Y
and O
beclin-1 B-GENE-Y
proteins. O
Blockade O
of O
autophagy O
with O
bafilomycin B-CHEMICAL
A1 I-CHEMICAL
or O
3-methyladenine B-CHEMICAL
sensitized O
the O
A549 O
and O
H1299 O
cells O
to O
apoptosis. O
Treatment O
of O
A549 O
and O
H1299 O
cells O
with O
dioscin B-CHEMICAL
caused O
a O
dose-dependent O
increase O
in O
ERK1/2 B-GENE-N
and O
JNK1/2 B-GENE-N

activity, O
accompanied O
with O
a O
decreased O
PI3K B-GENE-N
expression O
and O
decreased O
phosphorylation O
of O
Akt B-GENE-N
and O
mTOR. B-GENE-N
Taken O
together, O
this O
study O
demonstrated O
for O
the O
first O
time O
that O
autophagy O
occurred O
earlier O
than O
apoptosis O
during O
dioscin-induced B-CHEMICAL
human O
lung O
cancer O
cell O
line O
apoptosis. O
Dioscin-induced B-CHEMICAL
autophagy O
via O
ERK1/2 B-GENE-N
and O
JNK1/2 B-GENE-N
pathways O
may O
provide O
a O
protective O
mechanism O
for O
cell O
survival O
against O
dioscin-induced B-CHEMICAL
apoptosis O
to O
act O
as O
a O
cytoprotective O
reaction. O
2-Hydroxy-3-methylanthraquinone B-CHEMICAL

from O
Hedyotis O
diffusa O
Willd O
induces O
apoptosis O
in O
human O
leukemic O
U937 O
cells O
through O
modulation O
of O
MAPK B-GENE-N
pathways. O
The O
herb O
of O
Hedyotis O
diffusa O
Willd O
(H. O
diffusa O
Willd), O
an O
annual O
herb O
distributed O
in O
northeastern O
Asia, O
has O
been O
known O
as O
a O
traditional O
oriental O
medicine O
for O
the O
treatment O
of O
cancer. O
Recently, O
Chinese O
researchers O
have O
discovered O
that O
two O
anthraquinones B-CHEMICAL
isolated O
from O
a O
water O
extract O
of O
H. O
diffusa O
Willd O
showed O
apoptosis-inducing O
effects O
against O
cancer O
cells. O
However, O
the O
cellular O
and O
molecular O
mechanisms O
responsible O
for O

this O
phenomenon O
are O
poorly O
understood. O
The O
current O
study O
determines O
the O
role O
of O
mitogen-activated B-GENE-N
protein I-GENE-N
kinases I-GENE-N
(MAPK) B-GENE-N
in O
human O
leukemic O
U937 O
cells O
apoptosis O
induced O
by O
2-hydroxy-3-methylanthraquinone B-CHEMICAL
from O
H. O
diffusa. O
Our O
results O
showed O
that O
2-hydroxy-3-methylanthraquinone B-CHEMICAL
decreased O
phosphorylation-ERK1/2 B-GENE-N
(p-ERK1/2), B-GENE-N
and O
increased O
p-p38MAPK, B-GENE-N
but O
did O
not O
affect O
expressions O
of O
p-JNK1/2 B-GENE-N
in O

U937 O
cells. O
Moreover, O
treatment O
of O
U937 O
cells O
with O
2-hydroxy-3-methylanthraquinone B-CHEMICAL
resulted O
in O
activation O
of O
caspase-3. B-GENE-Y
Furthermore, O
PD98059 B-CHEMICAL
(ERK1/2 B-GENE-N
inhibitor) O
significantly O
enhanced O
2-hydroxy-3-methylanthraquinone-induced B-CHEMICAL
apoptosis O
in O
U937 O
cells, O
whereas O
caspase-3 B-GENE-Y
inhibitor O
or O
SB203580 B-CHEMICAL
(p-p38MAPK B-GENE-N
inhibitor), O
decreased O
apoptosis O
in O
U937 O
cells. O
Taken O
together, O
our O
study O
for O
the O
first O
time O
suggests O
that O

2-hydroxy-3-methylanthraquinone B-CHEMICAL
is O
able O
to O
enhance O
apoptosis O
of O
U937 O
cells, O
at O
least O
in O
part, O
through O
activation O
of O
p-p38MAPK B-GENE-N
and O
downregulation O
of O
p-ERK1/2. B-GENE-N
Moreover, O
the O
triggering O
of O
caspase-3 B-GENE-Y
activation O
mediated O
apoptotic O
induction. O
Hormonal O
therapy O
of O
prostate O
cancer. O
Of O
all O
cancers, O
prostate O
cancer O
is O
the O
most O
sensitive O
to O
hormones: O
it O
is O
thus O
very O
important O
to O
take O
advantage O
of O
this O
unique O
property O
and O
to O
always O
use O
optimal O
androgen B-CHEMICAL
blockade O
when O
hormone O
therapy O
is O
the O
appropriate O

treatment. O
A O
fundamental O
observation O
is O
that O
the O
serum O
testosterone B-CHEMICAL
concentration O
only O
reflects O
the O
amount O
of O
testosterone B-CHEMICAL
of O
testicular O
origin O
which O
is O
released O
in O
the O
blood O
from O
which O
it O
reaches O
all O
tissues. O
Recent O
data O
show, O
however, O
that O
an O
approximately O
equal O
amount O
of O
testosterone B-CHEMICAL
is O
made O
from O
dehydroepiandrosterone B-CHEMICAL
(DHEA) B-CHEMICAL
directly O
in O
the O
peripheral O
tissues, O
including O
the O
prostate, O
and O
does O
not O
appear O
in O
the O
blood. O
Consequently, O
after O
castration, O
the O
95-97% O
fall O
in O
serum O
testosterone B-CHEMICAL
does O
not O
reflect O
the O
40-50% O
testosterone B-CHEMICAL
(testo) B-CHEMICAL
and O
dihydrotestosterone B-CHEMICAL
(DHT) B-CHEMICAL

made O
locally O
in O
the O
prostate O
from O
DHEA B-CHEMICAL
of O
adrenal O
origin. O
In O
fact, O
while O
elimination O
of O
testicular O
androgens B-CHEMICAL
by O
castration O
alone O
has O
never O
been O
shown O
to O
prolong O
life O
in O
metastatic O
prostate O
cancer, O
combination O
of O
castration O
(surgical O
or O
medical O
with O
a O
gonadotropin-releasing B-GENE-Y
hormone I-GENE-Y
(GnRH) B-GENE-Y
agonist) O
with O
a O
pure O
anti-androgen B-CHEMICAL
has O
been O
the O
first O
treatment O
shown O
to O
prolong O
life. O
Most O
importantly, O
when O
applied O
at O
the O
localized O
stage, O
the O
same O
combined O
androgen B-CHEMICAL
blockade O
(CAB) O
can O
provide O
long-term O
control O
or O
cure O
of O
the O
disease O
in O
more O
than O
90% O

of O
cases. O
Obviously, O
since O
prostate O
cancer O
usually O
grows O
and O
metastasizes O
without O
signs O
or O
symptoms, O
screening O
with O
prostate-specific B-GENE-Y
antigen I-GENE-Y
(PSA) B-GENE-Y
is O
absolutely O
needed O
to O
diagnose O
prostate O
cancer O
at O
an O
'early' O
stage O
before O
metastasis O
occurs O
and O
the O
cancer O
becomes O
non-curable. O
While O
the O
role O
of O
androgens B-CHEMICAL
was O
believed O
to O
have O
become O
non-significant O
in O
cancer O
progressing O
under O
any O
form O
of O
androgen B-CHEMICAL
blockade, O
recent O
data O
have O
shown O
increased O
expression O
of O
the O
androgen B-GENE-Y
receptor I-GENE-Y
(AR) B-GENE-Y
in O
treatment-resistant O
disease O
with O
a O
benefit O
of O
further O
androgen B-CHEMICAL
blockade. O
Since O
the O
available O
anti-androgens B-CHEMICAL

have O
low O
affinity O
for O
AR B-GENE-Y
and O
cannot O
block O
androgen B-CHEMICAL
action O
completely, O
especially O
in O
the O
presence O
of O
increased O
AR B-GENE-Y
levels, O
it O
becomes O
important O
to O
discover O
more O
potent O
and O
purely O
antagonistic O
blockers O
of O
AR. B-GENE-Y
The O
data O
obtained O
with O
compounds O
under O
development O
are O
promising. O
While O
waiting O
for O
this O
(these) O
new O
anti-androgen(s), B-CHEMICAL
combined O
treatment O
with O
castration O
and O
a O
pure O
anti-androgen B-CHEMICAL
(bicalutamide, B-CHEMICAL
flutamide B-CHEMICAL
or O
nilutamide) B-CHEMICAL
is O
the O
only O
available O
and O
the O
best O
scientifically O
based O
means O
of O
treating O
prostate O
cancer O
by O
hormone O
therapy O
at O
any O
stage O
of O
the O
disease O
with O
the O
optimal O
chance O
of O
success O
and O
even O
cure O

in O
localized O
disease. O
Spectrum O
of O
mutations O
in O
mut B-GENE-Y
methylmalonic O
acidemia O
and O
identification O
of O
a O
common O
Hispanic O
mutation O
and O
haplotype. O
Cobalamin B-CHEMICAL
nonresponsive O
methylmalonic O
acidemia O
(MMA, O
mut O
complementation O
class) O
results O
from O
mutations O
in O
the O
nuclear O
gene O
MUT, B-GENE-Y
which O
codes O
for O
the O
mitochondrial O
enzyme O
methylmalonyl B-GENE-Y
CoA I-GENE-Y
mutase I-GENE-Y
(MCM). B-GENE-Y
To O
better O
elucidate O
the O
spectrum O
of O
mutations O
that O
cause O
MMA, O
the O
MUT B-GENE-Y
gene O
was O
sequenced O
in O
160 O
patients O
with O
mut B-GENE-Y
MMA. O
Sequence O
analysis O
identified O
mutations O
in O
96% O
of O
disease O

alleles. O
Mutations O
were O
found O
in O
all O
coding O
exons, O
but O
predominantly O
in O
exons O
2, O
3, O
6, O
and O
11. O
A O
total O
of O
116 O
different O
mutations, O
68 O
of O
which O
were O
novel, O
were O
identified. O
Of O
the O
116 O
different O
mutations, O
53% O
were O
missense O
mutations, O
22% O
were O
deletions, O
duplications O
or O
insertions, O
16% O
were O
nonsense O
mutations, O
and O
9% O
were O
splice-site O
mutations. O
Sixty-one O
of O
the O
mutations O
have O
only O
been O
identified O
in O
one O
family. O
A O
novel O
mutation O
in O
exon O
2, O
c.322C>T B-GENE-N
(p.R108C), B-GENE-N

was O
identified O
in O
16 O
of O
27 O
Hispanic O
patients. O
SNP O
genotyping O
data O
demonstrated O
that O
Hispanic O
patients O
with O
this O
mutation O
share O
a O
common O
haplotype. O
Three O
other O
mutations O
were O
seen O
exclusively O
in O
Hispanic O
patients: O
c.280G>A B-GENE-N
(p.G94R), B-GENE-N
c.1022dupA, O
and O
c.970G>A B-GENE-N
(p.A324T). B-GENE-N
Seven O
mutations O
were O
seen O
almost O
exclusively O
in O
black O
patients, O
including O
the O
previously O
reported O
c.2150G>T B-GENE-N
(p.G717V) B-GENE-N
mutation, O
which O
was O
identified O
in O
12 O
of O
29 O
black O
patients. O
Two O
mutations O
were O
seen O

only O
in O
Asian O
patients. O
Some O
frequently O
identified O
mutations O
were O
not O
population-specific O
and O
were O
identified O
in O
patients O
of O
various O
ethnic O
backgrounds. O
Some O
of O
these O
mutations O
were O
found O
in O
mutation O
clusters O
in O
exons O
2, O
3, O
6, O
and O
11, O
suggesting O
a O
recurrent O
mutation. O
Common O
resistance O
mechanisms O
to O
deoxynucleoside O
analogues O
in O
variants O
of O
the O
human O
erythroleukaemic O
line O
K562. O
Resistant O
variants O
of O
the O
human O
leukaemic O
line O
K562 O
were O
developed O
using O
selection O
with O
the O
deoxynucleoside O
analogues O
cytosine B-CHEMICAL
arabinoside, I-CHEMICAL

2-chlorodeoxyadenosine, B-CHEMICAL
fludarabine B-CHEMICAL
and O
gemcitabine. B-CHEMICAL
The O
resistant O
lines O
displayed O
a O
high O
degree O
of O
cross O
resistance O
to O
all O
deoxynucleoside O
analogues, O
with O
little O
or O
no O
cross O
resistance O
to O
other O
agents. O
There O
was O
a O
profound O
accumulation O
defect O
of O
all O
nucleoside O
analogues O
in O
the O
resistant O
variants O
but O
no O
significant O
defect O
in O
nucleoside O
transport O
in O
any O
of O
the O
variants. O
5' B-GENE-Y
nucleotidase I-GENE-Y
activity O
was O
strongly O
increased O
and O
deoxycytidine B-GENE-Y
kinase I-GENE-Y
activity O
was O
moderately O
reduced O
in O
all O
of O
the O
resistant O
variants, O
resulting O
in O
reduced O
accumulation O
of O
triphosphate B-CHEMICAL

analogues. O
In O
addition O
a O
deletion O
in O
one O
of O
the O
alleles O
of O
the O
deoxycytidine B-GENE-Y
kinase I-GENE-Y
was O
detected O
in O
the O
fludarabine-resistant B-CHEMICAL
line. O
Ribonucleotide B-GENE-N
reductase I-GENE-N
activity O
was O
found O
to O
be O
strongly O
increased O
in O
the O
gemcitabine-selected B-CHEMICAL
line O
and O
purine B-GENE-Y
nucleoside I-GENE-Y
phosphorylase I-GENE-Y
was O
increased O
in O
the O
2-chlorodeoxyadenosine-selected B-CHEMICAL
line. O
Free O
nucleotide B-CHEMICAL
pools O
were O
increased O
in O
the O
2-chlorodeoxyadenosine-selected B-CHEMICAL
line. O
There O
was O
no O
expression O
of O
the O
mdr1 B-GENE-Y

gene O
by O
the O
resistant O
lines. O
Karyotypic O
analysis O
and O
FISH O
experiments O
using O
a O
6q21 O
specific O
probe O
showed O
alterations O
in O
the O
6(q16-q22) O
region O
which O
contains O
the O
5'-nucleotidase B-GENE-Y
gene. O
Early O
events O
in O
the O
activation O
and O
degradation O
of O
deoxynucleoside O
analogues O
appear O
to O
constitute O
common O
mechanisms O
of O
resistance O
to O
these O
compounds. O
A O
new O
series O
of O
N2-substituted-5-(p-toluenesulfonylamino)phthalimide B-CHEMICAL
analogues O
as O
α-glucosidase B-GENE-N
inhibitors. O
Several O
members O
of O
a O
new O
family O
of O

non-sugar-type B-CHEMICAL
α-glycosidase B-GENE-N
inhibitors, O
bearing O
a O
5-(p-toluenesulfonylamino)phthalimide B-CHEMICAL
moiety O
and O
various O
substituent O
at O
the O
N2 O
position, O
were O
synthesized O
and O
their O
activities O
were O
investigated. O
The O
newly O
synthesized O
compounds O
displayed O
different O
inhibition O
profile O
towards O
yeast B-GENE-Y
α-glycosidase I-GENE-Y
and O
rat B-GENE-N
intestinal I-GENE-N
α-glycosidase. I-GENE-N
Almost O
all O
the O
compounds O
had O
strong O
inhibitory O
activities O
against O
yeast B-GENE-Y
α-glycosidase. I-GENE-Y
Regarding O
rat B-GENE-N
intestinal I-GENE-N
α-glycosidase, I-GENE-N
only O
analogs O
with O

N2-aromatic O
substituents O
displayed O
varying O
degrees O
of O
inhibitory O
activities O
on O
rat B-GENE-N
intestinal I-GENE-N
maltase I-GENE-N
and O
lactase B-GENE-N
and O
nearly O
all O
compounds O
showed O
no O
inhibition O
against O
rat B-GENE-N
intestinal I-GENE-N
α-amylase. I-GENE-N
Structure-activity O
relationship O
studies O
indicated O
that O
5-(p-toluenesulfonylamino)phthalimide B-CHEMICAL
moiety O
is O
a O
favorable O
scaffold O
to O
exert O
the O
α-glucosidase B-GENE-N
inhibitory O
activity O
and O
substituents O
at O
the O
N2 O
position O
have O
considerable O
influence O
on O
the O
efficacy O
of O
the O
inhibition O
activities. O
The O
R740S B-GENE-N
mutation O

in O
the O
V-ATPase B-GENE-N
a3 I-GENE-N
subunit O
increases O
lysosomal O
pH, O
impairs O
NFATc1 B-GENE-Y
translocation, O
and O
decreases O
in O
vitro O
osteoclastogenesis. O
Vacuolar B-GENE-N
H(+) I-GENE-N
-ATPase I-GENE-N
(V-ATPase), B-GENE-N
a O
multisubunit O
enzyme O
located O
at O
the O
ruffled O
border O
and O
in O
lysosomes O
of O
osteoclasts, O
is O
necessary O
for O
bone O
resorption. O
We O
previously O
showed O
that O
heterozygous O
mice O
with O
an O
R740S B-GENE-N
mutation O
in O
the O
a3 O
subunit O
of O
V-ATPase B-GENE-N

(+/R740S) O
have O
mild O
osteopetrosis O
resulting O
from O
an O
∼90% O
reduction O
in O
proton O
translocation O
across O
osteoclast O
membranes. O
Here O
we O
show O
that O
lysosomal O
pH O
is O
also O
higher O
in O
+/R740S B-GENE-N
compared O
with O
wild-type O
(+/+) O
osteoclasts. O
Both O
osteoclast O
number O
and O
size O
were O
decreased O
in O
cultures O
of O
+/R740S B-GENE-N
compared O
with O
+/+ O
bone O
marrow O
cells, O
with O
concomitant O
decreased O
expression O
of O
key O
osteoclast O
markers O
(TRAP, B-GENE-N
cathepsin B-GENE-N
K, I-GENE-N

OSCAR, B-GENE-N
DC-STAMP, B-GENE-N
and O
NFATc1), B-GENE-N
suggesting O
that O
low O
lysosomal O
pH O
plays O
an O
important O
role O
in O
osteoclastogenesis. O
To O
elucidate O
the O
molecular O
mechanism O
of O
this O
inhibition, O
NFATc1 B-GENE-N
activation O
was O
assessed. O
NFATc1 B-GENE-N
nuclear O
translocation O
was O
significantly O
reduced O
in O
+/R740S B-GENE-N
compared O
with O
+/+ O
cells; O
however, O
this O
was O
not O
because O
of O
impaired O
enzymatic O
activity O
of O
calcineurin, O
the O
phosphatase O
responsible O
for O
NFATc1 B-GENE-N
dephosphorylation. O
Protein O
and O

RNA O
expression O
levels O
of O
regulator O
of O
calcineurin B-GENE-N
1 I-GENE-N
(RCAN1), B-GENE-N
an O
endogenous O
inhibitor O
of O
NFATc1 B-GENE-N
activation O
and O
a O
protein O
degraded O
in O
lysosomes, O
were O
not O
significantly O
different O
between O
+/R740S B-GENE-N
and O
+/+ O
osteoclasts, O
but O
the O
RCAN1/NFATc1 B-GENE-N
ratio O
was O
significantly O
higher O
in O
+/R740S B-GENE-N
versus O
+/+ O
cells. O
The O
lysosomal O
inhibitor O
chloroquine B-CHEMICAL
significantly O
increased O
RCAN1 B-GENE-N
accumulation O
in O
+/+ O
cells, O
consistent O
with O
the O
hypothesis O
that O
higher O
lysosomal O
pH O

impairs O
RCAN1 B-GENE-N
degradation, O
leading O
to O
a O
higher O
RCAN1/NFATc1 B-GENE-N
ratio O
and O
consequently O
NFATc1 B-GENE-N
inhibition. O
Our O
data O
indicate O
that O
increased O
lysosomal O
pH O
in O
osteoclasts O
leads O
to O
decreased O
NFATc1 B-GENE-N
signaling O
and O
nuclear O
translocation, O
resulting O
in O
a O
cell O
autonomous O
impairment O
of O
osteoclastogenesis O
in O
vitro. O
p38 B-GENE-N
Mitogen B-GENE-N
Activated I-GENE-N
Protein I-GENE-N
Kinase I-GENE-N
Regulates O
the O
Nuclear B-GENE-N
Receptor I-GENE-N
CAR B-GENE-Y
to O
Activate O
the O
CYP2B6 B-GENE-Y
Gene. O
The O
constitutive B-GENE-Y
active/androstane I-GENE-Y
receptor I-GENE-Y

(CAR) B-GENE-Y
regulates O
hepatic O
drug O
metabolism O
by O
activating O
genes O
such O
as O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) B-GENE-N
and O
certain O
transferases. B-GENE-N
p38 B-GENE-N
mitogen B-GENE-N
activated I-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK) B-GENE-N
is O
highly O
activated O
in O
human O
primary O
hepatocytes O
but O
barely O
in O
human O
hepatoma O
cell-lines O
including O
HepG2 O
cells. O
Liganded-CAR B-GENE-Y
induced O
CYP2B6 B-GENE-Y
mRNA O
in O
human O
primary O
hepatocytes O
far O
more O
effectively O
than O
in O
HepG2 O
cells O
ectopically O
expressing O
CAR. B-GENE-Y
Here, O
we O
have O
now O
found O
that O
activation O
of O
p38 B-GENE-N

MAPK B-GENE-N
by O
anisomycin B-CHEMICAL
potentiated O
induction O
of O
CYP2B6 B-GENE-Y
mRNA O
by O
CAR B-GENE-Y
ligand O
in O
HepG2 O
cells O
to O
levels O
observed O
in O
ligand-treated O
human O
primary O
hepatocytes. O
siRNA O
knockdown O
of O
p38 B-GENE-N
MAPK B-GENE-N
abrogated O
the O
ability O
of O
anisomycin B-CHEMICAL
to O
synergistically O
induce O
CYP2B6 B-GENE-Y
mRNA. O
In O
addition O
to O
CYP2B6, B-GENE-Y
anisomycin B-CHEMICAL
co-treatment O
potentiated O
an O
increase O
in O
CYP2A7 B-GENE-Y
and O
CYP2C9 B-GENE-Y
mRNAs O
but O
not O
CYP3A4 B-GENE-Y
or O

UDP-glucuronosyltransferase B-GENE-Y
1A1 I-GENE-Y
mRNAs. O
Thus, O
activated O
p38 B-GENE-N
MAPK B-GENE-N
is O
required O
for O
liganded-CAR B-GENE-Y
to O
selectively O
activate O
a O
set O
of O
genes O
that O
encode O
drug O
metabolizing O
enzymes. O
Our O
present O
results O
suggest O
that O
CAR-mediated B-GENE-Y
induction O
of O
these O
enzymes O
can O
not O
be O
understood O
by O
ligand O
binding O
alone O
because O
the O
specificity O
and O
magnitude O
of O
induction O
are O
co-determined O
by O
a O
given O
cell O
signaling O
such O
as O
p38 B-GENE-N
MAPK; B-GENE-N
both O
physiological O
and O
pathophysiological O
states O
of O
cell O
signaling O
may O
have O
a O
strong O
impact O
in O
hepatic O
drug O
metabolizing O

capability O
during O
therapeutic O
treatments. O
Parnaparin, O
a O
low-molecular-weight O
heparin, O
prevents O
P-selectin-dependent B-GENE-Y
formation O
of O
platelet-leukocyte O
aggregates O
in O
human O
whole O
blood. O
Parnaparin, O
a O
low-molecular-weight O
heparin O
(LMWH), O
prevents O
platelet O
activation O
and O
interaction O
with O
polymorphonuclear O
leukocyte O
(PMN) O
in O
a O
washed O
cell O
system. O
The O
in-vitro O
effect O
of O
parnaparin O
was O
studied O
here O
on O
platelet-PMN O
aggregates O
formed O
with O
more O
physiologic O
approaches O
in O
whole O

blood, O
in O
parallel O
with O
unfractionated O
heparin O
and O
enoxaparin, O
another O
LMWH. O
Citrated O
blood O
from O
healthy O
subjects O
was O
stimulated: O
i) O
from O
passage O
through O
the O
"Platelet O
Function O
Analyzer" O
(PFA-100), O
a O
device O
that O
exposes O
blood O
to O
standardized O
high O
shear O
flow O
through O
collagen/ADP B-GENE-N
cartridges; O
ii) O
by O
collagen O
and O
ADP B-CHEMICAL
(2 O
and O
50 O
mug/ml, O
respectively) O
added O
in O
combination O
under O
stirring O
in O
an O
aggregometer O
cuvette; O
iii) O
with O
recombinant O
Tissue B-GENE-Y
Factor, I-GENE-Y

to O
generate O
thrombin B-GENE-Y
concentrations O
able O
to O
activate O
platelets O
without O
inducing O
blood O
clotting, O
or O
iv) O
the O
Thrombin O
Receptor O
Activating O
Peptide-6 O
(TRAP-6). O
Platelet B-GENE-Y
P-selectin I-GENE-Y
and O
platelet-PMN O
aggregates O
were O
measured O
by O
flow O
cytometry O
upon O
stimulation O
of O
blood. O
Fibrinogen B-GENE-N
binding O
to O
platelets O
and O
markers O
of O
PMN O
activation O
were O
also O
detected. O
Platelet B-GENE-Y
P-selectin I-GENE-Y
expression O
and O
platelet-PMN O
aggregate O
formation O
were O
induced O
in O
all O
four O
activation O
conditions O
tested. O
Parnaparin O
prevented O
in O
a O
concentration-dependent O
manner O

(0.3-0.8 O
IUaXa/ml) O
the O
expression O
of O
P-selectin B-GENE-Y
and O
the O
formation O
of O
mixed O
aggregates, O
while O
the O
two O
reference O
heparin O
preparations O
had O
a O
much O
weaker O
effect. O
Platelet B-GENE-N
fibrinogen I-GENE-N
binding O
and O
PMN O
activation O
markers O
(fibrinogen B-GENE-N
binding, O
CD11b B-GENE-Y
and O
CD40) B-GENE-Y
were O
also O
prevented O
by O
parnaparin. O
These O
data O
extend O
in O
more O
physiological O
systems O
of O
platelet O
activation, O
the O
anti-inflammatory O
profile O
of O
parnaparin, O
previously O
reported O
in O
washed O
cells. O
The O
greater O
effect O
of O
parnaparin, O
as O
compared O
to O
the O
reference O

heparins, O
could O
be O
due O
to O
chemico-physical O
differences O
possibly O
unrelated O
to O
their O
anticoagulant O
effect. O
Diverse O
effects O
of O
macromolecular O
crowding O
on O
the O
sequential O
glycan-processing O
pathway O
involved O
in O
glycoprotein O
quality O
control. O
Compared O
with O
in O
vitro O
conditions, O
the O
intracellular O
environment O
is O
highly O
crowded O
with O
biomolecules; O
this O
has O
numerous O
effects O
on O
protein O
functions, O
including O
enzymatic O
activity. O
We O
examined O
the O
effects O
of O
macromolecular O
crowding O
on O
glycan O
processing O
of O
N-glycoprotein B-CHEMICAL
in O
the O
endoplasmic O
reticulum O

as O
a O
model O
sequential O
metabolic O
pathway. O
Experiments O
with O
synthetic O
substrates O
of O
physiological O
glycan O
structure O
clearly O
showed O
that O
the O
first O
half O
of O
the O
pathway O
(glucose B-CHEMICAL
trimming) O
was O
accelerated, O
whereas O
the O
second O
(mannose B-CHEMICAL
trimming) O
was O
decelerated O
under O
molecular O
crowding O
conditions. O
Furthermore, O
calreticulin, B-GENE-Y
a O
lectin-like B-GENE-N
molecular O
chaperone, O
bound O
more O
strongly O
to O
a O
glycan-processing O
intermediate O
under O
these O
conditions. O
This O
study O
demonstrates O
the O
diverse O
effects O
of O
molecular O
crowding O
on O
sequential O
enzymatic O
processing, O
and O
the O
importance O
of O
the O
effects O
of O
macromolecular O
crowding O
on O
in O
vitro O

assays O
for O
understanding O
sequential O
metabolic O
pathways. O
X-ray O
structure O
analysis O
of O
a O
solid O
solution O
of O
milbemycins B-CHEMICAL
A3 I-CHEMICAL
and I-CHEMICAL
A4. I-CHEMICAL
Milbemycins B-CHEMICAL
A3 I-CHEMICAL
and I-CHEMICAL
A4 I-CHEMICAL
are O
pharmaceutically O
and O
agriculturally O
useful O
macrolides O
isolated O
from O
Streptomyces O
species. O
The O
molecular O
structures O
of O
the O
title O
compounds O
were O
unambiguously O
established O
by O
a O
single O
crystal O
X-ray O
analysis O
of O
the O
solid O
solution O
of O
both O
compounds. O
The O
crystals O
present O
trigonal O
system, O
space O
group O
P32 O
with O
Z O
= O
3, O
unit O
cell O
dimensions: O
a O
= O
12.2211(4), O
c O
= O

17.5372(7) O
Å; O
V O
= O
2268.4(1) O
Å(3), O
μ O
= O
0.082 O
mm(- O
1); O
d O
= O
1.183 O
g O
cm(- O
3). O
An O
interesting O
system O
of O
intramolecular O
hydrogen B-CHEMICAL
bonds O
and O
weak O
intermolecular O
CH…O B-CHEMICAL
type O
hydrogen B-CHEMICAL
bond O
was O
observed O
in O
the O
solid O
state. O
In O
vitro O
exploration O
of O
potential O
mechanisms O
of O
toxicity O
of O
the O
human O
hepatotoxic O
drug O
fenclozic B-CHEMICAL
acid. I-CHEMICAL
The O
carboxylic B-CHEMICAL
acid I-CHEMICAL
NSAID O
fenclozic B-CHEMICAL
acid I-CHEMICAL
exhibited O
an O
excellent O

preclinical O
safety O
profile O
and O
promising O
clinical O
efficacy, O
yet O
was O
withdrawn O
from O
clinical O
development O
in O
1971 O
due O
to O
hepatotoxicity O
observed O
in O
clinical O
trials. O
A O
variety O
of O
modern O
in O
vitro O
approaches O
have O
been O
used O
to O
explore O
potential O
underlying O
mechanisms. O
Covalent O
binding O
studies O
were O
undertaken O
with O
[(14)C]-fenclozic B-CHEMICAL
acid I-CHEMICAL
to O
investigate O
the O
possible O
role O
of O
reactive O
metabolites. O
Time-dependent O
covalent O
binding O
to O
protein O
was O
observed O
in O
NADPH-supplemented B-CHEMICAL
liver O
microsomes, O
although O
no O
metabolites O
were O
detected O
in O
these O
incubations O
or O
in O
reactive O
metabolite O
trapping O
experiments. O

In O
human O
hepatocytes, O
covalent O
binding O
was O
observed O
at O
lower O
levels O
than O
in O
microsomes O
and O
a O
minor O
uncharacterizable O
metabolite O
was O
also O
observed. O
In O
addition, O
covalent O
binding O
was O
observed O
in O
incubations O
undertaken O
with O
dog O
and O
rat O
hepatocytes, O
where O
a O
taurine B-CHEMICAL
conjugate O
of O
the O
drug O
was O
detected. O
Although O
an O
acyl B-CHEMICAL
glucuronide I-CHEMICAL
metabolite O
was O
detected O
when O
liver O
microsomes O
from O
human, O
rat O
and O
dog O
were O
supplemented O
with O
UDPGA, B-CHEMICAL
there O
was O
no O
detectable O
UDPGA-dependent B-CHEMICAL
covalent O
binding. O
No O
effects O
were O
observed O

when O
fenclozic B-CHEMICAL
acid I-CHEMICAL
was O
assessed O
for O
P450-dependent B-GENE-N
and O
P450-independent B-GENE-N
cytotoxicity O
to O
THLE O
cell O
lines, O
time-dependent O
inhibition O
of O
five O
major O
human B-GENE-N
cytochrome I-GENE-N
P450 I-GENE-N
enzymes, O
inhibition O
of O
the O
biliary O
efflux B-GENE-N
transporters I-GENE-N
BSEP B-GENE-Y
and O
MRP2 B-GENE-Y
or O
mitochondrial O
toxicity O
to O
THLE O
or O
HepG2 O
cells. O
These O
data O
suggest O
that O
Phase O
1 O
bioactivation O
plays O
a O
role O
in O
the O
hepatotoxicity O
of O
fenclozic B-CHEMICAL
acid I-CHEMICAL
and O
highlight O
the O
unique O
insight O
into O
mechanisms O
of O
human O
drug O
toxicity O
that O
can O
be O

provided O
by O
investigations O
of O
biotransformation O
and O
covalent O
binding O
to O
proteins. O
Mechanism O
of O
organophosphates B-CHEMICAL
(nerve O
gases O
and O
pesticides) O
and O
antidotes: O
electron O
transfer O
and O
oxidative O
stress. O
Evidence O
indicates O
that O
nerve O
gas O
toxins O
operate O
in O
ways O
in O
addition O
to O
inhibition O
of O
acetylcholine B-GENE-Y
esterase. I-GENE-Y
Alternative O
bioactivities O
are O
discussed O
with O
focus O
on O
electron O
transfer. O
The O
main O
class, O
including O
pralidoxime B-CHEMICAL
(2-PAM), B-CHEMICAL
incorporates O
conjugated O
iminium B-CHEMICAL
and O
oxime B-CHEMICAL
moieties O
that O
are O
electron O
affinic. O
Various O
physiological O

properties O
of O
iminium B-CHEMICAL
and O
oxime B-CHEMICAL
species O
are O
reviewed. O
The O
organophosphates B-CHEMICAL
encompass O
both O
nerve O
gases O
and O
insecticides, O
possessing O
similar O
properties, O
but O
different O
activities. O
Toxic O
manifestations O
are O
apparently O
due, O
in O
part, O
to O
oxidative O
stress. O
Alkylation O
of O
DNA O
takes O
place O
which O
may O
lead O
to O
generation O
of O
reactive O
oxygen B-CHEMICAL
species. O
Structure-activity O
relationships O
are O
examined, O
including O
reduction O
potentials O
and O
the O
captodative O
effect. O
Auranofin, B-CHEMICAL
as O
an O
anti-rheumatic O
gold O
compound, O
suppresses O
LPS-induced O
homodimerization O
of O
TLR4. B-GENE-Y
Toll-like B-GENE-N

receptors I-GENE-N
(TLRs), I-GENE-N
which O
are O
activated O
by O
invading O
microorganisms O
or O
endogenous O
molecules, O
evoke O
immune O
and O
inflammatory O
responses. O
TLR B-GENE-N
activation O
is O
closely O
linked O
to O
the O
development O
of O
many O
chronic O
inflammatory O
diseases O
including O
rheumatoid O
arthritis. O
Auranofin, B-CHEMICAL
an O
Au(I) B-CHEMICAL
compound, O
is O
a O
well-known O
and O
long-used O
anti-rheumatic O
drug. O
However, O
the O
mechanism O
as O
to O
how O
auranofin B-CHEMICAL
relieves O
the O
symptom O
of O
rheumatoid O
arthritis O
has O
not O
been O
fully O
clarified. O
Our O
results O
demonstrated O
that O
auranofin B-CHEMICAL
suppressed O
TLR4-mediated B-GENE-Y
activation O

of O
transcription O
factors, O
NF-kappaB B-GENE-N
and O
IRF3, B-GENE-Y
and O
expression O
of O
COX-2, B-GENE-Y
a O
pro-inflammatory O
enzyme. O
This O
suppression O
was O
well O
correlated O
with O
the O
inhibitory O
effect O
of O
auranofin B-CHEMICAL
on O
the O
homodimerization O
of O
TLR4 B-GENE-Y
induced O
by O
an O
agonist. O
Furthermore, O
auranofin B-CHEMICAL
inhibited O
NF-kappaB B-GENE-N
activation O
induced O
by O
MyD88-dependent B-GENE-Y
downstream O
signaling O
components O
of O
TLR4, B-GENE-Y
MyD88, B-GENE-Y
IKKbeta, B-GENE-Y
and O
p65. B-GENE-Y
IRF3 B-GENE-Y
activation O
induced O
by O
MyD88-independent B-GENE-Y
signaling O
components, O
TRIF B-GENE-Y

and O
TBK1, B-GENE-Y
was O
also O
downregulated O
by O
auranofin. B-CHEMICAL
Our O
results O
first O
demonstrate O
that O
auranofin B-CHEMICAL
suppresses O
the O
multiple O
steps O
in O
TLR4 B-GENE-Y
signaling, O
especially O
the O
homodimerization O
of O
TLR4. B-GENE-Y
The O
results O
suggest O
that O
the O
suppression O
of O
TLR4 B-GENE-Y
activity O
by O
auranofin B-CHEMICAL
may O
be O
the O
molecular O
mechanism O
through O
which O
auranofin B-CHEMICAL
exerts O
anti-rheumatic O
activity. O
Differential O
binding O
of O
fibroblast B-GENE-N
growth I-GENE-N
factor-2 I-GENE-N
and I-GENE-N
-7 I-GENE-N
to O
basement O
membrane O
heparan O
sulfate: B-CHEMICAL
comparison O
of O
normal O
and O
abnormal O
human O
tissues. O
Fibroblast B-GENE-N
growth I-GENE-N
factors I-GENE-N
(FGFs) B-GENE-N

play O
multiple O
roles O
during O
development O
and O
in O
adult O
tissues O
as O
paracrine O
regulators O
of O
growth O
and O
differentiation. O
FGFs B-GENE-N
signal O
through O
transmembrane B-GENE-N
receptor I-GENE-N
tyrosine I-GENE-N
kinases, I-GENE-N
but O
heparan O
sulfate B-CHEMICAL
is O
also O
required O
for O
signaling O
by O
members O
of O
the O
FGF B-GENE-N
family. O
In O
addition, O
heparan O
sulfate O
may O
be O
involved O
in O
determining O
tissue O
distribution O
of O
FGFs. B-GENE-N
Using O
biotinylated O
FGF-2 B-GENE-Y
and O
FGF-7 B-GENE-Y
(KGF) B-GENE-Y
as O
probes, O
we O
have O
identified O
specific O
interactions O
between O
FGFs B-GENE-N
and O
heparan O
sulfates B-CHEMICAL
in O
human O

tissues. O
Both O
FGF B-GENE-N
species O
bind O
to O
tissue O
mast O
cells O
and O
to O
epithelial O
cell O
membranes. O
Binding O
to O
basement O
membrane O
heparan O
sulfate B-CHEMICAL
is O
tissue O
source O
dependent O
and O
specific. O
Although O
FGF-2 B-GENE-Y
strongly O
binds O
to O
basement O
membrane O
heparan O
sulfate B-CHEMICAL
in O
skin O
and O
most O
other O
tissue O
sites O
examined, O
FGF-7 B-GENE-Y
fails O
to O
bind O
to O
basement O
membrane O
heparan O
sulfate B-CHEMICAL
in O
most O
locations. O
However, O
in O
subendothelial O
matrix O
in O
blood O
vessels O
and O
in O
the O
basement O
membrane O
of O
a O
papillary O
renal O
cell O
carcinoma, O
strong O
FGF-7 B-GENE-Y
binding O
is O

seen. O
In O
summary, O
distinct O
and O
specific O
affinities O
of O
heparan O
sulfates B-CHEMICAL
for O
different O
FGFs B-GENE-N
were O
identified O
that O
may O
affect O
growth O
factor O
activation O
and O
local O
distribution. O
Heparan O
sulfate B-CHEMICAL
may O
have O
a O
gatekeeper O
function O
to O
either O
restrict O
or O
permit O
diffusion O
of O
heparin-binding O
growth O
factors O
across O
the O
basement O
membrane. O
Vandetanib: B-CHEMICAL
opening O
a O
new O
treatment O
practice O
in O
advanced O
medullary O
thyroid O
carcinoma. O
Medullary O
thyroid O
cancer O
(MTC) O
is O
frequently O
diagnosed O
in O
a O
locally O
advanced O
or O
metastatic O
stage, O
and O
10-year O
survival O
rates O
in O
these O
cases O
are O
below O
20 O
%. O

Cytotoxic O
chemotherapy O
has O
no O
significant O
impact O
on O
overall O
or O
progression-free O
survival. O
Vandetanib B-CHEMICAL
(Caprelsa(®), B-CHEMICAL
AstraZeneca) O
is O
a O
once-daily O
oral O
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor O
that O
selectively O
inhibits O
signalling O
mediated O
by O
growth-factor B-GENE-N
receptor I-GENE-N
tyrosine I-GENE-N
kinase I-GENE-N
RET B-GENE-Y
(constitutively O
activated O
in O
roughly O
60 O
% O
of O
all O
MTCs), O
vascular B-GENE-N
endothelial I-GENE-N
growth-factor I-GENE-N
receptors I-GENE-N
2 I-GENE-N
and I-GENE-N
3, I-GENE-N
and O
epidermal B-GENE-Y
growth-factor I-GENE-Y
receptors. I-GENE-Y
It O
is O
the O
first O
systemic O
drug O
with O
demonstrated O
anti-tumor O
benefits O
in O
advanced O

MTC, O
and O
it O
has O
recently O
been O
approved O
for O
locally O
advanced O
or O
metastatic O
MTC O
by O
the O
United O
States O
Food O
and O
Drug O
Administration O
(April O
2011) O
and O
the O
European O
Medicines O
Agency O
(February O
2012). O
This O
review, O
starting O
from O
the O
phases O
II O
and O
III O
efficacy O
and O
safety O
data O
that O
led O
to O
these O
approvals, O
explores O
important O
issues O
related O
to O
dosing, O
patient O
selection, O
and O
strategies O
for O
managing O
the O
substantial O
risk O
of O
toxicity O
associated O
with O
the O
drug O
(including O
life-threatening O
cardiac O
events O
that O
are O
the O
subject O
of O
a O
black-box O
warning O
in O
the O
United O
States). O
All O
these O
issues O
still O
remain O
to O
be O
defined. O
Vandetanib B-CHEMICAL
is O
becoming O
a O
standard O
of O

care O
for O
symptomatic, O
progressive, O
metastatic O
MTCs, O
to O
be O
used O
selectively O
in O
those O
patients O
who O
are O
likely O
to O
benefit O
from O
it. O
Potent O
fibrinolysis O
inhibitor O
discovered O
by O
shape O
and O
electrostatic O
complementarity O
to O
the O
drug O
tranexamic B-CHEMICAL
Acid. I-CHEMICAL
Protein-protein O
interfaces O
provide O
an O
important O
class O
of O
drug O
targets O
currently O
receiving O
increased O
attention. O
The O
typical O
design O
strategy O
to O
inhibit O
protein-protein O
interactions O
usually O
involves O
large O
molecules O
such O
as O
peptides O
and O
macrocycles. O
One O
exception O
is O
tranexamic B-CHEMICAL
acid I-CHEMICAL
(TXA), B-CHEMICAL
which, O
as O
a O
lysine B-CHEMICAL
mimetic, O

inhibits O
binding O
of O
plasminogen B-GENE-Y
to O
fibrin. B-GENE-N
However, O
the O
daily O
dose O
of O
TXA B-CHEMICAL
is O
high O
due O
to O
its O
modest O
potency O
and O
pharmacokinetic O
properties. O
In O
this O
study, O
we O
report O
a O
computational O
approach, O
where O
the O
focus O
was O
on O
finding O
electrostatic O
potential O
similarities O
to O
TXA. B-CHEMICAL
Coupling O
this O
computational O
technique O
with O
a O
high-quality O
low-throughput O
screen O
identified O
5-(4-piperidyl)-3-isoxazolol B-CHEMICAL
(4-PIOL) B-CHEMICAL
as O
a O
potent O
plasminogen B-GENE-Y
binding O
inhibitor O
with O
the O
potential O
for O
the O
treatment O
of O
various O
bleeding O
disorders. O

Remarkably, O
4-PIOL B-CHEMICAL
was O
found O
to O
be O
more O
than O
four O
times O
as O
potent O
as O
the O
drug O
TXA. B-CHEMICAL
Gene O
deletion O
reveals O
roles O
for O
annexin B-GENE-Y
A1 I-GENE-Y
in O
the O
regulation O
of O
lipolysis O
and O
IL-6 B-GENE-Y
release O
in O
epididymal O
adipose O
tissue. O
In O
this O
study, O
epididymal O
adipose O
tissue O
from O
male O
annexin B-GENE-Y
1 I-GENE-Y
(ANXA1)-null B-GENE-Y
and O
wild-type O
control O
mice O
were O
used O
to O
explore O
the O
potential O
role O
of O
ANXA1 B-GENE-Y
in O
adipocyte O
biology. O
ANXA1 B-GENE-Y
was O
detected O
by O
Western O
blot O
analysis O
in O
wild-type O
tissue O
and O

localized O
predominantly O
to O
the O
stromal-vascular O
compartment. O
Epididymal O
fat O
pad O
mass O
was O
reduced O
by O
ANXA1 B-GENE-Y
gene O
deletion, O
but O
adipocyte O
size O
was O
unchanged, O
suggesting O
that O
ANXA1 B-GENE-Y
is O
required O
for O
the O
maintenance O
of O
adipocyte O
and/or O
preadipocyte O
cell O
number. O
Epididymal O
tissue O
from O
wild-type O
mice O
responded O
in O
vitro O
to O
noradrenaline B-CHEMICAL
and O
isoprenaline B-CHEMICAL
with O
increased O
glycerol B-CHEMICAL
release, O
reduced O
IL-6 B-GENE-Y
release, O
and O
increased O
cAMP B-CHEMICAL
accumulation. O
Qualitatively O
similar O
but O
significantly O
attenuated O
responses O
to O
the O

catecholamines B-CHEMICAL
were O
observed O
in O
tissue O
from O
ANXA1-null B-GENE-Y
mice, O
an O
effect O
that O
was O
not O
associated O
with O
changes O
in O
beta-adrenoceptor B-GENE-N
mRNA O
expression. O
Lipopolysaccharide O
(LPS) O
also O
stimulated O
lipolysis O
in O
vitro, O
but O
its O
effects O
were O
muted O
by O
ANXA1 B-GENE-Y
gene O
deletion. O
By O
contrast, O
LPS O
failed O
to O
influence O
IL-6 B-GENE-Y
release O
from O
wild-type O
tissue O
but O
stimulated O
the O
release O
of O
the O
cytokine B-GENE-N
from O
tissue O
from O
ANXA1-null B-GENE-Y
mice. O
ANXA1 B-GENE-Y
gene O
deletion O
did O
not O
affect O

glucocorticoid B-GENE-Y
receptor I-GENE-Y
expression O
or O
the O
ability O
of O
dexamethasone B-CHEMICAL
to O
suppress O
catecholamine-induced B-CHEMICAL
lipolysis. O
It O
did, O
however, O
augment O
IL-6 B-GENE-Y
expression O
and O
modify O
the O
inhibitory O
effects O
of O
glucocorticoids O
on O
IL-6 B-GENE-Y
release. O
Collectively, O
these O
studies O
suggest O
that O
ANXA1 B-GENE-Y
supports O
aspects O
of O
adipose O
tissue O
mass O
and O
alters O
the O
sensitivity O
of O
epididymal O
adipose O
tissue O
to O
catecholamines, B-CHEMICAL
glucocorticoids, O
and O
LPS, O
thereby O
modulating O
lipolysis O
and O
IL-6 B-GENE-Y
release. O

Phospholipase B-GENE-Y
A2 I-GENE-Y
inhibitors O
p-bromophenacyl B-CHEMICAL
bromide I-CHEMICAL
and O
arachidonyl B-CHEMICAL
trifluoromethyl I-CHEMICAL
ketone I-CHEMICAL
suppressed O
interleukin-2 B-GENE-Y
(IL-2) B-GENE-Y
expression O
in O
murine O
primary O
splenocytes. O
Phospholipase B-GENE-Y
A2 I-GENE-Y
(PLA2) B-GENE-Y
has O
been O
postulated O
to O
play O
a O
role O
in O
the O
regulation O
of O
cytokine B-GENE-N
expression. O
Therefore, O
the O
objective O
of O
the O
present O
study O
was O
to O
investigate O
the O
effects O
of O
PLA2 B-GENE-Y
inhibitors O
p-bromophenacyl B-CHEMICAL
bromide I-CHEMICAL
(BPB) B-CHEMICAL
and O

arachidonyl B-CHEMICAL
trifluoromethyl I-CHEMICAL
ketone I-CHEMICAL
(AACOCF3) B-CHEMICAL
on O
interleukin-2 B-GENE-Y
(IL-2) B-GENE-Y
expression O
in O
murine O
primary O
splenocytes. O
Pretreatment O
of O
the O
splenocytes O
with O
both O
BPB B-CHEMICAL
and O
AACOCF3 B-CHEMICAL
suppressed O
phorbol B-CHEMICAL
12-myristate I-CHEMICAL
13-acetate I-CHEMICAL
plus O
ionomycin-induced O
IL-2 B-GENE-Y
secretion O
in O
a O
concentration-dependent O
manner. O
Inhibition O
> O
90% O
of O
IL-2 B-GENE-Y
secretion O
was O
observed O
at O
1 O
microM O
BPB B-CHEMICAL
and O
10 O
microM O
AACOCF3 B-CHEMICAL
compared O
to O
the O

respective O
vehicle O
control. O
Likewise, O
IL-2 B-GENE-Y
steady-state O
mRNA O
expression O
was O
inhibited O
by O
both O
PLA2 B-GENE-Y
inhibitors O
in O
a O
concentration-dependent O
fashion O
with O
> O
90% O
inhibition O
at O
1 O
microM O
BPB B-CHEMICAL
and O
20 O
microM O
AACOCF3. B-CHEMICAL
Taken O
together, O
these O
data O
demonstrated O
that O
PLA2 B-GENE-Y
inhibitors O
BPB B-CHEMICAL
and O
AACOCF3 B-CHEMICAL
are O
robust O
inhibitors O
of O
IL-2 B-GENE-Y
expression O
at O
both O
the O
mRNA O
and O
protein O
levels O
in O
murine O
splenocytes. O
Moreover, O
these O
findings O
suggest O
that O
drugs O
and O
chemicals O
which O
inhibit O
PLA2 B-GENE-Y
may O
have O
marked O
effects O
on O
T-cell O
function. O

Polymorphisms O
in O
OCTN1 B-GENE-Y
and O
OCTN2 B-GENE-Y
transporters O
genes O
are O
associated O
with O
prolonged O
time O
to O
progression O
in O
unresectable O
gastrointestinal O
stromal O
tumours O
treated O
with O
imatinib B-CHEMICAL
therapy. O
The O
two O
basic O
mainstays O
of O
gastrointestinal O
stromal O
tumours O
(GIST) O
treatment O
are O
surgery O
and O
imatinib, B-CHEMICAL
a O
selective O
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor O
that O
allows O
achieving O
a O
stable O
or O
responding O
disease O
in O
about O
80% O
of O
patients O
with O
unresectable/metastatic O
GIST. O
Response O
to O
imatinib B-CHEMICAL
mainly O
depends O
from O
KIT B-GENE-Y

and O
PDGFRα B-GENE-Y
mutational O
status. O
Nevertheless, O
some O
patients O
with O
a O
potentially O
responsive O
genotype O
do O
not O
respond, O
and O
others O
develop O
a O
pattern O
of O
resistance O
to O
imatinib B-CHEMICAL
which O
is O
not O
associated O
with O
secondary O
mutations. O
This O
emphasizes O
the O
presence O
of O
mechanisms O
of O
resistance O
other O
than O
the O
receptor-related O
genotype, O
and O
the O
need O
of O
biological O
predictors O
to O
select O
the O
optimal O
therapeutic O
strategy, O
particularly O
now O
that O
other O
potent O
inhibitors O
are O
available. O
We O
investigated O
a O
panel O
of O
31 O
polymorphisms O
in O
11 O
genes, O
potentially O
associated O
with O
the O
pharmacogenetics O
of O
imatinib, B-CHEMICAL
in O
a O
group O
of O
54 O

unresectable/metastatic O
GISTs O
treated O
with O
imatinib B-CHEMICAL
400mg O
daily O
as O
first O
line O
therapy. O
Included O
in O
this O
analysis O
were O
polymorphisms O
in O
the O
transporters' O
family O
SLC22, B-GENE-N
SLCO, B-GENE-N
ABC, B-GENE-N
and O
in O
the O
metabolizing O
genes O
CYP-3A4 B-GENE-N
and I-GENE-N
-3A5. I-GENE-N
Time O
to O
progression O
was O
significantly O
improved O
in O
presence O
of O
the O
C O
allele O
in O
SLC22A4 B-GENE-Y
(OCTN1 B-GENE-Y
rs1050152), O
and O
the O
two O
minor O
alleles O
(G) O
in O
SLC22A5 B-GENE-Y
(OCTN2 B-GENE-Y

rs2631367 O
and O
rs2631372). O
Importantly, O
multivariate O
analysis, O
adjusting O
for O
age, O
gender, O
KIT/PDGFRα B-GENE-Y
mutational O
status, O
and O
tumour O
size, O
revealed O
that O
all O
the O
three O
genotypes O
maintained O
independent O
predictive O
significance. O
In O
conclusion, O
in O
this O
study O
we O
showed O
that O
SLC22A4 B-GENE-Y
and O
SLC22A5 B-GENE-Y
genotypes O
may O
be O
an O
important O
predictor O
of O
time O
to O
progression O
in O
GIST O
patients O
receiving O
imatinib B-CHEMICAL
therapy. O
Further O
investigations O
are O
required O
in O
an O
attempt O
to O
further O
personalize O
GIST O
therapy. O
Acute O

Macrovascular O
Dysfunction O
in O
Patients O
With O
Type O
2 O
Diabetes O
Induced O
by O
Ingestion O
of O
Advanced O
Glycated B-GENE-N
β-Lactoglobulins. I-GENE-N
OBJECTIVE O
Recent O
evidence O
indicates O
that O
heat-enhanced O
food O
advanced O
glycation O
end O
products O
(AGEs) O
adversely O
affect O
vascular O
function. O
The O
aim O
of O
this O
study O
was O
to O
examine O
the O
acute O
effects O
of O
an O
oral O
load O
of O
heat-treated, O
AGE-modified O
β-lactoglobulins B-GENE-N
(AGE-BLG) B-GENE-N
compared O
with O
heat-treated, O
nonglycated B-GENE-N
BLG I-GENE-N
(C-BLG) B-GENE-N
on O

vascular O
function O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM). O
RESEARCH O
DESIGN O
AND O
METHODS O
In O
a O
double-blind, O
controlled, O
randomized, O
crossover O
study, O
19 O
patients O
with O
T2DM O
received, O
on O
two O
different O
occasions, O
beverages O
containing O
either O
AGE-BLG B-GENE-N
or O
C-BLG. B-GENE-N
We O
measured O
macrovascular O
[brachial O
ultrasound O
of O
flow-mediated O
dilatation O
(FMD)] O
and O
microvascular O
(laser-Doppler O
measurements O
of O
reactive O
hyperemia O
in O
the O
hand) O
functions O
at O
baseline O

(T0), O
90 O
(T90), O
and O
180 O
(T180) O
min. O
RESULTS O
Following O
the O
AGE-BLG, B-GENE-N
FMD O
decreased O
at O
T90 O
by O
80% O
from O
baseline O
and O
remained O
decreased O
by O
42% O
at O
T180 O
(P O
< O
0.05 O
vs. O
baseline, O
P O
< O
0.05 O
vs. O
C-BLG B-GENE-N
at O
T90). O
By O
comparison, O
following O
C-BLG, B-GENE-N
FMD O
decreased O
by O
27% O
at O
T90 O
and O
51% O
at O
T180 O
(P O
< O
0.05 O
vs. O
baseline O
at O
T180). O

A O
significant O
decrease O
in O
nitrite B-CHEMICAL
(T180) O
and O
nitrate B-CHEMICAL
(T90 O
and O
T180), O
as O
well O
as O
a O
significant O
increase O
in O
N(ε)-carboxymethyllisine, B-CHEMICAL
accompanied O
intake O
of O
AGE-BLG. B-GENE-N
There O
was O
no O
change O
in O
microvascular O
function O
caused O
by O
either O
beverage. O
CONCLUSIONS O
In O
patients O
with O
T2DM, O
acute O
oral O
administration O
of O
a O
single O
AGE-modified O
protein O
class O
significantly O
though O
transiently O
impaired O
macrovascular O
function O
in O
concert O
with O
decreased O
nitric B-CHEMICAL
oxide I-CHEMICAL
bioavailability. O
These O
AGE-related O
changes O
were O
independent O
of O
heat O

treatment. O
In O
situ O
forming O
reduction-sensitive O
degradable O
nanogels O
for O
facile O
loading O
and O
triggered O
intracellular O
release O
of O
proteins. O
In O
situ O
forming O
reduction-sensitive O
degradable O
nanogels O
were O
designed O
and O
developed O
based O
on O
poly(ethylene B-CHEMICAL
glycol)-b-poly(2-(hydroxyethyl) I-CHEMICAL
methacrylate-co-acryloyl I-CHEMICAL
carbonate) I-CHEMICAL
(PEG-P(HEMA-co-AC)) B-CHEMICAL
block O
copolymers O
for O
efficient O
loading O
as O
well O
as O
triggered O
intracellular O
release O
of O
proteins. O

PEG-P(HEMA-co-AC) B-CHEMICAL
copolymers O
were O
prepared O
with O
controlled O
Mn O
of O
9.1, O
9.5, O
and O
9.9 O
kg/mol O
and O
varying O
numbers O
of O
AC O
units O
per O
molecule O
of O
7, O
9 O
and O
11, O
respectively O
(denoted O
as O
copolymer O
1, O
2, O
and O
3) O
by O
reversible O
addition-fragmentation O
chain O
transfer O
copolymerization. O
These O
copolymers O
were O
freely O
soluble O
in O
phosphate B-CHEMICAL
buffer O
but O
formed O
disulfide-cross-linked B-CHEMICAL
nanogels O
with O
defined O
sizes O
ranging O
from O
72.5 O
to O
124.1 O
nm O
in O
the O
presence O
of O
cystamine B-CHEMICAL

via O
ring-opening O
reaction O
with O
cyclic B-CHEMICAL
carbonate I-CHEMICAL
groups. O
The O
sizes O
of O
nanogels O
decreased O
with O
increasing O
AC O
units O
as O
a O
result O
of O
increased O
cross-linking O
density. O
Dynamic O
light O
scattering O
studies O
showed O
that O
these O
nanogels O
though O
stable O
at O
physiological O
conditions O
were O
rapidly O
dissociated O
in O
response O
to O
10 O
mM O
dithiothreitol B-CHEMICAL
(DTT). B-CHEMICAL
Interestingly, O
FITC-labeled B-CHEMICAL
cytochrome B-GENE-Y
C I-GENE-Y
(FITC-CC) B-CHEMICAL
could O
be O
readily O
loaded O
into O
nanogels O
with O
remarkable O
loading O
efficiencies O
(up O
to O
98.2%) O
and O
loading O
contents O
(up O
to O

48.2 O
wt.%). O
The O
in O
vitro O
release O
studies O
showed O
that O
release O
of O
FITC-CC B-CHEMICAL
was O
minimal O
under O
physiological O
conditions O
but O
significantly O
enhanced O
under O
reductive O
conditions O
in O
the O
presence O
of O
10 O
mM O
DTT B-CHEMICAL
with O
about O
96.8% O
of O
FITC-CC B-CHEMICAL
released O
in O
22 O
h O
from O
nanogel O
1. O
In O
contrast, O
protein O
release O
from O
1,4-butanediamine B-CHEMICAL
cross-linked O
nanogels O
(reduction-insensitive O
control) O
remained O
low O
under O
otherwise O
the O
same O
conditions. O
MTT B-CHEMICAL
assays O
showed O
that O
these O
nanogels O
were O
nontoxic O
to O
HeLa O
cells O

up O
to O
a O
tested O
concentration O
of O
2 O
mg/mL. O
Confocal O
microscopy O
results O
showed O
that O
nanogel O
1 O
delivered O
and O
released O
FITC-CC B-CHEMICAL
into O
the O
perinuclei O
region O
of O
HeLa O
cells O
following O
8 O
h O
incubation. O
CC-loaded B-GENE-Y
reductively O
degradable O
nanogels O
demonstrated O
apparently O
better O
apoptotic O
activity O
than O
free O
CC B-GENE-Y
as O
well O
as O
reduction-insensitive O
controls. O
These O
in O
situ O
forming, O
surfactant O
and O
oil-free, O
and O
reduction-sensitive O
degradable O
nanogels O
are O
highly O
promising O
for O
targeted O
protein O
therapy. O
Brugada O
syndrome. O
A O

novel O
clinical O
entity O
characterized O
by O
ST O
segment O
elevation O
in O
right O
precordial O
leads O
(V1 O
to O
V3), O
incomplete O
or O
complete O
right O
bundle O
branch O
block, O
and O
susceptibility O
to O
ventricular O
tachyarrhythmia O
and O
sudden O
cardiac O
death O
has O
been O
described O
by O
Brugada O
et O
al. O
in O
1992. O
This O
disease O
is O
now O
frequently O
called O
"Brugada O
syndrome" O
(BrS). O
The O
prevalence O
of O
BrS O
in O
the O
general O
population O
is O
unknown. O
The O
suggested O
prevalence O
ranges O
from O
5/1,000 O
(Caucasians) O
to O
14/1,000 O
(Japanese). O
Syncope, O
typically O
occurring O
at O

rest O
or O
during O
sleep O
(in O
individuals O
in O
their O
third O
or O
fourth O
decades O
of O
life) O
is O
a O
common O
presentation O
of O
BrS. O
In O
some O
cases, O
tachycardia O
does O
not O
terminate O
spontaneously O
and O
it O
may O
degenerate O
into O
ventricular O
fibrillation O
and O
lead O
to O
sudden O
death. O
Both O
sporadic O
and O
familial O
cases O
have O
been O
reported O
and O
pedigree O
analysis O
suggests O
an O
autosomal O
dominant O
pattern O
of O
inheritance. O
In O
approximately O
20% O
of O
the O
cases O
BrS O
is O
caused O
by O
mutations O
in O
the O
SCN5A B-GENE-Y
gene O
on O
chromosome O
3p21-23, O
encoding O
the O
cardiac O
sodium B-GENE-N
channel, I-GENE-N
a O
protein O
involved O
in O
the O
control O
of O

myocardial O
excitability. O
Since O
the O
use O
of O
the O
implantable O
cardioverter O
defibrillator O
(ICD) O
is O
the O
only O
therapeutic O
option O
of O
proven O
efficacy O
for O
primary O
and O
secondary O
prophylaxis O
of O
cardiac O
arrest, O
the O
identification O
of O
high-risk O
subjects O
is O
one O
of O
the O
major O
goals O
in O
the O
clinical O
decision-making O
process. O
Quinidine B-CHEMICAL
may O
be O
regarded O
as O
an O
adjunctive O
therapy O
for O
patients O
at O
higher O
risk O
and O
may O
reduce O
the O
number O
of O
cases O
of O
ICD O
shock O
in O
patients O
with O
multiple O
recurrences. O
Thiazolidinediones B-CHEMICAL
(TZDs) B-CHEMICAL
affect O
osteoblast O

viability O
and O
biomarkers O
independently O
of O
the O
TZD B-CHEMICAL
effects O
on O
aromatase. B-GENE-Y
Thiazolidinediones B-CHEMICAL
(TZDs) B-CHEMICAL
are O
insulin B-GENE-Y
sensitizers O
used O
for O
treatment O
of O
diabetes. O
We O
have O
previously O
reported O
that O
TZDs B-CHEMICAL
reduce O
estrogen B-CHEMICAL
synthesis O
by O
inhibiting O
aromatase B-GENE-Y
activity O
in O
human O
granulosa O
cells O
(HGC). O
Multiple O
clinical O
trials O
demonstrated O
that O
TZDs B-CHEMICAL
increase O
the O
risk O
of O
fractures O
in O
postmenopausal O
women O
with O
type O
2 O
diabetes. O
We O
studied O
mouse O
osteoblasts O
alone O
or O
in O
a O
co-culture O
with O
HGC O
to O
determine O
whether O
TZD B-CHEMICAL
inhibition O

of O
aromatase B-GENE-Y
plays O
a O
role O
in O
their O
effects O
on O
bone O
metabolism. O
Mouse O
osteoblasts O
were O
cultured O
with O
and O
without O
HGC, O
and O
incubated O
in O
a O
medium O
with O
or O
without O
testosterone, B-CHEMICAL
pioglitazone B-CHEMICAL
or O
rosiglitazone. B-CHEMICAL
Cell O
growth, O
oleic O
acid O
uptake, O
alkaline B-GENE-N
phosphatase I-GENE-N
activity, O
and O
osteocalcin B-GENE-Y
production O
were O
measured. O
TZDs B-CHEMICAL
inhibited O
estradiol B-CHEMICAL
production O
by O
up O
to O
84% O
in O
HGC/mouse O
osteoblast O
co-cultures. O
TZDs B-CHEMICAL
induced O
mouse O
osteoblast O
death O
and O
increased O

oleic B-CHEMICAL
acid I-CHEMICAL
uptake. O
TZDs B-CHEMICAL
also O
inhibited O
alkaline B-GENE-N
phosphatase I-GENE-N
activity O
(58-75%, O
p<0.046) O
and O
osteocalcin B-GENE-Y
production O
(52-75%, O
p<0.031). O
For O
all O
the O
parameters, O
there O
were O
no O
significant O
differences O
between O
the O
osteoblast O
cultures O
alone O
and O
the O
HCG/osteoblast O
co-cultures. O
TZD B-CHEMICAL
effects O
on O
osteoblast O
viability, O
oleic O
acid O
uptake, O
alkaline B-GENE-N
phosphatase I-GENE-N
and O
osteocalcin B-GENE-Y
production O
are O
independent O
of O
their O
effects O
on O

aromatase. B-GENE-Y
P2Y12, B-GENE-Y
a O
new O
platelet O
ADP B-GENE-N
receptor, I-GENE-N
target O
of O
clopidogrel. B-CHEMICAL
Clopidogrel B-CHEMICAL
is O
a O
potent O
antithrombotic O
drug O
that O
inhibits O
ADP-induced B-CHEMICAL
platelet O
aggregation. O
The O
results O
of O
large O
clinical O
trials O
have O
demonstrated O
an O
overall O
benefit O
of O
clopidogrel B-CHEMICAL
over O
aspirin B-CHEMICAL
in O
the O
prevention O
of O
vascular O
ischemic O
events O
(myocardial O
infarction, O
stroke, O
vascular O
death) O
in O
patients O
with O
a O
history O
of O
symptomatic O
atherosclerotic O
disease. O
The O
antiaggregating O
effect O
of O

clopidogrel B-CHEMICAL
is O
attributed O
to O
an O
irreversible O
inhibition O
of O
ADP B-CHEMICAL
binding O
to O
a O
purinergic B-GENE-N
receptor I-GENE-N
present O
at O
the O
platelet O
surface. O
Clopidogrel B-CHEMICAL
is O
not O
active O
in O
vitro O
and O
can O
be O
considered O
a O
precursor O
of O
an O
active O
metabolite O
formed O
in O
the O
liver. O
The O
chemical O
structure O
of O
this O
active O
metabolite O
and O
its O
biological O
activity O
have O
been O
described O
recently. O
Several O
purinergic B-GENE-N
receptors I-GENE-N
have O
been O
described O
on O
platelets; O
P2X B-GENE-Y
(1), I-GENE-Y
a O
calcium B-GENE-N
channel, I-GENE-N
and O
P2Y1 B-GENE-Y
a O
Gq-coupled B-GENE-N
seven-transmembrane I-GENE-N
domain I-GENE-N
receptor, I-GENE-N
have O
been O
found O
not O

to O
be O
antagonized O
by O
clopidogrel. B-CHEMICAL
Another O
Gi B-GENE-N
(2)-coupled I-GENE-N
receptor I-GENE-N
(named O
P2Y12) B-GENE-Y
has O
been O
recently O
cloned O
and O
stably O
expressed O
in O
CHO O
cells. O
These O
cells O
displayed O
a O
strong O
affinity O
for O
(33)P-2MeS-ADP, B-CHEMICAL
a O
stable O
analogue O
of O
ADP, B-CHEMICAL
the O
binding O
characteristics O
of O
which O
corresponded O
in O
all O
points O
to O
those O
observed O
on O
platelets. O
The O
binding O
of O
(33)P-2MeS-ADP B-CHEMICAL
to O
these O
cells O
was O
strongly O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel B-CHEMICAL
with O
a O
potency O
that O

was O
consistent O
with O
that O
observed O
for O
this O
compound O
on O
platelets. O
In O
these O
transfected O
CHO O
cells, O
as O
in O
platelets, O
ADP B-CHEMICAL
and O
2MeS-ADP B-CHEMICAL
induced O
adenylyl B-CHEMICAL
cyclase O
downregulation, O
an O
effect O
that O
was O
inhibited O
by O
the O
active O
metabolite O
of O
clopidogrel. B-CHEMICAL
These O
results O
demonstrate O
that O
this O
receptor O
corresponds O
to O
the O
previously O
called O
"P2t" B-GENE-Y
platelet B-GENE-N
receptor I-GENE-N
and O
show O
that O
the O
active O
metabolite O
of O
clopidogrel B-CHEMICAL
binds O
in O
a O
covalent O
manner O
to O
this O
receptor, O
thus O
explaining O
how O
it O
blocks O
the O
aggregating O
effect O
of O
ADP B-CHEMICAL

on O
platelets. O
Redesign O
of O
carnitine B-GENE-Y
acetyltransferase I-GENE-Y
specificity O
by O
protein O
engineering. O
In O
eukaryotes, O
L-carnitine B-CHEMICAL
is O
involved O
in O
energy O
metabolism O
by O
facilitating O
beta-oxidation O
of O
fatty B-CHEMICAL
acids. I-CHEMICAL
Carnitine B-GENE-Y
acetyltransferases I-GENE-Y
(CrAT) B-GENE-Y
catalyze O
the O
reversible O
conversion O
of O
acetyl-CoA B-CHEMICAL
and O
carnitine B-CHEMICAL
to O
acetylcarnitine B-CHEMICAL
and O
free O
CoA. O
To O
redesign O
the O
specificity O
of O
rat B-GENE-Y
CrAT I-GENE-Y
toward O
its O
substrates, O
we O
mutated O
Met564. O
The O
M564G B-GENE-N
mutated O

CrAT B-GENE-Y
showed O
higher O
activity O
toward O
longer O
chain O
acyl-CoAs: B-CHEMICAL
activity O
toward O
myristoyl-CoA B-CHEMICAL
was O
1250-fold O
higher O
than O
that O
of O
the O
wild-type O
CrAT, B-GENE-Y
and O
lower O
activity O
toward O
its O
natural O
substrate, O
acetyl-CoA. B-CHEMICAL
Kinetic O
constants O
of O
the O
mutant O
CrAT B-GENE-Y
showed O
modification O
in O
favor O
of O
longer O
acyl-CoAs B-CHEMICAL
as O
substrates. O
In O
the O
reverse O
case, O
mutation O
of O
the O
orthologous O
glycine B-GENE-N
(Gly553) I-GENE-N
to I-GENE-N
methionine I-GENE-N
in O
carnitine B-GENE-Y
octanoyltransferase I-GENE-Y
(COT) B-GENE-Y
decreased O

activity O
toward O
its O
natural O
substrates, O
medium- O
and O
long-chain O
acyl-CoAs, B-CHEMICAL
and O
increased O
activity O
toward O
short-chain O
acyl-CoAs. B-CHEMICAL
Another O
CrAT B-GENE-Y
mutant, O
M564A, B-GENE-N
was O
prepared O
and O
tested O
in O
the O
same O
way, O
with O
similar O
results. O
We O
conclude O
that O
Met564 O
blocks O
the O
entry O
of O
medium- O
and O
long-chain O
acyl-CoAs B-CHEMICAL
to O
the O
catalytic O
site O
of O
CrAT. B-GENE-Y
Three-dimensional O
models O
of O
wild-type O
and O
mutated O
CrAT B-GENE-Y
and O
COT B-GENE-Y
support O
this O
hypothesis. O
We O
show O
for O
the O
first O
time O
that O
a O
single O
amino B-CHEMICAL
acid I-CHEMICAL
is O
able O
to O
determine O

the O
substrate O
specificity O
of O
CrAT B-GENE-Y
and O
COT. B-GENE-Y
Cooperative O
homotropic O
interaction O
of O
L-noradrenaline B-CHEMICAL
with O
the O
catalytic O
site O
of O
phenylalanine B-GENE-Y
4-monooxygenase. I-GENE-Y
Catecholamines B-CHEMICAL
(adrenaline, B-CHEMICAL
noradrenaline B-CHEMICAL
and O
dopamine) B-CHEMICAL
are O
potent O
inhibitors O
of O
phenylalanine B-GENE-Y
4-monooxygenase I-GENE-Y
(phenylalanine B-GENE-Y
hydroxylase, I-GENE-Y
EC B-GENE-Y
1.14.16.1). I-GENE-Y
The O
amines O
bind O
to O
the O
enzyme O
by O
a O
direct O
coordination O
to O
the O
high-spin O
(S O
= O
5/2) O
Fe(III) O
at O

the O
active O
site O
(charge O
transfer O
interaction), O
as O
seen O
by O
resonance O
Raman O
and O
EPR O
spectroscopy. O
Experimental O
evidence O
is O
presented O
that O
a O
group O
with O
an O
apparent O
pKa O
value O
of O
about O
5.1 O
(20 O
degrees O
C) O
is O
involved O
in O
the O
interaction O
between O
the O
catecholamine B-CHEMICAL
and O
the O
enzyme. O
The O
high-affinity O
binding O
of O
L-noradrenaline B-CHEMICAL
to O
phenylalanine B-GENE-Y
hydroxylase, I-GENE-Y
as O
studied O
by O
equilibrium O
microdialysis O
(anaerobically) O
and O
ultrafiltration O
(aerobically), O
shows O
positive O
cooperativity O
(h O
= O
1.9); O
at O

pH O
7.2 O
and O
20 O
degrees O
C O
the O
rat O
enzyme O
binds O
about O
0.5 O
mol O
L-noradrenaline/mol B-CHEMICAL
subunit O
with O
a O
half-maximal O
binding O
(S50) O
at O
0.25 O
microM O
L-noradrenaline. B-CHEMICAL
No O
binding O
to O
the O
ferrous O
form O
of O
the O
enzyme O
was O
observed. O
The O
affinity O
decreases O
with O
decreasing O
pH, O
by O
phosphorylation O
and O
by O
preincubation O
of O
the O
enzyme O
with O
the O
substrate O
L-phenylalanine, B-CHEMICAL
while O
it O
increases O
after O
alkylation O
of O
the O
enzyme O
with O
the O
activator O
N-ethylmaleimide. B-CHEMICAL
Preincubation O

of O
the O
enzyme O
with O
L-phenylalanine B-CHEMICAL
also O
leads O
to O
a O
complete O
loss O
of O
the O
cooperativity O
of O
L-noradrenaline B-CHEMICAL
binding O
(h O
= O
1.0). O
The O
many O
similarities O
in O
binding O
properties O
of O
the O
inhibitor O
L-noradrenaline B-CHEMICAL
and O
the O
activator/substrate O
L-phenylalanine B-CHEMICAL
makes O
it O
likely O
that O
the O
cooperative O
interactions O
of O
these O
effectors O
are O
due O
to O
their O
binding O
to O
the O
same O
site. O
The O
high-affinity O
of O
catecholamines B-CHEMICAL
to O
phenylalanine B-GENE-Y
hydroxylase I-GENE-Y
is O
a O
valuable O
probe O
to O
study O
the O
active O
site O
of O
this O
enzyme O
and O
is O
also O
relevant O
for O

the O
homologous O
enzyme O
tyrosine B-GENE-Y
hydroxylase, I-GENE-Y
which O
is O
purified O
as O
a O
stable O
catecholamine-Fe(III) B-CHEMICAL
complex. O
The O
design O
and O
realization O
of O
a O
large-area O
flexible O
nanofiber-based O
mat O
for O
pollutant O
degradation: O
an O
application O
in O
photocatalysis. O
This O
work O
demonstrates O
a O
novel O
multifunctional O
nanofibrous O
mat O
for O
photocatalytic O
applications O
based O
on O
TiO2 B-CHEMICAL
nanocables O
functionalized O
by O
Ag B-CHEMICAL
nanoparticles O
and O
coated O
with O
a O
thin O
(∼2 O
nm) O
graphitic B-CHEMICAL
shell. O
In O
this O
mat, O
which O
was O
realized O
by O
an O

electrospinning O
technique, O
each O
component O
serves O
a O
unique O
function: O
the O
carbon B-CHEMICAL
coating O
acts O
as O
both O
an O
adsorption O
material O
for O
capturing O
pollutants O
and O
as O
a O
charge-transfer O
material, O
the O
Ag B-CHEMICAL
nanoparticles O
act O
as O
a O
visible-light O
sensitizing O
agent O
and O
also O
as O
a O
charge-transfer O
material, O
finally O
the O
TiO2 B-CHEMICAL
nanocable O
mat O
acts O
as O
a O
UV O
sensitive O
photocatalytic O
matrix O
and O
as O
the O
flexible O
substrate O
for O
the O
other O
functional O
components. O
This O
multicomponent O
nanocable O
mat O
exhibits O
excellent O
photocatalytic O
activity O
under O
simulated O
solar O
irradiation O
for O
the O
degradation O
of O
model O
pollutants O

including O
RhB B-CHEMICAL
and O
phenol. B-CHEMICAL
The O
significant O
photocatalytic O
properties O
are O
attributed O
to O
the O
synergetic O
effect O
of O
the O
three O
functional O
components O
and O
the O
unique O
charge O
transport O
"freeway" O
property O
of O
the O
nanofibrous O
mat. O
In O
addition, O
the O
porous O
carbon B-CHEMICAL
coating O
infiltrated O
into O
the O
nanocable O
matrix O
endows O
the O
mat O
with O
excellent O
flexibility O
and O
enables O
robust, O
large-area O
(10 O
× O
10 O
cm) O
fabrication, O
representing O
a O
significant O
advantage O
over O
previous O
brittle O
ceramic O
nanofibrous O
mat O
photocatalyst O
substrates. O
This O
study O
provides O
new O
insight O
into O
the O
design O
and O
preparation O
of O
an O
advanced, O
yet O
commercially O

practical O
and O
scaleable O
photocatalytic O
composite O
membrane O
material. O
The O
as-prepared O
photocatalytic O
mat O
might O
also O
be O
of O
interest O
in O
solar O
cell, O
catalysis, O
separation O
technology, O
biomedical O
engineering, O
and O
nanotechnology. O
The O
effects O
of O
kisspeptin B-GENE-N
in O
human O
reproductive O
function O
- O
therapeutic O
implications. O
Kisspeptin B-GENE-N
is O
a O
54-amino B-CHEMICAL
acid I-CHEMICAL
peptide O
which O
is O
encoded O
by O
the O
KiSS-1 B-GENE-Y
gene O
and O
activates O
the O
G B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
GPR54. B-GENE-Y
Evidence O
suggests O
that O
this O
system O
is O
a O
key O
regulator O
of O
mammalian O
and O
human O
reproduction. O
Animal O
studies O
have O
shown O
that O
GPR54-deficient B-GENE-Y
mice O

have O
abnormal O
sexual O
development. O
Central O
and O
peripheral O
administration O
of O
kisspeptin B-GENE-N
stimulates O
the O
hypothalamic-pituitary-gonadal O
(HPG) O
axis O
whilst O
pre-administration O
of O
a O
gonadotrophin B-GENE-Y
releasing I-GENE-Y
hormone I-GENE-Y
(GnRH) B-GENE-Y
antagonist O
abolishes O
this O
effect. O
In O
humans, O
inactivating O
GPR54 B-GENE-Y
mutations O
cause O
normosmic O
hypogonadotrophic O
hypogonadism O
whilst O
activation O
of O
GPR54 B-GENE-Y
signalling O
is O
associated O
with O
premature O
puberty. O
In O
healthy O
human O
volunteers, O
the O
acute O
intravenous O
administration O
of O
kisspeptin O
potently O
increases O
plasma O

luteinising B-GENE-N
hormone I-GENE-N
(LH) B-GENE-N
levels O
and O
significantly O
increases O
plasma O
follicle B-GENE-N
stimulating I-GENE-N
hormone I-GENE-N
(FSH) B-GENE-N
and O
testosterone B-CHEMICAL
without O
side O
effects O
in O
both O
males O
and O
in O
females O
particularly O
in O
the O
preovulatatory O
phase O
of O
the O
menstrual O
cycle. O
In O
infertility O
due O
to O
hypothalamic O
amenorrhoea O
acute O
administration O
of O
kisspeptin B-GENE-N
results O
in O
stimulation O
of O
reproductive O
hormones. O
The O
kisspeptin/GPR54 B-GENE-N
system O
therefore O
appears O
to O
play O
an O
important O
role O
in O
the O
regulation O
of O
reproduction O
in O
humans. O
Hence O
kisspeptin B-GENE-N
has O
potential O
as O
a O
novel O
tool O
for O
the O
manipulation O
of O
the O

HPG O
axis O
and O
treatment O
of O
infertility O
in O
humans. O
This O
review O
discusses O
the O
evidence O
highlighting O
kisspeptin's B-GENE-N
key O
role O
in O
human O
reproduction. O
Species-specific O
differences O
in O
the O
glucocorticoid B-GENE-Y
receptor I-GENE-Y
transactivation O
function O
upon O
binding O
with O
betamethasone-esters. B-CHEMICAL
Glucocorticoids O
(GCs) O
are O
the O
most O
effective O
drugs O
for O
anti-inflammatory O
diseases. O
A O
number O
of O
adverse O
side O
effects, O
however, O
limit O
chronic O
treatment O
with O
GCs. O
To O
improve O
their O
therapeutic O
usefulness, O
attempts O
have O
been O
made O
to O
dissociate O
the O
two O
main O
actions O
of O
the O
glucocorticoid B-GENE-Y
receptor I-GENE-Y

(GR), B-GENE-Y
transactivation O
and O
transrepression, O
which O
are O
believed O
to O
be O
responsible O
for O
the O
side O
effects O
and O
anti-inflammatory O
effects, O
respectively. O
We O
report O
here O
species-specific O
differences O
in O
the O
transactivation O
response O
mediated O
by O
GR. B-GENE-Y
Dexamethasone B-CHEMICAL
(DEX), B-CHEMICAL
betamethasone B-CHEMICAL
(BM), B-CHEMICAL
and O
their O
esterified-derivatives O
had O
full O
transrepression O
agonistic O
activity O
in O
a O
reporter O
assay O
using O
CV-1 O
cells O
transfected O
with O
either O
human B-GENE-N
or I-GENE-N
rat I-GENE-N
GR. I-GENE-N
These O
GCs O
also O
had O
full O
transactivation O
agonistic O
activity O
in O
CV-1 O
cells O

transfected O
with O
human B-GENE-Y
GR. I-GENE-Y
The O
esterified-BM, B-CHEMICAL
however, O
had O
only O
partial O
transactivation O
agonistic O
activity O
in O
cells O
transfected O
with O
rat B-GENE-Y
GR, I-GENE-Y
whereas O
BM B-CHEMICAL
and O
esterified-DEX B-CHEMICAL
had O
full O
transactivation O
agonistic O
activity. O
Moreover, O
in O
rat O
hepatoma O
H4-II-E O
cells, O
the O
esterified-BM B-CHEMICAL
failed O
to O
induce O
tyrosine B-GENE-Y
aminotransferase, I-GENE-Y
which O
is O
regulated O
by O
GR-mediated B-GENE-Y
transactivation O
activity. O
There O
were O
no O
significant O
differences O
between O
the O
binding O
affinity O
of O
these O
GCs O
to O
human B-GENE-N
and I-GENE-N
rat I-GENE-N
GR. I-GENE-N

Consistent O
with O
the O
weak O
transactivation O
activity O
of O
esterified-BM B-CHEMICAL
mediated O
by O
rat B-GENE-Y
GR, I-GENE-Y
there O
were O
few O
side O
effects, O
evaluated O
by O
thymus O
involution O
and O
body O
weight O
loss, O
in O
an O
antigen-induced O
asthmatic O
model O
in O
rats. O
These O
results O
suggest O
that O
the O
potency O
of O
esterified-BM B-CHEMICAL
to O
induce O
transactivation O
activity O
is O
different O
between O
species O
and O
that O
this O
difference O
is O
not O
due O
to O
differences O
in O
receptor O
binding. O
Amsacrine B-CHEMICAL
and O
etoposide B-CHEMICAL
hypersensitivity O
of O
yeast O
cells O
overexpressing O
DNA B-GENE-Y
topoisomerase I-GENE-Y
II. I-GENE-Y
Increasing O
the O
cellular O
concentration O
of O

DNA B-GENE-Y
topoisomerase I-GENE-Y
II I-GENE-Y
in O
yeast O
by O
expressing O
constitutively O
a O
plasmid-borne O
TOP2 B-GENE-Y
gene O
encoding O
the O
enzyme O
greatly O
increases O
the O
sensitivity O
of O
the O
cells O
to O
amsacrine B-CHEMICAL
and O
etoposide B-CHEMICAL
(VP-16). B-CHEMICAL
This O
increased O
drug O
sensitivity O
at O
a O
higher O
intracellular O
DNA B-GENE-Y
topoisomerase I-GENE-Y
II I-GENE-Y
level O
is O
observed O
in O
both O
RAD52+ B-GENE-Y
repair-proficient O
strains O
and O
rad52 B-GENE-Y
mutants O
that O
are O
defective O
in O
the O
repair O
of O
double-stranded O
breaks. O
These O
results O
provide O
strong O
support O
of O
the O
hypothesis O
that O
the O
cellular O
target O
of O
these O
drugs O
is O
DNA B-GENE-Y
topoisomerase I-GENE-Y
II, I-GENE-Y

and O
that O
these O
drugs O
kill O
cells O
by O
converting O
DNA B-GENE-Y
topoisomerase I-GENE-Y
II I-GENE-Y
into O
a O
DNA O
damaging O
agent. O
Characterization O
of O
insulin-like B-GENE-N
growth I-GENE-N
factor-binding I-GENE-N
protein-related I-GENE-N
proteins I-GENE-N
(IGFBP-rPs) I-GENE-N
1, I-GENE-N
2, I-GENE-N
and I-GENE-N
3 I-GENE-N
in O
human O
prostate O
epithelial O
cells: O
potential O
roles O
for O
IGFBP-rP1 B-GENE-N
and I-GENE-N
2 I-GENE-N
in O
senescence O
of O
the O
prostatic O
epithelium. O
Insulin-like B-GENE-N
growth I-GENE-N
factor I-GENE-N
(IGF)-binding I-GENE-N
protein I-GENE-N
(IGFBP)-related I-GENE-N
proteins I-GENE-N
(IGFBP-rPs) B-GENE-N
are O
newly O
described O

cysteine-rich B-CHEMICAL
proteins O
that O
share O
significant O
aminoterminal O
structural O
similarity O
with O
the O
conventional O
IGFBPs B-GENE-N
and O
are O
involved O
in O
a O
diversity O
of O
biological O
functions, O
including O
growth O
regulation. O
IGFBP-rP1 B-GENE-Y
(MAC25/Angiomodulin/prostacyclin-stimulating B-GENE-Y
factor) I-GENE-Y
is O
a O
potential O
tumor-suppressor O
gene O
that O
is O
differentially O
expressed O
in O
meningiomas, O
mammary O
and O
prostatic O
cancers, O
compared O
with O
their O
malignant O
counterparts. O
We O
have O
previously O
shown O
that O
IGFBP-rP1 B-GENE-Y
is O
preferentially O
produced O
by O
primary O
cultures O
of O
human O

prostate O
epithelial O
cells O
(HPECs) O
and O
by O
poorly O
tumorigenic O
P69SV40T O
cells, O
compared O
with O
the O
cancerous O
prostatic O
LNCaP, O
DU145, O
PC-3, O
and O
M12 O
cells. O
We O
now O
show O
that O
IGFBP-rP1 B-GENE-Y
increases O
during O
senescence O
of O
HPEC. O
IGFBP-rP2 B-GENE-Y
(also O
known O
as O
connective B-GENE-Y
tissue I-GENE-Y
growth I-GENE-Y
factor), I-GENE-Y
a O
downstream O
effector O
of O
transforming B-GENE-N
growth I-GENE-N
factor I-GENE-N
(TGF)-beta I-GENE-N
and O
modulator O
of O
growth O
for O
both O
fibroblasts O
and O
endothelial O
cells, O

was O
detected O
in O
most O
of O
the O
normal O
and O
malignant O
prostatic O
epithelial O
cells O
tested, O
with O
a O
marked O
up-regulation O
of O
IGFBP-rP2 B-GENE-Y
during O
senescence O
of O
HPEC. O
Moreover, O
IGFBP-rP2 B-GENE-Y
noticeably O
increased O
in O
response O
to O
TGF-beta1 B-GENE-Y
and O
all-trans B-CHEMICAL
retinoic I-CHEMICAL
acid I-CHEMICAL
(atRA) B-CHEMICAL
in O
HPEC O
and O
PC-3 O
cells, O
and O
it O
decreased O
in O
response O
to O
IGF-I B-GENE-Y
in O
HPEC. O
IGFBP-rP3 B-GENE-Y
[nephroblastoma B-GENE-Y
overexpressed I-GENE-Y
(NOV)], B-GENE-Y
the O
protein O

product O
of O
the O
NOV B-GENE-Y
protooncogene, O
was O
not O
detected O
in O
HPEC O
but O
was O
expressed O
in O
the O
tumorigenic O
DU145 O
and O
PC-3 O
cells. O
It O
was O
also O
synthesized O
by O
the O
SV40-T O
antigen-transformed O
P69 O
and O
malignant O
M12 O
cells, O
where O
it O
was O
down-regulated O
by O
atRA. B-CHEMICAL
These O
observations O
suggest O
biological O
roles O
of O
IGFBP-rPs B-GENE-N
in O
the O
human O
prostate. O
IGFBP-rP1 B-GENE-Y
and O
IGFBP-rP2 B-GENE-Y
are O
likely O
to O
negatively O
regulate O
growth, O
because O
they O
seem O
to O
increase O
during O
senescence O
of O
the O
prostate O

epithelium O
and O
in O
response O
to O
growth O
inhibitors O
(TGF-beta1 B-GENE-Y
and O
atRA). O
Although O
the O
data O
collected O
on O
IGFBP-rP3 B-GENE-Y
in O
prostate O
are O
modest, O
its O
role O
as O
a O
growth O
stimulator O
and/or O
protooncogene O
is O
supported O
by O
its O
preferential O
expression O
in O
cancerous O
cells O
and O
its O
down-regulation O
by O
atRA. B-CHEMICAL
[Disorders O
with O
eosinophilia, O
treatment O
of O
hypereosinophilic O
syndrome]. O
Eosinophilia O
may O
be O
associated O
with O
reactive O
conditions O
and O
with O
clonal O
disorders O
of O
the O
hematopoietic O

cells. O
The O
hypereosinophilic O
syndrome O
takes O
an O
intermedier O
place O
in O
this O
group. O
In O
this O
disease O
a O
sustained O
eosinophilia O
with O
end O
organ O
damage O
can O
occur. O
The O
author O
summarized O
the O
diagnostic O
procedures O
and O
differential O
diagnosis O
in O
the O
group O
of O
these O
diseases O
focusing O
on O
characteristics O
and O
treatment O
of O
hypereosinophilic O
syndrome. O
The O
treatment O
has O
been O
varied O
and O
included O
steroids, B-CHEMICAL
hydroxyurea, B-CHEMICAL
interferon-alpha, B-GENE-N
and O
in O
some O
cases O
chemotherapy. O
On O
the O
basis O
of O
FIP1L1-PDGFRa B-GENE-Y
fusion O
gene O
hypereosinophilic O
syndrome O
would O
be O

classified O
as O
a O
clonal O
disease O
and O
in O
the O
FIP1L1-PDGFRa B-GENE-Y
positive O
cases O
the O
tyrosine B-GENE-N
kinase I-GENE-N
inhibitor O
imatinib B-CHEMICAL
mesylate I-CHEMICAL
(Glivec) O
would O
be O
effective. O
Transport O
by O
OATP1B1 B-GENE-Y
and O
OATP1B3 B-GENE-Y
enhances O
the O
cytotoxicity O
of O
epigallocatechin B-CHEMICAL
3-O-gallate I-CHEMICAL
and O
several O
quercetin B-CHEMICAL
derivatives. O
Organic B-GENE-N
anion I-GENE-N
transporting I-GENE-N
polypeptides I-GENE-N
(OATPs) I-GENE-N
1B1 I-GENE-N
and I-GENE-N
1B3 I-GENE-N
are O
transporters O
that O
are O
expressed O
selectively O
in O
human O

hepatocytes O
under O
normal O
conditions. O
OATP1B3 B-GENE-Y
is O
also O
expressed O
in O
certain O
cancers. O
Flavonoids B-CHEMICAL
such O
as O
green O
tea O
catechins B-CHEMICAL
and O
quercetin B-CHEMICAL
glycosides I-CHEMICAL
have O
been O
shown O
to O
modulate O
the O
function O
of O
some O
OATPs. B-GENE-N
In O
the O
present O
study, O
the O
extent O
to O
which O
six O
substituted O
quercetin B-CHEMICAL
derivatives O
(1-6) O
affected O
the O
function O
of O
OATP1B1 B-GENE-Y
and O
OATP1B3 B-GENE-Y
was O
investigated. O
Uptake O
of O
the O
radiolabeled O
model O
substrates O
estradiol B-CHEMICAL
17β-glucuronide, I-CHEMICAL
estrone B-CHEMICAL

3-sulfate, I-CHEMICAL
and O
dehydroepiandrosterone B-CHEMICAL
sulfate I-CHEMICAL
(DHEAS) B-CHEMICAL
was O
determined O
in O
the O
absence O
and O
presence O
of O
compounds O
1-6 O
using O
Chinese O
hamster O
ovary O
(CHO) O
cells O
stably O
expressing O
either O
OATP1B1 B-GENE-Y
or O
OATP1B3. B-GENE-Y
Several O
of O
compounds O
1-6 O
inhibited O
OATP-mediated B-GENE-N
uptake O
of O
all O
three O
model O
substrates, O
suggesting O
that O
they O
could O
also O
be O
potential O
substrates. O
Compound O
6 O
stimulated O
OATP1B3-mediated B-GENE-Y
estradiol B-CHEMICAL
17β-glucuronide I-CHEMICAL
uptake O
by O
increasing O
the O

apparent O
affinity O
of O
OATP1B3 B-GENE-Y
for O
its O
substrate. O
Cytotoxicity O
assays O
demonstrated O
that O
epigallocatechin B-CHEMICAL
3-O-gallate I-CHEMICAL
(EGCG) B-CHEMICAL
and O
most O
of O
compounds O
1-6 O
killed O
preferentially O
OATP-expressing B-GENE-N
CHO O
cells. O
EGCG, B-CHEMICAL
1, O
and O
3 O
were O
the O
most O
potent O
cytotoxic O
compounds, O
with O
EGCG B-CHEMICAL
and O
3 O
selectively O
killing O
OATP1B3-expressing B-GENE-Y
cells. O
Given O
that O
OATP1B3 B-GENE-Y
is O
expressed O
in O
several O
cancers, O
EGCG B-CHEMICAL
and O
some O
of O
the O
quercetin B-CHEMICAL
derivatives O
studied O
might O

be O
promising O
lead O
compounds O
for O
the O
development O
of O
novel O
anticancer O
drugs. O
Silencing O
α1,3-fucosyltransferases B-GENE-N
in O
human O
leukocytes O
reveals O
a O
role O
for O
FUT9 B-GENE-Y
enzyme O
during O
E-selectin-mediated B-GENE-Y
cell O
adhesion. O
Leukocyte O
adhesion O
during O
inflammation O
is O
initiated O
by O
the O
binding O
of O
sialofucosylated O
carbohydrates B-CHEMICAL
expressed O
on O
leukocytes O
to O
endothelial O
E/P-selectin. B-GENE-N
Although O
the O
glycosyltransferases B-GENE-N
(glycoTs) B-GENE-N
constructing O
selectin-ligands B-GENE-N
have O
largely O
been O
identified O
using O

knock-out O
mice, O
important O
differences O
may O
exist O
between O
humans O
and O
mice. O
To O
address O
this, O
we O
developed O
a O
systematic O
lentivirus-based O
shRNA O
delivery O
workflow O
to O
create O
human O
leukocytic O
HL-60 O
cell O
lines O
that O
lack O
up O
to O
three O
glycoTs. B-GENE-N
Using O
this, O
the O
contributions O
of O
all O
three O
myeloid O
α1,3-fucosyltransferases B-GENE-N
(FUT4, B-GENE-Y
FUT7, B-GENE-Y
and O
FUT9) B-GENE-Y
to O
selectin-ligand B-GENE-N
biosynthesis O
were O
evaluated. O
The O
cell O
adhesion O
properties O
of O
these O
modified O
cells O
to O
L-, B-GENE-N
E-, I-GENE-N

and I-GENE-N
P-selectin I-GENE-N
under O
hydrodynamic O
shear O
were O
compared O
with O
bone O
marrow-derived O
neutrophils O
from O
Fut4(-/-)Fut7(-/-) B-GENE-Y
dual O
knock-out O
mice. O
Results O
demonstrate O
that O
predominantly O
FUT7, B-GENE-Y
and O
to O
a O
lesser O
extent O
FUT4, B-GENE-Y
forms O
the O
selectin-ligand B-GENE-N
at O
the O
N B-CHEMICAL
terminus O
of O
leukocyte O
P-selectin B-GENE-N
glycoprotein I-GENE-N
ligand-1 I-GENE-N
(PSGL-1) B-GENE-N
in O
humans O
and O
mice. O
Here, O
85% O
reduction O
in O
leukocyte O
interaction O
was O
observed O
in O
human B-GENE-N

FUT4(-)7(-) I-GENE-N
dual O
knockdowns O
on O
P/L-selectin B-GENE-N
substrates. O
Unlike O
Fut4(-/-)Fut7(-/-) B-GENE-Y
mouse O
neutrophils, O
however, O
human O
knockdowns O
lacking O
FUT4 B-GENE-Y
and O
FUT7 B-GENE-Y
only O
exhibited O
partial O
reduction O
in O
rolling O
interaction O
on O
E-selectin. B-GENE-Y
In O
this O
case, O
the O
third O
α1,3-fucosyltransferase B-GENE-N
FUT9 B-GENE-Y
played O
an O
important O
role O
because O
leukocyte O
adhesion O
was O
reduced O
by O
50-60% O
in O
FUT9-HL-60, B-GENE-Y

70-80% O
in O
dual O
knockdown O
FUT7(-)9(-) B-GENE-N
cells, O
and O
∼85% O
in O
FUT4(-)7(-)9(-) B-GENE-N
triple O
knockdowns. O
Gene O
silencing O
results O
are O
in O
agreement O
with O
gain-of-function O
experiments O
where O
all O
three O
fucosyltransferases B-GENE-N
conferred O
E-selectin-mediated B-GENE-Y
rolling O
in O
HEK293T O
cells. O
This O
study O
advances O
new O
tools O
to O
study O
human B-GENE-N
glycoT I-GENE-N
function. O
It O
suggests O
a O
species-specific O
role O
for O
FUT9 B-GENE-Y
during O
the O
biosynthesis O
of O
human B-GENE-Y
E-selectin I-GENE-Y

ligands. O
Optimization O
of O
frozen O
sour O
cherries O
vacuum O
drying O
process. O
The O
objective O
of O
this O
research O
was O
to O
optimize O
the O
vacuum-drying O
of O
frozen O
sour O
cherries O
in O
order O
to O
preserve O
health-beneficial O
phytochemicals, O
as O
well O
as O
textural O
characteristics. O
Investigated O
range O
of O
temperature O
was O
46-74°C O
and, O
of O
pressure, O
17-583mbar, O
in O
a O
new O
design O
of O
vacuum-dryer O
equipment. O
The O
total O
solids, O
a(w) O
value, O
total O
phenolics, B-CHEMICAL
vitamin B-CHEMICAL
C, I-CHEMICAL
antioxidant O
activity, O
anthocyanin B-CHEMICAL
content, O
total O

colour O
change O
and O
firmness O
were O
used O
as O
quality O
indicators O
of O
dried O
sour O
cherry. O
Within O
the O
experimental O
range O
of O
studied O
variables, O
the O
optimum O
conditions O
of O
54.03°C O
and O
148.16mbar O
were O
established O
for O
vacuum O
drying O
of O
sour O
cherry. O
Separate O
validation O
experiments O
were O
conducted, O
under O
optimum O
conditions, O
to O
verify O
predictions O
and O
adequacy O
of O
the O
second-order O
polynomial O
models. O
Under O
these O
optimal O
conditions, O
the O
predicted O
amount O
of O
total O
phenolics B-CHEMICAL
was O
744mg O
CAE/100 O
dw, O
vitamin B-CHEMICAL
C I-CHEMICAL
1.44mg/100g O
per O
dry O
weight O
(g O
dw), O

anthocyanin B-CHEMICAL
content O
125mg/100g O
dw, O
IC(50) O
3.23mg/ml, O
total O
solids O
70.72%, O
a(w) O
value O
0.646, O
total O
colour O
change O
52.61 O
and O
firmness O
3395.4g. O
The O
investigated O
parameters O
had O
a O
significant O
effect O
on O
the O
quality O
of O
the O
dried O
sour O
cherries. O
Dopamine B-GENE-Y
D2-receptor I-GENE-Y
imaging O
with O
123I-iodobenzamide B-CHEMICAL
SPECT O
in O
migraine O
patients O
abusing O
ergotamine: B-CHEMICAL
does O
ergotamine B-CHEMICAL
cross O
the O
blood O
brain O
barrier? O
Two O

migraine O
patients O
were O
studied O
by O
in O
vivo O
SPECT O
using O
the O
dopamine B-GENE-Y
D2-receptor I-GENE-Y
specific O
radioligand O
123I-3-iodo-6-methoxybenzamide B-CHEMICAL
(123I-IBZM) B-CHEMICAL
during O
ergotamine B-CHEMICAL
abuse O
and O
after O
withdrawal. O
Results O
were O
compared O
with O
15 O
healthy O
controls. O
Striatum/cerebellum O
and O
striatum/occipital O
cortex O
ratios O
of O
count O
rate O
density O
were O
calculated O
as O
a O
semiquantitative O
measurement O
for O
striatal O
dopamine B-GENE-Y
D2-receptor I-GENE-Y
binding O
potential. O
No O
differences O
were O
found O
in O
striatal O

uptake O
of O
123I-IBZM B-CHEMICAL
between O
healthy O
controls O
and O
the O
patients O
when O
on O
or O
off O
ergotamine. B-CHEMICAL
Preliminary O
evidence O
suggests O
that O
ergotamine B-CHEMICAL
may O
not O
occupy O
striatal O
dopamine B-GENE-Y
D2-receptors I-GENE-Y
to O
a O
large O
extent O
and O
thus O
may O
not O
cross O
the O
blood O
brain O
barrier O
in O
large O
quantities. O
Reboxetine B-CHEMICAL
versus O
fluvoxamine B-CHEMICAL
in O
the O
treatment O
of O
motor O
vehicle O
accident-related O
posttraumatic O
stress O
disorder: O
a O
double-blind, O
fixed-dosage, O
controlled O
trial. O
BACKGROUND: O
Motor O
vehicle O
accidents O
(MVAs) O
are O
a O
leading O
cause O
of O
posttraumatic O
stress O
disorder O

(PTSD) O
in O
the O
general O
population. O
Alterations O
in O
norepinephrine B-CHEMICAL
and O
serotonin B-CHEMICAL
systems O
have O
been O
proposed O
as O
mechanisms O
involved O
in O
the O
pathophysiology O
of O
the O
condition, O
with O
treatment O
directed O
at O
these O
neurotransmitter O
systems. O
Reboxetine, B-CHEMICAL
a O
selective O
norepinephrine B-CHEMICAL
reuptake O
inhibitor, O
exhibits O
high O
affinity O
and O
selectivity O
for O
the O
human B-GENE-Y
norepinephrine I-GENE-Y
transporter. I-GENE-Y
Inasmuch O
as O
PTSD O
may O
be O
associated O
with O
dysregulation O
of O
noradrenergic O
activity, O
the O
present O
double-blind O
randomized O
clinical O
trial O
intended O
to O
evaluate O

reboxetine's O
efficacy O
in O
the O
management O
of O
MVA-related O
PTSD O
and O
to O
compare O
its O
efficacy O
with O
a O
medication O
commonly O
used O
in O
PTSD, O
the O
selective O
serotonin B-CHEMICAL
reuptake O
inhibitor O
fluvoxamine. B-CHEMICAL
METHODS: O
Forty O
patients O
with O
MVA-related O
PTSD O
attending O
a O
local O
community O
mental O
health O
outpatient O
clinic O
were O
randomized O
to O
receive O
a O
fixed O
dose O
of O
either O
reboxetine B-CHEMICAL
(8 O
mg/d) O
or O
fluvoxamine B-CHEMICAL
(150 O
mg/d) O
in O
a O
double-blind O
fashion O
for O
a O
period O
of O
8 O
weeks. O
RESULTS: O
At O
baseline O
and O
at O
study O
end O

point, O
the O
2 O
subgroups O
demonstrated O
no O
statistical O
differences O
in O
scores O
on O
PTSD, O
depression, O
and O
anxiety O
rating O
scales. O
Both O
medications O
led O
to O
significant O
improvements O
in O
all O
clinical O
scales O
measured. O
Nine O
patients O
receiving O
reboxetine B-CHEMICAL
and O
3 O
receiving O
fluvoxamine B-CHEMICAL
withdrew O
from O
the O
study O
because O
of O
side O
effects. O
CONCLUSIONS: O
Study O
observations O
indicate O
comparable O
efficacy O
of O
reboxetine B-CHEMICAL
and O
fluvoxamine B-CHEMICAL
in O
the O
management O
of O
MVA-related O
PTSD O
despite O
reboxetine's O
selective O
noradrenergic O
activity. O
Reboxetine B-CHEMICAL
appears O
to O
be O
at O
least O
as O
effective O
as O
fluvoxamine B-CHEMICAL
and O
may O
offer O
an O
alternative O

management O
option O
in O
this O
often O
difficult-to-treat O
and O
disabling O
condition. O
A O
lower O
and O
flexible O
reboxetine B-CHEMICAL
dosing O
schedule O
will O
be O
recommended O
for O
future O
research O
to O
improve O
its O
tolerability O
in O
PTSD O
patients. O
Current O
understanding O
of O
TRPM7 B-GENE-Y
pharmacology O
and O
drug O
development O
for O
stroke. O
The O
initial O
excitement O
and O
countless O
efforts O
to O
find O
a O
pharmacological O
agent O
that O
disrupts O
the O
excitotoxic O
pathway O
of O
ischemic O
neuronal O
death O
have O
only O
led O
to O
disappointing O
clinical O
trials. O
Currently, O
a O
thrombolytic O
agent O
called O
recombinant B-GENE-Y
tissue I-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y

(rt-PA) B-GENE-Y
is O
the O
only O
pharmacological O
treatment O
available O
for O
patients O
with O
acute O
ischemic O
stroke O
in O
most O
countries. O
Even O
though O
its O
efficacy O
has O
been O
confirmed O
repeatedly, O
rt-PA B-GENE-Y
is O
considerably O
underused O
due O
to O
reasons O
including O
a O
short O
therapeutic O
window O
and O
repeated O
complications O
associated O
with O
its O
use. O
A O
search O
for O
alternative O
mechanisms O
that O
may O
operate O
dependently O
or O
independently O
with O
the O
well-established O
excitotoxic O
mechanism O
has O
led O
researchers O
to O
the O
discovery O
of O
newly O
described O
non-glutamate B-CHEMICAL
mechanisms. O
Among O
the O
latter, O
transient B-GENE-Y
receptor I-GENE-Y
potential I-GENE-Y
melastatin I-GENE-Y
7 I-GENE-Y
(TRPM7) B-GENE-Y
is O
one O
of O
the O
important O

nonglutamate O
mechanisms O
in O
stroke, O
which O
has O
been O
evaluated O
in O
both O
in-vitro O
and O
in-vivo. O
In O
this O
review, O
we O
will O
discuss O
the O
current O
state O
of O
pharmacological O
treatments O
of O
ischemic O
stroke O
and O
provide O
evidence O
that O
TRPM7 B-GENE-Y
is O
a O
promising O
therapeutic O
target O
of O
stroke. O
Analgesic O
and O
anti-inflammatory O
activities O
of O
aqueous O
extract O
from O
Glycine B-CHEMICAL
tomentella O
root O
in O
mice. O
In O
the O
present O
study, O
we O
have O
investigated O
the O
analgesic O
effect O
of O
the O
aqueous O
extract O
of O
the O
root O
of O
Glycine B-CHEMICAL
tomentella O
(AGT) O
using O
models O
of O
acetic B-CHEMICAL

acid-induced I-CHEMICAL
writhing O
response O
and O
formalin B-CHEMICAL
test, O
the O
anti-inflammatory O
effect O
of O
AGT O
using O
model O
of O
lambda-carrageenan-induced O
paw O
edema. O
In O
order O
to O
investigate O
the O
anti-inflammatory O
mechanism O
of O
AGT, O
we O
have O
detected O
the O
activities O
of O
glutathione B-GENE-N
peroxidase I-GENE-N
(GPx) B-GENE-N
and O
glutathione B-GENE-Y
reductase I-GENE-Y
(GRx) B-GENE-Y
in O
the O
liver O
and O
the O
levels O
of O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
and O
NO B-CHEMICAL
in O
the O
edema O
paw. O
In O
the O
analgesic O
test, O
AGT O
(0.5 O
and O
1.0 O

g/kg) O
decreased O
the O
acetic B-CHEMICAL
acid-induced I-CHEMICAL
writhing O
response O
and O
the O
licking O
time O
on O
the O
late O
phase O
in O
the O
formalin B-CHEMICAL
test. O
In O
the O
anti-inflammatory O
test, O
AGT O
(0.5 O
and O
1.0 O
g/kg) O
decreased O
the O
paw O
edema O
at O
the O
third, O
fourth, O
fifth O
and O
sixth O
hour O
after O
lambda-carrageenan O
administration, O
and O
increased O
the O
activities O
of O
SOD, B-GENE-N
GPx B-GENE-N
and O
GRx B-GENE-Y
in O
the O
liver O
tissue O
and O
decreased O
the O
MDA B-CHEMICAL
level O
in O
the O
edema O
paw O
at O
the O
third O
hour O
after O
lambda-carrageenan O
injection. O
However, O
AGT O
could O
not O

affect O
the O
NO B-CHEMICAL
level O
which O
induced O
by O
lambda-carrageenan. O
These O
results O
suggested O
that O
AGT O
possessed O
analgesic O
and O
anti-inflammatory O
effects. O
The O
anti-inflammatory O
mechanism O
of O
AGT O
might O
be O
related O
to O
the O
decrease O
in O
the O
level O
of O
MDA B-CHEMICAL
in O
the O
edema O
paw O
via O
increasing O
the O
activities O
of O
SOD, B-GENE-N
GPx B-GENE-N
and O
GRx B-GENE-Y
in O
the O
liver. O
Enhancing O
Raman O
Scattering O
without O
Plasmons: O
Unprecedented O
Sensitivity O
Achieved O
by O
TiO2 B-CHEMICAL
Shell-Based O
Resonators. O
A O
remarkable O
enhancement O
of O
Raman O
scattering O
is O
achieved O
by O

TiO2 B-CHEMICAL
shell-based O
spherical O
resonators O
in O
the O
absence O
of O
plasmonic O
enhancers. O
This O
effect O
is O
ascribed O
to O
the O
synergistic O
combination O
of O
high O
refractive O
index O
of O
the O
shell O
layer, O
multiple O
light O
scattering O
through O
the O
spheres, O
and O
related O
geometrical O
factors O
and O
can O
be O
exploited O
to O
fabricate O
a O
new O
generation O
of O
self-diagnostic, O
recyclable O
SERS-active O
substrates. O
Degradation O
of O
MAC13243 B-CHEMICAL
and O
studies O
of O
the O
interaction O
of O
resulting O
thiourea B-CHEMICAL
compounds O
with O
the O
lipoprotein B-GENE-N
targeting O
chaperone B-GENE-N
LolA. B-GENE-N
The O
discovery O
of O
novel O
small O
molecules O
that O
function O
as O

antibacterial O
agents O
or O
cellular O
probes O
of O
biology O
is O
hindered O
by O
our O
limited O
understanding O
of O
bacterial O
physiology O
and O
our O
ability O
to O
assign O
mechanism O
of O
action. O
We O
previously O
employed O
a O
chemical O
genomic O
strategy O
to O
identify O
a O
novel O
small O
molecule, O
MAC13243, B-CHEMICAL
as O
a O
likely O
inhibitor O
of O
the O
bacterial B-GENE-N
lipoprotein I-GENE-N
targeting O
chaperone, B-GENE-N
LolA. B-GENE-N
Here, O
we O
report O
on O
the O
degradation O
of O
MAC13243 B-CHEMICAL
into O
the O
active O
species, O
S-(4-chlorobenzyl)isothiourea. B-CHEMICAL
Analogs O
of O
this O
compound O
(e.g., O
A22) O
have O
previously O
been O
characterized O
as O

inhibitors O
of O
the O
bacterial B-GENE-N
actin-like I-GENE-N
protein, I-GENE-N
MreB. B-GENE-N
Herein, O
we O
demonstrate O
that O
the O
antibacterial O
activity O
of O
MAC13243 B-CHEMICAL
and O
the O
thiourea B-CHEMICAL
compounds O
are O
similar; O
these O
activities O
are O
suppressed O
or O
sensitized O
in O
response O
to O
increases O
or O
decreases O
of O
LolA B-GENE-N
copy O
number, O
respectively. O
We O
provide O
STD O
NMR O
data O
which O
confirms O
a O
physical O
interaction O
between O
LolA B-GENE-N
and O
the O
thiourea B-CHEMICAL
degradation O
product O
of O
MAC13243, B-CHEMICAL
with O
a O
Kd O
of O
~150 O
μM. O
Taken O
together, O
we O
conclude O
that O
the O
thiourea B-CHEMICAL
series O
of O
compounds O
share O
a O
similar O
cellular O
mechanism O

that O
includes O
interaction O
with O
LolA B-GENE-N
in O
addition O
to O
the O
well-characterized O
target O
MreB. B-GENE-N
Alpha1-adrenergic B-GENE-N
receptors I-GENE-N
and O
their O
inhibitors O
in O
lower O
urinary O
tract O
symptoms O
and O
benign O
prostatic O
hyperplasia. O
PURPOSE: O
We O
provide O
a O
comprehensive O
overview O
of O
the O
role O
of O
alpha1-adrenergic B-GENE-N
receptors I-GENE-N
(alpha1ARs) B-GENE-N
as O
critical O
mediators O
of O
lower O
urinary O
tract O
symptoms O
(LUTS) O
and O
pathophysiology O
in O
benign O
prostatic O
hyperplasia O
(BPH), O
and O
we O
review O
the O
pharmacological O
antagonists O
of O

alpha1ARs. B-GENE-N
MATERIALS O
AND O
METHODS: O
A O
review O
was O
performed O
of O
pertinent O
studies O
in O
the O
literature O
relating O
to O
the O
pathophysiology O
of O
LUTS O
and O
BPH, O
focusing O
on O
the O
role O
of O
alpha1ARs, B-GENE-N
and O
of O
clinical O
trial O
and O
practice O
data O
evaluating O
the O
different O
agents O
that O
inhibit O
these O
receptors. O
RESULTS: O
Further O
characterization O
of O
the O
alpha1AR B-GENE-N
gene O
family O
indicates O
that O
3 O
receptor O
subtypes O
exist O
in O
humans. O
Their O
different O
distribution O
between O
urinary O
tract O
and O
cardiovascular O
tissues O
has O
provided O
a O
strategy O
for O
the O
development O
of O
improved O
therapeutic O
agents. O
Since O
excessive O
activity O
of O
the O

alpha1aAR B-GENE-Y
and O
alpha1dAR B-GENE-Y
subtypes O
appears O
to O
be O
a O
common O
feature O
in O
symptomatic O
BPH O
and O
alpha1aARs B-GENE-Y
are O
enriched O
in O
prostatic O
tissue, O
drugs O
that O
demonstrate O
high O
alpha1aAR B-GENE-Y
selectivity O
have O
attracted O
attention. O
Tamsulosin, B-CHEMICAL
which O
has O
high O
affinity O
for O
alpha1aAR B-GENE-Y
and O
alpha1dAR B-GENE-Y
subtypes O
but O
not O
for O
alpha1bAR, B-GENE-Y
shows O
efficacy O
similar O
to O
the O
nonsubtype O
selective O
agents O
terazosin B-CHEMICAL
and O
doxazosin. B-CHEMICAL
It O
is O
associated O
with O
fewer O
cardiovascular O
side O
effects, O
although O
it O
has O
some O
ejaculatory O
side O

effects. O
The O
nonsubtype O
selective O
agent O
alfuzosin B-CHEMICAL
also O
demonstrates O
efficacy O
and O
offers O
an O
enhanced O
side O
effect O
profile, O
particularly O
minimizing O
hypotension. O
Other O
agents O
with O
super O
selective O
specificity O
for O
the O
alpha1aAR B-GENE-Y
subtype O
are O
under O
investigation. O
CONCLUSIONS: O
Further O
advances O
in O
the O
treatment O
of O
LUTS O
associated O
with O
BPH O
may O
depend O
not O
only O
on O
receptor O
subtype O
selectivity, O
but O
also O
on O
other O
pharmacokinetic O
and O
pharmacodynamic O
factors. O
Effect O
of O
low O
dose O
Bisphenol B-CHEMICAL
A I-CHEMICAL
on O
the O
early O
differentiation O
of O
human O
embryonic O
stem O
cells O
into O

mammary O
epithelial O
cells. O
It O
has O
been O
previously O
reported O
that O
Bisphenol B-CHEMICAL
A I-CHEMICAL
(BPA) B-CHEMICAL
can O
disturb O
the O
development O
of O
mammary O
structure O
and O
increase O
the O
risk O
of O
breast O
cancer O
in O
experimental O
animals. O
In O
this O
study, O
an O
in O
vitro O
model O
of O
human O
embryonic O
stem O
cell O
(hESC) O
differentiation O
into O
mammary O
epithelial O
cells O
was O
applied O
to O
investigate O
the O
effect O
of O
low O
dose O
BPA B-CHEMICAL
on O
the O
early O
stages O
of O
mammogenesis. O
A O
newly O
established O
hESC O
line O
was O
directionally O
differentiated O
into O
mammary O
epithelial O
cells O
by O
a O
well-established O

three-dimensional O
(3D) O
culture O
system. O
The O
differentiated O
mammary O
epithelial O
cells O
were O
characterized O
by O
immunofluorescence O
and O
western O
blotting O
assay, O
and O
were O
called O
induced O
differentiated O
mammary O
epithelial O
cells O
(iDMECs) O
based O
on O
these O
data. O
The O
hESCs O
were O
treated O
with O
low O
doses O
of O
BPA B-CHEMICAL
range O
10(-9)-10(-6)M O
during O
the O
differentiation O
process, O
with O
DMSO B-CHEMICAL
as O
the O
solvent O
control O
and O
17-β-estrodiol B-CHEMICAL
(E2) O
as O
the O
estrogen-positive O
control. O
Our O
results O
showed O
that O
low O
dose O

BPA B-CHEMICAL
and O
E2 O
could O
influence O
the O
mammosphere O
area O
of O
iDMECs O
and O
upregulate O
the O
expression O
level O
of O
Oct4 B-GENE-Y
and O
Nanog B-GENE-Y
proteins, O
while O
only O
BPA B-CHEMICAL
could O
downregulate O
the O
expression O
of O
E-cadherin B-GENE-Y
protein. O
Taken O
together, O
this O
study O
provides O
some O
insights O
into O
the O
effects O
of O
low O
dose O
BPA B-CHEMICAL
on O
the O
early O
differentiation O
stage O
of O
mammary O
epithelial O
cells O
and O
suggests O
an O
easier O
canceration O
status O
of O
iDMECs O
under O
the O
effect O
of O
low O
dose O
BPA B-CHEMICAL
during O
its O
early O
differentiation O
stage. O
Absence O
of O
correlation O
between O
oxysterol B-CHEMICAL
accumulation O
in O
lipid B-GENE-N

raft I-GENE-N
microdomains, I-GENE-N
calcium B-CHEMICAL
increase, O
and O
apoptosis O
induction O
on O
158N O
murine O
oligodendrocytes. O
There O
is O
some O
evidence O
that O
oxidized O
derivatives O
of O
cholesterol, B-CHEMICAL
7-ketocholesterol B-CHEMICAL
(7KC) B-CHEMICAL
and O
7β-hydroxycholesterol B-CHEMICAL
(7βOHC), B-CHEMICAL
are O
increased O
in O
the O
plasma O
of O
patients O
with O
neurodegenerative O
diseases O
associated O
with O
demyelinization O
of O
the O
central O
nervous O
system O
(CNS). O
It O
was O
therefore O
of O
interest O
to O
investigate O
the O
effects O
of O
these O
oxysterols B-CHEMICAL
on O

oligodendrocytes, O
the O
myelin-forming O
cells O
in O
the O
CNS. O
To O
this O
end, O
158N O
murine O
oligodendrocytes O
were O
treated O
with O
7KC B-CHEMICAL
or O
7βOHC B-CHEMICAL
inducing O
an O
apoptotic O
mode O
of O
cell O
death O
characterized O
by O
condensation/fragmentation O
of O
the O
nuclei, O
dephosphorylation O
of O
Akt B-GENE-Y
and O
GSK3, B-GENE-N
mitochondrial O
depolarization O
involving O
Mcl-1, B-GENE-Y
and O
caspase-3 B-GENE-Y
activation. O
In O
contrast, O
under O
treatment O
with O
27-hydroxycholesterol B-CHEMICAL
(27OHC), O
no O
cell O
death O

was O
observed. O
When O
the O
cells O
were O
stained O
with O
Fura-2, B-CHEMICAL
no O
significant O
Ca(2+) B-CHEMICAL
rise O
was O
found O
with O
the O
different O
oxysterols, B-CHEMICAL
whereas O
strong O
signals O
were O
detected O
with O
ionomycin B-CHEMICAL
used O
as O
positive O
control. O
At O
concentrations O
which O
induced O
apoptosis, O
7KC B-CHEMICAL
but O
not O
7βOHC B-CHEMICAL
accumulated O
in O
lipid O
rafts. O
Although O
not O
cytotoxic, O
27OHC B-CHEMICAL
was O
mainly O
detected O
in O
lipid O
rafts. O
It O
is O
noteworthy O
that O
α-tocopherol B-CHEMICAL
(but O
not O
ellagic B-CHEMICAL
acid I-CHEMICAL
and O
resveratrol) B-CHEMICAL
was O
able O
to O
counteract O
7KC- B-CHEMICAL

and O
7βOHC-induced B-CHEMICAL
apoptosis O
and O
to O
decrease O
the O
accumulation O
of O
7KC B-CHEMICAL
and O
27OHC B-CHEMICAL
in O
lipid O
rafts. O
Thus, O
in O
158N O
cells, O
the O
ability O
of O
oxysterols B-CHEMICAL
to O
trigger O
a O
mode O
of O
cell O
death O
by O
apoptosis O
involving O
GSK-3 B-GENE-N
and O
caspase-3 B-GENE-Y
activation O
is O
independent O
of O
the O
increase O
in O
the O
Ca(2+) B-CHEMICAL
level O
and O
of O
their O
accumulation O
in O
lipid O
raft O
microdomains. O
Can O
peripheral O
blood O
γδ O
T O
cells O
predict O
osteonecrosis O
of O
the O
jaw? O
An O
immunological O
perspective O
on O
the O
adverse O
drug O
effects O
of O

aminobisphosphonate B-CHEMICAL
therapy. O
Nitrogen-bisphosphonates B-CHEMICAL
(n-BP), B-CHEMICAL
often O
referred O
to O
as O
aminobisphosphonates, B-CHEMICAL
are O
the O
most O
commonly O
prescribed O
drugs O
for O
the O
treatment O
of O
disorders O
of O
bone O
fragility. O
However, O
long-term O
continuous O
treatment O
predisposes O
certain O
individuals O
to O
serious O
rare O
side O
effects, O
such O
as O
bisphosphonate-associated B-CHEMICAL
osteonecrosis O
of O
the O
jaw O
(BAONJ). O
n-BP B-CHEMICAL
use O
is O
known O
to O
unintentionally O
activate O
a O
subset O
of O
innate O
T O
cells O
called O
Vγ9Vδ2 O
T O
cells, O
but O
the O
consequence O

of O
this O
chronic O
immune O
stimulation O
has O
remained O
unexplored. O
The O
primary O
objectives O
of O
this O
study O
were O
to O
1) O
determine O
the O
fate O
of O
Vγ9Vδ2 O
T O
cells O
in O
osteoporotic O
patients O
on O
n-BP B-CHEMICAL
therapy O
as O
a O
function O
of O
time O
and O
type O
of O
therapy; O
2) O
evaluate O
the O
proportion O
of O
Vγ9Vδ2 O
T O
cells O
in O
patients O
who O
had O
recently O
experienced O
n-BP-associated B-CHEMICAL
ONJ. O
We O
found O
there O
is O
a O
notable O
loss O
of O
Vγ9Vδ2 O
T O
cells O
over O
time O
in O
osteoporotic O
patients O
on O
n-BP B-CHEMICAL
therapy, O
particularly O
those O
on O
intravenous O

(iv) O
therapy O
(Spearman O
r O
= O
-0.55, O
p O
< O
0.0001 O
iv; O
r O
= O
-0.3, O
p O
< O
0.03 O
oral) O
(n O
= O
68); O
no O
difference O
was O
observed O
in O
total O
T O
cells, O
monocytes, O
or O
granulocytes. O
Importantly, O
the O
observed O
negative O
effect O
on O
Vγ9Vδ2 O
T O
cells O
coincides O
with O
the O
reported O
route O
of O
administration O
and O
timing O
of O
the O
rare O
occurrence O
of O
BAONJ. O
Patients O
(n O
= O
6) O
who O
had O
experienced O
BAONJ O
were O
all O
found O
to O
be O
significantly O
deficient O
in O

Vγ9Vδ2 O
T O
cells O
(median O
= O
0.07%) O
in O
comparison O
to O
age- O
and O
sex-matched O
treatment-naïve O
controls O
(N O
= O
11; O
median O
= O
2.40%), O
U O
= O
0, O
p O
= O
0.001; O
this O
was O
the O
only O
consistent O
difference O
in O
the O
leukocytes O
assessed. O
All O
BAONJ O
cases O
had O
an O
underlying O
condition O
that O
further O
contributed O
to O
impaired O
immunity. O
We O
propose O
Vγ9Vδ2 O
T O
cells O
show O
a O
strong O
potential O
to O
serve O
as O
harbingers O
of O
possible O
adverse O
immune O
effects O
of O
n-BP B-CHEMICAL
therapy, O
particularly O
in O
those O
patients O
already O
having O
a O
compromised O
immune O
system O

as O
they O
may O
be O
most O
vulnerable O
to O
the O
development O
of O
conditions O
such O
as O
BAONJ. O
A O
PET O
study O
of O
dopamine B-GENE-N
D2 I-GENE-N
and I-GENE-N
serotonin I-GENE-N
5-HT2 I-GENE-N
receptor I-GENE-N
occupancy O
in O
patients O
with O
schizophrenia O
treated O
with O
therapeutic O
doses O
of O
ziprasidone. B-CHEMICAL
OBJECTIVE: O
Ziprasidone B-CHEMICAL
is O
an O
atypical O
antipsychotic O
drug O
that O
shows O
a O
higher O
affinity O
for O
serotonin B-CHEMICAL
5-HT(2) B-GENE-Y
receptors I-GENE-Y
compared O
with O
dopamine B-GENE-Y
D(2) I-GENE-Y
receptors I-GENE-Y
in O
vitro. O
The O
affinity O
of O
ziprasidone B-CHEMICAL
for O
these O
receptors O
in O

vivo O
in O
patients O
was O
examined O
in O
a O
positron O
emission O
tomography O
(PET) O
study. O
METHOD: O
The O
authors O
conducted O
a O
PET O
study O
to O
evaluate O
D(2) B-GENE-Y
occupancy O
(using O
[(11)C]raclopride) B-CHEMICAL
and O
5-HT(2) B-GENE-Y
occupancy O
(using O
[(18)F]setoperone) B-CHEMICAL
in O
brain O
regions O
of O
interest O
in O
16 O
patients O
with O
schizophrenia O
or O
schizoaffective O
disorder O
randomly O
assigned O
to O
receive O
40, O
80, O
120, O
or O
160 O
mg/day O
of O
ziprasidone, B-CHEMICAL
which O
reflected O
the O
recommended O

dose O
range. O
PET O
scanning O
was O
done O
after O
3 O
weeks O
of O
administration O
and O
at O
trough O
plasma O
levels, O
i.e., O
12-16 O
hours O
after O
the O
last O
dose. O
RESULTS: O
The O
mean O
5-HT(2) B-GENE-Y
receptor O
occupancy O
was O
significantly O
higher O
than O
the O
mean O
D(2) B-GENE-Y
receptor I-GENE-Y
occupancy O
(mean=76%, O
SD=15%, O
and O
mean=56%, O
SD=18%, O
respectively). O
The O
estimated O
plasma O
ziprasidone B-CHEMICAL
concentration O
associated O
with O
50% O
maximal O
5-HT(2) B-GENE-Y
receptor O
occupancy O
was O
almost O
four O
times O
lower O

than O
that O
for O
D(2) B-GENE-Y
receptor I-GENE-Y
occupancy. O
CONCLUSIONS: O
These O
data O
affirm O
that O
ziprasidone B-CHEMICAL
is O
similar O
to O
other O
novel O
antipsychotics O
in O
having O
greater O
5-HT(2) B-GENE-Y
than O
D(2) B-GENE-N
receptor I-GENE-N
occupancy O
at O
therapeutic O
doses O
and O
suggest O
that O
the O
optimal O
effective O
dose O
of O
ziprasidone B-CHEMICAL
is O
closer O
to O
120 O
mg/day O
than O
to O
the O
lower O
doses O
suggested O
by O
previous O
PET O
studies. O
The O
relatively O
high O
D(2) B-GENE-Y
receptor I-GENE-Y
occupancy, O
even O
at O
trough O
plasma O
levels, O
suggests O
that O
ziprasidone B-CHEMICAL
is O
more O
similar O

to O
risperidone B-CHEMICAL
and O
olanzapine O
in O
receptor O
occupancy O
profile O
than O
to O
clozapine B-CHEMICAL
and O
quetiapine. B-CHEMICAL
Since O
ziprasidone B-CHEMICAL
plasma O
levels O
show O
significant O
(more O
than O
twofold) O
variation O
within O
a O
single O
dose O
cycle, O
studies O
that O
are O
aimed O
at O
peak O
plasma O
levels O
(6 O
hours O
after O
the O
last O
dose) O
and O
that O
examine O
extrastriatal O
regions O
are O
required O
to O
fully O
characterize O
the O
in O
vivo O
occupancy O
profile O
of O
ziprasidone. B-CHEMICAL
Sulindac B-CHEMICAL
sulfide I-CHEMICAL
inhibits O
epidermal B-GENE-Y
growth I-GENE-Y
factor-induced I-GENE-Y
phosphorylation O
of O
extracellular-regulated B-GENE-N
kinase I-GENE-N

1/2 I-GENE-N
and O
Bad B-GENE-Y
in O
human O
colon O
cancer O
cells. O
Colorectal O
cancer O
is O
the O
second O
leading O
cause O
of O
cancer O
death O
in O
the O
United O
States. O
Nonsteroidal O
anti-inflammatory O
drugs O
including O
sulindac B-CHEMICAL
are O
promising O
chemopreventive O
agents O
for O
colorectal O
cancer. O
Sulindac B-CHEMICAL
and O
selective O
cyclooxygenase B-GENE-Y
(COX)-2 I-GENE-Y
inhibitors O
cause O
regression O
of O
colonic O
polyps O
in O
familial O
polyposis O
patients. O
Sulindac B-CHEMICAL
induces O
apoptotic O
cell O
death O
in O
cancer O
cells O
in O
vitro O
and O
in O
vivo. O
In O
tumor O
cells, O
activation O
of O

extracellular-regulated B-GENE-N
kinase I-GENE-N
(ERK) I-GENE-N
1/2 I-GENE-N
results O
in O
phosphorylation O
of O
several O
ERK1/2 B-GENE-N
effectors, O
including O
the O
proapoptotic O
protein O
Bad. B-GENE-Y
Phosphorylation O
of O
Ser112 B-CHEMICAL
by O
ERK1/2 B-GENE-N
inactivates O
Bad B-GENE-Y
and O
protects O
the O
tumor O
cell O
from O
apoptosis. O
Sulindac B-CHEMICAL
metabolites O
and O
other O
nonsteroidal O
anti-inflammatory O
drugs O
selectively O
inhibit O
ERK1/2 B-GENE-N
phosphorylation O
in O
human O
colon O
cancer O
cells. O
In O
this O
study O
we O
show O
that O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(EGF) B-GENE-Y
strongly O
induces O

phosphorylation O
of O
ERK1/2 B-GENE-N
and O
Bad B-GENE-Y
in O
HT29 O
colon O
cancer O
cells. O
EGF-stimulated B-GENE-Y
phosphorylation O
of O
ERK B-GENE-N
and O
Bad B-GENE-Y
is O
blocked O
by O
pretreatment O
with O
U0126, B-CHEMICAL
a O
selective O
MAP B-GENE-N
kinase I-GENE-N
kinase I-GENE-N
(MKK)1/2 I-GENE-N
inhibitor. O
Similarly, O
pretreatment O
with O
sulindac B-CHEMICAL
sulfide I-CHEMICAL
blocks O
the O
ability O
of O
EGF B-GENE-Y
to O
induce O
ERK1/2 B-GENE-N
and O
Bad B-GENE-Y
phosphorylation, O
but O
also O
down-regulates O
total O
Bad B-GENE-Y
but O
not O
ERK1/2 B-GENE-N
protein O
levels. O
The O
ability O
of O
sulindac B-CHEMICAL
to O

block O
ERK1/2 B-GENE-N
signaling O
by O
the O
EGF B-GENE-Y
receptor I-GENE-Y
may O
account O
for O
at O
least O
part O
of O
its O
potent O
growth-inhibitory O
effects O
against O
cancer O
cells. O
Fibrillar O
Morphology O
of O
Derivatives O
of O
Poly(3-alkylthiophene)s B-CHEMICAL
by O
Solvent O
Vapor O
Annealing: O
Effects O
of O
Conformational O
Transition O
and O
Conjugate O
Length. O
A O
fibrillar O
morphology O
was O
obtained, O
compared O
to O
the O
featherless O
pristine O
films, O
via O
solvent O
annealing O
the O
films O
of O
a O
series O
of O
derivatives O
of O
poly(3-alkylthiophene)s B-CHEMICAL

(P3ATs): B-CHEMICAL
poly(3-dodecylthiophene) B-CHEMICAL
(P3DDT), B-CHEMICAL
poly(3,3‴-didodecyl-quaterthiophene) B-CHEMICAL
(PQT12), B-CHEMICAL
and O
poly(2,5-bis(3-dodecylthiophen-2-yl)thieno[3,2-b]thiophene) B-CHEMICAL
(pBTTT12). B-CHEMICAL
Among O
the O
solvents O
used, O
including O
dichloromethane, B-CHEMICAL
chloroform, B-CHEMICAL

tetrahydrofuran, B-CHEMICAL
and O
carbon B-CHEMICAL
disulfide I-CHEMICAL
(CS2), B-CHEMICAL
CS2 B-CHEMICAL
was O
the O
best O
to O
induce O
fibril O
formation O
because O
its O
solubility O
parameter O
is O
closest O
to O
those O
of O
the O
P3AT B-CHEMICAL
derivatives. O
It O
was O
found O
that O
higher O
critical O
CS2 B-CHEMICAL
vapor O
pressures O
were O
needed O
to O
form O
crystal O
nuclei O
with O
increasing O
conjugation O
length O
and O
molecular O
weight O
of O
the O
P3AT B-CHEMICAL
derivatives; O
i.e., O
the O
critical O
vapor O
pressures O
for O
P3DDT B-CHEMICAL
13.9k O
and O
PQT12 B-CHEMICAL
15.5k O
were O
59.0% O
and O
80.7%, O
respectively, O
and O
there O
were O
no O
nuclei O
of O

fibrils O
for O
pBTTT12 B-CHEMICAL
15.6k O
with O
the O
highest O
conjugation O
length, O
even O
at O
a O
CS2 B-CHEMICAL
vapor O
pressure O
of O
98.3%. O
Meanwhile, O
at O
the O
highest O
vapor O
pressure, O
the O
fibril O
density O
decreased O
with O
increasing O
conjugation O
length O
and O
molecular O
weight O
of O
the O
P3AT B-CHEMICAL
derivatives. O
This O
is O
attributed O
to O
the O
rod-like O
conformation O
prevailing O
for O
polymers O
with O
larger O
conjugation O
length O
and O
higher O
molecular O
weight O
during O
solvent O
annealing, O
making O
the O
conformational O
transition O
toward O
coils O
more O
difficult O
and O
hindering O
diffusion O
of O
molecules. O
The O
results O
presented O
here O
are O
expected O
to O
be O
helpful O
for O
the O
design O
and O
processing O
of O

conjugated O
semiconductor O
polymers. O
Histamine B-GENE-Y
H4 I-GENE-Y
receptor I-GENE-Y
antagonism O
diminishes O
existing O
airway O
inflammation O
and O
dysfunction O
via O
modulation O
of O
Th2 B-GENE-N
cytokines. I-GENE-N
BACKGROUND: O
Airway O
remodeling O
and O
dysfunction O
are O
characteristic O
features O
of O
asthma O
thought O
to O
be O
caused O
by O
aberrant O
production O
of O
Th2 B-GENE-N
cytokines. I-GENE-N
Histamine B-GENE-Y
H4 I-GENE-Y
receptor I-GENE-Y
(H4R) B-GENE-Y
perturbation O
has O
previously O
been O
shown O
to O
modify O
acute O
inflammation O
and O
Th2 B-GENE-N
cytokine I-GENE-N
production O
in O
a O
murine O
model O
of O
asthma. O
We O
examined O

the O
ability O
of O
H4R B-GENE-Y
antagonists O
to O
therapeutically O
modify O
the O
effects O
of O
Th2 B-GENE-N
cytokine I-GENE-N
production O
such O
as O
goblet O
cell O
hyperplasia O
(GCH), O
and O
collagen B-GENE-N
deposition O
in O
a O
sub-chronic O
model O
of O
asthma. O
In O
addition, O
effects O
on O
Th2 O
mediated O
lung O
dysfunction O
were O
also O
determined. O
METHODS: O
Mice O
were O
sensitized O
to O
ovalbumin B-GENE-Y
(OVA) B-GENE-Y
followed O
by O
repeated O
airway O
challenge O
with O
OVA. B-GENE-Y
After O
inflammation O
was O
established O
mice O
were O
dosed O
with O
the O
H4R B-GENE-Y
antagonist, O
JNJ B-CHEMICAL
7777120, I-CHEMICAL
or O

anti-IL-13 B-GENE-Y
antibody O
for O
comparison. O
Airway O
hyperreactivity O
(AHR) O
was O
measured, O
lungs O
lavaged O
and O
tissues O
collected O
for O
analysis. O
RESULTS: O
Therapeutic O
H4R B-GENE-Y
antagonism O
inhibited O
T O
cell O
infiltration O
in O
to O
the O
lung O
and O
decreased O
Th2 B-GENE-N
cytokines I-GENE-N
IL-13 B-GENE-Y
and O
IL-5. B-GENE-Y
IL-13 B-GENE-Y
dependent O
remodeling O
parameters O
such O
as O
GCH O
and O
lung O
collagen B-GENE-N
were O
reduced. O
Intervention O
with O
H4R B-GENE-Y
antagonist O
also O
improved O
measures O
of O
central O
and O
peripheral O
airway O
dysfunction. O

CONCLUSIONS: O
These O
data O
demonstrate O
that O
therapeutic O
H4R B-GENE-Y
antagonism O
can O
significantly O
ameliorate O
allergen O
induced, O
Th2 B-GENE-N
cytokine I-GENE-N
driven O
pathologies O
such O
as O
lung O
remodeling O
and O
airway O
dysfunction. O
The O
ability O
of O
H4R B-GENE-Y
antagonists O
to O
affect O
these O
key O
manifestations O
of O
asthma O
suggests O
their O
potential O
as O
novel O
human O
therapeutics. O
Research O
on O
the O
preparation O
of O
antioxidant O
peptides O
derived O
from O
egg O
white O
with O
assisting O
of O
high-intensity O
pulsed O
electric O
field. O
Egg O
white O
protein O
powder, O
one O
of O
the O
main O
egg O
products, O
was O
hydrolysed O
by O

Alcalase, B-GENE-Y
Trypsin, B-GENE-N
and O
Pepsin B-GENE-N
respectively O
to O
prepare O
antioxidant O
peptides. O
All O
hydrolysates O
were O
assayed O
by O
determination O
of O
reducing O
power O
(RP) O
ability. O
Three O
kinds O
of O
hydrolysates O
were O
prepared O
under O
optimal O
enzymatic O
parameters O
that O
were O
obtained O
from O
the O
preliminary O
one-factor-at-a-time O
(OFAT) O
and O
response O
surface O
methodology O
(RSM) O
experiments. O
The O
results O
showed O
that O
the O
Alcalase B-GENE-Y
hydrolysates O
exerted O
the O
best O
RP O
ability. O
Thereafter, O
the O
Alcalase B-GENE-Y
hydrolysates O
were O
sequentially O

fractionated O
by O
ultra O
filtration O
membranes O
in O
cut-off O
molecular O
weight O
(MW) O
of O
30, O
10, O
and O
1kDa, O
and O
tested O
their O
antioxidant O
activities O
in O
terms O
of O
RP O
ability, O
DPPH B-CHEMICAL
radical O
scavenging O
ability, O
ABTS B-CHEMICAL
radical O
scavenging O
ability, O
and O
FRAP O
assay. O
Effects O
of O
high O
intensity O
pulsed O
electric O
field O
treatment O
were O
further O
investigated O
on O
antioxidant O
peptides O
to O
improve O
their O
activities. O
The O
results O
showed O
that O
Alcalase B-GENE-Y
hydrolysates O
possessed O
the O
strongest O
antioxidant O
ability O
compared O
with O
the O
other O
two O
hydrolysates, O
particularly O
for O

the O
Fraction-3 O
with O
MW O
<1kDa. O
After O
PEF O
treatment, O
this O
fraction O
showed O
a O
significant O
improvement O
of O
RP O
ability O
within O
5h O
(P<0.05). O
Development O
and O
validation O
of O
a O
non-radioactive O
DNA B-GENE-N
polymerase I-GENE-N
assay O
for O
studying O
cytomegalovirus O
resistance O
to O
foscarnet. B-CHEMICAL
Phenotypic O
characterisation O
of O
the O
human B-GENE-Y
cytomegalovirus I-GENE-Y
(HCMV) I-GENE-Y
pUL54 I-GENE-Y
DNA B-GENE-N
polymerase I-GENE-N
is O
a O
useful O
tool O
for O
testing O
for O
mutations O
in O
the O
UL54 B-GENE-Y
gene O
thought O
to O
render O
HCMV O
resistant O
to O
foscarnet. B-CHEMICAL

In O
this O
study, O
an O
in-house O
non-isotopic O
method O
for O
assessing O
polymerase O
enzymatic O
activity O
in O
the O
presence O
and O
absence O
of O
foscarnet B-CHEMICAL
was O
developed O
and O
its O
utility O
for O
HCMV B-GENE-N
polymerase I-GENE-N
phenotyping O
evaluated. O
Polymerase B-GENE-N
activity O
was O
assessed O
by O
monitoring O
the O
incorporation O
of O
digoxigenin-labelled B-CHEMICAL
nucleotides O
into O
the O
growing O
DNA O
chain O
and O
foscarnet B-CHEMICAL
concentrations O
inhibiting O
enzymatic O
activity O
by O
50% O
were O
determined. O
HCMV B-GENE-N
DNA I-GENE-N
polymerases I-GENE-N
were O
synthesised O
in O
vitro O
by O
expression O
of O
UL54 B-GENE-Y
under O
the O
control O
of O
the O
T7 B-GENE-N
promoter. I-GENE-N

Mutations O
of O
interest O
were O
introduced O
into O
the O
wild-type O
UL54 B-GENE-Y
gene O
by O
site-directed O
mutagenesis. O
Mutated O
polymerases B-GENE-N
and O
polymerases B-GENE-N
from O
HCMV O
reference O
strains O
were O
studied. O
The O
activity O
of O
polymerases B-GENE-N
containing O
mutations O
known O
to O
confer O
resistance O
to O
foscarnet B-CHEMICAL
(V715M, B-GENE-N
T700A B-GENE-N
and O
N495K) B-GENE-N
was O
inhibited O
by O
concentrations O
of O
foscarnet B-CHEMICAL
eight O
to O
14 O
times O
higher O
than O
those O
required O
to O
inhibit O
wild-type O
polymerases. B-GENE-N
Our O
in-house O
non-radioactive O
phenotypic O
assay O
was O
sensitive O
and O
reproducible. O
It O
is O
also O

easy O
to O
perform O
and O
could O
provide O
a O
convenient O
method O
for O
characterising O
mutations O
conferring O
resistance O
to O
foscarnet B-CHEMICAL
in O
HCMV. O
In O
vitro O
study O
of O
intestinal O
transport O
of O
fluoride B-CHEMICAL
using O
the O
Caco-2 O
cell O
line. O
Water O
and O
food O
are O
the O
main O
sources O
of O
fluoride B-CHEMICAL
exposure O
and O
therefore O
it O
is O
necessary O
to O
study O
intestinal O
absorption O
in O
order O
to O
make O
a O
correct O
evaluation O
of O
the O
risk/benefit O
associated O
with O
exposure O
to O
fluoride. B-CHEMICAL
The O
present O
study O
characterizes O
intestinal O
transport O
of O
fluoride, B-CHEMICAL
using O
the O
Caco-2 O
cell O
line O
as O
a O
model O
of O
the O
intestinal O

epithelium, O
and O
evaluates O
the O
coefficients O
of O
apparent O
permeability O
and O
intracellular O
accumulation O
in O
various O
conditions O
(pH, O
temperature, O
opening O
of O
cell O
junctions, O
presence O
of O
anions). O
The O
results O
indicate O
that O
fluoride B-CHEMICAL
is O
an O
element O
with O
moderate O
absorption O
(<70%) O
in O
both O
directions O
(absorptive O
and O
secretory). O
Both O
in O
absorption O
(apical-basolateral) O
and O
in O
secretion O
(basolateral-apical) O
there O
is O
transport O
by O
the O
paracellular O
pathway, O
which O
may O
be O
considered O
predominant. O
Absorption O
and O
secretion O
of O
fluoride B-CHEMICAL
increase O
at O
acid O

pH O
levels, O
possibly O
because O
of O
its O
non-ionized O
state O
at O
these O
pHs O
and/or O
because O
of O
participation O
of O
a O
F(-)/H(+) B-GENE-N
cotransporter I-GENE-N
or O
a O
F(-)/OH(-) B-GENE-N
antiporter. I-GENE-N
The O
results O
also O
suggest O
transcellular O
participation O
of O
mechanisms O
involved O
in O
transport O
of O
Cl(-) B-CHEMICAL
and O
of O
an O
active O
transport O
in O
the O
secretory O
direction. O
The O
present O
study O
extend O
the O
knowledge O
on O
the O
cellular O
transport O
of O
fluoride B-CHEMICAL
and O
provide O
the O
basis O
for O
future O
studies O
aimed O
at O
identifying O
potential O
transporters O
involved O
in O
human O
fluoride B-CHEMICAL
absorption. O
Structure O
activity O
relationship O
studies O
of O
tricyclic B-CHEMICAL

bispyran I-CHEMICAL
sulfone I-CHEMICAL
γ-secretase B-GENE-N
inhibitors. O
An O
investigation O
is O
detailed O
of O
the O
structure O
activity O
relationships O
(SAR) O
of O
two O
sulfone B-CHEMICAL
side O
chains O
of O
compound O
(-)-1a O
(SCH B-CHEMICAL
900229), I-CHEMICAL
a O
potent, O
PS1-selective B-GENE-Y
γ-secretase B-GENE-N
inhibitor O
and O
clinical O
candidate O
for O
the O
treatment O
of O
Alzheimer's O
disease. O
Specifically, O
4-CF(3) B-CHEMICAL
and O
4-Br B-CHEMICAL
substituted O
arylsulfone B-CHEMICAL
analogs, O
(-)-1b O
and O
(-)-1c, O
are O
equipotent O
to O
compound O
(-)-1a. O
On O
the O

right O
hand O
side O
chain, O
linker O
size O
and O
terminal O
substituents O
of O
the O
pendant O
sulfone B-CHEMICAL
group O
are O
also O
investigated. O
Formation O
of O
Mallory O
body-like O
inclusions O
and O
cell O
death O
induced O
by O
deregulated O
expression O
of O
keratin B-GENE-Y
18. I-GENE-Y
Mallory O
bodies O
(MBs) O
are O
cytoplasmic O
inclusions O
that O
contain O
keratin B-GENE-Y
8 I-GENE-Y
(K8) B-GENE-Y
and O
K18 B-GENE-Y
and O
are O
present O
in O
hepatocytes O
of O
individuals O
with O
alcoholic B-CHEMICAL
liver O
disease, O
nonalcoholic B-CHEMICAL
steatohepatitis, O
or O
benign O
or O
malignant O
hepatocellular O
neoplasia. O
Mice O
fed O
long O
term O
with O

griseofulvin B-CHEMICAL
are O
an O
animal O
model O
of O
MB O
formation. O
However, O
the O
lack O
of O
a O
cellular O
model O
has O
impeded O
understanding O
of O
the O
molecular O
mechanism O
of O
this O
process. O
Culture O
of O
HepG2 O
cells O
with O
griseofulvin B-CHEMICAL
has O
now O
been O
shown O
to O
induce O
both O
the O
formation O
of O
intracellular O
aggregates O
containing O
K18 B-GENE-Y
as O
well O
as O
an O
increase O
in O
the O
abundance O
of O
K18 B-GENE-Y
mRNA. O
Overexpression O
of O
K18 B-GENE-Y
in O
HepG2, O
HeLa, O
or O
COS-7 O
cells O
also O
induced O
the O
formation O
of O
intracellular O
aggregates O
that O
stained O
with O
antibodies O
to O
ubiquitin B-GENE-N
and O
with O

rhodamine B-CHEMICAL
B I-CHEMICAL
(characteristics O
of O
MBs O
formed O
in O
vivo), O
eventually O
leading O
to O
cell O
death. O
The O
MB-like O
aggregates O
were O
deposited O
around O
centrosomes O
and O
disrupted O
the O
microtubular O
array. O
Coexpression O
of O
K8 B-GENE-Y
with O
K18 B-GENE-Y
restored O
the O
normal O
fibrous O
pattern O
of O
keratin B-GENE-N
distribution O
and O
reduced O
the O
toxicity O
of O
K18. B-GENE-Y
In O
contrast, O
an O
NH(2)-terminal B-CHEMICAL
deletion O
mutant O
of O
K8 B-GENE-Y
promoted O
the O
formation O
of O
intracellular O
aggregates O
even O
in O
the O
absence O
of O
K18 B-GENE-Y
overexpression. O
Deregulated O
expression O
of O
K18, B-GENE-Y
or O
an O
imbalance O
between O

K8 B-GENE-Y
and O
K18, B-GENE-Y
may O
thus O
be O
an O
important O
determinant O
of O
MB O
formation, O
which O
compromises O
the O
function O
of O
centrosomes O
and O
the O
microtubule O
network O
and O
leads O
to O
cell O
death. O
Anti-Ulcerative O
Colitis O
Activity O
of O
Compounds O
from O
Euphorbia O
granuleta O
Forssk. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
anti-ulcerative O
colitis O
(UC) O
activity O
of O
the O
total O
alcohol B-CHEMICAL
extracts O
of O
Euphorbia O
granuleta O
Forssk. O
(Euphorpiaceae), O
isolate O
and O
identify O
the O
active O
compounds O
that O
could O

be O
responsible O
for O
the O
activity, O
in O
addition O
to O
determination O
of O
the O
possible O
mechanism O
of O
action. O
Six O
compounds O
were O
isolated O
and O
identified O
from O
this O
plant: O
three O
phenolic B-CHEMICAL
compounds O
(kampferol, B-CHEMICAL
kampferol-3-glucoside B-CHEMICAL
and O
kampferol-3-galactoside) B-CHEMICAL
in O
addition O
to O
three O
steroidal O
compounds O
(1-ethoxypentacosane, B-CHEMICAL
heptacosan-1-ol B-CHEMICAL
and O
β-sitosterol). B-CHEMICAL
Three O
compounds O
(heptacosan-1-ol, B-CHEMICAL
β-sitosterol B-CHEMICAL
and O

kampferol-3-galactoside) B-CHEMICAL
were O
found O
to O
be O
responsible O
for O
the O
anti-UC O
activity O
of O
E. O
granuleta O
extract. O
The O
anti-UC O
activity O
of O
these O
compounds O
may O
be O
explained O
by O
reducing O
the O
pro-inflammatory O
cytokine B-GENE-N
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-α), B-GENE-Y
in O
addition O
to O
reduction O
of O
colonic O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
contents. O
No O
side O
effects O
were O
reported O
on O
liver O
and O
kidney O
functions. O
The O
active O
compounds O
reduced O
both O
serum O
TNF-α B-GENE-Y
and O
mucosal O
MDA B-CHEMICAL
levels. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons, O

Ltd. O
MDMA- B-CHEMICAL
and O
p-chlorophenylalanine-induced B-CHEMICAL
reduction O
in O
5-HT B-CHEMICAL
concentrations: O
effects O
on O
serotonin B-GENE-Y
transporter I-GENE-Y
densities. O
Low O
levels O
of O
serotonin B-CHEMICAL
may O
reduce O
the O
density O
of O
the O
serotonin B-GENE-Y
transporter I-GENE-Y
(SERT) B-GENE-Y
by O
either O
increasing O
trafficking O
or O
reducing O
synthesis; O
a O
"neuroadaptive O
response". O
To O
determine O
whether O
3,4-methylenedioxymethamphetamine B-CHEMICAL
(MDMA)-induced B-CHEMICAL
reductions O
in O
SERT B-GENE-Y
density O
could O
be O
related O
to O
such O
a O
mechanism, O
p-chlorophenylalanine B-CHEMICAL
or O
MDMA B-CHEMICAL
was O

administered O
to O
rats, O
and O
brain O
serotonin B-CHEMICAL
and O
SERT B-GENE-Y
density O
were O
measured. O
As O
expected, O
both O
treatments O
led O
to O
serotonin B-CHEMICAL
depletion O
1, O
7 O
and O
14 O
days O
later. O
However, O
only O
MDMA B-CHEMICAL
reduced O
SERT B-GENE-Y
density. O
This O
observation O
suggests O
that O
MDMA-induced B-CHEMICAL
reductions O
in O
SERT B-GENE-Y
density O
do O
not O
represent O
neuroadaptive O
responses O
to O
decreased O
levels O
of O
brain O
serotonin, B-CHEMICAL
but O
may O
occur O
in O
response O
to O
some O
other O
stimulus O
or O
to O
the O
neurotoxic O
effects O
of O
MDMA. B-CHEMICAL
Curcumin B-CHEMICAL
improves O
TNBS-induced O
colitis O
in O
rats O
by O
inhibiting O

IL-27 B-GENE-Y
expression O
via O
the O
TLR4/NF-κB B-GENE-Y
signaling O
pathway. O
Curcumin B-CHEMICAL
is O
a O
widely O
used O
spice O
with O
anti-inflammatory O
and O
anticancer O
properties. O
It O
has O
been O
reported O
to O
have O
beneficial O
effects O
in O
experimental O
colitis. O
This O
study O
explored O
whether O
curcumin B-CHEMICAL
improves O
colonic O
inflammation O
in O
a O
rat O
colitis O
model O
through O
inhibition O
of O
the O
TLR4/NF-κB B-GENE-Y
signaling O
pathway O
and O
IL-27 B-GENE-Y
expression. O
After O
induction O
of O
colitis O
with O
2,4,6-trinitrobenzene B-CHEMICAL
sulfonic I-CHEMICAL
acid, I-CHEMICAL
rats O
were O
intragastrically O

administered O
with O
curcumin B-CHEMICAL
or O
sulfasalazine B-CHEMICAL
daily O
for O
one O
week. O
Rat O
intestinal O
mucosa O
was O
collected O
for O
evaluation O
of O
the O
disease O
activity O
index, O
colonic O
mucosa O
damage O
index, O
and O
histological O
score. O
Myeloperoxidase B-GENE-Y
activity O
was O
detected O
by O
immunohistochemistry, O
and O
mRNA O
and O
protein O
expression O
levels O
of O
TLR4, B-GENE-Y
NF-κB, B-GENE-N
and O
IL-27 B-GENE-Y
in O
colonic O
mucosa O
were O
detected O
by O
RT-PCR O
and O
Western O
blot. O
Compared O
with O
the O
untreated O
colitis O
group, O
the O
curcumin-treated B-CHEMICAL

group O
showed O
significant O
decreases O
in O
the O
disease O
activity O
index, O
colonic O
mucosa O
damage O
index, O
histological O
score, O
myeloperoxidase B-GENE-Y
activity, O
and O
expressions O
of O
NF-κB B-GENE-N
mRNA, O
IL-27 B-GENE-Y
mRNA, O
TLR4 B-GENE-Y
protein, O
NF-κB B-GENE-N
p65 B-GENE-Y
protein, O
and O
IL-27 B-GENE-Y
p28 B-GENE-Y
protein O
(p O
< O
0.05). O
TLR4 B-GENE-Y
mRNA O
expression O
did O
not O
differ O
between O
groups. O
Disease O
activity O
index O
decreased O
more O
rapidly O
in O
the O
curcumin-treated B-CHEMICAL
group O
than O
in O
the O
sulfasalazine-treated B-CHEMICAL
group O
(p O
< O
0.05). O
There O
was O

no O
significant O
difference O
in O
TLR4, B-GENE-Y
NF-κB, B-GENE-N
and O
IL-27 B-GENE-Y
mRNA O
and O
proteins O
between O
curcumin-treated B-CHEMICAL
and O
sulfasalazine-treated B-CHEMICAL
groups. O
Curcumin B-CHEMICAL
shows O
significant O
therapeutic O
effects O
on O
2,4,6-trinitrobenzene B-CHEMICAL
sulfonic I-CHEMICAL
acid-induced I-CHEMICAL
colitis O
that O
are O
comparable O
to O
sulfasalazine. B-CHEMICAL
The O
anti-inflammatory O
actions O
of O
curcumin B-CHEMICAL
on O
colitis O
may O
involve O
inhibition O
of O
the O
TLR4/NF-κB B-GENE-Y
signaling O
pathway O
and O
of O
IL-27 B-GENE-Y
expression. O
Bovine B-GENE-N
and I-GENE-N
ovine I-GENE-N

gonadotropin-releasing I-GENE-N
hormone I-GENE-N
(GnRH)-II I-GENE-N
ligand O
precursors O
and O
type B-GENE-N
II I-GENE-N
GnRH I-GENE-N
receptor I-GENE-N
genes O
are O
functionally O
inactivated. O
The O
decapeptide O
sequence O
of O
GnRH-II B-GENE-N
is O
conserved O
in O
all O
jawed O
vertebrate O
species O
studied O
to O
date. O
New O
data O
for O
cattle O
(Bos O
taurus) O
indicates O
a O
gene O
encoding O
GnRH-II B-GENE-Y
decapeptide O
possessing O
arginine B-CHEMICAL
(codon: O
CGG) B-CHEMICAL
rather O
than O
tryptophan B-CHEMICAL
(TGG) B-CHEMICAL
at O
position O
three O
in O
the O
mature O
peptide. O
This O
substitution O
is O
unique. O
We O
confirmed O

the O
DNA O
sequence O
after O
cloning O
part O
of O
the O
bovine B-GENE-Y
prepro-GnRH-II I-GENE-Y
gene. O
Bovine B-GENE-Y
GnRH-II I-GENE-Y
peptide O
was O
synthesized O
and O
pharmacologically O
characterized. O
It O
did O
not O
bind O
to O
mammalian O
GnRH B-GENE-N
receptors I-GENE-N
expressed O
in O
different O
types O
of O
cell O
nor O
did O
it O
exhibit O
agonist O
or O
antagonist O
properties O
on O
types B-GENE-N
I I-GENE-N
or I-GENE-N
II I-GENE-N
GnRH I-GENE-N
receptors I-GENE-N
expressed O
in O
COS-7 O
cells. O
Bovine O
primers O
facilitated O
cloning O
of O
ovine B-GENE-Y
GnRH-II I-GENE-Y
DNA. O
A O
premature O
stop O
codon O
(TGA) O
replaces O
the O
expected O

tryptophan B-CHEMICAL
codon O
at O
position O
seven O
of O
GnRH-II B-GENE-Y
in O
sheep O
DNA. O
Thus, O
both O
species O
possess O
prepro-GnRH-II B-GENE-N
genes O
encoding O
inactive O
peptides, O
as O
previously O
described O
for O
chimpanzee B-GENE-Y
GnRH-II. I-GENE-Y
The O
updated O
bovine B-GENE-Y
type I-GENE-Y
II I-GENE-Y
GnRH I-GENE-Y
receptor I-GENE-Y
gene O
sequence O
revealed O
inactivation O
by O
frame O
shifts, O
premature O
stop O
codons, O
and O
nucleotide B-CHEMICAL
changes O
specifying O
nonconservative O
replacement O
of O
amino B-CHEMICAL
acid I-CHEMICAL
residues, O
similar O
to O
inactivation O
of O
sheep B-GENE-Y
type I-GENE-Y
II I-GENE-Y
GnRH I-GENE-Y
receptor. I-GENE-Y
Spliced O
RNA O
transcripts O

from O
the O
disrupted O
receptor O
gene O
were O
not O
detected O
in O
bovine O
pituitary. O
In O
contrast, O
bovine B-GENE-Y
prepro-GnRH-I I-GENE-Y
and O
type B-GENE-Y
I I-GENE-Y
GnRH I-GENE-Y
receptor I-GENE-Y
genes O
are O
intact, O
encoding O
well-conserved O
protein O
sequences. O
These O
findings, O
and O
previous O
descriptions O
of O
inactivation O
of O
the O
human B-GENE-Y
type I-GENE-Y
II I-GENE-Y
GnRH I-GENE-Y
receptor I-GENE-Y
and O
deletions O
of O
prepro-GnRH-II B-GENE-N
and O
type B-GENE-N
II I-GENE-N
GnRH I-GENE-N
receptor I-GENE-N
in O
laboratory O
rodents, O
suggest O
the O
GnRH-II B-GENE-N
system O
has O
been O
replaced O
by O
the O
GnRH-I B-GENE-N
system O
or O
is O
redundant O
in O
certain O

mammals. O
Biosynthetic O
regulation O
and O
intracellular O
transport O
of O
phosphatidylserine B-CHEMICAL
in O
mammalian O
cells. O
In O
mammalian O
cells, O
phosphatidylserine B-CHEMICAL
(PtdSer) B-CHEMICAL
is O
synthesized O
through O
the O
action O
of O
the O
endoplasmic O
reticulum O
enzymes, O
PtdSer B-GENE-N
synthase I-GENE-N
1 I-GENE-N
and I-GENE-N
2, I-GENE-N
and O
the O
decarboxylation O
of O
PtdSer O
accounts O
for O
the O
majority O
of O
phosphatidylethanolamine B-CHEMICAL
(PtdEtn) B-CHEMICAL
synthesis. O
PtdSer B-CHEMICAL
decarboxylation O
for O

PtdEtn B-CHEMICAL
formation O
occurs O
in O
the O
mitochondria. O
In O
addition, O
the O
transport O
of O
PtdSer B-CHEMICAL
from O
the O
endoplasmic O
reticulum O
to O
the O
mitochondria O
is O
probably O
a O
rate O
limiting O
step O
for O
PtdEtn B-CHEMICAL
synthesis O
through O
the O
decarboxylation O
pathway. O
Therefore, O
the O
regulation O
of O
PtdSer B-CHEMICAL
synthesis O
and O
its O
intracellular O
transport O
appear O
to O
be O
essential O
events O
for O
the O
maintenance O
of O
normal O
cellular O
PtdSer B-CHEMICAL
and O
PtdEtn B-CHEMICAL
levels. O
Here O
we O
describe O
the O
current O
understanding O
of O
the O
regulation O
of O
PtdSer B-CHEMICAL
biosynthesis O
and O

the O
transport O
of O
PtdSer B-CHEMICAL
from O
the O
ER O
to O
the O
mitochondria O
in O
mammalian O
cells. O
Use O
of O
nitisinone B-CHEMICAL
in O
patients O
with O
alkaptonuria. O
Alkaptonuria, O
a O
rare O
autosomal O
recessive O
disorder O
caused O
by O
mutations O
in O
the O
HGD B-GENE-Y
gene O
and O
deficiency O
of O
homogentisate B-GENE-Y
1,2 I-GENE-Y
dioxygenase, I-GENE-Y
is O
characterized O
by O
ochronosis, O
arthritis, O
and O
daily O
excretion O
of O
gram O
quantities O
of O
homogentisic B-CHEMICAL
acid I-CHEMICAL
(HGA). B-CHEMICAL
Nitisinone, O
an O
inhibitor O
of O
the O
enzyme O

4-hydroxyphenylpyruvate B-GENE-Y
dioxygenase, I-GENE-Y
can O
drastically O
reduce O
urinary O
excretion O
of O
HGA B-CHEMICAL
in O
individuals O
with O
alkaptonuria. O
We O
investigated O
the O
safety O
and O
the O
HGA-depleting B-CHEMICAL
efficacy O
of O
nitisinone B-CHEMICAL
in O
an O
open-label, O
single-center O
study O
of O
9 O
alkaptonuria O
patients O
(5 O
women, O
4 O
men; O
35-69 O
years O
of O
age) O
over O
the O
course O
of O
3 O
to O
4 O
months. O
Each O
patient O
received O
nitisinone B-CHEMICAL
in O
incremental O
doses, O
0.35 O
mg O
bid O
followed O
by O
1.05 O
mg O
bid, O
and O
remained O
on O
this O

dosage O
and O
a O
regular O
diet O
for O
3 O
months. O
Nitisinone B-CHEMICAL
reduced O
urinary O
HGA B-CHEMICAL
levels O
from O
an O
average O
of O
4.0 O
+/- O
1.8 O
(SD) O
g/day O
to O
0.2 O
+/- O
0.2 O
g/day O
( O
P O
< O
.001). O
The O
average O
plasma O
tyrosine B-CHEMICAL
concentration, O
initially O
68 O
+/- O
18 O
mmicro O
mol/L, O
rose O
to O
760 O
+/- O
181 O
micro O
mol/L O
( O
P O
< O
.001). O
During O
the O
final O
week O
of O
the O
study, O
5 O
patients O
adhered O
to O
a O
protein-restricted O
diet O
(40 O

g/day), O
and O
their O
mean O
plasma O
tyrosine B-CHEMICAL
level O
fell O
from O
755 O
+/- O
167 O
to O
603 O
+/- O
114 O
mu O
mol/L. O
Six O
of O
the O
7 O
patients O
who O
received O
nitisinone B-CHEMICAL
for O
more O
than O
1 O
week O
reported O
decreased O
pain O
in O
their O
affected O
joints. O
Weekly O
ophthalmologic O
examinations O
showed O
no O
signs O
of O
corneal O
toxicity. O
Adverse O
events O
included O
the O
passing O
of O
kidney O
stones, O
the O
recognition O
of O
symptoms O
related O
to O
aortic O
stenosis, O
and O
elevation O
of O
liver O
transaminase B-GENE-N
levels. O
We O
conclude O
that O
low-dose O
nitisinone B-CHEMICAL
effectively O
reduced O
urinary O
HGA B-CHEMICAL

levels O
in O
patients O
with O
alkaptonuria. O
Future O
long-term O
clinical O
trials O
are O
planned O
to O
determine O
the O
benefits O
of O
nitisinone B-CHEMICAL
in O
preventing O
joint O
deterioration O
and O
providing O
pain O
relief, O
and O
its O
long-term O
side O
effects. O
Functional O
and O
molecular O
characterization O
of O
multiple O
K-Cl B-GENE-N
cotransporter I-GENE-N
isoforms O
in O
corneal O
epithelial O
cells. O
The O
dependence O
of O
regulatory O
volume O
decrease O
(RVD) O
activity O
on O
potassium-chloride B-GENE-N
cotransporter I-GENE-N
(KCC) B-GENE-N
isoform O
expression O
was O
characterized O
in O
corneal O
epithelial O
cells O
(CEC). O
During O
exposure O
to O
a O
50% O

hypotonic O
challenge, O
the O
RVD O
response O
was O
larger O
in O
SV40-immortalized O
human O
CEC O
(HCEC) O
than O
in O
SV40-immortalized O
rabbit O
CEC O
(RCEC). O
A O
KCC B-GENE-N
inhibitor-[(dihydroindenyl)oxy] B-CHEMICAL
alkanoic I-CHEMICAL
acid I-CHEMICAL
(DIOA)-blocked B-CHEMICAL
RVD O
more O
in O
HCEC O
than O
RCEC. O
Under O
isotonic O
conditions, O
N-ethylmaleimide B-CHEMICAL
(NEM) B-CHEMICAL
produced O
KCC B-GENE-N
activation O
and O
transient O
cell O
shrinkage. O
Both O
of O
these O
changes O
were O
greater O
in O
HCEC O
than O
in O
RCEC. O
Immunoblot O

analysis O
of O
HCEC, O
RCEC, O
primary O
human O
CEC O
(pHCEC), O
and O
primary O
bovine O
CEC O
(BCEC) O
plasma O
membrane O
enriched O
fractions O
revealed O
KCC1, B-GENE-N
KCC3, B-GENE-N
and O
KCC4 B-GENE-N
isoform O
expression, O
whereas O
KCC2 B-GENE-N
was O
undetectable. O
During O
a O
hypotonic O
challenge, O
KCC1 B-GENE-N
membrane O
content O
increased O
more O
rapidly O
in O
HCEC O
than O
in O
RCEC. O
Such O
a O
challenge O
induced O
a O
larger O
increase O
and O
more O
transient O
p44/42MAPK B-GENE-N
activation O
in O
HCEC O
than O
RCEC. O
On O
the O
other O
hand, O
HCEC O
and O
RCEC O

p38MAPK B-GENE-N
phosphorylation O
reached O
peak O
activations O
at O
2.5 O
and O
15 O
min, O
respectively. O
Only O
in O
HCEC, O
pharmacological O
manipulation O
of O
KCC B-GENE-N
activity O
modified O
the O
hypotonicity-induced O
activation O
of O
p44/42MAPK, B-GENE-N
whereas O
p38MAPK B-GENE-N
phosphorylation O
was O
insensitive O
to O
such O
procedures O
in O
both O
cell O
lines. O
Larger O
increases O
in O
HCEC O
KCC1 B-GENE-Y
membrane O
protein O
content O
correlated O
with O
their O
ability O
to O
undergo O
faster O
and O
more O
complete O
RVD. O
Furthermore, O
pharmacological O
activation O
of O
KCC B-GENE-N
increased O
p44/42MAPK B-GENE-N

phosphorylation O
in O
HCEC O
but O
not O
in O
RCEC, O
presumably O
a O
reflection O
of O
low O
KCC1 B-GENE-Y
membrane O
expression O
in O
RCEC. O
These O
findings O
suggest O
that O
KCC1 B-GENE-N
plays O
a O
role O
in O
(i) O
maintaining O
isotonic O
steady-state O
cell O
volume O
homeostasis, O
(ii) O
recovery O
of O
isotonic O
cell O
volume O
after O
a O
hypotonic O
challenge O
through O
RVD, O
and O
(iii) O
regulating O
hypotonicity-induced O
activation O
of O
the O
p44/42MAPK B-GENE-N
signaling O
pathway O
required O
for O
cell O
proliferation. O
Changes O
in O
morphometry O
and O
association O
between O
whole-body O
fatty B-CHEMICAL
acids I-CHEMICAL
and O
steroid B-CHEMICAL
hormone O

profiles O
in O
relation O
to O
bioaccumulation O
patterns O
in O
salmon O
larvae O
exposed O
to O
perfluorooctane B-CHEMICAL
sulfonic I-CHEMICAL
or I-CHEMICAL
perfluorooctane I-CHEMICAL
carboxylic I-CHEMICAL
acids. I-CHEMICAL
In O
the O
present O
study, O
we O
have O
used O
salmon O
embryos O
whose O
continuous O
exposure O
to O
waterborne O
PFOA B-CHEMICAL
or O
PFOS B-CHEMICAL
at O
100 O
μg/L O
started O
as O
freshly O
fertilized O
eggs, O
and O
lasted O
for O
a O
total O
of O
52 O
days. O
PFOS B-CHEMICAL
and O
PFOA B-CHEMICAL
were O
dissolved O
in O
methanol B-CHEMICAL
(carrier O
vehicle) O
whose O
concentration O
never O
exceeded O
0.01% O
of O
total O
tank O
volume. O
Samples O
were O
collected O
at O
day O
21, O

28, O
35, O
52, O
49 O
and O
56 O
after O
the O
start O
of O
the O
exposure. O
Note O
that O
days O
49 O
and O
56 O
represent O
end O
of O
exposure O
and O
1 O
week O
after O
a O
recovery O
period, O
respectively. O
Tissue O
bioaccumulations O
were O
determined O
by O
HPLC/MS/MS, O
steroid B-CHEMICAL
hormones, O
fatty B-CHEMICAL
acids I-CHEMICAL
(FAs) B-CHEMICAL
and O
lipids O
were O
determined O
by O
GC-MS, O
while O
mRNA O
expression O
levels O
of O
genes O
were O
determined O
by O
qPCR O
in O
whole O
body O
homogenate. O
We O
observed O
that O
PFOS B-CHEMICAL
and O
PFOA B-CHEMICAL
showed O
a O
steady O
increase O
in O
whole O
body O
burden O
during O
the O
exposure O
period, O
with O
a O
slight O
decrease O
after O
the O

recovery O
period. O
Calculated O
somatic O
indexes O
showed O
that O
PFOA B-CHEMICAL
produced O
increases O
in O
heart-, O
thymus-, O
liver- O
and O
kidney O
somatic O
indexes O
(HSI, O
TSI, O
LSI O
and O
KSI). O
PFOA B-CHEMICAL
and O
PFOS B-CHEMICAL
exposure O
produced O
significant O
decreases O
in O
whole O
body O
dehydroepiandrosterone B-CHEMICAL
(DHEA), B-CHEMICAL
estrone O
and O
testosterone B-CHEMICAL
at O
sampling O
day O
21 O
and O
a O
strong O
increase O
of O
cortisol B-CHEMICAL
and O
cholesterol B-CHEMICAL
at O
the O
end O
of O
recovery O
period O
(day O
56). O
PFOA B-CHEMICAL
and O
PFOS B-CHEMICAL
effects O
differed O
with O
DHEA B-CHEMICAL
and O
estrone. B-CHEMICAL
While O

PFOS B-CHEMICAL
decreased O
DHEA B-CHEMICAL
levels, O
PFOA B-CHEMICAL
produced O
an O
increase O
at O
day O
49, O
and O
while O
PFOS B-CHEMICAL
decreased O
estrone, B-CHEMICAL
PFOA B-CHEMICAL
produced O
a O
slight O
increase O
at O
day O
56. O
We O
observed O
changes O
in O
FA O
composition O
that O
predominantly O
involved O
increases O
in O
FA B-CHEMICAL
methyl I-CHEMICAL
esters I-CHEMICAL
(FAMEs), B-CHEMICAL
mono- B-CHEMICAL
and I-CHEMICAL
poly-unsaturated I-CHEMICAL
FA I-CHEMICAL
(MUFA B-CHEMICAL
and O
PUFA) B-CHEMICAL
and O
a O
decrease O
in O
n-3/n-6 O
PUFA B-CHEMICAL
ratio O
by O
both O
PFOA B-CHEMICAL
and O
PFOS. B-CHEMICAL
Particularly, O
an O
increase O
in O
- O
pentadecenoic B-CHEMICAL
MUFA I-CHEMICAL

(15:1), O
two O
n-3 O
PUFAs B-CHEMICAL
α-linolenic B-CHEMICAL
acid I-CHEMICAL
[ALA: B-CHEMICAL
18:3 O
n3] O
and O
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
[EPA: B-CHEMICAL
20:5 O
n-3] O
and O
n-6 O
PUFA: B-CHEMICAL
arachidonic B-CHEMICAL
acid I-CHEMICAL
[ARA: B-CHEMICAL
20:4 O
n6], O
docosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(DPA) B-CHEMICAL
by O
PFOA B-CHEMICAL
and O
PFOS B-CHEMICAL
were O
observed. O
These O
effects O
were O
associated O
with O
changes O
in O
mRNA O
expression O
of O
FA B-GENE-N
elongase I-GENE-N
(FAE), B-GENE-N
Δ5-desaturase B-GENE-Y

(FAD5) B-GENE-Y
and O
Δ6-desaturase B-GENE-Y
(FAD6) B-GENE-Y
genes. O
In O
summary, O
the O
changes O
in O
hormonal O
and O
FA O
profiles O
may O
represent O
cellular O
and/or O
physiological O
adaptation O
to O
continuous O
PFOS B-CHEMICAL
and O
PFOA B-CHEMICAL
exposure O
by O
increasing O
membrane O
fluidity, O
and/or O
overt O
developmental O
effects. O
The O
present O
findings O
provide O
some O
potential O
insights O
and O
basis O
for O
a O
better O
understanding O
on O
the O
possible O
mechanisms O
of O
PFCs O
toxicity O
in O
fish. O
Drugs O
in O
Development O
for O
Relapsing O
Multiple O
Sclerosis. O
Drug O
development O
for O
multiple O
sclerosis O
(MS), O
as O
with O
any O
other O
neurological O
disease, O
faces O
numerous O
challenges, O
with O

many O
drugs O
failing O
at O
various O
stages O
of O
development. O
The O
disease-modifying O
therapies O
(DMTs) O
first O
introduced O
for O
MS O
are O
only O
moderately O
effective, O
but O
given O
the O
lack O
of O
competition, O
they O
have O
been O
widely O
accepted O
in O
clinical O
practice. O
Although O
safety O
and O
efficacy O
continue O
to O
be O
the O
two O
main O
metrics O
by O
which O
drugs O
will O
be O
judged, O
the O
newer O
agents O
in O
the O
market O
also O
face O
challenges O
of O
a O
more O
comparative O
nature-are O
they O
more O
efficacious O
than O
the O
currently O
available O
drugs O
on O
the O
market? O
Are O
they O
safer O
or O
better O
tolerated? O
Do O
they O
offer O
any O
practical O
advantages O
over O
current O
treatments? O
Fingolimod B-CHEMICAL
represented O
a O
milestone O
following O
its O
approval O
as O

an O
oral O
drug O
for O
MS O
in O
2010, O
offering O
patients O
a O
far O
more O
convenient O
administration O
route. O
However, O
association O
with O
cardiovascular O
complications O
has O
led O
to O
a O
more O
cautious O
approach O
in O
its O
initial O
prescribing, O
now O
requiring O
cardiac O
monitoring O
for O
the O
first O
6 O
h O
as O
well O
as O
subsequent O
monitoring O
of O
blood O
pressure O
and O
for O
macular O
oedema. O
Natalizumab, O
amongst O
licensed O
drugs, O
represents O
the O
current O
benchmark O
for O
efficacy. O
The O
risk O
of O
progressive O
multifocal O
leukoencephalopathy O
during O
natalizumab O
treatment O
is O
now O
more O
quantifiable. O
Other O
monoclonal O
antibodies O
are O
in O
various O
phases O
of O
development. O
Marketing O
authorisation O
for O

alemtuzumab O
has O
been O
filed, O
and O
whilst O
trial O
data O
suggest O
that O
its O
efficacy O
outperforms O
both O
licensed O
drugs O
and O
others O
in O
development, O
there O
is O
a O
significant O
risk O
of O
secondary O
autoimmunity. O
Its O
once-yearly O
administration, O
however, O
seems O
particularly O
advantageous. O
Rituximab O
is O
unlikely O
to O
be O
developed O
further O
as O
its O
license O
will O
expire, O
but O
ocrelizumab, O
another O
monoclonal O
antibody O
directly O
targeting O
B O
cells, O
is O
currently O
in O
phase O
2 O
development O
and O
looks O
promising. O
Daclizumab O
is O
also O
moderately O
efficacious O
but O
may O
struggle O
to O
establish O
itself O
given O
its O
monthly O

subcutaneous O
dosing. O
There O
are O
new O
oral O
drugs O
in O
development, O
and O
it O
is O
likely O
that O
BG-12 B-CHEMICAL
will O
be O
licensed O
this O
year. O
This O
has O
been O
licensed O
for O
psoriasis O
so O
there O
are O
good O
safety O
data O
in O
humans O
that O
may O
also O
hold O
true O
in O
MS; O
however, O
its O
three O
times O
daily O
dosage O
will O
probably O
impact O
on O
patient O
compliance. O
Laquinimod B-CHEMICAL
has O
lower O
efficacy O
than O
BG-12 B-CHEMICAL
but O
appears O
safe O
and O
could O
find O
a O
place O
as O
a O
first-line O
agent. O
Teriflunomide B-CHEMICAL
has O
just O
been O
licensed O
by O
the O
US O
FDA O
and O
may O
challenge O
the O
current O
injectable O
first-line O
therapies O
as O
it O

has O
a O
similar O
efficacy O
but O
the O
advantage O
of O
being O
taken O
orally. O
However, O
risk O
of O
teratogenicity O
may O
caution O
against O
its O
use O
in O
some O
women O
of O
child-bearing O
potential. O
This O
review O
will O
examine O
drugs O
that O
have O
been O
recently O
approved O
as O
well O
as O
those O
that O
are O
in O
late O
phase O
2 O
or O
3 O
development O
as O
treatment O
for O
relapsing O
MS, O
highlighting O
their O
mechanism O
of O
action O
as O
well O
as O
the O
clinical O
trial O
and O
safety O
data O
before O
discussing O
their O
potential O
for O
success O
in O
an O
increasingly O
florid O
and O
complex O
DMT O
armamentarium. O
Toxicity O
of O
the O
flame-retardant O
BDE-49 B-CHEMICAL
on O
brain O
mitochondria O
and O
neuronal O
progenitor O

striatal O
cells O
enhanced O
by O
a O
PTEN-deficient B-GENE-Y
background. O
Polybrominated B-CHEMICAL
diphenyl I-CHEMICAL
ethers I-CHEMICAL
(PBDEs) B-CHEMICAL
represent O
an O
important O
group O
of O
flame O
retardants O
extensively O
used, O
tonnage O
of O
which O
in O
the O
environment O
has O
been O
steadily O
increasing O
over O
the O
past O
25 O
years. O
PBDEs B-CHEMICAL
or O
metabolites O
can O
induce O
neurotoxicity O
and O
mitochondrial O
dysfunction O
(MD) O
through O
a O
variety O
of O
mechanisms. O
Recently, O
PBDEs B-CHEMICAL
with O
< O
5 O
Br B-CHEMICAL
substitutions O
(i.e., O
2,2',4,4'-tetrabromodiphenyl B-CHEMICAL

ether I-CHEMICAL
[BDE-47] B-CHEMICAL
and O
2,2',4,5'-tetrabromodiphenyl B-CHEMICAL
ether I-CHEMICAL
[BDE-49]) B-CHEMICAL
have O
gained O
interest O
because O
of O
their O
high O
bioaccumulation. O
In O
particular, O
congeners O
such O
as O
BDE-49 B-CHEMICAL
arise O
as O
one O
of O
the O
most O
biologically O
active, O
with O
concentrations O
typically O
lower O
than O
those O
observed O
for O
BDE-47 B-CHEMICAL
in O
biological O
tissues; O
however, O
its O
potential O
to O
cause O
MD O
at O
biologically O
relevant O
concentrations O
is O
unknown. O
To O
this O
end, O
the O
effect O
of O
BDE-49 B-CHEMICAL
was O
studied O
in O
brain O
mitochondria O
and O
neuronal O

progenitor O
striatal O
cells O
(NPC). O
BDE-49 B-CHEMICAL
uncoupled O
mitochondria O
at O
concentrations O
< O
0.1 O
nM, O
whereas O
at O
> O
1 O
nM, O
it O
inhibited O
the O
electron O
transport O
at O
Complex O
V O
(mixed O
type O
inhibition; O
IC(50) O
= O
6 O
nM) O
and O
Complex O
IV O
(noncompetitive O
inhibition; O
IC(50) O
= O
40 O
nM). O
These O
concentrations O
are O
easily O
achieved O
in O
plasma O
concentrations O
considering O
that O
BDE-49 B-CHEMICAL
(this O
study, O
400-fold) O
and O
other O
PBDEs B-CHEMICAL
accumulate O
1-3 O
orders O
of O

magnitude O
in O
the O
cells, O
particularly O
in O
mitochondria O
and O
microsomes. O
Similar O
effects O
were O
observed O
in O
NPC O
and O
exacerbated O
with O
PTEN B-GENE-Y
(negative O
modulator O
of O
the O
PI3K/Akt B-GENE-N
pathway) O
deficiency, O
background O
associated O
with O
autism-like O
behavior, O
schizophrenia, O
and O
epilepsy. O
PBDE-mediated B-CHEMICAL
MD O
per O
se O
or O
enhanced O
by O
a O
background O
that O
confers O
susceptibility O
to O
this O
exposure O
may O
have O
profound O
implications O
in O
the O
energy O
balance O
of O
brain. O
Pharmacological O
properties O
of O
lorglumide B-CHEMICAL
as O
a O
member O
of O
a O
new O
class O
of O
cholecystokinin B-GENE-Y

antagonists. O
Derivatives O
of O
5-(dipentylamino)-5-oxo-pentanoic B-CHEMICAL
acid I-CHEMICAL
are O
a O
new O
class O
of O
non-peptide O
cholecystokinin B-GENE-Y
(CCK) B-GENE-Y
antagonists. O
The O
most O
potent O
compound, O
D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen B-CHEMICAL
tanoic I-CHEMICAL
acid I-CHEMICAL
(lorglumide, B-CHEMICAL
CR B-CHEMICAL
1409), I-CHEMICAL
has O
a O
great O
affinity O
for O
the O
pancreatic O
CCK B-GENE-N
receptors I-GENE-N
and O
is O
a O
competitive, O
specific O
and O

potent O
CCK B-GENE-Y
antagonist O
on O
the O
smooth O
muscles O
of O
the O
gall O
bladder O
and O
ileum O
of O
the O
guinea O
pig O
and O
on O
the O
CCK-induced B-GENE-Y
amylase B-GENE-N
secretion O
of O
isolated O
pancreatic O
acini. O
In O
vivo O
lorglumide B-CHEMICAL
antagonizes O
the O
contraction O
of O
the O
gall O
bladder O
of O
the O
guinea O
pig O
and O
of O
the O
dog O
provoked O
by O
i.v. O
CCK-8 B-GENE-N
or O
ceruletide B-CHEMICAL
(caerulein). B-CHEMICAL
It O
antagonizes O
the O
satiety O
effect O
of O
CCK-8 B-GENE-Y
in O
the O
rat O
and O
is O
protective O
against O
ceruletide-, B-CHEMICAL
taurocholate- B-CHEMICAL
and O

diet-induced O
pancreatitis. O
Lorglumide B-CHEMICAL
is O
therefore O
a O
useful O
pharmacological O
tool O
to O
study O
the O
functions O
of O
CCK. B-GENE-Y
For O
its O
pharmacological O
properties, O
its O
relatively O
low O
toxicity O
and O
because O
it O
is O
active O
also O
after O
oral O
administration, O
lorglumide B-CHEMICAL
is O
a O
candidate O
for O
diagnostic O
or O
therapeutic O
use O
in O
man O
when O
an O
involvement O
of O
CCK B-GENE-Y
is O
suspected. O
Synthesis O
and O
Structure-Activity O
Relationship O
Studies O
of O
Derivatives O
of O
the O
Dual O
Aromatase-Sulfatase B-GENE-Y
Inhibitor O

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl B-CHEMICAL
sulfamate. I-CHEMICAL
4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl B-CHEMICAL
sulfamate I-CHEMICAL
and O
its O
ortho-halogenated O
(F, B-CHEMICAL
Cl, B-CHEMICAL
Br) B-CHEMICAL
derivatives O
are O
first-generation O
dual O
aromatase B-GENE-Y
and O
sulfatase B-GENE-Y
inhibitors O

(DASIs). O
Structure-activity O
relationship O
studies O
were O
performed O
on O
these O
compounds, O
and O
various O
modifications O
were O
made O
to O
their O
structures O
involving O
relocation O
of O
the O
halogen B-CHEMICAL
atom, O
introduction O
of O
more O
halogen B-CHEMICAL
atoms, O
replacement O
of O
the O
halogen B-CHEMICAL
with O
another O
group, O
replacement O
of O
the O
methylene B-CHEMICAL
linker O
with O
a O
difluoromethylene B-CHEMICAL
linker, O
replacement O
of O
the O
para-cyanophenyl B-CHEMICAL
ring O
with O
other O
ring O
structures, O
and O
replacement O
of O
the O
triazolyl B-CHEMICAL
group O
with O
an O
imidazolyl B-CHEMICAL
group. O
The O
most O
potent O
in O
vitro O
DASI O
discovered O
is O
an O
imidazole B-CHEMICAL
derivative O

with O
IC50 O
values O
against O
aromatase B-GENE-Y
and O
steroid B-GENE-Y
sulfatase I-GENE-Y
in O
a O
JEG-3 O
cell O
preparation O
of O
0.2 O
and O
2.5 O
nM, O
respectively. O
The O
parent O
phenol B-CHEMICAL
of O
this O
compound O
inhibits O
aromatase B-GENE-Y
with O
an O
IC50 O
value O
of O
0.028 O
nM O
in O
the O
same O
assay. O
The O
circadian O
clock O
circuitry O
and O
the O
AHR B-GENE-Y
signaling O
pathway O
in O
physiology O
and O
pathology. O
Life O
forms O
populating O
the O
Earth O
must O
face O
environmental O
challenges O
to O
assure O
individual O
and O
species O
survival. O
The O
strategies O
predisposed O
to O
maintain O
organismal O
homeostasis O
and O
grant O
selective O
advantage O
rely O
on O

anticipatory O
phenomena O
facing O
periodic O
modifications, O
and O
compensatory O
phenomena O
facing O
unpredictable O
changes. O
Biological O
processes O
bringing O
about O
these O
responses O
are O
respectively O
driven O
by O
the O
circadian O
timing O
system, O
a O
complex O
of O
biological O
oscillators O
entrained O
to O
the O
environmental O
light/dark O
cycle, O
and O
by O
regulatory O
and O
metabolic O
networks O
that O
precisely O
direct O
the O
body's O
adjustments O
to O
variations O
of O
external O
conditions O
and O
internal O
milieu. O
A O
critical O
role O
in O
organismal O
homeostatic O
functions O
is O
played O
by O
the O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AHR) B-GENE-Y
complex, O
which O
senses O
environmental O
and O
endogenous O
compounds, O
influences O
metabolic O
responses O
controlling O
phase O
I/II O
gene O

expression, O
and O
modulates O
vital O
phenomena O
such O
as O
development, O
inflammation O
and O
adaptive O
immunity. O
A O
physiological O
cross-talk O
between O
circadian O
and O
AHR B-GENE-Y
signaling O
pathways O
has O
been O
evidenced. O
The O
alteration O
of O
AHR B-GENE-Y
signaling O
pathway O
deriving O
from O
genetic O
damage O
with O
polymorphisms O
or O
mutations, O
or O
produced O
by O
exogenous O
or O
endogenous O
AHR B-GENE-Y
activation, O
and O
chronodisruption O
caused O
by O
mismatch O
between O
the O
body's O
internal O
clock O
and O
geophysical O
time/social O
schedules, O
are O
capable O
of O
triggering O
pathological O
mechanisms O
involved O
in O
metabolic, O
immune-related O
and O
neoplastic O
diseases. O
On O
the O
other O

hand, O
the O
molecular O
components O
of O
the O
circadian O
clock O
circuitry O
and O
AHR B-GENE-Y
signaling O
pathway O
may O
represent O
useful O
tools O
for O
preventive O
interventions O
and O
valuable O
targets O
of O
therapeutic O
approaches. O
Protective O
effect O
of O
cinnamon O
polyphenols B-CHEMICAL
against O
STZ-diabetic B-CHEMICAL
mice O
fed O
high-sugar, O
high-fat O
diet O
and O
its O
underlying O
mechanism. O
This O
study O
was O
designed O
to O
investigate O
the O
potential O
effects O
of O
14days' O
intragastrically O
given O
of O
cinnamon O
polyphenols B-CHEMICAL
(CPS) O
in O
treating O
diabetic O
mice O
induced O
by O
intraperitoneal O
injection O
of O
streptozotocin B-CHEMICAL

(150mgkg(-1)) O
and O
fed O
high-sugar, B-CHEMICAL
high-fat O
diet. O
The O
diabetic O
mice O
model O
was O
successfully O
established O
through O
determining O
on O
fasting O
blood-glucose B-CHEMICAL
(FBG) O
test. O
As O
revealed O
by O
glucose B-GENE-N
oxidase I-GENE-N
(GOD) O
and O
radioimmunoassay O
(RIA), O
both O
dimethyldiguanide B-CHEMICAL
(DC, O
0.6gkg(-1)d(-1)) O
and O
CPS O
(0.3, O
0.6, O
1.2gkg(-1)d(-1)) O
treatments O

significantly O
resulted O
in O
down-regulation O
of O
blood O
glucose B-CHEMICAL
and O
insulin B-GENE-N
levels O
in O
serum, O
while O
the O
levels O
of O
oxidative O
stress O
markers O
were O
markedly O
lowered O
through O
ELISA O
assay. O
Meanwhile, O
the O
pathological O
damage O
in O
islet O
with O
pancreatic O
beta O
cells O
was O
ameliorated O
by O
treatment O
of O
CPS O
at O
different O
doses, O
as O
shown O
in O
HE O
stain. O
At O
the O
same O
time, O
the O
treatments O
also O
caused O
notable O
reduction O
of O
iNOS, B-GENE-Y
NF-κB B-GENE-N
expressions O
showing O
in O
Western O
blot O
analysis. O
These O
findings O
demonstrate O
that O
cinnamon O
polyphenols B-CHEMICAL
can O
exert O
the O
hypoglycemic O
and O

hypolipidemic O
effects O
through O
the O
mechanisms O
that O
may O
be O
associated O
with O
repairing O
pancreatic O
beta O
cells O
in O
diabetic O
mice O
and O
improving O
its O
anti-oxidative O
capacity, O
as O
well O
as O
attenuating O
cytotoxicity O
via O
inhibition O
of O
iNOS, B-GENE-Y
NF-κB B-GENE-N
activation. O
Nonadrenergic O
imidazoline B-CHEMICAL
binding O
sites O
on O
human O
platelets. O
Human O
platelets O
are O
shown O
to O
possess O
at O
least O
two O
high-affinity, O
imidazol(in)e-preferring B-CHEMICAL
binding O
sites O
that O
are O
pharmacologically O
distinct O
from O
alpha-2 B-GENE-N
adrenoceptors. I-GENE-N
These O

nonadrenergic O
sites O
were O
radiolabeled O
even O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine B-CHEMICAL
mask O
of O
alpha-2 B-GENE-N
adrenoceptors. I-GENE-N
Heterogeneity O
at O
the O
nonadrenergic O
sites O
was O
demonstrated O
by O
comparing O
[3H]idazoxan B-CHEMICAL
(IDX) B-CHEMICAL
binding O
vs. O
[125I]p-iodoclonidine B-CHEMICAL
(PIC) B-CHEMICAL
binding. O
Nonadrenergic O
[125I]PIC-labeled B-CHEMICAL
sites O
were O
enriched O
in O
platelet O
plasma O
membranes, O
whereas O
the O
nonadrenergic O
sites O
labeled O
by O
[3H] B-CHEMICAL
IDX I-CHEMICAL

were O
codistributed O
between O
plasma O
and O
internal O
membranes O
(nonadrenergic O
[125I]PIC-labeled B-CHEMICAL
sites O
had O
Bmax O
= O
62 O
fmol/mg O
in O
plasma O
membranes O
and O
20 O
fmol/mg O
in O
internal O
membranes O
vs. O
the O
[3H]IDX-labeled B-CHEMICAL
sites O
had O
Bmax O
= O
141 O
fmol/mg O
in O
plasma O
membranes O
and O
192 O
fmol/mg O
in O
internal O
membranes). O
Furthermore, O
competition O
binding O
studies O
in O
the O
presence O
of O
a O
10 O
microM O
norepinephrine B-CHEMICAL
mask O
revealed O
major O
(approximately O
75%) O
and O
minor O
(approximately O
25%) O
binding O
components O
on O

plasma O
membranes O
for O
[125I]PIC. B-CHEMICAL
Affinities O
for O
the O
major O
nonadrenergic O
[125I]PIC B-CHEMICAL
binding O
site O
were O
highly O
comparable O
to O
human B-GENE-Y
subtype-I1 I-GENE-Y
imidazol(in)e I-GENE-Y
receptor I-GENE-Y
sites O
in O
the O
brain O
stem O
(rank O
order: O
moxonidine B-CHEMICAL
> O
clonidine B-CHEMICAL
> O
cirazoline B-CHEMICAL
> O
IDX B-CHEMICAL
> O
amiloride). B-CHEMICAL
However, O
the O
minor O
component O
of O
[125I]PIC B-CHEMICAL
binding O
was O
similar O
to O
a O
site O
reported O
in O
kidney, O
having O
low O
affinities O
for O
all O
compounds O
tested, O
except O
guanabenz. B-CHEMICAL
Finally, O
a O
third O

nonadrenergic O
internal O
membrane O
site, O
labeled O
by O
[3H]IDX, B-CHEMICAL
was O
consistent O
with O
a O
subtype-I2 B-GENE-N
imidazol(in)e I-GENE-N
receptor I-GENE-N
site O
(rank O
order: O
cirazoline B-CHEMICAL
> O
IDX O
>> O
amiloride B-CHEMICAL
> O
moxonidine B-CHEMICAL
> O
clonidine). B-CHEMICAL
Thus, O
based O
on O
differential O
subcellular O
distributions O
and O
affinity O
constants, O
human O
platelets O
appear O
to O
possess O
imidazoline B-GENE-N
receptors I-GENE-N
(subtype-I1 B-GENE-Y
imidazol(in)e I-GENE-Y
receptor I-GENE-Y
and O
subtype-I2 B-GENE-N
imidazol(in)e I-GENE-N
receptor), I-GENE-N
plus O
a O
novel O

guanabenz-sensitive B-CHEMICAL
site, O
as O
well O
as O
an O
alpha-2A B-GENE-Y
adrenoceptor. I-GENE-Y
These O
nonadrenoceptor O
binding O
sites O
may O
explain O
certain O
novel O
platelet O
aggregatory O
properties O
previously O
ascribed O
to O
clonidine B-CHEMICAL
and O
endogenous O
clonidine-displacing B-CHEMICAL
substance(s), O
and O
may O
serve O
as O
markers O
of O
imidazoline B-GENE-N
receptors I-GENE-N
in O
humans. O
Age O
dependent O
differences O
in O
the O
regulation O
of O
hippocampal O
steroid B-CHEMICAL
hormones O
and O
receptor O
genes: O
relations O
to O
motivation O
and O
cognition O
in O
male O
rats. O
Estrogen B-CHEMICAL
and O
estrogenic O
functions O
are O
age-dependently O
involved O
in O
the O

modulation O
of O
learning, O
memory O
and O
mood O
in O
female O
humans O
and O
animals. O
However, O
the O
investigation O
of O
estrogenic O
effects O
in O
males O
has O
been O
largely O
neglected. O
Therefore, O
we O
investigated O
the O
hippocampal O
gene O
expression O
of O
estrogen B-GENE-N
receptors I-GENE-N
α I-GENE-N
and I-GENE-N
β I-GENE-N
(ERα, B-GENE-N
β) I-GENE-N
in O
8-week-old, O
12-week-old O
and O
24-week-old O
male O
rats. O
To O
control O
for O
possible O
interactions O
between O
the O
expression O
of O
the O
estrogen B-GENE-Y
receptor I-GENE-Y
genes O
and O
other O
learning-related O
steroid B-GENE-N
receptors, I-GENE-N
androgen B-GENE-Y
receptors I-GENE-Y
(AR), B-GENE-Y
corticosterone-binding B-CHEMICAL
glucocorticoid B-GENE-Y
receptors I-GENE-Y
(GR) B-GENE-Y
and O

mineralocorticoid B-GENE-Y
receptors I-GENE-Y
(MR) B-GENE-Y
were O
also O
measured. O
Furthermore, O
the O
concentrations O
of O
the O
ligands O
17β-estradiol, B-CHEMICAL
testosterone B-CHEMICAL
and O
corticosterone B-CHEMICAL
were O
measured. O
The O
spatial O
training O
was O
conducted O
in O
a O
hole-board. O
The O
8-week-old O
rats O
exhibited O
higher O
levels O
of O
general O
activity O
and O
exploration O
during O
the O
training O
and O
performed O
best O
with O
respect O
to O
spatial O
learning O
and O
memory, O
whereas O
no O
difference O
was O
found O
between O
the O
12-week-old O
and O
24-week-old O
rats. O
The O
trained O
8-week-old O
rats O
exhibited O
increased O
gene O
expression O
of O
ERα B-GENE-Y
compared O
with O
the O
untrained O
rats O
in O
this O
age O
group O

as O
well O
as O
the O
trained O
12-week-old O
and O
24-week-old O
rats. O
The O
concentrations O
of O
estradiol B-CHEMICAL
and O
testosterone, B-CHEMICAL
however, O
were O
generally O
higher O
in O
the O
24-week-old O
rats O
than O
in O
the O
8-week-old O
and O
12-week-old O
rats. O
The O
ERα B-GENE-Y
mRNA O
concentrations O
correlated O
positively O
with O
behavior O
that O
indicate O
general O
learning O
motivation. O
These O
results O
suggest O
a O
specific O
role O
of O
ERα B-GENE-Y
in O
the O
age-related O
differences O
in O
motivation O
and O
subsequent O
success O
in O
the O
task. O
Thus, O
estrogen B-CHEMICAL
and O
estrogenic O
functions O
may O
play O
a O
more O
prominent O
role O
in O
young O
male O
behavior O
and O
development O
than O
has O
been O
previously O
assumed. O
Effects O
of O

ORF B-CHEMICAL
17583, I-CHEMICAL
other O
histamine B-GENE-N
H2-receptor I-GENE-N
antagonists O
and O
omeprazole B-CHEMICAL
on O
gastric O
acid O
secretory O
states O
in O
rats O
and O
dogs. O
ORF B-CHEMICAL
17583, I-CHEMICAL
a O
histamine B-GENE-N
H2-receptor I-GENE-N
antagonist, O
inhibited O
gastric O
acid O
secretion O
in O
pylorus-ligated O
rats O
(ED50 O
= O
4.9 O
mg/kg O
intraduodenal; O
3.4 O
mg/kg O
p.o.; O
and O
0.21 O
mg/kg O
i.p.) O
and O
in O
total O
gastric O
fistula O
or O
Heidenhain O
pouch O
dogs O
stimulated O
by O
betazole B-CHEMICAL

(ED50 O
= O
0.12 O
mg/kg O
p.o. O
and O
0.08 O
mg/kg O
i.v.), O
histamine, B-CHEMICAL
tetragastrin, B-CHEMICAL
bethanechol, B-CHEMICAL
2-deoxy-D-glucose B-CHEMICAL
or O
a O
meal O
(ED50 O
values O
ranged O
from O
0.11-0.26 O
mg/kg O
p.o.). O
The O
nonspecific O
inhibition O
of O
gastric O
acid O
by O
ORF B-CHEMICAL
17583 I-CHEMICAL
supports O
the O
existence O
of O
interdependence O
between O
histamine B-GENE-N
and I-GENE-N
the I-GENE-N
gastrin I-GENE-N
and I-GENE-N
cholinergic I-GENE-N
receptors I-GENE-N
on O
the O
parietal O
cell O
surface. O
Antisecretory O

potency O
of O
ORF B-CHEMICAL
17583 I-CHEMICAL
after O
intraduodenal O
administration O
in O
pylorus-ligated O
rats O
was O
6.4 O
times O
greater O
than O
cimetidine, B-CHEMICAL
1.8 O
times O
greater O
than O
ranitidine, B-CHEMICAL
equal O
to O
that O
of O
omeprazole B-CHEMICAL
and O
8 O
times O
less O
than O
that O
of O
famotidine. B-CHEMICAL
Oral O
antisecretory O
potency O
of O
ORF B-CHEMICAL
17583 I-CHEMICAL
in O
gastric O
fistula O
dogs O
was O
31 O
times O
greater O
than O
cimetidine, B-CHEMICAL
3.7 O
times O
greater O
than O
ranitidine B-CHEMICAL
and O
equal O
to O
that O
of O
omeprazole B-CHEMICAL
and O
famotidine. B-CHEMICAL
Studies O
using O

equieffective O
antisecretory O
doses O
of O
ORF B-CHEMICAL
17583 I-CHEMICAL
and O
ranitidine B-CHEMICAL
in O
dogs O
suggested O
that O
ORF B-CHEMICAL
17583 I-CHEMICAL
has O
a O
short O
duration O
of O
antisecretory O
activity O
similar O
to O
that O
of O
ranitidine. B-CHEMICAL
Platelet-derived O
microparticles O
in O
overweight/obese O
women O
with O
the O
polycystic O
ovary O
syndrome. O
A O
substantial O
proportion O
of O
women O
with O
the O
polycystic O
ovary O
syndrome O
(PCOS) O
are O
obese O
and O
obesity O
is O
considered O
as O
a O
prothrombotic O
state. O
Platelet-derived O
microparticles O
(PMPs) O
might O
be O
implicated O
in O
the O
activation O
of O

the O
coagulation O
cascade. O
We O
aimed O
to O
assess O
plasma O
PMPs O
in O
overweight/obese O
women O
with O
PCOS. O
We O
measured O
plasma O
PMPs O
and O
determined O
anthropometric, O
metabolic, O
hormonal O
and O
ultrasonographic O
features O
of O
PCOS O
in O
67 O
overweight/obese O
women O
with O
PCOS O
(with O
body O
mass O
index O
[BMI] O
>25.0 O
kg/m(2)) O
and O
in O
21 O
BMI-matched O
healthy O
women. O
Circulating O
androgens B-CHEMICAL
and O
markers O
of O
insulin B-GENE-Y
resistance O
(IR) O
were O
higher O
in O
women O
with O
PCOS O
than O
in O
controls. O
Plasma O
PMPs O

were O
also O
higher O
in O
women O
with O
PCOS O
than O
in O
controls O
(p O
= O
0.046). O
In O
women O
with O
PCOS, O
plasma O
PMPs O
correlated O
with O
the O
mean O
number O
of O
follicles O
in O
the O
ovaries O
(r O
= O
0.343; O
p O
= O
0.006). O
In O
controls, O
plasma O
PMPs O
did O
not O
correlate O
with O
any O
of O
the O
studied O
parameters. O
In O
conclusion, O
plasma O
PMPs O
are O
elevated O
in O
overweight/obese O
women O
with O
PCOS O
compared O
with O
BMI-matched O
controls. O
The O
cause O
of O
this O
increase O
is O
unclear O
but O
both O
IR O
and O
hyperandrogenemia O
might O
be O
implicated. O
More O

studies O
are O
required O
to O
elucidate O
the O
pathogenesis O
of O
the O
elevation O
of O
PMPs O
in O
PCOS O
and O
to O
assess O
its O
implications O
on O
the O
cardiovascular O
risk O
of O
these O
patients. O
Underexpression O
of O
the O
Na+-dependent B-GENE-N
neutral I-GENE-N
amino I-GENE-N
acid I-GENE-N
transporter I-GENE-N
ASCT2 B-GENE-Y
in O
the O
spontaneously O
hypertensive O
rat O
kidney. O
This O
study O
examined O
the O
inward O
transport O
of O
l-[(14)C]alanine, B-CHEMICAL
an O
ASCT2 B-GENE-Y
preferential O
substrate, O
in O
monolayers O
of O
immortalized O
renal O
proximal O
tubular O
epithelial O
(PTE) O
cells O
from O
Wistar-Kyoto O
(WKY) O
and O
spontaneously O

hypertensive O
(SHR) O
rats. O
The O
expression O
of O
ASCT2 B-GENE-Y
in O
WKY O
and O
SHR O
PTE O
cells O
and O
kidney O
cortices O
from O
WKY O
and O
SHR O
was O
also O
evaluated. O
l-[(14)C]alanine B-CHEMICAL
uptake O
was O
highly O
dependent O
on O
extracellular O
Na(+). B-CHEMICAL
Replacement O
of O
NaCl B-CHEMICAL
by O
LiCl B-CHEMICAL
or O
choline B-CHEMICAL
chloride I-CHEMICAL
abolished O
transport O
activity O
in O
SHR O
and O
WKY O
PTE O
cells. O
In O
the O
presence O
of O
the O
system O
L O
inhibitor O
BCH, O
Na(+)-dependent B-CHEMICAL
l-alanine B-CHEMICAL
uptake O
in O
WKY O
and O
SHR O

PTE O
cells O
was O
inhibited O
by O
alanine, B-CHEMICAL
serine, B-CHEMICAL
and O
cysteine, B-CHEMICAL
which O
is O
consistent O
with O
amino B-CHEMICAL
acid I-CHEMICAL
transport O
through O
ASCT2. B-GENE-Y
The O
saturable O
component O
of O
Na(+)-dependent B-CHEMICAL
l-alanine B-CHEMICAL
transport O
under O
V(max) O
conditions O
in O
SHR O
PTE O
cells O
was O
one-half O
of O
that O
in O
WKY O
PTE O
cells, O
with O
similar O
K(m) O
values. O
Differences O
in O
magnitude O
of O
Na(+)-dependent B-CHEMICAL
l-alanine B-CHEMICAL
uptake O
through O
ASCT2 B-GENE-Y
between O
WKY O
and O
SHR O
PTE O
cells O
correlated O
positively O
with O
differences O
in O
ASCT2 B-GENE-Y

protein O
expression, O
this O
being O
more O
abundant O
in O
WKY O
PTE O
cells. O
Abundance O
of O
ASCT2 B-GENE-Y
transcript O
and O
protein O
in O
kidney O
cortices O
of O
SHR O
rats O
was O
also O
lower O
than O
that O
in O
normotensive O
WKY O
rats. O
In O
conclusion, O
immortalized O
SHR O
and O
WKY O
PTE O
cells O
take O
up O
l-alanine B-CHEMICAL
mainly O
through O
a O
high-affinity O
Na(+)-dependent B-GENE-N
amino I-GENE-N
acid I-GENE-N
transporter, I-GENE-N
with O
functional O
features O
of O
ASCT2 B-GENE-Y
transport. O
The O
activity O
and O
expression O
of O
the O
ASCT2 B-GENE-Y
transporter O
were O
considerably O
lower O
in O
the O
SHR O
cells. O
The O
antipsychotic O
drugs O

sertindole B-CHEMICAL
and O
pimozide B-CHEMICAL
block O
erg3, B-GENE-Y
a O
human B-GENE-N
brain I-GENE-N
K(+) I-GENE-N
channel. I-GENE-N
The O
antipsychotic O
drugs O
sertindole B-CHEMICAL
and O
pimozide B-CHEMICAL
are O
known O
to O
prolong O
the O
QT O
interval O
on O
the O
electrocardiogram O
via O
a O
high O
affinity O
block O
of O
the O
cardiac B-GENE-N
K(+) I-GENE-N
channel I-GENE-N
known O
as O
HERG B-GENE-Y
(human B-GENE-Y
ether-a-go-go-related I-GENE-Y
gene; I-GENE-Y
erg1). B-GENE-Y
We O
wished O
to O
test O
whether O
these O
drugs O
also O
displayed O
high O
affinity O
for O
the O
related O
neuronal B-GENE-N
K(+) I-GENE-N
channel I-GENE-N
erg3. B-GENE-Y
The O
cDNA O
encoding O
erg3 B-GENE-Y
channel O
was O

cloned O
from O
a O
human O
brain O
library. O
Northern O
analysis O
confirmed O
that O
the O
channel O
was O
localized O
to O
brain O
relative O
to O
other O
tissues O
including O
heart, O
liver O
and O
lung. O
Within O
the O
brain, O
erg3 B-GENE-Y
was O
expressed O
in O
higher O
amounts O
in O
the O
frontal O
lobe O
and O
cerebellum O
relative O
to O
the O
temporal, O
parietal O
and O
occipital O
lobes. O
Transient O
expression O
of O
erg3 B-GENE-Y
in O
Chinese O
hamster O
ovary O
cells O
produced O
outwardly O
directed O
K(+) B-CHEMICAL
currents O
that O
activated O
at O
approximately O
-50 O
mV O
and O
produced O
a O
large O
transient O
component O
at O
positive O
membrane O
potentials. O
Inward O
tail O
currents O
measured O
at O
-100 O
mV O
were O
blocked O
in O
a O

dose-dependent O
fashion O
by O
sertindole B-CHEMICAL
resulting O
in O
an O
IC(50) O
value O
of O
43 O
nM. O
Significant O
inhibition O
was O
observed O
at O
concentrations O
as O
low O
as O
3 O
nM. O
Block O
of O
erg3 B-GENE-Y
by O
sertindole B-CHEMICAL
also O
displayed O
a O
positive O
voltage-dependence. O
Pimozide B-CHEMICAL
blocked O
erg3 B-GENE-Y
channel O
currents O
with O
an O
IC(50) O
of O
103 O
nM O
and O
significant O
inhibition O
was O
noted O
at O
concentrations O
of O
10 O
nM O
and O
higher. O
We O
conclude O
that O
erg3 B-GENE-Y
can O
be O
blocked O
by O
certain O
antipsychotic O
drugs O
like O
sertindole B-CHEMICAL
and O
pimozide. B-CHEMICAL
Inhibition O
of O
erg3 B-GENE-Y
or O

related O
K(+) B-GENE-N
channels I-GENE-N
in O
the O
brain O
may O
contribute O
to O
the O
efficacy/side O
effect O
profiles O
of O
some O
antipsychotic O
drugs. O
Different O
neuroleptics O
show O
common O
dose O
and O
time O
dependent O
effects O
in O
quantitative O
field O
potential O
analysis O
in O
freely O
moving O
rats. O
Under O
the O
assumption O
that O
field O
potentials O
recorded O
from O
particular O
brain O
areas O
reflect O
the O
net O
balance O
of O
neurotransmitter O
activities, O
the O
dose- O
and O
time-dependent O
responses O
induced O
by O
intraperitoneal O
application O
of O
different O
neuroleptic O
drugs O
are O
quantified O
by O
spectral O
analysis O
of O
the O
electroencephalogram O
recorded O
from O
frontal O
cortex, O
hippocampus, O
striatum O

and O
reticular O
formation. O
The O
actions O
of O
haloperidol, B-CHEMICAL
chlorpromazine, B-CHEMICAL
clozapine, B-CHEMICAL
prothipendyl B-CHEMICAL
and O
thioridazine B-CHEMICAL
in O
general O
were O
characterized O
by O
increases O
of O
the O
spectral O
power O
in O
the O
alpha O
1 O
and O
beta O
range, O
at O
higher O
dosages O
also O
in O
the O
theta O
range. O
This O
observed O
pattern O
of O
changes O
is O
in O
line O
with O
the O
neuroleptic O
induced O
spectral O
changes O
reported O
in O
the O
literature O
for O
other O
animals O
and O
man. O
In O
the O
light O
of O
the O
already O
known O
effects O
of O
other O
psychoactive O
drugs O
on O
the O
frequency O
content O
of O
field O
potentials O
in O
the O
rat, O
it O
should O
now O
be O
possible O
to O

classify O
different O
drugs O
in O
terms O
of O
their O
clinical O
indication. O
With O
respect O
to O
the O
type O
of O
neurotransmitter O
control O
underlying O
the O
changes O
produced O
by O
various O
neuroleptics, O
it O
is O
quite O
obvious O
from O
the O
comparisons O
with O
the O
respective O
drug O
effects O
that O
dopamine-D1-receptor B-GENE-Y
controlled O
transmission O
is O
not O
responsible O
for O
this O
action. O
On O
the O
basis O
of O
earlier O
findings O
a O
possible O
interaction O
between O
dopamine-D2 B-GENE-Y
receptor I-GENE-Y
or O
glutamatergic O
transmitter O
control O
is O
discussed. O
Single-walled O
carbon B-CHEMICAL
nanotube O
surface O
control O
of O
complement O
recognition O
and O
activation. O
Carbon B-CHEMICAL
nanotubes O
(CNTs) O
are O
receiving O
considerable O
attention O
in O

site-specific O
drug O
and O
nucleic O
acid O
delivery, O
photodynamic O
therapy, O
and O
photoacoustic O
molecular O
imaging. O
Despite O
these O
advances, O
nanotubes O
may O
activate O
the O
complement O
system O
(an O
integral O
part O
of O
innate O
immunity), O
which O
can O
induce O
clinically O
significant O
anaphylaxis. O
We O
demonstrate O
that O
single-walled O
CNTs O
coated O
with O
human B-GENE-Y
serum I-GENE-Y
albumin I-GENE-Y
activate O
the O
complement O
system O
through O
C1q-mediated O
classical O
and O
the O
alternative O
pathways. O
Surface O
coating O
with O
methoxypoly(ethylene B-CHEMICAL
glycol)-based I-CHEMICAL
amphiphiles, O
which O
confers O
solubility O
and O
prolongs O
circulation O
profiles O
of O

CNTs, O
activates O
the O
complement O
system O
differently, O
depending O
on O
the O
amphiphile O
structure. O
CNTs O
with O
linear O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
amphiphiles O
trigger O
the O
lectin B-GENE-N
pathway O
of O
the O
complement O
through O
both O
L-ficolin O
and O
mannan-binding O
lectin B-GENE-N
recognition. O
The O
lectin B-GENE-N
pathway O
activation, O
however, O
did O
not O
trigger O
the O
amplification O
loop O
of O
the O
alternative O
pathway. O
An O
amphiphile O
with O
branched O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
architecture O
also O
activated O
the O
lectin B-GENE-N
pathway O
but O
only O
through O
L-ficolin O
recognition. O

Importantly, O
this O
mode O
of O
activation O
neither O
generated O
anaphylatoxins O
nor O
induced O
triggering O
of O
the O
effector O
arm O
of O
the O
complement O
system. O
These O
observations O
provide O
a O
major O
step O
toward O
nanomaterial O
surface O
modification O
with O
polymers O
that O
have O
the O
properties O
to O
significantly O
improve O
innate O
immunocompatibility O
by O
limiting O
the O
formation O
of O
complement O
C3 B-GENE-N
and I-GENE-N
C5 I-GENE-N
convertases. I-GENE-N
Conformational O
variations O
of O
both O
phosphodiesterase-5 B-GENE-Y
and O
inhibitors O
provide O
the O
structural O
basis O
for O
the O
physiological O
effects O
of O
vardenafil B-CHEMICAL
and O
sildenafil. B-CHEMICAL
Vardenafil B-CHEMICAL
has O
higher O
affinity O
to O

phosphodiesterase-5 B-GENE-Y
(PDE5) B-GENE-Y
than O
sildenafil B-CHEMICAL
and O
lower O
administered O
dosage O
for O
the O
treatment O
of O
erectile O
dysfunction. O
However, O
the O
molecular O
basis O
for O
these O
differences O
is O
puzzling O
because O
two O
drugs O
have O
similar O
chemical O
structures. O
Reported O
here O
is O
a O
crystal O
structure O
of O
the O
fully O
active O
and O
nonmutated O
PDE5A1 B-GENE-N
catalytic I-GENE-N
domain I-GENE-N
in O
complex O
with O
vardenafil. B-CHEMICAL
The O
structure O
shows O
that O
the O
conformation O
of O
the O
H-loop O
in O
the O
PDE5A1-vardenafil B-GENE-Y
complex O
is O
different O
from O
those O
of O
any O
known O
structures O
of O
the O
unliganded O
PDE5 B-GENE-Y
and O

its O
complexes O
with O
the O
inhibitors. O
In O
addition, O
the O
molecular O
configuration O
of O
vardenafil B-CHEMICAL
differs O
from O
that O
of O
sildenafil B-CHEMICAL
when O
bound O
to O
PDE5. B-GENE-Y
It O
is O
noteworthy O
that O
the O
binding O
of O
vardenafil B-CHEMICAL
causes O
loss O
of O
the O
divalent O
metal O
ions O
that O
have O
been O
observed O
in O
all O
the O
previously O
published O
PDE B-GENE-N
structures. O
The O
conformational O
variation O
of O
both O
PDE5 B-GENE-Y
and O
the O
inhibitors O
provides O
structural O
insight O
into O
the O
different O
potencies O
of O
the O
drugs. O
Cucurbitacin B-CHEMICAL
I I-CHEMICAL
inhibits O
rac1 B-GENE-Y
activation O
in O
breast O
cancer O
cells O
by O
a O
reactive O
oxygen B-CHEMICAL
species-mediated O
mechanism O
and O
independently O
of O
janus B-GENE-Y
tyrosine I-GENE-Y

kinase I-GENE-Y
2 I-GENE-Y
and O
p-rex1. B-GENE-Y
The O
small O
GTPase B-GENE-N
Rac1 B-GENE-Y
has O
been O
widely O
implicated O
in O
mammary O
tumorigenesis O
and O
metastasis. O
Previous O
studies O
established O
that O
stimulation O
of O
ErbB B-GENE-Y
receptors O
in O
breast O
cancer O
cells O
activates O
Rac1 B-GENE-Y
and O
enhances O
motility O
via O
the O
Rac-guanine B-GENE-N
nucleotide I-GENE-N
exchange I-GENE-N
factor I-GENE-N
P-Rex1. B-GENE-Y
As O
the O
Janus B-GENE-Y
tyrosine I-GENE-Y
kinase I-GENE-Y
2 I-GENE-Y
(Jak2)/signal B-GENE-Y
transducer I-GENE-Y
and I-GENE-Y
activator I-GENE-Y
of I-GENE-Y
transcription I-GENE-Y
3 I-GENE-Y
(Stat3) B-GENE-Y
pathway O
has O
been O
shown O
to O
be O
functionally O
associated O
with O
ErbB B-GENE-Y
receptors, O
we O

asked O
if O
this O
pathway O
could O
mediate O
P-Rex1/Rac1 B-GENE-Y
activation O
in O
response O
to O
ErbB B-GENE-Y
ligands. O
Here O
we O
found O
that O
the O
anticancer O
agent O
cucurbitacin B-CHEMICAL
I, I-CHEMICAL
a O
Jak2 B-GENE-N
inhibitor, O
reduced O
the O
activation O
of O
Rac1 B-GENE-Y
and O
motility O
in O
response O
to O
the O
ErbB3 B-GENE-Y
ligand O
heregulin B-GENE-Y
in O
breast O
cancer O
cells. O
However, O
Rac1 B-GENE-Y
activation O
was O
not O
affected O
by O
Jak2 B-GENE-Y
or O
Stat3 B-GENE-Y
RNA O
interference, O
suggesting O
that O
the O
effect O
of O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
occurs O
through O
a O
Jak2-independent B-GENE-N
mechanism. O
Cucurbitacin B-CHEMICAL
I I-CHEMICAL

also O
failed O
to O
affect O
the O
activation O
of O
P-Rex1 B-GENE-Y
by O
heregulin. B-GENE-Y
Subsequent O
analysis O
revealed O
that O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
strongly O
activates O
RhoA B-GENE-N
and O
the O
Rho B-GENE-N
effector O
Rho B-GENE-N
kinase I-GENE-N
(ROCK) B-GENE-N
in O
breast O
cancer O
cells O
and O
induces O
the O
formation O
of O
stress O
fibers. O
Interestingly, O
disruption O
of O
the O
RhoA-ROCK B-GENE-N
pathway O
prevented O
the O
inhibitory O
effect O
of O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
on O
Rac1 B-GENE-Y
activation O
by O
heregulin. B-GENE-Y
Lastly, O
we O
found O
that O
RhoA B-GENE-N
activation O
by O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
is O
mediated O
by O
reactive O
oxygen B-CHEMICAL
species O
(ROS). O
The O
ROS O

scavenger O
N-acetyl B-CHEMICAL
l-cysteine I-CHEMICAL
and O
the O
mitochondrial O
antioxidant O
Mito-TEMPO O
rescued O
the O
inhibitory O
effect O
of O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
on O
Rac1 B-GENE-Y
activation. O
In O
conclusion, O
these O
results O
indicate O
that O
ErbB-driven B-GENE-Y
Rac1 B-GENE-Y
activation O
in O
breast O
cancer O
cells O
proceeds O
independently O
of O
the O
Jak2 B-GENE-N
pathway. O
Moreover, O
they O
established O
that O
the O
inhibitory O
effect O
of O
cucurbitacin B-CHEMICAL
I I-CHEMICAL
on O
Rac1 B-GENE-Y
activity O
involves O
the O
alteration O
of O
the O
balance O
between O
Rho B-GENE-N
and O
Rac. B-GENE-N
Common O
and O
specific O
determinants O
for O
fibroblast B-GENE-N
growth I-GENE-N
factors I-GENE-N
in O
the O

ectodomain O
of O
the O
receptor B-GENE-N
kinase I-GENE-N
complex. O
The O
assembly O
and O
activation O
of O
oligomeric O
complexes O
of O
FGF, B-GENE-N
the O
transmembrane B-GENE-N
receptor I-GENE-N
kinase I-GENE-N
(FGFR), B-GENE-N
and O
heparan O
sulfate B-CHEMICAL
transmit O
intracellular O
signals O
regulating O
growth O
and O
function O
of O
cells. O
An O
understanding O
of O
the O
structural O
relationships O
between O
the O
three O
subunits O
and O
their O
redundancy O
and O
specificity O
is O
essential O
for O
understanding O
the O
ubiquitous O
FGF B-GENE-N
signaling O
system O
in O
health O
and O
disease. O
Previously, O
we O
reported O
that O
a O
primary O
heparin O
or O
heparan O
sulfate B-CHEMICAL
binding O
site O
resides O
in O
a O
distinct O
sequence O
in O

immunoglobulin B-GENE-N
(Ig)-like I-GENE-N
module I-GENE-N
II I-GENE-N
of O
the O
three O
modules O
of O
FGFR. B-GENE-N
Here O
we O
report O
that O
in O
the O
absence O
of O
flanking O
sequences, O
isolated O
Ig B-GENE-N
module I-GENE-N
II I-GENE-N
of O
FGFR1 B-GENE-Y
supports O
the O
binding O
of O
FGF-1, B-GENE-Y
FGF-2, B-GENE-Y
and O
FGF-7 B-GENE-Y
in O
respective O
order O
of O
affinity. O
None O
of O
the O
three O
FGFs B-GENE-N
detectably O
bind O
Ig B-GENE-N
module I-GENE-N
I I-GENE-N
or I-GENE-N
the I-GENE-N
IIIb I-GENE-N
and I-GENE-N
IIIc I-GENE-N
splice O
variants O
of O
Ig B-GENE-N
module I-GENE-N
III I-GENE-N
in O
the O
absence O
of O
flanking O
sequences. O
Ig B-GENE-N
module I-GENE-N
I I-GENE-N
and O
the O
C-terminus B-CHEMICAL
of O

Ig B-GENE-N
module I-GENE-N
III I-GENE-N
are O
dispensable O
for O
high-affinity O
binding O
of O
FGF-1, B-GENE-Y
FGF-2, B-GENE-Y
and O
FGF-7. B-GENE-Y
Alterations O
in O
highly O
conserved O
Ig B-GENE-N
module I-GENE-N
II I-GENE-N
in O
the O
heparin O
binding O
domain O
and O
substitution O
of O
individual O
sequence O
domains O
spanning O
the O
entire O
sequence O
of O
Ig B-GENE-N
module I-GENE-N
II I-GENE-N
with O
those O
from O
Ig B-GENE-N
module I-GENE-N
I I-GENE-N
obliterated O
FGF B-GENE-N
binding. O
Addition O
of O
a O
specific O
number O
of O
FGFR B-GENE-N
sequences O
to O
the O
C-terminus B-CHEMICAL
of O
Ig B-GENE-N
module I-GENE-N
II I-GENE-N
resulted O
in O
a O
gain O
in O
affinity O
for O
FGF-7. B-GENE-Y
Several O
site-specific O
alterations O
in O
the O

C-terminus B-CHEMICAL
of O
full-length O
FGFR1IIIc, B-GENE-N
an O
isoform O
that O
otherwise O
absolutely O
rejects O
FGF-7, B-GENE-Y
resulted O
in O
gain O
of O
FGF-7 B-GENE-Y
binding. O
These O
results O
suggest O
that O
a O
complex O
of O
Ig B-GENE-N
module I-GENE-N
II I-GENE-N
and O
heparan O
sulfate B-CHEMICAL
is O
the O
base O
common O
active O
core O
of O
the O
FGFR B-GENE-N
ectodomain I-GENE-N
and O
that O
flanking O
structural O
domains O
modify O
FGF B-GENE-N
affinity O
and O
determine O
specificity. O
Brain O
but O
not O
spinal O
NR2B B-GENE-Y
receptor O
is O
responsible O
for O
the O
anti-allodynic O
effect O
of O
an O
NR2B B-GENE-Y
subunit-selective O
antagonist O

CP-101,606 B-CHEMICAL
in O
a O
rat O
chronic O
constriction O
injury O
model. O
In O
order O
to O
examine O
the O
site O
of O
action O
of O
an O
NR2B B-GENE-Y
subtype-selective O
NMDA B-GENE-N
antagonist O
CP-101,606, B-CHEMICAL
we O
investigated O
its O
analgesic O
effect O
in O
a O
rat O
model O
of O
neuropathic O
pain O
at O
various O
routes O
of O
administration. O
Mechanical O
allodynia O
was O
induced O
by O
chronic O
constriction O
injury O
(CCI) O
of O
the O
sciatic O
nerve O
in O
male O
Sprague-Dawley O
rats. O
Subcutaneous O
treatment O
of O
the O
animals O
with O
CP-101,606 B-CHEMICAL
at O
10 O
mg/kg O
significantly O
inhibited O

CCI-induced O
mechanical O
allodynia. O
Intracerebroventricular O
injection O
of O
CP-101,606 B-CHEMICAL
at O
10, O
30 O
and O
100 O
nmol O
also O
inhibited O
the O
mechanical O
allodynia O
in O
a O
dose-dependent O
manner, O
the O
statistically O
significant O
effect O
being O
achieved O
at O
the O
highest O
dose O
tested O
(100 O
nmol) O
without O
producing O
any O
behavioral O
abnormalities. O
However, O
intrathecal O
injection O
of O
CP-101,606 B-CHEMICAL
at O
a O
dose O
of O
300 O
nmol O
failed O
to O
inhibit O
CCI-induced O
allodynia. O
A O
receptor O
binding O
assay O
using O
rat O
forebrain O
and O
spinal O
cord O
membrane O
preparations O
demonstrated O
that O

[3H]CP-101,606 B-CHEMICAL
bound O
to O
the O
brain O
NR2B B-GENE-Y
receptor O
with O
a O
greater O
extent O
compared O
to O
the O
spinal O
cord O
one. O
These O
findings O
suggest O
that O
the O
anti-allodynia O
effect O
of O
CP-101,606 B-CHEMICAL
is O
ascribable O
to O
blockade O
of O
NR2B B-GENE-Y
receptors O
at O
the O
brain, O
but O
not O
at O
the O
spinal O
cord. O
In O
contrast, O
intrathecal O
injection O
of O
a O
non-selective O
NMDA B-GENE-N
antagonist, O
memantine, B-CHEMICAL
significantly O
inhibited O
CCI-induced O
mechanical O
allodynia O
at O
a O
dose O
of O
300 O
nmol, O
indicating O
the O
difference O
in O
the O
site O
of O
action O
between O
the O

non-selective O
NMDA B-GENE-N
antagonist O
and O
the O
NR2B-specific B-GENE-Y
NMDA B-GENE-N
antagonist. O
Mutations O
within O
the O
human B-GENE-Y
GLYT2 I-GENE-Y
(SLC6A5) B-GENE-Y
gene O
associated O
with O
hyperekplexia. O
Hereditary O
hyperekplexia O
is O
a O
neuromotor O
disorder O
characterized O
by O
exaggerated O
startle O
reflexes O
and O
muscle O
stiffness O
in O
the O
neonate. O
The O
disease O
has O
been O
associated O
with O
mutations O
in O
the O
glycine B-GENE-N
receptor I-GENE-N
subunit O
genes O
GLRA1 B-GENE-Y
and O
GLRB. B-GENE-Y
Here, O
we O
describe O
mutations O
within O
the O
neuronal O
glycine B-GENE-Y
transporter I-GENE-Y
2 I-GENE-Y
gene O
(GLYT2, B-GENE-Y
or O

SLC6A5, B-GENE-Y
) O
of O
hyperekplexia O
patients, O
whose O
symptoms O
cannot O
be O
attributed O
to O
glycine B-GENE-N
receptor I-GENE-N
mutations. O
One O
of O
the O
GLYT2 B-GENE-Y
mutations O
identified O
causes O
truncation O
of O
the O
transporter B-GENE-N
protein I-GENE-N
and O
a O
complete O
loss O
of O
transport O
function. O
Our O
results O
are O
consistent O
with O
GLYT2 B-GENE-Y
being O
a O
disease O
gene O
in O
human O
hyperekplexia. O
Pharmacological O
properties O
of O
the O
anti-Parkinson O
drug O
rasagiline; B-CHEMICAL
modification O
of O
endogenous O
brain O
amines, B-CHEMICAL
reserpine B-CHEMICAL
reversal, O
serotonergic O
and O
dopaminergic O
behaviours. O
Rasagiline B-CHEMICAL

[N-propargyl-1R(+)-aminoindan; B-CHEMICAL
TVP1012] B-CHEMICAL
is O
a O
potent O
irreversible O
monoamine B-GENE-N
oxidase I-GENE-N
(MAO) B-GENE-N
inhibitor O
with O
selectivity O
for O
type O
B O
of O
the O
enzyme, O
which O
is O
being O
developed O
for O
treatment O
of O
Parkinson's O
disease. O
In O
this O
study O
we O
examined O
effects O
of O
rasagiline B-CHEMICAL
on O
CNS O
monoamine B-CHEMICAL
levels, O
modification O
of O
behavioural O
response O
to O
L-tryptophan, B-CHEMICAL
fluoxetine B-CHEMICAL
and O
L-DOPA, B-CHEMICAL
and O
reversal O
of O
reserpine B-CHEMICAL
syndrome. O
Reserpine-induced B-CHEMICAL
ptosis O
was O
reversed O
by O

rasagiline B-CHEMICAL
at O
doses O
above O
2 O
mg O
x O
kg(-1) O
i.p., O
which O
inhibit O
MAO-A B-GENE-Y
as O
well O
as O
MAO-B, B-GENE-Y
but O
not O
at O
MAO-B-selective B-GENE-Y
doses. O
However, O
combination O
of O
rasagiline B-CHEMICAL
(10 O
mg O
x O
kg(-1) O
i.p.) O
with O
L-DOPA B-CHEMICAL
or O
L-tryptophan B-CHEMICAL
(50 O
mg O
x O
kg(-1) O
i.p.), O
or O
rasagiline B-CHEMICAL
(10 O
mg O
x O
kg(-1) O
p.o.) O
with O
fluoxetine B-CHEMICAL
(10 O
mg O
x O

kg(-1) O
p.o.), O
did O
not O
induce O
the O
behavioural O
hyperactivity O
syndrome O
which O
is O
seen O
following O
inhibition O
of O
both O
MAO-A B-GENE-Y
and O
MAO-B B-GENE-Y
by O
tranylcypromine B-CHEMICAL
together O
with O
the O
monoamine B-CHEMICAL
precursors. O
Following O
oral O
administration, O
levels O
of O
noradrenaline B-CHEMICAL
(NA), B-CHEMICAL
5-hydroxytryptamine B-CHEMICAL
(5-HT) B-CHEMICAL
and O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
were O
unaffected O
in O
hippocampus O
and O
striatum O
after O
single O
doses O
of O
rasagiline B-CHEMICAL
up O
to O
2 O
mg O
x O
kg(-1). O

Following O
chronic O
oral O
administration O
(21 O
days, O
one O
dose O
daily), O
levels O
of O
NA, B-CHEMICAL
5-HT B-CHEMICAL
and O
DA B-CHEMICAL
in O
hippocampus O
and O
striatum O
were O
unaffected O
by O
rasagiline B-CHEMICAL
at O
doses O
up O
to O
1 O
mg O
x O
kg(-1). O
Rasagiline B-CHEMICAL
does O
not O
modify O
CNS O
monoamine B-CHEMICAL
tissue O
levels O
or O
monoamine-induced B-CHEMICAL
behavioural O
syndromes O
at O
doses O
which O
selectively O
inhibit O
MAO-B B-GENE-Y
but O
not O
MAO-A. B-GENE-Y
Characterization O
of O
the O
omega B-GENE-N
class I-GENE-N
of I-GENE-N
glutathione I-GENE-N
transferases. I-GENE-N
The O
Omega B-GENE-N
class I-GENE-N
of I-GENE-N
cytosolic I-GENE-N

glutathione I-GENE-N
transferases I-GENE-N
was O
initially O
recognized O
by O
bioinformatic O
analysis O
of O
human O
sequence O
databases, O
and O
orthologous O
sequences O
were O
subsequently O
discovered O
in O
mouse, O
rat, O
pig, O
Caenorhabditis O
elegans, O
Schistosoma O
mansoni, O
and O
Drosophila O
melanogaster. O
In O
humans O
and O
mice, O
two O
GSTO B-GENE-N
genes O
have O
been O
recognized O
and O
their O
genetic O
structures O
and O
expression O
patterns O
identified. O
In O
both O
species, O
GSTO1 B-GENE-Y
mRNA O
is O
expressed O
in O
liver O
and O
heart O
as O
well O
as O
a O
range O
of O
other O
tissues. O
GSTO2 B-GENE-Y
is O
expressed O
predominantly O
in O
the O
testis, O
although O
moderate O

levels O
of O
expression O
are O
seen O
in O
other O
tissues. O
Extensive O
immunohistochemistry O
of O
rat O
and O
human O
tissue O
sections O
has O
demonstrated O
cellular O
and O
subcellular O
specificity O
in O
the O
expression O
of O
GSTO1-1. B-GENE-Y
The O
crystal O
structure O
of O
recombinant O
human B-GENE-Y
GSTO1-1 I-GENE-Y
has O
been O
determined, O
and O
it O
adopts O
the O
canonical O
GST B-GENE-N
fold. I-GENE-N
A O
cysteine B-CHEMICAL
residue O
in O
place O
of O
the O
catalytic O
tyrosine B-CHEMICAL
or O
serine B-CHEMICAL
residues O
found O
in O
other O
GSTs B-GENE-N
was O
shown O
to O
form O
a O
mixed O
disulfide B-CHEMICAL
with O
glutathione. B-CHEMICAL
Omega B-GENE-N
class I-GENE-N
GSTs I-GENE-N
have O
dehydroascorbate B-GENE-N

reductase I-GENE-N
and O
thioltransferase B-GENE-N
activities O
and O
also O
catalyze O
the O
reduction O
of O
monomethylarsonate, B-CHEMICAL
an O
intermediate O
in O
the O
pathway O
of O
arsenic B-CHEMICAL
biotransformation. O
Other O
diverse O
actions O
of O
human B-GENE-Y
GSTO1-1 I-GENE-Y
include O
modulation O
of O
ryanodine B-GENE-N
receptors I-GENE-N
and O
interaction O
with O
cytokine B-GENE-N
release O
inhibitory O
drugs. O
In O
addition, O
GSTO1 B-GENE-Y
has O
been O
linked O
to O
the O
age O
at O
onset O
of O
both O
Alzheimer's O
and O
Parkinson's O
diseases. O
Several O
polymorphisms O
have O
been O
identified O
in O
the O
coding O
regions O
of O
the O
human B-GENE-Y
GSTO1 I-GENE-Y
and O
GSTO2 B-GENE-Y
genes. O

Our O
laboratory O
has O
expressed O
recombinant O
human B-GENE-Y
GSTO1-1 I-GENE-Y
and O
GSTO2-2 B-GENE-Y
proteins, O
as O
well O
as O
a O
number O
of O
polymorphic O
variants. O
The O
expression O
and O
purification O
of O
these O
proteins O
and O
determination O
of O
their O
enzymatic O
activity O
is O
described. O
Tmem64 B-GENE-Y
modulates O
calcium B-CHEMICAL
signaling O
during O
RANKL-mediated B-GENE-Y
osteoclast O
differentiation. O
Osteoclast O
maturation O
and O
function O
primarily O
depend O
on O
receptor B-GENE-Y
activator I-GENE-Y
of I-GENE-Y
NF-κB I-GENE-Y
ligand I-GENE-Y
(RANKL)-mediated B-GENE-Y
induction O
of O
nuclear B-GENE-Y
factor I-GENE-Y
of I-GENE-Y
activated I-GENE-Y
T I-GENE-Y
cells I-GENE-Y
c1 I-GENE-Y
(NFATc1), B-GENE-Y

which O
is O
further O
activated O
via O
increased O
intracellular O
calcium B-CHEMICAL
([Ca(2+)](i)) B-CHEMICAL
oscillation. O
However, O
the O
coordination O
mechanism O
that O
mediates O
Ca(2+) B-CHEMICAL
oscillation O
during O
osteoclastogenesis O
remains O
ill O
defined. O
Here, O
we O
identified O
transmembrane B-GENE-Y
protein I-GENE-Y
64 I-GENE-Y
(Tmem64) B-GENE-Y
as O
a O
regulator O
of O
Ca(2+) B-CHEMICAL
oscillation O
during O
osteoclastogenesis. O
We O
found O
that O
Tmem64-deficient B-GENE-Y
mice O
exhibit O
increased O
bone O
mass O
due O
in O
part O
to O
impaired O
osteoclast O
formation. O
Using O
in O
vitro O

osteoclast O
culture O
systems, O
we O
show O
here O
that O
Tmem64 O
interacts O
with O
sarcoplasmic O
endoplasmic O
reticulum O
Ca(2+) B-CHEMICAL
ATPase O
2 O
(SERCA2) O
and O
modulates O
its O
activity. O
Consequently, O
Tmem64 B-GENE-Y
deficiency O
significantly O
diminishes O
RANKL-induced B-GENE-Y
[Ca(2+)](i) B-CHEMICAL
oscillation, O
which O
results O
in O
reduced O
Ca(2+)/calmodulin-dependent B-GENE-Y
protein I-GENE-Y
kinases I-GENE-Y
(CaMK) I-GENE-Y
IV I-GENE-Y
and O
mitochondrial O
ROS, O
both O
of O
which O
contribute O
to O
achieving O
the O
CREB B-GENE-N

activity O
necessary O
for O
osteoclast O
formation. O
These O
data O
demonstrate O
that O
Tmem64 B-GENE-Y
is O
a O
positive O
modulator O
of O
osteoclast O
differentiation O
via O
SERCA2-dependent B-GENE-Y
Ca(2+) B-CHEMICAL
signaling. O
Bimodal O
occurrence O
of O
aspartoacylase B-GENE-Y
in O
myelin O
and O
cytosol O
of O
brain. O
The O
growing O
use O
of O
N-acetylaspartate B-CHEMICAL
as O
an O
indicator O
of O
neuronal O
viability O
has O
fostered O
interest O
in O
the O
biological O
function(s) O
of O
this O
unusual O
amino B-CHEMICAL
acid I-CHEMICAL
derivative. O
In O
considering O
the O
various O
physiological O
roles O
that O
have O
been O
proposed O
for O
this O
relatively O
abundant O
molecule O
one O
is O
obliged O
to O
take O
into O
account O
its O

unusual O
metabolic O
compartmentalization, O
according O
to O
which O
synthesis O
and O
storage O
occur O
in O
the O
neuron O
and O
hydrolytic O
cleavage O
in O
the O
oligodendrocyte. O
The O
latter O
reaction, O
catalyzed O
by O
aspartoacylase B-GENE-Y
(ASPA), B-GENE-Y
produces O
acetyl B-CHEMICAL
groups O
plus O
aspartate B-CHEMICAL
and O
has O
been O
proposed O
to O
occur O
in O
both O
soluble O
and O
membranous O
subfractions O
of O
white O
matter. O
Our O
study O
supports O
such O
bimodal O
occurrence O
and O
we O
now O
present O
immunoblot, O
proteomic, O
and O
biochemical O
evidence O
that O
the O
membrane-bound O
form O
of O
ASPA B-GENE-Y
is O
intrinsic O
to O
purified O
myelin O

membranes. O
This O
was O
supported O
by O
a O
novel O
TLC-based O
method O
for O
the O
assay O
of O
ASPA. B-GENE-Y
That O
observation, O
together O
with O
previous O
demonstrations O
of O
numerous O
lipid-synthesizing O
enzymes O
in O
myelin, O
suggests O
utilization O
of O
acetyl B-CHEMICAL
groups O
liberated O
by O
myelin-localized O
ASPA B-GENE-Y
for O
lipid O
synthesis O
within O
the O
myelin O
sheath. O
Such O
synthesis O
might O
be O
selective O
and O
could O
explain O
the O
deficit O
of O
myelin O
lipids O
in O
animals O
lacking O
ASPA. B-GENE-N
Chemoprevention O
for O
high-risk O
women: O
tamoxifen B-CHEMICAL
and O
beyond. O
The O
demonstration O
by O
the O
National O
Surgical O
Adjuvant O
Breast O
Project O

(NSABP) O
that O
5 O
years O
of O
tamoxifen B-CHEMICAL
therapy O
is O
associated O
with O
an O
approximate O
50% O
reduction O
in O
breast O
cancer O
incidence O
in O
high-risk O
women O
was O
a O
milestone O
in O
breast O
cancer O
prevention. O
Because O
tamoxifen B-CHEMICAL
is O
associated O
with O
increased O
risk O
of O
side-effects O
such O
as O
hot O
flashes, O
menstrual O
abnormalities, O
uterine O
cancer, O
and O
thromboembolic O
phenomena, O
its O
use O
will O
not O
be O
advisable O
or O
acceptable O
for O
all O
high-risk O
women. O
Women O
over O
50 O
years O
of O
age O
appear O
to O
be O
at O
highest O
risk O
for O
serious O
adverse O
events, O
such O
as O
uterine O
cancer O
and O
thromboembolic O
phenomena. O

Individuals O
in O
whom O
tamoxifen-associated B-CHEMICAL
breast O
cancer O
risk O
reduction O
appears O
to O
outweigh O
risk O
of O
serious O
side-effects O
include O
women O
with O
prior O
in O
situ O
or O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER)-positive B-GENE-Y
invasive O
cancer, O
atypical O
hyperplasia, O
and/or O
women O
ages O
35-49 O
with O
a O
calculated O
Gail O
5-year O
risk O
of O
> O
or O
=1.7%, O
hysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O
> O
or O
=2.5%, O
and O
nonhysterectomized O
women O
aged O
50 O
and O
older O
with O
a O
5-year O
Gail O
risk O
of O

>5.0%. O
It O
is O
not O
yet O
clear O
whether O
tamoxifen B-CHEMICAL
can O
reduce O
breast O
cancer O
incidence O
in O
women O
with O
BRCA1 B-GENE-Y
and O
BRCA2 B-GENE-Y
mutations, O
although O
preliminary O
evidence O
favors O
benefit O
for O
at O
least O
those O
with O
a O
BRCA2 B-GENE-Y
mutation. O
Raloxifene B-CHEMICAL
is O
a O
selective O
ER B-GENE-Y
modulator O
with O
less O
uterine O
estrogen B-CHEMICAL
agonist O
activity O
than O
tamoxifen, B-CHEMICAL
and O
it O
is O
hoped O
that O
it O
will O
result O
in O
fewer O
uterine O
cancers O
but O
will O
be O
equally O
efficacious O
in O
reducing O
the O
risk O
of O
breast O
cancer. O
The O
NSABP O
is O
currently O
conducting O
a O
randomized O
study O
of O
tamoxifen B-CHEMICAL
versus O

raloxifene B-CHEMICAL
in O
high-risk O
postmenopausal O
women. O
Approximately O
one O
third O
of O
invasive O
cancers O
are O
ER B-GENE-Y
negative. O
Tamoxifen B-CHEMICAL
does O
not O
reduce O
the O
incidence O
of O
ER-negative B-GENE-Y
cancers, O
nor O
does O
it O
appear O
to O
be O
effective O
in O
preventing O
the O
appearance O
of O
one O
third O
of O
ER-positive B-GENE-Y
cancers. O
Priorities O
in O
prevention O
research O
are O
to O
develop O
(a) O
biomarkers O
to O
refine O
short-term O
risk O
assessments O
based O
on O
epidemiologic O
models, O
(b) O
biomarkers O
predictive O
of O
response O
to O
specific O
classes O
of O
preventive O
agents, O
(c) O
drugs O
with O
fewer O
side-effects O
and/or O

effective O
in O
ER-negative B-GENE-Y
or O
ER-positive B-GENE-Y
tamoxifen-resistant B-CHEMICAL
precancerous O
disease, O
and O
(d) O
efficient O
clinical O
trial O
models O
to O
assess O
new O
agent O
efficacy. O
Breast O
intraepithelial O
neoplasia O
(IEN) O
may O
be O
sampled O
by O
minimally O
invasive O
techniques O
and O
is O
an O
attractive O
short-term O
risk O
biomarker. O
Molecular O
abnormalities O
observed O
in O
IEN O
may O
be O
used O
to O
select O
potential O
agents O
for O
testing/therapy, O
and O
modulation O
of O
these O
abnormalities O
may O
be O
used O
in O
phase O
I O
trials O
to O
select O
appropriate O
doses O
and O
in O
phase O
II O
trials O
to O
assess O
response. O
Breast O
density O
volume O
and O
certain O
serum O

markers O
such O
as O
insulin-like B-GENE-Y
growth I-GENE-Y
factor-1 I-GENE-Y
are O
also O
being O
studied O
as O
potential O
risk O
and O
response O
biomarkers. O
Reversal O
or O
prevention O
of O
advanced O
IEN O
as O
well O
as O
modulation O
of O
other O
risk O
biomarkers O
in O
randomized O
phase O
II O
and O
phase O
III O
trials O
is O
being O
evaluated O
as O
a O
means O
of O
more O
efficiently O
evaluating O
prevention O
drugs O
in O
the O
future. O
A O
number O
of O
agents O
are O
being O
developed O
that O
target O
molecular O
abnormalities O
in O
IEN, O
have O
fewer O
or O
different O
side O
effects O
than O
tamoxifen, B-CHEMICAL
and O
may O
be O
effective O
in O
ER-negative B-GENE-Y
or O
tamoxifen-resistant B-CHEMICAL
disease. O
Inhibition O
by O
troglitazone B-CHEMICAL
of O
the O

antigen-induced O
production O
of O
leukotrienes B-CHEMICAL
in O
immunoglobulin B-GENE-N
E-sensitized I-GENE-N
RBL-2H3 O
cells. O
1. O
The O
effect O
of O
troglitazone, B-CHEMICAL
an O
anti-diabetic O
drug O
with O
insulin-sensitizing B-GENE-N
action, O
on O
antigen-induced O
production O
of O
leukotriene B-CHEMICAL
(LT) I-CHEMICAL
B(4), I-CHEMICAL
C(4) I-CHEMICAL
and I-CHEMICAL
E(4) I-CHEMICAL
and O
prostaglandin B-CHEMICAL
D(2) I-CHEMICAL
(PGD(2)) B-CHEMICAL
was O
examined O
in O
dinitrophenol B-CHEMICAL
(DNP)-specific B-CHEMICAL

immunoglobulin B-GENE-N
E I-GENE-N
(IgE)-sensitized B-GENE-N
RBL-2H3 O
mast O
cells O
following O
stimulation O
by O
the O
antigen, O
DNP-conjugated B-CHEMICAL
human B-GENE-Y
serum I-GENE-Y
albumin. I-GENE-Y
Levels O
of O
LTB(4), B-CHEMICAL
C(4) O
and O
E(4) O
and O
PGD(2) B-CHEMICAL
in O
the O
conditioned O
medium O
were O
enzyme-immunoassayed. O
2. O
Troglitazone B-CHEMICAL
inhibited O
the O
antigen-induced O
production O
of O
LTB(4), B-CHEMICAL
C(4) O
and O
E(4) O
and O
the O
potency O
of O
the O
inhibition O
was O

comparable O
to O
that O
of O
zileuton, B-CHEMICAL
a O
specific O
inhibitor O
of O
5-lipoxygenase B-GENE-Y
(5-LOX) B-GENE-Y
and O
a O
clinically O
used O
anti-asthmatic O
drug. O
Neither O
troglitazone B-CHEMICAL
nor O
zileuton B-CHEMICAL
affected O
antigen-induced O
production O
of O
PGD(2), B-CHEMICAL
arachidonic B-CHEMICAL
acid I-CHEMICAL
release O
from O
membrane O
phospholipids O
and O
degranulation. O
3. O
Troglitazone B-CHEMICAL
inhibited O
LTB(4) B-CHEMICAL
production O
by O
the O
supernatant O
fraction O
of O
RBL-2H3 O
cell O
lysate O
with O
similar O
potency O
to O

zileuton, B-CHEMICAL
suggesting O
that O
troglitazone B-CHEMICAL
inhibits O
LT O
production O
by O
direct O
inhibition O
of O
5-LOX B-GENE-Y
activity. O
4. O
Furthermore, O
it O
was O
shown O
that O
troglitazone B-CHEMICAL
as O
well O
as O
zileuton B-CHEMICAL
inhibited O
LTB(4) B-CHEMICAL
production O
in O
A23187-stimulated B-CHEMICAL
rat O
peritoneal O
neutrophils. O
5. O
These O
findings O
suggest O
that O
troglitazone B-CHEMICAL
inhibits O
antigen-induced O
LT O
production O
in O
the O
IgE-sensitized B-GENE-N
RBL-2H3 O
cells O
and O
A23187-stimulated B-CHEMICAL
rat O

peritoneal O
neutrophils O
by O
direct O
inhibition O
of O
5-LOX B-GENE-Y
activity. O
[Protein O
profile O
and O
vitamin B-CHEMICAL
A I-CHEMICAL
in O
children O
of O
school O
age O
in O
Ivory O
Coast]. O
The O
purpose O
of O
this O
transverse O
prospective O
study O
was O
to O
determine O
blood O
nutritional, O
immunity O
and O
inflammatory O
proteins O
change O
in O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency O
in O
children O
of O
school-age O
(262 O
children, O
aged O
7 O
to O
15 O
years). O
Blood O
vitamin B-CHEMICAL
A I-CHEMICAL
has O
been O
determined O
by O
HPLC O
with O
UV O
detection. O
Proteins O
have O
been O
measured O
by O
radial O
immunodiffusion O
according O
to O
Mancini. O
Results O
showed O
that O
96 O
children O
(36.6%) O
presented O
a O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency O

(vitamin B-CHEMICAL
A I-CHEMICAL
< O
200 O
microg/L O
with O
a O
retinol B-GENE-N
binding I-GENE-N
protein/transthyretin I-GENE-N
molar O
ratio O
= O
0.29 O
+/- O
0.06) O
while O
166 O
(63.3%) O
children O
presented O
normal O
blood O
concentrations O
of O
vitamin B-CHEMICAL
A I-CHEMICAL
(vitamin B-CHEMICAL
A I-CHEMICAL
> O
or O
= O
200 O
microg/L O
with O
a O
Retinol B-GENE-N
Binding I-GENE-N
Protein/Transthyretin I-GENE-N
molar O
ratio O
= O
0.40 O
+/- O
0.08). O
This O
study O
showed O
that O
the O
retinol B-GENE-N
binding I-GENE-N
protein I-GENE-N
and O
the O
immunoglobulin B-GENE-N
A I-GENE-N
are O
lower O
in O
children O
with O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency. O
On O
the O
other O
hand, O
an O

isolated O
increase O
of O
alpha-1 B-GENE-Y
glycoprotein I-GENE-Y
acid I-GENE-Y
has O
been O
observed O
in O
boys O
with O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency. O
The O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency O
observed O
in O
this O
survey O
is O
due O
to O
a O
micronutrients O
deficiency O
in O
the O
diet O
which O
is O
essentially O
based O
on O
glucides. O
The O
positive O
correlation O
between O
vitamin B-CHEMICAL
A I-CHEMICAL
and O
immunoglobulin B-GENE-N
A I-GENE-N
concentrations O
might O
be O
the O
result O
of O
the O
vitamin B-CHEMICAL
A I-CHEMICAL
inductive O
effect O
during O
immunoglobulins B-GENE-N
A I-GENE-N
synthesis. O
The O
isolated O
increasing O
of O
alpha-1 B-GENE-Y
glycoprotein I-GENE-Y
acid I-GENE-Y
in O
boys O
with O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency O
has O
been O
assigned O
to O
the O
ecosensitiveness O
of O
the O

unfavourable O
environment. O
We O
therefore O
concluded O
that, O
in O
Ivorian O
primary-school-aged O
children O
with O
vitamin B-CHEMICAL
A I-CHEMICAL
deficiency, O
nutritional, O
immunity O
and O
inflammatory O
proteins O
which O
are O
modified O
are O
respectively O
retinol B-GENE-N
binding I-GENE-N
protein, I-GENE-N
immunoglobulin B-GENE-N
A I-GENE-N
and O
alpha-1 B-GENE-Y
glycoprotein I-GENE-Y
acid. I-GENE-Y
Verapamil B-CHEMICAL
prevents O
torsade O
de O
pointes O
by O
reduction O
of O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
early O
afterdepolarizations O
in O
an O
intact O
heart O
model O
of O
LQT3. O
BACKGROUND: O
In O
long O
QT O
syndrome O

(LQTS), O
prolongation O
of O
the O
QT-interval O
is O
associated O
with O
sudden O
cardiac O
death O
resulting O
from O
potentially O
life-threatening O
polymorphic O
tachycardia O
of O
the O
torsade O
de O
pointes O
(TdP) O
type. O
Experimental O
as O
well O
as O
clinical O
reports O
support O
the O
hypothesis O
that O
calcium B-GENE-N
channel I-GENE-N
blockers O
such O
as O
verapamil B-CHEMICAL
may O
be O
an O
appropriate O
therapeutic O
approach O
in O
LQTS. O
We O
investigated O
the O
electrophysiologic O
mechanism O
by O
which O
verapamil O
suppresses O
TdP, O
in O
a O
recently O
developed O
intact O
heart O
model O
of O
LQT3. O
METHODS O
AND O
RESULTS: O
In O

8 O
Langendorff-perfused O
rabbit O
hearts, O
veratridine B-CHEMICAL
(0.1 O
microM), O
an O
inhibitor O
of O
sodium B-GENE-N
channel I-GENE-N
inactivation, O
led O
to O
a O
marked O
increase O
in O
QT-interval O
and O
simultaneously O
recorded O
monophasic O
ventricular O
action O
potentials O
(MAPs) O
(p O
< O
0.05) O
thereby O
mimicking O
LQT3. O
In O
bradycardic O
(AV-blocked) O
hearts, O
simultaneous O
recording O
of O
up O
to O
eight O
epi- O
and O
endocardial O
MAPs O
demonstrated O
a O
significant O
increase O
in O
total O
dispersion O
of O
repolarization O
(56%, O
p O
< O

0.05) O
and O
reverse O
frequency-dependence. O
After O
lowering O
potassium B-CHEMICAL
concentration, O
veratridine B-CHEMICAL
reproducibly O
led O
to O
early O
afterdepolarizations O
(EADs) O
and O
TdP O
in O
6 O
of O
8 O
(75%) O
hearts. O
Additional O
infusion O
of O
verapamil B-CHEMICAL
(0.75 O
microM) O
suppressed O
EADs O
and O
consecutively O
TdP O
in O
all O
hearts. O
Verapamil B-CHEMICAL
significantly O
shortened O
endocardial O
but O
not O
epicardial O
MAPs O
which O
resulted O
in O
significant O
reduction O
of O
ventricular O
transmural O
dispersion O
of O
repolarization. O
CONCLUSIONS: O

Verapamil B-CHEMICAL
is O
highly O
effective O
in O
preventing O
TdP O
via O
shortening O
of O
endocardial O
MAPs, O
reduction O
of O
left O
ventricular O
transmural O
dispersion O
of O
repolarization O
and O
suppression O
of O
EADs O
in O
an O
intact O
heart O
model O
of O
LQT3. O
These O
data O
suggest O
a O
possible O
therapeutic O
role O
of O
verapamil B-CHEMICAL
in O
the O
treatment O
of O
LQT3 O
patients. O
Specificity O
of O
zebrafish B-GENE-Y
retinol I-GENE-Y
saturase: I-GENE-Y
formation O
of O
all-trans-13,14-dihydroretinol B-CHEMICAL
and O
all-trans-7,8- B-CHEMICAL
dihydroretinol. I-CHEMICAL

Metabolism O
of O
vitamin B-CHEMICAL
A, I-CHEMICAL
all-trans-retinol, B-CHEMICAL
leads O
to O
the O
formation O
of O
11-cis-retinaldehyde, B-CHEMICAL
the O
visual O
chromophore, O
and O
all-trans-retinoic B-CHEMICAL
acid, I-CHEMICAL
which O
is O
involved O
in O
the O
regulation O
of O
gene O
expression O
through O
the O
retinoic B-GENE-N
acid I-GENE-N
receptor. I-GENE-N
Enzymes O
and O
binding O
proteins O
involved O
in O
retinoid B-CHEMICAL
metabolism O
are O
highly O
conserved O
across O
species. O
We O
previously O
described O
a O
novel O
mammalian O
enzyme O
that O
saturates O
the O
13-14 O
double O
bond O
of O
all-trans-retinol B-CHEMICAL
to O
produce O

all-trans-13,14-dihydroretinol, B-CHEMICAL
which O
then O
follows O
the O
same O
metabolic O
fate O
as O
that O
of O
all-trans-retinol. B-CHEMICAL
Specifically, O
all-trans-13,14-dihydroretinol B-CHEMICAL
is O
transiently O
oxidized O
to O
all-trans-13,14-dihydroretinoic B-CHEMICAL
acid I-CHEMICAL
before O
being O
oxidized O
further O
by O
Cyp26 B-GENE-Y
enzymes. O
Here, O
we O
report O
the O
identification O
of O
two O
putative O
RetSat B-GENE-Y
homologues O
in O
zebrafish, O
one O
of O
which, O
zebrafish B-GENE-Y
RetSat I-GENE-Y
A I-GENE-Y

(zRetSat B-GENE-Y
A), I-GENE-Y
also O
had O
retinol B-GENE-Y
saturase I-GENE-Y
activity, O
whereas O
zebrafish B-GENE-Y
RetSat I-GENE-Y
B I-GENE-Y
(zRetSat B-GENE-Y
B) I-GENE-Y
was O
inactive O
under O
similar O
conditions. O
Unlike O
mouse B-GENE-Y
RetSat I-GENE-Y
(mRetSat), B-GENE-Y
zRetSat B-GENE-Y
A I-GENE-Y
had O
an O
altered O
bond O
specificity O
saturating O
either O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-retinol B-CHEMICAL
to O
produce O
either O
all-trans-13,14-dihydroretinol B-CHEMICAL
or O
all-trans-7,8-dihydroretinol, B-CHEMICAL
respectively. O

zRetSat B-GENE-Y
A I-GENE-Y
also O
saturated O
the O
13-14 O
or O
7-8 O
double O
bonds O
of O
all-trans-3,4-didehydroretinol B-CHEMICAL
(vitamin B-CHEMICAL
A2), I-CHEMICAL
a O
second O
endogenous O
form O
of O
vitamin B-CHEMICAL
A I-CHEMICAL
in O
zebrafish. O
The O
dual O
enzymatic O
activity O
of O
zRetSat B-GENE-Y
A I-GENE-Y
displays O
a O
newly O
acquired O
specificity O
for O
the O
13-14 O
double O
bond O
retained O
in O
higher O
vertebrates O
and O
also O
the O
evolutionarily O
preserved O
activity O
of O
bacterial B-GENE-N
phytoene I-GENE-N
desaturases I-GENE-N
and O
plant B-GENE-N
carotenoid I-GENE-N
isomerases. I-GENE-N
Expression O
of O
zRetSat B-GENE-Y
A I-GENE-Y
was O
restricted O
to O
the O

liver O
and O
intestine O
of O
hatchlings O
and O
adult O
zebrafish, O
whereas O
zRetSat B-GENE-Y
B I-GENE-Y
was O
expressed O
in O
the O
same O
tissues O
but O
at O
earlier O
developmental O
stages. O
Exogenous O
all-trans-retinol, B-CHEMICAL
all-trans-13,14-dihydroretinol, B-CHEMICAL
or O
all-trans-7,8-dihydroretinol B-CHEMICAL
led O
to O
the O
strong O
induction O
of O
the O
expression O
of O
the O
retinoic B-CHEMICAL
acid-metabolizing I-CHEMICAL
enzyme, O
Cyp26A1, B-GENE-Y
arguing O
for O
an O
active O
signaling O
function O
of O
dihydroretinoid B-CHEMICAL
metabolites O
in O
zebrafish. O
These O
findings O
point O

to O
a O
conserved O
function O
but O
altered O
specificity O
of O
RetSat B-GENE-Y
in O
vertebrates, O
leading O
to O
the O
generation O
of O
various O
dihydroretinoid B-CHEMICAL
compounds, O
some O
of O
which O
could O
have O
signaling O
functions. O
Estimation O
of O
warfarin B-CHEMICAL
maintenance O
dose O
based O
on O
VKORC1 B-GENE-Y
(-1639 B-GENE-N
G>A) I-GENE-N
and O
CYP2C9 B-GENE-Y
genotypes. O
BACKGROUND: O
CYP2C9 B-GENE-Y
polymorphisms O
are O
associated O
with O
decreased O
S-warfarin B-CHEMICAL
clearance O
and O
lower O
maintenance O
dosage. O
Decreased O
expression O
of O
VKORC1 B-GENE-Y
resulting O
from O
the O
-1639G>A B-GENE-N

substitution O
has O
also O
been O
implicated O
in O
lower O
warfarin B-CHEMICAL
dose O
requirements. O
We O
investigated O
the O
additional O
contribution O
of O
this O
polymorphism O
to O
the O
variance O
in O
warfarin B-CHEMICAL
dose. O
METHODS: O
Sixty-five O
patients O
with O
stable O
anticoagulation O
were O
genotyped O
for O
CYP2C9 B-GENE-Y
and O
VKORC1 B-GENE-Y
with O
Tag-It O
allele-specific O
primer O
extension O
technology. O
Plasma O
S-warfarin B-CHEMICAL
concentrations O
and O
warfarin B-CHEMICAL
maintenance O
dose O
were O
compared O
among O
patients O
on O
the O
basis O
of O
the O
VKORC1 B-GENE-Y
-1639G>A B-GENE-N
genotype. O
RESULTS: O
Eighty O
percent O
of O

CYP2C9*1/*1 B-GENE-Y
patients O
stabilized O
on O
<4.0 O
mg/day O
warfarin B-CHEMICAL
had O
at O
least O
1 O
VKORC1 B-GENE-Y
-1639A O
allele. O
Mean O
warfarin B-CHEMICAL
doses O
(SD) O
were O
6.7 O
(3.3), O
4.3 O
(2.2), O
and O
2.7 O
(1.2) O
mg/day O
for O
patients O
with O
the O
VKORC1 B-GENE-Y
-1639GG, O
GA, O
and O
AA O
genotypes, O
respectively. O
Steady-state O
plasma O
concentrations O
of O
S-warfarin B-CHEMICAL
were O
lowest O
in O
patients O
with O
the O
VKORC1 B-GENE-Y

-1639AA O
genotype O
and O
demonstrated O
a O
positive O
association O
with O
the O
VKORC1 B-GENE-Y
-1639G O
allele O
copy O
number O
(trend O
P O
= O
0.012). O
A O
model O
including O
VKORC1 B-GENE-Y
and O
CYP2C9 B-GENE-Y
genotypes, O
age, O
sex, O
and O
body O
weight O
accounted O
for O
61% O
of O
the O
variance O
in O
warfarin B-CHEMICAL
daily O
maintenance O
dose. O
CONCLUSIONS: O
The O
VKORC1 B-GENE-Y
-1639A O
allele O
accounts O
for O
low O
dosage O
requirements O
of O
most O
patients O
without O
a O
CYP2C9 B-GENE-Y
variant. O
Higher O
plasma O
S-warfarin B-CHEMICAL
concentrations O
corresponding O
to O
increased O
warfarin B-CHEMICAL

maintenance O
dosages O
support O
a O
hypothesis O
for O
increased O
expression O
of O
the O
VKORC1 B-GENE-Y
-1639G O
allele. O
VKORC1 B-GENE-Y
and O
CYP2C9 B-GENE-Y
genotypes, O
age, O
sex, O
and O
body O
weight O
account O
for O
the O
majority O
of O
variance O
in O
warfarin B-CHEMICAL
dose O
among O
our O
study O
population. O
The O
role O
of O
rasagiline B-CHEMICAL
in O
the O
treatment O
of O
Parkinson's O
disease. O
Parkinson's O
disease O
(PD) O
is O
the O
second O
most O
common O
neurodegenerative O
disorder, O
affecting O
1% O
to O
2% O
of O
people O
older O
than O
60 O
years. O
Treatment O
of O
PD O
consists O
of O
symptomatic O
therapies O
while O

neuroprotective O
strategies O
have O
remained O
elusive. O
Rasagiline B-CHEMICAL
is O
a O
novel, O
potent, O
and O
irreversible O
monoamine B-GENE-Y
oxidase I-GENE-Y
type I-GENE-Y
B I-GENE-Y
(MAO-B) B-GENE-Y
inhibitor O
which O
has O
been O
approved O
for O
treatment O
of O
PD. O
Rasagiline B-CHEMICAL
inhibits O
MAO-B B-GENE-Y
more O
potently O
than O
selegiline O
and O
has O
the O
advantage O
of O
once-daily O
dosing. O
In O
several O
large, O
randomized, O
placebo-controlled O
trials, O
rasagiline B-CHEMICAL
has O
demonstrated O
efficacy O
as O
monotherapy O
in O
early O
PD O
and O
as O
adjunctive O
therapy O
in O
advanced O
PD. O
In O
addition, O
rasagiline B-CHEMICAL
has O
been O
shown O

to O
have O
neuroprotective O
effects O
in O
in O
vitro O
and O
in O
vivo O
studies. O
The O
recently O
completed O
delayed-start O
ADAGIO O
(Attenuation O
of O
Disease O
Progression O
with O
Azilect O
Given O
Once-daily) O
trial O
suggests O
a O
potential O
disease-modifying O
effect O
for O
rasagiline B-CHEMICAL
1 O
mg/day, O
though O
the O
clinical O
import O
of O
this O
finding O
has O
yet O
to O
be O
established. O
Lithium B-CHEMICAL
modulates O
desensitization O
of O
the O
glutamate B-GENE-N
receptor I-GENE-N
subtype O
gluR3 B-GENE-Y
in O
Xenopus O
oocytes. O
Analysis O
of O
splice O
variants O
and O
site-directed O
mutants O
of O
the O
AMPA B-GENE-N
receptor I-GENE-N

GluR3 B-GENE-Y
expressed O
in O
Xenopus O
oocytes O
has O
shown O
that O
lithium B-CHEMICAL
produces O
a O
large O
potentiation O
of O
the O
GluR3 B-GENE-Y
flop I-GENE-Y
splice O
variant O
and O
suggested O
that O
lithium B-CHEMICAL
might O
inhibit O
rapid O
desensitization, O
which O
is O
characteristic O
of O
this O
receptor O
(Karkanias, O
N. O
and O
Papke, O
R., O
Subtype-specific O
effects O
of O
lithium B-CHEMICAL
on O
glutamate B-GENE-N
receptor I-GENE-N
function. O
J. O
Neurophysiol., O
81 O
(1999) O
1506-1512). O
We O
now O
show O
that O
mutation O
of O
the O
769R/ O
G O
desensitization O
site O

(Lomeli, O
H.M.J., O
Melcher, O
T., O
Hoger, O
T., O
Geiger, O
J.R., O
Kuner, O
T., O
Monyer, O
H., O
Higuchi, O
M.B.A. O
and O
Seeburg, O
P.H, O
Control O
of O
kinetic O
properties O
of O
AMPA B-GENE-N
receptor I-GENE-N
channels O
by O
nuclear O
RNA O
editing. O
Science, O
9(266) O
(1994) O
1709-1713) O
greatly O
attenuates O
the O
lithium-induced B-CHEMICAL
potentiation O
of O
GluR3. B-GENE-Y
Additionally, O
experiments O
with O
the O
non-desensitizing O
site-directed O
mutant O

GluR3(L507Y) B-GENE-Y
(Stern-Bach, O
Y., O
Russo, O
S., O
Neuman, O
M. O
and O
Rosenmund, O
C., O
A O
point O
mutation O
in O
the O
glutamate B-CHEMICAL
binding O
site O
blocks O
desensitization O
of O
AMPA B-GENE-N
receptors. I-GENE-N
Neuron, O
21 O
(1998) O
907-918) O
further O
confirms O
that O
lithium B-CHEMICAL
enhances O
GluR3 B-GENE-Y
responses O
by O
reducing O
desensitization, O
since O
lithium's O
effects O
are O
reversed O
in O
this O
mutant. O
Lithium's O
effects O
on O
GluR3 B-GENE-Y
desensitization O
are O
distinct O
from O
the O
effects O
of O

aniracetam B-CHEMICAL
on O
desensitization. O
Specifically, O
aniracetam, B-CHEMICAL
which O
potentiates O
wild-type O
AMPA B-GENE-N
receptors, I-GENE-N
is O
ineffective O
on O
the O
non-desensitizing O
GluR3(L507Y) B-GENE-Y
mutant, O
but O
has O
synergistic O
effects O
with O
lithium B-CHEMICAL
on O
wild-type O
receptors. O
Oral O
administration O
of O
tetrahydrobiopterin B-CHEMICAL
prevents O
endothelial O
dysfunction O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant B-GENE-N
rats. O
We O
have O
reported O
that O
a O
deficiency O
of O
tetrahydrobiopterin B-CHEMICAL

(BH(4)), B-CHEMICAL
an O
active O
cofactor O
of O
endothelial B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
(eNOS), B-GENE-Y
contributes O
to O
the O
endothelial O
dysfunction O
through O
reduced O
eNOS B-GENE-Y
activity O
and O
increased O
superoxide B-CHEMICAL
anion I-CHEMICAL
(O(2)(-)) B-CHEMICAL
generation O
in O
the O
insulin-resistant B-GENE-N
state. O
To O
further O
confirm O
this O
hypothesis, O
we O
investigated O
the O
effects O
of O
dietary O
treatment O
with O
BH(4) B-CHEMICAL
on O
endothelium-dependent O
arterial O
relaxation O
and O
vascular O
oxidative O
stress O
in O
the O
aortas O
of O
insulin-resistant B-GENE-N
rats. O
Oral O
supplementation O
of O
BH(4) B-CHEMICAL
(10 O

mg. O
kg(-1). O
d(-1)) O
for O
8 O
weeks O
significantly O
increased O
the O
BH(4) B-CHEMICAL
content O
in O
cardiovascular O
tissues O
of O
rats O
fed O
high O
levels O
of O
fructose B-CHEMICAL
(fructose-fed B-CHEMICAL
rats). O
Impairment O
of O
endothelium-dependent O
arterial O
relaxation O
in O
the O
aortic O
strips O
of O
the O
fructose-fed B-CHEMICAL
rats O
was O
reversed O
with O
BH(4) B-CHEMICAL
treatment. O
The O
BH(4) B-CHEMICAL
treatment O
was O
associated O
with O
a O
2-fold O
increase O
in O
eNOS B-GENE-Y
activity O
as O
well O
as O
a O
70% O
reduction O
in O
endothelial O

O(2)(-) B-CHEMICAL
production O
compared O
with O
those O
in O
fructose-fed B-CHEMICAL
rats. O
The O
BH(4) B-CHEMICAL
treatment O
also O
partially O
improved O
the O
insulin B-GENE-N
sensitivity O
and O
blood O
pressure, O
as O
well O
as O
the O
serum O
triglyceride B-CHEMICAL
concentration, O
in O
the O
fructose-fed B-CHEMICAL
rats. O
Moreover, O
BH(4) B-CHEMICAL
treatment O
of O
the O
fructose-fed B-CHEMICAL
rats O
markedly O
reduced O
the O
lipid O
peroxide B-CHEMICAL
content O
of O
both O
aortic O
and O
cardiac O
tissues O
and O
inhibited O
the O
activation O
of O
2 O
redox-sensitive O
transcription O
factors, O
nuclear B-GENE-N
factor-kappaB I-GENE-N
and O
activating B-GENE-Y
protein-1, I-GENE-Y
which O
were O
increased O
in O

fructose-fed B-CHEMICAL
rats. O
The O
BH(4) B-CHEMICAL
treatment O
of O
control O
rats O
did O
not O
have O
any O
significant O
effects O
on O
these O
parameters. O
These O
results O
indicate O
that O
BH(4) B-CHEMICAL
augmentation O
is O
essential O
for O
the O
restoration O
of O
eNOS B-GENE-Y
function O
and O
the O
reduction O
of O
vascular O
oxidative O
stress O
in O
insulin-resistant B-GENE-N
rats. O
A O
Re-evaluation O
of O
the O
Role O
of O
hCTR1, B-GENE-Y
the O
Human B-GENE-N
High I-GENE-N
Affinity I-GENE-N
Cu I-GENE-N
Transporter I-GENE-N
in O
Pt-Drug B-CHEMICAL
Entry O
into O
Human O
Cells. O
Cisplatin B-CHEMICAL
(cDDP) B-CHEMICAL
is O
an O
anti-cancer O
drug O
used O
in O
a O
number O
of O
malignancies O
including O

testicular, O
ovarian, O
cervical, O
bladder, O
lung, O
head, O
and O
neck O
cancers. O
Its O
use O
is O
limited O
by O
the O
development O
of O
resistance, O
often O
rationalized O
via O
effects O
on O
cellular O
uptake. O
It O
has O
been O
claimed O
that O
hCTR1, B-GENE-Y
the O
human B-GENE-N
high I-GENE-N
affinity I-GENE-N
copper I-GENE-N
transporter, I-GENE-N
is O
the O
major O
entry O
pathway O
for O
cDDP B-CHEMICAL
and O
related O
drugs O
via O
a O
mechanism O
that O
mimics O
copper. O
This O
is O
an O
unexpected O
property O
of O
hCTR1, B-GENE-Y
a O
highly O
selective O
copper B-GENE-N
(I) I-GENE-N
transporter. I-GENE-N
We O
compared O
the O
uptake O
rates O
of O
copper O
with O
cDDP O
(and O
several O
analogs) O
into O
HEK293 O

cells O
over-expressing O
wild-type O
or O
mutant O
hCTR1, B-GENE-Y
mouse O
embryonic O
fibroblasts O
(mefs) O
that O
do O
or O
do O
not O
express O
CTR1, B-GENE-Y
and O
human O
ovarian O
tumor O
cells, O
sensitive O
or O
resistant O
to O
cDDP. B-CHEMICAL
We O
have O
also O
compared O
the O
effects O
of O
extracellular O
copper, B-CHEMICAL
which O
causes O
regulatory O
endocytosis O
of O
hCTR1, B-GENE-Y
to O
those O
of O
cDDP. B-CHEMICAL
We O
confirm O
the O
correlation O
between O
higher O
hCTR1 B-GENE-Y
levels O
and O
higher O
Pt-drug B-CHEMICAL
uptake O
in O
tumor O
cells O
sensitive O
to O
the O
drug. O
However, O
we O
show O
that O
hCTR1 B-GENE-Y
is O
not O
the O
major O
entry O
route O

of O
platinum-drugs B-CHEMICAL
and O
that O
the O
copper B-CHEMICAL
transporter O
is O
not O
internalized O
in O
response O
to O
extracellular O
drug. O
Our O
data O
suggest O
the O
major O
entry O
pathway O
for O
platinum-drugs B-CHEMICAL
is O
not O
saturable O
at O
relevant O
concentrations O
and O
not O
protein-mediated. O
Clinical O
trials O
have O
been O
initiated O
that O
depend O
upon O
regulating O
membrane O
levels O
of O
hCTR1. B-GENE-Y
If O
reduced O
drug O
uptake O
is O
a O
major O
factor O
in O
resistance, O
hCTR1 B-GENE-Y
is O
unlikely O
to O
be O
a O
productive O
target O
in O
attempts O
to O
enhance O
efficacy, O
although O
the O
proteins O
involved O
in O
copper B-CHEMICAL
homeostasis O
may O
play O
a O
role. O
Acute O
effects O
of O
brexpiprazole B-CHEMICAL
on O
serotonin, B-CHEMICAL
dopamine, B-CHEMICAL
and O

norepinephrine B-CHEMICAL
systems: O
an O
in O
vivo O
electrophysiologic O
characterization. O
Brexpiprazole, B-CHEMICAL
a O
compound O
sharing O
structural O
molecular O
characteristics O
with O
aripiprazole, B-CHEMICAL
is O
currently O
under O
investigation O
for O
the O
treatment O
of O
schizophrenia O
and O
depression. O
Using O
electrophysiologic O
techniques, O
the O
present O
study O
assessed O
the O
in O
vivo O
action O
of O
brexpiprazole B-CHEMICAL
on O
serotonin B-GENE-N
(5-HT) I-GENE-N
receptor I-GENE-N
subtypes O
5-HT1A, B-GENE-Y
5-HT1B, B-GENE-Y
and O
5-HT2A; B-GENE-Y
dopamine B-GENE-Y
(DA) I-GENE-Y
D2 I-GENE-Y

autoreceptors, I-GENE-Y
and O
alpha1- B-GENE-N
and I-GENE-N
alpha2-adrenergic I-GENE-N
receptors. I-GENE-N
In O
addition, O
the O
effects O
on O
5-HT1A B-GENE-Y
autoreceptors O
in O
the O
dorsal O
raphe O
nucleus O
(DRN) O
and O
D2 B-GENE-Y
autoreceptors I-GENE-Y
in O
the O
ventral O
tegmental O
area O
(VTA) O
were O
compared O
with O
those O
of O
aripiprazole, B-CHEMICAL
an O
agent O
in O
wide O
clinical O
use. O
In O
the O
DRN, O
brexpiprazole B-CHEMICAL
completely O
inhibited O
the O
firing O
of O
5-HT B-CHEMICAL
neurons O
via O
5-HT1A B-GENE-Y
agonism O
and O
was O
more O
potent O
than O
aripiprazole B-CHEMICAL

(ED50 O
= O
230 O
and O
700 O
mug/kg, O
respectively). O
In O
the O
locus O
coeruleus, O
brexpiprazole B-CHEMICAL
reversed O
the O
inhibitory O
effect O
of O
the O
preferential O
5-HT2A B-GENE-Y
receptor O
agonist O
DOI B-CHEMICAL
(2,5-dimethoxy-4-iodoamphetamine) B-CHEMICAL
on O
norepinephrine B-CHEMICAL
neuronal O
firing O
(ED50 O
= O
110 O
mug/kg), O
demonstrating O
5-HT2A B-GENE-Y
antagonistic O
action. O
Brexpiprazole B-CHEMICAL
reversed O
the O
inhibitory O
effect O
of O
the O
DA B-CHEMICAL
agonist O
apomorphine B-CHEMICAL
on O
VTA O

DA O
neurons O
(ED50 O
= O
61 O
mug/kg), O
whereas O
it O
was O
ineffective O
when O
administered O
alone, O
indicating O
partial O
agonistic O
action O
on O
D2 B-GENE-Y
receptors. I-GENE-Y
Compared O
with O
aripiprazole, B-CHEMICAL
which O
significantly O
inhibited O
the O
firing O
activity O
of O
VTA O
DA B-CHEMICAL
neurons, O
brexpiprazole B-CHEMICAL
displayed O
less O
efficacy O
at O
D2 B-GENE-Y
receptors. I-GENE-Y
In O
the O
hippocampus, O
brexpiprazole B-CHEMICAL
acted O
as O
a O
full O
agonist O
at O
5-HT1A B-GENE-Y
receptors O
on O
pyramidal O
neurons. O
Furthermore, O
it O
increased O
5-HT B-CHEMICAL
release O
by O
terminal O
alpha2-adrenergic B-GENE-N
heteroceptor I-GENE-N
but O
not O

5-HT1B B-GENE-Y
autoreceptor O
antagonism. O
In O
the O
lateral O
geniculate O
nucleus, O
brexpiprazole B-CHEMICAL
displayed O
alpha1B-adrenoceptor B-GENE-Y
antagonistic O
action. O
Taken O
together, O
these O
results O
provide O
insight O
into O
the O
in O
vivo O
action O
of O
brexpiprazole B-CHEMICAL
on O
monoamine B-CHEMICAL
targets O
relevant O
in O
the O
treatment O
of O
depression O
and O
schizophrenia. O
Anti-asthmatic O
Effects O
of O
Baicalin B-CHEMICAL
in O
a O
Mouse O
Model O
of O
Allergic O
Asthma. O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
anti-asthmatic O
effects O
of O
baicalin B-CHEMICAL
(BA) O
and O
the O
possible O

mechanisms. O
Asthma O
model O
was O
established O
by O
ovalbumin B-GENE-Y
(OVA) B-GENE-Y
intraperitoneal O
injection. O
A O
total O
of O
60 O
mice O
were O
randomly O
assigned O
to O
six O
experimental O
groups: O
control, O
model, O
dexamethasone B-CHEMICAL
(2 O
mg/kg), O
and O
BA O
(10 O
mg/kg, O
20 O
mg/kg, O
40 O
mg/kg). O
Airway O
resistance O
(RI) O
and O
lung O
compliance O
(Cdyn) O
were O
measured, O
histological O
studies O
were O
evaluated O
by O
the O
hematoxylin B-CHEMICAL
and O
eosin B-CHEMICAL
staining, O
Th1/Th2, O
OVA-specific B-GENE-Y
serum, O
and O
BALF O

IgE B-GENE-N
levels O
and O
Th17 O
cytokines B-GENE-N
were O
evaluated O
by O
enzyme-linked O
immunosorbent O
assay, O
and O
Th17 O
cells O
was O
evaluated O
by O
flow O
cytometry O
(FCM). O
Our O
study O
demonstrated O
that O
BA O
inhibited O
OVA-induced B-GENE-Y
increases O
in O
RI O
and O
eosinophil O
count; O
interleukin O
(IL)-4, B-GENE-Y
IL-17A B-GENE-Y
levels, O
and O
Cdyn O
were O
recovered O
and O
increased O
IFN-γ B-GENE-Y
level O
in O
bronchoalveolar O
lavage O
fluid. O
Histological O
studies O
demonstrated O
that O
BA O
substantially O
inhibited O
OVA-induced B-GENE-Y

eosinophilia O
in O
lung O
tissue O
and O
airway O
tissue. O
FCM O
studies O
demonstrated O
that O
BA O
substantially O
inhibited O
Th17 O
cells. O
These O
findings O
suggest O
that O
BA O
may O
effectively O
ameliorate O
the O
progression O
of O
asthma O
and O
could O
be O
used O
as O
a O
therapy O
for O
patients O
with O
allergic O
asthma. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons, O
Ltd. O
Effects O
of O
fenofibrate, B-CHEMICAL
a O
PPAR-α B-GENE-Y
ligand, O
on O
the O
haemodynamics O
of O
glycerol-induced B-CHEMICAL
renal O
failure O
in O
rats. O
The O
modulating O
effect O
of O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
α I-GENE-Y

ligand O
on O
haemodynamic O
effects O
of O
phenylepherine B-CHEMICAL
(PE), O
angiotensin B-GENE-Y
II I-GENE-Y
(AII), B-GENE-Y
endothelin B-GENE-Y
1 I-GENE-Y
(ET1), B-GENE-Y
acetylcholine B-CHEMICAL
(Ach), B-CHEMICAL
sodium B-CHEMICAL
nitroprusside I-CHEMICAL
(SNP) B-CHEMICAL
and O
isoproterenol B-CHEMICAL
(ISO) B-CHEMICAL
were O
evaluated O
in O
glycerol-induced B-CHEMICAL
acute O
kidney O
injury O
in O
rats. O
The O
effect O
of O
PE O
on O
fenofibrate-treated B-CHEMICAL
animals O
was O
a O
dose-dependent O
increase O
in O
mean O
arterial O
blood O
pressure O
(MAP). O
For O
AII B-GENE-Y
and O
ET1, B-GENE-Y
MAP O
was O
also O

increased O
for O
the O
fenofibrate B-CHEMICAL
group O
but O
not O
in O
a O
dose-dependent O
fashion. O
On O
the O
medullary O
blood O
flow O
(MBF), O
while O
the O
lower O
doses O
of O
PE O
and O
AII B-GENE-Y
increased O
the O
perfusion O
unit O
on O
the O
fenofibrate-treated B-CHEMICAL
group, O
the O
higher O
doses O
decreased O
the O
perfusion O
unit. O
The O
ET1 B-GENE-Y
increased O
the O
perfusion O
unit O
on O
this O
group O
but O
not O
in O
dose-dependent O
fashion. O
The O
effects O
of O
PE O
and O
AII B-GENE-Y
on O
the O
cortical O
blood O
flow O
(CBF) O
of O
fenofibrate-treated B-CHEMICAL
group O
is O
similar O
to O
that O
of O
MBF O
for O
the O
same O
group O
but O
not O

for O
ET1. B-GENE-Y
The O
effect O
of O
Ach, B-CHEMICAL
SNP B-CHEMICAL
and O
ISO B-CHEMICAL
in O
all O
the O
groups O
was O
the O
decrease O
in O
MAP. O
ISO B-CHEMICAL
caused O
dose-dependent O
increase O
in O
MBF O
of O
fenofibrate-treated B-CHEMICAL
group. O
The O
effect O
of O
Ach, B-CHEMICAL
SNP B-CHEMICAL
and O
ISO B-CHEMICAL
on O
the O
CBF O
perfusion O
unit O
was O
that O
of O
the O
increase O
for O
the O
fenofibrate-treated B-CHEMICAL
group. O
The O
study O
showed O
that O
fenofibrate B-CHEMICAL
did O
not O
attenuate O
increased O
blood O
pressure O
induced O
by O
PE, O
AII B-GENE-Y
and O
ET1 B-GENE-Y
but O
caused O
enhanced O
vasodilation O
by O
Ach, B-CHEMICAL
SNP B-CHEMICAL
and O
ISO. B-CHEMICAL
Nanobody-albumin B-GENE-Y

nanoparticles O
(NANAPs) O
for O
the O
delivery O
of O
a O
multikinase B-GENE-N
inhibitor O
17864 B-CHEMICAL
to O
EGFR B-GENE-Y
overexpressing O
tumor O
cells. O
A O
novel, O
EGFR-targeted B-GENE-Y
nanomedicine O
has O
been O
developed O
in O
the O
current O
study. O
Glutaraldehyde B-CHEMICAL
crosslinked O
albumin B-GENE-Y
nanoparticles O
with O
a O
size O
of O
approximately O
100nm O
were O
loaded O
with O
the O
multikinase B-GENE-N
inhibitor O
17864-L(x)-a B-CHEMICAL
platinum-bound B-CHEMICAL
sunitinib B-CHEMICAL
analogue-which O
couples O
the O
drug O
to O
methionine B-CHEMICAL
residues O
of O
albumin B-GENE-Y
and O
is O
released O
in O
a O
reductive O

environment. O
Albumin B-GENE-Y
nanoparticles O
were O
surface-coated O
with O
bifunctional O
polyethylene B-CHEMICAL
glycol I-CHEMICAL
3500 O
(PEG) B-CHEMICAL
and O
a O
nanobody-the O
single O
variable O
domain O
of O
an O
antibody-(Ega1) O
against O
the O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR). B-GENE-Y
EGa1-PEG B-CHEMICAL
functionalized O
nanoparticles O
showed O
a O
40-fold O
higher O
binding O
to O
EGFR-positive B-GENE-Y
14C B-CHEMICAL
squamous O
head O
and O
neck O
cancer O
cells O
in O
comparison O
to O
PEGylated O
nanoparticles. O
17864-L(x) B-CHEMICAL

loaded O
EGa1-PEG B-CHEMICAL
nanoparticles O
were O
internalized O
by O
clathrin-mediated B-GENE-N
endocytosis O
and O
ultimately O
digested O
in O
lysosomes. O
The O
intracellular O
routing O
of O
EGa1 O
targeted O
nanoparticles O
leads O
to O
a O
successful O
release O
of O
the O
kinase B-GENE-N
inhibitor O
in O
the O
cell O
and O
inhibition O
of O
proliferation O
whereas O
the O
non-targeted O
formulations O
had O
no O
antiproliferative O
effects O
on O
14C B-CHEMICAL
cells. O
The O
drug O
loaded O
targeted O
nanoparticles O
were O
as O
effective O
as O
the O
free O
drug O
in O
vitro. O
These O
results O
demonstrate O
that O
multikinase B-GENE-N
inhibitor O
loaded O
nanoparticles O
are O

interesting O
nanomedicines O
for O
the O
treatment O
of O
EGFR-positive B-GENE-Y
cancers. O
Chromosomal O
localization, O
gene O
structure, O
and O
expression O
pattern O
of O
DDAH1: B-GENE-Y
comparison O
with O
DDAH2 B-GENE-Y
and O
implications O
for O
evolutionary O
origins. O
Endogenously O
produced O
asymmetrically O
methylated O
arginine B-CHEMICAL
residues O
are O
competitive O
inhibitors O
of O
all O
three O
isoforms O
of O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N
(NOS). B-GENE-N
The O
enzyme O
dimethylarginine B-GENE-N
dimethylaminohydrolase I-GENE-N
(DDAH) B-GENE-N
specifically O
hydrolyzes O
these O
asymmetrically O
methylated O
arginine B-CHEMICAL
residues O
to O

citrulline O
and O
methylamines. O
Previously O
we O
have O
proposed O
that O
regulation O
of O
asymmetric O
methylarginine B-CHEMICAL
concentration O
by O
DDAH B-GENE-N
may O
provide O
a O
novel O
mechanism O
for O
the O
regulation O
of O
NOS B-GENE-N
activity O
in O
vivo. O
Recently O
we O
reported O
the O
cloning O
of O
human B-GENE-N
DDAH I-GENE-N
and O
identified O
a O
novel O
human B-GENE-N
DDAH I-GENE-N
isoform O
(DDAH B-GENE-Y
I I-GENE-Y
and O
DDAH B-GENE-Y
II, I-GENE-Y
respectively). O
Here O
we O
report O
that O
the O
DDAH1 B-GENE-Y
gene O
maps O
to O
chromosome O
1p22 O
and O
confirm O
that O
DDAH2 B-GENE-Y
maps O
to O
the O
MHC O
III O
region O
of O
chromosome O
6p21.3. O
Extensive O
analysis O
of O
the O

distribution O
of O
DDAH1 B-GENE-Y
and O
DDAH2 B-GENE-Y
mRNA O
in O
50 O
human O
tissues O
indicates O
differential O
expression O
of O
DDAH B-GENE-N
isoforms O
in O
brain O
regions, O
in O
immune O
cells, O
and O
during O
development. O
DDAH2 B-GENE-Y
expression O
predominates O
in O
highly O
vascularized O
tissues O
that O
express O
the O
endothelial B-GENE-Y
NOS I-GENE-Y
isoform O
and O
in O
immune O
tissues O
that O
can O
express O
iNOS. B-GENE-Y
Whereas O
DDAH2 B-GENE-Y
is O
expressed O
at O
relatively O
high O
levels O
in O
all O
fetal O
tissues O
examined, O
DDAH1 B-GENE-Y
expression O
varies O
little O
between O
fetal O
and O
adult O
tissues. O
The O
chromosomal O
localization O
of O
the O
DDAHs B-GENE-N
is O
consistent O
with O
gene O
duplication, O

and O
consistent O
with O
this, O
comparison O
of O
the O
gene O
structures O
indicates O
that O
the O
intron/exon O
organization O
is O
highly O
conserved. O
Phylogenetic O
analysis O
of O
DDAH B-GENE-N
sequences O
from O
diverse O
species O
suggests O
that O
DDAH B-GENE-N
gene O
duplication O
occurred O
prior O
to O
the O
emergence O
of O
bony O
fish O
some O
400 O
million O
years O
ago. O
Overall O
the O
data O
suggest O
that O
DDAH2 B-GENE-Y
may O
be O
the O
more O
ancient O
of O
the O
two O
genes. O
Structure-based O
design O
of O
novel O
dihydroisoquinoline B-CHEMICAL
BACE-1 B-GENE-Y
inhibitors O
that O
do O
not O
engage O
the O
catalytic O
aspartates. B-CHEMICAL
The O
structure-activity O
relationship O
of O
a O
series O
of O
dihydroisoquinoline B-CHEMICAL

BACE-1 B-GENE-Y
inhibitors O
is O
described. O
Application O
of O
structure-based O
design O
to O
screening O
hit O
1 O
yielded O
sub-micromolar O
inhibitors. O
Replacement O
of O
the O
carboxylic B-CHEMICAL
acid I-CHEMICAL
of O
1 O
was O
guided O
by O
X-ray O
crystallography, O
which O
allowed O
the O
replacement O
of O
a O
key O
water-mediated O
hydrogen B-CHEMICAL
bond. O
This O
work O
culminated O
in O
compounds O
such O
as O
31, O
which O
possess O
good O
BACE-1 B-GENE-Y
potency, O
excellent O
permeability O
and O
a O
low O
P-gp B-GENE-N
efflux O
ratio. O
Antidepressant O
use O
and O
glycemic O
control. O
RATIONALE: O
Past O
research O
on O
the O
association O
of O
antidepressant O

medication O
use O
with O
glycemic O
control O
abnormalities O
has O
produced O
mixed O
results. O
OBJECTIVE: O
To O
examine O
the O
association O
of O
antidepressant O
use O
with O
glycemic O
control O
abnormalities O
and O
screen-positive O
diabetes O
in O
a O
representative O
population O
sample O
of O
US O
adults O
without O
a O
diagnosis O
of O
diabetes. O
METHODS: O
Using O
data O
from O
adult O
participants O
of O
the O
National O
Health O
and O
Nutrition O
Examination O
Survey O
(NHANES, O
2005-2010), O
the O
association O
of O
antidepressant O
use O
with O
continuous O
measures O
of O
HbA1c, B-GENE-Y
fasting O
blood O
sugar, B-CHEMICAL
2-h O
oral O
glucose B-CHEMICAL
tolerance O
test, O
insulin B-GENE-Y
sensitivity O
and O
screen-positive O
diabetes O

according O
to O
HbA1c, B-GENE-Y
fasting O
blood O
sugar O
and O
2-h O
oral O
glucose B-CHEMICAL
tolerance O
test O
were O
assessed. O
RESULTS: O
Antidepressant O
use O
was O
not O
associated O
with O
increased O
levels O
of O
HbA1c, B-GENE-Y
fasting O
blood O
sugar, B-CHEMICAL
2-h O
oral O
glucose B-CHEMICAL
tolerance O
test, O
reduced O
insulin B-GENE-Y
sensitivity O
or O
increased O
prevalence O
of O
screen-positive O
diabetes. O
Results O
were O
mostly O
consistent O
across O
sociodemographic O
groups O
and O
across O
different O
lengths O
of O
exposure, O
different O
classes O
of O
antidepressants O
and O
levels O
of O
body O
mass O
index. O
CONCLUSIONS: O
In O
this O
representative O
population O
sample, O
antidepressant O
use O
was O
not O
associated O
with O
an O

increased O
risk O
of O
abnormalities O
in O
glycemic O
control O
or O
undetected O
diabetes. O
Positive O
findings O
from O
past O
research O
may O
be O
attributable O
to O
detection O
bias, O
in O
that O
individuals O
prescribed O
antidepressants O
may O
be O
more O
likely O
to O
be O
tested O
and O
diagnosed O
with O
diabetes. O
Tissue-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
acts O
as O
a O
cytokine B-GENE-N
that O
triggers O
intracellular O
signal O
transduction O
and O
induces O
matrix B-GENE-Y
metalloproteinase-9 I-GENE-Y
gene O
expression. O
Tissue-type B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(tPA), B-GENE-Y
a O
serine B-GENE-N
protease I-GENE-N
well O
known O
for O
generating O
plasmin, B-GENE-Y

has O
been O
demonstrated O
to O
induce O
matrix B-GENE-Y
metalloproteinase-9 I-GENE-Y
(MMP-9) B-GENE-Y
gene O
expression O
and O
protein O
secretion O
in O
renal O
interstitial O
fibroblasts. O
However, O
exactly O
how O
tPA B-GENE-Y
transduces O
its O
signal O
into O
the O
nucleus O
to O
control O
gene O
expression O
is O
unknown. O
This O
study O
investigated O
the O
mechanism O
by O
which O
tPA B-GENE-Y
induces O
MMP-9 B-GENE-Y
gene O
expression. O
Both O
wild-type O
and O
non-enzymatic O
mutant O
tPA B-GENE-Y
were O
found O
to O
induce O
MMP-9 B-GENE-Y
expression O
in O
rat O
kidney O
interstitial O
fibroblasts O
(NRK-49F), O
indicating O
that O
the O
actions O
of O
tPA B-GENE-Y
are O

independent O
of O
its O
proteolytic O
activity. O
tPA B-GENE-Y
bound O
to O
the O
low B-GENE-Y
density I-GENE-Y
lipoprotein I-GENE-Y
receptor-related I-GENE-Y
protein-1 I-GENE-Y
(LRP-1) B-GENE-Y
in O
NRK-49F O
cells, O
and O
this O
binding O
was O
competitively O
abrogated O
by O
the O
LRP-1 B-GENE-Y
antagonist, O
the O
receptor-associated O
protein. O
In O
mouse O
embryonic O
fibroblasts O
(PEA-13) O
lacking O
LRP-1, B-GENE-Y
tPA B-GENE-Y
failed O
to O
induce O
MMP-9 B-GENE-Y
expression. O
Furthermore, O
tPA B-GENE-Y
induced O
rapid O
tyrosine B-CHEMICAL
phosphorylation O
on O
the O
beta O
subunit O
of O
LRP-1, B-GENE-Y
which O
was O
followed O
by O

the O
activation O
of O
Mek1 B-GENE-Y
and O
its O
downstream O
Erk-1 B-GENE-N
and I-GENE-N
-2. I-GENE-N
Blockade O
of O
Erk-1/2 B-GENE-N
activation O
by O
the O
Mek1 B-GENE-Y
inhibitor O
abolished O
MMP-9 B-GENE-Y
induction O
by O
tPA B-GENE-Y
in O
NRK-49F O
cells. O
Conversely, O
overexpression O
of O
constitutively B-GENE-Y
activated I-GENE-Y
Mek1 I-GENE-Y
induced O
Erk-1/2 B-GENE-N
phosphorylation O
and O
MMP-9 B-GENE-Y
expression. O
In O
mouse O
obstructed O
kidney, O
tPA, B-GENE-Y
LRP-1, B-GENE-Y
and O
MMP-9 B-GENE-Y
were O
concomitantly O
induced O
in O
the O
renal O
interstitium. O
Collectively, O
these O

results O
suggest O
that O
besides O
its O
classical O
proteolytic O
activity, O
tPA B-GENE-Y
acts O
as O
a O
cytokine B-GENE-N
that O
binds O
to O
the O
cell O
membrane O
receptor O
LRP-1, B-GENE-Y
induces O
its O
tyrosine B-CHEMICAL
phosphorylation, O
and O
triggers O
intracellular O
signal O
transduction, O
thereby O
inducing O
specific O
gene O
expression O
in O
renal O
interstitial O
fibroblasts. O
Cyclopenta[c]phenanthrenes B-CHEMICAL
- O
Chemistry O
and O
biological O
activity. O
Despite O
cyclopenta-fused B-CHEMICAL
polycyclic I-CHEMICAL
aromatic I-CHEMICAL
hydrocarbons I-CHEMICAL
(CP-PAHs) B-CHEMICAL
having O
been O
detected O
in O
the O

environment, O
the O
ability O
of O
these O
compounds O
to O
induce O
cellular O
and O
tissue O
responses O
remains O
poorly O
characterized. O
In O
this O
review, O
we O
look O
at O
the O
chemistry O
and O
biological O
activity O
of O
the O
cyclopenta[c]phenanthrenes B-CHEMICAL
(CP[c]Ph) B-CHEMICAL
as O
potential O
chemicals O
of O
concern O
in O
the O
process O
of O
risk O
assessment. O
The O
first O
part O
of O
the O
review O
deals O
with O
the O
environmental O
occurrence O
and O
chemistry O
of O
CP-PAHs, B-CHEMICAL
focusing O
on O
available O
methods O
of O
CP[c]Ph B-CHEMICAL
chemical O
synthesis. O
The O
most O
interesting O
structural O
feature O
of O
the O
CP[c]Ph B-CHEMICAL
is O
the O
presence O
of O
a O
pseudo O
fjord-region O
constructed O
by O
the O

cyclopentane B-CHEMICAL
ring. O
This O
compound O
can O
be O
treated O
either O
as O
a O
structurally O
similar O
one O
to O
B[c]Ph, B-CHEMICAL
or O
as O
a O
phenanthrene B-CHEMICAL
skeleton O
with O
an O
electrodonating O
alkyl B-CHEMICAL
substituent O
in O
the O
bay-region O
of O
the O
molecule. O
The O
second O
thread, O
providing O
available O
data O
on O
the O
adverse O
effects O
of O
CP[c]Ph B-CHEMICAL
compounds O
on O
cells O
and O
tissues O
of O
living O
organisms, O
mainly O
fish, O
improves O
our O
understanding O
of O
these O
possible O
environmental O
hazards. O
The O
data O
show O
that O
CP[c]Ph B-CHEMICAL
is O
less O
potent O
at O
inducing O
CYP1A B-GENE-N
gene O
expression O
in O
rainbow O
trout O
than O

benzo[a]pyrene B-CHEMICAL
(B[a]P), B-CHEMICAL
a O
well-known O
Ah-receptor O
agonist. O
Interestingly, O
the O
CP[c]Ph B-CHEMICAL
dependent O
up-regulation O
of O
CYP1A B-GENE-N
mRNA O
is O
positively O
correlated O
with O
the O
incidences O
of O
clastogenic O
changes O
in O
rainbow O
trout O
erythrocytes. O
CP[c]Ph B-CHEMICAL
has, O
comparably O
to O
B[a]P, B-CHEMICAL
a O
potential O
to O
repress O
expression O
of O
tumor B-GENE-Y
suppressor I-GENE-Y
p53, I-GENE-Y
in O
the O
head O
kidney O
of O
rainbow O
trout. O
Furthermore, O
estrogen B-CHEMICAL
responsive O
genes O
in O
fish O
liver, O
ERα B-GENE-Y
and O
VTG, B-GENE-Y
are O
not O

induced O
by O
CP[c]Ph, B-CHEMICAL
suggesting O
that O
the O
compound O
has O
no O
endocrine O
disrupting O
potential. O
However, O
some O
CP[c]Phs B-CHEMICAL
show O
mutagenic O
activity O
when O
investigated O
in O
the O
Ames O
test, O
and O
exhibit O
genotoxic O
properties O
in O
in O
vitro O
micronucleus O
assay. O
The O
above O
characteristics O
suggest O
that O
CP-PAHs B-CHEMICAL
are O
chemicals O
of O
concern O
for O
which O
potential O
pathways O
of O
exposure O
should O
be O
further O
identified. O
Zymogen O
factor B-GENE-Y
IX I-GENE-Y
potentiates O
factor B-GENE-Y
IXa-catalyzed I-GENE-Y
factor B-GENE-Y
X I-GENE-Y
activation. O
Intrinsic O
factor B-GENE-Y
X I-GENE-Y
activation O
is O
accelerated O
>10(7)-fold O
by O
assembly O
of O
the O

entire O
complex O
on O
the O
activated O
platelet O
surface. O
We O
have O
now O
observed O
that O
increasing O
the O
concentration O
of O
zymogen O
factor B-GENE-Y
IX I-GENE-Y
to O
physiologic O
levels O
( O
approximately O
100 O
nM) O
potentiates O
factor B-GENE-Y
IXa-catalyzed I-GENE-Y
activation O
of O
factor B-GENE-Y
X I-GENE-Y
on O
both O
activated O
platelets O
and O
on O
negatively O
charged O
phospholipid O
vesicles. O
In O
the O
presence O
and O
absence O
of O
factor B-GENE-Y
VIIIa, I-GENE-Y
factor B-GENE-Y
IX I-GENE-Y
(100 O
nM) O
lowered O
the O
K(d,appFIXa) B-GENE-Y
approximately O
4-fold O
on O
platelets O
and O
2-10-fold O
on O
lipid O
vesicles. O
Treatment O
of O
two O
factor B-GENE-Y
IX I-GENE-Y
preparations O
with O
active-site O

inhibitors O
did O
not O
affect O
these O
observations. O
Autoradiographs O
of O
PAGE-separated O
reactions O
containing O
either O
(125)I-labeled B-CHEMICAL
factor B-GENE-Y
IX I-GENE-Y
or O
(125)I-labeled B-CHEMICAL
factor B-GENE-Y
X I-GENE-Y
showed O
that O
the O
increased O
factor B-GENE-Y
X I-GENE-Y
activation O
was O
not O
due O
to O
factor B-GENE-Y
Xa-mediated I-GENE-Y
feedback O
activation O
of O
factor B-GENE-Y
IX I-GENE-Y
and O
that O
there O
was O
increased O
cleavage O
of O
factor B-GENE-Y
X I-GENE-Y
heavy I-GENE-Y
chain I-GENE-Y
in O
the O
presence O
of O
factor B-GENE-Y
IX I-GENE-Y
in O
comparison O
with O
control O
reactions O
but O
only O
in O
the O
presence O
of O
both O
the O
enzyme O
and O
the O
surface. O
Since O
plasma O
concentrations O
of O
prothrombin, B-GENE-Y
factor B-GENE-Y
VII, I-GENE-Y
protein B-GENE-Y
C, I-GENE-Y
or O
protein B-GENE-Y
S I-GENE-Y
did O
not O
by O
themselves O
potentiate O
factor B-GENE-N
Xa I-GENE-N
generation O
and O
did O
not O

interfere O
with O
the O
potentiation O
of O
the O
reaction O
of O
factor B-GENE-Y
IX, I-GENE-Y
the O
effect O
is O
specific O
for O
factor B-GENE-Y
IX I-GENE-Y
and O
is O
not O
attributable O
to O
the O
Gla B-GENE-N
domain I-GENE-N
of O
all O
vitamin B-CHEMICAL
K-dependent I-CHEMICAL
proteins. O
These O
observations O
indicate O
that O
under O
physiologic O
conditions, O
plasma O
levels O
of O
the O
zymogen O
factor B-GENE-Y
IX I-GENE-Y
specifically O
increase O
the O
affinity O
of O
factor B-GENE-Y
IXa I-GENE-Y
for O
the O
intrinsic O
factor B-GENE-Y
X I-GENE-Y
activation O
complex. O
Biosynthesis, O
assembly O
and O
secretion O
of O
coagulation B-GENE-Y
factor I-GENE-Y
VIII. I-GENE-Y
Factor B-GENE-Y
VIII I-GENE-Y
is O
a O
large O
complex O
glycoprotein O
that O
is O
deficient O
in O
hemophilia O
A. O
It O
has O
a O
domain O
organization O
consisting O
of O

A1-A2-B-A3-C1-C2 B-GENE-N
where O
the O
B B-GENE-N
domain I-GENE-N
is O
a O
heavily O
glycosylated O
region O
that O
is O
dispensable O
for O
procoagulant O
activity. O
Factor B-GENE-Y
VIII I-GENE-Y
expression O
is O
10-to O
20-fold O
lower O
than O
the O
homologous O
coagulation B-GENE-Y
factor I-GENE-Y
V. I-GENE-Y
Factor B-GENE-Y
VIII I-GENE-Y
expression O
is O
limited O
due O
to O
a O
low O
level O
of O
steady-state O
messenger O
RNA O
in O
the O
cytoplasm O
and O
inefficient O
transport O
of O
the O
primary O
translation O
product O
from O
the O
endoplasmic O
reticulum O
to O
the O
Golgi O
apparatus. O
Within O
the O
secretory O
pathway, O
factor B-GENE-Y
VIII I-GENE-Y
is O
processed O
to O
a O

heterodimer O
of O
the O
heavy O
chain O
(domains B-GENE-N
A1-A2-B) I-GENE-N
in O
a O
metal O
ion O
association O
with O
the O
light O
chain O
(domains B-GENE-N
A3-C1-C2). I-GENE-N
Upon O
secretion O
from O
the O
cell, O
von B-GENE-Y
Willebrand I-GENE-Y
factor I-GENE-Y
binds O
the O
light B-GENE-Y
chain I-GENE-Y
of I-GENE-Y
factor I-GENE-Y
VIII I-GENE-Y
and O
stabilizes O
the O
factor, O
preventing O
degradation. O
Protein O
folding O
within O
the O
mammalian O
secretory O
pathway O
is O
facilitated O
by O
molecular B-GENE-N
chaperones. I-GENE-N
Within O
the O
endoplasmic O
reticulum, O
factor B-GENE-Y
VIII I-GENE-Y
exhibits O
stable O
interaction O
with O
protein O
chaperones O
identified O
as O
the O
immunoglobulin-binding B-GENE-Y
protein I-GENE-Y
(BiP), B-GENE-Y

calnexin B-GENE-Y
and O
calreticulin. B-GENE-Y
BiP B-GENE-Y
is O
a O
peptide-dependent O
ATPase B-GENE-N
that O
interacts O
with O
exposed O
hydrophobic O
surfaces O
on O
unfolded O
proteins O
or O
unassembled O
protein O
subunits. O
A O
potential O
BiP B-GENE-N
binding I-GENE-N
site I-GENE-N
within O
factor B-GENE-Y
VIII I-GENE-Y
has O
been O
identified. O
Mutation O
of O
a O
single O
amino B-CHEMICAL
acid I-CHEMICAL
residue O
in O
the O
potential O
BiP B-GENE-N
binding I-GENE-N
site I-GENE-N
increased O
the O
secretion O
efficiency O
of O
factor B-GENE-Y
VIII I-GENE-Y
by O
threefold. O
Interestingly, O
the O
proposed O
BiP B-GENE-N
binding I-GENE-N
site I-GENE-N
is O
adjacent O
to O
a O
type-1 B-GENE-N
copper I-GENE-N
binding I-GENE-N
site I-GENE-N
within O
the O
A1 B-GENE-N
domain I-GENE-N
that O
is O
required O
for O
interaction O
between O
the O
factor B-GENE-N
VIII I-GENE-N
A1 I-GENE-N
domain I-GENE-N
and O
the O
A3 B-GENE-N
domain. I-GENE-N

We O
propose O
that O
Cu(I) B-CHEMICAL
binds O
the O
type-1 B-GENE-N
copper I-GENE-N
ion-binding I-GENE-N
site I-GENE-N
in O
the O
A1 B-GENE-N
domain I-GENE-N
and O
provides O
the O
essential O
requirement O
for O
a O
stable O
interaction O
between O
the O
heavy O
and O
light O
chains. O
Calnexin B-GENE-Y
and O
calreticulin B-GENE-Y
are O
transmembrane O
and O
lumenal O
proteins, O
respectively, O
localized O
to O
the O
endoplasmic O
reticulum, O
which O
associate O
transiently O
with O
many O
soluble O
and O
membrane O
glycoproteins O
during O
folding O
and O
subunit O
assembly. O
The O
calnexin B-GENE-Y
and O
calreticulin B-GENE-Y
interaction O
with O
factor B-GENE-Y
VIII I-GENE-Y
occurs O
primarily O
through O
amino-terminal B-CHEMICAL
linked O
oligosaccharides O
within O
the O
heavily O

glycosylated O
factor B-GENE-N
VIII I-GENE-N
B I-GENE-N
domain I-GENE-N
and O
this O
interaction O
appears O
to O
be O
required O
for O
factor B-GENE-Y
VIII I-GENE-Y
secretion. O
The O
findings O
suggest O
that O
factor B-GENE-Y
VIII I-GENE-Y
cycles O
through O
interactions O
with O
BiP, B-GENE-Y
calnexin B-GENE-Y
and O
calreticulin. B-GENE-Y
Although O
the O
interaction O
with O
BiP B-GENE-Y
does O
not O
appear O
to O
be O
required O
for O
factor B-GENE-Y
VIII I-GENE-Y
secretion, O
data O
suggest O
that O
the O
calnexin B-GENE-Y
and/or O
calreticulin B-GENE-Y
interaction O
is O
required O
for O
secretion. O
The O
observations O
suggest O
a O
unique O
requirement O
for O
carbohydrate B-CHEMICAL
processing O
and O
calnexin/calreticulin B-GENE-Y
interaction O
that O
may O
limit O
the O
productive O
secretion O
of O
factor B-GENE-Y
VIII I-GENE-Y
and O
have O

implications O
for O
approaches O
towards O
somatic O
cell O
gene O
therapy O
for O
hemophilia O
A. O
Identification O
of O
benzofuran B-CHEMICAL
central O
cores O
for O
the O
inhibition O
of O
leukotriene B-GENE-Y
A(4) I-GENE-Y
hydrolase. I-GENE-Y
Leukotrienes B-CHEMICAL
(LT's) O
are O
known O
to O
play O
a O
physiological O
role O
in O
inflammatory O
immune O
response. O
Leukotriene B-GENE-Y
A(4) I-GENE-Y
hydrolase I-GENE-Y
(LTA(4)H) B-GENE-Y
is O
a O
cystolic O
enzyme O
that O
stereospecifically O
catalyzes O
the O
transformation O
of O
LTA(4) B-CHEMICAL
to O
LTB(4). B-CHEMICAL
LTB(4) B-CHEMICAL

is O
a O
known O
pro-inflammatory O
mediator. O
This O
paper O
describes O
the O
identification O
and O
synthesis O
of O
substituted O
benzofurans B-CHEMICAL
as O
LTH(4)H B-GENE-Y
inhibitors. O
The O
benzofuran B-CHEMICAL
series O
demonstrated O
reduced O
mouse O
and O
human O
whole O
blood O
LTB(4) B-CHEMICAL
levels O
in O
vitro O
and O
led O
to O
the O
identification O
one O
analog O
for O
advanced O
profiling. O
Benzofuran B-CHEMICAL
28 O
showed O
dose O
responsive O
target O
engagement O
and O
provides O
a O
useful O
tool O
to O
explore O
a O
LTA(4)H B-GENE-Y
inhibitor O
for O
the O
treatment O
of O
inflammatory O
diseases, O
such O
as O
asthma O
and O
inflammatory O
bowel O
disease O
(IBD). O
Minocycline B-CHEMICAL

markedly O
protects O
the O
neonatal O
brain O
against O
hypoxic-ischemic O
injury. O
Hypoxic-ischemic O
brain O
injury O
in O
the O
perinatal O
period O
is O
a O
major O
cause O
of O
morbidity O
and O
mortality. O
Presently, O
there O
are O
no O
proven O
effective O
therapies O
with O
which O
to O
safeguard O
the O
human O
neonatal O
brain O
against O
this O
type O
of O
injury. O
Minocycline, B-CHEMICAL
a O
semisynthetic O
tetracycline, B-CHEMICAL
has O
been O
shown O
to O
be O
neuroprotective O
in O
certain O
adult O
ischemic O
injury/stroke O
and O
neurodegenerative O
disease O
models. O
However, O
minocycline's O

neuroprotective O
effects O
have O
not O
been O
assessed O
after O
insults O
to O
the O
neonatal O
brain. O
We O
now O
report O
that O
minocycline B-CHEMICAL
administered O
either O
immediately O
before O
or O
immediately O
after O
a O
hypoxic-ischemic O
insult O
substantially O
blocks O
tissue O
damage O
in O
a O
rodent O
model O
of O
neonatal O
hypoxic-ischemic O
brain O
injury. O
Minocycline B-CHEMICAL
treatment O
prevents O
the O
formation O
of O
activated O
caspase-3, B-GENE-Y
a O
known O
effector O
of O
apoptosis, O
as O
well O
as O
the O
appearance O
of O
a O
calpain B-GENE-N
cleaved O
substrate, O
a O
marker O
of O
excitotoxic/necrotic O
cell O
death. O

To O
our O
knowledge, O
this O
is O
the O
first O
report O
of O
a O
systemic O
treatment O
that O
can O
be O
administered O
after O
a O
hypoxic-ischemic O
insult, O
which O
provides O
robust, O
nearly O
complete O
neuroprotection O
to O
the O
developing O
brain. O
Our O
data O
suggest O
that O
minocycline B-CHEMICAL
or O
a O
related O
neuroprotective O
tetracycline B-CHEMICAL
may O
be O
a O
candidate O
to O
consider O
in O
human O
clinical O
trials O
to O
protect O
the O
developing O
brain O
against O
hypoxic-ischemic-induced O
damage. O
In O
vivo O
comparison O
of O
the O
reinforcing O
and O
dopamine B-GENE-Y
transporter I-GENE-Y
effects O
of O
local O
anesthetics O
in O
rhesus O
monkeys. O
Dopaminergic O

mechanisms O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
reinforcing O
effects O
of O
cocaine. B-CHEMICAL
Similar O
to O
cocaine, B-CHEMICAL
other O
local O
anesthetics O
bind O
to O
the O
dopamine B-GENE-N
transporter I-GENE-N
(DAT) B-GENE-N
and O
inhibit O
DA B-CHEMICAL
uptake O
in O
rodent O
and O
monkey O
brain. O
Additionally, O
local O
anesthetics O
are O
self-administered O
in O
rhesus O
monkeys, O
indicative O
of O
abuse O
liability. O
The O
present O
study O
examined O
the O
reinforcing O
and O
DAT B-GENE-Y
effects O
of O
the O
local O
anesthetics O
dimethocaine, B-CHEMICAL
procaine B-CHEMICAL
and O
cocaine B-CHEMICAL
using O
in O
vivo O
techniques. O
Monkeys O
were O
trained O
to O
respond O
under O
a O
second-order O
schedule O
for O

i.v. O
cocaine B-CHEMICAL
administration O
(0.10 O
or O
0.30 O
mg/kg/infusion). O
When O
responding O
was O
stable, O
dimethocaine B-CHEMICAL
(0.030-1.7 O
mg/kg/ O
infusion) O
or O
procaine B-CHEMICAL
(0.10-10 O
mg/kg/ O
infusion) O
was O
substituted O
for O
the O
cocaine B-CHEMICAL
training O
dose. O
Dimethocaine B-CHEMICAL
administration O
produced O
higher O
response O
rates O
compared O
with O
that O
of O
procaine, B-CHEMICAL
and O
was O
a O
more O
potent O
reinforcer. O
Drug O
effects O
on O
behavior O
were O
related O
to O
DAT B-GENE-Y
occupancy O
in O
monkey O
striatum O
during O
neuroimaging O
with O

positron O
emission O
tomography O
(PET). O
DAT B-GENE-Y
occupancy O
was O
determined O
by O
displacement O
of O
8-(2-[(18)F]fluroethyl)2beta-carbomethoxy-3beta-(4-chlorophenyl)nortropane B-CHEMICAL
(FECNT). B-CHEMICAL
DAT B-GENE-Y
occupancy O
was O
between O
66 O
and O
82% O
and O
<10-41% O
for O
doses O
of O
dimethocaine B-CHEMICAL
and O
procaine B-CHEMICAL
that O
maintained O
maximum O
response O
rates, O
respectively. O
Finally, O
in O
vivo O
microdialysis O
in O
awake O
subjects O
determined O
drug-induced O

changes O
in O
extracellular O
DA B-CHEMICAL
in O
the O
caudate O
nucleus. O
There O
was O
close O
correspondence O
between O
peak O
increases O
in O
DA B-CHEMICAL
and O
DAT B-GENE-Y
occupancy. O
Overall, O
reinforcing O
effects O
were O
consistent O
with O
DAT B-GENE-Y
effects O
determined O
with O
in O
vivo O
techniques. O
The O
results O
further O
support O
a O
role O
for O
the O
DAT B-GENE-Y
in O
the O
abuse O
liability O
of O
local O
anesthetics. O
Bone O
growth O
retardation O
in O
mouse O
embryos O
expressing O
human B-GENE-Y
collagenase I-GENE-Y
1. I-GENE-Y
Cellular O
growth O
and O
differentiation O
are O
readouts O
of O
multiple O
signaling O
pathways O
from O
the O
intercellular O
and/or O
extracellular O
milieu. O
The O
extracellular O
matrix O
through O
the O
activation O
of O
cellular O
receptors O

transmits O
these O
signals. O
Therefore, O
extracellular O
matrix O
proteolysis O
could O
affect O
cell O
fate O
in O
a O
variety O
of O
biological O
events. O
However, O
the O
biological O
consequence O
of O
inadequate O
extracellular O
matrix O
degradation O
in O
vivo O
is O
not O
clear. O
We O
developed O
a O
mouse O
model O
expressing O
human B-GENE-Y
collagenase I-GENE-Y
(matrix B-GENE-Y
metalloproteinase-1, I-GENE-Y
MMP-1) B-GENE-Y
under O
the O
control O
of O
Col2a1 B-GENE-N
promoter. I-GENE-N
The O
mice O
showed O
significant O
growth O
retardation O
during O
embryogenesis O
and O
a O
loss O
of O
the O
demarcation O
of O
zonal O
structure O
and O
columnar O
array O
of O
the O
cartilage. O
Immunological O
examination O
revealed O
increased O
degradation O
of O
type B-GENE-N
II I-GENE-N

collagen I-GENE-N
and O
upregulation O
of O
fibronectin B-GENE-Y
and O
alpha(5)-integrin B-GENE-Y
subunit O
in O
the O
transgenic O
cartilage. O
The O
resting O
zone O
and O
proliferating O
zone O
of O
the O
growth O
plate O
cartilage O
exhibited O
a O
simultaneous O
increase O
in O
bromodeoxyuridine B-CHEMICAL
(BrdU)-incorporated B-CHEMICAL
proliferating O
cells O
and O
terminal O
deoxynucleotidyl O
transferase-mediated O
X-dUTP O
nick-end O
labeling-positive O
apoptotic O
cells, O
respectively. O
Chondrocyte O
differentiation O
was O
not O
disturbed O
in O
the O
transgenic O
mice O
as O
evidenced O
by O
normal O
expression O
of O
the O

Ihh O
and O
type B-GENE-N
X I-GENE-N
collagen I-GENE-N
expression. O
These O
data O
demonstrate O
that O
type B-GENE-N
II I-GENE-N
collagen I-GENE-N
proteolysis O
is O
an O
important O
determinant O
for O
the O
skeletal O
outgrowth O
through O
modulation O
of O
chondrocyte O
survival O
and O
cartilagenous O
growth. O
Neurochemical O
effects O
of O
the O
monoamine B-GENE-N
oxidase I-GENE-N
inhibitor O
phenelzine B-CHEMICAL
on O
brain O
GABA B-CHEMICAL
and O
alanine: B-CHEMICAL
A O
comparison O
with O
vigabatrin. B-CHEMICAL
PURPOSE: O
To O
compare O
phenelzine B-CHEMICAL
(PLZ), B-CHEMICAL
an O
antidepressant O
drug O
with O
anxiolytic O
properties O
which O
inhibits O

monoamine B-GENE-N
oxidase I-GENE-N
(MAO) B-GENE-N
but O
also O
elevates O
rat O
brain O
levels O
of O
the O
amino B-CHEMICAL
acids I-CHEMICAL
?-aminobutyric B-CHEMICAL
acid I-CHEMICAL
(GABA) B-CHEMICAL
and O
alanine B-CHEMICAL
(ALA), B-CHEMICAL
with O
vigabatrin B-CHEMICAL
(VIG), B-CHEMICAL
an O
anticonvulsant O
which O
elevates O
brain O
GABA B-CHEMICAL
by O
inhibition O
of O
GABA B-GENE-Y
transaminase I-GENE-Y
(GABA-T), B-GENE-Y
with O
regard O
to O
their O
actions O
on O
brain O
levels O
of O
GABA B-CHEMICAL
and O
ALA B-CHEMICAL
and O
on O
activities O
of O
MAO, B-GENE-N
GABA-T B-GENE-Y
and O
ALA B-GENE-N
transaminase I-GENE-N
(ALA-T). B-GENE-N
METHODS: O

Male O
rats O
were O
administered O
PLZ B-CHEMICAL
(10 O
mg/kg) O
or O
VIG B-CHEMICAL
(1,000 O
mg/kg) O
i.p., O
and O
the O
rats O
were O
euthanized O
4 O
hours O
later O
and O
the O
brains O
removed O
for O
analysis O
of O
levels O
of O
GABA B-CHEMICAL
and O
ALA B-CHEMICAL
(by O
electron O
capture O
gas O
chromatography O
after O
derivatization) O
and O
activities O
of O
MAO, B-GENE-N
GABA-T B-GENE-Y
and O
ALA-T B-GENE-N
(radiochemical O
assays). O
RESULTS: O
Both O
PLZ B-CHEMICAL
and O
VIG B-CHEMICAL
inhibited O
GABA-T B-GENE-Y
and O
elevated O
GABA B-CHEMICAL
levels. O
Only O
PLZ B-CHEMICAL
inhibited O
MAO B-GENE-N
and O

ALA-T B-GENE-N
and O
elevated O
ALA B-CHEMICAL
levels. O
The O
effects O
of O
PLZ B-CHEMICAL
on O
both O
amino B-CHEMICAL
acids I-CHEMICAL
and O
their O
transaminases B-GENE-N
were O
blocked O
by O
pre-treatment O
with O
the O
MAO B-GENE-N
inhibitor O
tranylcypromine. B-CHEMICAL
This O
pretreament O
had O
no O
effect O
on O
the O
inhibition O
of O
GABA-T B-GENE-Y
or O
the O
elevation O
of O
brain O
GABA B-CHEMICAL
levels O
produced O
by O
VIG. B-CHEMICAL
CONCLUSIONS: O
At O
the O
doses O
studied, O
PLZ B-CHEMICAL
was O
as O
effective O
as O
VIG B-CHEMICAL
at O
elevating O
brain O
GABA B-CHEMICAL
levels, O
but, O
unlike O
VIG, B-CHEMICAL
also O
inhibited O
MAO B-GENE-N
and O
ALA-T B-GENE-N
(and O
increased O
brain O

ALA B-CHEMICAL
levels). O
Pretreatment O
of O
rats O
with O
the O
MAO B-GENE-N
inhibitor O
tranylcypromine B-CHEMICAL
prevented O
the O
increase O
in O
brain O
GABA B-CHEMICAL
and O
ALA B-CHEMICAL
levels O
with O
PLZ, B-CHEMICAL
but O
did O
not O
block O
the O
effect O
of O
VIG B-CHEMICAL
on O
GABA. B-CHEMICAL
These O
observations O
with O
tranylcypromine B-CHEMICAL
and O
PLZ B-CHEMICAL
support O
the O
hypothesis O
that O
an O
active O
metabolite O
of O
PLZ B-CHEMICAL
produced O
by O
the O
actions O
of O
MAO B-GENE-N
on O
this O
drug O
plays O
a O
major O
role O
in O
its O
GABA- B-CHEMICAL
and O
ALA-elevating B-CHEMICAL
actions. O
Clinical O
pharmacology O
of O
enalkiren, B-CHEMICAL
a O
novel, O
dipeptide B-CHEMICAL
renin B-GENE-Y

inhibitor. O
Enalkiren B-CHEMICAL
(A-64662), B-CHEMICAL
a O
potent, O
dipeptide B-CHEMICAL
renin B-GENE-Y
inhibitor, O
mimics O
the O
transition O
state O
of O
the O
human B-GENE-Y
renin I-GENE-Y
substrate, O
angiotensinogen. B-GENE-Y
Enalkiren B-CHEMICAL
has O
been O
shown O
to O
produce O
dose-related O
suppression O
of O
plasma O
renin B-GENE-Y
activity O
(PRA) O
and O
angiotensin B-GENE-Y
II I-GENE-Y
when O
administered O
intravenously. O
Doses O
of O
enalkiren B-CHEMICAL
of O
less O
than O
0.1 O
mg/kg O
induced O
little O
hemodynamic O
response O
in O
normotensive O
and O
hypertensive O
volunteers O
despite O
marked O
suppression O
of O
PRA. O
However, O
at O
doses O
of O
0.3 O
and O

1.2 O
mg/kg, O
enalkiren B-CHEMICAL
produced O
significant, O
dose-related O
decreases O
in O
systolic O
and O
diastolic O
blood O
pressure O
(BP) O
in O
hypertensive O
patients, O
and O
the O
BP O
response O
was O
enhanced O
by O
pretreatment O
with O
hydrochlorothiazide. B-CHEMICAL
The O
effects O
of O
enalkiren B-CHEMICAL
on O
PRA O
and O
BP O
are O
prolonged O
despite O
its O
relatively O
short O
elimination O
phase O
plasma O
half-life O
(1.6 O
h). O
Persistent O
pharmacologic O
activity O
without O
evidence O
of O
tachyphylaxis O
was O
demonstrated O
during O
1 O
week O
of O
treatment O
in O
hypertensive O
patients. O
The O
observed O
dissociation O

between O
suppression O
of O
PRA O
and O
BP O
response O
and O
the O
recruitment O
of O
dose-related O
BP O
decrements, O
despite O
complete O
suppression O
of O
PRA, O
are O
unexplained O
phenomena. O
The O
results O
of O
clinical O
trials O
with O
enalkiren B-CHEMICAL
are O
encouraging, O
and O
suggest O
that O
renin B-GENE-Y
inhibitors O
may O
be O
safe, O
useful O
therapeutic O
agents O
in O
the O
management O
of O
hypertension. O
Methylenedioxymethamphetamine B-CHEMICAL
decreases O
plasmalemmal O
and O
vesicular O
dopamine B-CHEMICAL
transport: O
mechanisms O
and O
implications O
for O
neurotoxicity. O
Administration O
of O
a O
high-dose O
regimen O
of O
methamphetamine B-CHEMICAL
(METH) B-CHEMICAL
rapidly O
and O
profoundly O
decreases O

plasmalemmal O
and O
vesicular O
dopamine B-CHEMICAL
(DA) B-CHEMICAL
transport O
in O
the O
striatum, O
as O
assessed O
in O
synaptosomes O
and O
purified O
vesicles, O
respectively. O
To O
determine O
whether O
these O
responses O
were O
common O
to O
other O
amphetamines B-CHEMICAL
of O
abuse, O
effects O
of O
methylenedioxymethamphetamine B-CHEMICAL
(MDMA) B-CHEMICAL
on O
the O
plasmalemmal O
DA B-GENE-Y
transporter I-GENE-Y
(DAT) B-GENE-Y
and O
vesicular B-GENE-Y
monoamine I-GENE-Y
transporter-2 I-GENE-Y
(VMAT-2) B-GENE-Y
were O
assessed. O
Similar O
to O
effects O
of O
METH B-CHEMICAL
reported O
previously, O
multiple O
high-dose O
MDMA B-CHEMICAL
administrations O
rapidly O
(within O
1 O

h) O
decreased O
plasmalemmal O
DA B-CHEMICAL
uptake, O
as O
assessed O
ex O
vivo O
in O
synaptosomes O
prepared O
from O
treated O
rats. O
Unlike O
effects O
of O
multiple O
METH B-CHEMICAL
injections, O
this O
deficit O
was O
reversed O
completely O
24 O
h O
after O
drug O
treatment. O
Also O
in O
contrast O
to O
effects O
of O
multiple O
METH B-CHEMICAL
injections, O
1) O
MDMA B-CHEMICAL
caused O
little O
or O
no O
decrease O
in O
binding O
of O
the O
DAT B-GENE-Y
ligand O
WIN35428, B-CHEMICAL
and O
2) O
neither O
prevention O
of O
hyperthermia O
nor O
prior O
depletion O
of O
DA B-CHEMICAL
prevented O
the O
MDMA-induced B-CHEMICAL
reduction O
in O
plasmalemmal O
DA B-CHEMICAL
transport. O
However, O
a O
role O
for O
phosphorylation O

was O
suggested O
because O
pretreatment O
with O
protein B-GENE-Y
kinase I-GENE-Y
C I-GENE-Y
inhibitors O
attenuated O
the O
deficit O
caused O
by O
MDMA B-CHEMICAL
in O
an O
in O
vitro O
model O
system. O
In O
addition O
to O
affecting O
DAT B-GENE-Y
function, O
MDMA B-CHEMICAL
rapidly O
decreased O
vesicular O
DA B-CHEMICAL
transport O
as O
assessed O
in O
striatal O
vesicles O
prepared O
from O
treated O
rats. O
Unlike O
effects O
of O
multiple O
METH B-CHEMICAL
injections O
reported O
previously, O
this O
decrease O
partially O
recovered O
by O
24 O
h O
after O
drug O
treatment. O
Taken O
together, O
these O
results O
reveal O
several O
differences O
between O
effects O
of O
MDMA B-CHEMICAL
and O
previously O
reported O
METH B-CHEMICAL
on O
DAT B-GENE-Y
and O
VMAT-2; B-GENE-Y
differences O
that O
may O
underlie O
the O
dissimilar O

neurotoxic O
profile O
of O
these O
agents. O
Concentration-dependent O
inhibitory O
effects O
of O
baicalin B-CHEMICAL
on O
the O
metabolism O
of O
dextromethorphan, B-CHEMICAL
a O
dual O
probe O
of O
CYP2D B-GENE-N
and O
CYP3A, B-GENE-N
in O
rats. O
Baicalin B-CHEMICAL
has O
been O
shown O
to O
possess O
many O
pharmacological O
effects, O
including O
antiviral, O
antioxidant, O
anti-cancer O
and O
anti-inflammatory O
properties. O
In O
the O
current O
study, O
we O
reveal O
the O
inhibitory O
effects O
of O
baicalin B-CHEMICAL
on O
the O
metabolism O
of O
dextromethorphan B-CHEMICAL
(DXM), B-CHEMICAL
a O
dual O
probe O
substrate O
of O

CYP2D B-GENE-N
and O
CYP3A, B-GENE-N
in O
rats. O
Lineweaver-Burk O
plots O
demonstrated O
that O
baicalin B-CHEMICAL
inhibited O
the O
activities O
of O
CYP2D B-GENE-N
and O
CYP3A B-GENE-N
in O
a O
non-competitive O
manner O
in O
rat O
liver O
microsomes O
(RLMs). O
Concomitant O
administration O
of O
baicalin B-CHEMICAL
(0.90g/kg, O
i.v.) O
and O
DXM B-CHEMICAL
(10mg/kg, O
i.v.) O
increased O
the O
maximum O
drug O
concentration O
(Cmax) O
(37%) O
and O
the O
area O
under O
concentration-time O
curve O
(AUC) O

(42%) O
and O
decreased O
the O
clearance O
(CL) O
(27%) O
of O
DXM B-CHEMICAL
in O
a O
randomised, O
crossover O
study O
in O
rats O
(P<0.01). O
The O
change O
in O
the O
AUC O
of O
DXM B-CHEMICAL
was O
significantly O
correlated O
with O
the O
Cmax O
and O
AUC O
of O
baicalin B-CHEMICAL
(P<0.05). O
The O
inhibitory O
effects O
of O
multiple O
doses O
of O
baicalin B-CHEMICAL
(0.90g/kg, O
i.v., O
12days) O
on O
the O
metabolism O
of O
DXM B-CHEMICAL
were O
similar O
to O
those O
observed O
following O
a O
single O
dose O
in O
rats. O
The O
activity O
of O
CYP3A B-GENE-N
in O

excised O
liver O
samples O
from O
rats O
following O
multiple O
baicalin B-CHEMICAL
treatment O
was O
significantly O
decreased O
compared O
to O
that O
of O
the O
control O
group O
(P<0.05), O
whereas O
multiple O
doses O
of O
baicalin B-CHEMICAL
had O
no O
obvious O
effect O
on O
the O
activity O
of O
CYP2D. B-GENE-N
Taken O
together, O
these O
data O
demonstrate O
that O
baicalin B-CHEMICAL
inhibits O
the O
metabolism O
of O
DXM B-CHEMICAL
in O
a O
concentration-dependent O
manner O
in O
rats, O
possibly O
through O
inhibiting O
hepatic O
CYP2D B-GENE-N
and O
CYP3A B-GENE-N
activities. O
Identification O
of O
a O
novel O
benzimidazole B-CHEMICAL
derivative O
as O
a O
highly O
potent O
NPY B-GENE-Y
Y5 I-GENE-Y
receptor I-GENE-Y
antagonist O

with O
an O
anti-obesity O
profile. O
Optimization O
of O
HTS O
hit O
1 O
for O
NPY B-GENE-Y
Y5 I-GENE-Y
receptor I-GENE-Y
binding O
affinity, O
CYP450 B-GENE-N
inhibition, O
solubility O
and O
metabolic O
stability O
led O
to O
the O
identification O
of O
some O
orally O
available O
oxygen-linker B-CHEMICAL
derivatives O
for O
in O
vivo O
study. O
Among O
them, O
derivative O
4i O
inhibited O
food O
intake O
induced O
by O
the O
NPY B-GENE-Y
Y5 I-GENE-Y
selective O
agonist, O
and O
chronic O
oral O
administration O
of O
4i O
in O
DIO O
mice O
caused O
a O
dose-dependent O
reduction O
of O
body O
weight O
gain. O
Esmolol B-CHEMICAL
reduces O
autonomic O
hypersensitivity O
and O
length O
of O
seizures O
induced O
by O

electroconvulsive O
therapy. O
We O
evaluated O
the O
clinical O
effectiveness O
of O
esmolol, B-CHEMICAL
an O
ultra-short-acting O
beta B-GENE-Y
1-adrenergic I-GENE-Y
receptor I-GENE-Y
blocking O
drug, O
to O
control O
the O
sinus O
tachycardia O
and O
increase O
in O
arterial O
blood O
pressures O
induced O
by O
electroconvulsive O
therapy O
(ECT). O
Each O
of O
20 O
patients, O
ASA O
physical O
status O
I-III, O
participated O
in O
a O
double-blind, O
randomized O
study, O
involving O
four O
match-pair O
trials O
(placebo O
versus O
esmolol) B-CHEMICAL
during O
ECT. O
Each O
patient O
acted O
as O
his O
or O
her O
own O
control O
(total O
number O
of O
ECT O
procedures, O
160). O
We O

administered O
a O
4-min O
infusion O
of O
either O
placebo O
or O
esmolol B-CHEMICAL
at O
the O
rate O
of O
500 O
micrograms.kg-1.min-1. O
We O
then O
induced O
anesthesia O
with O
methohexital B-CHEMICAL
and O
succinylcholine. B-CHEMICAL
After O
administration O
of O
electrical O
stimulation O
for O
ECT, O
the O
rate O
of O
infusion O
decreased O
to O
300 O
micrograms.kg-1.min-1 O
for O
three O
additional O
minutes O
and O
was O
then O
discontinued. O
Statistically O
significant O
reductions O
in O
mean O
heart O
rate O
from O
minute O
2 O
until O
minute O
15 O
and O
in O
maximum O
heart O
rate O
(the O
mean O
of O
each O
patient's O
maximum O
heart O
rate O
after O
seizure O
changed O
from O
152 O

+/- O
23 O
to O
115 O
+/- O
24 O
beats/min) O
occurred O
in O
patients O
given O
esmolol. B-CHEMICAL
During O
and O
immediately O
after O
infusion, O
arterial O
blood O
pressure O
also O
decreased. O
Finally, O
the O
length O
of O
seizures O
decreased, O
as O
manifested O
clinically O
from O
48 O
+/- O
18 O
to O
39 O
+/- O
14 O
s O
and O
on O
electroencephalogram O
from O
86 O
+/- O
41 O
to O
67 O
+/- O
28 O
s. O
We O
conclude O
that O
esmolol B-CHEMICAL
effectively O
controls O
the O
hyperdynamic O
response O
to O
ECT O
and O
reduces O
the O
length O
of O
seizures. O
The O
significance O
of O
the O
latter O
to O
the O
overall O
effectiveness O
of O
ECT O
is O
not O
known. O

A O
genetically O
encoded O
and O
gate O
for O
cell-targeted O
metabolic O
labeling O
of O
proteins. O
We O
describe O
a O
genetic O
AND O
gate O
for O
cell-targeted O
metabolic O
labeling O
and O
proteomic O
analysis O
in O
complex O
cellular O
systems. O
The O
centerpiece O
of O
the O
AND O
gate O
is O
a O
bisected O
methionyl-tRNA B-GENE-Y
synthetase I-GENE-Y
(MetRS) B-GENE-Y
that O
charges O
the O
Met B-CHEMICAL
surrogate O
azidonorleucine B-CHEMICAL
(Anl) B-CHEMICAL
to O
tRNA(Met). B-CHEMICAL
Cellular O
protein O
labeling O
occurs O
only O
upon O
activation O
of O
two O
different O
promoters O
that O
drive O
expression O
of O
the O
N- B-CHEMICAL
and O
C-terminal B-CHEMICAL
fragments O
of O
the O
bisected O
MetRS. B-GENE-Y

Anl-labeled B-CHEMICAL
proteins O
can O
be O
tagged O
with O
fluorescent O
dyes O
or O
affinity O
reagents O
via O
either O
copper-catalyzed B-CHEMICAL
or O
strain-promoted O
azide-alkyne O
cycloaddition. O
Protein O
labeling O
is O
apparent O
within O
5 O
min O
after O
addition O
of O
Anl B-CHEMICAL
to O
bacterial O
cells O
in O
which O
the O
AND O
gate O
has O
been O
activated. O
This O
method O
allows O
spatial O
and O
temporal O
control O
of O
proteomic O
labeling O
and O
identification O
of O
proteins O
made O
in O
specific O
cellular O
subpopulations. O
The O
approach O
is O
demonstrated O
by O
selective O
labeling O
of O
proteins O
in O
bacterial O
cells O
immobilized O
in O
the O
center O
of O
a O
laminar-flow O

microfluidic O
channel, O
where O
they O
are O
exposed O
to O
overlapping, O
opposed O
gradients O
of O
inducers O
of O
the O
N- B-CHEMICAL
and O
C-terminal B-CHEMICAL
MetRS B-GENE-Y
fragments. O
The O
observed O
labeling O
profile O
is O
predicted O
accurately O
from O
the O
strengths O
of O
the O
individual O
input O
signals. O
Relative O
myotoxic O
and O
haemodynamic O
effects O
of O
the O
beta-agonists O
fenoterol B-CHEMICAL
and O
clenbuterol B-CHEMICAL
measured O
in O
conscious O
unrestrained O
rats. O
The O
beta(2)-adrenoceptor B-GENE-Y
(beta(2)-AR) B-GENE-Y
agonists O
clenbuterol B-CHEMICAL
and O
fenoterol B-CHEMICAL
have O
similar O
beneficial O
effects O
in O
animal O
models O

of O
heart O
failure. O
However, O
large O
doses O
of O
clenbuterol B-CHEMICAL
can O
induce O
cardiomyocyte O
death, O
and O
it O
is O
not O
known O
which O
of O
these O
agents O
has O
the O
most O
favourable O
therapeutic O
profile. O
We O
have O
investigated O
the O
cardiotoxicity O
of O
clenbuterol B-CHEMICAL
and O
fenoterol B-CHEMICAL
alongside O
that O
of O
isoprenaline, B-CHEMICAL
and O
compared O
their O
haemodynamic O
effects. O
Wistar O
rats O
(n O
= O
6 O
per O
group) O
were O
subcutaneously O
injected O
with O
each O
beta-agonist O
(0.003-3 O
mmol O
kg(-1)) O
or O
saline, O
and O
cardiomyocyte O

apoptosis O
was O
detected O
by O
caspase B-GENE-Y
3 I-GENE-Y
immunohistochemistry. O
In O
a O
separate O
experiment, O
rats O
(n O
= O
4) O
were O
given O
equivalent O
doses O
to O
those O
used O
in O
the O
myotoxicity O
studies, O
in O
a O
randomized O
cross-over O
design, O
and O
their O
blood O
pressure O
recorded O
via O
radiotelemetry. O
Injection O
of O
0.3 O
mmol O
kg(-1) O
fenoterol B-CHEMICAL
or O
isoprenaline, B-CHEMICAL
but O
not O
clenbuterol, B-CHEMICAL
induced O
significant O
cardiomyocyte O
apoptosis O
(0.4 O
+/- O
0.05%; O
P O
< O
0.05). O
At O
3 O

mmol O
kg(-1), O
all O
agonists O
induced O
apoptosis O
(fenoterol, B-CHEMICAL
1.1 O
+/- O
0.1%; O
isoprenaline, B-CHEMICAL
0.9 O
+/- O
0.8%; O
and O
clenbuterol, B-CHEMICAL
0.4 O
+/- O
0.07%; O
P O
< O
0.05). O
beta(1)-Adrenoceptor B-GENE-Y
antagonism O
(10 O
mg O
kg(-1) O
bisoprolol) B-CHEMICAL
prevented O
92% O
(P O
< O
0.05) O
of O
apoptosis O
induced O
by O
all O
three O
agonists, O
but O

clenbuterol-induced B-CHEMICAL
apoptosis O
could O
also O
be O
prevented O
by O
96% O
(P O
< O
0.05) O
by O
beta(2)-AR B-GENE-Y
antagonism O
(10 O
mg O
kg(-1) O
ICI O
118 O
551). O
Clenbuterol B-CHEMICAL
decreased O
diastolic O
(1.3- O
to O
1.6-fold; O
P O
< O
0.05) O
and O
systolic O
blood O
pressure O
(1.3-fold; O
P O
< O
0.05), O
and O
doses O
> O
0.3 O
mmol O
kg(-1) O
increased O
heart O
rate O
(1.4-fold; O
P O
< O

0.05). O
Fenoterol B-CHEMICAL
increased O
heart O
rate O
(1.2- O
to O
1.4-fold; O
P O
< O
0.05), O
and O
doses O
> O
0.3 O
mmol O
kg(-1) O
decreased O
diastolic O
blood O
pressure O
(1.3-fold; O
P O
< O
0.05). O
In O
conclusion, O
the O
cardiotoxicity O
of O
fenoterol B-CHEMICAL
was O
similar O
to O
isoprenaline B-CHEMICAL
and O
greater O
than O
clenbuterol, B-CHEMICAL
and O
fenoterol B-CHEMICAL
had O
less O
desirable O
haemodynamic O
effects. O
Characterization O
of O
four O
new O
mouse B-GENE-N
cytochrome I-GENE-N
P450 I-GENE-N
enzymes O
of O
the O

CYP2J B-GENE-N
subfamily. O
The O
cytochrome B-GENE-N
P450 I-GENE-N
superfamily O
encompasses O
a O
diverse O
group O
of O
enzymes O
that O
catalyze O
the O
oxidation O
of O
various O
substrates. O
The O
mouse O
CYP2J B-GENE-N
subfamily O
includes O
members O
that O
have O
wide O
tissue O
distribution O
and O
are O
active O
in O
the O
metabolism O
of O
arachidonic B-CHEMICAL
acid I-CHEMICAL
(AA), O
linoleic B-CHEMICAL
acid I-CHEMICAL
(LA), O
and O
other O
lipids O
and O
xenobiotics. O
The O
mouse B-GENE-N
Cyp2j I-GENE-N
locus O
contains O
seven O
genes O
and O
three O
pseudogenes O
located O
in O
a O
contiguous O
0.62 O
megabase O
cluster O
on O
chromosome O
4. O
We O
describe O
four O
new O
mouse B-GENE-N
CYP2J I-GENE-N
isoforms O

(designated O
CYP2J8, B-GENE-Y
CYP2J11, B-GENE-Y
CYP2J12, B-GENE-Y
and O
CYP2J13). B-GENE-Y
The O
four O
cDNAs O
contain O
open O
reading O
frames O
that O
encode O
polypeptides O
with O
62-84% O
identity O
with O
the O
three O
previously O
identified O
mouse B-GENE-N
CYP2Js. I-GENE-N
All O
four O
new O
CYP2J B-GENE-N
proteins O
were O
expressed O
in O
Sf21 O
insect O
cells. O
Each O
recombinant O
protein O
metabolized O
AA O
and O
LA O
to O
epoxides B-CHEMICAL
and O
hydroxy B-CHEMICAL
derivatives. O
Specific O
antibodies, O
mRNA O
probes, O
and O
polymerase O
chain O
reaction O
primer O
sets O
were O
developed O
for O
each O
mouse O

CYP2J B-GENE-N
to O
examine O
their O
tissue O
distribution. O
CYP2J8 B-GENE-Y
transcripts O
were O
found O
in O
the O
kidney, O
liver, O
and O
brain, O
and O
protein O
expression O
was O
confirmed O
in O
the O
kidney O
and O
brain O
(neuropil). O
CYP2J11 B-GENE-Y
transcripts O
were O
most O
abundant O
in O
the O
kidney O
and O
heart, O
with O
protein O
detected O
primarily O
in O
the O
kidney O
(proximal O
convoluted O
tubules), O
liver, O
and O
heart O
(cardiomyocytes). O
CYP2J12 B-GENE-Y
transcripts O
were O
prominently O
present O
in O
the O
brain, O
and O
CYP2J13 B-GENE-Y
transcripts O
were O
detected O
in O
multiple O
tissues, O
with O
the O
highest O
expression O
in O
the O
kidney. O

CYP2J12 B-GENE-Y
and O
CYP2J13 B-GENE-Y
protein O
expression O
could O
not O
be O
determined O
because O
the O
antibodies O
developed O
were O
not O
immunospecific. O
We O
conclude O
that O
the O
four O
new O
CYP2J B-GENE-N
isoforms O
might O
be O
involved O
in O
the O
metabolism O
of O
AA O
and O
LA O
to O
bioactive O
lipids O
in O
mouse O
hepatic O
and O
extrahepatic O
tissues. O
The O
effect O
of O
manganese B-CHEMICAL
on O
dopamine B-CHEMICAL
toxicity O
and O
dopamine B-GENE-Y
transporter I-GENE-Y
(DAT) B-GENE-Y
in O
control O
and O
DAT B-GENE-Y
transfected O
HEK O
cells. O
Chronic O
exposure O
to O
Mn B-CHEMICAL
results O
in O
the O
development O
of O
a O
neurological O
disorder O
known O
as O
manganism O
characterized O
by O
neurological O

deficits O
resembling O
that O
seen O
in O
Parkinsonism. O
Although O
dopaminergic O
neurons O
within O
the O
nigrostriatal O
pathway O
appear O
intact, O
Mn-induced B-CHEMICAL
irregularities O
in O
DA O
transmission O
have O
been O
observed O
including O
decreased O
amphetamine-induced B-CHEMICAL
DA O
release O
and O
loss O
of O
the O
dopamine B-GENE-Y
transporter I-GENE-Y
(DAT). B-GENE-Y
Results O
of O
studies O
to O
evaluate O
the O
effect O
of O
Mn B-CHEMICAL
and O
DA O
on O
cell O
viability O
in O
control O
and O
DAT-transfected B-GENE-Y
HEK O
cells O
reveal O
that O
Mn B-CHEMICAL
is O
equally O
toxic O
to O
both O
cell O
lines O
whereas O
DA O
was O
only O
toxic O
to O
cells O
containing O
DAT. B-GENE-Y
DA O
toxicity O
was O
saturable O
suggesting O
that O
transport O
may O

be O
rate O
limiting. O
When O
Mn B-CHEMICAL
and O
DA O
were O
added O
simultaneously O
to O
the O
media, O
cell O
toxicity O
was O
similar O
to O
that O
produced O
by O
Mn B-CHEMICAL
alone O
suggesting O
that O
Mn B-CHEMICAL
may O
suppress O
DA O
uptake O
in O
the O
DAT B-GENE-Y
containing O
cells. O
Preincubation O
of O
DA O
prior O
to O
the O
addition O
of O
Mn B-CHEMICAL
resulted O
in O
cell O
death O
which O
was O
essentially O
additive O
with O
that O
produced O
independently O
by O
the O
two O
agents. O
Mn B-CHEMICAL
was O
also O
shown O
to O
decrease O
DA O
uptake O
and O
amphetamine-induced B-CHEMICAL
DA O
efflux O
in O
DAT B-GENE-Y
containing O
cells. O
Time-lapsed O
confocal O
microscopy O
indicates O
that O
Mn B-CHEMICAL
can O
promote O
trafficking O
of O
cell O
surface O

DAT B-GENE-Y
into O
intracellular O
compartments O
which O
may O
account O
for O
the O
decrease O
in O
DA O
uptake O
and O
DA O
efflux O
in O
these O
cells. O
Mn-induced B-CHEMICAL
internalization O
of O
DAT B-GENE-Y
may O
provide O
an O
explanation O
for O
disruption O
in O
DA O
transmission O
previously O
reported O
in O
the O
striatum. O
Structural O
model O
of O
carnitine B-GENE-Y
palmitoyltransferase I-GENE-Y
I I-GENE-Y
based O
on O
the O
carnitine B-GENE-Y
acetyltransferase I-GENE-Y
crystal. O
CPT B-GENE-Y
I I-GENE-Y
(carnitine B-GENE-Y
palmitoyltransferase I-GENE-Y
I) I-GENE-Y
catalyses O
the O
conversion O
of O
palmitoyl-CoA B-CHEMICAL
into O
palmitoylcarnitine B-CHEMICAL
in O
the O
presence O
of O

L-carnitine, B-CHEMICAL
facilitating O
the O
entry O
of O
fatty B-CHEMICAL
acids I-CHEMICAL
into O
mitochondria. O
We O
propose O
a O
3-D O
(three-dimensional) O
structural O
model O
for O
L-CPT B-GENE-Y
I I-GENE-Y
(liver B-GENE-Y
CPT I-GENE-Y
I), I-GENE-Y
based O
on O
the O
similarity O
of O
this O
enzyme O
to O
the O
recently O
crystallized O
mouse B-GENE-Y
carnitine I-GENE-Y
acetyltransferase. I-GENE-Y
The O
model O
includes O
607 O
of O
the O
773 O
amino B-CHEMICAL
acids I-CHEMICAL
of O
L-CPT B-GENE-Y
I, I-GENE-Y
and O
the O
positions O
of O
carnitine, B-CHEMICAL
CoA B-CHEMICAL
and O
the O
palmitoyl B-CHEMICAL
group O
were O
assigned O
by O
superposition O
and O
docking O
analysis. O
Functional O
analysis O
of O
this O
3-D O
model O
included O
the O

mutagenesis O
of O
several O
amino B-CHEMICAL
acids I-CHEMICAL
in O
order O
to O
identify O
putative O
catalytic O
residues. O
Mutants O
D477A, B-GENE-N
D567A B-GENE-N
and O
E590D B-GENE-N
showed O
reduced O
L-CPT B-GENE-Y
I I-GENE-Y
activity. O
In O
addition, O
individual O
mutation O
of O
amino B-CHEMICAL
acids I-CHEMICAL
forming O
the O
conserved O
Ser685-Thr686-Ser687 O
motif O
abolished O
enzyme O
activity O
in O
mutants O
T686A B-GENE-N
and O
S687A B-GENE-N
and O
altered O
K(m) O
and O
the O
catalytic O
efficiency O
for O
carnitine B-CHEMICAL
in O
mutant O
S685A. B-GENE-N
We O
conclude O
that O
the O
catalytic O
residues O
are O
His473 O
and O
Asp477, O

while O
Ser687 O
probably O
stabilizes O
the O
transition O
state. O
Several O
conserved O
lysines, O
i.e. O
Lys455, O
Lys505, O
Lys560 O
and O
Lys561, O
were O
also O
mutated. O
Only O
mutants O
K455A B-GENE-N
and O
K560A B-GENE-N
showed O
decreases O
in O
activity O
of O
50%. O
The O
model O
rationalizes O
the O
finding O
of O
nine O
natural O
mutations O
in O
patients O
with O
hereditary O
L-CPT B-GENE-Y
I I-GENE-Y
deficiencies. O
Oxysterols B-CHEMICAL
in O
cancer O
cell O
proliferation O
and O
death. O
Oxysterols B-CHEMICAL
have O
been O
shown O
to O
interfere O
with O
proliferation O
and O
cause O
the O
death O
of O
many O
cancer O
cell O
types, O
such O

as O
leukaemia, O
glioblastoma, O
colon, O
breast O
and O
prostate O
cancer O
cells, O
while O
they O
have O
little O
or O
no O
effect O
on O
senescent O
cells. O
The O
mechanisms O
by O
which O
oxysterols B-CHEMICAL
may O
influence O
proliferation O
are O
manifold: O
they O
control O
the O
transcription O
and O
the O
turnover O
of O
the O
key O
enzyme O
in O
cholesterol B-CHEMICAL
synthesis, O
3-hydroxy-3-methylglutaryl B-GENE-Y
CoA I-GENE-Y
reductase, I-GENE-Y
by O
binding O
to O
Insig-1, B-GENE-Y
Insig-2 B-GENE-Y
and O
liver B-GENE-N
X I-GENE-N
receptors. I-GENE-N
Oxysterols B-CHEMICAL
are O
thought O
to O
be O
generated O
in O
proportion O
to O
the O
rate O
of O
cholesterol B-CHEMICAL
synthesis. O
Although O

there O
is O
no O
consensus O
about O
the O
mechanism O
by O
which O
these O
oxysterols B-CHEMICAL
are O
generated O
in O
vivo, O
it O
clearly O
has O
to O
be O
ubiquitous. O
The O
25- B-GENE-N
and I-GENE-N
the I-GENE-N
27-cholesterol I-GENE-N
hydroxylases, I-GENE-N
present O
in O
almost O
all O
tissues, O
are O
possible O
candidates. O
Cholesterol B-CHEMICAL
uptake O
from O
lipoproteins, B-GENE-N
intracellular O
vesicle O
transport O
and O
lipid O
transfer O
are O
also O
modified O
by O
oxysterols. B-CHEMICAL
Oxysterols B-CHEMICAL
interfere O
with O
ERK, B-GENE-N
hedgehog B-GENE-N
and O
wnt B-GENE-N
pathways O
of O
proliferation O
and O
differentiation. O
When O
administered O
in O
vitro O
to O
cancer O
cell O
lines, O
oxysterols B-CHEMICAL

invariably O
both O
slow O
down O
proliferation O
and O
provoke O
cell O
death. O
Perhaps O
is O
it O
sufficient O
to O
stop O
proliferation O
of O
a O
cancer O
to O
provoke O
its O
eradication. O
Therefore, O
the O
two O
facets O
of O
oxysterol B-CHEMICAL
action O
that O
seem O
important O
for O
cancer O
treatment, O
cytostaticity O
and O
cytotoxicity, O
will O
be O
discussed. O
In O
vivo O
HIF-mediated B-GENE-N
reductive O
carboxylation O
is O
regulated O
by O
citrate B-CHEMICAL
levels O
and O
sensitizes O
VHL-deficient B-GENE-Y
cells O
to O
glutamine B-CHEMICAL
deprivation. O
Hypoxic O
and O
VHL-deficient B-GENE-Y
cells O
use O
glutamine B-CHEMICAL
to O
generate O
citrate B-CHEMICAL
and O

lipids O
through O
reductive O
carboxylation O
(RC) O
of O
α-ketoglutarate. B-CHEMICAL
To O
gain O
insights O
into O
the O
role O
of O
HIF B-GENE-N
and O
the O
molecular O
mechanisms O
underlying O
RC, O
we O
took O
advantage O
of O
a O
panel O
of O
disease-associated O
VHL B-GENE-Y
mutants O
and O
showed O
that O
HIF B-GENE-N
expression O
is O
necessary O
and O
sufficient O
for O
the O
induction O
of O
RC O
in O
human O
renal O
cell O
carcinoma O
(RCC) O
cells. O
HIF B-GENE-N
expression O
drastically O
reduced O
intracellular O
citrate B-CHEMICAL
levels. O
Feeding O
VHL-deficient B-GENE-Y
RCC O
cells O
with O
acetate B-CHEMICAL
or O
citrate B-CHEMICAL
or O
knocking O
down O
PDK-1 B-GENE-Y
and O
ACLY B-GENE-Y
restored O
citrate B-CHEMICAL
levels O

and O
suppressed O
RC. O
These O
data O
suggest O
that O
HIF-induced B-GENE-N
low O
intracellular O
citrate B-CHEMICAL
levels O
promote O
the O
reductive O
flux O
by O
mass O
action O
to O
maintain O
lipogenesis. O
Using O
[(1-13)C]glutamine, B-CHEMICAL
we O
demonstrated O
in O
vivo O
RC O
activity O
in O
VHL-deficient B-GENE-Y
tumors O
growing O
as O
xenografts O
in O
mice. O
Lastly, O
HIF B-GENE-N
rendered O
VHL-deficient B-GENE-Y
cells O
sensitive O
to O
glutamine B-CHEMICAL
deprivation O
in O
vitro, O
and O
systemic O
administration O
of O
glutaminase B-GENE-N
inhibitors O
suppressed O
the O
growth O
of O
RCC O
cells O
as O
mice O
xenografts. O
Bioactive O

flavaglines B-CHEMICAL
and O
other O
constituents O
isolated O
from O
Aglaia O
perviridis. O
Eight O
new O
compounds, O
including O
two O
cyclopenta[b]benzopyran B-CHEMICAL
derivatives O
(1, O
2), O
two O
cyclopenta[b]benzofuran B-CHEMICAL
derivatives O
(3, O
4), O
three O
cycloartane B-CHEMICAL
triterpenoids I-CHEMICAL
(5-7), O
and O
an O
apocarotenoid O
(8), O
together O
with O
16 O
known O
compounds, O
were O
isolated O
from O
the O
chloroform-soluble B-CHEMICAL
partitions O
of O
separate O
methanol B-CHEMICAL
extracts O
of O
a O
combination O
of O
the O

fruits, O
leaves, O
and O
twigs O
and O
of O
the O
roots O
of O
Aglaia O
perviridis O
collected O
in O
Vietnam. O
Isolation O
work O
was O
monitored O
using O
human O
colon O
cancer O
cells O
(HT-29) O
and O
facilitated O
with O
an O
LC/MS O
dereplication O
procedure. O
The O
structures O
of O
the O
new O
compounds O
(1-8) O
were O
determined O
on O
the O
basis O
of O
spectroscopic O
data O
interpretation. O
The O
Mosher O
ester O
method O
was O
employed O
to O
determine O
the O
absolute O
configurations O
of O
5-7, O
and O
the O
absolute O
configuration O
of O
the O
9,10-diol B-CHEMICAL
unit O
of O
compound O
8 O
was O
established O
by O
a O
dimolybdenum B-CHEMICAL

tetraacetate I-CHEMICAL
[Mo2(AcO)4] B-CHEMICAL
induced O
circular O
dichroism O
procedure. O
Seven O
known O
rocaglate B-CHEMICAL
derivatives O
(9-15) O
exhibited O
significant O
cytotoxicity O
against O
the O
HT-29 O
cell O
line, O
with O
rocaglaol B-CHEMICAL
(9) O
being O
the O
most O
potent O
(ED50 O
0.0007 O
μM). O
The O
new O
compounds O
2-4 O
were O
also O
active O
against O
this O
cell O
line, O
with O
ED50 O
values O
ranging O
from O
0.46 O
to O
4.7 O
μM. O
The O
cytotoxic O
compounds O
were O
evaluated O
against O
a O
normal O
colon O
cell O
line, O

CCD-112CoN. O
In O
addition, O
the O
new O
compound O
perviridicin B-CHEMICAL
B I-CHEMICAL
(2), O
three O
known O
rocaglate B-CHEMICAL
derivatives O
(9, O
11, O
12), O
and O
a O
known O
sesquiterpene, B-CHEMICAL
2-oxaisodauc-5-en-12-al B-CHEMICAL
(17), O
showed O
significant O
NF-κB B-GENE-N
(p65) B-GENE-Y
inhibitory O
activity O
in O
an O
ELISA O
assay. O
Synthesis O
and O
biological O
evaluation O
of O
novel O
aliphatic B-CHEMICAL
amido-quaternary I-CHEMICAL
ammonium I-CHEMICAL
salts I-CHEMICAL
for O
anticancer O
chemotherapy: O
Part O
II. O
A O

series O
of O
novel O
aliphatic B-CHEMICAL
amido-quaternary I-CHEMICAL
ammonium I-CHEMICAL
salts I-CHEMICAL
were O
synthesized O
and O
evaluated O
for O
their O
anticancer O
effects O
involving O
induction O
of O
RhoB. B-GENE-Y
Most O
of O
these O
compounds, O
featuring O
open-ring O
forms O
of O
aliphatic B-CHEMICAL
amido-quaternary I-CHEMICAL
ammonium I-CHEMICAL
salts, I-CHEMICAL
exhibited O
potent O
anti-proliferative O
activities O
in O
human O
cancer O
cell O
lines, O
including O
PC-3, O
NUGC-3, O
MDA-MB-231, O
ACHN, O
HCT-15, O
and O
NCI-H23. O
In O
further O
evaluation, O
the O
representative O
compound O

N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium B-CHEMICAL
bromide I-CHEMICAL
(3b) O
exhibited O
potent O
pro-apoptotic O
activity, O
through O
RhoB B-GENE-Y
activation, O
in O
HeLa O
cells. O
RNA O
interference-triggered O
reversal O
of O
ABCC2-dependent B-GENE-Y
cisplatin B-CHEMICAL
resistance O
in O
human O
cancer O
cells. O
The O
adenosine B-GENE-N
triphosphate I-GENE-N
binding I-GENE-N
cassette I-GENE-N
(ABC)-transporter I-GENE-N
ABCC2 B-GENE-Y
(MRP2/cMOAT) B-GENE-Y
can O
mediate O
resistance O
against O
the O
commonly O
used O

anticancer O
drugs O
cisplatin B-CHEMICAL
and O
paclitaxel. B-CHEMICAL
To O
overcome O
the O
ABCC2-depending B-GENE-Y
drug O
resistance, O
two O
specific O
anti-ABCC2 B-GENE-Y
small O
interfering O
RNAs O
(siRNAs) O
were O
designed O
for O
transient O
triggering O
of O
the O
gene-silencing O
RNA O
interference O
(RNAi) O
pathway O
in O
the O
cisplatin-resistant B-CHEMICAL
human O
ovarian O
carcinoma O
cell O
line O
A2780RCIS. O
Since O
both O
siRNAs O
showed O
biological O
activity, O
for O
stable O
inhibition O
of O
ABCC2 B-GENE-Y
a O
corresponding O
short O
hairpin O
RNA O
(shRNA)-encoding O
expression O
vector O
was O
designed. O
By O
treatment O
of O

A2780RCIS O
cells O
with O
this O
construct, O
the O
expressions O
of O
the O
targeted O
ABCC2 B-GENE-Y
encoding O
mRNA O
and O
transport O
protein O
were O
inhibited. O
These O
effects O
were O
accompanied O
by O
reversal O
of O
resistance O
against O
cisplatin B-CHEMICAL
and O
paclitaxel. B-CHEMICAL
Thus, O
the O
data O
demonstrate O
the O
utility O
of O
the O
analyzed O
RNAs O
as O
powerful O
laboratory O
tools O
and O
indicate O
that O
siRNA- O
and O
shRNA-mediated O
RNAi-based O
gene O
therapeutic O
approaches O
may O
be O
applicable O
in O
preventing O
and O
reversing O
ABCC2-depending B-GENE-Y
drug O
resistance. O
Epinastine B-CHEMICAL
(WAL B-CHEMICAL
801CL) I-CHEMICAL
modulates O
the O
noncholinergic O
contraction O
in O

guinea-pig O
airways O
in O
vitro O
by O
a O
prejunctional O
5-HT1-like B-GENE-N
receptor. I-GENE-N
Electrical O
field O
stimulation O
(EFS) O
of O
guinea-pig O
airways, O
in O
vitro, O
evokes O
an O
excitatory O
nonadrenergic O
noncholinergic O
(eNANC) O
contraction O
mediated O
by O
release O
of O
tachykinins O
from O
sensory O
nerve O
endings. O
Epinastine B-CHEMICAL
(WAL B-CHEMICAL
801CL) I-CHEMICAL
is O
an O
antihistaminic O
drug O
with O
binding O
affinity O
at O
certain O
other O
receptors, O
including O
alpha-adrenergic B-GENE-N
receptors I-GENE-N
and O
various O
serotonin B-GENE-N

(5-HT) I-GENE-N
receptor I-GENE-N
subtypes. O
It O
is O
used O
in O
asthma O
treatment; O
however, O
its O
mechanism O
of O
action O
remains O
to O
be O
fully O
defined. O
We O
have O
investigated O
whether O
epinastine B-CHEMICAL
could O
modulate O
the O
eNANC O
contraction O
in O
guinea-pig O
airways O
in O
vitro, O
and O
have O
tried O
to O
elucidate O
its O
receptor O
mechanism. O
Epinastine B-CHEMICAL
(0.1-100 O
microM) O
produced O
a O
concentration-dependent O
inhibition O
of O
the O
noncholinergic O
contraction, O
with O
a O
maximum O
inhibition O
of O
91 O
+/- O
7% O
at O
100 O
microM. O
Pretreatment O
of O
the O
tissues O

with O
combined O
5-HT1/5-HT2 B-GENE-N
antagonists, O
methysergide B-CHEMICAL
(1 O
microM) O
or O
methiothepin B-CHEMICAL
(0.1 O
microM), O
significantly O
attenuated O
the O
inhibitory O
effect O
of O
epinastine B-CHEMICAL
on O
the O
noncholinergic O
contraction. O
Pretreatment O
with O
tropisetron B-CHEMICAL
(1 O
microM), O
a O
5-HT3 B-GENE-N
antagonist, O
ketanserin B-CHEMICAL
(10 O
microM), O
a O
5-HT2 B-GENE-N
antagonist, O
thioperamide B-CHEMICAL
(10 O
microM), O
a O
histamine B-GENE-Y
H3 I-GENE-Y
antagonist, O
or O
phentolamine B-CHEMICAL

(10 O
microM), O
an O
alpha-adrenergic O
antagonist, O
however, O
had O
no O
effect. O
Chlorpheniramine B-CHEMICAL
(10 O
microM), O
another O
histamine B-GENE-Y
H1 I-GENE-Y
receptor I-GENE-Y
antagonist O
without O
significant O
5-HT B-GENE-N
receptor I-GENE-N
binding O
affinity, O
did O
not O
produce O
any O
inhibition O
of O
the O
eNANC O
contraction. O
Epinastine B-CHEMICAL
(100 O
microM) O
did O
not O
displace O
the O
dose-response O
curve O
to O
exogenously O
applied O
substance B-GENE-Y
P I-GENE-Y
(0.01-10 O
microM). O
These O
results O
suggest O
that O
epinastine, B-CHEMICAL
although O
identified O
as O
a O
5-HT B-CHEMICAL
antagonist, O
acts O
as O
a O
5-HT1 B-GENE-N

agonist O
and O
that O
it O
inhibits O
the O
noncholinergic O
contraction O
in O
guinea-pig O
airways O
through O
stimulation O
of O
a O
prejunctional O
5-HT1-like B-GENE-N
receptor, I-GENE-N
located O
to O
sensory O
nerves. O
Vitamin B-CHEMICAL
C I-CHEMICAL
forestalls O
cigarette O
smoke O
induced O
NF-κB B-GENE-N
activation O
in O
alveolar O
epithelial O
cells. O
Cigarette O
smoking O
causes O
cellular O
oxidative O
stress O
resulting O
in O
inflammatory O
diseases O
of O
lung O
wherein O
transcription O
factor O
NF-κB B-GENE-N
plays O
an O
important O
role. O
It O
is O
possible O
that O
vitamin B-CHEMICAL
C, I-CHEMICAL
an O
antioxidant, O
may O
prevent O
cigarette O
smoke O
(CS)-induced O
NF-κB B-GENE-N

activation O
that O
involves O
degradation O
of O
I-κBε B-GENE-Y
and O
nuclear O
translocation O
of O
c-Rel/p50 B-GENE-Y
in O
alveolar O
epithelial O
cells. O
Therefore, O
to O
examine O
the O
hypothesis, O
we O
verified O
the O
effect O
of O
vitamin B-CHEMICAL
C I-CHEMICAL
on O
CS-induced O
expression O
of O
NF-κB B-GENE-N
driven O
luciferase O
reporter O
and O
NF-κB B-GENE-N
binding O
at O
its O
target O
DNA O
by O
EMSA O
in O
alveolar O
epithelial O
A549 O
cells. O
We O
also O
examined O
the O
level O
of O
I-κBε B-GENE-Y
and O
sub-cellular O
distribution O
of O
c-Rel B-GENE-Y
by O
western O
blotting O
and O
immunofluorescence O

respectively O
in O
CSE-treated O
A549 O
cells O
with O
or O
without O
vitamin B-CHEMICAL
C I-CHEMICAL
pretreatment. O
We O
observed O
a O
significant O
reduction O
in O
CSE O
induced O
luciferase O
expression, O
NF-κB B-GENE-N
DNA O
binding, O
I-κBε B-GENE-Y
degradation O
and O
c-Rel B-GENE-Y
nuclear O
translocation O
in O
cells O
pretreated O
with O
vitamin B-CHEMICAL
C. I-CHEMICAL
To O
further O
validate O
the O
result, O
we O
examined O
sub-cellular O
distribution O
of O
c-Rel B-GENE-Y
in O
lungs O
of O
CS-exposed O
guinea O
pigs O
treated O
or O
untreated O
with O
vitamin B-CHEMICAL
C. I-CHEMICAL
Result O
showed O
that O
vitamin B-CHEMICAL
C I-CHEMICAL
treatment O
resulted O
in O
markedly O
reduced O
c-Rel B-GENE-Y
nuclear O
translocation. O
All O

these O
results O
demonstrate O
that O
vitamin B-CHEMICAL
C I-CHEMICAL
prevents O
CS(E)-induced O
NF-κB B-GENE-N
activation O
and O
thus O
it O
could O
be O
used O
for O
the O
prevention O
of O
CS-induced O
inflammatory O
diseases. O
Catalpol B-CHEMICAL
suppresses O
advanced O
glycation O
end-products-induced O
inflammatory O
responses O
through O
inhibition O
of O
reactive O
oxygen B-CHEMICAL
species O
in O
human O
monocytic O
THP-1 O
cells. O
Advanced O
glycation O
end-products O
(AGEs) O
play O
a O
pivotal O
role O
in O
the O
development O
of O
diabetic O
complications O
by O
inducing O
inflammation. O
We O
previously O
reported O
that O
the O
fresh O
roots O
of O
Rehmannia O
glutinosa O
Libosch., O
which O
have O
been O
used O
for O
the O
treatment O
of O
diabetes O

in O
traditional O
Korean O
medicine, O
also O
have O
the O
potential O
to O
suppress O
AGE-mediated O
inflammatory O
response O
in O
THP-1 O
cells. O
In O
the O
present O
study, O
we O
isolated O
catalpol B-CHEMICAL
from O
R. O
glutinosa, O
and O
examined O
whether O
it O
has O
anti-inflammatory O
effects O
on O
AGE-stimulated O
THP-1 O
cells. O
Catalpol B-CHEMICAL
reduced O
the O
expression O
of O
pro-inflammatory O
mediates, O
such O
as O
monocyte B-GENE-Y
chemotactic I-GENE-Y
protein-1 I-GENE-Y
(MCP-1), B-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α), B-GENE-Y
inducible B-GENE-Y
NO I-GENE-Y
synthase I-GENE-Y
(iNOS), B-GENE-Y
and O
receptor B-GENE-Y
for I-GENE-Y

AGE I-GENE-Y
(RAGE). B-GENE-Y
Promoter O
and O
electromobility O
shift O
assays O
showed O
that O
transcriptional O
activation O
of O
NF-κB B-GENE-N
was O
significantly O
reduced O
by O
catalpol B-CHEMICAL
treatment, O
while O
AP-1 B-GENE-Y
was O
not. O
Catalpol B-CHEMICAL
also O
suppressed O
AGE-induced O
phosphorylation O
of O
mitogen B-GENE-N
activated I-GENE-N
protein I-GENE-N
(MAP) I-GENE-N
kinases, I-GENE-N
degradation O
of O
IκBα B-GENE-Y
and O
the O
nuclear O
localization O
of O
NF-κB. B-GENE-N
Moreover, O
the O
production O
of O
intracellular O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
elicited O
by O
AGE O
was O
also O
suppressed O
by O
catalpol B-CHEMICAL
treatment, O
through O
dual O
action O
of O
reducing O
ROS O
itself O

and O
inhibiting O
NADPH B-GENE-N
oxidase I-GENE-N
activity. O
Our O
findings O
indicate O
that O
catalpol B-CHEMICAL
suppresses O
AGE-mediated O
inflammation O
by O
inhibiting O
ROS O
production O
and O
NF-κB B-GENE-N
activity. O
We O
suggest O
that O
catalpol, B-CHEMICAL
a O
major O
constituent O
of O
the O
fresh O
roots O
of O
R. O
glutinosa, O
contributes O
to O
the O
prevention O
of O
AGE-mediated O
diabetic O
complications. O
Moxifloxacin B-CHEMICAL
enhances O
etoposide-induced B-CHEMICAL
cytotoxic, O
apoptotic O
and O
anti-topoisomerase B-GENE-Y
II I-GENE-Y
effects O
in O
a O
human O
colon O
carcinoma O
cell O
line. O

Etoposide B-CHEMICAL
(VP-16) B-CHEMICAL
is O
a O
topoisomerase-II B-GENE-Y
(topo B-GENE-Y
II) I-GENE-Y
inhibitor O
chemotherapeutic O
agent. O
Studies O
have O
shown O
that O
a O
combination O
of O
VP-16 B-CHEMICAL
with O
other O
drugs O
demonstrates O
better O
clinical O
responses. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
moxifloxacin B-CHEMICAL
(MXF) B-CHEMICAL
and O
VP-16 B-CHEMICAL
on O
cellular O
topo B-GENE-Y
II I-GENE-Y
activity O
in O
drug-treated O
cells O
and O
evaluate O
the O
influence O
of O
MXF B-CHEMICAL
on O
the O
mode O
of O
action O
of O
VP-16, B-CHEMICAL
on O
proliferation O
and O
apoptosis O
of O
HT-29 O
cells. O
Decatenation O
assay, O
band O

depletion O
and O
Western O
blot O
analysis, O
cytotoxic O
assay O
(MTT), B-CHEMICAL
flow O
cytometric O
studies O
(cell O
cycle O
and O
survivin O
expression), O
apoptosis O
(DAPI-sulforhodamine B-CHEMICAL
staining O
and O
caspase B-GENE-Y
3 I-GENE-Y
activity) O
and O
IL-8 B-GENE-Y
and O
VEGF B-GENE-Y
secretion O
were O
determined. O
MXF B-CHEMICAL
or O
VP-16 B-CHEMICAL
slightly O
affected O
cellular O
topo B-GENE-Y
II I-GENE-Y
activity O
in O
nuclear O
extracts O
derived O
from O
drug-treated O
cells O
while O
the O
combination O
enhanced O
inhibitory O
activity O
and O
the O
reduction O
in O
band O
depletion O
of O
topo B-GENE-Y
II. I-GENE-Y
VP-16 B-CHEMICAL
induced O
cell O
cycle O
arrest O
at O

G2/M O
and O
the O
appearance O
of O
the O
subG1 O
peak O
which O
was O
increased O
by O
the O
addition O
of O
MXF. B-CHEMICAL
Apoptosis O
studies O
(DAPI B-CHEMICAL
staining O
and O
caspase B-GENE-Y
3 I-GENE-Y
activity) O
showed O
a O
marked O
increase O
in O
the O
presence O
of O
MXF B-CHEMICAL
and O
VP-16 B-CHEMICAL
compared O
to O
VP-16 B-CHEMICAL
alone. O
VP-16 B-CHEMICAL
induced O
the O
release O
of O
IL-8, B-GENE-Y
and O
addition O
of O
MXF B-CHEMICAL
reduced O
enhanced O
release O
and O
the O
spontaneous O
release O
of O
VEGF B-GENE-Y
from O
the O
cells. O
In O
conclusion, O
the O
results O
suggest O
that O
the O
enhancement O
in O
the O
reduction O
of O
topo B-GENE-Y
II I-GENE-Y
activity O
by O
the O
combined O
MXF/VP-16 B-CHEMICAL
treatments O
was O
probably O

due O
to O
the O
increase O
in O
the O
level O
of O
the O
DNA-enzyme O
cleavable O
complexes O
formed O
by O
both O
drugs. O
The O
unique O
combination O
of O
MXF/VP-16 B-CHEMICAL
may O
have O
clinical O
benefits O
and O
a O
cytotoxic O
drug O
'sparing O
effect' O
and O
should O
be O
further O
studied O
in O
vivo. O
Thymidine B-GENE-N
kinase I-GENE-N
and O
thymidine B-GENE-Y
phosphorylase I-GENE-Y
level O
as O
the O
main O
predictive O
parameter O
for O
sensitivity O
to O
TAS-102 B-CHEMICAL
in O
a O
mouse O
model. O
TAS-102 B-CHEMICAL
is O
a O
new O
oral O
anti-cancer O
drug O
preparation, O
composed O
of O
a O
1:0.5 O
mixture O
(on O
a O
molar O
basis) O
of O

alpha,alpha,alpha-trifluorothymidine B-CHEMICAL
(FTD) B-CHEMICAL
and O
5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]-2,4(1H,3H)-pyrimidinedione B-CHEMICAL
hydrochloride I-CHEMICAL
(TPI). B-CHEMICAL
TAS-102 B-CHEMICAL
currently O
undergoing O
clinical O
trials, O
has O
been O
demonstrated O
to O
have O
at O
least O
two O
mechanisms, O
inhibition O
of O
TS B-GENE-Y
and O
incorporation O
into O
DNA. O
We O
hypothesized O
that O
the O
thymidine B-CHEMICAL
metabolism O
enzyme O
may O
be O
a O
crucial O
factor O
that O
affects O
the O
antitumor O

activity O
of O
TAS-102. B-CHEMICAL
In O
the O
present O
study, O
we O
measured O
the O
enzyme O
activity O
of O
thymidine B-GENE-N
kinase I-GENE-N
(TK), B-GENE-N
thymidine B-GENE-Y
phosphorylase I-GENE-Y
(TP) B-GENE-Y
and O
thymidilate B-GENE-Y
synthase I-GENE-Y
(TS) B-GENE-Y
in O
human O
cancer O
xenografts O
to O
investigate O
the O
contribution O
of O
these O
enzymes O
to O
the O
sensitivity O
of O
TAS-102. B-CHEMICAL
Antitumor O
activity O
of O
TAS-102 B-CHEMICAL
appears O
to O
be O
associated O
with O
TK, B-GENE-N
tumor O
growth O
and O
TS. B-GENE-Y
However, O
the O
most O
related O
factors O
in O
this O
study O
were O
the O
TK B-GENE-N
and O
TP B-GENE-Y
ratio. O
There O
was O
a O
significant O
correlation O

(p=0.04) O
between O
tumor O
growth O
inhibition O
and O
this O
ratio. O
These O
results O
suggested O
that O
the O
activation O
and O
degradation O
pattern O
of O
FTD B-CHEMICAL
plays O
an O
important O
role O
in O
the O
efficacy O
of O
TAS-102 B-CHEMICAL
and O
that O
it O
is O
possible O
to O
use O
the O
TK/TP B-GENE-N
ratio O
to O
predict O
response O
to O
TAS-102 B-CHEMICAL
therapy. O
We O
also O
studied O
the O
influence O
of O
TPI B-CHEMICAL
on O
the O
capacity O
of O
exogenous O
dThd O
to O
reverse O
FTD-dependent B-CHEMICAL
growth O
inhibition. O
Thymidine B-CHEMICAL
(dThd) O
levels O
rescued O
the O
effect O
of O
FTD B-CHEMICAL
in O
vitro O
and O
significantly O
increased O
in O
serum O
after O
administration O
of O

TAS-102 B-CHEMICAL
or O
TPI B-CHEMICAL
alone O
but O
not O
FTD B-CHEMICAL
alone. O
This O
may O
suggest O
the O
possibility O
of O
a O
decrease O
in O
antitumor O
effect. O
However, O
our O
study O
indicated O
that O
the O
therapeutic O
index O
was O
clearly O
increased O
by O
FTD B-CHEMICAL
combined O
with O
TPI, B-CHEMICAL
compared O
with O
FTD B-CHEMICAL
alone, O
suggesting O
FTD-induced B-CHEMICAL
toxicity O
to O
sensitive O
host O
tissue O
can O
be O
selectively O
reversed O
with O
dThd. O
In O
conclusion, O
TK B-GENE-N
and O
TPI B-CHEMICAL
effects O
on O
TP B-GENE-Y
play O
important O
roles O
in O
the O
cytotoxic O
action O
of O
TAS-102, B-CHEMICAL
and O
it O
is O
possible O
to O
use O
the O
TK/TP B-GENE-N
ratio O
to O
predict O
more O
precisely O
individual O

resistance O
or O
sensitivity. O
Furanodiene B-CHEMICAL
Presents O
Synergistic O
Anti-proliferative O
Activity O
With O
Paclitaxel B-CHEMICAL
Via O
Altering O
Cell O
Cycle O
and O
Integrin B-GENE-N
Signaling O
in O
95-D O
Lung O
Cancer O
Cells. O
Furanodiene B-CHEMICAL
(FUR) B-CHEMICAL
is O
a O
natural O
terpenoid B-CHEMICAL
isolated O
from O
Rhizoma O
Curcumae, O
a O
well-known O
Chinese O
medicinal O
herb O
that O
presents O
anti-proliferative O
activities O
in O
several O
cancer O
cell O
lines. O
Recently, O
we O
found O
that O
the O
combined O
treatment O
of O
FUR B-CHEMICAL
with O
paclitaxel B-CHEMICAL
(TAX) B-CHEMICAL
showed O
synergetic O
anti-proliferative O

activities O
in O
95-D O
lung O
cancer O
cells. O
Herein, O
we O
showed O
that O
FUR B-CHEMICAL
reduced O
the O
cell O
numbers O
distributed O
in O
mitosis O
phase O
induced O
by O
TAX B-CHEMICAL
while O
increased O
those O
in O
G1 O
phase. O
The O
protein O
levels O
of O
cyclin B-GENE-Y
D1, I-GENE-Y
cyclin B-GENE-Y
B1, I-GENE-Y
CDK6 B-GENE-Y
and O
c-Myc B-GENE-Y
were O
all O
down-regulated O
in O
the O
group O
of O
combined O
treatment. O
The O
dramatically O
down-regulated O
expression O
of O
integrin B-GENE-Y
β4, I-GENE-Y
focal B-GENE-Y
adhesion I-GENE-Y
kinase I-GENE-Y
and O
paxillin B-GENE-Y
might O
partially O
contribute O
to O
the O
synergic O
effect. O
Though O
FUR B-CHEMICAL
alone O
obviously O
induced O
endoplasmic O
reticulum O
stress, O

this O
signaling O
pathway O
may O
not O
contribute O
to O
the O
synergetic O
anti-proliferative O
effect O
as O
the O
protein O
expression O
of O
CHOP B-GENE-Y
and O
BIP B-GENE-Y
was O
similar O
in O
FUR B-CHEMICAL
alone O
and O
combined O
treatment O
group. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons, O
Ltd. O
The O
mechanisms O
responsible O
for O
garlic O
- O
drug O
interactions O
and O
their O
in O
vivo O
relevance. O
Garlic O
phytochemicals O
and O
garlic O
supplements O
influence O
the O
pharmacokinetic O
and O
pharmacodynamic O
behavior O
of O
concomitantly O
ingested O
drugs. O
In O
this O
paper O
we O
have O
summarized O
the O
mechanisms O
responsible O
for O
first-pass O
intestinal O
pharmacokinetic O
interactions O
by O
investigating O
the O

intestinal O
permeability O
of O
some O
cardiovascular, O
antiviral O
drugs, O
their O
transport O
with O
hepatic O
transporters O
and O
CYP3A4 B-GENE-Y
metabolism. O
Transporter-enzyme O
interplay O
was O
studied O
with O
several O
in O
vitro O
models O
of O
varying O
complexity: O
rat O
small O
intestine O
and O
Caco-2 O
cell O
monolayers O
were O
used O
in O
studies O
of O
intestinal O
processes, O
and O
hepatic O
pharmacokinetics O
was O
monitored O
in O
HepG2 O
cells, O
isolated O
rat O
hepatocytes O
and O
rat O
liver O
slices. O
Garlic O
phytochemicals O
from O
aged O
garlic O
extract O
modified O
the O
activities O
of O
secretory O
and O

absorptive O
transporters O
in O
both O
intestine O
and O
liver O
and O
competitively O
inhibited O
CYP3A4 B-GENE-Y
enzyme. O
The O
increased O
activities O
of O
the O
most O
important O
intestinal O
efflux O
(P-glycoprotein B-GENE-N
- O
Pgp, B-GENE-N
Multidrug B-GENE-Y
Resistance I-GENE-Y
Associated I-GENE-Y
Protein I-GENE-Y
2 I-GENE-Y
- O
MRP-2, B-GENE-Y
Breast B-GENE-Y
Cancer I-GENE-Y
Resistance I-GENE-Y
Protein I-GENE-Y
- O
BCRP) B-GENE-Y
and O
uptake O
(MonoCarboxylate B-GENE-Y
Transporter I-GENE-Y
1 I-GENE-Y
- O
MCT1, B-GENE-Y
Organic B-GENE-N
Anion I-GENE-N
Transporting I-GENE-N
Polypeptide I-GENE-N
- O
OATP, B-GENE-N
Peptide B-GENE-Y
transporter I-GENE-Y
1 I-GENE-Y
- O
PepT1) B-GENE-Y
transporters O
were O

caused O
by O
changes O
in O
electrophysiological O
membrane O
properties O
and O
by O
allosteric O
modifications. O
Because O
clinical O
studies O
investigating O
interactions O
between O
garlic O
and O
human B-GENE-N
immunodeficiency I-GENE-N
virus I-GENE-N
protease I-GENE-N
inhibitors O
saquinavir B-CHEMICAL
and O
ritonavir B-CHEMICAL
have O
already O
been O
performed, O
we O
used O
these O
in O
vivo O
data O
to O
evaluate O
the O
in O
vitro O
results O
and O
the O
reliability O
of O
the O
models O
employed O
as O
screening O
tools O
for O
forecasting O
the O
potential O
of O
first-pass O
intestinal O
metabolism O
changes. O
We O
also O
assessed O
the O
probability O
of O
pharmacokinetic O
interactions O
with O
garlic O
of O
the O
novel O
drug O
darunavir B-CHEMICAL
and O
other O
cardiovascular O
drugs. O
Finally, O
selected O
garlic O

phytochemicals O
were O
tested O
for O
their O
ability O
to O
influence O
P-glycoprotein B-GENE-N
and O
CYP3A4 B-GENE-Y
activities. O
The O
effects O
of O
labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
on O
isolated O
cardiovascular O
preparations O
of O
the O
guinea-pig O
and O
rat. O
Differing O
effects O
of O
labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
on O
cardiovascular O
preparations O
have O
been O
reported. O
I O
have O
studied O
the O
effects O
of O
labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
on O
the O
contractile O
responses O
of O
the O
rat O
and O
guinea-pig O
left O
atria O
and O
rat O
portal O
vein. O
On O
the O
guinea-pig O
left O
atria O
low O
concentrations O
of O

labetalol B-CHEMICAL
(> O
or O
= O
10(-8) O
M) O
and O
of O
dilevalol B-CHEMICAL
(> O
or O
= O
10(-7) O
M) O
inhibited O
to O
a O
small O
extent O
the O
responses O
to O
electrical O
cardiac O
stimulation, O
which O
is O
indicative O
of O
membrane O
stabilizing O
activity. O
Labetalol B-CHEMICAL
(> O
or O
= O
3 O
x O
10(-8) O
M) O
and O
dilevalol B-CHEMICAL
(> O
or O
= O
10(-8) O
M) O
caused O
surmountable O
antagonism O
of O
the O
isoprenaline B-CHEMICAL
responses O
of O
the O
atria O
and O
the O
pA2 O
values O
were O
8.60 O
and O
8.98 O
at O
the O
beta B-GENE-N

1-adrenoceptors I-GENE-N
of O
the O
rat O
left O
atria O
and O
7.90 O
and O
8.31, O
respectively, O
on O
the O
guinea-pig O
left O
atria O
which O
has O
functional O
beta B-GENE-N
1- I-GENE-N
and I-GENE-N
beta I-GENE-N
2-adrenoceptors. I-GENE-N
Labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
(both O
at O
> O
or O
= O
10(-7) O
M) O
attenuated O
the O
spontaneous O
contractile O
activity O
of O
the O
rat O
portal O
vein O
and O
the O
attenuation O
to O
labetalol B-CHEMICAL
at O
10(-6) O
M O
was O
abolished O
by O
ICI B-CHEMICAL
118,551 I-CHEMICAL
which O
illustrates O
that O
the O
labetalol-induced B-CHEMICAL
attenuation O
is O
beta B-GENE-Y

2-adrenoceptor I-GENE-Y
mediated. O
The O
isoprenaline B-CHEMICAL
attenuation O
responses O
of O
the O
portal O
vein O
were O
inhibited O
by O
labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
(both O
at O
> O
or O
= O
10(-7) O
M) O
and O
the O
pA2 O
value O
for O
the O
labetalol B-CHEMICAL
at O
beta B-GENE-N
2-adrenoceptors I-GENE-N
was O
7.59. O
It O
is O
concluded O
that O
labetalol B-CHEMICAL
and O
dilevalol B-CHEMICAL
are O
beta B-GENE-N
1-adrenoceptor I-GENE-N
selective O
antagonists. O
[Effect O
of O
mifepristone B-CHEMICAL
on O
the O
expression O
of O
progesterone B-GENE-Y
receptor I-GENE-Y
messenger O
RNA O
and O
protein O
in O
uterine O

leiomyomata]. O
OBJECTIVE: O
To O
determine O
the O
expression O
of O
progesterone B-GENE-Y
receptor I-GENE-Y
(PR) B-GENE-Y
mRNA O
and O
PR B-GENE-Y
protein I-GENE-Y
levels O
in O
the O
myometrium O
and O
leiomyomata O
from O
untreated O
and O
mifepristone B-CHEMICAL
pretreated O
women O
with O
leiomyoma O
and O
to O
examine O
the O
mechanism O
of O
mifepristone B-CHEMICAL
treatment O
on O
uterine O
leiomyomata. O
METHODS: O
Expression O
of O
PR B-GENE-N
mRNA I-GENE-N
and O
PR B-GENE-Y
protein I-GENE-Y
were O
determined O
by O
Northern O
blot O
and O
HAP O
of O
single-dose O
saturated O
analysis O
in O
myometrium O
and O
leiomyomata O

(center O
and O
marginal O
area) O
from O
27 O
untreated O
and O
6 O
mifepristone B-CHEMICAL
pretreated O
women O
with O
leiomyomata. O
RESULTS: O
PR B-GENE-N
mRNA I-GENE-N
abundance O
and O
PR B-GENE-Y
protein I-GENE-Y
levels O
in O
both O
myomatous O
center O
and O
marginal O
area O
were O
significantly O
greater O
than O
those O
in O
corporal O
myometrium O
(P O
< O
0.01) O
in O
both O
follicular O
and O
luteal O
phases, O
but O
similar O
between O
myomatous O
center O
and O
marginal O
area O
(P O
> O
0.05). O
6 O
cases O
pretreated O
with O
mifepristone B-CHEMICAL
25 O
mg/day O
for O
3 O
months O
were O
operated, O
all O
but O

one O
patient O
displayed O
a O
decrease O
in O
leiomyomata O
volume. O
PR B-GENE-N
mRNA I-GENE-N
abundance O
in O
both O
myometruim O
and O
leiomyomata O
(center O
and O
marginal O
area) O
was O
significantly O
decreased O
in O
4 O
patients O
continuing O
mifepristone B-CHEMICAL
treatment O
before O
the O
operation O
but O
not O
in O
the O
other O
2 O
patients O
stopping O
RU486 B-CHEMICAL
1 O
month O
before O
operation. O
PR B-GENE-Y
protein I-GENE-Y
levels O
in O
these O
tissues O
showed O
significant O
decrease O
in O
all O
6 O
cases. O
CONCLUSION: O
There O
are O
overexpression O
of O
PRmRNA B-GENE-N
and O
PR B-GENE-Y
protein I-GENE-Y
in O
leiomyomata. O
One O
of O
the O
mechanism O
of O
mifepristone B-CHEMICAL
action O
on O
decreasing O

leiomyomata O
volume O
may O
be O
related O
to O
suppression O
on O
expression O
of O
PR B-GENE-Y
gene. I-GENE-Y
It O
seems O
that O
suppression O
on O
transcription O
of O
PR B-GENE-Y
gene I-GENE-Y
is O
reversible, O
but O
on O
translation O
of O
PR B-GENE-Y
gene I-GENE-Y
may O
maintain O
in O
a O
relatively O
longer O
period. O
Accumulation O
of O
cystathionine, B-CHEMICAL
cystathionine B-CHEMICAL
ketimine, I-CHEMICAL
and O
perhydro-1,4-thiazepine-3,5-dicarboxylic B-CHEMICAL
acid I-CHEMICAL
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
of O
D, B-CHEMICAL
L-propargylglycine-treated I-CHEMICAL
rats. O
Experimental O
cystathioninuria O
was O
induced O
in O

rats O
by O
administration O
of O
the O
cystathionine B-GENE-Y
gamma-lyase I-GENE-Y
inhibitor, O
D,L-propargylglycine. B-CHEMICAL
The O
cystathionine B-CHEMICAL
metabolites, O
cystathionine B-CHEMICAL
ketimine I-CHEMICAL
(CK) B-CHEMICAL
and O
perhydro-1,4-thiazepine-3,5-dicarboxylic B-CHEMICAL
acid I-CHEMICAL
(PHTZDC), B-CHEMICAL
were O
identified O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
in O
D,L-propargylglycine-treated B-CHEMICAL
rats. O
The O
concentration O
of O
CK B-CHEMICAL
and O
PHTZDC B-CHEMICAL
in O
whole O
brain O
and O
various O

regions O
of O
the O
brain O
increased O
gradually O
after O
administration O
of O
D,L-propargylglycine, B-CHEMICAL
and O
reached O
the O
highest O
value O
at O
about O
20 O
hours. O
CK B-CHEMICAL
and O
PHTZDC B-CHEMICAL
accumulated O
in O
whole O
brain O
and O
various O
regions O
of O
the O
brain O
in O
proportion O
to O
the O
amount O
of O
accumulated O
cystathionine O
after O
D,L-propargylglycine B-CHEMICAL
administration. O
The O
concentration O
of O
these O
compounds O
in O
the O
cerebellum O
was O
higher O
versus O
the O
other O
regions O
of O
the O
rat O
brain. O
Changes O
in O
A1C B-GENE-Y
Levels O
Are O
Significantly O
Associated O
With O
Changes O
in O
Levels O
of O
the O
Cardiovascular O
Risk O
Biomarker O
hs-CRP: B-GENE-Y

Results O
from O
SteP O
Study. O
OBJECTIVEThe O
effect O
of O
therapeutic O
strategies O
on O
cardiovascular O
(CV) O
disease O
can O
be O
evaluated O
by O
monitoring O
changes O
in O
CV O
risk O
biomarkers. O
This O
study O
investigated O
the O
effect O
of O
a O
structured O
self-monitoring O
of O
blood O
glucose B-CHEMICAL
(SMBG) O
protocol O
and O
the O
resulting O
improvements O
in O
glycemic O
control O
on O
changes O
in O
high-sensitivity O
C-reactive B-GENE-Y
protein I-GENE-Y
(hs-CRP) B-GENE-Y
in O
insulin-naïve B-GENE-Y
patients O
with O
type O
2 O
diabetes.RESEARCH O
DESIGN O
AND O
METHODSThe O
Structured O
Testing O
Program O
(STeP) O
study O
was O

a O
prospective, O
cluster-randomized, O
multicenter O
trial O
in O
which O
483 O
poorly O
controlled, O
insulin-naïve B-GENE-Y
patients O
with O
type O
2 O
diabetes O
were O
randomized O
to O
active O
control O
(ACG) O
or O
structured O
testing O
(STG) O
that O
included O
quarterly O
structured O
SMBG. O
Changes O
in O
A1C, B-GENE-Y
hs-CRP, B-GENE-Y
and O
glycemic O
variability O
(STG O
subjects O
only) O
were O
measured O
at O
baseline O
and O
quarterly.RESULTSReductions O
in O
geometric O
mean O
hs-CRP B-GENE-Y
values O
were O
significantly O
greater O
in O
the O
STG O
group O
at O
months O
3 O
(P O
= O
0.005), O
6 O
(P O

= O
0.0003), O
and O
12 O
(P O
= O
0.04) O
than O
in O
the O
ACG O
group. O
STG O
patients O
at O
high O
CV O
risk O
(>3 O
mg/L) O
showed O
significantly O
greater O
reductions O
in O
hs-CRP B-GENE-Y
levels O
than O
ACG O
patients O
at O
high O
CV O
risk: O
-3.64 O
mg/dL O
(95% O
CI O
-4.21 O
to O
-3.06) O
versus O
-2.18 O
mg/dL O
(-2.93 O
to O
-1.43), O
respectively O
(P O
= O
0.002). O
There O
was O
a O
strong O
correlation O
between O
reductions O
in O

hs-CRP B-GENE-Y
and O
A1C B-GENE-Y
in O
both O
groups: O
standardized O
coefficient O
(β) O
was O
0.25 O
for O
the O
entire O
cohort O
(P O
< O
0.0001), O
0.31 O
for O
STG O
(P O
< O
0.0001), O
and O
0.16 O
for O
ACG O
(P O
= O
0.02).CONCLUSIONSReductions O
in O
hs-CRP B-GENE-Y
level O
are O
associated O
with O
reductions O
in O
A1C B-GENE-Y
but O
not O
reductions O
in O
lipids O
or O
glycemic O
variability. O
Comprehensive O
structured O
SMBG-based O
interventions O
that O
lower O
A1C B-GENE-Y
may O
translate O
into O
improvements O
in O
CV O
risk, O

as O
evidenced O
by O
levels O
of O
the O
biomarker O
hs-CRP. B-GENE-Y
Adenosine B-GENE-N
receptor I-GENE-N
antagonists O
intensify O
the O
benzodiazepine B-CHEMICAL
withdrawal O
signs O
in O
mice. O
The O
aim O
of O
the O
present O
experiment O
was O
to O
assess O
the O
involvement O
of O
adenosine B-GENE-N
receptor I-GENE-N
antagonists O
in O
benzodiazepine B-CHEMICAL
(BDZ) B-CHEMICAL
withdrawal O
signs, O
observed O
as O
the O
seizure O
susceptibility O
in O
mice. O
The O
discontinuation O
of O
chronic O
treatment O
with O
temazepam B-CHEMICAL
or O
diazepam B-CHEMICAL
decreased O
seizure O
threshold O
(one O
of O
BDZ B-CHEMICAL
withdrawal O
signs). O
The O
concomitant O
application O
of O
subconvulsive O
dose O
of O

pentetrazole B-CHEMICAL
(55.0 O
mg/kg) O
with O
low O
dose O
of O
flumazenil B-CHEMICAL
(5.0 O
mg/kg) O
- O
a O
BDZ B-GENE-N
receptor I-GENE-N
antagonist, O
immediately O
induced O
BDZ B-CHEMICAL
withdrawal O
signs O
in O
these O
animals. O
The O
non-selective O
adenosine B-GENE-N
receptor I-GENE-N
antagonist O
(caffeine), B-CHEMICAL
and O
the O
selective O
adenosine B-GENE-Y
A1 I-GENE-Y
receptor I-GENE-Y
antagonist O
(DPCPX), B-CHEMICAL
injected O
15 O
min O
before O
the O
application O
of O
pentetrazole B-CHEMICAL
and O
flumazenil, B-CHEMICAL
were O
able O
to O
intensify O
BDZ B-CHEMICAL
withdrawal O
signs O
in O
mice. O
The O
most O
apparent O
effects O
were O
observed O
after O
administration O
of O

DPCPX, B-CHEMICAL
indicating O
that O
the O
adenosine B-GENE-Y
A1 I-GENE-Y
receptor I-GENE-Y
may O
play O
a O
more O
important O
role O
in O
these O
effects. O
The O
obtained O
data O
demonstrate O
that O
the O
adenosinergic O
system O
is O
involved O
in O
BDZ B-CHEMICAL
withdrawal O
signs O
in O
mice, O
and O
adenosine B-GENE-Y
A1 I-GENE-Y
receptor I-GENE-Y
plays O
an O
important O
role O
in O
this O
process. O
Cross-inhibition O
of O
SR-BI- B-GENE-Y
and O
ABCA1-mediated B-GENE-Y
cholesterol B-CHEMICAL
transport O
by O
the O
small O
molecules O
BLT-4 O
and O
glyburide. B-CHEMICAL
Scavenger B-GENE-Y
receptor I-GENE-Y
class I-GENE-Y
B I-GENE-Y
type I-GENE-Y
I I-GENE-Y
(SR-BI) B-GENE-Y
and O
ABCA1 B-GENE-N
are O
structurally O
dissimilar O
cell O
surface O
proteins O
that O
play O

key O
roles O
in O
HDL B-GENE-N
metabolism. O
SR-BI B-GENE-Y
is O
a O
receptor O
that O
binds O
HDL B-GENE-N
with O
high O
affinity O
and O
mediates O
both O
the O
selective O
lipid O
uptake O
of O
cholesteryl B-CHEMICAL
esters I-CHEMICAL
from O
lipid-rich O
HDL B-GENE-N
to O
cells O
and O
the O
efflux O
of O
unesterified O
cholesterol B-CHEMICAL
from O
cells O
to O
HDL. B-GENE-N
ABCA1 B-GENE-Y
mediates O
the O
efflux O
of O
unesterified O
cholesterol B-CHEMICAL
and O
phospholipids O
from O
cells O
to O
lipid-poor O
apolipoprotein B-GENE-Y
A-I I-GENE-Y
(apoA-I). B-GENE-Y
The O
activities O
of O
ABCA1 B-GENE-Y
and O
other O
ATP B-GENE-N
binding I-GENE-N
cassette I-GENE-N
superfamily I-GENE-N

members O
are O
inhibited O
by O
the O
drug O
glyburide, B-CHEMICAL
and O
SR-BI-mediated B-GENE-Y
lipid O
transport O
is O
blocked O
by O
small O
molecule O
inhibitors O
called O
BLTs. O
Here, O
we O
show O
that O
one O
BLT, B-CHEMICAL
[1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] B-CHEMICAL
(BLT-4), B-CHEMICAL
blocked O
ABCA1-mediated B-GENE-Y
cholesterol B-CHEMICAL
efflux O
to O
lipid-poor O
apoA-I B-GENE-Y
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
SR-BI B-GENE-Y
(IC(50) O

approximately O
55-60 O
microM). O
Reciprocally, O
glyburide B-CHEMICAL
blocked O
SR-BI-mediated B-GENE-Y
selective O
lipid O
uptake O
and O
efflux O
at O
a O
potency O
similar O
to O
that O
for O
its O
inhibition O
of O
ABCA1 B-GENE-Y
(IC(50) O
approximately O
275-300 O
microM). O
As O
is O
the O
case O
with O
BLTs, O
glyburide B-CHEMICAL
increased O
the O
apparent O
affinity O
of O
HDL B-GENE-N
binding O
to O
SR-BI. B-GENE-Y
The O
reciprocal O
inhibition O
of O
SR-BI B-GENE-Y
and O
ABCA1 B-GENE-Y
by O
BLT-4 O
and O
glyburide B-CHEMICAL
raises O
the O
possibility O
that O
these O
proteins O
may O
share O

similar O
or O
common O
steps O
in O
their O
mechanisms O
of O
lipid O
transport. O
Protective O
effect O
of O
butylated B-CHEMICAL
hydroxytoluene I-CHEMICAL
on O
ferric B-CHEMICAL
nitrilotriacetate I-CHEMICAL
induced O
hepatotoxicity O
and O
oxidative O
stress O
in O
mice. O
The O
present O
study O
was O
undertaken O
to O
evaluate O
the O
possible O
ameliorating O
effect O
of O
butylated B-CHEMICAL
hydroxyl I-CHEMICAL
toluene I-CHEMICAL
(BHT), B-CHEMICAL
associated O
with O
ferric B-CHEMICAL
nitrilotriacetate I-CHEMICAL
(Fe-NTA)-induced B-CHEMICAL
oxidative O
stress O
and O
liver O
injury O
in O
mice. O
The O
treatment O
of O
mice O
with O
Fe-NTA B-CHEMICAL
alone O
enhances O

ornithine B-GENE-Y
decarboxylase I-GENE-Y
activity O
to O
4.6 O
folds, O
protein O
carbonyl B-CHEMICAL
formation O
increased O
up O
to O
2.9 O
folds O
and O
DNA O
synthesis O
expressed O
in O
terms O
of O
[(3)H] B-CHEMICAL
thymidine I-CHEMICAL
incorporation O
increased O
to O
3.2 O
folds, O
and O
antioxidants O
and O
antioxidant O
enzymes O
decreased O
to O
1.8-2.5 O
folds, O
compared O
with O
the O
corresponding O
saline-treated O
controls. O
These O
changes O
were O
reversed O
significantly O
(p O
< O
0.001) O
in O
animals O
receiving O
a O
pretreatment O
of O
BHT. B-CHEMICAL
Our O
data O
show O
that O
BHT B-CHEMICAL
can O
reciprocate O
the O
toxic O
effects O
of O

Fe-NTA B-CHEMICAL
and O
can O
serve O
as O
a O
potent O
chemopreventive O
agent. O
AKRs B-GENE-N
expression O
in O
peripheral O
blood O
lymphocytes O
from O
smokers: O
The O
role O
of O
body O
mass O
index. O
Aldo-keto B-GENE-N
reductases I-GENE-N
(AKRs) B-GENE-N
metabolize O
a O
wide O
range O
of O
substrates, O
including O
polycyclic B-CHEMICAL
aromatic I-CHEMICAL
hydrocarbons I-CHEMICAL
(PAHs), B-CHEMICAL
generating O
metabolites O
(o-quinones) B-CHEMICAL
and O
reactive O
oxygen B-CHEMICAL
species O
(ROS), O
which O
are O
capable O
of O
initiating O
and O
promoting O
carcinogenesis. O
Exposure O
to O
PAHs, B-CHEMICAL
their O

metabolites, O
and O
ROS O
further O
increase O
AKRs B-GENE-N
isoform O
expression O
that O
may O
amplify O
oxidative O
damage. O
Human B-GENE-N
AKR I-GENE-N
enzymes O
are O
highly O
polymorphic, O
and O
allelic O
variants O
may O
contribute O
to O
different O
AKRs B-GENE-N
expression O
in O
individuals. O
Despite O
the O
importance O
of O
AKRs B-GENE-N
in O
PAHs B-CHEMICAL
metabolism, O
there O
are O
no O
studies O
that O
evaluate, O
in O
general O
human O
populations, O
the O
effect O
of O
PAHs B-CHEMICAL
on O
AKRs B-GENE-N
expression O
in O
peripheral O
blood O
lymphocytes O
(PBLs). O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
effect O
of O
tobacco O
smoke O
exposure, O
and O
AKR1A1*2 B-GENE-Y
and O

AKR1C3*2 B-GENE-Y
polymorphisms, O
on O
AKR1A1 B-GENE-Y
and O
AKR1C1-AKR1C3 B-GENE-Y
messenger O
RNA O
(mRNA) O
levels O
in O
PBLs O
from O
smokers. O
In O
the O
smoker O
group, O
there O
is O
a O
statistically O
significant O
positive O
association O
between O
AKR1A1, B-GENE-Y
AKR1C1, B-GENE-Y
and O
AKR1C3 B-GENE-Y
mRNA O
induction O
and O
urine O
cotinine B-CHEMICAL
levels O
in O
individuals O
with O
a O
body O
mass O
index O
(BMI) O
less O
than O
25. O
However, O
AKR1A1*2 B-GENE-Y
and O
AKR1C3*2 B-GENE-Y
alleles O
did O
not O
influence O

AKR1A1 B-GENE-Y
and O
AKR1C1-AKR1C3 B-GENE-Y
mRNA O
levels. O
These O
results O
suggest O
that O
AKRs B-GENE-N
induction O
by O
PAHs B-CHEMICAL
in O
smokers' O
PBLs O
is O
associated O
with O
BMI; O
therefore, O
the O
role O
of O
adipose O
tissue O
accumulation O
in O
PAHs' B-CHEMICAL
effects O
needs O
further O
investigation. O
Administration O
of O
the O
optimized O
β-Lapachone-poloxamer-cyclodextrin B-CHEMICAL
ternary O
system O
induces O
apoptosis, O
DNA O
damage O
and O
reduces O
tumor O
growth O
in O
a O
human O
breast O
adenocarcinoma O
xenograft O
mouse O
model. O

β-Lapachone B-CHEMICAL
(β-Lap) B-CHEMICAL
is O
a O
1,2-orthonaphthoquinone B-CHEMICAL
that O
selectively O
induces O
cell O
death O
in O
human O
cancer O
cells O
through O
NAD(P)H:quinone B-GENE-Y
oxidoreductase-1 I-GENE-Y
(NQO1). B-GENE-Y
NQO1 B-GENE-Y
is O
overexpressed O
in O
a O
variety O
of O
tumors, O
as O
compared O
to O
normal O
adjacent O
tissue. O
However, O
the O
low O
solubility O
and O
non-specific O
distribution O
of O
β-Lap B-CHEMICAL
limit O
its O
suitability O
for O
clinical O
assays. O
We O
formulated O
β-Lap B-CHEMICAL
in O
an O
optimal O
random O

methylated-β-cyclodextrin/poloxamer B-CHEMICAL
407 I-CHEMICAL
mixture O
(i.e., O
β-Lap B-CHEMICAL
ternary O
system) O
and, O
using O
human O
breast O
adenocarcinoma O
MCF-7 O
cells O
and O
immunodeficient O
mice, O
performed O
in O
vitro O
and O
in O
vivo O
evaluation O
of O
its O
anti-tumor O
effects O
on O
proliferation, O
cell O
cycle, O
apoptosis, O
DNA O
damage, O
and O
tumor O
growth. O
This O
ternary O
system O
is O
fluid O
at O
room O
temperature, O
gels O
over O
29°C, O
and O
provides O
a O
significant O
amount O
of O
drug, O
thus O
facilitating O
intratumoral O

delivery, O
in O
situ O
gelation, O
and O
the O
formation O
of O
a O
depot O
for O
time-release. O
Administration O
of O
β-Lap B-CHEMICAL
ternary O
system O
to O
MCF-7 O
cells O
induces O
an O
increase O
in O
apoptosis O
and O
DNA O
damage, O
while O
producing O
no O
changes O
in O
cell O
cycle. O
Moreover, O
in O
a O
mouse O
xenograft O
tumor O
model, O
intratumoral O
injection O
of O
the O
system O
significantly O
reduces O
tumor O
volume, O
while O
increasing O
apoptosis O
and O
DNA O
damage O
without O
visible O
toxicity O
to O
liver O
or O
kidney. O
These O
anti-tumoral O
effects O
and O
lack O
of O
visible O
toxicity O
make O
this O
system O
a O
promising O
new O
therapeutic O
agent O
for O
breast O
cancer O
treatment. O
Lanthanum B-CHEMICAL

(III) I-CHEMICAL
regulates O
the O
nitrogen B-CHEMICAL
assimilation O
in O
soybean O
seedlings O
under O
ultraviolet-B O
radiation. O
Ultraviolet-B O
(UV-B, O
280-320 O
nm) O
radiation O
has O
seriously O
affected O
the O
growth O
of O
plants. O
Finding O
the O
technology/method O
to O
alleviate O
the O
damage O
of O
UV-B O
radiation O
has O
become O
a O
frontal O
topic O
in O
the O
field O
of O
environmental O
science. O
The O
pretreatment O
with O
rare O
earth O
elements O
(REEs) O
is O
an O
effective O
method, O
but O
the O
regulation O
mechanism O
of O
REEs O
is O
unknown. O
Here, O
the O
regulation O
effects O
of O
lanthanum B-CHEMICAL
(La(III)) B-CHEMICAL
on O
nitrogen B-CHEMICAL
assimilation O

in O
soybean O
seedlings O
(Glycine O
max O
L.) O
under O
ultraviolet-B O
radiation O
were O
investigated O
to O
elucidate O
the O
regulation O
mechanism O
of O
REEs O
on O
plants O
under O
UV-B O
radiation. O
UV-B O
radiation O
led O
to O
the O
inhibition O
in O
the O
activities O
of O
the O
key O
enzymes O
(nitrate B-GENE-N
reductase, I-GENE-N
glutamine B-GENE-N
synthetase, I-GENE-N
glutamate B-GENE-N
synthase) I-GENE-N
in O
the O
nitrogen B-CHEMICAL
assimilation, O
the O
decrease O
in O
the O
contents O
of O
nitrate B-CHEMICAL
and O
soluble O
proteins, O
as O
well O
as O
the O
increase O
in O
the O
content O
of O
amino B-CHEMICAL
acid I-CHEMICAL
in O
soybean O
seedlings. O
The O
change O
degree O
of O

UV-B O
radiation O
at O
the O
high O
level O
(0.45 O
W O
m(-2)) O
was O
higher O
than O
that O
of O
UV-B O
radiation O
at O
the O
low O
level O
(0.15 O
W O
m(-2)). O
The O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) B-CHEMICAL
could O
alleviate O
the O
effects O
of O
UV-B O
radiation O
on O
the O
activities O
of O
nitrate B-GENE-N
reductase, I-GENE-N
glutamine B-GENE-N
synthetase, I-GENE-N
glutamate B-GENE-N
synthase, I-GENE-N
and O
glutamate B-GENE-N
dehydrogenase, I-GENE-N
promoting O
amino B-CHEMICAL
acid I-CHEMICAL
conversion O
and O
protein O
synthesis O
in O
soybean O
seedlings. O
The O
regulation O
effect O
of O

La(III) B-CHEMICAL
under O
UV-B O
radiation O
at O
the O
low O
level O
was O
better O
than O
that O
of O
UV-B O
radiation O
at O
the O
high O
level. O
The O
results O
indicated O
that O
the O
pretreatment O
with O
20 O
mg O
L(-1) O
La(III) B-CHEMICAL
could O
alleviate O
the O
inhibition O
of O
UV-B O
radiation O
on O
nitrogen B-CHEMICAL
assimilation O
in O
soybean O
seedlings. O
Significant O
receptor O
affinities O
of O
metabolites O
and O
a O
degradation O
product O
of O
mometasone B-CHEMICAL
furoate. I-CHEMICAL
Mometasone B-CHEMICAL
furoate I-CHEMICAL
(MF) B-CHEMICAL
is O
a O
highly O
potent O
glucocorticoid O
used O
topically O
to O
treat O
inflammation O
in O
the O
lung, O
nose O

and O
on O
the O
skin. O
However, O
so O
far O
no O
information O
has O
been O
published O
on O
the O
human B-GENE-Y
glucocorticoid I-GENE-Y
receptor I-GENE-Y
activity O
of O
the O
metabolites O
or O
degradation O
products O
of O
MF. B-CHEMICAL
We O
have O
now O
determined O
the O
relative O
receptor O
binding O
affinities O
of O
the O
known O
metabolite O
6beta-OH B-CHEMICAL
MF I-CHEMICAL
and O
the O
degradation O
product O
9,11-epoxy B-CHEMICAL
MF I-CHEMICAL
to O
understand O
their O
possible O
contribution O
to O
undesirable O
systemic O
side O
effects. O
In O
competition O
experiments O
with O
human B-GENE-Y
lung I-GENE-Y
glucocorticoid I-GENE-Y
receptors I-GENE-Y
we O
have O
determined O
the O
relative O
receptor O
affinities O
(RRA) O
of O
these O
substances O
with O
reference O
to O
dexamethasone B-CHEMICAL

(RRA O
= O
100). O
We O
have O
discovered O
that O
6beta-OH B-CHEMICAL
MF I-CHEMICAL
and O
9,11-epoxy B-CHEMICAL
MF I-CHEMICAL
display O
RRAs O
of O
206 O
+/- O
15 O
and O
220 O
+/- O
22, O
respectively. O
This O
level O
of O
activity O
is O
similar O
to O
that O
of O
the O
clinically O
used O
inhaled O
corticosteroid B-CHEMICAL
flunisolide B-CHEMICAL
(RRA O
180 O
+/- O
11). O
Furthermore O
we O
observed O
that O
9,11-epoxy B-CHEMICAL
MF I-CHEMICAL
is O
a O
chemically O
reactive O
metabolite. O
In O
recovery O
experiments O
with O
human O
plasma O
and O
lung O
tissue O
we O
found O
a O
time O
dependent O
decrease O
in O
extractability O
of O
the O
compound. O
Hence, O

we O
provide O
data O
that O
might O
contribute O
to O
the O
understanding O
of O
the O
pharmacokinetics O
as O
well O
as O
the O
clinical O
effects O
of O
MF. B-CHEMICAL
Inhibition O
of O
monoamine B-GENE-N
oxidase I-GENE-N
by O
phthalide B-CHEMICAL
analogues. O
Based O
on O
recent O
reports O
that O
the O
small O
molecules, O
isatin B-CHEMICAL
and O
phthalimide, B-CHEMICAL
are O
suitable O
scaffolds O
for O
the O
design O
of O
high O
potency O
monoamine B-GENE-N
oxidase I-GENE-N
(MAO) B-GENE-N
inhibitors, O
the O
present O
study O
examines O
the O
MAO B-GENE-N
inhibitory O
properties O
of O
a O
series O
of O
phthalide B-CHEMICAL
[2-benzofuran-1(3H)-one] B-CHEMICAL

analogues. O
Phthalide B-CHEMICAL
is O
structurally O
related O
to O
isatin B-CHEMICAL
and O
phthalimide B-CHEMICAL
and O
it O
is O
demonstrated O
here O
that O
substitution O
at O
C6 O
of O
the O
phthalide B-CHEMICAL
moiety O
yields O
compounds O
endowed O
with O
high O
binding O
affinities O
to O
both O
human B-GENE-N
MAO I-GENE-N
isoforms. O
Among O
the O
nineteen O
homologues O
evaluated, O
the O
lowest O
IC(50) O
values O
recorded O
for O
the O
inhibition O
of O
MAO-A B-GENE-N
and I-GENE-N
-B I-GENE-N
were O
0.096 O
and O
0.0014 O
μM, O
respectively. O
In O
most O
instances, O
C6-substituted O
phthalides B-CHEMICAL
exhibit O
MAO-B B-GENE-Y
specific O
inhibition. O
Among O
a O
series O

of O
6-benzyloxyphthalides B-CHEMICAL
bearing O
substituents O
on O
the O
para O
position O
of O
the O
phenyl B-CHEMICAL
ring O
the O
general O
order O
of O
potency O
was O
CF(3) B-CHEMICAL
> O
I B-CHEMICAL
> O
Br B-CHEMICAL
> O
Cl B-CHEMICAL
> O
F B-CHEMICAL
> O
CH(3) B-CHEMICAL
> O
H. B-CHEMICAL
The O
results O
also O
show O
that O
the O
binding O
modes O
of O
representative O
phthalides B-CHEMICAL
are O
reversible O
and O
competitive O
at O
both O
MAO B-GENE-N
isoforms. O
Based O
on O
these O
data, O
C6-substituted B-CHEMICAL
phthalides B-CHEMICAL
may O
serve O
as O
leads O
for O
the O
development O
of O
therapies O
for O
neurodegenerative O
disorders O
such O
as O
Parkinson's O
disease. O
Long O
range O
effect O
of O
mutations O
on O

specific O
conformational O
changes O
in O
the O
extracellular O
loop O
2 O
of O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor. I-GENE-Y
The O
topology O
of O
the O
second O
extracellular O
loop O
(ECL2) O
and O
its O
interaction O
with O
ligands O
is O
unique O
in O
each O
G B-GENE-N
protein-coupled I-GENE-N
receptor. I-GENE-N
When O
the O
orthosteric O
ligand O
pocket O
located O
in O
the O
transmembrane O
(TM) O
domain O
is O
occupied, O
ligand-specific O
conformational O
changes O
occur O
in O
the O
ECL2. O
In O
more O
than O
90% O
of O
G B-GENE-N
protein-coupled I-GENE-N
receptors, I-GENE-N
ECL2 O
is O
tethered O
to O
the O
third O
TM O
helix O
via O
a O
disulfide O
bond. O
Therefore, O

understanding O
the O
extent O
to O
which O
the O
TM O
domain O
and O
ECL2 O
conformations O
are O
coupled O
is O
useful. O
To O
investigate O
this, O
we O
examined O
conformational O
changes O
in O
ECL2 O
of O
the O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
(AT1R) B-GENE-Y
by O
introducing O
mutations O
in O
distant O
sites O
that O
alter O
the O
activation O
state O
equilibrium O
of O
the O
AT1R. B-GENE-Y
Differential O
accessibility O
of O
reporter O
cysteines B-CHEMICAL
introduced O
at O
four O
conformation-sensitive O
sites O
in O
ECL2 O
of O
these O
mutants O
was O
measured. O
Binding O
of O
the O
agonist O
angiotensin B-GENE-Y
II I-GENE-Y
(AngII) B-GENE-Y
and O
inverse O
agonist O
losartan B-CHEMICAL
in O
wild-type O
AT1R B-GENE-Y
changed O
the O

accessibility O
of O
reporter O
cysteines, B-CHEMICAL
and O
the O
pattern O
was O
consistent O
with O
ligand-specific O
"lid" O
conformations O
of O
ECL2. O
Without O
agonist O
stimulation, O
the O
ECL2 O
in O
the O
gain O
of O
function O
mutant O
N111G B-GENE-N
assumed O
a O
lid O
conformation O
similar O
to O
AngII-bound B-GENE-Y
wild-type O
AT1R. B-GENE-Y
In O
the O
presence O
of O
inverse O
agonists, O
the O
conformation O
of O
ECL2 O
in O
the O
N111G B-GENE-N
mutant O
was O
similar O
to O
the O
inactive O
state O
of O
wild-type O
AT1R. B-GENE-Y
In O
contrast, O
AngII B-GENE-Y
did O
not O
induce O
a O
lid O
conformation O
in O
ECL2 O
in O
the O
loss O
of O
function O

D281A B-GENE-N
mutant, O
which O
is O
consistent O
with O
the O
reduced O
AngII B-GENE-Y
binding O
affinity O
in O
this O
mutant. O
However, O
a O
lid O
conformation O
was O
induced O
by O
[Sar(1),Gln(2),Ile(8)] B-CHEMICAL
AngII, B-GENE-Y
a O
specific O
analog O
that O
binds O
to O
the O
D281A B-GENE-N
mutant O
with O
better O
affinity O
than O
AngII. B-GENE-Y
These O
results O
provide O
evidence O
for O
the O
emerging O
paradigm O
of O
domain O
coupling O
facilitated O
by O
long O
range O
interactions O
at O
distant O
sites O
on O
the O
same O
receptor. O
Immunohistochemical O
characterization O
of O
pyrimidine B-CHEMICAL
synthetic O
enzymes, O
thymidine B-GENE-Y
kinase-1 I-GENE-Y
and O
thymidylate B-GENE-Y
synthase, I-GENE-Y
in O

various O
types O
of O
cancer. O
Thymidine B-GENE-Y
kinase-1 I-GENE-Y
(TK-1) B-GENE-Y
and O
thymidylate B-GENE-Y
synthase I-GENE-Y
(TS) B-GENE-Y
are O
key O
enzymes O
for O
salvage O
and O
de O
novo O
pyrimidine B-CHEMICAL
synthesis, O
respectively. O
Numerous O
studies O
have O
suggested O
that O
increased O
TS B-GENE-Y
levels O
are O
associated O
closely O
with O
resistance O
to O
fluoropyrimidine-based B-CHEMICAL
chemotherapy. O
TAS-102 B-CHEMICAL
is O
a O
novel O
drug O
containing O
trifluorothymidine, B-CHEMICAL
which O
is O
phosphorylated O
by O
TK-1 B-GENE-Y
to O
its O
active O
monophosphated O
form, O
that O
in O
turn O
can O
inhibit O
TS. B-GENE-Y

TAS-102 B-CHEMICAL
has O
been O
shown O
to O
exhibit O
antitumor O
activity O
in O
fluoropyrimidine-resistant B-CHEMICAL
human O
cancer O
cells. O
TAS-102 B-CHEMICAL
is O
currently O
undergoing O
clinical O
trials O
for O
use O
in O
gastrointestinal O
cancers. O
In O
the O
present O
study, O
we O
used O
immunohistochemistry O
to O
investigate O
the O
expression O
of O
TK-1 B-GENE-Y
and O
TS B-GENE-Y
in O
various O
types O
of O
cancer. O
TK-1 B-GENE-Y
and O
TS B-GENE-Y
expression O
was O
markedly O
different O
between O
cancer O
types. O
High O
TK-1 B-GENE-Y
expression O
was O
detected O
prominently O
in O
gastrointestinal O
adenocarcinomas O
and O
esophageal O
and O
uterine O
squamous O

cell O
carcinomas. O
Gastrointestinal O
adenocarcinomas O
and O
squamous O
cell O
uterine O
carcinomas O
were O
often O
accompanied O
by O
high O
TS B-GENE-Y
expression, O
indicating O
activation O
of O
pyrimidine B-CHEMICAL
synthesis O
through O
both O
the O
salvage O
and O
de O
novo O
pathways. O
These O
results O
led O
us O
to O
consider O
that O
TAS-102 B-CHEMICAL
may O
also O
be O
effective O
for O
esophageal O
and O
uterine O
squamous O
cell O
carcinomas, O
as O
well O
as O
for O
gastrointestinal O
adenocarcinomas, O
even O
in O
fluoropyrimidine-resistant B-CHEMICAL
cases O
with O
high O
TS B-GENE-Y
expression. O
In O
contrast, O

thyroid O
papillary O
carcinomas, O
lung O
adenocarcinomas, O
hepatocellular O
carcinomas, O
pancreatic O
ductal O
carcinomas, O
and O
renal O
cell O
carcinomas, O
which O
exhibit O
low O
TK-1 B-GENE-Y
expression, O
may O
be O
resistant O
to O
TAS-102. B-CHEMICAL
In O
non-small O
cell O
lung O
cancers, O
high O
TK-1 B-GENE-Y
expression O
was O
demonstrated O
in O
squamous O
cell O
carcinomas, O
but O
not O
in O
adenocarcinomas. O
This O
result O
suggests O
that O
TAS-102 B-CHEMICAL
efficacy O
and O
the O
pyrimidine B-CHEMICAL
synthetic O
pathway O
may O
differ O
depending O
on O

histological O
type. O
Our O
results O
indicate O
that O
administration O
of O
TAS-102 B-CHEMICAL
could O
be O
selected O
on O
the O
basis O
of O
the O
immunohistochemical O
evaluation O
of O
TK-1 B-GENE-Y
and O
TS. B-GENE-Y
Increased O
muscarinic B-GENE-N
receptor I-GENE-N
activity O
of O
airway O
smooth O
muscle O
isolated O
from O
a O
mouse O
model O
of O
allergic O
asthma. O
The O
mechanisms O
leading O
to O
airway O
hyper-responsiveness O
(AHR) O
in O
asthma O
are O
still O
not O
fully O
understood. O
AHR O
could O
be O
produced O
by O
hypersensitivity O
of O
the O
airway O
smooth O
muscle O
or O
hyperreactivity O
of O
the O
airways. O
This O
study O

was O
conducted O
to O
ascertain O
whether O
AHR O
in O
a O
murine O
model O
of O
asthma O
is O
produced O
by O
changes O
at O
the O
level O
of O
the O
airway O
smooth O
muscle. O
Airway O
smooth O
muscle O
responses O
were O
characterised O
in O
vitro O
in O
isolated O
trachea O
spirals O
from O
naive O
mice O
and O
from O
an O
acute O
ovalbumin B-GENE-Y
(OVA) B-GENE-Y
challenge O
model O
of O
allergic O
asthma. O
AHR O
was O
investigated O
in O
vivo O
in O
conscious, O
freely O
moving O
mice. O
Inflammatory O
cell O
influx O
into O
the O
lungs O
and O
antibody O
responses O
to O
the O
antigen O
were O
also O
measured. O
In O
vitro O
study O
of O
tracheal O
airway O
smooth O
muscle O

from O
naive O
mice O
demonstrated O
concentration-related O
contractions O
to O
methacholine B-CHEMICAL
and O
5-HT, B-CHEMICAL
but O
no O
responses O
to O
histamine B-CHEMICAL
or O
adenosine B-CHEMICAL
or O
its O
stable O
analogue, O
5'-N-ethyl-carboxamidoadenosine. B-CHEMICAL
The O
contractions O
to O
5-HT B-CHEMICAL
were O
inhibited O
by O
ketanserin B-CHEMICAL
and O
alosetron B-CHEMICAL
indicating O
involvement O
of O
5-HT(2A) B-GENE-Y
and O
5-HT(3) B-GENE-Y
receptors, O
respectively. O
In O
an O
acute O
model O
of O
allergic O
asthma, O
OVA-treated B-GENE-Y
mice O
were O
shown O
to O
be O
atopic O
by O
inflammatory O
cell O
influx O
to O
the O
lungs O
after O

OVA B-GENE-Y
challenge, O
increases O
in O
total O
IgE B-GENE-N
and O
OVA-specific B-GENE-Y
IgG B-GENE-N
levels O
and O
contractions O
to O
OVA B-GENE-Y
in O
isolated O
trachea. O
In O
the O
asthmatic O
model, O
AHR O
to O
methacholine B-CHEMICAL
was O
demonstrated O
in O
conscious, O
freely O
moving O
mice O
in O
vivo O
and O
in O
isolated O
trachea O
in O
vitro O
24 O
and O
72h O
after O
OVA B-GENE-Y
challenge. O
No O
AHR O
in O
vitro O
was O
seen O
for O
5-HT, B-CHEMICAL
histamine B-CHEMICAL
or O
adenosine. B-CHEMICAL
These O
results O
suggest O
that, O
in O
our O
mouse O
model O
of O
asthma, O
changes O
occur O
at O
the O
level O
of O
the O
muscarinic B-GENE-N

receptor I-GENE-N
transduction O
pathway O
of O
coupling O
to O
airway O
smooth O
muscle O
contraction. O
These O
changes O
are O
maintained O
when O
tissues O
are O
removed O
from O
the O
inflammatory O
environment O
and O
for O
at O
least O
3 O
days. O
Design, O
synthesis, O
characterization O
and O
anti-inflammatory O
evaluation O
of O
novel O
pyrazole B-CHEMICAL
amalgamated O
flavones. B-CHEMICAL
A O
series O
of O
novel O
pyrazole B-CHEMICAL
amalgamated O
flavones B-CHEMICAL
has O
been O
designed O
and O
synthesized O
from O
1-methyl-5-(2,4,6-trimethoxy-phenyl)-1H-pyrazole B-CHEMICAL
6. O
The O
structures O
of O
regioisomers O
6 O
and O
7 O
were O
resolved O
by O
2D O

(1)H-(1)H B-CHEMICAL
COSY, O
(1)H-(13)C B-CHEMICAL
HSQC O
and O
(1)H-(13)C B-CHEMICAL
HMBC O
experiments. O
The O
newly O
synthesized O
compounds O
were O
tested O
for O
their O
in O
vitro O
COX B-GENE-N
inhibition O
and O
in O
vivo O
carrageenan O
induced O
hind O
paw O
edema O
in O
rats O
and O
acetic B-CHEMICAL
acid I-CHEMICAL
induced O
vascular O
permeability O
in O
mice. O
Although O
the O
compounds O
have O
inhibitory O
profile O
against O
both O
COX-1 B-GENE-Y
and O
COX-2, B-GENE-Y
some O
of O
the O
compounds O
are O
found O
to O
be O
selective O
against O
COX-2, B-GENE-Y
supported O
by O
inhibition O
of O
paw O
edema O

and O
vascular O
permeability. O
Docking O
studies O
were O
also O
carried O
out O
to O
determine O
the O
structural O
features O
which O
sway O
the O
anti-inflammatory O
activity O
of O
the O
tested O
compounds. O
The O
keto B-CHEMICAL
and O
phenolic B-CHEMICAL
-OH B-CHEMICAL
are O
major O
factors O
that O
are O
prominently O
involved O
in O
interaction O
with O
COX-2 B-GENE-Y
active O
site. O
Superparamagnetic O
Hollow O
Hybrid O
Nanogels O
as O
a O
Potential O
Guidable O
Vehicle O
System O
of O
Stimuli-Mediated O
MR O
Imaging O
and O
Multiple O
Cancer O
Therapeutics. O
Hollow O
hybrid O
nanogels O
were O
prepared O
first O
by O
co-assembly O
of O
the O
citric B-CHEMICAL
acid-coated I-CHEMICAL
superparamagnetic O
iron B-CHEMICAL
oxide I-CHEMICAL
nanoparticles O

(SPIONs) O
(44 O
wt%) O
with O
the O
graft O
copolymer O
(56 O
wt%) O
comprising O
acrylic B-CHEMICAL
acid I-CHEMICAL
and O
2-methacryloylethyl B-CHEMICAL
acrylate I-CHEMICAL
units O
as O
the O
backbone O
and O
poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
and O
poly(N-isopropylacrylamide) B-CHEMICAL
as O
the O
grafts O
in O
aqueous O
phase O
of O
pH O
3.0 O
into O
the O
hybrid O
vesicle O
structure, O
followed O
by O
in O
situ O
covalent O
stabilization O
via O
the O
photo-initiated O
polymerization O
of O
MEA B-CHEMICAL
residues O
within O
vesicles. O
The O
resultant O

hollow O
nanogels, O
though O
slightly O
swollen, O
satisfactorily O
retain O
the O
structural O
integrity O
while O
the O
medium O
pH O
being O
adjusted O
to O
7.4. O
Confining O
SPION O
clusters O
to O
such O
a O
high O
level O
(44 O
wt%) O
within O
the O
pH-responsive O
thin O
gel O
layer O
remarkably O
enhances O
the O
transverse O
relaxivity O
(r2) O
and O
renders O
the O
MR O
imaging O
highly O
pH-tunable. O
For O
example, O
with O
the O
pH O
being O
adjusted O
from O
4.0 O
to O
7.4, O
the O
r2 O
value O
can O
be O
dramatically O
increased O
from O
138.5 O
to O
265.5 O
mM-1 O
s-1. O
The O

DOX-loaded O
hybrid O
nanogels O
also O
exhibit O
accelerated O
drug O
release O
in O
response O
to O
both O
pH O
reduction O
and O
temperature O
increase O
due O
to O
the O
substantial O
disruption O
of O
the O
interactions O
between O
drug O
molecules O
and O
copolymer O
components. O
With O
magnetic O
transport O
guidance O
toward O
the O
target O
and O
subsequent O
exposure O
to O
alternating O
magnetic O
field, O
this O
DOX-loaded O
nanogel O
system O
possessing O
combined O
capabilities O
of O
hyperthermia O
and O
stimuli-triggered O
drug O
release O
showed O
superior O
in O
vitro O
cytotoxicity O
against O
HeLa O
cells O
as O
compared O
to O
the O
case O
with O
only O
free O
drug O
or O
hyperthermia O
alone. O
This O
work O
demonstrates O
that O
the O
hollow O
inorganic/organic O
hybrid O

nanogels O
show O
great O
potential O
to O
serve O
as O
a O
multimodal O
theranostic O
vehicle O
functionalized O
with O
such O
desirable O
features O
as O
guidable O
delivery O
of O
stimuli-mediated O
diagnostic O
imaging O
and O
hyperthermia/chemotherapies. O
Progesterone B-GENE-Y
receptor I-GENE-Y
induces O
bcl-x B-GENE-Y
expression O
through O
intragenic B-GENE-N
binding I-GENE-N
sites I-GENE-N
favoring O
RNA B-GENE-N
polymerase I-GENE-N
II I-GENE-N
elongation. O
Steroid B-GENE-N
receptors I-GENE-N
were O
classically O
described O
for O
regulating O
transcription O
by O
binding O
to O
target O
gene O
promoters. O
However, O
genome-wide O
studies O
reveal O
that O
steroid B-GENE-N
receptors-binding I-GENE-N
sites I-GENE-N
are O
mainly O
located O
at O
intragenic O
regions. O
To O
determine O
the O
role O
of O
these O

sites, O
we O
examined O
the O
effect O
of O
progestins O
on O
the O
transcription O
of O
the O
bcl-x B-GENE-Y
gene, O
where O
only O
intragenic B-GENE-N
progesterone I-GENE-N
receptor-binding I-GENE-N
sites I-GENE-N
(PRbs) B-GENE-N
were O
identified. O
We O
found O
that O
in O
response O
to O
hormone O
treatment, O
the O
PR B-GENE-Y
is O
recruited O
to O
these O
sites O
along O
with O
two O
histone B-GENE-N
acetyltransferases I-GENE-N
CREB-binding B-GENE-Y
protein I-GENE-Y
(CBP) B-GENE-Y
and O
GCN5, B-GENE-Y
leading O
to O
an O
increase O
in O
histone B-GENE-N
H3 I-GENE-N
and O
H4 B-GENE-N
acetylation O
and O
to O
the O
binding O
of O
the O
SWI/SNF B-GENE-N
complex. I-GENE-N
Concomitant, O
a O
more O
relaxed O
chromatin O

was O
detected O
along O
bcl-x B-GENE-Y
gene O
mainly O
in O
the O
regions O
surrounding O
the O
intragenic O
PRbs. B-GENE-N
PR B-GENE-Y
also O
mediated O
the O
recruitment O
of O
the O
positive B-GENE-N
elongation I-GENE-N
factor I-GENE-N
pTEFb, B-GENE-N
favoring O
RNA B-GENE-N
polymerase I-GENE-N
II I-GENE-N
(Pol B-GENE-N
II) I-GENE-N
elongation O
activity. O
Together O
these O
events O
promoted O
the O
re-distribution O
of O
the O
active O
Pol B-GENE-N
II I-GENE-N
toward O
the O
3'-end O
of O
the O
gene O
and O
a O
decrease O
in O
the O
ratio O
between O
proximal O
and O
distal O
transcription. O
These O
results O
suggest O
a O
novel O
mechanism O
by O
which O
PR B-GENE-Y
regulates O
gene O
expression O
by O
facilitating O
the O
proper O
passage O
of O
the O
polymerase B-GENE-N
along O
hormone-dependent O
genes. O
Lipoxygenase B-GENE-N
and O

urease B-GENE-N
inhibition O
of O
the O
aerial O
parts O
of O
the O
Polygonatum O
verticillatum. O
Over O
expression O
of O
lipoxygenase B-GENE-N
(LOX) B-GENE-N
and O
urease B-GENE-N
has O
already O
contributed O
to O
the O
pathology O
of O
different O
human O
disease. O
Targeting O
the O
inhibition O
of O
these O
enzymes O
has O
proved O
great O
clinical O
utility. O
The O
aim O
of O
the O
present O
study O
was O
to O
scrutinised O
the O
inhibitory O
profile O
of O
the O
aerial O
parts O
of O
the O
Polygonatum O
verticillatum O
enzyme O
against O
LOX, B-GENE-N
urease, B-GENE-N
acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
and O
butyrylcholinesterase B-GENE-Y

(BChE) B-GENE-Y
using O
standard O
experimental O
protocols. O
When O
checked O
against O
lipoxygenase, B-GENE-N
the O
extracts O
revealed O
significant O
attenuation. O
Of O
the O
tested O
extracts, O
the O
ethyl B-CHEMICAL
acetate I-CHEMICAL
fraction O
was O
the O
most O
potent O
(half-maximal O
inhibitory O
concentration O
(IC50): O
97 O
µg/mL) O
followed O
by O
aqueous O
fraction O
IC50: O
109 O
µg/mL). O
Regarding O
urease B-GENE-N
inhibition, O
n-butanol B-CHEMICAL
was O
the O
most O
potent O
fraction O
(IC50: O
97 O
µg/mL). O
However, O
the O
extracts O
did O
not O
show O
significant O
inhibition O
on O

AChE B-GENE-Y
and O
BChE. B-GENE-Y
In O
the O
preliminary O
phytochemical O
tests, O
the O
aerial O
parts O
of O
the O
plant O
showed O
the O
presence O
of O
saponins, B-CHEMICAL
alkaloids, O
flavonoids, B-CHEMICAL
phenols, B-CHEMICAL
tannins B-CHEMICAL
and O
terpenoids. B-CHEMICAL
The O
current O
findings O
could O
be O
attributed O
to O
these O
groups O
of O
compounds. O
A O
physiologically O
based O
pharmacokinetic O
model O
for O
the O
oxime B-CHEMICAL
TMB-4: B-CHEMICAL
simulation O
of O
rodent O
and O
human O
data. O
Multiple O
oximes B-CHEMICAL
have O
been O
synthesized O
and O
evaluated O
for O
use O
as O
countermeasures O
against O
chemical O
warfare O
nerve O
agents. O
The O
current O
U.S. O
military O
and O
civilian O

oxime B-CHEMICAL
countermeasure, O
2-[(hydroxyimino)methyl]-1-methylpyridin-1-ium B-CHEMICAL
chloride I-CHEMICAL
(2-PAM), B-CHEMICAL
is O
under O
consideration O
for O
replacement O
with O
a O
more O
effective O
acetylcholinesterase B-GENE-Y
reactivator, O
1,1'-methylenebis{4-hydroxyiminomethyl}pyridinium B-CHEMICAL
dimethanesulfonate I-CHEMICAL
(MMB-4). B-CHEMICAL
Kinetic O
data O
in O
the O
scientific O
literature O
for O
MMB-4 B-CHEMICAL
are O
limited; O
therefore, O
a O
physiologically O
based O

pharmacokinetic O
(PBPK) O
model O
was O
developed O
for O
a O
structurally O
related O
oxime, B-CHEMICAL
1,1'-trimethylenebis{4-hydroximinomethyl}pyridinium B-CHEMICAL
dibromide. I-CHEMICAL
Based O
on O
a O
previous O
model O
structure O
for O
the O
organophosphate B-CHEMICAL
diisopropylfluorophosphate, B-CHEMICAL
the O
model O
includes O
key O
sites O
of O
acetylcholinesterase B-GENE-Y
inhibition O
(brain O
and O
diaphragm), O
as O
well O
as O
fat, O
kidney, O
liver, O
rapidly O
perfused O
tissues O
and O
slowly O
perfused O
tissues. O
All O
tissue O
compartments O

are O
diffusion O
limited. O
Model O
parameters O
were O
collected O
from O
the O
literature, O
predicted O
using O
quantitative O
structure-property O
relationships O
or, O
when O
necessary, O
fit O
to O
available O
pharmacokinetic O
data O
from O
the O
literature. O
The O
model O
was O
parameterized O
using O
rat O
plasma, O
tissue O
and O
urine O
time O
course O
data O
from O
intramuscular O
administration, O
as O
well O
as O
human O
blood O
and O
urine O
data O
from O
intravenous O
and O
intramuscular O
administration; O
sensitivity O
analyses O
were O
performed. O
The O
PBPK O
model O
successfully O
simulates O
rat O
and O
human O
data O
sets O
and O
has O
been O
evaluated O
by O
predicting O
intravenous O
mouse O
and O
intramuscular O
human O
data O
not O
used O
in O
the O
development O
of O
the O

model. O
Monte O
Carlo O
analyses O
were O
performed O
to O
quantify O
human O
population O
kinetic O
variability O
in O
the O
human O
evaluation O
data O
set. O
The O
model O
identifies O
potential O
pharmacokinetic O
differences O
between O
rodents O
and O
humans, O
indicated O
by O
differences O
in O
model O
parameters O
between O
species. O
The O
PBPK O
model O
can O
be O
used O
to O
optimize O
the O
dosing O
regimen O
to O
improve O
oxime B-CHEMICAL
therapeutic O
efficacy O
in O
a O
human O
population. O
Creb1-Mecp2-(m)CpG B-GENE-Y
complex O
transactivates O
postnatal O
murine O
neuronal O
glucose B-GENE-Y
transporter I-GENE-Y
isoform I-GENE-Y
3 I-GENE-Y
expression. O
The O
murine O
neuronal O

facilitative O
glucose B-GENE-Y
transporter I-GENE-Y
isoform I-GENE-Y
3 I-GENE-Y
(Glut3) B-GENE-Y
is O
developmentally O
regulated, O
peaking O
in O
expression O
at O
postnatal O
day O
(PN)14. O
In O
the O
present O
study, O
we O
characterized O
a O
canonical O
CpG B-CHEMICAL
island O
spanning O
the O
5'-flanking O
region O
of O
the O
glut3 B-GENE-Y
gene. O
Methylation-specific O
PCR O
and O
bisulfite B-CHEMICAL
sequencing O
identified O
methylation O
of O
this O
CpG B-CHEMICAL
((m)CpG) B-CHEMICAL
island O
of O
the O
glut3 B-GENE-Y
gene, O
frequency O
of O
methylation O
increasing O
2.5-fold O
with O
a O
1.6-fold O
increase O
in O
DNA B-GENE-Y
methyl I-GENE-Y

transferase I-GENE-Y
3a I-GENE-Y
concentrations O
noted O
with O
advancing O
postnatal O
age O
(PN14 O
vs O
PN3). O
5'-flanking O
region O
of O
glut3-luciferase B-GENE-Y
reporter O
transient O
transfection O
in O
HT22 O
hippocampal O
neurons O
demonstrated O
that O
(m)CpGs B-CHEMICAL
inhibit O
glut3 B-GENE-Y
transcription. O
Contrary O
to O
this O
biological O
function, O
glut3 B-GENE-Y
expression O
rises O
synchronously O
with O
(m)CpGs B-CHEMICAL
in O
PN14 O
vs O
PN3 O
neurons. O
Chromatin O
immunoprecipitation O
(IP) O
revealed O
that O

methyl-CpG B-GENE-Y
binding I-GENE-Y
protein I-GENE-Y
2 I-GENE-Y
(Mecp2) B-GENE-Y
bound O
the O
glut3-(m)CpGs. B-GENE-Y
Depending O
on O
association O
with O
specific O
coregulators, O
Mecp2, B-GENE-Y
a O
dual O
regulator O
of O
gene O
transcription, O
may O
repress O
or O
activate O
a O
downstream O
gene. O
Sequential O
chromatin O
IP O
uncovered O
the O
glut3-(m)CpGs B-GENE-Y
to O
bind O
Mecp2 B-GENE-Y
exponentially O
upon O
recruitment O
of O
Creb1 B-GENE-Y
rather O
than O
histone B-GENE-Y
deacetylase I-GENE-Y
1. I-GENE-Y
Co-IP O
and O
coimmunolocalization O
confirmed O
that O
Creb1 B-GENE-Y
associated O
with O

Mecp2 B-GENE-Y
and O
cotransfection O
with O
glut3-(m)CpG B-GENE-Y
in O
HT22 O
cells O
enhanced O
glut3 B-GENE-Y
transcription. O
Separate O
5-aza-2'-deoxycytidine B-CHEMICAL
pretreatment O
or O
in O
combination O
with O
trichostatin B-CHEMICAL
A I-CHEMICAL
reduced O
(m)CpG B-CHEMICAL
and O
specific O
small O
interference O
RNAs O
targeting O
Mecp2 B-GENE-Y
and O
Creb1 B-GENE-Y
separately O
or O
together O
depleting O
Mecp2 B-GENE-Y
and/or O
Creb1 B-GENE-Y
binding O
of O
glut3-(m)CpGs B-GENE-Y
reduced O
glut3 B-GENE-Y
expression O
in O
HT22 O
cells. O

We O
conclude O
that O
Glut3 B-GENE-Y
is O
a O
methylation-sensitive O
neuronal O
gene O
that O
recruits O
Mecp2. B-GENE-Y
Recruitment O
of O
Creb1-Mecp2 B-GENE-Y
by O
glut3-(m)CpG B-GENE-Y
contributes O
towards O
transactivation, O
formulating O
an O
escape O
from O
(m)CpG-induced B-CHEMICAL
gene O
suppression, O
and O
thereby O
promoting O
developmental O
neuronal O
glut3 B-GENE-Y
gene O
transcription O
and O
expression. O
Structure O
of O
human B-GENE-Y
microsomal I-GENE-Y
cytochrome I-GENE-Y
P450 I-GENE-Y
2C8. I-GENE-Y
Evidence O
for O
a O
peripheral B-GENE-N
fatty I-GENE-N
acid I-GENE-N
binding I-GENE-N
site. I-GENE-N
A O
2.7-Angstrom O
molecular O
structure O
of O
human B-GENE-Y
microsomal I-GENE-Y

cytochrome I-GENE-Y
P450 I-GENE-Y
2C8 I-GENE-Y
(CYP2C8) B-GENE-Y
was O
determined O
by O
x-ray O
crystallography. O
The O
membrane O
protein O
was O
modified O
for O
crystallization O
by O
replacement O
of O
the O
hydrophobic O
N-terminal O
transmembrane O
domain O
with O
a O
short O
hydrophilic O
sequence O
before O
residue O
28. O
The O
structure O
of O
the O
native O
sequence O
is O
complete O
from O
residue O
28 O
to O
the O
beginning O
of O
a O
C-terminal B-CHEMICAL
histidine B-CHEMICAL
tag O
used O
for O
purification. O
CYP2C8 B-GENE-Y
is O
one O
of O
the O
principal O
hepatic O
drug-metabolizing O
enzymes O
that O
oxidizes O
therapeutic O
drugs O
such O
as O
taxol O
and O

cerivastatin O
and O
endobiotics O
such O
as O
retinoic O
acid O
and O
arachidonic O
acid. O
Consistent O
with O
the O
relatively O
large O
size O
of O
its O
preferred O
substrates, O
the O
active O
site O
volume O
is O
twice O
that O
observed O
for O
the O
structure O
of O
CYP2C5. B-GENE-Y
The O
extended O
active O
site O
cavity O
is O
bounded O
by O
the O
beta1 B-GENE-N
sheet I-GENE-N
and O
helix B-GENE-N
F' I-GENE-N
that O
have O
not O
previously O
been O
implicated O
in O
substrate O
recognition O
by O
mammalian B-GENE-N
P450s. I-GENE-N
CYP2C8 B-GENE-Y
crystallized O
as O
a O
symmetric O
dimer O
formed O
by O
the O
interaction O
of O
helices B-GENE-N
F, I-GENE-N
F', I-GENE-N
G', I-GENE-N
and I-GENE-N
G. I-GENE-N
Two O
molecules O
of O
palmitic B-CHEMICAL

acid I-CHEMICAL
are O
bound O
in O
the O
dimer O
interface. O
The O
dimer O
is O
observed O
in O
solution, O
and O
mass O
spectrometry O
confirmed O
the O
association O
of O
palmitic B-CHEMICAL
acid I-CHEMICAL
with O
the O
enzyme. O
This O
novel O
finding O
identifies O
a O
peripheral O
binding O
site O
in O
P450s B-GENE-N
that O
may O
contribute O
to O
drug-drug O
interactions O
in O
P450 B-GENE-N
metabolism. O
Resistance O
to O
conventional O
insecticides O
in O
Pakistani O
populations O
of O
Musca O
domestica O
L. O
(Diptera: O
Muscidae): O
a O
potential O
ectoparasite O
of O
dairy O
animals. O
The O
house O
fly, O
Musca O
domestica O
L., O
is O
an O
important O
hygienic O
pest O
of O
humans O
and O
dairy O
animals O
with O
the O
potential O
to O
develop O

resistance O
to O
most O
chemical O
classes O
of O
insecticides. O
Six O
adult O
house O
fly O
strains O
from O
dairy O
farms O
in O
Punjab, O
Pakistan O
were O
evaluated O
for O
resistance O
to O
selected O
insecticides O
from O
organochlorine, B-CHEMICAL
organophosphate, B-CHEMICAL
carbamate B-CHEMICAL
and O
pyrethroid B-CHEMICAL
classes. O
For O
a O
chlorocyclodiene B-CHEMICAL
and O
two O
organophosphates B-CHEMICAL
tested, O
the O
resistance O
ratios O
(RR) O
at O
LC50 O
were O
in O
the O
range O
of O
5.60-22.02 O
fold O
for O
endosulfan, B-CHEMICAL
7.66-23.24 O
fold O
for O
profenofos O
and O
2.47-7.44 O
fold O
for O

chlorpyrifos. B-CHEMICAL
For O
two O
pyrethroids B-CHEMICAL
and O
one O
carbamate, B-CHEMICAL
the O
RR O
values O
at O
LC50 O
were O
30.22-70.02 O
for O
cypermethrin, B-CHEMICAL
5.73-18.31 O
for O
deltamethrin, B-CHEMICAL
and O
4.39-15.50 O
for O
methomyl. B-CHEMICAL
This O
is O
the O
first O
report O
of O
resistance O
to O
different O
classes O
of O
insecticides O
in O
Pakistani O
dairy O
populations O
of O
house O
flies. O
Regular O
insecticide O
resistance O
monitoring O
programs O
on O
dairy O
farms O
are O
needed O
to O
prevent O
field O
control O
failures. O
Moreover, O
integrated O
approaches O
including O
the O
judicious O
use O
of O
insecticides O
are O
needed O
to O
delay O
the O
development O

of O
insecticide O
resistance O
in O
house O
flies. O
Effect O
of O
antidepressant O
drugs O
in O
mice O
lacking O
the O
norepinephrine B-GENE-Y
transporter. I-GENE-Y
One O
of O
the O
main O
theories O
concerning O
the O
mechanism O
of O
action O
of O
antidepressant O
drugs O
(ADs) O
is O
based O
on O
the O
notion O
that O
the O
neurochemical O
background O
of O
depression O
involves O
an O
impairment O
of O
central O
noradrenergic O
transmission O
with O
a O
concomitant O
decrease O
of O
the O
norepinephrine B-CHEMICAL
(NE) B-CHEMICAL
in O
the O
synaptic O
gap. O
Many O
ADs O
increase O
synaptic O
NE B-CHEMICAL
availability O
by O
inhibition O
of O
the O
reuptake O
of O
NE. B-CHEMICAL
Using O
mice O
lacking O
NE B-GENE-Y
transporter I-GENE-Y

(NET-/-) B-GENE-Y
we O
examined O
their O
baseline O
phenotype O
as O
well O
as O
the O
response O
in O
the O
forced O
swim O
test O
(FST) O
and O
in O
the O
tail O
suspension O
test O
(TST) O
upon O
treatment O
with O
ADs O
that O
display O
different O
pharmacological O
profiles. O
In O
both O
tests, O
the O
NET-/- B-GENE-Y
mice O
behaved O
like O
wild-type O
(WT) O
mice O
acutely O
treated O
with O
ADs. O
Autoradiographic O
studies O
showed O
decreased O
binding O
of O
the O
beta-adrenergic O
ligand O
[3H]CGP12177 B-CHEMICAL
in O
the O
cerebral O
cortex O
of O
NET-/- B-GENE-Y
mice, O
indicating O
the O
changes O
at O

the O
level O
of O
beta-adrenergic B-GENE-N
receptors I-GENE-N
similar O
to O
those O
obtained O
with O
ADs O
treatment. O
The O
binding O
of O
[3H]prazosin B-CHEMICAL
to O
alpha1-adrenergic B-GENE-N
receptors I-GENE-N
in O
the O
cerebral O
cortex O
of O
NET-/- B-GENE-Y
mice O
was O
also O
decreased, O
most O
probably O
as O
an O
adaptive O
response O
to O
the O
sustained O
elevation O
of O
extracellular O
NE B-CHEMICAL
levels O
observed O
in O
these O
mice. O
A O
pronounced O
NET B-GENE-Y
knockout-induced O
shortening O
of O
the O
immobility O
time O
in O
the O
TST O
(by O
ca O
50%) O
compared O
to O
WT O
mice O
was O
not O
reduced O
any O
further O
by O
NET-inhibiting B-GENE-Y
ADs O
such O
as O
reboxetine, B-CHEMICAL

desipramine, B-CHEMICAL
and O
imipramine. B-CHEMICAL
Citalopram, B-CHEMICAL
which O
is O
devoid O
of O
affinity O
for O
the O
NET, B-GENE-Y
exerted O
a O
significant O
reduction O
of O
immobility O
time O
in O
the O
NET-/- B-GENE-Y
mice. O
In O
the O
FST, O
reboxetine, B-CHEMICAL
desipramine, B-CHEMICAL
imipramine, B-CHEMICAL
and O
citalopram B-CHEMICAL
administered O
acutely O
did O
not O
reduce O
any O
further O
the O
immobility O
time O
shortened O
by O
NET B-GENE-Y
knockout O
itself O
(ca O
25%); O
however, O
antidepressant-like O
action O
of O
repeatedly O
(7 O
days) O
administered O
desipramine B-CHEMICAL
was O
observed O
in O
NET-/- B-GENE-Y
mice, O

indicating O
that O
the O
chronic O
presence O
of O
this O
drug O
may O
also O
affect O
other O
neurochemical O
targets O
involved O
in O
the O
behavioral O
reactions O
monitored O
by O
this O
test. O
From O
the O
present O
study, O
it O
may O
be O
concluded O
that O
mice O
lacking O
the O
NET B-GENE-Y
may O
represent O
a O
good O
model O
of O
some O
aspects O
of O
depression-resistant O
behavior, O
paralleled O
with O
alterations O
in O
the O
expression O
of O
adrenergic B-GENE-N
receptors, I-GENE-N
which O
result O
as O
an O
adaptation O
to O
elevated O
levels O
of O
extracellular O
NE. B-CHEMICAL
In O
vitro O
inhibitory O
effects O
of O
non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
on O
4-methylumbelliferone B-CHEMICAL
glucuronidation O
in O
recombinant O
human B-GENE-Y

UDP-glucuronosyltransferase I-GENE-Y
1A9--potent I-GENE-Y
inhibition O
by O
niflumic B-CHEMICAL
acid. I-CHEMICAL
The O
inhibitory O
potencies O
of O
non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
(NSAIDs) O
on O
UDP-glucuronosyltransferase B-GENE-Y
(UGT) I-GENE-Y
1A9 I-GENE-Y
activity O
were O
investigated O
in O
recombinant O
human B-GENE-Y
UGT1A9 I-GENE-Y
using O
4-methylumbelliferone B-CHEMICAL
(4-MU) B-CHEMICAL
as O
a O
substrate O
for O
glucuronidation. O
4-MU B-CHEMICAL
glucuronidation O
(4-MUG) O

showed O
Michaelis-Menten O
kinetics O
with O
a O
Km O
value O
of O
6.7 O
microM. O
The O
inhibitory O
effects O
of O
the O
following O
seven O
NSAIDs O
were O
investigated: O
acetaminophen, B-CHEMICAL
diclofenac, B-CHEMICAL
diflunisal, B-CHEMICAL
indomethacin, B-CHEMICAL
ketoprofen, B-CHEMICAL
naproxen B-CHEMICAL
and O
niflumic B-CHEMICAL
acid. I-CHEMICAL
Niflumic B-CHEMICAL
acid I-CHEMICAL
had O
the O
most O
potent O
inhibitory O
effect O
on O
4-MUG O
with O
an O
IC50 O
value O
of O
0.0341 O
microM. O
The O
IC50 O
values O
of O
diflunisal, B-CHEMICAL
diclofenac B-CHEMICAL
and O

indomethacin B-CHEMICAL
were O
1.31, O
24.2, O
and O
34.1 O
microM, O
respectively, O
while O
acetaminophen, B-CHEMICAL
ketoprofen B-CHEMICAL
and O
naproxen B-CHEMICAL
showed O
less O
potent O
inhibition. O
Niflumic B-CHEMICAL
acid, I-CHEMICAL
diflunisal, B-CHEMICAL
diclofenac B-CHEMICAL
and O
indomethacin B-CHEMICAL
inhibited O
4-MUG O
competitively O
with O
Ki O
values O
of O
0.0275, O
0.710, O
53.3 O
and O
69.9 O
microM, O
respectively, O
being O
similar O
to O
each O
IC50 O
value. O
In O
conclusion, O
of O
the O
seven O
NSAIDs O
investigated, O

niflumic B-CHEMICAL
acid I-CHEMICAL
was O
the O
most O
potent O
inhibitor O
of O
recombinant O
UGT1A9 B-GENE-Y
via O
4-MUG O
in O
a O
competitive O
manner. O
Affinities O
of O
venlafaxine B-CHEMICAL
and O
various O
reuptake O
inhibitors O
for O
the O
serotonin B-GENE-N
and I-GENE-N
norepinephrine I-GENE-N
transporters. I-GENE-N
In O
vitro O
radioligand O
binding O
studies O
were O
carried O
out O
in O
rat O
brain O
membranes O
to O
assess O
the O
affinity O
of O
various O
reuptake O
inhibitors O
for O
the O
serotonin B-GENE-N
(5-hydroxytryptamine, I-GENE-N
5-HT) I-GENE-N
and I-GENE-N
the I-GENE-N
norepinephrine I-GENE-N
transporters I-GENE-N
using O
the O
selective O

ligands O
[3H]cyanoimipramine B-CHEMICAL
and O
[3H]nisoxetine, B-CHEMICAL
respectively. O
The O
selective O
5-HT B-CHEMICAL
reuptake O
inhibitors O
paroxetine, B-CHEMICAL
indalpine B-CHEMICAL
and O
fluvoxamine B-CHEMICAL
displayed O
a O
high O
affinity O
for O
the O
5-HT B-GENE-Y
transporter, I-GENE-Y
whereas O
the O
norepinephrine B-CHEMICAL
reuptake O
inhibitor O
desipramine B-CHEMICAL
had O
a O
high O
affinity O
for O
the O
norepinephrine B-GENE-Y
transporter. I-GENE-Y
Duloxetine, B-CHEMICAL
a O
dual O
5-HT B-CHEMICAL
and O
norepinephrine B-CHEMICAL
reuptake O
inhibitor, O
displayed O
a O
high O
affinity O
for O
both O
the O
5-HT B-GENE-N
and I-GENE-N
the I-GENE-N

norepinephrine I-GENE-N
transporters. I-GENE-N
Interestingly, O
venlafaxine, B-CHEMICAL
a O
dual O
5-HT B-CHEMICAL
and O
norepinephrine B-CHEMICAL
reuptake O
inhibitor, O
displayed O
only O
a O
moderate O
affinity O
for O
the O
5-HT B-GENE-Y
transporter I-GENE-Y
(Ki O
= O
74 O
nM) O
and O
a O
very O
low O
affinity O
for O
the O
norepinephrine B-GENE-Y
transporter I-GENE-Y
(Ki O
= O
1.26 O
microM). O
The O
relatively O
low O
affinities O
of O
venlafaxine B-CHEMICAL
contrast O
with O
its O
potent O
in O
vivo O
5-HT B-CHEMICAL
and O
norepinephrine B-CHEMICAL
reuptake O
blocking O
properties. O
These O
results O
raise O
the O
possibility O
that O
the O
in O
vivo O
effects O

on O
the O
5-HT B-CHEMICAL
and O
norepinephrine B-CHEMICAL
reuptake O
observed O
with O
venlafaxine B-CHEMICAL
may O
not O
be O
mediated O
solely O
by O
its O
binding O
to O
the O
[3H]cyanoimipramine B-CHEMICAL
and O
[3H]nisoxetine B-CHEMICAL
binding O
sites. O
Xanthurenic O
aciduria O
due O
to O
a O
mutation O
in O
KYNU B-GENE-Y
encoding O
kynureninase. B-GENE-Y
Massive O
urinary O
excretion O
of O
xanthurenic B-CHEMICAL
acid, I-CHEMICAL
3-hydroxykynurenine B-CHEMICAL
and O
kynurenine, B-CHEMICAL
known O
as O
xanthurenic O
aciduria O
or O

hydroxykynureninuria, O
in O
a O
young O
Somali O
boy O
suggested O
kynureninase B-GENE-Y
deficiency. O
Mutation O
analysis O
of O
KYNU B-GENE-Y
encoding O
kynureninase B-GENE-Y
of O
the O
index O
case O
revealed O
homozygosity O
for O
a O
c.593 O
A B-GENE-N
> I-GENE-N
G I-GENE-N
substitution O
leading O
to O
a O
threonine-to-alanine B-GENE-N
(T198A) B-GENE-N
shift. O
A O
younger O
brother O
was O
found O
to O
have O
a O
similar O
excretion O
pattern O
and O
the O
same O
genotype. O
At O
present, O
neither O
of O
the O
two O
boys O
has O
symptoms O
of O
niacin O
deficiency. O
This O
is O
the O
first O
report O
linking O
xanthurenic O
aciduria O
to O

a O
mutation O
in O
the O
gene O
encoding O
kynureninase. B-GENE-Y
Co-C B-CHEMICAL
bond O
activation O
in O
methylmalonyl-CoA B-GENE-Y
mutase I-GENE-Y
by O
stabilization O
of O
the O
post-homolysis O
product O
Co2+ B-CHEMICAL
cobalamin. B-CHEMICAL
Despite O
decades O
of O
research, O
the O
mechanism O
by O
which O
coenzyme B-CHEMICAL
B12 I-CHEMICAL
(adenosylcobalamin, B-CHEMICAL
AdoCbl)-dependent B-CHEMICAL
enzymes O
promote O
homolytic O
cleavage O
of O
the O
cofactor's O
Co-C B-CHEMICAL
bond O
to O
initiate O
catalysis O
has O
continued O
to O
elude O
researchers. O
In O
this O
work, O
we O
utilized O
magnetic O
circular O
dichroism O

spectroscopy O
to O
explore O
how O
the O
electronic O
structure O
of O
the O
reduced O
B12 O
cofactor O
(i.e., O
the O
post-homolysis O
product O
Co2+ B-CHEMICAL
Cbl) I-CHEMICAL
is O
modulated O
by O
the O
enzyme O
methylmalonyl-CoA B-GENE-Y
mutase. I-GENE-Y
Our O
data O
reveal O
a O
fairly O
uniform O
stabilization O
of O
the O
Co O
3d O
orbitals O
relative O
to O
the O
corrin O
pi/pi*-based O
molecular O
orbitals O
when O
Co2+ B-CHEMICAL
Cbl I-CHEMICAL
is O
bound O
to O
the O
enzyme O
active O
site, O
particularly O
in O
the O
presence O
of O
substrate. O
Contrastingly, O
our O
previous O
studies O
(Brooks, O
A. O

J.; O
Vlasie, O
M.; O
Banerjee, O
R.; O
Brunold, O
T. O
C. O
J. O
Am. O
Chem. O
Soc. O
2004, O
126, O
8167-8180.) O
showed O
that O
when O
AdoCbl B-CHEMICAL
is O
bound O
to O
the O
MMCM B-GENE-Y
active O
site, O
no O
enzymatic O
perturbation O
of O
the O
Co3+ B-CHEMICAL
Cbl I-CHEMICAL
electronic O
structure O
occurs, O
even O
in O
the O
presence O
of O
substrate O
(analogues). O
Collectively, O
these O
observations O
provide O
direct O
evidence O
that O
enzymatic O
Co-C B-CHEMICAL
bond O
activation O
involves O
stabilization O
of O
the O
post-homolysis O
product, O
Co2+ B-CHEMICAL

Cbl, I-CHEMICAL
rather O
than O
destabilization O
of O
the O
Co3+ B-CHEMICAL
Cbl I-CHEMICAL
"ground" O
state. O
Neurotoxicity O
of O
"ecstasy" B-CHEMICAL
and O
its O
metabolites O
in O
human O
dopaminergic O
differentiated O
SH-SY5Y O
cells. O
"Ecstasy" B-CHEMICAL
(3,4-methylenedioxymethamphetamine B-CHEMICAL
or O
MDMA) B-CHEMICAL
is O
a O
widely O
abused O
recreational O
drug, O
reported O
to O
produce O
neurotoxic O
effects, O
both O
in O
laboratory O
animals O
and O
in O
humans. O
MDMA B-CHEMICAL
metabolites O
can O
be O
major O
contributors O
for O
MDMA B-CHEMICAL
neurotoxicity. O
This O
work O
studied O
the O

neurotoxicity O
of O
MDMA B-CHEMICAL
and O
its O
catechol B-CHEMICAL
metabolites, O
α-methyldopamine B-CHEMICAL
(α-MeDA) B-CHEMICAL
and O
N-methyl-α-methyldopamine B-CHEMICAL
(N-Me-α-MeDA) B-CHEMICAL
in O
human O
dopaminergic O
SH-SY5Y O
cells O
differentiated O
with O
retinoic B-CHEMICAL
acid I-CHEMICAL
and O
12-O-tetradecanoyl-phorbol-13-acetate. B-CHEMICAL
Differentiation O
led O
to O
SH-SY5Y O
neurons O
with O
higher O
ability O
to O
accumulate O
dopamine B-CHEMICAL
and O
higher O
resistance O
towards O
dopamine B-CHEMICAL

neurotoxicity. O
MDMA B-CHEMICAL
catechol B-CHEMICAL
metabolites O
were O
neurotoxic O
to O
SH-SY5Y O
neurons, O
leading O
to O
caspase B-GENE-Y
3-independent I-GENE-Y
cell O
death O
in O
a O
concentration- O
and O
time-dependent O
manner. O
MDMA B-CHEMICAL
did O
not O
show O
a O
concentration- O
and O
time-dependent O
death. O
Pre-treatment O
with O
the O
antioxidant O
and O
glutathione B-CHEMICAL
precursor, O
N-acetylcysteine B-CHEMICAL
(NAC), B-CHEMICAL
resulted O
in O
strong O
protection O
against O
the O
MDMA B-CHEMICAL
metabolites' O
neurotoxicity. O
Neither O
the O
superoxide B-CHEMICAL
radical O
scavenger, O
tiron, O
nor O
the O

inhibitor O
of O
the O
dopamine B-GENE-Y
(DA) I-GENE-Y
transporter, I-GENE-Y
GBR B-CHEMICAL
12909, I-CHEMICAL
prevented O
the O
metabolites' O
toxicity. O
Cells O
exposed O
to O
α-MeDA B-CHEMICAL
showed O
an O
increase O
in O
intracellular O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
levels, O
which, O
at O
the O
48 O
h O
time-point, O
was O
not O
dependent O
in O
the O
activity O
increase O
of O
γ-glutamylcysteine B-GENE-Y
synthetase I-GENE-Y
(γ-GCS), B-GENE-Y
revealing O
a O
possible O
transient O
effect. O
Importantly, O
pre-treatment O
with O
buthionine B-CHEMICAL
sulfoximine I-CHEMICAL
(BSO), B-CHEMICAL
an O
inhibitor O
of O

γ-GCS, B-GENE-Y
prevented O
α-MeDA B-CHEMICAL
induced O
increase O
in O
GSH B-CHEMICAL
levels, O
but O
did O
not O
augment O
this O
metabolite O
cytotoxicity. O
Even O
so, O
BSO B-CHEMICAL
pre-treatment O
abolished O
NAC B-CHEMICAL
protective O
effects O
against O
α-MeDA B-CHEMICAL
neurotoxicity, O
which O
were, O
at O
least O
partially, O
due O
to O
GSH B-CHEMICAL
de O
novo O
synthesis. O
Inversely, O
pre-treatment O
of O
cells O
with O
BSO B-CHEMICAL
augmented O
N-Me-α-MeDA-induced B-CHEMICAL
neurotoxicity, O
but O
only O
slightly O
affected O
NAC B-CHEMICAL
neuroprotection. O
In O
conclusion, O
MDMA B-CHEMICAL
catechol B-CHEMICAL
metabolites O

promote O
differential O
toxic O
effects O
to O
differentiated O
dopaminergic O
human O
SH-SY5Y O
cells. O
A O
New O
Proposed O
Rodent O
Model O
of O
Chemically O
Induced O
Prostate O
Carcinogenesis: O
Distinct O
Time-Course O
Prostate O
Cancer O
Progression O
in O
the O
Dorsolateral O
and O
Ventral O
Lobes. O
BACKGROUND: O
Characterization O
of O
novel O
rodent O
models O
for O
prostate O
cancer O
studies O
requires O
evaluation O
of O
either O
spontaneous O
and O
carcinogen-induced O
tumors O
as O
well O
as O
tumor O
incidence O
in O
different O
prostatic O
lobes. O
We O
propose O
a O
new O
short-term O
rodent O
model O
of O
chemically O
induced O
prostate O

carcinogenesis O
in O
which O
prostate O
cancer O
progression O
occurs O
differentially O
in O
the O
dorsolateral O
and O
ventral O
lobes. O
METHODS: O
Adult O
gerbils O
were O
treated O
with O
MNU B-CHEMICAL
alone O
or O
associated O
with O
testosterone B-CHEMICAL
for O
3 O
or O
6 O
months O
of O
treatment. O
Tumor O
incidence, O
latency, O
localization, O
and O
immunohistochemistry O
(AR, B-GENE-N
PCNA, B-GENE-N
smooth B-GENE-N
muscle I-GENE-N
α-actin, I-GENE-N
p63, B-GENE-N
MGMT, B-GENE-N
and O
E-cadherin) B-GENE-Y
were O
studied O
in O
both O
lobes. O
RESULTS: O
Comparisons O
between O
both O
lobes O
revealed O
that O
lesions O
developed O
first O
in O
the O
DL O
while O
the O

VL O
presented O
longer O
tumor O
latency. O
However, O
after O
6 O
months, O
there O
was O
a O
dramatic O
increase O
in O
tumor O
multiplicity O
in O
the O
VL, O
mainly O
in O
MNU-treated B-CHEMICAL
groups. O
Lesions O
clearly O
progressed O
from O
a O
premalignant O
to O
a O
malignant O
phenotype O
over O
time O
and O
tumor O
latency O
was O
decreased O
by O
MNU B-CHEMICAL
+ O
testosterone B-CHEMICAL
administration. O
Three-dimensional O
reconstruction O
of O
the O
prostatic O
complex O
showed O
that O
the O
DL O
developed O
tumors O
exclusively O
in O
the O
periurethral O
area O
and O
showed O
intense O
AR, B-GENE-N
PCNA, B-GENE-N
and O
MGMT B-GENE-N
immunostaining. O
Moreover, O
VL O
lesions O
emerged O
throughout O
the O
entire O
lobe. O
MNU-induced B-CHEMICAL

lesions O
presented O
markers O
indicative O
of O
an O
aggressive O
phenotype: O
lack O
of O
basal O
cells, O
rupture O
of O
the O
smooth O
muscle O
cell O
layer, O
loss O
of O
E-cadherin, B-GENE-Y
and O
high O
MGMT B-GENE-N
staining. O
CONCLUSIONS: O
There O
are O
distinct O
pathways O
involved O
in O
tumor O
progression O
in O
gerbil O
prostate O
lobes. O
This O
animal O
provides O
a O
good O
model O
for O
prostate O
cancer O
since O
it O
allows O
the O
investigation O
of O
advanced O
steps O
of O
carcinogenesis O
with O
shorter O
latency O
periods O
in O
both O
lobes. O
Prostate O
© O
2013 O
Wiley O
Periodicals, O
Inc. O
Green O
tea O
extract O
alleviates O
arsenic-induced B-CHEMICAL
biochemical O
toxicity O
and O
lipid O

peroxidation O
in O
rats. O
The O
present O
work O
was O
undertaken O
to O
evaluate O
the O
protective O
effect O
of O
an O
aqueous O
extract O
of O
green O
tea O
(GT, O
Camellia O
sinensis) O
leaves O
against O
arsenic B-CHEMICAL
(NaAsO2)-induced B-CHEMICAL
biochemical O
toxicity O
and O
lipid O
peroxidation O
production O
in O
experimental O
rats. O
The O
treatment O
with O
arsenic B-CHEMICAL
exhibited O
a O
significant O
increase O
in O
some O
serum O
hepatic O
and O
renal O
biochemical O
parameters O
(alanine B-GENE-N
aminotransferase, I-GENE-N
aspartate B-GENE-N
aminotransferase, I-GENE-N
alkaline B-GENE-N
phosphatase, I-GENE-N
total O
protein, O
albumin, B-GENE-Y
bilirubin, B-CHEMICAL

cholesterol, B-CHEMICAL
urea B-CHEMICAL
and O
creatinine). B-CHEMICAL
But O
the O
co-administration O
of O
GT O
has O
increased O
the O
level O
of O
plasmatic O
concentration O
of O
biochemical O
parameters. O
Exposure O
of O
rats O
to O
arsenic B-CHEMICAL
caused O
also O
a O
significant O
increase O
in O
liver, O
kidney O
and O
testicular O
thiobarbituric B-CHEMICAL
acid I-CHEMICAL
reactive O
substances O
compared O
to O
control. O
However, O
the O
co-administration O
of O
GT O
was O
effective O
in O
reducing O
its O
level. O
To O
conclude, O
our O
data O
suggest O
that O
arsenic B-CHEMICAL
exposure O
enhanced O
an O
oxidative O
stress O
by O
disturbing O
the O
tissue O
antioxidant O
defense O
system, O
but O
the O
GT O
co-administration O
alleviates O
the O
toxicity O
induced O
by O
arsenic B-CHEMICAL

exposure. O
Synthesis, O
receptor O
binding O
and O
functional O
studies O
of O
mesoridazine B-CHEMICAL
stereoisomers. O
The O
four O
stereoisomers O
of O
mesoridazine B-CHEMICAL
were O
synthesized O
and O
evaluated O
in O
D2, B-GENE-Y
5-HT1A, B-GENE-Y
5-HT2A, B-GENE-Y
5-HT2C, B-GENE-Y
D1, B-GENE-Y
and O
D3 B-GENE-Y
receptor I-GENE-Y
binding O
and O
functional O
assays. O
Two O
isomers O
demonstrated O
potent O
D2 O
receptor O
binding O
(Ki O
< O
3 O
nM) O
and O
functional O
antagonism O
(IC50 O
< O
or O
= O
10 O
nM) O
activities. O
These O
two O
isomers O
also O
showed O
moderate O
affinity O
for O
the O
5-HT2A B-GENE-Y

and O
D3 B-GENE-Y
receptors. I-GENE-Y
A O
third O
isomer O
was O
devoid O
of O
significant O
D2 B-GENE-Y
receptor I-GENE-Y
binding, O
but O
did O
have O
moderate O
affinity O
for O
the O
5-HT2A B-GENE-Y
and O
D3 B-GENE-Y
receptors. I-GENE-Y
The O
fourth O
isomer O
demonstrated O
poor O
affinity O
for O
all O
the O
receptors O
tested. O
Most O
significantly, O
the O
stereochemistry O
of O
the O
sulfoxide B-CHEMICAL
moiety O
played O
a O
dominant O
role O
in O
the O
observed O
structure-activity O
relationship O
(SAR). O
Sex O
differences O
in O
the O
antidepressant-like O
effects O
of O
ketamine. B-CHEMICAL
Current O
medications O
for O
major O
depression O
suffer O
from O
numerous O
limitations. O
Once O
the O
right O
drug O
for O
treatment O
has O
been O
determined, O
it O
still O
takes O
several O
weeks O
for O
it O
to O
take O
effect O
and O

improve O
mood. O
This O
time O
lag O
is O
a O
serious O
concern O
for O
the O
healthcare O
community O
when O
dealing O
with O
patients O
with O
suicidal O
thoughts. O
However, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low-dose O
injection O
of O
ketamine, B-CHEMICAL
an O
N-methyl B-GENE-N
d-aspartate I-GENE-N
receptor I-GENE-N
(NMDAR) B-GENE-N
antagonist, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting. O
Although O
major O
depression O
affects O
twice O
as O
many O
women O
as O
men, O
all O
studies O
examining O
the O
rapid O
antidepressant O
effects O
of O
ketamine B-CHEMICAL
have O
focused O
on O
male O
subjects. O
Thus, O
we O
have O
investigated O
the O
behavioral O
and O
molecular O
effects O
of O
ketamine B-CHEMICAL
in O
both O
male O

and O
female O
rats O
and O
demonstrated O
greater O
sensitivity O
in O
female O
rats O
at O
a O
low O
dose O
of O
ketamine, B-CHEMICAL
a O
dose O
does O
not O
have O
antidepressant-like O
effects O
in O
male O
rats. O
The O
antidepressant-like O
effects O
of O
this O
low O
dose O
of O
ketamine B-CHEMICAL
were O
completely O
abolished O
when O
female O
rats O
were O
ovariectomized O
(OVX), O
and O
restored O
when O
physiological O
levels O
of O
estrogen B-CHEMICAL
and O
progesterone B-CHEMICAL
were O
supplemented, O
suggesting O
a O
critical O
role O
for O
gonadal O
hormones O
in O
enhancing O
the O
antidepressant-like O
effects O
of O
ketamine B-CHEMICAL
in O
female O
rats. O
In O
preclinical O
studies, O
the O
mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y

rapamycin I-GENE-Y
(mTOR) B-GENE-Y
in O
the O
medial O
prefrontal O
cortex O
and O
the O
eukaryotic B-GENE-N
elongation I-GENE-N
factor I-GENE-N
(eEF2) B-GENE-Y
in O
the O
hippocampus O
have O
been O
proposed O
as O
critical O
mediators O
of O
ketamine's B-CHEMICAL
rapid O
antidepressant O
actions. O
In O
our O
hands, O
the O
increased O
sensitivity O
of O
female O
rats O
to O
a O
low O
dose O
of O
ketamine B-CHEMICAL
was O
not O
mediated O
through O
phosphorylation O
of O
mTOR B-GENE-Y
or O
eEF2. B-GENE-Y
Effects O
of O
17α-ethynylestradiol-induced B-CHEMICAL
cholestasis O
on O
the O
pharmacokinetics O
of O
doxorubicin B-CHEMICAL
in O

rats: O
reduced O
biliary O
excretion O
and O
hepatic O
metabolism O
of O
doxorubicin. B-CHEMICAL
Abstract O
1. O
Since O
the O
prevalent O
hormonal O
combination O
therapy O
with O
estrogen B-CHEMICAL
analogues O
in O
cancer O
patients O
has O
frequency O
and O
possibility O
to O
induce O
the O
cholestasis, O
the O
frequent O
combination O
therapy O
with O
17α-ethynylestradiol B-CHEMICAL
(EE, O
an O
oral O
contraceptive) O
and O
doxorubicin B-CHEMICAL
(an O
anticancer O
drug) O
might O
be O
monitored O
in O
aspect O
of O
efficacy O
and O
safety. O
Doxorubicin B-CHEMICAL
is O
mainly O
excreted O
into O
the O
bile O
via O
P-glycoprotein B-GENE-N

(P-gp) B-GENE-N
and O
multidrug B-GENE-Y
resistance-associated I-GENE-Y
protein I-GENE-Y
2 I-GENE-Y
(Mrp2) B-GENE-Y
in O
hepatobiliary O
route O
and O
metabolized O
via O
cytochrome B-GENE-N
P450 I-GENE-N
(CYP) I-GENE-N
3A I-GENE-N
subfamily. O
Also O
the O
hepatic O
Mrp2 B-GENE-Y
(not O
P-gp) B-GENE-N
and O
CYP3A B-GENE-N
subfamily O
levels O
were O
reduced O
in O
EE-induced O
cholestatic O
(EEC) O
rats. O
Thus, O
we O
herein O
report O
the O
pharmacokinetic O
changes O
of O
doxorubicin B-CHEMICAL
with O
respect O
to O
the O
changes O
in O
its O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
EEC O

rats. O
2. O
The O
pharmacokinetic O
study O
of O
doxorubicin B-CHEMICAL
after O
intravenous O
administration O
of O
its O
hydrochloride B-CHEMICAL
was O
conducted O
along O
with O
the O
investigation O
of O
bile O
flow O
rate O
and O
hepatobiliary O
excretion O
of O
doxorubicin B-CHEMICAL
in O
control O
and O
EEC O
rats. O
3. O
The O
significantly O
greater O
AUC O
(58.7% O
increase) O
of O
doxorubicin B-CHEMICAL
in O
EEC O
rats O
was O
due O
to O
the O
slower O
CL O
(32.9% O
decrease). O
The O
slower O
CL O
was O
due O
to O
the O
reduction O
of O
hepatic O
biliary O
excretion O

(67.0% O
decrease) O
and O
hepatic O
CYP3A B-GENE-N
subfamily-mediated O
metabolism O
(21.9% O
decrease) O
of O
doxorubicin. B-CHEMICAL
These O
results O
might O
have O
broader O
implications O
to O
understand O
the O
altered O
pharmacokinetics O
and/or O
pharmacologic O
effects O
of O
doxorubicin B-CHEMICAL
via O
biliary O
excretion O
and O
hepatic O
metabolism O
in O
experimental O
and O
clinical O
estrogen-induced B-CHEMICAL
cholestasis. O
Corticotropin-releasing B-GENE-Y
hormone I-GENE-Y
reduces O
pressure O
pain O
sensitivity O
in O
humans O
without O
involvement O
of O
beta-endorphin(1-31), B-GENE-Y
but O
does O
not O
reduce O
heat O
pain O

sensitivity. O
In O
the O
present O
study O
the O
effects O
of O
intravenously O
administered O
corticotropin-releasing B-GENE-Y
hormone I-GENE-Y
(CRH) B-GENE-Y
on O
the O
release O
of O
proopiomelanocortin B-GENE-Y
(POMC) B-GENE-Y
derivatives O
such O
as O
adrenocorticotropic B-GENE-Y
hormone I-GENE-Y
(ACTH), B-GENE-Y
beta-lipotropin B-GENE-Y
(beta-LPH) B-GENE-Y
and O
beta-endorphin B-GENE-Y
(beta-END) B-GENE-Y
as O
well O
as O
direct O
effects O
of O
CRH B-GENE-Y
on O
pain O
sensitivity O
were O
examined. O
In O
16 O
healthy O
volunteers O
we O
studied O
the O
effects O
of O
100 O
microg O
intravenously O
administered O
CRH B-GENE-Y
in O
absence O
or O
presence O
of O
12 O
mg O

naloxone B-CHEMICAL
on O
heat O
or O
pressure O
pain O
sensitivity, O
using O
a O
double-blind, O
cross-over O
and O
placebo-controlled O
design. O
To O
evaluate O
analgesic O
effects O
of O
CRH B-GENE-Y
via O
release O
of O
POMC B-GENE-Y
derivatives, O
we O
determined O
plasma O
concentrations O
of O
beta-END-immunoreactive B-GENE-Y
material O
(IRM), O
authentic O
beta-END B-GENE-Y
(beta-END(1-31)) B-GENE-Y
and O
beta-LPH B-GENE-Y
IRM, O
in O
parallel O
with O
heat O
and O
pressure O
pain O
tolerance O
thresholds O
before O
and O
15 O
and O
30 O
min O
after O
treatment O
with O
CRH B-GENE-Y
(or O
placebo), O
and O
5 O
min O
after O
naloxone B-CHEMICAL

(or O
placebo) O
administration O
which O
was O
administered O
40 O
min O
after O
CRH B-GENE-Y
(or O
placebo) O
injection. O
CRH B-GENE-Y
increased O
levels O
of O
beta-END B-GENE-Y
IRM, O
beta-END(1-31) B-GENE-Y
and O
beta-LPH B-GENE-Y
IRM. O
As O
compared O
to O
beta-END B-GENE-Y
IRM O
levels O
measured O
by O
a O
commercial O
RIA O
kit, O
the O
beta-END(1-31) B-GENE-Y
levels O
determined O
by O
a O
highly O
specific O
two-site O
RIA, O
proved O
to O
be O
remarkably O
small. O
Furthermore, O
CRH B-GENE-Y
did O
not O
induce O
increases O
of O
heat O
pain O
tolerance O
thresholds, O
but O
of O
pressure O
pain O
tolerance O
thresholds, O
which, O
however, O

were O
not O
reversible O
by O
naloxone. B-CHEMICAL
Neither O
beta-END B-GENE-Y
nor O
beta-LPH B-GENE-Y
IRM O
nor O
beta-END(1-31) B-GENE-Y
levels O
correlated O
with O
heat O
or O
pressure O
pain O
tolerance O
thresholds. O
We O
conclude O
that O
CRH B-GENE-N
does O
not O
modulate O
heat, O
but O
pressure O
pain; O
POMC B-GENE-Y
derivatives O
like O
beta-END B-GENE-Y
IRM, O
beta-END(1-31) B-GENE-Y
or O
beta-LPH B-GENE-Y
do O
not O
mediate O
this O
effect. O
Activation O
of O
AMP-activated B-GENE-N
Protein I-GENE-N
Kinase I-GENE-N
and O
Phosphorylation O
of O
Glycogen B-GENE-Y
Synthase I-GENE-Y
Kinase3 I-GENE-Y
β I-GENE-Y

Mediate O
Ursolic B-CHEMICAL
Acid I-CHEMICAL
Induced O
Apoptosis O
in O
HepG2 O
Liver O
Cancer O
Cells. O
Despite O
the O
antitumour O
effect O
of O
ursolic B-CHEMICAL
acid I-CHEMICAL
observed O
in O
several O
cancers, O
the O
underlying O
mechanism O
remains O
unclear. O
Thus, O
in O
the O
present O
study, O
the O
roles O
of O
AMP-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(AMPK) B-GENE-N
and O
glycogen B-GENE-Y
synthase I-GENE-Y
kinase I-GENE-Y
3 I-GENE-Y
beta I-GENE-Y
(GSK3β) B-GENE-Y
were O
examined O
in O
ursolic O
acid O
induced O
apoptosis O
in O
HepG2 O
hepatocellular O
carcinoma O
cells. O
Ursolic B-CHEMICAL
acid I-CHEMICAL
significantly O
exerted O
cytotoxicity, O
increased O
the O

sub-G1 O
population O
and O
the O
number O
of O
ethidium B-CHEMICAL
homodimer O
and O
terminal O
deoxynucleotidyl O
transferase(TdT) O
mediated O
dUTP B-CHEMICAL
nick O
end O
labeling O
positive O
cells O
in O
HepG2 O
cells. O
Also, O
ursolic O
acid O
enhanced O
the O
cleavages O
of O
poly-ADP-ribose B-GENE-N
polymerase I-GENE-N
(PARP) B-GENE-N
and O
caspase3, B-GENE-Y
attenuated O
the O
expression O
of O
astrocyte B-GENE-Y
elevated I-GENE-Y
gene I-GENE-Y
(AEG1) B-GENE-Y
and O
survivin B-GENE-Y
in O
HepG2 O
cells. O
Interestingly, O
ursolic B-CHEMICAL
acid I-CHEMICAL
increased O
the O
phosphorylation O

of O
AMPK B-GENE-N
and O
coenzyme B-GENE-N
A I-GENE-N
carboxylase I-GENE-N
and O
also O
enhanced O
phosphorylation O
of O
GSK3β B-GENE-Y
at O
inactive O
form O
serine B-CHEMICAL
9, O
whereas O
ursolic B-CHEMICAL
acid I-CHEMICAL
attenuated O
the O
phosphorylation O
of O
AKT B-GENE-N
and O
mTOR B-GENE-Y
in O
HepG2 O
cells. O
Conversely, O
AMPK B-GENE-N
inhibitor O
compound B-CHEMICAL
C I-CHEMICAL
or O
GSK3β B-GENE-Y
inhibitor O
SB216763 B-CHEMICAL
blocked O
the O
cleavages O
of O
PARP B-GENE-N
and O
caspase B-GENE-Y
3 I-GENE-Y
induced O
by O
ursolic B-CHEMICAL
acid I-CHEMICAL
in O
HepG2 O
cells. O
Furthermore, O
proteosomal O
inhibitor O
MG132 B-CHEMICAL
suppressed O
AMPK B-GENE-N

activation, O
GSK3β B-GENE-Y
phosphorylation, O
cleaved O
PARP B-GENE-N
and O
deceased O
AEG-1 B-GENE-Y
induced O
by O
ursolic B-CHEMICAL
acid I-CHEMICAL
in O
HepG2 O
cells. O
Overall, O
our O
findings O
suggest O
that O
ursolic B-CHEMICAL
acid I-CHEMICAL
induced O
apoptosis O
in O
HepG2 O
cells O
via O
AMPK B-GENE-N
activation O
and O
GSK3β B-GENE-Y
phosphorylation O
as O
a O
potent O
chemopreventive O
agent. O
Copyright O
© O
2013 O
John O
Wiley O
& O
Sons, O
Ltd. O
Adverse O
outcome O
pathways O
during O
zebrafish O
embryogenesis: O
a O
case O
study O
with O
paraoxon. B-CHEMICAL
Using O
paraoxon B-CHEMICAL
as O
a O
reference O

acetylcholinesterase B-GENE-Y
(AChE) B-GENE-Y
inhibitor, O
the O
objective O
of O
this O
study O
was O
to O
develop O
an O
adverse O
outcome O
pathway O
(AOP) O
that O
provided O
quantitative O
linkages O
across O
levels O
of O
biological O
organization O
during O
zebrafish O
embryogenesis. O
Within O
normal O
zebrafish O
embryos, O
we O
first O
demonstrated O
that O
ache B-GENE-Y
transcripts O
and O
AChE B-GENE-Y
activity O
increased O
in O
a O
stage-dependent O
manner O
following O
segmentation. O
We O
then O
showed O
that O
static O
exposure O
of O
embryos O
to O
paraoxon B-CHEMICAL
(31.2-500 O
nM) O
from O
5 O
to O
96 O
hpf O
resulted O
in O
significant O
stage- O
and O
concentration-dependent O
AChE B-GENE-Y

inhibition, O
albeit O
these O
effects O
were O
fully O
reversible O
within O
48 O
h O
following O
transfer O
to O
clean O
water. O
However, O
even O
in O
the O
presence O
of O
significant O
AChE B-GENE-Y
inhibition, O
exposure O
to O
non-teratogenic O
paraoxon B-CHEMICAL
concentrations O
(≤250 O
nM) O
did O
not O
adversely O
impact O
secondary O
motoneuron O
development O
at O
96 O
hpf. O
Therefore, O
we O
investigated O
the O
potential O
effects O
of O
paraoxon B-CHEMICAL
exposure O
on O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
an O
early O
locomotor O
behavior O
that O
results O
from O
innervation O
of O
primary O
(not O
secondary) O
motoneuron O
axons O
to O
target O
axial O
muscles. O
Based O
on O
these O
studies, O
the O

frequency O
of O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
- O
a O
developmental O
stage O
with O
minimal O
AChE B-GENE-Y
expression O
and O
activity O
- O
was O
significantly O
higher O
following O
exposure O
to O
paraoxon B-CHEMICAL
concentrations O
as O
low O
as O
31.2 O
nM. O
Overall, O
our O
data O
suggest O
that O
(1) O
normal O
AChE B-GENE-Y
activity O
is O
not O
required O
for O
secondary O
motoneuron O
development O
and O
(2) O
spontaneous O
tail O
contractions O
at O
26 O
hpf O
are O
sensitive O
to O
paraoxon B-CHEMICAL
exposure, O
an O
effect O
that O
may O
be O
independent O
of O
AChE B-GENE-Y
inhibition. O
Using O
a O
well-studied O
reference O
chemical, O
this O
study O
highlights O
the O
potential O
challenges O
in O
developing O
quantitative O
AOPs O
to O
support O
chemical O
screening O
and O

prioritization O
strategies. O
Depletion O
of O
molecular O
chaperones O
from O
the O
endoplasmic O
reticulum O
and O
fragmentation O
of O
the O
Golgi O
apparatus O
associated O
with O
pathogenesis O
in O
Pelizaeus-Merzbacher O
disease. O
Missense O
mutations O
in O
the O
proteolipid B-GENE-Y
protein I-GENE-Y
1 I-GENE-Y
(PLP1) B-GENE-Y
gene O
cause O
a O
wide O
spectrum O
of O
hypomyelinating O
disorders, O
from O
mild O
spastic O
paraplegia O
type O
2 O
to O
severe O
Pelizaeus-Merzbacher O
disease O
(PMD). O
Mutant O
PLP1 B-GENE-Y
accumulates O
in O
the O
endoplasmic O
reticulum O
(ER) O
and O

induces O
ER O
stress. O
However, O
the O
link O
between O
the O
clinical O
severity O
of O
PMD O
and O
the O
cellular O
response O
induced O
by O
mutant O
PLP1 B-GENE-Y
remains O
largely O
unknown. O
Accumulation O
of O
misfolded O
proteins O
in O
the O
ER O
generally O
leads O
to O
up-regulation O
of O
ER O
chaperones O
to O
alleviate O
ER O
stress. O
Here, O
we O
found O
that O
expression O
of O
the O
PLP1-A243V B-GENE-Y
mutant, O
which O
causes O
severe O
disease, O
depletes O
some O
ER O
chaperones O
with O
a O
KDEL B-GENE-N
(Lys-Asp-Glu-Leu) B-GENE-N
motif, O
in O
HeLa O
cells, O
MO3.13 O

oligodendrocytic O
cells, O
and O
primary O
oligodendrocytes. O
The O
same O
PLP1 B-GENE-Y
mutant O
also O
induces O
fragmentation O
of O
the O
Golgi O
apparatus O
(GA). O
These O
organelle O
changes O
are O
less O
prominent O
in O
cells O
with O
milder O
disease-associated O
PLP1 B-GENE-Y
mutants. O
Similar O
changes O
are O
also O
observed O
in O
cells O
expressing O
another O
disease-causing O
gene O
that O
triggers O
ER O
stress, O
as O
well O
as O
in O
cells O
treated O
with O
brefeldin B-CHEMICAL
A, I-CHEMICAL
which O
induces O
ER O
stress O
and O
GA O
fragmentation O
by O
inhibiting O
GA O
to O
ER O
trafficking. O
We O
also O
found O
that O
mutant O
PLP1 B-GENE-Y
disturbs O
localization O
of O
the O

KDEL B-GENE-N
receptor, O
which O
transports O
the O
chaperones O
with O
the O
KDEL B-GENE-N
motif I-GENE-N
from O
the O
GA O
to O
the O
ER. O
These O
data O
show O
that O
PLP1 B-GENE-Y
mutants O
inhibit O
GA O
to O
ER O
trafficking, O
which O
reduces O
the O
supply O
of O
ER O
chaperones O
and O
induces O
GA O
fragmentation. O
We O
propose O
that O
depletion O
of O
ER O
chaperones O
and O
GA O
fragmentation O
induced O
by O
mutant O
misfolded O
proteins O
contribute O
to O
the O
pathogenesis O
of O
inherited O
ER O
stress-related O
diseases O
and O
affect O
the O
disease O
severity. O
Endogenous O
opioid O
systems O
and O
alcohol B-CHEMICAL
addiction. O
Alcohol B-CHEMICAL
exerts O
numerous O
pharmacological O
effects O
through O
its O
interaction O
with O
various O

neurotransmitters O
and O
neuromodulators. O
Among O
the O
latter, O
the O
endogenous O
opioids O
play O
a O
key O
role O
in O
the O
rewarding O
(addictive) O
properties O
of O
ethanol. B-CHEMICAL
Three O
types O
of O
opioid B-GENE-N
receptors I-GENE-N
(mu, I-GENE-N
delta I-GENE-N
and I-GENE-N
kappa) I-GENE-N
represent O
the O
respective O
targets O
of O
the O
major O
opioid B-GENE-N
peptides I-GENE-N
(beta-endorphin, B-GENE-Y
enkephalins B-GENE-N
and O
dynorphins, B-GENE-Y
respectively). O
The O
rewarding O
(reinforcing) O
properties O
of O
mu- B-GENE-N
and I-GENE-N
delta-receptor I-GENE-N
ligands O
are O
brought O
by O
activation O
of O
the O
mesolimbic O
dopamine O

system O
which O
ascends O
from O
the O
ventral O
tegmentum O
of O
the O
midbrain O
(VTA) O
to O
rostral O
structures; O
of O
these, O
the O
nucleus O
accumbens O
(NAC) O
is O
of O
particular O
importance O
in O
drug O
addiction. O
In O
contrast, O
dysphoria O
results O
from O
activation O
of O
kappa-receptors. B-GENE-N
The O
neurochemical O
manifestations O
of O
these O
opposing O
effects O
are, O
respectively, O
increases O
and O
decreases O
in O
dopamine B-CHEMICAL
release O
in O
the O
NAC. O
Several O
lines O
of O
evidence O
indicate O
that O
alcohol B-CHEMICAL
interferes O
with O
endogenous O
opioid O
mechanisms O
which O
are O
closely O
linked O
with O
dopamine B-CHEMICAL
transmission O
in O
the O
mesolimbic O
pathway. O
The O

view O
that O
condensation O
products O
of O
dopamine B-CHEMICAL
and O
alcohol-derived B-CHEMICAL
aldehyde B-CHEMICAL
(tetrahydroisoquinolines) B-CHEMICAL
play O
a O
role O
remains O
controversial. O
There O
is, O
however, O
much O
information O
on O
the O
direct O
(acute O
and O
chronic) O
effects O
of O
alcohol B-CHEMICAL
on O
the O
binding O
properties O
of O
opioid B-GENE-N
receptors, I-GENE-N
as O
well O
as O
modulation O
of O
opioid B-GENE-N
peptide I-GENE-N
synthesis O
and O
secretion O
(e.g. O
a O
suggested O
increase O
in O
beta-endorphin B-GENE-Y
release). O
In O
view O
of O
the O
reinforcing O
properties O
of O
alcohol, B-CHEMICAL
it O
is O
relevant O
to O
consider O
behavioural O
studies O
involving O
alcohol B-CHEMICAL
self-administration O
in O
rodents O
and O

primates. O
Low O
doses O
of O
morphine O
have O
been O
found O
to O
increase, O
and O
higher O
doses O
of O
the O
opiate O
to O
decrease, O
alcohol B-CHEMICAL
consumption. O
Conversely, O
opioid O
antagonists O
such O
as O
naloxone B-CHEMICAL
and O
naltrexone B-CHEMICAL
(which O
bind O
to O
non-selectively O
opioid B-GENE-N
receptors) I-GENE-N
have O
been O
shown O
to O
decrease O
alcohol B-CHEMICAL
consumption O
under O
various O
experimental O
conditions. O
Similar O
results O
have O
been O
reported O
when O
selective O
mu- B-GENE-N
or I-GENE-N
delta-receptor I-GENE-N
antagonists O
are O
administered. O
Results O
obtained O
in O
genetic O
models O
of O
high O
preference O
for O
alcohol B-CHEMICAL
also O
support O
the O
view O
that O
alcohol O
intake O
depends O
on O
the O
activity O
of O
the O
endogenous O
opioid O
reward O
system O
and O
that O
alcohol B-CHEMICAL

consumption O
may O
serve O
to O
compensate O
for O
inherent O
deficits O
in O
this O
system. O
One O
hypothetical O
model O
proposes O
that O
reward O
results O
from O
activation O
of O
mu-opioid B-GENE-Y
receptors I-GENE-Y
in O
the O
VTA O
and/or O
delta-receptor B-GENE-Y
in O
the O
NAC; O
both O
these O
nuclei O
are O
targets O
of O
endogenous O
beta-endorphin. B-GENE-Y
It O
is O
suggested O
that O
alcohol B-CHEMICAL
interferes O
with O
this O
reward O
pathway O
either O
directly O
or O
indirectly. O
The O
available O
experimental O
data O
accord O
well O
with O
those O
obtained O
from O
clinical O
studies O
which O
opioid O
antagonists O
have O
been O
used O
to O
prevent O
relapse O
in O
alcoholics. O
Conceptual O
considerations O
concerning O
communalities O
between O
various O
forms O
of O
addictions O
are O
also O
discussed O
in O

this O
review. O
Dynamics O
of O
NO B-CHEMICAL
rebinding O
to O
the O
heme B-GENE-N
domain I-GENE-N
of I-GENE-N
NO I-GENE-N
synthase-like I-GENE-N
proteins I-GENE-N
from O
bacterial O
pathogens. O
Some O
Gram-positive O
bacterial O
pathogens O
harbor O
a O
gene O
that O
encodes O
a O
protein O
(HNS, B-GENE-N
Heme B-GENE-N
domain I-GENE-N
of I-GENE-N
NO I-GENE-N
Synthase-like I-GENE-N
proteins) I-GENE-N
with O
striking O
sequence O
identity O
to O
the O
oxygenase B-GENE-N
domain I-GENE-N
of O
mammalian B-GENE-N
NO I-GENE-N
synthases I-GENE-N
(NOS). B-GENE-N
However, O
they O
lack O
the O
N-terminal B-GENE-N
and I-GENE-N
the I-GENE-N
Zn-cysteine I-GENE-N
motif I-GENE-N
participating O
to O
the O
stability O
of O
an O
active O
dimer O
in O
the O
mammalian O
isoforms. O
The O
unique O
properties O
of O
HNS B-GENE-N
make O
it O

an O
excellent O
model O
system O
for O
probing O
how O
the O
heme O
environment O
tunes O
NO B-CHEMICAL
dynamics O
and O
for O
comparing O
it O
to O
the O
endothelial B-GENE-N
NO I-GENE-N
synthase I-GENE-N
heme I-GENE-N
domain I-GENE-N
(eNOS(HD)) B-GENE-N
using O
ultrafast O
transient O
spectroscopy. O
NO B-CHEMICAL
rebinding O
in O
HNS B-GENE-N
from O
Staphylococcus O
aureus O
(SA-HNS) B-GENE-N
is O
faster O
than O
that O
measured O
for O
either O
Bacillus O
anthracis O
(BA-HNS) B-GENE-N
or O
for O
eNOS(HD) B-GENE-N
in O
both O
oxidized O
and O
reduced O
forms O
in O
the O
presence O
of O
arginine. B-CHEMICAL
To O
test O
whether O
these O
distinct O
rates O
arise O
from O
different O
energy O

barriers O
for O
NO B-CHEMICAL
recombination, O
we O
measured O
rebinding O
kinetics O
at O
several O
temperatures. O
Our O
data O
are O
consistent O
with O
different O
barriers O
for O
NO B-CHEMICAL
recombination O
in O
SA-HNS B-GENE-N
and O
BA-HNS B-GENE-N
and O
the O
presence O
of O
a O
second O
NO-binding B-CHEMICAL
site. O
The O
hypothesis O
that O
an O
additional O
NO-binding B-CHEMICAL
cavity O
is O
present O
in O
BA-HNS B-GENE-N
is O
also O
consistent O
with O
the O
effect O
of O
the O
NO B-CHEMICAL
concentration O
on O
its O
rebinding. O
The O
lack O
of O
the O
effect O
of O
NO B-CHEMICAL
concentration O
on O
the O
geminate O
rebinding O
in O
SA-HNS B-GENE-N
could O
be O
due O
to O
an O
isolated O
second O
site. O
We O
confirm O
the O
existence O
of O
a O
second O
NO B-CHEMICAL
site O
in O
the O
oxygenase B-GENE-N

domain I-GENE-N
of O
the O
reduced B-GENE-Y
eNOS I-GENE-Y
as O
previously O
hypothesized O
[A. O
Slama-Schwok, O
M. O
Negrerie, O
V. O
Berka, O
J.C. O
Lambry, O
A.L. O
Tsai, O
M.H. O
Vos, O
J.L. O
Martin, O
Nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
traffic O
in O
endothelial B-GENE-Y
NO I-GENE-Y
synthase. I-GENE-Y
Evidence O
for O
a O
new O
NO B-CHEMICAL
binding O
site O
dependent O
on O
tetrahydrobiopterin? B-CHEMICAL
J. O
Biol. O
Chem. O
277 O
(2002) O
7581-7586]. O
This O
site O
requires O
the O
presence O

of O
arginine B-CHEMICAL
and O
BH(4); B-CHEMICAL
and O
we O
propose O
that O
NO B-CHEMICAL
dynamic O
and O
escape O
from O
eNOS B-GENE-Y
is O
regulated O
by O
the O
active O
site O
H-bonding B-CHEMICAL
network O
connecting O
between O
the O
heme, O
the O
substrate, O
and O
cofactor. O
Nonthrombolytic O
intervention O
in O
acute O
myocardial O
infarction. O
Alternative O
interventions O
are O
available O
for O
patients O
in O
whom O
thrombolytic O
therapy O
is O
inappropriate O
after O
an O
acute O
myocardial O
infarction. O
Administration O
of O
a O
beta O
blocker O
within O
the O
first O
24 O
hours O
of O
the O
patient's O
admission O
to O
the O
coronary O
care O
unit O
can O
reduce O
overall O
morbidity O
and O
mortality O
within O
the O
first O

7 O
days O
by O
about O
15%. O
Maintenance O
therapy O
with O
an O
oral O
beta O
blocker O
can O
reduce O
mortality O
within O
the O
succeeding O
3 O
years O
by O
about O
25%. O
Esmolol, B-CHEMICAL
a O
unique O
cardioselective O
beta B-GENE-Y
1-adrenergic I-GENE-Y
receptor I-GENE-Y
blocker O
with O
a O
half-life O
of O
9 O
minutes, O
can O
enable O
some O
patients O
with O
relative O
contraindications O
to O
beta O
blockers O
to O
nevertheless O
benefit O
from O
early O
beta-blocking O
therapy. O
It O
also O
is O
useful O
in O
screening O
patients O
for O
subsequent O
therapy O
with O
beta O
blockers. O
Those O
who O
tolerate O
the O
esmolol B-CHEMICAL
infusion O
can O
be O
given O
a O
long-acting O
beta O
blocker. O
For O
patients O
who O
exhibit O
intolerance O

to O
esmolol, B-CHEMICAL
the O
infusion O
can O
be O
terminated O
with O
rapid O
return O
to O
baseline O
hemodynamics. O
Snake B-GENE-N
venom I-GENE-N
metalloproteinases. I-GENE-N
Recent O
proteomic O
analyses O
of O
snake O
venoms O
show O
that O
metalloproteinases B-GENE-N
represent O
major O
components O
in O
most O
of O
the O
Crotalid O
and O
Viperid O
venoms. O
In O
this O
chapter O
we O
discuss O
the O
multiple O
activities O
of O
the O
SVMPs. B-GENE-N
In O
addition O
to O
hemorrhagic O
activity, O
members O
of O
the O
SVMP B-GENE-N
family O
also O
have O
fibrin(ogen)olytic O
activity, O
act O
as O
prothrombin B-GENE-Y
activators, O
activate O
blood O
coagulation B-GENE-Y
factor I-GENE-Y

X, I-GENE-Y
possess O
apoptotic O
activity, O
inhibit O
platelet O
aggregation, O
are O
pro-inflammatory O
and O
inactivate O
blood O
serine B-GENE-N
proteinase I-GENE-N
inhibitors. O
Clearly O
the O
SVMPs B-GENE-N
have O
multiple O
functions O
in O
addition O
to O
their O
well-known O
hemorrhagic O
activity. O
The O
realization O
that O
there O
are O
structural O
variations O
in O
the O
SVMPs B-GENE-N
and O
the O
early O
studies O
that O
led O
to O
their O
classification O
represents O
an O
important O
event O
in O
our O
understanding O
of O
the O
structural O
forms O
of O
the O
SVMPs. B-GENE-N
The O
SVMPs B-GENE-N
were O
subdivided O
into O
the O
P-I, O
P-II O
and O
P-III O
protein O
classes. O
The O
noticeable O
characteristic O
that O
distinguished O
the O
different O
classes O
was O
their O
size O

(molecular O
weight) O
differences O
and O
domain O
structure: O
Class O
I O
(P-I), O
the O
small O
SVMPs, B-GENE-N
have O
molecular O
masses O
of O
20-30 O
kDa, O
contain O
only O
a O
pro B-GENE-N
domain I-GENE-N
and O
the O
proteinase B-GENE-N
domain; I-GENE-N
Class O
II O
(P-II), O
the O
medium O
size O
SVMPs, B-GENE-N
molecular O
masses O
of O
30-60 O
kDa, O
contain O
the O
pro B-GENE-N
domain, I-GENE-N
proteinase B-GENE-N
domain I-GENE-N
and O
disintegrin B-GENE-N
domain; I-GENE-N
Class O
III O
(P-III), O
the O
large O
SVMPs, B-GENE-N
have O
molecular O
masses O
of O
60-100 O
kDa, O
contain O
pro, B-GENE-N
proteinase, B-GENE-N
disintegrin-like B-GENE-N
and O

cysteine-rich B-GENE-N
domain I-GENE-N
structure. O
Another O
significant O
advance O
in O
the O
SVMP B-GENE-N
field O
was O
the O
characterization O
of O
the O
crystal O
structure O
of O
the O
first O
P-I B-GENE-N
class I-GENE-N
SVMP. I-GENE-N
The O
structures O
of O
other O
P-I B-GENE-N
SVMPs I-GENE-N
soon O
followed O
and O
the O
structures O
of O
P-III B-GENE-N
SVMPs I-GENE-N
have O
also O
been O
determined. O
The O
active O
site O
of O
the O
metalloproteinase B-GENE-N
domain I-GENE-N
has O
a O
consensus O
HEXXHXXGXXHD B-GENE-N
sequence O
and O
a O
Met-turn. B-CHEMICAL
The O
"Met-turn" B-CHEMICAL
structure O
contains O
a O
conserved O
Met B-CHEMICAL
residue O
that O
forms O
a O
hydrophobic O
basement O
for O
the O
three O
zinc-binding B-CHEMICAL
histidines B-CHEMICAL
in O
the O
consensus O
sequence. O

Catalytic O
properties O
of O
mouse B-GENE-Y
carbonic I-GENE-Y
anhydrase I-GENE-Y
V. I-GENE-Y
A O
cDNA O
encoding O
the O
mouse B-GENE-Y
carbonic I-GENE-Y
anhydrase I-GENE-Y
V I-GENE-Y
gene O
was O
isolated O
by O
reverse O
transcription O
and O
polymerase O
chain O
reaction O
from O
BALB/c O
mouse O
liver O
mRNA. O
Vectors O
containing O
the O
full O
coding O
sequence O
as O
well O
as O
two O
different O
NH2-terminal B-CHEMICAL
truncated O
genes O
expressed O
enzymatically O
active O
protein O
in O
Escherichia O
coli. O
The B-GENE-Y
carbonic I-GENE-Y
anhydrase I-GENE-Y
V I-GENE-Y
produced O
by O
a O
vector O
containing O
the O
full O
coding O
sequence, O
which O
includes O
a O
possible O
NH2-terminal B-CHEMICAL
mitochondrial O
targeting O
signal, O
was O
proteolytically O
processed O
by O
E. O
coli O
and O

contained O
several O
amino-terminal B-CHEMICAL
ends. O
The O
two O
NH2-terminal B-CHEMICAL
truncated O
vectors O
deleted, O
respectively, O
1) O
the O
29-amino B-CHEMICAL
acid I-CHEMICAL
putative O
targeting O
sequence O
and O
2) O
51 O
amino B-CHEMICAL
acids, I-CHEMICAL
yielding O
a O
protein O
equivalent O
to O
a O
carbonic B-GENE-Y
anhydrase I-GENE-Y
(CA) I-GENE-Y
V I-GENE-Y
isolated O
from O
mouse O
liver O
mitochondria; O
and O
both O
vectors O
produced O
homogeneous O
protein O
fractions. O
These O
latter O
two O
forms O
of O
CA B-GENE-Y
V I-GENE-Y
had O
identical O
steady-state O
constants O
for O
the O
hydration O
of O
CO2, B-CHEMICAL
with O
maximal O
values O
of O
kcat/Km O
at O
3 O
x O
10(7) O
M-1 O
s-1 O
and O
kcat O
at O
3 O
x O

10(5) O
s-1 O
with O
an O
apparent O
pKa O
for O
catalysis O
of O
7.4 O
determined O
from O
kcat/Km. O
In O
catalytic O
properties, O
mouse B-GENE-Y
CA I-GENE-Y
V I-GENE-Y
is O
closest O
to O
CA B-GENE-Y
I; I-GENE-Y
however, O
in O
inhibition O
by O
acetazolamide, B-CHEMICAL
ethoxzolamide, B-CHEMICAL
and O
cyanate, B-CHEMICAL
CA B-GENE-Y
V I-GENE-Y
is O
very O
similar O
to O
CA B-GENE-Y
II. I-GENE-Y
Mouse B-GENE-Y
CA I-GENE-Y
V I-GENE-Y
has O
a O
tyrosine O
at O
position O
64, O
where O
the O
highly O
active O
isozyme O
II O
has O
histidine B-CHEMICAL
serving O
as O
a O
proton O
shuttle O
in O
the O
catalytic O
pathway. O
Investigation O
of O
a O
site-specific O
mutant O
of O
CA B-GENE-Y
V I-GENE-Y
containing O
the O
replacement O

Tyr64-->His B-GENE-N
showed O
that O
the O
unique O
kinetic O
properties O
of O
CA B-GENE-Y
V I-GENE-Y
are O
not O
due O
to O
the O
presence O
of O
tyrosine B-CHEMICAL
at O
position O
64. O
Kinetic O
characterization O
of O
adenylosuccinate B-GENE-Y
synthetase I-GENE-Y
from O
the O
thermophilic O
archaea O
Methanocaldococcus O
jannaschii. O
Adenylosuccinate B-GENE-Y
synthetase I-GENE-Y
(AdSS) B-GENE-Y
catalyzes O
the O
Mg2+ B-CHEMICAL
dependent O
condensation O
of O
a O
molecule O
of O
IMP O
with O
aspartate B-CHEMICAL
to O
form O
adenylosuccinate, B-CHEMICAL
in O
a O
reaction O
driven O
by O
the O
hydrolysis O
of O
GTP B-CHEMICAL
to O

GDP. B-CHEMICAL
AdSS B-GENE-Y
from O
the O
thermophilic O
archaea, O
Methanocaldococcus O
jannaschii O
(MjAdSS) B-GENE-Y
is O
345 O
amino B-CHEMICAL
acids I-CHEMICAL
long O
against O
an O
average O
length O
of O
430-457 O
amino B-CHEMICAL
acids I-CHEMICAL
for O
most O
mesophilic O
AdSS. B-GENE-Y
This O
short O
AdSS B-GENE-Y
has O
two O
large O
deletions O
that O
map O
to O
the O
middle O
and O
C-terminus B-CHEMICAL
of O
the O
protein. O
This O
article O
discusses O
the O
detailed O
kinetic O
characterization O
of O
MjAdSS. B-GENE-Y
Initial O
velocity O
and O
product O
inhibition O
studies, O
carried O
out O
at O
70 O
degrees O
C, O
suggest O
a O
rapid O
equilibrium O
random O
AB O
steady-state O
ordered O
C O
kinetic O
mechanism O
for O
the O

MjAdSS B-GENE-Y
catalyzed O
reaction. O
AdSS B-GENE-Y
are O
known O
to O
exhibit O
monomer-dimer O
equilibrium O
with O
the O
dimer O
being O
implicated O
in O
catalysis. O
In O
contrast, O
our O
studies O
show O
that O
MjAdSS B-GENE-Y
is O
an O
equilibrium O
mixture O
of O
dimers O
and O
tetramers O
with O
the O
tetramer O
being O
the O
catalytically O
active O
form. O
The O
tetramer O
dissociates O
into O
dimers O
with O
a O
minor O
increase O
in O
ionic O
strength O
of O
the O
buffer, O
while O
the O
dimer O
is O
extremely O
stable O
and O
does O
not O
dissociate O
even O
at O
1.2 O
M O
NaCl. B-CHEMICAL
Phosphate, B-CHEMICAL
a O
product O
of O
the O
reaction, O

was O
found O
to O
be O
a O
potent O
inhibitor O
of O
MjAdSS B-GENE-Y
showing O
biphasic O
inhibition O
of O
enzyme O
activity. O
The O
inhibition O
was O
competitive O
with O
IMP O
and O
noncompetitive O
with O
GTP. B-CHEMICAL
MjAdSS, B-GENE-Y
like O
the O
mouse B-GENE-N
acidic I-GENE-N
isozyme, I-GENE-N
exhibits O
substrate O
inhibition, O
with O
IMP O
inhibiting O
enzyme O
activity O
at O
subsaturating O
GTP B-CHEMICAL
concentrations. O
Regulation O
of O
enzyme O
activity O
by O
the O
glycolytic O
intermediate, O
fructose B-CHEMICAL
1,6 B-CHEMICAL
bisphosphate, I-CHEMICAL
was O
also O
observed O
with O
the O
inhibition O
being O
competitive O
with O
IMP O
and O
noncompetitive O
against O
GTP. B-CHEMICAL
Inhibition O
of O

NF-kappa B-GENE-N
B I-GENE-N
by O
sodium O
salicylate O
and O
aspirin. O
The O
transcription O
factor O
nuclear B-GENE-N
factor-kappa I-GENE-N
B I-GENE-N
(NF-kappa B-GENE-N
B) I-GENE-N
is O
critical O
for O
the O
inducible O
expression O
of O
multiple O
cellular O
and O
viral O
genes O
involved O
in O
inflammation O
and O
infection O
including O
interleukin-1 B-GENE-N
(IL-1), B-GENE-N
IL-6, B-GENE-Y
and O
adhesion O
molecules. O
The O
anti-inflammatory O
drugs O
sodium B-CHEMICAL
salicylate I-CHEMICAL
and O
aspirin B-CHEMICAL
inhibited O
the O
activation O
of O
NF-kappa B-GENE-N
B, I-GENE-N
which O
further O
explains O
the O
mechanism O
of O
action O
of O
these O
drugs. O
This O
inhibition O
prevented O
the O
degradation O
of O
the O
NF-kappa B-GENE-N

B I-GENE-N
inhibitor, O
I B-GENE-N
kappa I-GENE-N
B, I-GENE-N
and O
therefore O
NF-kappa B-GENE-N
B I-GENE-N
was O
retained O
in O
the O
cytosol. O
Sodium B-CHEMICAL
salicylate I-CHEMICAL
and O
aspirin B-CHEMICAL
also O
inhibited O
NF-kappa B-GENE-N
B-dependent I-GENE-N
transcription O
from O
the O
Ig B-GENE-Y
kappa I-GENE-Y
enhancer O
and O
the O
human O
immunodeficiency O
virus O
(HIV) O
long O
terminal O
repeat O
(LTR) O
in O
transfected O
T O
cells. O
Galanin B-GENE-Y
attenuates O
cyclic B-GENE-N
AMP I-GENE-N
regulatory I-GENE-N
element-binding I-GENE-N
protein I-GENE-N
(CREB) B-GENE-N
phosphorylation O
induced O
by O
chronic O
morphine B-CHEMICAL
and O
naloxone B-CHEMICAL
challenge O
in O
Cath.a O
cells O
and O
primary O

striatal O
cultures. O
Repeated O
morphine B-CHEMICAL
administration O
leads O
to O
molecular O
alterations O
of O
the O
neural O
circuitry O
in O
the O
locus O
coeruleus O
and O
nucleus O
accumbens. O
These O
changes O
include O
increased O
activity O
of O
several O
components O
of O
the O
cAMP B-CHEMICAL
signaling O
pathway O
that O
are O
thought O
to O
be O
associated O
with O
psychological O
and O
somatic O
signs O
of O
opiate O
withdrawal. O
The O
neuropeptide O
galanin B-GENE-Y
has O
been O
shown O
to O
attenuate O
cAMP B-CHEMICAL
signaling O
in O
multiple O
cell O
types. O
The O
current O
study O
demonstrates O
that O
acute O
galanin B-GENE-Y
treatment O
blocks O
the O
consequences O
of O
increased O
cAMP B-CHEMICAL
signaling O
following O
chronic O
opiate O
administration O
and O
withdrawal O
in O
Cath.a O

cells O
and O
primary O
cultures O
of O
striatal O
neurons O
as O
measured O
by O
phosphorylation O
of O
the O
transcription O
factor O
cAMP B-GENE-N
regulatory I-GENE-N
element-binding I-GENE-N
protein I-GENE-N
(CREB). B-GENE-N
In O
addition, O
galanin-mediated B-GENE-Y
attenuation O
of O
CREB B-GENE-N
phosphorylation O
is O
independent O
of O
galanin-induced B-GENE-Y
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) I-GENE-N
1/2 I-GENE-N
phosphorylation O
in O
Cath.a O
cells. O
These O
data O
suggest O
that O
galanin B-GENE-N
receptors I-GENE-N
may O
serve O
as O
an O
additional O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
opiate O
withdrawal. O
Na+/Ca2+ B-CHEMICAL
exchange O
inhibitors: O
a O
new O

class O
of O
calcium B-CHEMICAL
regulators. O
The O
Na(+)/Ca(2+) B-GENE-N
exchanger I-GENE-N
(NCX) B-GENE-N
is O
a O
bidirectional O
transporter O
that O
normally O
extrudes O
Ca(2+) B-CHEMICAL
from O
the O
cell O
(forward O
mode), O
but O
also O
brings O
Ca(2+) B-CHEMICAL
into O
the O
cell O
(reverse O
mode) O
under O
special O
conditions O
such O
as O
intracellular O
Na(+) B-CHEMICAL
(Na(+)(i)) B-CHEMICAL
accumulation O
or O
membrane O
depolarization. O
There O
are O
three O
mammalian B-GENE-N
NCX I-GENE-N
isoforms: O
NCX1 B-GENE-Y
is O
widely O
expressed O
in O
the O
heart, O
kidney, O
brain, O
blood O
vessels, O
and O
so O

on; O
whereas O
the O
expression O
of O
NCX2 B-GENE-Y
and O
NCX3 B-GENE-Y
is O
limited O
mainly O
to O
the O
brain O
and O
skeletal O
muscle. O
The O
pharmacology O
of O
NCX B-GENE-N
inhibitors O
has O
been O
studied O
extensively O
since O
the O
development O
of O
KB-R7943, B-CHEMICAL
a O
prototype O
benzyloxyphenyl B-CHEMICAL
NCX B-GENE-N
inhibitor, O
in O
1996. O
Currently, O
experiments O
are O
actively O
progressing O
with O
more O
selective O
inhibitors: O
SEA0400, B-CHEMICAL
SN-6, B-CHEMICAL
and O
YM-244769. B-CHEMICAL
Intriguingly, O
the O
inhibitory O
potency O
of O
benzyloxyphenyl B-CHEMICAL
NCX B-GENE-N
inhibitors O
is O
directly O
coupled O
to O
the O
rate O

of O
Na(+)(i)-dependent B-CHEMICAL
inactivation. O
Therefore, O
the O
benzyloxyphenyl B-CHEMICAL
inhibitors O
are O
apparently O
dormant O
during O
the O
forward O
mode O
under O
normal O
conditions O
(low O
Na(+)(i)), B-CHEMICAL
but O
become O
effective O
during O
the O
reverse O
mode O
under O
pathological O
conditions O
(high O
Na(+)(i)). B-CHEMICAL
This O
should O
be O
an O
ideal O
profile O
for O
calcium B-CHEMICAL
regulators O
against O
Na(+)(i)-related B-CHEMICAL
diseases, O
such O
as O
ischemia/reperfusion O
injuries, O
salt-dependent O
hypertension, O
and O
digitalis O
arrhythmia. O
Existing O
ion B-GENE-N
channel I-GENE-N

blockers, O
such O
as O
amiodarone, B-CHEMICAL
dronedarone, B-CHEMICAL
bepridil, B-CHEMICAL
aprindine, B-CHEMICAL
and O
cibenzoline, B-CHEMICAL
have O
been O
found O
to O
have O
an O
NCX B-GENE-N
inhibitory O
action. O
It O
is O
possible O
that O
this O
property O
is O
partly O
responsible O
for O
their O
antiarrhythmic O
and O
cardioprotective O
effects. O
This O
article O
presents O
the O
characteristics O
of O
selective O
and O
non-selective O
NCX B-GENE-N
inhibitors O
and O
their O
therapeutic O
potential O
as O
a O
new O
calcium B-CHEMICAL
regulator. O
Efficacy O
and O
safety O
of O
the O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
inhibitor, O
sitagliptin, B-CHEMICAL
in O
patients O
with O
type O
2 O
diabetes O

mellitus O
inadequately O
controlled O
on O
glimepiride B-CHEMICAL
alone O
or O
on O
glimepiride B-CHEMICAL
and O
metformin. B-CHEMICAL
AIM: O
To O
assess O
the O
efficacy O
and O
safety O
of O
a O
24-week O
treatment O
with O
sitagliptin, B-CHEMICAL
a O
highly O
selective O
once-daily O
oral O
dipeptidyl B-GENE-Y
peptidase-4 I-GENE-Y
(DPP-4) B-GENE-Y
inhibitor, O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
[glycosylated B-GENE-Y
haemoglobin I-GENE-Y
(HbA(1c)) B-GENE-Y
>or=7.5% O
and O
<or=10.5%] O
while O
on O

glimepiride O
alone O
or O
in O
combination O
with O
metformin. O
METHODS: O
After O
a O
screening, O
diet/exercise O
run-in O
and O
drug O
wash-off O
period, O
a O
glimepiride O
+/- O
metformin O
dose O
titration/stabilization O
period O
and O
a O
2-week, O
single-blind O
placebo O
run-in, O
441 O
patients O
(of O
ages O
18-75 O
years) O
were O
randomized O
to O
receive O
the O
addition O
of O
sitagliptin O
100 O
mg O
once O
daily O
or O
placebo O
in O
a O
1 O
: O
1 O
ratio O
for O
24 O
weeks. O
Of O
these O
patients, O
212 O
were O
on O
glimepiride O

(>or=4 O
mg/day) O
monotherapy O
and O
229 O
were O
on O
glimepiride O
(>or=4 O
mg/day) O
plus O
metformin O
(>or=1,500 O
mg/day) O
combination O
therapy. O
Patients O
exceeding O
pre-specified O
glycaemic O
thresholds O
during O
the O
double-blind O
treatment O
period O
were O
provided O
open-label O
rescue O
therapy O
(pioglitazone) O
until O
study O
end. O
The O
primary O
efficacy O
analysis O
evaluated O
the O
change O
in O
HbA(1c) O
from O
baseline O
to O
Week O
24. O
Secondary O
efficacy O
endpoints O
included O
fasting O
plasma O
glucose O
(FPG), O
2-h O

post-meal O
glucose O
and O
lipid O
measurements. O
RESULTS: O
Mean O
baseline O
HbA(1c) O
was O
8.34% O
in O
the O
sitagliptin O
and O
placebo O
groups. O
After O
24 O
weeks, O
sitagliptin O
reduced O
HbA(1c) O
by O
0.74% O
(p O
< O
0.001) O
relative O
to O
placebo. O
In O
the O
subset O
of O
patients O
on O
glimepiride O
plus O
metformin, O
sitagliptin O
reduced O
HbA(1c) O
by O
0.89% O
relative O
to O
placebo, O
compared O
with O
a O
reduction O
of O
0.57% O
in O
the O
subset O
of O

patients O
on O
glimepiride O
alone. O
The O
addition O
of O
sitagliptin O
reduced O
FPG O
by O
20.1 O
mg/dl O
(p O
< O
0.001) O
and O
increased O
homeostasis O
model O
assessment-beta, O
a O
marker O
of O
beta-cell O
function, O
by O
12% O
(p O
< O
0.05) O
relative O
to O
placebo. O
In O
patients O
who O
underwent O
a O
meal O
tolerance O
test O
(n O
= O
134), O
sitagliptin O
decreased O
2-h O
post-prandial O
glucose O
(PPG) O
by O
36.1 O
mg/dl O
(p O
< O
0.001) O
relative O
to O
placebo. O
The O
addition O
of O

sitagliptin O
was O
generally O
well O
tolerated, O
although O
there O
was O
a O
higher O
incidence O
of O
overall O
(60 O
vs. O
47%) O
and O
drug-related O
adverse O
experiences O
(AEs) O
(15 O
vs. O
7%) O
in O
the O
sitagliptin O
group O
than O
in O
the O
placebo O
group. O
This O
was O
largely O
because O
of O
a O
higher O
incidence O
of O
hypoglycaemia O
AEs O
(12 O
vs. O
2%, O
respectively) O
in O
the O
sitagliptin O
group O
compared O
with O
the O
placebo O
group. O
Body O
weight O
modestly O
increased O
with O
sitagliptin O
relative O
to O
placebo O
(+0.8 O
vs. O
-0.4 O
kg; O
p O
< O

0.001). O
CONCLUSIONS: O
Sitagliptin O
100 O
mg O
once O
daily O
significantly O
improved O
glycaemic O
control O
and O
beta-cell O
function O
in O
patients O
with O
type O
2 O
diabetes O
who O
had O
inadequate O
glycaemic O
control O
with O
glimepiride O
or O
glimepiride O
plus O
metformin O
therapy. O
The O
addition O
of O
sitagliptin O
was O
generally O
well O
tolerated, O
with O
a O
modest O
increase O
in O
hypoglycaemia O
and O
body O
weight, O
consistent O
with O
glimepiride O
therapy O
and O
the O
observed O
degree O
of O
glycaemic O
improvement. O
Compound O
and O
compositions O
as O
TGR5 B-GENE-Y

agonists: O
WO2012082947. O
The O
patent O
application O
WO2012082947 O
claims O
novel O
compounds O
as O
agonists O
of O
a O
plasma B-GENE-Y
membrane-bound I-GENE-Y
bile I-GENE-Y
acid I-GENE-Y
receptor I-GENE-Y
TGR5. B-GENE-Y
By O
activating O
TGR5, B-GENE-Y
the O
agonists O
improve O
glycemic O
control O
and O
enhance O
energy O
expenditure. O
The O
basic O
generic O
claim O
of O
the O
patent O
covers O
pyrazole B-CHEMICAL
derivatives, O
different O
permutations O
on O
the O
core O
pyrazole B-CHEMICAL
ring O
are O
covered O
in O
the O
subsidiary O
claims. O
The O
claimed O
compounds O
are O
human B-GENE-Y
TGR5 I-GENE-Y
agonists O
having O
potency O
in O
the O
nM O
range. O
Hydroxysafflor B-CHEMICAL

yellow I-CHEMICAL
a I-CHEMICAL
inhibits O
lipopolysaccharide-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells. O
Hydroxysafflor B-CHEMICAL
yellow I-CHEMICAL
A I-CHEMICAL
(HSYA) B-CHEMICAL
is O
an O
active O
ingredient O
obtained O
from O
the O
flower O
of O
Carthamus O
tinctorius O
L. O
The O
present O
study O
investigated O
the O
effects O
of O
HSYA B-CHEMICAL
on O
lipopolysaccharide O
(LPS)-induced O
inflammatory O
signal O
transduction O
in O
human O
alveolar O
epithelial O
A549 O
cells. O
A549 O
cells O
stimulated O
with O
LPS O
were O
incubated O
with O
three O
doses O

of O
HSYA B-CHEMICAL
(1, O
4 O
and O
16μmol/L). O
HSYA B-CHEMICAL
suppressed O
the O
expression O
of O
TLR-4, B-GENE-Y
Myd88, B-GENE-Y
ICAM-1, B-GENE-Y
TNFα, B-GENE-Y
IL-1β B-GENE-Y
and O
IL-6 B-GENE-Y
at O
the O
mRNA O
and O
protein O
level, O
and O
inhibited O
the O
adhesion O
of O
leukocytes O
to O
A549 O
cells. O
HSYA B-CHEMICAL
treatment O
also O
decreased O
NF-κB B-GENE-N
p65 B-GENE-Y
nuclear O
translocation O
and O
inhibited O
the O
phosphorylation O
of O
p38 B-GENE-N
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(p38 B-GENE-N
MAPK). B-GENE-N
These O
findings O

suggest O
that O
HSYA B-CHEMICAL
effectively O
inhibits O
LPS-induced O
inflammatory O
signal O
transduction O
in O
A549 O
cells. O
Synthesis O
and O
biological O
evaluation O
of O
phosphorylated B-CHEMICAL
flavonoids I-CHEMICAL
as O
potent O
and O
selective O
inhibitors O
of O
cholesterol B-GENE-Y
esterase. I-GENE-Y
A O
series O
of O
phosphorylated B-CHEMICAL
flavonoids I-CHEMICAL
were O
synthesized O
and O
investigated O
in O
vitro O
as O
inhibitors O
of O
pancreatic O
cholesterol B-GENE-Y
esterase I-GENE-Y
(CEase) B-GENE-Y
and O
acetylcholinesterase B-GENE-Y
(AChE). B-GENE-Y
The O
results O
showed O
that O
most O
of O
the O
synthesized O
compounds O
exhibited O
nanomolar O
potency O
against O

CEase, B-GENE-Y
much O
better O
than O
the O
parent O
flavonoids. B-CHEMICAL
Furthermore, O
these O
phosphorylated B-CHEMICAL
flavonoids I-CHEMICAL
demonstrated O
good O
to O
high O
selectivity O
for O
CEase B-GENE-Y
over O
AChE, B-GENE-Y
which O
only O
showed O
micromolar O
potency O
inhibition O
of O
AChE. B-GENE-Y
The O
most O
selective O
and O
potent O
inhibitor O
of O
CEase B-GENE-Y
(3e) O
had O
IC50 O
value O
of O
0.72 O
nM O
and O
11800-fold O
selectivity O
for O
CEase B-GENE-Y
over O
AChE. B-GENE-Y
The O
structure-activity O
relationships O
revealed O
that O
the O
free O
hydroxyl B-CHEMICAL
group O
at O
position O
5 O
and O
phosphate B-CHEMICAL
group O
at O
position O
7 O
of O
the O
phosphorylated B-CHEMICAL

flavonoids I-CHEMICAL
are O
favorable O
to O
the O
inhibition O
of O
CEase. B-GENE-Y
The O
inhibition O
mechanism O
and O
kinetic O
characterization O
studies O
indicated O
that O
they O
are O
irreversible O
competitive O
inhibitors O
of O
CEase. B-GENE-Y
5-Amino-2-hydroxybenzoic B-CHEMICAL
acid I-CHEMICAL
4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl B-CHEMICAL
ester I-CHEMICAL
(ATB-429), B-CHEMICAL
a O
hydrogen B-CHEMICAL
sulfide-releasing I-CHEMICAL
derivative O
of O
mesalamine, B-CHEMICAL
exerts O
antinociceptive O
effects O
in O
a O
model O
of O
postinflammatory O
hypersensitivity. O

H(2)S B-CHEMICAL
functions O
as O
a O
neuromodulator O
and O
exerts O
anti-inflammatory O
activities. O
Recent O
data O
indicate O
that O
irritable O
bowel O
syndrome O
(IBS) O
is O
linked O
to O
inflammation O
of O
the O
gastrointestinal O
tract. O
In O
this O
study, O
we O
have O
investigated O
the O
role O
of O
a O
novel O
H(2)S-releasing B-CHEMICAL
derivative O
of O
mesalamine B-CHEMICAL
(5-amino-2-hydroxybenzoic B-CHEMICAL
acid I-CHEMICAL
4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl I-CHEMICAL
ester, I-CHEMICAL
ATB-429) B-CHEMICAL
in O

modulating O
nociception O
to O
colorectal O
distension O
(CRD), O
a O
model O
that O
mimics O
some O
features O
of O
IBS, O
in O
healthy O
and O
postcolitic O
rats. O
Four O
graded O
(0.4-1.6 O
ml O
of O
water) O
CRDs O
were O
produced O
in O
conscious O
rats, O
and O
colorectal O
sensitivity O
and O
pain O
were O
assessed O
by O
measuring O
the O
abdominal O
withdrawal O
response O
and O
spinal O
c-Fos B-GENE-Y
expression. O
In O
healthy O
rats, O
ATB-429 B-CHEMICAL
dose O
dependently O
(25, O
50, O
or O
100 O
mg/kg) O
attenuated O
CRD-induced O
hypersensitivity O
and O
significantly O
inhibited O

CRD-induced O
overexpression O
of O
spinal O
c-FOS B-GENE-Y
mRNA, O
whereas O
mesalamine B-CHEMICAL
had O
no O
effect. O
ATB-429-induced B-CHEMICAL
antinociception O
was O
reversed O
by O
glibenclamide, B-CHEMICAL
a O
ATP-sensitive B-GENE-N
K(+) I-GENE-N
(K(ATP)) I-GENE-N
channel I-GENE-N
inhibitor. O
The O
antinociceptive O
effect O
of O
ATB-429 B-CHEMICAL
was O
maintained O
in O
a O
rodent O
model O
of O
postinflammatory O
hypersensitivity O
(4 O
weeks O
after O
colitis O
induction). O
At O
a O
dose O
of O
100 O
mg/kg, O
ATB-429 B-CHEMICAL
reversed O
the O
allodynic O
response O
caused O

by O
CRD O
in O
postcolitic O
rats. O
Colonic O
cyclooxygenase-2 B-GENE-Y
and O
interkeukin-1beta B-GENE-Y
mRNA O
and O
spinal O
c-FOS B-GENE-Y
mRNA O
expression O
were O
significantly O
down-regulated O
by O
ATB-429, B-CHEMICAL
but O
not O
by O
mesalamine. B-CHEMICAL
ATB-429, B-CHEMICAL
but O
not O
mesalamine, B-CHEMICAL
increased O
blood O
concentrations O
of O
H(2)S B-CHEMICAL
in O
both O
healthy O
and O
postcolitic O
rats. O
Taken O
together, O
these O
data O
suggest O
that O
ATB-429 B-CHEMICAL
inhibits O
hypersensitivity O
induced O
by O
CRD O
in O
both O
healthy O
and O

postcolitic, O
allodynic O
rats O
by O
a O
K(ATP) B-GENE-N
channel-mediated I-GENE-N
mechanism. O
This O
study O
provides O
evidence O
that O
H(2)S-releasing B-CHEMICAL
drugs O
might O
have O
beneficial O
effects O
in O
the O
treatment O
of O
painful O
intestinal O
disorders. O
Block O
of O
human B-GENE-Y
NaV1.5 I-GENE-Y
sodium B-GENE-N
channels I-GENE-N
by O
novel O
alpha-hydroxyphenylamide B-CHEMICAL
analogues O
of O
phenytoin. B-CHEMICAL
Voltage-gated B-GENE-N
sodium I-GENE-N
(Na) I-GENE-N
channels I-GENE-N
are O
a O
critical O
component O
of O
electrically O
excitable O
cells. O
Phenytoin B-CHEMICAL
(diphenylhydantoin, B-CHEMICAL
DPH) B-CHEMICAL
is O
an O
established O
sodium B-GENE-N
channel I-GENE-N
blocker O
and O
is O

a O
useful O
anticonvulsant O
and O
class O
1b O
antiarrhythmic, O
and O
has O
been O
effectively O
used O
in O
the O
treatment O
of O
neuropathic O
pain. O
In O
this O
study, O
we O
have O
synthesized O
novel O
alpha-hydroxyphenylamide B-CHEMICAL
analogues O
of O
diphenylhydantoin B-CHEMICAL
and O
examined O
their O
ability O
to O
inhibit O
human B-GENE-Y
Na(V)1.5 I-GENE-Y
sodium B-GENE-N
channels I-GENE-N
expressed O
in O
Chinese O
Hamster O
Ovary O
(CHO-K1) O
cells. O
Phenyl B-CHEMICAL
ring O
substitutions O
were O
examined O
including O
para-methyl, B-CHEMICAL
para-fluoro, B-CHEMICAL
para-chloro, B-CHEMICAL
ortho-chloro B-CHEMICAL
and O

meta-chloro. B-CHEMICAL
We O
have O
found O
that O
phenyl B-CHEMICAL
ring O
substitutions O
with O
electron O
withdrawing O
properties O
resulted O
in O
compounds O
with O
greater O
activity. O
In O
comparison O
to O
diphenylhydantoin, B-CHEMICAL
the O
novel O
chloro-substituted B-CHEMICAL
alpha-hydroxyphenylamide B-CHEMICAL
compounds O
produced O
as O
much O
as O
a O
20-fold O
greater O
tonic O
and O
frequency-dependent O
blockade O
of O
Na(V)1.5 B-GENE-Y
channels O
with O
an O
IC(50) O
value O
of O
14.5 O
microM. O
In O
addition, O
the O
chloro-substitutions B-CHEMICAL
have O
position O
specific O
state O
dependent O
blocking O
properties. O
The O
ortho-, B-CHEMICAL
meta- I-CHEMICAL
and I-CHEMICAL

para-chloro I-CHEMICAL
substitutions O
have O
an O
8-, O
13- O
and O
3-fold O
increased O
affinity O
for O
the O
inactivated O
state, O
respectively. O
Molecular O
modeling O
suggests O
that O
these O
differences O
in O
affinity O
are O
due O
to O
a O
direct O
interaction O
with O
the O
receptor. O
Comparing O
models O
of O
diphenylhydantoin B-CHEMICAL
to O
the O
novel O
alpha-hydroxyphenlyamide B-CHEMICAL
compound O
suggests O
that O
the O
increased O
activity O
may O
be O
due O
to O
an O
optimized O
phenyl B-CHEMICAL
ring O
position O
and O
increased O
molecular O
volume. O
This O
information O
may O
be O
useful O
in O
the O
development O
of O
more O
potent O
sodium B-GENE-N
channel I-GENE-N
blockers. O
Effects O
of O
a O
serotonin B-GENE-Y
5-HT(4) I-GENE-Y
receptor I-GENE-Y
antagonist O

SB-207266 B-CHEMICAL
on O
gastrointestinal O
motor O
and O
sensory O
function O
in O
humans. O
BACKGROUND: O
Serotonin B-GENE-Y
5-HT(4) I-GENE-Y
receptors I-GENE-Y
are O
located O
on O
enteric O
cholinergic O
neurones O
and O
may O
regulate O
peristalsis. O
5-HT(4) B-GENE-Y
receptors O
on O
primary O
afferent O
neurones O
have O
been O
postulated O
to O
modulate O
visceral O
sensation. O
While O
5-HT(4) B-GENE-Y
agonists O
are O
used O
as O
prokinetic O
agents, O
the O
physiological O
role O
of O
5-HT(4) B-GENE-Y
receptors O
in O
the O
human O
gut O
is O
unknown. O

AIMS: O
Our O
aim O
was O
to O
characterise O
the O
role O
of O
5-HT(4) B-GENE-Y
receptors O
in O
regulating O
gastrointestinal O
motor O
and O
sensory O
function O
in O
healthy O
subjects O
under O
baseline O
and O
stimulated O
conditions O
with O
a O
5-HT(4) B-GENE-Y
receptor O
antagonist. O
METHODS: O
Part O
A O
compared O
the O
effects O
of O
placebo O
to O
four O
doses O
of O
a O
5-HT(4) B-GENE-Y
receptor O
antagonist O
(SB-207266) B-CHEMICAL
on O
the O
cisapride B-CHEMICAL
mediated O
increase O
in O
plasma O
aldosterone B-CHEMICAL
(a O
5-HT(4) B-GENE-Y
mediated O
response) O
and O
orocaecal O
transit O
in O
18 O
subjects. O
In O
part O

B, O
52 O
healthy O
subjects O
received O
placebo, O
or O
0.05, O
0.5, O
or O
5 O
mg O
of O
SB-207266 B-CHEMICAL
for O
10-12 O
days; O
gastric, O
small O
bowel, O
and O
colonic O
transit O
were O
measured O
by O
scintigraphy O
on O
days O
7-9, O
and O
fasting O
and O
postprandial O
colonic O
motor O
function, O
compliance, O
and O
sensation O
during O
distensions O
were O
assessed O
on O
day O
12. O
RESULTS: O
Part O
A: O
0.5, O
5, O
and O
20 O
mg O
doses O
of O
SB-207266 B-CHEMICAL
had O
significant O
and O
quantitatively O
similar O
effects, O
antagonising O
the O

cisapride O
mediated O
increase O
in O
plasma O
aldosterone B-CHEMICAL
and O
acceleration O
of O
orocaecal O
transit. O
Part O
B: O
SB-207266 B-CHEMICAL
tended O
to O
delay O
colonic O
transit O
(geometric O
centre O
of O
isotope O
at O
24 O
(p=0.06) O
and O
48 O
hours O
(p=0.08)), O
but O
did O
not O
have O
dose O
related O
effects O
on O
transit, O
fasting O
or O
postprandial O
colonic O
motor O
activity, O
compliance, O
or O
sensation. O
CONCLUSION: O
5-HT(4) B-GENE-Y
receptors O
are O
involved O
in O
the O
regulation O
of O
cisapride B-CHEMICAL
stimulated O
orocaecal O
transit; O

SB B-CHEMICAL
207266 I-CHEMICAL
tends O
to O
modulate O
colonic O
transit O
but O
not O
sensory O
functions O
or O
compliance O
in O
healthy O
human O
subjects. O
Structures O
of O
wild-type O
and O
mutant O
human B-GENE-Y
spermidine/spermine I-GENE-Y
N1-acetyltransferase, I-GENE-Y
a O
potential O
therapeutic O
drug O
target. O
Spermidine/spermine B-GENE-Y
N1-acetyltransferase I-GENE-Y
(SSAT) B-GENE-Y
is O
a O
key O
enzyme O
in O
the O
control O
of O
polyamine B-CHEMICAL
levels O
in O
human O
cells, O
as O
acetylation O
of O
spermidine B-CHEMICAL
and O
spermine B-CHEMICAL
triggers O
export O
or O
degradation. O
Increased O
intracellular O
polyamine B-CHEMICAL
levels O
accompany O
several O
types O
of O
cancers O

as O
well O
as O
other O
human O
diseases, O
and O
compounds O
that O
affect O
the O
expression, O
activity, O
or O
stability O
of O
SSAT B-GENE-Y
are O
being O
explored O
as O
potential O
therapeutic O
drugs. O
We O
have O
expressed O
human B-GENE-Y
SSAT I-GENE-Y
from O
the O
cloned O
cDNA O
in O
Escherichia O
coli O
and O
have O
determined O
high-resolution O
structures O
of O
wild-type O
and O
mutant O
SSAT, B-GENE-Y
as O
the O
free O
dimer O
and O
in O
binary O
and O
ternary O
complexes O
with O
CoA, B-CHEMICAL
acetyl-CoA B-CHEMICAL
(AcCoA), B-CHEMICAL
spermine, B-CHEMICAL
and O
the O
inhibitor O
N1,N11bis-(ethyl)-norspermine B-CHEMICAL

(BE-3-3-3). O
These O
structures O
show O
details O
of O
binding O
sites O
for O
cofactor, O
substrates, O
and O
inhibitor O
and O
provide O
a O
framework O
to O
understand O
enzymatic O
activity, O
mutations, O
and O
the O
action O
of O
potential O
drugs. O
Two O
dimer O
conformations O
were O
observed: O
a O
symmetric O
form O
with O
two O
open O
surface O
channels O
capable O
of O
binding O
substrate O
or O
cofactor, O
and O
an O
asymmetric O
form O
in O
which O
only O
one O
of O
the O
surface O
channels O
appears O
capable O
of O
binding O
and O
acetylating O
polyamines. B-CHEMICAL
SSAT B-GENE-Y
was O
found O
to O
self-acetylate B-CHEMICAL
lysine-26 B-CHEMICAL
in O
the O
presence O
of O
AcCoA B-CHEMICAL
and O
absence O
of O

substrate, O
a O
reaction O
apparently O
catalzyed O
by O
AcCoA B-CHEMICAL
bound O
in O
the O
second O
channel O
of O
the O
asymmetric O
dimer. O
These O
unexpected O
and O
intriguing O
complexities O
seem O
likely O
to O
have O
some O
as O
yet O
undefined O
role O
in O
regulating O
SSAT B-GENE-Y
activity O
or O
stability O
as O
a O
part O
of O
polyamine B-CHEMICAL
homeostasis. O
Sequence O
signatures O
group O
SSAT B-GENE-Y
with O
proteins O
that O
appear O
to O
have O
thialysine B-GENE-Y
Nepsilon-acetyltransferase I-GENE-Y
activity. O
Suppression O
of O
nuclear B-GENE-Y
factor I-GENE-Y
erythroid I-GENE-Y
2-related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
via O
extracellular B-GENE-N
signal-regulated I-GENE-N
kinase I-GENE-N
contributes O
to O
bleomycin-induced B-CHEMICAL

oxidative O
stress O
and O
fibrogenesis. O
Pulmonary O
fibrosis O
is O
a O
serious O
and O
irreversible O
lung O
injury O
with O
obscure O
etiologic O
mechanisms O
and O
no O
effective O
treatment O
to O
date. O
This O
study O
explored O
a O
crucial O
link O
between O
oxidative O
stress O
and O
pulmonary O
fibrogenesis, O
focusing O
on O
nuclear B-GENE-Y
factor I-GENE-Y
erythroid I-GENE-Y
2-related I-GENE-Y
factor I-GENE-Y
2 I-GENE-Y
(Nrf2), B-GENE-Y
a O
core O
transcription O
factor O
in O
antioxidative O
regulation O
systems. O
Treatment O
of O
C57 O
BL/6 O
mice O
with O
bleomycin B-CHEMICAL
increased O
fibroblast O
viability O
and O
collagen B-GENE-N
production O
and O
significantly O
downregulated O
Nrf2. B-GENE-N
In O

addition, O
prominent O
oxidative O
stress O
was O
indicated O
by O
changes O
in O
superoxide B-GENE-N
dismutase, I-GENE-N
catalase B-GENE-N
activity, O
and O
glutathione B-CHEMICAL
and O
thiobarbituric B-CHEMICAL
acid-reactive I-CHEMICAL
substance O
levels. O
In O
a O
cell-based O
model, O
bleomycin B-CHEMICAL
suppressed O
Nrf2 B-GENE-Y
activation O
via O
extracellular B-GENE-N
signal-related I-GENE-N
kinase I-GENE-N
phosphorylation, O
enhancing O
intracellular O
reactive O
oxygen B-CHEMICAL
species O
in O
lung O
fibroblasts O
and O
stimulating O
abnormal O
cell O
proliferation O
and O
collagen O
secretion. O
To O
confirm O
this O
novel O
mechanism O
of O
bleomycin-induced B-CHEMICAL
fibrogenesis, O
we O
attempted O
to O
upregulate O
Nrf2 B-GENE-Y
and O

related O
antioxidant O
proteins O
in O
bleomycin-treated O
fibroblasts O
using O
a O
putative O
Nrf2 B-GENE-Y
activator, O
caffeic B-CHEMICAL
acid I-CHEMICAL
phenethyl I-CHEMICAL
ester, I-CHEMICAL
and O
the O
results O
showed O
that O
bleomycin-induced B-CHEMICAL
fibroblast O
proliferation O
and O
collagen B-GENE-N
content O
were O
attenuated O
through O
improved O
redox O
balance. O
Collectively, O
these O
results O
disclose O
a O
potential O
regulatory O
mechanism O
in O
pulmonary O
fibrosis O
that O
will O
aid O
the O
development O
of O
new O
therapies. O
Pharmacokinetic O
and O
pharmacodynamic O
modeling O
of O
hedgehog B-GENE-N
inhibitor O
TAK-441 B-CHEMICAL
for O
the O
inhibition O
of O
Gli1 B-GENE-Y

messenger O
RNA O
expression O
and O
antitumor O
efficacy O
in O
xenografted O
tumor O
model O
mice. O

6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide B-CHEMICAL
(TAK-441) B-CHEMICAL
is O
a O
potent, O
selective O
hedgehog B-GENE-N

signaling O
pathway O
inhibitor O
that O
binds O
to O
Smo B-GENE-Y
and O
is O
being O
developed O
for O
the O
treatment O
of O
cancer. O
The O
objectives O
of O
these O
studies O
were O
to O
explore O
the O
possibility O
of O
establishing O
of O
a O
link O
between O
the O
pharmacokinetics O
of O
TAK-441 B-CHEMICAL
and O
the O
responses O
of O
Gli1 B-GENE-Y
mRNA O
in O
tumor-associated O
stromal O
or O
skin O
cells O
and O
the O
antitumor O
effect O
of O
hedgehog B-GENE-N
inhibition. O
To O
this O
end, O
we O
built O
pharmacokinetic O
and O
pharmacodynamic O
models O
that O
describe O
the O
relationship O
of O
the O
concentrations O
of O
TAK-441 B-CHEMICAL
plasma O
to O
the O
responses O
of O
Gli1 B-GENE-Y
mRNA O
in O
the O
tumor O

(target) O
and O
skin O
(surrogate) O
and O
to O
tumor O
growth O
inhibition O
in O
mice O
bearing O
xenografts O
of O
human O
pancreatic O
tumors O
(PAN-04). O
The O
responses O
of O
Gli1 B-GENE-Y
mRNA O
and O
tumor O
growth O
were O
described O
by O
an O
indirect O
response O
model O
and O
an O
exponential O
tumor O
growth O
model, O
respectively. O
The O
IC50 O
values O
for O
Gli1 B-GENE-Y
mRNA O
inhibition O
in O
the O
tumor O
and O
skin O
by O
TAK-441 B-CHEMICAL
were O
estimated O
to O
be O
0.0457 O
and O
0.113 O
μg/ml, O
respectively. O
The O
IC90 O
value O
for O
tumor O
growth O
inhibition O
was O
estimated O
to O
be O

0.68 O
μg/ml. O
These O
results O
suggest O
that O
a O
>83% O
inhibition O
of O
Gli1 B-GENE-Y
mRNA O
expression O
in O
the O
skin O
or O
a O
>94% O
inhibition O
of O
Gli1 B-GENE-Y
mRNA O
expression O
in O
the O
tumor O
would O
be O
required O
to O
sufficiently O
inhibit O
(>90%) O
hedgehog-related B-GENE-N
tumor O
growth O
in O
the O
xenografted O
model O
mice. O
We O
conclude O
that O
Gli1 B-GENE-Y
mRNA O
expression O
in O
the O
tumor O
and O
skin O
could O
be O
a O
useful O
biomarker O
for O
predicting O
the O
antitumor O
effect O
of O
hedgehog B-GENE-N
inhibitors. O
Synergistic O
effects O
of O
new O
chemopreventive O
agents O
and O
conventional O

cytotoxic O
agents O
against O
human O
lung O
cancer O
cell O
lines. O
Non-small O
cell O
lung O
cancer O
(NSCLC) O
cells O
have O
constitutively O
high O
expression O
of O
cytosolic B-GENE-Y
phospholipase I-GENE-Y
A2 I-GENE-Y
(cPLA2) B-GENE-Y
and O
cyclooxygenase B-GENE-Y
(COX) I-GENE-Y
2. I-GENE-Y
These O
NSCLC O
cells O
also O
have O
increased O
prostaglandin B-CHEMICAL
expression O
(PGE2). B-CHEMICAL
Many O
lung O
cancers O
also O
express O
12-lipoxygenase B-GENE-Y
RNA O
and O
12-lipoxygenase B-GENE-Y
protein O
and O
biosynthesize O

12(S)-hydroxyeicosatetraenoic B-CHEMICAL
acid, I-CHEMICAL
which O
correlates O
with O
their O
metastatic O
potential. O
Several O
studies O
have O
demonstrated O
that O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
inhibitors O
could O
inhibit O
the O
in O
vitro O
growth O
of O
human O
lung O
cancer O
cell O
lines. O
In O
this O
report, O
we O
evaluated O
the O
growth-inhibitory O
effects O
of O
sulindac B-CHEMICAL
sulfide, I-CHEMICAL
a O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
inhibitor; O
exisulind B-CHEMICAL
(sulindac B-CHEMICAL
sulfone), I-CHEMICAL
a O
novel O
proapoptotic O
agent O
that O
does O
not O
inhibit O
COX B-GENE-N
enzymes; O
and O

nordihydroguaiaretic B-CHEMICAL
acid I-CHEMICAL
(NDGA), B-CHEMICAL
a O
lipoxygenase B-GENE-N
inhibitor O
on O
human O
lung O
cancer O
cell O
lines. O
We O
compared O
these O
effects O
with O
those O
of O
13-cis-retinoic B-CHEMICAL
acid, I-CHEMICAL
a O
chemoprevention O
agent, O
and O
with O
the O
cytotoxic O
chemotherapeutic O
agents O
paclitaxel B-CHEMICAL
and O
cisplatin, B-CHEMICAL
alone O
or O
in O
combination. O
Our O
goal O
was O
to O
develop O
new O
chemoprevention O
and O
treatment O
strategies. O
Each O
of O
the O
six O
agents O
tested O
inhibited O
the O
in O
vitro O
growth O
of O
three O
NSCLC O
and O
three O
SCLC O

cell O
lines O
at O
the O
highest O
concentration. O
Paclitaxel B-CHEMICAL
was O
the O
most O
potent O
agent O
(IC50 O
= O
0.003-0.150 O
microM); O
sulindac B-CHEMICAL
sulfide, I-CHEMICAL
NDGA, B-CHEMICAL
and O
13-cis-retinoic B-CHEMICAL
acid I-CHEMICAL
had O
intermediate O
potency O
(IC50 O
= O
4-80 O
microM), O
and O
cisplatin B-CHEMICAL
and O
exisulind B-CHEMICAL
were O
the O
least O
potent O
(IC50 O
= O
150-500 O
microM). O
Combination O
studies O
showed O
synergistic O
interactions O
for O
sulindac B-CHEMICAL
sulfide, I-CHEMICAL
exisulind, B-CHEMICAL
and O
NDGA B-CHEMICAL
with O

paclitaxel, B-CHEMICAL
cisplatin, B-CHEMICAL
and O
13-cis-retinoic B-CHEMICAL
acid, I-CHEMICAL
regardless O
of O
drug-resistance O
phenotype. O
At O
high O
concentrations, O
the O
combination O
of O
13-cis-retinoic B-CHEMICAL
acid I-CHEMICAL
and O
each O
of O
the O
five O
other O
drugs O
resulted O
in O
a O
strong O
synergistic O
effect. O
These O
studies O
provide O
a O
rationale O
for O
chemoprevention O
(exisulind B-CHEMICAL
+/- O
retinoic B-CHEMICAL
acid I-CHEMICAL
+/- O
NDGA) B-CHEMICAL
and O
therapeutic O
(exisulind B-CHEMICAL
+/- O
paclitaxel B-CHEMICAL
+/- O
cisplatin) B-CHEMICAL
studies O
in O
patients O
at O
risk O

for, O
or O
with, O
lung O
cancer. O
Phenothiazines B-CHEMICAL
inhibit O
S100A4 B-GENE-Y
function O
by O
inducing O
protein O
oligomerization. O
S100A4, B-GENE-Y
a O
member O
of O
the O
S100 B-GENE-N
family O
of O
Ca(2+)-binding B-CHEMICAL
proteins, O
regulates O
carcinoma O
cell O
motility O
via O
interactions O
with O
myosin-IIA. B-GENE-Y
Numerous O
studies O
indicate O
that O
S100A4 B-GENE-Y
is O
not O
simply O
a O
marker O
for O
metastatic O
disease, O
but O
rather O
has O
a O
direct O
role O
in O
metastatic O
progression. O
These O
observations O
suggest O
that O
S100A4 B-GENE-Y
is O
an O
excellent O
target O
for O
therapeutic O
intervention. O
Using O
a O
unique O
biosensor-based O

assay, O
trifluoperazine B-CHEMICAL
(TFP) B-CHEMICAL
was O
identified O
as O
an O
inhibitor O
that O
disrupts O
the O
S100A4/myosin-IIA B-GENE-Y
interaction. O
To O
examine O
the O
interaction O
of O
S100A4 B-GENE-Y
with O
TFP, B-CHEMICAL
we O
determined O
the O
2.3 O
A O
crystal O
structure O
of O
human O
Ca(2+)-S100A4 B-CHEMICAL
bound O
to O
TFP. B-CHEMICAL
Two O
TFP B-CHEMICAL
molecules O
bind O
within O
the O
hydrophobic O
target O
binding O
pocket O
of O
Ca(2+)-S100A4 B-CHEMICAL
with O
no O
significant O
conformational O
changes O
observed O
in O
the O
protein O
upon O
complex O
formation. O
NMR O
chemical O
shift O
perturbations O
are O
consistent O
with O

the O
crystal O
structure O
and O
demonstrate O
that O
TFP B-CHEMICAL
binds O
to O
the O
target O
binding O
cleft O
of O
S100A4 B-GENE-Y
in O
solution. O
Remarkably, O
TFP B-CHEMICAL
binding O
results O
in O
the O
assembly O
of O
five O
Ca(2+)-S100A4/TFP B-CHEMICAL
dimers O
into O
a O
tightly O
packed O
pentameric O
ring. O
Within O
each O
pentamer O
most O
of O
the O
contacts O
between O
S100A4 B-GENE-Y
dimers O
occurs O
through O
the O
TFP B-CHEMICAL
moieties. O
The O
Ca(2+)-S100A4/prochlorperazine B-CHEMICAL
(PCP) B-CHEMICAL
complex O
exhibits O
a O
similar O
pentameric O
assembly. O
Equilibrium O

sedimentation O
and O
cross-linking O
studies O
demonstrate O
the O
cooperative O
formation O
of O
a O
similarly O
sized O
S100A4/TFP B-GENE-Y
oligomer O
in O
solution. O
Assays O
examining O
the O
ability O
of O
TFP B-CHEMICAL
to O
block O
S100A4-mediated B-GENE-Y
disassembly O
of O
myosin-IIA B-GENE-Y
filaments O
demonstrate O
that O
significant O
inhibition O
of O
S100A4 B-GENE-Y
function O
occurs O
only O
at O
TFP B-CHEMICAL
concentrations O
that O
promote O
S100A4 B-GENE-Y
oligomerization. O
Together O
these O
studies O
support O
a O
unique O
mode O
of O
inhibition O
in O
which O
phenothiazines B-CHEMICAL
disrupt O
the O
S100A4/myosin-IIA B-GENE-Y
interaction O
by O
sequestering O

S100A4 B-GENE-Y
via O
small O
molecule-induced O
oligomerization. O
Substrates O
of O
IAP B-GENE-N
ubiquitin B-GENE-N
ligases I-GENE-N
identified O
with O
a O
designed O
orthogonal O
E3 B-GENE-N
ligase, I-GENE-N
the O
NEDDylator. O
Inhibitors B-GENE-N
of I-GENE-N
Apoptosis I-GENE-N
Protein I-GENE-N
(IAPs) B-GENE-N
are O
guardian O
ubiquitin B-GENE-N
ligases I-GENE-N
that O
keep O
classic O
proapoptotic O
proteins O
in O
check. O
Systematic O
identification O
of O
additional O
IAP O
substrates O
is O
challenged O
by O
the O
heterogeneity O
and O
sheer O
number O
of O
ubiquitinated O
proteins O
(>5,000). O
Here O
we O
report O
a O
powerful O
catalytic O
tagging O

tool, O
the O
NEDDylator, O
which O
fuses O
a O
NEDD8 B-GENE-Y
E2-conjugating B-GENE-N
enzyme, I-GENE-N
Ubc12, B-GENE-Y
to O
the O
ubiquitin B-GENE-N
ligase, I-GENE-N
XIAP B-GENE-Y
or O
cIAP1. B-GENE-Y
This O
permits O
transfer O
of O
the O
rare O
ubiquitin B-GENE-N
homolog O
NEDD8 B-GENE-Y
to O
the O
ubiquitin B-GENE-N
E3 I-GENE-N
substrates, O
allowing O
them O
to O
be O
efficiently O
purified O
for O
LC-MS/MS O
identification. O
We O
have O
identified O
>50 O
potential O
IAP B-GENE-N
substrates O
of O
both O
cytosolic O
and O
mitochondrial O
origin O
that O
bear O
hallmark O
N-terminal B-CHEMICAL
IAP B-GENE-N
binding O
motifs. O
These O
substrates O
include O
the O
recently O

discovered O
protein B-GENE-N
phosphatase I-GENE-N
PGAM5, B-GENE-Y
which O
we O
show O
is O
proteolytically O
processed, O
accumulates O
in O
cytosol O
during O
apoptosis, O
and O
sensitizes O
cells O
to O
death. O
These O
studies O
reveal O
mechanisms O
and O
antagonistic O
partners O
for O
specific O
IAPs, B-GENE-N
and O
provide O
a O
powerful O
technology O
for O
labeling O
binding O
partners O
in O
transient O
protein-protein O
complexes. O
Cloning O
and O
expression O
of O
the O
liver O
and O
muscle O
isoforms O
of O
ovine B-GENE-Y
carnitine I-GENE-Y
palmitoyltransferase I-GENE-Y
1: I-GENE-Y
residues O
within O
the O
N-terminus B-CHEMICAL
of O
the O
muscle O
isoform O
influence O
the O
kinetic O
properties O
of O
the O
enzyme. O
The O

nucleotide B-CHEMICAL
sequence O
data O
reported O
will O
appear O
in O
DDBJ, O
EMBL, O
GenBank(R) O
and O
GSDB O
Nucleotide B-CHEMICAL
Sequence O
Databases; O
the O
sequences O
of O
ovine B-GENE-Y
CPT1A I-GENE-Y
and O
CPT1B B-GENE-Y
cDNAs O
have O
the O
accession O
numbers O
Y18387 B-GENE-Y
and O
AJ272435 B-GENE-Y
respectively O
and O
the O
partial O
adipose O
tissue O
and O
liver O
CPT1A B-GENE-Y
clones O
have O
the O
accession O
numbers O
Y18830 B-GENE-Y
and O
Y18829 B-GENE-Y
respectively. O
Fatty B-CHEMICAL
acid I-CHEMICAL
and O
ketone B-CHEMICAL
body O
metabolism O
differ O
considerably O
between O
monogastric O
and O
ruminant O
species. O
The O
regulation O
of O

the O
key O
enzymes O
involved O
may O
differ O
accordingly. O
Carnitine B-GENE-Y
palmitoyltransferase I-GENE-Y
1 I-GENE-Y
(CPT B-GENE-Y
1) I-GENE-Y
is O
the O
key O
locus O
for O
the O
control O
of O
long-chain O
fatty B-CHEMICAL
acid I-CHEMICAL
beta-oxidation O
and O
liver O
ketogenesis. O
Previously O
we O
showed O
that O
CPT B-GENE-N
1 I-GENE-N
kinetics O
in O
sheep O
and O
rat O
liver O
mitochondria O
differ. O
We O
cloned O
cDNAs O
for O
both O
isoforms O
[liver- O
(L-) O
and O
muscle- O
(M-)] O
of O
ovine B-GENE-Y
CPT I-GENE-Y
1 I-GENE-Y
in O
order O
to O
elucidate O
the O
structural O
features O
of O
these O
proteins O
and O
their O
genes O
( O
CPT1A B-GENE-Y
and O

CPT1B B-GENE-Y
). O
Their O
deduced O
amino B-CHEMICAL
acid I-CHEMICAL
sequences O
show O
a O
high O
degree O
of O
conservation O
compared O
with O
orthologues O
from O
other O
mammalian O
species, O
with O
the O
notable O
exception O
of O
the O
N-terminus B-CHEMICAL
of O
ovine B-GENE-Y
M-CPT I-GENE-Y
1. I-GENE-Y
These O
differences O
were O
also O
present O
in O
bovine B-GENE-Y
M-CPT I-GENE-Y
1, I-GENE-Y
whose O
N-terminal B-CHEMICAL
sequence O
we O
determined. O
In O
addition, O
the O
5'-end O
of O
the O
sheep B-GENE-Y
CPT1B I-GENE-Y
cDNA O
suggested O
a O
different O
promoter O
architecture O
when O
compared O
with O
previously O
characterized O
CPT1B B-GENE-Y
genes. O
Northern O
blotting O
revealed O
differences O
in O
tissue O
distribution O
for O
both O
CPT1A B-GENE-Y
and O

CPT1B B-GENE-Y
transcripts O
compared O
with O
other O
species. O
In O
particular, O
ovine B-GENE-Y
CPT1B I-GENE-Y
mRNA O
was O
less O
tissue O
restricted, O
and O
the O
predominant O
transcript O
in O
the O
pancreas O
was O
CPT1B. B-GENE-Y
Expression O
in O
yeast O
allowed O
kinetic O
characterization O
of O
the O
two O
native O
enzymes, O
and O
of O
a O
chimaera O
in O
which O
the O
distinctive O
N-terminal B-CHEMICAL
segment O
of O
ovine B-GENE-Y
M-CPT I-GENE-Y
1 I-GENE-Y
was O
replaced O
with O
that O
from O
rat B-GENE-Y
M-CPT I-GENE-Y
1. I-GENE-Y
The O
ovine O
N-terminal B-CHEMICAL
segment O
influences O
the O
kinetics O
of O
the O
enzyme O
for O
both O
its O
substrates, O
such O
that O
the O
K O
(m) O
for O
palmitoyl-CoA B-CHEMICAL

is O
decreased O
and O
that O
for O
carnitine B-CHEMICAL
is O
increased O
for O
the O
chimaera, O
relative O
to O
the O
parental O
ovine B-GENE-Y
M-CPT I-GENE-Y
1. I-GENE-Y
Cardiac O
effects O
of O
the O
beta B-GENE-Y
3-adrenoceptor I-GENE-Y
agonist O
BRL35135 B-CHEMICAL
in O
man. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
cardiac O
effects O
of O
the O
beta B-GENE-Y
3-adrenoceptor I-GENE-Y
agonist O
BRL35135, B-CHEMICAL
and O
determine O
whether O
beta B-GENE-Y
3-receptors I-GENE-Y
are O
involved O
in O
mediating O
chronotropic O
or O
inotropic O
responses O
in O
man. O
Eight O
normal O
males O
received O
single O
oral O
doses O
of O
BRL35135 B-CHEMICAL
8 O
mg O
(BRL) B-CHEMICAL
or O

the O
selective O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
agonist O
salbutamol B-CHEMICAL
8 O
mg O
(SAL), B-CHEMICAL
after O
pretreatment O
with O
either O
placebo O
(PL), O
bisoprolol B-CHEMICAL
5 O
mg O
(B5) O
as O
a O
selective O
beta B-GENE-Y
1-adrenoceptor I-GENE-Y
antagonist, O
or O
nadolol B-CHEMICAL
20 O
mg O
(N20) O
to O
block O
beta B-GENE-N
1- I-GENE-N
and I-GENE-N
beta I-GENE-N
2- I-GENE-N
but I-GENE-N
not I-GENE-N
beta I-GENE-N
3-receptors. I-GENE-N
Both O
BRL B-CHEMICAL
and O
SAL B-CHEMICAL
produced O
a O
significant O
increase O
in O
postural O
finger O
tremor O
in O
keeping O
with O
beta B-GENE-Y
2-adrenoceptor I-GENE-Y
stimulation, O
and O
this O
response O
was O
totally O
abolished O
by O

pretreatment O
with O
N20. O
Significant O
increases O
in O
systolic O
blood O
pressure O
and O
Doppler O
stroke O
distance O
occurred O
with O
BRL B-CHEMICAL
and O
SAL B-CHEMICAL
which O
were O
unaffected O
by O
pretreatment O
with O
B5 O
and O
completely O
blocked O
by O
N20, O
in O
keeping O
with O
beta B-GENE-Y
2-mediated I-GENE-Y
effects. O
BRL B-CHEMICAL
and O
SAL B-CHEMICAL
produced O
significant O
chronotropic O
and O
minute O
distance O
responses O
which O
were O
unaffected O
by O
beta B-GENE-Y
1-adrenoceptor I-GENE-Y
blockade. O
However, O
whereas O
N20 O
blocked O
these O
responses O
to O
SAL, B-CHEMICAL
a O
small O
but O
significant O
response O
occurred O
with O
BRL B-CHEMICAL
in O
comparison O
with O
placebo O
despite O
complete O
blockade O
of O
co-existing O
beta B-GENE-Y

2-mediated I-GENE-Y
effects. O
Compared O
with O
PL, O
the O
mean O
responses O
to O
N20/BRL, B-CHEMICAL
and O
the O
95% O
confidence O
interval O
for O
the O
differences O
between O
the O
means O
were O
7.4 O
beats O
min-1 O
[3.2 O
to O
11.6] O
(P O
= O
0.002) O
for O
heart O
rate, O
and O
208.8 O
cm O
[38.3 O
to O
379.3] O
(P O
= O
0.02) O
for O
minute O
distance O
responses.(ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS) O
Aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor-mediated I-GENE-Y
disruption O
of O
contact O
inhibition O
is O
associated O
with O
connexin43 B-GENE-Y

downregulation O
and O
inhibition O
of O
gap O
junctional O
intercellular O
communication. O
The O
aryl B-GENE-Y
hydrocarbon I-GENE-Y
receptor I-GENE-Y
(AhR) B-GENE-Y
contributes O
to O
the O
control O
of O
cell-to-cell O
communication, O
cell O
adhesion, O
migration O
or O
proliferation. O
In O
the O
present O
study, O
we O
investigated O
the O
regulation O
of O
connexin43 B-GENE-Y
(Cx43) B-GENE-Y
and O
Cx43-mediated B-GENE-Y
gap O
junctional O
intercellular O
communication O
(GJIC) O
during O
the O
AhR-dependent B-GENE-Y
disruption O
of O
contact O
inhibition O
in O
non-tumorigenic O
liver O
epithelial O
cells. O
The O
contact O
inhibition O
of O
cell O
proliferation O
is O
a O
process O
restricting O
the O
cell O
division O
of O

confluent O
non-transformed O
cells, O
which O
is O
frequently O
abolished O
in O
cancer O
cells; O
however, O
the O
mechanisms O
contributing O
to O
its O
disruption O
are O
still O
only O
partially O
understood. O
Disruption O
of O
contact O
inhibition, O
which O
was O
induced O
by O
toxic O
AhR B-GENE-Y
ligands O
2,3,7,8-tetrachlorodibenzo-p-dioxin B-CHEMICAL
(TCDD) B-CHEMICAL
or O
polycyclic B-CHEMICAL
aromatic I-CHEMICAL
hydrocarbons I-CHEMICAL
in O
epithelial O
WB-F344 O
cells, O
reduced O
Cx43 B-GENE-Y
protein O
levels, O
possibly O
via O
enhanced O
proteasomal O
degradation, O
significantly O
decreased O
the O
amount O
of O
gap O

junction O
plaques O
and O
downregulated O
GJIC, O
in O
an O
AhR-dependent B-GENE-Y
manner. O
Although O
both O
intracellular O
and O
membrane O
Cx43 B-GENE-Y
pools O
were O
markedly O
reduced O
in O
cells O
released O
from O
contact O
inhibition O
by O
TCDD, B-CHEMICAL
siRNA-mediated O
Cx43 B-GENE-Y
knock-down O
was O
not O
sufficient O
to O
stimulate O
proliferation O
in O
contact-inhibited O
cells. O
Our O
data O
suggest O
that O
downregulation O
of O
Cx43/GJIC B-GENE-Y
in O
non-transformed O
epithelial O
cells O
is O
an O
inherent O
part O
of O
disruption O
of O
contact O
inhibition, O
which O
occurs O
at O
the O
post-transcriptional O
level. O
This O
process O
runs O
in O
parallel O
with O
alterations O
of O
other O

forms O
of O
cell-to-cell O
communication, O
thus O
suggesting O
that O
toxic O
AhR B-GENE-Y
agonists O
may O
simultaneously O
abrogate O
contact O
inhibition O
and O
reduce O
GJIC, O
two O
essential O
mechanisms O
linked O
to O
deregulation O
of O
cell-to-cell O
communication O
during O
tumor O
promotion O
and O
progression. O
Heteromtoxin B-GENE-Y
(HmTx), B-GENE-Y
a O
novel O
heterodimeric O
phospholipase B-GENE-N
A(2) I-GENE-N
from O
Heterometrus O
laoticus O
scorpion O
venom. O
Heteromtoxin B-GENE-Y
(HmTx) B-GENE-Y
is O
a O
group B-GENE-N
III I-GENE-N
phospholipase I-GENE-N
A(2) I-GENE-N
produced O
in O
Heterometrus O

laoticus, O
in O
Thailand. O
In O
this O
study, O
HmTx B-GENE-Y
was O
purified O
from O
venom O
by O
separation O
chromatography, O
and O
the O
PLA(2) B-GENE-N
activity O
of O
the O
fractions O
was O
determined O
by O
lecithin O
agar O
assay. O
The O
enzyme O
is O
an O
acidic O
protein O
with O
a O
pI O
of O
5.6 O
and O
an O
apparent O
molecular O
weight O
of O
14018.4 O
Da. O
The O
nucleotide B-CHEMICAL
sequence O
of O
HmTx B-GENE-Y
contains O
649 O
bp, O
and O
the O
mature O
protein O
is O
predicted O
to O
have O
131 O
amino B-CHEMICAL
acid I-CHEMICAL
residues-104 O
of O
which O
make O
up O
the O
large O
subunit, O
and O
27 O
of O
which O
make O
up O
the O
small O
subunit. O
The O
subunit O

structure O
of O
HmTx B-GENE-Y
is O
highly O
similar O
to O
that O
of O
the O
other O
toxin, O
Pandinus O
imperator O
imperatoxin O
I O
(IpTx(i)) O
and O
to O
Mesobuthus B-GENE-N
tamulus I-GENE-N
phospholipase I-GENE-N
A(2) I-GENE-N
(MtPLA(2)). B-GENE-N
The O
3D-structure O
of O
HmTx B-GENE-Y
consists O
of O
three O
conserved O
alpha-helices: O
h1 O
(Lys24-His34), B-CHEMICAL
h2 O
(Cys59-Asp71), B-CHEMICAL
and O
h3 O
(Ala80-Phe89). B-CHEMICAL
The O

beta-sheet O
consisted O
of O
a O
single O
stranded O
anti-parallel O
beta-sheet O
(b1.1 O
at O
Glu43-Lys45 B-CHEMICAL
and O
b1.2 O
at O
Lys48-Asn50) B-CHEMICAL
that O
was O
highly O
similar O
to O
the O
conserved O
sequences O
(-CGXG-, O
-CCXXHDXC- O
and O
CXCEXXXXXC-) O
of O
Apis O
mellifera O
(bee) O
phospholipases. B-GENE-N
Comparative O
phosphoproteomic O
analysis O
of O
checkpoint O
recovery O
identifies O
new O
regulators O
of O
the O
DNA O
damage O
response. O
How O
cells O
recover O
from O
a O
DNA O
damage-induced O

arrest O
is O
currently O
poorly O
understood. O
We O
performed O
large-scale O
quantitative O
phosphoproteomics O
to O
identify O
changes O
in O
protein O
phosphorylation O
that O
occurred O
during O
recovery O
from O
arrest O
in O
the O
G2 O
phase O
of O
the O
cell O
cycle O
caused O
by O
DNA O
damage. O
We O
identified O
154 O
proteins O
that O
were O
differentially O
phosphorylated, O
and O
systematic O
depletion O
of O
each O
of O
these O
differentially O
phosphorylated O
proteins O
by O
small O
interfering O
RNA O
(siRNA) O
identified O
at O
least O
10 O
potential O
regulators O
of O
recovery. O
Astrin, B-GENE-Y
a O
protein O
associated O
with O
the O
mitotic O
spindle, O
was O
among O
the O
potential O
regulators O
of O
recovery. O
We O
found O
that O

astrin B-GENE-Y
controlled O
the O
abundance O
of O
the O
cell O
cycle O
regulator O
p53 B-GENE-Y
during O
DNA O
damage-induced O
arrest. O
Cells O
in O
which O
astrin B-GENE-Y
was O
depleted O
had O
decreased O
murine B-GENE-Y
double I-GENE-Y
minute I-GENE-Y
2 I-GENE-Y
(MDM2) B-GENE-Y
abundance O
and O
increased O
p53 B-GENE-Y
at O
the O
later O
stages O
of O
the O
DNA O
damage O
response. O
Astrin B-GENE-Y
was O
required O
for O
continued O
expression O
of O
genes O
encoding O
proteins O
that O
promote O
cell O
cycle O
progression O
in O
arrested O
cells. O
Thus, O
by O
controlling O
p53 B-GENE-Y
abundance O
in O
cells O
recovering O
from O
DNA O
damage, O
astrin B-GENE-Y
maintains O
the O
cells O
in O
a O
state O
competent O
to O
resume O
the O
cell O
cycle. O
Molecular O
mechanism O
of O
terbinafine B-CHEMICAL
resistance O
in O
Saccharomyces O

cerevisiae. O
Ten O
mutants O
of O
the O
yeast O
Saccharomyces O
cerevisiae O
resistant O
to O
the O
antimycotic O
terbinafine B-CHEMICAL
were O
isolated O
after O
chemical O
or O
UV O
mutagenesis. O
Molecular O
analysis O
of O
these O
mutants O
revealed O
single O
base O
pair O
exchanges O
in O
the O
ERG1 B-GENE-Y
gene O
coding O
for O
squalene B-GENE-Y
epoxidase, I-GENE-Y
the O
target O
of O
terbinafine. B-CHEMICAL
The O
mutants O
did O
not O
show O
cross-resistance O
to O
any O
of O
the O
substrates O
of O
various O
pleiotropic O
drug O
resistance O
efflux O
pumps O
tested. O
The O
ERG1 B-GENE-Y
mRNA O
levels O
in O
the O
mutants O
did O
not O
differ O
from O
those O
in O
the O
wild-type O
parent O

strains. O
Terbinafine B-CHEMICAL
resistance O
was O
transmitted O
with O
the O
mutated O
alleles O
in O
gene O
replacement O
experiments, O
proving O
that O
single O
amino B-CHEMICAL
acid I-CHEMICAL
substitutions O
in O
the O
Erg1 B-GENE-Y
protein O
were O
sufficient O
to O
confer O
the O
resistance O
phenotype. O
The O
amino B-CHEMICAL
acid I-CHEMICAL
changes O
caused O
by O
the O
point O
mutations O
were O
clustered O
in O
two O
regions O
of O
the O
Erg1 B-GENE-Y
protein. O
Seven O
mutants O
carried O
the O
amino B-CHEMICAL
acid I-CHEMICAL
substitutions O
F402L B-GENE-N
(one O
mutant), O
F420L B-GENE-N
(one O
mutant), O
and O
P430S B-GENE-N
(five O
mutants) O
in O
the O
C-terminal B-CHEMICAL
part O
of O
the O
protein; O
and O
three O
mutants O
carried O
an O
L251F B-GENE-N
exchange O

in O
the O
central O
part O
of O
the O
protein. O
Interestingly, O
all O
exchanges O
identified O
involved O
amino B-CHEMICAL
acids I-CHEMICAL
which O
are O
conserved O
in O
the O
squalene B-GENE-N
epoxidases I-GENE-N
of O
yeasts O
and O
mammals. O
Two O
mutations O
that O
were O
generated O
by O
PCR O
mutagenesis O
of O
the O
ERG1 B-GENE-Y
gene O
and O
that O
conferred O
terbinafine B-CHEMICAL
resistance O
mapped O
in O
the O
same O
regions O
of O
the O
Erg1 B-GENE-Y
protein, O
with O
one O
resulting O
in O
an O
L251F B-GENE-N
exchange O
and O
the O
other O
resulting O
in O
an O
F433S B-GENE-N
exchange. O
The O
results O
strongly O
indicate O
that O
these O
regions O
are O
responsible O
for O
the O
interaction O
of O
yeast B-GENE-Y
squalene I-GENE-Y
epoxidase I-GENE-Y
with O
terbinafine. B-CHEMICAL
Ornithine B-CHEMICAL
metabolism O

in O
male O
and O
female O
rat O
kidney: O
mitochondrial O
expression O
of O
ornithine B-GENE-Y
aminotransferase I-GENE-Y
and O
arginase B-GENE-Y
II. I-GENE-Y
In O
the O
kidney, O
L-ornithine B-CHEMICAL
is O
reabsorbed O
along O
the O
proximal O
convoluted O
tubule O
(PCT), O
transported O
by O
basolateral O
carriers, O
and O
produced O
by O
arginase B-GENE-Y
II I-GENE-Y
(AII). B-GENE-Y
Here, O
the O
renal O
metabolic O
fate O
of O
L-ornithine B-CHEMICAL
was O
analyzed O
in O
male O
and O
female O
rats. O
Kidneys O
and O
renal O
zones O
were O
dissected O
and O
used O
for O
Western O
blot O
analysis, O
immunofluorescence, O

and O
electron O
microscopic O
studies. O
Ornithine B-GENE-Y
aminotransferase I-GENE-Y
(OAT) B-GENE-Y
and O
AII B-GENE-Y
were O
localized O
using O
specific O
antibodies. O
Ornithine B-CHEMICAL
oxidation O
was O
determined O
by O
incubating O
microdissected O
tubules O
with O
L-[1-14C] B-CHEMICAL
or O
L-[U-14C]ornithine B-CHEMICAL
in O
the O
presence O
or O
absence O
of O
energy-providing O
substrates. O
Ornithine B-GENE-Y
decarboxylase I-GENE-Y
(ODC) B-GENE-Y
mRNAs O
were O
localized O
by O
in O
situ O
hybridization. O
The O
48-kDa O
OAT B-GENE-Y
protein O
was O
detected O
in O
male O
and O
female O
kidneys, O
but O
its O
level O
was O

fourfold O
higher O
in O
the O
latter. O
OAT B-GENE-Y
relative O
distribution O
increased O
from O
the O
superficial O
cortex O
toward O
the O
outer O
medulla O
to O
reach O
its O
highest O
level. O
Almost O
all O
OAT B-GENE-Y
protein O
was O
localized O
in O
cortical O
and O
medullary O
proximal O
straight O
tubules O
(CPST O
and O
OSPST, O
respectively). O
In O
proximal O
straight O
tubule O
(PST), O
AII B-GENE-Y
protein O
distribution O
overlapped O
that O
of O
OAT. B-GENE-Y
No O
gender O
difference O
in O
AII B-GENE-Y
protein O
level O
was O
found. O
OAT B-GENE-Y
and O
AII B-GENE-Y
were O
colocalized O
within O
PST O
mitochondria. O
L-[1-14C]ornithine B-CHEMICAL

decarboxylation O
occurred O
in O
all O
tubules, O
but O
predominantly O
in O
proximal O
tubules. O
L-[1-14C]ornithine B-CHEMICAL
decarboxylation O
was O
enhanced O
when O
L-[1-14C]ornithine B-CHEMICAL
was O
given O
to O
tubules O
as O
the O
sole O
substrate. O
The O
use O
of O
L-[U-14C]ornithine B-CHEMICAL
demonstrated O
the O
complete O
oxidation O
of O
ornithine. B-CHEMICAL
In O
conclusion, O
the O
OAT B-GENE-Y
gene O
was O
expressed O
more O
in O
female O
rat O
proximal O
tubules O
than O
in O
male. O
Because O
OAT B-GENE-Y
and O
AII B-GENE-Y
proteins O
overlapped O
in O
PST O
mitochondria, O

L-arginine-derived B-CHEMICAL
ornithine B-CHEMICAL
may O
be O
preferentially O
converted O
to O
L-glutamate, B-CHEMICAL
as O
proven O
by O
ornithine B-CHEMICAL
oxidation. O
However, O
the O
coexpression O
of O
ODC, B-GENE-Y
glutamate B-GENE-N
decarboxylase, I-GENE-N
and O
glutamine B-GENE-Y
synthetase I-GENE-Y
in O
PST O
suggests O
that O
L-ornithine B-CHEMICAL
can O
also O
be O
metabolized O
to O
putrescine, B-CHEMICAL
GABA, B-CHEMICAL
and O
L-glutamine. B-CHEMICAL
The O
fate O
of O
L-ornithine B-CHEMICAL
may O
depend O
on O
the O
cellular O
context. O
Dexamethasone B-CHEMICAL
suppresses O
histamine B-CHEMICAL
synthesis O
by O
repressing O
both O

transcription O
and O
activity O
of O
HDC B-GENE-Y
in O
allergic O
rats. O
BACKGROUND: O
Histamine B-CHEMICAL
synthesized O
by O
histidine B-GENE-Y
decarboxylase I-GENE-Y
(HDC) B-GENE-Y
from O
L-histidine B-CHEMICAL
is O
a O
major O
chemical O
mediator O
in O
the O
development O
of O
nasal O
allergy O
which O
is O
characterized O
by O
nasal O
hypersensitivity. O
However O
the O
regulatory O
mechanism O
of O
histamine B-CHEMICAL
synthesis O
by O
HDC B-GENE-Y
remains O
to O
be O
elucidated. O
The O
objectives O
of O
the O
present O
study O
were O
to O
examine O
the O
changes O
of O
histamine B-CHEMICAL
content, O
HDC B-GENE-Y
activity O
and O
HDC B-GENE-Y
mRNA O
expression O
in O
the O
nasal O
mucosa O
of O
allergy O
model O
rats O
sensitized O

by O
the O
exposure O
to O
toluene B-CHEMICAL
diisocyanate I-CHEMICAL
(TDI) B-CHEMICAL
and O
to O
investigate O
the O
effect O
of O
dexamethasone B-CHEMICAL
on O
the O
above O
mentioned O
allergic O
parameters. O
METHODS: O
Rats O
were O
sensitized O
and O
provocated O
by O
TDI B-CHEMICAL
and O
the O
nasal O
allergy-like O
behaviors O
were O
scored O
during O
a O
10 O
minute O
period O
after O
provocation. O
Histamine B-CHEMICAL
content O
and O
HDC B-GENE-Y
activity O
in O
the O
nasal O
mucosa O
were O
determined O
using O
fluorometric O
high O
performance O
liquid O
chromatography. O
The O
expression O
of O
HDC B-GENE-N
mRNA O
in O
nasal O
mucosa O
was O
determined O
using O
real-time O
quantitative O
reverse O
transcriptase-polymerase O

chain O
reaction O
(RT-PCR). O
RESULTS: O
In O
TDI-sensitized B-CHEMICAL
rats, O
nasal O
allergy-like O
behaviors O
such O
as O
sneezing O
and O
watery O
rhinorrhea O
were O
induced. O
Histamine B-CHEMICAL
content, O
HDC B-GENE-Y
activity O
and O
HDC B-GENE-Y
mRNA O
expression O
in O
nasal O
mucosa O
were O
also O
significantly O
increased O
after O
TDI B-CHEMICAL
provocation. O
Pretreatment O
with O
dexamethasone B-CHEMICAL
significantly O
suppressed O
nasal O
allergy-like O
behaviors, O
up-regulation O
of O
histamine B-CHEMICAL
content, O
HDC B-GENE-Y
activity O
and O
HDC B-GENE-Y
mRNA O
induced O
by O
TDI B-CHEMICAL
in O
TDI-sensitized B-CHEMICAL
rats. O

CONCLUSIONS: O
These O
findings O
indicate O
that O
increased O
synthesis O
of O
histamine B-CHEMICAL
through O
up-regulation O
of O
HDC B-GENE-Y
gene O
expression O
and O
HDC B-GENE-Y
activity O
in O
nasal O
mucosa O
plays O
an O
important O
role O
in O
the O
development O
of O
nasal O
hypersensitivity. O
Repression O
of O
HDC B-GENE-Y
gene O
expression O
and O
HDC B-GENE-Y
activity O
by O
dexamethasone B-CHEMICAL
may O
underlie O
its O
therapeutic O
effect O
in O
the O
treatment O
of O
allergy. O
The O
Effects O
of O
Carbohydrate, B-CHEMICAL
Unsaturated O
Fat, O
and O
Protein O
Intake O
on O
Measures O
of O
Insulin B-GENE-Y
Sensitivity: O
Results O
from O
the O
OmniHeart O
Trial. O

OBJECTIVE O
Impaired O
insulin B-GENE-Y
sensitivity O
increases O
the O
risk O
of O
cardiovascular O
disease. O
Although O
calorie O
restriction O
and O
weight O
loss O
increase O
insulin B-GENE-Y
sensitivity, O
the O
effects O
of O
modifying O
macronutrient O
composition O
on O
insulin B-GENE-Y
sensitivity O
are O
uncertain. O
The O
purpose O
of O
this O
study O
is O
to O
determine O
the O
effects O
on O
insulin B-GENE-Y
sensitivity O
of O
a O
carbohydrate-rich B-CHEMICAL
diet O
(CARB; B-CHEMICAL
similar O
to O
the O
Dietary O
Approaches O
to O
Stop O
Hypertension O
[DASH] O
diet), O
a O
protein-rich O
diet O
(PROT; O
protein O
predominantly O
from O
plant O
sources), O
and O
an O
unsaturated O
fat-rich O
diet O

(UNSAT; O
predominantly O
monounsaturated). O
RESEARCH O
DESIGN O
AND O
METHODS O
This O
study O
was O
a O
randomized, O
controlled, O
three-period, O
crossover O
feeding O
study. O
The O
study O
participants O
were O
164 O
individuals O
with O
prehypertension O
or O
stage O
1 O
hypertension O
without O
diabetes. O
Diets O
were O
administered O
for O
6 O
weeks O
each, O
with O
a O
washout O
period O
between O
diets O
of O
2-4 O
weeks. O
Weight O
was O
held O
constant O
throughout O
the O
study. O
For O
our O
primary O
outcome, O
we O
calculated O
the O
quantitative O
insulin B-GENE-Y
sensitivity O
check O
index O
(QUICKI) O
using O
the O
end-of-period O

fasting O
serum O
glucose B-CHEMICAL
and O
insulin. B-GENE-Y
QUICKI O
is O
a O
validated O
measure O
of O
insulin B-GENE-Y
sensitivity. O
The O
primary O
analyses O
used O
generalized O
estimating O
equations. O
RESULTS O
At O
baseline, O
mean O
(SD) O
BMI O
was O
30.2 O
(6.1) O
kg/m(2), O
and O
mean O
(SD) O
QUICKI O
was O
0.35 O
(0.04). O
The O
UNSAT O
diet O
increased O
QUICKI O
by O
0.005, O
more O
than O
the O
CARB B-CHEMICAL
diet O
(P O
= O
0.04). O
PROT O
had O
no O
significant O
effect O
compared O
with O
CARB. B-CHEMICAL

CONCLUSIONS O
A O
diet O
that O
partially O
replaces O
carbohydrate B-CHEMICAL
with O
unsaturated O
fat O
may O
improve O
insulin B-GENE-Y
sensitivity O
in O
a O
population O
at O
risk O
for O
cardiovascular O
disease. O
Given O
the O
well-recognized O
challenges O
of O
sustaining O
weight O
loss, O
our O
results O
suggest O
an O
alternative O
approach O
for O
improving O
insulin B-GENE-Y
sensitivity. O
Antiobesity O
action O
of O
peripheral O
exenatide O
(exendin-4) O
in O
rodents: O
effects O
on O
food O
intake, O
body O
weight, O
metabolic O
status O
and O
side-effect O
measures. O
BACKGROUND: O
Exenatide O
(exendin-4) O
is O
an O
incretin B-GENE-Y
mimetic O
currently O
marketed O
as O
an O

antidiabetic O
agent O
for O
patients O
with O
type O
2 O
diabetes. O
In O
preclinical O
models, O
a O
reduction O
in O
body O
weight O
has O
also O
been O
shown O
in O
low-fat-fed, O
leptin B-GENE-N
receptor-deficient I-GENE-N
rodents. O
OBJECTIVE: O
To O
more O
closely O
model O
the O
polygenic O
and O
environmental O
state O
of O
human O
obesity, O
we O
characterized O
the O
effect O
of O
exenatide O
on O
food O
intake O
and O
body O
weight O
in O
high-fat-fed, O
normal O
(those O
with O
an O
intact O
leptin B-GENE-N
signaling O
system) O
rodents. O
As O
glucagon-like B-GENE-N
peptide-1 I-GENE-N
receptor I-GENE-N
agonism O
has O
been O
found O
to O
elicit O
behaviors O

associated O
with O
visceral O
illness O
in O
rodents, O
we O
also O
examined O
the O
effect O
of O
peripheral O
exenatide O
on O
kaolin B-CHEMICAL
consumption O
and O
locomotor O
activity. O
METHODS O
AND O
RESULTS: O
High-fat-fed O
C57BL/6 O
mice O
and O
Sprague-Dawley O
rats O
were O
treated O
with O
exenatide O
(3, O
10 O
and O
30 O
microg/kg/day) O
for O
4 O
weeks O
via O
subcutaneously O
implanted O
osmotic O
pumps. O
Food O
intake O
and O
body O
weight O
were O
assessed O
weekly. O
At O
4 O
weeks, O
body O
composition O
and O
plasma O
metabolic O
profiles O
were O
measured. O
Kaolin B-CHEMICAL
consumption O
and O

locomotor O
activity O
were O
measured O
in O
fasted O
Sprague-Dawley O
rats O
following O
a O
single O
intraperitoneal O
injection O
of O
exenatide O
(0.1-10 O
microg/kg). O
Exenatide O
treatment O
in O
mice O
and O
rats O
dose-dependently O
decreased O
food O
intake O
and O
body O
weight; O
significant O
reductions O
in O
body O
weight O
gain O
were O
observed O
throughout O
treatment O
at O
10 O
and O
30 O
microg/kg/day O
(P<0.05). O
Decreased O
body O
weight O
gain O
was O
associated O
with O
a O
significant O
decrease O
in O
fat O
mass O
(P<0.05) O
with O
sparing O
of O
lean O
tissue. O
Plasma O

cholesterol, B-CHEMICAL
triglycerides B-CHEMICAL
and O
insulin B-GENE-N
were O
also O
significantly O
reduced O
(P<0.05). O
Exenatide O
at O
10 O
microg/kg O
significantly O
reduced O
food O
intake O
(P<0.05) O
but O
failed O
to O
induce O
kaolin B-CHEMICAL
intake. O
In O
general, O
locomotor O
activity O
was O
reduced O
at O
doses O
of O
exenatide O
that O
decreased O
food O
intake, O
although O
a O
slightly O
higher O
dose O
was O
required O
to O
produce O
significant O
changes O
in O
activity. O
CONCLUSION: O
Systemic O
exenatide O
reduces O
body O
weight O
gain O
in O
normal, O
high-fat-fed O
rodents, O
a O
model O
that O
parallels O
human O
genetic O
variation O
and O
food O
consumption O
patterns, O
and O

may O
play O
a O
role O
in O
metabolic O
pathways O
mediating O
food O
intake. O
Different O
effects O
of O
clopidogrel B-CHEMICAL
and O
clarithromycin B-CHEMICAL
on O
the O
enantioselective O
pharmacokinetics O
of O
sibutramine B-CHEMICAL
and O
its O
active O
metabolites O
in O
healthy O
subjects. O
In O
this O
study, O
we O
assessed O
the O
effects O
of O
clopidogrel B-CHEMICAL
and O
clarithromycin, B-CHEMICAL
known O
CYP2B6 B-GENE-Y
and O
CYP3A B-GENE-N
inhibitors, O
respectively, O
on O
the O
enantioselective O
disposition O
of O
racemic B-CHEMICAL
sibutramine I-CHEMICAL
in O
conjunction O
with O
CYP2B6 B-GENE-Y
polymorphisms O
in O
humans. O

Sibutramine B-CHEMICAL
showed O
enantioselective O
plasma O
profiles O
with O
consistently O
higher O
concentrations O
of O
R-enantiomers. O
Clopidogrel B-CHEMICAL
and O
clarithromycin B-CHEMICAL
significantly O
increased O
the O
sibutramine B-CHEMICAL
plasma O
concentration, O
but O
their O
effects O
differed O
between O
enantiomers; O
a O
2.2-fold O
versus O
4.1-fold O
increase O
in O
the O
AUC O
in O
S-enantiomer O
and O
1.8-fold O
versus O
2.0-fold O
for O
the O
R-enantiomer, O
respectively. O
The O
AUCs O
of O
S- O
and O
R-desmethyl O
metabolites O
changed O
significantly O
during O
the O
clopidogrel B-CHEMICAL
phase O

(P O
< O
.001 O
and O
P O
< O
.001, O
respectively) O
but O
not O
during O
the O
clarithromycin B-CHEMICAL
phase O
(P O
= O
.099 O
and O
P O
= O
.090, O
respectively). O
Exposure O
to O
sibutramine B-CHEMICAL
was O
higher O
in O
subjects O
with O
the O
CYP2B6*6/*6 B-GENE-Y
genotype, O
but O
no O
statistical O
difference O
was O
observed O
among O
the O
CYP2B6 B-GENE-Y
genotypes. O
These O
results O
suggest O
that O
the O
enantioselective O
disposition O
of O
sibutramine B-CHEMICAL
and O
its O
active O
metabolites O
are O
influenced O
by O
the O
altered O
genetic O
and O
environmental O
factors O
of O
CYP2B6 B-GENE-Y
and O

CYP3A B-GENE-N
activity O
in O
vivo. O
New O
selective O
inhibitors O
of O
MMP-13 B-GENE-Y
for O
inflammatory O
diseases: O
a O
patent O
evaluation O
(W02012151158). O
A O
series O
of O
compounds O
incorporating O
an O
aromatic O
scaffold O
based O
on O
isoxazolines B-CHEMICAL
were O
prepared O
in O
the O
patent O
application O
(WO2012151158). O
The O
new O
compounds O
from O
the O
patent O
are O
defined O
to O
be O
biologically O
active O
metabolites, O
prodrugs, O
isomers, O
stereoisomers, O
solvates, O
hydrates O
and O
pharmaceutically O
acceptable O
salts, O
they O
are O
claimed O
to O
be O
useful O
for O
treating O

immunological O
conditions O
because O
of O
their O
inhibitory O
activities O
on O
matrix B-GENE-N
metalloproteinase I-GENE-N
(MMP-13), B-GENE-Y
although O
no O
specific O
MMP-13 B-GENE-Y
inhibition O
data O
or O
other O
rationale O
to O
explain O
their O
biological O
effects O
is O
provided. O
The O
compounds O
have O
a O
broad O
potential O
utility O
with O
osteoarthritis, O
rheumatoid O
arthritis, O
juvenile O
arthritis, O
psoriatic O
arthritis, O
degenerative O
joint O
disease O
or O
systemic O
lupus O
erythematosus O
among O
the O
likely O
preferred O
indications. O
LIVER B-GENE-N
X I-GENE-N
RECEPTORS, I-GENE-N
NERVOUS O
SYSTEM O
AND O
LIPID O

METABOLISM. O
Lipids O
in O
the O
nervous O
system O
are O
represented O
by O
cholesterol B-CHEMICAL
and O
phospholipids O
as O
constituents O
of O
cell O
membranes O
and, O
in O
particular, O
of O
myelin. O
Therefore, O
lipids O
are O
finely O
regulated O
to O
guarantee O
physiological O
functions. O
In O
the O
central O
nervous O
system, O
cholesterol B-CHEMICAL
is O
locally O
synthesized O
due O
to O
the O
presence O
of O
the O
blood O
brain O
barrier. O
In O
the O
peripheral O
nervous O
system O
cholesterol B-CHEMICAL
is O
either O
uptaken O
by O
lipoproteins O
and/or O
produced O
by O
de O
novo O
biosynthesis. O
Defects O
in O
lipid O
homeostasis O
in O
these O
tissues O
lead O
to O
structural O
and O

functional O
changes O
that O
often O
result O
in O
different O
pathological O
conditions O
depending O
on O
the O
affected O
pathways O
(i.e. O
cholesterol B-CHEMICAL
biosynthesis, O
cholesterol B-CHEMICAL
efflux, O
fatty B-CHEMICAL
acid I-CHEMICAL
biosynthesis O
etc.). O
Alterations O
in O
cholesterol B-CHEMICAL
metabolism O
in O
the O
central O
nervous O
system O
are O
linked O
to O
several O
disorders O
such O
as O
Alzheimer's O
disease, O
Huntington O
disease, O
Parkinson O
disease, O
Multiple O
Sclerosis, O
Smith-Lemli-Opitz O
syndrome, O
Niemann-Pick O
type O
C O
disease, O
and O
glioblastoma. O
In O
the O
peripheral O
nervous O
system O
changes O
in O
lipid O
metabolism O
are O
associated O
with O
the O
development O
of O
peripheral O

neuropathy O
that O
may O
be O
caused O
by O
metabolic O
disorders, O
injuries, O
therapeutics O
and O
autoimmune O
diseases. O
Transcription O
factors, O
such O
as O
the O
Liver B-GENE-N
X I-GENE-N
receptors I-GENE-N
(LXRs), B-GENE-N
regulate O
both O
cholesterol B-CHEMICAL
and O
fatty B-CHEMICAL
acid I-CHEMICAL
metabolism O
in O
several O
tissues O
including O
the O
nervous O
system. O
In O
the O
last O
few O
years O
several O
studies O
elucidated O
the O
biology O
of O
LXRs B-GENE-N
in O
nervous O
system O
due O
to O
the O
availability O
of O
knock-out O
mice O
and O
the O
development O
of O
synthetic O
ligands. O
Here, O
we O
review O
a O
survey O
of O
the O
literature O
focused O
on O
central O
and O
peripheral O
nervous O
system O
and O
in O
physiological O
and O
pathological O
settings O
with O
particular O
attention O
on O
the O
roles O
played O

by O
LXRs B-GENE-N
in O
both O
districts. O
Cysteinyl B-CHEMICAL
leukotriene-dependent I-CHEMICAL
interleukin-5 B-GENE-Y
production O
leading O
to O
eosinophilia O
during O
late O
asthmatic O
response O
in O
guinea-pigs. O
BACKGROUND: O
Allergic O
airway O
eosinophilia O
is O
suppressed O
by O
cysteinyl B-GENE-Y
leukotriene I-GENE-Y
(CysLT) I-GENE-Y
receptor I-GENE-Y
(CysLT1 B-GENE-Y
receptor) O
antagonists O
in O
several O
species O
including O
humans O
and O
guinea-pigs, O
suggesting O
that O
CysLTs B-CHEMICAL
are O
directly O
or O
indirectly O
involved O
in O
induction O
of O
the O
response. O
OBJECTIVE: O

We O
examined O
the O
effect O
of O
CysLT B-CHEMICAL
antagonists O
(pranlukast B-CHEMICAL
and O
MCI-826) B-CHEMICAL
on O
antigen O
inhalation-induced O
eosinophilia O
in O
peripheral O
blood O
and O
lung, O
and O
on O
IL-5 B-GENE-Y
activity O
in O
serum O
during O
late O
increase O
of O
airway O
resistance O
(late O
asthmatic O
response, O
LAR) O
in O
sensitized O
guinea-pigs. O
METHODS: O
Guinea-pigs O
inhaled O
ovalbumin B-GENE-Y
(OVA) B-GENE-Y
+ O
Al(OH)3 B-CHEMICAL
and O
OVA B-GENE-Y
mists O
alternately O
for O
sensitization O
and O
challenge, O
respectively, O
once O
every O
2 O
weeks. O
At O
the O
fifth O
challenge, O

the O
effects O
of O
CysLT B-CHEMICAL
antagonists O
and O
an O
anti-IL-5 B-GENE-Y
antibody O
(TRFK-5) O
on O
the O
occurrence O
of O
LAR, O
and O
blood O
and O
lung O
eosinophilia, O
which O
appeared O
at O
5 O
h O
after O
challenge, O
were O
examined. O
The O
time-course O
of O
IL-5 B-GENE-Y
activity O
in O
the O
serum O
after O
the O
challenge O
was O
evaluated O
by O
measuring O
in O
vitro O
'eosinophil O
survival O
prolongation O
activity'. O
The O
influence O
of O
CysLT B-CHEMICAL
antagonists O
on O
IL-5 B-GENE-Y
activity O
was O
assessed. O
RESULTS: O
CysLT B-CHEMICAL
antagonists O
and O
TRFK-5 O
completely O
abolished O
blood O

and O
lung O
eosinophilia. O
LAR O
was O
suppressed O
by O
both O
MCI-826 B-CHEMICAL
and O
TRFK-5 O
by O
40-50%. O
Sera O
obtained O
from O
sensitized, O
challenged O
animals O
3 O
h O
and O
4 O
h O
after O
challenge O
induced O
an O
obvious O
prolongation O
of O
eosinophil O
survival. O
The O
activity O
of O
the O
sera O
was O
completely O
neutralized O
by O
prior O
exposure O
to O
TRFK-5, O
suggesting O
that O
it O
reflected O
IL-5 B-GENE-Y
activity. O
Increased O
IL-5 B-GENE-Y
activity O
in O
the O
serum O
was O
inhibited O
by O
both O
pranlukast B-CHEMICAL
and O
MCI-826 B-CHEMICAL
by O
over O
90%. O

CONCLUSIONS: O
CysLTs B-CHEMICAL
produced O
after O
antigen O
provocation O
sequentially O
induced O
IL-5 B-GENE-Y
production O
from O
some O
immune O
component O
cells O
via O
CysLT1 B-GENE-Y
receptor O
activation. O
Thus, O
it O
is O
likely O
that O
CysLTs B-CHEMICAL
indirectly O
cause O
antigen-induced O
eosinophilia O
through O
IL-5 B-GENE-Y
production. O
Theoretical O
study O
of O
the O
decomposition O
of O
ethyl B-CHEMICAL
and I-CHEMICAL
ethyl I-CHEMICAL
3-phenyl I-CHEMICAL
glycidate. I-CHEMICAL
The O
mechanism O
of O
the O
decomposition O
of O
ethyl B-CHEMICAL
and I-CHEMICAL
ethyl I-CHEMICAL
3-phenyl I-CHEMICAL
glycidate I-CHEMICAL
in O
gas O
phase O
was O
studied O
by O
density O
functional O
theory O
(DFT) O
and O
MP2 O
methods. O

A O
proposed O
mechanism O
for O
the O
reaction O
indicates O
that O
the O
ethyl B-CHEMICAL
side O
of O
the O
ester O
is O
eliminated O
as O
ethylene B-CHEMICAL
through O
a O
concerted O
six-membered O
cyclic O
transition O
state, O
and O
the O
unstable O
intermediate O
glycidic B-CHEMICAL
acid I-CHEMICAL
decarboxylates O
rapidly O
to O
give O
the O
corresponding O
aldehyde. B-CHEMICAL
Two O
possible O
pathways O
for O
glycidic B-CHEMICAL
acid I-CHEMICAL
decarboxylation O
were O
studied: O
one O
via O
a O
five-membered O
cyclic O
transition O
state, O
and O
the O
other O
via O
a O
four-membered O
cyclic O
transition O
state. O
The O
results O
of O
the O
calculations O
indicate O
that O
the O
decarboxylation O
reaction O
occurs O
via O
a O
mechanism O
with O
five-membered O

cyclic O
transition O
state. O
Meclofenamic B-CHEMICAL
acid I-CHEMICAL
and O
diclofenac, B-CHEMICAL
novel O
templates O
of O
KCNQ2/Q3 B-GENE-N
potassium B-GENE-N
channel I-GENE-N
openers, O
depress O
cortical O
neuron O
activity O
and O
exhibit O
anticonvulsant O
properties. O
The O
voltage-dependent O
M-type O
potassium B-CHEMICAL
current O
(M-current) O
plays O
a O
major O
role O
in O
controlling O
brain O
excitability O
by O
stabilizing O
the O
membrane O
potential O
and O
acting O
as O
a O
brake O
for O
neuronal O
firing. O
The O
KCNQ2/Q3 B-GENE-N
heteromeric O
channel O
complex O
was O
identified O
as O
the O
molecular O
correlate O
of O
the O
M-current. O
Furthermore, O
the O

KCNQ2 B-GENE-Y
and O
KCNQ3 B-GENE-Y
channel I-GENE-Y
alpha I-GENE-Y
subunits I-GENE-Y
are O
mutated O
in O
families O
with O
benign O
familial O
neonatal O
convulsions, O
a O
neonatal O
form O
of O
epilepsy. O
Enhancement O
of O
KCNQ2/Q3 B-GENE-N
potassium B-CHEMICAL
currents O
may O
provide O
an O
important O
target O
for O
antiepileptic O
drug O
development. O
Here, O
we O
show O
that O
meclofenamic B-CHEMICAL
acid I-CHEMICAL
(meclofenamate) B-CHEMICAL
and O
diclofenac, B-CHEMICAL
two O
related O
molecules O
previously O
used O
as O
anti-inflammatory O
drugs, O
act O
as O
novel O
KCNQ2/Q3 B-GENE-N
channel O
openers. O
Extracellular O
application O
of O

meclofenamate B-CHEMICAL
(EC(50) O
= O
25 O
microM) O
and O
diclofenac B-CHEMICAL
(EC(50) O
= O
2.6 O
microM) O
resulted O
in O
the O
activation O
of O
KCNQ2/Q3 B-GENE-N
K(+) O
currents, O
heterologously O
expressed O
in O
Chinese O
hamster O
ovary O
cells. O
Both O
openers O
activated O
KCNQ2/Q3 B-GENE-N
channels O
by O
causing O
a O
hyperpolarizing O
shift O
of O
the O
voltage O
activation O
curve O
(-23 O
and O
-15 O
mV, O
respectively) O
and O
by O
markedly O
slowing O
the O
deactivation O
kinetics. O
The O
effects O
of O
the O
drugs O
were O
stronger O
on O

KCNQ2 B-GENE-Y
than O
on O
KCNQ3 B-GENE-Y
channel I-GENE-Y
alpha I-GENE-Y
subunits. I-GENE-Y
In O
contrast, O
they O
did O
not O
enhance O
KCNQ1 B-GENE-Y
K(+) O
currents. O
Both O
openers O
increased O
KCNQ2/Q3 B-GENE-N
current O
amplitude O
at O
physiologically O
relevant O
potentials O
and O
led O
to O
hyperpolarization O
of O
the O
resting O
membrane O
potential. O
In O
cultured O
cortical O
neurons, O
meclofenamate B-CHEMICAL
and O
diclofenac B-CHEMICAL
enhanced O
the O
M-current O
and O
reduced O
evoked O
and O
spontaneous O
action O
potentials, O
whereas O
in O
vivo O
diclofenac B-CHEMICAL
exhibited O
an O
anticonvulsant O
activity O
(ED(50) O
= O
43 O

mg/kg). O
These O
compounds O
potentially O
constitute O
novel O
drug O
templates O
for O
the O
treatment O
of O
neuronal O
hyperexcitability O
including O
epilepsy, O
migraine, O
or O
neuropathic O
pain. O
Atomoxetine B-CHEMICAL
increases O
extracellular O
levels O
of O
norepinephrine B-CHEMICAL
and O
dopamine B-CHEMICAL
in O
prefrontal O
cortex O
of O
rat: O
a O
potential O
mechanism O
for O
efficacy O
in O
attention O
deficit/hyperactivity O
disorder. O
The O
selective O
norepinephrine B-GENE-Y
(NE) I-GENE-Y
transporter I-GENE-Y
inhibitor O
atomoxetine B-CHEMICAL
(formerly O
called O
tomoxetine B-CHEMICAL
or O
LY139603) B-CHEMICAL
has O
been O
shown O
to O
alleviate O
symptoms O
in O
Attention O

Deficit/Hyperactivity O
Disorder O
(ADHD). O
We O
investigated O
the O
mechanism O
of O
action O
of O
atomoxetine B-CHEMICAL
in O
ADHD O
by O
evaluating O
the O
interaction O
of O
atomoxetine B-CHEMICAL
with O
monoamine B-GENE-N
transporters, I-GENE-N
the O
effects O
on O
extracellular O
levels O
of O
monoamines, B-CHEMICAL
and O
the O
expression O
of O
the O
neuronal O
activity O
marker O
Fos B-GENE-Y
in O
brain O
regions. O
Atomoxetine B-CHEMICAL
inhibited O
binding O
of O
radioligands O
to O
clonal O
cell O
lines O
transfected O
with O
human B-GENE-N
NE, I-GENE-N
serotonin I-GENE-N
(5-HT) I-GENE-N
and I-GENE-N
dopamine I-GENE-N
(DA) I-GENE-N
transporters I-GENE-N
with O
dissociation O
constants O

(K(i)) O
values O
of O
5, O
77 O
and O
1451 O
nM, O
respectively, O
demonstrating O
selectivity O
for O
NE B-GENE-Y
transporters. I-GENE-Y
In O
microdialysis O
studies, O
atomoxetine B-CHEMICAL
increased O
extracellular O
(EX) O
levels O
of O
NE B-CHEMICAL
in O
prefrontal O
cortex O
(PFC) O
3-fold, O
but O
did O
not O
alter O
5-HT(EX) O
levels. O
Atomoxetine B-CHEMICAL
also O
increased O
DA(EX) O
concentrations O
in O
PFC O
3-fold, O
but O
did O
not O
alter O
DA(EX) O
in O
striatum O
or O
nucleus O
accumbens. O
In O
contrast, O
the O

psychostimulant O
methylphenidate, B-CHEMICAL
which O
is O
used O
in O
ADHD O
therapy, O
increased O
NE(EX) O
and O
DA(EX) O
equally O
in O
PFC, O
but O
also O
increased O
DA(EX) O
in O
the O
striatum O
and O
nucleus O
accumbens O
to O
the O
same O
level. O
The O
expression O
of O
the O
neuronal O
activity O
marker O
Fos B-GENE-Y
was O
increased O
3.7-fold O
in O
PFC O
by O
atomoxetine B-CHEMICAL
administration, O
but O
was O
not O
increased O
in O
the O
striatum O
or O
nucleus O
accumbens, O
consistent O
with O
the O
regional O
distribution O
of O
increased O
DA(EX). O
We O

hypothesize O
that O
the O
atomoxetine-induced B-CHEMICAL
increase O
of O
catecholamines B-CHEMICAL
in O
PFC, O
a O
region O
involved O
in O
attention O
and O
memory, O
mediates O
the O
therapeutic O
effects O
of O
atomoxetine B-CHEMICAL
in O
ADHD. O
In O
contrast O
to O
methylphenidate, B-CHEMICAL
atomoxetine B-CHEMICAL
did O
not O
increase O
DA B-CHEMICAL
in O
striatum O
or O
nucleus O
accumbens, O
suggesting O
it O
would O
not O
have O
motoric O
or O
drug O
abuse O
liabilities. O
Locally O
administered O
prostaglandin B-CHEMICAL
E2 I-CHEMICAL
prevents O
aeroallergen-induced O
airway O
sensitization O
in O
mice O
through O
immunomodulatory O
mechanisms. O

Prostaglandin B-CHEMICAL
E2 I-CHEMICAL
attenuates O
airway O
pathology O
in O
asthmatic O
patients O
and O
exerts O
a O
protective O
effect O
in O
antigen-sensitized O
mice O
when O
administered O
systemically. O
We O
aimed O
to O
establish O
the O
consequences O
of O
intranasal O
PGE2 B-CHEMICAL
administration O
on O
airway O
reactivity O
to O
aeroallergens O
in O
mice O
and O
reveal O
the O
underlying O
immunoinflammatory O
mechanisms. O
PGE2 B-CHEMICAL
was O
administered O
either O
daily O
during O
a O
10-day O
exposure O
to O
house O
dust O
mite O
(HDM) O
extracts O
or O
for O
limited O
intervals. O
Airway O
hyperreactivity O
was O
measured O
by O
whole-body O
and O

invasive O
plethysmography. O
The O
phenotypes O
of O
lung O
immune O
cells O
and O
cytokine B-GENE-N
production O
were O
analysed O
by O
flow O
cytometry O
and O
ELISA, O
respectively. O
Airway O
hyperreactivity O
was O
sustainably O
reduced O
only O
when O
PGE2 B-CHEMICAL
administration O
was O
restricted O
to O
the O
initial O
5 O
days O
of O
exposure O
to O
HDM. O
Lung O
inflammation, O
IL-4 B-GENE-Y
production, O
and O
airway O
mast O
cell O
activity O
were O
also O
prevented O
under O
this O
early O
short-term O
treatment O
with O
PGE2. B-CHEMICAL
Interestingly, O
a O
Th2 O
response O
was O
already O
committed O
on O
day O
5 O
of O
exposure O
to O
HDM. O
This O
was O
paralleled O
by O

GM-CSF B-GENE-Y
and O
osteopontin B-GENE-Y
upregulation O
and O
a O
decreased O
number O
of O
plasmacytoid O
dendritic O
and O
T O
regulatory O
cells, O
as O
well O
as O
a O
trend O
towards O
reduced O
IL-10 B-GENE-Y
expression. O
Local O
PGE2 B-CHEMICAL
administration O
prevented O
the O
increase O
of O
airway O
IL-13 B-GENE-Y
and O
osteopontin B-GENE-Y
and O
kept O
lung O
plasmacytoid O
dendritic O
cell O
counts O
close O
to O
baseline. O
GM-CSF B-GENE-Y
and O
Tregs O
were O
unaffected O
by O
the O
treatment. O
These O
findings O
suggest O
that O
the O
protection O
provided O
by O
PGE2 B-CHEMICAL
is O
a O
result O
of O
the O
modulation O
of O
early O
lung O
immunomodulatory O

mechanisms, O
and O
possibly O
a O
shift O
in O
the O
balance O
of O
dendritic O
cells O
towards O
a O
tolerogenic O
profile. O
In O
vitro O
investigation O
of O
efficacy O
of O
new O
reactivators O
on O
OPC O
inhibited O
rat B-GENE-Y
brain I-GENE-Y
acetylcholinesterase. I-GENE-Y
Organophosphorus B-CHEMICAL
compounds O
(OPC) O
were O
developed O
as O
warfare O
nerve O
agents. O
They O
are O
also O
widely O
used O
as O
pesticides. O
The O
drug O
therapy O
of O
intoxication O
with O
OPC O
includes O
mainly O
combination O
of O
cholinesterase B-GENE-Y
(ChE) B-GENE-Y
reactivators O
and O
cholinolytics. O
There O
is O
no O
single O
ChE B-GENE-Y
reactivator O
having O
an O
ability O
to O
reactivate O
sufficiently O
the O
inhibited O

enzyme O
due O
to O
the O
high O
variability O
of O
chemical O
structure O
of O
the O
inhibitors. O
The O
difficulties O
in O
reactivation O
of O
ChE B-GENE-Y
activity O
and O
slight O
antidote O
effect O
regarding O
intoxication O
with O
some O
OPC O
are O
some O
of O
the O
reasons O
for O
continuous O
efforts O
to O
obtain O
new O
reactivators O
of O
ChE. B-GENE-Y
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
of O
some O
ChE B-GENE-Y
reactivators O
against O
OPC O
intoxication O
(tabun, B-CHEMICAL
paraoxon B-CHEMICAL
and O
dichlorvos) B-CHEMICAL
in O
in O
vitro O
experiments O
and O
to O
compare O
their O
activity O
to O
that O
known O
for O
some O
currently O
used O
oximes B-CHEMICAL
(obidoxime, B-CHEMICAL
HI-6, B-CHEMICAL

2-PAM). B-CHEMICAL
Experiments O
were O
carried O
out O
using O
rat B-GENE-Y
brain I-GENE-Y
acetylcholinesterase I-GENE-Y
(AChE). B-GENE-Y
Reactivators O
showed O
different O
activity O
in O
the O
reactivation O
of O
rat B-GENE-Y
brain I-GENE-Y
AChE I-GENE-Y
after O
dichlorvos, B-CHEMICAL
paraoxon B-CHEMICAL
and O
tabun B-CHEMICAL
inhibition. O
AChE B-GENE-Y
was O
easier O
reactivated O
after O
paraoxon B-CHEMICAL
treatment. O
The O
best O
effect O
showed O
BT-07-4M, B-CHEMICAL
obidoxime, B-CHEMICAL
TMB-4 B-CHEMICAL
and O
BT-08 B-CHEMICAL
from O
the O
group O
of O
symmetric O
oximes, B-CHEMICAL
and O
Toxidin, B-CHEMICAL
BT-05 B-CHEMICAL
and O
BT-03 B-CHEMICAL
from O
asymmetric O
compounds. O
The O

reactivation O
of O
brain O
AChE B-GENE-Y
inhibited O
with O
tabun O
demonstrated O
better O
activity O
of O
new O
compound O
BT-07-4M, B-CHEMICAL
TMB-4 B-CHEMICAL
and O
obidoxime B-CHEMICAL
from O
symmetric O
oximes, B-CHEMICAL
and O
BT-05 B-CHEMICAL
and O
BT-03 B-CHEMICAL
possessing O
asymmetric O
structure. O
All O
compounds O
showed O
low O
activity O
toward O
inhibition O
of O
AChE B-GENE-Y
caused O
by O
dichlorvos. B-CHEMICAL
Comparison O
of O
two O
main O
structure O
types O
(symmetric/asymmetric) O
showed O
that O
the O
symmetric O
compounds O
reactivated O
better O
AChE, B-GENE-Y
inhibited O
with O
this O
OPC, O
than O
asymmetric O
ones. O
State-dependent O
mibefradil B-CHEMICAL
block O

of O
Na+ B-GENE-N
channels. I-GENE-N
Mibefradil B-CHEMICAL
is O
a O
T-type B-GENE-N
Ca2+ I-GENE-N
channel I-GENE-N
antagonist O
with O
reported O
cross-reactivity O
with O
other O
classes O
of O
ion O
channels, O
including O
K+, B-GENE-N
Cl-, I-GENE-N
and I-GENE-N
Na+ I-GENE-N
channels. I-GENE-N
Using O
whole-cell O
voltage O
clamp, O
we O
examined O
mibefradil B-CHEMICAL
block O
of O
four O
Na+ B-GENE-N
channel I-GENE-N
isoforms O
expressed O
in O
human O
embryonic O
kidney O
cells: O
Nav1.5 B-GENE-Y
(cardiac), O
Nav1.4 B-GENE-Y
(skeletal O
muscle), O
Nav1.2 B-GENE-Y
(brain), O
and O
Nav1.7 B-GENE-Y
(peripheral O
nerve). O
Mibefradil B-CHEMICAL
blocked O

Nav1.5 B-GENE-Y
in O
a O
use/frequency-dependent O
manner, O
indicating O
preferential O
binding O
to O
states O
visited O
during O
depolarization. O
Mibefradil B-CHEMICAL
blocked O
currents O
of O
all O
Na+ B-GENE-N
channel I-GENE-N
isoforms O
with O
similar O
affinity O
and O
a O
dependence O
on O
holding O
potential, O
and O
drug O
off-rate O
was O
slowed O
at O
depolarized O
potentials O
(k(off) O
was O
0.024/s O
at O
-130 O
mV O
and O
0.007/s O
at O
-100 O
mV O
for O
Nav1.5). B-GENE-Y
We O
further O
probed O
the O
interaction O
of O
mibefradil B-CHEMICAL
with O
inactivated O
Nav1.5 B-GENE-Y
channels. O
Neither O
the O

degree O
nor O
the O
time O
course O
of O
block O
was O
dependent O
on O
the O
stimulus O
duration, O
which O
dramatically O
changed O
the O
residency O
time O
of O
channels O
in O
the O
fast-inactivated O
state. O
In O
addition, O
inhibiting O
the O
binding O
of O
the O
fast O
inactivation O
lid O
(Nav1.5 B-GENE-Y
ICM O
+ O
MTSET) O
did O
not O
alter O
mibefradil B-CHEMICAL
block, O
confirming O
that O
the O
drug O
does O
not O
preferentially O
interact O
with O
the O
fast-inactivated O
state. O
We O
also O
tested O
whether O
mibefradil B-CHEMICAL
interacted O
with O
slow-inactivated O
state(s). O
When O
selectively O
applied O
to O
channels O
after O
inducing O
slow O
inactivation O
with O
a O
60-s O
pulse O
to O
-10 O

mV, O
mibefradil B-CHEMICAL
(1 O
microM) O
produced O
45% O
fractional O
block O
in O
Nav1.5 B-GENE-Y
and O
greater O
block O
(88%) O
in O
an O
isoform O
(Nav1.4) B-GENE-Y
that O
slow-inactivates O
more O
completely. O
Our O
results O
suggest O
that O
mibefradil B-CHEMICAL
blocks O
Na+ B-GENE-N
channels I-GENE-N
in O
a O
state-dependent O
manner O
that O
does O
not O
depend O
on O
fast O
inactivation O
but O
probably O
involves O
interaction O
with O
one O
or O
more O
slow-inactivated O
state(s). O
Enhanced O
heterodimerization O
of O
Bax B-GENE-Y
by O
Bcl-2 B-GENE-Y
mutants O
improves O
irradiated O
cell O
survival. O

B B-GENE-Y
Cell I-GENE-Y
Lymphoma-2 I-GENE-Y
(Bcl-2) B-GENE-Y
protein O
suppresses O
ionizing O
radiation-induced O
apoptosis O
in O
hemato-lymphoid O
system. O
To O
enhance O
the O
survival O
of O
irradiated O
cells, O
we O
have O
compared O
the O
effects O
and O
mechanism O
of O
Bcl-2 B-GENE-Y
and O
its O
functional O
variants, O
D34A B-GENE-N
(caspase-3 B-GENE-Y
resistant) O
and O
S70E B-GENE-N
(mimics O
phosphorylation O
on O
S70). O
Bcl-2 B-GENE-Y
and O
its O
mutants O
were O
transfected O
into O
hematopoietic O
cell O
line O
and O
assessed O
for O
cell O
survival, O
clonogenicity O
and O
cell O
cycle O

perturbations O
upon O
exposure O
to O
ionizing O
radiation. O
The O
electrostatic O
potential O
of O
BH3 B-GENE-N
cleft I-GENE-N
of O
Bcl-2/mutants B-GENE-Y
and O
their O
heterodimerization O
with O
Bcl-2 B-GENE-Y
associated I-GENE-Y
X I-GENE-Y
protein I-GENE-Y
(Bax) B-GENE-Y
were O
computationally O
evaluated. O
Correspondingly, O
these O
results O
were O
verified O
by O
co-immunoprecipitation O
and O
western O
blotting. O
The O
mutants O
afford O
higher O
radioprotective O
effect O
than O
Bcl-2 B-GENE-Y
in O
apoptotic O
and O
clonogenic O
assays O
at O
D(0) O
(radiation O
dose O
at O
which O
37 O
% O
cell O
survival O
was O

observed). O
The O
computational O
and O
functional O
analysis O
indicates O
that O
mutants O
have O
higher O
propensity O
to O
neutralize O
Bax B-GENE-Y
protein O
by O
heterodimerization O
and O
have O
increased O
caspase-9 B-GENE-Y
suppression O
capability, O
which O
is O
responsible O
for O
enhanced O
survival. O
This O
study O
implies O
potential O
of O
Bcl-2 B-GENE-Y
mutants O
or O
their O
chemical/peptide O
mimics O
to O
elicit O
radioprotective O
effect O
in O
cells O
exposed O
to O
radiation. O
[Treatment O
of O
androgen-independent B-CHEMICAL
hormone O
refractory O
prostate O
cancer O
using O
docetaxel]. B-CHEMICAL
Although O
prostate O
cancer O
patients O
with O
metastatic O
lesion O
initially O
respond O
to O
androgen B-CHEMICAL
ablation O
therapy, O
almost O
patients O

develop O
to O
hormone-refractory O
states. O
The O
optimal O
treatment O
for O
men O
with O
hormone O
refractory O
prostate O
cancer O
(HRPC) O
has O
not O
been O
established. O
Docetaxel B-CHEMICAL
is O
a O
semisynthetic O
taxane B-CHEMICAL
that O
inhibit O
tumor O
growth O
by O
induction O
of O
microtubule O
stabilization O
and O
promotion O
of O
bcl-2 B-GENE-Y
inactivation, O
which O
induce O
apoptosis. O
Docetaxel B-CHEMICAL
as O
single O
agent O
has O
significant O
anti-tumor O
effect O
in O
HRPC O
patients. O
Docetaxel B-CHEMICAL
combined O
with O
estramustine B-CHEMICAL
or O
other O
antimicrotubular O
agents O
have O
shown O
further O
significant O
cytotoxicity O
in O

HRPC O
patients. O
In O
the O
United O
States, O
Food O
and O
Drug O
Administration O
(FDA) O
approved O
docetaxel, B-CHEMICAL
injection O
in O
combination O
with O
prednisone B-CHEMICAL
for O
the O
treatment O
of O
patients O
with O
advanced O
metastatic O
prostate O
cancer O
in O
2004. O
ABCB1 B-GENE-Y
polymorphisms O
influence O
steady-state O
plasma O
levels O
of O
9-hydroxyrisperidone B-CHEMICAL
and O
risperidone B-CHEMICAL
active O
moiety. O
Risperidone B-CHEMICAL
is O
metabolized O
to O
its O
active O
metabolite, O
9-hydroxyrisperidone, B-CHEMICAL
mainly O
by O
the O
cytochrome B-GENE-N
P450 I-GENE-N
enzymes O
CYP2D6 B-GENE-N
and I-GENE-N

3A4. I-GENE-N
Its O
antipsychotic O
effect O
is O
assumed O
to O
be O
related O
to O
the O
active O
moiety, O
that O
is, O
the O
sum O
of O
risperidone B-CHEMICAL
and O
9-hydroxyrisperidone. B-CHEMICAL
Both O
risperidone B-CHEMICAL
and O
9-hydroxyrisperidone B-CHEMICAL
are O
substrates O
of O
P-glycoprotein B-GENE-N
(P-gp), B-GENE-N
a O
transport O
protein O
involved O
in O
drug O
absorption, O
distribution, O
and O
elimination. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
influence O
of O
polymorphisms O
in O
genes O
encoding O
CYP3A5 B-GENE-Y
and O
P-gp B-GENE-N
(ABCB1) B-GENE-Y

on O
the O
steady-state O
plasma O
levels O
of O
risperidone, B-CHEMICAL
9-hydroxyrisperidone, B-CHEMICAL
and O
the O
active O
moiety, O
taking O
CYP2D6 B-GENE-Y
genotype O
status O
into O
account. O
Forty-six O
white O
patients O
with O
schizophrenia O
treated O
with O
risperidone B-CHEMICAL
(1-10 O
mg/d) O
in O
monotherapy O
for O
4-6 O
weeks O
were O
genotyped, O
and O
their O
plasma O
concentrations O
of O
risperidone B-CHEMICAL
and O
9-hydroxyrisperidone B-CHEMICAL
were O
measured. O
Dose-corrected O
plasma O
concentrations O
(C/D) O
of O
risperidone, B-CHEMICAL

9-hydroxyrisperidone, B-CHEMICAL
and O
active O
moiety O
showed O
up O
to O
68-, O
9-, O
and O
10-fold O
interindividual O
variation, O
respectively. O
Six O
patients O
carried O
1 O
CYP3A5*1 B-GENE-Y
allele O
and O
therefore O
were O
likely O
to O
express O
the O
CYP3A5 B-GENE-Y
enzyme. O
The O
CYP3A5 B-GENE-Y
genotype O
did O
not O
influence O
risperidone, B-CHEMICAL
9-hydroxyrisperidone, B-CHEMICAL
or O
active O
moiety O
C/Ds. O
The O
CYP2D6 B-GENE-Y
genotype O
in O
these O
46 O
patients O
was O
again O
associated O
with O
risperidone B-CHEMICAL

C/D O
(P O
= O
0.001) O
but O
not O
with O
9-hydroxyrisperidone B-CHEMICAL
C/D O
or O
active O
moiety O
C/D, O
as O
previously O
shown O
by O
our O
group O
in O
37 O
of O
these O
patients. O
Patients O
homozygous O
for O
the O
ABCB1 B-GENE-Y
3435T/2677T/1236T O
haplotype O
had O
significantly O
lower O
C/Ds O
of O
9-hydroxyrisperidone B-CHEMICAL
(P O
= O
0.026) O
and O
active O
moiety O
(P O
= O
0.028) O
than O
patients O
carrying O
other O
ABCB1 B-GENE-Y
genotypes. O
In O

conclusion, O
our O
results O
confirmed O
the O
significant O
effect O
of O
CYP2D6 B-GENE-Y
genotype O
on O
the O
steady-state O
plasma O
levels O
of O
risperidone B-CHEMICAL
and O
showed O
that O
ABCB1 B-GENE-Y
polymorphisms O
have O
a O
moderate O
effect O
on O
those O
of O
9-hydroxyrisperidone B-CHEMICAL
and O
the O
active O
moiety. O
Polyamine B-CHEMICAL
metabolism O
in O
a O
member O
of O
the O
phylum O
Microspora O
(Encephalitozoon O
cuniculi): O
effects O
of O
polyamine B-CHEMICAL
analogues. O
The O
uptake, O
biosynthesis O
and O
catabolism O
of O
polyamines B-CHEMICAL
in O
the O
microsporidian O
parasite O

Encephalitozoon O
cuniculi O
are O
detailed O
with O
reference O
to O
the O
effects O
of O
oligoamine B-CHEMICAL
and O
arylamine B-CHEMICAL
analogues O
of O
polyamines. B-CHEMICAL
Enc. O
cuniculi, O
an O
intracellular O
parasite O
of O
mammalian O
cells, O
has O
both O
biosynthetic O
and O
catabolic O
enzymes O
of O
polyamine B-CHEMICAL
metabolism, O
as O
demonstrated O
in O
cell-free O
extracts O
of O
mature O
spores. O
The O
uptake O
of O
polyamines B-CHEMICAL
was O
measured O
in O
immature, O
pre-emergent O
spores O
isolated O
from O
host O
cells O
by O
Percoll O
gradient. O
Spermine O
was O
rapidly O
taken O
up O
and O
metabolized O
to O

spermidine O
and O
an O
unknown, O
possibly O
acetamidopropanal, O
by O
spermidine/spermine B-GENE-N
N(1)-acetyltransferase I-GENE-N
(SSAT) B-GENE-N
and O
polyamine B-GENE-N
oxidase I-GENE-N
(PAO). B-GENE-N
Most O
of O
the O
spermidine B-CHEMICAL
and O
the O
unknown O
product O
were O
found O
in O
the O
cell O
incubation O
medium, O
indicating O
they O
were O
released O
from O
the O
cell. O
bis(Ethyl) B-CHEMICAL
oligoamine I-CHEMICAL
analogues O
of O
polyamines, B-CHEMICAL
such O
as O
SL-11144 B-CHEMICAL
and O
SL-11158, B-CHEMICAL
as O
well O
as O
arylamine B-CHEMICAL
analogues O
[BW-1, B-CHEMICAL

a O
bis(phenylbenzyl) B-CHEMICAL
3-7-3 O
analogue] O
blocked O
uptake O
and O
interconversion O
of O
spermine B-CHEMICAL
at O
micromolar O
levels O
and, O
in O
the O
case O
of O
BW-1, B-CHEMICAL
acted O
as O
substrate O
for O
PAO. B-GENE-N
The O
Enc. B-GENE-N
cuniculi I-GENE-N
PAO I-GENE-N
activity O
differed O
from O
that O
found O
in O
mammalian O
cells O
with O
respect O
to O
pH O
optimum, O
substrate O
specificity O
and O
sensitivity O
to O
known O
PAO B-GENE-N
inhibitors. O
SL-11158 B-CHEMICAL
inhibited O
SSAT B-GENE-N
activity O
with O
a O
mixed O
type O
of O
inhibition O
in O
which O
the O
analogue O
had O
a O
70-fold O
higher O
affinity O
for O
the O
enzyme O
than O
the O
natural O

substrate, O
spermine. B-CHEMICAL
The O
interest O
in O
Enc. O
cuniculi O
polyamine O
metabolism O
and O
the O
biochemical O
effects O
of O
these O
polyamine B-CHEMICAL
analogues O
is O
warranted O
since O
they O
cure O
model O
infections O
of O
Enc. O
cuniculi O
in O
mice O
and O
are O
potential O
candidates O
for O
human O
clinical O
trials. O
Synthesis O
and O
in O
vitro O
evaluation O
of O
N-Aryl B-CHEMICAL
pyrido-quinazolines I-CHEMICAL
derivatives O
as O
potent O
EGFR B-GENE-Y
inhibitors. O
A O
series O
of O
pyrido-quinazolines B-CHEMICAL
have O
been O
synthesised, O
characterised O
and O
tested O
for O
their O
in O
vitro O
EGFR B-GENE-Y
tyrosine B-GENE-N
kinase I-GENE-N
inhibitory O

activity. O
The O
compounds O
were O
prepared O
from O
Alkylideno/arylideno-bis-ureas. B-CHEMICAL
Their O
final O
structure O
of O
the O
compounds O
were O
elucidated O
on O
the O
basis O
of O
spectral O
studies O
(IR., O
1H B-CHEMICAL
NMR, O
FT-IR O
and O
EI-MS). O
The O
cellular O
EGFR B-GENE-Y
internalization O
response O
of O
selected O
compounds O
was O
evaluated O
using O
HeLa O
cells. O
Most O
of O
the O
synthesized O
compounds O
displayed O
potent O
EGFR-TK B-GENE-Y
inhibitory O
activity O
and O
structurally O
halogenated O
derivatives O
had O
a O
pronounced O
effect O
in O
inhibiting O
EGFR B-GENE-Y
internalization. O
© O
2013 O
John O
Wiley O

& O
Sons O
A/S. O
A O
fluorescent O
polymeric O
heparin O
sensor. O
Linear O
copolymers O
have O
been O
developed O
which O
carry O
binding O
sites O
tailored O
for O
sulfated O
sugars. O
All O
binding O
monomers O
are O
based O
on O
the O
methacrylamide B-CHEMICAL
skeleton O
and O
ensure O
statistical O
radical O
copolymerization. O
They O
are O
decorated O
with O
o-aminomethylphenylboronates B-CHEMICAL
for O
covalent O
ester O
formation O
and/or O
alkylammonium B-CHEMICAL
ions O
for O
noncovalent O
Coulomb O
attraction. O
Alcohol B-CHEMICAL
sidechains O
maintain O
a O
high O
water O
solubility; O
a O
dansyl B-CHEMICAL
monomer O
was O
constructed O
as O
a O
fluorescence O

label. O
Statistical O
copolymerization O
of O
comonomer O
mixtures O
with O
optimized O
ratios O
was O
started O
by O
AIBN B-CHEMICAL
(AIBN=2,2'-azoisobutyronitrile) B-CHEMICAL
and O
furnished O
water-soluble O
comonomers O
with O
an O
exceptionally O
high O
affinity O
for O
glucosaminoglucans. O
Heparin O
can O
be O
quantitatively O
detected O
with O
an O
unprecedented O
30 O
nM O
sensitivity, O
and O
a O
neutral O
polymer O
without O
any O
ammonium B-CHEMICAL
cation I-CHEMICAL
is O
still O
able O
to O
bind O
the O
target O
with O
almost O
micromolar O
affinity. O
From O
this O
unexpected O
result, O
we O
propose O
a O
new O
binding O
scheme O
between O
the O
boronate B-CHEMICAL
and O
a O

sulfated O
ethylene B-CHEMICAL
glycol I-CHEMICAL
or O
aminoethanol B-CHEMICAL
unit. O
Although O
the O
mechanism O
of O
heparin O
binding O
involves O
covalent O
boronate B-CHEMICAL
ester I-CHEMICAL
formation, O
it O
can O
be O
completely O
reversed O
by O
protamine O
addition, O
similar O
to O
heparin's O
complex O
formation O
with O
antithrombin B-GENE-Y
III. I-GENE-Y
Impaired O
cliff O
avoidance O
reaction O
in O
dopamine B-GENE-Y
transporter I-GENE-Y
knockout O
mice. O
RATIONALE: O
Impulsivity O
is O
a O
key O
feature O
of O
disorders O
that O
include O
attention-deficit/hyperactivity O
disorder O
(ADHD). O
The O
cliff O
avoidance O
reaction O
(CAR) O
assesses O
maladaptive O

impulsive O
rodent O
behavior. O
Dopamine B-GENE-Y
transporter I-GENE-Y
knockout O
(DAT-KO) B-GENE-Y
mice O
display O
features O
of O
ADHD O
and O
are O
candidates O
in O
which O
to O
test O
other O
impulsive O
phenotypes. O
OBJECTIVES: O
Impulsivity O
of O
DAT-KO B-GENE-Y
mice O
was O
assessed O
in O
the O
CAR O
paradigm. O
For O
comparison, O
attentional O
deficits O
were O
also O
assessed O
in O
prepulse O
inhibition O
(PPI) O
in O
which O
DAT-KO B-GENE-Y
mice O
have O
been O
shown O
to O
exhibit O
impaired O
sensorimotor O
gating. O
RESULTS: O
DAT-KO B-GENE-Y
mice O
exhibited O
a O
profound O

CAR O
impairment O
compared O
to O
wild-type O
(WT) O
mice. O
As O
expected, O
DAT-KO B-GENE-Y
mice O
showed O
PPI O
deficits O
compared O
to O
WT O
mice. O
Furthermore, O
the O
DAT-KO B-GENE-Y
mice O
with O
the O
most O
impaired O
CAR O
exhibited O
the O
most O
severe O
PPI O
deficits. O
Treatment O
with O
methylphenidate B-CHEMICAL
or O
nisoxetine B-CHEMICAL
ameliorated O
CAR O
impairments O
in O
DAT-KO B-GENE-Y
mice. O
CONCLUSION: O
These O
results O
suggest O
that O
DAT-KO B-GENE-Y
mice O
exhibit O
impulsive O
CAR O
behavior O
that O
correlates O
with O
their O
PPI O
deficits. O
Blockade O
of O

monoamine B-GENE-N
transporters, I-GENE-N
especially O
the O
norepinephrine B-GENE-Y
transporter I-GENE-Y
(NET) B-GENE-Y
in O
the O
prefrontal O
cortex O
(PFC), O
may O
contribute O
to O
pharmacological O
improvement O
of O
impulsivity O
in O
these O
mice. O
SPACRCAN, B-GENE-N
a O
novel O
human B-GENE-N
interphotoreceptor I-GENE-N
matrix I-GENE-N
hyaluronan-binding I-GENE-N
proteoglycan I-GENE-N
synthesized O
by O
photoreceptors O
and O
pinealocytes. O
The O
interphotoreceptor O
matrix O
is O
a O
unique O
extracellular O
complex O
occupying O
the O
interface O
between O
photoreceptors O
and O
the O
retinal O
pigment O
epithelium O
in O
the O
fundus O
of O
the O
eye. O
Because O
of O

the O
putative O
supportive O
role O
in O
photoreceptor O
maintenance, O
it O
is O
likely O
that O
constituent O
molecules O
play O
key O
roles O
in O
photoreceptor O
function O
and O
may O
be O
targets O
for O
inherited O
retinal B-CHEMICAL
disease. O
In O
this O
study O
we O
identify O
and O
characterize O
SPACRCAN, B-GENE-N
a O
novel O
chondroitin O
proteoglycan O
in O
this O
matrix. O
SPACRCAN B-GENE-N
was O
cloned O
from O
a O
human O
retinal B-CHEMICAL
cDNA O
library O
and O
the O
gene O
localized O
to O
chromosome O
3q11.2. O
Analysis O
of O
SPACRCAN B-GENE-N
mRNA O
and O
protein O
revealed O
that O
SPACRCAN B-GENE-N
is O
expressed O
exclusively O
by O
photoreceptors O
and O
pinealocytes. O

SPACRCAN B-GENE-N
synthesized O
by O
photoreceptors O
is O
localized O
to O
the O
interphotoreceptor O
matrix O
where O
it O
surrounds O
both O
rods O
and O
cones. O
The O
functional O
protein O
contains O
1160 O
amino B-CHEMICAL
acids I-CHEMICAL
with O
a O
large O
central O
mucin B-GENE-N
domain, I-GENE-N
three O
consensus O
sites O
for O
glycosaminoglycan O
attachment, O
two O
epidermal O
growth O
factor-like O
repeats, O
a O
putative O
hyaluronan-binding B-GENE-N
motif, I-GENE-N
and O
a O
potential O
transmembrane O
domain O
near O
the O
C-terminal. B-CHEMICAL
Lectin B-GENE-N
and O
Western O
blotting O
indicate O
an O
M(r) O
around O
400,000 O
before O
and O
230,000 O
after O
chondroitinase B-GENE-N
ABC I-GENE-N

digestion. O
Removal O
of O
N- B-CHEMICAL
and O
O-linked B-CHEMICAL
oligosaccharides O
reduces O
the O
M(r) O
to O
approximately O
160,000, O
suggesting O
that O
approximately O
60% O
of O
the O
mass O
of O
SPACRCAN B-GENE-N
is O
carbohydrate. B-CHEMICAL
Finally, O
we O
demonstrate O
that O
SPACRCAN B-GENE-N
binds O
hyaluronan B-GENE-N
and O
propose O
that O
associations O
between O
SPACRCAN B-GENE-N
and O
hyaluronan B-GENE-N
may O
be O
involved O
in O
organization O
of O
the O
insoluble O
interphotoreceptor O
matrix, O
particularly O
as O
SPACRCAN B-GENE-N
is O
the O
major O
proteoglycan O
present O
in O
this O
matrix. O
Validation O
of O
an O
in O

vitro O
exposure O
system O
for O
toxicity O
assessment O
of O
air-delivered O
nanomaterials. O
To O
overcome O
the O
limitations O
of O
in O
vitro O
exposure O
of O
submerged O
lung O
cells O
to O
nanoparticles O
(NPs), O
we O
validated O
an O
integrated O
low O
flow O
system O
capable O
of O
generating O
and O
depositing O
airborne O
NPs O
directly O
onto O
cells O
at O
an O
air-liquid O
interface O
(ALI). O
The O
in O
vitro O
exposure O
system O
was O
shown O
to O
provide O
uniform O
and O
controlled O
dosing O
of O
particles O
with O
70.3% O
efficiency O
to O
epithelial O
cells O
grown O
on O
transwells. O
This O
system O
delivered O
a O
continuous O
airborne O
exposure O
of O
NPs O
to O
lung O
cells O
without O
loss O
of O

cell O
viability O
in O
repeated O
4h O
exposure O
periods. O
We O
sequentially O
exposed O
cells O
to O
air-delivered O
copper B-CHEMICAL
(Cu) B-CHEMICAL
NPs O
in O
vitro O
to O
compare O
toxicity O
results O
to O
our O
prior O
in O
vivo O
inhalation O
studies. O
The O
evaluation O
of O
cellular O
dosimetry O
indicated O
that O
a O
large O
amount O
of O
Cu B-CHEMICAL
was O
taken O
up, O
dissolved O
and O
released O
into O
the O
basolateral O
medium O
(62% O
of O
total O
mass). O
Exposure O
to O
Cu B-CHEMICAL
NPs O
decreased O
cell O
viability O
to O
73% O
(p<0.01) O
and O
significantly O
(p<0.05) O
elevated O
levels O
of O
lactate B-GENE-N
dehydrogenase, I-GENE-N

intracellular O
reactive O
oxygen B-CHEMICAL
species O
and O
interleukin-8 B-GENE-Y
that O
mirrored O
our O
findings O
from O
subacute O
in O
vivo O
inhalation O
studies O
in O
mice. O
Our O
results O
show O
that O
this O
exposure O
system O
is O
useful O
for O
screening O
of O
NP O
toxicity O
in O
a O
manner O
that O
represents O
cellular O
responses O
of O
the O
pulmonary O
epithelium O
in O
vivo. O
Thioredoxin-mimetic B-GENE-Y
peptides O
(TXM) O
reverse O
auranofin B-CHEMICAL
induced O
apoptosis O
and O
restore O
insulin B-GENE-N
secretion O
in O
insulinoma O
cells. O
The O
thioredoxin B-GENE-N
reductase/thioredoxin I-GENE-N
system O
(TrxR/Trx1) B-GENE-N
plays O

a O
major O
role O
in O
protecting O
cells O
from O
oxidative O
stress. O
Disruption O
of O
the O
TrxR-Trx1 B-GENE-N
system O
keeps O
Trx1 B-GENE-Y
in O
the O
oxidized O
state O
leading O
to O
cell O
death O
through O
activation O
of O
the O
ASK1-Trx1 B-GENE-Y
apoptotic O
pathway. O
The O
potential O
mechanism O
and O
ability O
of O
tri- O
and O
tetra-oligopeptides O
derived O
from O
the O
canonical O
-CxxC- B-GENE-N
motif I-GENE-N
of O
the O
Trx1-active B-GENE-Y
site O
to O
mimic O
and O
enhance O
Trx1 B-GENE-Y
cellular O
activity O
was O
examined. O
The O
Trx B-GENE-Y
mimetics O
peptides O

(TXM) O
protected O
insulinoma O
INS O
832/13 O
cells O
from O
oxidative O
stress O
induced O
by O
selectively O
inhibiting O
TrxR B-GENE-N
with O
auranofin B-CHEMICAL
(AuF). B-CHEMICAL
TXM O
reversed O
the O
AuF-effects B-CHEMICAL
preventing O
apoptosis, O
and O
increasing O
cell-viability. O
The O
TXM O
peptides O
were O
effective O
in O
inhibiting O
AuF-induced B-CHEMICAL
MAPK, B-GENE-N
JNK B-GENE-N
and O
p38(MAPK) B-GENE-N
phosphorylation, O
in O
correlation O
with O
preventing O
caspase-3 B-GENE-Y
cleavage O
and O
thereby O
PARP-1 B-GENE-Y
dissociation. O
The O
ability O
to O
form O
a O

disulfide-bridge-like B-CHEMICAL
conformation O
was O
estimated O
from O
molecular O
dynamics O
simulations. O
The O
TXM O
peptides O
restored O
insulin B-GENE-N
secretion O
and O
displayed O
Trx1 B-GENE-Y
denitrosylase B-GENE-N
activity. O
Their O
potency O
was O
10-100-fold O
higher O
than O
redox O
reagents O
like O
NAC, B-CHEMICAL
AD4, B-CHEMICAL
or O
ascorbic B-CHEMICAL
acid. I-CHEMICAL
Unable O
to O
reverse O
ERK1/2 B-GENE-N
phosphorylation, O
TXM-CB3 O
(NAc-Cys-Pro-Cys B-CHEMICAL
amide) I-CHEMICAL
appeared O
to O
function O
in O
part, O
through O
inhibiting O
ASK1-Trx B-GENE-Y
dissociation. O
These O

highly O
effective O
anti-apoptotic O
effects O
of O
Trx1 B-GENE-Y
mimetic O
peptides O
exhibited O
in O
INS O
832/13 O
cells O
could O
become O
valuable O
in O
treating O
adverse O
oxidative-stress O
related O
disorders O
such O
as O
diabetes. O
Preferential O
block O
of O
late O
sodium B-CHEMICAL
current O
in O
the O
LQT3 B-GENE-Y
DeltaKPQ I-GENE-Y
mutant I-GENE-Y
by O
the O
class O
I(C) O
antiarrhythmic O
flecainide. B-CHEMICAL
Flecainide B-CHEMICAL
block O
of O
Na(+) B-CHEMICAL
current O
(I(Na)) B-CHEMICAL
was O
investigated O
in O
wild-type O
(WT) O
or O
the O
long B-GENE-Y
QT I-GENE-Y
syndrome I-GENE-Y
3 I-GENE-Y
(LQT3) I-GENE-Y
sodium I-GENE-Y

channel I-GENE-Y
alpha I-GENE-Y
subunit O
mutation O
with O
three O
amino B-CHEMICAL
acids I-CHEMICAL
deleted O
(DeltaKPQ) B-GENE-Y
stably O
transfected O
into O
human O
embryonic O
kidney O
293 O
cells O
using O
whole-cell, O
patch-clamp O
recordings. O
Flecainide B-CHEMICAL
(1-300 O
mM) O
caused O
tonic O
and O
use-dependent O
block O
(UDB) O
of O
I(Na) B-CHEMICAL
in O
a O
concentration-dependent O
manner. O
Compared O
with O
WT, O
DeltaKPQ B-GENE-Y
I(Na) B-CHEMICAL
was O
more O
sensitive O
to O
flecainide, B-CHEMICAL
and O
flecainide B-CHEMICAL
preferentially O
inhibited O
late O
I(Na) B-CHEMICAL
(mean O
current O
between O
20 O
and O
23.5 O
ms O

after O
depolarization) O
compared O
with O
peak O
I(Na). B-CHEMICAL
The O
IC(50) O
value O
of O
peak O
and O
late O
I(Na) B-CHEMICAL
for O
WT O
was O
127 O
+/- O
6 O
and O
44 O
+/- O
2 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ B-GENE-Y
was O
80 O
+/- O
9 O
and O
19 O
+/- O
2 O
microM O
(n O
= O
31) O
respectively. O
UDB O
of O
peak O
I(Na) B-CHEMICAL
was O
greater O
and O
developed O
more O
slowly O
during O
pulse O
trains O
for O
DeltaKPQ B-GENE-Y
than O
for O
WT. O
The O
IC(50) O
value O
for O
UDB O
of O
peak O
I(Na) O
for O
WT O

was O
29 O
+/- O
4 O
microM O
(n O
= O
20) O
and O
for O
DeltaKPQ B-GENE-Y
was O
11 O
+/- O
1 O
microM O
(n O
= O
26). O
For O
DeltaKPQ, B-GENE-Y
UDB O
of O
late O
I(Na) B-CHEMICAL
was O
greater O
than O
for O
peak O
I(Na). B-CHEMICAL
Recovery O
from O
block O
was O
slower O
for O
DeltaKPQ B-GENE-Y
than O
for O
WT. O
We O
conclude O
that O
DeltaKPQ B-GENE-Y
interacts O
differently O
with O
flecainide B-CHEMICAL
than O
with O
WT, O
leading O
to O
increased O
block O
and O
slowed O
recovery, O
especially O
for O
late O
I(Na). B-CHEMICAL
These O
data O
provide O
insights O
into O
mechanisms O
for O
flecainide B-CHEMICAL
block O
and O
provide O
a O
rationale O

at O
the O
cellular O
and O
molecular O
level O
that O
open O
channel O
block O
may O
be O
a O
useful O
pharmacological O
property O
for O
treatment O
of O
LQT3. O
In O
vivo O
and O
in O
vitro O
characterization O
of O
naltrindole-derived B-CHEMICAL
ligands O
at O
the O
κ-opioid B-GENE-Y
receptor. I-GENE-Y
Accumulating O
evidence O
supports O
a O
role O
for O
κ-opioid B-GENE-Y
receptor I-GENE-Y
antagonists O
in O
the O
treatment O
of O
mood O
disorders. O
Standard O
κ-antagonists O
have O
an O
unusual O
pharmacodynamic O
action, O
with O
a O
single O
injection O
blocking O
receptor O
signaling O
for O
several O
weeks. O
Here, O
we O
have O
characterized O
the O
κ-selective O
properties O
of O
two O
ligands, O

5'-(2-aminomethyl) B-CHEMICAL
naltrindole I-CHEMICAL
(5'-AMN) B-CHEMICAL
and O
N-((Naltrindol-5-yl) B-CHEMICAL
methyl) I-CHEMICAL
pentanimidamide I-CHEMICAL
(5'-MABN), B-CHEMICAL
to O
identify O
whether O
modifications O
of O
the O
naltrindole B-CHEMICAL
side O
chain O
produces O
short-acting O
κ-antagonists. O
Opioid B-GENE-N
receptor I-GENE-N
binding O
affinity O
and O
activity O
were O
assessed O
using O
[(3)H]-diprenorphine B-CHEMICAL
binding, O
guanosine-5'-O-(3-[35S]-thio) B-CHEMICAL
triphosphate I-CHEMICAL

([(35)S]-GTPγS) B-CHEMICAL
binding O
and O
isolated O
guinea-pig O
ileum. O
Pharmacodynamic O
profiles O
of O
5'-AMN B-CHEMICAL
and O
5'-MABN B-CHEMICAL
(1-10 O
mg/kg) O
were O
investigated O
using O
the O
tail-withdrawal O
assay O
and O
diuresis. O
Efficacy O
was O
also O
determined O
in O
depression- O
and O
anxiety-related O
behavioral O
paradigms O
in O
CD-1 O
mice. O
Both O
5'-AMN B-CHEMICAL
and O
5'-MABN B-CHEMICAL
had O
high O
affinity O
for O
κ-receptors B-GENE-Y
(K O
(i) O
1.36 O
± O
0.98 O
and O
0.27 O
± O

0.08, O
respectively) O
and O
were O
revealed O
as O
potent O
κ-antagonists O
(pA(2) O
7.43 O
and O
8.18, O
respectively) O
and O
μ-receptor B-GENE-Y
antagonists O
(pA(2) O
7.62 O
and O
7.85, O
respectively) O
in O
the O
ileum. O
Contrary O
to O
our O
hypothesis, O
in O
vivo, O
5'-AMN B-CHEMICAL
and O
5'-MABN B-CHEMICAL
displayed O
long-lasting O
antagonist O
effects O
in O
mice, O
reducing O
the O
antinociceptive O
actions O
of O
U50,488 B-CHEMICAL
(10 O
mg/kg) O
at O
28 O
and O
21 O
days O
post-injection, O
respectively. O
Interestingly, O
while O

5'-AMN B-CHEMICAL
and O
5'-MABN B-CHEMICAL
were O
not O
κ-selective, O
both O
compounds O
did O
show O
significant O
antidepressant- O
and O
anxiolytic-like O
effects O
at O
7-14 O
days O
post-injection O
in O
mice. O
Design O
and O
synthesis O
of O
highly O
selective, O
orally O
active O
Polo-like B-GENE-Y
kinase-2 I-GENE-Y
(Plk-2) B-GENE-Y
inhibitors. O
Polo-like B-GENE-Y
kinase-2 I-GENE-Y
(Plk-2) B-GENE-Y
is O
a O
potential O
therapeutic O
target O
for O
Parkinson's O
disease O
and O
this O
Letter O
describes O
the O
SAR O
of O
a O
series O
of O
dihydropteridinone B-CHEMICAL
based O
Plk-2 B-GENE-Y
inhibitors. O
By O
optimizing O
both O

the O
N-8 O
substituent O
and O
the O
biaryl O
region O
of O
the O
inhibitors O
we O
obtained O
single O
digit O
nanomolar O
compounds O
such O
as O
37 O
with O
excellent O
selectivity O
for O
Plk-2 B-GENE-Y
over O
Plk-1. B-GENE-Y
When O
dosed O
orally O
in O
rats, O
compound O
37 O
demonstrated O
a O
41-45% O
reduction O
of O
pS129-α-synuclein B-GENE-Y
levels O
in O
the O
cerebral O
cortex. O
Effect O
of O
bioactive O
peptide O
of O
Carapax O
Trionycis O
on O
TGF-β1-induced B-GENE-Y
intracellular O
events O
in O
hepatic O
stellate O
cells. O

ETHNOPHARMACOLOGICAL O
RELEVANCE: O
In O
traditional O
Chinese O
medicines O
for O
hepatic O
fibrosis O
therapy, O
Carapax O
Trionycis O
is O
used O
usually O
as O
an O
indispensable O
component O
and O
has O
a O
long O
history O
of O
medical O
use O
in O
China. O
Previous O
studies O
have O
demonstrated O
that O
extracts O
of O
Carapax O
Trionycis O
were O
able O
to O
protect O
liver O
against O
fibrosis O
in O
CCl4 O
animal O
models. O
AIM O
OF O
THE O
STUDY: O
The O
purpose O
of O
this O
study O
is O
to O
verify O
the O
inhibitory O
effect O
and O
the O
underlying O
mechanisms O
of O
Carapax O
Trionycis O
extract O
peptide O

(CTEP) O
on O
activated O
hepatic O
stellate O
cells O
which O
play O
a O
central O
role O
in O
liver O
fibrogenesis. O
MATERIALS O
AND O
METHODS: O
Hepatic O
stellate O
cells O
induced O
by O
TGF-β1 B-GENE-Y
were O
applied O
to O
evaluate O
the O
anti-fibrotic O
effect O
of O
CTEP O
in O
vitro. O
MTS B-CHEMICAL
assay, O
enzyme-linked O
immunosorbent O
assay O
and O
western O
blotting O
were O
then O
used O
to O
further O
investigate O
the O
molecular O
mechanisms. O
RESULTS: O
The O
results O
show O
that O
the O
contents O
of O
collagen B-GENE-N
I, I-GENE-N
collagen B-GENE-N
III I-GENE-N
and O

TIMP-1 B-GENE-Y
were O
significantly O
inhibited O
and O
the O
level O
of O
collagen B-GENE-N
I, I-GENE-N
collagen B-GENE-N
III, I-GENE-N
p-Smad B-GENE-Y
3, I-GENE-Y
TIMP-1 B-GENE-Y
and O
α-SMA B-GENE-Y
proteins O
decreased O
significantly O
in O
a O
concentration-dependence O
manner O
after O
treatment O
with O
CTEP. O
Interestingly, O
the O
level O
of O
Smad B-GENE-Y
3 I-GENE-Y
protein O
was O
not O
different O
significantly. O
CONCLUSIONS: O
Our O
data O
indicate O
that O
CTEP O
efficiently O
inhibits O
cultured O
HSC-T6 O
cell O
activation O
and O
proliferation O
via O
the O
TGF-β1/Smad B-GENE-Y
pathway O
as O
well O
as O
by O
the O
elimination O
of O
the O
extracellular O
matrix. O

Sphingosine-1-phosphate B-CHEMICAL
promotes O
the O
nuclear O
translocation O
of O
β-catenin B-GENE-N
and O
thereby O
induces O
osteoprotegerin B-GENE-N
gene O
expression O
in O
osteoblast-like O
cell O
lines. O
Sphingosine-1-phosphate B-CHEMICAL
(S1P) B-CHEMICAL
is O
a O
well-known O
signaling O
sphingolipid B-CHEMICAL
and O
bioactive O
lipid O
mediator. O
Recently, O
it O
was O
reported O
that O
S1P B-CHEMICAL
inhibits O
osteoclast O
differentiation O
and O
bone O
resorption. O
On O
the O
other O
hand, O
S1P B-CHEMICAL
effects O
on O
osteoblasts O
and O
bone O
formation O
are O
little O
known. O
In O
this O
study, O
we O
investigated O

the O
effects O
of O
S1P B-CHEMICAL
on O
osteoblasts, O
using O
two O
osteoblast-like O
cell O
lines, O
SaOS-2 O
and O
MC3T3-E1. O
S1P B-CHEMICAL
activated O
phosphatidylinositol B-GENE-N
3-kinase I-GENE-N
(PI3K)/Akt B-GENE-N
signaling, O
leading O
to O
the O
inhibition O
of O
glycogen B-GENE-N
synthase I-GENE-N
kinase-3β I-GENE-N
and O
the O
nuclear O
translocation O
of O
β-catenin, B-GENE-N
followed O
by O
the O
increase O
of O
the O
transcriptional O
activity O
by O
β-catenin/T-cell B-GENE-N
factor I-GENE-N
complex O
formation O
in O
both O
SaOS-2 O
cells O
and O

MC3T3-E1 O
cells. O
The O
inhibitors O
of O
PI3K B-GENE-N
and O
Akt B-GENE-N
suppressed O
S1P-induced B-CHEMICAL
nuclear O
localization O
of O
β-catenin. B-GENE-N
We O
further O
investigated O
the O
effects O
of O
PI3K/Akt B-GENE-N
signaling O
on O
the O
Wnt/β-catenin B-GENE-N
signaling O
pathway, O
since O
β-catenin B-GENE-N
takes O
a O
central O
role O
in O
this O
signaling O
pathway. O
Both O
inhibitors O
for O
PI3K B-GENE-N
and O
Akt B-GENE-N
suppressed O
the O
nuclear O
localization O
of O
β-catenin B-GENE-N
and O
T-cell B-GENE-N
factor I-GENE-N
transcriptional O
activity O
induced O
by O
Wnt-3a. B-GENE-N
S1P B-CHEMICAL
increased O
the O
amount O
of O

osteoprotegerin B-GENE-N
at O
both O
mRNA O
and O
protein O
levels, O
and O
increased O
the O
activity O
of O
alkaline B-GENE-N
phosphatase, I-GENE-N
leading O
to O
the O
mineralization. O
These O
findings O
suggest O
that O
S1P B-CHEMICAL
activates O
the O
PI3K/Akt B-GENE-N
signaling O
pathway O
leading O
to O
the O
promotion O
of O
nuclear O
translocation O
of O
β-catenin B-GENE-N
in O
osteoblast-like O
cells, O
resulting O
in O
the O
upregulation O
of O
osteoptotegerin B-GENE-N
and O
osteoblast O
differentiation O
markers O
including O
alkaline B-GENE-N
phosphatase, I-GENE-N
probably O
relating O
to O
the O
inhibition O
of O
osteoclast O
formation O
and O
the O
mineralization, O
respectively. O

Plerixafor, B-CHEMICAL
a O
CXCR4 B-GENE-Y
antagonist O
for O
the O
mobilization O
of O
hematopoietic O
stem O
cells. O
Stem O
cells O
harvested O
from O
peripheral O
blood O
are O
the O
most O
commonly O
used O
graft O
source O
in O
hematopoietic O
stem O
cell O
transplantation. O
While O
G-CSF B-GENE-Y
is O
the O
most O
frequently O
used O
agent O
for O
stem O
cell O
mobilization, O
the O
use O
of O
G-CSF B-GENE-Y
alone O
results O
in O
suboptimal O
stem O
cell O
yields O
in O
a O
significant O
proportion O
of O
patients O
undergoing O
autologous O
transplantation. O
Plerixafor B-CHEMICAL
(AMD3100, B-CHEMICAL
Genzyme O
Corporation) O
is O
a O
bicyclam B-CHEMICAL
molecule O
that O
antagonizes O
the O

binding O
of O
the O
chemokine B-GENE-N
stromal B-GENE-Y
cell-derived I-GENE-Y
factor-1 I-GENE-Y
(SDF-1) B-GENE-Y
to O
its O
cognate O
receptor O
CXCR4. B-GENE-Y
Plerixafor B-CHEMICAL
results O
in O
the O
rapid O
and O
reversible O
mobilization O
of O
hematopoietic O
stem O
cells O
into O
the O
peripheral O
circulation O
and O
is O
synergistic O
when O
combined O
with O
G-CSF. B-GENE-Y
In O
clinical O
studies O
of O
autologous O
stem O
cell O
transplantation, O
the O
combination O
of O
plerixafor B-CHEMICAL
and O
G-CSF B-GENE-Y
allows O
the O
collection O
of O
large O
numbers O
of O
stem O
cells O
in O
fewer O
apheresis O
sessions O
and O
can O
salvage O
those O
who O
fail O
G-CSF B-GENE-Y
mobilization O
alone. O

Supra-normal O
stimulation O
of O
dopamine B-GENE-Y
D1 I-GENE-Y
receptors I-GENE-Y
in O
the O
prelimbic O
cortex O
blocks O
behavioral O
expression O
of O
both O
aversive O
and O
rewarding O
associative O
memories O
through O
a O
cyclic-AMP-dependent B-CHEMICAL
signaling O
pathway. O
Dopamine B-GENE-N
(DA) I-GENE-N
receptor I-GENE-N
transmission O
through O
either O
D(1) B-GENE-Y
or O
D(2)-like B-GENE-Y
subtypes O
is O
involved O
critically O
in O
the O
processing O
of O
emotional O
information O
within O
the O
medial O
prefrontal O
cortex O
(mPFC). O
However O
the O
functional O
role O
of O
specific O
DA B-GENE-Y
D(1)-like I-GENE-Y
receptor I-GENE-Y
transmission O
in O
the O
expression O
of O
emotionally O
salient O
associative O
memories O
(either O
aversive O

or O
rewarding) O
is O
not O
currently O
understood. O
Here O
we O
demonstrate O
that O
specific O
activation O
of O
DA B-GENE-Y
D(1) I-GENE-Y
receptors I-GENE-Y
in O
the O
prelimbic O
(PLC) O
division O
of O
the O
mPFC O
causes O
a O
transient O
block O
in O
the O
behavioral O
expression O
of O
both O
aversive O
and O
rewarding O
associative O
memories. O
We O
report O
that O
intra-PLC O
microinfusions O
of O
a O
selective O
D(1) B-GENE-Y
receptor I-GENE-Y
agonist O
block O
the O
spontaneous O
expression O
of O
an O
associative O
olfactory O
fear O
memory, O
without O
altering O
the O
stability O
of O
the O
original O
memory O
trace. O
Furthermore, O
using O
an O
unbiased O
place O
conditioning O
procedure O
(CPP), O

intra-PLC O
D(1) B-GENE-Y
receptor I-GENE-Y
activation O
blocks O
the O
spontaneous O
expression O
of O
an O
associative O
morphine B-CHEMICAL
(5 O
mg/kg; O
i.p.) O
reward O
memory, O
while O
leaving O
morphine-primed B-CHEMICAL
memory O
expression O
intact. O
Interestingly, O
both O
intra-PLC O
D(1)-receptor B-GENE-Y
mediated O
block O
of O
either O
fear-related O
or O
reward-related O
associative O
memories O
were O
dependent O
upon O
downstream O
cyclic-AMP B-CHEMICAL
(cAMP) B-CHEMICAL
signaling O
as O
both O
effects O
were O
rescued O
by O
co-administration O
of O
a O
cAMP B-CHEMICAL
signaling O
inhibitor. O
The O
blockade O
of O
both O
rewarding O
and O
aversive O

associative O
memories O
is O
mediated O
through O
a O
D(1)-specific B-GENE-Y
signaling O
pathway, O
as O
neither O
forms O
of O
spontaneous O
memory O
expression O
were O
blocked O
by O
intra-PLC O
microinfusions O
of O
a O
D(2)-like B-GENE-Y
receptor I-GENE-Y
agonist. O
Our O
results O
demonstrate O
that O
the O
spontaneous O
expression O
of O
either O
rewarding O
or O
aversive O
emotionally O
salient O
memories O
shares O
a O
common, O
D(1)-receptor B-GENE-Y
mediated O
substrate O
within O
the O
mPFC. O
P21-activated B-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(Pak1) B-GENE-Y
mediates O
the O
cross O
talk O
between O
insulin B-GENE-N
and O
β-catenin B-GENE-Y
on O
proglucagon B-GENE-N
gene O
expression O
and O
its O
ablation O
affects O
glucose B-CHEMICAL

homeostasis O
in O
male O
C57BL/6 O
mice. O
In O
gut O
endocrine O
L O
cells, O
the O
Wnt B-GENE-N
signaling O
pathway O
effector O
β-catenin B-GENE-Y
(β-cat)/transcription B-GENE-Y
factor I-GENE-Y
7-like I-GENE-Y
2 I-GENE-Y
mediates O
the O
stimulatory O
effect O
of O
insulin B-GENE-Y
on O
proglucagon B-GENE-N
(gcg) B-GENE-Y
expression O
and O
glucagon-like B-GENE-Y
peptide-1 I-GENE-Y
(GLP-1) B-GENE-Y
production. O
In O
several O
other O
cell O
lineages, O
insulin B-GENE-N
is O
able O
to O
stimulate O
p21-activated B-GENE-Y
protein I-GENE-Y
kinase I-GENE-Y
1 I-GENE-Y
(Pak1). B-GENE-Y
Here O
we O
determined O
the O
role O
of O
Pak1 B-GENE-Y
in O
gcg B-GENE-Y
expression O
and O
the O

effect O
of O
Pak1 B-GENE-Y
deletion O
on O
glucose B-CHEMICAL
homeostasis. O
Insulin B-GENE-N
stimulated O
Pak1 B-GENE-Y
activation O
through O
increasing O
its O
Thr423 B-CHEMICAL
phosphorylation O
in O
gut O
gcg-expressing B-GENE-Y
cell O
lines, O
associated O
with O
increased O
gcg B-GENE-Y
mRNA O
levels. O
This O
stimulation O
was O
attenuated O
by O
the O
Pak B-GENE-N
inhibitor O
2,2'-dihydroxy-1,1'-dinaphthyldisulfide B-CHEMICAL
(IPA3) B-CHEMICAL
or O
dominant-negative O
Pak1. B-GENE-Y
Both O
insulin B-GENE-N
and O
cAMP-promoting B-CHEMICAL
agents O
activated O
β-cat O
Ser675 B-CHEMICAL
phosphorylation, O
which O
was O
attenuated O
by O

IPA3 O
or O
protein B-GENE-N
kinase I-GENE-N
A I-GENE-N
inhibition, O
respectively. O
Gut O
gcg B-GENE-Y
levels O
were O
reduced O
in O
male O
Pak1(-/-) B-GENE-Y
mice, O
associated O
with O
impaired O
glucose B-CHEMICAL
tolerance O
after O
an O
ip O
or O
oral O
glucose B-CHEMICAL
challenge. O
These O
mice O
had O
lower O
circulating O
active O
GLP-1 B-GENE-Y
levels O
after O
a O
glucose B-CHEMICAL
challenge O
as O
well O
as O
reduced O
distal O
ileum O
GLP-1 B-GENE-Y
content O
after O
insulin O
treatment. O
Finally, O
the O
Pak1(-/-) B-GENE-Y
mice O
exhibited O
reduced O
brainstem O
gcg O
level O
and O
abolished O
β-cat B-GENE-Y
Ser675 B-CHEMICAL
phosphorylation O
in O
brain O
neurons O
after O
insulin B-GENE-N
treatment. O
We O
suggest O
that O
Pak1 B-GENE-Y
mediates O
the O
cross O
talk O
between O

insulin B-GENE-N
and O
Wnt B-GENE-N
signaling O
pathways O
on O
gut O
and O
brain O
gcg B-GENE-Y
expression, O
and O
its O
ablation O
impairs O
glucose B-CHEMICAL
homeostasis. O
Characterization O
of O
the O
regulation O
of O
renal B-GENE-N
Na+/H+ I-GENE-N
exchanger I-GENE-N
NHE3 B-GENE-Y
by O
insulin. B-GENE-Y
Insulin B-GENE-Y
receptors I-GENE-Y
are O
widely O
distributed O
in O
the O
kidney O
and O
affect O
multiple O
aspects O
of O
renal O
function. O
In O
the O
proximal O
tubule, O
insulin B-GENE-Y
regulates O
volume O
and O
acid-base O
regulation O
through O
stimulation O
of O
the O
Na(+)/H(+) B-GENE-N
exchanger I-GENE-N
NHE3. B-GENE-Y
This O
paper O
characterizes O
the O
signaling O
pathway O
by O
which O
insulin B-GENE-Y
stimulates O
NHE3 B-GENE-Y
in O
a O
cell O
culture O
model O

[opossum O
kidney O
(OK) O
cell]. O
Insulin B-GENE-Y
has O
two O
distinct O
phases O
of O
action O
on O
NHE3. B-GENE-Y
Chronic O
insulin B-GENE-Y
(24 O
h) O
activates O
NHE3 B-GENE-Y
through O
the O
classic O
phosphatidylinositol B-GENE-N
3-kinase-serum- I-GENE-N
and I-GENE-N
glucocorticoid-dependent I-GENE-N
kinase I-GENE-N
1 I-GENE-N
(PI3K-SGK1) B-GENE-N
pathway O
as O
insulin B-GENE-Y
stimulates O
SGK1 B-GENE-N
phosphorylation O
and O
the O
insulin B-GENE-Y
effect O
can O
be O
blocked O
by O
the O
PI3K B-GENE-N
inhibitor O
wortmannin B-CHEMICAL
or O
a O
dominant-negative O
SGK1. B-GENE-N
We O
showed O
that O
SGK1 B-GENE-N

transcript O
and O
protein O
are O
expressed O
in O
rat O
proximal O
tubule O
and O
OK O
cells. O
We O
previously O
showed O
that O
glucocorticoids O
augment O
the O
effect O
of O
insulin B-GENE-Y
on O
NHE3 B-GENE-Y
(Klisic O
J, O
Hu O
MC, O
Nief O
V, O
Reyes O
L, O
Fuster O
D, O
Moe O
OW, O
Ambuhl O
PM. O
Am O
J O
Physiol O
Renal O
Physiol O
283: O
F532-F539, O
2002). O
Part O
of O
this O
can O
be O
mediated O
via O
induction O
of O
SGK1 B-GENE-Y
by O
glucocorticoids, O
and O
indeed O
the O
insulin B-GENE-Y
effect O
on O
NHE3 B-GENE-Y
can O
also O
be O
amplified O
by O

overexpression O
of O
SGK1. B-GENE-Y
We O
next O
addressed O
the O
acute O
effect O
of O
insulin B-GENE-Y
(1-2 O
h) O
on O
NHE3 B-GENE-Y
by O
systematically O
examining O
the O
candidate O
signaling O
cascades O
and O
activation O
mechanisms O
of O
NHE3. B-GENE-Y
We O
ruled O
out O
the O
PI3K-SGK1-Akt B-GENE-N
and O
TC10 B-GENE-N
pathways, O
increased O
surface O
NHE3, B-GENE-Y
NHE3 B-GENE-Y
phosphorylation, O
NHE3 B-GENE-Y
association O
with O
calcineurin B-GENE-N
homologous I-GENE-N
protein I-GENE-N
1 I-GENE-N
or O
megalin B-GENE-Y
as O
mechanisms O
of O
acute O
activation O
of O
NHE3 B-GENE-Y
by O
insulin. B-GENE-Y
In O
summary, O
insulin B-GENE-Y
stimulates O
NHE3 B-GENE-Y
acutely O
via O

yet O
undefined O
pathways O
and O
mechanisms. O
The O
chronic O
effect O
of O
insulin B-GENE-Y
is O
mediated O
by O
the O
classic O
PI3K-SGK1 B-GENE-N
route. O
The O
effects O
of O
adulthood O
olanzapine B-CHEMICAL
treatment O
on O
cognitive O
performance O
and O
neurotrophic B-GENE-N
factor I-GENE-N
content O
in O
male O
and O
female O
rats O
neonatally O
treated O
with O
quinpirole. B-CHEMICAL
Male O
and O
female O
Sprague-Dawley O
rats O
were O
administered O
quinpirole B-CHEMICAL
(1 O
mg/kg, O
i.p.) O
or O
saline O
once O
daily O
from O
postnatal O
day O
(P)1 O
to O
P21. O
This O
drug O
treatment O
has O
been O
shown O
to O
produce O
long-term O
priming O
of O
the O

D2 B-GENE-Y
receptor. I-GENE-Y
Beginning O
on O
P62, O
rats O
were O
administered O
the O
atypical O
antipsychotic O
olanzapine B-CHEMICAL
(2.5 O
mg/kg) O
or O
saline O
twice O
daily O
(i.p.) O
for O
28 O
days. O
One O
day O
after O
olanzapine B-CHEMICAL
treatment O
ceased, O
rats O
were O
tested O
on O
the O
place O
and O
match-to-place O
versions O
of O
the O
Morris O
water O
maze O
(MWM) O
for O
seven O
consecutive O
days. O
Dopamine B-GENE-Y
D2 I-GENE-Y
receptor I-GENE-Y
priming O
was O
verified O
through O
a O
yawning O
behavioural O
test, O
a O
D2 B-GENE-Y
receptor-mediated I-GENE-Y
event, O
before O
olanzapine B-CHEMICAL
was O
administered O
as O
well O
as O
after O

olanzapine B-CHEMICAL
treatment O
and O
behavioural O
testing O
were O
complete. O
Results O
showed O
that O
neonatal O
quinpirole B-CHEMICAL
treatment O
induced O
D2 B-GENE-Y
priming O
that O
was O
eliminated O
by O
olanzapine B-CHEMICAL
treatment. O
On O
the O
MWM O
place O
version, O
D2-primed B-GENE-Y
rats O
demonstrated O
a O
significant O
impairment O
that O
was O
eliminated O
by O
olanzapine B-CHEMICAL
treatment, O
but O
olanzapine B-CHEMICAL
treatment O
to O
animals O
neonatally O
treated O
with O
saline O
produced O
a O
significant O
deficit O
on O
the O
place O
version O
of O
the O
MWM. O
There O
were O
no O
significant O
deficits O
on O
the O
match-to-place O
version. O
Brain O
tissue O
analyses O
revealed O
that O
neonatal O
quinpirole B-CHEMICAL
treatment O

produced O
a O
significant O
decrease O
in O
hippocampal O
NGF, B-GENE-Y
BDNF B-GENE-Y
and O
ChAT B-GENE-Y
that O
was O
eliminated O
by O
olanzapine B-CHEMICAL
treatment. O
Neonatal O
quinpirole B-CHEMICAL
treatment O
produced O
a O
significant O
decrease O
in O
BDNF B-GENE-Y
and O
ChAT B-GENE-Y
in O
the O
frontal O
cortex O
that O
was O
unaffected O
by O
olanzapine B-CHEMICAL
treatment. O
These O
results O
show O
that O
olanzapine B-CHEMICAL
eliminates O
D2 B-GENE-Y
receptor I-GENE-Y
priming O
and O
cognitive O
impairment O
and O
also O
alleviates O
decreases O
in O
neurotrophins O
and O
acetylcholinergic O
markers O
produced O
by O
D2 B-GENE-Y
priming O
in O
the O
hippocampus. O
Temperature O
Effects O
of O

Sputtering O
of O
Langmuir-Blodgett O
Multilayers. O
Time-of-flight O
secondary O
ion O
mass O
spectrometry O
(TOF-SIMS) O
and O
atomic O
force O
microscopy O
(AFM) O
are O
employed O
to O
characterize O
a O
wedge-shaped O
crater O
eroded O
by O
a O
40 O
keV O
C(60) B-CHEMICAL
(+) I-CHEMICAL
cluster O
ion O
beam O
on O
an O
organic O
thin O
film O
of O
402 O
nm O
of O
barium B-CHEMICAL
arachidate I-CHEMICAL
(AA) O
multilayers O
prepared O
by O
the O
Langmuir-Blodgett O
(LB) O
technique. O
Sample O
cooling O
to O
90 O
K O
was O
used O
to O
help O
reduce O
chemical O
damage, O

improve O
depth O
resolution O
and O
maintain O
constant O
erosion O
rate O
during O
depth O
profiling. O
The O
film O
was O
characterized O
at O
90 O
K, O
135 O
K, O
165 O
K, O
205 O
K, O
265 O
K O
and O
300 O
K. O
It O
is O
shown O
that O
sample O
cooling O
to O
205 O
K O
or O
lower O
helps O
to O
inhibit O
erosion O
rate O
decay, O
whereas O
at O
300 O
K O
and O
265 O
K O
the O
erosion O
rate O
continues O
to O
drop O
after O
250 O
nm O
of O
erosion, O
reaching O
about O
half O
of O
the O
initial O
value O
after O
removal O
of O
the O
entire O
film. O
Depth O
profiles O
are O
acquired O
from O
the O
SIMS O
images O
of O
the O
eroded O
wedge O
crater. O
The O
results O
suggest O
that O
sample O
cooling O
only O
slightly O
improves O
the O
altered O
layer O
thickness, O
but O
eliminates O
the O

decrease O
in O
erosion O
rate O
observed O
above O
265 O
K. O
An O
engineered O
human B-GENE-Y
follistatin I-GENE-Y
variant: O
insights O
into O
the O
pharmacokinetic O
and O
pharmocodynamic O
relationships O
of O
a O
novel O
molecule O
with O
broad O
therapeutic O
potential. O
Human B-GENE-Y
follistatin I-GENE-Y
is O
a O
regulatory O
glycoprotein O
with O
widespread O
biologic O
functions, O
including O
antiinflammatory O
activities, O
wound-healing O
properties, O
and O
muscle-stimulating O
effects. O
The O
role O
of O
follistatin B-GENE-Y
in O
a O
wide O
range O
of O
biologic O
activities O
shows O
promise O
for O
potential O
clinical O
application, O
which O
has O
prompted O
considerable O
interest O
in O
the O
investigation O
of O
the O
protein O
as O
a O
potential O

disease-modifying O
agent. O
In O
spite O
of O
this O
potential, O
the O
development O
of O
follistatin B-GENE-Y
as O
a O
broad O
use O
biotherapeutic O
has O
been O
severely O
hindered O
by O
a O
poor O
understanding O
and O
characterization O
of O
its O
pharmacokinetic/pharmacodynamic O
(PK/PD) O
relationships. O
Therefore, O
to O
better O
define O
these O
relationships, O
we O
performed O
in-depth O
analyses O
of O
the O
PK/PD O
relationships O
of O
native O
follistatin-315 B-GENE-Y
(FST315). B-GENE-Y
Our O
data O
indicate O
that O
the O
intrinsic O
PK/PD O
properties O
of O
native O
FST315 B-GENE-Y
are O
poorly O
suited O
for O
acting O
as O
a O
parentally O
administered O

biotherapeutic O
with O
broad O
systemic O
effects. O
Here, O
we O
leveraged O
protein O
engineering O
to O
modify O
the O
PK O
characteristics O
of O
the O
native O
molecule O
by O
fusing O
FST315 B-GENE-Y
to O
a O
murine B-GENE-N
IgG(1) I-GENE-N
Fc I-GENE-N
and O
removing O
the O
intrinsic O
heparan O
sulfate-binding B-CHEMICAL
activity O
of O
follistatin. B-GENE-Y
The O
engineered O
variant O
molecule O
had O
~100- O
and O
~1600-fold O
improvements O
in O
terminal O
half-life O
and O
exposure, O
respectively. O
In O
contrast O
to O
the O
native O
FST315, B-GENE-Y
the O
variant O
showed O
a O
robust, O
dose-dependent O
pharmacological O
effect O
when O
administered O
subcutaneously O
on O
a O
weekly O
basis O
in O
mouse O

models O
of O
muscle O
atrophy O
and O
degeneration. O
These O
studies O
highlight O
the O
underappreciated O
and O
critical O
relationship O
between O
optimizing O
multiple O
physical O
and O
chemical O
properties O
of O
follistatin B-GENE-Y
on O
its O
overall O
PK/PD O
profile. O
Moreover, O
our O
findings O
provide O
the O
first O
documented O
strategy O
toward O
the O
development O
of O
a O
follistatin B-GENE-Y
therapeutic O
with O
potential O
use O
in O
patients O
affected O
with O
skeletal O
muscle O
diseases. O
Suppression O
of O
Src/ERK B-GENE-Y
and O
GSK-3/β-catenin B-GENE-N
signaling O
by O
pinosylvin B-CHEMICAL
inhibits O
the O
growth O
of O
human O
colorectal O
cancer O
cells. O
Pinosylvin, B-CHEMICAL
a O
naturally O
occurring O

trans-stilbenoid B-CHEMICAL
mainly O
found O
in O
Pinus O
species, O
has O
exhibited O
a O
potential O
cancer O
chemopreventive O
activity. O
However, O
the O
growth O
inhibitory O
activity O
against O
cancer O
cells O
and O
the O
underlying O
molecular O
mechanisms O
remain O
to O
be O
elucidated. O
Therefore, O
the O
anti-proliferative O
activity O
of O
pinosylvin B-CHEMICAL
was O
investigated O
in O
human O
colorectal O
HCT O
116 O
cancer O
cells. O
Pinosylvin B-CHEMICAL
inhibited O
the O
proliferation O
of O
HCT O
116 O
cells O
by O
arresting O
transition O
of O
cell O
cycle O
from O
G1 O
to O
S O
phase O
along O
with O
the O
downregulation O
of O
cyclin B-GENE-Y
D1, I-GENE-Y
cyclin B-GENE-Y
E, I-GENE-Y
cyclin B-GENE-Y

A, I-GENE-Y
cyclin B-GENE-Y
dependent I-GENE-Y
kinase I-GENE-Y
2 I-GENE-Y
(CDK2), B-GENE-Y
CDK4, B-GENE-Y
c-Myc, B-GENE-Y
and O
retinoblastoma B-GENE-Y
protein I-GENE-Y
(pRb), B-GENE-Y
and O
the O
upregulation O
of O
p21(WAF1/CIP1) B-GENE-Y
and O
p53. B-GENE-Y
Pinosylvin B-CHEMICAL
was O
also O
found O
to O
attenuate O
the O
activation O
of O
proteins O
involved O
in O
focal B-GENE-Y
adhesion I-GENE-Y
kinase I-GENE-Y
(FAK)/c-Src/extracellular B-GENE-Y
signal-regulated I-GENE-N
kinase I-GENE-N
(ERK) B-GENE-N
signaling, O
and O
phosphoinositide B-GENE-N
3-kinase I-GENE-N
(PI3K)/Akt/ B-GENE-N
glycogen B-GENE-Y

synthase I-GENE-Y
kinase I-GENE-Y
3β I-GENE-Y
(GSK-3β) B-GENE-Y
signaling O
pathway. O
Subsequently, O
pinosylvin B-CHEMICAL
suppressed O
the O
nuclear O
translocation O
of O
β-catenin, B-GENE-Y
one O
of O
downstream O
molecules O
of O
PI3K/Akt/GSK-3β B-GENE-N
signaling, O
and O
these O
events O
led O
to O
the O
sequential O
downregulation O
of O
β-catenin-mediated B-GENE-Y
transcription O
of O
target O
genes O
including O
BMP4, B-GENE-Y
ID2, B-GENE-Y
survivin, B-GENE-Y
cyclin B-GENE-Y
D1, I-GENE-Y
MMP7, B-GENE-Y
and O
c-Myc. B-GENE-Y
These O
findings O
demonstrate O
that O
the O
anti-proliferative O
activity O
of O
pinosylvin B-CHEMICAL
might O
be O
associated O

with O
the O
cell O
cycle O
arrest O
and O
downregulation O
of O
cell O
proliferation O
regulating O
signaling O
pathways O
in O
human O
colorectal O
cancer O
cells. O
The O
Interaction O
of O
Adrenomedullin B-GENE-Y
and O
Macrophages O
Induces O
Ovarian O
Cancer O
Cell O
Migration O
via O
Activation O
of O
RhoA B-GENE-Y
Signaling O
Pathway. O
Tumor-associated O
macrophages O
(TAMs) O
are O
correlated O
with O
poor O
prognosis O
in O
many O
human O
cancers; O
however, O
the O
mechanism O
by O
which O
TAMs O
facilitate O
ovarian O
cancer O
cell O
migration O
and O
invasion O
remains O
unknown. O
This O
study O
was O
aimed O
to O
examine O
the O
function O
of O
adrenomedullin B-GENE-Y
(ADM) B-GENE-Y
in O

macrophage O
polarization O
and O
their O
further O
effects O
on O
the O
migration O
of O
ovarian O
cancer O
cells. O
Exogenous O
ADM B-GENE-Y
antagonist O
and O
small O
interfering O
RNA O
(siRNA) O
specific O
for O
ADM B-GENE-Y
expression O
were O
treated O
to O
macrophages O
and O
EOC O
cell O
line O
HO8910, O
respectively. O
Then O
macrophages O
were O
cocultured O
with O
HO8910 O
cells O
without O
direct O
contact. O
Flow O
cytometry, O
Western O
blot O
and O
real-time O
PCR O
were O
used O
to O
detect O
macrophage O
phenotype O
and O
cytokine B-GENE-N
production. O
The O
migration O
ability O
and O
cytoskeleton O
rearrangement O
of O
ovarian O

cancer O
cells O
were O
determined O
by O
Transwell O
migration O
assay O
and O
phalloidin B-CHEMICAL
staining. O
Western O
blot O
was O
performed O
to O
evaluate O
the O
activity O
status O
of O
signaling O
molecules O
in O
the O
process O
of O
ovarian O
cancer O
cell O
migration. O
The O
results O
showed O
that O
ADM B-GENE-Y
induced O
macrophage O
phenotype O
and O
cytokine B-GENE-N
production O
similar O
to O
TAMs. O
Macrophages O
polarized O
by O
ADM B-GENE-Y
promoted O
the O
migration O
and O
cytoskeleton O
rearrangement O
of O
HO8910 O
cells. O
The O
expression O
of O
RhoA B-GENE-Y
and O
its O
downstream O
effector, O
cofilin, B-GENE-N
were O
upregulated O
in O
macrophage-induced O
migration O
of O

HO8910 O
cells. O
In O
conclusion, O
ADM B-GENE-Y
could O
polarize O
macrophages O
similar O
to O
TAMs, O
and O
then O
polarized O
macrophages O
promote O
the O
migration O
of O
ovarian O
cancer O
cells O
via O
activation O
of O
RhoA B-GENE-Y
signaling O
pathway O
in O
vitro. O
Influence O
of O
nitrogen B-CHEMICAL
supply O
on O
the O
production O
of O
higher O
alcohols/esters B-CHEMICAL
and O
expression O
of O
flavour-related O
genes O
in O
cachaça O
fermentation. O
This O
study O
provides O
the O
first O
attempt O
to O
analyse O
the O
influence O
of O
ammonium B-CHEMICAL
supplements O
on O
sugar-cane B-CHEMICAL
juice O
fermentation O
and O
the O
flavour O
profile O
in O
a O
cachaça O

industrial O
process. O
The O
objective O
was O
to O
find O
a O
relationship O
between O
higher O
alcohol/ester B-CHEMICAL
content O
and O
the O
transcription O
levels O
of O
the O
main O
genes O
involved O
in O
production O
of O
these O
compounds O
under O
cachaça O
fermentation. O
Sugar-cane B-CHEMICAL
juice O
with O
a O
low O
amount O
of O
assimilable O
nitrogen B-CHEMICAL
(81 O
mg O
N/L), O
was O
further O
supplemented O
with O
mid-range O
or O
high O
concentrations O
of O
ammonium B-CHEMICAL
sulfate. I-CHEMICAL
Overall, O
higher O
alcohol B-CHEMICAL
production O
was O
reduced O
by O
ammonium B-CHEMICAL
supplementation, O
and O
this O
can O
be O
correlated O
with O
a O
general O
downregulation O
of O
genes O
encoding O
decarboxylases B-GENE-N
and O
dehydrogenases B-GENE-N
of O
the O
Ehrlich B-GENE-N
pathway. I-GENE-N

The O
production O
of O
acetate B-CHEMICAL
esters I-CHEMICAL
was O
enhanced O
by O
mid-range O
ammonium B-CHEMICAL
supplementation O
and O
the O
production O
of O
acyl B-CHEMICAL
esters I-CHEMICAL
by O
high O
ammonium B-CHEMICAL
supplementation. O
The O
acyl B-CHEMICAL
esters I-CHEMICAL
could O
be O
correlated O
with O
expression O
of O
alcohol B-GENE-Y
acyl-transferase I-GENE-Y
EEB1 I-GENE-Y
and O
the O
acyl B-GENE-Y
esterase I-GENE-Y
IAH1. I-GENE-Y
Novel O
analgesic/anti-inflammatory O
agents: O
1,5-diarylpyrrole B-CHEMICAL
nitrooxyalkyl I-CHEMICAL
ethers I-CHEMICAL
and O
related O
compounds O
as O
cyclooxygenase-2 B-GENE-Y
inhibiting O
nitric B-CHEMICAL
oxide I-CHEMICAL
donors. O
A O
series O
of O
3-substituted B-CHEMICAL

1,5-diarylpyrroles I-CHEMICAL
bearing O
a O
nitrooxyalkyl B-CHEMICAL
side O
chain O
linked O
to O
different O
spacers O
were O
designed. O
New O
classes O
of O
pyrrole-derived B-CHEMICAL
nitrooxyalkyl B-CHEMICAL
inverse O
esters, B-CHEMICAL
carbonates, B-CHEMICAL
and O
ethers B-CHEMICAL
(7-10) O
as O
COX-2 B-GENE-Y
selective O
inhibitors O
and O
NO B-CHEMICAL
donors O
were O
synthesized O
and O
are O
herein O
reported. O
By O
taking O
into O
account O
the O
metabolic O
conversion O
of O
nitrooxyalkyl B-CHEMICAL
ethers I-CHEMICAL
(9, O
10) O
into O
corresponding O
alcohols, B-CHEMICAL
derivatives O
17 O
and O
18 O
were O
also O
studied. O
Nitrooxy B-CHEMICAL
derivatives O
showed O
NO-dependent B-CHEMICAL
vasorelaxing O
properties, O

while O
most O
of O
the O
compounds O
proved O
to O
be O
very O
potent O
and O
selective O
COX-2 B-GENE-Y
inhibitors O
in O
in O
vitro O
experimental O
models. O
Further O
in O
vivo O
studies O
on O
compounds O
9a,c O
and O
17a O
highlighted O
good O
anti-inflammatory O
and O
antinociceptive O
activities. O
Compound O
9c O
was O
able O
to O
inhibit O
glycosaminoglycan O
(GAG) O
release O
induced O
by O
interleukin-1β B-GENE-Y
(IL-1β), B-GENE-Y
showing O
cartilage O
protective O
properties. O
Finally, O
molecular O
modeling O
and O
(1)H- B-CHEMICAL
and O
(13)C-NMR B-CHEMICAL
studies O
performed O
on O
compounds O
6c,d, O

9c, O
and O
10b O
allowed O
the O
right O
conformation O
of O
nitrooxyalkyl B-CHEMICAL
ester I-CHEMICAL
and I-CHEMICAL
ether I-CHEMICAL
side O
chain O
of O
these O
molecules O
within O
the O
COX-2 B-GENE-Y
active O
site O
to O
be O
assessed. O
The O
clinical O
profile O
of O
the O
angiotensin B-GENE-N
II I-GENE-N
receptor I-GENE-N
blocker O
eprosartan. B-CHEMICAL
Angiotensin B-GENE-N
II I-GENE-N
receptor I-GENE-N
antagonists O
block O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
(AT1) I-GENE-Y
receptors I-GENE-Y
and O
reduce O
the O
pressor O
effects O
of O
angiotensin B-GENE-Y
in O
the O
vasculature. O
By O
this O
mechanism, O
they O
induce O
similar O
pharmacological O
effects O
to O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
(ACE) B-GENE-Y
inhibitors, O
resulting O

in O
a O
lowering O
of O
blood O
pressure O
(BP). O
However, O
AT1 B-GENE-Y
antagonists O
differ O
from O
ACE B-GENE-Y
inhibitors O
with O
respect O
to O
side O
effects, O
and O
induce O
less O
cough, O
which O
is O
related O
to O
bradykinin B-GENE-Y
activation. O
Within O
the O
class O
of O
angiotensin B-GENE-Y
II I-GENE-Y
antagonists, O
eprosartan O
differs O
from O
other O
currently O
clinically O
available O
agents O
in O
terms O
of O
its O
chemical O
structure O
and O
its O
dual O
pharmacological O
mode O
of O
action. O
Eprosartan B-CHEMICAL
acts O
not O
only O
at O
vascular O
AT1 B-GENE-Y
receptors O
but O
also O
at O
presynaptic O
AT1 B-GENE-Y
receptors, O
causing O
inhibition O
of O
sympathetically O
stimulated O
noradrenaline B-CHEMICAL
release. O

Eprosartan B-CHEMICAL
is O
not O
metabolized O
by O
cytochrome B-GENE-N
P450 I-GENE-N
enzymes O
and O
therefore O
has O
a O
low O
potential O
for O
metabolic O
drug O
interactions, O
which O
may O
be O
of O
importance O
when O
treating O
the O
elderly O
and O
patients O
on O
multiple O
drugs. O
In O
clinical O
trials O
eprosartan B-CHEMICAL
has O
proven O
to O
be O
at O
least O
as O
effective O
as O
the O
ACE B-GENE-Y
inhibitor O
enalapril O
in O
reducing O
BP, O
but O
with O
a O
significantly O
lower O
incidence O
of O
side O
effects. O
Eprosartan B-CHEMICAL
is O
safe, O
effective O
and O
well O
tolerated O
in O
long-term O
treatment, O
either O
as O
monotherapy O
or O
in O
combination O
with O
other O
antihypertensive O
drugs O
such O
as O

hydrochlorothiazide. B-CHEMICAL
Protective O
Effects O
of O
a O
Purified O
Saponin B-CHEMICAL
Mixture O
from O
Astragalus O
corniculatus O
Bieb., O
in O
vivo O
Hepatotoxicity O
Models. O
In O
this O
study, O
the O
in O
vivo O
effects O
of O
a O
purified O
saponin B-CHEMICAL
mixture O
(PSM), O
obtained O
from O
Astragalus O
corniculatus O
Bieb., O
were O
investigated O
using O
two O
in O
vivo O
hepatotoxicity O
models O
based O
on O
liver O
damage O
caused O
by O
paracetamol B-CHEMICAL
(PC) O
and O
carbon B-CHEMICAL
tetrachloride I-CHEMICAL
(CCl4 B-CHEMICAL
). O
The O

effects O
of O
PSM O
were O
compared O
with O
silymarin. B-CHEMICAL
Male O
Wistar O
rats O
were O
challenged O
orally O
with O
20% O
CCl4 B-CHEMICAL
or O
PC O
(2 O
g/kg) O
four O
days O
after O
being O
pre-treated O
with O
PSM O
(100 O
mg/kg) O
or O
silymarin B-CHEMICAL
(200 O
mg/kg). O
A O
significant O
decrease O
of O
aspartate B-GENE-Y
aminotransferase, I-GENE-Y
alanine B-GENE-N
aminotransferase, I-GENE-N
lactate B-GENE-N
dehydrogenase I-GENE-N
(LDH) B-GENE-N
activities O
and O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
levels O
and O
an O
increase O
of O
malondialdehyde B-CHEMICAL
(MDA) B-CHEMICAL
quantity O
was O

observed O
after O
CCl4 B-CHEMICAL
and O
PC O
administration O
alone. O
PSM O
pre-treatment O
decreased O
serum B-GENE-N
transaminases I-GENE-N
and O
LDH B-GENE-N
activities O
and O
MDA B-CHEMICAL
levels O
and O
increased O
the O
levels O
of O
cell O
protector O
GSH. B-CHEMICAL
Biotransformation O
phase O
I O
enzymes O
were O
also O
assessed O
in O
both O
models. O
In O
the O
CCl4 B-CHEMICAL
hepatotoxicity O
model, O
pre-treatment O
with O
PSM O
or O
silymarin B-CHEMICAL
resulted O
in O
significantly O
increased O
activities O
of O
ethylmorphine-N-demethylase B-GENE-N
and O
aniline B-GENE-N
4-hydroxylase I-GENE-N
activity O
and O
cytochrome B-GENE-N
P450, I-GENE-N
compared O
to O
the O
CCl4 B-CHEMICAL
only O
group. O

Neither O
silymarin B-CHEMICAL
nor O
PSM O
influenced O
PC O
biotransformation. O
Our O
results O
suggest O
that O
PSM, O
obtained O
from O
A. O
corniculatus, O
Bieb. O
showed O
in O
vivo O
hepatoprotective O
and O
antioxidant O
activities O
against O
CCl4 B-CHEMICAL
and O
PC-induced O
liver O
damage O
comparable O
to O
that O
of O
silymarin. B-CHEMICAL
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons, O
Ltd. O
In O
vitro O
inhibition O
of O
diacylglycerol B-GENE-Y
acyltransferase I-GENE-Y
by O
prenylflavonoids B-CHEMICAL
from O
Sophora O
flavescens. O
Four O
prenylflavonoids, B-CHEMICAL
kurarinone B-CHEMICAL

( O
1), O
a O
chalcone B-CHEMICAL
of O
1, O
kuraridin B-CHEMICAL
( O
2), O
kurarinol B-CHEMICAL
( O
3), O
kushenol B-CHEMICAL
H I-CHEMICAL
( O
4) O
and O
kushenol B-CHEMICAL
K I-CHEMICAL
( O
5) O
isolated O
from O
the O
roots O
of O
Sophora O
flavescens O
were O
investigated O
for O
their O
inhibitory O
effects O
on O
diacylglycerol B-GENE-Y
acyltransferase I-GENE-Y
(DGAT). B-GENE-Y
The O
flavonoids B-CHEMICAL
inhibited O
DGAT B-GENE-Y
activity O
in O
a O
dose-dependent O
manner O
with O
IC50 O
values O
of O
10.9 O
microM O
( O
1), O
9.8 O
microM O
( O
2), O

8.6 O
microM O
( O
3), O
142.0 O
microM O
( O
4) O
and O
250 O
microM O
( O
5). O
The O
prenylflavonoids B-CHEMICAL
without O
C3-OH B-CHEMICAL
( O
1, O
2, O
3) O
showed O
stronger O
inhibition O
than O
those O
with O
C3-OH B-CHEMICAL
( O
4, O
5). O
On O
the O
other O
hand, O
flavonoids B-CHEMICAL
without O
side O
chains O
(hesperetin, B-CHEMICAL
naringenin, B-CHEMICAL
quercetin B-CHEMICAL
and O
kaempferol) B-CHEMICAL
did O
not O
inhibit O
the O
enzyme O
activity O
at O
a O
final O
concentration O
of O
800 O
microM. O
These O
data O
suggest O
that O
the O
lavandulyl B-CHEMICAL
side O
chain O
and O
the O
position O
of O

the O
hydroxy B-CHEMICAL
group O
are O
important O
for O
high O
DGAT B-GENE-Y
inhibitory O
activity. O
Compound O
1 O
also O
inhibited O
de O
novo O
synthesis O
of O
triacylglycerol B-CHEMICAL
(TG) B-CHEMICAL
in O
Raji O
cells. O
IL-4 B-GENE-Y
stimulates O
the O
expression O
of O
CXCL-8, B-GENE-Y
E-selectin, B-GENE-Y
VEGF, B-GENE-Y
and O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
mRNA O
by O
equine O
pulmonary O
artery O
endothelial O
cells. O
Little O
is O
known O
concerning O
the O
possible O
contribution O
of O
T O
helper O
2 O
(Th2)-type O
cytokines B-GENE-N
to O
the O
recruitment O
of O
neutrophils O
into O
the O

lung O
tissue. O
In O
the O
present O
study, O
endothelial O
cells O
from O
equine O
pulmonary O
arteries O
were O
cultured O
in O
the O
presence O
of O
recombinant O
equine B-GENE-Y
(re) I-GENE-Y
IL-4 I-GENE-Y
and O
reIL-5, B-GENE-Y
and O
the O
cytokine B-GENE-N
mRNA O
expression O
of O
molecules O
implicated O
in O
the O
chemotaxis O
and O
migration O
of O
neutrophils O
was O
studied O
using O
real-time O
RT-PCR. O
The O
functional O
response O
of O
reIL-4-induced B-GENE-Y
endothelial O
cell O
stimulation O
on O
neutrophil O
migration O
was O
also O
studied O
using O
a O
chemotaxis O
chamber. O
ReIL-4 B-GENE-Y
either O
increased O
the O

expression O
of O
CXCL-8, B-GENE-Y
E-selectin, B-GENE-Y
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF), B-GENE-Y
and O
inducible B-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
(iNOS), B-GENE-Y
or O
potentiated O
the O
coeffects O
of O
lipopolysaccharide O
(LPS) O
and O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-alpha I-GENE-Y
(TNF-alpha) B-GENE-Y
on O
CXCL-8. B-GENE-Y
Supernatants O
collected O
from O
cultured O
endothelial O
cells O
stimulated O
with O
reIL-4 B-GENE-Y
significantly O
promoted O
neutrophil O
migration O
in O
a O
dose-dependent O
manner. O
Dexamethasone B-CHEMICAL
(DXM) B-CHEMICAL

decreased O
the O
expression O
of O
CXCL-8, B-GENE-Y
VEGF, B-GENE-Y
and O
iNOS B-GENE-Y
induced O
by O
reIL-4, B-GENE-Y
while O
1400W B-CHEMICAL
dihydrochloride I-CHEMICAL
(1400W), B-CHEMICAL
a O
selective O
inhibitor O
of O
iNOS, B-GENE-Y
decreased O
the O
expression O
of O
E-selectin, B-GENE-Y
VEGF, B-GENE-Y
and O
iNOS. B-GENE-Y
DXM B-CHEMICAL
and O
1400W B-CHEMICAL
attenuated O
the O
mRNA O
expression O
of O
E-selectin B-GENE-Y
and O
iNOS B-GENE-Y
induced O
by O
the O
costimulation O
of O
reIL-4, B-GENE-Y
reTNF-alpha, B-GENE-Y
and O
LPS. O
Neither O
equine B-GENE-N
nor I-GENE-N
human I-GENE-N
recombinant I-GENE-N
IL-5 I-GENE-N
influenced O
the O
mRNA O

expression O
of O
CXCL-8, B-GENE-Y
E-selectin, B-GENE-Y
or O
VEGF. B-GENE-Y
These O
findings O
suggest O
that O
Th2-type O
cytokines B-GENE-N
may O
contribute O
to O
pulmonary O
neutrophilia O
during O
allergic O
inflammation O
by O
the O
increased O
expression O
of O
neutrophil O
chemokines B-GENE-N
and O
adhesion B-GENE-N
molecules I-GENE-N
by O
endothelial O
cells. O
DXM B-CHEMICAL
and O
the O
iNOS B-GENE-Y
inhibitors O
may O
decrease O
pulmonary O
neutrophilia O
due, O
in O
part, O
to O
a O
direct O
inhibition O
of O
some O
of O
these O
factors. O
Hydroxy-terminated B-CHEMICAL
conjugated O
polymer O
nanoparticles O
have O
near-unity O
bright O
fraction O
and O
reveal O

cholesterol-dependence B-CHEMICAL
of O
IGF1R B-GENE-N
nanodomains. I-GENE-N
Fluorescent O
nanoparticles O
have O
enabled O
many O
discoveries O
regarding O
how O
molecular O
machines O
function. O
Quantum O
dots O
have O
been O
the O
dominant O
class O
of O
fluorescent O
nanoparticles O
but O
suffer O
from O
blinking O
and O
from O
a O
substantial O
dark O
fraction--particles O
where O
the O
fluorescence O
is O
never O
seen--complicating O
any O
analysis O
of O
biological O
function. O
Nanoparticles O
composed O
of O
conjugated O
fluorescent O
polymers O
(Pdots) O
have O
recently O
been O
shown O
to O
have O
high O
brightness O
and O
no O
blinking. O
Here O
we O
develop O
a O
robust O
and O
efficient O
means O
to O
measure O
the O
dark O
fraction O

of O
Pdots, O
conjugating O
Atto O
dyes O
to O
the O
nanoparticles O
and O
testing O
fluorescence O
colocalization O
of O
dye O
and O
Pdot O
puncta. O
This O
established O
that O
the O
Pdots O
we O
generated O
had O
minimal O
dark O
fraction: O
∼3%. O
The O
application O
of O
nanoparticles O
in O
biological O
environments O
is O
highly O
sensitive O
to O
surface O
functionalization. O
For O
Pdots O
we O
found O
that O
passivation O
with O
uncharged O
hydroxy-terminated B-CHEMICAL
polyethylene B-CHEMICAL
glycol I-CHEMICAL
caused O
a O
dramatic O
reduction O
in O
nonspecific O
cell O
binding O
and O
aggregation O
compared O
to O
a O
charged O
coating. O
Using O
carbonyl B-CHEMICAL

di-imidazole I-CHEMICAL
the O
hydroxy-Pdots B-CHEMICAL
were O
functionalized O
efficiently O
with O
streptavidin O
for O
high O
stability O
targeting, O
allowing O
specific O
labeling O
of O
mammalian O
cells. O
Type B-GENE-Y
I I-GENE-Y
insulin-like I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(IGF1R) B-GENE-Y
regulates O
cell O
survival O
and O
development, O
with O
roles O
in O
aging, O
heart O
disease, O
and O
cancer. O
We O
used O
hydroxy-Pdots B-CHEMICAL
to O
track O
the O
dynamics O
of O
IGF1R B-GENE-Y
on O
a O
breast O
cancer O
cell-line, O
determining O
the O
diffusion O
characteristics O
and O
showing O
cholesterol-containing B-CHEMICAL
membrane O
nanodomains O
were O
important O
for O
receptor O
mobility O
at O
the O
plasma O

membrane. O
The O
near-unity O
bright O
fraction O
and O
low O
nonspecific O
binding O
of O
hydroxy-Pdots, B-CHEMICAL
combined O
with O
Pdot O
photostability O
and O
lack O
of O
blinking, O
provides O
many O
advantages O
for O
investigations O
at O
the O
single O
molecule O
level. O
Medroxyprogesterone B-CHEMICAL
acetate I-CHEMICAL
but O
not O
drospirenone B-CHEMICAL
ablates O
the O
protective O
function O
of O
17 B-CHEMICAL
beta-estradiol I-CHEMICAL
in O
aldosterone B-CHEMICAL
salt-treated O
rats. O
Controversial O
results O
obtained O
from O
human O
and O
animal O
studies O
on O
the O
prevention O
of O
heart O
disease O
by O
estrogens B-CHEMICAL
and O
progestins B-CHEMICAL
warrant O
a O
better O
understanding O
of O
nuclear B-GENE-N
hormone I-GENE-N
receptor I-GENE-N
function O
and O
interaction. O

To O
address O
this O
issue O
and O
taking O
into O
account O
that O
effects O
of O
synthetic O
progestins B-CHEMICAL
are O
not O
only O
referable O
to O
action O
through O
the O
progesterone B-GENE-Y
receptor I-GENE-Y
but O
may O
also O
be O
mediated O
by O
other O
steroid B-GENE-N
receptors, I-GENE-N
we O
characterized O
cardiovascular O
function O
and O
inflammatory O
gene O
expression O
in O
aldosterone B-CHEMICAL
salt-treated O
rats O
on O
long-term O
administration O
of O
17beta-estradiol, B-CHEMICAL
medroxyprogesterone B-CHEMICAL
acetate, I-CHEMICAL
and O
drospirenone, B-CHEMICAL
a O
new O
progestogen B-CHEMICAL
exhibiting O
antimineralocorticoid O
activity. O
The O
complex O
pattern O
of O
cardiovascular O
injury O
in O
ovariectomized O
Wistar O
rats O

induced O
by O
chronic O
aldosterone B-CHEMICAL
infusion O
plus O
a O
high-salt O
diet O
was O
significantly O
attenuated O
in O
sham-ovariectomized O
rats O
and O
by O
coadministration O
of O
17beta-estradiol B-CHEMICAL
in O
ovariectomized O
animals O
after O
8 O
weeks O
of O
continuous O
treatment. O
The O
beneficial O
role O
of O
17beta-estradiol B-CHEMICAL
on O
blood O
pressure, O
cardiac O
hypertrophy, O
vascular O
osteopontin B-GENE-Y
expression, O
perivascular O
fibrosis, O
and O
impaired O
NO-dependent B-CHEMICAL
relaxation O
of O
isolated O
aortic O
rings O
was O
completely O
abrogated O
by O
coadministration O
of O

medroxyprogesterone B-CHEMICAL
acetate. I-CHEMICAL
In O
contrast, O
drospirenone B-CHEMICAL
was O
either O
neutral O
or O
additive O
to O
17beta-estradiol B-CHEMICAL
in O
protecting O
against O
aldosterone B-CHEMICAL
salt-induced O
cardiovascular O
injury O
and O
inflammation. O
The O
current O
results O
support O
the O
hypothesis O
of O
complex O
interactions O
among O
estrogen, B-GENE-N
progesterone, I-GENE-N
glucocorticoid, I-GENE-N
androgen, I-GENE-N
and I-GENE-N
mineralocorticoid I-GENE-N
receptor I-GENE-N
signaling O
in O
cardiovascular O
injury O
and O
inflammation. O
Novel O
progestins, B-CHEMICAL
such O
as O
drospirenone, B-CHEMICAL
confer O
superior O
effects O
compared O
with O
medroxyprogesterone B-CHEMICAL
acetate I-CHEMICAL
in O
a O
model O
of O

aldosterone-induced B-CHEMICAL
heart O
disease O
because O
of O
its O
antimineralocorticoid O
properties. O
Effect O
of O
ifenprodil B-CHEMICAL
on O
GluN1/GluN2B B-GENE-Y
N-methyl-D-aspartate B-GENE-N
receptor I-GENE-N
gating. O
Ifenprodil B-CHEMICAL
is O
an O
allosteric O
inhibitor O
of O
GluN1/GluN2B B-GENE-Y
N-methyl-D-aspartate B-GENE-N
receptors. I-GENE-N
Despite O
its O
widespread O
use O
as O
a O
prototype O
for O
drug O
development O
and O
a O
subtype-selective O
tool O
for O
physiologic O
experiments, O
its O
precise O
effect O
on O
GluN1/GluN2B B-GENE-Y

gating O
is O
yet O
to O
be O
fully O
understood. O
Interestingly, O
recent O
crystallographic O
evidence O
identified O
that O
ifenprodil, B-CHEMICAL
unlike O
zinc, B-CHEMICAL
binds O
at O
the O
interface O
of O
the O
GluN1/GluN2B B-GENE-Y
amino B-CHEMICAL
terminal O
domain O
dimer O
by O
an O
induced-fit O
mechanism. O
To O
delineate O
the O
effect O
of O
this O
unique O
binding O
on O
GluN1/GluN2B B-GENE-Y
receptor O
gating, O
we O
recorded O
steady-state O
currents O
from O
cell-attached O
and O
outside-out O
patches. O
At O
pH O
7.9 O
in O
cell-attached O
patches, O
ifenprodil B-CHEMICAL
increased O
the O
occupancy O
of O
the O
long-lived O
shut O

conformations, O
thereby O
reducing O
the O
open O
probability O
of O
the O
receptor O
with O
no O
change O
in O
the O
mean O
open O
time. O
In O
addition, O
ifenprodil B-CHEMICAL
selectively O
affected O
the O
area O
of O
shut O
time O
constants, O
but O
not O
the O
time O
constants O
themselves. O
Kinetic O
analyses O
suggested O
that O
ifenprodil B-CHEMICAL
prevents O
the O
transition O
of O
the O
receptor O
to O
an O
open O
state O
and O
increases O
its O
dwell O
time O
in O
an O
intrinsically O
occurring O
closed O
conformation O
or O
desensitized O
state. O
We O
found O
distinct O
differences O
in O
the O
action O
of O
ifenprodil B-CHEMICAL
at O
GluN1/GluN2B B-GENE-Y
in O
comparison O
with O
previous O
studies O
on O
the O
effect O
of O
zinc B-CHEMICAL
on O

GluN1/GluN2A B-GENE-Y
gating, O
which O
may O
arise O
due O
to O
their O
unique O
binding O
sites. O
Our O
data O
also O
uncover O
the O
potential O
pH-dependent O
action O
of O
ifenprodil B-CHEMICAL
on O
gating. O
At O
a O
low O
pH O
(pH O
7.4), O
but O
not O
pH O
7.9, O
ifenprodil B-CHEMICAL
reduces O
the O
mean O
open O
time O
of O
GluN1/GluN2B B-GENE-Y
receptors, O
which O
may O
be O
responsible O
for O
its O
usefulness O
as O
a O
context-dependent O
inhibitor O
in O
conditions O
like O
ischemia O
and O
stroke, O
when O
the O
pH O
of O
the O
extracellular O
milieu O
becomes O
acidic. O
mTOR B-GENE-Y
Regulates O

Nox4-Mediated B-GENE-Y
Podocyte O
Depletion O
in O
Diabetic O
Renal O
Injury. O
Podocyte O
apoptosis O
is O
a O
critical O
mechanism O
for O
excessive O
loss O
of O
urinary O
albumin B-GENE-Y
that O
eventuates O
in O
kidney O
fibrosis. O
Pharmacological O
doses O
of O
the O
mTOR B-GENE-Y
inhibitor O
rapamycin B-CHEMICAL
reduce O
albuminura O
in O
diabetes. O
We O
explored O
the O
hypothesis O
that O
mTOR B-GENE-Y
mediates O
podocyte O
injury O
in O
diabetes. O
High O
glucose B-CHEMICAL
(HG) O
induces O
apoptosis O
of O
podocytes, O
inhibits O
AMPK B-GENE-N
activation, O
inactivates O
tuberin B-GENE-Y
and O
activates O

mTOR. B-GENE-Y
HG O
also O
increases O
the O
levels O
of O
Nox4 B-GENE-Y
and O
Nox1 B-GENE-Y
and O
NADPH B-GENE-N
oxidase I-GENE-N
activity. O
Inhibition O
of O
mTOR B-GENE-Y
by O
low O
dose O
rapamycin B-CHEMICAL
decreases O
HG-induced O
Nox4 B-GENE-Y
and O
Nox1, B-GENE-Y
NADPH B-GENE-N
oxidase I-GENE-N
activity O
and O
podocyte O
apoptosis. O
Inhibition O
of O
mTOR B-GENE-Y
had O
no O
effect O
on O
AMPK B-GENE-N
or O
tuberin B-GENE-Y
phosphorylation O
indicating O
that O
mTOR B-GENE-Y
is O
downstream O
of O
these O
signaling O
molecules. O
In O
isolated O
glomeruli O
of O
OVE26 O
mice, O
there O
is O
similar O
decrease O
in O
the O
activation O
of O

AMPK B-GENE-N
and O
tuberin B-GENE-Y
and O
activation O
of O
mTOR B-GENE-Y
with O
increase O
in O
Nox4 B-GENE-Y
and O
NADPH B-GENE-N
oxidase I-GENE-N
activity. O
Inhibition O
of O
mTOR B-GENE-Y
by O
small O
dose O
of O
rapamycin B-CHEMICAL
reduces O
podocyte O
apoptosis, O
attenuates O
glomerular O
injury O
and O
albuminuria. O
Our O
data O
provide O
evidence O
for O
a O
novel O
function O
of O
mTOR B-GENE-Y
in O
Nox4-derived B-GENE-Y
ROS O
generation O
and O
podocyte O
apoptosis O
that O
contributes O
to O
urinary O
albumin B-GENE-Y
excretion O
in O
type O
1 O
diabetes. O
Thus O
mTOR B-GENE-Y
and O
or O
NADPH B-GENE-N
oxidase I-GENE-N
inhibition O
may O

represent O
a O
therapeutic O
modality O
of O
diabetic O
kidney O
disease. O
Cavity O
Ringdown O
Spectroscopy O
of O
the O
Hydroxy-Methyl-Peroxy B-CHEMICAL
Radical. O
We O
report O
vibrational O
and O
electronic O
spectra O
of O
the O
hydroxyl-methyl-peroxy B-CHEMICAL
radical O
(HOCH2OO, B-CHEMICAL
or O
HMP), B-CHEMICAL
the O
primary O
product O
of O
the O
reaction O
of O
the O
hydroperoxy B-CHEMICAL
radical, O
HO2, B-CHEMICAL
and O
formaldehyde, B-CHEMICAL
HCHO. B-CHEMICAL
The O
ν1 O
vibrational O
(OH B-CHEMICAL
stretch) O
spectrum O
and O
the O
Ã-X O
electronic O
spectrum O
of O
HMP B-CHEMICAL
were O
detected O
by O

Infrared O
Cavity O
Ringdown O
Spectroscopy O
(IR-CRDS), O
and O
assignments O
were O
verified O
with O
density O
functional O
calculations. O
The O
HMP B-CHEMICAL
radical O
was O
generated O
in O
reactions O
of O
HCHO B-CHEMICAL
with O
HO2. B-CHEMICAL
Free O
radical O
reactions O
were O
initiated O
by O
pulsed O
laser O
photolysis O
(PLP) O
of O
Cl2 B-CHEMICAL
in O
the O
presence O
of O
HCHO B-CHEMICAL
and O
O2 B-CHEMICAL
in O
a O
flow O
reactor O
at O
300-330 O
Torr O
and O
295K. O
IR-CRDS O
spectra O
were O
measured O
in O
mid-IR O
and O
near-IR O
regions O
over O
the O
ranges O
3525-3700 O
cm(-1) O
(ν1) O

and O
7250-7800 O
cm(-1) O
(Ã-X) O
(respectively, O
at O
a O
delay O
time O
100 O
µs O
after O
photolysis. O
The O
ν1 O
spectrum O
had O
an O
origin O
at O
3622 O
cm(-1) O
and O
exhibited O
partially O
resolved O
P- O
and O
R-branch O
contours O
and O
a O
small O
Q O
branch. O
At O
these O
short O
delay O
times, O
spectral O
interference O
from O
HOOH B-CHEMICAL
and O
HCOOH B-CHEMICAL
was O
minimal, O
and O
could O
be O
subtracted. O
From O
B3LYP/6-31G+(d,p) O
calculations, O
we O
found O
that O
the O
anharmonic O
vibrational O
frequency O
and O
band O
contour O
predicted O
for O
the O
lowest O

energy O
conformer, O
HMP-A, B-CHEMICAL
The O
calculated O
anharmonic O
vibrational O
frequency O
and O
band O
contour O
computed O
using O
B3LYP/63-1G(d,p) O
level O
were O
in O
good O
agreement O
with O
the O
observed O
spectrum. O
In O
the O
near-IR, O
we O
observed O
four O
well O
spaced O
vibronic O
bands, O
each O
with O
partially O
resolved O
rotational O
contours. O
We O
assigned O
the O
apparent O
origin O
of O
the O
electronic O
spectrum O
of O
HMP B-CHEMICAL
at O
7392 O
cm(-1) O
and O
two O
bands O
to O
the O
blue O
to O
a O
progression O
in O
ν15', O
the O
lowest O
torsional O
mode O
of O
the O
state O
(ν15'= O
171 O

cm(-1)). O
The O
band O
furthest O
to O
the O
red O
was O
assigned O
as O
a O
hot O
band O
in O
ν15", O
leading O
to O
a O
ground O
state O
torsional O
frequency O
of O
(ν15"= O
122 O
cm(-1)). O
We O
simulated O
the O
spectrum O
using O
second O
order O
vibrational O
perturbation O
theory O
(VPT2) O
with O
B3LYP/6-31+G(d,p) O
calculations O
at O
the O
minimum O
energy O
geometries O
of O
the O
HMP-A B-CHEMICAL
conformer O
on O
the O
X O
̃ O
and O
A O
̃ O
states. O
The O
predictions O
of O
the O
electronic O
origin O
frequency, O
torsional O
frequencies, O
anharmonicities O

and O
rotational O
band O
contours O
matched O
the O
observed O
spectrum. O
We O
investigated O
the O
torsional O
modes O
more O
explicitly O
by O
computing O
potential O
energy O
surfaces O
of O
HMP B-CHEMICAL
as O
a O
function O
of O
the O
two O
dihedral O
angles O
τOCOH B-CHEMICAL
and O
τOOCO. B-CHEMICAL
Wave O
functions O
and O
energy O
levels O
were O
calculated O
based O
on O
this O
potential O
surface; O
these O
results O
were O
used O
to O
calculate O
the O
Franck-Condon O
factors, O
which O
reproduced O
the O
vibronic O
band O
intensities O
in O
the O
observed O
electronic O
spectrum. O
The O
transitions O
that O
we O
observed O
all O
involved O
states O
with O
wave O
functions O
localized O
on O
the O
minimum O
energy O
conformer, O
HMP-A. B-CHEMICAL
Our O
calculations O
indicated O
that O
the O
observed O
near-IR O

spectrum O
was O
that O
of O
the O
minimum O
energy O
conformer O
HMP-A, B-CHEMICAL
but O
that O
this O
conformer O
is O
not O
the O
lowest O
energy O
conformer O
in O
the O
state, O
which O
remains O
unobserved. O
We O
estimated O
that O
the O
energy O
of O
this O
lowest O
conformer O
(HMP-B) B-CHEMICAL
of O
the O
Ã O
state O
to O
be O
T0 O
(Ã) O
≈ O
7200 O
cm(-1), O
based O
on O
the O
energy O
difference O
E0(HMP-B) B-CHEMICAL
- O
E0(HMP-A) B-CHEMICAL
on O
the O
Ã O
state O
computed O
at O
the O
B3LYP/6-31+G(d,p) O
level. O
Systemic O
administration O
of O

beta2-adrenoceptor B-GENE-Y
agonists, O
formoterol B-CHEMICAL
and O
salmeterol, B-CHEMICAL
elicit O
skeletal O
muscle O
hypertrophy O
in O
rats O
at O
micromolar O
doses. O
beta(2)-Adrenoceptor B-GENE-Y
agonists O
provide O
a O
potential O
therapy O
for O
muscle O
wasting O
and O
weakness, O
but O
their O
use O
may O
be O
limited O
by O
adverse O
effects O
on O
the O
heart, O
mediated O
in O
part, O
by O
beta(1)-adrenoceptor B-GENE-Y
activation. O
Two O
beta(2)-agonists, O
formoterol B-CHEMICAL
and O
salmeterol, B-CHEMICAL
are O
approved O
for O
treating O
asthma O
and O
have O
an O
extended O
duration O
of O
action O
and O
increased O

safety, O
associated O
with O
greater O
beta(2)-adrenoceptor B-GENE-Y
selectivity. O
The O
pharmacological O
profiles O
of O
formoterol B-CHEMICAL
and O
salmeterol B-CHEMICAL
and O
their O
effects O
on O
skeletal O
and O
cardiac O
muscle O
mass O
were O
investigated O
in O
12-week-old, O
male O
F344 O
rats. O
Formoterol B-CHEMICAL
and O
salmeterol B-CHEMICAL
were O
each O
administered O
via O
daily O
i.p. O
injection O
at O
one O
of O
seven O
doses O
(ranging O
from O
1 O
to O
2,000 O
microg O
kg(-1) O
day(-1)), O
for O
4 O
weeks. O
Rats O
were O
anaesthetised O
and O
the O
EDL O
and O
soleus O
muscles O
and O
the O
heart O

were O
excised O
and O
weighed. O
Dose-response O
curves O
were O
constructed O
based O
on O
skeletal O
and O
cardiac O
muscle O
hypertrophy. O
Formoterol B-CHEMICAL
was O
more O
potent O
than O
salmeterol, B-CHEMICAL
with O
a O
significantly O
lower O
ED(50) O
in O
EDL O
muscles O
(1 O
and O
130 O
microg O
kg(-1) O
day(-1), O
P O
<0.05), O
whereas O
salmeterol B-CHEMICAL
had O
greater O
intrinsic O
activity O
than O
formoterol B-CHEMICAL
in O
both O
EDL O
and O
soleus O
muscles O
(12% O
greater O
hypertrophy O
than O
formoterol). B-CHEMICAL
The O
drugs O
had O
similar O
potency O
and O
intrinsic O
activity O
in O
the O
heart, O
with O
a O

smaller O
leftward O
shift O
for O
formoterol B-CHEMICAL
than O
seen O
in O
skeletal O
muscle. O
A O
dose O
of O
25 O
microg O
kg(-1) O
day(-1) O
of O
formoterol B-CHEMICAL
elicited O
greater O
EDL O
and O
soleus O
hypertrophy O
than O
salmeterol, B-CHEMICAL
but O
resulted O
in O
similar O
beta-adrenoceptor B-GENE-N
downregulation. O
These O
results O
show O
that O
doses O
as O
low O
as O
1 O
microg O
kg(-1) O
day(-1) O
of O
formoterol B-CHEMICAL
can O
elicit O
significant O
muscle O
hypertrophy O
with O
minimal O
cardiac O
hypertrophy O
and O
provide O
important O
information O
regarding O
the O
potential O
therapeutic O
use O
of O
formoterol B-CHEMICAL
and O

salmeterol B-CHEMICAL
for O
muscle O
wasting. O
Clinical O
utility O
of O
acarbose, B-CHEMICAL
an O
alpha-glucosidase B-GENE-Y
inhibitor O
in O
cardiometabolic O
disorders. O
Diabetes O
is O
associated O
with O
an O
increase O
risk O
for O
cardiovascular O
disease O
(CVD). O
Recently, O
macrovascular O
complications O
of O
diabetes O
have O
been O
shown O
to O
start O
before O
the O
development O
of O
diabetes. O
Indeed, O
several O
clinical O
studies O
have O
confirmed O
the O
increased O
risk O
of O
CVD O
in O
patients O
with O
impaired O
glucose B-CHEMICAL
tolerance O
(IGT). O
Since O
postprandial O
hyperglycemia O
and O
insulin B-GENE-Y
resistance O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
development O
and O
progression O
of O
CVD O
in O
patients O

with O
IGT, O
amelioration O
of O
postprandial O
hyperglycemia O
as O
well O
as O
insulin B-GENE-Y
resistance O
is O
a O
therapeutic O
target O
for O
the O
prevention O
of O
CVD O
in O
these O
high-risk O
patients. O
Acarbose, B-CHEMICAL
an O
alpha-glucosidase B-GENE-Y
inhibitor, O
delays O
the O
absorption O
of O
carbohydrate B-CHEMICAL
from O
the O
small O
intestine, O
thereby O
reducing O
postprandial O
hyperglycemia. O
Further, O
recently, O
acarbose B-CHEMICAL
has I-CHEMICAL
been I-CHEMICAL
shown I-CHEMICAL
to I-CHEMICAL
improve I-CHEMICAL
insulin I-CHEMICAL
resistance I-CHEMICAL
in I-CHEMICAL
vivo. I-CHEMICAL
These O
findings O
suggest O
that O
acarbose B-CHEMICAL
is O
a O
promising O
metabolic O
modifier O
that O
could O
reduce O
the O
risk O
of O
CVD O
in O

patients O
with O
the O
metabolic O
syndrome. O
In O
this O
paper, O
we O
review O
the O
clinical O
utility O
of O
acarbose B-CHEMICAL
in O
various O
cardiometabolic O
disorders. O
Hematologic O
and O
hepatic O
responses O
of O
the O
freshwater O
fish O
Hoplias O
malabaricus O
after O
saxitoxin B-CHEMICAL
exposure. O
The O
bioaccumulation O
of O
saxitoxins B-CHEMICAL
(STX) B-CHEMICAL
in O
the O
trophic O
chain, O
mainly O
in O
freshwater, O
are O
not O
completely O
known. O
This O
work O
aimed O
to O
elucidate O
the O
effects O
of O
STX B-CHEMICAL
on O
Hoplias O
malabaricus O
through O
trophic O
bioassay. O
The O
fish O
were O
fed O
once O
every O
five O
days O
with O

Astyanax O
sp. O
before O
being O
subjected O
to O
an O
intraperitoneal O
inoculation O
with O
the O
lysate O
of O
Cylindrospermopsis O
raciborskii O
culture O
containing O
97% O
STX B-CHEMICAL
and O
3% O
by O
neosaxitoxin B-CHEMICAL
and O
gonyautoxin B-CHEMICAL
during O
20 O
days. O
The O
animal's O
liver O
was O
assessed O
using O
biomarkers O
as O
activities O
of O
superoxide B-GENE-N
dismutase I-GENE-N
(SOD), B-GENE-N
catalase B-GENE-N
(CAT), B-GENE-N
glutathione B-GENE-N
S-transferase I-GENE-N
(GST), B-GENE-N
and O
glutathione B-GENE-N
peroxidase I-GENE-N
(GPx), B-GENE-N
and O
concentrations O
of O

reduced B-CHEMICAL
glutathione I-CHEMICAL
(GSH) B-CHEMICAL
and O
lipoperoxidation O
(LPO) O
and O
protein O
carbonylation O
(PCO). O
In O
the O
blood O
was O
analyzed O
the O
genotoxic O
and O
hematological O
parameters. O
The O
hepatosomatic O
index O
and O
the O
relative O
condition O
factor O
did O
not O
show O
a O
significant O
difference O
between O
the O
exposed O
and O
control O
groups. O
The O
values O
of O
mean O
corpuscular O
hemoglobin B-GENE-N
concentration O
and O
mean O
corpuscular O
hemoglobin B-GENE-N
increased O
in O
the O
STX B-CHEMICAL
group. O
The O
hepatic O
tissue O
from O
both O
groups O
exhibited O
a O
typical O
pattern O
that O
have O
been O
already O
described O
for O
most O
teleost O
fish. O
The O
results O
suggested O
the O

generation O
of O
reactive O
oxygen B-CHEMICAL
species, O
with O
increased O
activity O
of O
GPx B-GENE-N
and O
concentrations O
of O
LPO O
and O
GSH; B-CHEMICAL
whereas O
the O
specific O
activity O
of O
SOD B-GENE-N
decreased. O
However, O
no O
changes O
were O
observed O
in O
the O
CAT, B-GENE-N
PCO, O
and O
DNA O
damage. O
Although O
the O
STX B-CHEMICAL
effects O
are O
known O
as O
neurotoxic, O
this O
cyanotoxin O
caused O
liver O
biochemical O
alterations O
that O
can O
be O
considered O
ecologically O
relevant. O
The O
Protective O
Effects O
of O
α-Lipoic B-CHEMICAL
Acid I-CHEMICAL
on O
Kidneys O
in O
Type O
2 O
Diabetic O
Goto-Kakisaki O
Rats O
via O
Reducing O
Oxidative O
Stress. O
To O
evaluate O
the O

protective O
effects O
of O
α-lipoic B-CHEMICAL
acid I-CHEMICAL
on O
the O
kidneys O
of O
Goto-Kakisaki O
(GK) O
diabetic O
rats, O
ten O
GK O
diabetic O
rats O
were O
randomly O
divided O
into O
a O
diabetic O
control O
group O
and O
a O
lipoic B-CHEMICAL
acid-treated I-CHEMICAL
diabetic O
group O
with O
α-lipoic B-CHEMICAL
acid I-CHEMICAL
35 O
mg·Kg-1 O
intraperitoneal O
injections. O
Four O
healthy O
Wistar O
rats O
served O
as O
normal O
controls. O
Malonaldehyde B-CHEMICAL
(MDA), B-CHEMICAL
ascorbic B-CHEMICAL
acid I-CHEMICAL
(vitamin B-CHEMICAL
C), I-CHEMICAL
vitamin B-CHEMICAL
E, I-CHEMICAL
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
and O
superoxide B-GENE-N

dismutase I-GENE-N
(SOD) B-GENE-N
levels O
in O
renal O
homogenate, O
and O
urine O
protein O
excretion O
were O
measured. O
The O
expression O
of O
mRNA O
for O
NF-κB, B-GENE-N
NADPH B-GENE-N
oxidase I-GENE-N
subunits O
p22phox B-GENE-Y
and O
p47phox B-GENE-Y
in O
renal O
tissue O
was O
examined O
by O
realtime O
PCR. O
Pathological O
changes O
in O
renal O
tissue O
were O
evaluated O
by O
light O
and O
electron O
microscopy. O
There O
were O
significant O
increases O
in O
urine O
protein O
excretion, O
MDA B-CHEMICAL
levels O
and O
the O
expression O
of O
mRNA O
of O
NF-κB, B-GENE-N
p22phox B-GENE-Y
and O
p47phox, B-GENE-Y
and O
significant O
decreases O

in O
GSH, B-CHEMICAL
SOD, B-GENE-N
vitamin B-CHEMICAL
C I-CHEMICAL
and O
vitamin B-CHEMICAL
E I-CHEMICAL
levels O
in O
the O
diabetic O
control O
group O
compared O
with O
the O
normal O
control O
group. O
Pathological O
changes O
of O
renal O
tissue O
were O
more O
progressive O
in O
the O
diabetic O
control O
group O
than O
in O
the O
normal O
control O
group. O
All O
the O
parameters O
above O
were O
improved O
in O
the O
α-lipoic B-CHEMICAL
acid-treated I-CHEMICAL
diabetic O
group. O
Oxidative O
stress O
is O
increased O
in O
the O
kidney O
of O
type O
2 O
diabetic O
GK O
rats. O
It O
is O
associated O
with O
the O
progression O
of O
diabetic O
nephropathy. O
α-lipoic B-CHEMICAL
acid I-CHEMICAL
can O
protect O
renal O
function O
in O
diabetic O
rats O
via O
its O

antioxidant O
activity. O
Alcohol O
intoxications O
during O
adolescence O
increase O
motivation O
for O
alcohol O
in O
adult O
rats O
and O
induce O
neuroadaptations O
in O
the O
nucleus O
accumbens. O
Adolescent O
alcohol O
binge O
drinking O
constitutes O
a O
major O
vulnerability O
factor O
to O
develop O
alcoholism. O
However, O
mechanisms O
underlying O
this O
susceptibility O
remain O
unknown. O
We O
evaluated O
the O
effect O
of O
adolescent O
binge-like O
ethanol B-CHEMICAL
intoxication O
on O
vulnerability O
to O
alcohol O
abuse O
in O
Sprague-Dawley O
rats. O
To O
model O
binge-like O
ethanol B-CHEMICAL
intoxication, O
every O
2 O
days, O
rats O
received O
an O
ethanol B-CHEMICAL
injection O
(3.0 O
g/kg) O

for O
2 O
consecutive O
days O
across O
14 O
days O
either O
from O
postnatal O
day O
30 O
(PND30) O
to O
43 O
(early O
adolescence) O
or O
from O
PND O
45 O
to O
PND O
58 O
(late O
adolescence). O
In O
young O
adult O
animals, O
we O
measured O
free O
ethanol B-CHEMICAL
consumption O
in O
the O
two-bottle O
choice O
paradigm, O
motivation O
for O
ethanol B-CHEMICAL
in O
the O
operant O
self-administration O
task O
and O
both O
ethanol's B-CHEMICAL
rewarding O
and O
aversive O
properties O
in O
the O
conditioned O
place O
preference O
(CPP) O
and O
taste O
aversion O
(CTA) O
paradigms. O
While O
intermittent O
ethanol B-CHEMICAL
intoxications O
(IEI) O
during O
late O
adolescence O
had O
no O
effect O
on O

free-choice O
10% O
ethanol B-CHEMICAL
consumption, O
we O
found O
that O
IEI O
during O
early O
adolescence O
promoted O
free-choice O
10% O
ethanol B-CHEMICAL
consumption, O
enhanced O
motivation O
for O
ethanol B-CHEMICAL
in O
the O
self-administration O
paradigm O
and O
induced O
a O
loss O
of O
both O
ethanol-induced B-CHEMICAL
CPP O
and O
CTA O
in O
young O
adults. O
No O
modification O
in O
either O
sucrose B-CHEMICAL
self-administration O
or O
amphetamine-induced B-CHEMICAL
CPP O
was O
observed. O
As O
the O
nucleus O
accumbens O
(Nac) O
is O
particularly O
involved O
in O
addictive O
behavior, O
we O
analyzed O
IEI-induced O
long-term O
neuroadaptations O
in O
the O
Nac O
using O
c-Fos B-GENE-Y
immunohistochemistry O

and O
an O
array O
of O
neurotransmission-related O
genes. O
This O
vulnerability O
to O
ethanol B-CHEMICAL
abuse O
was O
associated O
with O
a O
lower O
c-Fos B-GENE-Y
immunoreactivity O
in O
the O
Nac O
and O
enduring O
alterations O
of O
the O
expression O
of O
Penk B-GENE-Y
and O
Slc6a4, B-GENE-Y
2 O
neurotransmission-related O
genes O
that O
have O
been O
shown O
to O
play O
critical O
roles O
in O
the O
behavioral O
effects O
of O
ethanol B-CHEMICAL
and O
alcoholism. O
Gliotransmission O
and O
brain O
glucose B-CHEMICAL
sensing: O
critical O
role O
of O
endozepines. B-GENE-N
Hypothalamic O
glucose B-CHEMICAL
sensing O
is O
involved O
in O
the O
control O
of O
feeding O
behavior O
and O
peripheral O
glucose B-CHEMICAL
homeostasis, O
and O
glial O
cells O
are O

suggested O
to O
play O
an O
important O
role O
in O
this O
process. O
Diazepam-binding B-GENE-Y
inhibitor I-GENE-Y
(DBI) B-GENE-Y
and O
its O
processing O
product O
the O
octadecaneuropeptide B-GENE-N
(ODN), B-GENE-N
collectively O
named O
endozepines, B-GENE-N
are O
secreted O
by O
astroglia, O
and O
ODN B-GENE-N
is O
a O
potent O
anorexigenic O
factor. O
Therefore, O
we O
investigated O
the O
involvement O
of O
endozepines O
in O
brain O
glucose B-CHEMICAL
sensing. O
First, O
we O
showed O
that O
intracerebroventricular O
administration O
of O
glucose B-CHEMICAL
in O
rats O
increases O
DBI B-GENE-Y
expression O
in O
hypothalamic O
glial-like O
tanycytes. O
We O
then O
demonstrated O
that O
glucose B-CHEMICAL

stimulates O
endozepine O
secretion O
from O
hypothalamic O
explants. O
Feeding O
experiments O
indicate O
that O
the O
anorexigenic O
effect O
of O
central O
administration O
of O
glucose B-CHEMICAL
was O
blunted O
by O
coinjection O
of O
an O
ODN B-GENE-N
antagonist. O
Conversely, O
the O
hyperphagic O
response O
elicited O
by O
central O
glucoprivation O
was O
suppressed O
by O
an O
ODN B-GENE-N
agonist. O
The O
anorexigenic O
effects O
of O
centrally O
injected O
glucose B-CHEMICAL
or O
ODN B-GENE-N
agonist O
were O
suppressed O
by O
blockade O
of O
the O
melanocortin-3/4 B-GENE-N
receptors, I-GENE-N
suggesting O
that O
glucose B-CHEMICAL
sensing O
involves O
endozepinergic O
control O
of O
the O

melanocortin B-GENE-N
pathway. O
Finally, O
we O
found O
that O
brain O
endozepines B-GENE-N
modulate O
blood O
glucose B-CHEMICAL
levels, O
suggesting O
their O
involvement O
in O
a O
feedback O
loop O
controlling O
whole-body O
glucose B-CHEMICAL
homeostasis. O
Collectively, O
these O
data O
indicate O
that O
endozepines B-GENE-N
are O
a O
critical O
relay O
in O
brain O
glucose B-CHEMICAL
sensing O
and O
potentially O
new O
targets O
in O
treatment O
of O
metabolic O
disorders. O
Tyrosine B-GENE-Y
hydroxylase I-GENE-Y
binds O
tetrahydrobiopterin B-CHEMICAL
cofactor O
with O
negative O
cooperativity, O
as O
shown O
by O
kinetic O
analyses O
and O
surface O
plasmon O
resonance O
detection. O
Kinetic O
studies O
of O
tetrameric O
recombinant O
human B-GENE-Y

tyrosine I-GENE-Y
hydroxylase I-GENE-Y
isoform I-GENE-Y
1 I-GENE-Y
(hTH1) B-GENE-Y
have O
revealed O
properties O
so O
far O
not O
reported O
for O
this O
enzyme. O
Firstly, O
with O
the O
natural O
cofactor O
(6R)-Lerythro-5,6,7, B-CHEMICAL
8-tetrahydrobiopterin I-CHEMICAL
(H4biopterin) B-CHEMICAL
a O
time-dependent O
change O
(burst) O
in O
enzyme O
activity O
was O
observed, O
with O
a O
half-time O
of O
about O
20 O
s O
for O
the O
kinetic O
transient. O
Secondly, O
nonhyperbolic O
saturation O
behaviour O
was O
found O
for O
H4biopterin B-CHEMICAL
with O
a O
pronounced O
negative O

cooperativity O
(0.39 O
< O
h O
< O
0.58; O
[S]0.5 O
= O
24 O
+/- O
4 O
microM). O
On O
phosphorylation O
of O
Ser40 B-CHEMICAL
by O
protein B-GENE-N
kinase I-GENE-N
A, I-GENE-N
the O
affinity O
for O
H4biopterin B-CHEMICAL
increased O
([S]0.5 O
= O
11 O
+/- O
2 O
microM) O
and O
the O
negative O
cooperativity O
was O
amplified O
(h O
= O
0.27 O
+/- O
0.03). O
The O
dimeric O
C-terminal B-CHEMICAL
deletion O
mutant O
(Delta473-528) O
of O
hTH1 B-GENE-Y
also O
showed O
negative O
cooperativity O
of O

H4biopterin B-CHEMICAL
binding O
(h O
= O
0.4). O
Cooperativity O
was O
not O
observed O
with O
the O
cofactor O
analogues O
6-methyl-5,6,7,8-tetrahydropterin B-CHEMICAL
(h O
= O
0.9 O
+/- O
0.1; O
Km O
= O
62.7 O
+/- O
5.7 O
microM) O
and O
3-methyl-5,6,7, B-CHEMICAL
8-tetrahydropterin I-CHEMICAL
(H43-methyl-pterin)(h B-CHEMICAL
= O
1.0 O
+/- O
0.1; O
Km O
= O
687 O

+/- O
50 O
microM). O
In O
the O
presence O
of O
1 O
mM O
H43-methyl-pterin, B-CHEMICAL
used O
as O
a O
competitive O
cofactor O
analogue O
to O
BH4, O
hyperbolic O
saturation O
curves O
were O
also O
found O
for O
H4biopterin B-CHEMICAL
(h O
= O
1.0), O
thus O
confirming O
the O
genuine O
nature O
of O
the O
kinetic O
negative O
cooperativity. O
This O
cooperativity O
was O
confirmed O
by O
real-time O
biospecific O
interaction O
analysis O
by O
surface O
plasmon O
resonance O
detection. O
The O
equilibrium O
binding O
of O
H4biopterin B-CHEMICAL
to O
the O
immobilized O
iron-free O
apoenzyme O
results O

in O
a O
saturable O
positive O
resonance O
unit O
(DeltaRU) O
response O
with O
negative O
cooperativity O
(h O
= O
0.52-0.56). O
Infrared O
spectroscopic O
studies O
revealed O
a O
reduced O
thermal O
stability O
both O
of O
the O
apo-and O
the O
holo-hTH1 B-GENE-Y
on O
binding O
of O
H4biopterin B-CHEMICAL
and O
Lerythro-dihydrobiopterin B-CHEMICAL
(H2biopterin). B-CHEMICAL
Moreover, O
the O
ligand-bound O
forms O
of O
the O
enzyme O
also O
showed O
a O
decreased O
resistance O
to O
limited O
tryptic O
proteolysis. O
These O
findings O
indicate O
that O
the O
binding O
of O

H4biopterin B-CHEMICAL
at O
the O
active O
site O
induces O
a O
destabilizing O
conformational O
change O
in O
the O
enzyme O
which O
could O
be O
related O
to O
the O
observed O
negative O
cooperativity. O
Thus, O
our O
studies O
provide O
new O
insight O
into O
the O
regulation O
of O
TH B-GENE-Y
by O
the O
concentration O
of O
H4biopterin B-CHEMICAL
which O
may O
have O
significant O
implications O
for O
the O
physiological O
regulation O
of O
catecholamine B-CHEMICAL
biosynthesis O
in O
neuroendocrine O
cells. O
Disposition O
of O
a O
specific O
cyclooxygenase-2 B-GENE-Y
inhibitor, O
valdecoxib, B-CHEMICAL
in O
human. O
Valdecoxib B-CHEMICAL
is O
a O
potent O
and O
specific O
inhibitor O
of O

cyclooxygenase-2, B-GENE-Y
which O
is O
used O
for O
the O
treatment O
of O
rheumatoid O
arthritis, O
osteoarthritis, O
and O
the O
dysmenorrhea O
pain. O
Eight O
male O
human O
subjects O
each O
received O
a O
single O
50-mg O
oral O
dose O
of O
[(14)C]valdecoxib. B-CHEMICAL
Urine, O
feces, O
and O
blood O
samples O
were O
collected O
after O
administration O
of O
the O
radioactive O
dose. O
Most O
of O
the O
radioactivity O
in O
plasma O
was O
associated O
with O
valdecoxib B-CHEMICAL
and O
the O
hydroxylated O
metabolite O
of O
valdecoxib B-CHEMICAL
(M1). O
The O
estimated O

terminal O
half-life O
for O
valdecoxib B-CHEMICAL
was O
about O
7 O
h. O
About O
76.1% O
of O
the O
radioactive O
dose O
was O
recovered O
in O
urine O
and O
18% O
of O
the O
radioactive O
dose O
was O
recovered O
in O
feces. O
Valdecoxib B-CHEMICAL
was O
extensively O
metabolized O
in O
human, O
and O
nine O
phase O
I O
metabolites O
were O
identified. O
The O
primary O
oxidative O
metabolic O
pathways O
of O
valdecoxib B-CHEMICAL
involved O
hydroxylation O
at O
either O
the O
methyl B-CHEMICAL
group O
to O
form O
M1 O
or O
N-hydroxylation B-CHEMICAL
at O
the O
sulfonamide B-CHEMICAL
moiety O
to O
form O
M2. O
Further O
oxidation O
of O
M1 O
led O
to O
the O
formation O
of O
several O
other O

phase O
I O
metabolites. O
Oxidative O
breakdown O
of O
the O
N-hydroxy B-CHEMICAL
sulfonamide I-CHEMICAL
function O
group O
in O
M2 O
led O
to O
the O
formation O
of O
corresponding O
sulfinic B-CHEMICAL
acid I-CHEMICAL
and O
sulfonic B-CHEMICAL
acid I-CHEMICAL
metabolites. O
The O
O-glucuronide B-CHEMICAL
conjugate O
of O
M1 O
and O
N-glucuronide B-CHEMICAL
conjugate O
of O
valdecoxib B-CHEMICAL
were O
the O
major O
urinary O
metabolites, O
which O
accounted O
for O
23.3 O
and O
19.5% O
of O
the O
total O
administered O
dose, O
respectively. O
The O
remaining O
urinary O
metabolites O
were O
glucuronide O
conjugates O
of O

other O
phase O
I O
metabolites. O
Only O
3% O
of O
the O
administered O
dose O
was O
recovered O
in O
urine O
as O
unchanged O
parent, O
suggesting O
that O
renal O
clearance O
is O
insignificant O
for O
valdecoxib. B-CHEMICAL
Absorption O
of O
valdecoxib B-CHEMICAL
was O
excellent O
since O
the O
recovery O
of O
unchanged O
valdecoxib B-CHEMICAL
in O
feces O
was O
<1% O
of O
the O
administered O
dose. O
Defective O
DNA O
damage O
response O
and O
repair O
in O
liver O
cells O
expressing O
hepatitis B-GENE-Y
B I-GENE-Y
virus I-GENE-Y
surface I-GENE-Y
antigen. I-GENE-Y
Hepatitis O
B O
virus O
(HBV) O
is O
implicated O
in O
liver O
cancer. O
The O
aim O
of O
this O
study O
was O
to O
find O
out O
whether O
HBV O
or O
its O
components O

[HBV B-GENE-Y
surface I-GENE-Y
antigen I-GENE-Y
(HBsAg), B-GENE-Y
HBV B-GENE-Y
core I-GENE-Y
protein I-GENE-Y
(HBc), B-GENE-Y
and O
HBV B-GENE-Y
X I-GENE-Y
protein I-GENE-Y
(HBx)] B-GENE-Y
could O
interfere O
with O
the O
host O
DNA O
damage O
response O
and O
repair O
pathway. O
The O
full O
HBV O
genome O
or O
individual O
HBV B-GENE-N
open-reading I-GENE-N
frame I-GENE-N
(ORF) B-GENE-N
was O
introduced O
into O
HepG2 O
cells O
to O
examine O
the O
effect O
on O
host O
genomic O
stability, O
DNA O
repair O
efficacy O
in O
response O
to O
double-strand O
DNA O
damage, O
and O
DNA O
damage-induced O
cell O
death. O
Responses O
to O
apoptosis O
induction O
in O
the O
HBV B-GENE-N
ORF-transfected I-GENE-N

HepG2 O
cells O
were O
also O
compared O
with O
those O
in O
HBV-positive O
and O
HBV-negative O
human O
hepatocellular O
carcinoma O
(HCC) O
cells. O
In O
the O
absence O
of O
HBV O
replication, O
accumulation O
of O
HBsAg B-GENE-Y
in O
liver O
cells O
without O
other O
HBV O
proteins O
enhanced O
DNA O
repair O
protein O
and O
tumor O
suppressor O
promyelocytic B-GENE-Y
leukemia I-GENE-Y
(PML) B-GENE-Y
degradation, O
which O
resulted O
in O
resistance O
to O
apoptosis O
induction O
and O
deficient O
double-strand O
DNA O
repair. O
However, O
HBsAg-positive B-GENE-Y
cells O
exhibited O
increased O
cell O
death O
with O
exposure O
to O
the O

poly(ADP-ribose) B-GENE-N
polymerase I-GENE-N
inhibitor O
that O
blocks O
single-strand O
DNA O
repair. O
These O
results O
indicate O
that O
suppression O
of O
PML B-GENE-Y
by O
HBsAg B-GENE-Y
disrupts O
cellular O
mechanisms O
that O
respond O
to O
double-strand O
DNA O
damage O
for O
DNA O
repair O
or O
apoptosis O
induction, O
which O
may O
facilitate O
hepatocarcinogenesis O
and O
open O
up O
a O
synthetic O
lethality O
strategy O
for O
HBsAg-positive B-GENE-Y
HCC O
treatment.-Chung, O
Y.-L. O
Defective O
DNA O
damage O
response O
and O
repair O
in O
liver O
cells O
expressing O
hepatitis B-GENE-Y
B I-GENE-Y
virus I-GENE-Y
surface I-GENE-Y
antigen. I-GENE-Y
Effects O
of O
labor O
and O
delivery O
on O
fibrinolysis. O
Because O

timing O
of O
sampling O
is O
crucial O
in O
an O
investigation O
of O
the O
effects O
of O
labor O
and O
delivery O
on O
fibrinolysis O
we O
conducted O
a O
study O
of O
fibrinolytic O
markers O
in O
plasma O
of O
10 O
healthy O
multiparous O
women O
in O
whom O
labor O
was O
induced, O
which O
allowed O
standardization O
of O
sampling O
times O
in O
relation O
to O
the O
course O
of O
labor O
and O
delivery. O
Blood O
samples O
were O
taken O
5 O
min O
before O
the O
start O
of O
oxytocin B-GENE-Y
infusion, O
at O
full O
cervical O
dilatation, O
and O
within O
5 O
min O
after O
delivery O
of O
the O
placenta. O
A O
sample O
of O
mixed O
free O
flowing O
cord O
blood O
was O
obtained O
after O
delivery O
with O
the O
placenta O
in O
situ. O
Variables O
determined O
were O

tissue-type B-GENE-Y
plasminogen-activator I-GENE-Y
(t-PA) B-GENE-Y
and O
the O
plasminogen B-GENE-Y
activator I-GENE-Y
inhibitors I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
(PAI-1) B-GENE-Y
and O
type O
2 O
(PAI-2). B-GENE-Y
The O
only O
significant O
change O
between O
the O
beginning O
of O
the O
induction O
of O
labor O
and O
the O
end O
of O
the O
first O
stage O
of O
labor O
was O
a O
rise O
in O
t-PA B-GENE-Y
antigen O
(P O
= O
0.01). O
All O
variables, O
except O
PAI-2 B-GENE-Y
antigen, O
changed O
significantly O
after O
delivery O
of O
the O
placenta: O
t-PA B-GENE-Y
antigen O
and O
activity O
showed O
a O
rise O
(P O
< O
0.05), O
accompanied O
by O
a O
fall O
in O

PAI-1 B-GENE-Y
antigen O
and O
activity O
(P O
< O
0.01). O
T-PA B-GENE-Y
activity O
in O
cord O
plasma O
was O
higher O
(P O
< O
0.01) O
in O
comparison O
with O
maternal O
plasma O
concentrations O
at O
the O
end O
of O
the O
first O
stage O
of O
labor, O
t-PA B-GENE-Y
antigen O
levels O
were O
similar, O
and O
PAI-1 B-GENE-Y
antigen O
and O
activity O
and O
PAI-2 B-GENE-Y
antigen O
were O
lower O
in O
cord O
plasma O
(P O
< O
0.001). O
Our O
study O
shows O
that O
activation O
of O
the O
maternal O
fibrinolytic O
system O
can O
already O
be O
detected O
during O
labor, O
with O
a O
marked O
further O
increase O
in O
fibrinolytic O
potential O
after O
placental O
separation. O

Toxicity O
and O
toxicokinetics O
of O
binary O
combinations O
of O
petroleum B-CHEMICAL
hydrocarbon I-CHEMICAL
distillates O
with O
the O
earthworm O
Eisenia O
andrei. O
Petroleum B-CHEMICAL
hydrocarbons I-CHEMICAL
(PHCs) B-CHEMICAL
act O
via O
narcosis O
and O
are O
expected O
to O
have O
additive O
toxicity. O
However, O
previous O
work O
has O
demonstrated O
less-than-additive O
toxicity O
with O
PHC B-CHEMICAL
distillates O
and O
earthworms. O
A O
study O
was O
initiated O
to O
investigate O
this O
through O
toxicity O
and O
toxicokinetic O
studies O
with O
the O
earthworm O
Eisenia O
andrei. O
Three O
petroleum O
distillate O
fractions, O
F2 O

(>C10-C16), B-CHEMICAL
F3a O
(>C16-C23), B-CHEMICAL
and O
F3b O
(>C23-C34), B-CHEMICAL
were O
used O
in O
two O
binary O
combinations, O
F2F3a O
and O
F3aF3b. O
In O
the O
toxicity O
study, O
clean O
soil O
was O
spiked O
with O
equitoxic O
combinations O
of O
the O
two O
distillates O
ranging O
from O
0.5 O
to O
2.5 O
toxic O
units. O
In O
the O
toxicokinetic O
study, O
a O
binary O
combination O
consisting O
of O
one O
concentration O
of O
each O
distillate O
was O
used. O
On O
a O
soil O
concentration O
basis, O
the O
toxicity O
of O
the O
binary O
combinations O
of O

distillates O
was O
less O
than O
additive. O
Accumulation O
of O
the O
individual O
distillates, O
however, O
was O
generally O
reduced O
when O
a O
second O
distillate O
was O
present, O
resulting O
in O
lower O
body O
burden. O
This O
is O
thought O
to O
be O
due O
to O
the O
presence O
of O
a O
nonaqueous-phase O
liquid O
at O
the O
soil O
concentrations O
used. O
On O
a O
tissue O
concentration O
basis, O
toxicity O
was O
closer O
to O
additive. O
The O
results O
demonstrate O
that O
tissue O
concentrations O
are O
the O
preferred O
metric O
for O
toxicity O
for O
earthworms. O
They O
also O
demonstrate O
that O
the O
Canada-wide O
soil O
standards O
based O
on O
individual O
distillates O
are O
likely O
protective. O
Environ. O
Toxicol. O

Chem. O
2013;32:1016-1026. O
© O
2013 O
SETAC. O
Pharmacogenetics O
of O
Allopurinol-Making B-CHEMICAL
an O
Old O
Drug O
Safer. O
Allopurinol B-CHEMICAL
is O
a O
drug O
that O
has O
been O
used O
for O
decades O
to O
lower O
serum O
urate O
levels O
in O
patients O
with O
gout O
or O
chronic O
renal O
failure O
and O
in O
cancer O
patients O
undergoing O
chemotherapy O
at O
risk O
of O
tumor O
lysis O
syndrome. O
Patients O
may O
develop O
cutaneous O
hypersensitivity O
reactions, O
ranging O
from O
mild O
rashes O
to O
potentially O
fatal O
severe O
cutaneous O
adverse O
reactions O
(SCARs) O
namely O
drug O
hypersensitivity O

syndrome, O
Stevens-Johnson O
syndrome O
(SJS), O
and O
toxic O
epidermal O
necrolysis O
(TEN). O
Recent O
studies O
have O
demonstrated O
the O
association O
between O
human B-GENE-Y
leukocyte I-GENE-Y
antigen I-GENE-Y
(HLA) I-GENE-Y
B*58:01 I-GENE-Y
allele O
and O
allopurinol-induced B-CHEMICAL
SCARs, O
which O
might O
explain O
ethnic O
differences O
in O
their O
incidences. O
Genotyping O
is O
now O
required O
before O
starting O
abacavir B-CHEMICAL
and O
carbamazepine B-CHEMICAL
so O
as O
to O
identify O
individuals O
susceptible O
to O
SJS. O
However, O
no O
genetic O
screening O
is O
advocated O
before O
commencement O
of O
allopurinol. B-CHEMICAL
The O
lack O
of O
availability O
of O

a O
rapid O
and O
inexpensive O
screening O
test O
for O
the O
HLA-B*58:01 B-GENE-Y
allele O
is O
one O
of O
the O
obstacles O
to O
such O
screening. O
Development O
of O
a O
test O
that O
is O
quick, O
accurate, O
and O
cost-effective O
is O
warranted. O
Silibinin B-CHEMICAL
triggers O
apoptosis O
and O
cell-cycle O
arrest O
of O
SGC7901 O
cells. O
Silibinin, B-CHEMICAL
a O
flavonoid B-CHEMICAL
compound, O
has O
shown O
to O
be O
of O
chemopreventive O
potential O
against O
many O
cancers. O
However, O
its O
efficacy O
against O
gastric O
cancer O
has O
not O
been O
well O
elucidated. O
Here, O
we O
assessed O
the O
activity O
of O
Silibinin B-CHEMICAL
on O

apoptosis O
and O
cell-cycle O
arrest O
in O
human O
gastric O
cells O
culture O
system O
using O
SGC-7901 O
as O
the O
model. O
Silibinin B-CHEMICAL
treatment O
could O
inhibit O
the O
cell O
growth O
and O
cause O
a O
prominent O
G2 O
phase O
arrest O
and O
apoptosis O
in O
dose- O
and O
time-dependent O
manner. O
In O
mechanistic O
studies, O
Silibinin B-CHEMICAL
decreased O
the O
protein O
level O
of O
p34cdc2, B-GENE-Y
which O
might O
be O
the O
possible O
molecular O
mechanism O
of O
Silibinin B-CHEMICAL
efficacy O
on O
the O
growth O
inhibition O
in O
SGC-7901 O
cells. O
In O
addition, O
Silibinin B-CHEMICAL
caused O
an O
increase O
in O
p53 B-GENE-Y
and O
p21 B-GENE-Y
protein O
level O
as O
well O
as O

mRNA O
levels. O
Interestingly, O
Silibinin-induced B-CHEMICAL
apoptosis O
in O
SGC-7901 O
cells O
was O
independent O
of O
caspases O
activation. O
These O
results O
indicated O
that O
Silibinin B-CHEMICAL
is O
a O
cell-cycle O
regulator O
and O
apoptosis O
inducer O
in O
human O
gastric O
carcinoma O
SGC-7901 O
cells O
and O
might O
be O
used O
as O
a O
candidate O
chemopreventive O
agent O
for O
gastric O
carcinoma O
prevention O
and O
intervention. O
Copyright O
© O
2012 O
John O
Wiley O
& O
Sons, O
Ltd. O
Influence O
of O
developmental O
lead O
exposure O
on O
expression O
of O
DNA B-GENE-N
methyltransferases I-GENE-N
and O
methyl B-GENE-N
cytosine-binding I-GENE-N
proteins I-GENE-N

in O
hippocampus. O
Developmental O
exposure O
to O
lead O
(Pb) B-CHEMICAL
has O
adverse O
effects O
on O
cognitive O
functioning O
and O
behavior O
that O
can O
persist O
into O
adulthood. O
Exposures O
that O
occur O
during O
fetal O
or O
early O
life O
periods O
may O
produce O
changes O
in O
brain O
related O
to O
physiological O
re-programming O
from O
an O
epigenetic O
influence O
such O
as O
altered O
DNA O
methylation O
status. O
Since O
DNA O
methylation O
is O
regulated O
by O
DNA B-GENE-N
methyltransferases I-GENE-N
and O
methyl B-GENE-N
cytosine-binding I-GENE-N
proteins, I-GENE-N
this O
study O
assessed O
the O
extent O
to O
which O
developmental O
Pb B-CHEMICAL
exposure O
might O
affect O
expression O
of O
these O
proteins O
in O
the O
hippocampus. O
Long O
Evans O
dams O
were O
fed O
chow O

with O
or O
without O
added O
Pb B-CHEMICAL
acetate I-CHEMICAL
(0, O
150, O
375, O
750 O
ppm) O
prior O
to O
breeding O
and O
remained O
on O
the O
same O
diet O
through O
weaning O
(perinatal O
exposure O
group). O
Other O
animals O
were O
exposed O
to O
the O
same O
doses O
of O
Pb B-CHEMICAL
but O
exposure O
started O
on O
postnatal O
day O
1 O
and O
continued O
through O
weaning O
(early O
postnatal O
exposure O
group). O
All O
animals O
were O
euthanized O
on O
day O
55 O
and O
hippocampi O
were O
removed. O
Western O
blot O
analyses O
showed O
significant O
effects O
of O
Pb B-CHEMICAL
exposure O
on O
DNMT1, B-GENE-Y
DNMT3a, B-GENE-Y
and O
MeCP2 B-GENE-Y
expression, O
with O
effects O
often O
seen O

at O
the O
lowest O
level O
of O
exposure O
and O
modified O
by O
sex O
and O
developmental O
window O
of O
Pb B-CHEMICAL
exposure. O
These O
data O
suggest O
potential O
epigenetic O
effects O
of O
developmental O
Pb B-CHEMICAL
exposure O
on O
DNA O
methylation O
mediated O
at O
least O
in O
part O
through O
dysregulation O
of O
methyltransferases. B-GENE-N
Synergy O
between O
pairs O
of O
competitive O
antagonists O
at O
adult O
human B-GENE-N
muscle I-GENE-N
acetylcholine I-GENE-N
receptors. I-GENE-N
BACKGROUND: O
Synergistic O
neuromuscular O
blocking O
effects O
have O
been O
observed O
clinically O
with O
certain O
pairs O
of O
nicotinic B-GENE-N
acetylcholine I-GENE-N
receptor I-GENE-N
(nAChR) B-GENE-N
competitive O
antagonists. O
The O
mechanism O
for O

synergy O
has O
not O
been O
elucidated. O
We O
tested O
the O
hypothesis O
that O
synergy O
arises O
from O
a O
differential O
selectivity O
of O
antagonists O
for O
the O
two O
ligand O
binding O
sites O
on O
adult O
human B-GENE-N
nAChR. I-GENE-N
METHODS: O
We O
expressed O
nAChR B-GENE-N
in O
BOSC23 O
cells. O
We O
applied O
ACh O
with O
or O
without O
antagonists O
to O
outside-out O
patches O
and O
measured O
macroscopic O
currents O
at O
room O
temperature. O
We O
determined O
the O
IC(90) O
for O
(+)-tubocurarine, B-CHEMICAL
metocurine, B-CHEMICAL
pancuronium, B-CHEMICAL
vecuronium, B-CHEMICAL
cisatracurium, B-CHEMICAL

rocuronium, B-CHEMICAL
and O
atracurium. B-CHEMICAL
For O
15 O
combinations O
of O
two O
antagonists, O
we O
determined O
the O
IC(90) O
for O
one O
antagonist O
in O
the O
presence O
of O
the O
IC(70) O
of O
a O
second O
antagonist. O
We O
constructed O
isobolograms O
for O
90% O
inhibition. O
For O
single O
antagonists, O
we O
measured O
inhibition O
of O
receptors O
containing O
mutations O
in O
the O
epsilon- O
and O
delta-subunits O
to O
determine O
site O
selectivity. O
RESULTS: O
Two O
pairs O
of O
antagonists, O
metocurine+cisatracurium B-CHEMICAL
and O
cisatracurium+ B-CHEMICAL
atracurium B-CHEMICAL
exhibited O
additive O

inhibition. O
Ten O
combinations, O
including O
(+)-tubocurarine+ B-CHEMICAL
pancuronium B-CHEMICAL
and O
pancuronium+vecuronium, B-CHEMICAL
were O
highly O
synergistic O
such O
that O
the O
combination O
was O
two O
to O
three O
times O
more O
effective O
than O
expected O
for O
additivity. O
Three O
combinations O
were O
1.5-1.6 O
times O
more O
effective O
than O
expected O
for O
additivity. O
Inhibition O
by O
(+)-tubocurarine B-CHEMICAL
and O
metocurine B-CHEMICAL
was O
sensitive O
to O
mutations O
in O
the O
epsilon-subunit O
only. O
Vecuronium B-CHEMICAL
was O
affected O
by O
the O
delta-subunit O
mutation O
only. O
Inhibition O
by O
other O
antagonists O
was O
decreased O

by O
mutations O
in O
either O
subunit. O
CONCLUSIONS: O
Many O
combinations O
of O
antagonists O
exhibited O
synergistic O
effects O
on O
adult O
human B-GENE-N
nAChR. I-GENE-N
Synergy O
was O
observed O
with O
structurally O
similar O
and O
dissimilar O
antagonists. O
The O
degree O
of O
synergy O
did O
not O
always O
correlate O
well O
with O
site O
specificity O
assayed O
with O
mutants. O
In O
some, O
but O
not O
all O
cases, O
the O
synergy O
at O
the O
receptor O
level O
correlated O
with O
clinical O
determinations O
of O
synergy. O
We O
conclude O
that O
the O
synergistic O
actions O
of O
muscle O
relaxants O
can O
be O
partially O
explained O
by O
direct O
interactions O
with O
adult O
human B-GENE-N

nAChR. I-GENE-N
The O
interaction O
between O
mGluR1 B-GENE-Y
and O
the O
calcium B-GENE-N
channel I-GENE-N
Cav₂.₁ B-GENE-Y
preserves O
coupling O
in O
the O
presence O
of O
long B-GENE-N
Homer I-GENE-N
proteins. I-GENE-N
Group B-GENE-N
I I-GENE-N
metabotropic I-GENE-N
glutamate I-GENE-N
receptors I-GENE-N
(mGluR1 B-GENE-N
and I-GENE-N
5) I-GENE-N
are O
G B-GENE-N
protein I-GENE-N
coupled I-GENE-N
receptors I-GENE-N
that O
regulate O
neuronal O
activity O
in O
a O
number O
of O
ways. O
Some O
of O
the O
most O
well O
studied O
functions O
of O
group B-GENE-N
I I-GENE-N
mGluRs, I-GENE-N
such O
as O
initiation O
of O
multiple O
forms O
of O
mGluR-dependent B-GENE-N
long-term O
depression, O
require O
receptor O
localization O
near O
the O
post-synaptic O
density O
(PSD). O
This O
localization O
is O
in O
turn O
dependent O

on O
the O
Homer B-GENE-N
family O
of O
scaffolding O
proteins O
which O
bind O
to O
a O
small O
motif O
on O
the O
distal O
C-termini B-CHEMICAL
of O
mGluR1 B-GENE-N
and I-GENE-N
5, I-GENE-N
localize O
the O
receptors O
near O
the O
PSD, O
strengthen O
coupling O
to O
post-synaptic O
effectors O
and O
simultaneously O
uncouple O
the O
mGluRs B-GENE-N
from O
extra-synaptic O
effectors O
such O
as O
voltage B-GENE-N
dependent I-GENE-N
ion I-GENE-N
channels. I-GENE-N
Here O
the O
selectivity O
of O
this O
uncoupling O
process O
was O
examined O
by O
testing O
the O
ability O
of O
Homer-2b B-GENE-Y
to O
uncouple O
mGluR1 B-GENE-Y
from O
multiple O
voltage B-GENE-N
dependent I-GENE-N
calcium I-GENE-N
channels I-GENE-N
including O

Ca(V2.2) B-GENE-Y
(N-type), B-GENE-N
Ca(V3.2) B-GENE-Y
(T-type), B-GENE-N
and O
Ca(V2.1) B-GENE-Y
(P/Q-type) B-GENE-N
expressed O
in O
rat O
sympathetic O
neurons O
from O
the O
superior O
cervical O
ganglion O
(SCG). O
Of O
these, O
only O
the O
mGluR1-Ca(V2.1) B-GENE-Y
modulatory O
pathway O
was O
insensitive O
to O
Homer-2b B-GENE-Y
expression. O
Uncoupling O
from O
this O
channel O
was O
achieved O
by O
co-expression O
of O
an O
mGluR1 B-GENE-Y
C-terminal B-CHEMICAL
protein O
designed O
to O
disrupt O
a O
previously O

described O
direct O
interaction O
between O
these O
two O
proteins, O
suggesting O
that O
this O
interaction O
allows O
incorporation O
of O
Ca(V2.1) B-GENE-Y
into O
the O
mGluR1/Homer B-GENE-Y
signaling O
complex, O
thereby O
preserving O
modulation O
in O
the O
presence O
of O
scaffolding O
Homer B-GENE-N
proteins. I-GENE-N
This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
'Metabotropic B-GENE-N
Glutamate I-GENE-N
Receptors'. I-GENE-N
Transfection O
of O
HepG2 O
cells O
with O
hGSTA4 B-GENE-Y
provides O
protection O
against O
4-hydroxynonenal-mediated B-CHEMICAL
oxidative O
injury. O
4-Hydroxynonenal B-CHEMICAL
(4-HNE) B-CHEMICAL
is O
a O

mutagenic O
alpha,beta-unsaturated B-CHEMICAL
aldehyde I-CHEMICAL
produced O
during O
oxidative O
injury O
that O
is O
conjugated O
by O
several O
glutathione B-GENE-N
S-transferase I-GENE-N
(GST) B-GENE-N
isoforms. O
The O
alpha O
class O
human B-GENE-Y
GSTA4-4 I-GENE-Y
enzyme O
(hGSTA4-4) B-GENE-Y
has O
a O
particularly O
high O
catalytic O
efficiency O
toward O
4-HNE B-CHEMICAL
conjugation. O
However, O
hGST4-4 B-GENE-Y
expression O
is O
low O
in O
most O
human O
cells O
and O
there O
are O
other O
aldehyde B-CHEMICAL
metabolizing O
enzymes O
that O
detoxify O
4-HNE. B-CHEMICAL
In O
the O
current O
study, O
we O
determined O
the O
effect O

of O
over-expression O
of O
hGSTA4 B-GENE-Y
mRNA O
on O
the O
sensitivity O
of O
HepG2 O
cells O
to O
4-HNE B-CHEMICAL
injury. O
HepG2 O
cells O
transfected O
with O
an O
hGSTA4 B-GENE-Y
vector O
construct O
exhibited O
high O
steady-state O
hGSTA4 B-GENE-Y
mRNA, O
high O
GST-4-HNE B-GENE-Y
catalytic O
activities, O
but O
lower O
basal O
glutathione B-CHEMICAL
(GSH) B-CHEMICAL
concentrations O
relative O
to O
insert-free O
vector O
(control) O
cells. O
Exposure O
to O
4-HNE B-CHEMICAL
elicited O
an O
increase O
in O
GSH B-CHEMICAL
concentrations O
in O
the O
control O
and O
hGSTA4 B-GENE-Y
cells, O
although O
the O
dose-response O
of O
GSH B-CHEMICAL

induction O
differed O
among O
the O
two O
cell O
types. O
Specifically, O
hGSTA4 B-GENE-Y
cells O
had O
significantly O
higher O
GSH B-CHEMICAL
concentrations O
when O
exposed O
to O
5-15 O
microM O
4-HNE, B-CHEMICAL
but O
not O
at O
20 O
microM O
4-HNE, B-CHEMICAL
suggesting O
extensive O
GSH B-CHEMICAL
utilization O
at O
high O
concentrations O
of O
4-HNE. B-CHEMICAL
The O
hGSTA4 B-GENE-Y
cells O
exhibited O
a O
significant O
growth O
advantage O
relative O
to O
control O
cells O
in O
the O
absence O
of O
4-HNE, B-CHEMICAL
and O
a O
trend O
towards O
increased O
growth O
at O
low O
dose O
exposures O
to O
4-HNE. B-CHEMICAL
However, O
the O
hGSTA4 B-GENE-Y
cells O
did O
not O
exhibit O
a O
growth O
advantage O
relative O
to O
control O
cells O
at O
higher O

4-HNE B-CHEMICAL
exposures O
associated O
with O
increased O
GSH B-CHEMICAL
utilization. O
As O
expected, O
the O
hGSTA4 B-GENE-Y
cells O
showed O
resistance O
to O
4-HNE B-CHEMICAL
stimulated O
lipid O
peroxidation O
at O
all O
4-HNE B-CHEMICAL
doses. O
In O
summary, O
our O
data O
indicates O
that O
over-expression O
of O
hGSTA4 B-GENE-Y
at O
levels O
conferring O
high O
GST-4-HNE B-GENE-N
conjugating O
activity O
confers O
a O
partial O
growth O
advantage O
to O
HepG2 O
cells O
and O
protects O
against O
4-HNE B-CHEMICAL
oxidative O
injury. O
However, O
the O
loss O
of O
proliferative O
capacity O
of O
hGSTA4 B-GENE-Y
cells O
challenged O
with O
levels O
of O

4-HNE B-CHEMICAL
associated O
with O
severe O
oxidative O
stress O
indicates O
a O
role O
of O
other O
aldehyde B-CHEMICAL
metabolizing O
enzymes, O
and/or O
GSH-electrophile B-CHEMICAL
transporter O
proteins, O
in O
providing O
full O
cellular O
protection O
against O
4-HNE B-CHEMICAL
toxicity. O
DRF B-CHEMICAL
2655: I-CHEMICAL
a O
unique O
molecule O
that O
reduces O
body O
weight O
and O
ameliorates O
metabolic O
abnormalities. O
OBJECTIVE: O
Preclinical O
evaluation O
of O
DRF B-CHEMICAL
2655, I-CHEMICAL
a O
peroxisome B-GENE-Y
proliferator-activated I-GENE-Y
receptor I-GENE-Y
alpha I-GENE-Y
(PPARalpha) B-GENE-Y
and O
PPARgamma B-GENE-Y
agonist, O
as O
a O
body-weight O
lowering, O

hypolipidemic O
and O
euglycemic O
agent. O
RESEARCH O
METHODS O
AND O
PROCEDURES: O
DRF B-CHEMICAL
2655 I-CHEMICAL
was O
studied O
in O
different O
genetic, O
normal, O
and O
hyperlipidemic O
animal O
models. O
HEK O
293 O
cells O
were O
used O
to O
conduct O
the O
reporter-based O
transactivation O
of O
PPARalpha B-GENE-Y
and O
PPARgamma. B-GENE-Y
To O
understand O
the O
biochemical O
mechanism O
of O
lipid-, O
body-weight-, O
and O
glucose-lowering B-CHEMICAL
effects, O
activities O
of O
key O
beta-oxidation O
and O
lipid O
catabolism O
enzymes O
and O
gluconeogenic O
enzymes O
were O
studied O
in O

db/db O
mice O
treated O
with O
DRF B-CHEMICAL
2655. I-CHEMICAL
3T3L1 O
cells O
were O
used O
for O
adipogenesis O
study, O
and O
HepG2 O
cells O
were O
used O
to O
study O
the O
effect O
of O
DRF B-CHEMICAL
2655 I-CHEMICAL
on O
total O
cholesterol B-CHEMICAL
and O
triglyceride B-CHEMICAL
synthesis O
using O
[(14)C]acetate B-CHEMICAL
and O
[(3)H]glycerol. B-CHEMICAL
RESULTS: O
DRF B-CHEMICAL
2655 I-CHEMICAL
showed O
concentration-dependent O
transactivation O
of O
PPARalpha B-GENE-Y
and O
PPARgamma. B-GENE-Y
In O
the O
3T3L1 O
cell-differentiation O
study, O
DRF B-CHEMICAL
2655 I-CHEMICAL
and O

rosiglitazone B-CHEMICAL
showed O
369% O
and O
471% O
increases, O
respectively, O
in O
triglyceride B-CHEMICAL
accumulation. O
DRF B-CHEMICAL
2655 I-CHEMICAL
showed O
body-weight O
lowering O
and O
euglycemic O
and O
hypolipidemic O
effects O
in O
various O
animal O
models. O
db/db O
mice O
treated O
with O
DRF B-CHEMICAL
2655 I-CHEMICAL
showed O
5- O
and O
3.6-fold O
inhibition O
in O
phosphoenolpyruvate B-GENE-Y
carboxykinase I-GENE-Y
and O
glucose B-GENE-Y
6-phosphatase I-GENE-Y
activity O
and O
651% O
and O
77% O
increases O
in O
the O
beta-oxidation O
enzymes O
carnitine B-GENE-N
palmitoyltransferase I-GENE-N
and O

carnitine B-GENE-Y
acetyltransferase, I-GENE-Y
respectively. O
HepG2 O
cells O
treated O
with O
DRF B-CHEMICAL
2655 I-CHEMICAL
showed O
significant O
reduction O
in O
lipid O
synthesis. O
DISCUSSION: O
DRF B-CHEMICAL
2655 I-CHEMICAL
showed O
excellent O
euglycemic O
and O
hypolipidemic O
activities O
in O
different O
animal O
models. O
An O
exciting O
finding O
is O
its O
body-weight O
lowering O
effect O
in O
these O
models, O
which O
might O
be O
mediated O
by O
the O
induction O
of O
target O
enzymes O
involved O
in O
hepatic O
lipid O
catabolism O
through O
PPARalpha B-GENE-Y
activation. O
Expression O
and O
selective O
inhibition O
of O
the O
constitutive B-GENE-N
and I-GENE-N
inducible I-GENE-N
forms I-GENE-N
of I-GENE-N
human I-GENE-N

cyclo-oxygenase. I-GENE-N
The O
enzyme O
cyclo-oxygenase B-GENE-N
catalyses O
the O
oxygenation O
of O
arachidonic B-CHEMICAL
acid, I-CHEMICAL
leading O
to O
the O
formation O
of O
prostaglandins. B-CHEMICAL
Recently O
two O
forms O
of O
cyclo-oxygenase B-GENE-N
have O
been O
described: O
a O
constitutive O
(COX-1) B-GENE-Y
enzyme O
present O
in O
most O
cells O
and O
tissues, O
and O
an O
inducible O
(COX-2) B-GENE-Y
isoenzyme O
observed O
in O
many O
cells O
in O
response O
to O
pro-inflammatory O
cytokines. B-GENE-N
Constitutive B-GENE-N
and I-GENE-N
inducible I-GENE-N
forms I-GENE-N
of I-GENE-N
human I-GENE-N
cyclo-oxygenase I-GENE-N

(hCOX-1 B-GENE-Y
and O
hCOX-2) B-GENE-Y
were O
cloned O
and O
expressed O
in O
insect O
cells, O
utilizing O
a O
baculovirus O
expression O
system. O
hCOX-1 B-GENE-Y
had O
a O
specific O
activity O
of O
18.8 O
mumol O
of O
O2/mg B-CHEMICAL
with O
a O
Km O
of O
13.8 O
microM O
for O
arachidonate B-CHEMICAL
and O
Vmax. O
of O
1500 O
nmol O
of O
O2/nmol O
of O
enzyme, O
whereas O
hCOX-2 B-GENE-Y
had O
a O
specific O
activity O
of O
12.2 O
mumol O
of O
O2/mg B-CHEMICAL
with O
a O
Km O
of O
8.7 O
microM O
for O
arachidonate B-CHEMICAL
and O
a O
Vmax. O

of O
1090 O
nmol O
of O
O2/nmol B-CHEMICAL
of O
enzyme. O
Indomethacin B-CHEMICAL
inhibited O
both O
hCOX-1 B-GENE-Y
and O
hCOX-2, B-GENE-Y
whereas O
NS-398 B-CHEMICAL
and O
Dup-697 B-CHEMICAL
selectively O
inhibited O
hCOX-2. B-GENE-Y
Both O
NS-398 B-CHEMICAL
and O
Dup-697 B-CHEMICAL
exhibited O
time-dependent O
inactivation O
of O
hCOX-2, B-GENE-Y
as O
did O
indomethacin B-CHEMICAL
on O
both O
enzymes. O
The O
competitive O
inhibitor O
of O
hCOX-1, B-GENE-Y
mefenamic B-CHEMICAL
acid, I-CHEMICAL
also O
displayed O
competitive O
inhibition O
of O
hCOX-2. B-GENE-Y
These O
results O
demonstrate O
the O

ability O
to O
generate O
selective O
non-steroidal B-CHEMICAL
anti-inflammatory O
drugs O
(NSAIDs), O
which O
could O
provide O
useful O
improvement O
therapeutically O
in O
the O
treatment O
of O
chronic O
inflammatory O
disease. O
Dose-response O
effect O
of O
tetracyclines B-CHEMICAL
on O
cerebral O
matrix B-GENE-Y
metalloproteinase-9 I-GENE-Y
after O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
hyperstimulation. O
Brain O
arteriovenous O
malformations O
(BAVMs) O
are O
a O
potentially O
life-threatening O
disorder. O
Matrix B-GENE-Y
metalloproteinase I-GENE-Y
(MMP)-9 I-GENE-Y
activity O
was O
greatly O
increased O
in O
BAVM O
tissue O
specimens. O
Doxycycline B-CHEMICAL
was O
shown O
to O
decrease O
cerebral O

MMP-9 B-GENE-Y
activities O
and O
angiogenesis O
induced O
by O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF). B-GENE-Y
In O
the O
present O
study, O
we O
determined O
the O
dose-response O
effects O
of O
doxycycline B-CHEMICAL
and O
minocycline B-CHEMICAL
on O
cerebral O
MMP-9 B-GENE-Y
using O
our O
mouse O
model O
with O
VEGF B-GENE-Y
focal O
hyperstimulation O
delivered O
with O
adenoviral O
vector O
(AdVEGF) B-GENE-Y
in O
the O
brain. O
Mice O
were O
treated O
with O
doxycycline B-CHEMICAL
or O
minocycline, B-CHEMICAL
respectively, O
at O
1, O
5, O
10, O
30, O
50, O
or O
100 O
mg/kg/day O
through O
drinking O
water O
for O
1 O
week. O
Our O

results O
have O
shown O
that O
MMP-9 B-GENE-Y
messenger O
ribonucleic O
acid O
(mRNA) O
expression O
was O
inhibited O
by O
doxycycline B-CHEMICAL
starting O
at O
10 O
mg/kg/day O
(P<0.02). O
Minocycline B-CHEMICAL
showed O
more O
potent O
inhibition O
on O
MMP-9 B-GENE-Y
mRNA O
expression, O
starting O
at O
1 O
(P<0.005) O
and O
further O
at O
more O
than O
30 O
(P<0.001) O
mg/kg/day. O
At O
the O
enzymatic O
activity O
level, O
doxycycline B-CHEMICAL
started O
to O
suppress O
MMP-9 B-GENE-Y
activity O
at O
5 O
mg/kg/day O

(P<0.001), O
while O
minocycline B-CHEMICAL
had O
an O
effect O
at O
a O
lower O
dose, O
1 O
mg/kg/day O
(P<0.02). O
The O
inhibition O
of O
cerebral O
MMP-9 B-GENE-Y
mRNA O
and O
activity O
were O
highly O
correlated O
with O
drug O
levels O
in O
the O
brain O
tissue. O
We O
also O
assessed O
the O
potential O
relevant O
signaling O
pathway O
in O
vitro O
to O
elucidate O
the O
mechanisms O
underlying O
the O
MMP-9 B-GENE-Y
inhibition O
by O
tetracyclines. B-CHEMICAL
In O
vitro, O
minocycline, B-CHEMICAL
but O
not O
doxycycline, B-CHEMICAL
inhibits O
MMP-9, B-GENE-Y
at O
least O
in O
part, O
via O
the O

extracellular B-GENE-N
signaling-related I-GENE-N
kinase I-GENE-N
1/2 I-GENE-N
(ERK1/2)-mediated B-GENE-N
pathway. O
This O
study O
provided O
the O
evidence O
that O
the O
tetracyclines B-CHEMICAL
inhibit O
stimulated O
cerebral O
MMP-9 B-GENE-Y
at O
multiple O
levels O
and O
are O
effective O
at O
very O
low O
doses, O
offering O
great O
potential O
for O
therapeutic O
use. O
Investigating O
the O
regulation O
of O
one-carbon B-CHEMICAL
metabolism O
in O
Arabidopsis O
thaliana. O
Serine B-CHEMICAL
(Ser) B-CHEMICAL
biosynthesis O
in O
C(3) O
plants O
can O
occur O
via O
several O
pathways. O
One O
major O
route O
involves O
the O
tetrahydrofolate B-CHEMICAL
(THF)-dependent B-CHEMICAL
activities O
of O
the O
glycine B-GENE-N

decarboxylase I-GENE-N
complex I-GENE-N
(GDC, B-GENE-N
EC B-GENE-Y
2.1.1.10) I-GENE-Y
and O
serine B-GENE-N
hydroxymethyltransferase I-GENE-N
(SHMT, B-GENE-N
EC B-GENE-Y
2.1.2.1) I-GENE-Y
with O
glycine B-CHEMICAL
(Gly) B-CHEMICAL
as O
one-carbon B-CHEMICAL
(1-C) B-CHEMICAL
source. O
An O
alternative O
THF-dependent B-CHEMICAL
pathway O
involves O
the O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
activities O
with O
formate B-CHEMICAL
as O
1-C B-CHEMICAL
source. O
Here, O
we O
have O
investigated O
aspects O
of O
the O
regulation O
of O
these O
two O
folate-mediated O
pathways O
in O
Arabidopsis O
thaliana O
(L.) O
Heynh. O
Columbia O
using O

two O
approaches. O
Firstly, O
transgenic O
plants O
overexpressing O
formate B-GENE-Y
dehydrogenase I-GENE-Y
(FDH, B-GENE-Y
EC B-GENE-Y
1.2.1.2) I-GENE-Y
were O
used O
to O
continue O
our O
previous O
studies O
on O
the O
function O
of O
FDH B-GENE-Y
in O
formate B-CHEMICAL
metabolism. O
The O
formate B-CHEMICAL
pool O
size O
was O
approximately O
73 O
nmol O
(g O
FW)(-1) O
in O
wild O
type O
(WT) O
Arabidopsis O
plants; O
three O
independent O
transgenic O
lines O
had O
similar-sized O
pools O
of O
formate. B-CHEMICAL
Transgenic O
plants O
produced O
more O
(13)CO(2) B-CHEMICAL
from O
supplied O
[(13)C]formate B-CHEMICAL
than O
did O
WT O
plants O
but O
were O

not O
significantly O
different O
from O
WT O
plants O
in O
their O
synthesis O
of O
Ser. B-CHEMICAL
We O
concluded O
that O
FDH B-GENE-Y
has O
no O
direct O
role O
in O
the O
regulation O
of O
the O
above O
two O
pathways O
of O
Ser B-CHEMICAL
synthesis; O
the O
breakdown O
of O
formate B-CHEMICAL
to O
CO(2) B-CHEMICAL
by O
the O
FDH B-GENE-Y
reaction O
is O
the O
primary O
and O
preferred O
fate O
of O
the O
organic O
acid O
in O
Arabidopsis. O
The O
ratio O
between O
the O
GDC/SHMT B-GENE-N
and O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
pathways O
of O
Ser B-CHEMICAL
synthesis O
from O
[alpha-(13)C]Gly B-CHEMICAL
and O
[(13)C]formate, B-CHEMICAL
respectively, O
in O
Arabidopsis O
shoots O
was O
21 O
: O
1; O
in O

roots, O
9 O
: O
1. O
In O
shoots, O
therefore, O
the O
pathway O
from O
formate B-CHEMICAL
plays O
only O
a O
small O
role O
in O
Ser B-CHEMICAL
synthesis; O
in O
the O
case O
of O
roots, O
results O
indicated O
that O
the O
9 O
: O
1 O
ratio O
was O
as O
a O
result O
of O
greater O
fluxes O
of O
(13)C B-CHEMICAL
through O
both O
pathways O
together O
with O
a O
relatively O
higher O
contribution O
from O
the O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
route O
than O
in O
shoots. O
We O
also O
examined O
the O
synthesis O
of O
Ser B-CHEMICAL
in O
a O
GDC-deficient B-GENE-N
mutant O
of O
Arabidopsis O
(glyD) B-CHEMICAL
where O
the O
GDC/SHMT B-GENE-N
pathway O
was O
impaired. O
Compared O
with O
WT, O
glyD B-CHEMICAL
plants O
accumulated O

5-fold O
more O
Gly B-CHEMICAL
than O
WT O
after O
supplying O
[alpha-(13)C]Gly B-CHEMICAL
for O
24 O
h; O
the O
accumulation O
of O
Ser B-CHEMICAL
from O
[alpha-(13)C]Gly B-CHEMICAL
was O
reduced O
by O
25% O
in O
the O
same O
time O
period. O
On O
the O
other O
hand, O
the O
accumulation O
of O
Ser B-CHEMICAL
through O
the O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
pathway O
in O
glyD B-CHEMICAL
plants O
was O
2.5-fold O
greater O
than O
that O
in O
WT O
plants. O
Our O
experiments O
confirmed O
that O
the O
GDC/SHMT B-GENE-N
and O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
pathways O
normally O
operate O
independently O
in O
Arabidopsis O
plants O
but O
that O

when O
the O
primary O
GDC/SHMT B-GENE-N
pathway O
is O
impaired O
the O
alternative O
C1-THF B-GENE-Y
synthase/SHMT I-GENE-Y
pathway O
can O
partially O
compensate O
for O
deficiencies O
in O
the O
synthesis O
of O
Ser. B-CHEMICAL
Studies O
of O
the O
biogenic B-GENE-N
amine I-GENE-N
transporters. I-GENE-N
13. O
Identification O
of O
"agonist" O
and O
"antagonist" O
allosteric O
modulators O
of O
amphetamine-induced B-CHEMICAL
dopamine B-CHEMICAL
release. O
Recent O
studies O
identified O
novel O
allosteric O
modulators O
of O
the O
dopamine B-GENE-Y
(DA) I-GENE-Y
transporter I-GENE-Y
(DAT). B-GENE-Y

N-(Diphenylmethyl)-2-phenyl-4-quinazolinamine B-CHEMICAL
(SoRI-9804), B-CHEMICAL
N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine B-CHEMICAL
(SoRI-20040), B-CHEMICAL
and O
N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine B-CHEMICAL
(SoRI-20041) B-CHEMICAL
partially O
inhibited O

[(125)I]3beta-(4'-iodophenyl)tropan-2beta-carboxylic B-CHEMICAL
acid I-CHEMICAL
methyl I-CHEMICAL
ester I-CHEMICAL
(RTI-55) B-CHEMICAL
binding, O
slowed O
the O
dissociation O
rate O
of O
[(125)I]RTI-55 B-CHEMICAL
from O
the O
DAT, B-GENE-Y
and O
partially O
inhibited O
[(3)H]dopamine B-CHEMICAL
uptake. O
In O
the O
present O
study, O
we O
report O
that O
SoRI-9804 B-CHEMICAL
and O
SoRI-20040, B-CHEMICAL
at O
doses O
that O
do O
not O
alter O
release, O
partially O
inhibited O
d-amphetamine-induced B-CHEMICAL

DAT-mediated B-GENE-Y
release O
of O
[(3)H]1-methyl-4-phenylpyridinium B-CHEMICAL
(MPP(+))or[(3)H]dopamine B-CHEMICAL
from O
striatal O
synaptosomes O
("DAT-mediated B-GENE-Y
DA B-CHEMICAL
release") O
in O
a O
dose-dependent O
manner. O
SoRI-20041, B-CHEMICAL
which O
does O
not O
alter O
DAT-mediated B-GENE-Y
DA B-CHEMICAL
release O
measured O
with O
[(3)H]DA, B-CHEMICAL
reversed O
the O
effect O
of O
SoRI-20040. B-CHEMICAL
SoRI-20040 B-CHEMICAL
and O
SoRI-9804 B-CHEMICAL
also O
partially O
inhibited O

DAT-mediated B-GENE-Y
DA B-CHEMICAL
release O
induced O
by O
DA B-CHEMICAL
or O
(+/-)-3,4-methylenedioxyamphetamine, B-CHEMICAL
demonstrating O
that O
the O
observed O
partial O
inhibition O
is O
not O
specific O
for O
a O
particular O
DAT B-GENE-Y
substrate. O
SoRI-9804 B-CHEMICAL
and O
SoRI-20040 B-CHEMICAL
did O
not O
attenuate O
D-amphetamine-induced B-CHEMICAL
release O
of O
[(3)H]5-hydroxytryptamine B-CHEMICAL
from O
serotonergic, O
or O
[(3)H]MPP(+) B-CHEMICAL
from O
noradrenergic, O
nerve O
terminals. O
Kinetic O
experiments O
demonstrated O
that O

SoRI-9804, B-CHEMICAL
in O
contrast O
to O
cocaine, B-CHEMICAL
slowed O
D-amphetamine-induced B-CHEMICAL
release O
of O
[(3)H]MPP(+) B-CHEMICAL
from O
dopaminergic O
nerve O
terminals O
without O
altering O
the O
apparent O
rate O
constants. O
The O
two O
major O
findings O
of O
this O
study O
are O
1) O
the O
identification O
of O
both O
"agonist" O
(SoRI-9804 B-CHEMICAL
and O
SoRI-20040) B-CHEMICAL
and O
"antagonist" O
(SoRI-20041) B-CHEMICAL
allosteric O
modulators O
of O
D-amphetamine-induced B-CHEMICAL
DAT-mediated B-GENE-Y
DA B-CHEMICAL
release O
and O
2) O
[(3)H]DA B-CHEMICAL

uptake O
and O
d-amphetamine-induced B-CHEMICAL
DAT-mediated B-GENE-Y
efflux O
can O
be O
separately O
modulated. O
Such O
agents O
may O
have O
therapeutic O
potential O
for O
the O
treatment O
of O
stimulant O
addiction, O
Parkinson's O
disease, O
and O
other O
psychiatric O
disorders. O
Enhanced O
beta2-adrenergic B-GENE-Y
receptor I-GENE-Y
(beta2AR) B-GENE-Y
signaling O
by O
adeno-associated O
viral O
(AAV)-mediated O
gene O
transfer. O
BACKGROUND: O
Beta2-adrenergic B-GENE-Y
receptors I-GENE-Y
(beta2AR) B-GENE-Y
play O
important O
regulatory O
roles O
in O
a O
variety O
of O
cells O
and O
organ O
systems O
and O
are O
important O
therapeutic O
targets O
in O
the O
treatment O
of O
airway O

and O
cardiovascular O
disease. O
Prolonged O
use O
of O
beta-agonists O
results O
in O
tolerance O
secondary O
to O
receptor O
down-regulation O
resulting O
in O
reduced O
therapeutic O
efficiency. O
The O
purpose O
of O
this O
work O
is O
to O
evaluate O
the O
signaling O
capabilities O
of O
the O
beta2AR B-GENE-Y
expressed O
by O
a O
recombinant O
adeno-associated O
viral O
(AAV) O
vector O
that O
also O
included O
an O
enhanced O
green O
fluorescent O
protein O
(EGFP) O
gene O
(AAV-beta2AR/EGFP). B-GENE-Y
RESULTS: O
By O
epifluorescence O
microscopy, O
approximately O
40% O
of O
infected O
HEK O
293 O
cells O
demonstrated O
EGFP O
expression. O

beta2AR B-GENE-Y
density O
measured O
with O
[3H]dihydroalprenolol B-CHEMICAL
([3H]DHA) B-CHEMICAL
increased O
either O
13- O
or O
77-fold O
in O
infected O
cells O
compared O
to O
mock O
infected O
controls O
depending O
on O
the O
culture O
conditions O
used. O
The O
[3H]DHA B-CHEMICAL
binding O
was O
to O
a O
single O
receptor O
population O
with O
a O
dissociation O
constant O
of O
0.42 O
nM, O
as O
would O
be O
expected O
for O
wild-type O
beta2AR. B-GENE-Y
Agonist O
competition O
assays O
with O
[3H]DHA B-CHEMICAL
showed O
the O
following O
rank O
order O
of O
potency: O
isoproterenol>epinephrine> B-CHEMICAL

norepinephrine, B-CHEMICAL
consistent O
with O
beta2AR B-GENE-Y
interaction. O
Isoproterenol-stimulated B-CHEMICAL
cyclic B-CHEMICAL
AMP I-CHEMICAL
levels O
were O
5-fold O
higher O
in O
infected O
cells O
compared O
to O
controls O
(314 O
+/- O
43 O
vs. O
63.4 O
+/- O
9.6 O
nmol/dish; O
n O
= O
3). O
Receptor O
trafficking O
demonstrated O
surface O
expression O
of O
beta2AR B-GENE-Y
with O
vehicle O
treatment O
and O
internalization O
following O
isoproterenol B-CHEMICAL
treatment. O
CONCLUSIONS: O
We O
conclude O
that O
HEK O
293 O
cells O
infected O
with O
AAV-beta2AR/EGFP B-GENE-Y
effectively O
express O
beta2AR B-GENE-Y
and O
that O
increased O
expression O

of O
these O
receptors O
results O
in O
enhanced O
beta2AR B-GENE-Y
signaling. O
This O
method O
of O
gene O
transfer O
may O
provide O
an O
important O
means O
to O
enhance O
function O
in O
in O
vivo O
systems. O
Update O
on O
rivastigmine. B-CHEMICAL
BACKGROUND: O
Rivastigmine B-CHEMICAL
is O
a O
carbamate B-CHEMICAL
drug O
designed O
to O
inhibit O
both O
acetylcholinesterase B-GENE-Y
and O
butyrylcholinesterase B-GENE-Y
by O
reversibly O
covalently O
bonding O
to O
these O
enzymes. O
Butyrylcholinesterase B-GENE-Y
in-creases O
as O
Alzheimer O
disease O
progresses, O
so O
its O
inhibition O
may O
become O
more O
important O
as O
the O
disease O
worsens. O
Metabolism O
of O

rivastigmine B-CHEMICAL
occurs O
at O
the O
synapse O
rather O
than O
at O
the O
liver O
and O
previous O
studies O
have O
demonstrated O
no O
drug-drug O
interactions. O
Rivastigmine B-CHEMICAL
has O
a O
half-life O
at O
the O
synapse O
of O
9 O
hours O
allowing O
for O
bid O
dosing. O
REVIEW O
SUMMARY: O
Effective O
therapy O
requires O
up-titration O
from O
initial O
dosage O
of O
3 O
mg/d O
to O
6 O
mg/d O
with O
additional O
increases O
to O
9 O
mg O
or O
12 O
mg/d O
giving O
additional O
benefits O
in O
some O
patients. O
Beneficial O
effects O
with O
rivastigmine B-CHEMICAL
therapy O
in O
the O
functioning O
of O
activities O
of O
daily O
living, O
behavior, O

cognition, O
and O
global O
functioning O
have O
been O
demonstrated O
in O
patients O
with O
mild O
to O
moderate O
Alzheimer O
disease O
in O
4 O
large O
double-blind, O
placebo-controlled O
multicenter O
clinical O
trials. O
Potential O
adverse O
effects O
of O
nausea, O
vomiting, O
or O
diarrhea O
in O
these O
original O
Alzheimer O
trials O
with O
rapid O
(every O
week) O
dosage O
increases O
occurred O
in O
up O
to O
34% O
of O
patients O
and O
can O
be O
minimized O
by O
slower O
monthly O
up-titrations. O
Rivastigmine B-CHEMICAL
also O
was O
proven O
effective O
in O
decreasing O
psychiatric O
symptoms O
and O
cognitive O
deficits O
in O
a O
large O
double-blind, O
placebo-controlled O
trial O
in O
patients O
with O
diffuse O
Lewy O
body O
disease. O

Other O
studies O
have O
suggested O
that O
rivastigmine B-CHEMICAL
improves O
symptoms O
in O
nursing O
home O
patients O
with O
more O
severe O
stage O
Alzheimer O
disease, O
Parkinson O
dementia, O
and O
subcortical O
dementia. O
Follow-up O
studies O
have O
suggested O
that O
rivastigmine B-CHEMICAL
may O
delay O
disease O
progression O
and, O
in O
patients O
discontinuing O
the O
drug, O
no O
withdrawal O
effects O
were O
seen. O
CONCLUSION: O
Rivastigmine B-CHEMICAL
is O
an O
effective O
therapeutic O
agent O
for O
treating O
cognitive O
and O
behavioral O
symptoms O
in O
Alzheimer O
disease O
and O
diffuse O
Lewy O
body O
disease O
and O
may O
also O
have O
beneficial O
effects O
in O
vascular O
and O
Parkinson O
dementias. O
The O
therapeutic O
potential O
of O
allosteric O
ligands O

for O
free O
fatty B-CHEMICAL
acid I-CHEMICAL
sensitive O
GPCRs. B-GENE-N
G B-GENE-N
protein I-GENE-N
coupled I-GENE-N
receptors I-GENE-N
(GPCRs) B-GENE-N
are O
the O
most O
historically O
successful O
therapeutic O
targets. O
Despite O
this O
success O
there O
are O
many O
important O
aspects O
of O
GPCR B-GENE-N
pharmacology O
and O
function O
that O
have O
yet O
to O
be O
exploited O
to O
their O
full O
therapeutic O
potential. O
One O
in O
particular O
that O
has O
been O
gaining O
attention O
in O
recent O
times O
is O
that O
of O
GPCR B-GENE-N
ligands O
that O
bind O
to O
allosteric O
sites O
on O
the O
receptor O
distinct O
from O
the O
orthosteric O
site O
of O
the O
endogenous O
ligand. O
As O
therapeutics, O
allosteric O
ligands O
possess O
many O
theoretical O
advantages O
over O
their O
orthosteric O
counterparts, O
including O
more O
complex O

modes O
of O
action, O
improved O
safety, O
more O
physiologically O
appropriate O
responses, O
better O
target O
selectivity, O
and O
reduced O
likelihood O
of O
desensitisation O
and O
tachyphylaxis. O
Despite O
these O
advantages, O
the O
development O
of O
allosteric O
ligands O
is O
often O
difficult O
from O
a O
medicinal O
chemistry O
standpoint O
due O
to O
the O
more O
complex O
challenge O
of O
identifying O
allosteric O
leads O
and O
their O
often O
flat O
or O
confusing O
SAR. O
The O
present O
review O
will O
consider O
the O
advantages O
and O
challenges O
associated O
with O
allosteric O
GPCR B-GENE-N
ligands, O
and O
examine O
how O
the O
particular O
properties O
of O
these O
ligands O
may O
be O
exploited O
to O
uncover O
the O
therapeutic O
potential O
for O
free O
fatty B-CHEMICAL
acid I-CHEMICAL
sensitive O
GPCRs. B-GENE-N

Chemokine B-GENE-N
expression O
is O
upregulated O
in O
chondrocytes O
in O
diabetic O
fracture O
healing. O
Chemokines B-GENE-N
are O
thought O
to O
play O
an O
important O
role O
in O
several O
aspects O
of O
bone O
metabolism O
including O
the O
recruitment O
of O
leukocytes O
and O
the O
formation O
of O
osteoclasts. O
We O
investigated O
the O
impact O
of O
diabetes O
on O
chemokine B-GENE-N
expression O
in O
normal O
and O
diabetic O
fracture O
healing. O
Fracture O
of O
the O
femur O
was O
performed O
in O
streptozotocin-induced B-CHEMICAL
diabetic O
and O
matched O
normoglycemic O
control O
mice. O
Microarray O
analysis O
was O
carried O
out O
and O
chemokine B-GENE-N
mRNA O
levels O
in O

vivo O
were O
assessed. O
CCL4 B-GENE-Y
were O
examined O
in O
fracture O
calluses O
by O
immunohistochemistry O
and O
the O
role O
of O
TNF B-GENE-N
in O
diabetes-enhanced O
expression O
was O
investigated O
by O
treatment O
of O
animals O
with O
the O
TNF-specific B-GENE-N
inhibitor, O
pegsunercept. O
In O
vitro O
studies O
were O
conducted O
with O
ATDC5 O
chondrocytes. O
Diabetes O
significantly O
upregulated O
mRNA O
levels O
of O
several O
chemokines B-GENE-N
in O
vivo O
including O
CCL4, B-GENE-Y
CCL8, B-GENE-Y
CCL6, B-GENE-Y
CCL11, B-GENE-Y
CCL20, B-GENE-Y
CCL24, B-GENE-Y
CXCL2, B-GENE-Y
CXCL5 B-GENE-Y
and O

chemokine B-GENE-N
receptors I-GENE-N
CCR5 B-GENE-Y
and O
CXCR4. B-GENE-Y
Chondrocytes O
were O
identified O
as O
a O
significant O
source O
of O
CCL4 B-GENE-Y
and O
its O
expression O
in O
diabetic O
fractures O
was O
dependent O
on O
TNF B-GENE-N
(P<0.05). O
TNF-α B-GENE-Y
significantly O
increased O
mRNA O
levels O
of O
several O
chemokines B-GENE-N
in O
vitro O
which O
were O
knocked O
down O
with O
FOXO1 B-GENE-Y
siRNA O
(P<0.05). O
CCL4 B-GENE-Y
expression O
at O
the O
mRNA O
and O
proteins O
levels O
was O
induced O
by O
FOXO1 B-GENE-Y
over-expression O
and O
reduced O
by O
FOXO1 B-GENE-Y
knockdown. O
The O
current O
studies O
point O
to O
the O

importance O
of O
TNF-α B-GENE-Y
as O
a O
mechanism O
for O
diabetes O
enhanced O
chemokine B-GENE-N
expression O
by O
chondrocytes, O
which O
may O
contribute O
to O
the O
accelerated O
loss O
of O
cartilage O
observed O
in O
diabetic O
fracture O
healing. O
Moreover, O
in O
vitro O
results O
point O
to O
FOXO1 B-GENE-Y
as O
a O
potentially O
important O
transcription O
factor O
in O
mediating O
this O
effect. O
Allelopathic O
activity O
studies O
of O
Mikania O
scandens. O
Preliminary O
investigation O
of O
a O
number O
of O
plant O
extracts O
for O
allelopathic O
activity O
using O
seed O
germination O
inhibition O
bioassay O
showed O
a O
promising O
activity O
of O
the O
water O
extract O
of O
the O
aerial O
parts O
of O
Mikania O
scandens. O

Activity-guided O
fractionation O
of O
the O
M. O
scandens O
extract O
led O
to O
the O
isolation O
of O
the O
highly O
allelopathic O
active O
compound O
mikanolide, B-CHEMICAL
with O
minimum O
inhibitory O
concentration O
of O
0.083 O
µM O
mL(-1). O
As O
M. O
scandens O
is O
a O
highly O
abundant O
invasive O
plant O
in O
Sri O
Lanka O
and O
other O
South O
Asian O
countries, O
this O
plant O
could O
be O
developed O
as O
an O
environment O
friendly O
natural O
herbicide, O
either O
in O
crude O
form O
as O
shredded O
plant O
material O
or O
as O
pure O
mikanolide, B-CHEMICAL
which O
is O
the O
major O
constituent O
(∼0.02%) O
in O
the O
plant. O
Glioma O
cell O
sensitivity O
to O

topotecan: B-CHEMICAL
the O
role O
of O
p53 B-GENE-Y
and O
topotecan-induced B-CHEMICAL
DNA O
damage. O
Topotecan B-CHEMICAL
is O
a O
topoisomerase B-GENE-Y
I I-GENE-Y
inhibitor O
which O
is O
currently O
evaluated O
as O
an O
adjuvant O
agent O
for O
malignant O
glioma. O
Here, O
we O
analysed O
the O
effects O
of O
topotecan B-CHEMICAL
on O
12 O
human O
malignant O
glioma O
cell O
lines O
in O
vitro. O
All O
cell O
lines O
expressed O
topoisomerase B-GENE-Y
I I-GENE-Y
mRNA. O
High O
p53 B-GENE-Y
protein O
levels, O
but O
not O
genetic O
or O
functional O
p53 B-GENE-Y
status, O
were O
associated O
with O
increased O
topotecan-induced B-CHEMICAL
DNA/topoisomerase B-GENE-Y
I I-GENE-Y
complex O
formation. O
Neither O
functional O
p53 B-GENE-Y

status, O
nor O
p53 B-GENE-Y
protein O
levels, O
nor O
complex O
formation O
predicted O
topotecan-induced B-CHEMICAL
growth O
inhibition. O
We O
thus O
confirm O
a O
possible O
role O
for O
p53 B-GENE-Y
protein O
in O
modulating O
topoisomerase B-GENE-Y
I I-GENE-Y
activity O
but O
conclude O
that O
the O
major O
molecular O
determinants O
of O
topotecan B-CHEMICAL
sensitivity O
in O
glioma O
cells O
await O
identification. O
Binding O
site O
of O
amiloride B-CHEMICAL
to O
urokinase B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
depends O
on O
species. O
A O
novel O
drug O
candidate O
is O
checked O
on O
its O
potency O
on O
animal O
models O
before O
it O
can O
advance O
to O
human O
phase O
of O
the O
research. O
Usually O
negative O
results O
on O
animal O
phase O
disqualify O
it. O

Targeting O
specific O
enzymes O
by O
small O
chemicals O
raises O
the O
question O
about O
the O
appropriateness O
of O
this O
approach. O
As O
an O
example, O
the O
urokinase B-GENE-Y
(uPA) B-GENE-Y
is O
recognized O
as O
an O
important O
enzyme O
responsible O
for O
cancer O
metastasis O
and O
angiogenesis. O
It O
is O
therefore O
important O
to O
ask O
the O
question O
if O
a O
small O
chemical O
will O
inhibit O
uPA B-GENE-N
of O
different O
species O
with O
the O
same O
or O
different O
potency. O
Using O
DNA O
sequence O
and O
known O
structure O
of O
uPA B-GENE-N
we O
have O
modeled O
3D O
structures O
of O
uPAs B-GENE-N
for O
several O
different O
species. O
By O
theoretical O
calculations O
we O
have O
determined O
most O
probable O
structure O
of O
amiloride/uPAs B-CHEMICAL
complexes. O
Catalytic O
triad O

(B57, O
B102, O
B195) O
and O
specificity O
pocket O
(B187-B197, O
B212-B229) O
are O
highly O
conserved O
in O
all O
cases, O
and O
are O
the O
regions O
responsible O
for O
proteolytic O
activity O
and O
recognition O
of O
the O
substrate. O
Significant O
differences O
were O
observed O
in O
a O
different O
region O
(loop O
B93-B101), O
that O
we O
identified O
as O
binding O
site O
of O
amiloride B-CHEMICAL
to O
the O
tissue B-GENE-Y
plasminogen I-GENE-Y
activator I-GENE-Y
(tPA). B-GENE-Y
Although O
tPA B-GENE-Y
shares O
the O
same O
function O
of O
activating O
plasminogen O
and O
it O
is O
structurally O
similar O
to O

uPA. B-GENE-Y
Amiloride B-CHEMICAL
is O
a O
specific O
inhibitor O
of O
uPA B-GENE-N
but O
does O
not O
inhibit O
tPA. B-GENE-Y
Our O
study O
shows O
that O
predicted O
position O
of O
amiloride B-CHEMICAL
depends O
on O
species O
and O
in O
some O
cases O
was O
located, O
as O
expected, O
in O
the O
specificity O
pocket, O
but O
in O
the O
other O
cases O
close O
to O
the O
loop O
B93-B101. O
This O
location O
could O
weaken O
affinity O
of O
binding O
or O
prevent O
inhibition O
of O
uPA. B-GENE-Y
Therefore, O
drug O
screening O
and O
elimination O
process O
based O
solely O
on O
animal O
study, O
without O
careful O
structural O
analysis, O
could O
lead O
to O
the O
elimination O
of O
potential O
drugs O
for O
humans. O
Threshold O
concentrations O
of O
endothelin-1: B-GENE-Y
the O
effects O
on O

contractions O
induced O
by O
5-hydroxytryptamine B-CHEMICAL
in O
isolated O
rat O
cerebral O
and O
mesenteric O
arteries. O
This O
study O
compares O
the O
effects O
of O
threshold O
concentrations O
of O
endothelin-1 B-GENE-Y
in O
isolated O
rat O
basilar O
arteries O
with O
those O
in O
mesenteric O
arterial O
branches O
and O
investigates O
the O
mechanisms O
of O
inhibitory O
and O
potentiating O
endothelin-1-effects. B-GENE-Y
In O
basilar O
arteries, O
endothelin-1 B-GENE-Y
reduces O
the O
contractions O
induced O
by O
5-hydroxytryptamine B-CHEMICAL
(5-HT), B-CHEMICAL
by O
the O
thromboxane B-CHEMICAL
A2 I-CHEMICAL
agonist O
U46619, B-CHEMICAL
and O
by O

vasopressin. B-GENE-Y
The O
inhibitory O
effect O
of O
endothelin-1 B-GENE-Y
on O
the O
contraction O
induced O
by O
5-HT B-CHEMICAL
is O
abolished O
by O
deendothelialization, O
by O
the O
endothelin B-GENE-Y
ET(B) I-GENE-Y
receptor I-GENE-Y
antagonist O
RES B-CHEMICAL
701-1, I-CHEMICAL
by O
indomethacin, B-CHEMICAL
or O
by O
glibenclamide. B-CHEMICAL
In O
mesenteric O
arteries, O
endothelin-1 B-GENE-Y
potentiates O
the O
contractile O
effects O
of O
5-HT, B-CHEMICAL
U46619, B-CHEMICAL
and O
vasopressin. B-GENE-Y
The O
potentiation O
of O
the O
contractile O
effect O
induced O
by O
5-HT B-CHEMICAL
is O
only O
somewhat O
modified O
by O

deendothelialization, O
but O
abolished O
by O
the O
thromboxane B-GENE-Y
A2 I-GENE-Y
receptor I-GENE-Y
antagonists O
GR32191 B-CHEMICAL
and O
ridogrel. B-CHEMICAL
U46619 B-CHEMICAL
potentiates O
the O
5-HT-effect B-CHEMICAL
in O
mesenteric O
arteries. O
Thus, O
though O
the O
contractile O
endothelin B-GENE-N
ET(A) I-GENE-N
receptors I-GENE-N
were O
not O
blocked, O
threshold O
concentrations O
of O
endothelin-1 B-GENE-N
inhibited O
contractile O
effects O
in O
the O
rat O
basilar O
artery O
via O
activation O
of O
endothelial B-GENE-Y
ET(B) I-GENE-Y
receptors. I-GENE-Y
Prostaglandins B-CHEMICAL
and O
ATP-sensitive B-GENE-N
K+ I-GENE-N
channels I-GENE-N
are O
involved O
in O
this O
inhibitory O
action. O
In O
contrast, O

endothelin-1 B-GENE-N
potentiates O
contractile O
actions O
in O
mesenteric O
arteries O
via O
the O
release O
of O
endogeneous O
thromboxane B-CHEMICAL
A2 I-CHEMICAL
from O
non-endothelial O
cells. O
The O
study O
points O
out O
the O
completely O
different O
role O
of O
the O
endothelium O
in O
combined O
effects O
of O
endothelin-1 B-GENE-Y
between O
cerebral O
and O
mesenteric O
arteries. O
ABCA1 B-GENE-Y
single O
nucleotide B-CHEMICAL
polymorphisms O
on O
high-density B-GENE-N
lipoprotein-cholesterol I-GENE-N
and O
overweight: O
the O
D.E.S.I.R. O
study. O
The O
adenosine B-GENE-Y
triphosphate-binding I-GENE-Y
cassette I-GENE-Y
A1 I-GENE-Y

(ABCA1) B-GENE-Y
gene O
plays O
a O
key O
role O
in O
reverse O
cholesterol B-CHEMICAL
transport. O
Some O
ABCA1 B-GENE-Y
gene O
polymorphisms O
have O
been O
associated O
with O
high-density B-GENE-N
lipoprotein-cholesterol I-GENE-N
(HDL-C) B-GENE-N
concentrations. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
three O
polymorphisms, O
C69T, B-GENE-N
G378C, B-GENE-N
and O
G1051A B-GENE-N
(R219K), B-GENE-N
on O
HDL-C B-GENE-N
levels O
and O
their O
interaction O
with O
BMI O
in O
more O
than O
5000 O
French O
whites O
from O
the O
D.E.S.I.R. O
(Data O
from O
an O

Epidemiological O
Study O
on O
the O
Insulin B-GENE-Y
Resistance O
syndrome) O
cohort O
study. O
The O
T O
allele O
of O
the O
C69T B-GENE-N
single O
nucleotide O
polymorphism O
(SNP) O
was O
associated O
with O
higher O
HDL-C B-GENE-N
levels O
in O
normal-weight O
men O
(BMI O
<25 O
kg/m(2)). O
The O
C O
allele O
of O
the O
G378C B-GENE-N
SNP O
was O
associated O
with O
lower O
HDL-C B-GENE-N
in O
overweight O
subjects O
(BMI O
> O
or O
=25 O
kg/m(2)). O
For O
the O
G1051A B-GENE-N
SNP, O
in O
the O
normal-weight O
group, O
the O
minor O

A O
allele O
was O
significantly O
associated O
with O
higher O
HDL-C B-GENE-N
levels. O
In O
contrast, O
in O
overweight O
people, O
the O
minor O
allele O
was O
associated O
with O
lower O
HDL-C B-GENE-N
levels. O
After O
accounting O
for O
multiple O
testing, O
empiric O
p O
values O
remained O
significant O
for O
the O
associations O
between O
G378C B-GENE-N
SNP O
and O
HDL-C B-GENE-N
in O
the O
overweight O
group O
and O
between O
G1051A B-GENE-N
SNP O
and O
HDL-C B-GENE-N
in O
the O
normal-weight O
group. O
This O
study O
suggests O
that O
ABCA1 B-GENE-Y
gene O
polymorphisms O
modulate O
HDL-C B-GENE-N
concentrations, O
in O
interaction O
with O
BMI, O
and, O
thus, O
they O
might O
influence O
cardiovascular O

risk O
in O
the O
general O
population. O
Metformin B-CHEMICAL
and O
Sulfonylureas B-CHEMICAL
in O
Relation O
to O
Cancer O
Risk O
in O
Type O
II O
Diabetes O
Patients: O
A O
Meta-analysis O
using O
primary O
data O
of O
published O
studies. O
INTRODUCTION: O
Accumulating O
evidence O
suggests O
that O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
and O
hyperinsulinemia O
are O
at O
increased O
risk O
for O
developing O
malignancies. O
It O
remains O
to O
be O
fully O
elucidated O
whether O
use O
of O
metformin, B-CHEMICAL
an O
insulin B-GENE-Y
sensitizer, O
and/or O
sulfonylureas, B-CHEMICAL
insulin B-GENE-Y
secretagogues, O
affect O
cancer O

incidence O
in O
subjects O
with O
T2DM. O
MATERIAL O
& O
METHODS: O
We O
performed O
a O
meta-analysis O
using O
PubMed, O
of O
randomized O
control O
trials O
(RCTs), O
cohorts, O
and O
case-control O
studies O
published O
through O
July O
2012 O
that O
assess O
effects O
of O
metformin B-CHEMICAL
and/or O
sulfonylurea B-CHEMICAL
sulfonylureas B-CHEMICAL
on O
cancer O
risk O
at O
any O
site, O
in O
subjects O
with O
T2DM. O
Fixed O
and O
random O
effects O
meta-analysis O
models O
were O
used, O
and O
the O
effect O
size O
was O
summarized O
as O
relative O
risk O
(RR) O
for O
RCTs/cohorts O
and O
as O
odds O
ratio O

(OR) O
for O
the O
case-control O
studies. O
RESULTS: O
Analysis O
of O
24 O
metformin B-CHEMICAL
studies O
in O
subjects O
with O
T2DM O
showed O
that O
metformin B-CHEMICAL
use O
is O
associated O
with O
reduced O
risk O
for O
the O
development O
of O
cancer, O
in O
both O
cohort O
(RR=0.70 O
[95% O
CI=0.67-0.73]) O
and O
case-control O
studies O
(OR=0.90 O
[95% O
CI=0.84-0.98]), O
but O
this O
finding O
was O
not O
supported O
by O
RCTs O
(RR=1.01[95% O

CI=0.81-1.26]). O
Data O
from O
18 O
sulfonylurea B-CHEMICAL
studies O
in O
subjects O
with O
T2DM O
showed O
that O
sulfonylurea B-CHEMICAL
use O
is O
associated O
with O
an O
increase O
in O
all-cancer O
risk, O
in O
cohort O
studies O
(RR=1.55 O
[95% O
CI=1.48 O
-1.63]), O
though O
data O
from O
RCTs O
(RR=1.17 O
[95% O
CI=0.95-1.45]) O
and O
case-control O
studies O
(OR=1.02 O
[95% O

CI=0.93-1.13]) O
failed O
to O
demonstrate O
a O
statistically O
significant O
effect. O
CONCLUSIONS: O
This O
analysis O
using O
pooled O
primary O
data O
demonstrates O
that O
metformin B-CHEMICAL
use O
reduces, O
while O
sulfonylurea B-CHEMICAL
use O
may O
be O
associated O
with O
an O
increased O
cancer O
risk O
in O
subjects O
with O
T2DM. O
These O
findings O
need O
to O
be O
confirmed O
in O
large-scale O
RCTs O
before O
they O
are O
translated O
into O
clinical O
practice. O
Discovery O
and O
structure-activity O
relationships O
of O
small O
molecules O
that O
block O
the O
human B-GENE-N
immunoglobulin I-GENE-N
G-human I-GENE-N
neonatal I-GENE-Y
Fc I-GENE-Y
receptor I-GENE-Y

(hIgG-hFcRn) B-GENE-N
protein-protein O
interaction. O
The O
neonatal B-GENE-Y
Fc I-GENE-Y
receptor, I-GENE-Y
FcRn, B-GENE-Y
prolongs O
the O
half-life O
of O
IgG B-GENE-N
in O
the O
serum O
and O
represents O
a O
potential O
therapeutic O
target O
for O
the O
treatment O
of O
autoimmune O
disease. O
Small O
molecules O
that O
block O
the O
protein-protein O
interactions O
of O
human B-GENE-N
IgG-human I-GENE-N
FcRn I-GENE-Y
may O
lower O
pathogenic O
autoantibodies O
and O
provide O
effective O
treatment. O
A O
novel O
class O
of O
quinoxalines B-CHEMICAL
has O
been O
discovered O
as O
antagonists O
of O
the O
IgG:FcRn B-GENE-N
protein-protein O
interaction O
through O
optimization O
of O
a O

hit O
derived O
from O
a O
virtual O
ligand-based O
screen. O
Comparative O
formation O
of O
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-CHEMICAL
(PhIP) B-CHEMICAL
in O
creatinine/phenylalanine B-CHEMICAL
and O
creatinine/phenylalanine/4-oxo-2-nonenal B-CHEMICAL
reaction O
mixtures. O
The O
comparative O
formation O
of O
the O
heterocyclic O
aromatic O
amine O
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine B-CHEMICAL

(PhIP) B-CHEMICAL
in O
both O
creatinine/phenylalanine B-CHEMICAL
(CRN/Phe) B-CHEMICAL
and O
creatinine/phenylalanine/4-oxo-2-nonenal B-CHEMICAL
(CRN/Phe/ON) B-CHEMICAL
systems O
was O
studied O
to O
analyse O
the O
ability O
of O
lipid-derived O
reactive O
carbonyls B-CHEMICAL
to O
promote O
PhIP B-CHEMICAL
formation. O
Although O
PhIP B-CHEMICAL
was O
produced O
to O
some O
extent O
in O
the O
CRN/Phe B-CHEMICAL
system, O
the O
presence O
of O
the O
oxidized O
lipid O
increased O
considerably O
the O
amount O
of O
PhIP B-CHEMICAL
produced. O
This O
increase O
seemed O
to O
be O
a O
consequence O
of O
the O
decrease O
in O
the O

E(a) O
of O
the O
reaction O
when O
the O
lipid O
was O
present, O
which O
diminished O
from O
112.9 O
to O
80.9 O
kJ/mol. O
On O
the O
other O
hand, O
the O
addition O
of O
the O
lipid O
did O
not O
seem O
to O
produce O
PhIP B-CHEMICAL
by O
an O
alternative O
mechanism O
because O
PhIP B-CHEMICAL
was O
formed O
analogously O
in O
both O
CRN/Phe B-CHEMICAL
and O
CRN/Phe/ON B-CHEMICAL
systems O
as O
a O
function O
of O
pH, O
creatinine B-CHEMICAL
concentration, O
phenylalanine B-CHEMICAL
concentration, O
time, O
temperature, O
oxygen B-CHEMICAL
concentration O
in O
the O
reaction O
atmosphere, O
and O
the O
addition O
of O
different O
amounts O
of O
ammonia. B-CHEMICAL
All O
these O
results O
suggest O
that O
the O
ability O
of O
lipid O
oxidation O

products O
to O
produce O
PhIP B-CHEMICAL
is O
related O
to O
their O
capacity O
to O
induce O
the O
Strecker O
degradation O
of O
phenylalanine B-CHEMICAL
to O
phenylacetaldehyde. B-CHEMICAL
Therefore, O
any O
other O
reactive O
carbonyl B-CHEMICAL
compound O
that O
can O
produce O
the O
Strecker O
degradation O
of O
phenylalanine B-CHEMICAL
should O
also O
be O
considered O
as O
a O
potential O
inducer O
of O
PhIP B-CHEMICAL
formation O
under O
appropriate O
conditions. O
Agmatine: B-CHEMICAL
an O
endogenous O
clonidine-displacing B-CHEMICAL
substance O
in O
the O
brain. O
Clonidine, B-CHEMICAL
an O
antihypertensive O
drug, O
binds O
to O
alpha B-GENE-N
2-adrenergic I-GENE-N
and I-GENE-N
imidazoline I-GENE-N
receptors. I-GENE-N
The O
endogenous O

ligand O
for O
imidazoline B-GENE-N
receptors I-GENE-N
may O
be O
a O
clonidine-displacing B-CHEMICAL
substance, O
a O
small O
molecule O
isolated O
from O
bovine O
brain. O
This O
clonidine-displacing B-CHEMICAL
substance O
was O
purified O
and O
determined O
by O
mass O
spectroscopy O
to O
be O
agmatine B-CHEMICAL
(decarboxylated B-CHEMICAL
arginine), I-CHEMICAL
heretofore O
not O
detected O
in O
brain. O
Agmatine B-CHEMICAL
binds O
to O
alpha B-GENE-N
2-adrenergic I-GENE-N
and I-GENE-N
imidazoline I-GENE-N
receptors I-GENE-N
and O
stimulates O
release O
of O
catecholamines B-CHEMICAL
from O
adrenal O
chromaffin O
cells. O
Its O
biosynthetic O
enzyme, O

arginine B-GENE-Y
decarboxylase, I-GENE-Y
is O
present O
in O
brain. O
Agmatine, B-CHEMICAL
locally O
synthesized, O
is O
an O
endogenous O
agonist O
at O
imidazoline B-GENE-N
receptors, I-GENE-N
a O
noncatecholamine B-CHEMICAL
ligand O
at O
alpha B-GENE-N
2-adrenergic I-GENE-N
receptors I-GENE-N
and O
may O
act O
as O
a O
neurotransmitter. O
Amino B-CHEMICAL
acids I-CHEMICAL
as O
co-amorphous O
stabilizers O
for O
poorly O
water O
soluble O
drugs O
- O
Part O
1: O
Preparation, O
stability O
and O
dissolution O
enhancement. O
Poor O
aqueous O
solubility O
of O
an O
active O
pharmaceutical O
ingredient O
(API) O
is O
one O
of O
the O
most O
pressing O
problems O
in O
pharmaceutical O
research O
and O
development O
because O

up O
to O
90% O
of O
new O
API O
candidates O
under O
development O
are O
poorly O
water O
soluble. O
These O
drugs O
usually O
have O
a O
low O
and O
variable O
oral O
bioavailability, O
and O
therefore O
an O
unsatisfactory O
therapeutic O
effect. O
One O
of O
the O
most O
promising O
approaches O
to O
increase O
dissolution O
rate O
and O
solubility O
of O
these O
drugs O
is O
the O
conversion O
of O
a O
crystalline O
form O
of O
the O
drug O
into O
its O
respective O
amorphous O
form, O
usually O
by O
incorporation O
into O
hydrophilic O
polymers, O
forming O
glass O
solutions. O
However, O
this O
strategy O
only O
led O
to O
a O
small O
number O
of O
marketed O
products O
usually O
because O
of O
inadequate O
physical O
stability O
of O
the O
drug O
(crystallization). O
In O
this O
study, O
we O

investigated O
a O
fundamentally O
different O
approach O
to O
stabilize O
the O
amorphous O
form O
of O
drugs, O
namely O
the O
use O
of O
amino B-CHEMICAL
acids I-CHEMICAL
as O
small O
molecular O
weight O
excipients O
that O
form O
specific O
molecular O
interactions O
with O
the O
drug O
resulting O
in O
co-amorphous O
forms. O
The O
two O
poorly O
water O
soluble O
drugs O
carbamazepine B-CHEMICAL
and O
indomethacin B-CHEMICAL
were O
combined O
with O
amino B-CHEMICAL
acids I-CHEMICAL
from O
the O
binding O
sites O
of O
the O
biological O
receptors O
of O
these O
drugs. O
Mixtures O
of O
drug O
and O
the O
amino B-CHEMICAL
acids I-CHEMICAL
arginine, B-CHEMICAL
phenylalanine, B-CHEMICAL
tryptophan B-CHEMICAL
and O
tyrosine B-CHEMICAL
were O
prepared O
by O
vibrational O
ball O
milling. O
Solid-state O
characterization O
with O

X-ray O
powder O
diffraction O
(XRPD) O
and O
differential O
scanning O
calorimetry O
(DSC) O
revealed O
that O
the O
various O
blends O
could O
be O
prepared O
as O
homogeneous, O
single O
phase O
co-amorphous O
formulations O
indicated O
by O
the O
appearance O
of O
an O
amorphous O
halo O
in O
the O
XRPD O
diffractograms O
and O
a O
single O
glass O
transition O
temperature O
(Tg) O
in O
the O
DSC O
measurements. O
In O
addition, O
the O
Tgs O
of O
the O
co-amorphous O
mixtures O
were O
significantly O
increased O
over O
those O
of O
the O
individual O
drugs. O
The O
drugs O
remained O
chemically O
stable O
during O
the O
milling O
process O
and O
the O

co-amorphous O
formulations O
were O
generally O
physically O
stable O
over O
at O
least O
6months O
at O
40°C O
under O
dry O
conditions. O
The O
dissolution O
rate O
of O
all O
co-amorphous O
drug-amino B-CHEMICAL
acid I-CHEMICAL
mixtures O
was O
significantly O
increased O
over O
that O
of O
the O
respective O
crystalline O
and O
amorphous O
pure O
drugs. O
Amino B-CHEMICAL
acids I-CHEMICAL
thus O
appear O
as O
promising O
excipients O
to O
solve O
challenges O
connected O
with O
the O
stability O
and O
dissolution O
of O
amorphous O
drugs. O
Disposition O
and O
Metabolism O
of O
GSK2251052 B-CHEMICAL
in O
Humans: O
A O
Novel O
Boron-Containing B-CHEMICAL
Antibiotic. O

(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole B-CHEMICAL
(GSK2251052) B-CHEMICAL
is O
a O
novel O
boron-containing B-CHEMICAL
antibiotic O
that O
inhibits O
bacterial B-GENE-N
leucyl I-GENE-N
tRNA I-GENE-N
synthetase, I-GENE-N
and O
that O
has O
been O
in O
development O
for O
the O
treatment O
of O
serious O
Gram-negative O
infections. O
In O
this O
study, O
six O
healthy O
adult O
male O
subjects O
received O
a O
single O
i.v. O
dose O
of O

[(14)C]GSK2251052, B-CHEMICAL
1500 O
mg O
infused O
over O
1 O
hour. O
Blood, O
urine, O
and O
feces O
were O
collected O
over O
an O
extended O
period O
of O
14 O
days, O
and O
accelerator O
mass O
spectrometry O
was O
used O
to O
quantify O
low O
levels O
of O
radioactivity O
in O
plasma O
at O
later O
time O
points O
to O
supplement O
the O
less-sensitive O
liquid O
scintillation O
counting O
technique. O
An O
excellent O
mass O
balance O
recovery O
was O
achieved O
representing O
a O
mean O
total O
of O
98.2% O
of O
the O
dose, O
including O
90.5% O
recovered O
in O
the O
urine. O
Pharmacokinetic O
analysis O
demonstrated O
that O
radioactivity O
was O
moderately O
associated O
with O

the O
blood O
cellular O
components, O
and O
together O
with O
GSK2251052, B-CHEMICAL
both O
were O
highly O
distributed O
into O
tissues. O
The O
parent O
compound O
had O
a O
much O
shorter O
half-life O
than O
total O
radioactivity O
in O
plasma, O
approximately O
11.6 O
hours O
compared O
with O
96 O
hours. O
GSK2251052 B-CHEMICAL
and O
its O
major O
metabolite O
M3, O
which O
resulted O
from O
oxidation O
of O
the O
propanol B-CHEMICAL
side O
chain O
to O
the O
corresponding O
carboxylic B-CHEMICAL
acid, I-CHEMICAL
comprised O
the O
majority O
of O
the O
plasma O
radioactivity, O
37 O
and O
53% O
of O
the O
area O
under O
the O
plasma O
versus O
time O
concentration O
curve O
from O
time O
zero O
to O
infinity, O
respectively. O
Additionally, O
M3 O

was O
eliminated O
renally, O
and O
was O
demonstrated O
to O
be O
responsible O
for O
the O
long O
plasma O
radioactivity O
elimination O
half-life. O
A O
combination O
of O
in O
vitro O
metabolism O
experiments O
and O
a O
pharmacokinetic O
study O
in O
monkeys O
with O
the O
inhibitor O
4-methylpyrazole B-CHEMICAL
provided O
strong O
evidence O
that O
alcohol B-GENE-N
dehydrogenase, I-GENE-N
potentially O
in O
association O
with O
aldehyde B-GENE-N
dehydrogenase, I-GENE-N
is O
the O
primary O
enzyme O
involved O
in O
the O
formation O
of O
the O
M3 O
metabolite. O
Identification O
of O
a O
novel O
polymorphism O
in O
the O
3'UTR O
of O
the O
L-arginine B-GENE-N
transporter I-GENE-N
gene O

SLC7A1: B-GENE-Y
contribution O
to O
hypertension O
and O
endothelial O
dysfunction. O
BACKGROUND: O
Endothelial O
dysfunction O
because O
of O
reduced O
nitric B-CHEMICAL
oxide I-CHEMICAL
bioavailability O
is O
a O
key O
feature O
of O
essential O
hypertension. O
We O
have O
found O
that O
normotensive O
siblings O
of O
subjects O
with O
essential O
hypertension O
have O
impaired O
endothelial O
function O
accompanied O
by O
altered O
arginine B-CHEMICAL
metabolism. O
METHODS O
AND O
RESULTS: O
We O
have O
identified O
a O
novel O
C/T O
polymorphism O
in O
the O
3'UTR O
of O
the O
principal O
arginine B-GENE-N

transporter, I-GENE-N
solute I-GENE-N
carrier I-GENE-N
family I-GENE-N
7 I-GENE-N
(cationic I-GENE-N
amino I-GENE-N
acid I-GENE-N
transporter, I-GENE-N
y+ I-GENE-N
system), I-GENE-N
member I-GENE-N
1 I-GENE-N
gene I-GENE-N
(SLC7A1). B-GENE-Y
The O
minor O
T O
allele O
significantly O
attenuates O
reporter O
gene O
expression O
(P<0.01) O
and O
is O
impaired O
in O
its O
capacity O
to O
form O
DNA-protein O
complexes O
(P<0.05). O
In O
278 O
hypertensive O
subjects O
the O
frequency O
of O
the O
T O
allele O
was O
13.3% O
compared O
with O
7.6% O
in O
498 O
normotensive O
subjects O
(P<0.001). O
Moreover, O
the O
overall O
genotype O
distribution O
observed O
in O

hypertensives O
differed O
significantly O
from O
that O
in O
normotensives O
(P<0.001). O
To O
complement O
these O
studies, O
we O
generated O
an O
endothelial-specific O
transgenic O
mouse O
overexpressing O
L-arginine B-GENE-N
transporter I-GENE-N
SLC7A1. B-GENE-Y
The O
Slc7A1 B-GENE-Y
transgenic O
mice O
exhibited O
significantly O
enhanced O
responses O
to O
the O
endothelium-dependent O
vasodilator O
acetylcholine B-CHEMICAL
(-log O
EC50 O
for O
wild-type O
versus O
Slc7A1 B-GENE-Y
transgenic: O
6.87+/-0.10 O
versus O

7.56+/-0.13; O
P<0.001). O
This O
was O
accompanied O
by O
elevated O
production O
of O
nitric B-CHEMICAL
oxide I-CHEMICAL
by O
isolated O
aortic O
endothelial O
cells. O
CONCLUSIONS: O
The O
present O
study O
identifies O
a O
key, O
functionally O
active O
polymorphism O
in O
the O
3'UTR O
of O
SLC7A1. B-GENE-Y
As O
such, O
this O
polymorphism O
may O
account O
for O
the O
apparent O
link O
between O
altered O
endothelial O
function, O
L-arginine, B-CHEMICAL
and O
nitric B-CHEMICAL
oxide I-CHEMICAL
metabolism O
and O
predisposition O
to O
essential O
hypertension. O
Identification O
of O
an O
Allosteric O

Modulator O
of O
Serotonin B-GENE-Y
Transporter I-GENE-Y
with O
Novel O
Mechanism O
of O
Action. O
Serotonin B-GENE-Y
transporters I-GENE-Y
(SERT) B-GENE-Y
play O
an O
essential O
role O
in O
the O
termination O
and O
regulation O
of O
serotonin B-CHEMICAL
signaling O
in O
the O
brain. O
SERT B-GENE-Y
is O
also O
the O
target O
of O
antidepressants O
and O
psychostimulants. O
Molecules O
with O
novel O
activities O
and O
modes O
of O
interaction O
with O
regard O
to O
SERT B-GENE-Y
function O
are O
of O
great O
scientific O
and O
clinical O
interest. O
We O
explored O
structural O
regions O
outside O
the O
putative O
serotonin B-CHEMICAL
translocation O
pathway O
to O
identify O
potential O
binding O
sites O
for O
allosteric O
transporter O
modulators O
(ATMs). O

Mutational O
studies O
revealed O
a O
pocket O
of O
amino B-CHEMICAL
acids I-CHEMICAL
outside O
the O
orthosteric O
substrate O
binding O
sites O
located O
in O
the O
interface O
between O
extracellular O
loops O
1 O
and O
3 O
that O
when O
mutated O
affect O
transporter O
function. O
Using O
the O
structure O
of O
the O
bacterial O
transporter O
homologue O
leucine B-GENE-N
transporter I-GENE-N
as O
a O
template, O
we O
developed O
a O
structural O
model O
of O
SERT. B-GENE-Y
We O
performed O
molecular O
dynamics O
simulations O
to O
further O
characterize O
the O
allosteric O
pocket O
that O
was O
identified O
by O
site-directed O
mutagenesis O
studies O
and O
employed O
this O
pocket O
in O
a O
virtual O
screen O
for O
small-molecule O
modulators O
of O
SERT B-GENE-Y
function. O
In O
functional O
transport O
assays, O
we O
found O
that O
one O

of O
the O
identified O
molecules, O
ATM7, O
increased O
the O
reuptake O
of O
serotonin, B-CHEMICAL
possibly O
by O
facilitating O
the O
interaction O
of O
serotonin B-CHEMICAL
with O
transport-ready O
conformations O
of O
SERT B-GENE-Y
when O
concentrations O
of O
serotonin B-CHEMICAL
were O
low O
and O
rate O
limiting. O
In O
addition, O
ATM7 O
potentiates O
3,4-methylenedioxy-N-methylamphetamine B-CHEMICAL
(MDMA, B-CHEMICAL
"Ecstasy")-induced O
reversed O
transport O
by O
SERT. B-GENE-Y
Taking O
advantage O
of O
a O
conformationally O
sensitive O
residue O
in O
transmembrane O
domain O
6, O
we O
demonstrate O
that O
ATM7 O
mechanistically O

stabilizes O
an O
outward-facing O
conformation O
of O
SERT. B-GENE-Y
Taken O
together O
these O
observations O
demonstrate O
that O
ATM7 O
acts O
through O
a O
novel O
mechanism O
that O
involves O
allosteric O
modulation O
of O
SERT B-GENE-Y
function. O
Structural O
basis O
for O
the O
altered O
drug O
sensitivities O
of O
non-small O
cell O
lung O
cancer-associated O
mutants O
of O
human B-GENE-Y
epidermal I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor. I-GENE-Y
The O
epidermal B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(EGFR) B-GENE-Y
has O
an O
essential O
role O
in O
multiple O
signaling O
pathways, O
including O
cell O
proliferation O
and O
migration, O
through O
extracellular O
ligand O
binding O
and O
subsequent O
activation O
of O
its O
intracellular O
tyrosine B-GENE-N
kinase I-GENE-N

(TK) I-GENE-N
domain. I-GENE-N
The O
non-small O
cell O
lung O
cancer O
(NSCLC)-associated O
EGFR B-GENE-Y
mutants, O
L858R B-GENE-N
and O
G719S, B-GENE-N
are O
constitutively O
active O
and O
oncogenic. O
They O
display O
sensitivity O
to O
TK B-GENE-N
inhibitors, O
including O
gefitinib B-CHEMICAL
and O
erlotinib. B-CHEMICAL
In O
contrast, O
the O
secondary O
mutation O
of O
the O
gatekeeper O
residue, O
T790M, B-GENE-N
reportedly O
confers O
inhibitor O
resistance O
on O
the O
oncogenic O
EGFR B-GENE-Y
mutants. O
In O
this O
study, O
our O
biochemical O
analyses O
revealed O
that O
the O
introduction O
of O
the O
T790M B-GENE-N
mutation O
confers O

gefitinib B-CHEMICAL
resistance O
on O
the O
G719S B-GENE-N
mutant. O
The O
G719S/T790M B-GENE-N
double O
mutant O
has O
enhanced O
activity O
and O
retains O
high O
gefitinib-binding B-CHEMICAL
affinity. O
The O
T790M B-GENE-N
mutation O
increases O
the O
ATP B-CHEMICAL
affinity O
of O
the O
G719S B-GENE-N
mutant, O
explaining O
the O
acquired O
drug O
resistance O
of O
the O
double O
mutant. O
Structural O
analyses O
of O
the O
G719S/T790M B-GENE-N
double O
mutant, O
as O
well O
as O
the O
wild O
type O
and O
the O
G719S B-GENE-N
and O
L858R B-GENE-N
mutants, O
revealed O
that O
the O
T790M B-GENE-N
mutation O
stabilizes O
the O
hydrophobic O
spine O
of O
the O
active O

EGFR-TK B-GENE-Y
conformation. O
The O
Met790 B-CHEMICAL
side O
chain O
of O
the O
G719S/T790M B-GENE-N
double O
mutant, O
in O
the O
apo O
form O
and O
gefitinib- B-CHEMICAL
and O
AMPPNP-bound O
forms, O
adopts O
different O
conformations O
that O
explain O
the O
accommodation O
of O
these O
ligands. O
In O
the O
L858R B-GENE-N
mutant O
structure, O
the O
active-site O
cleft O
is O
expanded O
by O
the O
repositioning O
of O
Phe723 B-CHEMICAL
within O
the O
P-loop. O
Notably, O
the O
introduction O
of O
the O
F723A B-GENE-N
mutation O
greatly O
enhanced O
the O
gefitinib B-CHEMICAL
sensitivity O
of O
the O
wild-type O

EGFR B-GENE-Y
in O
vivo, O
supporting O
our O
hypothesis O
that O
the O
expansion O
of O
the O
active-site O
cleft O
results O
in O
enhanced O
gefitinib B-CHEMICAL
sensitivity. O
Taken O
together, O
our O
results O
provide O
a O
structural O
basis O
for O
the O
altered O
drug O
sensitivities O
caused O
by O
distinct O
NSCLC-associated O
EGFR B-GENE-Y
mutations. O
Chemopreventive O
effects O
of O
Ginkgo O
biloba O
extract O
in O
estrogen-negative B-CHEMICAL
human O
breast O
cancer O
cells. O
Excessive O
level O
of O
estrogen B-CHEMICAL
is O
considered O
as O
a O
main O
cause O
of O
breast O
cancer, O
therefore, O
many O
studies O
have O
focused O
on O
estrogen B-GENE-Y
receptor I-GENE-Y
(ER)-positive B-GENE-Y
breast O
cancer, O
even O

though O
ER-negative B-GENE-Y
cancer O
has O
a O
poor O
prognosis O
than O
ER-positive B-GENE-Y
breast O
cancer. O
We O
evaluated O
the O
anti-cancer O
effects O
of O
Ginkgo O
biloba O
extract O
(GBE) O
in O
estrogen-independent B-CHEMICAL
breast O
cancer. O
GBE O
has O
been O
traditionally O
used O
as O
a O
platelet O
activating O
factor, O
a O
circulatory O
stimulant, O
a O
tonic, O
and O
anti-asthmatic O
drug, O
and O
anti-cancer O
agent. O
However, O
anti-cancer O
effects O
of O
GBE O
on O
ER-negative B-GENE-Y
breast O
cancer O
have O
not O
been O
proved O
yet. O
In O
this O
study, O
we O
tested O
chemotherapeutic O
potential O
of O
GBE O
in O

the O
MDA-MB-231 O
(ER-negative) B-GENE-Y
human O
breast O
cancer O
cell O
line. O
Our O
results O
showed O
that O
cytotoxicity O
effects O
of O
GBE O
in O
MDA-MB-231 O
lead O
to O
DNA O
fragmentation O
at O
high O
concentrations O
(500 O
and O
1,000 O
μg/ml). O
Caspase-3 B-GENE-Y
was O
significantly O
activated O
and O
mRNA O
levels O
of O
apoptosis-related O
genes O
(Bcl-2 B-GENE-Y
and O
Bax) B-GENE-Y
were O
altered. O
These O
results O
indicate O
that O
GBE O
induces O
apoptosis O
in O
MDA-MB-231 O
cells. O
It O
is O
presumed O
that O
GBE O
has O
chemopreventive O
effects O

in O
ER-independent B-GENE-Y
breast O
cancer O
through O
anti-proliferation O
and O
apoptosis-inducing O
activities. O
Biosynthesis O
of O
iron-sulphur B-CHEMICAL
clusters O
is O
a O
complex O
and O
highly O
conserved O
process. O
Iron-sulphur B-CHEMICAL
([Fe-S]) B-CHEMICAL
clusters O
are O
simple O
inorganic O
prosthetic O
groups O
that O
are O
contained O
in O
a O
variety O
of O
proteins O
having O
functions O
related O
to O
electron O
transfer, O
gene O
regulation, O
environmental O
sensing O
and O
substrate O
activation. O
In O
spite O
of O
their O
simple O
structures, O
biological O
[Fe-S] B-CHEMICAL
clusters O
are O
not O
formed O
spontaneously. O
Rather, O
a O
consortium O
of O
highly O
conserved O
proteins O
is O
required O
for O
both O
the O
formation O
of O

[Fe-S] B-CHEMICAL
clusters O
and O
their O
insertion O
into O
various O
protein O
partners. O
Among O
the O
[Fe-S] B-CHEMICAL
cluster O
biosynthetic O
proteins O
are O
included O
a O
pyridoxal B-CHEMICAL
phosphate-dependent I-CHEMICAL
enzyme O
(NifS) B-GENE-Y
that O
is O
involved O
in O
the O
activation O
of O
sulphur B-CHEMICAL
from O
l-cysteine, B-CHEMICAL
and O
a O
molecular O
scaffold O
protein O
(NifU) B-GENE-N
upon O
which O
[Fe-S] B-CHEMICAL
cluster O
precursors O
are O
formed. O
The O
formation O
or O
transfer O
of O
[Fe-S] B-CHEMICAL
clusters O
appears O
to O
require O
an O
electron-transfer O
step. O
Another O
complexity O
is O
that O
molecular O
chaperones O
homologous O
to O
DnaJ O
and O

DnaK O
are O
involved O
in O
some O
aspect O
of O
the O
maturation O
of O
[Fe-S]-cluster-containing B-CHEMICAL
proteins. O
It O
appears O
that O
the O
basic O
biochemical O
features O
of O
[Fe-S] B-CHEMICAL
cluster O
formation O
are O
strongly O
conserved O
in O
Nature, O
since O
organisms O
from O
all O
three O
life O
Kingdoms O
contain O
the O
same O
consortium O
of O
homologous O
proteins O
required O
for O
[Fe-S] B-CHEMICAL
cluster O
formation O
that O
were O
discovered O
in O
the O
eubacteria. O
Copolymerization O
of O
2-methylene-1,3-dioxepane B-CHEMICAL
and O
glycidyl B-CHEMICAL
methacrylate, I-CHEMICAL
a O
well-defined O
and O
efficient O
process O
for O
achieving O
functionalized O

polyesters B-CHEMICAL
for O
covalent O
binding O
of O
bioactive O
molecules. O
The O
understanding O
of O
cell-material O
interactions O
is O
important O
for O
creating O
personalized O
implants O
for O
tissue O
engineering. O
This O
has O
resulted O
in O
an O
interest O
in O
developing O
polymers O
with O
functional O
groups O
with O
the O
possibility O
of O
controlling O
the O
macromolecular O
surface. O
We O
have O
in O
a O
one-pot O
reaction O
synthesized O
a O
series O
of O
amorphous O
and O
degradable O
polyester-based B-CHEMICAL
copolymers O
with O
active O
functional O
groups O
by O
copolymerization O
of O
2-methylene-1,3-dioxepane B-CHEMICAL
and O
glycidyl B-CHEMICAL
methacrylate. I-CHEMICAL
The O
properties O
of O
the O
final O

polymers O
were O
varied O
by O
varying O
the O
feed O
ratios O
of O
the O
monomers O
and O
it O
was O
seen O
that O
it O
was O
possible O
to O
control O
the O
amount O
of O
active O
functional O
groups. O
The O
resulting O
epoxy-functionalized B-CHEMICAL
polyester I-CHEMICAL
was O
further O
modified O
by O
covalent O
immobilization O
of O
heparin. O
The O
heparinization O
was O
done O
in O
order, O
in O
a O
future O
aspect, O
to O
enhance O
the O
osteogenic O
differentiation O
of O
mesenchymal O
stem O
cells. O
Heparin O
binds O
directly O
with O
the O
growth O
factor O
bone B-GENE-Y
morphogenetic I-GENE-Y
protein-2 I-GENE-Y
and O
helps O
to O
retain O
its O
activity. O
The O
molecular O
structure O
of O
the O
copolymers O
was O
characterized O
by O
nuclear O
magnetic O

resonance, O
size O
exclusion O
chromatography, O
and O
fourier O
transform O
infrared O
spectroscopy. O
Differential O
scanning O
calorimetry O
and O
tensile O
testing O
showed O
that O
the O
monomer O
feed O
ratio O
had O
a O
great O
influence O
on O
the O
properties O
of O
the O
final O
polymer O
and O
that O
it O
thus O
was O
possible O
to O
control O
the O
mechanical O
properties O
to O
suit O
an O
intended O
application. O
The O
presence O
of O
heparin O
was O
verified O
by O
toluidine B-CHEMICAL
blue I-CHEMICAL
staining O
and O
all O
the O
films O
tested O
showed O
positive O
signals O
for O
heparin. O
DNA B-GENE-Y
polymerase I-GENE-Y
POLQ I-GENE-Y
and O
cellular O
defense O
against O
DNA O
damage. O
In O
mammalian O
cells, O
POLQ B-GENE-Y
(pol B-GENE-Y
θ) I-GENE-Y
is O
an O
unusual O
specialized O
DNA B-GENE-N

polymerase I-GENE-N
whose O
in O
vivo O
function O
is O
under O
active O
investigation. O
POLQ B-GENE-Y
has O
been O
implicated O
by O
different O
experiments O
to O
play O
a O
role O
in O
resistance O
to O
ionizing O
radiation O
and O
defense O
against O
genomic O
instability, O
in O
base O
excision O
repair, O
and O
in O
immunological O
diversification. O
The O
protein O
is O
formed O
by O
an O
N-terminal B-GENE-N
helicase-like I-GENE-N
domain, I-GENE-N
a O
C-terminal B-GENE-N
DNA I-GENE-N
polymerase I-GENE-N
domain, I-GENE-N
and O
a O
large B-GENE-N
central I-GENE-N
domain I-GENE-N
that O
spans O
between O
the O
two. O
This O
arrangement O
is O
also O
found O
in O
the O
Drosophila B-GENE-Y
Mus308 I-GENE-Y
protein, O
which O
functions O
in O
resistance O
to O
DNA O
interstrand O
crosslinking O
agents. O
Homologs O
of O

POLQ B-GENE-Y
and O
Mus308 B-GENE-Y
are O
found O
in O
multicellular O
eukaryotes, O
including O
plants, O
but O
a O
comparison O
of O
phenotypes O
suggests O
that O
not O
all O
of O
these O
genes O
are O
functional O
orthologs. O
Flies O
defective O
in O
Mus308 B-GENE-Y
are O
sensitive O
to O
DNA O
interstrand O
crosslinking O
agents, O
while O
mammalian O
cells O
defective O
in O
POLQ B-GENE-Y
are O
primarily O
sensitive O
to O
DNA O
double-strand O
breaking O
agents. O
Cells O
from O
Polq(-/-) B-GENE-Y
mice O
are O
hypersensitive O
to O
radiation O
and O
peripheral O
blood O
cells O
display O
increased O
spontaneous O
and O
ionizing O
radiation-induced O
levels O
of O
micronuclei O
(a O

hallmark O
of O
gross O
chromosomal O
aberrations), O
though O
mice O
apparently O
develop O
normally. O
Loss O
of O
POLQ B-GENE-N
in O
human O
and O
mouse O
cells O
causes O
sensitivity O
to O
ionizing O
radiation O
and O
other O
double O
strand O
breaking O
agents O
and O
increased O
DNA O
damage O
signaling. O
Retrospective O
studies O
of O
clinical O
samples O
show O
that O
higher O
levels O
of O
POLQ B-GENE-Y
gene O
expression O
in O
breast O
and O
colorectal O
cancer O
are O
correlated O
with O
poorer O
outcomes O
for O
patients. O
A O
clear O
understanding O
of O
the O
mechanism O
of O
action O
and O
physiologic O
function O
of O
POLQ B-GENE-Y
in O
the O
cell O
is O
likely O
to O
bear O
clinical O
relevance. O
Impaired O
in O
vivo O
binding O
of O
MeCP2 B-GENE-Y
to O
chromatin O
in O

the O
absence O
of O
its O
DNA B-GENE-N
methyl-binding I-GENE-N
domain. I-GENE-N
MeCP2 B-GENE-Y
is O
a O
methyl-CpG-binding B-GENE-N
protein I-GENE-N
that O
is O
a O
main O
component O
of O
brain O
chromatin O
in O
vertebrates. O
In O
vitro O
studies O
have O
determined O
that O
in O
addition O
to O
its O
specific O
methyl-CpG-binding B-GENE-N
domain I-GENE-N
(MBD) B-GENE-N
MeCP2 B-GENE-Y
also O
has O
several O
chromatin B-GENE-N
association I-GENE-N
domains. I-GENE-N
However, O
the O
specific O
interactions O
of O
MeCP2 B-GENE-Y
with O
methylated O
or O
non-methylated O
chromatin O
regions O
and O
the O
structural O
characteristics O
of O
the O
resulting O
DNA O
associations O
in O
vivo O
remain O
poorly O
understood. O
We O
analysed O
the O
role O
of O
the O

MBD B-GENE-N
in O
MeCP2-chromatin B-GENE-Y
associations O
in O
vivo O
using O
an O
MeCP2 B-GENE-Y
mutant O
Rett O
syndrome O
mouse O
model O
(Mecp2(tm)(1)(.)(1)(Jae)) B-GENE-Y
in O
which O
exon O
3 O
deletion O
results O
in O
an O
N-terminal B-CHEMICAL
truncation O
of O
the O
protein, O
including O
most O
of O
the O
MBD. B-GENE-N
Our O
results O
show O
that O
in O
mutant O
mice, O
the O
truncated O
form O
of O
MeCP2 B-GENE-Y
(ΔMeCP2) B-GENE-Y
is O
expressed O
in O
different O
regions O
of O
the O
brain O
and O
liver, O
albeit O
at O
50% O
of O
its O
wild-type O
(wt) O
counterpart. O
In O

contrast O
to O
the O
punctate O
nuclear O
distribution O
characteristic O
of O
wt O
MeCP2, B-GENE-Y
ΔMeCP2 B-GENE-Y
exhibits O
both O
diffuse O
nuclear O
localization O
and O
a O
substantial O
retention O
in O
the O
cytoplasm, O
suggesting O
a O
dysfunction O
of O
nuclear O
transport. O
In O
mutant O
brain O
tissue, O
neuronal O
nuclei O
are O
smaller, O
and O
ΔMeCP2 B-GENE-Y
chromatin O
is O
digested O
faster O
by O
nucleases, B-GENE-N
producing O
a O
characteristic O
nuclease-resistant O
dinucleosome. O
Although O
a O
fraction O
of O
ΔMeCP2 B-GENE-Y
is O
found O
associated O
with O
nucleosomes, O
its O
interaction O
with O
chromatin O
is O
transient O
and O
weak. O

Thus, O
our O
results O
unequivocally O
demonstrate O
that O
in O
vivo O
the O
MBD B-GENE-N
of O
MeCP2 B-GENE-Y
together O
with O
its O
adjacent O
region O
in O
the O
N-terminal O
domain O
are O
critical O
for O
the O
proper O
interaction O
of O
the O
protein O
with O
chromatin, O
which O
cannot O
be O
replaced O
by O
any O
other O
of O
its O
protein O
domains. O
Pseudohypoaldosteronism O
type O
1 O
and O
the O
genes O
encoding O
prostasin, B-GENE-Y
alpha-spectrin, B-GENE-Y
and O
Nedd4. B-GENE-Y
Pseudohypoaldosteronism O
type O
1 O
(PHA1), O
a O
rare O
disorder O
of O
infancy, O
presents O
with O
potential O
life-threatening O
salt O
wasting O
and O
failure O
to O
thrive. O
Thus O

far, O
PHA1 O
has O
been O
attributed O
to O
mutations O
affecting O
the O
mineralocorticoid B-GENE-Y
receptor I-GENE-Y
or O
any O
of O
the O
three O
subunits O
assembling O
the O
amiloride-sensitive B-GENE-N
epithelial I-GENE-N
sodium I-GENE-N
channel I-GENE-N
(ENaC). B-GENE-N
However, O
a O
lot O
of O
patients O
with O
a O
phenotype O
resembling O
PHA1, O
show O
no O
defects O
in O
these O
proteins, O
making O
it O
likely O
that O
further O
genes O
are O
involved O
in O
the O
aetiology O
of O
this O
disease. O
Recent O
studies O
have O
elucidated O
additional O
participants O
(alpha-spectrin B-GENE-Y
and O
members O
of O
the O
families O
of O
transmembrane B-GENE-N
serine I-GENE-N
proteases, I-GENE-N
ubiquitin-protein B-GENE-N

ligases, I-GENE-N
and O
serum- B-GENE-N
and I-GENE-N
glucocorticoid-regulated I-GENE-N
kinases, I-GENE-N
respectively) O
regulating O
and/or O
interacting O
in O
the O
complex O
pathway O
of O
sodium B-CHEMICAL
retention O
in O
the O
amiloride-sensitive B-CHEMICAL
distal O
nephron. O
This O
led O
us O
to O
investigate O
whether O
PHA1 O
can O
also O
be O
associated O
with O
mutations O
in O
some O
of O
these O
genes. O
Our O
data O
suggest O
that O
at O
least O
the O
prostasin B-GENE-Y
gene O
might O
be O
excluded O
as O
a O
causative O
locus. O
Cerebral O
and O
extracerebral O
cholesterol B-CHEMICAL
metabolism O
and O
CSF O
markers O
of O
Alzheimer's O
disease. O
The O
disturbances O
of O
the O
cholesterol B-CHEMICAL
synthesis O
and O
metabolism O
described O

in O
Alzheimer's O
disease O
(AD) O
may O
be O
both O
a O
consequence O
of O
the O
neurodegenerative O
process O
and O
a O
contributor O
to O
the O
pathogenesis. O
These O
putative O
relationships O
and O
their O
underlying O
mechanisms O
are O
not O
well O
understood. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
between O
the O
cerebral O
and O
extracerebral O
cholesterol B-CHEMICAL
synthesis O
and O
metabolism, O
and O
the O
AD O
pathology O
as O
reflected O
by O
CSF O
markers O
in O
humans. O
We O
evaluated O
the O
relationships O
between O
the O
plasma O
and O
the O
cerebrospinal O
fluid O
(CSF) O
concentrations O
of O
cholesterol, B-CHEMICAL
the O
cholesterol B-CHEMICAL
precursors O
lanosterol, B-CHEMICAL
lathosterol B-CHEMICAL

and O
desmosterol, B-CHEMICAL
and O
the O
cholesterol B-CHEMICAL
elimination O
products O
24S-hydroxycholesterol B-CHEMICAL
and O
27-hydroxycholesterol, B-CHEMICAL
and O
the O
CSF O
markers O
for O
AD O
pathology O
Aβ1-42 B-GENE-Y
and O
p-tau181 B-GENE-Y
in O
86 O
subjects O
with O
normal O
cognition O
and O
in O
107 O
AD O
patients. O
CSF O
desmosterol, B-CHEMICAL
cholesterol B-CHEMICAL
and O
24S-hydroxycholesterol B-CHEMICAL
in O
the O
AD O
group, O
and O
CSF O
24S-hydroxycholesterol B-CHEMICAL
in O
the O
control O
group O
correlated O
with O
the O
p-tau181 B-GENE-Y
levels. O
Neither O

CSF O
nor O
plasma O
concentrations O
of O
the O
included O
compounds O
correlated O
with O
the O
CSF O
Aβ1-42 B-GENE-Y
levels. O
In O
multivariate O
regression O
tests O
including O
age, O
gender, O
albumin O
ratio, O
number O
of O
the O
APOEɛ4 B-GENE-Y
alleles, O
and O
diagnosis, O
p-tau181 B-GENE-Y
levels O
independently O
predicted O
the O
CSF O
desmosterol, B-CHEMICAL
cholesterol B-CHEMICAL
and O
24S-hydroxycholesterol B-CHEMICAL
concentrations. O
The O
associations O
remained O
significant O
for O
CSF O
cholesterol B-CHEMICAL
and O
24S-hydroxycholesterol B-CHEMICAL
when O
analyses O
were O
separately O
performed O
in O
the O
AD O
group. O
The O
results O
suggest O
that O
alterations O
of O
CNS O

cholesterol B-CHEMICAL
de O
novo O
genesis O
and O
metabolism O
are O
related O
to O
neurodegeneration O
and O
in O
particular O
to O
the O
cerebral O
accumulation O
of O
phosphorylated B-GENE-Y
tau. I-GENE-Y
In O
vivo O
genotoxicity O
of O
methyleugenol B-CHEMICAL
in O
gpt B-GENE-Y
delta O
transgenic O
rats O
following O
medium-term O
exposure. O
Methyleugenol B-CHEMICAL
(MEG), B-CHEMICAL
which O
is O
commonly O
used O
as O
a O
fragrance O
and O
flavoring O
agent, O
has O
been O
shown O
to O
induce O
hepatocellular O
tumors O
in O
rodents. O
However, O
the O
role O
of O
genotoxicity O
as O
a O
possible O
mechanism O
of O
action O
is O
not O
fully O
understood O
even O
though O
the O
DNA-reactive O

metabolite O
of O
MEG B-CHEMICAL
has O
been O
identified. O
In O
this O
study, O
a O
gpt B-GENE-Y
delta O
transgenic O
rat O
model O
was O
used O
to O
clarify O
whether O
genotoxic O
mechanisms O
are O
involved O
in O
MEG-induced B-CHEMICAL
hepatocarcinogenesis O
following O
medium-term O
exposure. O
F344 O
gpt B-GENE-Y
delta O
rats O
were O
subjected O
to O
repeated O
oral O
administration O
of O
MEG B-CHEMICAL
at O
dosages O
of O
0, O
10, O
30, O
or O
100mg/kg O
(a O
carcinogenic O
dose) O
for O
13 O
weeks. O
The O
relative O
weight O
of O
the O
liver O
of O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG B-CHEMICAL
and O
the O
absolute O
weight O
of O
the O

liver O
of O
the O
male O
rats O
that O
were O
administered O
100mg/kg O
MEG B-CHEMICAL
were O
significantly O
increased. O
In O
addition, O
the O
number O
and O
area O
of O
glutathione B-GENE-N
S-transferase I-GENE-N
placental I-GENE-N
form I-GENE-N
(GST-P) B-GENE-N
positive O
foci O
and O
proliferating B-GENE-Y
cell I-GENE-Y
nuclear I-GENE-Y
antigen I-GENE-Y
(PCNA) B-GENE-Y
positive O
cell O
ratios O
in O
the O
hepatocytes O
were O
significantly O
increased O
in O
the O
male O
and O
female O
rats O
that O
were O
administered O
100mg/kg O
MEG B-CHEMICAL
compared O
with O
the O
control O
animals. O
In O
the O
in O
vivo O
mutation O
assays, O
a O
significant O
increase O
in O
the O
gpt B-GENE-Y
and O
Spi(-) B-GENE-N
mutant O
frequencies O
was O
observed O
in O
both O
sexes O
at O
the O

carcinogenic O
dose. O
These O
results O
suggest O
the O
possible O
participation O
of O
genotoxic O
mechanisms O
in O
MEG-induced B-CHEMICAL
hepatocarcinogenesis. O
Structural O
Investigation O
and O
Biological O
Activity O
of O
Sesquiterpene B-CHEMICAL
Lactones I-CHEMICAL
from O
the O
Traditional O
Chinese O
Herb O
Inula O
racemosa. O
Five O
new O
sesquiterpene B-CHEMICAL
lactones, I-CHEMICAL
racemosalactones B-CHEMICAL
A-E I-CHEMICAL
(1-5), O
along O
with O
19 O
known O
sesquiterpene B-CHEMICAL
latones I-CHEMICAL
(6-24), O
were O
isolated O
from O
the O
roots O
of O
Inula O
racemosa. O
Their O
structures O
were O
elucidated O
by O
extensive O
spectroscopic O

analysis, O
and O
the O
absolute O
configuration O
of O
2 O
was O
deduced O
from O
X-ray O
diffraction O
analysis. O
Compounds O
1, O
6, O
8, O
10, O
12, O
14, O
and O
17 O
exhibited O
antiproliferative O
activities O
with O
IC50 O
values O
ranging O
from O
0.38 O
to O
4.19 O
μg/mL O
against O
human O
non-small-cell O
lung O
cancer O
A549, O
hepatocellular O
carcinoma O
HepG2, O
and O
human O
fibrosarcoma O
HT1080 O
cells. O
Compounds O
6 O
and O
8 O
exhibited O
antiproliferative O
activities O
against O
endothelial O
cells O
with O
IC50 O
values O

of O
2.4 O
and O
2.5 O
μg/mL, O
respectively. O
Furthermore, O
compounds O
6 O
and O
8 O
both O
inhibited O
endothelial O
cell O
tube O
formation O
at O
1.0 O
μg/mL. O
A O
method O
for O
the O
rapid O
and O
straightforward O
preparative-scale O
isolation O
of O
compound O
6 O
from O
alantolides B-CHEMICAL
is O
described. O
Narirutin B-CHEMICAL
fraction O
from O
citrus O
peels O
attenuates O
alcoholic O
liver O
disease O
in O
mice. O
This O
study O
aimed O
to O
demonstrate O
protective O
activities O
of O
the O
narirutin B-CHEMICAL
fraction O
from O
peels O
of O
Citrus O
unshiu O
against O
ethanol-induced B-CHEMICAL
hepatic O
damage O
through O
an O
animal O
study. O

Citrus O
narirutin B-CHEMICAL
fraction O
(CNF), O
contained O
75% O
of O
narirutin, B-CHEMICAL
was O
obtained O
by O
an O
ultra-sonicated O
extraction O
and O
further O
purification. O
ICR O
mice O
were O
divided O
into O
four O
groups; O
normaldiet O
control, O
ethanol B-CHEMICAL
control O
(6.5g O
ethanol/kg), B-CHEMICAL
low-CNF O
(ethanol+150mg B-CHEMICAL
CNF/kg) O
and O
high-CNF O
(ethanol+300mg B-CHEMICAL
CNF/kg) O
groups. O
Consumption O
of O
alcohol B-CHEMICAL
for O
8weeks O
induced O
severe O
liver O
damage O
with O
increases O
in O
prognostic O
indicators O
such O
as O
aspartate B-GENE-N
transaminase, I-GENE-N

alanine B-GENE-N
transaminase I-GENE-N
in O
serum O
whereas O
co-administration O
of O
CNF O
suppressed O
their O
increases. O
Excessive O
accumulations O
in O
liver O
TG O
and O
TC O
in O
ethanol B-CHEMICAL
control O
group O
were O
also O
suppressed O
by O
co-administration O
of O
CNF. O
Co-administration O
of O
CNF O
maintained O
SOD B-GENE-N
activity, O
GSH B-CHEMICAL
and O
malondialdehyde B-CHEMICAL
levels O
close O
to O
those O
of O
the O
normal O
diet O
group. O
Chronic O
consumption O
of O
alcohol B-CHEMICAL
also O
stimulated O
abrupt O
increases O
in O
pro-inflammatory O
cytokines O
such O
as O
nuclear B-GENE-N
factor I-GENE-N
(NF)-κB, I-GENE-N
tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
(TNF)-α I-GENE-Y
and O
interleukin B-GENE-Y

(IL)-1β I-GENE-Y
in O
liver O
otherwise O
co-administration O
of O
CNF O
effectively O
suppressed O
production O
of O
these O
cytokines B-GENE-N
dose-dependently. O
These O
results O
indicate O
that O
co-administration O
of O
CNF O
with O
alcohol B-CHEMICAL
can O
alleviate O
alcohol B-CHEMICAL
induced O
liver O
damage O
through O
preventing O
lipid O
formation, O
protecting O
antioxidant O
system O
and O
suppressing O
productions O
of O
pro-inflammatory O
cytokines. B-GENE-N
Impaired O
local O
production O
of O
pro-resolving O
lipid O
mediators O
in O
obesity O
and O
17-HDHA B-CHEMICAL
as O
a O
potential O
treatment O
for O
obesity-associated O
inflammation. O
Obesity-induced O
chronic O
low-grade O
inflammation O
originates O
from O
adipose O
tissue O
and O
is O
crucial O
for O

obesity-driven O
metabolic O
deterioration O
including O
insulin B-GENE-Y
resistance O
and O
type O
2 O
diabetes.Chronic O
inflammation O
may O
be O
a O
consequence O
of O
a O
failure O
to O
actively O
resolve O
inflammation,and O
could O
result O
from O
a O
lack O
of O
local O
specialized O
pro-resolving O
lipid O
mediators O
(SPM) O
such O
as O
resolvins B-CHEMICAL
and O
protectins, O
which O
derive O
from O
the O
n-3 O
polyunsaturated B-CHEMICAL
fatty I-CHEMICAL
acids I-CHEMICAL
eicosapentaenoic B-CHEMICAL
acid I-CHEMICAL
(EPA) B-CHEMICAL
and O
docosahexaenoic B-CHEMICAL
acid I-CHEMICAL
(DHA). B-CHEMICAL
We O
assessed O
obesity-induced O
changes O
of O
n-3-derived O
SPM O
in O
adipose O
tissue O
and O
effects O

of O
dietary O
EPA/DHA B-CHEMICAL
thereon.Moreover, O
we O
treated O
obese O
mice O
with O
SPM O
precursors O
and O
investigated O
effects O
on O
inflammation O
and O
metabolic O
dysregulation. O
Obesity O
significantly O
decreased O
DHA-derived B-CHEMICAL
17-hydroxydocosahexaenoic B-CHEMICAL
acid I-CHEMICAL
(17-HDHA, B-CHEMICAL
resolvin B-CHEMICAL
D1 I-CHEMICAL
precursor) O
and O
protectin B-CHEMICAL
D1 I-CHEMICAL
levels O
in O
murine O
adipose O
tissue. O
Dietary O
EPA/DHA B-CHEMICAL
treatment O
restored O
endogenous O
biosynthesis O
of O
n-3 O
derived O
lipid O
mediators O
in O
obesity O
while O
attenuating O
adipose O
tissue O
inflammation O
and O
improving O
insulin B-GENE-N
sensitivity. O

Notably, O
17-HDHA B-CHEMICAL
treatment O
reduced O
adipose O
tissue O
expression O
of O
inflammatory O
cytokines, B-GENE-N
increased O
adiponectin B-GENE-Y
expression O
and O
improved O
glucose B-CHEMICAL
tolerance O
parallel O
to O
insulin B-GENE-N
sensitivity O
in O
obese O
mice. O
These O
findings O
indicate O
that O
impaired O
biosynthesis O
of O
certain O
SPM O
and O
SPM O
precursors O
including O
17-HDHA B-CHEMICAL
and O
protectin B-CHEMICAL
D1 I-CHEMICAL
contributes O
to O
adipose O
tissue O
inflammation O
in O
obesity O
and O
suggest O
17-HDHA B-CHEMICAL
as O
a O
novel O
treatment O
option O
for O
obesity-associated O
complications. O
The O
glycogen B-GENE-Y
synthase I-GENE-Y
kinase-3β/nuclear I-GENE-Y
factor-kappa I-GENE-N
B I-GENE-N
pathway O
is O
involved O
in O

cinobufagin-induced B-CHEMICAL
apoptosis O
in O
cultured O
osteosarcoma O
cells. O
Cinobufagin, B-CHEMICAL
a O
major O
component O
of O
cinobufacini O
(huachansu), O
is O
an O
important O
cardenolidal B-CHEMICAL
steroid. I-CHEMICAL
Several O
studies O
have O
suggested O
that O
cinobufagin B-CHEMICAL
has O
potent O
anti-cancer O
effects. O
The O
present O
study O
examines O
the O
apoptosis-inducing O
activity O
and O
the O
underlying O
mechanism O
of O
action O
of O
cinobufagin B-CHEMICAL
in O
osteosarcoma O
(OS) O
cells. O
Our O
results O
showed O
that O
cinobufagin B-CHEMICAL
potently O
inhibited O
the O
proliferation O
of O
U2OS, O

MG63 O
and O
SaOS-2 O
cells. O
Significant O
increases O
in O
G2/M O
cell-cycle O
arrest O
and O
apoptosis O
in O
OS O
cells O
were O
also O
observed. O
The O
expression O
levels O
of O
several O
apoptotic O
proteins O
were O
assessed O
after O
cinobufagin B-CHEMICAL
treatment O
in O
U2OS O
cells. O
Among O
them, O
xIAP, B-GENE-Y
cIAP-1, B-GENE-Y
survivin B-GENE-Y
and O
Bcl-2 B-GENE-Y
levels O
decreased O
remarkably, O
while O
the O
levels O
of O
Bax B-GENE-Y
and O
cleaved-PARP B-GENE-N
increased. O
Furthermore, O
we O
validated O
the O
inhibition O
of O
GSK-3β/NF-κB B-GENE-Y
signaling O
following O
cinobufagin B-CHEMICAL

treatment. O
Western O
blots O
showed O
a O
decrease O
in O
nuclear O
p65 B-GENE-Y
protein O
expression O
after O
exposure O
to O
different O
concentrations O
of O
cinobufagin, B-CHEMICAL
while O
the O
phosphorylation O
of O
GSK-3β B-GENE-Y
was O
simultaneously O
increased. O
Transduction O
with O
constitutively O
active O
forms O
of O
GSK-3β B-GENE-Y
could O
protect O
against O
the O
downregulation O
of O
p65 B-GENE-Y
and O
upregulation O
of O
cleaved-PARP B-GENE-N
that O
are O
induced O
by O
cinobufagin B-CHEMICAL
treatment. O
However, O
combined O
treatment O
with O
cinobufagin B-CHEMICAL
and O
SB216367 B-CHEMICAL
resulted O
in O
a O
significant O
reduction O
in O
p65 B-GENE-Y
and O
an O
increase O
in O

cleaved-PARP B-GENE-N
in O
U2OS O
cells. O
Altogether, O
these O
results O
show O
that O
cinobufagin B-CHEMICAL
is O
a O
promising O
agent O
for O
the O
treatment O
of O
OS. O
These O
studies O
are O
the O
first O
to O
reveal O
the O
involvement O
of O
the O
GSK-3β/NF-κB B-GENE-Y
pathway O
in O
cinobufagin-induced B-CHEMICAL
apoptosis. O
Arsenic B-CHEMICAL
activates O
endothelin-1 B-GENE-Y
Gi B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
signaling O
to O
inhibit O
stem O
cell O
differentiation O
in O
adipogenesis. O
Dysfunctional O
lipid O
and O
glucose B-CHEMICAL
metabolism O
contribute O
to O
metabolic O
syndrome-a O
major O
public O
health O
concern O
that O
enhances O
cardiovascular O
disease O
risk. O

Arsenic B-CHEMICAL
(As(III)) B-CHEMICAL
exposure O
may O
increase O
metabolic O
syndrome O
and O
cardiovascular O
disease O
risk O
by O
impairing O
adipose O
tissue O
differentiation, O
function, O
and O
insulin O
sensitivity O
through O
pathogenic O
mechanisms O
that O
remain O
unclear. O
We O
hypothesized O
that O
As(III) B-CHEMICAL
signals O
through O
the O
Pertussis B-GENE-N
toxin I-GENE-N
(Ptx) B-GENE-N
sensitive, O
Gi B-GENE-N
protein-coupled I-GENE-N
receptor I-GENE-N
(GPCR) B-GENE-N
to O
impair O
adipogenesis, O
as O
previously O
demonstrated O
for O
its O
stimulation O
of O
vascular O
oxidant O
generation, O
angiogenesis, O
and O
remodeling. O
Because O
both O
As(III) B-CHEMICAL
and O
GPCR B-GENE-N
ligands O
inhibit O
progenitor O

cell O
differentiation O
into O
adipocytes, O
we O
investigated O
the O
hypothesis O
in O
a O
model O
of O
low-passage O
human O
mesenchymal O
stem O
cells O
(hMSC). O
As(III) B-CHEMICAL
(0.1-1.0 O
µM) O
suppressed O
dexamethasone/insulin-induced B-CHEMICAL
hMSC O
adipogenesis, O
as O
indicated O
by O
decreased O
transcriptional O
promoters O
of O
differentiation, O
decreased O
fat O
droplet O
formation, O
and O
decreased O
expression O
of O
differentiated O
adipocyte O
markers, O
such O
as O
adiponectin B-GENE-Y
and O
perilipin. B-GENE-Y
Preincubating O
hMSC O
with O
Ptx B-GENE-N
prevented O
90% O
of O
the O
suppressive O
effect O
of O

As(III). B-CHEMICAL
Selective O
competitive O
antagonists O
of O
Gi-coupled B-GENE-N
endothelin-1 B-GENE-N
type I-GENE-N
A I-GENE-N
and I-GENE-N
B I-GENE-N
receptors I-GENE-N
were O
~60% O
effective O
in O
blocking O
As(III) B-CHEMICAL
inhibition O
and O
combination O
of O
antagonists O
to O
both O
receptors O
were O
85% O
effective. O
In O
contrast, O
antagonists O
to O
the O
sphingosine-1-phosphate B-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
(previously O
shown O
to O
mediate O
As(III) B-CHEMICAL
vascular O
effects) O
or O
the O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
were O
ineffective O
in O
blocking O
As(III) B-CHEMICAL
effects. O
These O
studies O
suggest O
a O
majority O
of O
arsenic-inhibited B-CHEMICAL
adipocyte O
differentiation, O
and O
metabolism O
requires O

endothelin-1 B-GENE-Y
GPCRs B-GENE-N
and O
that O
As(III) B-CHEMICAL
effects O
on O
GPCR B-GENE-N
signaling O
are O
tissue O
and O
context O
specific. O
This O
may O
represent O
a O
significant O
mechanism O
for O
the O
contribution O
of O
arsenic B-CHEMICAL
exposure O
to O
increased O
metabolic O
and O
cardiovascular O
diseases. O
Activation-dependent O
exposure O
of O
the O
inter-EGF B-GENE-N
sequence I-GENE-N
Leu83-Leu88 B-GENE-N
in O
factor B-GENE-Y
Xa I-GENE-Y
mediates O
ligand O
binding O
to O
effector B-GENE-Y
cell I-GENE-Y
protease I-GENE-Y
receptor-1. I-GENE-Y
Binding O
of O
factor B-GENE-Y
Xa I-GENE-Y
to O
human O
umbilical O
vein O
endothelial O
cells O
(HUVEC) O
is O
contributed O
by O
effector B-GENE-Y
cell I-GENE-Y
protease I-GENE-Y
receptor-1 I-GENE-Y

(EPR-1). B-GENE-Y
The O
structural O
requirements O
of O
this O
recognition O
were O
investigated. O
Factor B-GENE-Y
Xa I-GENE-Y
or O
catalytically O
inactive O
5-dimethylaminonaphthalene-1sulfonyl B-CHEMICAL
(dansyl) I-CHEMICAL
Glu-Gly-Arg-(DEGR)-chloromethylketone-factor I-CHEMICAL
Xa I-GENE-Y
bound O
indistinguishably O
to O
HUVEC O
and O
EPR-1 B-GENE-Y
transfectants, O
and O
inhibited O
equally O
well O
the O
binding O
of O
125I-factor B-GENE-Y
Xa I-GENE-Y
to O
these O
cells. O
Similarly, O
factor B-GENE-Y
Xa I-GENE-Y
active O
site O
inhibitors O
TAP O
or O
NAP5 O
did O
not O

reduce O
ligand O
binding O
to O
EPR-1. B-GENE-Y
A O
factor B-GENE-Y
X I-GENE-Y
peptide O
duplicating O
the O
inter-EGF B-GENE-N
sequence I-GENE-N
Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- B-GENE-N
(Gly) I-GENE-N
inhibited O
factor B-GENE-Y
V/Va-independent I-GENE-Y
prothrombin B-GENE-Y
activation O
by O
HUVEC O
and O
blocked O
binding O
of O
125I-factor B-CHEMICAL
Xa I-GENE-Y
to O
these O
cells O
in O
a O
dose-dependent O
manner O
(IC50 O
approximately O
20-40 O
microM). O
In O
contrast, O
none O
of O
the O
other O
factor B-GENE-Y
X I-GENE-Y
peptides O
tested O
or O
a O

control O
peptide O
with O
the O
inter-EGF B-GENE-N
sequence I-GENE-N
in O
scrambled O
order O
was O
effective. O
A O
recombinant O
chimeric O
molecule O
expressing O
the O
factor B-GENE-Y
X I-GENE-Y
sequence O
Leu83-Leu88 B-GENE-N
within O
a O
factor B-GENE-Y
IX I-GENE-Y
backbone O
inhibited O
binding O
of O
125I-factor B-CHEMICAL
Xa I-GENE-Y
to O
HUVEC O
and O
EPR-1 B-GENE-Y
transfectants O
in O
a O
dose-dependent O
fashion, O
while O
recombinant O
factor B-GENE-Y
IX I-GENE-Y
or O
plasma O
IXa B-GENE-Y
had O
no O
effect. O
An O
antibody O
generated O
against O
the O
factor B-GENE-Y
X I-GENE-Y
peptide O
83-88, O
and O
designated O
JC15, O
inhibited O
125I-factor B-GENE-Y
Xa I-GENE-Y
binding O
to O

HUVEC. O
The O
JC15 O
antibody O
bound O
to O
factor B-GENE-Y
Xa I-GENE-Y
and O
the O
recombinant O
IX/X83-88 O
chimera O
in O
a O
concentration O
dependent O
manner, O
while O
no O
specific O
reactivity O
with O
factors B-GENE-N
X I-GENE-N
or I-GENE-N
IXa I-GENE-N
was O
observed. O
Furthermore, O
binding O
of O
125I-factor B-CHEMICAL
Xa I-GENE-Y
to O
immobilized O
JC15 O
was O
inhibited O
by O
molar O
excess O
of O
unlabeled O
factor B-GENE-Y
Xa, I-GENE-Y
but O
not O
by O
comparable O
concentrations O
of O
factors B-GENE-N
X I-GENE-N
or I-GENE-N
IXa. I-GENE-N
These O
findings O
identify O
the O
inter-EGF B-GENE-N
sequence I-GENE-N
Leu83-Leu88 B-GENE-N
in O
factor B-GENE-Y
Xa I-GENE-Y
as O
a O
novel O
recognition O

site O
for O
EPR-1, B-GENE-Y
and O
suggest O
its O
potential O
role O
as O
a O
protease O
activation-dependent O
neo-epitope. O
This O
interacting O
motif O
may O
help O
elucidate O
the O
contribution O
of O
factor B-GENE-Y
Xa I-GENE-Y
to O
cellular O
assembly O
of O
coagulation O
and O
vascular O
injury. O
[6]-gingerol: B-CHEMICAL
a O
novel O
AT₁ B-GENE-Y
antagonist O
for O
the O
treatment O
of O
cardiovascular O
disease. O
Considering O
the O
prevalence O
of O
cardiovascular O
disease O
in O
public O
health O
and O
the O
limited O
validated O
therapeutic O
options, O
this O
study O
aimed O
to O
find O
novel O
compounds O
targeting O
the O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor, I-GENE-Y
accepted O
as O
a O
therapeutic O
target O
in O
cardiovascular O
disease. O
A O
small O
library O
consisting O
of O
89 O
compounds O

from O
39 O
Chinese O
herbs O
was O
profiled O
using O
a O
cell-based O
calcium O
mobilization O
assay O
which O
was O
developed O
and O
characterized O
for O
high-throughput O
screening. O
[6]-Gingerol B-CHEMICAL
derived O
from O
Zingiber O
officinale O
Roscoe O
(ginger) O
was O
identified O
as O
a O
novel O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
antagonist, O
with O
an O
IC50 O
value O
of O
8.173 O
µM. O
The O
hit O
was O
further O
tested O
by O
a O
specificity O
assay O
indicating O
that O
it O
had O
no O
antagonistic O
effects O
on O
other O
evaluated O
GPCRs, B-GENE-N
such O
as O
endothelin B-GENE-N
receptors. I-GENE-N
The O
major O
ingredient O
of O
ginger, O
[6]-gingerol, B-CHEMICAL

could O
inhibit O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor I-GENE-Y
activation, O
which O
partially O
clarified O
the O
mechanism O
of O
ginger O
regulating O
blood O
pressure O
and O
strengthening O
heart O
in O
the O
cardiovascular O
system. O
Osteochondral O
tissue O
regeneration O
using O
a O
bilayered O
composite O
hydrogel O
with O
modulating O
dual O
growth O
factor O
release O
kinetics O
in O
a O
rabbit O
model. O
Biodegradable O
oligo(poly(ethylene B-CHEMICAL
glycol) I-CHEMICAL
fumarate) I-CHEMICAL
(OPF) B-CHEMICAL
composite O
hydrogels O
have O
been O
investigated O
for O
the O
delivery O
of O
growth O
factors O
(GFs) O
with O
the O
aid O
of O
gelatin O
microparticles O

(GMPs) O
and O
stem O
cell O
populations O
for O
osteochondral O
tissue O
regeneration. O
In O
this O
study, O
a O
bilayered O
OPF B-CHEMICAL
composite O
hydrogel O
that O
mimics O
the O
distinctive O
hierarchical O
structure O
of O
native O
osteochondral O
tissue O
was O
utilized O
to O
investigate O
the O
effect O
of O
transforming B-GENE-Y
growth I-GENE-Y
factor-β3 I-GENE-Y
(TGF-β3) B-GENE-Y
with O
varying O
release O
kinetics O
and/or O
insulin-like B-GENE-Y
growth I-GENE-Y
factor-1 I-GENE-Y
(IGF-1) B-GENE-Y
on O
osteochondral O
tissue O
regeneration O
in O
a O
rabbit O
full-thickness O
osteochondral O
defect O
model. O
The O
four O
groups O
investigated O
included O
(i) O
a O
blank O
control O

(no O
GFs), O
(ii) O
GMP-loaded O
IGF-1 B-GENE-Y
alone, O
(iii) O
GMP-loaded O
IGF-1 B-GENE-Y
and O
gel-loaded O
TGF-β3, B-GENE-Y
and O
(iv) O
GMP-loaded O
IGF-1 B-GENE-Y
and O
GMP-loaded O
TGF-β3 B-GENE-Y
in O
OPF B-CHEMICAL
composite O
hydrogels. O
The O
results O
of O
an O
in O
vitro O
release O
study O
demonstrated O
that O
TGF-β3 B-GENE-Y
release O
kinetics O
could O
be O
modulated O
by O
the O
GF O
incorporation O
method. O
At O
12weeks O
post-implantation, O
the O
quality O
of O

tissue O
repair O
in O
both O
chondral O
and O
subchondral O
layers O
was O
analyzed O
based O
on O
quantitative O
histological O
scoring. O
All O
groups O
incorporating O
GFs O
resulted O
in O
a O
significant O
improvement O
in O
cartilage O
morphology O
compared O
to O
the O
control. O
Single O
delivery O
of O
IGF-1 B-GENE-Y
showed O
higher O
scores O
in O
subchondral O
bone O
morphology O
as O
well O
as O
chondrocyte O
and O
glycosaminoglycan O
amount O
in O
adjacent O
cartilage O
tissue O
when O
compared O
to O
a O
dual O
delivery O
of O
IGF-1 B-GENE-Y
and O
TGF-β3, B-GENE-Y
independent O
of O
the O
TGF-β3 B-GENE-Y
release O
kinetics. O
The O
results O
suggest O
that O
although O
the O
dual O
delivery O

of O
TGF-β3 B-GENE-Y
and O
IGF-1 B-GENE-Y
may O
not O
synergistically O
enhance O
the O
quality O
of O
engineered O
tissue, O
the O
delivery O
of O
IGF-1 B-GENE-Y
alone O
from O
bilayered O
composite O
hydrogels O
positively O
affects O
osteochondral O
tissue O
repair O
and O
holds O
promise O
for O
osteochondral O
tissue O
engineering O
applications. O
LDL B-GENE-N
Cholesterol B-CHEMICAL
Goals O
in O
High-Risk O
Patients: O
How O
Low O
Do O
We O
Go O
and O
How O
Do O
We O
Get O
There? O
It O
is O
widely O
recognised O
that O
low-density B-GENE-N
lipoprotein I-GENE-N
cholesterol B-CHEMICAL
(LDL-C) B-GENE-N
is O
one O
of O
the O
most O
important O
and O

modifiable O
risk O
factors O
for O
cardiovascular O
disease O
(CVD). O
Statins O
(HMG-CoA B-GENE-Y
reductase I-GENE-Y
inhibitors) O
have O
consistently O
been O
shown O
to O
decrease O
both O
LDL-C B-GENE-N
and O
CVD O
risk O
in O
almost O
all O
patient O
categories, O
with O
the O
exception O
of O
heart O
and O
kidney O
failure O
as O
well O
as O
advanced O
aortic O
stenosis. O
As O
a O
consequence, O
statins O
have O
become O
the O
cornerstone O
in O
current O
prevention O
guidelines. O
In O
patients O
who O
do O
not O
reach O
the O
LDL-C B-GENE-N
target, O
combination O
therapy O
with O
additional O
LDL-C B-GENE-N
lowering O
drugs O
(e.g. O
ezetimibe, B-CHEMICAL
bile B-CHEMICAL
acid I-CHEMICAL

sequestrants O
or O
fibrates) B-CHEMICAL
should O
be O
considered. O
Guidelines O
provide O
different O
LDL-C B-GENE-N
levels O
to O
strive O
for, O
depending O
on O
the O
CVD O
risk. O
In O
this O
review, O
we O
describe O
the O
rationale O
for O
these O
LDL-C B-GENE-N
targets O
and O
how O
these O
goals O
might O
be O
reached O
by O
current O
and O
future O
therapies. O
Contrasting O
effects O
of O
N5-substituted B-CHEMICAL
tetrahydrobiopterin I-CHEMICAL
derivatives O
on O
phenylalanine B-GENE-Y
hydroxylase, I-GENE-Y
dihydropteridine B-GENE-Y
reductase I-GENE-Y
and O
nitric B-GENE-N
oxide I-GENE-N
synthase. I-GENE-N
Tetrahydrobiopterin B-CHEMICAL

[(6R)-5,6,7,8-tetrahydro-L-biopterin, B-CHEMICAL
H(4)biopterin] B-CHEMICAL
is O
one O
of O
several O
cofactors O
of O
nitric B-GENE-N
oxide I-GENE-N
synthases I-GENE-N
(EC B-GENE-Y
1.14.13.39). I-GENE-Y
Here O
we O
compared O
the O
action O
of O
N(5)-substituted B-CHEMICAL
derivatives O
on O
recombinant O
rat B-GENE-Y
neuronal I-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthase I-GENE-Y
with O
their O
effects O
on O
dihydropteridine B-GENE-Y
reductase I-GENE-Y
(EC B-GENE-Y
1.6.99.7) I-GENE-Y
and O
phenylalanine B-GENE-Y
hydroxylase I-GENE-Y
(EC B-GENE-Y

1.14.16.1),the I-GENE-Y
well-studied O
classical O
H(4)biopterin-dependent B-CHEMICAL
reactions. O
H(4)biopterin B-CHEMICAL
substituted O
at O
N(5) B-CHEMICAL
with O
methyl, B-CHEMICAL
hydroxymethyl, B-CHEMICAL
formyl B-CHEMICAL
and O
acetyl B-CHEMICAL
groups O
were O
used. O
Substitution O
at O
N(5) B-CHEMICAL
occurs O
at O
a O
position O
critical O
to O
the O
redox O
cycle O
of O
the O
cofactor O
in O
phenylalanine B-GENE-Y
hydroxylase/dihydropteridine I-GENE-Y
reductase. I-GENE-Y
We O
also O
included O
N(2)'-methyl B-CHEMICAL
H(4)biopterin, I-CHEMICAL
a O

derivative O
substituted O
at O
a O
position O
not O
directly O
involved O
in O
redox O
cycling, O
as O
a O
control. O
As O
compared O
with O
N(5)-methyl B-CHEMICAL
H(4)biopterin, I-CHEMICAL
N(5)-formyl B-CHEMICAL
H(4)biopterin I-CHEMICAL
bound O
with O
twice O
the O
capacity O
but O
stimulated O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N
to O
a O
lesser O
extent. O
Depending O
on O
the O
substituent O
used, O
N(5)-substituted B-CHEMICAL
derivatives O
were O
redox-active: O
N(5)-methyl- B-CHEMICAL
and O
N(5)-hydroxyl B-CHEMICAL
methyl I-CHEMICAL
H(4)biopterin, I-CHEMICAL
but O
not O

N(5)-formyl- B-CHEMICAL
and O
N(5)-acetyl B-CHEMICAL
H(4)biopterin, I-CHEMICAL
reduced O
2,6-dichlorophenol B-CHEMICAL
indophenol. I-CHEMICAL
N(5)-Substituted B-CHEMICAL
H(4)biopterin I-CHEMICAL
derivatives O
were O
not O
oxidized O
to O
products O
serving O
as O
substrates O
for O
dihydropteridine B-GENE-Y
reductase I-GENE-Y
and,depending O
on O
the O
substituent, O
were O
competitive O
inhibitors O
of O
phenylalanine B-GENE-Y
hydroxylase: I-GENE-Y
N(5)-methyl- B-CHEMICAL
and O
N(5)-hydroxymethyl B-CHEMICAL

H(4)biopterin I-CHEMICAL
inhibited O
phenylalanine B-GENE-Y
hydroxylase, I-GENE-Y
whereas O
N(5)-formyl- B-CHEMICAL
and O
N(5)-acetyl B-CHEMICAL
H(4)biopterin I-CHEMICAL
had O
no O
effect. O
Our O
data O
demonstrate O
differences O
in O
the O
mechanism O
of O
stimulation O
of O
phenylalanine B-GENE-Y
hydroxylase I-GENE-Y
and O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N
by O
H(4)biopterin. B-CHEMICAL
They O
are O
compatible O
with O
a O
novel, O
non-classical, O
redox-active O
contribution O
of O
H(4)biopterin B-CHEMICAL
to O
the O
catalysis O
of O
the O
nitric B-GENE-N
oxide I-GENE-N
synthase I-GENE-N

reaction. O
Vesicular B-GENE-Y
monoamine I-GENE-Y
transporter-1 I-GENE-Y
(VMAT-1) B-GENE-Y
mRNA O
and O
immunoreactive O
proteins O
in O
mouse O
brain. O
OBJECTIVE: O
Vesicular B-GENE-Y
monoamine I-GENE-Y
transporter I-GENE-Y
1 I-GENE-Y
(VMAT-1) B-GENE-Y
mRNA O
and O
protein O
were O
examined O
(1) O
to O
determine O
whether O
adult O
mouse O
brain O
expresses O
full-length O
VMAT-1 B-GENE-Y
mRNA O
that O
can O
be O
translated O
to O
functional O
transporter O
protein O
and O
(2) O
to O
compare O
immunoreactive O
VMAT-1 B-GENE-Y
proteins O
in O
brain O
and O
adrenal. O
METHODS: O
VMAT-1 B-GENE-Y
mRNA O

was O
detected O
in O
mouse O
brain O
with O
RT-PCR. O
The O
cDNA O
was O
sequenced, O
cloned O
into O
an O
expression O
vector, O
transfected O
into O
COS-1 O
cells, O
and O
cell O
protein O
was O
assayed O
for O
VMAT-1 B-GENE-Y
activity. O
Immunoreactive O
proteins O
were O
examined O
on O
western O
blots O
probed O
with O
four O
different O
antibodies O
to O
VMAT-1. B-GENE-Y
RESULTS: O
Sequencing O
confirmed O
identity O
of O
the O
entire O
coding O
sequences O
of O
VMAT-1 B-GENE-Y
cDNA O
from O
mouse O
medulla O
oblongata/pons O
and O
adrenal O
to O
a O
Gen-Bank O
reference O
sequence. O

Transfection O
of O
the O
brain O
cDNA O
into O
COS-1 O
cells O
resulted O
in O
transporter O
activity O
that O
was O
blocked O
by O
the O
VMAT B-GENE-N
inhibitor O
reserpine B-CHEMICAL
and O
a O
proton O
ionophore, O
but O
not O
by O
tetrabenazine, B-CHEMICAL
which O
has O
a O
high O
affinity O
for O
VMAT-2. B-GENE-Y
Antibodies O
to O
either O
the O
C- B-CHEMICAL
or O
N- B-CHEMICAL
terminus O
of O
VMAT-1 B-GENE-Y
detected O
two O
proteins O
(73 O
and O
55 O
kD) O
in O
transfected O
COS-1 O
cells. O
The O
C-terminal B-CHEMICAL
antibodies O
detected O
both O
proteins O
in O
extracts O
of O
mouse O
medulla/pons, O
cortex, O
hypothalamus, O

and O
cerebellum O
but O
only O
the O
73 O
kD O
protein O
and O
higher O
molecular O
weight O
immunoreactive O
proteins O
in O
mouse O
adrenal O
and O
rat O
PC12 O
cells, O
which O
are O
positive O
controls O
for O
rodent B-GENE-Y
VMAT-1. I-GENE-Y
CONCLUSIONS: O
These O
findings O
demonstrate O
that O
a O
functional O
VMAT-1 B-GENE-Y
mRNA O
coding O
sequence O
is O
expressed O
in O
mouse O
brain O
and O
suggest O
processing O
of O
VMAT-1 B-GENE-Y
protein O
differs O
in O
mouse O
adrenal O
and O
brain. O
Chloride B-GENE-N
channels I-GENE-N
in O
renal O
disease. O
Recent O
studies O
of O
hereditary O
renal O
tubular O
disorders O
have O
facilitated O
the O
identification O
and O
roles O
of O
chloride B-GENE-N
channels I-GENE-N
and I-GENE-N
cotransporters I-GENE-N
in O

the O
regulation O
of O
the O
most O
abundant O
anion, O
Cl-, B-CHEMICAL
in O
the O
ECF. O
Thus, O
mutations O
that O
result O
in O
a O
loss O
of O
function O
of O
the O
voltage-gated B-GENE-N
chloride I-GENE-N
channel, I-GENE-N
CLC-5, B-GENE-Y
are O
associated O
with O
Dent's O
disease, O
which O
is O
characterized O
by O
low-molecular O
weight O
proteinuria, O
hypercalciuria, O
nephrolithiasis, O
and O
renal O
failure. O
Mutations O
of O
another O
voltage-gated B-GENE-N
chloride I-GENE-N
channel, I-GENE-N
CLC-Kb, B-GENE-Y
are O
associated O
with O
a O
form O
of O
Bartter's O
syndrome, O
whereas O
other O
forms O
of O
Bartter's O
syndrome O
are O
caused O
by O
mutations O
in O
the O

bumetanide-sensitive B-GENE-N
sodium-potassium-chloride I-GENE-N
cotransporter I-GENE-N
(NKCC2) B-GENE-Y
and O
the O
potassium B-GENE-N
channel, I-GENE-N
ROMK. B-GENE-Y
Finally, O
mutations O
of O
the O
thiazide-sensitive B-GENE-Y
sodium-chloride I-GENE-Y
cotransporter I-GENE-Y
(NCCT) B-GENE-Y
are O
associated O
with O
Gitelman's O
syndrome. O
These O
studies O
have O
helped O
to O
elucidate O
some O
of O
the O
renal O
tubular O
mechanisms O
regulating O
mineral O
homeostasis O
and O
the O
role O
of O
chloride B-GENE-N
channels. I-GENE-N
Mitochondrial B-GENE-Y
arginase I-GENE-Y
II I-GENE-Y
modulates O
nitric-oxide B-CHEMICAL
synthesis O
through O
nonfreely O
exchangeable O
L-arginine B-CHEMICAL
pools O
in O
human O

endothelial O
cells. O
Reduced O
synthesis O
of O
nitric B-CHEMICAL
oxide I-CHEMICAL
(NO) B-CHEMICAL
contributes O
to O
the O
endothelial O
dysfunction O
and O
may O
be O
related O
to O
limited O
availability O
of O
L-arginine, B-CHEMICAL
the O
common O
substrate O
of O
constitutive B-GENE-Y
nitric-oxide I-GENE-Y
synthase I-GENE-Y
(NOS) B-GENE-N
and O
cytosolic O
arginase B-GENE-Y
I I-GENE-Y
and O
mitochondrial B-GENE-Y
arginase I-GENE-Y
II. I-GENE-Y
To O
determine O
whether O
arginases B-GENE-N
modulate O
the O
endothelial O
NO B-CHEMICAL
synthesis, O
we O
investigated O
the O
effects O
of O
the O
competitive O
arginase B-GENE-N
inhibitor O

N(omega)-hydroxy-nor-L-arginine B-CHEMICAL
(Nor-NOHA) B-CHEMICAL
on O
the O
activity O
of O
NOS, B-GENE-N
arginases, B-GENE-N
and O
L-arginine B-GENE-N
transporter I-GENE-N
and O
on O
NO B-CHEMICAL
release O
at O
surface O
of O
human O
umbilical O
vein O
endothelial O
cells O
(HUVECs). O
In O
unstimulated O
cells, O
Nor-NOHA B-CHEMICAL
dose-dependently O
reduced O
the O
arginase B-GENE-N
activity O
with O
maximal O
inhibition O
at O
20 O
microM. O
When O
HUVECs O
were O
stimulated O
by O
thrombin B-GENE-Y
without O
extracellular O
L-arginine, B-CHEMICAL

Nor-NOHA B-CHEMICAL
dose-dependently O
increased O
the O
NOS B-GENE-N
activity O
and O
the O
NO B-CHEMICAL
release O
with O
maximal O
effects O
at O
20 O
microM. O
Extracellular O
L-arginine B-CHEMICAL
also O
dose-dependently O
increased O
NO B-CHEMICAL
release O
and O
arginase B-GENE-N
activity. O
When O
HUVECs O
were O
stimulated O
by O
thrombin B-GENE-Y
in O
the O
presence O
of O
100 O
microM O
L-arginine, B-CHEMICAL
NOS B-GENE-N
activity O
and O
NO B-CHEMICAL
release O
were O
similar O
in O
untreated O
and O
Nor-NOHA-treated B-CHEMICAL
cells. O
However, O
despite O
activation O
of O
L-arginine B-CHEMICAL
uptake, O
the O
inhibition O
of O
arginase B-GENE-N
activity O
by O
Nor-NOHA B-CHEMICAL
was O
still O

significant. O
The O
depletion O
of O
freely O
exchangeable O
L-arginine B-CHEMICAL
pools O
with O
extracellular O
L-lysine B-CHEMICAL
did O
not O
prevent O
Nor-NOHA B-CHEMICAL
from O
increasing O
the O
NO B-CHEMICAL
release. O
This O
indicates O
the O
presence O
of O
pools, O
which O
are O
accessible O
to O
NOS B-GENE-N
and O
arginase, B-GENE-N
but O
not O
exchangeable. O
Interestingly, O
the O
mitochondrial B-GENE-Y
arginase I-GENE-Y
II I-GENE-Y
was O
constitutively O
expressed, O
whereas O
the O
cytosolic O
arginase B-GENE-Y
I I-GENE-Y
was O
barely O
detectable O
in O
HUVECs. O
These O
data O
suggest O
that O
endothelial O
NO B-CHEMICAL
synthesis O
depends O
on O
the O
activity O
of O
arginase B-GENE-Y
II I-GENE-Y
in O
mitochondria O

and O
l-arginine B-CHEMICAL
carriers O
in O
cell O
membrane. O
The O
role O
of O
late O
I O
and O
antiarrhythmic O
drugs O
in O
EAD O
formation O
and O
termination O
in O
Purkinje O
fibers. O
Multiple O
components O
of O
cardiac O
Na B-CHEMICAL
current O
play O
a O
role O
in O
determining O
electrical O
excitation O
in O
the O
heart. O
Recently, O
the O
role O
of O
nonequilibrium O
components O
in O
controlling O
cardiac O
action O
potential O
plateau O
duration, O
and O
their O
importance O
in O
regulating O
the O
occurrence O
of O
afterdepolarizations O
and O
arrhythmias O
have O
garnered O
more O
attention. O
In O
particular, O
late O
Na B-CHEMICAL
current O
(late O
I(Na)) B-CHEMICAL
has O
been O
shown O
to O
be O
important O
in O
LQT2 O
and O

LQT3 O
arrhythmias. O
Class O
III O
agents O
like O
dofetilide, B-CHEMICAL
clofilium, B-CHEMICAL
and O
sotalol, B-CHEMICAL
which O
can O
all O
cause O
a O
drug-induced O
form O
of O
LQT2, O
significantly O
lengthen O
action O
potential O
duration O
at O
50% O
and O
90% O
repolarization O
in O
isolated O
rabbit O
Purkinje O
fibers, O
and O
can O
initiate O
the O
formation O
of O
early O
afterdepolarizations, O
and O
extra O
beats. O
These O
actions O
can O
lead O
to O
the O
development O
of O
a O
serious O
ventricular O
tachycardia, O
torsades O
de O
pointes, O
in O
animal O
models O
and O
patients. O
However, O
pretreatment O
with O

agents O
that O
block O
late O
I(Na), B-CHEMICAL
like O
lidocaine, B-CHEMICAL
mexiletine, B-CHEMICAL
and O
RSD1235, B-CHEMICAL
a O
novel O
mixed O
ion B-GENE-N
channel I-GENE-N
blocker O
for O
the O
rapid O
pharmacologic O
conversion O
of O
atrial O
fibrillation, O
significantly O
attenuates O
the O
prolonging O
effects O
of O
Class O
III O
agents O
or O
those O
induced O
by O
ATX-II, O
a O
specific O
toxin O
that O
delays O
Na B-GENE-N
channel I-GENE-N
inactivation O
and O
amplifies O
late O
I(Na) B-CHEMICAL
greatly, O
mimicking O
LQT3. O
The O
Na B-GENE-N
channel I-GENE-N
block O
caused O
by O
lidocaine B-CHEMICAL
and O
RSD1235 B-CHEMICAL
can O
be O
through O
the O
open O
or O
inactivated O
states O
of O

the O
channel, O
but O
both O
equivalently O
inhibit O
a O
late O
component O
of O
Na B-CHEMICAL
current O
(I(Na)), B-CHEMICAL
recorded O
at O
22 O
degrees O
C O
using O
whole-cell O
patch O
clamp O
of O
Nav B-GENE-Y
1.5 I-GENE-Y
expressed O
in O
HEK O
cells. O
These O
protective O
actions O
of O
lidocaine, B-CHEMICAL
mexiletine, B-CHEMICAL
and O
RSD1235 B-CHEMICAL
may O
result, O
at O
least O
in O
part, O
from O
their O
ability O
to O
inhibit O
late O
I(Na) B-CHEMICAL
during O
action O
potential O
repolarization, O
and O
inhibition O
of O
the O
inward O
currents O
contributing O
to O
EAD O
and O
arrhythmia O
formation. O
Polyamine B-CHEMICAL
depletion O
delays O
apoptosis O
of O
rat O
intestinal O

epithelial O
cells. O
The O
polyamines B-CHEMICAL
spermidine, B-CHEMICAL
spermine, B-CHEMICAL
and O
their O
precursor O
putrescine B-CHEMICAL
are O
essential O
for O
cell O
growth O
and O
the O
regulation O
of O
the O
cell O
cycle. O
Recent O
studies O
suggest O
that O
excessive O
accumulation O
of O
polyamines B-CHEMICAL
favors O
either O
malignant O
transformation O
or O
apoptosis, O
depending O
on O
the O
cell O
type O
and O
the O
stimulus. O
This O
study O
examines O
the O
involvement O
of O
polyamines B-CHEMICAL
in O
the O
induction O
of O
apoptosis O
by O
the O
DNA B-GENE-Y
topoisomerase I-GENE-Y
I I-GENE-Y
inhibitor, O
camptothecin. O
In O
IEC-6 O
cells, O
camptothecin B-CHEMICAL
induced O
apoptosis O
within O
6 O
h, O
accompanied O
by O
detachment O
of O
cells. O

Detached O
cells O
showed O
DNA O
laddering O
and O
caspase B-GENE-Y
3 I-GENE-Y
induction, O
characteristic O
features O
of O
apoptosis. O
Depletion O
of O
putrescine, B-CHEMICAL
spermidine, B-CHEMICAL
and O
spermine B-CHEMICAL
by O
DL-alpha-difluoromethylornithine B-CHEMICAL
(DFMO), B-CHEMICAL
a O
specific O
inhibitor O
of O
ornithine B-GENE-Y
decarboxylase I-GENE-Y
(ODC) B-GENE-Y
that O
is O
the O
first O
rate-limiting O
enzyme O
for O
polyamine B-CHEMICAL
biosynthesis, O
decreased O
the O
apoptotic O
index. O
Delayed O
apoptosis O
was O
accompanied O
by O
a O
decrease O
in O
caspase B-GENE-Y
3 I-GENE-Y
activity O
in O
polyamine-depleted B-CHEMICAL
cells. O
Addition O

of O
putrescine B-CHEMICAL
restored O
the O
induction O
of O
apoptosis O
as O
indicated O
by O
an O
increase O
in O
the O
number O
of O
detached O
cells O
and O
caspase B-GENE-Y
3 I-GENE-Y
activity. O
Polyamine B-CHEMICAL
depletion O
did O
not O
change O
the O
level O
of O
caspase B-GENE-Y
3 I-GENE-Y
protein. O
Inhibition O
of O
S-adenosylmethionine B-GENE-Y
decarboxylase I-GENE-Y
by O
a O
specific O
inhibitor O
[diethylglyoxal B-CHEMICAL
bis-(guanylhydrazone); I-CHEMICAL
DEGBG] B-CHEMICAL
led O
to O
depletion O
of O
spermidine B-CHEMICAL
and O
spermine B-CHEMICAL
with O
a O
significant O
accumulation O
of O
putrescine B-CHEMICAL
and O
induction O
of O
ODC. B-GENE-Y
The O
DEGBG-treated B-CHEMICAL
cells O
showed O
an O
increase O

in O
apoptosis, O
suggesting O
the O
importance O
of O
putrescine B-CHEMICAL
in O
the O
apoptotic O
process. O
Addition O
of O
putrescine B-CHEMICAL
to O
DFMO-treated B-CHEMICAL
cell O
extracts O
did O
not O
increase O
caspase B-GENE-Y
3 I-GENE-Y
activity. O
The O
above O
results O
indicate O
that O
polyamine B-CHEMICAL
depletion O
delays O
the O
onset O
of O
apoptosis O
in O
IEC-6 O
cells O
and O
confers O
protection O
against O
DNA O
damaging O
agents, O
suggesting O
that O
polyamines B-CHEMICAL
might O
be O
involved O
in O
the O
caspase B-GENE-N
activating O
signal O
cascade. O
Profile O
of O
certolizumab O
and O
its O
potential O
in O
the O
treatment O
of O
psoriatic O
arthritis. O
Psoriatic O

arthritis O
(PsA) O
is O
a O
chronic O
inflammatory O
arthropathy O
associated O
with O
psoriasis O
(PsO). O
PsA O
could O
be O
considered O
an O
enthesal O
disease O
because O
of O
the O
link O
between O
mechanical O
stress O
(entheses) O
and O
immunologically O
active O
tissue O
(synovium). O
Evidence O
of O
efficacy O
of O
anti-tumor B-GENE-Y
necrosis I-GENE-Y
factor I-GENE-Y
alpha I-GENE-Y
(TNF-alpha) B-GENE-Y
is O
supported O
by O
reduction O
of O
histological O
vascularity O
and O
immune O
cell O
infiltrates O
in O
synovial O
tissue O
after O
treatment. O
Certolizumab O
pegol O
(CZP) O
is O
a O

polyethylene O
glycolylated O
(PEGylated) O
Fab' B-GENE-N
fragment O
of O
a O
humanized O
monoclonal O
antibody O
that O
binds O
and O
neutralizes O
human B-GENE-Y
TNF-alpha. I-GENE-Y
The O
PEG B-CHEMICAL
moiety O
of O
the O
Fab B-GENE-N
fragment, O
markedly O
increases O
the O
half-life O
of O
CZP O
and O
confers O
to O
the O
drug O
a O
unique O
structure O
that O
differs O
from O
the O
other O
anti-TNF-alpha B-GENE-Y
agents O
tested O
for O
the O
treatment O
of O
Crohn's O
disease, O
rheumatoid O
arthritis, O
ankylosing O
spondylitis, O
axial O
spondyloarthritis, O

nonradiographic O
spondyloarthritis, O
PsO, O
and O
PsA. O
In O
contrast O
to O
other O
anti-TNF-alpha B-GENE-Y
agents, O
CZP O
did O
not O
mediate O
increased O
levels O
of O
apoptosis, O
suggesting O
that O
these O
mechanisms O
are O
not O
essential O
for O
the O
anti-TNF-alpha B-GENE-Y
efficacy O
in O
Crohn's O
disease. O
As O
CZP, O
infliximab, O
and O
adalimumab, O
but O
not O
etanercept, O
almost O
completely O
inhibited O
lipopolysaccharide-induced O
interleukin-1 B-GENE-Y
beta I-GENE-Y
release O
from O
monocytes, O
this O

cytokine-production B-GENE-N
inhibition O
may O
be O
relevant O
for O
drug O
efficacy. O
Due O
to O
these O
characteristics, O
it O
has O
been O
demonstrated O
in O
clinical O
studies O
that O
CZP O
effectively O
improves O
signs O
and O
symptoms O
of O
arthritis O
and O
physical O
function O
and O
skin O
manifestations O
of O
PsO, O
with O
a O
safety O
profile O
similar O
to O
rheumatoid O
arthritis. O
This O
drug O
can O
be O
considered O
as O
a O
valid O
treatment O
in O
patients O
affected O
by O
PsA. O
The O
efficacy O
and O
tolerability O
profiles O
suggest O
CZP O
as O
a O
suitable O
antipsoriatic O
drug O
in O
the O
treatment O
of O
PsA. O
Predictive O
modeling O
of O
insulin B-GENE-Y
release O
profile O
from O
cross-linked O

chitosan O
microspheres. O
Insulin-loaded B-GENE-Y
microspheres O
composed O
of O
chitosan O
3% O
(w/v), O
and O
loading O
120 O
IU O
insulin B-GENE-Y
were O
produced O
by O
emulsion O
cross-linking O
method. O
Cross-linking O
time O
was O
5 O
h O
and O
glutaraldehyde B-CHEMICAL
3.5% O
(v/v) O
was O
used O
as O
cross-linker. O
Swelling O
ratio O
studies O
were O
evaluated O
to O
predict O
release O
of O
insulin B-GENE-Y
from O
chitosan O
microspheres. O
Bacitracin B-CHEMICAL
and O
sodium B-CHEMICAL
taurocholate I-CHEMICAL
were O
incorporated O
in O
the O
formulations O
as O
proteolytic O
enzyme O
inhibitor O
and O
absorption O

enhancer, O
respectively. O
In O
vitro O
insulin B-GENE-Y
release O
studies O
were O
performed O
in O
phosphate B-CHEMICAL
buffer O
pH O
7.4 O
and O
also O
in O
HCl B-CHEMICAL
pH O
2 O
with O
and O
without O
trypsin. B-GENE-N
Activity O
of O
bacitracin B-CHEMICAL
was O
also O
evaluated. O
In O
vitro O
release O
showed O
a O
controlled O
profile O
up O
to O
12 O
h O
and O
the O
formulation O
containing O
0.15% O
(w/v) O
of O
bacitracin B-CHEMICAL
revealed O
a O
maximum O
biological O
activity O
of O
about O
49.1 O
± O
4.1%. O
Mathematical O
modeling O
using O
Higuchi O
and O
Korsmeyer-Peppas O
suggested O
a O
non-Fickian O
diffusion O
as O
the O
mechanism O
of O
insulin B-GENE-Y
release. O

Insulin-loaded B-GENE-Y
chitosan O
microspheres O
for O
oral O
delivery O
showed O
to O
be O
an O
innovative O
and O
reliable O
delivery O
system O
to O
overcome O
conventional O
insulin B-GENE-Y
therapy. O
Serum O
carvedilol B-CHEMICAL
concentration O
and O
its O
relation O
to O
change O
in O
plasma O
brain B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
level O
in O
the O
treatment O
of O
heart O
failure: O
a O
preliminary O
study. O
OBJECTIVE: O
To O
examine O
the O
influence O
of O
carvedilol B-CHEMICAL
dose O
and O
concentration O
in O
serum O
on O
plasma O
brain B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(BNP), B-GENE-Y
a O
measure O
of O
heart O
failure O
progression. O
METHODS: O
12 O
patients O
with O
New O
York O
Heart O
Association O
(NYHA) O
functional O
class O
II-III O
chronic O
heart O

failure O
were O
enrolled O
in O
the O
study. O
They O
received O
carvedilol B-CHEMICAL
at O
daily O
doses O
of O
1-20 O
mg O
with O
a O
1-2 O
weekly O
adjustment. O
Serum O
carvedilol B-CHEMICAL
trough O
concentrations O
were O
measured O
in O
steady-state O
using O
a O
specific O
fluorescence O
HPLC O
method. O
The O
degree O
of O
improvement O
in O
heart O
failure O
was O
assessed O
from O
the O
ratio O
of O
change O
in O
the O
plasma O
BNP B-GENE-Y
concentration, O
2 O
weeks, O
1 O
month O
and O
3 O
months O
after O
the O
commencement O
of O
carvedilol B-CHEMICAL
administration. O
RESULTS: O
From O
the O
pharmacokinetic O
aspect, O
there O
was O
no O
valid O
correlation O
between O
the O
trough O
serum O
carvedilol B-CHEMICAL
concentration O
(Cmin) O
and O
daily O

dose O
per O
body O
weight O
(Dd/BW), O
indicating O
that O
there O
was O
a O
wide O
difference O
in O
the O
carvedilol B-CHEMICAL
elimination O
capacity O
among O
individuals. O
A O
significant O
decrease O
in O
the O
BNP B-GENE-Y
was O
observed O
at O
the O
3rd O
month O
in O
patients O
treated O
with O
the O
high O
dose O
(> O
750 O
mg/3 O
months). O
On O
the O
other O
hand, O
in O
patients O
with O
a O
mean O
serum O
carvedilol B-CHEMICAL
level O
(Cmin) O
of O
less O
than O
2.5 O
nmol/l O
up O
to O
2 O
weeks O
after O
the O
start O
ofcarvedilol B-CHEMICAL
therapy, O
the O
degree O
of O
reduction O
in O
the O
BNP B-GENE-Y
value O
after O
the O
3rd O
month O
was O
significantly O
larger, O
relative O
to O
the O
patient O
group O
with O
Cmin O

over O
2.5 O
nmol/l. O
CONCLUSIONS: O
The O
total O
carvedilol B-CHEMICAL
dose O
was O
confirmed O
to O
be O
one O
of O
the O
determinants O
for O
improvement O
in O
heart O
failure, O
and O
it O
was O
suggested O
that O
the O
initial O
serum O
level O
also O
plays O
an O
important O
role O
in O
therapeutic O
outcome. O
Therefore, O
it O
may O
be O
important O
to O
monitor O
the O
serum O
carvedilol B-CHEMICAL
level O
at O
the O
introductory O
period O
to O
determine O
the O
daily O
dose O
requirements O
because O
of O
the O
wide O
inter-individual O
variability O
in O
its O
metabolic O
clearance. O
Mechanism O
of O
action O
of O
leflunomide B-CHEMICAL
in O
rheumatoid O
arthritis. O
Leflunomide, B-CHEMICAL
a O

novel O
drug O
with O
proven O
efficacy O
in O
rheumatoid O
arthritis, O
is O
an O
isoxazol B-CHEMICAL
derivative O
structurally O
unrelated O
to O
other O
immunomodulatory O
drugs. O
Leflunomide B-CHEMICAL
is O
rapidly O
metabolized O
to O
its O
active O
form, O
A77 B-CHEMICAL
1726. I-CHEMICAL
Two O
mechanisms O
of O
action O
have O
been O
identified O
for O
A77 B-CHEMICAL
1726: I-CHEMICAL
inhibition O
of O
dihydroorotate B-GENE-Y
dehydrogenase I-GENE-Y
(DHODH) B-GENE-Y
and O
inhibition O
of O
tyrosine B-GENE-N
kinases. I-GENE-N
DHODH B-GENE-Y
inhibition O
occurs O
at O
lower O
concentrations O
of O
A77 B-CHEMICAL
1726 I-CHEMICAL
than O
that O
of O
tyrosine B-GENE-N

kinases I-GENE-N
and O
is O
currently O
considered O
the O
major O
mode O
of O
action. O
Stimulated O
lymphocytes O
must O
increase O
ribonucleotide O
levels O
from O
8 O
to O
16-fold O
before O
proceeding O
from O
the O
G1 O
into O
the O
S O
phase. O
Increased O
levels O
of O
ribonucleotides O
can O
only O
be O
met O
by O
de O
novo O
ribonucleotide O
synthesis. O
At O
low O
levels O
of O
ribonucleotides, O
p53, B-GENE-Y
a O
"sensor" O
molecule, O
gets O
activated O
and O
prevents O
progression O
through O
the O
cell O
cycle. O
Therefore, O
an O
inhibitor O
of O
de O
novo O
uridine B-CHEMICAL
monophosphate I-CHEMICAL
synthesis O
would O
predictably O
arrest O
stimulated O
cells O
at O
the O
G1 O

phase. O
In O
support O
of O
this O
mechanism O
of O
action, O
in O
vitro O
mitogen O
stimulated O
human O
peripheral O
blood O
lymphocytes O
treated O
with O
A77 B-CHEMICAL
1726 I-CHEMICAL
undergo O
arrest O
at O
the O
G1 O
phase; O
this O
inhibition O
is O
reversed O
by O
uridine. B-CHEMICAL
L-proline B-CHEMICAL
accumulation O
and O
freeze O
tolerance O
of O
Saccharomyces O
cerevisiae O
are O
caused O
by O
a O
mutation O
in O
the O
PRO1 B-GENE-Y
gene O
encoding O
gamma-glutamyl B-GENE-Y
kinase. I-GENE-Y
We O
previously O
isolated O
a O
mutant O
which O
showed O
a O
high O
tolerance O
to O
freezing O
that O
correlated O
with O
higher O
levels O
of O
intracellular O
L-proline B-CHEMICAL
derived O
from O
L-proline B-CHEMICAL
analogue-resistant O
mutants. O
The O
mutation O

responsible O
for O
the O
analogue O
resistance O
and O
L-proline B-CHEMICAL
accumulation O
was O
a O
single O
nuclear O
dominant O
mutation. O
By O
introducing O
the O
mutant-derived O
genomic O
library O
into O
a O
non-L-proline-utilizing B-CHEMICAL
strain, O
the O
mutant O
was O
found O
to O
carry O
an O
allele O
of O
the O
wild-type O
PRO1 B-GENE-Y
gene O
encoding O
gamma-glutamyl B-GENE-Y
kinase, I-GENE-Y
which O
resulted O
in O
a O
single O
amino B-CHEMICAL
acid I-CHEMICAL
replacement; O
Asp B-CHEMICAL
(GAC) B-GENE-N
at O
position O
154 O
was O
replaced O
by O
Asn B-CHEMICAL
(AAC). B-GENE-N
Interestingly, O
the O
allele O
of O
PRO1 B-GENE-Y
was O
shown O
to O
enhance O
the O
activities O
of O
gamma-glutamyl B-GENE-Y
kinase I-GENE-Y
and O
gamma-glutamyl B-GENE-Y

phosphate I-GENE-Y
reductase, I-GENE-Y
both O
of O
which O
catalyze O
the O
first O
two O
steps O
of O
L-proline B-CHEMICAL
synthesis O
from O
L-glutamate B-CHEMICAL
and O
which O
together O
may O
form O
a O
complex O
in O
vivo. O
When O
cultured O
in O
liquid O
minimal O
medium, O
yeast O
cells O
expressing O
the O
mutated O
gamma-glutamyl B-GENE-Y
kinase I-GENE-Y
were O
found O
to O
accumulate O
intracellular O
L-proline B-CHEMICAL
and O
showed O
a O
prominent O
increase O
in O
cell O
viability O
after O
freezing O
at O
-20 O
degrees O
C O
compared O
to O
the O
viability O
of O
cells O
harboring O
the O
wild-type O
PRO1 B-GENE-Y
gene. O
These O
results O
suggest O
that O
the O
altered O
gamma-glutamyl B-GENE-Y
kinase I-GENE-Y
results O
in O
stabilization O

of O
the O
complex O
or O
has O
an O
indirect O
effect O
on O
gamma-glutamyl B-GENE-Y
phosphate I-GENE-Y
reductase I-GENE-Y
activity, O
which O
leads O
to O
an O
increase O
in O
L-proline B-CHEMICAL
production O
in O
Saccharomyces O
cerevisiae. O
The O
approach O
described O
in O
this O
paper O
could O
be O
a O
practical O
method O
for O
breeding O
novel O
freeze-tolerant O
yeast O
strains. O
Structural O
optimization O
of O
2,5-thiophene B-CHEMICAL
amides I-CHEMICAL
as O
highly O
potent O
and O
selective O
17β-hydroxysteroid B-GENE-Y
dehydrogenase I-GENE-Y
type I-GENE-Y
2 I-GENE-Y
inhibitors O
for O
the O
treatment O
of O
osteoporosis. O
Inhibition O
of O
17β-HSD2 B-GENE-Y
is O
an O
attractive O
mechanism O
for O
the O
treatment O
of O

osteoporosis. O
We O
report O
here O
the O
optimization O
of O
human B-GENE-Y
17β-HSD2 I-GENE-Y
inhibitors O
in O
the O
2,5-thiophene B-CHEMICAL
amide I-CHEMICAL
class O
by O
varying O
the O
size O
of O
the O
linker O
(n O
equals O
0 O
and O
2) O
between O
the O
amide B-CHEMICAL
moiety O
and O
the O
phenyl B-CHEMICAL
group. O
While O
none O
of O
the O
phenethylamides B-CHEMICAL
(n O
= O
2) O
were O
active, O
most O
of O
the O
anilides B-CHEMICAL
(n O
= O
0) O
turned O
out O
to O
moderately O
or O
strongly O
inhibit O
17β-HSD2. B-GENE-Y
The O
four O
most O
active O
compounds O
showed O
an O
IC₅₀ O
of O
around O
60 O
nM O
and O
a O
very O

good O
selectivity O
toward O
17β-HSD1, B-GENE-Y
17β-HSD4, B-GENE-Y
17β-HSD5, B-GENE-Y
11β-HSD1, B-GENE-Y
11β-HSD2 B-GENE-Y
and O
the O
estrogen B-GENE-N
receptors I-GENE-N
α I-GENE-N
and I-GENE-N
β. I-GENE-N
The O
investigated O
compounds O
inhibited O
monkey O
17β-HSD2 B-GENE-Y
moderately, O
and O
one O
of O
them O
showed O
good O
inhibitory O
activity O
on O
mouse B-GENE-Y
17β-HSD2. I-GENE-Y
SAR O
studies O
allowed O
a O
first O
characterization O
of O
the O
human B-GENE-Y
17β-HSD2 I-GENE-Y
active O
site, O
which O
is O
predicted O
to O
be O
considerably O
larger O
than O
that O
of O
17β-HSD1. B-GENE-Y
Changes O
in O
submaxillary O
gland O
gene O
expression O

in O
F344 O
rats O
by O
multiple O
dosing O
of O
theophylline. B-CHEMICAL
Multiple O
exposure O
to O
theophylline, B-CHEMICAL
a O
phosphodiesterase B-GENE-N
(PDE) B-GENE-N
inhibitor, O
induces O
acinar O
hypertrophy O
in O
the O
salivary O
gland. O
This O
study O
examined O
the O
effect O
of O
theophylline B-CHEMICAL
on O
the O
gene O
expression O
of O
secretory O
proteins O
and O
phosphodiesterases B-GENE-N
in O
the O
submaxillary O
gland. O
Male O
F344 O
rats O
received O
saline O
or O
theophylline B-CHEMICAL
(50 O
mg/kg) O
intraperitoneally O
for O
4 O
days. O
The O
gene O
expressions O
for O
the O
secretory O
protein, O

cystatin B-GENE-Y
S I-GENE-Y
(CysS), B-GENE-Y
and O
PDE B-GENE-N
subfamilies I-GENE-N
3A I-GENE-N
and I-GENE-N
4D I-GENE-N
in O
the O
submaxillary O
gland O
were O
quantified O
using O
RT-PCR. O
Theophylline B-CHEMICAL
exposure O
resulted O
in O
a O
sustained O
increase O
in O
mRNA O
expression O
for O
CysS B-GENE-Y
and O
PDE3A, B-GENE-Y
but O
PDE4D B-GENE-Y
gene O
expression O
was O
unchanged. O
Our O
results O
suggest O
that O
submaxillary O
hypertrophy O
is O
primarily O
caused O
by O
the O
enhanced O
transcription O
of O
CysS, B-GENE-Y
and O
that O
the O
transcription O
of O
each O
PDE B-GENE-N
subfamily O
gene O
is O
regulated O
differently. O
eIF4F B-GENE-Y
suppression O
in O
breast O
cancer O
affects O
maintenance O
and O

progression. O
Levels O
of O
eukaryotic B-GENE-Y
initiation I-GENE-Y
factor I-GENE-Y
4E I-GENE-Y
(eIF4E) B-GENE-Y
are O
frequently O
elevated O
in O
human O
cancers O
and O
in O
some O
instances O
have O
been O
associated O
with O
poor O
prognosis O
and O
outcome. O
Here O
we O
utilize O
transgenic O
and O
allograft O
breast O
cancer O
models O
to O
demonstrate O
that O
increased O
mammalian B-GENE-Y
target I-GENE-Y
of I-GENE-Y
rapamycin I-GENE-Y
(mTOR) B-GENE-Y
signalling O
can O
be O
a O
significant O
contributor O
to O
breast O
cancer O
progression O
in O
vivo. O
Suppressing O
mTOR B-GENE-Y
activity, O
as O
well O
as O
levels O
and O
activity O
of O
the O
downstream O
translation O
regulators, O
eIF4E B-GENE-Y
and O
eIF4A, B-GENE-Y
delayed O
breast O
cancer O
progression, O
onset O
of O
associated O
pulmonary O

metastasis O
in O
vivo O
and O
breast O
cancer O
cell O
invasion O
and O
migration O
in O
vitro. O
Translation O
of O
vascular B-GENE-Y
endothelial I-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
(VEGF), B-GENE-Y
matrix B-GENE-Y
metallopeptidase I-GENE-Y
9 I-GENE-Y
(MMP9) B-GENE-Y
and O
cyclin B-GENE-Y
D1 I-GENE-Y
mRNAs, O
which O
encode O
products O
associated O
with O
the O
metastatic O
phenotype, O
is O
inhibited O
upon O
eIF4E B-GENE-Y
suppression. O
Our O
results O
indicate O
that O
the O
mTOR/eIF4F B-GENE-Y
axis O
is O
an O
important O
contributor O
to O
tumor O
maintenance O
and O
progression O
programs O
in O
breast O
cancer. O
Targeting O
this O
pathway O
may O
be O
of O
therapeutic O
benefit. O
[Psychopharmacological O
profile O

of O
venlafaxine]. B-CHEMICAL
Venlafaxine B-CHEMICAL
is O
an O
antidepressant O
which O
blocks O
reuptake O
of O
noradrenaline B-CHEMICAL
and O
serotonin B-CHEMICAL
and, O
to O
a O
lesser O
extent, O
dopamine. B-CHEMICAL
These O
data O
have O
been O
confirmed O
by O
behavioral O
tests. O
It O
has O
been O
shown O
that O
by O
decreasing O
the O
overall O
cerebral O
quantity O
of O
5-HT B-CHEMICAL
and O
NA, B-CHEMICAL
venlafaxine B-CHEMICAL
continued O
to O
have O
an O
antidepressant O
action O
in O
animal O
models. O
In O
addition, O
the O
drug O
has O
been O
shown O
to O
act O
preferentially O
on O
5-HT1A B-GENE-Y
and O
5-HT1B B-GENE-Y
receptors. O

Transcriptome O
alterations O
following O
developmental O
atrazine B-CHEMICAL
exposure O
in O
zebrafish O
are O
associated O
with O
disruption O
of O
neuroendocrine O
and O
reproductive O
system O
function, O
cell O
cycle, O
and O
carcinogenesis. O
Atrazine, B-CHEMICAL
a O
herbicide O
commonly O
applied O
to O
agricultural O
areas O
and O
a O
common O
contaminant O
of O
potable O
water O
supplies, O
is O
implicated O
as O
an O
endocrine-disrupting O
chemical O
(EDC) O
and O
potential O
carcinogen. O
Studies O
show O
that O
EDCs O
can O
cause O
irreversible O
changes O
in O
tissue O
formation, O
decreased O
reproductive O
potential, O
obesity, O
and O
cancer. O
The O
U.S. O
Environmental O
Protection O
Agency O
considers O
an O
atrazine B-CHEMICAL
concentration O
of O

≤ O
3 O
ppb O
in O
drinking O
water O
safe O
for O
consumption. O
The O
specific O
adverse O
human O
health O
effects O
associated O
with O
a O
developmental O
atrazine B-CHEMICAL
exposure O
and O
the O
underlying O
genetic O
mechanisms O
of O
these O
effects O
are O
not O
well O
defined. O
In O
this O
study, O
zebrafish O
embryos O
were O
exposed O
to O
a O
range O
of O
atrazine B-CHEMICAL
concentrations O
to O
establish O
toxicity. O
Morphological, O
transcriptomic, O
and O
protein O
alterations O
were O
then O
assessed O
at O
72h O
postfertilization O
following O
developmental O
atrazine B-CHEMICAL
exposure O
at O
0, O
0.3, O
3, O
or O
30 O
ppb. O
A O
significant O
increase O
in O
head O
length O
was O
observed O
in O
all O
three O
atrazine B-CHEMICAL
treatments. O

Transcriptomic O
profiles O
revealed O
21, O
62, O
and O
64 O
genes O
with O
altered O
expression O
in O
the O
0.3, O
3, O
and O
30 O
ppb O
atrazine B-CHEMICAL
treatments, O
respectively. O
Altered O
genes O
were O
associated O
with O
neuroendocrine O
and O
reproductive O
system O
development, O
function, O
and O
disease; O
cell O
cycle O
control; O
and O
carcinogenesis. O
There O
was O
a O
significant O
overlap O
(42 O
genes) O
between O
the O
3 O
and O
30 O
ppb O
differentially O
expressed O
gene O
lists, O
with O
two O
of O
these O
genes O
(CYP17A1 B-GENE-Y
and O
SAMHD1) B-GENE-Y
present O
in O
all O
three O
atrazine B-CHEMICAL
treatments. O
Increased O
transcript O
levels O
were O
translated O
to O
significant O

upregulation O
in O
protein O
expression. O
Overall, O
this O
study O
identifies O
genetic O
and O
molecular O
targets O
altered O
in O
response O
to O
a O
developmental O
atrazine B-CHEMICAL
exposure O
to O
further O
define O
the O
biological O
pathways O
and O
mechanisms O
of O
toxicity. O
Effects O
of O
bambuterol B-CHEMICAL
and O
terbutaline B-CHEMICAL
on O
isolated O
rat's O
tracheal O
smooth O
muscle. O
Terbutaline B-CHEMICAL
(Bricanyl) B-CHEMICAL
and O
its O
prodrug O
Bambuterol B-CHEMICAL
(Bambec) B-CHEMICAL
are O
highly O
potent O
beta(2)-adrenoceptor B-GENE-Y
agonists O
often O
used O
in O
asthma O
patients. O
Terbutaline B-CHEMICAL
in O
the O
form O
of O
inhaled O
short-acting O

bronchodilator O
relieves O
asthmatic O
symptoms. O
However, O
the O
effects O
of O
bambuterol B-CHEMICAL
given O
intratracheally O
have O
rarely O
been O
explored. O
To O
verify O
the O
effect O
of O
bambuterol B-CHEMICAL
and O
terbutaline, B-CHEMICAL
which O
act O
on O
the O
tracheal O
smooth O
muscle O
directly O
in O
vitro, O
we O
used O
our O
preparation O
to O
test O
the O
effects O
of O
bambuterol B-CHEMICAL
on O
isolated O
rat's O
tracheal O
smooth O
muscle O
compared O
with O
terbutaline. B-CHEMICAL
The O
following O
assessments O
of O
bambuterol B-CHEMICAL
and O
terbutaline B-CHEMICAL
were O
performed: O
(1) O
effect O
on O
tracheal O
smooth O
muscle O
resting O

tension; O
(2) O
effect O
on O
contraction O
caused O
by O
10(-6) O
M O
methacholine B-CHEMICAL
as O
a O
parasympathetic O
mimetic; O
(3) O
effect O
of O
the O
drugs O
on O
electrically O
induced O
tracheal O
smooth O
muscle O
contractions. O
The O
results O
indicated O
that O
adding O
bambuterol B-CHEMICAL
induced O
a O
significant O
further O
contraction O
to O
10(-6) O
M O
methacholine-induced B-CHEMICAL
contraction O
when O
the O
preparation O
was O
increased O
to O
10(-4) O
M. O
But O
terbutaline B-CHEMICAL
elicited O
a O
relaxation O
response O
at O
a O
dose O
of O
10(-6) O
M O
or O
more. O
Both O
bambuterol B-CHEMICAL
and O

terbutaline B-CHEMICAL
could O
inhibit O
electrical O
field O
stimulation O
(EFS) O
induced O
spike O
contraction. O
Terbutaline B-CHEMICAL
had O
an O
anti-cholinergic O
effect O
that O
could O
relieve O
asthmatic O
symptoms. O
But O
the O
effect O
of O
bambuterol O
acting O
on O
tracheal O
smooth O
muscle O
directly O
was O
controversial. O
(+/-)-tamsulosin, B-CHEMICAL
an O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
antagonist, O
inhibits O
the O
positive O
inotropic O
effect O
but O
not O
the O
accumulation O
of O
inositol B-CHEMICAL
phosphates I-CHEMICAL
in O
rabbit O
heart. O
The O
influence O
of O
(+/-)-tamsulosin, B-CHEMICAL
a O
selective O
alpha B-GENE-Y

1A-adrenoceptor I-GENE-Y
antagonist, O
on O
the O
positive O
inotropic O
effect O
and O
the O
accumulation O
of O
inositol B-CHEMICAL
phosphates I-CHEMICAL
that O
are O
induced O
via O
alpha B-GENE-N
1-adrenoceptors I-GENE-N
was O
studied O
in O
comparison O
with O
that O
of O
another O
alpha B-GENE-Y
1A-adrenoceptor I-GENE-Y
ligand O
oxymetazoline B-CHEMICAL
in O
the O
rabbit O
ventricular O
myocardium. O
Phenylephrine B-CHEMICAL
elicited O
a O
concentration-dependent O
positive O
inotropic O
effect O
via O
alpha B-GENE-N
1-adrenoceptors I-GENE-N
in O
the O
presence O
of O
either O
(+/-)-bupranolol B-CHEMICAL
or O

S(-)-timolol. B-CHEMICAL
The O
mode O
of O
antagonism O
induced O
by O
(+/-)-tamsulosin B-CHEMICAL
on O
the O
effect O
of O
phenylephrine B-CHEMICAL
was O
dependent O
or O
the O
concentration O
applied: O
(+/-)-tamsulosin B-CHEMICAL
at O
1 O
and O
3 O
nM O
acted O
in O
a O
competitive O
manner, O
the O
slope O
of O
the O
regression O
line O
of O
the O
Schild O
plot O
being O
unity O
and O
the O
pA2 O
value O
being O
9.12; O
at O
10 O
nM, O
it O
shifted O
further O
the O
concentration-response O
curve O
to O
the O
right O
without O
affecting O
the O
maximal O
response O
but O
the O
slope O
became O
less O
than O
unity. O
At O
100 O
nM O

and O
higher, O
it O
suppressed O
the O
maximal O
response O
to O
phenylephrine. B-CHEMICAL
(+/-)-Tamsulosin B-CHEMICAL
effectively O
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine B-CHEMICAL
even O
after O
inactivation O
of O
alpha B-GENE-Y
1B-adrenoceptors I-GENE-Y
by O
treatment O
with O
chlorethylclonidine, B-CHEMICAL
which O
is O
an O
indication O
that O
the O
(+/-)-tamsulosin-sensitive B-CHEMICAL
subtype O
belongs O
to O
a O
class O
resistant O
to O
chlorethylclonidine. B-CHEMICAL
(+/-)-Tamsulosin, B-CHEMICAL
over O
the O
range O
of O
concentrations O
at O
which O
it O
antagonized O

the O
positive O
inotropic O
effect O
mediated O
by O
alpha B-GENE-N
1-adrenoceptors, I-GENE-N
did O
not O
affect O
the O
accumulation O
of O
[3H]inositol B-CHEMICAL
phosphates I-CHEMICAL
that O
was O
induced O
by O
10 O
microM O
phenylephrine. B-CHEMICAL
Oxymetazoline B-CHEMICAL
antagonized O
the O
positive O
inotropic O
effect O
of O
phenylephrine B-CHEMICAL
in O
a O
competitive O
manner O
without O
affecting O
the O
accumulation O
of O
inositol B-CHEMICAL
monophosphate I-CHEMICAL
induced O
by O
phenylephrine. B-CHEMICAL
These O
results O
indicate O
that O
the O
positive O
inotropic O
effect, O
mediated O
via O
(+/-)-tamsulosin- B-CHEMICAL
and O
oxymetazoline-sensitive B-CHEMICAL

subtype O
of O
alpha B-GENE-N
1-adrenoceptors, I-GENE-N
is O
exerted O
by O
a O
subcellular O
mechanism O
that O
is O
independent O
of O
the O
accumulation O
of O
inositol B-CHEMICAL
phosphates. I-CHEMICAL
Pterostilbene B-CHEMICAL
exerts O
antitumor O
activity O
against O
human O
osteosarcoma O
cells O
by O
inhibiting O
the O
JAK2/STAT3 B-GENE-Y
signaling O
pathway. O
Osteosarcoma O
is O
a O
high-grade O
malignant O
bone O
tumor. O
Pterostilbene B-CHEMICAL
(PTE) B-CHEMICAL
is O
a O
natural, O
dimethylated O
analog O
of O
resveratrol B-CHEMICAL
with O
higher O
bioavailability. O
While O
PTE B-CHEMICAL
has O
been O
shown O

to O
have O
potent O
antitumor O
activity O
against O
various O
types O
of O
cancer, O
the O
molecular O
mechanisms O
underlying O
the O
effects O
of O
PTE B-CHEMICAL
remain O
largely O
unknown. O
The O
Janus B-GENE-Y
kinase I-GENE-Y
2/Signal I-GENE-Y
Transducer I-GENE-Y
and I-GENE-Y
Activator I-GENE-Y
of I-GENE-Y
Transcription I-GENE-Y
3 I-GENE-Y
(JAK2/STAT3) B-GENE-Y
signaling O
pathway O
plays O
a O
crucial O
role O
in O
tumorigenesis O
and O
immune O
development. O
In O
this O
study, O
we O
assessed O
the O
antitumor O
activity O
of O
PTE B-CHEMICAL
against O
human O
osteosarcoma O
cells O
and O
explored O
the O
role O
of O
JAK2/STAT3 B-GENE-Y
and O
apoptosis-related O
signaling O
pathways O
on O
the O
activity O
of O
PTE. B-CHEMICAL
PTE B-CHEMICAL
treatment O
resulted O
in O
a O

dose- O
and O
time-dependent O
inhibition O
of O
osteosarcoma O
cell O
viability. O
Additionally, O
PTE B-CHEMICAL
exhibited O
strong O
antitumor O
activity, O
as O
evidenced O
not O
only O
by O
reductions O
in O
tumor O
cell O
adhesion, O
migration O
and O
mitochondrial O
membrane O
potential O
(MMP) O
but O
also O
by O
increases O
in O
the O
apoptotic O
index, O
reactive O
oxygen B-CHEMICAL
species O
(ROS) O
and O
several O
biochemical O
parameters. O
Furthermore, O
PTE B-CHEMICAL
treatment O
directly O
inhibited O
the O
phosphorylation O
of O
JAK2 B-GENE-Y
at O
Tyr B-CHEMICAL
1007 O
and O
the O
downstream O
activation O
of O
STAT3. B-GENE-Y
PTE B-CHEMICAL
also O
down-regulated O
the O
expression O
of O
STAT3 B-GENE-Y
target O
genes, O
including O

the O
anti-apoptotic O
proteins O
Bcl-xL B-GENE-Y
and O
Mcl-1, B-GENE-Y
leading O
to O
the O
up-regulation O
of O
mitochondrial O
apoptosis O
pathway-related O
proteins O
(Bax, B-GENE-Y
Bak, B-GENE-Y
cytosolic O
Cytochrome B-GENE-Y
c, I-GENE-Y
and O
cleaved O
Caspase3) B-GENE-Y
and O
cyclin-dependent B-GENE-N
kinase I-GENE-N
inhibitors O
such O
as O
p21 B-GENE-Y
and O
p27. B-GENE-Y
PTE, B-CHEMICAL
used O
in O
combination O
with O
a O
known O
JAK2/STAT3 B-GENE-Y
inhibitor, O
AG490, B-CHEMICAL
further O
decreased O
the O
viability O
of O
osteosarcoma O
cells. O
Taken O
together, O
PTE B-CHEMICAL
is O
a O
potent O

inhibitor O
of O
osteosarcoma O
cell O
growth O
that O
targets O
the O
JAK2/STAT3 B-GENE-Y
signaling O
pathway. O
These O
data O
suggest O
that O
inhibition O
of O
JAK2/STAT3 B-GENE-Y
signaling O
is O
a O
novel O
mechanism O
of O
action O
for O
PTE B-CHEMICAL
during O
therapeutic O
intervention O
in O
osteosarcoma O
cancers. O
Effect O
of O
sinapic B-CHEMICAL
acid I-CHEMICAL
against O
dimethylnitrosamine-induced B-CHEMICAL
hepatic O
fibrosis O
in O
rats. O
Sinapic B-CHEMICAL
acid I-CHEMICAL
is O
a O
member O
of O
the O
phenylpropanoid B-CHEMICAL
family O
and O
is O
abundant O
in O
cereals, O
nuts, O
oil O
seeds, O
and O
berries. O
It O
exhibits O
a O
wide O
range O
of O

pharmacological O
properties. O
In O
this O
study, O
we O
investigated O
the O
hepatoprotective O
and O
antifibrotic O
effects O
of O
sinapic B-CHEMICAL
acid I-CHEMICAL
on O
dimethylnitrosamine B-CHEMICAL
(DMN)-induced B-CHEMICAL
chronic O
liver O
injury O
in O
rats. O
Sinapic B-CHEMICAL
acid I-CHEMICAL
remarkably O
prevented O
DMN-induced B-CHEMICAL
loss O
of O
body O
weight. O
This O
was O
accompanied O
by O
a O
significant O
increase O
in O
levels O
of O
serum O
alanine B-GENE-N
transaminase, I-GENE-N
aspartate B-GENE-Y
transaminase, I-GENE-Y
and O
liver O
malondialdehyde B-CHEMICAL
content. O
Furthermore, O
sinapic B-CHEMICAL
acid I-CHEMICAL
reduced O
hepatic O
hydroxyproline B-CHEMICAL
content, O
which O
correlated O
with O
a O
reduction O

in O
the O
expression O
of O
type B-GENE-N
I I-GENE-N
collagen I-GENE-N
mRNA O
and O
histological O
analysis O
of O
collagen B-GENE-N
in O
liver O
tissue. O
Additionally, O
the O
expression O
of O
hepatic O
fibrosis-related O
factors O
such O
as O
α-smooth B-GENE-Y
muscle I-GENE-Y
actin I-GENE-Y
and O
transforming B-GENE-Y
growth I-GENE-Y
factor-β1 I-GENE-Y
(TGF-β1), B-GENE-Y
were O
reduced O
in O
rats O
treated O
with O
sinapic B-CHEMICAL
acid. I-CHEMICAL
Sinapic B-CHEMICAL
acid I-CHEMICAL
exhibited O
strong O
scavenging O
activity. O
In O
conclusion, O
we O
find O
that O
sinapic B-CHEMICAL
acid I-CHEMICAL
exhibits O
hepatoprotective O
and O
antifibrotic O
effects O
against O
DMN-induced B-CHEMICAL
liver O
injury, O
most O
likely O
due O
to O
its O
antioxidant O
activities O

of O
scavenging O
radicals, O
its O
capacity O
to O
suppress O
TGF-β1 B-GENE-Y
and O
its O
ability O
to O
attenuate O
activation O
of O
hepatic O
stellate O
cells. O
This O
suggests O
that O
sinapic B-CHEMICAL
acid I-CHEMICAL
is O
a O
potentially O
useful O
agent O
for O
the O
protection O
against O
liver O
fibrosis O
and O
cirrhosis. O
Glutathione B-GENE-N
S-transferase I-GENE-N
M1 I-GENE-N
and I-GENE-N
P1 I-GENE-N
polymorphisms O
and O
risk O
of O
breast O
cancer O
and O
fibrocystic O
breast O
conditions O
in O
Chinese O
women. O
Enzymes O
encoded O
by O
the O
glutathione B-GENE-Y
S-tranferase I-GENE-Y
mu I-GENE-Y
1 I-GENE-Y
(GSTM1) B-GENE-Y
and O
pi B-GENE-Y
1 I-GENE-Y

(GSTP1) B-GENE-Y
genes, O
which O
are O
expressed O
in O
breast O
tissue, O
catalyze O
the O
detoxification O
of O
endogenous O
and O
exogenous O
electrophiles. O
Reduced O
enzyme O
activity, O
due O
to O
carriage O
of O
the O
GSTM1 B-GENE-Y
deletion O
or O
the O
GSTP1 B-GENE-Y
Ile105Val O
Val O
allele, O
may O
therefore O
affect O
susceptibility O
to O
breast O
cancer O
and O
related O
conditions. O
In O
a O
case-control O
study O
of O
Chinese O
women, O
we O
examined O
whether O
these O
polymorphisms O
were O
associated O
with O
risk O
of O
breast O
cancer O
and O
fibrocystic O
breast O
conditions. O
Women O
diagnosed O
with O
breast O
cancer O

(n=615) O
or O
fibrocystic O
breast O
conditions O
(n=467) O
were O
compared O
to O
women O
without O
clinical O
breast O
disease O
(n=878). O
We O
also O
examined O
whether O
these O
associations O
differed O
by O
menopausal O
status O
or O
by O
presence O
of O
proliferation O
in O
the O
extra-tumoral O
epithelium O
among O
women O
with O
breast O
cancer O
and O
in O
lesions O
among O
women O
with O
fibrocystic O
conditions. O
No O
overall O
association O
of O
either O
GST B-GENE-N
polymorphism O
with O
risk O
of O
breast O
cancer O
or O
fibrocystic O
breast O
conditions O
was O
observed. O
There O
was O
some O
evidence O
of O
slightly O
elevated O
cancer O
risk O
associated O
with O
carriage O
of O
the O
GSTM1 B-GENE-Y
null O

genotype O
and O
at O
least O
one O
GSTP1 B-GENE-Y
105-Val O
allele O
(OR=1.33, O
95% O
CI, O
0.99-1.80), O
compared O
to O
carriage O
of O
the O
GSTM1 B-GENE-Y
non-null O
and O
GSTP1 B-GENE-Y
Ile/Ile O
genotypes. O
This O
relationship O
was O
stronger O
in O
women O
who O
had O
breast O
cancer O
with O
extra-tumoral O
tissue O
proliferation O
(OR=1.77, O
95% O
CI, O
1.03-3.04). O
Our O
results O
suggest O
that O
GSTM1 B-GENE-Y
and O
GSTP1 B-GENE-Y
genotypes O
do O
not O
individually O
influence O

susceptibility O
to O
breast O
cancer O
or O
fibrocystic O
breast O
conditions. O
The O
observed O
increased O
risk O
of O
breast O
cancer O
associated O
with O
joint O
carriage O
of O
the O
GSTM1 B-GENE-Y
null O
genotype O
and O
GSTP1 B-GENE-Y
105-Val O
allele O
needs O
confirmation O
in O
other O
studies. O
Candesartan B-CHEMICAL
cilexetil--a I-CHEMICAL
review O
of O
effects O
on O
cardiovascular O
complications O
in O
hypertension O
and O
chronic O
heart O
failure. O
UNLABELLED: O
Therapeutic O
interventions O
that O
block O
the O
renin-angiotensin-aldosterone B-GENE-Y
system O
(RAAS) O
have O
an O
important O
role O
in O
slowing O
the O
progression O
of O
cardiovascular O
risk O
actors O
to O

established O
cardiovascular O
diseases. O
In O
recent O
years, O
angiotensin B-GENE-N
receptor I-GENE-N
blockers O
(ARBs) O
have O
emerged O
as O
effective O
and O
well-tolerated O
alternatives O
to O
an O
angiotensin-converting B-GENE-Y
enzyme I-GENE-Y
inhibitor O
(ACEi) O
for O
RAAS O
blockade. O
The O
ARB O
candesartan B-CHEMICAL
was O
initially O
established O
as O
an O
effective O
once-daily O
antihypertensive O
treatment, O
providing O
24-h O
blood O
pressure O
(BP) O
control O
with O
a O
trough:peak O
ratio O
close O
to O
100%. O
SCOPE: O
A O
Medline O
literature O
search O
was O
undertaken O
to O
identify O
randomised, O
controlled O
trials O
that O
examined O
the O
efficacy O
and O
cardiovascular O
outcomes O
associated O
with O

candesartan B-CHEMICAL
cilexetil I-CHEMICAL
in O
hypertension O
and O
chronic O
heart O
failure O
(CHF). O
FINDINGS: O
Compared O
with O
other O
ARBs, O
candesartan B-CHEMICAL
demonstrates O
the O
strongest O
binding O
affinity O
to O
the O
angiotensin B-GENE-Y
II I-GENE-Y
type I-GENE-Y
1 I-GENE-Y
receptor. I-GENE-Y
Clinical O
trials O
have O
demonstrated O
that O
candesartan B-CHEMICAL
is O
well O
tolerated O
in O
combination O
with O
diuretics O
or O
calcium B-GENE-N
channel I-GENE-N
blockers O
(CCBs), O
making O
it O
a O
suitable O
treatment O
option O
for O
patients O
whose O
hypertension O
is O
not O
adequately O
controlled O
by O
monotherapy. O
Subsequently, O
candesartan B-CHEMICAL
became O
the O
only O
ARB O
licensed O
in O
the O
UK O
to O
treat O
patients O
with O

CHF O
and O
left O
ventricular O
ejection O
fraction O
< O
or O
= O
40% O
as O
add-on O
therapy O
to O
an O
ACEi O
or O
when O
an O
ACEi O
is O
not O
tolerated. O
Studies O
in O
patients O
with O
symptomatic O
HF O
have O
indicated O
that O
candesartan B-CHEMICAL
treatment O
was O
associated O
with O
significant O
relative O
risk O
reductions O
in O
cardiovascular O
mortality O
and O
hospitalisation O
due O
to O
CHF. O
CONCLUSIONS: O
There O
are O
clear O
indications O
that O
the O
clinical O
benefits O
of O
candesartan B-CHEMICAL
may O
extend O
beyond O
its O
proven O
antihypertensive O
effects O
to O
a O
wider O
range O
of O
complications O
across O
the O
cardiovascular O
continuum, O
including O
diabetes, O
left O

ventricular O
hypertrophy, O
atherosclerosis O
and O
stroke. O
Such O
results O
suggest O
that O
candesartan B-CHEMICAL
treatment O
may O
offer O
significant O
patient O
benefits O
as O
well O
as O
practical O
advantages O
over O
conventional O
treatment. O
Interacting O
Glutamate B-GENE-N
Receptor-Like I-GENE-N
Proteins O
in O
Phloem O
Regulate O
Lateral O
Root O
Initiation O
in O
Arabidopsis. O
Molecular, O
genetic, O
and O
electrophysiological O
evidence O
indicates O
that O
at O
least O
one O
of O
the O
plant O
Glu B-GENE-N
receptor-like I-GENE-N
molecules, O
GLR3.4, B-GENE-N
functions O
as O
an O
amino B-GENE-N
acid-gated I-GENE-N
Ca(2+) I-GENE-N
channel I-GENE-N
at O
the O
plasma O
membrane. O
The O
aspect O
of O
plant O

physiology, O
growth, O
or O
development O
to O
which O
GLR3.4 B-GENE-N
contributes O
is O
an O
open O
question. O
Protein O
localization O
studies O
performed O
here O
provide O
important O
information. O
In O
roots, O
GLR3.4 B-GENE-N
and O
the O
related O
GLR3.2 B-GENE-N
protein O
were O
present O
primarily O
in O
the O
phloem, O
especially O
in O
the O
vicinity O
of O
the O
sieve O
plates. O
GLR3.3 B-GENE-N
was O
expressed O
in O
most O
cells O
of O
the O
growing O
primary O
root O
but O
was O
not O
enriched O
in O
the O
phloem, O
including O
the O
sieve O
plate O
area. O
GLR3.2 B-GENE-N
and O
GLR3.4 B-GENE-N
physically O
interacted O
with O
each O
other O
better O
than O
with O
themselves O
as O
evidenced O
by O

a O
biophotonic O
assay O
performed O
in O
human O
embryonic O
kidney O
cells O
and O
Nicotiana O
benthamiana O
leaf O
cells. O
GLR3.3 B-GENE-N
interacted O
poorly O
with O
itself O
or O
the O
other O
two O
GLRs. B-GENE-N
Mutations O
in O
GLR3.2, B-GENE-N
GLR3.4, B-GENE-N
or O
GLR3.2 B-GENE-N
and O
GLR3.4 B-GENE-N
caused O
the O
same O
and O
equally O
severe O
phenotype, O
namely, O
a O
large O
overproduction O
and O
aberrant O
placement O
of O
lateral O
root O
primordia. O
Loss O
of O
GLR3.3 B-GENE-N
did O
not O
affect O
lateral O
root O
primordia. O
These O
results O
support O
the O
hypothesis O
that O

apoplastic O
amino B-CHEMICAL
acids I-CHEMICAL
acting O
through O
heteromeric O
GLR3.2/GLR3.4 B-GENE-N
channels O
affect O
lateral O
root O
development O
via O
Ca(2+) B-CHEMICAL
signaling O
in O
the O
phloem. O
Purification O
and O
structural O
characterisation O
of O
phospholipase B-GENE-N
A1 I-GENE-N
(Vespapase, B-GENE-N
Ves B-GENE-N
a I-GENE-N
1) I-GENE-N
from O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
venom. O
The O
Thai O
banded O
tiger O
wasp O
(Vespa O
affinis) O
is O
one O
of O
the O
most O
dangerous O
vespid O
species O
in O
Southeast O
Asia, O
and O
stinging O
accidents O
involving O
this O
species O
still O
cause O
fatalities. O
In O

the O
present O
study, O
four O
forms O
of O
V. B-GENE-N
affinis I-GENE-N
phospholipase I-GENE-N
A(1) I-GENE-N
were O
identified O
through O
a O
proteomics O
approach. O
Two O
of O
these O
enzymes O
were O
purified O
by O
reverse-phase O
chromatography, O
and O
their O
biochemical O
properties O
were O
characterised. O
These O
enzymes, O
designated O
Ves B-GENE-N
a I-GENE-N
1s, I-GENE-N
are O
not O
glycoproteins O
and O
exist O
as O
33441.5 O
and O
33474.4 O
Da O
proteins, O
which O
corresponded O
with O
the O
34-kDa O
band O
observed O
via O
SDS-PAGE. O
The O
thermal O
stabilities O
of O
these O
enzymes O
were O
stronger O
than O
snake O
venom. O
Using O
an O
in O

vivo O
assay, O
no O
difference O
was O
found O
in O
the O
toxicities O
of O
the O
different O
isoforms. O
Furthermore, O
the O
toxicity O
of O
these O
enzymes O
does O
not O
appear O
to O
be O
correlated O
with O
their O
PLA(1) B-GENE-N
activity. O
The O
cDNAs O
of O
the O
full-length O
version O
of O
Ves B-GENE-N
a I-GENE-N
1s I-GENE-N
revealed O
that O
the O
Ves B-GENE-N
a I-GENE-N
1 I-GENE-N
gene O
consists O
of O
a O
1005-bp O
ORF, O
which O
encodes O
334 O
amino B-CHEMICAL
acid I-CHEMICAL
residues, O
and O
67- O
and O
227-bp O
5' O
and O
3' O
UTRs, O
respectively. O
The O
two O
isoforms O
are O
different O
by O
three O
nucleotide B-CHEMICAL
substitutions, O
resulting O
in O
the O
replacement O

of O
two O
amino B-CHEMICAL
acids. I-CHEMICAL
Through O
sequence O
alignment, O
these O
enzymes O
were O
classified O
as O
members O
of O
the O
pancreatic B-GENE-N
lipase I-GENE-N
family. O
The O
structural O
modelling O
of O
Ves B-GENE-N
a I-GENE-N
1 I-GENE-N
used O
the O
rat B-GENE-Y
pancreatic I-GENE-Y
lipase-related I-GENE-Y
protein I-GENE-Y
2 I-GENE-Y
(1bu8A) B-GENE-Y
as O
a O
template O
because O
it O
has O
PLA(1) B-GENE-N
activity, O
which O
demonstrated O
that O
this O
enzyme O
belongs O
to O
the O
α/β B-GENE-N
hydrolase I-GENE-N
fold O
family. O
The O
Ves B-GENE-N
a I-GENE-N
1 I-GENE-N
structure, O
which O
is O
composed O
of O
seven O
α-helixes O
and O
eleven O
β-strands, O
contains O
the O
β-strand/ɛSer/α-helix O
structural O
motif, O
which O
contains O
the O

Gly-X-Ser-X-Gly B-GENE-N
consensus O
sequence. O
The O
typical O
surface O
structures O
that O
play O
important O
roles O
in O
substrate O
selectivity O
(the O
lid O
domain O
and O
the O
β9 O
loop) O
were O
shortened O
in O
the O
Ves B-GENE-N
a I-GENE-N
1 I-GENE-N
structure, O
which O
suggests O
that O
this O
enzyme O
may O
only O
exhibit O
phospholipase B-GENE-N
activity. O
Moreover, O
the O
observed O
insertion O
of O
proline B-CHEMICAL
into O
the O
lid O
domain O
of O
the O
Ves B-GENE-N
a I-GENE-N
1 I-GENE-N
structure O
is O
rare. O
We O
therefore O
propose O
that O
this O
proline B-CHEMICAL
residue O
might O
be O
involved O
in O
the O
stability O
and O
activity O
of O
Ves B-GENE-N
a I-GENE-N
1s. I-GENE-N
Thalidomide B-CHEMICAL
inhibits O
growth O
of O
tumors O
through O
COX-2 B-GENE-Y
degradation O
independent O
of O

antiangiogenesis. O
Thalidomide B-CHEMICAL
is O
an O
antiangiogenic O
drug O
and O
is O
clinically O
useful O
in O
a O
number O
of O
cancers. O
However, O
the O
molecular O
mechanism O
by O
which O
thalidomide B-CHEMICAL
exerts O
its O
antitumor O
effects O
is O
poorly O
understood. O
This O
study O
was O
designed O
to O
clarify O
the O
relationship O
between O
antiangiogenesis O
and O
antitumor O
effects O
of O
thalidomide B-CHEMICAL
and O
to O
explore O
the O
molecular O
mechanism O
for O
its O
antitumor O
activity. O
We O
evaluated O
the O
effects O
of O
thalidomide B-CHEMICAL
on O
the O
growth O
of O
human O
tumor O
cells O
expressing O
(MCF-7 O
and O
HL-60) O
or O
not O
expressing O
(HeLa O
and O

K562) O
COX-2 B-GENE-Y
in O
vitro. O
We O
also O
studied O
the O
effects O
of O
thalidomide B-CHEMICAL
on O
COX-1, B-GENE-Y
COX-2 B-GENE-Y
or O
bcl-2 B-GENE-Y
expression, O
TNFalpha, B-GENE-Y
VEGF, B-GENE-Y
GSH O
and O
cytochrome B-GENE-Y
c I-GENE-Y
in O
these O
cells. O
Thalidomide B-CHEMICAL
could O
inhibit O
tumor O
growth O
in O
a O
concentration-dependent O
manner O
in O
MCF-7 O
and O
HL-60; O
its O
IC50s O
for O
them O
were O
18.36+/-2.34 O
and O
22.14+/-2.15 O
microM, O
respectively, O
while O
this O
effect O
was O

not O
observed O
in O
HeLa O
and O
K562. O
Thalidomide B-CHEMICAL
reduced O
COX-2 B-GENE-Y
expression O
accompanied O
by O
a O
decrease O
of O
bcl-2 B-GENE-Y
protein, O
TNFalpha, B-GENE-Y
VEGF, B-GENE-Y
GSH O
and O
an O
increased O
cytochrome B-GENE-Y
c, I-GENE-Y
but O
had O
no O
effect O
on O
that O
of O
COX-1, B-GENE-Y
in O
MCF-7 O
and O
HL-60. O
Moreover, O
cells O
not O
expressing O
COX-2 B-GENE-Y
were O
insensitive O
to O
the O
growth-inhibitory O
and O
effects O
on O
cytokines B-GENE-N
of O
thalidomide. B-CHEMICAL
In O
our O
mouse O
xenograft O
model O
of O
OVCAR-3 O
and O

HCT-8, O
we O
found O
that O
thalidomide B-CHEMICAL
could O
decrease O
intratumoral O
microvessel O
density O
in O
both O
tumors; O
it O
exerted O
antitumor O
effects O
only O
on O
OVCAR-3 O
expressing O
COX-2 B-GENE-Y
but O
did O
not O
on O
HCT-8 O
not O
expressing O
COX-2. B-GENE-Y
Effect O
of O
thalidomide B-CHEMICAL
on O
COX-1 B-GENE-Y
and O
COX-2 B-GENE-Y
in O
vivo O
was O
consistent O
with O
that O
of O
in O
vitro. O
These O
results O
demonstrated O
that O
thalidomide B-CHEMICAL
might O
inhibit O
growth O
of O
tumors O
through O
COX-2 B-GENE-Y
degradation O
independent O
of O
antiangiogenesis. O
Toxicological O
impact O
of O
inhaled O
electric O

mosquito-repellent O
liquid O
on O
the O
rat: O
a O
hematological, O
cytokine B-GENE-N
indications, O
oxidative O
stress O
and O
tumor O
markers. O
Abstract O
Context: O
High O
malaria O
burden O
has O
led O
to O
the O
increased O
use O
of O
insecticides O
in O
the O
tropics O
and O
subtropics. O
This O
study O
thus O
aimed O
at O
assessing O
the O
hematological O
effects O
alteration O
of O
pyrethroid B-CHEMICAL
insecticide O
exposure O
using O
the O
experimental O
animal O
model. O
Objective: O
A O
commonly O
available O
Electric O
Mosquito-Repellent O
Liquid O
pyrethroid B-CHEMICAL
insecticide O
containing O
prallethrin B-CHEMICAL
1.6% O
w/w O
is O

widely O
used O
for O
mosquito O
control O
in O
Saudi O
Arabia. O
The O
immunotoxic O
effects O
after O
inhalation O
exposures O
to O
the O
preparation O
for O
a O
continuous O
period O
of O
24, O
48, O
and O
72 O
h O
were O
investigated O
in O
rats. O
Methods O
and O
materials: O
Rats O
were O
exposed O
to O
prallethrin B-CHEMICAL
1.6% O
w/w O
by O
inhalation O
for O
72 O
consecutive O
hours. O
Total O
blood O
count, O
blood O
indices O
of O
creatine B-GENE-N
kinase I-GENE-N
(CK), B-GENE-N
gamma-glutamyltranspeptidase B-GENE-Y
(γ-GT), B-GENE-Y
superoxide B-GENE-N
dismutase I-GENE-N
(SOD), B-GENE-N
nitric B-CHEMICAL
oxide I-CHEMICAL

(NO), B-CHEMICAL
malondialdehyde B-CHEMICAL
(MDA), B-CHEMICAL
interleukin B-GENE-Y
(IL)-2, I-GENE-Y
tumor B-GENE-Y
necrosis I-GENE-Y
factors I-GENE-Y
(TNF)α, I-GENE-Y
alpha-fetoprotein B-GENE-Y
(AFP), B-GENE-Y
carbohydrate B-GENE-N
antigen I-GENE-N
(CA) I-GENE-N
19.9 I-GENE-N
and O
carcinoembrionic B-GENE-N
antigen I-GENE-N
(CEA) B-GENE-N
were O
assayed. O
Results: O
The O
administration O
of O
prallethrin B-CHEMICAL
1.6% O
w/w O
created O
significant O
increased O
changes O
in O
the O
levels O
of O
total O
WBC, O
lymphocytes, O
RBC, O
hemoglobin, B-GENE-N
packed O
cell O
volume, O

platelets, O
mean O
corpuscular O
volume, O
and O
mean O
corpuscular O
hemoglobin B-GENE-N
in O
rats O
after O
24, O
48, O
and O
72 O
h O
of O
continuous O
inhalation; O
however, O
there O
was O
a O
significant O
reduction O
in O
neutrophils O
at O
transient O
reduction O
in O
the O
monocytes O
after O
24 O
and O
48 O
h O
to O
return O
to O
normal O
after O
72 O
h. O
Significant O
increases O
in O
the O
levels O
of O
CK, B-GENE-N
γ-GT, B-GENE-Y
SOD, B-GENE-N
NO, B-CHEMICAL
MDA, B-CHEMICAL
AFP, B-GENE-Y
IL-2, B-GENE-Y
and O
TNFα B-GENE-Y
were O
recorded. O
CA B-GENE-N
and O
CEA B-GENE-N
did O
not O
exhibit O
any O
change. O
Conclusions: O
Continuous O
inhalation O
to O

prallethrin B-CHEMICAL
1.6% O
insecticides O
poses O
toxicity O
on O
hematological O
variables. O
It O
is O
also O
concluded O
that O
pyrethroid B-CHEMICAL
group O
of O
insecticide O
may O
cause O
hematological, O
biochemical, O
cytokine B-GENE-N
disturbances O
and O
possible O
mutagenic O
damage O
to O
the O
tissues. O
Contribution O
of O
the O
m1 O
transmembrane O
helix O
and O
pre-m1 O
region O
to O
positive O
allosteric O
modulation O
and O
gating O
of O
N-methyl-d-aspartate B-GENE-N
receptors. I-GENE-N
N-methyl-d-aspartate B-GENE-N
(NMDA) I-GENE-N
receptors I-GENE-N
are O
glutamate-gated B-GENE-N
ion I-GENE-N
channels I-GENE-N
whose O

function O
is O
critical O
for O
normal O
excitatory O
synaptic O
transmission O
in O
the O
brain O
and O
whose O
dysfunction O
has O
been O
implicated O
in O
several O
neurologic O
conditions. O
NMDA B-GENE-N
receptor I-GENE-N
function O
is O
subject O
to O
extensive O
allosteric O
regulation O
both O
by O
endogenous O
compounds O
and O
by O
exogenous O
small O
molecules. O
Elucidating O
the O
structural O
determinants O
and O
mechanism O
of O
action O
by O
which O
allosteric O
regulators O
control O
gating O
will O
enhance O
our O
understanding O
of O
NMDA B-GENE-N
receptor I-GENE-N
activation O
and O
facilitate O
the O
development O
of O
novel O
therapeutics. O
Here, O
we O
investigated O
the O
structural O
determinants O
for O

(3-chlorophenyl)(6,7-dimethoxy-1-((4-methoxyphenoxy)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone B-CHEMICAL
(CIQ), B-CHEMICAL
a O
GluN2C/2D-selective O
positive O
allosteric O
modulator. O
We O
show O
that O
CIQ B-CHEMICAL
does O
not O
bind O
to O
the O
amino-terminal B-CHEMICAL
domain O
of O
the O
NMDA B-GENE-N
receptor I-GENE-N
and O
does O
not O
share O
structural O
determinants O
with O
modulators O
acting O
at O
the O
agonist-binding O

domain O
dimer O
interface O
or O
ion B-GENE-N
channel I-GENE-N
pore. O
Rather, O
we O
identified O
critical O
determinants O
of O
CIQ B-CHEMICAL
modulation O
in O
the O
region O
near O
the O
first O
transmembrane O
helix O
of O
GluN2D, O
including O
in O
a O
putative O
pre-M1 O
cuff O
helix O
that O
may O
influence O
channel O
gating. O
We O
also O
show O
that O
mutations O
within O
the O
GluN2D O
pre-M1 O
region O
alter O
open O
probability O
of O
the O
NMDA B-GENE-N
receptor. I-GENE-N
These O
results O
suggest O
a O
novel O
site O
of O
action O
for O
potentiation O
of O
NMDA B-GENE-N
receptors I-GENE-N
by O
small O
molecules O
and O
implicate O
the O
pre-M1 O
region O
in O
NMDA B-GENE-N
receptor I-GENE-N
gating. O

Association O
of O
ATP-binding B-GENE-N
cassette I-GENE-N
transporter I-GENE-N
variants O
with O
the O
risk O
of O
Alzheimer's O
disease. O
Aim: O
A O
number O
of O
studies O
have O
demonstrated O
that O
ABCB1 B-GENE-Y
and O
BCRP B-GENE-Y
(ABCG2) B-GENE-Y
actively O
transport O
Aβ. B-GENE-Y
We O
aimed O
to O
investigate O
the O
association O
of O
genetic O
variants O
of O
selected O
multidrug B-GENE-N
transporters I-GENE-N
with O
Alzheimer's O
disease O
(AD) O
in O
histopathologically O
confirmed O
AD O
cases O
and O
controls. O
Materials O
& O
methods: O
DNA O
from O
brain O
tissue O
of O
71 O
AD O
cases O
with O
Consortium O
to O
Establish O
a O
Registry O
for O
Alzheimer's O
Disease O
(CERAD) O
neuropathological O
stages O
B/C O
and O
81 O
controls O
was O

genotyped O
for O
selected O
variants O
in O
ABCA1, B-GENE-Y
ABCA7, B-GENE-Y
ABCB1, B-GENE-Y
ABCC2 B-GENE-Y
and O
ABCG2. B-GENE-Y
In O
addition, O
the O
APOE4 B-GENE-Y
status O
was O
analyzed. O
Results: O
The O
novel O
ABCA7 B-GENE-Y
SNP, O
rs3752246, O
tended O
to O
be O
associated O
with O
AD O
in O
our O
study. O
Variants O
in O
ABCB1 B-GENE-Y
were O
significantly O
less O
frequent O
in O
AD O
cases O
older O
than O
65 O
years O
of O
age O
and O
among O
females. O
This O
association O
of O
ABCB1 B-GENE-Y
2677G>T B-GENE-N
(rs2032582) O
was O
more O
pronounced O
in O
APOE4-negative B-GENE-Y
cases O
(p O
= O

0.005). O
However, O
only O
ABCC2 B-GENE-Y
3972C>T B-GENE-N
(rs3740066) O
was O
significantly O
associated O
with O
AD O
risk O
after O
logistic O
regression O
analysis O
including O
all O
variants. O
Other O
transporters O
showed O
a O
lack O
of O
association. O
Conclusion: O
Our O
results O
support O
the O
hypothesis O
that O
ABCB1 B-GENE-Y
and O
possibly O
other O
ABC-transporters B-GENE-N
are O
involved O
in O
the O
process O
of O
Aβ B-GENE-Y
accumulation O
in O
the O
aging O
brain O
and O
may O
modulate O
the O
risk O
for O
AD O
in O
an O
allele-specific O
manner, O
and O
thus O
might O
represent O
a O
new O
target O
for O
prevention O
and O
treatment O
of O
AD. O
Original O
submitted O
8 O
October O
2012; O
Revision O
submitted O
22 O

January O
2013. O
Dandelion O
leaf O
extract O
protects O
against O
liver O
injury O
induced O
by O
methionine- B-CHEMICAL
and O
choline-deficient B-CHEMICAL
diet O
in O
mice. O
We O
investigated O
the O
hepatoprotective O
effects O
of O
the O
extract O
of O
dandelion O
leaves O
(EDL) O
on O
a O
murine O
model O
of O
methionine- B-CHEMICAL
and O
choline-deficient B-CHEMICAL
(MCD) O
diet-induced O
nonalcoholic O
steatohepatitis O
(NASH). O
C57BL/6 O
mice O
were O
fed O
for O
4 O
weeks O
with O
one O
of O
the O
following O
diets: O
control O
diet O
(Cont), O
MCD O
diet O

(MCD), O
MCD O
diet O
supplemented O
with O
EDL O
at O
200 O
mg/kg O
body O
weight·daily O
(MCD+D200), O
and O
MCD O
diet O
supplemented O
with O
EDL O
at O
500 O
mg/kg O
body O
weight·daily O
(MCD+D500). O
Hepatic O
function O
was O
assessed O
by O
evaluating O
the O
following O
parameters: O
liver O
histology; O
plasma O
levels O
of O
alanine B-GENE-N
aminotransferase I-GENE-N
(ALT), B-GENE-N
triglyceride B-CHEMICAL
(TG), O
malondialdehyde B-CHEMICAL
(MDA), B-CHEMICAL
and O
reduced B-CHEMICAL
glutathione I-CHEMICAL
(GSH); B-CHEMICAL
expression O
levels O
of O

TNF-α B-GENE-Y
and O
IL-6; B-GENE-Y
and O
levels O
of O
caspase-3 B-GENE-Y
and O
pJNK/JNK B-GENE-N
protein. O
Histopathological O
evaluations O
revealed O
that O
addition O
of O
EDL O
to O
the O
MCD O
diet O
dampens O
the O
severity O
of O
the O
clinical O
signs O
of O
NASH. O
Moreover, O
EDL O
led O
to O
a O
significant O
decrease O
in O
the O
serum O
levels O
of O
ALT, B-GENE-N
hepatic O
TG, O
and O
MDA, B-CHEMICAL
and O
in O
the O
expression O
levels O
of O
TNF-α, B-GENE-Y
and O
IL-6; B-GENE-Y
on O
the O
contrary, O
the O
levels O
of O
reduced B-CHEMICAL
GSH I-CHEMICAL
increased. O
At O
the O
post-transcriptional O
level, O
EDL O

significantly O
decreased O
the O
activation O
of O
procaspase-3 B-GENE-Y
to O
active O
caspase-3, B-GENE-Y
and O
the O
phosphorylation O
of O
JNK. B-GENE-N
These O
results O
suggest O
that O
the O
beneficial O
effects O
of O
EDL O
on O
NASH O
are O
mainly O
due O
to O
its O
antioxidant O
and O
anti-inflammatory O
activities. O
A O
novel O
tyrosine B-GENE-N
kinase I-GENE-N
switch O
is O
a O
mechanism O
of O
imatinib B-CHEMICAL
resistance O
in O
gastrointestinal O
stromal O
tumors. O
KIT B-GENE-Y
or O
alpha-platelet-derived B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
receptor I-GENE-Y
(alpha-PDGFR) B-GENE-Y
activating O
mutations O
are O
the O
pathogenic O
mechanisms O
that O
characterize O
gastrointestinal O

stromal O
tumors O
(GIST). O
Despite O
excellent O
responses O
to O
imatinib B-CHEMICAL
mesylate I-CHEMICAL
(IM), B-CHEMICAL
patients O
are O
relapsing. O
We O
developed O
an O
IM-resistant B-CHEMICAL
GIST O
cell O
line O
(GIST-R) O
from O
the O
IM-sensitive B-CHEMICAL
GIST882 O
cell O
line O
(GIST-S) O
by O
growing O
these O
cells O
in O
IM. B-CHEMICAL
Gene O
expression O
profiling O
(GEP) O
of O
GIST-S, O
GIST-R O
cells O
and O
two O
IM B-CHEMICAL
resistant O
GIST O
patients O
demonstrated O
that O
KIT B-GENE-Y
is O
downregulated O
implying O
a O
major O
role O
in O

IM B-CHEMICAL
resistance. O
Instead, O
GIST-R O
cells O
have O
acquired O
IM B-CHEMICAL
resistance O
by O
overexpressing O
the O
oncogenic B-GENE-N
receptor I-GENE-N
tyrosine I-GENE-N
kinase I-GENE-N
- O
AXL B-GENE-Y
- O
in O
a O
'kinase B-GENE-N
switch'. O
Further, O
the O
two O
IM B-CHEMICAL
resistant O
GIST O
patients O
express O
AXL B-GENE-Y
and O
not O
c-Kit, B-GENE-Y
seen O
by O
immunohistochemistry O
(IHC). O
Real O
time O
reverse O
transcriptase-polymerase O
chain O
reaction O
and O
Western O
blotting O
of O
the O
GIST-S O
and O
GIST-R O
cells O
confirmed O
the O
switch O
from O
Kit B-GENE-Y
to O
AXL. B-GENE-Y
In O
GIST-R, O

AXL B-GENE-Y
is O
tyrosine B-CHEMICAL
phosphorylated O
and O
its O
ligand O
growth-arrest-specific B-GENE-Y
gene I-GENE-Y
6 I-GENE-Y
is O
overexpressed O
implying O
autocrine O
activation. O
The O
kinase B-GENE-N
switch O
is O
associated O
with O
a O
morphological O
change O
from O
spindle O
to O
epithelioid. O
Molecular O
modeling O
of O
the O
kinase B-GENE-N
domain I-GENE-N
of O
mutant O
c-Kit B-GENE-Y
(V654A) B-GENE-N
and O
AXL B-GENE-Y
showed O
no O
binding O
to O
IM B-CHEMICAL
but O
efficient O
binding O
to O
MP470, B-CHEMICAL
a O
novel O
c-Kit/AXL B-GENE-Y
kinase B-GENE-N
inhibitor. O
MP470 B-CHEMICAL
synergizes O
with O
docetaxel B-CHEMICAL
(taxotere) B-CHEMICAL
and O
is O

cytotoxic O
to O
GIST O
cells. O
Differential O
interactions O
of O
heparin O
and O
heparan O
sulfate O
glycosaminoglycans O
with O
the O
selectins. B-GENE-N
Implications O
for O
the O
use O
of O
unfractionated O
and O
low O
molecular O
weight O
heparins O
as O
therapeutic O
agents. O
The O
selectins B-GENE-N
are O
calcium-dependent B-CHEMICAL
C-type B-GENE-N
lectins I-GENE-N
that O
bind O
certain O
sialylated, O
fucosylated, O
sulfated O
glycoprotein O
ligands. O
L-selectin B-GENE-Y
also O
recognizes O
endothelial O
proteoglycans O
in O
a O
calcium-dependent B-CHEMICAL
manner, O
via O
heparan O

sulfate O
(HS) O
glycosaminoglycan O
chains O
enriched O
in O
unsubstituted O
glucosamine B-CHEMICAL
units. O
We O
now O
show O
that O
these O
HS O
chains O
can O
also O
bind O
P-selectin, B-GENE-Y
but O
not O
E-selectin. B-GENE-Y
However, O
while O
L-selectin B-GENE-Y
binding O
requires O
micromolar O
levels O
of O
free O
calcium, O
P-selectin B-GENE-Y
recognition O
is O
largely O
divalent O
cation-independent. O
Despite O
this, O
HS O
chains O
bound O
to O
P-selectin B-GENE-Y
are O
eluted O
by O
ethylenediamine B-CHEMICAL
tetraacetic I-CHEMICAL
acid I-CHEMICAL
(EDTA), B-CHEMICAL
but O
only O
at O
high O
concentrations. O
Porcine O

intestinal O
mucosal O
(mast O
cell-derived) O
heparin O
(PIM-heparin) O
shows O
similar O
properties, O
with O
no O
binding O
to O
E-selectin, B-GENE-Y
calcium-dependent B-CHEMICAL
binding O
of O
a O
subfraction O
to O
L-selectin B-GENE-Y
and O
to O
P-selectin, B-GENE-Y
and O
calcium-independent B-CHEMICAL
binding O
of O
a O
larger O
fraction O
to O
P-selectin, B-GENE-Y
the O
latter O
being O
disrupted O
by O
high O
EDTA B-CHEMICAL
concentrations. O
Analysis O
of O
defined O
heparin O
fragment O
pools O
shows O
a O
size O
dependence O
for O
interaction, O
with O
tetradecasaccharides B-CHEMICAL
showing O
easily O
detectable O
binding O
to O
L- B-GENE-N
and I-GENE-N
P-selectin I-GENE-N
affinity O
columns. O

L-selectin B-GENE-Y
binding O
fragments O
include O
more O
heavily O
sulfated O
and O
epimerized O
regions O
and, O
as O
with O
the O
endothelial O
HS O
chains, O
they O
are O
enriched O
in O
free B-CHEMICAL
amino I-CHEMICAL
groups. O
The O
P-selectin B-GENE-Y
binding O
component O
includes O
this O
fraction O
as O
well O
as O
some O
less O
highly O
modified O
regions. O
Thus, O
endothelium-derived O
HS O
chains O
and O
mast O
cell-derived O
heparins O
could O
play O
a O
role O
in O
modulating O
the O
biology O
of O
selectins B-GENE-N
in O
vivo. O
Notably, O
P- B-GENE-N
and I-GENE-N
L-selectin I-GENE-N
binding O
to O
sialyl-Lewisx O
and O
to O
HL-60 O
cells O
(which O
are O
known O
to O

carry O
the O
native O
ligand O
PSGL-1) B-GENE-Y
is O
inhibited O
by O
unfractionated O
pharmaceutical O
heparin O
preparations O
at O
concentrations O
12-50-fold O
lower O
than O
those O
recommended O
for O
effective O
anticoagulation O
in O
vivo. O
In O
contrast, O
two O
low O
molecular O
weight O
heparins O
currently O
considered O
as O
clinical O
replacements O
for O
unfractionated O
heparin O
are O
much O
poorer O
inhibitors. O
Thus, O
patients O
undergoing O
heparin O
therapy O
for O
other O
reasons O
may O
be O
experiencing O
clinically O
significant O
inhibition O
of O
L- B-GENE-N
and I-GENE-N
P-selectin I-GENE-N
function, O
and O
the O
current O
switchover O
to O
low-molecular O
weight O
heparins O
may O
come O
at O
some O
loss O
of O

this O
effect. O
Low-dose O
unfractionated O
heparin O
should O
be O
investigated O
as O
a O
treatment O
option O
for O
acute O
and O
chronic O
diseases O
in O
which O
P- B-GENE-N
and I-GENE-N
L-selectin I-GENE-N
play O
pathological O
roles. O
Differentiation O
of O
opioid O
drug O
effects O
by O
hierarchical O
multi-site O
phosphorylation. O
Differences O
in O
the O
ability O
of O
opioid O
drugs O
to O
promote O
regulated O
endocytosis O
of O
μ-opioid B-GENE-Y
receptors I-GENE-Y
are O
related O
to O
their O
tendency O
to O
produce O
drug O
tolerance O
and O
dependence. O
Here O
we O
show O
that O
drug-specific O
differences O
in O
receptor O
internalization O
are O
determined O
by O
a O
conserved, O
10-residue O
sequence O
in O
the O
receptor's O

carboxyl-terminal B-GENE-N
cytoplasmic I-GENE-N
tail. I-GENE-N
Diverse O
opioids O
induce O
receptor O
phosphorylation O
at O
serine B-CHEMICAL
(S)375, O
present O
in O
the O
middle O
of O
this O
sequence, O
but O
opioids O
differ O
markedly O
in O
their O
ability O
to O
drive O
higher-order O
phosphorylation O
on O
flanking O
residues O
[threonine B-CHEMICAL
(T)370, O
T376, O
and O
T379]. O
Multi-phosphorylation O
is O
required O
for O
the O
endocytosis-promoting O
activity O
of O
this O
sequence O
and O
occurs O
both O
sequentially O
and O
hierarchically, O
with O
S375 O
representing O
the O
initiating O

site. O
Higher-order O
phosphorylation O
involving O
T370, O
T376, O
and O
T379 O
specifically O
requires O
GRK2/3 B-GENE-N
isoforms, O
and O
the O
same O
sequence O
controls O
opioid B-GENE-N
receptor I-GENE-N
internalization O
in O
neurons. O
These O
results O
reveal O
a O
biochemical O
mechanism O
differentiating O
the O
endocytic O
activity O
of O
opioid O
drugs. O
Effects O
of O
changeover O
from O
voglibose B-CHEMICAL
to O
acarbose B-CHEMICAL
on O
postprandial O
triglycerides B-CHEMICAL
in O
type O
2 O
diabetes O
mellitus O
patients. O
INTRODUCTION: O
In O
this O
study, O
we O
examined O
the O
effects O
of O
the O

alpha-glucosidase B-GENE-N
inhibitors O
acarbose B-CHEMICAL
and O
voglibose B-CHEMICAL
on O
postprandial O
plasma O
glucose B-CHEMICAL
and O
serum O
triglyceride O
levels O
in O
patients O
with O
type O
2 O
diabetes O
mellitus. O
METHODS: O
Twenty-one O
Japanese O
patients O
with O
type O
2 O
diabetes O
were O
enrolled O
in O
this O
study. O
Subjects O
had O
been O
treated O
with O
voglibose B-CHEMICAL
for O
at O
least O
3 O
months. O
They O
underwent O
a O
400 O
kcal O
balanced O
food O
meal O
tolerance O
test O
before O
and O
8 O
weeks O
after O
the O
changeover O
from O
voglibose B-CHEMICAL
to O
acarbose. B-CHEMICAL
Subjects O
were O
divided O
into O
two O
groups: O
the O
first O
group O

(low-dose O
group; O
n=11) O
was O
changed O
over O
from O
0.6 O
mg/day O
voglibose B-CHEMICAL
to O
150 O
mg/day O
acarbose, B-CHEMICAL
and O
the O
other O
(high-dose O
group; O
n=10) O
from O
0.9 O
mg/day O
voglibose B-CHEMICAL
to O
300 O
mg/day O
acarbose. O
RESULTS: O
The O
increment O
rate O
of O
postprandial O
plasma O
glucose B-CHEMICAL
([plasma O
glucose B-CHEMICAL
2 O
hours O
after O
test O
meal O
- O
fasting O
glucose]/fasting B-CHEMICAL
glucose) B-CHEMICAL
decreased O
from O
34.7%+/-23.9% O
to O

25.0%+/-24.6% O
(P=0.13) O
in O
the O
low-dose O
group, O
and O
decreased O
significantly O
from O
56.1%+/-53.1% O
to O
31.5%+/-36.0% O
(P=0.03) O
in O
the O
high-dose O
group O
after O
changeover. O
However, O
there O
were O
no O
significant O
changes O
in O
blood O
glycated B-GENE-Y
hemoglobin I-GENE-Y
(HbA(1c)) B-GENE-Y
levels O
before O
and O
after O
changeover O
in O
either O
group. O
The O
increment O
rate O
of O
postprandial O
serum O
triglyceride B-CHEMICAL
(TG) B-CHEMICAL

([serum O
TG B-CHEMICAL
2 O
hours O
after O
test O
meal O
- O
fasting O
TG]/fasting B-CHEMICAL
TG) B-CHEMICAL
decreased O
significantly O
only O
in O
the O
high-dose O
group O
(52.4%+/-60.0% O
to O
24.3%+/-16.6%) O
(P=0.05). O
No O
significant O
changes O
in O
serum O
high-density O
lipoprotein O
cholesterol B-CHEMICAL
levels O
were O
observed O
in O
either O
group, O
whereas O
serum O
low-density B-GENE-N
lipoprotein I-GENE-N
cholesterol B-CHEMICAL
levels O
decreased O
significantly O
from O
3.20+/-0.25 O
to O
2.65+/-0.18 O

mmol/L O
(P=0.04), O
only O
in O
the O
high-dose O
group. O
CONCLUSIONS: O
In O
patients O
with O
type O
2 O
diabetes O
our O
findings O
suggest O
that O
acarbose B-CHEMICAL
300 O
mg/day O
is O
superior O
to O
voglibose B-CHEMICAL
0.9 O
mg/day O
in O
improving O
postprandial O
hyperglycemia O
and O
hypertriglyceridemia. O
Modulation O
of O
the O
JAK/ERK/STAT B-GENE-N
signaling O
in O
melanocortin-induced B-GENE-Y
inhibition O
of O
local O
and O
systemic O
responses O
to O
myocardial O
ischemia/reperfusion. O
The O
janus B-GENE-N

kinases I-GENE-N
(JAK), B-GENE-N
extracellular B-GENE-N
signal-regulated I-GENE-N
kinases I-GENE-N
(ERK) B-GENE-N
and O
signal B-GENE-N
transducers I-GENE-N
and I-GENE-N
activators I-GENE-N
of I-GENE-N
transcription I-GENE-N
(STAT) B-GENE-N
pathways O
have O
been O
shown O
to O
play O
a O
cardioprotective O
role. O
We O
previously O
gave O
evidence O
that O
melanocortins B-GENE-Y
afford O
cardioprotection O
in O
conditions O
of O
myocardial O
ischemia/reperfusion. O
Here O
we O
aimed O
to O
investigate O
the O
influence O
of O
melanocortins B-GENE-Y
on O
the O
JAK/ERK/STAT B-GENE-N
signaling O
in O
cardiac O
and O
systemic O
responses O
to O
prolonged O
myocardial O
ischemia/reperfusion. O

Ischemia O
was O
produced O
in O
rats O
by O
ligature O
of O
the O
left O
anterior O
descending O
coronary O
artery O
for O
30min. O
At O
the O
end O
of O
the O
2-h O
reperfusion, O
western O
blot O
analysis O
of O
the O
cardioprotective O
transcription O
factors O
pJAK2, B-GENE-Y
pERK1/2, B-GENE-N
pTyr-STAT3 B-GENE-Y
and O
pSer-STAT3, B-GENE-Y
the O
inflammatory O
mediator O
tumor B-GENE-Y
necrosis I-GENE-Y
factor-α I-GENE-Y
(TNF-α), B-GENE-Y
the O
pro-apoptotic O
factors O
BAX B-GENE-Y
and O
c-jun B-GENE-N
N-terminal I-GENE-N
kinases I-GENE-N
(pJNK), B-GENE-N
the O

anti-apoptotic O
protein O
Bcl-XL, B-GENE-Y
as O
well O
as O
of O
the O
cardioprotective O
enzyme O
heme B-GENE-Y
oxygenase-1 I-GENE-Y
(HO-1), B-GENE-Y
was O
performed O
in O
the O
left O
ventricle O
and O
spleen. O
Intravenous O
treatment, O
during O
coronary O
artery O
occlusion, O
with O
the O
melanocortin B-GENE-Y
analogs O
[Nle(4), B-CHEMICAL
D-Phe(7)]α-melanocyte-stimulating B-CHEMICAL
hormone I-GENE-Y
(NDP-α-MSH) B-GENE-Y
and O
adrenocorticotropic B-GENE-Y
hormone I-GENE-Y
1-24 I-GENE-Y

[ACTH-(1-24)], B-GENE-Y
induced O
a O
left O
ventricle O
up-regulation O
of O
pJAK2, B-GENE-Y
pERK1/2 B-GENE-N
and O
pTyr-STAT3 B-GENE-Y
(JAK-dependent), B-GENE-N
and O
a O
reduction O
in O
pJNK B-GENE-N
and O
TNF-α B-GENE-Y
levels; O
these O
effects O
of O
NDP-α-MSH B-GENE-Y
and O
ACTH-(1-24) B-GENE-Y
were O
associated O
with O
over-expression O
of O
the O
pro-survival O
proteins O
HO-1 B-GENE-Y
and O
Bcl-XL, B-GENE-Y
and O
marked O
decrease O
of O
the O
myocardial O
infarct O
size. O
Melanocortin B-GENE-Y
treatment O
did O

not O
affect O
left O
ventricle O
pSer-STAT3 B-GENE-Y
(ERK1/2-dependent) B-GENE-N
and O
BAX B-GENE-Y
levels. O
In O
the O
spleen, O
NDP-α-MSH B-GENE-Y
and O
ACTH-(1-24) B-GENE-Y
induced O
similar O
effects O
on O
the O
expression O
of O
the O
above O
transcription O
factors/proteins, O
except O
for O
pERK1/2 B-GENE-N
(down-regulated) O
and O
HO-1 B-GENE-Y
(unaffected). O
Blockade O
of O
JAK B-GENE-N
and O
ERK B-GENE-N
pathways O
with O
AG490 B-CHEMICAL
and O
U0126, B-CHEMICAL
respectively, O
abrogated O
the O
myocardial O
infarct O
size O
reduction O
by O

NDP-α-MSH. B-GENE-Y
These O
results O
indicate O
that O
melanocortins B-GENE-Y
inhibit O
local O
and O
systemic O
inflammatory O
and O
apoptotic O
cascades O
triggered O
by O
prolonged O
myocardial O
ischemia/reperfusion, O
with O
consequent O
reduction O
in O
myocardium O
infarct O
size, O
seemingly O
via O
activation O
of O
the O
JAK/STAT B-GENE-N
signaling O
and O
with O
modulation O
of O
an O
ERK B-GENE-N
(STAT B-GENE-N
unrelated) O
signaling O
pathway. O
Cyclooxygenase B-GENE-N
and O
5-lipoxygenase B-GENE-Y
inhibitors O
protect O
against O
mononuclear O
phagocyte O
neurotoxicity. O

Neuroinflammation O
and O
oxidative O
stress O
are O
believed O
to O
be O
contributing O
factors O
to O
neurodegeneration O
in O
normal O
aging, O
as O
well O
as O
in O
age-related O
neurological O
disorders. O
Reactive O
microglia O
are O
found O
in O
increased O
numbers O
in O
aging O
brain O
and O
are O
prominently O
associated O
with O
lesions O
in O
such O
age-related O
degenerative O
conditions O
as O
Alzheimer's O
disease O
(AD), O
Parkinson's O
disease O
(PD) O
and O
amyotrophic O
lateral O
sclerosis O
(ALS). O
In O
vitro, O
stimulated O
microglia O
or O
microglial-like O
cells O
secrete O
neurotoxic O
materials O
and O
are O
generators O
of O

free O
radicals O
through O
their O
respiratory O
burst O
system. O
Agents O
that O
suppress O
microglial O
activation O
are O
therefore O
candidates O
for O
neuroprotection. O
We O
have O
developed O
quantitative O
in O
vitro O
assays O
for O
measuring O
neurotoxicity O
of O
microglia O
or O
other O
mononuclear O
phagocytes. O
Neuronal O
like O
SH-SY5Y O
cells O
are O
cultured O
in O
supernatants O
from O
activated O
cells O
of O
the O
human O
monocytic O
THP-1 O
line O
and O
their O
survival O
is O
followed. O
Respiratory O
burst O
is O
directly O
measured O
on O
the O
activated O
cells. O
We O
tested O
inhibitors O
of O
the O
cyclooxygenase B-GENE-N

(COX) B-GENE-N
or O
the O
5-lipoxygenase B-GENE-Y
(5-LOX) B-GENE-Y
pathways O
as O
possible O
neuroprotective O
agents. O
The O
COX B-GENE-N
pathway O
generates O
inflammatory O
prostaglandins, B-CHEMICAL
while O
the O
5-LOX B-GENE-Y
pathway O
generates O
inflammatory O
leukotrienes. B-CHEMICAL
We O
found O
that O
inhibitors O
of O
both O
these O
pathways O
suppressed O
neurotoxicity O
in O
a O
dose-dependent O
fashion. O
They O
included O
the O
COX-1 B-GENE-Y
inhibitor O
indomethacin; O
the O
COX-2 B-GENE-Y
inhibitor O
NS-398; B-CHEMICAL
the O
mixed O
COX-1/COX-2 B-GENE-Y
inhibitor O
ibuprofen; B-CHEMICAL
the O
nitric B-CHEMICAL
oxide I-CHEMICAL

(NO) B-CHEMICAL
derivatives O
of O
indomethacin, B-CHEMICAL
ibuprofen B-CHEMICAL
and O
flurbiprofen; B-CHEMICAL
the O
5-LOX B-GENE-Y
inhibitor O
REV B-CHEMICAL
5901; I-CHEMICAL
and O
the O
5-LOX B-GENE-Y
activating I-GENE-Y
protein I-GENE-Y
(FLAP) B-GENE-Y
inhibitor O
MK-886. B-CHEMICAL
The O
FLAP B-GENE-Y
inhibitor O
also O
reduced O
respiratory O
burst O
activity O
in O
a O
more O
potent O
manner O
than O
indomethacin. O
Combinations O
of O
COX B-GENE-N
and O
5-LOX B-GENE-Y
inhibitors O
were O
more O
effective O
than O
single O
inhibitors. O
The O
data O
suggest O
that O
both O
COX B-GENE-N
inhibitors O
and O
5-LOX B-GENE-Y
inhibitors O
may O
be O
neuroprotective O
in O
vivo O
by O

suppressing O
toxic O
actions O
of O
microglia/macrophages, O
and O
that O
combinations O
of O
the O
two O
might O
have O
greater O
therapeutic O
potential O
than O
single O
inhibitors O
of O
either O
class. O
Cyperi O
Rhizoma O
inhibits O
the O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced B-CHEMICAL
reduction O
in O
nigrostriatal O
dopaminergenic O
neurons O
in O
estrogen-deprived B-CHEMICAL
mice. O
ETHNOPHARMACOLOGICAL O
RELEVANCE: O
Cyperi O
Rhizoma O
has O
commonly O
been O
used O
for O
the O
treatment O
of O

gynecological O
and O
neuropsychiatric O
disorders O
in O
traditional O
medicine. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
estrogenic O
properties O
and O
neuroprotective O
effects O
of O
Cyperi O
Rhizoma O
under O
estrogen-deprived B-CHEMICAL
condition O
in O
female O
mice. O
MATERIALS O
AND O
METHODS: O
To O
determine O
the O
estrogen-like B-CHEMICAL
effect O
of O
Cyperi O
Rhizoma O
extract O
(CRE), O
we O
measured O
luciferase O
expression O
after O
transfection O
of O
a O
promoter O
construct O
containing O
an O
estrogen B-GENE-N
response I-GENE-N
element I-GENE-N
(ERE) B-GENE-N
and O
treatment O
of O
CRE. O
To O
evaluate O
the O
neuroprotective O
effect O
of O

CRE, O
we O
measured O
striatal O
dopamine, B-CHEMICAL
movement O
ability, O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
(TH) B-GENE-Y
immunoreactivity, O
and O
apoptosis-related O
protein O
expression O
levels O
after O
treatment O
of O
CRE O
either O
with O
or O
without O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine B-CHEMICAL
(MPTP) B-CHEMICAL
in O
ovariectomized O
female O
mice. O
RESULTS: O
CRE O
significantly O
induced O
the O
luciferase O
expression O
driven O
by O
an O
ERE B-GENE-N
in O
PC12 O
cells, O
a O
dopaminergic O
cell O

line, O
in O
a O
dose-dependent O
manner. O
In O
mice, O
MPTP B-CHEMICAL
significantly O
decreased O
the O
levels O
of O
dopamine B-CHEMICAL
in O
the O
striatum O
and O
behavior O
performance; O
in O
contrast, O
both O
CRE O
and O
17β-estradiol B-CHEMICAL
benzoate I-CHEMICAL
(EB) O
recovered O
these O
parameters O
to O
normal O
levels. O
CRE O
and O
EB O
treatment O
also O
recovered O
TH B-GENE-Y
immunopositive O
fibers O
and O
cells, O
respectively, O
from O
MPTP B-CHEMICAL
toxicity. O
Additionally, O
MPTP B-CHEMICAL
significantly O
down-regulated O
Bcl-2 B-GENE-Y
expression O
in O
the O
mitochondria O
of O
dopaminergic O
cells O
in O
the O
SN, O
followed O
by O
an O
increase O
in O
Bax B-GENE-Y
expression, O

cytochrome B-GENE-Y
C I-GENE-Y
translocation O
to O
the O
cytosol, O
andcleaved-caspase-3 B-GENE-Y
expression, O
whereas O
these O
were O
inhibited O
by O
CRE O
or O
EB O
treatment. O
CONCLUSIONS: O
These O
findings O
provide O
the O
first O
evidence O
that O
CRE O
has O
estrogen-like B-CHEMICAL
and O
neuroprotective O
effects O
on O
dopaminergic O
neurons O
in O
estrogen-deprived B-CHEMICAL
mice O
treated O
with O
MPTP-toxin. B-CHEMICAL
New O
progestagens B-CHEMICAL
for O
contraceptive O
use. O
The O
progestins B-CHEMICAL
have O
different O
pharmacologic O
properties O
depending O
upon O
the O
parent O
molecule, O
usually O
testosterone B-CHEMICAL
or O

progesterone B-CHEMICAL
(P), O
from O
which O
they O
are O
derived. O
Very O
small O
structural O
changes O
in O
the O
parent O
molecule O
may O
induce O
considerable O
differences O
in O
the O
activity O
of O
the O
derivative. O
In O
hormonal O
contraceptives, O
progestins O
represent O
the O
major O
agent O
designed O
for O
suppressing O
ovulation O
and O
are O
used O
in O
combination O
with O
estrogen B-CHEMICAL
(E) O
usually O
ethinyl-estradiol B-CHEMICAL
(EE). B-CHEMICAL
The O
development O
of O
new O
generations O
of O
progestins B-CHEMICAL
with O
improved O
selectivity O
profiles O
has O
been O
a O
great O
challenge. O
Steroidal B-CHEMICAL
and O
nonsteroidal O
progesterone B-GENE-Y
receptor I-GENE-Y
(PR) B-GENE-Y
agonists O
have O
been O
synthesized O
as O

well, O
although O
the O
latter O
are O
still O
in O
a O
very O
early O
stage O
of O
development. O
Several O
new O
progestins, B-CHEMICAL
have O
been O
synthesized O
in O
the O
last O
two O
decades. O
These O
include O
dienogest B-CHEMICAL
(DNG), B-CHEMICAL
drospirenone B-CHEMICAL
(DRSP), B-CHEMICAL
Nestorone B-CHEMICAL
(NES), B-CHEMICAL
nomegestrol B-CHEMICAL
acetate I-CHEMICAL
(NOMAc) B-CHEMICAL
and O
trimegestone B-CHEMICAL
(TMG). B-CHEMICAL
These O
new O
progestins B-CHEMICAL
have O
been O
designed O
to O
have O
no O
androgenic O
or O
estrogenic O
actions O
and O
to O
be O
closer O
in O
activity O
to O
the O
physiological O
hormone O
P. O
DRSP B-CHEMICAL
differs O
from O
the O
classic O
progestins B-CHEMICAL
as O
it O

is O
derived O
from O
spirolactone. B-CHEMICAL
It O
is O
essentially O
an O
antimineralocorticoid O
steroid B-CHEMICAL
with O
no O
androgenic O
effect O
but O
a O
partial O
antiandrogenic O
effect. O
The O
antiovulatory O
potency O
of O
the O
different O
progestins B-CHEMICAL
varies. O
TMG B-CHEMICAL
and O
NES B-CHEMICAL
are O
the O
most O
potent O
progestins B-CHEMICAL
synthesized O
to O
date, O
followed O
by O
two O
of O
the O
older O
progestins, B-CHEMICAL
keto-desogestrel B-CHEMICAL
(keto-DSG) B-CHEMICAL
and O
levonorgestrel B-CHEMICAL
(LNG). B-CHEMICAL
The O
new O
molecules O
TMG, B-CHEMICAL
DRSP B-CHEMICAL
and O
DNG B-CHEMICAL
also O
have O
antiandrogenic O
activity. O

Striking O
differences O
exist O
regarding O
the O
side O
effects O
among O
the O
progestins B-CHEMICAL
and O
the O
combination O
with O
EE B-CHEMICAL
leads O
to O
other O
reactions O
related O
to O
the O
E O
itself O
and O
whether O
the O
associated O
progestin B-CHEMICAL
counterbalances, O
more O
or O
less, O
the O
estrogenic O
action. O
The O
19-norprogesterone B-CHEMICAL
molecules O
and O
the O
new O
molecules O
DRSP B-CHEMICAL
and O
DNG B-CHEMICAL
are O
not O
androgenic O
and, O
therefore, O
have O
no O
negative O
effect O
on O
the O
lipid O
profile. O
Given O
their O
pharmacological O
properties, O
it O
is O
likely O
that O
the O
new O
progestins B-CHEMICAL
may O
have O
neutral O
effects O
on O
metabolic O
or O
vascular O
risks. O
However, O
this O
hypothesis O
must O
be O
confirmed O
in O
large O

clinical O
trials. O
Add-on O
therapy O
with O
the O
DPP-4 B-GENE-Y
inhibitor O
sitagliptin B-CHEMICAL
improves O
glycemic O
control O
in O
insulin-treated B-GENE-Y
Japanese O
patients O
with O
type O
2 O
diabetes O
mellitus. O
The O
effect O
of O
add-on O
therapy O
with O
sitagliptin B-CHEMICAL
on O
glycemic O
control O
was O
prospectively O
investigated O
in O
patients O
with O
type O
2 O
diabetes O
mellitus O
(T2DM) O
receiving O
insulin B-GENE-Y
alone O
or O
insulin B-GENE-N
combined O
with O
oral O
antidiabetic O
drugs. O
Seventy-one O
patients O
were O
evaluated O
(38 O
men O
and O
33 O
women O
aged O
63.9±10.2 O
years). O
They O
were O
divided O
into O
three O
groups, O
which O
were O
45 O
patients O
receiving O

premixed O
insulin B-GENE-Y
twice O
daily, O
15 O
patients O
receiving O
multiple O
daily O
insulin B-GENE-Y
injections, O
and O
11 O
patients O
receiving O
basal O
insulin B-GENE-Y
with O
oral O
antidiabetic O
drugs O
(basal O
insulin B-GENE-Y
therapy). O
Concomitant O
oral O
drugs O
included O
sulfonylureas, B-CHEMICAL
α-glucosidase B-GENE-N
inhibitors O
and O
metformin. B-CHEMICAL
The O
hemoglobin B-GENE-Y
A1c I-GENE-Y
(HbA1c) B-GENE-Y
of O
all O
patients O
improved O
significantly O
from O
8.1±1.2% O
to O
7.6±1.1% O
after O
12 O
weeks O
of O
add-on O
therapy O
with O
sitagliptin B-CHEMICAL
(p<0.01), O
and O
the O
insulin B-GENE-Y
dosage O

was O
reduced O
from O
27.3±15.8 O
U/day O
to O
24.5±16.5 O
U/day O
(p<0.001). O
Body O
weight O
did O
not O
change O
after O
the O
start O
of O
concomitant O
therapy O
and O
severe O
hypoglycemia O
was O
not O
observed. O
The O
baseline O
HbA1c B-GENE-Y
and O
glycated B-GENE-Y
albumin I-GENE-Y
levels O
were O
identified O
as O
factors O
that O
predicted O
the O
response O
to O
add-on O
therapy O
with O
sitagliptin. B-CHEMICAL
These O
findings O
suggest O
that O
add-on O
therapy O
with O
sitagliptin B-CHEMICAL
can O
be O
expected O
to O
achieve O
improvement O
of O
poor O
glycemic O
control O
irrespective O
of O
a O

patient's O
demographic O
profile. O
Stratified O
analysis O
based O
on O
the O
insulin B-GENE-Y
regimen O
revealed O
a O
stronger O
antidiabetic O
effect O
and O
a O
high O
efficacy O
of O
sitagliptin B-CHEMICAL
when O
it O
was O
added O
to O
basal O
insulin B-GENE-Y
therapy. O
The O
results O
of O
this O
investigation O
confirmed O
that O
add-on O
therapy O
with O
sitagliptin B-CHEMICAL
to O
various O
insulin B-GENE-Y
regimens O
could O
improve O
glycemic O
control O
without O
severe O
hypoglycemia O
and/or O
weight O
gain. O
Effect O
of O
blood-retinal O
barrier O
development O
on O
formation O
of O
selenite B-CHEMICAL
nuclear O
cataract O
in O
rat. O
Selenite B-CHEMICAL
cataract, O
as O
an O
experimental O
animal O
model O
of O
nuclear O
cataract O
to O
mimic O
human O

senile O
cataract, O
is O
produced O
only O
when O
overdose O
selenite B-CHEMICAL
is O
injected O
to O
neonatal O
rats O
before O
eyelid O
opening. O
To O
clarify O
the O
cause O
of O
age O
differences O
on O
selenite B-CHEMICAL
cataract O
formation O
in O
rats, O
mRNA O
expression O
of O
GPx1, B-GENE-Y
MsrA B-GENE-Y
and O
MsrB1, B-GENE-Y
as O
well O
as O
GPx B-GENE-N
activity O
in O
Wistar O
rat O
lens O
at O
different O
ages O
were O
assayed, O
level O
of O
lipid O
peroxidation, O
extent O
of O
lens O
damage O
induced O
by O
sodium B-CHEMICAL
selenite I-CHEMICAL
and O
barricade O
function O
of O
blood-retinal O
barrier O
(BRB) O
were O
investigated. O
The O
results O

showed O
that O
mRNA O
expressions O
and O
activity O
of O
antioxidant O
enzymes O
in O
neonatal O
rat O
lens O
before O
eyelid O
opening O
were O
the O
highest O
and O
then O
decreased O
with O
age, O
and O
revealed O
by O
transmission O
electron O
microscopy O
(TEM) O
using O
lanthanum B-CHEMICAL
hydroxide I-CHEMICAL
as O
tracer O
that O
higher O
selenite B-CHEMICAL
content O
entering O
eyes O
injured O
lens O
and O
resulted O
in O
cataract O
formation O
for O
immature O
BRB O
before O
eyelid O
opening, O
moreover, O
a O
little O
selenite B-CHEMICAL
content O
entering O
eyes O
was O
not O
enough O
to O
induce O
cataract O
formation O
after O
eyelid O
opening O
because O
of O
mature O
BRB. O
Lowering O
interleukin-1 B-GENE-N
activity O
with O

anakinra O
improves O
myocardial O
deformation O
in O
rheumatoid O
arthritis. O
OBJECTIVE: O
Inhibition O
of O
interleukin-1 B-GENE-N
activity O
improves O
nitro-oxidative B-CHEMICAL
stress, O
endothelial O
and O
coronary O
function. O
The O
authors O
investigated O
(a) O
the O
association O
of O
nitro-oxidative B-CHEMICAL
stress O
and O
endothelial O
function O
with O
myocardial O
deformation, O
(b) O
the O
effects O
of O
anakinra, O
an O
interleukin-1a B-GENE-Y
receptor I-GENE-Y
antagonist O
on O
myocardial O
deformation O
in O
patients O
with O

rheumatoid O
arthritis O
(RA). O
METHODS: O
The O
authors O
compared O
46 O
RA O
patients O
to O
23 O
normal O
controls. O
23 O
patients O
received O
anakinra O
(150 O
mg O
subcutaneously O
once O
daily) O
and O
23 O
patients O
a O
5-mg O
increase O
of O
prednisolone B-CHEMICAL
dose O
for O
30 O
days. O
At O
baseline O
and O
post-treatment O
this O
study O
assessed O
(a) O
the O
left O
ventricular O
(LV) O
longitudinal, O
circumferential O
and O
radial O
strain O
and O
strain O
rate, O
using O
speckle O
tracking O
echocardiography, O
(b) O
the O
coronary O
flow O
reserve O
(CFR), O

(c) O
the O
flow-mediated O
endothelial-dependent O
dilation O
of O
the O
brachial O
artery O
(FMD) O
and O
(d) O
nitrotyrosine B-CHEMICAL
(NT) B-CHEMICAL
and O
malondialdehyde B-CHEMICAL
blood O
levels. O
RESULTS: O
Patients O
had O
impaired O
baseline O
myocardial O
deformation O
indices O
compared O
to O
controls O
(p<0.05). O
CFR O
and O
NT B-CHEMICAL
levels O
were O
related O
to O
longitudinal O
strain, O
systolic O
and O
diastolic O
strain O
rate, O
circumferential O
strain O
and O
systolic O
strain O
rate O
(p<0.05). O
FMD O

was O
related O
to O
longitudinal O
and O
circumferential O
diastolic O
strain O
rate O
(p<0.01). O
Compared O
to O
baseline, O
anakinra-treated O
patients O
increased O
the O
longitudinal O
strain O
(-17.8% O
(3.7%) O
vs O
-22.1% O
(3.5%)), O
systolic O
(-1.02 O
(0.23) O
l/s O
vs O
-1.25 O
(0.23) O
l/s) O
and O
diastolic O
(0.96 O
(0.37) O
l/s O
vs O
1.20 O
(0.39) O
l/s) O
longitudinal O

strain O
rate, O
circumferential O
strain O
and O
strain O
rate O
(p<0.05 O
for O
all O
comparisons). O
No O
significant O
changes O
were O
observed O
among O
prednisolone-treated B-CHEMICAL
patients O
CONCLUSIONS: O
Myocardial O
deformation O
is O
impaired O
in O
RA O
patients O
and O
is O
related O
to O
nitro-oxidative B-CHEMICAL
stress O
and O
endothelial O
dysfunction. O
Chronic O
inhibition O
of O
IL-1 B-GENE-N
improves O
LV O
deformation O
in O
parallel O
with O
endothelial O
function O
and O
nitro-oxidative B-CHEMICAL
stress. O
A O
molecular O
mechanism O
of O
pyruvate B-CHEMICAL
protection O
against O
cytotoxicity O
of O

reactive O
oxygen B-CHEMICAL
species O
in O
osteoblasts. O
We O
demonstrated O
previously O
that O
exogenous O
pyruvate B-CHEMICAL
has O
a O
protective O
action O
against O
cell O
death O
by O
hydrogen B-CHEMICAL
peroxide I-CHEMICAL
in O
cultured O
osteoblasts O
through O
a O
mechanism O
associated O
with O
its O
antioxidative O
property. O
In O
the O
present O
study, O
we O
have O
evaluated O
possible O
participation O
of O
monocarboxylate B-GENE-N
transporters I-GENE-N
(MCTs) B-GENE-N
responsible O
for O
the O
bidirectional O
membrane O
transport O
of O
pyruvate B-CHEMICAL
in O
the O
cytoprotective O
property O
in O
osteoblasts. O
Expression O
of O
the O
MCT2 B-GENE-Y
isoform O
was O
found O
in O
cultured O
rat O
calvarial O

osteoblasts O
and O
in O
osteoblasts O
located O
on O
mouse O
tibia O
at O
both O
mRNA O
and O
protein O
levels. O
The O
accumulation O
of O
[14C]pyruvate B-CHEMICAL
occurred O
in O
a O
temperature- O
and O
pH-dependent O
manner O
in O
osteoblasts O
cultured O
for O
7 O
days O
with O
high O
sensitivity O
to O
a O
specific O
MCT B-GENE-N
inhibitor, O
whereas O
pyruvate B-CHEMICAL
was O
released O
into O
extracellular O
spaces O
from O
cultured O
osteoblasts O
in O
a O
fashion O
sensitive O
to O
the O
MCT B-GENE-N
inhibitor. O
Transient O
overexpression O
of O
the O
MCT2 B-GENE-Y
isoform O
led O
to O
reduced O
vulnerability O
to O
the O
cytotoxicity O
of O
hydrogen B-CHEMICAL
peroxide I-CHEMICAL

with O
an O
increased O
activity O
of O
[14C]pyruvate B-CHEMICAL
accumulation O
in O
murine O
osteoblastic O
MC3T3-E1 O
cells. O
Ovariectomy O
significantly O
decreased O
the O
content O
of O
pyruvate B-CHEMICAL
in O
femoral O
bone O
marrows O
in O
mice O
in O
vivo, O
whereas O
daily O
i.p. O
administration O
of O
pyruvate B-CHEMICAL
at O
0.25 O
g/kg O
significantly O
prevented O
alterations O
of O
several O
histomorphometric O
parameters O
as O
well O
as O
cancellous O
bone O
loss O
in O
femurs O
by O
ovariectomy O
on O
28 O
days O
after O
the O
operation. O
These O
results O
suggest O
that O
MCTs B-GENE-N
may O
be O
functionally O
expressed O
by O

osteoblasts O
to O
play O
a O
pivotal O
role O
in O
mechanisms O
related O
to O
the O
cytoprotective O
property O
of O
pyruvate. B-CHEMICAL
Lower O
Adiponectin B-GENE-Y
Levels O
at O
First O
Trimester O
of O
Pregnancy O
Are O
Associated O
With O
Increased O
Insulin B-GENE-Y
Resistance O
and O
Higher O
Risk O
of O
Developing O
Gestational O
Diabetes O
Mellitus. O
OBJECTIVETo O
evaluate O
the O
associations O
between O
adiponectin B-GENE-Y
levels O
and O
1) O
the O
risk O
of O
developing O
gestational O
diabetes O
mellitus O
(GDM), O
and O
2) O
insulin B-GENE-Y
resistance/sensitivity, O
β-cell O
function, O
and O
compensation O
indices O
in O
a O

prospective O
cohort O
representative O
of O
the O
general O
population O
of O
pregnant O
women.RESEARCH O
DESIGN O
AND O
METHODSWe O
performed O
anthropometric O
measurements O
and O
collected O
blood O
samples O
at O
1st O
(6-13 O
weeks) O
and O
2nd O
(24-28 O
weeks) O
trimesters. O
Diagnosis O
of O
GDM O
was O
made O
at O
2nd O
trimester, O
based O
on O
a O
75-g O
oral O
glucose B-CHEMICAL
tolerance O
test O
(International O
Association O
of O
Diabetes O
and O
Pregnancy O
Study O
Group O
criteria). O
Insulin B-GENE-Y
was O
measured O
(ELISA; O
Luminex) O
to O
estimate O
homeostasis O
model O
assessment O
of O
insulin B-GENE-Y
resistance O

(HOMA-IR), O
β-cell O
function O
(HOMA-B), O
insulin B-GENE-Y
sensitivity O
(Matsuda O
index), O
insulin B-GENE-Y
secretion O
(AUC(insulin/glucose)), B-GENE-Y
and O
β-cell O
compensation O
(insulin B-GENE-Y
secretion O
sensitivity O
index-2). O
Adiponectin B-GENE-Y
was O
measured O
by O
radioimmunoassay.RESULTSAmong O
the O
445 O
participants O
included O
in O
this O
study, O
38 O
women O
developed O
GDM. O
Women O
who O
developed O
GDM O
had O
lower O
1st-trimester O
adiponectin B-GENE-Y
levels O
(9.67 O
± O
3.84 O
vs. O
11.92 O
± O

4.59 O
µg/mL O
in O
women O
with O
normal O
glucose B-CHEMICAL
tolerance). O
Lower O
adiponectin B-GENE-Y
levels O
were O
associated O
with O
higher O
risk O
of O
developing O
GDM O
(OR, O
1.12 O
per O
1 O
µg/mL O
decrease O
of O
adiponectin B-GENE-Y
levels; O
P O
= O
0.02, O
adjusted O
for O
BMI O
and O
HbA(1c) O
at O
1st O
trimester). O
Adiponectin B-GENE-Y
levels O
at O
1st O
and O
2nd O
trimesters O
were O
associated O
with O
HOMA-IR O
(both: O
r O
= O
-0.22, O
P O
< O
0.0001) O
and O
Matsuda O
index O
(r O
= O

0.28, O
P O
< O
0.0001, O
and O
r O
= O
0.29, O
P O
< O
0.0001). O
After O
adjustment O
for O
confounding O
factors, O
we O
found O
no O
significant O
association O
with O
HOMA-B O
and O
AUC(insulin/glucose).CONCLUSIONSPregnant B-GENE-Y
women O
with O
lower O
adiponectin B-GENE-Y
levels O
at O
1st O
trimester O
have O
higher O
levels O
of O
insulin B-GENE-Y
resistance O
and O
are O
more O
likely O
to O
develop O
GDM O
independently O
of O
adiposity O
or O
glycemic O
measurements. O
Reduced O
plasma O
oxytocin B-GENE-Y
levels O
in O
female O
patients O
with O
borderline O
personality O
disorder. O
The O
neuropeptide O

oxytocin B-GENE-Y
is O
involved O
in O
social O
cognition O
and O
interaction O
across O
species O
and O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
affiliative O
behaviors. O
Oxytocin B-GENE-Y
levels O
in O
cerebrospinal O
fluid O
(CSF), O
but O
also O
in O
plasma O
or O
urine, O
have O
been O
shown O
to O
be O
negatively O
associated O
with O
childhood O
traumata, O
aggressive O
behavior, O
and O
suicide O
attempts. O
Recently, O
an O
altered O
activity O
of O
the O
oxytocin B-GENE-Y
system O
has O
been O
discussed O
to O
play O
a O
prominent O
role O
in O
borderline O
personality O
disorder O
(BPD), O
which O
is O
thought O
to O
be O
closely O
related O
to O
traumatic O
experiences O
in O
childhood O
and O
is O
characterized O
by O
(para)suicidal O
behaviors O
as O
well O

as O
aggressive O
outbursts. O
In O
the O
present O
study, O
we O
compared O
plasma O
oxytocin B-GENE-Y
levels O
of O
women O
with O
and O
without O
BPD O
in O
the O
follicular O
phase O
and O
assessed O
the O
relationship O
between O
oxytocin B-GENE-Y
concentrations O
and O
childhood O
traumata. O
Women O
diagnosed O
with O
BPD O
had O
significantly O
reduced O
oxytocin B-GENE-Y
concentrations, O
even O
after O
controlling O
for O
estrogen, B-CHEMICAL
progesterone, B-CHEMICAL
and O
contraceptive O
intake. O
In O
addition, O
plasma O
oxytocin B-GENE-Y
correlated O
negatively O
with O
experiences O
of O
childhood O
traumata, O
in O
particular O
with O
emotional O
neglect O
and O
abuse. O
The O
results O
of O
mediation O
analyses O
do O
not O
support O
a O
model O
of O
oxytocin B-GENE-Y
being O
a O
prominent O
mediator O
in O

the O
link O
between O
childhood O
trauma O
and O
BPD. O
Thus, O
the O
findings O
indicate O
dysregulations O
in O
the O
oxytocin B-GENE-Y
system O
of O
patients O
diagnosed O
with O
BPD O
with O
more O
longitudinal O
research O
being O
necessary O
to O
disentangle O
the O
relationship O
between O
childhood O
adversities, O
oxytocin B-GENE-Y
system, O
and O
psychopathology. O
Interferon-gamma B-GENE-Y
is O
causatively O
involved O
in O
experimental O
inflammatory O
bowel O
disease O
in O
mice. O
Cytokines B-GENE-N
may O
be O
crucially O
involved O
in O
the O
pathogenesis O
of O
inflammatory O
bowel O
diseases O
(IBD), O
but O
it O
remains O
controversial O
whether O
interferon B-GENE-Y
(IFN)-gamma, I-GENE-Y
a O
typical O

proinflammatory O
cytokine, B-GENE-N
is O
an O
essential O
mediator O
to O
cause O
the O
disorders. O
In O
the O
present O
study, O
IFN-gamma(-/-) B-GENE-Y
and O
wild-type O
(WT) O
C57BL/6 O
mice O
were O
fed O
2.5% O
dextran O
sodium O
sulphate O
(DSS) O
in O
drinking O
water O
for O
7 O
days, O
in O
order O
to O
investigate O
DSS-induced O
intestinal O
inflammation. O
The O
DSS-treated O
WT O
mice O
exhibited O
a O
robust O
production O
of O
IFN-gamma B-GENE-Y
in O
the O
gut, O
a O
remarkable O
loss O
of O
body O
weight, O
as O
well O
as O
high O
rate O
of O
mortality O

(60%). O
In O
striking O
contrast, O
IFN-gamma B-GENE-Y
deficient O
mice O
did O
not O
develop O
DSS-induced O
colitis, O
as O
indicated O
by O
the O
maintenance O
of O
body O
weight O
and O
survival O
rate O
of O
100%. O
Severe O
intestinal O
inflammation O
was O
demonstrated O
exclusively O
in O
WT O
animals O
in O
terms O
of O
the O
shortening O
of O
the O
bowel O
as O
well O
as O
the O
elevation O
of O
the O
disease O
activity O
index, O
myeloperoxidase B-GENE-Y
(MPO) B-GENE-Y
activity O
and O
serum B-GENE-Y
haptoglobin I-GENE-Y
level. O
Histological O
study O
of O
DSS-treated O
WT O
intestine O
revealed O
disruption O
of O
mucosal O
epithelium O
and O
massive O
infiltration O

of O
inflammatory O
cells, O
while O
the O
organ O
from O
IFN-gamma(-/-) B-GENE-Y
mice O
remained O
virtually O
normal O
in O
appearance. O
Enzyme-linked O
immunosorbent O
assay O
(ELISA) O
analyses O
indicated O
abundant O
production O
of O
three O
chemokines, B-GENE-N
i.e. O
monokine B-GENE-Y
induced I-GENE-Y
by I-GENE-Y
interferon-gamma I-GENE-Y
(MIG), B-GENE-Y
interferon-inducible B-GENE-Y
protein I-GENE-Y
10 I-GENE-Y
(IP-10) B-GENE-Y
and O
monocyte B-GENE-Y
chemoattractant I-GENE-Y
protein-1 I-GENE-Y
(MCP-1), B-GENE-Y
in O
the O
DSS-irritated O
intestine O
of O
WT O
but O
not O
of O

IFN-gamma(-/-) B-GENE-Y
mice. O
The O
present O
results O
demonstrate O
clearly O
that O
IFN-gamma B-GENE-Y
plays O
indispensable O
roles O
in O
the O
initiation O
of O
DSS O
colitis, O
and O
some O
chemokines B-GENE-N
are O
produced O
in O
an O
IFN-gamma-dependent B-GENE-Y
fashion. O
Formoterol B-CHEMICAL
in O
the O
management O
of O
chronic O
obstructive O
pulmonary O
disease. O
Bronchodilators O
represent O
the O
hallmark O
of O
symptomatic O
treatment O
of O
Chronic O
Obstructive O
Pulmonary O
Disease O
(COPD). O
There O
are O
four O
categories O
of O
bronchodilators: O
anticholinergics, O

methylxanthines, B-CHEMICAL
short-acting O
beta2-agonists, O
and O
long-acting O
beta2-agonists O
such O
as O
formoterol. B-CHEMICAL
Significant O
research O
has O
been O
performed O
to O
investigate O
the O
efficacy, O
safety O
and O
tolerability O
of O
formoterol B-CHEMICAL
in O
the O
therapeutic O
field O
of O
COPD. O
Formoterol B-CHEMICAL
exhibits O
a O
rapid O
onset O
of O
bronchodilation O
similar O
to O
that O
observed O
with O
salbutamol, B-CHEMICAL
yet O
its O
long O
bronchodilatory O
duration O
is O
comparable O
to O
salmeterol. B-CHEMICAL
In O
addition, O
formoterol B-CHEMICAL
presents O
with O
a O
clear O
superiority O
in O
lung O
function O
improvement O
compared O
with O
either O
ipratropium B-CHEMICAL

bromide I-CHEMICAL
or O
oral O
theophylline, B-CHEMICAL
while O
its O
efficacy O
improves O
when O
administered O
in O
combination O
with O
ipratropium. B-CHEMICAL
Formoterol B-CHEMICAL
has O
been O
shown O
to O
better O
reduce O
dynamic O
hyperinflation, O
which O
is O
responsible O
for O
exercise O
intolerance O
and O
dyspnea O
in O
COPD O
patients, O
compared O
with O
other O
bronchodilators, O
whereas O
it O
exerts O
synergistic O
effect O
with O
tiotropium. O
Moreover, O
formoterol B-CHEMICAL
reduces O
exacerbations, O
increases O
days O
free O
of O
use O
of O
rescue O
medication O
and O
improves O
patients' O
quality O
of O
life O
and O
disease O
symptoms. O
Formoterol B-CHEMICAL
has O
a O
favorable O
safety O
profile O
and O

is O
better O
tolerated O
than O
theophylline. B-CHEMICAL
Collectively, O
data O
extracted O
from O
multicenter O
clinical O
trials O
support O
formoterol B-CHEMICAL
as O
a O
valid O
therapeutic O
option O
in O
the O
treatment O
of O
COPD. O
Comparative O
genomics, O
molecular O
evolution O
and O
computational O
modeling O
of O
ALDH1B1 B-GENE-Y
and O
ALDH2. B-GENE-Y
Vertebrate B-GENE-Y
ALDH2 I-GENE-Y
genes O
encode O
mitochondrial O
enzymes O
capable O
of O
metabolizing O
acetaldehyde B-CHEMICAL
and O
other O
biological O
aldehydes B-CHEMICAL
in O
the O
body. O
Mammalian B-GENE-Y
ALDH1B1, I-GENE-Y
another O
mitochondrial O
enzyme O
sharing O
72% O
identity O
with O
ALDH2, B-GENE-Y
is O
also O
capable O
of O
metabolizing O

acetaldehyde B-CHEMICAL
but O
has O
a O
tissue O
distribution O
and O
pattern O
of O
activity O
distinct O
from O
that O
of O
ALDH2. B-GENE-Y
Bioinformatic O
analyses O
of O
several O
vertebrate O
genomes O
were O
undertaken O
using O
known O
ALDH2 B-GENE-Y
and O
ALDH1B1 B-GENE-Y
amino B-CHEMICAL
acid I-CHEMICAL
sequences. O
Phylogenetic O
analysis O
of O
many O
representative O
vertebrate O
species O
(including O
fish, O
amphibians, O
birds O
and O
mammals) O
indicated O
the O
presence O
of O
ALDH1B1 B-GENE-Y
in O
many O
mammalian O
species O
and O
in O
frogs O
(Xenopus O
tropicalis); O
no O
evidence O
was O
found O
for O
ALDH1B1 B-GENE-Y
in O
the O
genomes O
of O
birds, O
reptiles O
or O

fish. O
Predicted O
vertebrate B-GENE-Y
ALDH2 I-GENE-Y
and O
ALDH1B1 B-GENE-Y
subunit O
sequences O
and O
structures O
were O
highly O
conserved, O
including O
residues O
previously O
shown O
to O
be O
involved O
in O
catalysis O
and O
coenzyme O
binding O
for O
human B-GENE-Y
ALDH2. I-GENE-Y
Studies O
of O
ALDH1B1 B-GENE-Y
sequences O
supported O
the O
hypothesis O
that O
the O
ALDH1B1 B-GENE-N
gene O
originated O
in O
early O
vertebrates O
from O
a O
retrotransposition O
of O
the O
vertebrate O
ALDH2 B-GENE-Y
gene. O
Given O
the O
high O
degree O
of O
similarity O
between O
ALDH2 B-GENE-Y
and O
ALDH1B1, B-GENE-Y
it O
is O
surprising O
that O
individuals O
with O
an O
inactivating O
mutation O
in O

ALDH2 B-GENE-Y
(ALDH2*2) B-GENE-Y
do O
not O
exhibit O
a O
compensatory O
increase O
in O
ALDH1B1 B-GENE-Y
activity. O
We O
hypothesized O
that O
the O
similarity O
between O
the O
two O
ALDHs B-GENE-N
would O
allow O
for O
dominant O
negative O
heterotetramerization O
between O
the O
inactive O
ALDH2 B-GENE-Y
mutants O
and O
ALDH1B1. B-GENE-Y
Computational-based O
molecular O
modeling O
studies O
examining O
predicted O
protein-protein O
interactions O
indicated O
that O
heterotetramerization O
between O
ALDH2 B-GENE-Y
and O
ALDH1B1 B-GENE-Y
subunits O
was O
highly O
probable O
and O
may O
partially O
explain O
a O
lack O
of O
compensation O
by O
ALDH1B1 B-GENE-Y
in O

ALDH2(∗)2 B-GENE-Y
individuals. O
Influence O
of O
chain O
length O
and O
double O
bond O
on O
the O
aqueous O
behavior O
of O
choline B-CHEMICAL
carboxylate I-CHEMICAL
soaps. O
In O
preceding O
studies, O
we O
demonstrated O
that O
choline B-CHEMICAL
carboxylates I-CHEMICAL
ChC(m) B-CHEMICAL
with O
alkyl B-CHEMICAL
chain O
lengths O
of O
m O
= O
12 O
- O
18 O
are O
highly O
water-soluble O
(for O
m O
= O
12, O
soluble O
up O
to O
93 O
wt O
% O
soap O
and O
0 O
°C). O
In O
addition, O
choline B-CHEMICAL
soaps O
are O
featured O
by O
an O
extraordinary O
lyotropic O
phase O
behavior. O
With O
decreasing O
water O
concentration, O
the O
following O
phases O
were O
found: O
micellar O
phase O

(L(1)), O
discontinuous O
cubic O
phase O
(I(1)' O
and O
I(1)"), O
hexagonal O
phase O
(H(1)), O
bicontinuous O
cubic O
phase O
(V(1)), O
and O
lamellar O
phase O
(L(α)). O
The O
present O
work O
is O
also O
focused O
on O
the O
lyotropic O
phase O
behavior O
of O
choline B-CHEMICAL
soaps O
but O
with O
shorter O
alkyl B-CHEMICAL
chains O
or O
different O
alkyl B-CHEMICAL
chain O
properties. O
We O
have O
investigated O
the O
aqueous O
phase O
behavior O
of O
choline B-CHEMICAL
soaps O
with O
C(8) B-CHEMICAL
and O
C(10) B-CHEMICAL
chain-lengths O

(choline B-CHEMICAL
octanoate I-CHEMICAL
and O
choline B-CHEMICAL
decanoate) I-CHEMICAL
and O
with O
a O
C(18) B-CHEMICAL
chain-length O
with O
a O
cis-double O
bond O
(choline B-CHEMICAL
oleate). I-CHEMICAL
We O
found O
that O
choline B-CHEMICAL
decanoate I-CHEMICAL
follows O
the O
lyotropic O
phase O
behavior O
of O
the O
longer-chain O
homologues O
mentioned O
above. O
Choline B-CHEMICAL
octanoate I-CHEMICAL
in O
water O
shows O
no O
discontinuous O
cubic O
phases, O
but O
an O
extended, O
isotropic O
micellar O
solution O
phase. O
In O
addition, O
choline B-CHEMICAL
octanoate I-CHEMICAL
is O
at O
the O
limit O
between O
a O
surfactant O
and O
a O
hydrotrope. O
The O

double O
bond O
in O
choline B-CHEMICAL
oleate I-CHEMICAL
leads O
also O
to O
a O
better O
solubility O
in O
water O
and O
a O
decrease O
of O
the O
solubilization O
temperature. O
It O
also O
influences O
the O
Gaussian O
curvature O
of O
the O
aggregates O
which O
results O
in O
a O
loss O
of O
discontinuous O
cubic O
phases O
in O
the O
binary O
phase O
diagram. O
The O
different O
lyotropic O
mesophases O
were O
identified O
by O
the O
penetration O
scan O
technique O
with O
polarizing O
light O
microscope O
and O
visual O
observations. O
To O
clarify O
the O
structural O
behavior O
small O
(SAXS) O
and O
wide O
(WAXS) O
angle O
X-ray O
scattering O
were O
performed. O
To O
further O
characterize O
the O
extended, O
isotropic O

micellar O
solution O
phase O
in O
the O
binary O
phase O
diagram O
of O
choline B-CHEMICAL
octanoate I-CHEMICAL
viscosity O
and O
conductivity O
measurements O
were O
also O
carried O
out. O
Loss O
of O
Kruppel-like B-GENE-Y
Factor I-GENE-Y
3 I-GENE-Y
(KLF3/BKLF) B-GENE-Y
leads O
to O
upregulation O
of O
the O
insulin-sensitizing B-GENE-Y
factor I-GENE-Y
adipolin I-GENE-Y
(FAM132A/CTRP12/C1qdc2). B-GENE-Y
Krüppel-like B-GENE-Y
Factor I-GENE-Y
3 I-GENE-Y
(KLF3) B-GENE-Y
is O
a O
transcriptional O
regulator O
that O
we O
have O
shown O
to O
be O
involved O
in O
the O
regulation O
of O
adipogenesis O
in O
vitro. O
Here O
we O
report O
that O

KLF3 B-GENE-Y
null O
mice O
are O
lean O
and O
protected O
from O
diet-induced O
obesity O
and O
glucose B-CHEMICAL
intolerance. O
On O
a O
chow O
diet, O
plasma O
levels O
of O
leptin B-GENE-Y
are O
decreased, O
and O
adiponectin B-GENE-Y
is O
increased. O
Despite O
significant O
reductions O
in O
body O
weight O
and O
adiposity, O
wildtype O
and O
knockout O
animals O
show O
equivalent O
energy O
intake, O
expenditure O
and O
excretion. O
To O
investigate O
the O
molecular O
events O
underlying O
these O
observations, O
we O
used O
microarray O
analysis O
to O
compare O
gene O
expression O
in O
Klf3(+/+) B-GENE-Y
and O
Klf3(-/-) B-GENE-Y
tissues. O
We O
found O
that O
mRNA O
expression O
of O
Fam132a, B-GENE-Y

which O
encodes O
a O
newly O
identified O
insulin-sensitizing B-GENE-N
adipokine, B-GENE-N
adipolin, B-GENE-Y
is O
significantly O
upregulated O
in O
the O
absence O
of O
KLF3. B-GENE-Y
We O
confirmed O
that O
KLF3 B-GENE-Y
binds O
the O
Fam132a B-GENE-N
promoter I-GENE-N
in O
vitro O
and O
in O
vivo O
and O
that O
this O
leads O
to O
repression O
of O
promoter O
activity. O
Further, O
plasma O
adipolin B-GENE-Y
levels O
were O
significantly O
increased O
in O
Klf3(-/-) B-GENE-Y
mice O
compared O
to O
wild-type O
littermates. O
Boosting O
levels O
of O
adipolin B-GENE-Y
via O
targeting O
of O
KLF3 B-GENE-Y
offers O
a O
novel O
potential O
therapeutic O
strategy O
for O
the O
treatment O
of O
insulin B-GENE-N
resistance. O
Salicylate B-CHEMICAL

pre-treatment O
attenuates O
intensity O
of O
bronchial O
and O
nasal O
symptoms O
precipitated O
by O
aspirin B-CHEMICAL
in O
aspirin-intolerant B-CHEMICAL
patients. O
Aspirin B-CHEMICAL
(ASA) B-CHEMICAL
and O
other O
non-steroidal B-CHEMICAL
anti-inflammatory O
drugs, O
which O
are O
cyclooxygenase B-GENE-N
(COX) B-GENE-N
inhibitors, O
precipitate O
asthmatic O
attacks O
in O
ASA-intolerant B-CHEMICAL
patients, O
while O
sodium B-CHEMICAL
salicylate, I-CHEMICAL
hardly O
active O
on O
COX B-GENE-N
by O
itself, O
is O
well O
tolerated O
by O
these O
patients. O
However, O
salicylate B-CHEMICAL
moiety O
appears O
to O
interfere O
with O
aspirin B-CHEMICAL

inhibitory O
action O
on O
platelets O
and O
vascular O
COX. B-GENE-N
Such O
interaction, O
if O
present O
at O
the O
level O
of O
respiratory O
tract, O
may O
be O
of O
interest O
to O
pathogenesis O
of O
ASA-induced B-CHEMICAL
asthma. O
We O
performed O
a O
double-blind, O
placebo-controlled, O
randomized O
cross-over O
study O
on O
the O
effect O
of O
choline B-CHEMICAL
magnesium I-CHEMICAL
trisalicylate I-CHEMICAL
(CMT, B-CHEMICAL
trilisate) B-CHEMICAL
pre-treatment O
on O
ASA-induced B-CHEMICAL
adverse O
reactions O
in O
nine O
patients. O
Pulmonary O
function O
tests, O
nasal O
symptoms O
score, O
PNIF O
and O
serum O
salicylate B-CHEMICAL
levels O
were O
monitored O
following O
challenges O
with O
threshold O
doses O
of O

ASA. B-CHEMICAL
Trilisate B-CHEMICAL
administered O
at O
a O
dose O
of O
3000 O
mg O
daily O
for O
3 O
days, O
offered O
a O
moderate O
protection O
against O
ASA-induced B-CHEMICAL
symptoms; O
it O
diminished O
the O
severity O
and/or O
delayed O
the O
appearance O
of O
FEV1 O
fall. O
Maximal O
decreases O
in O
FEV1 O
as O
well O
as O
reaction O
intensity O
indexes O
were O
significantly O
lower O
(P O
less O
than O
0.02 O
and O
P O
less O
than O
0.002, O
respectively) O
after O
trilisate B-CHEMICAL
pre-treatment O
as O
compared O
to O
placebo. O
Trilisate B-CHEMICAL
also O
attenuated O
nasal O
symptoms O
in O
three O
out O
of O
five O
patients. O
Although O
the O
precise O
mechanism O
of O
the O
protective O
action O
of O
trilisate B-CHEMICAL
is O

unknown, O
our O
data O
support O
the O
possibility O
of O
interaction O
between O
salicylate B-CHEMICAL
and O
ASA B-CHEMICAL
on O
cyclo-oxygenase B-GENE-N
locus O
in O
the O
respiratory O
tract O
in O
ASA-intolerant B-CHEMICAL
patients. O
Minocycline B-CHEMICAL
inhibits O
cytochrome B-GENE-Y
c I-GENE-Y
release O
and O
delays O
progression O
of O
amyotrophic O
lateral O
sclerosis O
in O
mice. O
Minocycline B-CHEMICAL
mediates O
neuroprotection O
in O
experimental O
models O
of O
neurodegeneration. O
It O
inhibits O
the O
activity O
of O
caspase-1, B-GENE-Y
caspase-3, B-GENE-Y
inducible B-GENE-Y
form I-GENE-Y
of I-GENE-Y
nitric I-GENE-Y
oxide I-GENE-Y
synthetase I-GENE-Y
(iNOS) B-GENE-Y
and O

p38 B-GENE-N
mitogen-activated B-GENE-N
protein I-GENE-N
kinase I-GENE-N
(MAPK). B-GENE-N
Although O
minocycline B-CHEMICAL
does O
not O
directly O
inhibit O
these O
enzymes, O
the O
effects O
may O
result O
from O
interference O
with O
upstream O
mechanisms O
resulting O
in O
their O
secondary O
activation. O
Because O
the O
above-mentioned O
factors O
are O
important O
in O
amyotrophic O
lateral O
sclerosis O
(ALS), O
we O
tested O
minocycline B-CHEMICAL
in O
mice O
with O
ALS. O
Here O
we O
report O
that O
minocycline B-CHEMICAL
delays O
disease O
onset O
and O
extends O
survival O
in O
ALS O
mice. O
Given O
the O
broad O
efficacy O
of O
minocycline, B-CHEMICAL
understanding O
its O
mechanisms O
of O
action O
is O
of O
great O
importance. O
We O
find O
that O
minocycline B-CHEMICAL
inhibits O
mitochondrial O

permeability-transition-mediated O
cytochrome B-GENE-Y
c I-GENE-Y
release. O
Minocycline-mediated B-CHEMICAL
inhibition O
of O
cytochrome B-GENE-Y
c I-GENE-Y
release O
is O
demonstrated O
in O
vivo, O
in O
cells, O
and O
in O
isolated O
mitochondria. O
Understanding O
the O
mechanism O
of O
action O
of O
minocycline B-CHEMICAL
will O
assist O
in O
the O
development O
and O
testing O
of O
more O
powerful O
and O
effective O
analogues. O
Because O
of O
the O
safety O
record O
of O
minocycline, B-CHEMICAL
and O
its O
ability O
to O
penetrate O
the O
blood-brain O
barrier, O
this O
drug O
may O
be O
a O
novel O
therapy O
for O
ALS. O
Use O
of O
the O
Combination O
Index O
to O
determine O
interactions O
between O
plant-derived O
phenolic B-CHEMICAL
acids I-CHEMICAL
on O

hepatotoxicity O
endpoints O
in O
human O
and O
rat O
hepatoma O
cells. O
The O
beneficial O
or O
adverse O
effects O
of O
isolated O
phytochemicals O
are O
not O
always O
concordant O
with O
effects O
of O
the O
botanical O
dietary O
supplements O
from O
which O
they O
were O
derived. O
This O
disparity O
could O
be O
due O
to O
interactions O
between O
the O
various O
phytochemicals O
present O
in O
the O
whole O
plant. O
The O
phenolic B-CHEMICAL
acids, I-CHEMICAL
rosmarinic B-CHEMICAL
acid I-CHEMICAL
(RA), O
caffeic B-CHEMICAL
acid I-CHEMICAL
(CA) O
and O
ferulic B-CHEMICAL
acid I-CHEMICAL
(FA) O
are O
widely O
present O
in O
foods O
and O
dietary O
supplements, O
and O
they O
are O
assumed O
to O
exert O
various O
beneficial O

biological O
effects. O
However, O
there O
is O
little O
data O
on O
the O
potential O
biological O
interactions O
of O
these O
three O
phenolic B-CHEMICAL
acids I-CHEMICAL
which O
commonly O
occur O
together O
and O
are O
linked O
metabolically. O
In O
the O
present O
study, O
liver O
toxicity O
of O
the O
three O
phenolic B-CHEMICAL
acids I-CHEMICAL
was O
assessed O
on O
the O
three O
compounds O
singly O
and O
in O
various O
binary O
and O
one O
ternary O
combinations. O
A O
series O
of O
in O
vitro O
endpoints O
relevant O
to O
liver O
toxicity O
were O
evaluated O
in O
both O
a O
human O
(HepG2/C3A) O
and O
rat O
(MH1C1) O
hepatocyte O
cell O
line. O
The O
Combination O
Index O
(CI) O
was O
calculated O
for O
each O
endpoint O
from O
both O

the O
concentration O
responses O
of O
the O
single O
compounds O
and O
the O
responses O
of O
the O
various O
binary O
and O
ternary O
mixtures. O
Both O
synergistic O
and O
antagonistic O
interactions O
were O
observed O
for O
some O
endpoints O
and O
some O
combinations O
of O
test O
agents. O
Interactions O
were O
most O
prevalent O
in O
measures O
of O
oxidative O
stress O
and O
cytochrome B-GENE-N
P450 I-GENE-N
activities O
in O
both O
cell O
types. O
There O
was O
only O
a O
53% O
concordance O
between O
the O
rat O
and O
human O
cells O
which O
may O
be O
suggestive O
of O
species O
differences. O
The O
data O
suggest O
an O
approach O
for O
better O
characterizing O
the O
beneficial O
or O
adverse O
effects O
of O
complex O
botanical O
products O
through O
evaluation O
of O
interactions O
between O
individual O
phytochemical O
components. O

Heterogeneous O
expression O
and O
polymorphic O
genotype O
of O
glutathione B-GENE-N
S-transferases I-GENE-N
in O
human O
lung. O
BACKGROUND: O
Glutathione B-GENE-N
S-transferases I-GENE-N
(GSTs) B-GENE-N
are O
involved O
in O
the O
detoxification O
of O
xenobiotics O
by O
conjugation O
with O
glutathione. B-CHEMICAL
One O
of O
the O
mu O
class O
genes O
of O
this O
superfamily O
of O
enzymes, O
GSTM1, B-GENE-Y
is O
polymorphic O
because O
of O
a O
partial O
gene O
deletion. O
This O
results O
in O
a O
failure O
to O
express O
GSTM1 B-GENE-Y
in O
approximately O
50% O
of O
individuals. O
Several O
studies O
have O
linked O
GSTM1 B-GENE-Y

null O
status O
to O
an O
increased O
risk O
of O
lung O
carcinoma. O
This O
study O
investigated O
the O
expression O
and O
distribution O
of O
GST B-GENE-N
isoenzymes O
in O
human O
lung, O
and O
developed O
a O
polymerase O
chain O
reaction O
(PCR) O
assay O
which O
would O
allow O
genotyping O
of O
archival, O
paraffin O
embedded O
lung O
tissue. O
METHODS: O
Distribution O
was O
examined O
using O
a O
panel O
of O
polyclonal O
anti-GST B-GENE-N
antibodies O
for O
immunohistochemistry O
in O
normal O
tissue O
of O
21 O
tumour-bearing O
lungs. O
DNA O
for O
PCR O
was O
extracted O
from O
paraffin O
blocks O
and O
a O
control O
group O
of O
350 O
blood O
lysates. O
As O
a O
positive O
control O

each O
assay O
amplified O
part O
of O
GSTM4, B-GENE-Y
a O
mu O
class O
gene O
which O
is O
not O
polymorphic O
but O
which O
shows O
strong O
sequence O
homology O
to O
GSTM1. B-GENE-Y
The O
presence O
of O
GST B-GENE-N
in O
bronchoalveolar O
lavage O
fluid O
was O
sought O
by O
Western O
analysis. O
RESULTS: O
Proximal O
airways O
contained O
pi B-GENE-Y
class I-GENE-Y
GST, I-GENE-Y
alpha B-GENE-N
class I-GENE-N
GST, I-GENE-N
and O
mu B-GENE-N
class I-GENE-N
GST I-GENE-N
with O
expression O
concentrated O
in O
the O
brush O
border. O
In O
distal O
airspaces O
no O
alpha B-GENE-N
GST I-GENE-N
was O
expressed O
but O
pi B-GENE-Y
GST I-GENE-Y
and O
mu B-GENE-N
GST I-GENE-N
were O
present O
in O
alveolar O
cells O
and O
also O

alveolar O
macrophages. O
Pi B-GENE-Y
class I-GENE-Y
GST I-GENE-Y
was O
present O
in O
bronchoalveolar O
lavage O
fluid. O
The O
PCR O
assay O
enabled O
genotypic O
determination O
using O
DNA O
extracted O
from O
archival O
material. O
Of O
the O
control O
group O
56% O
were O
null O
at O
the O
GSTM1 B-GENE-Y
locus. O
CONCLUSIONS: O
The O
distribution O
of O
GST B-GENE-N
isoenzymes O
in O
the O
lung O
is O
heterogeneous O
with O
an O
apparent O
decrease O
in O
GST B-GENE-N
in O
distal O
lung. O
Since O
GSTM1 B-GENE-Y
status O
has O
already O
been O
associated O
with O
susceptibility O
to O
disease, O
the O
PCR O
assay O
developed O
will O
allow O
further O

studies O
of O
the O
relation O
between O
genotype O
and O
structural O
disorders O
in O
the O
lung O
using O
archival O
pathological O
material. O
Monoacylglycerol B-GENE-Y
lipase I-GENE-Y
inhibition-induced O
changes O
in O
plasma O
corticosterone B-CHEMICAL
levels, O
anxiety O
and O
locomotor O
activity O
in O
male O
CD1 O
mice. O
The O
hypothalamus-pituitary-adrenal-axis O
is O
strongly O
controlled O
by O
the O
endocannabinoid O
system. O
The O
specific O
impact O
of O
enhanced O
2-arachidonoylglycerol B-CHEMICAL
signaling O
on O
corticosterone B-CHEMICAL
plasma O
levels, O
however, O
was O
not O
investigated O
so O
far. O
Here O
we O
studied O
the O
effects O
of O
the O

recently O
developed O
monoacylglycerol B-GENE-Y
lipase I-GENE-Y
inhibitor O
JZL184 B-CHEMICAL
on O
basal O
and O
stress-induced O
corticosterone B-CHEMICAL
levels O
in O
male O
CD1 O
mice, O
and O
found O
that O
this O
compound O
dramatically O
increased O
basal O
levels O
without O
affecting O
stress O
responses. O
Since O
acute O
changes O
in O
corticosterone B-CHEMICAL
levels O
can O
affect O
behavior, O
JZL184 B-CHEMICAL
was O
administered O
concurrently O
with O
the O
corticosterone B-CHEMICAL
synthesis O
inhibitor O
metyrapone, B-CHEMICAL
to O
investigate O
whether O
the O
previously O
shown O
behavioral O
effects O
of O
JZL184 B-CHEMICAL
are O
dependent O
on O
corticosterone. B-CHEMICAL
We O
found O
that O
in O
the O
elevated O
plus-maze, O
the O
effects O
of O
JZL184 B-CHEMICAL

on O
"classical" O
anxiety-related O
measures O
were O
abolished O
by O
corticosterone B-CHEMICAL
synthesis O
blockade. O
By O
contrast, O
effects O
on O
the O
"ethological" O
measures O
of O
anxiety O
(i.e. O
risk O
assessment) O
were O
not O
affected O
by O
metyrapone. B-CHEMICAL
In O
the O
open-field, O
the O
locomotion-enhancing O
effects O
of O
the O
compound O
were O
not O
changed O
either. O
These O
findings O
show O
that O
monoacylglycerol B-GENE-Y
lipase I-GENE-Y
inhibition O
dramatically O
increases O
basal O
levels O
of O
corticosterone. B-CHEMICAL
This O
endocrine O
effect O
partly O
affects O
the O
anxiolytic, O
but O
not O
the O
locomotion-enhancing O
effects O
of O

monoacylglycerol B-GENE-Y
lipase I-GENE-Y
blockade. O
Induction O
of O
the O
liver O
cancer-down-regulated O
long O
noncoding O
RNA O
uc002mbe.2 B-GENE-Y
mediates O
trichostatin-induced B-CHEMICAL
apoptosis O
of O
liver O
cancer O
cells. O
Differential O
expression O
of O
long O
non-coding O
RNAs O
(lncRNAs) O
plays O
critical O
roles O
in O
hepatocarcinogenesis. O
Considerable O
attention O
has O
focused O
on O
the O
antitumor O
effect O
of O
histone B-GENE-N
deacetylase I-GENE-N
inhibitor O
(Trichostatin B-CHEMICAL
A, I-CHEMICAL
TSA) B-CHEMICAL
as O
well O
as O
the O
coding O
gene O
expression-induced O
apoptosis O
of O
cancer O
cells. O
However, O
it O

is O
not O
known O
whether O
lncRNA O
has O
a O
role O
in O
TSA-induced B-CHEMICAL
apoptosis O
of O
human O
hepatocellular O
carcinoma O
(HCC) O
cells. O
The O
global O
expression O
of O
lncRNAs O
and O
coding O
genes O
was O
analyzed O
with O
the O
Human O
LncRNA O
Array O
V2.0 O
after O
24h O
treatment. O
Expression O
was O
verified O
in O
cell O
lines O
and O
tissues O
by O
quantitative O
real-time O
PCR. O
The O
data O
showed O
that O
4.8% O
(959) O
of O
lncRNA O
and O
6.1% O
(1849) O
of O
protein O
coding O
gene O
were O
significantly O
differentially O
expressed. O
The O
differential O
expressions O
of O
lncRNA O
and O
protein O
coding O
genes O

had O
distinguishable O
hierarchical O
clustering O
expression O
profiling O
pattern. O
Among O
these O
differentially O
expressed O
lncRNAs, O
the O
greatest O
change O
was O
noted O
for O
uc002mbe.2, B-GENE-Y
which O
had O
more O
than O
300 O
folds O
induction O
upon O
TSA B-CHEMICAL
treatment. O
TSA B-CHEMICAL
selectively O
induced O
uc002mbe.2 B-GENE-Y
in O
four O
studied O
HCC O
cell O
lines. O
Compared O
with O
normal O
human O
hepatocytes O
and O
adjacent O
noncancerous O
tissues, O
uc002mbe.2 B-GENE-Y
expression O
level O
was O
significantly O
lower O
in O
the O
HCC O
cell O
lines O
and O
liver O
cancer O
tissues. O
The O
TSA-induced B-CHEMICAL
uc002mbe.2 B-GENE-Y
expression O
was O
positively O

correlated O
with O
the O
apoptotic O
effect O
of O
TSA B-CHEMICAL
in O
HCC O
cells. O
In O
addition, O
knockdown O
the O
expression O
of O
uc002mbe.2 B-GENE-Y
significantly O
reduced O
TSA-induced B-CHEMICAL
apoptosis O
of O
Huh7cells. O
Therefore, O
TSA-induced B-CHEMICAL
apoptosis O
of O
HCC O
cells O
is O
uc002mbe.2 B-GENE-Y
dependent O
and O
reduced O
expression O
of O
uc002mbe.2 B-GENE-Y
may O
be O
associated O
with O
liver O
carcinogenesis. O
The O
mannose B-CHEMICAL
6-phosphate-binding I-CHEMICAL
sites O
of O
M6P/IGF2R B-CHEMICAL
determine O
its O
capacity O
to O
suppress O
matrix O
invasion O
by O
squamous O
cell O
carcinoma O
cells. O
The O

M6P B-CHEMICAL
(mannose B-CHEMICAL
6-phosphate)/IGF2R I-CHEMICAL
(insulin-like B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
II I-GENE-Y
receptor) I-GENE-Y
interacts O
with O
a O
variety O
of O
factors O
that O
impinge O
on O
tumour O
invasion O
and O
metastasis. O
It O
has O
been O
shown O
that O
expression O
of O
wild-type O
M6P/IGF2R B-CHEMICAL
reduces O
the O
tumorigenic O
and O
invasive O
properties O
of O
receptor-deficient O
SCC-VII O
squamous O
cell O
carcinoma O
cells. O
We O
have O
now O
used O
mutant O
forms O
of O
M6P/IGF2R B-CHEMICAL
to O
assess O
the O
relevance O
of O
the O
different O
ligand-binding O
sites O
of O
the O
receptor O
for O
its O
biological O
activities O
in O

this O
cellular O
system. O
The O
results O
of O
the O
present O
study O
demonstrate O
that O
M6P/IGF2R B-CHEMICAL
does O
not O
require O
a O
functional O
binding O
site O
for O
insulin-like B-GENE-Y
growth I-GENE-Y
factor I-GENE-Y
II I-GENE-Y
for O
inhibition O
of O
anchorage-independent O
growth O
and O
matrix O
invasion O
by O
SCC-VII O
cells. O
In O
contrast, O
the O
simultaneous O
mutation O
of O
both O
M6P-binding B-CHEMICAL
sites O
is O
sufficient O
to O
impair O
all O
cellular O
functions O
of O
the O
receptor O
tested. O
These O
findings O
highlight O
that O
the O
interaction O
between O
M6P/IGF2R B-CHEMICAL
and O
M6P-modified B-CHEMICAL
ligands O
is O
not O
only O
important O
for O
intracellular O
accumulation O
of O
lysosomal O
enzymes O
and O
formation O
of O
dense O

lysosomes, O
but O
is O
also O
crucial O
for O
the O
ability O
of O
the O
receptor O
to O
suppress O
SCC-VII O
growth O
and O
invasion. O
The O
present O
study O
also O
shows O
that O
some O
of O
the O
biological O
activities O
of O
M6P/IGF2R B-CHEMICAL
in O
SCC-VII O
cells O
strongly O
depend O
on O
a O
functional O
M6P-binding B-CHEMICAL
site O
within O
domain O
3, O
thus O
providing O
further O
evidence O
for O
the O
non-redundant O
cellular O
functions O
of O
the O
individual O
carbohydrate-binding B-CHEMICAL
domains O
of O
the O
receptor. O
Orlistat, B-CHEMICAL
a O
new O
lipase B-GENE-N
inhibitor O
for O
the O
management O
of O
obesity. O
Orlistat, B-CHEMICAL
a O
weight-loss O
agent O
with O
a O
novel O
mechanism O
of O
action, O
recently O

was O
approved O
by O
the O
Food O
and O
Drug O
Administration O
for O
the O
treatment O
of O
obesity. O
It O
inhibits O
gastric B-GENE-N
and I-GENE-N
pancreatic I-GENE-N
lipases I-GENE-N
in O
the O
lumen O
of O
the O
gastrointestinal O
tract O
to O
decrease O
systemic O
absorption O
of O
dietary O
fat. O
In O
several O
trials O
lasting O
up O
to O
2 O
years, O
orlistat B-CHEMICAL
was O
more O
effective O
than O
diet O
alone O
for O
weight O
reduction O
and O
maintenance O
of O
lost O
weight. O
Orlistat B-CHEMICAL
treatment O
also O
results O
in O
modest O
improvements O
in O
total O
cholesterol, B-CHEMICAL
low-density B-GENE-N
lipoprotein, I-GENE-N
blood O
pressure, O
and O
fasting O
glucose B-CHEMICAL
and O
insulin B-GENE-Y
concentrations. O
The O
major O
adverse O
effects O
are O
gastrointestinal, O
usually O
occur O
early O
in O

therapy, O
and O
tend O
to O
decrease O
with O
continued O
treatment. O
Because O
orlistat B-CHEMICAL
may O
decrease O
the O
absorption O
of O
fat-soluble O
vitamins, B-CHEMICAL
a O
standard O
multiple-vitamin B-CHEMICAL
supplement O
is O
recommended O
daily O
during O
therapy O
to O
prevent O
abnormalities O
in O
vitamin B-CHEMICAL
serum O
concentrations. O
The O
potential O
for O
severe O
gastrointestinal O
discomfort O
and O
the O
modest O
degree O
of O
weight O
loss O
may O
limit O
the O
agent's O
clinical O
utility. O
Its O
long-term O
safety O
and O
effectiveness O
for O
weight O
maintenance, O
cost-effectiveness O
of O
treatment, O
and O
overall O
reduction O
in O
obesity-related O
morbidity O
and O
mortality O
remain O
to O
be O
determined. O
The O
Atrial B-GENE-Y
Natriuretic I-GENE-Y
Peptide I-GENE-Y
Genetic O
Variant O
Rs5068 B-GENE-Y
Is O

Associated O
With O
a O
Favorable O
Cardiometabolic O
Phenotype O
in O
a O
Mediterranean O
Population. O
OBJECTIVEWe O
hypothesized O
that O
the O
minor O
allele O
of O
the O
atrial B-GENE-Y
natriuretic I-GENE-Y
peptide I-GENE-Y
(ANP) B-GENE-Y
genetic O
variant O
rs5068 B-GENE-Y
is O
associated O
with O
a O
favorable O
cardiometabolic O
phenotype O
in O
a O
general O
Mediterranean O
population.RESEARCH O
DESIGN O
AND O
METHODSWe O
genotyped O
a O
random O
sample O
of O
the O
residents O
of O
Ventimiglia O
di O
Sicilia, O
Sicily, O
for O

rs5068.RESULTSGenotype B-GENE-Y
frequencies O
of O
rs5068 B-GENE-Y
are O
AA, O
93.5%; O
AG, O
6.4%; O
and O
GG, O
0.1%. O
All O
subsequent O
analyses O
are O
AA O
versus O
AG+GG. O
After O
adjusting O
for O
age O
and O
sex, O
the O
minor O
G O
allele O
is O
associated O
with O
lower O
BMI O
(estimate O
[SE]: O
-1.7 O
kg/m(2) O
[0.8], O
P O
= O
0.04). O
In O
the O
AG+GG O
group, O
males O
with O
HDL B-GENE-N
cholesterol B-CHEMICAL
levels O
<40 O
mg/dL O

are O
less O
frequent O
(P O
= O
0.05) O
and O
obesity O
tends O
to O
be O
less O
prevalent O
(P O
= O
0.07). O
Importantly, O
the O
G O
allele O
is O
associated O
with O
a O
lower O
prevalence O
of O
metabolic O
syndrome O
(P O
= O
0.02). O
After O
adjusting O
for O
BMI, O
the O
above O
associations O
were O
attenuated. O
Independently O
of O
age, O
sex, O
and O
BMI, O
the O
minor O
allele O
is O
also O
associated O
with O
lower O
systolic O
blood O
pressure O
(-6.0 O
mmHg O
[2.5], O
P O
= O
0.02) O
and O
lower O
prevalence O
of O
hypertension O
(odds O
ratio O
0.41 O

[95% O
CI O
0.20-0.83], O
P O
= O
0.01).CONCLUSIONSThe O
association O
between O
the O
minor O
allele O
of O
rs5068 B-GENE-Y
and O
a O
favorable O
cardiometabolic O
phenotype O
that O
we O
previously O
reported O
in O
a O
U.S. O
population O
is O
now O
replicated O
in O
a O
Mediterranean O
population O
in O
which O
the O
G O
allele O
of O
rs5068 B-GENE-Y
is O
associated O
with O
lower O
blood O
pressure, O
BMI, O
and O
prevalence O
of O
hypertension O
and O
metabolic O
syndrome. O
These O
findings O
may O
lead O
to O
a O
diagnostic O
strategy O
to O
assess O
cardiometabolic O
risk O
and O
lay O
the O
foundation O
for O
the O
future O

development O
of O
an O
ANP B-GENE-Y
or O
ANP-like B-GENE-Y
therapy O
for O
metabolic O
syndrome. O
The O
microsomal/peroxidase B-GENE-Y
antigen: I-GENE-Y
modulation O
of O
its O
expression O
in O
thyroid O
cells. O
Evidence O
has O
accumulated O
in O
the O
last O
few O
years O
that O
the O
expression O
of O
the O
microsomal/peroxidase B-GENE-Y
antigen I-GENE-Y
(M/TPO-Ag) B-GENE-Y
in O
thyroid O
cells O
is O
induced O
by O
TSH, B-GENE-N
through O
pathways O
which O
involve O
intracellular O
cAMP B-CHEMICAL
accumulation O
and O
protein O
synthesis. O
These O
data O
have O
been O
found O
true O
in O
any O
thyroid O
system O
studied O
so O
far, O
both O
in O
terms O
of O
immunologic O
and O
enzymatic O
activity O
of O

TPO. B-GENE-Y
TSH B-GENE-N
and O
cAMP B-CHEMICAL
also O
increase O
the O
levels O
of O
the O
specific O
mRNA O
for O
TPO B-GENE-Y
in O
thyroid O
cells O
from O
different O
species. O
Whether O
this O
phenomenon O
is O
due O
to O
a O
direct O
transcriptional O
regulation O
of O
the O
TPO B-GENE-Y
gene, O
as O
shown O
in O
dog O
thyroid O
cells, O
or O
to O
posttranscriptional O
effects, O
as O
it O
would O
appear O
in O
FRTL-5 O
cells, O
remains O
to O
be O
clarified O
by O
future O
experiments. O
Thyroid B-GENE-N
stimulating I-GENE-N
antibody I-GENE-N
(TSAb) B-GENE-N
of O
Graves' O
disease O
also O
stimulates O
the O
expression O
of O
M/TPO-Ag. B-GENE-Y
This O
finding O
gives O
further O
support O
to O
the O
relevance O
of O

TSAb B-GENE-N
in O
the O
pathogenesis O
of O
hyperthyroidism O
and O
explains O
the O
well O
known O
observation O
that O
the O
"microsomal" O
antigen O
is O
particularly O
abundant O
in O
glands O
of O
Graves' O
patients. O
The O
modulation O
of O
M/TPO-Ag B-GENE-Y
surface O
expression O
by O
TSH B-GENE-N
can O
explain O
the O
decrease O
of O
circulating O
anti-MAb O
observed O
during O
L-thyroxine B-CHEMICAL
therapy O
in O
hypothyroid O
patients O
with O
Hashimoto's O
thyroiditis. O
Other O
agents, O
such O
as O
methimazole B-CHEMICAL
and O
sodium B-CHEMICAL
iodide, I-CHEMICAL
which O
influence O
thyroid O
cell O
function, O
do O
not O
directly O
interfere O
with O
the O
expression O
of O

M/TPO-Ag. B-GENE-Y
Cytokines, B-GENE-N
such O
as O
gamma-interferon, B-GENE-Y
interleukin-1, B-GENE-N
and O
interleukin-6 B-GENE-Y
have O
been O
shown O
to O
inhibit O
the O
TSH-induced B-GENE-N
increase O
of O
TPO B-GENE-Y
mRNA, O
but O
further O
investigations O
are O
required O
to O
elucidate O
the O
exact O
role O
of O
cytokines B-GENE-N
in O
the O
regulation O
of O
M/TPO-Ag B-GENE-Y
expression. O
Structural O
and O
functional O
characterization O
of O
a O
phosphatase B-GENE-N
domain I-GENE-N
within O
yeast O
general O
transcription O
factor O
TFIIIC. B-GENE-Y
Saccharomyces B-GENE-Y
cerevisiae I-GENE-Y
τ55, I-GENE-Y
a O
subunit O
of O
the O
RNA B-GENE-N
polymerase I-GENE-N

III-specific I-GENE-N
general O
transcription O
factor O
TFIIIC, B-GENE-Y
comprises O
an O
N-terminal B-GENE-N
histidine I-GENE-N
phosphatase I-GENE-N
domain I-GENE-N
(τ55-HPD) B-GENE-Y
whose O
catalytic O
activity O
and O
cellular O
function O
is O
poorly O
understood. O
We O
solved O
the O
crystal O
structures O
of O
τ55-HPD B-GENE-Y
and O
its O
closely O
related O
paralogue O
Huf B-GENE-N
and O
used O
in O
silico O
docking O
methods O
to O
identify O
phospho-serine B-CHEMICAL
and O
phospho-tyrosine B-CHEMICAL
containing O
peptides O
as O
possible O
substrates O
that O
were O
subsequently O
validated O
using O
in O
vitro O
phosphatase B-GENE-N
assays. O
A O
comparative O
phospho-proteomic B-CHEMICAL
study O
identified O

additional O
phosphopeptides O
as O
possible O
targets, O
which O
show O
the O
involvement O
of O
these O
two O
phosphatases B-GENE-N
in O
the O
regulation O
of O
a O
variety O
of O
cellular O
functions. O
Our O
results O
identify O
τ55-HPD B-GENE-Y
and O
Huf O
as O
bona O
fide O
protein B-GENE-N
phosphatases, I-GENE-N
characterize O
their O
substrate O
specificities O
and O
provide O
a O
small O
set O
of O
regulated O
phosphosite O
targets O
in O
vivo. O
A O
novel O
benzo[d]imidazole B-CHEMICAL
derivate O
prevents O
the O
development O
of O
dextran O
sulfate O
sodium-induced B-CHEMICAL
murine O
experimental O
colitis O
via O
inhibition O
of O
NLRP3 B-GENE-Y
inflammasome. O

NLRP3 B-GENE-Y
inflammasome O
has O
been O
reported O
to O
be O
associated O
with O
various O
kinds O
of O
immunological O
diseases O
including O
colitis. O
However, O
there O
are O
few O
drug O
candidates O
targeting O
inflammasomes O
for O
the O
treatment O
of O
colitis. O
In O
the O
present O
study, O
we O
aimed O
at O
examining O
the O
effect O
of O
1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, B-CHEMICAL
a O
synthetic O
small O
molecular O
compound O
also O
named O
Fc11a-2, B-CHEMICAL
for O
the O
treatment O
of O
dextran O
sulfate B-CHEMICAL
sodium B-CHEMICAL
(DSS)-induced O
experimental O
colitis O

in O
mice O
via O
targeting O
NLRP3 B-GENE-Y
inflammasome. O
Treatment O
with O
Fc11a-2 O
dose-dependently O
attenuated O
the O
loss O
of O
body O
weight O
and O
shortening O
of O
colon O
length O
induced O
by O
DSS. O
In O
addition, O
the O
disease O
activity O
index, O
histopathologic O
scores O
and O
myeloperoxidase B-GENE-N
activity O
were O
also O
significantly O
reduced O
by O
Fc11a-2 B-CHEMICAL
treatment. O
Moreover, O
protein O
and O
mRNA O
levels O
of O
DSS-induced O
proinflammatory O
cytokines B-GENE-N
in O
colon, O
including O
TNF-α, B-GENE-Y
IL-1β, B-GENE-Y
IL-18, B-GENE-Y
IL-17A B-GENE-Y
and O

IFN-γ, B-GENE-Y
were O
markedly O
suppressed O
by O
Fc11a-2. B-CHEMICAL
Furthermore, O
a O
decreased O
CD11c(+) O
macrophage O
infiltration O
in O
colons O
and O
inactivation O
of O
caspase-1 B-GENE-Y
in O
peritoneal O
macrophages O
were O
detected O
in O
Fc11a-2-treated B-CHEMICAL
mice. O
The O
mechanism O
of O
action O
of O
Fc11a-2 B-CHEMICAL
was O
related O
to O
the O
inhibition O
of O
the O
cleavage O
of O
pro-caspase-1, B-GENE-Y
pro-IL-1β B-GENE-Y
and O
pro-IL-18 B-GENE-Y
which O
in O
turn O
suppressed O
the O
activation O
of O
NLRP3 B-GENE-Y

inflammasome. O
Taken O
together, O
our O
results O
demonstrate O
the O
ability O
of O
Fc11a-2 B-CHEMICAL
to O
inhibit O
NLRP3 B-GENE-Y
inflammasome O
activation O
and O
its O
potential O
use O
in O
the O
treatment O
of O
inflammatory O
bowel O
diseases. O
Methylphenidate B-CHEMICAL
administration O
to O
juvenile O
rats O
alters O
brain O
areas O
involved O
in O
cognition, O
motivated O
behaviors, O
appetite, O
and O
stress. O
Thousands O
of O
children O
receive O
methylphenidate B-CHEMICAL
(MPH; B-CHEMICAL
Ritalin) B-CHEMICAL
for O
attention O
deficit/hyperactivity O
disorder O
(ADHD), O
yet O
the O
long-term O
neurochemical O
consequences O
of O
MPH B-CHEMICAL
treatment O
are O
unknown. O
To O
mimic O
clinical O
Ritalin B-CHEMICAL
treatment O
in O

children, O
male O
rats O
were O
injected O
with O
MPH B-CHEMICAL
(5 O
mg/kg) O
or O
vehicle O
twice O
daily O
from O
postnatal O
day O
7 O
(PND7)-PND35. O
At O
the O
end O
of O
administration O
(PND35) O
or O
in O
adulthood O
(PND135), O
brain O
sections O
from O
littermate O
pairs O
were O
immunocytochemically O
labeled O
for O
neurotransmitters O
and O
cytological O
markers O
in O
16 O
regions O
implicated O
in O
MPH B-CHEMICAL
effects O
and/or O
ADHD O
etiology. O
At O
PND35, O
the O
medial O
prefrontal O
cortex O
(mPFC) O
of O
rats O
given O
MPH B-CHEMICAL
showed O
55% O
greater O

immunoreactivity O
(-ir) O
for O
the O
catecholamine B-CHEMICAL
marker O
tyrosine B-GENE-Y
hydroxylase I-GENE-Y
(TH), B-GENE-Y
60% O
more O
Nissl-stained O
cells, O
and O
40% O
less O
norepinephrine B-GENE-Y
transporter I-GENE-Y
(NET)-ir B-GENE-Y
density. O
In O
hippocampal O
dentate O
gyrus, O
MPH-receiving B-CHEMICAL
rats O
showed O
a O
51% O
decrease O
in O
NET-ir B-GENE-Y
density O
and O
a O
61% O
expanded O
distribution O
of O
the O
new-cell O
marker O
PSA-NCAM B-GENE-Y
(polysialylated O
form O
of O
neural B-GENE-Y
cell I-GENE-Y
adhesion I-GENE-Y
molecule). I-GENE-Y
In O
medial O

striatum, O
TH-ir B-GENE-Y
decreased O
by O
21%, O
and O
in O
hypothalamus O
neuropeptide B-GENE-Y
Y-ir I-GENE-Y
increased O
by O
10% O
in O
MPH-exposed B-CHEMICAL
rats. O
At O
PND135, O
MPH-exposed O
rats O
exhibited O
decreased O
anxiety O
in O
the O
elevated O
plus-maze O
and O
a O
trend O
for O
decreased O
TH-ir B-GENE-Y
in O
the O
mPFC. O
Neither O
PND35 O
nor O
PND135 O
rats O
showed O
major O
structural O
differences O
with O
MPH B-CHEMICAL
exposure. O
These O
findings O
suggest O
that O
developmental O
exposure O
to O
high O
therapeutic O
doses O
of O
MPH B-CHEMICAL
has O
short-term O
effects O
on O
select O
neurotransmitters O
in O
brain O
regions O

involved O
in O
motivated O
behaviors, O
cognition, O
appetite, O
and O
stress. O
Although O
the O
observed O
neuroanatomical O
changes O
largely O
resolve O
with O
time, O
chronic O
modulation O
of O
young O
brains O
with O
MPH B-CHEMICAL
may O
exert O
effects O
on O
brain O
neurochemistry O
that O
modify O
some O
behaviors O
even O
in O
adulthood. O
